Nonylphenol diethoxylate	B-T131
inhibits	B-T052
apoptosis	B-T043
induced	B-T169
in	O
PC12 cells	B-T025
Nonylphenol	B-T131
and	O
short-chain nonylphenol ethoxylates	B-T131
such	O
as	O
NP2 EO	B-T131
are	O
present	B-T033
in	O
aquatic environment	B-T067
as	O
wastewater	B-T069
contaminants	B-T167
,	O
and	O
their	O
toxic effects	B-T037
on	O
aquatic species	B-T001
have	O
been	O
reported.	O
Apoptosis	B-T043
has	O
been	O
shown	O
to	O
be	O
induced	B-T169
by	O
serum	B-T031
deprivation	B-T080
or	O
copper	B-T121
treatment	B-T169
.	O
To	O
understand	O
the	O
toxicity	B-T080
of	O
nonylphenol diethoxylate	B-T131
,	O
we	O
investigated	O
the	O
effects of	B-T080
NP2 EO	B-T131
on	O
apoptosis	B-T043
induced	B-T169
by	O
serum	B-T031
deprivation	B-T080
and	O
copper	B-T121
by	O
using	O
PC12 cell system	B-T025
.	O
Nonylphenol diethoxylate	B-T131
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell viability	B-T043
from	O
apoptosis	B-T043
.	O
In	O
addition,	O
nonylphenol diethoxylate	B-T131
decreased	B-T081
DNA fragmentation	B-T044
caused	O
by	O
apoptosis	B-T043
in	O
PC12 cells	B-T025
.	O
This	O
phenomenon	B-T067
was	O
confirmed	O
after	O
treating	B-T169
apoptotic	B-T080
PC12 cells	B-T025
with	O
nonylphenol diethoxylate	B-T131
,	O
whereas	O
the	O
cytochrome c	B-T116
release	O
into	O
the	O
cytosol	B-T026
decreased	B-T081
as	O
compared	O
to	O
that	O
in	O
apoptotic cells	B-T025
not	O
treated	B-T169
with	O
nonylphenol diethoxylate	B-T131
s.	O
Furthermore,	O
Bax	B-T116
contents	B-T077
in	O
apoptotic cells	B-T025
were	O
reduced	B-T080
after	O
exposure to	B-T080
nonylphenol diethoxylate	B-T131
.	O
Thus,	O
nonylphenol diethoxylate	B-T131
has	O
the	O
opposite effect	B-T080
on	O
apoptosis	B-T043
in	O
PC12 cells	B-T025
compared	O
to	O
nonylphenol	B-T131
,	O
which	O
enhances	B-T052
apoptosis	B-T043
induced	B-T169
by	O
serum	B-T031
deprivation	B-T080
.	O
The	O
difference	B-T080
in	O
structure	B-T082
of	O
the	O
two	O
compounds	B-T103
is	O
hypothesized	B-T078
to	O
be	O
responsible	O
for	O
this	O
phenomenon	B-T067
.	O
These	O
results	B-T033
indicated	O
that	O
nonylphenol diethoxylate	B-T131
has	O
capability	B-T080
to	O
affect	O
cell differentiation	B-T043
and	O
development	B-T039
and	O
has	O
potentially	B-T080
harmful effect	B-T037
on	O
organisms	B-T001
because	O
of	O
its	O
unexpected	O
impact	B-T080
on	O
apoptosis	B-T043
.	O
©	O
2015	O
Wiley	O
Periodicals,	O
Inc.	O
Environ	O
Toxicol	O
31:	O
1389-1398,	O
2016.	O

EZH2	B-T028
and	O
ZFX	B-T028
oncogenes	B-T028
in	O
malignant behaviour	B-T080
of	O
parathyroid neoplasms	B-T191
Several	O
studies	B-T062
reported	O
somatic mutations	B-T049
of	O
many	O
genes	B-T028
(	O
MEN1	B-T028
,	O
CTNNB1	B-T028
,	O
CDKIs	B-T028
and	O
others)	O
in	O
parathyroid adenoma	B-T191
,	O
although	O
with	O
different	B-T080
prevalence	B-T081
.	O
Recently,	O
activating	B-T052
mutations	B-T045
of	O
the	O
EZH2	B-T028
and	O
ZFX	B-T028
oncogenes	B-T028
were	O
identified	O
in	O
benign	B-T080
parathyroid adenoma	B-T191
by	O
whole exome sequencing	B-T063
.	O
The	O
same	O
mutations	B-T045
had	O
been	O
found	O
in	O
blood	B-T031
and	O
ovary	B-T023
malignant tumours	B-T191
.	O
On	O
one	O
hand,	O
this	O
result	O
raised	O
the	O
hypothesis	B-T078
that	O
these	O
oncogenes	B-T028
may	O
play	O
a	O
role	O
in	O
the	O
onset	B-T080
of	O
parathyroid tumour	B-T191
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	B-T080
,	O
rather	O
benign	B-T080
,	O
parathyroid neoplasm	B-T191
.	O
Our	O
aim	B-T078
was	O
to	O
verify	O
the	O
occurrence	B-T079
of	O
selected	O
mutations	B-T045
of	O
the	O
EZH2	B-T028
and	O
ZFX genes	B-T028
in	O
an	O
Italian	B-T098
cohort	B-T098
of	O
23	O
sporadic	B-T079
parathyroid carcinomas	B-T191
,	O
12	O
atypical	B-T080
and	O
45	O
typical	B-T080
adenomas	B-T191
.	O
DNA	B-T114
was	O
extracted	B-T061
from	O
paraffin-embedded tissues	B-T024
,	O
PCR	B-T063
amplified	B-T067
and	O
directly	O
sequenced	B-T169
.	O
No	B-T033
mutations	B-T045
were	O
detected	B-T033
in	O
the	O
coding sequence	B-T114
and	O
boundaries	B-T114
of	O
both	O
genes	B-T028
in	O
any	O
of	O
the	O
samples	B-T167
.	O
Two	O
polymorphisms	B-T045
of	O
the	O
EZH2 gene	B-T028
were	O
identified	B-T080
with	O
different	B-T080
prevalence	B-T081
:	O
the	O
rs2072407 variant	B-T028
was	O
present	B-T033
in	O
the	O
30	O
%	O
of	O
the	O
samples	B-T167
,	O
in	O
keeping	O
with	O
the	O
overall	B-T080
frequency	B-T079
in	O
larger	B-T081
populations	B-T081
,	O
while	O
the	O
rs78589034 variant	B-T028
,	O
located	O
close	O
to	O
the	O
5' end	B-T114
of	O
the	O
exon 16	B-T114
,	O
was	O
detected	B-T033
in	O
only	O
one	O
proband	B-T099
with	O
familial	B-T169
isolated	B-T169
hyperparathyroidism	B-T047
;	O
we	O
investigated	B-T169
the	O
possible	O
outcome	B-T169
on	O
the	O
splicing process	B-T045
.	O
EZH2	B-T028
and	O
ZFX genes	B-T028
do	O
not	O
seem	O
to	O
have	O
an	O
impact	B-T080
on	O
the	O
onset	B-T080
of	O
most	O
parathyroid tumours	B-T191
,	O
both	O
benign	B-T080
and	O
malignant	B-T080
,	O
though	O
further	O
studies	O
on	O
larger	B-T081
cohorts	B-T098
of	O
different	B-T080
ethnicity	B-T080
are	O
needed.	O

Patient	B-T101
-	O
Physician	B-T097
Discordance	B-T080
in	O
Global Assessment	B-T062
in	O
Rheumatoid Arthritis	B-T047
:	O
A	O
Systematic	B-T169
Literature Review	B-T170
With	O
Meta-Analysis	B-T062
The	O
integration	O
of	O
the	O
patient	B-T101
in	O
therapeutic	B-T169
decision-making	B-T041
is	O
important	O
in	O
the	O
management	B-T058
of	O
rheumatoid arthritis	B-T047
(	O
RA	B-T047
),	O
but	O
the	O
patient	B-T101
opinion	B-T041
regarding	O
disease	B-T047
status	B-T080
may	O
differ	O
from	O
the	O
physician's	B-T097
opinion	B-T041
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
assess	B-T052
in	O
the	O
published literature	B-T170
the	O
frequency	B-T079
and	O
drivers	O
of	O
patient	B-T101
-	O
physician	B-T097
discordance	B-T080
in	O
global assessment	B-T062
in	O
RA	B-T047
.	O
A	O
systematic	B-T169
literature review	B-T170
of	O
all	O
articles	B-T170
published	B-T057
up	O
to	O
January	O
2015	O
in	O
Medline	B-T170
or	O
Embase	B-T170
,	O
reporting	O
discordance	B-T080
in	O
RA	B-T047
,	O
was	O
conducted	O
by	O
2	O
investigators	B-T097
.	O
Discordance	B-T080
was	O
defined	O
based	O
on	O
the	O
absolute difference	B-T080
of	O
patient global	B-T170
(	O
PGA	B-T170
)	O
and	O
physician global assessments	B-T062
(	O
PhGA	B-T062
)	O
on	O
0-10-cm	O
scales.	O
The	O
frequency	B-T079
of	O
discordance	B-T080
and	O
its	O
predictors	B-T033
were	O
collected	O
in	O
each	O
study	B-T062
.	O
Frequencies	B-T079
of	O
discordance	B-T080
were	O
pooled	B-T169
by	O
meta-analysis	B-T062
using	O
random	B-T080
effect	B-T080
.	O
In	O
all,	O
12	O
studies	B-T062
were	O
selected	O
(i.e.,	O
11,879	O
patients	B-T101
):	O
weighted mean	B-T081
±	O
SD	O
age	B-T032
was	O
55.1	O
±	O
13.9	O
years	B-T079
,	O
weighted mean	B-T081
±	O
SD	O
disease duration	B-T079
was	O
10.4	O
±	O
9.3	O
years	B-T079
,	O
and	O
80.7%	O
were	O
women	B-T098
.	O
The	O
value	B-T081
of	O
the	O
difference	B-T081
|	O
PGA	B-T170
-	O
PhGA	B-T062
|	O
defining	O
discordance	B-T080
varied	O
between	O
≥0.5	O
cm	O
(n	O
=	O
2	O
studies)	O
to	O
≥3	O
cm	O
(n	O
=	O
5	O
studies);	O
the	O
weighted mean value	B-T081
was	O
2.7	O
cm.	O
The	O
pooled	B-T169
percentage	B-T081
of	O
patients	B-T101
with	O
discordance	B-T080
was	O
43%	O
(95%	O
confidence interval	B-T081
36%-51%;	O
range	B-T081
25%-76%).	O
PGA	B-T170
was	O
usually	O
higher	B-T080
than	O
PhGA	B-T062
.	O
The	O
drivers	O
of	O
PGA	B-T170
were	O
pain	B-T184
and	O
functional	B-T169
incapacity	B-T201
,	O
whereas	O
drivers	O
of	O
PhGA	B-T062
were	O
joint counts	B-T170
and	O
acute-phase reactants	B-T116
.	O
Discordance	B-T080
in	O
global assessment	B-T062
was	O
most	O
frequently	B-T079
defined	O
as	O
a	O
difference	B-T080
of	O
3	O
points	O
or	O
more;	O
even	O
with	O
such	O
a	O
stringent	O
definition,	O
up	O
to	O
half	B-T081
the	O
patients	B-T101
were	O
found	O
to	O
be	O
discordant	B-T080
.	O
The	O
long-term	B-T079
consequences	B-T169
of	O
this	O
discordance	B-T080
remain	O
to	O
be	O
determined.	O

A	O
Randomized Controlled Noninferiority Trial	B-T062
of	O
Single Dose	B-T081
of	O
Oral Dexamethasone	B-T200
Versus	O
5	O
Days	B-T079
of	O
Oral Prednisone	B-T200
in	O
Acute	O
Adult	B-T100
Asthma	B-T047
Oral dexamethasone	B-T200
demonstrates	B-T052
bioavailability	B-T081
similar	B-T080
to	O
that	O
of	O
oral prednisone	B-T200
but	O
has	O
a	O
longer	O
half-life	B-T079
.	O
We	O
evaluate	O
whether	O
a	O
single dose	B-T081
of	O
oral dexamethasone	B-T200
plus	B-T169
4	O
days	B-T079
of	O
placebo	B-T122
is	O
not	O
inferior	B-T082
to	O
5	O
days	B-T079
of	O
oral prednisone	B-T200
in	O
treatment	B-T169
of	O
adults	B-T100
with	O
mild	B-T033
to	O
moderate	B-T033
asthma exacerbations	B-T033
to	O
prevent	B-T169
relapse	B-T067
defined	O
as	O
an	O
unscheduled	B-T079
return	O
visit	O
for	O
additional treatment	B-T033
for	O
persistent	B-T047
or	O
worsening	B-T080
asthma	B-T047
within	O
14	O
days	B-T079
.	O
Adult	B-T100
emergency department	B-T073
patients	B-T101
(	O
aged	B-T032
18	O
to	O
55	O
years	B-T079
)	O
were	O
randomized	B-T062
to	O
receive	B-T080
either	O
a	O
single dose	B-T081
of	O
12	O
mg	O
of	O
oral dexamethasone	B-T200
with	O
4	O
days	B-T079
of	O
placebo	B-T122
or	O
a	O
5-	O
day	B-T079
course	B-T079
of	O
oral prednisone	B-T200
60	O
mg	O
a	O
day	B-T079
.	O
Outcomes	B-T169
including	B-T169
relapse	B-T067
were	O
assessed	B-T052
by	O
a	O
follow-up telephone interview	B-T058
at	O
2	O
weeks	B-T079
.	O
One	O
hundred seventy-three	B-T081
dexamethasone	B-T109
and	O
203	O
prednisone	B-T109
subjects	B-T096
completed	B-T080
the	O
study	O
regimen	O
and	O
telephone follow-up	B-T058
.	O
The	O
dexamethasone	B-T109
group	B-UnknownType
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8%	O
difference	B-T080
between	O
groups	B-UnknownType
for	O
noninferiority	B-T080
in	O
relapse	B-T067
rates	B-T081
within	O
14	O
days	B-T079
(12.1%	O
versus	O
9.8%;	O
difference	B-T080
2.3%;	O
95%	O
confidence interval	B-T081
-4.1%	O
to	O
8.6%).	O
Subjects	B-T096
in	O
the	O
2	O
groups	B-UnknownType
had	O
similar	O
rates	B-T081
of	O
hospitalization	B-T058
for	O
their	O
relapse	B-T067
visit	B-T058
(	O
dexamethasone	B-T109
3.4%	O
versus	O
prednisone	B-T109
2.9%;	O
difference	B-T080
0.5%;	O
95%	O
confidence interval	B-T081
-4.1%	O
to	O
3.1%).	O
Adverse effect	B-T080
rates	B-T081
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	B-UnknownType
.	O
A	O
single dose	B-T081
of	O
oral dexamethasone	B-T200
did	O
not	O
demonstrate	B-T052
noninferiority	B-T080
to	O
prednisone	B-T109
for	O
5	O
days	B-T079
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	B-T169
of	O
adults	B-T100
with	O
mild	B-T033
to	O
moderate	B-T033
asthma exacerbations	B-T033
.	O
Enhanced	B-T052
compliance	B-T033
and	O
convenience	B-T080
may	O
support	O
the	O
use	B-T169
of	O
dexamethasone	B-T109
regardless.	O

Malignancy	B-T191
is	O
associated with	B-T080
microcalcification	B-T046
and	O
higher AP/T ratio	B-T081
in	O
ultrasonography	B-T060
,	O
but	O
not	O
with	O
Hashimoto's thyroiditis	B-T047
in	O
histopathology	B-T059
in	O
patients	B-T101
with	O
thyroid nodules	B-T191
evaluated	O
as	O
Bethesda Category III	B-T191
(	O
AUS	B-T049
/	O
FLUS	B-T033
)	O
in	O
cytology	B-T059
The	O
predictors	B-T170
of	O
malignancy	B-T191
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B-T058
in	O
nodules	B-T191
with	O
atypia of undetermined significance	B-T049
/	O
follicular lesion of undetermined significance	B-T033
(	O
AUS	B-T049
/	O
FLUS	B-T033
).	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	B-T170
,	O
clinical	B-T170
,	O
and	O
biochemical predictors	B-T170
of	O
malignancy	B-T191
in	O
these	O
patients	B-T101
.	O
A	O
total	O
of	O
427	O
patients	B-T101
with	O
cytologically Bethesda Category III	B-T191
(	O
AUS	B-T049
/	O
FLUS	B-T033
)	O
thyroid nodules	B-T191
were	O
included	O
in	O
this	O
retrospective study	B-T062
.	O
We	O
divided	O
the	O
nodules	B-T191
into	O
two	O
subgroups	B-T098
according	O
to	O
the	O
histopathology	B-T059
as	O
benign	B-T080
and	O
malignant	B-T080
,	O
and	O
compared	O
the	O
preoperative	B-T079
ultrasonographical	B-T201
,	O
clinical	B-T201
,	O
and	O
biochemical findings	B-T033
.	O
In	O
overall,	O
427	O
patients	B-T101
with	O
449	O
AUS	B-T049
/	O
FLUS	B-T033
nodules	B-T191
who	O
had	O
undergone	O
surgery	B-T061
,	O
the	O
rate	O
of	O
malignancy	B-T191
was	O
23.4	O
%	O
(105/449).	O
When	O
evaluated	O
separately,	O
the	O
rate	O
of	O
malignancy	B-T191
was	O
25.8	O
%	O
in	O
nodules	B-T191
with	O
AUS	B-T049
(82/318)	O
and	O
17.6	O
%	O
in	O
nodules	B-T191
with	O
FLUS	B-T033
(23/131)	O
(p	O
=	O
0.061).	O
The	O
vast	O
majority	O
of	O
malignant specimens	B-T077
in	O
histopathology	B-T059
consisted	O
of	O
papillary thyroid carcinoma	B-T191
(	O
PTC	B-T191
)	O
(n	O
=	O
91,	O
86.7	O
%).	O
Preoperative	B-T079
ultrasonographic features	B-T201
of	O
105	O
malignant nodules	B-T191
in	O
histopathology	B-T059
were	O
compared	O
with	O
the	O
344	O
benign nodules	B-T191
in	O
histopathology	B-T059
.	O
Anteroposterior/Transverse (AP/T) ratio	B-T081
was	O
significantly	O
higher	O
in	O
malignant group	B-T098
compared	O
to	O
benign group	B-T098
(p	O
=	O
0.013).	O
In	O
multiple logistic analysis	B-T062
,	O
we	O
found	O
that	O
higher AP/T ratio	B-T081
and	O
microcalcification	B-T046
were	O
independently	O
associated with	B-T080
malignancy	B-T191
(p	O
<	O
0.05).	O
The	O
malignancy	B-T191
-associated	O
cut-off	O
value	O
of	O
AP/T ratio	B-T081
at	O
maximum	O
sensitivity and specificity	B-T081
was	O
≥0.81.	O
We	O
did	O
not	O
find	O
any	O
correlation	B-T080
between	O
malignancy	B-T191
and	O
Hashimoto's thyroiditis	B-T047
in	O
histopathology	B-T059
in	O
multivariate analysis	B-T081
(p	O
>	O
0.05).	O
In	O
Bethesda Category III nodules	B-T191
with	O
higher AP/T ratio	B-T081
and	O
microcalcification	B-T046
,	O
surgery	B-T061
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine-needle aspiration biopsy	B-T060
or	O
observation	B-T062
.	O

Impact	B-T080
of	O
cofactor	B-T123
-	O
binding loop	B-T087
mutations	B-T045
on	O
thermotolerance	B-T039
and	O
activity	B-T044
of	O
E. coli	B-T007
transketolase	B-T116
Improvement	B-T077
of	O
thermostability	B-T070
in	O
engineered enzymes	B-T116
can	O
allow	O
biocatalysis	B-T070
on	O
substrates	B-T167
with	O
poor	O
aqueous	B-T080
solubility	B-T080
.	O
Denaturation	B-T044
of	O
the	O
cofactor	B-T123
-	O
binding loops	B-T087
of	O
Escherichia coli	B-T007
transketolase	B-T116
(	O
TK	B-T116
)	O
was	O
previously	O
linked	O
to	O
the	O
loss	B-T081
of	O
enzyme activity	B-T044
under	O
conditions	B-T080
of	O
high	B-T080
pH	B-T081
or	O
urea	B-T109
.	O
Incubation	B-T059
at	O
temperatures	B-T081
just	O
below	O
the	O
thermal melting transition	B-T070
,	O
above	O
which	O
the	O
protein	B-T116
aggregates	B-T169
,	O
was	O
also	O
found	O
to	O
anneal	B-T169
the	O
enzyme	B-T116
to	O
give	O
an	O
increased	B-T081
specific	O
activity	B-T044
.	O
The	O
potential	O
role	B-T077
of	O
cofactor	B-T123
-	O
binding loop	B-T087
instability	B-T033
in	O
this	O
process	O
remained	O
unclear.	O
In	O
this	O
work,	O
the	O
two	O
cofactor	B-T123
-	O
binding loops	B-T087
(	O
residues 185-192	B-T087
and	O
382-392	B-T087
)	O
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	B-T086
from	O
the	O
thermostable	B-T080
Thermus thermophilus	B-T007
TK	B-T116
and	O
variants	B-T028
assessed	B-T052
for	O
their	O
impact	B-T080
on	O
both	O
thermostability	B-T070
and	O
activity	B-T052
.	O
Cofactor-binding loop 2	B-T086
variants	B-T028
had	O
detrimental effects	B-T080
on	O
specific	O
activity	B-T052
at	O
elevated	B-T080
temperatures	B-T081
,	O
whereas	O
the	O
H192P mutation	B-T045
in	O
cofactor-binding loop 1	B-T086
resulted	O
in	O
a	O
two-fold	O
improved	O
stability	B-T070
to	O
inactivation	B-T169
at	O
elevated	B-T080
temperatures	B-T081
,	O
and	O
increased	B-T081
the	O
critical onset temperature	B-T081
for	O
aggregation	B-T169
.	O
The	O
specific	O
activity	B-T052
of	O
H192P	B-T045
was	O
3-fold	O
and	O
19-fold	O
higher	B-T080
than	O
that	O
for	O
wild-type	B-T028
at	O
60°C	O
and	O
65°C	O
respectively,	O
and	O
also	O
remained	O
2.7-4	O
fold	O
higher	B-T080
after	O
re-cooling	B-T070
from	O
pre-incubations	B-T059
at	O
either	O
55°C	O
or	O
60°C	O
for	O
1h.	O
Interestingly,	O
H192P	B-T045
was	O
also	O
2-times	O
more	O
active	B-T169
than	O
wild-type	B-T028
TK	B-T116
at	O
25°C.	O
Optimal	B-T080
activity	B-T052
was	O
achieved	O
at	O
60°C	O
for	O
H192P	B-T045
compared	O
to	O
55°C	O
for	O
wild type	B-T028
.	O
These	O
results	O
show	O
that	O
cofactor-binding loop 1	B-T086
,	O
plays	O
a	O
pivotal	O
role	B-T077
in	O
partial	B-T081
denaturation	B-T044
and	O
aggregation	B-T169
at	O
elevated	B-T080
temperatures	B-T081
.	O
Furthermore,	O
a	O
single rigidifying mutation	B-T045
within	O
this	O
loop	B-T086
can	O
significantly	O
improve	O
the	O
enzyme specific activity	B-T044
,	O
as	O
well	O
as	O
the	O
stability	B-T070
to	O
thermal	B-T070
denaturation	B-T044
and	O
aggregation	B-T169
,	O
to	O
give	O
an	O
increased	B-T081
temperature	B-T081
optimum	B-T080
for	O
activity	B-T044
.	O

Safety	B-T062
of	O
transradial diagnostic cardiac catheterization	B-T060
in	O
patients	B-T101
under	O
oral	B-T082
anticoagulant therapy	B-T061
Cardiac catheterization	B-T058
in	O
anticoagulated	B-UnknownType
patients	B-T101
is	O
usually	O
performed	B-T169
after	O
the	O
anticoagulation	B-T061
has	O
been	O
withdrawn	B-T061
,	O
at	O
least	O
in	O
the	O
previous	O
48h,	O
and	O
sometimes	O
bridging therapy with heparin	B-T061
is	O
used.	O
A	O
prospective	O
observational study	B-T062
including	O
489	O
patients	B-T101
undergoing	O
transradial catheterization	B-T058
was	O
conducted.	O
A	O
total	O
of	O
140	O
patients	B-T101
were	O
under	O
acenocoumarol	B-T109
(	O
group A	B-T185
)	O
and	O
they	O
were	O
compared	B-T052
with	O
the	O
remainder	B-T080
(	O
group B	B-T185
)	O
for	O
complications	B-T046
after	O
the	O
procedure	B-T058
(	O
bleeding	B-T046
and	O
vascular access complications	B-T046
).	O
Patients	B-T101
in	O
group A	B-T185
were	O
older	B-T098
(74±12	O
years	O
vs.	O
68±17	O
years,	O
p<0.01)	O
and	O
the	O
main	O
indication	B-T078
for	O
anticoagulation	B-T061
was	O
atrial fibrillation	B-T047
(58.6%).	O
No	B-T033
complications	B-T046
occurred	O
during	O
the	O
procedures	B-T058
.	O
There	O
were	O
no	B-T033
acute bleedings	B-T046
just	O
after	B-T079
the	O
bandage	B-T074
removal	B-T052
.	O
During	O
the	O
first	O
24h,	O
only	O
3	O
(2.1%)	O
radial occlusions	B-T046
in	O
group A	B-T185
and	O
2	O
(0.6%)	O
in	O
group B	B-T185
(p=0.14)	O
were	O
recorded	B-T080
.	O
Hematomas	B-T046
between	O
5	O
and	O
10cm	O
appeared	O
in	O
5%	O
of	O
the	O
group A	B-T185
vs.	O
4.6%	O
in	O
group B	B-T185
.	O
During	O
the	O
1-month	B-T079
follow-up	B-T058
period	B-T079
,	O
one	O
more	O
radial occlusion	B-T046
in	O
each	O
group	B-T078
was	O
recorded	B-T080
and	O
there	O
were	O
4	O
(1.1%)	O
additional	O
mild	B-T080
hematomas	B-T046
in	O
group B	B-T185
and	O
none	O
in	O
group A	B-T185
(p=0.48).	O
Performing	B-T169
a	O
transradial diagnostic cardiac catheterization	B-T060
without	B-T080
removal	B-T052
of	O
the	O
oral	B-T082
chronic anticoagulation	B-UnknownType
appears	O
safe	B-T033
in	O
patients	B-T101
under	O
acenocumarol	B-T109
therapy	B-T061
.	O

Does	O
infrared	B-T074
visualization	B-T169
improve	O
selection	B-T052
of	O
venipuncture	B-T060
sites	B-T082
for	O
indwelling	B-T169
needle	B-T074
at	O
the	O
forearm	B-T023
in	O
second-year	O
nursing students	B-T097
?	O
To	O
evaluate	O
the	O
effectiveness	B-T080
of	O
a	O
vein visualization display system	B-T074
using	O
near-infrared light	B-T070
("	O
Vein Display	B-T074
")	O
for	O
the	O
safe	O
and	O
proper	O
selection	B-T052
of	O
venipuncture	B-T060
sites	B-T082
for	O
indwelling	B-T169
needle	B-T074
placement	O
in	O
the	O
forearm	B-T023
.	O
Ten	O
second	O
year	O
nursing students	B-T097
were	O
recruited	O
to	O
apply	O
an	O
indwelling	B-T169
needle	B-T074
line	O
with	O
and	O
without	O
Vein	B-T023
Display	B-T169
.	O
Another	O
ten	O
participants	B-T098
were	O
recruited	O
from	O
various	O
faculty	B-T097
to	O
serve	O
as	O
patients	B-T101
.	O
The	O
quality	O
of	O
the	O
venipuncture procedure	B-T060
at	O
various	O
selected	O
sites	B-T082
was	O
evaluated	O
according	O
to	O
a	O
scale	B-T170
developed	O
by	O
the	O
authors	B-T097
.	O
Time	B-T079
,	O
scores	B-T081
and	O
patterns	B-T080
of	O
puncture	B-T060
-	O
site	B-T082
selection	B-T052
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods:	O
[1]	O
attempt	O
1	O
(	O
tourniquet	B-T074
only),	O
[2]	O
attempt	O
2	O
(	O
Vein Display	B-T074
only)	O
and	O
[3]	O
attempt	O
3	O
(both).	O
To	O
validate	O
the	O
effectiveness	B-T080
of	O
Vein	B-T023
Display	B-T169
,	O
52	O
trials	O
were	O
conducted	O
in	O
total.	O
We	O
found	O
that	O
venipuncture	B-T060
site	B-T082
selection	B-T052
time	O
was	O
significantly	O
improved	O
with	O
the	O
Vein Display	B-T074
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	B-T169
venipuncture	B-T060
sites	B-T082
.	O
Overall,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-T060
quality	B-T080
,	O
as	O
determined	O
by	O
our	O
scale	B-T170
.	O
These	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
Vein Display	B-T074
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical skills	B-T080
,	O
such	O
as	O
venipuncture	B-T060
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	B-T098
patients	B-T101
.	O

Elective	B-T061
Nephron Sparing Surgery	B-T061
Decreases	B-T081
Other Cause Mortality	B-T033
Relative	B-T080
to	O
Radical Nephrectomy	B-T061
Only	O
in	O
Specific	B-T080
Subgroups	B-T185
of	O
Patients	B-T101
with	O
Renal Cell Carcinoma	B-T191
There	O
is	O
no	O
consensus	B-T054
regarding	O
a	O
protective effect	B-T033
on	O
mortality	B-T081
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-T191
in	O
patients	B-T101
treated with	B-T061
elective	B-T061
nephron sparing surgery	B-T061
relative	B-T080
to	O
their	O
radical nephrectomy	B-T061
counterparts.	O
We	O
test	B-T169
whether	O
the	O
protective effect	B-T033
of	O
nephron sparing surgery	B-T061
relative	B-T080
to	O
radical nephrectomy	B-T061
is	O
universal	B-T080
or	O
present	O
in	O
specific	B-T080
subgroups	B-T185
of	O
patients	B-T101
.	O
A	O
collaborative	B-T081
database	B-T170
of	O
5	O
institutions	B-T078
was	O
queried	B-T170
to	O
evaluate	B-T058
1,783	O
patients	B-T101
without	O
chronic kidney disease	B-T047
diagnosed	B-T033
with	O
a	O
clinical	B-T080
T1 renal mass	B-T191
that	O
was	O
treated with	B-T061
nephron sparing surgery	B-T061
or	O
radical nephrectomy	B-T061
.	O
Multivariable Cox regression analysis	B-T170
was	O
done	O
to	O
assess	B-T058
the	O
impact	B-T080
of	O
surgery	B-T061
type	O
(	O
nephron sparing surgery	B-T061
vs	O
radical nephrectomy	B-T061
)	O
on	O
other cause mortality	B-T033
after	O
adjustment	O
for	O
patient	B-T101
and	O
cancer	B-T191
characteristics	B-T080
.	O
Interaction	B-T169
terms	O
were	O
used	O
to	O
test	B-T169
the	O
hypothesis	O
that	O
the	O
impact	B-T080
of	O
surgery	B-T061
type	O
varies	O
according	O
to	O
specific	B-T080
subcohorts	B-T098
of	O
patients	B-T101
.	O
Ten-year	B-T079
other cause mortality	B-T033
-free	O
survival rates	B-T081
were	O
90%	O
and	O
88%	O
after	O
nephron sparing surgery	B-T061
and	O
radical nephrectomy	B-T061
,	O
respectively.	O
In	O
the	O
overall	B-T080
population	B-T098
radical nephrectomy	B-T061
was	O
not	O
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
of	O
other cause mortality	B-T033
on	O
multivariable analysis	B-T081
compared	O
to	O
nephron sparing surgery	B-T061
(	O
HR	B-T081
0.91,	O
95%	O
CI	B-T081
0.6-1.38,	O
p	O
=	O
0.6).	O
However,	O
radical nephrectomy	B-T061
increased	B-T081
the	O
risk	B-T078
of	O
other cause mortality	B-T033
according	O
to	O
the	O
increasing	B-T081
baseline	B-T081
Charlson comorbidity index	B-T170
(	O
interaction	B-T169
test	B-T169
p	O
=	O
0.0008).	O
For	O
example,	O
in	O
a	O
patient	B-T101
with	O
a	O
Charlson comorbidity index	B-T170
of	O
4	O
the	O
probability	B-T081
of	O
10-year	B-T079
other cause mortality	B-T033
-free	O
survival	B-T052
was	O
86%	O
after	O
nephron sparing surgery	B-T061
and	O
60%	O
after	O
radical nephrectomy	B-T061
.	O
Elective	B-T061
nephron sparing surgery	B-T061
does	O
not	O
improve	B-T033
other	O
cause	O
survival	B-T052
relative	B-T080
to	O
radical nephrectomy	B-T061
consistently	O
in	O
all	O
patients	B-T101
with	O
kidney cancer	B-T191
.	O
Patients	B-T101
who	O
are	O
more	O
ill	B-T184
with	O
relevant	B-T080
comorbidities	B-T078
are	O
those	O
who	O
benefit	B-T081
the	O
most	O
from	O
nephron sparing surgery	B-T061
in	O
terms	O
of	O
other cause mortality	B-T033
.	O

Prospective	O
study	O
of	O
dietary	B-T168
Non Enzymatic Antioxidant Capacity	B-T059
on	O
the	O
risk	B-T078
of	O
hip fracture	B-T037
in	O
the	O
elderly	B-T098
Dietary antioxidants	B-T168
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone loss	B-T047
and	O
associated	O
fractures	B-T037
by	O
reducing	O
levels	O
of	O
oxidative stress	B-T049
.	O
We	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	B-T168
Non Enzymatic Antioxidant Capacity	B-T059
(	O
NEAC	B-T059
)	O
and	O
the	O
risk	B-T078
of	O
hip fracture	B-T037
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	B-T055
.	O
In	O
the	O
Swedish National March Cohort	B-T098
13,409	O
men	B-T098
and	O
women	B-T098
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	B-T191
,	O
cardiovascular disease	B-T047
or	O
hip fracture	B-T037
,	O
were	O
followed	O
through	O
record-linkages	B-T062
from	O
1997	O
through	O
2010.	O
NEAC	B-T059
was	O
assessed	O
by	O
a	O
validated	O
food frequency questionnaire	B-T170
collected	O
at	O
baseline	B-T081
.	O
We	O
categorized	O
the	O
distribution	O
of	O
NEAC	B-T059
into	O
sex	B-T032
-	O
specific	B-T080
quartiles	B-T080
and	O
used	O
multivariable adjusted Cox proportional hazards regression models	B-T081
to	O
estimate	O
hazard ratios	B-T081
(	O
HRs	B-T081
)	O
with	O
95%	O
confidence intervals	B-T081
(95%	O
CI	B-T081
).	O
During	O
a	O
mean	O
follow-up	B-T058
time	B-T079
of	O
12.4years,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip fracture	B-T037
.	O
Subjects	O
in	O
the	O
highest	O
quartile	B-T080
of	O
dietary	B-T168
NEAC	B-T059
had	O
a	O
39%	O
lower risk	B-T033
of	O
incident	O
hip fracture	B-T037
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	B-T080
(	O
HR	B-T081
:	O
0.61;	O
95%	O
CI	B-T081
:	O
0.44-0.85).	O
The	O
association	O
was	O
non-linear	O
(p	O
for	O
non-linearity:	O
0.004)	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	B-T080
and	O
no	O
further	O
risk reduction	B-T055
at	O
higher	O
levels	O
of	O
dietary	B-T168
NEAC	B-T059
.	O
Due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	B-T168
NEAC	B-T059
and	O
smoking	B-T055
on	O
a	O
multiplicative	B-T081
or	O
additive scale	B-T081
.	O
Higher	O
dietary	O
NEAC	B-T059
intake	O
is	O
associated	O
with	O
lower	O
risk	B-T078
of	O
hip fracture	B-T037
in	O
the	O
elderly.	O

Function	B-T041
and	O
clinical	B-T080
meaningfulness	B-T080
of	O
treatments	B-T061
for	O
mild	B-T080
Alzheimer's disease	B-T047
Effectiveness	B-T080
of	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
)	O
treatments	B-T061
is	O
commonly	O
evaluated	O
with	O
coprimary outcomes	B-T169
;	O
cognition	B-T041
with	O
function	B-T041
to	O
ensure	O
clinical	B-T080
meaningfulness	B-T080
of	O
a	O
cognitive	B-T041
effect	B-T080
.	O
We	O
reviewed	B-T080
the	O
literature	B-T170
for	O
functional	B-T041
outcomes	B-T169
in	O
mild	B-T080
AD	B-T047
or	O
mild cognitive impairment	B-T048
(	O
MCI	B-T048
)	O
patients	B-T101
(distinct	O
from	O
combined	O
mild-moderate	B-T080
/	O
severe	B-T080
AD	B-T047
)	O
treated with	B-T061
approved	O
AD	B-T047
drugs	B-T121
.	O
Cognitive	B-T061
and	O
functional	B-T041
treatment	B-T061
differences	O
in	O
mild	B-T080
AD	B-T047
patients	B-T101
in	O
solanezumab	B-T116
EXPEDITION	B-T052
/	O
EXPEDITION2	B-T052
studies	B-T062
were	O
compared	B-T052
across	O
time	B-T079
.	O
Seven	O
publications	B-T073
provided	O
MCI	B-T048
/	O
mild	B-T080
AD	B-T047
functional	B-T041
outcomes	B-T169
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	B-T041
treatment effect	B-T033
.	O
Secondary analyses	B-UnknownType
of	O
EXPEDITION	B-T052
studies	B-T062
suggested	O
a	O
smaller	O
functional	B-T041
effect	B-T080
of	O
solanezumab	B-T116
relative	O
to	O
cognition	B-T041
.	O
An	O
increasing	B-T169
effect	B-T080
of	O
solanezumab	B-T116
over	O
18	O
months	B-T079
was	O
shown	O
for	O
cognition	B-T041
and	O
function	B-T041
.	O
Function	B-T041
as	O
the	O
sole	O
measure	B-T081
to	O
demonstrate	O
clinical	B-T080
meaningfulness	B-T080
of	O
cognitive	B-T041
effects	B-T080
in	O
mild	B-T080
AD	B-T047
may	O
have	O
limitations	B-T169
.	O
For	O
disease	B-T047
-	O
modifying	B-T169
treatments	B-T061
,	O
point	O
differences	O
on	O
cognitive	B-T041
and	O
functional	B-T041
scales	B-T170
should	O
be	O
qualified	O
with	O
duration of treatment	B-T079
.	O

In	O
Search	O
of	O
the	O
E. coli	B-T007
Compounds	B-T123
that	O
Change	O
the	O
Antibiotic	B-T195
Production	B-T169
Pattern	O
of	O
Streptomyces coelicolor	B-T007
During	O
Inter-species Interaction	B-T054
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	B-T169
the	O
interaction	B-T169
between	O
E.coli	B-T007
and	O
Streptomyces coelicolor A3 (2)	B-T007
for	O
the	O
increased	B-T081
production	B-T169
of	O
undecylprodigiosin	B-T109
and	O
identify	O
the	O
E. coli	B-T007
actives	B-T169
mediating	B-T054
this	O
inter-species interaction	B-T054
.	O
The	O
antibiotics	B-T195
of	O
interest	O
were	O
the	O
red-pigmented undecylprodigiosin	B-T109
and	O
blue-pigmented	B-T080
actinorhodin	B-T109
.	O
Pure	O
cultures	B-T059
of	O
S. coelicolor	B-T007
in	O
a	O
defined	O
medium	B-T130
produced	O
higher	O
concentrations	B-T081
of	O
actinorhodin	B-T109
compared	B-T052
to	O
those	O
of	O
undecylprodigiosin	B-T109
.	O
The	O
latter	O
however,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	B-T040
and	O
antitumor properties	B-T042
.	O
As	O
a	O
strategy	O
to	O
increase	B-T169
undecylprodigiosin	B-T109
production	B-T169
,	O
we	O
added	O
separately,	O
live cells	B-T025
and	O
heat-killed	B-T067
cells	B-T025
of	O
E. coli C600	B-T007
,	O
and	O
the	O
cell-free supernatant	B-T031
of	O
E. coli	B-T007
culture	B-T059
to	O
S. coelicolor	B-T007
cultures in shake flasks	B-T059
.	O
The	O
interaction	B-T169
with	O
live cells	B-T025
of	O
E. coli	B-T007
altered	O
the	O
antibiotic	B-T195
production	B-T169
pattern	O
and	O
undecylprodigiosin	B-T109
production	B-T169
was	O
enhanced	B-T052
by	O
3.5-fold	O
compared	O
to	O
the	O
pure cultures	B-T059
of	O
S. coelicolor	B-T007
and	O
actinorhodin	B-T109
decreased	B-T081
by	O
15-fold.	O
The	O
heat-killed	B-T067
cells	B-T025
of	O
E. coli	B-T007
however,	O
had	O
no effect	B-T080
on	O
antibiotic	B-T195
production	B-T169
.	O
In	O
all	O
cases,	O
growth	B-T040
and	O
glucose consumption	B-T033
of	O
S. coelicolor	B-T007
remained	O
almost	O
the	O
same	B-T080
as	O
those	O
observed	B-T169
in	O
the	O
pure culture	B-T059
indicating	O
that	O
the	O
changes	B-T169
in	O
antibiotic	B-T195
production	B-T169
were	O
not	O
due	O
to	O
nutritional	B-T040
stress	B-T033
.	O
Results	B-T169
with	O
cell-free supernatant	B-T031
of	O
E. coli	B-T007
culture	B-T059
indicated	O
that	O
the	O
interaction	B-T169
between	O
S. coelicolor	B-T007
and	O
E. coli	B-T007
was	O
mediated	B-T054
via	O
diffusible molecule(s)	B-T123
.	O
Using	O
a	O
set	O
of	O
extraction procedures	B-T059
and	O
agar-well diffusion bioassays	B-T059
,	O
we	O
isolated	B-T169
and	O
preliminarily	O
identified	B-T080
a	O
class of compounds	B-T123
.	O
For	O
the	O
preliminary	O
verification	B-T169
,	O
we	O
added	O
the	O
compound	B-T123
which	O
was	O
the	O
common	O
chemical structural moiety	B-T104
in	O
this	O
class of compounds	B-T123
to	O
the	O
pure	O
S. coelicolor	B-T007
cultures	B-T059
.	O
We	O
observed	O
similar	O
effects	B-T080
on	O
antibiotic	B-T195
production	B-T169
as	O
with	O
the	O
live	O
E. coli	B-T007
cells	B-T025
and	O
their	O
supernatant	B-T031
indicating	O
that	O
this	O
class of compounds	B-T123
secreted	B-T043
by	O
E. coli	B-T007
indeed	O
could	O
act	O
as	O
actives	B-T169
during	O
interspecies interaction	B-T054
and	O
increase	B-T169
the	O
production	B-T169
of	O
undecylprodigiosin	B-T109
.	O

Group III/IV muscle	B-T024
afferents	B-T025
limit	B-T169
the	O
intramuscular	B-T082
metabolic	B-T169
perturbation	B-T169
during	O
whole body	B-T017
exercise	B-T056
in	O
humans	B-T016
The	O
purpose	B-T169
of	O
this	O
study	B-T062
was	O
to	O
determine	B-T059
the	O
role	B-T077
of	O
group III/IV muscle	B-T024
afferents	B-T025
in	O
limiting	B-T169
the	O
endurance	B-T033
exercise	B-T056
-	O
induced	B-T169
metabolic	B-T169
perturbation	B-T169
assayed	B-T059
in	O
muscle	B-T024
biopsy samples	B-T024
taken	O
from	O
locomotor	B-T040
muscle	B-T024
.	O
Lumbar	B-T029
intrathecal	B-T030
fentanyl	B-T109
was	O
used	O
to	O
attenuate	B-T052
the	O
central	B-T082
projection	B-T082
of	O
μ-opioid receptor	B-T116
-	O
sensitive	B-T169
locomotor	B-T040
muscle	B-T024
afferents	B-T025
during	O
a	O
5	O
km	O
cycling	B-T079
time	B-T079
trial	B-T062
.	O
The	O
findings	B-T033
suggest	O
that	O
the	O
central	B-T082
projection	B-T082
of	O
group III/IV muscle	B-T024
afferent	B-T025
feedback	B-T039
constrains	B-T077
voluntary	B-T055
neural	B-T169
'	O
drive	B-T041
'	O
to	O
working	B-T169
locomotor	B-T040
muscle	B-T024
and	O
limits	B-T169
the	O
exercise	B-T056
-	O
induced	B-T169
intramuscular	B-T082
metabolic	B-T169
perturbation	B-T169
.	O
Therefore,	O
the	O
CNS	B-T022
might	O
regulate	B-T038
the	O
degree	B-T081
of	O
metabolic	B-T169
perturbation	B-T169
within	O
locomotor	B-T040
muscle	B-T024
and	O
thereby	O
limit	B-T169
peripheral	B-T082
fatigue	B-T184
.	O
It	O
appears	B-T080
that	O
the	O
group III/IV muscle	B-T024
afferents	B-T025
are	O
an	O
important	B-T080
neural	B-T169
link	B-T030
in	O
this	O
regulatory	B-T038
mechanism	B-T169
,	O
which	O
probably	B-T078
serves	O
to	O
protect	B-T033
locomotor	B-T040
muscle	B-T024
from	O
the	O
potentially	B-T080
severe	B-T080
functional impairment	B-T033
as	O
a	O
consequence	B-T169
of	O
severe	B-T080
intramuscular	B-T082
metabolic	B-T169
disturbance	B-T080
.	O
To	O
investigate	B-T169
the	O
role	B-T077
of	O
metabo	B-T040
-	O
and	O
mechanosensitive	B-T080
group III/IV muscle	B-T024
afferents	B-T025
in	O
limiting	B-T169
the	O
intramuscular	B-T082
metabolic	B-T169
perturbation	B-T169
during	O
whole body	B-T017
endurance	B-T033
exercise	B-T056
,	O
eight	O
subjects	B-T096
performed	B-T169
5	O
km	O
cycling	B-T079
time	B-T079
trials	B-T062
under control conditions	B-T033
(	O
CTRL	B-T033
)	O
and	O
with	O
lumbar	B-T029
intrathecal	B-T030
fentanyl	B-T109
impairing	B-T169
lower limb	B-T023
muscle	B-T024
afferent	B-T025
feedback	B-T039
(	O
FENT	B-T039
).	O
Vastus lateralis	B-T023
muscle	B-T024
biopsies	B-T024
were	O
obtained	B-T169
before	B-T079
and	O
immediately	B-T079
after	B-T079
exercise	B-T056
.	O
Motoneuronal	B-T025
output was estimated	B-T060
through	O
vastus lateralis surface	B-T023
electromyography	B-T060
(	O
EMG	B-T060
).	O
Exercise	B-T056
-	O
induced	B-T169
changes	B-T169
in	O
intramuscular	B-T082
metabolites	B-T123
were	O
determine	B-T059
d	O
using	O
liquid	B-T167
and	O
gas chromatography-mass spectrometry	B-T059
.	O
Quadriceps	B-T023
fatigue	B-T184
was	O
quantified	B-T081
by	O
pre	B-T079
-	O
to	O
post	B-T079
-	O
exercise	B-T056
changes	B-T169
in	O
potentiated quadriceps twitch torque	B-T067
(	O
ΔQTsingle	B-T067
)	O
evoked	B-T080
by	O
electrical	B-T169
femoral nerve	B-T023
stimulation	B-T061
.	O
Although	O
motoneuronal	B-T025
output	B-T052
was	O
21	O
±	O
12%	O
higher	B-T080
during	O
FENT	B-T039
compared	B-T052
to	O
CTRL	B-T033
(P	O
<	O
0.05),	O
time	B-T079
to	O
complete	B-T080
the	O
time	B-T079
trial	B-T062
was	O
similar	B-T080
(∼8.8	O
min).	O
Compared	B-T052
to	O
CTRL	B-T033
,	O
power output	B-T070
during	O
FENT	B-T039
was	O
10	O
±	O
4%	O
higher	B-T080
in	O
the	O
first half	B-T033
of	O
the	O
time	B-T079
trial	B-T062
,	O
but	O
11	O
±	O
5%	O
lower	B-T080
in	O
the	O
second half	B-T033
(both	O
P	O
<	O
0.01).	O
The	O
exercise	B-T056
-	O
induced	B-T169
increase	B-T169
in	O
intramuscular	B-T082
inorganic phosphate	B-T121
,	O
H(+)	B-T196
,	O
adenosine diphosphate	B-T114
,	O
lactate	B-T109
and	O
phosphocreatine	B-T116
depletion	B-T169
was	O
55	O
±	O
30,	O
62	O
±	O
18,	O
129	O
±	O
63,	O
47	O
±	O
14	O
(P	O
<	O
0.001)	O
and	O
27	O
±	O
14%	O
(P	O
<	O
0.01)	O
greater	B-T081
in	O
FENT	B-T039
than	O
CTRL	B-T033
.	O
ΔQTsingle	B-T067
was	O
greater	B-T081
following	O
FENT	B-T039
than	O
CTRL	B-T033
(-52	O
±	O
2	O
vs	O
-31	O
±	O
1%,	O
P	O
<	O
0.001)	O
and	O
this	O
difference	B-T081
was	O
positively	B-T033
correlated	B-T080
with	O
the	O
difference	B-T081
in	O
inorganic phosphate	B-T121
(r(2)	O
=	O
0.79;	O
P	O
<	O
0.01)	O
and	O
H(+)	O
(r(2)	O
=	O
0.92;	O
P	O
<	O
0.01).	O
In	O
conclusion	B-T078
,	O
during	O
whole body	B-T017
exercise	B-T056
,	O
group III/IV muscle	B-T024
afferents	B-T025
provide	B-T052
feedback	B-T039
to	O
the	O
CNS	B-T022
which,	O
in	O
turn,	O
constrains	B-T077
motoneuronal	B-T025
output	B-T052
to	O
the	O
active	B-T169
skeletal muscle	B-T024
.	O
This	O
regulatory	B-T038
mechanism	B-T169
limits	B-T169
the	O
exercise	B-T056
-	O
induced	B-T169
intramuscular	B-T082
metabolic	B-T169
perturbation	B-T169
,	O
preventing	O
an	O
abnormal homeostatic	B-T033
challenge	B-T058
and	O
excessive	B-T080
peripheral	B-T082
fatigue	B-T184
.	O

Mitochondrial	B-T026
Ultrastructure	B-T025
and	O
Glucose Signaling Pathways	B-T044
Attributed	O
to	O
the	O
Kv1.3 Ion Channel	B-T116
Gene-targeted	B-T063
deletion	B-T045
of	O
the	O
potassium channel Kv1.3	B-T116
(	O
Kv1.3(-∕-)) results i	B-T034
n	O
"S	O
uper-smeller" mice	B-T015
with	O
a	O
se	O
nsory p	B-T080
h	O
enotype t	B-T032
hat	O
includes	O
an	O
increased	B-T081
olfactory	B-T040
ability	B-T032
linked	O
to	O
changes	O
in	O
olfactory	B-T040
circuitry	B-UnknownType
,	O
increased	B-T081
abundance	B-T080
of	O
olfactory cilia	B-T026
,	O
and	O
increased	B-T081
expression	B-T045
of	O
odorant receptors	B-T116
and	O
the	O
G-protein, Golf	B-T116
.	O
Kv1.3(-∕-) mice a	B-T015
lso	O
have	O
a	O
metabolic p	B-T169
h	O
enotype i	B-T032
ncluding	O
lo	O
wer b	B-T081
o	O
dy weight a	B-T032
nd	O
de	O
creased a	B-T081
d	O
iposity,	B-T032
in	O
creased total energy expenditure	B-T033
(	O
TEE	B-T033
),	O
increased	B-T081
locomotor activity	B-T040
,	O
and	O
resistance	B-T041
to	O
both	O
diet	B-T168
-	O
and	O
genetic-induced	B-T045
obesity	B-T047
.	O
We	O
explored	O
two	O
cellular aspects	B-T080
to	O
elucidate	O
the	O
mechanism	B-T169
by	O
which	O
loss	B-T081
of	O
Kv1.3 channel	B-T116
in	O
the	O
olfactory bulb	B-T023
(	O
OB	B-T023
)	O
may	O
enhance	O
glucose utilization	B-T044
and	O
metabolic rate	B-T039
.	O
First,	O
using	O
in situ hybridization	B-T063
we	O
find	O
that	O
Kv1.3	B-T116
and	O
the	O
insulin	B-T116
-	O
dependent	B-T080
glucose transporter type 4	B-T116
(	O
GLUT4	B-T116
)	O
are	O
co-localized	O
to	O
the	O
mitral	B-T023
cell layer	B-T025
of	O
the	O
OB	B-T023
.	O
Disruption	B-T169
of	O
Kv1.3	B-T116
conduction	B-T070
via	O
construction	O
of	O
a	O
pore mutation	B-T045
(	O
W386F Kv1.3	B-T045
)	O
was	O
sufficient	O
to	O
independently	O
translocate	B-T043
GLUT4	B-T116
to	O
the	O
plasma membrane	B-T026
in	O
HEK 293 cells	B-T025
.	O
Because	O
olfactory sensory perception	B-T040
and	O
the	O
maintenance	B-T052
of	O
action potential (AP)	B-T043
firing	O
frequency	O
by	O
mitral	B-T023
cells	B-T025
of	O
the	O
OB	B-T023
is	O
highly	O
energy	O
demanding	O
and	O
Kv1.3	B-T116
is	O
also	O
expressed	O
in	O
mitochondria	B-T026
,	O
we	O
next	O
explored	O
the	O
structure	O
of	O
this	O
organelle	B-T026
in	O
mitral	B-T023
cells	B-T025
.	O
We	O
challenged	O
wildtype	B-T015
(	O
WT	B-T015
)	O
and	O
Kv1.3(-∕-) male mice	B-T015
with	O
a	O
m	O
oderately high-fat diet (	B-T061
M	O
HF,	B-T061
31.8	O
%	O
kcal	O
fat)	O
for	O
4	O
months	B-T079
and	O
then	O
examined	O
OB	B-T023
ultrastructure	B-T025
using	O
transmission electron microscopy	B-T059
.	O
In	O
WT mice	B-T015
,	O
mitochondria	B-T026
were	O
significantly	O
enlarged	B-T080
following	O
diet-induced obesity	B-T047
(	O
DIO	B-T047
)	O
and	O
there	O
were	O
fewer	O
mitochondria	B-T026
,	O
likely	O
due	O
to	O
mitophagy	B-T043
.	O
Interestingly,	O
mitochondria	B-T026
were	O
significantly	O
smaller	B-T080
in	O
Kv1.3(-∕-) mice c	B-T015
ompared	O
with	O
that	O
of	O
W	O
T mice.	B-T015
Similar	O
to	O
their	O
m	O
etabolic r	B-T169
esistance	O
to	O
D	O
IO,	B-T047
the	O
K	O
v1.3(-∕-) mice ha	B-T015
d	O
unchanged	O
mit	O
ochondria in	B-T026
terms	O
of	O
cros	O
s sectional	B-T082
area	B-T082
and	O
abundance	B-T080
following	O
a	O
challenge	O
with	O
modified diet	B-T061
.	O
We	O
are	O
very	O
interested	O
to	O
understand	O
how	O
targeted	O
disruption	B-T169
of	O
the	O
Kv1.3 channel	B-T116
in	O
the	O
OB	B-T023
can	O
modify	O
TEE	B-T033
.	O
Our	O
study	O
demonstrates	O
that	O
Kv1.3	B-T116
regulates	O
mitochondrial structure	B-T026
and	O
alters	O
glucose utilization	B-T044
;	O
two	O
important	O
metabolic	B-T169
changes	O
that	O
could	O
drive	O
whole	O
system	O
changes	O
in	O
metabolism	B-T040
initiated	O
at	O
the	O
OB	B-T023
.	O

The	O
effects of	B-T080
paternal	B-T080
high-fat diet	B-T168
exposure	B-T080
on	O
offspring	B-T099
metabolism	B-T040
with	O
epigenetic changes	B-T045
in	O
the	O
mouse	O
adiponectin	B-T028
and	O
leptin	B-T028
gene promoters	B-T028
Recent	O
studies	B-T062
have	O
demonstrated	O
that	O
epigenetic changes	B-T045
resulting	O
from	O
malnutrition	B-T047
might	O
play	O
important	O
roles	B-T077
in	O
transgenerational links	B-T102
with	O
metabolic diseases	B-T047
.	O
Previously,	O
we	O
observed	B-T169
that	O
exposure	B-T080
to	O
a	O
high-fat diet	B-T168
(	O
HFD	B-T168
)	O
in utero	B-T100
caused	B-T169
a	O
metabolic	B-T169
syndrome	B-T047
-like	O
phenomenon	B-T067
through	B-T169
epigenetic modifications	B-T045
of	O
the	O
adiponectin	B-T028
and	O
leptin genes	B-T028
that	O
persisted	O
for	O
multiple	B-T081
generations	B-T079
.	O
Recent	O
etiological	B-T169
studies	B-T062
indicated	B-T033
that	O
paternal	B-T080
BMI	B-T201
had	O
effects	B-T080
on	O
offspring	B-T099
BMI	B-T201
that	O
were	O
independent of	B-T169
but	O
additive	B-T080
to	O
maternal	B-T033
BMI	B-T201
effects	B-T080
.	O
Thus,	O
we	O
examined	O
whether	O
paternal	B-T080
HFD	B-T168
-	O
induced	B-T169
obesity	B-T047
affected	B-T080
the	O
metabolic	B-T169
status	B-T080
of	O
offspring	B-T099
through	B-T169
epigenetic changes	B-T045
in	O
the	O
adiponectin	B-T028
and	O
leptin genes	B-T028
.	O
Additionally,	O
we	O
investigated	B-T169
whether	O
a	O
normal diet	B-T056
during	B-T079
subsequent generations	B-T078
abolished	B-T052
the	O
epigenetic changes	B-T045
associated with	B-T080
paternal	B-T080
HFD	B-T168
exposure	B-T080
before	B-T079
conception	B-T040
.	O
We	O
observed	B-T169
the	O
effects of	B-T080
paternal	B-T080
HFD	B-T168
exposure	B-T080
before	B-T079
conception	B-T040
over	O
multiple	B-T081
generations	B-T079
on	O
offspring	B-T099
metabolic	B-T169
traits	B-T032
,	O
including	B-T169
weight	B-T033
and	O
fat	B-T109
gain	B-T081
,	O
glucose intolerance	B-T047
,	O
hypertriglyceridemia	B-T047
,	O
abnormal adipocytokine	B-T116
levels	B-T080
,	O
hypertension	B-T047
,	O
and	O
adiponectin	B-T028
and	O
leptin gene	B-T028
expression	B-T045
and	O
epigenetic changes	B-T045
.	O
Normal diet	B-T056
consumption	O
by	O
male	O
offspring	B-T099
during	O
the	O
subsequent	O
generation	O
following	O
paternal	B-T080
HFD	B-T168
exposure	B-T080
diminished	B-T081
whereas	O
consumption	B-T052
for	O
two	O
generations	B-T079
completely	O
abolished	B-T052
the	O
effect	B-T080
of	O
paternal	B-T080
HFD	B-T168
exposure	B-T080
on	O
metabolic	B-T169
traits	B-T032
and	O
adipocytokine	B-T116
promoter	O
epigenetic changes	B-T045
in	O
the	O
offspring	B-T099
.	O
The	O
effects of	B-T080
paternal	B-T080
HFD	B-T168
exposure	B-T080
on	O
offspring	B-T099
were	O
relatively	O
weaker	B-T080
than	O
those	O
following	B-T079
HFD	B-T168
exposure	B-T080
in utero	B-T100
.	O
However,	O
paternal	B-T080
HFD	B-T168
exposure	B-T080
had	O
an	O
additive	B-T080
metabolic	B-T169
effect	B-T080
for	O
two	O
generations	B-T079
,	O
suggesting	O
that	O
both	O
paternal	B-T080
and	O
maternal	B-T033
nutrition	B-T040
might	O
affect	B-T080
offspring	B-T099
metabolism	B-T040
through	B-T169
epigenetic modifications	B-T045
of	O
adipocytokine genes	B-T028
for	O
multiple	B-T081
generations	B-T079
.	O

Study	B-T059
of	O
the	O
Microfocus	B-T082
X-Ray Tube	B-T074
Based	O
on	O
a	O
Point-Like Target	B-T169
Used	O
for	O
Micro-Computed Tomography	B-T060
For	O
a	O
micro-Computed Tomography (Micro-CT) system	B-T060
,	O
the	O
microfocus	B-T082
X-ray tube	B-T074
is	O
an	O
essential	B-T080
component	O
because	O
the	O
spatial	B-T082
resolution	B-T081
of	O
CT	B-T060
images	B-T170
,	O
in	O
theory	B-T078
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	B-T082
and	O
stability	B-T080
of	O
the	O
X-ray	B-T060
focal spot	B-T082
of	O
the	O
microfocus	B-T082
X-ray tube	B-T074
.	O
However,	O
many	O
factors	B-T169
,	O
including	O
voltage	B-T081
fluctuations	B-T079
,	O
mechanical	B-T070
vibrations	B-T070
,	O
and	O
temperature changes	B-T080
,	O
can	O
cause	B-T078
the	O
size	B-T082
and	O
the	O
stability	B-T080
of	O
the	O
X-ray	B-T060
focal spot	B-T082
to	O
degrade	B-T067
.	O
A	O
new	O
microfocus	B-T082
X-ray tube	B-T074
based	O
on	O
a	O
point-like micro-target	B-T169
in	O
which	O
the	O
X-ray	B-T060
target	B-T169
is	O
irradiated	B-T067
with	O
an	O
unfocused	O
electron beam	B-T073
was	O
investigated	B-T169
.	O
EGS4 Monte Carlo simulation code	B-T081
was	O
employed	O
for	O
the	O
calculation	B-T052
of	O
the	O
X-ray	B-T060
intensity	B-T070
produced	O
from	O
the	O
point-like micro-target	B-T169
and	O
the	O
substrate	B-T167
.	O
The	O
effects of	B-T080
several	O
arrangements	O
of	O
the	O
target	B-T169
material	B-T167
,	O
target	B-T169
and	O
beam	B-T073
size	B-T082
were	O
studied	B-T059
.	O
The	O
simulation	B-T062
results	B-T169
demonstrated	O
that	O
if	O
the	O
intensity	B-T070
of	O
X-rays	B-T060
generated	B-T080
at	O
the	O
point-like target	B-T169
is	O
greater than	B-T081
half	O
of	O
the	O
X-ray	B-T060
intensity	B-T070
produced	O
on	O
the	O
substrate	B-T167
,	O
the	O
X-ray	B-T060
focal spot	B-T082
is	O
determined	O
in	O
part	O
by	O
the	O
point-like target	B-T169
rather	O
than	O
by	O
the	O
electron beam	B-T073
in	O
the	O
conventional	B-T080
X-ray tube	B-T074
.	O
In	O
theory	B-T078
,	O
since	O
it	O
is	O
able	O
to	O
reduce	B-T080
those	O
unfavorable	O
effects	B-T080
such	O
as	O
the	O
electron beam trajectory swinging	B-T033
and	O
the	O
beam	B-T073
size	B-T082
changing	B-T169
for	O
the	O
microfocus	B-T082
X-ray tube	B-T074
,	O
it	O
could	O
alleviate	B-T080
CT	B-T060
image	B-T170
artifacts	B-T068
caused	B-T078
by	O
the	O
X-ray	B-T060
focal spot	B-T082
shift	B-T033
and	O
size change	B-T081
.	O

Early	B-T079
assessment	B-T058
of	O
bilateral inguinal hernia repair	B-T061
:	O
A	O
comparison	B-T052
between	O
the	O
laparoscopic total extraperitoneal	B-T061
and	O
Stoppa approaches	B-T061
The	O
present	B-T079
clinical trial	B-T062
was	O
designed	O
to	O
compare	B-T052
the	O
results	B-T169
of	O
bilateral inguinal hernia repair	B-T061
between	O
patients	B-T101
who	O
underwent	O
the	O
conventional	B-T169
Stoppa technique	B-T061
and	O
laparoscopic total extraperitoneal repair	B-T061
(	O
LTE	B-T061
)	O
with	O
a	O
single	O
mesh	B-T074
and	O
without	O
staple fixation	B-T061
.	O
This	O
controlled,	O
randomised	B-T062
clinical trial	B-T062
was	O
conducted	O
at	O
General Surgery and Trauma of the Clinics Hospital	B-T093
,	O
Medical School	B-T093
,	O
the	O
University of Sγo Paulo	B-T093
between	O
September	O
2010	O
and	O
February	O
2011.	O
Totally,	O
50	O
male	B-T032
patients	B-T101
,	O
with	O
a	O
bilateral inguinal hernia	B-T190
,	O
older	O
than	O
25	O
years	B-T079
were	O
considered	O
eligible	B-T080
for	O
the	O
study	B-T062
.	O
The	O
following	O
parameters	B-T077
were	O
analysed	B-T062
during	O
the	O
early	B-T079
post-operative period	B-T079
:	O
(1)	O
The	O
intensity	B-T080
of	O
surgical trauma	B-T033
,	O
operation time	B-T079
,	O
C-reactive protein	B-T116
(	O
CRP	B-T116
)	O
levels	B-T080
,	O
white blood cell count	B-T059
,	O
bleeding	B-T046
and	O
pain intensity	B-T201
;	O
(2)	O
quality of life	B-T078
assessment	B-T058
;	O
and	O
(3)	O
post-operative complications	B-T046
.	O
LTE procedure	B-T061
was	O
longer	B-T080
than	O
the	O
Stoppa procedure	B-T061
(134.6	O
min	O
΁	O
38.3	O
vs.	O
90.6	O
min	O
΁	O
41.3;	O
P	O
<	O
0.05).	O
The	O
levels	B-T080
of	O
CRP	B-T116
were	O
higher	B-T080
in	O
the	O
Stoppa	B-T061
group	B-T078
(P	O
<	O
0.05)	O
but	O
the	O
number	O
of	O
leucocytes	B-T025
,	O
haematocrit	B-T033
,	O
and	O
haemoglobin	B-T116
were	O
similar	B-T080
between	O
the	O
groups	B-T078
(P	O
>	O
0.05).	O
There	O
was	O
no difference	B-T033
in	O
pain	B-T184
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post-operative	B-T033
,	O
physical functioning	B-T033
,	O
physical limitation	B-T169
,	O
the	O
impact	B-T080
of	O
pain	B-T184
on	O
daily activities	B-T056
,	O
and	O
the	O
Carolinas Comfort Scale	B-T170
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post-operative	B-T033
(P	O
>	O
0.05).	O
Complications	B-T046
occurred	O
in	O
88%	O
of	O
Stoppa	B-T061
group	B-T078
(22	O
patients	B-T101
)	O
and	O
64%	O
in	O
LTE	B-T061
group	B-T078
(16	O
patients	B-T101
)	O
(P	O
<	O
0.05).	O
The	O
comparative study	B-T062
between	O
the	O
Stoppa	B-T061
and	O
LTE	B-T061
approaches	O
for	O
the	O
bilateral inguinal hernia repair	B-T061
demonstrated	O
that:	O
(1)	O
The	O
LTE	B-T061
approach	O
showed	O
less	O
surgical trauma	B-T033
despite	O
the	O
longer	B-T080
operation time	B-T079
;	O
(2)	O
Quality of life	B-T078
during	O
the	O
early	B-T079
post-operative period	B-T079
were	O
similar	B-T080
;	O
and	O
(3)	O
Complication	B-T046
rates	B-T081
were	O
higher	B-T080
in	O
the	O
Stoppa	B-T061
group	B-T078
.	O

Morphological	B-T082
characteristics	B-T080
regulating	O
phallic glans	B-T023
engorgement	B-T047
in	O
the	O
American alligator	B-T014
The	O
distal part	B-T082
of	O
the	O
crocodilian	B-T014
phallus	B-T023
consists	O
of	O
a	O
bulbous glans	B-T023
containing	O
well-developed	O
vascular tissues	B-T024
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual activity	B-T053
,	O
enlarging	B-T080
and	O
elaborating	O
the	O
glans	B-T023
into	O
a	O
complex	B-T080
,	O
though	O
still	O
functionally	B-T169
undefined	B-T078
,	O
copulatory	B-T054
structure.	O
An	O
enlarged	B-T080
glans	B-T023
putatively	O
interacts	B-T169
with	O
the	O
female	B-T032
cloaca	B-T023
and	O
may	O
change	B-T169
the	O
shape	B-T082
of	O
her reproductive tract	B-T022
to	O
facilitate	O
insemination	B-T042
and	O
increase	B-T169
the	O
probability	B-T081
of	O
fertilization	B-T040
.	O
Here,	O
we	O
investigated	O
the	O
cellular-level properties	B-T043
of	O
the	O
glans	B-T023
and	O
other	O
inflatable phallic tissues	B-T024
associated	O
with	O
the	O
sperm	B-T025
-conducting	O
sulcus	B-T030
spermaticus	B-T023
in	O
the	O
American alligator	B-T014
(	O
Alligator mississippiensis	B-T014
).	O
Using	O
histochemical staining	B-T059
,	O
we	O
visualized	O
and	O
defined	O
collagen	B-T116
and	O
elastin fiber	B-T024
densities	B-T081
and	O
orientations	B-T082
in	O
these	O
tissues	B-T024
.	O
Extracellular matrix	B-T024
architectures	O
provided	O
insights	O
about	O
phallic glans	B-T023
material	O
properties	O
and	O
how	O
they	O
may	O
affect	B-T169
tissue	B-T024
strength	B-T081
and	O
flexibility	B-T080
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	B-T054
forces	B-T067
.	O
We	O
also	O
investigated	O
the	O
potential	B-T080
sources	O
of	O
fluids	B-T167
that	O
induce	B-T169
inflation	O
in	O
alligator	B-T014
phalli	B-T023
.	O
Combining	O
serial sectioning	B-T059
and	O
three-dimensional reconstruction	B-T059
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal plexus vascular	B-T023
bodies	B-T026
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	B-T014
phallus	B-T023
that	O
extend	O
distally adjacent	B-T082
to	O
ventro-medial sulcus tissues	B-T024
.	O
Together,	O
our	O
gross	B-T080
and	O
histological examination	B-T033
of	O
the	O
American alligator	B-T014
phallic glans	B-T023
suggests	O
that	O
its	O
tissues	B-T024
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	B-T023
inflation	O
to	O
expand	O
the	O
glans	B-T023
to	O
a	O
specific	O
and	O
repeatable	O
shape	B-T082
,	O
and	O
potentially	B-T080
release	O
secretory products	B-T026
into	O
the	O
female reproductive tract	B-T022
.	O
Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	B-T054
sexual selection	B-T054
,	O
by	O
mechanically	B-T169
and/or	O
chemically	O
affecting female reproductive physiology	B-T039
.	O

A	O
novel	O
role	B-T077
for	O
poly(C) binding proteins	B-T116
in	O
programmed ribosomal frameshifting	B-T045
Translational	B-T045
control	B-T080
through	O
programmed ribosomal frameshifting	B-T045
(	O
PRF	B-T045
)	O
is	O
exploited	O
widely	O
by	O
viruses	B-T005
and	O
increasingly	O
documented	O
in	O
cellular	B-T025
genes	B-T028
.	O
Frameshifting	B-T045
is	O
induced	B-T169
by	O
mRNA secondary structures	B-T114
that	O
compromise	O
ribosome	B-T026
fidelity	B-T043
during	O
decoding	B-T169
of	O
a	O
heptanucleotide 'slippery' sequence	B-T086
.	O
The	O
nsp2	B-T116
PRF	B-T045
signal	B-T044
of	O
porcine reproductive and respiratory syndrome virus	B-T005
is	O
distinctive	O
in	O
directing	O
both	O
-2	B-T045
and	O
-1 PRF	B-T045
and	O
in	O
its	O
requirement	B-T169
for	O
a	O
trans-acting protein factor	B-T116
,	O
the	O
viral	B-T005
replicase subunit nsp1β	B-T116
.	O
Here	O
we	O
show	O
that	O
the	O
the	O
trans-activation	B-T045
of	O
frameshifting	B-T045
is	O
carried	O
out	O
by	O
a	O
protein complex	B-T116
composed	O
of	O
nsp1β	B-T116
and	O
a	O
cellular	B-T025
poly(C) binding protein	B-T116
(	O
PCBP	B-T116
).	O
From	O
the	O
results	O
of	O
in vitro	B-T080
translation	B-T045
and	O
electrophoretic mobility shift assays	B-T059
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	B-T116
/	O
nsp1β	B-T116
complex	B-T116
binds	O
to	O
a	O
C-rich sequence	B-T086
downstream	B-T082
of	O
the	O
slippery sequence	B-T086
and	O
here	O
mimics	O
the	O
activity	B-T052
of	O
a	O
structured	O
mRNA	B-T114
stimulator	B-T123
of	O
PRF	B-T045
.	O
This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	B-T077
for	O
a	O
trans-acting cellular protein	B-T116
in	O
PRF	B-T045
.	O
The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	B-T052
associated with	B-T080
poly(C) binding proteins	B-T116
and	O
prototypes	B-T080
a	O
new	O
class	O
of	O
virus	B-T005
-	O
host	B-T001
interactions	B-T169
.	O

Production	O
of	O
bioactive	B-T167
conjugated linoleic acid	B-T109
by	O
the	O
multifunctional	B-T116
enolase	B-T116
from	O
Lactobacillus plantarum	B-T007
Lactobacillus plantarum	B-T007
α-enolase	B-T116
,	O
a	O
multifunctional	B-T116
-anchorless-	O
surface protein	B-T116
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	B-T116
with	O
a	O
central	O
role	O
in	O
glycolytic	B-T044
metabolism	B-T040
,	O
was	O
characterized	B-T052
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate metabolism	B-T040
of	O
biohydrogenation	B-T070
of	O
linoleic acid	B-T109
,	O
catalyzing	B-T070
the	O
formation	B-T169
of	O
bioactive	B-T167
9-cis-11-trans-CLA	B-T109
through	O
dehydration	B-T067
and	O
isomerization	B-T044
of	O
10-hydroxy-12-cis-octadecenoic acid	B-T109
.	O
The	O
identity	O
of	O
the	O
enolase	B-T116
was	O
confirmed	O
through	O
mass spectrometric analysis	B-T059
that	O
showed	O
the	O
characteristic	O
442	O
amino acid sequence	B-T087
with	O
a	O
molecular mass	B-T081
of	O
48.03	O
kDa	B-T081
.	O
The	O
enolase	B-T116
was	O
not	O
capable	O
of	O
using	O
linoleic acid	B-T109
directly	O
as	O
a	O
substrate	B-T167
but	O
instead	O
uses	O
its	O
hydroxyl	B-T197
derivative	B-T169
10-hydroxi-12-cis-octadecenoic acid	B-T109
to	O
finally	O
form	O
bioactive	B-T167
conjugated linoleic acid	B-T109
.	O
Biochemical	B-T169
optimization	B-T052
studies	B-T062
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9-cis-11-trans-CLA	B-T109
and	O
maximum	O
stability	B-T044
of	O
α-enolase	B-T116
when	O
catalyzing	B-T070
this	O
reaction	B-T067
.	O
Furthermore,	O
through	O
structural analysis	B-T061
of	O
the	O
protein	B-T116
,	O
we	O
propose	O
the	O
binding sites	B-T192
of	O
substrate	B-T167
and	O
product	B-T071
molecules	B-T167
that	O
were	O
characterized	B-T052
as	O
two	O
hydrophobic	B-T080
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	B-T116
connected	O
through	O
a	O
channel	B-T116
where	O
the	O
catalysis	B-T070
of	O
dehydration	B-T067
and	O
isomerization	B-T044
might	O
occur.	O
These	O
results	O
prove	O
that	O
multifunctional	B-T116
α-enolase	B-T116
also	O
plays	O
a	O
role	O
in	O
cell detoxification	B-T043
from	O
polyunsaturated fatty acids	B-T109
such	O
as	O
linoleic acid	B-T109
,	O
along	O
with	O
the	O
linoleate isomerase	B-T116
complex	B-T104
.	O

Associations	B-T080
of	O
Body Mass Index	B-T201
and	O
Physical Activity	B-T056
With	O
Sexual Dysfunction	B-T047
in	O
Breast Cancer	B-T191
Survivors	B-T101
Sexual dysfunction	B-T047
is	O
a	O
common	O
and	O
distressing	B-T033
consequence of	B-T169
breast cancer	B-T191
(	O
BC	B-T191
)	O
treatment	B-T061
.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
investigated	O
the	O
sexual functioning	B-T040
of	O
BC	B-T191
patients	B-T101
and	O
its	O
association	B-T041
with	O
women's	B-T098
personal	B-T032
characteristics	B-T080
and	O
cancer treatments	B-T061
.	O
In	O
this	O
cross-sectional study	B-T062
,	O
sexual function	B-T040
was	O
assessed	O
using	O
the	O
Female Sexual Function Index	B-T170
(	O
FSFI	B-T170
).	O
The	O
health-related quality of life	B-T078
(	O
HRQOL	B-T078
)	O
was	O
measured	O
using	O
the	O
European Organization for Research and Treatment of Cancer	B-T093
(	O
EORTC	B-T093
)	O
QLQ-C30	B-T170
and	O
its	O
breast module BR-23	B-T170
.	O
Of	O
the	O
235	O
participants	B-T098
approached,	O
216	O
participants	B-T098
were	O
included	O
in	O
the	O
study.	O
Of	O
these,	O
63	O
patients	B-T101
reported	O
no sexual activity	B-T033
in	O
the	O
last	O
month	B-T079
and	O
thus	O
were	O
analyzed	O
only	O
in	O
relation	O
to	O
the	O
sexual desire	B-T041
domain	B-T169
of	O
FSFI	B-T170
.	O
A	O
total	O
of	O
154	O
(71.3	O
%)	O
patients	B-T101
were	O
classified	O
with	O
hypoactive sexual desire disorder	B-T048
(	O
HSDD	B-T048
).	O
From	O
those	O
patients	B-T101
reporting	O
sexual activity	B-T053
in	O
the	O
last	O
month	B-T079
,	O
63.3	O
%	O
(97	O
out	O
of	O
153)	O
were	O
classified	O
with	O
sexual dysfunction	B-T047
.	O
Using	O
hierarchical logistic regression	B-T062
,	O
the	O
variance	O
explained	O
(change	O
in	O
R	O
(2))	O
by	O
the	O
addition	O
of	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
and	O
mild	O
to	O
moderate	O
physical activity	B-T056
in	O
the	O
prediction	B-T078
models	B-T170
of	O
sexual dysfunction	B-T047
and	O
HSDD	B-T048
were	O
6.8	O
and	O
7.2	O
%,	O
respectively.	O
Age	B-T032
,	O
BMI	B-T201
,	O
and	O
physical activity	B-T056
were	O
independently	O
associated	O
with	O
sexual dysfunction	B-T047
and	O
HSDD	B-T048
.	O
Additionally,	O
BC	B-T191
patients	B-T101
with	O
sexual dysfunction	B-T047
reported	O
lower	B-T081
scores	B-T081
on	O
global	O
HRQOL	B-T078
,	O
role	O
functioning	B-T169
,	O
and	O
fatigue	B-T184
.	O
Based	O
on	O
our	O
findings	B-T033
,	O
BC	B-T191
survivors	B-T101
should	O
be	O
encouraged	O
to	O
practice	B-T041
regular	O
physical activity	B-T056
and	O
to	O
lose weight	B-UnknownType
in	O
order	O
to	O
avoid	O
sexual dysfunction	B-T047
.	O
However,	O
future	O
clinical trials	B-T062
are	O
needed	O
to	O
confirm	O
these	O
findings	B-T033
.	O

Combination	B-T121
of	O
telmisartan	B-T109
with	O
sildenafil	B-T109
ameliorate	B-T080
progression	B-T046
of	O
diabetic nephropathy	B-T047
in	O
streptozotocin	B-T109
-	O
induced	B-T169
diabetic	B-T033
model	O
Diabetic nephropathy	B-T047
(	O
DN	B-T047
)	O
is	O
a	O
leading	O
cause	O
of	O
end-stage renal disease	B-T047
in	O
the	O
world.	O
Several	O
signaling pathways	B-T044
are	O
involved	O
in	O
the	O
pathogenesis	B-T046
of	O
DN	B-T047
including	O
elevation	B-T082
in	O
level	O
of	O
angiotensin II	B-T116
,	O
formation	B-T169
of	O
advanced glycation end products	B-T109
(	O
AGE	B-T109
),	O
activation	B-T043
of	O
protein kinase c	B-T116
(	O
PKC	B-T116
),	O
and	O
lipid accumulation	B-T033
.	O
These	O
pathways	B-T044
activate	B-T052
one	O
another	O
mutually	O
leading	O
to	O
oxidative stress	B-T049
,	O
increasing	O
expression	B-T045
of	O
transforming growth factor beta-1	B-T116
(	O
TGF-β 1	B-T116
)	O
and	O
release	B-T169
of	O
interleukins	B-T116
and	O
adhesion molecules	B-T116
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B-T033
pathway	B-T077
to	O
ameliorate	B-T080
the	O
progression	B-T046
of	O
DN	B-T047
.	O
In	O
the	O
present	O
study	B-T062
,	O
white male rats	B-T015
(N=48)	O
were	O
divided	O
into	O
six	O
groups	O
(8	O
rats	B-T015
each),	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal control	B-T096
and	O
a	O
control vehicle group	B-T096
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B-T033
by	O
a	O
single	O
intraperitoneal injection	B-T061
of	O
Streptozotocin	B-T109
(	O
STZ	B-T109
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
DN	B-T047
.	O
Thereafter,	O
the	O
rats	B-T015
were	O
divided	O
into	O
DN	B-T047
group,	O
DN	B-T047
group	O
receiving	O
Telmisartan	B-T109
or	O
Sildenafil	B-T109
or	O
Telmisartan	B-T109
Sildenafil	B-T109
combination	B-T121
.	O
After	O
the	O
specified	B-T080
treatment	B-T169
period	B-T079
,	O
urine samples	B-T031
were	O
collected	B-T078
(using	O
metabolic cages	B-T073
)	O
to	O
measure	O
proteinuria	B-T033
,	O
animals	B-T008
were	O
then	O
euthanized	B-T054
,	O
blood	B-T031
and	O
tissue samples	B-T024
were	O
collected	B-T078
for	O
measurement of Blood glucose	B-T059
,	O
BUN	B-T059
,	O
S.Cr	B-T059
,	O
LDL	B-T059
,	O
NO	B-T059
,	O
TGF-β1	B-T059
,	O
IL-1β	B-T059
,	O
AGEPs	B-T059
,	O
and	O
SOD	B-T059
.	O
The	O
combination therapy	B-T061
showed	O
significant	O
decrease	O
in	O
BUN	B-T123
,	O
S.Cr	B-T109
,	O
LDL	B-T109
,	O
TGF-β1	B-T116
,	O
IL-1β	B-T116
,	O
Proteinuria	B-T033
and	O
AGEPs	B-T109
and	O
significant	O
increase	O
in	O
SOD	B-T116
and	O
NO	B-T121
.	O
The	O
findings	O
showed	O
that	O
combination therapy	B-T061
was	O
able	O
to	O
ameliorate	B-T080
DN	B-T047
and	O
that	O
the	O
effects	O
were	O
superior	B-T080
to	O
the	O
single	O
drugs	B-T121
alone.	O

Analysis	B-T062
of	O
Low-Biomass	B-T081
Microbial Communities	B-T001
in	O
the	O
Deep Biosphere	B-UnknownType
Over	O
the	O
past	O
few decades	B-T081
,	O
the	O
subseafloor biosphere	B-UnknownType
has	O
been	O
explored	O
by	O
scientific ocean drilling	B-T169
to	O
depths	B-T082
of	O
about	O
2.5km	O
below	O
the	O
seafloor	B-UnknownType
.	O
Although	O
organic-rich anaerobic sedimentary habitats	B-T082
in	O
the	O
ocean margins harbor	B-T082
large	O
numbers	O
of	O
microbial cells	B-T001
,	O
microbial populations	B-T001
in	O
ultraoligotrophic aerobic sedimentary habitats	B-T082
in	O
the	O
open	O
ocean gyres	B-T169
are	O
several	O
orders	O
of	O
magnitude	B-T081
less	O
abundant	B-T080
.	O
Despite	O
advances	O
in	O
cultivation-independent molecular ecological techniques	B-T169
,	O
exploring	O
the	O
low-biomass	B-T081
environment	B-T082
remains	O
technologically challenging	B-T080
,	O
especially	O
in	O
the	O
deep subseafloor biosphere	B-UnknownType
.	O
Reviewing	B-T080
the	O
historical background	B-T170
of	O
deep-biosphere	B-UnknownType
analytical methods	B-T170
,	O
the	O
importance	B-T080
of	O
obtaining	O
clean samples	B-T167
and	O
tracing	B-T033
contamination	B-T078
,	O
as	O
well	O
as	O
methods	B-T170
for	O
detecting	B-T033
microbial	B-T001
life	B-T078
,	O
technological aspects	B-UnknownType
of	O
molecular microbiology	B-T091
,	O
and	O
detecting	B-T033
subseafloor	B-UnknownType
metabolic activity	B-T040
will	O
be	O
discussed.	O

The	O
sensitivity and specifity	B-T081
of	O
DR-70	B-T123
immunoassay	B-T059
as	O
a	O
tumor marker	B-T123
for	O
non-small cell lung cancer	B-T191
Lung cancer	B-T191
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer related mortality	B-T081
.	O
Patients	B-T101
with	O
lung cancer	B-T191
are	O
usually	O
diagnosed	B-T060
at	O
advanced	B-T029
or	O
locally advanced stage	B-T029
,	O
for	O
this	O
reason	O
early diagnosis	B-T060
of	O
lung cancer	B-T191
is	O
very	O
important.	O
For	O
early detection	B-T060
of	O
lung cancer	B-T191
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low-dose computed tomography	B-T060
or	O
tumor biomarkers	B-T123
.	O
In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B-T058
DR-70	B-T123
sensitivity and specificity	B-T081
as	O
a	O
tumor marker	B-T123
in	O
detection	B-T061
of	O
non-small cell lung cancers	B-T191
.	O
Between	O
May	B-T079
2013	O
and	O
April	B-T079
2014,	O
the	O
serum samples	B-T031
from	O
88	O
non lung cancer	B-T191
patients	B-T101
,	O
86	O
patients	B-T101
with	O
chronic obstructive pulmonary disesase	B-T047
were	O
obtained.	O
Blood samples	B-T031
from	O
each	O
participant	B-T098
were	O
analyzed	B-T062
for	O
DR-70	B-T123
level	B-T080
.	O
Totally	O
174	O
patients	B-T101
were	O
enrolled	O
to	O
the	O
study	B-T062
(152	O
male	B-T098
,	O
22	O
female	B-T098
).	O
Histopathologically	B-T169
47(53.4%)	O
patients	B-T101
were	O
diagnosed	B-T060
with	O
squamous cell lung cancer	B-T191
,	O
34	O
(38.6%)	O
with	O
adenocarcinoma	B-T191
,	O
and	O
7	O
(8%)	O
with	O
non-small cell lung cancer	B-T191
.	O
The	O
mean serum DR-70	B-T123
levels	B-T080
in	O
lung cancer	B-T191
patients	B-T101
(2.43	O
±	O
1.82	O
µg/mL)	O
was	O
significantly higher	B-T033
compared	B-T052
to	O
the	O
86	O
non-cancerous	B-T033
subjects	B-T098
(1.15	O
±	O
0.70	O
µg/mL)	O
(p<	O
0.01).	O
DR-70	B-T123
exhibited	O
clinical	B-T080
sensitivity and specificity	B-T081
of	O
54.5	O
and	O
83.7%,	O
respectively,	O
at	O
an	O
optimal	B-T080
cut off	B-T169
at	O
1.98	O
µg/mL.	O
It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B-T047
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR-70	B-T123
level	B-T080
is	O
1.98	O
µg/mL	O
and	O
higher.	O
DR-70	B-T123
,	O
a	O
marker	B-T123
used	O
to	O
measure	B-T081
fibrin degradation products	B-T116
,	O
generated	O
by	O
all	O
major	O
cancers	B-T191
,	O
may	O
helps	O
to	O
find	O
high risk	B-T033
lung cancer	B-T191
patients	B-T101
.	O

Catastrophic expenditure	B-T081
and	O
impoverishment	B-T081
of	O
patients	B-T101
affected	O
by	O
7	O
rare diseases	B-T047
in	O
China	B-T083
China	B-T083
is	O
actively	O
promoting	B-T052
regulation	O
of	O
rare diseases	B-T047
,	O
rare disease	B-T047
and	O
orphan drugs	B-T121
have	O
been	O
formally	O
incorporated	O
into	O
the	O
national planning	B-UnknownType
.	O
However,	O
few	O
studies	B-T062
have	O
been	O
done	O
to	O
evaluate	O
the	O
affordability	B-T081
of	O
rare disease	B-T047
patients	B-T101
in	O
China	B-T083
.	O
This	O
study	O
aims	O
to	O
provide	O
policy	B-T170
recommendations	B-T078
for	O
the	O
establishment	B-T080
of	O
social security mechanism	B-T170
for	O
rare diseases	B-T047
in	O
China	B-T083
,	O
so	O
as	O
to	O
address	O
the	O
problem	O
of	O
poverty	B-T102
caused	O
by	O
these	O
diseases	B-T047
.	O
A	O
total	O
of	O
7	O
rare diseases	B-T047
were	O
selected	O
by	O
Delphi method	B-T062
.	O
Affordability	B-T081
of	O
treatment	B-T061
for	O
the	O
7	O
rare diseases	B-T047
was	O
assessed	B-T052
through	O
annual per capital income	B-T081
,	O
catastrophic expenditure	B-T081
and	O
impoverishment	B-T081
expenditure	B-T081
among	O
urban	B-T098
and	O
rural residents	B-T098
in	O
China	B-T083
.	O
Assessed	B-T052
through	O
annual per capital income	B-T081
,	O
health expenditure	B-T081
for	O
the	O
7	O
rare diseases	B-T047
are	O
all	O
rather	O
high.	O
The	O
highest	O
health expenditure	B-T081
is	O
equivalent	O
to	O
income	B-T081
of	O
69.34	O
years	B-T079
of	O
one	O
urban resident	B-T098
,	O
and	O
the	O
burden	O
is	O
heavier	O
for	O
rural residents	B-T098
.	O
Through	O
catastrophic expenditure	B-T081
assessment	B-T052
,	O
proportions	B-T081
of	O
the	O
population	B-T098
experiencing	O
catastrophic expenditure	B-T081
caused	O
by	O
the	O
7	O
rare diseases	B-T047
are	O
all	O
under	O
0.167	O
‰.	O
However,	O
once	O
one	O
is	O
ill	B-T184
and	O
taking	O
medications	B-T170
,	O
he	O
will	O
suffer	O
from	O
catastrophic health expenditure	B-T081
.	O
Through	O
impoverishment	B-T081
expenditure	B-T081
assessment	B-T052
,	O
the	O
proportions	B-T081
of	O
impoverishment	B-T081
payment	B-T081
are	O
low	O
among	O
both	O
urban	B-T098
and	O
rural residents	B-T098
,	O
but	O
the	O
7	O
rare diseases	B-T047
could	O
lead	O
nearly	O
4.6	O
million	O
people	B-T098
into	O
poverty	B-T102
on	O
a	O
national	O
scale.	O
The	O
affordability	B-T081
of	O
treatment	B-T061
for	O
rare disease	B-T047
as	O
well	O
as	O
orphan drugs	B-T121
is	O
rather	O
poor	B-T080
.	O
Residents	B-T098
of	O
different	O
income levels	B-T080
all	O
have	O
difficulties	O
to	O
afford	O
the	O
treatment	B-T061
for	O
rare diseases	B-T047
,	O
so	O
poverty	B-T102
caused	O
by	O
rare diseases	B-T047
is	O
quite	O
widespread	B-T082
.	O
Therefore,	O
social security mechanism	B-T170
for	O
rare disease	B-T047
patients	B-T101
should	O
be	O
established	O
and	O
specific	O
payment	B-T081
pattern	O
for	O
orphan drugs	B-T121
should	O
be	O
set	O
up.	O

Experimental study	B-T062
in	O
pulmonary artery	B-T023
sealing	B-T061
with	O
a	O
vessel-sealing device	B-T074
The	O
development	O
of	O
vessel-sealing devices	B-T074
will	O
facilitate	O
safety	B-T068
in	O
video-assisted thoracoscopic surgery	B-T061
.	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
feasibility	B-T080
and	O
safety	B-T068
of	O
sealing	B-T061
pulmonary arteries	B-T023
with	O
the	O
Enseal tissue-sealing device	B-T074
.	O
Pulmonary arteries	B-T023
from	O
beagle dogs	B-T015
(mean	O
body	O
weight	O
13.1	O
kg,	O
range	O
10.5-15.4	O
kg)	O
were	O
divided	O
into	O
3	O
groups	B-T096
according	O
to	O
the	O
in-vivo	B-T082
sealing method	B-T170
used	O
(	O
Enseal	B-T074
,	O
ligation	B-T061
,	O
and	O
proximal	B-T082
ligation	B-T061
plus	O
distal	B-T082
Enseal	B-T074
)	O
and	O
extracted	O
to	O
evaluate	O
the	O
pressure	B-T067
tolerance	B-T080
up	O
to	O
75	O
mm	O
Hg	O
at	O
the	O
sealed	B-T169
end	B-T082
.	O
A	O
left	O
lower	O
lobectomy	B-T061
was	O
performed	O
to	O
evaluate	O
chronic-phase	B-T079
durability	O
of	O
the	O
sealed stumps	B-T074
in	O
a	O
survival model	B-T008
.	O
Two	O
or	O
three	O
branches	O
of	O
the	O
pulmonary arteries	B-T023
in	O
each	O
dog	B-T015
were	O
allocated	O
to	O
each	O
of	O
the	O
3	O
groups	B-T096
.	O
After	O
the	O
scheduled	O
survival	B-T052
period	B-T079
,	O
the	O
pulmonary arteries	B-T023
were	O
sampled.	O
Pressure	B-T067
tolerance	B-T080
at	O
the	O
sealed	B-T169
end	B-T082
was	O
evaluated	O
in	O
91	O
pulmonary artery	B-T023
sections.	O
All	O
sealed	B-T169
ends	B-T082
showed	O
pressure	B-T067
tolerance	B-T080
>75	O
mm	O
Hg.	O
A	O
left	O
lower	O
lobectomy	B-T061
was	O
performed	O
in	O
13	O
dogs	B-T015
in	O
which	O
35	O
pulmonary artery	B-T023
sections	O
had	O
been	O
allocated	O
into	O
the	O
3	O
groups	B-T096
.	O
No	B-T033
sealing	B-T061
failure	B-T169
was	O
found,	O
and	O
pathological	B-T169
findings	B-T033
showed	O
healing	B-T040
and	O
persistent	B-T079
hemostasis	B-T042
at	O
all	O
sealed	B-T169
ends	B-T082
of	O
the	O
pulmonary arteries	B-T023
after	O
2	O
and	O
4	O
weeks	B-T079
of	O
the	O
survival	B-T052
period	B-T079
.	O
Pulmonary arteries	B-T023
sealed	B-T169
in vivo	B-T082
with	O
the	O
Enseal device	B-T074
showed	O
pressure	B-T067
tolerance	B-T080
>75	O
mm	O
Hg	O
in	O
the	O
acute phase	B-T079
,	O
and	O
persistent	B-T079
hemostasis	B-T042
after	O
2	O
or	O
4	O
weeks	B-T079
.	O
Pulmonary artery	B-T023
sealing	B-T061
with	O
the	O
Enseal device	B-T074
is	O
feasible	B-T080
and	O
safe	B-T068
in	O
thoracic surgery	B-T061
settings.	O

Pathophysiology	B-T169
,	O
treatment	B-T061
and	O
prevention	B-T061
of	O
ovarian hyperstimulation syndrome	B-T047
Severe	B-T080
ovarian hyperstimulation syndrome	B-T047
(	O
OHSS	B-T047
)	O
is	O
an	O
iatrogenic	B-T080
condition	B-T080
that	O
affects	B-T077
1%	O
of	O
women	B-T098
that	O
undergo	O
treatment	B-T061
with	O
assisted reproductive technology	B-T061
.	O
The	O
review	B-T170
aims	B-T078
to	O
summarize	B-T170
recent	B-T079
evidence	B-T078
on	O
pathophysiology	B-T169
,	O
treatment	B-T061
,	O
and	O
prevention	B-T061
of	O
OHSS	B-T047
.	O
The	O
pathophysiology	B-T169
is	O
still	O
not	O
completely	B-T080
understood	B-T041
;	O
however,	O
vascular endothelial growth factor	B-T116
is	O
likely	O
to	O
be	O
an	O
important	B-T080
mediator.	O
Human chorionic gonadotropin	B-T116
was	O
previously	O
thought	B-T041
to	O
be	O
necessary	O
for	O
OHSS	B-T047
to	O
occur	B-T052
;	O
however,	O
recent case reports	B-T170
have	O
proven	B-T080
otherwise.	O
The	O
contribution	B-T052
of	O
an	O
attenuated	B-T052
anti-Mullerian hormone	B-T116
signalling pathway	B-T043
and	O
CD11c	B-T116
+	O
HLA-DR	B-T116
+	O
dendritic cells	B-T025
and	O
associated	B-T080
interleukins	B-T116
has	O
been	O
explored	O
recently	B-T079
as	O
contributors	B-T052
to	O
pathogenesis	B-T046
.	O
Treatment	B-T061
is	O
largely	O
supportive	B-T061
and	O
is	O
based	B-T078
mainly	O
on	O
consensus	B-T054
statements	B-T078
rather	O
than	O
evidence	B-T078
.	O
Therefore,	O
it	O
is	O
important	B-T080
to	O
prevent	B-T169
this	O
condition	B-T080
by	O
identifying	B-T058
women	B-T098
at risk	B-T080
,	O
allowing	B-T054
the	O
clinician	B-T097
to	O
implement	B-T052
preventive strategies	B-T170
,	O
including	B-T169
the	O
use	O
of	O
GnRH antagonist	B-T121
cycles	B-T079
with	O
agonist	B-T121
triggers.	O
More	O
research	B-T062
is	O
required	B-T169
to	O
elucidate	O
the	O
pathophysiology	B-T169
behind	O
the	O
condition	B-T080
.	O
Clinicians	B-T097
should	O
employ	B-T169
strategies	B-T041
to	O
prevent	B-T061
OHSS	B-T047
.	O

Eosinophilic Gastroenteritis	B-T047
as	O
a	O
Rare	B-T080
Cause	B-T169
of	O
Recurrent Epigastric Pain	B-UnknownType
Eosinophilic gastroenteritis	B-T047
(	O
EGE	B-T047
)	O
is	O
a	O
rare	O
inflammatory disorder	B-T047
of	O
gastrointestinal tract	B-T022
characterized	B-T052
by	O
eosinophilic infiltration	B-T046
of	O
the	O
bowel wall	B-T023
.	O
It	O
can	O
mimic	O
many	O
gastrointestinal disorders	B-T047
due	O
to	O
its	O
wide spectrum of presentations	B-T033
.	O
Diagnose	B-T033
is	O
mostly	O
based	O
on	O
excluding	B-T169
other	B-T080
disorders	B-T047
and	O
a	O
high	B-T080
suspicion	B-T041
.	O
Here	O
we	O
report a case	B-T170
of	O
26	O
year	B-T079
old	B-T079
man	B-T098
with	O
a	O
history	B-T033
of	O
sever epigastric pain	B-T184
followed	O
by	O
nausea	B-T184
,	O
vomiting	B-T184
since	O
a	O
few	B-T081
days	B-T079
before	B-T079
admission	B-T058
with	O
final	O
diagnosis	B-T033
of	O
EGE	B-T047
.	O

Comparison	O
of	O
sonoelastography	B-T060
with	O
sonourethrography	B-T060
and	O
retrograde urethrography	B-T060
in	O
the	O
evaluation	B-T058
of	O
male	B-T032
anterior urethral strictures	B-T190
Retrograde urethrography	B-T060
(	O
RUG	B-T060
)	O
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging modality	B-T169
for	O
imaging	B-T060
of	O
the	O
anterior urethral strictures	B-T190
despite	O
its	O
well-known	O
limitations	B-T169
and	O
disadvantages.	O
Sonourethrography	B-T060
(	O
SUG	B-T060
)	O
was	O
introduced	O
in	O
1988	O
to	O
overcome	B-T052
the	O
limitations	B-T169
of	O
RUG	B-T060
and	O
to	O
provide	O
more	O
accurate results	B-T080
.	O
As	O
proper	O
selection	O
of	O
imaging modality	B-T169
is	O
very	O
important	O
for	O
planning the treatment	B-T170
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required.	O
One	O
of	O
the	O
major	O
factors	O
for	O
recurrence	B-T067
of	O
stricture disease	B-T047
is	O
spongiofibrosis	B-T046
.	O
Sonoelastography	B-T060
(	O
SE	B-T060
)	O
is	O
a	O
newer technique	B-T062
,	O
tried	O
in	O
various	O
other	O
pathologies	B-T091
.	O
In	O
this	O
study,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	B-T080
in	O
the	O
evaluation	O
of	O
anterior urethral stricture disease	B-T190
by	O
comparison	O
with	O
RUG	B-T060
and	O
SUG	B-T060
.	O
Between	O
August	O
2014	O
and	O
May	O
2015,	O
77	O
patients	B-T101
with	O
clinical	O
features	O
of	O
anterior urethral stricture disease	B-T190
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
RUG	B-T060
followed	O
by	O
SUG	B-T060
and	O
SE	B-T060
for	O
stricture	B-T047
location	B-T082
,	O
length	B-T081
,	O
depth	B-T201
of	O
spongiofibrosis	B-T046
and	O
periurethral	B-T029
pathologies	B-T091
.	O
The	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological findings	B-T169
.	O
Overall	O
diagnostic accuracy	B-T080
of	O
SE	B-T060
,	O
SUG	B-T060
,	O
and	O
RGU	B-T060
for	O
the	O
estimation	O
of	O
stricture	B-T047
location	B-T082
,	O
and	O
length	B-T081
were	O
estimated	O
92.68%	O
vs.	O
91.54%,	O
79%	O
vs.	O
78.87%	O
and	O
80.48%	O
vs.	O
43.66%,	O
respectively,	O
while	O
for	O
depth	B-T201
of	O
spongiofibrosis	B-T046
SE	B-T060
,	O
and	O
SUG	B-T060
had	O
accuracy rates	B-T080
of	O
87.3%,	O
48%,	O
respectively.	O
The	O
mean	O
length	O
measured	O
on	O
SE	B-T060
was	O
nearest	O
to	O
the	O
mean	O
intra-operative	B-T079
stricture	B-T047
length	B-T081
(21.34+11.8	O
mm).	O
SE	B-T060
findings	O
significantly	O
correlated	O
with	O
the	O
colour of bladder mucosa	B-T033
on	O
cystoscopic examination	B-T060
(p=0.003)	O
whereas	O
the	O
association	O
was	O
non-significant	O
(p=0.127)	O
for	O
difficulty	O
in	O
incision	B-T061
.	O
While	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
SUG	B-T060
findings	O
related	O
both	O
to	O
the	O
colour of the bladder mucosa	B-T033
and	O
difficulty	O
in	O
incision	B-T061
on	O
cystoscopy	B-T060
,	O
SE	B-T060
findings	O
had	O
a	O
significant	O
association	O
(p<0.001)	O
with	O
histopathology findings	B-T169
for	O
severe	O
degree of fibrosis	B-T060
.	O
Sonoelastography	B-T060
estimates	O
stricture site and length	B-T082
better	O
in	O
comparison	O
with	O
RUG	B-T060
and	O
SUG	B-T060
.	O
It	O
estimates	O
degree	O
of	O
spongiofibrosis	B-T046
which	O
serves	O
as	O
an	O
important	O
prognostic factor	B-T201
for	O
stricture recurrence	B-T067
more	O
accurately	B-T080
than	O
SUG	B-T060
.	O

Changes	B-T169
in	O
risk factors	B-T033
for	O
young	B-T079
male	B-T032
suicide	B-T033
in	O
Newcastle upon Tyne	B-T083
,	O
1961-2009	O
Aims	B-T078
and	O
method	B-T170
To	O
ascertain	O
differences	B-T080
in	O
patterns of suicide	B-T033
in	O
young	B-T079
men	B-T098
over	O
three	O
decades	B-T081
(1960s,	O
1990s	O
and	O
2000s)	O
and	O
discuss	O
implications	B-T080
for	O
suicide	B-T033
prevention	B-T080
.	O
Data	B-T078
on	O
suicides	B-T033
and	O
open verdicts	B-T064
in	O
men	B-T098
aged	O
15-34	O
were	O
obtained	O
from	O
coroner's records	B-T170
in	O
Newcastle upon Tyne	B-T083
and	O
analysed	B-T062
using	O
SPSS software	B-T073
.	O
Results	B-T169
An	O
increase	B-T169
in	O
suicide rates	B-T033
from	O
the	O
first	O
to	O
the	O
second	O
decade	B-T081
was	O
followed	O
by	O
a	O
fall	O
in	O
the	O
third	O
decade	B-T081
.	O
This	O
was	O
associated with	B-T080
an	O
increasing	B-T169
proportion	B-T081
of	O
single	B-T081
men	B-T098
,	O
those	O
living alone	B-T033
,	O
unemployment	B-T033
,	O
consumption of alcohol	B-T055
,	O
use	O
of	O
hanging	B-T037
,	O
previous	B-T079
suicide attempt	B-T033
and	O
history of treatment	B-UnknownType
for	O
mental illness	B-T048
.	O
Clinical	B-T080
implications	B-T080
This	O
study	B-T062
highlights	O
the	O
need	O
for	O
more	O
interventions	B-T061
and	O
focus	B-T041
to	O
be	O
given	O
to	O
young	B-T079
males	B-T032
in	O
the	O
suicide	B-T033
prevention area	B-T080
and	O
is	O
of	O
high	O
importance	O
in	O
the	O
field of public health	B-T170
.	O
Areas	O
that	O
could	O
be	O
tackled	O
include	O
reducing	B-T080
access	B-T082
to	O
means	B-T077
of	O
suicide	B-T033
,	O
reducing	B-T080
alcohol use	B-T055
,	O
support	B-T077
for	O
relationship	B-T080
difficulties	B-T080
,	O
engagement	B-T058
with	O
mental health services	B-T058
and	O
management	B-T058
of	O
chronic illness	B-T047
.	O

Social cognition	B-T054
in	O
schizophrenia	B-T048
:	O
Factor structure	B-T081
of	O
emotion	B-T041
processing	B-T041
and	O
theory of mind	B-T078
Factor analytic studies	B-T081
examining	O
social cognition	B-T054
in	O
schizophrenia	B-T048
have	O
yielded	O
inconsistent	O
results	B-T169
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality of measures	B-T170
.	O
With	O
the	O
recent	O
conclusion	O
of	O
Phase 3	B-T079
of	O
the	O
Social Cognition	B-T054
Psychometric Evaluation (SCOPE) Study	B-T060
,	O
the	O
most	O
psychometrically	B-T060
sound measures	B-T060
of	O
social cognition	B-T054
have	O
been	O
identified.	O
Therefore,	O
the	O
aims	O
of	O
the	O
present	O
study	B-T062
were	O
to:	O
1)	O
examine	B-T033
the	O
factor structure	B-T081
of	O
social cognition	B-T054
in	O
schizophrenia	B-T048
through	O
the	O
utilization	O
of	O
psychometrically	B-T060
sound measures	B-T060
,	O
2)	O
examine	B-T033
the	O
stability	B-T080
of	O
the	O
factor structure	B-T081
across	O
two	O
study	B-T062
visits,	O
3)	O
compare	O
the	O
factor structure	B-T081
of	O
social cognition	B-T054
in	O
schizophrenia	B-T048
to	O
that	O
in	O
healthy controls	B-T080
,	O
and	O
4)	O
examine	B-T033
the	O
relationship	O
between	O
the	O
factors	B-T081
and	O
relevant	O
outcome measures	B-T081
including	O
social functioning	B-T054
and	O
symptoms	B-T184
.	O
Results	B-T169
supported	O
a	O
one-factor model	B-T170
for	O
the	O
patient	B-T101
and	O
healthy control	B-T080
samples	O
at	O
both	O
visits	B-T058
visits	B-T058
.	O
This	O
single	O
factor	O
was	O
significantly	O
associated with	B-T080
negative symptoms	B-T184
in	O
the	O
schizophrenia	B-T048
sample	B-T167
and	O
with	O
social functioning	B-T054
in	O
both	O
groups	B-T098
at	O
both	O
study	B-T062
visits	B-T058
.	O

Assessment	B-T058
of	O
Residual Disease	B-T191
With	O
Molecular Breast Imaging	B-T060
in	O
Patients	B-T101
Undergoing	O
Neoadjuvant Therapy	B-T061
:	O
Association	O
With	O
Molecular	B-T080
Subtypes	B-T185
Assessment	B-T058
of	O
residual disease	B-T191
after	O
neoadjuvant therapy	B-T061
for	O
breast cancer	B-T191
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B-T023
imaging	B-T060
.	O
This	O
study	B-T062
evaluates	B-T058
the	O
accuracy	B-T080
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular breast imaging	B-T060
(	O
MBI	B-T060
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium zinc telluride	B-T197
detectors	B-T073
in	O
assessing	O
residual disease	B-T191
after	O
neoadjuvant therapy	B-T061
in	O
patients	B-T101
with	O
breast cancer	B-T191
.	O
Clinical data	B-T170
,	O
imaging	B-T060
,	O
surgical	B-T169
,	O
and	O
pathological	B-T169
findings	B-T033
of	O
51	O
women	B-T098
with	O
breast cancer	B-T191
undergoing	O
neoadjuvant therapy	B-T061
were	O
recorded.	O
MBI	B-T060
findings	B-T033
were	O
correlated	B-T080
with	O
surgical pathology results	B-T170
.	O
Accuracy	B-T080
of	O
MBI	B-T060
in	O
predicting	O
complete pathological response	B-T033
and	O
size	B-T082
of	O
residual disease	B-T191
was	O
assessed	O
according	O
to	O
molecular	B-T080
subtypes	B-T185
.	O
The	O
size	B-T082
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-T060
correlated	B-T080
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	B-T169
(r	O
=	O
0.55;	O
P	O
<	O
.001).	O
This	O
correlation	B-T080
was	O
stronger	O
for	O
triple negative	B-T191
and	O
HER2/neu positive	B-T201
subtypes	B-T185
(r	O
=	O
0.92	O
and	O
0.62,	O
respectively).	O
Sixteen	O
patients	B-T101
(31%)	O
had	O
complete pathological response	B-T033
.	O
The	O
sensitivity	B-T081
and	O
specificity	B-T081
of	O
MBI	B-T060
for	O
detecting	O
residual disease	B-T191
were	O
83%	O
(95%	O
confidence interval	B-T081
[	O
CI	B-T081
],	O
66-93)	O
and	O
69%	O
(95%	O
CI	B-T081
,	O
42-88),	O
respectively.	O
For	O
triple negative	B-T191
or	O
HER2/neu positive	B-T201
disease	O
the	O
sensitivity	B-T081
and	O
specificity	B-T081
were	O
88%	O
(95%	O
CI	B-T081
,	O
62-98)	O
and	O
75%	O
(95%	O
CI	B-T081
,	O
43-93),	O
respectively.	O
The	O
accuracy	B-T080
of	O
MBI	B-T060
in	O
assessing	O
residual disease	B-T191
after	O
neoadjuvant treatment	B-T061
might	O
be	O
related	O
to	O
the	O
molecular	B-T080
subtype	B-T185
.	O
Accuracy	B-T080
is	O
highest	O
in	O
the	O
triple negative	B-T191
and	O
HER2/neu positive	B-T201
subtypes	B-T185
.	O

The	O
relationship	B-T080
between	O
histological	B-T169
prostatitis	B-T047
and	O
lower urinary tract symptoms	B-T184
and	O
sexual function	B-T040
This	O
prospective analysis	B-T062
assessed	B-T052
the	O
effect	B-T080
of	O
histological	B-T169
prostatitis	B-T047
on	O
lower urinary tract	B-T022
functions	B-T169
and	O
sexual function	B-T040
.	O
The	O
patients	B-T101
were	O
separated	B-T080
into	O
two	O
groups	B-T078
as	O
histologically	B-T169
observed	B-T169
prostatitis	B-T047
(	O
Group A	B-T078
)	O
and	O
no prostatitis	B-T033
(	O
Group B	B-T078
)	O
according	O
to	O
the	O
biopsy	B-T060
outcomes	B-T169
.	O
International prostate symptom score	B-T170
,	O
international index of erectile function-5 scores	B-T201
,	O
maximal	B-T033
and	O
average flow rate	B-T033
,	O
and	O
residual urine volumes	B-T033
were	O
compared	B-T052
statistically	O
between	O
groups	B-T078
.	O
There	O
was	O
no	O
significant	B-T081
difference	B-T080
(P>0.05)	O
in	O
baseline	B-T081
age	B-T032
(t=0.64),	O
body mass index value	B-T201
(t=0.51),	O
prostate volume	B-T081
(t=0.87),	O
prostate-specific antigen levels	B-T059
(t=0.43),	O
maximal	B-T033
(t=0.84)	O
and	O
average flow rate	B-T033
(t=0.59),	O
and	O
post-void	B-T079
residual urine volume	B-T033
(t=0.71).	O
Mean	B-T081
international prostate symptom score	B-T170
in	O
patients	B-T101
with	O
prostatitis	B-T047
was	O
numerically	B-T081
but	O
not	O
significantly higher	B-T081
than	O
that	O
in	O
those	O
without	B-T080
prostatitis	B-T047
(t=0.794,	O
P=0.066).	O
Mean	B-T081
international index of erectile function-5 score	B-T201
in	O
the	O
prostatitis	B-T047
group	B-T078
was	O
significantly lower	B-T081
than	O
that	O
in	O
those	O
without	B-T080
prostatitis	B-T047
(t=1.854,	O
P=0.013).	O
Histological	B-T169
prostatitis	B-T047
notably	O
affected	B-T169
sexual function	B-T040
of	O
patients	B-T101
and	O
may	O
serve	O
as	O
a	O
major	B-T080
risk factor	B-T033
for	O
sexual dysfunction	B-T047
while	O
having	O
little	O
effect	B-T080
on	O
lower urinary tract symptoms	B-T184
.	O

Beyond	O
"	O
Median	B-T081
Waiting Time	B-T079
":	O
Development	B-T169
and	O
Validation	B-T062
of	O
a	O
Competing	O
Risk Model	B-UnknownType
to	O
Predict	B-T078
Outcomes	B-T169
on	O
the	O
Kidney	B-T023
Transplant Waiting List	B-T170
Median	B-T081
historical	B-T079
time	B-T079
to	O
kidney transplant	B-T061
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	B-T078
of	O
death	B-T040
or	O
removal from the waiting list	B-T033
.	O
We	O
developed	O
and	O
validated	O
a	O
competing	O
risk model	B-UnknownType
to	O
calculate	B-T052
likelihood	O
of	O
outcomes	B-T080
for	O
kidney transplant	B-T061
candidates	B-T098
and	O
demonstrate	O
how	O
this	O
information	B-T078
differs	B-T080
from	O
median	B-T081
time	B-T079
to	O
transplant	B-T061
.	O
Data	B-T078
were	O
obtained	B-T169
from	O
the	O
US Scientific Registry	B-T170
of	O
Transplant Recipients	B-T101
.	O
The	O
retrospective cohort	B-T062
included	O
163	O
636	O
adults	B-T100
listed	O
for	O
kidney transplant	B-T061
before	O
December	O
31,	O
2011.	O
Predictors	B-T033
were	O
age	B-T032
,	O
sex	B-T032
,	O
blood type	B-T201
,	O
calculated	B-T059
panel-reactive antibodies	B-T059
,	O
donation	B-T061
service area	B-T083
,	O
dialysis	B-T061
duration	B-T079
,	O
comorbid conditions	B-T033
,	O
and	O
body mass index	B-T201
.	O
Outcomes	B-T080
were	O
deceased	O
or	O
living donor	B-T098
transplant	B-T061
,	O
death	B-T040
or	O
removal from the list	B-T033
due to	B-T169
deteriorating	B-T080
medical	B-T169
condition	B-T080
,	O
or	O
removal	B-T033
due to	B-T169
other reasons	B-T033
.	O
We	O
calculated	B-T169
hazards	B-T080
for	O
the	O
possible	B-T033
outcomes	B-T080
,	O
then	O
the	O
cumulative	B-T080
incidence	B-T081
function	B-T039
for	O
a	O
given	O
candidate	B-T098
using	O
competing	O
risk	B-T078
methodology	B-T078
.	O
Discrimination	B-T041
and	O
calibration	B-T081
were	O
assessed	B-T052
through	B-T169
C statistics	B-UnknownType
and	O
calibration	B-T081
plots	B-T169
for	O
each	B-T081
cause	B-T169
-	O
specific	B-T080
Cox proportional hazard model	B-T081
.	O
C statistics	B-UnknownType
ranged	O
from	O
0.64	O
to	O
0.73.	O
Calibration	B-T081
plots	B-T169
showed	O
good	B-T080
calibration	B-T081
.	O
The	O
competing	O
risk model	B-UnknownType
shows	O
probability	B-T081
of	O
all	O
possible	B-T033
outcomes	B-T080
for	O
up	O
to	O
12 years	B-T079
given	O
a	O
candidate's	B-T098
characteristics	B-T080
,	O
contrasted	O
with	O
the	O
median	B-T081
waiting time	B-T079
for	O
that	O
candidate's	B-T098
donation	B-T061
service area	B-T083
.	O
A	O
competing	O
risk model	B-UnknownType
conveys	O
more	O
relevant	B-T080
information	B-T078
than	O
the	O
median	B-T081
waiting time	B-T079
for	O
a	O
given	B-T077
transplant center	B-T093
.	O
This	O
model	B-T081
will	O
be	O
updated	B-T079
to	O
create	B-T052
a	O
calculator	O
reflecting	O
the	O
most	O
recent	B-T079
outcomes	B-T080
and	O
changes	B-T169
in	O
allocation	B-T052
policy	B-T170
.	O
It	O
illustrates	O
the	O
conversations	B-T054
that	O
should	O
be	O
initiated	B-T169
with	O
transplant	B-T061
candidates	B-T098
.	O

Tead1	B-T028
regulates	O
the	O
expression	B-T045
of	O
Peripheral Myelin Protein 22	B-T028
during	O
Schwann cell development	B-T043
Schwann cells	B-T025
are	O
myelinating glia	B-T025
in	O
the	O
peripheral nervous system	B-T022
that	O
form	O
the	O
myelin sheath	B-T026
.	O
A	O
major	O
cause	O
of	O
peripheral neuropathy	B-T047
is	O
a	O
copy number variant	B-T086
involving	O
the	O
Peripheral Myelin Protein 22 (PMP22) gene	B-T028
,	O
which	O
is	O
located	O
within	O
a	O
1.4-Mb	O
duplication	B-T045
on	O
chromosome 17	B-T026
associated	O
with	O
the	O
most	O
common	O
form	O
of	O
Charcot-Marie-Tooth Disease	B-T047
(	O
CMT1A	B-T047
).	O
Rodent models	B-T050
of	O
CMT1A	B-T047
have	O
been	O
used	O
to	O
show	O
that	O
reducing	O
Pmp22	B-T028
overexpression	B-T045
mitigates	O
several	O
aspects	O
of	O
a	O
CMT1A	B-T047
-related	O
phenotype	B-T032
.	O
Mechanistic	B-T169
studies	B-T062
of	O
Pmp22	B-T028
regulation	B-T045
identified	O
enhancers	B-T114
regulated	O
by	O
the	O
Sox10	B-T116
(	O
SRY sex determining region Y-box 10	B-T116
)	O
and	O
Egr2	B-T116
/	O
Krox20	B-T116
(	O
Early growth response protein 2	B-T116
)	O
transcription factors	B-T116
in	O
myelinated nerves	B-T026
.	O
However,	O
relatively	O
little	O
is	O
known	O
regarding	O
how	O
other	O
transcription factors	B-T116
induce	B-T169
Pmp22	B-T028
expression	B-T045
during	O
Schwann cell development	B-T043
and	O
myelination	B-T043
.	O
Here,	O
we	O
examined	O
Pmp22	B-T028
enhancers	B-T114
as	O
a	O
function	O
of	O
cell type-specificity	B-T044
,	O
nerve injury	B-T037
and	O
development	B-T169
.	O
While	O
Pmp22	B-T028
enhancers	B-T114
marked	O
by	O
active	B-T169
histone modifications	B-T044
were	O
lost	B-T169
or	O
remodeled	O
after	O
injury	B-T037
,	O
we	O
found	O
that	O
these	O
enhancers	B-T114
were	O
permissive	O
in	O
early	O
development	B-T169
prior	O
to	O
Pmp22	B-T028
upregulation	B-T044
.	O
Pmp22	B-T028
enhancers	B-T114
contain	O
binding motifs	B-T116
for	O
TEA domain	B-T116
(	O
Tead	B-T116
)	O
transcription factors	B-T116
of	O
the	O
Hippo signaling pathway	B-T043
.	O
We	O
discovered	O
that	O
Tead1	B-T028
and	O
co-activators	O
Yap	B-T028
and	O
Taz	B-T028
are	O
required	O
for	O
Pmp22	B-T028
expression	B-T045
,	O
as	O
well	O
as	O
for	O
the	O
expression	B-T045
of	O
Egr2	B-T028
Tead1	B-T028
directly	O
binds	O
Pmp22	B-T028
and	O
Egr2	B-T028
enhancers	B-T114
early	O
in	O
development	B-T169
and	O
Tead1	B-T028
binding	B-T044
is	O
induced	B-T169
during	O
myelination	B-T043
,	O
correlating	O
with	O
Pmp22	B-T028
expression	B-T045
.	O
The	O
data	B-T078
identify	O
Tead1	B-T028
as	O
a	O
novel	O
regulator	B-T028
of	O
Pmp22	B-T028
expression	B-T045
during	O
development	B-T169
in	O
concert	O
with	O
Sox10	B-T028
and	O
Egr2	B-T028
.	O

Neutrophil gelatinase-associated lipocalin	B-T116
in	O
a	O
triphasic	B-T079
rat model	B-T008
of	O
adenine	B-T114
-	O
induced	B-T169
kidney injury	B-T037
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NGAL	B-T116
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	B-T201
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal tubulointerstitial insult	B-T047
caused	O
by	O
adenine	B-T114
.	O
Subsequently,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
NGAL	B-T116
as	O
a	O
biomarker	B-T201
of	O
any	O
acute kidney injury	B-T037
,	O
on	O
top	O
of	O
chronic interstitial disease	B-T047
,	O
if	O
NGAL	B-T116
levels	B-T080
are	O
stable	B-T080
through	B-T169
the	O
chronic phase	B-T079
of	O
our	O
adenine model	B-T008
.	O
Study group	B-T098
rats	B-T015
were	O
fed	O
an	O
adenine	B-T114
diet	B-T168
,	O
and	O
control group	B-T096
rats	B-T015
were	O
fed	O
a	O
regular diet	B-T056
only.	O
Blood	B-T031
and	O
urine samples	B-T031
for	O
urea	B-T109
,	O
creatinine	B-T109
and	O
NGAL	B-T116
were	O
drawn	O
from	O
each	O
rat	B-T015
at	O
the	O
beginning	B-T079
of	O
the	O
study	B-T062
and	O
after	O
1,	O
3,	O
4,	O
5,	O
6,	O
7	O
and	O
8	O
weeks.	O
Kidney	B-T023
slices	B-T167
from	O
these	O
rats	B-T015
were	O
stained	B-T059
with	O
Hematoxylin-eosin	B-T059
(	O
HE	B-T059
)	O
and	O
β-actin	B-T116
stainings	B-T059
.	O
Serum urea	B-T034
,	O
creatinine	B-T059
and	O
NGAL	B-T116
levels	B-T080
and	O
urinary NGAL/creatinine ratio	B-T201
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	B-T081
and	O
than	O
in	O
the	O
control group	B-T096
;	O
these	O
differences	O
were	O
statistically significant	B-T081
in	O
some	O
of	O
the	O
intervals	B-T079
.	O
Tubulointerstitial	B-T047
changes	O
and	O
adenine	B-T114
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	B-T015
.	O
In	O
the	O
rats	B-T015
fed	O
adenine	B-T114
,	O
serum urea	B-T034
,	O
creatinine	B-T059
and	O
NGAL	B-T116
levels	B-T080
and	O
urinary NGAL/creatinine ratio	B-T201
followed	O
a	O
triphasic pattern	B-T033
of	O
kidney injury	B-T037
:	O
an	O
acute phase	B-T079
while	O
on	O
the	O
adenine	B-T114
diet	B-T168
,	O
a	O
partial	B-T081
recovery	B-T040
phase	B-T079
after	O
switching	O
to	O
the	O
regular diet	B-T056
and	O
a	O
chronic kidney disease	B-T047
phase	B-T079
after	O
stabilization	O
of	O
renal function	B-T042
.	O
NGAL	B-T116
can	O
serve	O
a	O
biomarker	B-T201
for	O
acute kidney injury	B-T037
and	O
possibly	O
for	O
chronic kidney disease	B-T047
in	O
the	O
tubulointerstitial	B-T047
rat model	B-T008
.	O

Talking	B-T056
or	O
Keeping Silent	B-T080
About	O
Parental	B-T099
Mental Health Problems	B-T033
-A	O
Grounded Theory	B-T170
of	O
Parents	B-T099
'	O
Decision Making	B-T041
and	O
Experiences	B-T041
with	O
Their	O
Children	B-T100
This	O
grounded theory	B-T170
study	B-T062
explored	O
parents	B-T099
'	O
experiences	B-T041
of	O
responding	O
to	O
their	O
children's	B-T100
need	O
for	O
understanding	O
parental	B-T099
mental health	B-T041
concerns	B-T078
.	O
Fifteen	O
parents	B-T099
with	O
severe	B-T080
and	O
enduring	O
mental health difficulties	B-T033
participated	O
in	O
the	O
study	B-T062
.	O
The	O
findings	B-T033
suggest	O
four	O
main	O
social processes	B-T068
that	O
influence	O
parents	B-T099
'	O
talk	B-T056
with	O
their	O
children	B-T100
about	O
parental	B-T099
mental health issues	B-T033
,	O
namely	O
"	O
Protecting	B-T041
and	O
being protected	B-T041
,"	O
"	O
Responding	B-T032
to	O
children's	B-T100
search	B-T052
for	O
understanding	B-T041
,"	O
"	O
Prioritizing	B-T079
family life	B-T054
,"	O
and	O
"	O
Relating to others	B-T053
."	O
Implications	O
of	O
the	O
findings	B-T033
for	O
clinical practice	B-T058
and	O
future	O
research	B-T062
are	O
considered.	O
In	O
particular,	O
the	O
need	O
for	O
more	O
family-orientated services	B-T058
where	O
parents	B-T099
experience	B-T041
parental	B-T099
mental health problems	B-T033
is	O
highlighted.	O

A	O
case	B-T077
of	O
bilateral	B-T082
pneumothoraces	B-T047
resulting	O
from	O
tracheostomy	B-T061
for	O
advanced	B-UnknownType
laryngeal cancer	B-T191
Pneumothorax	B-T047
is	O
a	O
possible	O
complication	B-T046
of	O
tracheostomy	B-T061
.	O
We	O
report	B-T058
a	O
rare	O
case	O
of	O
bilateral	B-T082
pneumothoraces	B-T047
resulting	O
from	O
tracheostomy	B-T061
in	O
an	O
advanced	B-UnknownType
laryngeal cancer	B-T191
patient	B-T101
.	O
A	O
59-year-old	O
man	B-T032
was	O
referred	O
to	O
our	O
clinic	B-T073
for	O
evaluation	B-T058
and	O
treatment	B-T061
of	O
laryngeal tumor	B-T191
.	O
Laryngeal endoscopy	B-T060
showed	O
limited movement	B-T033
of	O
bilateral vocal cords	B-T023
,	O
and	O
computed tomography	B-T060
revealed	O
a	O
tumor	B-T191
lesion	B-T033
extending	O
from	O
the	O
vocal cords	B-T023
to	O
the	O
subglottic area	B-T023
.	O
Three	O
days	B-T079
after	O
the	O
first visit	B-T033
,	O
the	O
patient	B-T101
developed	O
respiratory difficulty	B-T184
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency tracheostomy	B-T061
for	O
airway management	B-T061
.	O
Immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	B-T061
,	O
he	O
began	O
hyperventilating	B-T033
,	O
and	O
complained	O
of	O
respiratory discomfort	B-T033
and	O
chest pain	B-T184
.	O
We	O
then	O
recognized	O
a	O
mediastinal	B-T029
air leak	B-T047
,	O
and	O
we	O
suspected	B-T080
pneumothorax	B-T047
resulting	O
from	O
the	O
tracheostomy	B-T061
.	O
Chest X-ray	B-T060
showed	O
bilateral	B-T082
pneumothoraces	B-T047
;	O
therefore,	O
we	O
inserted	B-T058
bilateral	B-T082
chest	B-T029
drainage tubes	B-T074
,	O
which	O
stabilized	B-T033
his	O
respiratory condition	B-T033
.	O
We	O
speculated	O
that	O
the	O
pathogenesis	B-T046
of	O
the	O
bilateral	B-T082
pneumothoraces	B-T047
was	O
weakened	B-T080
alveolar walls	B-T023
secondary	O
to	O
long-term	B-T079
smoking	B-T055
,	O
and	O
a	O
significant	O
rise	B-T169
in	O
airway pressure	B-T201
because	O
of	O
airway constriction	B-T184
by	O
the	O
neck-extended position	B-T082
and	O
hyperventilation	B-T033
,	O
during	O
tracheostomy	B-T061
.	O

Arsenic Triglutathione	B-T116
[	O
As(GS)3	B-T116
]	O
Transport	B-T043
by	O
Multidrug Resistance Protein 1	B-T116
(	O
MRP1	B-T116
/	O
ABCC1	B-T116
)	O
Is	O
Selectively	O
Modified	B-T169
by	O
Phosphorylation	B-T044
of	O
Tyr920/Ser921	B-T087
and	O
Glycosylation	B-T044
of	O
Asn19/Asn23	B-T087
The	O
ATP-binding cassette (ABC) transporter	B-T116
multidrug resistance protein 1	B-T116
(	O
MRP1	B-T116
/	O
ABCC1	B-T116
)	O
is	O
responsible	O
for	O
the	O
cellular	B-T025
export	B-T067
of	O
a	O
chemically	O
diverse	B-T080
array	B-T082
of	O
xenobiotics	B-T123
and	O
endogenous	B-T169
compounds	B-T167
.	O
Arsenic	B-T121
,	O
a	O
human	B-T016
carcinogen	B-T131
,	O
is	O
a	O
high-affinity	B-T080
MRP1	B-T116
substrate	B-T167
as	O
arsenic triglutathione	B-T116
[	O
As(GS)3	B-T116
].	O
In	O
this	O
study,	O
marked	O
differences	O
in	O
As(GS)3	B-T116
transport	B-T043
kinetics	B-T090
were	O
observed	O
between	O
MRP1	B-T116
-enriched	O
membrane	B-T026
vesicles	B-T026
prepared	B-T052
from	O
human	B-T016
embryonic	B-T018
kidney	B-T023
293 (HEK)	B-T025
(	O
Km	B-T081
3.8	O
µM	O
and	O
Vmax	B-T067
307	O
pmol/mg	O
per	O
minute)	O
and	O
HeLa	B-T025
(	O
Km	B-T081
0.32	O
µM	O
and	O
Vmax	B-T067
42	O
pmol/mg	O
per	O
minute)	O
cells	B-T025
.	O
Mutant	B-T116
MRP1	B-T116
lacking	O
N-linked	O
glycosylation	B-T044
[	O
Asn19/23/1006Gln	B-T087
;	O
sugar-free	O
(SF)-MRP1	B-T116
]	O
expressed	B-T045
in	O
either	O
HEK293	B-T025
or	O
HeLa cells	B-T025
had	O
low	O
Km	B-T081
and	O
Vmax	B-T067
values	O
for	O
As(GS)3	B-T116
,	O
similar	B-T080
to	O
HeLa wild-type	B-T025
(WT)	O
MRP1	B-T116
.	O
When	O
prepared	B-T052
in	O
the	O
presence	B-T033
of	O
phosphatase inhibitors	B-T121
,	O
both	O
WT-	B-T116
and	O
SF-MRP1	B-T116
-enriched	O
membrane	B-T026
vesicles	B-T026
had	O
a	O
high	O
Km	B-T081
value	O
for	O
As(GS)3	B-T116
(3-6	O
µM),	O
regardless	O
of	O
the	O
cell line	B-T025
.	O
Kinetic parameters	B-T033
of	O
As(GS)3	B-T116
for	O
HEK	B-T025
-	O
Asn19/23Gln-MRP1	B-T116
were	O
similar	B-T080
to	O
those	O
of	O
HeLa	B-T025
/	O
HEK	B-T025
-	O
SF-MRP1	B-T116
and	O
HeLa-WT	B-T025
-	O
MRP1	B-T116
,	O
whereas	O
those	O
of	O
single	B-T081
glycosylation	B-T044
mutants	B-T116
were	O
like	O
those	O
of	O
HEK-WT	B-T025
-MRP1.	O
Mutation	B-T045
of	O
19	O
potential	B-T080
MRP1	O
phosphorylation	B-T044
sites	B-T082
revealed	O
that	O
HEK	B-T025
-	O
Tyr920Phe/Ser921Ala-MRP1	B-T116
transported	B-T043
As(GS)3	B-T116
like	O
HeLa-WT	B-T025
-	O
MRP1	B-T116
,	O
whereas	O
individual	O
HEK	B-T025
-	O
Tyr920Phe-	B-T116
and	O
-	O
Ser921Ala-MRP1	B-T116
mutants	B-T116
were	O
similar	B-T080
to	O
HEK-WT	B-T025
-	O
MRP1	B-T116
.	O
Together,	O
these	O
results	B-T033
suggest	O
that	O
Asn19/Asn23	B-T087
glycosylation	B-T044
and	O
Tyr920/Ser921	B-T087
phosphorylation	B-T044
are	O
responsible	O
for	O
altering	B-T169
the	O
kinetics	B-T090
of	O
MRP1	B-T116
-mediated	O
As(GS)3	B-T116
transport	B-T043
.	O
The	O
kinetics	B-T090
of	O
As(GS)3	B-T116
transport	B-T043
by	O
HEK	B-T025
-	O
Asn19/23Gln/Tyr920Glu/Ser921Glu	B-T087
were	O
similar	B-T080
to	O
HEK-WT	B-T025
-	O
MRP1	B-T116
,	O
indicating	O
that	O
the	O
phosphorylation	B-T044
-mimicking	O
substitutions	O
abrogated	O
the	O
influence	B-T077
of	O
Asn19/23Gln	B-T087
glycosylation	B-T044
.	O
Overall,	O
these	O
data	O
suggest	O
that	O
cross-talk	O
between	O
MRP1	B-T116
glycosylation	B-T044
and	O
phosphorylation	B-T044
occurs	O
and	O
that	O
phosphorylation	B-T044
of	O
Tyr920	B-T087
and	O
Ser921	B-T087
can	O
switch	O
MRP1	B-T116
to	O
a	O
lower-affinity	B-T080
,	O
higher-capacity	B-T080
As(GS)3	B-T116
transporter	B-T116
,	O
allowing	O
arsenic	B-T121
detoxification	B-T043
over	O
a	O
broad	B-T082
concentration	B-T081
range	B-T081
.	O

Naphthohydroquinones	B-T121
,	O
naphthoquinones	B-T109
,	O
anthraquinones	B-T109
,	O
and	O
a	O
naphthohydroquinone	B-T121
dimer	B-T104
isolated	B-T169
from	O
the	O
aerial parts	B-T002
of	O
Morinda parvifolia	B-T002
and	O
their	O
cytotoxic effects	B-T049
through	O
up-regulation	B-T045
of	O
p53	B-T028
Five	O
unknown	B-T080
compounds	B-T121
,	O
morindaparvins C-G	B-T121
,	O
consisting	O
of	O
naphthohydroquinones	B-T121
,	O
a	O
naphthoquinone	B-T109
,	O
an	O
anthraquinone	B-T109
,	O
and	O
a	O
naphthohydroquinone	B-T121
dimer	B-T104
,	O
together	O
with	O
three	O
known	O
quinones	B-T109
and	O
seven	O
other	O
known	O
compounds	B-T121
,	O
were	O
isolated	B-T169
from	O
the	O
aerial parts	B-T002
of	O
Morinda parvifolia	B-T002
.	O
The	O
structures	O
of	O
morindaparvins C	B-T121
,	O
D	B-T121
,	O
E	B-T121
,	O
F	B-T121
,	O
and	O
G	B-T121
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-T059
or	O
X-ray diffraction analysis	B-T059
as	O
methyl 4-hydroxy-1,6-dimethoxy-naphthalene-2-carboxylate	B-T121
,	O
methyl 4,8-dihydroxy-1-methoxy-naphthalene-2-carboxylate	B-T121
,	O
3-amino-6-methoxy-2-methoxycarbonyl-1,4-naphthoquinone	B-T121
,	O
1,4-dihydroxy-7-hydroxymethyl-anthraquinone	B-T121
,	O
and	O
dimethyl 1,1'-dihydroxy-4,4',7,7'-tetramethoxy-2,2'-binaphthalene-3,3'-dicarboxylate	B-T121
,	O
respectively.	O
Naphthoquinones	B-T109
and	O
naphthohydroquinone	B-T121
dimers	B-T104
were	O
previously	O
unknown	B-T080
in	O
the	O
genus	B-T185
Morinda	B-T002
.	O
In	O
addition,	O
the	O
compounds	B-T121
were	O
tested	B-T169
for	O
cytotoxicity	B-T049
against	O
four	O
human	B-T016
cancer cell lines	B-T025
HeLa	B-T025
,	O
A2780	B-T025
,	O
Ketr3	B-T025
and	O
MCF-7	B-T025
and	O
their	O
effects	B-T080
on	O
p53	B-T028
-	O
activated	B-T052
transcription	B-T045
.	O
Three	O
naphthoquinones	B-T109
had	O
moderate	B-T080
cytotoxic effects	B-T049
with	O
IC50	B-T081
values	O
ranging	B-T081
from	O
1.51	O
to	O
9.56	O
μM,	O
through	O
up-regulation	B-T045
of	O
p53	B-T028
transcriptional activity	B-T045
.	O

Identification	B-T041
and	O
SAR	B-T080
Evaluation	B-T058
of	O
Hemozoin	B-T109
-	O
Inhibiting	B-T052
Benzamides	B-T109
Active	B-T169
against	O
Plasmodium falciparum	B-T204
Quinoline	B-T109
antimalarials	B-T121
target	B-T169
hemozoin	B-T109
formation	B-T169
causing	O
a	O
cytotoxic	B-T169
accumulation	B-T033
of	O
ferriprotoporphyrin IX	B-T109
(	O
Fe(III)PPIX	B-T109
).	O
Well-developed	O
SAR	B-T080
models	B-T170
exist	O
for	O
β-hematin	B-T109
inhibition	B-T052
,	O
parasite	B-T204
activity	B-T052
,	O
and	O
cellular mechanisms	B-T044
for	O
this	O
compound class	B-T170
,	O
but	O
no	O
comparably	O
detailed	O
investigations	B-T033
exist	O
for	O
other	O
hemozoin	B-T109
inhibiting	B-T052
chemotypes	B-T121
.	O
Here,	O
benzamide	B-T109
analogues	B-T104
based	O
on	O
previous	O
HTS	B-T059
hits	O
have	O
been	O
purchased	B-T052
or	O
synthesized	B-T052
.	O
Only	O
derivatives containing an electron deficient aromatic ring	B-T104
and	O
capable	O
of	O
adopting	O
flat conformations	B-T082
,	O
optimal	O
for	O
π-π interactions	B-T169
with	O
Fe(III)PPIX	B-T109
,	O
inhibited	B-T080
β-hematin	B-T109
formation	B-T169
.	O
The	O
two	O
most	O
potent	O
analogues	B-T104
showed	O
nanomolar	B-T081
parasite	B-T204
activity	B-T052
,	O
with	O
little	O
CQ	B-T109
cross-resistance	B-T046
,	O
low	O
cytotoxicity	B-T049
,	O
and	O
high	O
in vitro	B-T080
microsomal	B-T080
stability	B-T080
.	O
Selected	O
analogues	B-T104
inhibited	B-T080
hemozoin	B-T109
formation	B-T169
in	O
Plasmodium falciparum	B-T204
causing	O
high	O
levels	B-T080
of	O
free	O
heme	B-T109
.	O
In	O
contrast	O
to	O
quinolines	B-T109
,	O
introduction	B-T169
of	O
amine side chains	B-T104
did	O
not	O
lead	O
to	O
benzamide	B-T109
accumulation	B-T033
in	O
the	O
parasite	B-T204
.	O
These	O
data	B-T078
reveal	O
complex	O
relationships	B-T080
between	O
heme binding	B-T044
,	O
free	O
heme	B-T109
levels	B-T080
,	O
cellular accumulation	B-T043
,	O
and	O
in vitro	B-T080
activity	B-T052
of	O
potential	O
novel	B-T080
antimalarials	B-T121
.	O

Shear modulus	B-T081
of	O
structured	B-T082
electrorheological fluid	B-T167
mixtures	B-T167
Some	O
immiscible blends	B-T167
under	O
a	O
strong	O
electric field	B-T070
often	O
exhibit	O
periodic	B-T079
structures	B-T082
,	O
bridging	O
the	O
gap	O
between	O
two	O
electrodes	B-T074
.	O
Upon	O
shear	B-T070
,	O
the	O
structures	B-T082
tilt	B-T080
,	O
and	O
exhibit	O
an	O
elastic	B-T169
response	O
which	O
is	O
mostly	O
governed	O
by	O
the	O
electric energy	B-T070
.	O
Assuming	O
a	O
two-dimensional	B-T081
stripe structure	B-T082
,	O
we	O
calculate	O
the	O
Maxwell stress	B-T070
,	O
and	O
derive	O
an	O
expression	B-T078
for	O
the	O
shear modulus	B-T081
,	O
demonstrating	O
how	O
it	O
depends	O
on	O
the	O
external	O
electric field	B-T070
,	O
the	O
composition	B-T070
,	O
and	O
the	O
dielectric properties	B-T081
of	O
the	O
blend	B-T167
.	O
We	O
also	O
suggest	O
the	O
notion	O
of	O
effective	O
interfacial tension	B-T070
,	O
which	O
renormalizes	O
the	O
effect of	B-T080
the	O
electric field	B-T070
.	O
This	O
leads	O
to	O
a	O
simple	O
derivation	B-T080
of	O
the	O
scaling law	B-T170
for	O
the	O
selection	O
of	O
the	O
wavelength	B-T081
of	O
the	O
structure	B-T082
formed	O
under	O
an	O
electric field	B-T070
.	O

Sequence-specific DNA binding	B-T045
by	O
long hairpin	B-T104
pyrrole-imidazole polyamides	B-T109
containing	O
an	O
8-amino-3,6-dioxaoctanoic acid	B-T109
unit	O
With	O
the	O
aim	O
of	O
improving	O
aqueous solubility	B-T081
,	O
we	O
designed	B-T052
and	O
synthesized	B-T052
five	O
N-methylpyrrole (Py)-N-methylimidazole (Im) polyamides	B-T109
capable	O
of	O
recognizing	O
9-bp sequences	B-T086
.	O
Their	O
DNA-binding	B-T045
affinities	B-T070
and	O
sequence	B-T086
specificities	B-T081
were	O
evaluated	O
by	O
SPR	B-T063
and	O
Bind-n-Seq analyses	B-T062
.	O
The	O
design	B-T052
of	O
polyamide 1	B-T109
was	O
based	O
on	O
a	O
conventional	O
model	B-T170
,	O
with	O
three	O
consecutive	O
Py	B-T109
or	O
Im	B-T109
rings	O
separated	O
by	O
a	O
β-alanine	B-T116
to	O
match	O
the	O
curvature	O
and	O
twist	B-T082
of	O
long	O
DNA	B-T114
helices	B-T082
.	O
Polyamides 2 and 3	B-T109
contained	O
an	O
8-amino-3,6-dioxaoctanoic acid	B-T109
(	O
AO	B-T109
)	O
unit,	O
which	O
has	O
previously	O
only	O
been	O
used	O
as	O
a	O
linker	B-T109
within	O
linear	O
Py-Im polyamides	B-T109
or	O
between	O
Py	B-T109
Py - Im hairpin motifs	B-T104
Im	B-T109
hairpin	O
motifs	O
for	O
tandem hairpin	B-T104
.	O
It	O
is	O
demonstrated	O
herein	O
that	O
AO	B-T109
also	O
functions	O
as	O
a	O
linker element	B-T109
that	O
can	O
extend	O
to	O
2-bp	B-T086
in	O
hairpin motifs	B-T104
.	O
Notably,	O
although	O
the	O
AO	B-T109
-containing	O
unit	O
can	O
fail	B-T169
to	O
bind	B-T052
the	O
expected	O
sequence	B-T086
,	O
polyamide 4	B-T109
,	O
which	O
has	O
two	O
AO	B-T109
units	O
facing	O
each	O
other	O
in	O
a	O
hairpin form	B-T082
,	O
successfully	O
showed	O
the	O
expected	O
motif	B-T082
and	O
a	O
KD value	B-T081
of	O
16nM	O
was	O
recorded.	O
Polyamide 5	B-T109
,	O
containing	O
a	O
β-alanine-β-alanine	B-T116
unit	O
instead	O
of	O
the	O
AO	B-T109
of	O
polyamide 2	B-T109
,	O
was	O
synthesized	B-T052
for	O
comparison	B-T052
.	O
The	O
aqueous solubilities	B-T081
and	O
nuclear localization	B-T038
of	O
three	O
of	O
the	O
polyamides	B-T109
were	O
also	O
examined.	O
The	O
results	B-T169
suggest	O
the	O
possibility	O
of	O
applying	O
the	O
AO	B-T109
unit	O
in	O
the	O
core	B-T082
of	O
Py-Im polyamide compounds	B-T109
.	O

Causes of Death	B-T033
among	O
Children	B-T100
Aged	B-T032
5	O
to	O
14	O
Years	B-T079
Old	B-T079
from	O
2008	O
to	O
2013	O
in	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(Kersa	O
HDSS),	O
Ethiopia	B-T083
The	O
global	O
burden	O
of	O
mortality among children	B-T081
is	O
still	O
very	O
huge	O
though	O
its	O
trend	B-T079
has	O
started	O
declining	O
following	O
the	O
improvements	B-T077
in	O
the	O
living standard	B-T081
.	O
It	O
presents	O
serious	O
challenges	B-T058
to	O
the	O
well-being	O
of	O
children	B-T100
in	O
many	O
African countries	B-T083
.	O
Today,	O
Sub-Saharan Africa	B-T083
alone	O
accounts	O
for	O
about	O
50%	O
of	O
global	B-T080
child mortality	B-T081
.	O
The	O
overall	O
objective	B-T170
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	B-T081
and	O
distribution	B-T169
of	O
causes of death	B-T033
among	O
children	B-T100
aged	B-T032
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	B-T098
of	O
Kersa	O
HDSS	O
using	O
verbal	B-T080
autopsy	B-T060
method	O
for	O
the	O
period	B-T079
2008	O
to	O
2013.	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(Kersa	O
HDSS)	O
was	O
established	O
in	O
September	B-T079
2007.	O
The	O
center	O
consists	O
of	O
10	O
rural	B-T082
and	O
2	O
urban	B-T082
kebeles	B-T098
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	B-T098
in	O
the	O
district	B-T083
.	O
Thus	O
this	O
study	O
was	O
conducted	O
in	O
Kersa	O
HDSS	O
and	O
data	B-T078
was	O
taken	O
from	O
Kersa HDSS database	B-T170
.	O
The	O
study	B-T062
population	B-T098
included	O
all	O
children	B-T100
aged	B-T032
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	B-T079
of	O
2008	O
to	O
2013	O
in	O
Kersa	O
HDSS	O
using	O
age	B-T032
specific	O
VA	O
questionnaires	B-T170
.	O
Data	B-T078
were	O
extracted	O
from	O
SPSS database	B-T170
and	O
analyzed	O
using	O
STATA	B-T170
.	O
A	O
total	O
of	O
229	O
deaths	B-T033
were	O
recorded	O
over	O
the	O
period	B-T079
of	O
six	O
years	O
with	O
a	O
crude	O
death rate	B-T081
of	O
219.6	O
per	O
100,000	O
population	B-T098
of	O
this	O
age group	B-T100
over	O
the	O
study	B-T062
period	B-T079
.	O
This	O
death rate	B-T081
was	O
217.5	O
and	O
221.5	O
per	O
100,000	O
populations	B-T098
for	O
females	B-T032
and	O
males	B-T032
,	O
respectively.	O
75%	O
of	O
deaths	B-T033
took	O
place	O
at	O
home.	O
The	O
study	B-T062
identified	O
severe	O
malnutrition	B-T047
(33.9%),	O
intestinal infectious diseases	B-T047
(13.8%)	O
and	O
acute lower respiratory infections	B-T047
(9.2%)	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes of death	B-T033
.	O
In	O
broad	O
causes of death	B-T033
classification	B-T185
,	O
injuries	B-T037
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause of death	B-T033
next	O
to	O
communicable diseases	B-T047
(56.3%)	O
attributing	O
to	O
13.1%	O
of	O
the	O
total	O
deaths	B-T033
.	O
In	O
specific	O
causes of death	B-T033
classification	B-T185
severe	O
malnutrition	B-T047
,	O
intestinal infectious diseases	B-T047
and	O
acute lower respiratory infections	B-T047
were	O
the	O
three	O
leading	O
causes of death	B-T033
where,	O
in	O
broad	O
causes of death	B-T033
communicable diseases	B-T047
and	O
injuries	B-T037
were	O
among	O
the	O
leading	O
causes of death	B-T033
.	O
Hence,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	B-T081
from	O
these	O
causes of death	B-T033
and	O
further	O
inferential analysis	B-T062
into	O
the	O
prevention	B-T061
and	O
management	B-T058
of	O
infectious diseases	B-T047
should	O
also	O
be	O
taken.	O

Naïve	B-T025
CD8(+) T cell	B-T025
derived	O
tumor	B-T191
-	O
specific	B-T080
cytotoxic effectors	B-T025
as	O
a	O
potential	O
remedy	B-T077
for	O
overcoming	O
TGF-β	B-T116
immunosuppression	B-T047
in	O
the	O
tumor microenvironment	B-T070
Despite	O
of	O
the	O
potential	O
implications	O
for	O
cancer immunotherapy	B-T061
,	O
conventional	B-T080
approaches	B-T169
using	O
in vitro	B-T080
expanded	B-T082
CD8(+) T cells	B-T025
have	O
suboptimal	B-T080
outcomes	B-T080
,	O
mostly	O
due	O
to	O
loss	B-T081
of	O
functionality	B-T169
from	O
cellular	B-T025
exhaustion	B-UnknownType
.	O
We	O
therefore	O
investigated	O
the	O
phenotypic	B-T032
and	O
functional	B-T169
differences	B-T080
among	O
in vitro	B-T080
activated	B-T052
CD8(+) T cells	B-T025
of	O
three	O
different	O
sources	B-T033
,	O
namely	O
naïve	B-T025
(	O
NTeff	B-T025
),	O
memory	B-T025
(	O
MTeff	B-T025
)	O
and	O
tumor-infiltrating lymphocytes	B-T025
(	O
TILeff	B-T025
)	O
from	O
human	B-T016
and	O
mice	B-T015
,	O
to	O
better	O
understand	O
mechanisms	B-T169
behind	O
potent	O
effector	B-T025
functions	B-T169
and	O
potential	O
for	O
overcoming	O
current	O
limitations	B-T169
.	O
In	O
line	O
with	O
the	O
greater	O
proliferation	B-T043
activity	B-T052
and	O
longer	O
telomere	B-T026
lengths	B-T081
of	O
NTeff populations	B-T025
,	O
cells	B-T025
of	O
naïve origin	B-T079
exhibited	O
significantly	O
less	O
amounts	O
of	O
T cell	B-T025
exhaustion	B-UnknownType
markers	B-T201
than	O
those	O
of	O
MTeff	B-T025
and	O
TILeff	B-T025
,	O
and	O
moreover,	O
acquired	O
distinct	O
expression patterns	B-T045
of	O
memory-promoting transcription factors	B-T116
,	O
T-bet	B-T116
and	O
Eomes	B-T116
,	O
induced	B-T169
in	O
a	O
rapid	B-T080
and	O
sustainable	B-T169
manner	B-T169
.	O
NTeff cells	B-T025
appeared	O
to	O
have	O
lower	O
expression	B-T045
of	O
Foxp1	B-T116
and	O
were	O
refractory	O
to	O
apoptosis	B-T043
upon	O
TGF-β	B-T116
conditioning	B-T169
,	O
implying	O
better	O
survival	B-T043
potential	B-T080
and	O
resistance	B-T169
to	O
tumor	B-T191
-	O
induced	B-T169
immune suppression	B-T047
.	O
Of	O
CD8(+) T cell	B-T025
pools	O
activated	B-T052
to	O
tumor	B-T191
-	O
specific	B-T080
CTLs	B-T025
,	O
naïve cell	B-T025
generated	B-T052
effectors	B-T025
possessed	O
the	O
most	O
potent	O
cytotoxic activity	B-T033
,	O
validating	O
implications	O
for	O
use	O
in	O
rational	O
design	B-T052
of	O
adoptive immunotherapy	B-T061
.	O

Antiadipogenic Activity	B-T033
of	O
γ-Oryzanol	B-T109
and	O
Its	O
Stability	B-T080
in	O
Pigmented	B-T080
Rice	B-T168
γ-Oryzanol	B-T109
,	O
a	O
prevalent	O
compound	O
in	O
pigmented	B-T080
rice	B-T168
varieties	B-T080
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
obesity-associated metabolic disorders	B-T047
.	O
Antiadipogenic activities	B-T033
of	O
γ-oryzanol	B-T109
were	O
determined	O
in	O
human	B-T016
adipose	B-T024
-	O
derived	B-T078
mesenchymal stem cells	B-T025
and	O
mouse	B-T015
-	O
derived	B-T078
3T3-L1 cells	B-T025
.	O
γ-Oryzanol	B-T109
significantly	O
decreased	B-T081
lipid accumulation	B-T033
and	O
reduced	B-T080
glycerol-3-phosphate dehydrogenase activities	B-T044
in	O
both	O
adipocytes	B-T025
.	O
In	O
addition,	O
γ-oryzanol	B-T109
in	O
four	O
pigmented	B-T080
rice	B-T168
varieties	B-T080
(	O
black with giant embryo	B-T168
,	O
brown	B-T168
,	O
sugary brown	B-T168
,	O
and	O
red	B-T168
)	O
was	O
stable	B-T080
when	O
stored	B-T169
at	O
4°C	O
and	O
also	O
at	O
room temperature	B-T080
for	O
22	O
weeks,	O
whereas	O
other	O
bioactives	B-T167
such	O
as	O
lutein	B-T109
and	O
β-carotene	B-T109
were	O
stable	B-T080
only	O
at	O
-80°C.	O
Furthermore,	O
the	O
yield	B-T081
of	O
γ-oryzanol	B-T109
from	O
these	O
rice	B-T168
varieties	B-T080
was	O
significantly	O
increased	O
through	O
steaming	B-T067
and	O
roasting processes	B-T067
.	O
Therefore,	O
γ-oryzanol	B-T109
exerts	O
antiadipogenic activity	B-T033
by	O
suppressing	B-T169
adipocyte differentiations	B-T043
and	O
is	O
stable	B-T080
in	O
pigmented	B-T080
rice	B-T168
for	O
an	O
extended	B-T169
period of time	B-T079
during	O
storage	B-T169
and	O
after	B-T079
cooking	B-T056
.	O
Thus,	O
the	O
intake	B-T169
of	O
pigmented	B-T080
rice	B-T168
may	O
be	O
a	O
useful	O
strategy	O
for	O
preventing	B-T169
obesity	B-T047
.	O

Impact	B-T080
of	O
Chemotherapy	B-T061
on	O
Diet	B-T168
and	O
Nutritional Status	B-T033
of	O
Women	B-T098
with	O
Breast Cancer	B-T191
:	O
A	O
Prospective Study	B-T062
Certain	O
food groups	B-T168
are	O
often	O
rejected	B-T080
during	O
chemotherapy	B-T061
(	O
CT	B-T061
)	O
due	O
to	O
the	O
side effects of treatment	B-T046
,	O
which	O
may	O
interfere with	B-T169
adequate diet	B-UnknownType
and	O
nutritional status	B-T033
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
treatment	B-T169
impact	B-T080
on	O
the	O
diet	B-T168
and	O
nutritional status	B-T033
of	O
women	B-T098
with	O
breast cancer	B-T191
(	O
BC	B-T191
).	O
In	O
this	O
prospective longitudinal study	B-T062
,	O
conducted	O
in	O
2014-2015,	O
55	O
women	B-T098
diagnosed	O
with	O
BC	B-T191
,	O
with	O
a	O
mean	O
age	B-T032
51.5±10.1	O
years	B-T079
,	O
were	O
followed	O
and	O
data	B-T078
were	O
collected	O
at	O
three	O
different	O
times.	O
Anthropometric	B-T081
and	O
dietary assessments	B-T060
were	O
performed,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary recall	B-T061
s,	O
by	O
using	O
the	O
Brazilian Healthy Eating Index Revised	B-T170
(	O
BHEI-R	B-T170
),	O
and	O
calculating	B-T052
the	O
prevalence	B-T081
of	O
inadequacy	B-T080
by	O
the	O
EAR cut-off point method	B-T170
.	O
Regarding	O
the	O
BHEI-R	B-T170
analysis	B-T062
,	O
the	O
majority	O
of	O
women	B-T098
had	O
a	O
"	O
diet	B-T168
requires	O
modification	B-T033
',	O
both	O
at	O
the	O
beginning	B-T079
(T0,	O
58.2%,	O
n	O
=	O
32)	O
and	O
during treatment	B-T079
(T1,	O
54.5%,	O
n	O
=	O
30).	O
However,	O
after	O
the	O
end	O
of	O
the	O
CT	B-T061
,	O
the	O
greater percentage	B-T081
of	O
patients	B-T101
(T2,	O
49.1%,	O
n	O
=	O
27)	O
were	O
classified	O
as	O
having	O
an	O
"	O
inadequate diet	B-T033
",	O
since	O
the	O
Total	B-T080
Fruit	B-T168
consumption	B-T052
as	O
well	O
as	O
the	O
Dark Green	B-T168
and	O
Orange Vegetable	B-T168
and	O
Legume	B-T002
consumption	B-T052
decreased significantly	B-T081
during treatment	B-T079
(p	O
=	O
0.043	O
and	O
p	O
=	O
0.026,	O
respectively).	O
There	O
was	O
a	O
significant reduction	B-T080
in	O
the	O
intake	B-T169
of	O
macro	B-T077
and	O
micronutrients	B-T123
,	O
with	O
a	O
high	O
prevalence	B-T081
of	O
inadequacy	B-T080
,	O
of	O
up	O
to	O
100%,	O
for	O
calcium	B-T197
,	O
iron	B-T197
,	O
phosphorus	B-T196
,	O
magnesium	B-T196
,	O
niacin	B-T109
,	O
riboflavin	B-T109
,	O
thiamin	B-T109
,	O
vitamin B6	B-T109
,	O
vitamin C	B-T109
and	O
zinc	B-T196
.	O
Assessment	B-T060
of	O
the	O
nutritional status	B-T033
indicated	O
that	O
56%	O
(n	O
=	O
31)	O
of	O
patients	B-T101
were	O
overweight	B-T184
at	O
these	O
three	O
different	O
times.	O
Weight	B-T032
,	O
BMI	B-T201
and	O
Waist Circumference	B-T201
increased significantly	B-T081
,	O
indicating	O
a	O
worse	B-T033
nutritional status	B-T033
,	O
and	O
there	O
was	O
a	O
correlation	B-T080
between	O
poor diet quality	B-T080
and	O
higher values	B-T080
for	O
BMI	B-T201
,	O
Waist-Hip Ratio	B-T032
and	O
Waist-to-Height Ratio	B-T033
.	O
Chemotherapy	B-T061
interferes	B-T169
in	O
the	O
patients	B-T101
'	O
diet	B-T168
generating	O
a	O
negative impact	B-T080
on	O
the	O
quality	B-T080
and	O
intake	B-T169
of	O
micro	B-T123
and	O
macronutrients	B-T077
,	O
as	O
well	O
as	O
an	O
impact	B-T080
on	O
their	O
nutritional status	B-T033
,	O
with	O
an	O
increase	O
in	O
anthropometric measurements	B-T081
.	O

Benefit	O
and	O
risk	B-T058
in	O
short	O
term	O
after	O
total hip arthroplasty	B-T061
by	O
direct anterior approach	B-T082
combined	O
with	O
dual mobility cup	B-T074
No	O
previous	O
reports	O
have	O
described	O
the	O
benefits	O
and	O
risks	B-T058
associated	O
with	O
the	O
dual mobility cup	B-T074
(	O
DMC	B-T074
)	O
in	O
primary	O
THA	B-T061
via	O
direct anterior approach	B-T082
(	O
DAA	B-T082
).	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
compare	O
the	O
safety	B-T062
and	O
rate	O
of	O
early	O
postoperative complication	B-T046
of	O
the	O
DAA	B-T082
with	O
the	O
DMC	B-T074
for	O
THA	B-T061
with	O
those	O
of	O
the	O
DAA	B-T082
with	O
a	O
single standard cup	B-T074
,	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-T074
on	O
intra	B-T079
-	O
and	O
perioperative	B-T079
outcomes	B-T169
.	O
We	O
retrospectively	O
investigated	O
60	O
hips	B-T023
treated	B-T061
in	O
the	O
single-	O
DAA	B-T082
group	B-T078
and	O
60	O
hips	B-T023
treated	B-T061
in	O
the	O
dual-	O
DAA	B-T082
group	B-T078
.	O
A	O
primary	B-T080
/	O
secondary	B-T081
outcome	B-T169
variable	O
was	O
the	O
presence	O
of	O
any	O
intra	B-T046
-	O
or	O
perioperative	B-T079
complication	B-T046
within	O
the	O
first	O
6	O
months	B-T079
/the	O
operative time	B-T079
and	O
hip	O
function	O
at	O
6	O
months	B-T079
postoperatively	B-T079
.	O
We	O
also	O
analyzed	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-T074
on	O
intra	B-T079
-	O
and	O
perioperative	B-T079
outcomes	B-T169
.	O
No	B-T033
intraoperative complications	B-T046
were	O
observed	O
in	O
either	O
group	B-T078
.	O
One	O
anterior dislocation	B-T037
and	O
one	O
periprosthetic hip fracture	B-T037
were	O
occurred	O
in	O
the	O
single-	O
DAA	B-T082
group	B-T078
.	O
The	O
surgical times	B-T079
in	O
the	O
single-	O
DAA	B-T082
and	O
dual-	O
DAA	B-T082
groups	B-T078
were	O
112.0	O
±	O
20.9	O
and	O
121.0	O
±	O
26.9	O
min	O
(p	O
<	O
0.001).	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
6-	O
month	B-T079
postoperative	B-T079
hip function scores	B-T081
between	O
the	O
two	O
groups	B-T078
.	O
There	O
was	O
no	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-T074
on	O
intra	B-T079
-	O
and	O
perioperative	B-T079
outcomes	B-T169
.	O
We	O
have	O
demonstrated	O
the	O
short-term	O
safety	B-T062
and	O
lack	O
of	O
inferiority	O
of	O
using	O
the	O
DMC	B-T074
in	O
the	O
DAA	B-T082
compared	O
with	O
the	O
standard single mobility cup	B-T074
.	O

Diffuse traumatic brain injury	B-T037
affects	O
chronic	B-T079
corticosterone	B-T109
function	B-T169
in	O
the	O
rat	B-T015
As	O
many	O
as	O
20-55%	O
of	O
patients	B-T101
with	O
a	O
history	B-T033
of	O
traumatic brain injury	B-T037
(	O
TBI	B-T037
)	O
experience	O
chronic	B-T079
endocrine dysfunction	B-T047
,	O
leading	O
to	O
impaired quality of life	B-T054
,	O
impaired	B-T169
rehabilitation	B-T169
efforts	B-T051
and	O
lowered life expectancy	B-T033
.	O
Endocrine dysfunction	B-T047
after	O
TBI	B-T037
is	O
thought	O
to	O
result	B-T169
from	O
acceleration	B-T067
-	O
deceleration	B-T070
forces	B-T067
to	O
the	O
brain	B-T023
within	O
the	O
skull	B-T023
,	O
creating	O
enduring	O
hypothalamic	B-T023
and	O
pituitary	B-T023
neuropathology	B-T046
,	O
and	O
subsequent	O
hypothalamic	B-T023
hypothalamic -pituitary endocrine	B-T022
(	O
HPE	B-T022
)	O
dysfunction	B-T046
.	O
These	O
experiments	B-T062
were	O
designed	O
to	O
test	O
the	O
hypothesis	B-T078
that	O
a	O
single	O
diffuse TBI	B-T037
results	B-T169
in	O
chronic	B-T079
dysfunction	B-T046
of	O
corticosterone	B-T109
(	O
CORT	B-T109
),	O
a	O
glucocorticoid	B-T109
released	B-T169
in	O
response	O
to	O
stress	B-T046
and	O
testosterone	B-T109
.	O
We	O
used	O
a	O
rodent model	B-T050
of	O
diffuse TBI	B-T037
induced	O
by	O
midline fluid percussion injury	B-T037
(	O
mFPI	B-T037
).	O
At	O
2	O
months	B-T079
postinjury	B-T079
compared	B-T052
with	O
uninjured control animals	B-T008
,	O
circulating	B-T169
levels	B-T080
of	O
CORT	B-T109
were	O
evaluated	O
at rest	B-T169
,	O
under	O
restraint stress	B-T046
and	O
in	O
response	O
to	O
dexamethasone	B-T109
,	O
a	O
synthetic glucocorticoid	B-T109
commonly	O
used	O
to	O
test	O
HPE	B-T022
axis	B-T082
regulation	B-T038
.	O
Testosterone	B-T109
was	O
evaluated	B-T169
at rest	B-T169
.	O
Further,	O
we	O
assessed	O
changes	B-T169
in	O
injury	B-T037
-	O
induced	B-T169
neuron	B-T025
morphology	B-T080
(	O
Golgi stain	B-T059
),	O
neuropathology	B-T046
(	O
silver stain	B-T059
)	O
and	O
activated	B-T043
astrocytes	B-T025
(	O
GFAP	B-T059
)	O
in	O
the	O
paraventricular nucleus	B-T023
(	O
PVN	B-T023
)	O
of	O
the	O
hypothalamus	B-T023
.	O
Resting	O
plasma	B-T031
CORT	B-T109
levels	B-T080
were	O
decreased	B-T081
at	O
2	O
months	B-T079
postinjury	B-T079
and	O
there	O
was	O
a	O
blunted	O
CORT	B-T109
increase	B-T081
in	O
response	O
to	O
restraint induced stress	B-T046
.	O
No changes	B-T033
in	O
testosterone	B-T109
were	O
measured	B-T080
.	O
These	O
changes	B-T169
in	O
CORT	B-T109
were	O
observed	O
concomitantly	B-T079
with	O
altered	B-T169
complexity	B-T080
of	O
neuron	B-T025
processes	B-T043
in	O
the	O
PVN	B-T023
over	O
time	B-T079
,	O
devoid	O
of	O
neuropathology	B-T046
or	O
astrocytosis	B-T046
.	O
Results	B-T169
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse TBI	B-T037
leads	O
to	O
changes	B-T169
in	O
CORT	B-T109
function	B-T169
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence of symptoms	B-T033
related	O
to	O
endocrine dysfunction	B-T047
.	O
Future	O
experiments	B-T062
aim	O
to	O
evaluate	B-T169
additional	O
HP-related hormones	B-T125
and	O
endocrine	B-T022
circuit pathology	B-T169
following	O
diffuse TBI	B-T037
.	O

Methamphetamine	B-T109
,	O
3,4-methylenedioxymethamphetamine	B-T109
(	O
MDMA	B-T109
)	O
and	O
3,4-methylenedioxypyrovalerone	B-T109
(	O
MDPV	B-T109
)	O
induce	B-T169
differential	B-T080
cytotoxic effects	B-T049
in	O
bovine	B-T015
brain	B-T023
microvessel	B-T023
endothelial cells	B-T025
Designer drugs	B-T131
such	O
as	O
synthetic psychostimulants	B-T121
are	O
indicative	O
of	O
a	O
worldwide	O
problem	B-T033
of	O
drug abuse	B-T048
and	O
addiction	B-T048
.	O
In	O
addition	O
to	O
methamphetamine	B-T109
(	O
METH	B-T109
),	O
these	O
drugs	B-T131
include	O
3,4-methylenedioxy-methamphetamine	B-T109
(	O
MDMA	B-T109
)	O
and	O
commercial	B-T170
preparations	B-T052
of	O
synthetic cathinones	B-T109
including	O
3,4-methylenedioxypyrovalerone	B-T109
(	O
MDPV	B-T109
),	O
typically	O
referred	O
to	O
as	O
"	O
bath salts	B-T109
."	O
These	O
psychostimulants	B-T121
exert	O
neurotoxic effects	B-T037
by	O
altering	B-T078
monoamine systems	B-UnknownType
in	O
the	O
brain	B-T023
.	O
Additionally,	O
METH	B-T109
and	O
MDMA	B-T109
adversely affect	B-T046
the	O
integrity	B-T080
of	O
the	O
blood-brain barrier	B-T023
(	O
BBB	B-T023
):	O
there	O
are	O
no	O
current	O
reports	B-T170
on	O
the	O
effects of	B-T080
MDPV	B-T109
on	O
the	O
BBB	B-T023
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
compare	B-T052
the	O
effects of	B-T080
METH	B-T109
,	O
MDMA	B-T109
and	O
MDPV	B-T109
on	O
bovine	B-T015
brain	B-T023
microvessel	B-T023
endothelial cells	B-T025
(	O
bBMVECs	B-T025
),	O
an	O
accepted	O
in vitro model	B-T062
of	O
the	O
BBB	B-T023
.	O
Confluent	B-T080
bBMVEC	B-T025
monolayers	B-T023
were	O
treated	B-T169
with	O
METH	B-T109
,	O
MDMA	B-T109
and	O
MDPV	B-T109
(0.5mM-2.5mM)	O
for	O
24h.	O
METH	B-T109
and	O
MDMA	B-T109
increased	B-T081
lactate dehydrogenase	B-T116
release	B-T169
only	O
at	O
the	O
highest	B-T080
concentration	B-T081
(2.5mM),	O
whereas	O
MDPV	B-T109
induced	B-T169
cytotoxicity	B-T049
at	O
all	O
concentration	B-T081
s.	O
MDMA	B-T109
and	O
METH	B-T109
decreased	B-T081
cellular proliferation	B-T043
only	O
at	O
2.5mM,	O
with	O
similar	O
effects	B-T080
observed	O
after	O
MDPV	B-T109
exposures	B-T080
starting	O
at	O
1mM.	O
Only	O
MDPV	B-T109
increased	B-T081
reactive oxygen species	B-T123
production	B-T052
at	O
all	O
concentrations	B-T081
tested	B-T169
whereas	O
all	O
3	O
drugs	B-T131
increased	B-T081
nitric oxide	B-T121
production	B-T052
.	O
Morphological analysis	B-T062
revealed	O
different	B-T080
patterns	O
of	O
compound	B-T103
-	O
induced	B-T169
cell damage	B-T049
.	O
METH	B-T109
induced	B-T169
vacuole	B-T026
formatio	B-T169
n	O
at	O
1mM	O
and	O
disruption	B-T169
of	O
the	O
monolayer	B-T023
at	O
2.5mM.	O
MDMA	B-T109
induced	B-T169
disruption	B-T169
of	O
the	O
endothelial	B-T025
monolayer	B-T023
from	O
1mM	O
without	O
vacuolization	B-T033
.	O
On	O
the	O
other	O
hand,	O
MDPV	B-T109
induced	B-T169
monolayer	B-T023
disruption	B-T169
at	O
doses	B-T081
≥0.5mM	O
without	O
vacuole	B-T026
formation	B-T169
;	O
at	O
2.5mM,	O
the	O
few	O
remaining	O
cells	B-T025
lacked	O
endothelial morphology	B-T080
.	O
These	O
data	B-T078
suggest	O
that	O
even	O
though	O
these	O
synthetic psychostimulants	B-T121
alter	O
monoaminergic systems	B-UnknownType
,	O
they	O
each	O
induce	B-T169
BBB	B-T023
toxicity	B-T037
by	O
different	B-T080
mechanisms	B-T169
with	O
MDPV	B-T109
being	O
the	O
most	O
toxic	B-T080
.	O

Alleviation	B-T080
of	O
hepatic	B-T029
fat accumulation	B-T033
by	O
betaine	B-T109
involves	O
reduction	B-T080
of	O
homocysteine	B-T116
via	O
up-regulation	B-T044
of	O
betaine-homocysteine methyltransferase	B-T116
(	O
BHMT	B-T116
)	O
We	O
investigated	B-T169
the	O
anti-lipogenic effect	B-T169
of	O
betaine	B-T109
in	O
rats	B-T015
fed	O
methionine	B-T116
and	O
choline	B-T109
-	O
deficient	B-T080
diet	B-T168
(	O
MCD	B-T168
).	O
Intake	O
of	O
MCD	B-T168
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	B-T078
accumulation	B-T033
of	O
hepatic	B-T029
lipids	B-T109
,	O
which	O
was	O
prevented	B-T080
by	O
betaine	B-T109
supplementation	B-T061
in	O
drinking water	B-T167
(1%).	O
Phosphorylation	B-T044
of	O
AMP-activated protein kinase	B-T116
(	O
AMPK	B-T116
),	O
acetyl-CoA carboxylase	B-T116
(	O
ACC	B-T116
),	O
sterol regulatory element-binding protein 1c	B-T116
(	O
SREBP-1c	B-T116
),	O
and	O
liver kinase B1	B-T116
(	O
LKB1	B-T116
)	O
was	O
inhibited	B-T080
by	O
MCD	B-T168
intake	B-T169
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	B-T080
by	O
betaine	B-T109
feeding	B-T058
.	O
Meanwhile,	O
betaine	B-T109
supplementation	B-T061
reversed	B-T169
the	O
reduction	B-T080
of	O
methionine and S-adenosylmethionine	B-T044
(	O
SAM	B-T044
),	O
and	O
the	O
elevation	B-T080
of	O
homocysteine levels	B-T059
in	O
the	O
liver,	B-T023
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	B-T045
of	O
betaine-homocysteine methyltransfease	B-T116
(	O
BHMT	B-T116
)	O
and	O
methionine adenosyltransferase	B-T116
(	O
MAT	B-T116
).	O
Different	B-T080
cell lines	B-T025
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	B-T116
on	O
activation	B-T044
of	O
the	O
AMPK	B-T116
pathway	B-T044
.	O
Homocysteine	B-T116
treatment	B-T169
decreased	B-T081
pAMPK	B-T116
,	O
pACC	B-T116
,	O
pSREBP-1c	B-T116
and	O
pLKB1	B-T116
in	O
HepG2 cells	B-T025
.	O
Metformin	B-T109
-	O
induced	B-T169
activation	B-T044
of	O
AMPK	B-T116
was	O
also	O
inhibited	B-T080
by	O
homocysteine	B-T116
.	O
Treatment	B-T169
with	O
hydroxylamine	B-T197
,	O
a	O
cystathionine β-synthase	B-T116
inhibitor	B-T121
,	O
resulted	O
in	O
a	O
reduction	B-T080
of	O
pAMPK	B-T116
,	O
pACC	B-T116
and	O
pSREBP-1c	B-T116
,	O
accompanied	O
by	O
an	O
elevation	B-T080
of	O
intracellular	B-T082
homocysteine	B-T116
.	O
Betaine	B-T109
treatment	B-T061
prevented	B-T080
the	O
homocysteine	B-T116
-	O
induced	B-T169
reduction	B-T080
of	O
pAMPK	B-T116
,	O
pACC	B-T116
,	O
pSREBP-1c	B-T116
and	O
pLKB1	B-T116
in	O
H4IIE cells	B-T025
,	O
but	O
not	O
in	O
HepG2 cells	B-T025
.	O
Also	O
the	O
elevation	B-T080
of	O
cellular	O
homocysteine	B-T116
and	O
inhibition	B-T052
of	O
protein expression	B-T045
of	O
BHMT	B-T116
were	O
prevented	B-T080
by	O
betaine	B-T109
only	O
in	O
H4IIE cells	B-T025
which	O
express	B-T045
BHMT	B-T116
.	O
The	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	B-T109
against	O
hepatic	B-T029
lipid	B-T109
accumulation	B-T033
may	O
be	O
attributed	B-T078
,	O
at	O
least	O
in	O
part,	O
to	O
the	O
depletion	B-T169
of	O
homocysteine	B-T116
via	O
up-regulation	B-T044
of	O
BHMT	B-T116
in	O
hepatocytes	B-T025
.	O

Dual-color STED microscopy	B-T059
reveals	O
a	O
sandwich structure	B-T082
of	O
Bassoon	B-T116
and	O
Piccolo	B-T116
in	O
active zones	B-T026
of	O
adult	B-T100
and	O
aged	B-T032
mice	B-T015
Presynaptic active zones	B-T026
play	O
a	O
pivotal	O
role	O
as	O
synaptic vesicle	B-T026
release sites	B-T029
for	O
synaptic transmission	B-T043
,	O
but	O
the	O
molecular architecture	B-T082
of	O
active zones	B-T026
in	O
mammalian	B-T015
neuromuscular junctions	B-T026
(	O
NMJs	B-T026
)	O
at	O
sub-diffraction limited resolution	B-T077
remains	O
unknown.	O
Bassoon	B-T116
and	O
Piccolo	B-T116
are	O
active zone	B-T026
specific	O
cytosolic	B-T026
proteins	B-T116
essential	O
for	O
active zone assembly	B-T043
in	O
NMJs	B-T026
,	O
ribbon synapses	B-T030
,	O
and	O
brain	B-T023
synapses	B-T030
.	O
These	O
proteins	B-T116
are	O
thought	O
to	O
colocalize	B-T082
and	O
share	O
some	O
functions	O
at	O
active zones	B-T026
.	O
Here,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non-overlapping localization	B-T043
of	O
these	O
two	O
proteins	B-T116
in	O
mouse	B-T015
NMJs	B-T026
revealed	O
using	O
dual-color stimulated emission depletion	B-T070
(	O
STED	B-T070
)	O
super resolution microscopy	B-T059
.	O
Piccolo	B-T116
puncta	B-T033
sandwiched	O
Bassoon	B-T116
puncta	B-T033
and	O
aligned	B-T081
in	O
a	O
Piccolo	B-T116
-	O
Bassoon	B-T116
-	O
Piccolo	B-T116
structure	B-T082
in	O
adult	B-T100
NMJs	B-T026
.	O
P/Q-type voltage-gated calcium channel	B-T116
(	O
VGCC	B-T116
)	O
puncta	B-T033
colocalized	B-T082
with	O
Bassoon	B-T116
puncta	B-T033
.	O
The	O
P/Q-type VGCC	B-T116
and	O
Bassoon	B-T116
protein levels	B-T034
decreased	B-T081
significantly	O
in	O
NMJs	B-T026
from	O
aged	B-T032
mouse	B-T015
.	O
In	O
contrast,	O
the	O
Piccolo	B-T116
levels	B-T034
in	O
NMJs	B-T026
from	O
aged	B-T032
mice	B-T015
were	O
comparable	O
to	O
levels	B-T034
in	O
adult	B-T100
mice	B-T015
.	O
This	O
study	O
revealed	O
the	O
molecular architecture	B-T082
of	O
active zones	B-T026
in	O
mouse	B-T015
NMJs	B-T026
at	O
sub-diffraction limited resolution	B-T077
,	O
and	O
described	O
the	O
selective degeneration mechanism	B-T043
of	O
active zone	B-T026
proteins	B-T116
in	O
NMJs	B-T026
from	O
aged	B-T032
mice	B-T015
.	O
Interestingly,	O
the	O
localization pattern	B-T043
of	O
active zone	B-T026
proteins	B-T116
described	O
herein	O
is	O
similar	O
to	O
active zone	B-T026
structures	B-T082
described	O
using	O
electron microscope tomography	B-T059
.	O

Molecular	B-T080
serum	B-T031
signature	B-T201
of	O
treatment resistant depression	B-T048
A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major depressive disorder	B-T048
(	O
MDD	B-T048
)	O
do	O
not	O
respond	O
to	O
multiple	B-T081
trials	B-T062
of	O
anti-depressants	B-T121
,	O
develop	O
a	O
chronic	B-T079
course of disease	B-T046
and	O
become	O
treatment	B-T061
resistant	B-T039
.	O
Most	O
of	O
the	O
studies	O
investigating	O
molecular	B-T080
changes	B-T169
in	O
treatment-resistant depression	B-T048
(	O
TRD	B-T048
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	B-T028
.	O
Consequently,	O
biomarkers	B-T201
associated	O
with	O
TRD	B-T048
are	O
still	O
lacking.	O
This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high-throughput proteomic platforms	B-T091
to	O
identify	O
peripheral	B-T082
biomarkers	B-T201
of	O
TRD	B-T048
defined	O
by	O
two	O
staging models	B-T170
,	O
the	O
Thase and Rush staging model	B-T170
(	O
TRM	B-T170
)	O
and	O
the	O
Maudsley Staging Model	B-T170
(	O
MSM	B-T170
).	O
Serum	B-T031
collected	O
from	O
an	O
inpatient	B-T101
cohort	O
of	O
65	O
individuals	B-T098
suffering	O
from	O
MDD	B-T048
was	O
analysed	O
using	O
two	O
different	O
mass spectrometric-based platforms	B-T059
,	O
label-free liquid chromatography mass spectrometry	B-T059
(	O
LC-MS(E)	B-T059
)	O
and	O
selective reaction monitoring	B-T169
(	O
SRM	B-T169
),	O
as	O
well	O
as	O
a	O
multiplex bead based assay	B-T059
.	O
In	O
the	O
LC-MS(E) analysis	B-T059
,	O
proteins	B-T116
involved	O
in	O
the	O
acute phase response	B-T046
and	O
complement activation	B-T044
and	O
coagulation	B-T039
were	O
significantly	O
different	O
between	O
the	O
staging groups	B-T170
in	O
both	O
models	B-T170
.	O
In	O
the	O
multiplex bead-based assay	B-T059
analysis	O
TNF-α levels	B-T059
(	O
log(odds)	B-T081
=	O
-4.95,	O
p	O
=	O
0.045)	O
were	O
significantly	B-T081
different	B-T080
in	O
the	O
TRM	B-T170
comparison	B-T052
.	O
Using	O
SRM	B-T169
,	O
significant	B-T081
changes	B-T169
of	O
three	O
apolipoproteins A-I	B-T116
(β	O
=	O
0.029,	O
p	O
=	O
0.035),	O
M	B-T116
(β	O
=	O
-0.017,	O
p	O
=	O
0.009)	O
and	O
F	B-T116
(β	O
=	O
-0.031,	O
p	O
=	O
0.024)	O
were	O
associated	O
with	O
the	O
TRM	B-T170
but	O
not	O
the	O
MSM	B-T170
.	O
Overall,	O
our	O
findings	B-T033
suggest	O
that	O
proteins	B-T116
,	O
which	O
are	O
involved	O
in	O
immune	B-T043
and	O
complement activation	B-T044
,	O
may	O
represent	O
potential	O
biomarkers	B-T201
that	O
could	O
be	O
used	O
by	O
clinicians	B-T097
to	O
identify	O
high-risk	B-T033
patients	B-T101
.	O
Nevertheless,	O
given	O
that	O
the	O
molecular	B-T080
changes	B-T169
between	O
the	O
staging groups	B-T170
were	O
subtle,	O
the	O
results	O
need	O
to	O
be	O
interpreted	B-T169
cautiously.	O

Benchmark	O
study	B-T062
on	O
fine-mode aerosol	B-T073
in	O
a	O
big urban area	B-UnknownType
and	O
relevant doses	B-T081
deposited	B-T169
in	O
the	O
human	B-T016
respiratory tract	B-T023
It	O
is	O
well-known	O
that	O
the	O
health	B-T078
effects	B-T080
of	O
PM	B-T131
increase	O
as	O
particle size	B-T081
decreases:	O
particularly,	O
great	O
concern	O
has	O
risen	O
on	O
the	O
role	O
of	O
UltraFine Particles	B-T104
(	O
UFPs	B-T104
).	O
Starting	O
from	O
the	O
knowledge	O
that	O
the	O
main	O
fraction of	B-T081
atmospheric	B-T070
aerosol	B-T073
in	O
Rome	B-T083
is	O
characterized	O
by	O
significant	O
levels	B-T080
of	O
PM2.5	B-T131
(almost	O
75%	O
of	O
PM10	B-T131
fraction	O
is	O
PM2.5	B-T131
),	O
the	O
paper	O
is	O
focused	O
on	O
submicron particles	B-T104
in	O
such	O
great urban area	B-UnknownType
.	O
The	O
daytime	B-T079
/	O
nighttime	B-T079
,	O
work-	B-T079
/	O
weekdays	B-T079
and	O
cold	B-T070
/	O
hot	B-T070
seasonal trends	B-T079
of	O
submicron particles	B-T104
will	O
be	O
investigated	O
and	O
discussed	O
along	O
with	O
NOx	B-T197
and	O
total	O
PAH	B-T109
drifts	O
demonstrating	O
the	O
primary	O
origin	O
of	O
UFPs	B-T104
from	O
combustion processes	B-T067
.	O
Furthermore,	O
moving	O
from	O
these	O
data,	O
the	O
total	O
dose	B-T081
of	O
submicron particles	B-T104
deposited	B-T169
in	O
the	O
respiratory system	B-T022
(i.e.,	O
head	B-T029
,	O
tracheobronchial	B-T023
and	O
alveolar regions	B-T023
in	O
different	O
lung lobes	B-T023
)	O
has	O
been	O
estimated.	O
Dosimeter	B-T074
estimates	B-T081
were	O
performed	O
with	O
the	O
Multiple-Path Particle Dosimetry model	B-T170
(	O
MPPD v.2.1	B-T170
).	O
The	O
paper	O
discusses	O
the	O
aerosol	B-T073
doses	B-T081
deposited	B-T169
in	O
the	O
respiratory system	B-T022
of	O
individuals	B-T098
exposed	B-T080
in	O
proximity	O
of	O
traffic	B-T033
.	O
During	O
traffic	B-T033
peak	O
hours	B-T079
,	O
about	O
6.6	O
×	O
10(10)	O
particles	B-T104
are	O
deposited	B-T169
into	O
the	O
respiratory system	B-T022
.	O
Such	O
dose	B-T081
is	O
almost	O
entirely	O
made	O
of	O
UFPs	B-T104
.	O
According	O
to	O
the	O
greater	O
dose	B-T081
estimated	B-T081
,	O
right lung lobes	B-T023
are	O
expected	O
to	O
be	O
more	O
susceptible	B-T169
to	O
respiratory	B-T169
pathologies	B-T046
than	O
left lobes	B-T023
.	O

International Liver Transplant Society Practice Guidelines	B-T170
:	O
Diagnosis	B-T033
and	O
Management	B-T058
of	O
Hepatopulmonary Syndrome	B-T047
and	O
Portopulmonary Hypertension	B-T047
Two	O
distinct	O
pulmonary vascular disorders	B-T047
,	O
hepatopulmonary syndrome	B-T047
(	O
HPS	B-T047
)	O
and	O
portopulmonary hypertension	B-T047
(	O
POPH	B-T047
)	O
may	O
occur	O
as	O
a	O
consequence of	B-T169
hepatic parenchymal	B-T023
or	O
vascular abnormalities	B-T033
.	O
HPS	B-T047
and	O
POPH	B-T047
have	O
major	O
clinical	B-T080
implications	B-T033
for	O
liver transplantation	B-T061
.	O
A	O
European Respiratory Society Task Force	B-T064
on	O
Pulmonary-Hepatic Disorders	B-T047
convened	O
in	O
2002	O
to	O
standardize	O
the	O
diagnosis	B-T033
and	O
guide management	B-T170
of	O
these	O
disorders	B-T047
.	O
These	O
International Liver Transplant Society diagnostic and management guidelines	B-T170
are	O
based	O
on	O
that	O
task force	B-T064
consensus	O
and	O
should	O
continue	O
to	O
evolve	O
as	O
clinical	B-T080
experience	O
dictates.	O
Based	O
on	O
a	O
review	O
of	O
over	O
1000	O
published	O
HPS	B-T047
and	O
POPH	B-T047
articles	O
identified	O
via	O
a	O
MEDLINE search	B-T170
(1985-2015),	O
clinical guidelines	B-T170
were	O
based	O
on,	O
selected single care reports	B-T058
,	O
small series	B-T081
,	O
registries	B-T170
,	O
databases	B-T170
,	O
and	O
expert opinion	B-T077
.	O
The	O
paucity	O
of	O
randomized, controlled trials	B-T062
in	O
either	O
of	O
these	O
disorders	B-T047
was	O
noted.	O
Guidelines	B-T170
are	O
presented	O
in	O
5	O
parts;	O
I.	O
Definitions	B-T170
/	O
Diagnostic criteria	B-T170
;	O
II.	O
Hepatopulmonary syndrome	B-T047
;	O
III.	O
Portopulmonary hypertension	B-T047
;	O
IV.	O
Implications	B-T033
for	O
liver transplantation	B-T061
;	O
and	O
V.	O
Suggestions	B-T078
for	O
future	O
clinical research	B-T062
.	O

Uveitis	B-T047
in	O
children	B-T100
The	O
review	O
provides	O
updates	O
on	O
novel	B-T080
risk markers	B-T080
for	O
the	O
development	B-T169
of	O
pediatric	B-T080
inflammatory uveitis	B-T047
and	O
a	O
severe disease course	B-T046
,	O
on	O
treatment	B-T061
of	O
refractory disease	B-T033
,	O
and	O
on	O
the	O
measurement	B-T169
of	O
visual outcomes	B-T169
.	O
There	O
are	O
several	O
new	O
genetic markers	B-T045
,	O
biomarkers	B-T201
,	O
and	O
clinical	B-T080
factors	B-T169
that	O
may	O
influence	O
a	O
child's	B-T100
uveitis	B-T047
disease course	B-T046
.	O
It	O
is	O
important	O
to	O
identify	O
children	B-T100
at	O
risk	B-T078
for	O
poor visual outcomes	B-T169
and	O
who	O
are	O
refractory	B-T169
to	O
traditional therapy	B-T061
.	O
Racial disparities	B-T033
have	O
recently	O
been	O
reported	B-T170
.	O
We	O
describe	O
agents	B-T120
of	O
potential benefit	B-T081
.	O
In	O
addition,	O
we	O
discuss	O
the	O
importance	O
of	O
patient reported outcomes	B-T170
in	O
this	O
population	B-T101
.	O
Uveitis	B-T047
can	O
lead	O
to	O
vision-threatening complications	B-T046
.	O
Timely and aggressive treatment	B-T061
of	O
children	B-T100
identified	O
to	O
be	O
at	O
risk	B-T078
for	O
a	O
severe uveitis course	B-T046
may	O
lead	O
to	O
improved outcomes	B-T169
.	O

Utility	B-T169
of	O
a	O
mHealth App	B-T170
for	O
Self-Management	B-T058
and	O
Education	B-T065
of	O
Cardiac Diseases	B-T047
in	O
Spanish	B-T083
Urban and Rural Areas	B-T083
Analyze	B-T062
the	O
utility	B-T169
of	O
a	O
mobile health app	B-T170
named	O
HeartKeeper	B-T170
in	O
several groups of population	B-T098
and	O
obtain	B-T169
conclusions	B-T078
to	O
be	O
applied	B-T169
to	O
other similar apps	B-T170
.	O
A	O
questionnaire	B-T170
has	O
been	O
designed	B-T052
to	O
evaluate	O
the	O
usage	B-T169
and	O
utility	B-T169
of	O
the	O
HeartKeeper app	B-T170
.	O
The	O
questionnaire	B-T170
information	B-T078
was	O
collected	B-T169
by	O
collaborating	O
cardiologists	B-T097
from	O
32	O
patients	B-T101
before and after	B-UnknownType
they	O
used	B-T169
the	O
app	B-T170
.	O
Patients	B-T101
were	O
randomly selected	B-T062
with	O
established	O
quotas	B-T062
within	O
interest groups	B-T098
,	O
so	O
that	O
men	B-T098
and	O
women	B-T098
,	O
patients	B-T101
older	B-T098
or	O
younger	B-T079
than	O
60	O
years old	B-T079
and	O
patients	B-T101
living	O
in	O
urban or rural areas	B-T083
were	O
equally represented	B-T052
.	O
Using	O
the	O
appropriate	O
statistical techniques	B-T062
we	O
see	O
that	O
the	O
HeartKeeper app	B-T170
was	O
useful	O
for	O
patients	B-T101
as	O
they	O
qualify	B-T080
with	O
70	O
points	O
(out	O
of	O
100)	O
the	O
overall opinion	B-T033
of	O
the	O
app	B-T170
,	O
it	O
helps	O
them	O
remember	B-T041
more	O
easily	O
taking	O
their	O
pills	B-T122
with	O
a	O
mean	O
improvement	B-T077
of	O
20.94	O
points	O
(p	O
<	O
0.001)	O
and	O
they	O
perceive	O
a	O
global improvement	B-T077
of	O
their	O
health	O
(8.28	O
points,	O
p	O
<	O
0.001).	O
We	O
also	O
observe	B-T169
that	O
these	O
improvements	B-T077
do	O
not	O
depend,	O
in	O
general,	O
on	O
the	O
area (urban or rural)	B-T083
where	O
the	O
patient	B-T101
comes	O
from	O
or	O
on	O
their	O
sex	B-T032
.	O
Although	O
older patients	B-T098
needed	B-T080
more	O
help	O
to	O
use	B-T169
the	O
app	B-T170
and	O
used	B-T169
it	O
slightly	O
less frequently	B-T079
,	O
the	O
improvements	B-T077
on	O
several measures	B-T081
considered,	O
such	O
as	O
remembering	B-T041
taking	O
pills	B-T122
,	O
breathing problems	B-T184
or	O
trouble developing activities	B-T184
,	O
depend	O
significantly	O
(p	O
<	O
0.05)	O
on	O
age	O
with	O
older patients	B-T098
reporting	O
higher	B-T080
improvements	B-T077
than	O
younger ones	B-T100
.	O
The	O
results	B-T169
obtained	O
with	O
the	O
sample	B-T081
of	O
patients	B-T101
considered	O
in	O
this	O
research	B-T062
prove	O
the	O
utility	B-T169
of	O
the	O
HeartKeeper app	B-T170
.	O
This	O
utility	B-T169
is	O
similar	O
in	O
urban and rural areas	B-T083
and	O
for	O
patients	B-T101
of	O
both sexes	B-T032
and,	O
to some extent	B-T080
,	O
depends	O
on	O
the	O
age	B-T100
of	O
the	O
patient	B-T101
with	O
older patients	B-T098
reporting	O
slightly lower frequency	B-T079
of	O
use	B-T169
but	O
higher	B-T080
health improvements	B-T077
than	O
younger ones	B-T100
.	O

A	O
holistic approach	B-T078
to	O
age	B-T032
estimation	B-T041
in	O
refugee	B-T098
children	B-T100
Many	O
refugee	B-T098
children	B-T100
arriving	O
in	O
Australia	B-T083
have	O
an	O
inaccurately	B-T080
documented	B-T058
date of birth	B-T170
(	O
DOB	B-T170
).	O
A	O
medical assessment	B-T058
of	O
a	O
child's age	B-T032
is	O
often	O
requested	O
when	O
there	O
is	O
a	O
concern	B-T078
that	O
their	O
documented	B-T058
DOB	B-T170
is	O
incorrect	B-T080
.	O
This	O
study's	O
aim	O
was	O
to	O
assess	B-T058
the	O
accuracy	B-T080
a	O
holistic age assessment tool	B-T170
(	O
AAT	B-T170
)	O
in	O
estimating	B-T041
the	O
age	B-T032
of	O
refugee	B-T098
children	B-T100
newly	O
settled	O
in	O
Australia	B-T083
.	O
A	O
holistic AAT	B-T170
that	O
combines	O
medical	B-UnknownType
and	O
non-medical approaches	B-T078
was	O
used	O
to	O
estimate	B-T041
the	O
ages	B-T032
of	O
60	O
refugee	B-T098
children	B-T100
with	O
a	O
known	O
DOB	B-T170
.	O
The	O
tool	B-T170
used	O
four	O
components	B-T077
to	O
assess	B-T058
age	B-T032
:	O
an	O
oral	B-T082
narrative	B-T054
,	O
developmental	B-T080
assessment	B-T058
,	O
anthropometric measures	B-T170
and	O
pubertal	B-T033
assessment	B-T058
.	O
Assessors	B-T097
were	O
blinded	B-T062
to	O
the	O
true	B-T080
age	B-T032
of	O
the	O
child	B-T100
.	O
Correlation coefficients	B-T081
for	O
the	O
actual	B-T080
and	O
estimated	B-T041
age	B-T032
were	O
calculated	B-T052
for	O
the	O
tool	B-T170
overall and individual components	B-T077
.	O
The	O
correlation coefficient	B-T081
between	O
the	O
actual	B-T080
and	O
estimated	B-T041
age	B-T032
from	O
the	O
AAT	B-T170
was	O
very	O
strong	O
at	O
0.9802	O
(	O
boys	B-T100
0.9748,	O
girls	B-T100
0.9876).	O
The	O
oral	B-T082
narrative	B-T054
component	B-T077
of	O
the	O
tool	B-T170
performed	O
best	O
(R	O
=	O
0.9603).	O
Overall,	O
86.7%	O
of	O
age	B-T032
estimates	B-T041
were	O
within	O
1	O
year	B-T079
of	O
the	O
true	B-T080
age	B-T032
.	O
The	O
range	O
of	O
differences	O
was	O
-1.43	O
to	O
3.92	O
years	B-T079
with	O
a	O
standard deviation	B-T081
of	O
0.77	O
years	B-T079
(9.24	O
months	B-T079
).	O
The	O
AAT	B-T170
is	O
a	O
holistic	B-T078
,	O
simple	B-T080
and	O
safe	B-UnknownType
instrument	O
that	O
can	O
be	O
used	O
to	O
estimate	B-T041
age	B-T032
in	O
refugee	B-T098
children	B-T100
with	O
results	O
comparable	O
with	O
radiological methods	B-T091
currently	O
used.	O

CAGEd-oPOSSUM	B-T170
:	O
motif enrichment analysis	B-T062
from	O
CAGE	B-T170
-derived	O
TSSs	B-T114
With	O
the	O
emergence	O
of	O
large-scale Cap Analysis of Gene Expression (CAGE) datasets	B-T170
from	O
individual labs	B-T073
and	O
the	O
FANTOM consortium	B-T077
,	O
one	O
can	O
now	O
analyze	O
the	O
cis-regulatory regions	B-T114
associated	O
with	O
gene transcription	B-T045
at	O
an	O
unprecedented level of refinement	B-T080
.	O
By	O
coupling	O
transcription factor binding site	B-T044
(	O
TFBS	B-T044
)	O
enrichment analysis	B-T062
with	O
CAGE	B-T170
-derived	O
genomic regions	B-T028
,	O
CAGEd-oPOSSUM	B-T170
can	O
identify	B-T080
TFs	B-T116
that	O
act	O
as	O
key	B-T077
regulators	B-T077
of	O
genes	B-T028
involved	O
in	O
specific	B-T080
mammalian cell	B-T025
and	O
tissue types	B-T024
.	O
The	O
webtool	B-T170
allows	O
for	O
the	O
analysis	B-T062
of	O
CAGE	B-T170
-derived	O
transcription start sites	B-T114
(	O
TSSs	B-T114
)	O
either	O
provided	O
by	O
the	O
user	B-T098
or	O
selected	O
from	O
∼1300	O
mammalian	B-T015
samples	B-T167
from	O
the	O
FANTOM5 project	B-T077
with	O
pre-computed	B-T052
TFBS	B-T044
predicted	O
with	O
JASPAR TF binding profiles	B-T170
.	O
The	O
tool	B-T170
helps	O
power	O
insights	B-T041
into	O
the	O
regulation of genes	B-T045
through	O
the	O
study	B-T062
of	O
the	O
specific	B-T080
usage	B-T169
of	O
TSSs	B-T114
within	O
specific	B-T080
cell types	B-T170
and/or	O
under	O
specific conditions	B-T080
.	O
The	O
CAGEd-oPOSUM web tool	B-T170
is	O
implemented	O
in	O
Perl	B-T170
,	O
MySQL	B-T170
and	O
Apache	B-T170
and	O
is	O
available	O
at	O
http://cagedop.cmmt.ubc.ca/CAGEd_oPOSSUM	B-T170
CONTACTS:	O
anthony.mathelier@ncmm.uio.no	B-T170
or	O
wyeth@cmmt.ubc.ca	B-T170
Supplementary information	B-T170
:	O
Supplementary data	B-T170
are	O
available	O
at	O
Bioinformatics	B-T170
online	B-T073
.	O

Self-assembled	B-T044
polymeric	B-T104
vectors	B-T074
mixtures	B-T167
:	O
characterization	B-T052
of	O
the	O
polymorphism	B-T080
and	O
existence	O
of	O
synergistic	B-T080
effects	B-T080
in	O
photodynamic therapy	B-T061
The	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	B-T081
of	O
polymeric	B-T104
self-assemblies	B-T044
vectors	B-T074
solution	B-T167
and	O
their	O
photodynamic therapeutic	B-T061
efficiency	B-T081
.	O
For	O
this,	O
several	O
amphiphilic	B-T121
block copolymers	B-T104
of	O
poly(ethyleneoxide-b-ε-caprolactone)	B-T109
have	O
been	O
used	O
to	O
form	O
self-assemblies	B-T044
with	O
different	O
morphologies	B-T080
(	O
micelles	B-T109
,	O
worm-like micelles	B-T109
or	O
vesicles	B-T080
).	O
In	O
a	O
first	O
step,	O
controlled mixtures	B-T167
of	O
preformed	O
micelles	B-T109
and	O
vesicles	B-T080
have	O
been	O
characterized	O
both	O
by	O
dynamic light scattering	B-T059
and	O
asymmetrical flow field flow fractionation	B-T059
(	O
AsFlFFF	B-T059
).	O
For	O
this,	O
a	O
custom-made	B-T052
program	B-T073
,	O
STORMS	B-T073
,	O
was	O
developed	O
to	O
analyze	O
DLS	B-T059
data	B-T078
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	B-T077
.	O
This	O
showed	O
that	O
DLS	B-T059
only	O
sensed	O
the	O
larger	B-T081
vesicles	B-T080
when	O
the	O
micelles	B-T109
/	O
vesicles	B-T080
ratio	B-T081
was	O
80/20	O
w/w.	O
On	O
the	O
other	O
hand,	O
AsFlFFF	B-T059
allowed	O
clear	O
detection	B-T033
of	O
the	O
presence	O
of	O
micelles	B-T109
when	O
this	O
same	O
ratio	B-T081
was	O
as	O
low	O
as	O
10/90.	O
Subsequently,	O
the	O
photodynamic therapy	B-T061
efficiency	B-T081
of	O
various	O
controlled mixtures	B-T167
was	O
assessed	O
using	O
multicellular	O
spheroids	B-T033
when	O
a	O
photosensitizer	B-T121
,	O
pheophorbide a	B-T109
,	O
was	O
encapsulated	B-T080
in	O
the	O
polymer	B-T104
self-assemblies	B-T044
.	O
Some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	B-T080
as	O
monomorphous systems	B-T033
.	O
In	O
some	O
cases,	O
mixtures	B-T167
were	O
found	O
to	O
exhibit	O
a	O
higher	O
PDT	B-T061
efficiency	B-T081
compared	O
to	O
the	O
individual	O
nano	B-T081
-	O
objects	B-T072
,	O
revealing	O
a	O
synergistic	B-T080
effect	B-T080
for	O
the	O
efficient	O
delivery	B-T070
of	O
the	O
photosensitizer	B-T121
.	O
Polymorphous	B-T080
vectors	B-T074
can	O
therefore	O
be	O
superior	O
in	O
therapeutic applications	B-T169
.	O

Fuzheng Qingjie Granules	B-T123
Inhibit	B-T052
Growth	B-T039
of	O
Hepatoma Cells	B-T025
via	O
Inducing	B-T169
Mitochondria	B-T026
-Mediated	O
Apoptosis	B-T043
and	O
Enhancing	B-T052
Immune Function	B-T042
Fuzheng Qingjie	B-T123
(FZQJ) granules	B-T123
,	O
a	O
compound	B-T103
Chinese medicine	B-T091
,	O
have	O
been	O
used	O
as	O
an	O
adjuvant therapy	B-T061
for	O
alimentary tract	B-T022
cancers	B-T191
.	O
However,	O
the	O
underlying	O
anticancer	B-T033
mechanisms	B-T169
are	O
still	O
not	O
well	O
understood.	O
In	O
the	O
present	B-T079
study	B-T062
,	O
HepG2 cells	B-T025
were	O
treated	B-T169
with	O
FZQJ	B-T123
-	O
containing	B-T052
serum	B-T031
.	O
Cell proliferation	B-T043
was	O
evaluated	B-T058
using	O
MTT assay	B-T062
.	O
Apoptosis	B-T043
was	O
analyzed	B-T062
using	O
a	O
flow cytometer	B-T074
.	O
Cell ultrastructure	B-T025
was	O
observed	B-T169
under	O
a	O
transmission electron microscope	B-T074
.	O
The	O
mitochondrial membrane potential	B-T043
(	O
Δψ	B-T043
)	O
was	O
examined	B-T033
with	O
JC-1 dye	B-T130
.	O
In	O
H22 tumor-bearing mice	B-T191
,	O
CD4(+) T cells	B-T025
,	O
CD8(+) T cells	B-T025
,	O
CD3(+) T cells	B-T025
,	O
and	O
natural killer cells	B-T025
(	O
NK	B-T025
)	O
in	O
peripheral blood	B-T031
were	O
evaluated	O
cytometrically	B-T074
.	O
Interleukin (IL)-2	B-T116
and	O
tumor necrosis factor	B-T116
(TNF)-α	B-T116
levels	B-T080
were	O
measured	B-T080
using	O
radioimmunoassay	B-T059
.The	O
mRNA	B-T114
levels	B-T080
of	O
Bax	B-T028
and	O
Bcl-2	B-T028
were	O
examined	B-T033
by	O
reverse transcription-polymerase chain reaction	B-T063
.	O
The	O
protein	B-T116
levels	B-T080
of	O
Bax	B-T116
,	O
Bcl-2	B-T116
,	O
cytochrome C	B-T116
,	O
caspase 3	B-T116
and	O
9	B-T116
,	O
PARP	B-T116
,	O
and	O
CD69	B-T116
were	O
examined	B-T033
by	O
Western blotting	B-T059
.	O
The	O
apoptotic	B-T080
cells	B-T025
in	O
tissues	B-T024
were	O
observed	B-T169
using	O
TUNEL method	B-T063
.	O
Alanine transaminase	B-T116
(	O
ALT	B-T116
),	O
aspartate transaminase	B-T116
(	O
AST	B-T116
),	O
blood urea nitrogen	B-T123
(	O
BUN	B-T123
),	O
and	O
creatinine	B-T109
(	O
CRE	B-T109
)	O
were	O
detected	B-T033
by	O
an	O
automatic	B-T169
biochemical	B-T169
analyzer	B-T074
.	O
The	O
results	B-T169
showed	O
that	O
FZQJ	B-T123
-	O
containing	B-T052
serum	B-T031
remarkably	O
inhibited	B-T052
proliferation	B-T043
of	O
HepG2 cells	B-T025
in	O
dose	B-T081
-	O
and	O
time	B-T079
-	O
dependent	B-T080
manners,	O
induced	B-T169
HepG2 cell	B-T025
apoptosis	B-T043
and	O
caused	O
a	O
decrease	B-T081
of	O
Δψ	B-T043
.	O
Analysis	B-T062
of	O
tumor tissue	B-T024
showed	O
that	O
FZQJ	B-T123
-	O
induced	B-T169
apoptosis	B-T043
was	O
accompanied	O
by	O
downregulation	B-T044
of	O
Bcl-2	B-T116
and	O
upregulation	B-T044
of	O
Bax	B-T116
,	O
release	B-T169
of	O
cytochrome c	B-T116
,	O
activation	B-T044
of	O
caspase 3	B-T116
and	O
9	B-T116
,	O
and	O
cleavage	B-T044
of	O
PARP	B-T116
.	O
In	O
addition,	O
FZQJ	B-T123
increased	B-T081
the	O
percentages	B-T081
of	O
CD4(+) T	B-T025
and	O
NK cells	B-T025
,	O
the	O
ratio	B-T081
of	O
CD4(+)	B-T025
/	O
CD8(+) T cells	B-T025
as	O
well	O
as	O
the	O
levels	B-T080
of	O
serum	B-T031
TNF-α	B-T116
.	O
FZQJ	B-T123
also	O
increased	B-T081
CD69	B-T116
expression	B-T045
in	O
tumor tissue	B-T024
.	O
No hepatorenal toxicity	B-T033
was	O
observed	B-T169
in	O
H22 tumor-bearing mice	B-T191
.	O
These	O
results	B-T169
indicated	B-T033
that	O
FZQJ	B-T123
could	O
inhibit	B-T052
the	O
growth	B-T039
of	O
hepatoma cells	B-T025
via	O
regulating	O
immune function	B-T042
and	O
inducing	B-T169
mitochondria	B-T026
mediated	O
apoptosis	B-T043
.	O

Professional reinventions	B-T170
:	O
Swedish	B-T098
psychologists	B-T097
,	O
1990-2010	O
Since	O
the	O
early	O
20th century	B-T079
,	O
the	O
Swedish	B-T098
psychology profession	B-T091
has	O
undergone	O
several	O
changes	B-T169
in	O
its	O
essential tasks	B-T052
,	O
epistemological foundations	B-T170
,	O
and	O
social roles	B-T054
.	O
These	O
changes	B-T169
occurred	B-T052
through	O
an	O
ongoing	O
"tuning"	O
with	O
Swedish	B-T098
society	B-T092
,	O
in	O
which	O
the	O
profession	B-T090
strove	O
to	O
appear	O
relevant	O
to	O
society's	B-T092
concerns	B-T078
and	O
problems	B-T033
as	O
well	O
as	O
enroll	O
others	O
to	O
share	O
the	O
profession's	B-T090
goals	B-T170
and	O
aims	B-T078
.	O
Studying	O
the	O
history	B-T169
of	O
the	O
profession	B-T090
can	O
thus	O
shed	O
light	O
on	O
the	O
changing	B-T169
definitions	B-T170
and	O
contours	B-T082
of	O
the	O
psychology profession	B-T091
itself	O
as	O
well	O
as	O
on	O
the	O
organization	B-T169
of	O
the	O
society	B-T092
in	O
which	O
it	O
acts.	O
This	O
article	B-T170
examines	O
the	O
history	B-T169
of	O
the	O
Swedish	B-T098
psychology profession	B-T091
from	O
1990	O
to	O
2010,	O
through	O
an	O
analysis	B-T062
of	O
the	O
discussions	B-T054
and	O
debates	B-T052
taking	O
place	O
in	O
the	O
Swedish	B-T098
Psychological Association's journal	B-T073
.	O
The	O
analytical framework	B-T077
used	O
draws	O
on	O
work	O
done	O
within	O
actor-network theory	B-T170
and	O
science studies	B-T062
.	O
We	O
argue	O
that	O
the	O
profession's	B-T090
institutional connections	B-T080
,	O
defining	O
tasks	B-T052
,	O
epistemological	B-T170
underpinnings	B-T078
,	O
and	O
social position	B-UnknownType
have	O
changed	B-T169
in	O
major	O
ways	O
during	O
these	O
2	O
decades	B-T081
.	O
Overall,	O
as	O
a	O
result	O
of	O
an	O
increasingly	O
felt	O
insecurity	B-T041
,	O
the	O
profession	B-T090
has	O
turned	O
outward	O
and	O
tried	O
to	O
find	O
new	O
ways	O
to	O
legitimize	B-T169
itself	O
to	O
politicians	B-T097
,	O
the	O
media	B-T170
,	O
patients	B-T101
,	O
and	O
customers	B-T077
through	O
means	O
such	O
as	O
a	O
more	O
economized	B-T169
vocabulary	B-T170
and	O
novel	B-T080
forms	O
of	O
empirical research	B-T062
.	O
These	O
changes	B-T169
have	O
led	O
to	O
a	O
more	O
socialized	B-T054
profession	B-T090
,	O
now	O
more	O
closely	O
tuned	O
to	O
other	O
actors	B-T097
in	O
Swedish	B-T098
society	B-T092
,	O
leading	O
to	O
conflicts	B-T080
within	O
the	O
profession	B-T090
over	O
whether	O
this	O
is	O
an	O
opportunity	O
to	O
better	O
control	B-T080
their	O
own	O
destiny	O
or	O
if	O
it	O
will	O
lead	O
to	O
a	O
loss of autonomy	B-T033
.	O
(	O
PsycINFO Database Record	B-T170

Personally Meaningful Rituals	B-T053
:	O
A	O
Way	O
to	O
Increase	B-T169
Compassion	B-T054
and	O
Decrease	B-T081
Burnout	B-T033
among	O
Hospice	B-T058
Staff	B-T097
and	O
Volunteers	B-T098
Rituals	B-T053
can	O
increase	B-T169
a	O
sense of connectedness	B-UnknownType
,	O
meaning	B-T078
,	O
and	O
support	B-T054
,	O
especially	O
after	O
the	O
death	B-T040
of	O
those	O
for	O
whom	O
we	O
care.	O
Hospice	B-T058
staff	B-T097
may	O
benefit	O
from	O
the	O
use	O
of	O
personal rituals	B-T053
as	O
they	O
cope with	B-T055
the	O
frequent deaths	B-T081
of	O
their	O
patients	B-T101
,	O
ultimately	O
aiming	O
to	O
provide	O
compassionate care	B-T052
while	O
minimizing	O
burnout	B-T033
.	O
This	O
study	O
investigated	O
the	O
role	O
of	O
personally meaningful rituals	B-T053
in	O
increasing	B-T169
compassion	B-T054
and	O
decreasing	B-T080
burnout	B-T033
among	O
hospice	B-T058
staff	B-T097
and	O
volunteers	B-T098
.	O
An	O
online survey	B-T170
was	O
completed	O
by	O
members	O
of	O
the	O
National Hospice and Palliative Care Organization	B-T073
Hospice	B-T058
and	O
Palliative	O
Care	O
Organization	O
(	O
NHPCO	B-T073
)	O
which	O
inquired	O
about	O
personal ritual	B-T053
practices,	O
and	O
included	O
the	O
Professional Quality of Life (ProQOL) scale	B-T170
ProQOL	B-T170
)	O
scale	O
to	O
measure	O
current	O
levels	O
of	O
Compassion	B-T054
Satisfaction	B-T041
,	O
Burnout	B-T033
,	O
and	O
Secondary Traumatic Stress	B-T048
.	O
Three	O
hundred	O
ninety	O
hospice	B-T058
staff	B-T097
and	O
volunteers	B-T098
from	O
across	O
38	O
states	B-T083
completed	O
the	O
online survey	B-T170
.	O
The	O
majority	O
of	O
participants	B-T098
were	O
Caucasian	B-T098
and	O
female	B-T032
,	O
with	O
an	O
average	O
of	O
nine	O
years	O
of	O
experience	O
in	O
hospice	B-T058
hospice and palliative care	B-T073
.	O
The	O
majority	O
of	O
hospice	B-T058
staff	B-T097
and	O
volunteers	B-T098
used	O
personally	O
meaningful	O
rituals	B-T053
after	O
the	O
death	B-T040
of	O
their	O
patients	B-T101
to	O
help	O
them	O
cope	B-T055
(71%).	O
Those	O
who	O
used	O
rituals	B-T053
demonstrated	O
significantly	O
higher	O
Compassion	B-T054
Satisfaction	B-T041
and	O
significantly	O
lower	O
Burnout	B-T033
as	O
measured	O
by	O
the	O
ProQOL	B-T170
,	O
with	O
professional support	B-T033
,	O
social support	B-T054
,	O
and	O
age	B-T032
playing	O
significant roles	B-T033
as	O
well.	O
Rituals	B-T053
may	O
be	O
an	O
important	O
way	O
to	O
increase	B-T169
compassion	B-T054
and	O
decrease	B-T081
burnout	B-T033
among	O
hospice	B-T058
staff	B-T097
and	O
volunteers	B-T098
.	O
Organizations	B-T073
may	O
benefit	O
from	O
providing	O
training and support	B-T065
for	O
personalized rituals	B-T053
among	O
team	O
members,	O
especially	O
new staff	B-T097
who	O
may	O
be	O
at greater risk	B-T080
for	O
burnout	B-T033
.	O

Activation	B-T052
of	O
the	O
orphan receptor GPR55	B-T116
by	O
lysophosphatidylinositol	B-T109
promotes	B-T052
metastasis	B-T191
in	O
triple-negative breast cancer	B-T191
The	O
orphan G protein-coupled receptor	B-T116
GPR55	B-T116
has	O
been	O
directly	B-T080
or	O
indirectly	B-T080
related	B-T080
to	O
basic	O
alterations	B-T078
that	O
drive	O
malignant	B-T080
growth	B-T040
:	O
uncontrolled	B-T080
cancer	O
cell proliferation	B-T043
,	O
sustained angiogenesis	B-T042
,	O
and	O
cancer	O
cell adhesion	B-T043
and	O
migration	B-T067
.	O
However,	O
little	B-T081
is	O
known	B-T080
about	O
the	O
involvement	B-T169
of	O
this	O
receptor	B-T116
in	O
metastasis	B-T191
.	O
Here,	O
we	O
show	O
that	O
elevated	B-T080
GPR55 expression	B-T045
in	O
human	B-T016
tumors	B-T191
is	O
associated with	B-T080
the	O
aggressive basal	B-T191
/	O
triple-negative breast cancer	B-T191
population	B-T098
,	O
higher probability	B-T081
to	O
develop	O
metastases	B-T191
,	O
and	O
therefore	O
poor	B-T080
patient	B-T101
prognosis	B-T058
.	O
Activation	B-T052
of	O
GPR55	B-T116
by	O
its	O
proposed	O
endogenous	B-T169
ligand	B-T103
lysophosphatidylinositol	B-T109
confers	O
pro-invasive	B-T080
features	B-T080
on	O
breast cancer cells	B-T025
both	O
in vitro	B-T080
and	O
in vivo	B-T082
.	O
Specifically,	O
this	O
effect	B-T080
is	O
elicited by	B-T080
coupling	B-T169
to	O
Gq/11 heterotrimeric proteins	B-T116
and	O
the	O
subsequent	B-T079
activation	B-T052
,	O
through	O
ERK	B-T116
,	O
of	O
the	O
transcription factor ETV4	B-T116
/	O
PEA3	B-T116
.	O
Together	B-T080
,	O
these	O
data	B-T078
show	O
that	O
GPR55	B-T116
promotes	B-T052
breast cancer	B-T191
metastasis	B-T191
,	O
and	O
supports	B-T077
the	O
notion	O
that	O
this	O
orphan receptor	B-T116
may	O
constitute	O
a	O
new	B-T080
therapeutic	B-T169
target	B-T169
and	O
potential	B-T080
biomarker	B-T201
in	O
the	O
highly	O
aggressive triple-negative subtype	B-T185
.	O

Effect	B-T080
of	O
ultrasonic	B-T169
processing	B-T052
on	O
the	O
changes	O
in	O
activity	B-T044
,	O
aggregation	B-T169
and	O
the	O
secondary	B-T082
and	O
tertiary structure	B-T082
of	O
polyphenol oxidase	B-T116
in	O
oriental	B-T083
sweet melon	B-T168
(	O
Cucumis melo var. makuwa Makino	B-T002
)	O
Polyphenol oxidase	B-T116
(	O
PPO	B-T116
)	O
mainly	O
contributes	B-T052
to	O
the	O
browning reaction	B-T070
of	O
fruits	B-T168
and	O
vegetables	B-T168
and	O
causes	O
serious	B-T080
damage	B-T169
to	O
the	O
quality	B-T080
of	O
sweet melon	B-T168
products	B-T071
.	O
However,	O
traditional	B-T169
methods	B-T169
to	O
inactivate	B-T169
browning	B-T070
may	O
induce	B-T169
more	O
unexpected	B-T170
risks	B-T078
than	O
ultrasonic	B-T169
processing	B-T052
.	O
Meanwhile,	O
there	O
are	O
no	O
reports	B-T170
on	O
the	O
effect	B-T080
of	O
ultrasound	B-T070
on	O
PPO	B-T116
directly	O
purified	B-T169
from	O
sweet melon	B-T168
.	O
The	O
PPO	B-T116
in	O
the	O
original	B-T078
juice	B-T168
was	O
less	O
inactivated	B-T169
than	O
the	O
purified	B-T169
form	O
when	O
treated with	B-T061
ultrasound	B-T070
.	O
As	O
for	O
purified	B-T169
PPO	B-T116
,	O
superior	O
to	O
thermal treatment	B-T061
,	O
less	O
heat	B-T070
was	O
needed	O
to	O
inactivate	B-T169
the	O
PPO	B-T116
with	O
ultrasonic	B-T169
treatment	B-T061
.	O
At	O
intensity lower	B-T033
than	O
200	O
W,	O
ultrasound	B-T070
did	O
not	O
significantly	B-T078
affect	O
the	O
structure	B-T082
and	O
activity	B-T078
of	O
PPO	B-T116
(P	O
>	O
0.05),	O
and	O
latent	B-T080
PPO	B-T116
was	O
activated	B-T052
.	O
At	O
intensity higher	B-T033
than	O
200	O
W,	O
ultrasound	B-T070
inactivated	B-T169
PPO	B-T116
,	O
induced	B-T169
aggregation	B-T169
and	O
dissociation	B-T044
of	O
PPO	B-T116
particles	B-T104
and	O
significantly decreased	B-T081
the	O
α-helix structure	B-T082
content.	O
Low-frequency	B-T079
high-intensity	B-T185
ultrasound	B-T070
caused	O
an	O
inactivation	B-T169
effect	B-T080
and	O
conformational changes	B-T044
of	O
purified	B-T169
PPO	B-T116
from	O
oriental	B-T083
sweet melons	B-T168
.	O
Changes	B-T169
in	O
the	O
PPO	B-T116
structure	B-T082
induced	B-T169
by	O
ultrasound	B-T070
eventually	O
inactivated	B-T169
the	O
enzyme	B-T116
.	O
Ultrasound	B-T070
may	O
be	O
a	O
potential	B-T080
method	B-T169
to	O
inactivate	B-T169
PPO	B-T116
in	O
oriental	B-T083
sweet melons	B-T168
.	O
©	O
2016	O
Society	O
of	O
Chemical	O
Industry.	O

Phylogeography	B-T090
of	O
the	O
Spanish	B-T098
Moon Moth	B-T204
Graellsia isabellae	B-T204
(	O
Lepidoptera	B-T204
,	O
Saturniidae	B-T204
)	O
Geographic	B-T077
and	O
demographic factors	B-T078
as	O
well	O
as	O
specialisation	B-T090
to	O
a	O
new	O
host-plant	B-UnknownType
may	O
lead	O
to	O
host	B-UnknownType
-	O
associated	B-T080
differentiation	B-T169
in	O
plant	B-T002
-feeding	O
insects	B-T204
.	O
We	O
explored	O
the	O
phylogeography	B-T090
of	O
a	O
protected	B-T169
moth	B-T204
,	O
Graellsia isabellae	B-T204
,	O
and	O
its	O
two	O
recognised	O
host-plant	B-UnknownType
species	B-T185
(	O
Pinus sylvestris	B-T002
and	O
P. nigra	B-T002
)	O
in	O
order	O
to	O
seek	O
for	O
any	O
concordance	O
useful	O
to	O
disentangle	O
the	O
evolutionary history	B-T169
of	O
this	O
iconic	O
lepidopteran	B-T204
.	O
DNA	B-T114
variation	B-T070
in	O
one	O
mitochondrial	B-T026
marker	B-T086
and	O
nine	O
nuclear	B-T026
microsatellite loci	B-T028
revealed	O
a	O
strong	O
phylogeographic pattern	B-T033
across	O
28	O
populations	O
of	O
G. isabellae	B-T204
studied	O
in	O
Spain	B-T083
and	O
France	B-T083
comprising	O
six	O
groups	B-T078
mostly	O
distributed	B-T169
along	O
different	B-T080
mountain ranges	B-T083
.	O
Reanalysis	B-T062
of	O
a	O
previously	O
published	O
chloroplast	B-T026
microsatellite dataset	B-T170
revealed	B-T080
a	O
three	O
and	O
two-	O
group structure	B-T102
for	O
Spanish	B-T098
P. sylvestris	B-T002
and	O
P. nigra	B-T002
,	O
respectively.	O
Overall,	O
the	O
population	O
groupings	O
of	O
this	O
protected	B-T169
moth	B-T204
did	O
not	O
match	B-T080
the	O
ones	O
of	O
P. sylvestris	B-T002
and	O
P. nigra	B-T002
.	O
There	O
was	O
no evidence of	B-T080
host	B-UnknownType
-	O
associated	B-T080
differentiation	B-T169
between	O
populations	O
using	O
P. sylvestris	B-T002
and	O
the	O
ones	O
inhabiting	B-T169
P. nigra	B-T002
.	O
The	O
two	O
major	B-T080
mitochondrial	B-T026
clades	B-T078
of	O
G. isabellae	B-T204
likely	O
diverged	O
before	O
the	O
Last Glacial Maximum	B-T079
and	O
geographically	B-T082
separated	B-T080
the	O
species	B-T185
into	O
a	O
"	O
southern	B-T082
"	O
(	O
Central and Southern Iberian clusters	B-T081
)	O
and	O
a	O
"	O
northern	B-T082
"	O
lineage	B-T077
(	O
Eastern Iberian	B-T081
,	O
Pyrenean	B-T081
and	O
French Alpine clusters	B-T081
).	O
The	O
Eastern Iberian System	B-T081
,	O
where	O
this	O
insect	B-T204
uses	O
both	O
host-plants	B-UnknownType
,	O
harboured	O
the	O
highest	B-T080
level	B-T080
of	O
genetic	B-T169
diversity	B-T080
.	O
Such	O
a	O
group	B-T078
independently	O
colonised	B-T033
the	O
West	B-T082
and	O
East parts	B-T082
of	O
the	O
Pyrenees	B-UnknownType
.	O
Our	O
results	O
point	O
to	O
a	O
native	B-T169
origin	B-T079
for	O
the	O
French populations	B-T081
occurring	B-T079
in	O
the	O
Alps	B-T083
,	O
genetically	B-T169
related	O
to	O
the	O
Eastern Iberian	B-UnknownType
and	O
Pyrenean sites	B-UnknownType
.	O
The	O
Central Iberian group	B-T078
derived	O
from	O
Southern Iberian	B-UnknownType
ancestors	B-T099
.	O
Secondary	B-T081
contacts	B-T080
were	O
inferred	O
between	O
the	O
Southern/Central Iberian populations	B-T081
and	O
Eastern Iberian cluster	B-T081
as	O
well	O
as	O
between	O
the	O
two	O
Pyrenean ones	B-T081
.	O
The	O
mito-nuclear discordance	B-T081
observed	O
with	O
regard	O
to	O
the	O
Eastern Iberian cluster	B-T081
is	O
congruent	B-T080
with	O
a	O
secondary	B-T081
contact	B-T080
after	O
the	O
evolution	B-T045
of	O
mito-nuclear incompatibilities	B-T080
in	O
geographically isolated areas	B-UnknownType
.	O

Prevalence	B-T081
of	O
Physical Activity	B-T056
and	O
Sitting	B-T039
Time	B-T079
Among	O
South Korean	B-T098
Adolescents	B-T100
:	O
Results	B-T033
From	O
the	O
Korean	B-T098
National Health and Nutrition Examination Survey	B-T062
,	O
2013	O
This	O
study	O
aimed	O
to	O
describe	O
physical activity	B-T056
(	O
PA	B-T056
)	O
and	O
sitting	B-T039
time	B-T079
,	O
and	O
to	O
examine	O
associations	B-T080
between	O
sociodemographic factors	B-T078
,	O
weight	B-T032
status	B-T080
,	O
PA	B-T056
,	O
and	O
sitting	B-T039
time	B-T079
among	O
South Korean	B-T098
adolescents	B-T100
(12-18	O
years	B-T079
).	O
Findings	B-T169
are	O
based	O
on	O
self-report data	B-T062
from	O
638	O
participants	B-T098
in	O
the	O
2013	O
Korea	B-T083
National Health and Nutrition Examination Survey	B-T062
.	O
Only	O
4.9%	O
of	O
adolescents	B-T100
accumulated	O
60	O
minutes	B-T079
of	O
moderate-to-vigorous PA	B-T056
daily	B-T079
.	O
Adolescents	B-T100
spent	O
532.4	O
±	O
9.3	O
mins/d	B-T079
sitting	B-T039
.	O
After	O
controlling	O
for	O
age	B-T032
and	O
sex	B-T032
,	O
individuals	B-T098
in	O
higher income groups	B-T098
compared	B-T052
with	O
the	O
lowest income group	B-T098
,	O
living	B-T052
in	O
nonmetro	B-T082
Seoul	B-T083
compared	B-T052
with	O
metro	B-T082
Seoul	B-T083
,	O
and	O
who	O
were	O
overweight	B-T184
compared	B-T052
with	O
nonoverweight	B-T032
were	O
more	O
likely	O
to	O
meet	O
PA	B-T056
guidelines	B-T170
.	O
Participants	B-T098
in	O
the	O
highest income group	B-T098
compared	B-T052
with	O
lowest income group	B-T098
,	O
and	O
residing	B-T052
in	O
nonmetro	B-T082
Seoul	B-T083
compared	B-T052
with	O
metro	B-T082
Seoul	B-T083
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
high	O
sitting	B-T039
time	B-T079
group	B-T078
(>720	O
min/d	B-T079
)	O
(P	O
<	O
.05).	O
Increasing	B-T169
PA	B-T056
and	O
reducing	B-T080
sitting	B-T039
should	O
be	O
a	O
public health	B-T170
priority	B-T079
in	O
South Korea	B-T083
.	O

Graphene	B-T196
/	O
Nafion	B-T109
composite film	B-T167
modified	O
glassy	B-T080
carbon electrode	B-T074
for	O
simultaneous	B-T079
determination	B-T059
of	O
paracetamol	B-T109
,	O
aspirin	B-T109
and	O
caffeine	B-T109
in	O
pharmaceutical formulations	B-T077
A	O
graphene	B-T196
-	O
Nafion	B-T109
composite film	B-T167
was	O
fabricated	B-T057
on	O
the	O
glassy	B-T080
carbon electrode	B-T074
(	O
GR-NF/GCE	B-T074
),	O
and	O
used	O
for	O
simultaneous	B-T079
determination	B-T059
of	O
paracetamol	B-T109
(	O
PAR	B-T109
),	O
aspirin	B-T109
(	O
ASA	B-T109
)	O
and	O
caffeine	B-T109
(	O
CAF	B-T109
).	O
The	O
electrochemical behaviors	B-T080
of	O
PAR	B-T109
,	O
ASA	B-T109
and	O
CAF	B-T109
were	O
investigated	B-T169
by	O
cyclic voltammetry	B-UnknownType
and	O
square-wave adsorptive anodic stripping voltammetry	B-T059
.	O
By	O
using	O
stripping	B-T059
one	O
for	O
simultaneous	B-T079
determination	B-T059
of	O
PAR	B-T109
,	O
ASA	B-T109
and	O
CAF	B-T109
,	O
their	O
electrochemical oxidation peaks	B-T080
appeared	B-T080
at	O
+0.64,	O
1.04	O
and	O
1.44V,	O
and	O
good	B-T080
linear current responses	B-T080
were	O
obtained	B-T169
with	O
the	O
detection limits	B-T081
of	O
18ngmL(-1)	O
(1.2×10(-9)M),	O
11.7ngmL(-1)	O
(6.5×10(-8)M)	O
and	O
7.3ngmL(-1)	O
(3.8×10(-8)M),	O
respectively.	O
Finally,	O
the	O
proposed	B-T078
electrochemical sensor	B-T073
was	O
successfully	B-T080
applied	B-T169
for	O
quantifying	B-T081
PAR	B-T109
,	O
ASA	B-T109
and	O
CAF	B-T109
in	O
commercial	B-T170
tablet formulations	B-T077
.	O

Long-term	B-T079
antibiofilm activity	B-T052
of	O
carboxymethyl chitosan	B-T109
on	O
mixed biofilm	B-T007
on	O
silicone	B-T109
Silicone	B-T109
voice prostheses	B-T074
are	O
most	O
frequently	B-T079
used	O
in	O
voice rehabilitation	B-T061
of	O
laryngectomized	B-T061
patients	B-T101
.	O
However,	O
the	O
functional device	B-T033
lifetimes	B-T079
are	O
limited	B-T169
due to	B-T169
formation	B-T169
of	O
mixed biofilms	B-T007
.	O
Existing	O
in vitro models	B-T062
simulating	O
biofilm formation	B-T043
are	O
restricted	B-T169
to	O
only	O
short-term	B-T079
periods	B-T079
.	O
The	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
effect	B-T080
of	O
carboxymethyl chitosan	B-T109
on	O
mixed biofilm formation	B-T043
of	O
fungi	B-T004
and	O
bacteria	B-T007
on	O
silicone	B-T109
over	O
a	O
long-term	B-T079
period	B-T079
.	O
Mixed	O
species	B-T185
biofilms	B-T007
of	O
Candida albicans	B-T004
,	O
Candida tropicalis	B-T004
,	O
Lactobacillus gasseri	B-T007
,	O
Streptococcus salivarius	B-T007
,	O
Rothia dentocariosa	B-T007
,	O
and	O
Staphylococcus epidermidis	B-T007
were	O
cultivated	B-T067
on	O
the	O
surfaces	B-T082
of	O
medical-grade silicone	B-T109
with	O
and	O
without	O
addition	O
of	O
carboxymethyl chitosan	B-T109
.	O
Biofilm kinetics	B-T070
was	O
monitored	O
using	O
specially	O
designed image analysis software	B-T170
to	O
calculate	B-T052
the	O
percentual surface covering	B-T169
of	O
each	O
platelet	B-T025
.	O
Biofilm architecture	B-T082
was	O
investigated	B-T169
by	O
scanning electron microscopy	B-T059
.	O
A	O
cover	B-T169
of	O
living	B-T078
mixed biofilm	B-T007
could	O
be	O
generated	O
over	O
22	O
days	B-T079
on	O
silicone	B-T109
and	O
the	O
maximum	B-T081
of	O
22%	O
biofilm	B-T007
surface covering	B-T169
at	O
day	B-T079
22.	O
However,	O
less than	B-T081
4%	O
surface coverage	B-T169
was	O
observed	B-T169
on	O
the	O
carboxymethyl chitosan	B-T109
-	O
treated	B-T169
plates	O
in	O
the	O
testing	B-T169
period	B-T079
.	O
Scanning electron microscopy	B-T059
confirms	B-T033
that,	O
on	O
surfaces	B-T082
treated	B-T169
by	O
carboxymethyl chitosan	B-T109
,	O
the	O
biofilm	B-T007
was	O
less	B-T080
dense	B-T080
.	O
In	O
addition,	O
there	O
were	O
fewer	B-T081
layers	O
of	O
cells	B-T025
and	O
profuse cellular debris	B-T033
,	O
together	B-T080
with	O
degrading	O
and	O
morphologically altered	B-T190
yeast	B-T004
yeast cells	B-T025
.	O
Carboxymethyl chitosan	B-T109
may	O
serve	O
as	O
a	O
possible	B-T033
antibiofilm agent	B-T167
to	O
limit	O
biofilm formation	B-T043
on	O
voice prostheses	B-T074
.	O
NA	O
Laryngoscope	B-T074
,	O
126:E404-E408,	O
2016.	O

Spectral fingerprints	B-T059
of	O
large-scale	O
cortical	B-T023
dynamics	B-T070
during	B-T079
ambiguous	B-T080
motion perception	B-T041
Ambiguous	B-T169
stimuli	B-T067
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	B-T025
correlates	B-T080
of	O
consciousness	B-T041
.	O
Recently,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	B-T041
perception	B-T041
might	O
arise	O
from	O
the	O
dynamic	B-T169
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical areas	B-T023
.	O
While	O
previous	O
research	O
mainly	O
focused	O
on	O
phase coupling	B-T042
as	O
a	O
correlate	B-T080
of	O
cortical	B-T023
communication,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling modes	B-T042
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical functions	B-T042
.	O
Here,	O
we	O
studied	O
two	O
coupling modes	B-T042
,	O
namely	O
phase and envelope coupling	B-T042
,	O
which	O
might	O
differ	O
in	O
their	O
origins,	O
putative	O
functions	O
and	O
dynamics	B-T070
.	O
Therefore,	O
we	O
recorded	O
128-channel	O
EEG	B-T060
while	O
participants	B-T098
performed	O
a	O
bistable motion task	B-T060
and	O
utilized	O
state-of-the-art	O
source-space	O
connectivity	B-T169
analysis	B-T062
techniques	B-T169
to	O
study	O
the	O
functional relevance	B-T077
of	O
different	O
coupling modes	B-T042
for	O
cortical	B-T023
communication.	O
Our	O
results	O
indicate	O
that	O
gamma-band phase coupling	B-T042
in	O
extrastriate	B-T029
visual cortex	B-T023
might	O
mediate	O
the	O
integration	O
of	O
visual tokens	B-T060
into	O
a	O
moving	B-T040
stimulus	B-T067
during	O
ambiguous	B-T080
visual stimulation	B-T060
.	O
Furthermore,	O
our	O
results	O
suggest	O
that	O
long-range	O
fronto-occipital	O
gamma-band	O
envelope coupling	B-T042
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	B-T080
motion perception	B-T041
.	O
Additionally,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local parieto-occipital	B-T023
alpha-band phase coupling	B-T042
controls	O
the	O
inter-	O
hemispheric	B-T082
information transfer	B-T169
.	O
These	O
findings	O
provide	O
correlative	B-T080
evidence	B-T078
for	O
the	O
notion	O
that	O
synchronized	B-T079
oscillatory	O
brain activity	B-T039
reflects	O
the	O
processing of sensory	B-T042
input	O
as	O
well	O
as	O
the	O
information integration	B-T040
across	O
several	O
spatiotemporal scales	B-T062
.	O
The	O
results	O
indicate	O
that	O
distinct coupling modes	B-T081
are	O
involved	O
in	O
different	O
cortical	B-T023
computations	B-T052
and	O
that	O
the	O
rich	O
spatiotemporal correlation	B-T062
structure of the brain	B-T023
might	O
constitute	O
the	O
functional	B-T169
architecture	O
for	O
cortical	B-T023
processing	O
and	O
specific	O
multi-site	O
communication.	O
Hum	O
Brain	O
Mapp	O
37:4099-4111,	O
2016.	O
©	O
2016	O
Wiley	O
Periodicals,	O
Inc.	O

Beneficial effects	B-UnknownType
of	O
voglibose	B-T109
administration	B-T061
on	O
body weight	B-T032
and	O
lipid metabolism	B-T044
via	O
gastrointestinal	B-T022
bile acid	B-T109
modification	B-UnknownType
This	O
study	B-T062
was	O
designed	O
with	O
the	O
goal	B-T170
of	O
examining	O
the	O
effects	B-T169
of	O
voglibose	B-T109
administration	B-T061
on	O
body weight	B-T032
and	O
lipid metabolism	B-T044
and	O
underlying	O
mechanism	B-T169
high fat diet	B-T061
-induced	O
obese mice	B-T015
.	O
Male	B-T032
C57BL/6 mice	B-T015
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	B-T096
:	O
a	O
control diet	B-T096
(	O
CTL	B-T096
),	O
high-fat diet	B-T096
(	O
HF	B-T096
),	O
high-fat diet supplemented with voglibose	B-T096
(	O
VO	B-T096
),	O
and	O
high fat diet pair-fed group	B-T096
(	O
PF	B-T096
).	O
After	O
12	O
weeks	B-T079
,	O
the	O
following	O
characteristics	B-T080
were	O
investigated:	O
serum lipid	B-T059
and	O
glucose levels	B-T034
,	O
serum	O
polar	O
metabolite	O
profiles,	O
and	O
expression levels	B-T081
of	O
genes	B-T028
involved	O
in	O
lipid	B-T044
and	O
bile acid metabolism	B-T044
.	O
In	O
addition,	O
pyrosequencing	B-T059
was	O
used	O
to	O
analyze	O
the	O
composition	B-T201
of	O
gut microbiota	B-T001
found	O
in	O
feces	B-T031
.	O
Total body weight gain	B-T033
was	O
significantly lower	B-T081
in	O
the	O
VO group	B-T096
than	O
in	O
the	O
CTL	B-T096
,	O
HF	B-T096
,	O
and	O
PF groups	B-T096
.	O
The	O
VO group	B-T096
exhibited	O
improved	O
metabolic profiles	B-T039
including	O
those	O
of	O
blood glucose	B-T059
,	O
triglyceride	B-T034
,	O
and	O
total cholesterol levels	B-T034
.	O
The	O
12-	O
week	B-T079
voglibose	B-T109
administration	B-T061
decreased	O
the	O
ratio	O
of	O
Firmicutes	B-T007
to	O
Bacteroidetes	B-T007
found	O
in	O
feces	B-T031
.	O
Circulating	O
levels	B-T080
of	O
taurocholic	B-T109
and	O
cholic acid	B-T109
were	O
significantly higher	B-T081
in	O
the	O
VO group	B-T096
than	O
in	O
the	O
HF	B-T096
and	O
CTL groups	B-T096
.	O
Deoxycholic acid	B-T109
levels	B-T080
tended	O
to	O
be	O
higher	O
in	O
the	O
VO group	B-T096
than	O
in	O
the	O
HF group	B-T096
.	O
Voglibose	B-T109
administration	B-T061
downregulated	B-T044
expression levels	B-T081
of	O
CYP8B1	B-T028
and	O
HNF4α genes	B-T028
and	O
upregulated	B-T044
those	O
of	O
PGC1α	B-T028
,	O
whereas	O
FXRα	B-T028
was	O
not	O
affected.	O
Voglibose	B-T109
administration	B-T061
elicits	O
changes	O
in	O
the	O
composition	B-T201
of	O
the	O
intestinal microbiota	B-T001
and	O
circulating metabolites	B-T123
,	O
which	O
ultimately	O
has	O
systemic effects	B-UnknownType
on	O
body weight	B-T032
and	O
lipid metabolism	B-T044
in	O
mice	B-T015
.	O

Supramolecular Recognition	B-T044
of	O
Amino Acids	B-T116
by	O
Twisted Cucurbit[14]uril	B-T109
Binding	B-T044
interactions	B-T169
between	B-T082
twisted cucurbit[14]uril	B-T109
(tQ[14])	B-T109
and	O
twenty	O
standard	B-T080
amino acids	B-T116
(AAs)	B-T116
have	O
been	O
investigated	B-T169
by	O
NMR spectroscopy	B-T060
and	O
isothermal titration calorimetry	B-T059
(ITC)	B-T059
in	O
aqueous	B-T121
HCl solutions	B-T130
and	O
in	O
DMSO	B-T109
.	O
The	O
results	B-T169
showed	O
that	O
tQ[14]	B-T109
displays	B-T169
clear	O
binding	B-T044
affinity	B-T070
for	O
AAs	B-T116
with	O
a	O
positively charged side chain	B-T104
or	O
containing	B-T169
an	O
aromatic ring	B-T109
,	O
but	O
weaker	B-T080
binding	B-T044
affinity	B-T070
for	O
AAs	B-T116
with	O
hydrophobic	B-T120
or	O
polar side chains	B-T120
,	O
with	O
the	O
binding	B-T044
mode	B-T169
depending	O
on	O
the	O
type	O
of	O
side chain	B-T104
present	O
in	O
the	O
AAs	B-T116
.	O

Comparison	B-T052
of	O
alkaline phosphatase activity	B-T044
of	O
MC3T3-E1 cells	B-T025
cultured	O
on	O
different	O
Ti	B-T196
surfaces	B-T082
:	O
modified	O
sandblasted	B-T067
with	O
large	O
grit	B-T104
and	O
acid-etched	B-T067
(	O
MSLA	B-T196
),	O
laser-treated	B-T067
,	O
and	O
laser and acid-treated	B-T067
Ti	B-T196
surfaces	B-T082
In	O
this	O
study	B-T062
,	O
the	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
effect	O
of	O
implant	O
surface	B-T082
treatment	O
on	O
cell differentiation	B-T043
of	O
osteoblast cells	B-T025
.	O
For	O
this	O
purpose,	O
three	O
surfaces	B-T082
were	O
compared:	O
(1)	O
a	O
modified	O
SLA	O
(MSLA:	O
sand-blasted	O
with	O
large	O
grit	B-T104
,	O
acid-etched,	O
and	O
immersed	O
in	O
0.9%	O
NaCl	B-T121
),	O
(2)	O
a	O
laser treatment	B-T067
(	O
LT	B-T067
:	O
laser treatment	B-T067
)	O
titanium	B-T196
surface	B-T082
and	O
(3)	O
a	O
laser and acid-treated	B-T067
(LAT:	O
laser treatment, acid-etched	B-T067
)	O
titanium	B-T196
surface	B-T082
.	O
The	O
MSLA	B-T196
surfaces	B-T082
were	O
considered	O
as	O
the	O
control group	B-T096
,	O
and	O
LT	B-T196
and	O
LAT	B-T196
surfaces	B-T082
as	O
test groups	B-T078
.	O
Alkaline phosphatase	B-T116
expression	B-T045
(	O
ALP	B-T116
)	O
was	O
used	O
to	O
quantify	O
osteoblastic differentiation	B-T043
of	O
MC3T3-E1 cell	B-T025
.	O
Surface	B-T082
roughness	B-T080
was	O
evaluated	B-T058
by	O
a	O
contact profilometer	B-T074
(URFPAK-SV;	O
Mitutoyo,	O
Kawasaki,	O
Japan	B-T083
)	O
and	O
characterized	O
by	O
two	O
parameters:	O
mean roughness	B-T080
(	O
Ra	B-T080
)	O
and	O
maximum peak-to-valley height	B-T081
(	O
Rt	B-T081
).	O
Scanning electron microscope	B-T074
revealed	O
that	O
MSLA	O
(	O
control group	B-T096
)	O
surface	B-T082
was	O
not	O
as	O
rough	B-T080
as	O
LT	B-T196
,	O
LAT	B-T196
surface	B-T082
(	O
test groups	B-T078
).	O
Alkaline phosphatase	B-T116
expression	B-T045
,	O
the	O
measure	O
of	O
osteoblastic differentiation	B-T043
,	O
and	O
total	O
ALP	B-T116
expression	B-T045
by	O
surface-adherent cells	B-T025
were	O
found	O
to	O
be	O
highest	O
at	O
21	O
days	B-T079
for	O
all	O
three	O
surfaces	B-T082
tested	O
(P<.05).	O
Furthermore,	O
ALP	B-T116
expression	B-T045
levels	B-T080
of	O
MSLA	B-T196
and	O
LAT	B-T196
surfaces	B-T082
were	O
significantly	O
higher	O
than	O
expression	B-T045
levels	B-T080
of	O
LT	B-T196
surface-adherent cells	B-T025
at	O
7,	O
14,	O
and	O
21	O
days	B-T079
,	O
respectively	O
(P<.05).	O
However,	O
ALP	B-T116
expression	B-T045
levels	B-T080
between	O
MSLA	B-T196
and	O
LAT	B-T196
surface	B-T082
were	O
equal	O
at	O
7,	O
14,	O
and	O
21	O
days	B-T079
(P>.05).	O
This	O
study	B-T062
suggested	O
that	O
MSLA	B-T196
and	O
LAT	B-T196
surfaces	B-T082
exhibited	O
more	O
favorable	B-T080
environment	B-T082
for	O
osteoblast differentiation	B-T043
when	O
compared	O
with	O
LT	B-T196
surface	B-T082
,	O
the	O
results	O
that	O
are	O
important	O
for	O
implant	B-T074
surface	B-T082
modification	B-T169
studies	B-T062
.	O

Overcoming	B-T052
structural	B-T082
inequalities	B-T080
in	O
oral health	B-T058
:	O
the	O
role	O
of	O
dental	B-T058
curricula	B-T170
To	O
date	O
the	O
role	O
of	O
health professional schools	B-T073
in	O
addressing	O
oral health	B-T058
inequalities	B-T080
have	O
been	O
minimal,	O
as	O
attempts	B-T051
have	O
focused	B-T169
principally	O
upon	O
systemic	B-T169
reform	B-T078
and	O
broader	O
societal obligations	B-T078
.	O
Professionalism	B-T078
is	O
a	O
broad	O
competency	B-T080
that	O
is	O
taught	O
throughout	O
dental schools	B-T073
and	O
encompasses	O
a	O
range	B-T081
of	O
attributes.	O
Professionalism	B-T078
as	O
a	O
competency	B-T080
draws	O
some	O
debate	B-T052
and	O
appears	O
to	O
be	O
a	O
shifting phenomenon	B-T169
.	O
We	O
may	O
ask	O
if	O
professionalism	B-T078
in	O
the	O
dental	B-T058
curricula	B-T170
may	O
be	O
better	O
addressed	O
by	O
social accountability	B-T078
?	O
Social accountability	B-T078
directs	O
oral health	B-T058
professional curricula	B-T170
(	O
education	B-T185
,	O
research	B-T062
,	O
and	O
service activities	B-T058
)	O
towards	O
addressing	O
the	O
priority	B-T079
health	B-T078
concerns	B-T078
of	O
the	O
community	B-T096
,	O
in	O
our	O
case	O
oral health	B-T058
inequalities	B-T080
.	O
Although	O
working	O
toward	O
dental schools	B-T073
becoming	O
more	O
socially accountable	B-T078
seems	O
like	O
a	O
sensible	O
way	O
to	O
address	B-T170
oral health	B-T058
inequalities	B-T080
,	O
it	O
might	O
have	O
limitations.	O
We	O
will	O
consider	O
some	O
of	O
the	O
challenges	O
in	O
the	O
dental	B-T058
curricula	B-T170
by	O
considering	O
some	O
of	O
the	O
political	B-T068
,	O
structural	B-T082
,	O
social	B-T102
and	O
ethical	B-T078
factors	B-T169
that	O
influence	B-T077
our	O
institutions	B-T093
and	O
our	O
graduates	B-T098
.	O

Function	B-T169
analysis	B-T062
of	O
Mef2c	B-T028
promoter	B-T114
in	O
muscle differentiation	B-T043
Regeneration of adult skeletal muscle	B-T042
following	O
injury	B-T037
occurs	O
through	O
the	O
activation	B-T043
of	O
satellite cells	B-T025
,	O
that	O
proliferates	B-T043
,	O
differentiates	B-T043
,	O
and	O
fuses	B-T043
with	O
injured	B-T169
myofibers	B-T023
.	O
Myocyte enhancer factor 2 (MEF2) proteins	B-T116
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	B-T100
muscle regeneration	B-T033
.	O
In	O
order	O
to	O
further	O
understand	O
Mef2c gene	B-T028
,	O
the	O
promoter	B-T114
of	O
pig	B-T015
Mef2c gene	B-T028
was	O
analyzed	O
in	O
this	O
paper.	O
Quantitative real-time PCR	B-T063
(	O
qRT-PCR	B-T063
)	O
revealed	O
the	O
expression	B-T045
pattern	O
of	O
Mef2c gene	B-T028
in	O
muscle	B-T024
of	O
eight	O
tissues	B-T024
.	O
The	O
Mef2c	B-T028
promoter	B-T114
had	O
the	O
higher	O
transcriptional activity	B-T045
in	O
differentiated	B-T043
C2C12 cells	B-T025
than	O
that	O
in	O
proliferating	B-T043
C2C12 cells	B-T025
,	O
which	O
was	O
accompanied	O
by	O
the	O
up-regulation	B-T045
of	O
mRNA expression	B-T045
of	O
Mef2c gene	B-T028
.	O
Function	B-T169
deletion	B-T045
and	O
mutation	B-T045
analyses	B-T062
showed	O
that	O
MyoD	B-T116
and	O
MEF2	B-T116
binding sites	B-T087
within	O
the	O
Mef2c	B-T028
promoter	B-T114
were	O
responsible	O
for	O
the	O
regulation	B-T045
of	O
Mef2c	B-T028
transcription	B-T045
.	O
MEF2C	B-T028
could	O
up-regulate the transcriptional activities	B-T045
of	O
Mef2c	B-T028
promoter constructs	B-T114
which	O
contained	O
a	O
3'-end nucleotide sequence	B-T086
with	O
p300	B-T116
binding site	B-T086
.	O
The	O
Electrophoretic mobility shift assays	B-T059
(	O
EMSA	B-T059
)	O
and	O
chromatin immunoprecipitation (ChIP) assays	B-T059
determined	O
the	O
MyoD	B-T116
binding site	B-T087
in	O
Mef2c	B-T028
promoter	B-T114
.	O
These	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	B-T114
of	O
the	O
pig	B-T015
Mef2c gene	B-T028
.	O
And	O
the	O
study	O
of	O
Mef2c	B-T028
promoter	B-T114
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation mechanisms	B-T045
of	O
Mef2c	B-T028
in	O
muscle differentiation	B-T043
or	O
muscle repair	B-T061
and	O
regeneration	B-T033
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Novel	O
insights	O
into	O
development	O
of	O
diabetic	B-T033
bladder disorder	B-T047
provided	O
by	O
metabolomic analysis	B-T091
of	O
the	O
rat	B-T015
nondiabetic	O
and	O
diabetic	B-T033
detrusor	B-T023
and	O
urothelial layer	B-T024
There	O
are	O
at	O
present	O
no	O
published	O
studies	O
providing	O
a	O
global	O
overview	O
of	O
changes	B-T169
in	O
bladder	B-T023
metabolism	B-T040
resulting	O
from	O
diabetes	B-T047
.	O
Such	O
studies	O
have	O
the	O
potential	O
to	O
provide	O
mechanistic	O
insight	O
into	O
the	O
development	O
of	O
diabetic	B-T033
bladder disorder (DBD)	B-T047
.	O
In	O
the	O
present	O
study,	O
we	O
compared	O
the	O
metabolome	B-T070
of	O
detrusor	B-T023
and	O
urothelial layer	B-T024
in	O
a	O
1-mo	O
streptozotocin	B-T109
-induced	O
rat	B-T015
model	B-T050
of	O
type 1 diabetes	B-T047
with	O
nondiabetic controls	B-T096
.	O
Our	O
studies	O
revealed	O
that	O
diabetes	B-T047
caused	O
both	O
common	O
and	O
differential	O
changes	B-T169
in	O
the	O
detrusor	B-T023
and	O
urothelial layer's	B-T024
metabolome	B-T070
.	O
Diabetes	B-T047
resulted	O
in	O
similar	O
changes	B-T169
in	O
the	O
levels	O
of	O
previously	O
described	O
diabetic	B-T047
markers	B-T201
in	O
both	O
tissues	B-T024
,	O
such	O
as	O
glucose	B-T109
,	O
lactate	B-T109
,	O
2-hydroxybutyrate	B-T109
,	O
branched-chain amino acid degradation products	B-T116
,	O
bile acids	B-T109
,	O
and	O
1,5-anhydroglucitol	B-T109
,	O
as	O
well	O
as	O
markers	B-T201
of	O
oxidative stress	B-T049
.	O
In	O
the	O
detrusor	B-T023
(but	O
not	O
the	O
urothelial layer	B-T024
),	O
diabetes	B-T047
caused	O
activation	O
of	O
the	O
pentose-phosphate	B-T109
and	O
polyol	B-T109
pathways	B-T044
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
TCA cycle	B-T044
and	O
β-oxidation	B-T044
.	O
Changes	B-T169
in	O
detrusor	B-T023
energy-generating pathways	B-T044
resulted	O
in	O
an	O
accumulation	O
of	O
sorbitol	B-T109
that,	O
through	O
generation	O
of	O
advanced glycation end products	B-T109
,	O
is	O
likely	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
DBD	B-T047
.	O
In	O
the	O
diabetic	B-T033
urothelial layer	B-T024
there	O
was	O
decreased	O
flux	B-T070
of	O
glucose	B-T109
via	O
glycolysis	B-T044
and	O
changes	B-T169
changes	B-T169
in	O
lipid metabolism	B-T044
,	O
particularly	O
prostaglandin	B-T109
synthesis	B-T052
,	O
which	O
also	O
potentially	O
contributes	O
to	O
detrusor	B-T023
dysfunction	B-T046
.	O

Proximal Soil Sensing	B-T059
-	O
A	O
Contribution	B-T052
for	O
Species	B-T185
Habitat	B-T082
Distribution	B-T169
Modelling	B-T062
of	O
Earthworms	B-T204
in	O
Agricultural	B-T082
Soils	B-T167
?	O
Earthworms	B-T204
are	O
important	O
for	O
maintaining	O
soil	B-T167
ecosystem	B-T070
functioning	B-T169
and	O
serve	O
as	O
indicators	B-T130
of	O
soil	B-T167
fertility	B-T080
.	O
However,	O
detection	O
of	O
earthworms	B-T204
is	O
time-consuming	B-T080
,	O
which	O
hinders	O
the	O
assessment	B-T052
of	O
earthworm	B-T204
abundances	B-T080
with	O
high	O
sampling	B-T078
density	B-T081
over	O
entire	O
fields	B-T082
.	O
Recent	O
developments	O
of	O
mobile terrestrial sensor platforms	B-T073
for	O
proximal soil sensing	B-T059
(	O
PSS	B-T059
)	O
provided	O
new	O
tools	B-T073
for	O
collecting	O
dense	O
spatial	O
information	B-T078
of	O
soils	B-T167
using	O
various	O
sensing principles	B-T170
.	O
Yet,	O
the	O
potential	O
of	O
PSS	B-T059
for	O
assessing	B-T052
earthworm	B-T204
habitats	B-T082
is	O
largely	O
unexplored.	O
This	O
study	B-T062
investigates	B-T169
whether	O
PSS	B-T059
data	B-T078
contribute	O
to	O
the	O
spatial	O
prediction	B-T078
of	O
earthworm	B-T204
abundances	B-T080
in	O
species	B-T185
distribution	B-T169
models	B-T170
of	O
agricultural	B-T082
soils	B-T167
.	O
Proximal soil sensing	B-T059
data	B-T078
,	O
e.g.,	O
soil	B-T167
electrical conductivity	B-T081
(	O
EC	B-T081
),	O
pH	B-T081
,	O
and	O
near infrared absorbance	B-T059
(	O
NIR	B-T059
),	O
were	O
collected	B-T078
in	O
real-time	B-T079
in	O
a	O
field	B-T082
with	O
two	O
management strategies	B-T170
(	O
reduced	B-T080
tillage	B-T067
/	O
conventional	O
tillage	B-T067
)	O
and	O
sandy	B-T167
to	O
loam soils	B-T167
.	O
PSS	B-T059
was	O
related	O
to	O
observations	B-T062
from	O
a	O
long-term	B-T079
(11	O
years	B-T079
)	O
earthworm	B-T204
observation study	B-T033
conducted	O
at	O
42	O
plots	B-T082
.	O
Earthworms	B-T204
were	O
sampled	B-T078
from	O
0.5	O
x	O
0.5	O
x	O
0.2	O
m³	O
soil	B-T167
blocks	O
and	O
identified	B-T080
to	O
species	B-T185
level	B-T080
.	O
Sensor	B-T075
data	B-T078
were	O
highly	O
correlated	O
with	O
earthworm	B-T204
abundances	B-T080
observed	B-T169
in	O
reduced	B-T080
tillage	B-T067
but	O
less	O
correlated	B-T080
with	O
earthworm	B-T204
abundances	B-T080
observed	B-T169
in	O
conventional tillage	B-T067
.	O
This	O
may	O
indicate	O
that	O
management	B-T057
influences	B-T077
the	O
sensor	B-T075
-	O
earthworm	B-T204
relationship.	O
Generalized	O
additive	O
models	B-T170
and	O
state-space models	B-T170
showed	O
that	O
modelling	B-T062
based	O
on	O
data	B-T078
fusion	O
from	O
EC	B-T081
,	O
pH	B-T081
,	O
and	O
NIR	B-T059
sensors	B-T075
produced	O
better	O
results	B-T033
than	O
modelling	B-T062
without	O
sensor	B-T075
data	B-T078
or	O
data	B-T078
from	O
just	O
a	O
single	O
sensor	B-T075
.	O
Regarding	O
the	O
individual	O
earthworm	B-T204
species	B-T185
,	O
particular	O
sensor	B-T075
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	B-T082
requirements	B-T169
of	O
the	O
earthworms	B-T204
.	O
Earthworm	B-T204
species	B-T185
with	O
soil	B-T167
-specific	O
habitat	B-T082
preferences	B-T078
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	B-T080
by	O
PSS	B-T059
than	O
more	O
ubiquitous	B-T080
species	B-T185
.	O
Our	O
findings	B-T033
suggest	O
that	O
PSS	B-T059
contributes	O
to	O
the	O
spatial	O
modelling	B-T062
of	O
earthworm	B-T204
abundances	B-T080
at	O
field scale	B-UnknownType
and	O
that	O
it	O
will	O
support	O
species	B-T185
distribution	B-T169
modelling	B-T062
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	B-T167
-	O
earthworm	B-T204
relationships	O
in	O
agroecosystems	B-T070
.	O

Size	B-T081
matters	O
to	O
function:	O
Brain volume	B-T081
correlates	B-T080
with	O
intrinsic	B-T082
brain activity	B-T039
across	O
healthy	B-T080
individuals	B-T098
A	O
fundamental	O
issue	O
in	O
neuroscience	B-T091
is	O
to	O
understand	O
the	O
structural	B-T082
substrates	B-T169
of	O
neural	O
activities.	O
Intrinsic	B-T082
brain activity	B-T039
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive functions	B-T041
.	O
Structurally,	O
cognitive functions	B-T041
have	O
also	O
shown	O
a	O
relation	O
with	O
brain volume	B-T081
/	O
size	B-T081
.	O
Therefore,	O
an	O
association	B-T080
between	O
intrinsic	B-T082
brain activities	B-T039
and	O
brain volume	B-T081
/	O
size	B-T081
can	O
be	O
hypothesized,	O
and	O
brain volume	B-T081
/	O
size	B-T081
may	O
impact	B-T080
intrinsic	B-T082
brain activity	B-T039
in	O
human	B-T016
brains	B-T023
.	O
The	O
present	O
study	B-T062
aimed	O
to	O
explicitly	O
investigate	B-T169
this	O
brain structure	B-T023
-	O
function	B-T039
relationship	B-T080
using	O
two	O
large	O
independent	O
cohorts	B-T098
of	O
176	O
and	O
236	O
young adults	B-T100
.	O
Structural	B-T082
-	O
MRI	B-T060
was	O
performed	B-T169
to	O
estimate	B-T081
the	O
brain volume	B-T081
,	O
and	O
resting-state functional-MRI	B-T060
was	O
applied	O
to	O
extract	O
the	O
amplitude of low-frequency fluctuations	B-T081
(	O
ALFF	B-T081
),	O
an	O
imaging	O
measure	O
of	O
intrinsic	B-T082
brain activity	B-T039
.	O
Intriguingly,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	B-T082
correlation	B-T080
between	O
whole-brain size	B-T081
and	O
ALFF	B-T081
.	O
Moreover,	O
specific	B-T080
brain lobes	B-T023
/	O
regions	B-T029
,	O
including	O
the	O
frontal lobe	B-T023
,	O
the	O
left middle frontal gyrus	B-T023
,	O
anterior cingulate gyrus	B-T023
,	O
Rolandic operculum	B-T023
,	O
and	O
insula	B-T023
,	O
also	O
showed	O
a	O
reliable	B-T080
,	O
positive	B-T033
volume	B-T081
-	O
ALFF	B-T081
correlation	B-T080
in	O
the	O
two	O
cohorts	B-T098
.	O
These	O
findings	O
offer	O
direct	B-T080
,	O
empirical	B-T080
evidence of	B-T169
a	O
strong	B-T080
association	B-T080
between	O
brain size	B-T081
/	O
volume	B-T081
and	O
intrinsic	B-T082
brain activity	B-T039
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	B-T082
substrates	B-T169
of	O
the	O
intrinsic	B-T082
brain activity	B-T039
of	O
the	O
human	B-T016
brain	B-T023
.	O

On	O
the	O
Control	B-T169
of	O
Social	B-T169
Approach-Avoidance Behavior	B-T033
:	O
Neural	B-T169
and	O
Endocrine	B-T169
Mechanisms	B-T169
The	O
ability	B-T032
to	O
control	B-T169
our	O
automatic	B-T169
action	B-T052
tendencies	B-T078
is	O
crucial	B-T080
for	O
adequate	B-T080
social interactions	B-T033
.	O
Emotional	B-T033
events	B-T051
trigger	B-T080
automatic	B-T169
approach and avoidance	B-T033
tendencies	B-T078
.	O
Although	O
these	O
actions	B-T052
may	O
be	O
generally	O
adaptive	B-T169
,	O
the	O
capacity	B-T081
to	O
override	B-T052
these	O
emotional reactions	B-T033
may	O
be	O
key	B-T077
to	O
flexible	B-T080
behavior	B-T053
during	O
social interaction	B-T033
.	O
The	O
present	B-T079
chapter	B-T078
provides	B-T052
a	O
review	B-T078
of	O
the	O
neuroendocrine	B-T022
mechanisms	B-T169
underlying	O
this	O
ability	B-T032
and	O
their	O
relation	B-T080
to	O
social	B-T169
psychopathologies	B-T091
.	O
Aberrant	B-T080
social behavior	B-T054
,	O
such	O
as	O
observed	B-T169
in	O
social anxiety	B-T048
or	O
psychopathy	B-T048
,	O
is	O
marked	B-T080
by	O
abnormalities	B-T033
in	O
approach-avoidance	B-T033
tendencies	B-T078
and	O
the	O
ability	B-T032
to	O
control	B-T169
them.	O
Key	B-T077
neural	B-T169
regions	B-T082
involved	B-T169
in	O
the	O
regulation	B-T038
of	O
approach-avoidance behavior	B-T033
are	O
the	O
amygdala	B-T023
,	O
widely	O
implicated	B-T080
in	O
automatic	B-T169
emotional	B-T033
processing	B-T041
,	O
and	O
the	O
anterior	B-T082
prefrontal cortex	B-T023
,	O
which	O
exerts	B-T040
control	B-T169
over	O
the	O
amygdala	B-T023
.	O
Hormones	B-T125
,	O
especially	O
testosterone	B-T109
and	O
cortisol	B-T109
,	O
have	O
been	O
shown	O
to	O
affect	B-T041
approach-avoidance behavior	B-T033
and	O
the	O
associated	B-T080
neural	B-T169
mechanisms	B-T169
.	O
The	O
present	B-T079
chapter	B-T078
also	O
discusses	O
ways	O
to	O
directly	B-T080
influence	B-T077
social	B-T169
approach and avoidance behavior	B-T033
and	O
will	O
end	O
with	O
a	O
research	B-T062
agenda	B-T170
to	O
further	O
advance	B-T169
this	O
important	B-T080
research field	B-T062
.	O
Control	B-T169
over	O
approach-avoidance	B-T033
tendencies	B-T078
may	O
serve	O
as	O
an	O
exemplar	B-T170
of	O
emotional	B-T033
action	B-T052
regulation	B-T038
and	O
might	O
have	O
a	O
great	B-T081
value	B-T080
in	O
understanding	B-T041
the	O
underlying	O
mechanisms	B-T169
of	O
the	O
development	B-T169
of	O
affective disorders	B-T048
.	O

High	O
Occurrence	O
of	O
Non-Clear Cell Renal Cell Carcinoma	B-T191
in	O
Oman	B-T083
It	O
is	O
conventionally	O
accepted	O
that	O
renal cell carcinoma	B-T191
(	O
RCC	B-T191
)	O
occurs	O
in	O
older patients	B-T101
and	O
the	O
clear cell type	B-T191
is	O
the	O
most	O
common	O
histology	B-T091
.	O
However,	O
ethnic variations	B-T080
exist	O
and	O
this	O
study	B-T062
was	O
carried	O
out	O
to	O
determine	O
the	O
epidemiological pattern	B-UnknownType
of	O
RCC	B-T191
in	O
Oman	B-T083
.	O
Ninety	O
RCC	B-T191
patients	B-T101
who	O
presented	B-T078
to	O
a	O
tertiary care center	B-T073
in	O
the	O
Sultanate of Oman	B-T083
from	O
2010	O
to	O
2014	O
were	O
studied	B-T062
.	O
The	O
main findings	B-T033
were	O
that	O
the	O
median age	B-T032
of	O
presentation	B-T078
was	O
low	B-T080
,	O
more	O
patients	B-T101
presented	B-T078
with	O
localized	B-T082
stage	B-T079
,	O
and	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
non-clear	B-T191
(especially	O
papillary	B-T191
)	O
histology	B-T091
.	O
Data	B-T078
from	O
other	O
Gulf countries	B-T083
and	O
possible	O
reasons	O
for	O
the	O
different	O
profile	O
are	O
discussed.	O

Patient Mobility	B-T061
for	O
Elective	B-UnknownType
Secondary Health Care Services	B-T058
in	O
Response	B-T041
to	O
Patient Choice Policies	B-T089
:	O
A	O
Systematic Review	B-T170
Our	O
review	O
establishes	O
the	O
empirical	B-T080
evidence	B-T078
for	O
patient mobility	B-T061
for	O
elective secondary care services	B-T058
in	O
countries	B-T083
that	O
allow	O
patients	B-T101
to	O
choose	O
their	O
health care provider	B-T097
.	O
PubMed	B-T170
and	O
Embase	B-T170
were	O
searched	O
for	O
relevant	O
articles	B-T170
between	O
1990	O
and	O
2015.	O
Of	O
5,994	O
titles	B-T170
/	O
abstracts	B-T170
reviewed	B-T080
,	O
26	O
studies	B-T062
were	O
included.	O
The	O
studies	B-T062
used	O
three	O
main	O
methodological	B-T057
models	B-T170
to	O
establish	O
mobility	B-T033
.	O
Variation	B-T080
in	O
the	O
extent	O
of	O
patient mobility	B-T061
was	O
observed	O
across	O
the	O
studies.	O
Mobility	B-T033
was	O
positively	O
associated with	B-T080
lower waiting times	B-T079
,	O
indicators	B-T169
of	O
better service quality	B-T058
,	O
and	O
access	O
to	O
advanced technology	B-T092
.	O
It	O
was	O
negatively	O
associated	O
with	O
advanced age	B-T098
or	O
lower	O
socioeconomic	B-T077
backgrounds.	O
From	O
a	O
policy	B-T170
perspective	B-T170
we	O
demonstrate	O
that	O
a	O
significant	O
proportion	B-T081
of	O
patients	B-T101
are	O
prepared	O
to	O
travel	B-T056
beyond	O
their	O
nearest	O
provider	B-T097
for	O
elective services	B-UnknownType
.	O
As	O
a	O
consequence,	O
some	O
providers	B-T097
are	O
likely	O
to	O
be	O
"	O
winners	B-T058
"	O
and	O
others	O
"	O
losers	B-T033
,"	O
which	O
could	O
result	O
in	O
overall	O
decreased	B-T081
provider	B-T097
capacity	B-T081
or	O
inefficient	B-T169
utilization	O
of	O
existing	O
services	B-T058
.	O
Equity	B-T080
also	O
remains	O
a	O
key	O
concern.	O

New	B-T080
Breast Pain	B-T184
Chart	B-T074
for	O
Objective Record	B-T170
of	O
Mastalgia	B-T184
Mastalgia	B-T184
is	O
the	O
commonest	B-T081
affliction	B-T041
of	O
mammary gland	B-T023
among	O
ladies	B-T098
of	O
the	O
reproductive	B-T079
age group	B-T100
.	O
Since	O
etiopathogenesis	B-T169
and	O
therapy	B-T061
are	O
different	B-T080
for	O
cyclical	B-T184
and	O
noncyclical pain	B-T184
,	O
it	O
is	O
imperative	O
to	O
ascertain	O
the	O
exact	O
type	O
correctly.	O
This	O
is	O
usually	O
done	O
in	O
the	O
breast clinics	B-T073
by	O
advising	O
the	O
patient	B-T101
to	O
fill	O
a	O
pain diary	B-T170
over	O
a	O
period	B-T079
of	O
2	O
months	B-T079
over	O
two	O
menstrual cycles	B-T040
.	O
The	O
Cardiff pain chart records	B-T074
the	O
severity	B-T080
of	O
pain	B-T184
in	O
the	O
form	O
of	O
a	O
triangle	B-T077
for	O
mild	B-T080
to	O
moderate pain	B-T184
and	O
a	O
square	B-T082
for	O
severe pain	B-T033
.	O
Moreover,	O
Cardiff pain chart	B-T074
does	O
not	O
allow	O
a	O
patient	B-T101
to	O
record	B-T080
the	O
severity	B-T080
of	O
pain	B-T184
on	O
days	B-T079
of	O
menses	B-T040
,	O
as	O
she	O
has	O
to	O
put	O
the	O
letter	O
"P"	O
in	O
the	O
box.	O
These	O
problems	B-T033
have	O
been	O
resolved	B-T077
in	O
the	O
new	B-T080
breast pain	B-T184
chart	B-T074
.	O
In	O
the	O
new	B-T080
pain chart	B-T074
,	O
the	O
lady	B-T098
records	B-T080
pain	B-T184
severity	B-T080
in	O
the	O
form	O
of	O
visual linear analogue scale score	B-T201
on	O
every day	B-T079
of	O
menstrual cycle	B-T040
.	O
She	O
enters	O
her	O
menstrual	B-T040
experience	B-T041
on	O
a	O
separate	O
part	O
of	O
chart	B-T074
,	O
which	O
allows	O
us	O
to	O
visualize	B-T082
the	O
full	O
month's	B-T079
pain	B-T184
severity	B-T080
in	O
an	O
uncluttered	O
way.	O

The	O
Demand	O
for	O
Cigarettes	B-T073
in	O
Tanzania	B-T083
and	O
Implications	B-UnknownType
for	O
Tobacco	B-T109
Taxation Policy	B-UnknownType
The	O
study	B-T062
attempts	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-T073
in	O
Tanzania	B-T083
and	O
presents	O
simulation	B-T062
results	B-T169
on	O
the	O
effect	B-T080
of	O
the	O
cigarette	B-T073
excise tax	B-UnknownType
on	O
smoking	B-T055
participation	B-T169
,	O
government revenue	B-UnknownType
,	O
and	O
related	O
topics.	O
After	O
briefly	O
summarizing	O
the	O
magnitude	B-T081
and	O
spread	O
of	O
cigarette consumption	B-T033
in	O
the	O
country	B-T083
,	O
the	O
paper	O
reviews	O
some	O
empirical	O
estimates	O
from	O
African	B-T083
and	O
other	O
countries	B-T083
.	O
The	O
2008	O
Tanzanian	B-T083
household budget	B-T170
survey	B-T170
was	O
used	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-T073
in	O
Tanzania	B-T083
.	O
The	O
descriptive	O
statistics	O
suggest	O
that	O
the	O
smoking	B-T055
prevalence	O
for	O
Tanzania	B-T083
is	O
15.35	O
percent	O
with	O
low	O
variability	O
across	O
expenditure (income) groups	B-UnknownType
.	O
Smoking	B-T055
intensity	O
and	O
per capita consumption	B-UnknownType
were	O
estimated	O
at	O
7.08	O
cigarettes	B-T073
and	O
1.33	O
cigarettes	B-T073
,	O
respectively,	O
a	O
relatively	O
low	O
value.	O
A	O
two-part demand equation model	B-T170
was	O
used	O
to	O
estimate	O
various	O
elasticities	B-UnknownType
.	O
For	O
the	O
overall	O
equation	B-T077
,	O
the	O
price elasticities	B-UnknownType
of	O
smoking	B-T055
participation	B-T169
,	O
smoking	B-T055
intensity,	O
and	O
total	O
elasticity	B-UnknownType
were	O
estimated	O
at	O
-0.879,	O
-0.853,	O
and	O
-1.732,	O
respectively.	O
Compared	O
to	O
similar	O
results	O
in	O
other	O
developing countries	B-T080
,	O
the	O
estimates	O
appear	O
quite	O
high.	O
When	O
estimated	O
by	O
expenditure (income) groups	B-UnknownType
,	O
the	O
magnitude	B-T081
of	O
the	O
elasticity	B-UnknownType
appears	O
higher	O
among	O
high expenditure groups	B-UnknownType
than	O
among	O
low expenditure groups	B-UnknownType
.	O
Two	O
simulation	B-T062
exercises	O
were	O
undertaken.	O
First,	O
the	O
effect	B-T080
of	O
different	O
excise	B-UnknownType
rates	B-T081
on	O
smoking	B-T055
participation rate	B-T081
,	O
cigarette consumption	B-T033
,	O
tax revenue	B-UnknownType
,	O
and	O
related	O
responses	O
was	O
estimated	O
and	O
highlighted.	O
Second,	O
the	O
same	O
exercise	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	B-T080
of	O
a	O
given	O
increase	B-T169
in	O
the	O
cigarette	B-T073
excise tax	B-UnknownType
on	O
various	O
expenditure groups	B-UnknownType
.	O
The	O
overall	O
results	B-T169
suggest	O
that	O
an	O
increase	B-T169
in	O
the	O
excise tax	B-UnknownType
on	O
cigarettes	B-T073
in	O
Tanzania	B-T083
would	O
reduce	O
cigarette consumption	B-T033
and	O
increase	B-T169
government tax revenue	B-UnknownType
.	O

Physicians'	B-T097
knowledge	O
on	O
the	O
work-related	B-T047
chronic obstructive pulmonary disease	B-T047
Chronic obstructive pulmonary disease	B-T047
(	O
COPD	B-T047
)	O
may	O
be	O
induced	O
by	O
the	O
work environment	B-T082
conditions	B-T080
.	O
According	O
to	O
the	O
estimates	B-T081
,	O
10-20%	O
of	O
all	O
COPD	B-T047
cases	B-T169
are	O
associated with	B-T080
occupational exposure	B-T037
to	O
dusts	B-T167
and	O
irritant	B-T131
gases	B-T104
.	O
However,	O
in	O
2014,	O
only	O
11	O
cases	B-T169
of	O
work-related	B-T047
COPD	B-T047
were	O
recognized	O
in	O
Poland	B-T083
.	O
The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
analyze	B-T062
the	O
reasons	O
for	O
the	O
low	B-T080
incidence	B-T081
of	O
work-related	B-T047
COPD	B-T047
in	O
the	O
context	B-T078
of	O
pulmonologists	B-T097
'	O
knowledge	O
about	O
occupational	B-T169
risk factors	B-T033
and	O
procedures	B-T169
on	O
reporting	B-T058
suspected	B-T047
occupational diseases	B-T047
.	O
A	O
survey	B-T170
included	O
94	O
pulmonologists	B-T097
randomly	B-T080
selected	O
out	O
of	O
225	O
specialists	B-T097
registered	O
at	O
the	O
Local Physicians Chamber	B-T093
in	O
Łódź	B-UnknownType
.	O
The	O
study	B-T062
was	O
performed	B-T169
anonymously	B-T080
with	O
the	O
use	O
of	O
original	O
questionnaire	B-T170
.	O
More	O
than	O
a	O
half	O
of	O
the	O
surveyed	B-T170
pulmonologists	B-T097
identified	B-T080
environmental	B-T082
risk factors	B-T033
for	O
COPD	B-T047
correctly,	O
while	O
only	O
23.4%	O
properly	O
identified	B-T080
the	O
main	O
occupational	B-T169
risk factors	B-T033
as	O
the	O
cause	B-T078
of	O
COPD	B-T047
.	O
Only	O
58.5%	O
of	O
the	O
pulmonologists	B-T097
always	O
asked	O
their	O
patients	B-T101
suffering	B-T033
from	O
COPD	B-T047
about	O
their	O
job	B-T090
/	O
profession	B-T090
and	O
60.6%	O
of	O
them	O
did	O
not	O
have	O
any	O
knowledge	O
about	O
procedures	B-T169
on	O
reporting	B-T058
suspected	B-T047
occupational diseases	B-T047
.	O
The	O
physicians	B-T097
rarely	B-T080
ask	O
patients	B-T101
suffering	B-T033
from	O
COPD	B-T047
about	O
their	O
job	B-T090
/	O
profession	B-T090
and	O
the	O
relationship	B-T080
between	O
their	O
ailments	B-T184
and	O
occupational exposure	B-T037
.	O
What	O
is	O
more,	O
they	O
do	O
not	O
know	O
legal regulations	B-T089
on	O
proper	O
referral of a patient	B-T058
with	O
a	O
suspected	B-T047
case	B-T169
of	O
occupational disease	B-T047
.	O
The	O
results	B-T169
of	O
the	O
study	B-T062
clearly	O
indicate	B-T078
that	O
there	O
is	O
an	O
urgent	O
need	O
for	O
increasing	B-T169
pulmonologists	B-T097
'	O
knowledge	O
on	O
work-related	B-T047
COPD	B-T047
.	O
Med	O
Pr	O
2016;67(3):375-384.	O

Case Report	B-T170
of	O
Necrotizing Fasciitis	B-T047
Associated with	B-T080
Streptococcus pneumoniae	B-T007
Necrotizing fasciitis	B-T047
,	O
caused	O
by	O
Streptococcus pneumoniae	B-T007
,	O
is	O
an	O
extremely rare	B-T080
and	O
life-threatening	B-T033
bacterial	B-T007
soft tissue infection	B-T047
.	O
We	O
report	B-T058
a	O
case	B-T169
of	O
early	O
necrotizing fasciitis	B-T047
associated with	B-T080
Streptococcus pneumoniae	B-T007
infection	B-T046
in	O
a	O
26-	O
year	B-T079
-old	O
man	B-T098
who	O
was	O
immunocompromised	B-T033
with	O
mixed connective tissue disease	B-T047
.	O
The	O
patient	B-T101
presented	O
with	O
acute	B-T079
,	O
painful	B-T184
,	O
erythematous	B-T169
,	O
and	O
edematous skin	B-T046
lesions	B-T033
of	O
his	O
right lower back	B-T029
,	O
which	O
rapidly	O
progressed	B-T169
to	O
the	O
right knee	B-T023
.	O
The	O
patient	B-T101
underwent	O
surgical exploration	B-T060
,	O
and	O
a	O
diagnosis	B-T033
of	O
necrotizing fasciitis	B-T047
was	O
confirmed	O
by	O
pathological	B-T169
evidence	B-T078
of	O
necrosis	B-T042
of	O
the	O
fascia	B-T024
and	O
neutrophil infiltration	B-T039
in	O
tissue biopsies	B-T060
.	O
Cultures	B-T059
of	O
fascial	B-T029
tissue biopsies	B-T060
and	O
blood samples	B-T031
were	O
positive	B-T033
for	O
Streptococcus pneumoniae	B-T007
.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
report	B-T058
of	O
necrotizing fasciitis	B-T047
resulting	O
from	O
Streptococcus pneumoniae	B-T007
diagnosed	B-T033
at	O
early	O
phase	B-T079
;	O
the	O
patient recovered	B-T032
well	O
without	O
surgical debridement	B-T061
.	O

A	O
Comparative Study	B-T062
of	O
the	O
Efficacy	B-T080
of	O
IV	B-T082
Dexketoprofen	B-T109
,	O
Lornoxicam	B-T109
,	O
and	O
Diclophenac Sodium	B-T121
on	O
Postoperative Analgesia	B-T061
and	O
Tramadol	B-T109
Consumption	B-UnknownType
in	O
Patients	B-T101
Receiving	O
Patient-Controlled	B-T061
Tramadol	B-T109
This	O
study	B-T062
was	O
designed	B-T052
to	O
compare	B-T052
the	O
effects of	B-T080
dexketoprofen	B-T109
,	O
lornoxicam	B-T109
,	O
and	O
diclophenac sodium	B-T121
on	O
postoperative analgesia	B-T061
and	O
tramadol	B-T109
consumption	B-UnknownType
in	O
patients	B-T101
receiving	O
postoperative	B-T079
patient-controlled	B-T061
tramadol	B-T109
after	O
a	O
major	B-T080
abdominal surgery	B-T061
.	O
Eighty	O
patients	B-T101
were	O
randomized	B-T033
to	O
receive	O
one	O
of	O
the	O
four	O
study	B-T062
drugs	B-T121
.	O
Patients	B-T101
in	O
group	B-T078
dexketoprofen	B-T109
(	O
DT	B-T109
)	O
received	O
IV	B-T082
50	O
mg	O
dexketoprofen	B-T109
,	O
group	B-T078
lornoxicam	B-T109
(	O
LR	B-T109
)	O
received	O
IV	B-T082
8	O
mg	O
lornoxicam	B-T109
,	O
group	B-T078
diclophenac sodium	B-T121
(	O
DS	B-T121
)	O
received	O
75	O
mg	O
IV	B-T082
diclophenac sodium	B-T121
and	O
group	B-T078
saline	B-T167
(	O
S	B-T167
)	O
received	O
0.9%	O
saline	B-T167
in	O
2	O
mL	O
syringes	B-T074
,	O
20	O
min	B-T079
before	O
the	O
end	O
of	O
anaesthesia	B-T061
.	O
A	O
standardized	B-T080
(1	O
mg	O
kg(-1))	O
dose	B-T081
of	O
tramadol	B-T109
was	O
routinely	B-T080
administered	B-T169
to	O
all	O
patients	B-T101
as	O
the	O
loading dose	B-T081
at	O
the	O
end	O
of	O
surgery	B-T061
.	O
Postoperatively	B-T079
,	O
whenever	O
patients	B-T101
requested,	O
they	O
were	O
allowed	O
to	O
use	O
a	O
tramadol	B-T109
patient-controlled analgesia device	B-T033
giving	O
a	O
bolus dose	B-T061
(0.2	O
mg	O
kg(-1))	O
of	O
tramadol	B-T109
.	O
Pain	B-T184
,	O
discomfort	B-T184
,	O
and	O
sedation	B-T033
scores	B-T081
,	O
cumulative	B-T080
tramadol	B-T109
consumption	B-UnknownType
,	O
supplemental	B-T169
meperidine	B-T109
requirement	B-T169
,	O
and	O
side effects	B-T046
were	O
recorded.	O
Visual rating scale	B-T081
and	O
patient	B-T101
discomfort	B-T184
scores	B-T081
were	O
significantly	B-T078
lower	B-T052
in	O
DT	B-T109
,	O
LR	B-T109
and	O
DS	B-T121
groups	B-T078
compared	O
to	O
those	O
in	O
in	O
group	B-T078
S	B-T167
(p<0.001).	O
Cumulative	B-T080
tramadol	B-T109
consumption	B-UnknownType
was	O
significantly	B-T078
lower	B-T052
in	O
non-steroidal anti-inflammatory drug	B-T121
(	O
NSAID	B-T121
)-	O
treated	B-T169
groups	B-T078
at	O
each	O
study period	B-T062
after	O
the	O
second	O
postoperative	B-T079
hour	B-T079
than	O
in	O
group	B-T078
S	B-T167
(p<0.001).	O
Supplemental	B-T169
meperidine	B-T109
requirement	B-T169
was	O
significantly	B-T078
higher	O
in	O
group	B-T078
S	B-T167
at	O
each	O
study period	B-T062
after	O
postoperative	B-T079
30	O
min	B-T079
than	O
in	O
NSAID	B-T121
-	O
treated	B-T169
groups	B-T078
(p<0.01).	O
After	O
major	B-T080
abdominal surgery	B-T061
,	O
adding	O
IV	B-T082
diclophenac	B-T109
,	O
lornoxicam	B-T109
or	O
dexketoprofen	B-T109
to	O
patient-controlled	B-T061
tramadol	B-T109
resulted	O
in	O
lower	B-T052
pain	B-T184
scores	B-T081
,	O
smaller	B-T080
tramadol	B-T109
consumption	B-UnknownType
,	O
less	O
rescue	O
supplemental	B-T169
analgesic	B-T109
requirement	B-T169
,	O
and	O
fewer	O
side effects	B-T046
compared	O
with	O
the	O
tramadol	B-T109
alone	O
group	B-T078
.	O

Perioperative Management	B-T058
of	O
Severe Hypertension	B-T033
during	O
Laparoscopic Surgery	B-T061
for	O
Pheochromocytoma	B-T191
Phaeochromocytoma	B-T191
is	O
a	O
catecholamine-secreting	B-T043
vascular tumour	B-T191
that	O
is	O
derived	O
from	O
chromaffin cell	B-T025
.	O
Lethal	B-T033
cardiovascular complications	B-T046
,	O
such	O
as	O
serious	O
hypertension	B-T047
,	O
myocardial infarction	B-T047
and	O
aortic dissection	B-T047
,	O
may	O
occur	O
because	O
of	O
uncontrolled catecholamine release	B-T191
.	O
Each	O
stage	B-T079
of	O
anaesthesia management	B-T061
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive catecholamine secretion	B-T191
that	O
may	O
occur	O
during	O
induction	B-T061
,	O
perioperative stage	B-T079
and	O
surgical manipulation	B-T061
.	O
In	O
this	O
study,	O
we	O
report	O
regarding	O
the	O
preoperative preparation	B-T058
and	O
severe, persistent hypertension attack management	B-T058
with	O
a	O
combination	O
of	O
α-adrenergic blockade	B-T121
,	O
β-adrenergic blockade	B-T121
,	O
sodium nitroprusside	B-T109
and	O
remifentanil	B-T109
in	O
a	O
patient	B-T101
who	O
underwent	O
laparoscopic surgery	B-T061
for	O
phaeochromocytoma	B-T191
.	O

A	O
case	B-T169
based	O
reflection	B-T033
on	O
communicating end	B-T169
of	O
life	B-T078
information	B-T078
in	O
non-English speaking	B-T033
patients	B-T101
Mr	O
X	O
was	O
a	O
56	O
year old	B-T079
Chinese	B-T098
man	B-T098
(	O
non-English speaking	B-T033
),	O
who	O
presented	O
to	O
the	O
emergency department	B-T073
with	O
a	O
range	O
of	O
non-specific	B-T080
symptoms	B-T184
.	O
On	O
full	O
workup,	O
he	O
was	O
diagnosed	B-T033
with	O
an	O
advanced cancer of the pancreas	B-T191
.	O
It	O
was	O
an	O
aggressive	B-T191
,	O
highly	O
treatment resistant cancer	B-T047
,	O
with	O
an	O
alarmingly	O
poor prognosis	B-T033
.	O
Before	O
the	O
diagnosis	B-T033
had	O
been	O
made,	O
the	O
family	B-T099
had	O
informed	O
our	O
team	B-T058
that	O
we	O
were	O
not	O
to	O
discuss	O
medical	B-T169
issues	B-T033
with	O
Mr	O
X	O
directly,	O
and	O
that	O
upon	O
arriving	O
on	O
a	O
diagnosis	B-T033
we	O
were	O
to	O
come	O
to	O
them	O
first	O
and	O
they	O
would	O
subsequently	O
inform	O
him.	O
They	O
reported	O
that	O
Mr	O
X	O
was	O
in	O
support	B-T077
of	O
this	O
arrangement.	O
Eventually	O
we	O
told	O
the	O
family	B-T099
about	O
Mr	O
X's	O
diagnosis	B-T033
,	O
and	O
they	O
asserted	O
their	O
collective will	B-UnknownType
to	O
keep	O
this	O
information	B-T078
from	O
him,	O
reaffirming	O
that	O
all	O
medical	B-T169
discussion	B-T061
go	O
through	O
them.	O
However,	O
the	O
doctor in charge	B-T097
explained	O
the	O
diagnosis	B-T033
to	O
Mr	O
X	O
using	O
an	O
interpreter	B-T097
while	O
his	O
family	B-T099
were	O
away	O
from	O
his	O
bed	B-T073
.	O
In	O
this	O
discussion,	O
I	O
consider	O
this	O
case	B-T169
from	O
the	O
perspective	O
of	O
respecting patients' and families' preferences	B-T061
around	O
medical treatment and care	B-T058
.	O

Difference-in-Differences Method	B-T062
in	O
Comparative Effectiveness Research	B-T062
:	O
Utility	O
with	O
Unbalanced Groups	B-UnknownType
Comparative effectiveness research	B-T062
(	O
CER	B-T062
)	O
often	O
includes	O
observational studies	B-T170
utilizing	O
administrative data	B-T033
.	O
Multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
CER	B-T062
to	O
adjust	O
for	O
group	B-UnknownType
differences	B-T080
,	O
including	O
difference-in-differences (DiD) estimation	B-T062
.	O
This	O
study	O
presents	O
DiD	B-T062
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	B-T170
to	O
estimate	O
treatment outcomes	B-T080
in	O
the	O
CER	B-T062
setting	O
by	O
utilizing	O
the	O
MarketScan® Databases	B-T170
for	O
multiple sclerosis	B-T047
(	O
MS	B-T047
)	O
patients	B-T101
receiving	O
different	O
therapies	B-T061
.	O
The	O
sample	O
included	O
6762	O
patients	B-T101
,	O
with	O
363	O
in	O
the	O
Test Cohort	B-T098
[	O
glatiramer acetate	B-T116
(	O
GA	B-T116
)	O
switched	B-T058
to	O
fingolimod	B-T109
(	O
FTY	B-T109
)]	O
and	O
6399	O
in	O
the	O
Control Cohort	B-T096
(	O
GA	B-T116
only,	O
no switch	B-T033
)	O
from	O
a	O
US administrative claims database	B-T170
.	O
A	O
trend analysis	B-UnknownType
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	B-T170
to	O
the	O
mean	B-T081
and	O
to	O
compare	O
relapse	B-T067
rates	O
among	O
treatment cohorts	B-T098
.	O
DiD analysis	B-T062
was	O
used	O
to	O
enable	O
comparisons	B-T052
among	O
the	O
Test	B-T098
and	O
Control Cohorts	B-T096
.	O
Logistic regression	B-T062
was	O
used	O
to	O
estimate	O
the	O
probability	B-T081
of	O
relapse	B-T067
after	O
switching	B-T058
from	O
GA	B-T116
to	O
FTY	B-T109
,	O
and	O
to	O
compare	B-T052
group	B-UnknownType
differences	B-T080
in	O
the	O
pre	B-T079
-	O
and	O
post	B-T079
-	O
index periods	B-T079
.	O
Crude	O
DiD analysis	B-T062
showed	O
that	O
in	O
the	O
pre	B-T079
-	O
index period	B-T079
more	O
patients	B-T101
in	O
the	O
Test Cohort	B-T098
experienced	O
an	O
MS	B-T047
relapse	B-T067
and	O
had	O
a	O
higher	O
mean number	B-T081
of	O
relapses	B-T067
than	O
in	O
the	O
Control Cohort	B-T096
.	O
During	O
the	O
pre	B-T079
-	O
index period	B-T079
,	O
numeric	B-T080
and	O
relative	O
data	O
for	O
MS	B-T047
relapses	B-T067
in	O
patients	B-T101
in	O
the	O
Test Cohort	B-T098
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control Cohort	B-T096
,	O
while	O
no significant	B-T033
between-	O
group	B-UnknownType
differences	B-T080
emerged	O
during	O
the	O
post	B-T079
-	O
index period	B-T079
.	O
Generalized	O
linear modeling	B-T081
with	O
DiD	B-T062
regression estimation	B-UnknownType
showed	O
that	O
the	O
mean	O
number	O
of	O
MS	B-T047
relapses	B-T067
decreased	O
significantly	O
in	O
the	O
post	B-T079
-	O
index period	B-T079
among	O
patients	B-T101
in	O
the	O
Test Cohort	B-T098
compared	O
with	O
patients	B-T101
in	O
the	O
Control Cohort	B-T096
.	O
In	O
this	O
study,	O
an	O
MS	B-T047
population	B-T098
was	O
utilized	O
to	O
demonstrate	O
how	O
DiD	B-T062
can	O
be	O
applied	O
to	O
estimate	O
treatment effects	B-T033
in	O
a	O
heterogeneous	B-T080
population	B-T098
,	O
where	O
the	O
Test	B-T098
and	O
Control Cohorts	B-T096
varied	O
greatly.	O
The	O
results	O
show	O
that	O
DiD	B-T062
offers	O
a	O
robust	O
method	O
for	O
comparing	B-T052
diverse	B-T080
cohorts	B-T098
when	O
other	O
risk-adjustment methods	B-T081
may	O
not	O
be	O
adequate.	O

Metabolomic	B-T091
analysis	B-T169
of	O
glycerophospholipid	B-T109
signatures	O
of	O
inflammation	B-T046
treated with	B-T061
non-steroidal anti-inflammatory drugs	B-T121
-induced-	O
RAW264.7 cells	B-T025
using	O
(1)H NMR	B-T060
and	O
U-HPLC	B-T059
/	O
Q-TOF-MS	B-T059
Non-destructive proton nuclear magnetic resonance ((1)H NMR) spectroscopy	B-T060
and	O
highly sensitive	B-T080
ultra-performance liquid chromatography	B-T059
quadrupole time-of-flight mass spectrometry	B-T059
(	O
U-HPLC	B-T059
/	O
Q-TOF-MS	B-T059
)	O
coupled	O
to	O
data processing	B-T066
methods	B-T170
were	O
applied	O
to	O
analyze	O
the	O
metabolic profiling	B-T091
changes	O
of	O
glycerophospholipids	B-T109
(	O
GPLs	B-T109
)	O
in	O
RAW264.7 cells	B-T025
from	O
inflammation	B-T046
to	O
prognosis	B-T058
.	O
Analysis	B-T062
of	O
(1)H NMR	B-T060
was	O
shown	O
that	O
the	O
models	B-T170
were	O
grouped	B-T169
successfully,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	B-T080
.	O
Based	O
on	O
the	O
highly simple	B-T080
,	O
accurate	B-T080
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
(1)H NMR	B-T060
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory drugs	B-T121
in	O
the	O
metabolic profiling	B-T091
of	O
GPLs	B-T109
.	O
58	O
GPLs	B-T109
were	O
identified	B-T080
by	O
U-HPLC	B-T059
/	O
Q-TOF-MS	B-T059
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	B-T080
in	O
this	O
study	B-T062
compared	O
with	O
our	O
previous	O
results.	O
In	O
addition,	O
ten	O
potential	B-T080
biomarkers	B-T201
were	O
proved,	O
of	O
which	O
phosphatidylcholine	B-T109
(	O
PC	B-T109
)	O
(16:0/18:1)	O
and	O
(18:0/18:1)	O
changed	B-T081
consistently	O
in	O
three	O
drug-induced	B-T169
groups	B-T078
and	O
might	O
be	O
the	O
important	O
biomarkers	B-T201
.	O
Compared	O
with	O
(1)H NMR	B-T060
,	O
U-HPLC	B-T059
/	O
Q-TOF-MS	B-T059
showed	O
higher	B-T080
sensitivity and specificity	B-T081
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-T059
of	O
biomarkers	B-T201
apart	O
from	O
the	O
deficiency	B-T080
of	O
time-consuming	B-T080
sample preparation steps	B-T059
and	O
unambiguous	O
metabolite	B-T123
identification	B-T080
.	O
Therefore,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	B-T081
of	O
GPLs	B-T109
during	O
inflammation	B-T046
by	O
combining	O
(1)H NMR spectroscopy	B-T060
with	O
U-HPLC	B-T059
/	O
Q-TOF-MS	B-T059
.	O
The	O
metabolic profiling	B-T091
of	O
GPLs	B-T109
provides	O
valuable	O
evidence	B-T078
for	O
inflammation	B-T046
diagnosis	B-T033
and	O
prognosis	B-T058
,	O
and	O
might	O
unravel	O
the	O
mechanisms	B-T169
involved	O
in	O
inflammation	B-T046
progression	B-T046
.	O

Characterization	B-T052
of	O
novel	B-T080
DeoR-family	B-T116
member	B-T096
from	O
the	O
Streptomyces ahygroscopicus	B-T007
strain CK-15	B-T001
that	O
acts	O
as	O
a	O
repressor	B-T116
of	O
morphological	B-T082
development	B-T169
Wuyiencin	B-T131
is	O
produced	B-T052
by	O
Streptomyces ahygroscopicus var. wuyiensis	B-T007
,	O
which	O
has	O
been	O
widely	O
used	O
in	O
China	B-T083
as	O
an	O
industrially	B-T092
produced	B-T057
biopesticide	B-T131
to	O
control	B-T080
various	O
fungal diseases	B-T047
.	O
Although	O
its	O
mechanism	B-T169
of	O
action	B-T052
,	O
breeding	B-T040
,	O
and	O
fermentation	B-T044
had	O
been	O
extensively	O
characterized	B-T052
,	O
less	O
is	O
known	O
about	O
the	O
regulatory functions	B-T044
that	O
affect	O
its	O
biosynthesis	B-T169
or	O
morphological	B-T082
development	B-T169
.	O
The	O
wysR3 gene	B-T028
of	O
S. ahygroscopicus	B-T007
strain CK-15	B-T001
,	O
a	O
novel	B-T080
member	B-T096
of	O
the	O
DeoR family	B-T116
of	O
regulatory genes	B-T028
,	O
was	O
assessed	B-T052
to	O
determine	O
its	O
function	B-T169
by	O
gene knockdown	B-T063
.	O
Herein,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
DeoR family proteins	B-T116
derived	O
from	O
the	O
same	O
source	B-T033
are	O
likely	O
to	O
be	O
a	O
single	B-T081
branch	B-T082
in	O
a	O
phylogenetic tree	B-T080
and	O
show	O
that	O
wysR3	B-T028
acts	O
as	O
a	O
repressor	B-T116
for	O
its	O
morphological	B-T082
development	B-T169
without	O
effecting	O
wuyiencin	B-T131
production	B-T052
.	O
We	O
found	O
that	O
the	O
ΔwysR3	B-T028
strain	B-T001
can	O
grow	O
quickly	O
to	O
reach	O
a	O
plateau	B-T081
stage	B-T079
of	O
maximum	O
biomass	B-T081
at	O
60	O
h,	O
which	O
is	O
~12	O
h	O
faster	B-T080
than	O
the	O
wild-type	B-T028
strain	B-T001
.	O
In	O
the	O
industrial	B-T092
fermentation	B-T044
production	B-T057
process	B-T067
,	O
the	O
ΔwysR3	B-T028
strain	B-T001
can	O
reduce	B-T080
consumption	B-T052
and	O
save	O
both	O
time	B-T079
and	O
money	B-T073
.	O

Targeting	B-T169
the	O
ecology	B-T090
within:	O
The	O
role	B-T077
of	O
the	O
gut-brain axis	B-T082
and	O
human	B-T016
microbiota	B-T001
in	O
drug addiction	B-T048
Despite	O
major advances	B-T079
in	O
our	O
understanding	B-T041
of	O
the	O
brain	B-T023
using	B-T169
traditional neuroscience	B-T091
,	O
reliable	B-T170
and	O
efficacious	B-T080
treatments	B-T061
for	O
drug addiction	B-T048
have	O
remained elusive	B-T033
.	O
Hence,	O
the	O
time	B-T079
has	O
come	O
to	O
utilize	B-T169
novel	B-T080
approaches	B-T082
,	O
particularly	O
those	O
drawing	B-T080
upon	O
contemporary	B-T079
advances	B-T079
in	O
fields	B-T077
outside	O
of	O
established	B-T080
neuroscienc	B-T091
e	O
and	O
psychiatry	B-T091
.	O
Put	O
another	O
way,	O
the	O
time	B-T079
has	O
come	O
for	O
a	O
paradigm shift	B-T062
in	O
the	O
addiction	B-T048
sciences	B-T090
.	O
Apropos	B-T080
,	O
a	O
revolution	B-T169
in	O
the	O
area	B-T082
of	O
human	B-T016
health	B-T078
is	O
underway	B-T169
,	O
which	O
is	O
occurring	B-T052
at	O
the	O
nexus	B-T080
between	O
enteric	B-T082
microbiology	B-T091
and	O
neuroscience	B-T091
.	O
It	O
has	O
become	O
increasingly	B-T169
clear	B-T080
that	O
the	O
human	B-T016
microbiota	B-T001
(the	O
vast	O
ecology	B-T090
of	O
bacteria	B-T007
residing	B-T052
within	O
the	O
human	B-T016
organism	B-T001
),	O
plays	O
an	O
important	B-T080
role	B-T077
in	O
health	B-T078
and	O
disease	B-T047
.	O
This	O
is	O
not	O
surprising,	O
as	O
it	O
has	O
been	O
estimated	B-T081
that	O
bacteria	B-T007
living	B-T052
in	O
the	O
human body	B-T016
(	O
approximately	B-T080
1kg	O
of	O
mass	B-T081
,	O
roughly	O
equivalent	B-T080
to	O
that	O
of	O
the	O
human	B-T016
brain	B-T023
)	O
outnumber	O
human cells	B-T034
10	O
to	O
1.	O
While	O
advances	O
in	O
the	O
understanding	B-T041
of	O
the	O
role	B-T077
of	O
microbiota	B-T001
in	O
other	O
areas	B-T082
of	O
human	B-T016
health	B-T078
have	O
yielded	B-T081
intriguing	B-T080
results	B-T169
(e.g.,	O
Clostridium difficile	B-T047
,	O
irritable bowel syndrome	B-T047
,	O
autism	B-T048
,	O
etc.),	O
to	O
date	B-T079
,	O
no	O
systematic	B-T169
programs	B-T169
of	O
research	B-T062
have	O
examined	B-T033
the	O
role	B-T077
of	O
microbiota	B-T001
in	O
drug addiction	B-T048
.	O
The	O
current	B-T079
hypothesis	B-T078
,	O
therefore,	O
is	O
that	O
gut dysbiosis	B-T184
plays	O
a	O
key	O
role	B-T077
in	O
addictive	B-T048
disorders	B-T047
.	O
In	O
the	O
context	B-T078
of	O
this	O
hypothesis	B-T078
,	O
this	O
paper	B-T170
provides	B-T052
a	O
rationale	B-T078
for	O
future	B-T079
research	B-T062
to	O
target	B-T169
the	O
"	O
gut	B-T023
-	O
brain	B-T023
axis	B-T082
"	O
in	O
addiction	B-T048
.	O
A	O
brief	O
background	B-T077
of	O
the	O
gut	B-T023
-	O
brain	B-T023
axis	B-T082
is	O
provided	B-T052
,	O
along	O
with	O
a	O
series	B-T081
of	O
hypothesis-driven	B-T078
ideas	B-T078
outlining	O
potential	B-T080
treatments	B-T061
for	O
addiction	B-T048
via	O
manipulations	B-T033
of	O
the	O
"	O
ecology	B-T090
within."	O

Homogeneous	B-T080
synthesis	B-T052
of	O
Ag nanoparticles	B-T073
-doped	O
water-soluble cellulose acetate	B-T109
for	O
versatile	B-T080
applications	B-T169
We	O
report	B-T170
a	O
facile	B-T080
and	O
efficient	B-T080
approach	B-T082
for	O
synthesis	B-T052
of	O
well-dispersed	B-T082
and	O
stable	B-T080
silver nanoparticles	B-T073
(	O
Ag NPs	B-T073
)	O
using	O
water-soluble cellulose acetate	B-T109
(	O
CA	B-T109
)	O
as	O
both	O
reductant	B-T130
and	O
stabilizer	B-T167
.	O
Partially	B-T081
substituted	O
CA	B-T109
with	O
highly	B-T080
active	B-T169
hydroxyl groups	B-T197
and	O
excellent	B-T080
water-solubility	B-T081
is	O
able	B-T033
to	O
reduce	B-T070
silver ions	B-T196
in	O
homogeneous	B-T080
aqueous	B-T080
medium	B-T167
effectively	B-T080
.	O
The	O
synthesized	B-T052
Ag NPs	B-T073
were	O
characterized	B-T052
by	O
UV-vis spectroscopy	B-T059
,	O
X-ray diffraction	B-T059
,	O
X-ray photoelectron spectroscopy	B-T059
,	O
transmission electron microscopy	B-T059
and	O
energy dispersive X-ray spectroscope	B-T059
analysis	B-T059
.	O
The	O
as-	O
prepared	B-T033
Ag NPs	B-T073
were	O
well-dispersed	B-T082
,	O
showing	O
a	O
surface plasmon resonance	B-T063
peak	B-T080
at	O
426	O
nm	B-T081
.	O
The	O
resulted	O
Ag NPs	B-T073
@	O
CA	B-T109
nanohybrids	B-T073
exhibit	O
high	B-T080
catalytic activity	B-T169
for	O
the	O
reduction	B-T070
of	O
4-nitrophenol	B-T109
to	O
4-aminophenol	B-T109
in	O
the	O
presence	O
of	O
NaBH4	B-T130
.	O
Meanwhile,	O
the	O
nanohybrids	B-T073
are	O
also	O
effective	B-T080
in	O
inhibiting	B-T052
the	O
growth	B-T040
of	O
bacterial	B-T007
.	O
This	O
environmentally friendly method	B-T057
promotes	B-T052
the	O
use of	B-T169
renewable natural resources	B-T078
to	O
prepare	B-T052
a	O
variety	B-T077
of	O
inorganic-organic materials	B-T167
for	O
catalysis	B-T070
,	O
antibacterial	B-T195
,	O
sensors	B-T073
and	O
other	O
applications	B-T169
.	O

ISX-9	B-T109
can	O
potentiate	O
cell proliferation	B-T043
and	O
neuronal	B-T025
commitment	B-T043
in	O
the	O
rat	B-T015
dentate gyrus	B-T023
Adult	B-T100
hippocampal	B-T023
neurogenesis	B-T040
can	O
be	O
modulated	B-T082
by	O
various	O
physiological	B-T039
and	O
pathological conditions	B-T046
,	O
including	O
stress	B-T033
,	O
affective disorders	B-T048
,	O
and	O
several	O
neurological	B-T080
conditions	B-T080
.	O
Given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural plasticity	B-T042
in	O
the	O
functioning	B-T039
of	O
the	O
hippocampus	B-T023
(namely	O
learning	B-T041
and	O
memory	B-T041
and	O
affective	B-T078
behaviors	B-T053
),	O
it	O
is	O
believed	O
that	O
alterations	B-T078
in	O
hippocampal	B-T023
neurogenesis	B-T040
might	O
underlie	O
some	O
of	O
the	O
behavioral	B-T053
deficits	B-T080
associated with	B-T080
these	O
psychiatric	B-T169
and	O
neurological	B-T080
conditions	B-T080
.	O
Thus,	O
the	O
search	B-T052
for	O
compounds	B-T121
that	O
can	O
reverse	B-T169
these	O
deficits	B-T080
with	O
minimal	B-T080
side effects	B-T046
has	O
become	O
a	O
recognized	O
priority.	O
In	O
the	O
present	O
study	B-T062
we	O
tested	B-T169
the	O
pro-neurogenic	B-T080
effects	B-T080
of	O
isoxazole 9	B-T109
(	O
Isx-9	B-T109
),	O
a	O
small	O
synthetic	B-T052
molecule	B-T167
that	O
has	O
been	O
recently	O
identified	B-T080
through	O
the	O
screening of chemical libraries	B-T059
in	O
stem cell-based assays	B-T059
.	O
We	O
found	O
that	O
administration	B-T061
of	O
Isx-9	B-T109
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell proliferation	B-T043
and	O
increase	B-T169
the	O
number	B-T081
of	O
immature	B-T080
neurons	B-T025
in	O
the	O
hippocampal	B-T023
DG	B-T023
of	O
adult	B-T100
rats	B-T015
.	O
In addition	B-T169
,	O
Isx-9	B-T109
treatment	B-T061
was	O
able	O
to	O
completely	B-T080
reverse	B-T169
the	O
marked	B-T080
reduction	B-T080
in	O
these	O
initial	B-T079
stages	B-T079
of	O
the	O
neurogenic process	B-T042
observed	B-T169
in	O
vehicle	B-T122
-	O
treated	B-T169
animals	B-T008
(which	O
were	O
submitted	O
to	O
repeated	B-T169
handling	B-T059
and	O
exposure to	B-T080
daily	B-T079
intraperitoneal injections	B-T061
).	O
Based	O
on	O
these	O
results	B-T034
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	B-T040
studies	B-T062
that	O
require	O
repeated	B-T169
handling	B-T059
and	O
manipulation	B-T061
of	O
animals	B-T008
should	O
include	O
a	O
naïve	O
(non-manipulated)	O
control	B-T080
to	O
determine	O
the	O
baseline	B-T081
levels	B-T080
of	O
hippocampal	B-T023
cell proliferation	B-T043
and	O
neuronal	B-T025
differentiation	B-T043
.	O
Overall,	O
these	O
findings	B-T033
demonstrate	O
that	O
Isx-9	B-T109
is	O
a	O
promising	O
synthetic	B-T052
compound	B-T121
for	O
the	O
mitigation	B-T067
of	O
stress	B-T033
-	O
induced	B-T169
deficits	B-T080
in	O
adult	B-T100
hippocampal	B-T023
neurogenesis	B-T040
.	O
Future	O
studies	B-T062
are	O
thus	O
warranted	O
to	O
evaluate	B-T058
the	O
pro-neurogenic	B-T080
properties	B-T080
of	O
Isx-9	B-T109
in	O
animal models	B-T008
of	O
affective	B-T048
and	O
neurological disorders	B-T047
associated with	B-T080
impaired	B-T169
hippocampal	B-T023
structural plasticity	B-T042
.	O

Changes	B-T169
in	O
parenting	B-T054
strategies	B-T041
after	O
a	O
young	B-T079
person's	B-T098
self-harm	B-T037
:	O
a	O
qualitative study	B-T062
When	O
faced	O
with	O
the	O
discovery	B-T052
of	O
their	O
child's	B-T100
self-harm	B-T037
,	O
mothers	B-T099
and	O
fathers	B-T099
may	O
re-evaluate	B-T058
their	O
parenting	B-T054
strategies	B-T041
.	O
This	O
can	O
include	O
changes	B-T169
to	O
the	O
amount	O
of	O
support	B-T054
they	O
provide	O
their	O
child	B-T100
and	O
changes	B-T169
to	O
the	O
degree	B-T081
to	O
which	O
they	O
control	B-T080
and	O
monitor	B-T052
their	O
child	B-T100
.	O
We	O
conducted	O
an	O
in-depth qualitative study	B-T062
with	O
37	O
parents	B-T099
of	O
young	B-T079
people	B-T098
who	O
had	O
self-harmed	B-T037
in	O
which	O
we	O
explored	O
how	O
and	O
why	O
their	O
parenting	B-T054
changed	B-T169
after	O
the	O
discovery	B-T052
of	O
self-harm	B-T037
.	O
Early	B-T079
on,	O
parents	B-T099
often	O
found	O
themselves	O
"walking	O
on	O
eggshells"	O
so	O
as	O
not	O
to	O
upset	B-T041
their	O
child	B-T100
,	O
but	O
later	O
they	O
felt	O
more	O
able	O
to	O
take	O
some	O
control	B-T080
.	O
Parents	B-T099
'	O
reactions	B-T169
to	O
the	O
self-harm	B-T037
often	O
depended	O
on	O
how	O
they	O
conceptualised	O
it:	O
as	O
part	O
of	O
adolescence	B-T079
,	O
as	O
a	O
mental health issue	B-T048
or	O
as	O
"	O
naughty behaviour	B-T053
".	O
Parenting	B-T054
of	O
other	O
children	B-T100
in	O
the	O
family	B-T099
could	O
also	O
be	O
affected,	O
with	O
parents	B-T099
worrying	O
about	O
less	O
of	O
their	O
time	B-T079
being	O
available	O
for	O
siblings	B-T099
.	O
Many	O
parents	B-T099
developed	O
specific	O
strategies	B-T041
they	O
felt	O
helped	O
them	O
to	O
be	O
more	O
effective	O
parents	B-T099
,	O
such	O
as	O
learning	B-T041
to	O
avoid	O
blaming	B-T041
themselves	O
or	O
their	O
child	B-T100
for	O
the	O
self-harm	B-T037
and	O
developing	O
new	O
ways	O
to	O
communicate	B-T033
with	O
their	O
child	B-T100
.	O
Parents	B-T099
were	O
generally	O
eager	O
to	O
pass	O
their	O
knowledge	B-T170
on	O
to	O
other	O
people	B-T098
in	O
the	O
same	O
situation	B-T169
.	O
Parents	B-T099
reported	O
changes	B-T169
in	O
their	O
parenting	B-T054
behaviours	B-T053
after	O
the	O
discovery	B-T052
of	O
a	O
child	B-T100
's	O
self-harm	B-T037
.	O
Professionals	B-T097
involved	O
in	O
the	O
care	B-T052
of	O
young	B-T079
people	B-T098
who	O
self-harm	B-T037
might	O
use	O
this	O
information	B-T078
in	O
supporting	B-T077
and	O
advising	B-T052
parents	B-T099
.	O

Optimizing	B-T052
Survival	B-T169
of	O
Patients	B-T101
With	O
Marginally Operable	B-T080
Stage IIIA Non-Small-Cell Lung Cancer	B-T191
Receiving	O
Chemoradiotherapy	B-T061
With	B-T169
or	O
Without	B-T080
Surgery	B-T169
For	O
marginally operable	B-T080
stage IIIA non-small-cell lung cancer	B-T191
(	O
NSCLC	B-T191
),	O
surgery	B-T169
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B-T061
concurrent chemoradiotherapy	B-T061
(	O
CCRT	B-T061
)	O
for	O
reasons	O
(	O
unresectable	B-T201
or	O
medically inoperable	B-T080
conditions	B-T080
,	O
or	O
patient refusal	B-T055
).	O
This	O
study	B-T062
aims	O
to	O
investigate	B-T169
the	O
outcomes	B-T169
of	O
a	O
phased CCRT protocol	B-T061
established	O
to	O
maximize	O
the	O
operability	B-T169
of	O
marginally operable	B-T080
stage IIIA NSCLC	B-T191
and	O
to	O
care	O
for	O
reassessed	B-T052
inoperable patients	B-T101
,	O
in	O
comparison	O
with	O
continuous-course definitive CCRT	B-T061
.	O
Forty-seven	O
patients	B-T101
with	O
marginally operable	B-T080
stage IIIA NSCLC	B-T191
receiving	O
CCRT	B-T061
were	O
included.	O
Twenty-eight	O
patients	B-T101
were	O
treated	B-T169
with	O
our	O
phased CCRT protocol	B-T061
,	O
including	O
neoadjuvant	B-T061
CCRT	B-T061
followed	O
by	O
surgery	B-T169
(	O
group A	B-T078
,	O
n	O
=	O
16)	O
or,	O
for	O
reassessed	B-T052
inoperable patients	B-T101
patients	B-T101
,	O
maintenance chemotherapy	B-T033
and	O
split-course CCRT	B-T061
boost	B-T169
(	O
group B	B-T078
,	O
n	O
=	O
12).	O
The	O
other	O
19	O
were	O
treated	B-T169
with	O
continuous-course definitive CCRT	B-T061
(	O
group C	B-T078
).	O
Overall survival	B-T081
(	O
OS	B-T081
)	O
and	O
progression-free survival	B-T081
(	O
PFS	B-T081
)	O
were	O
analyzed	B-T062
.	O
Among	O
all,	O
median	B-T081
OS	B-T081
and	O
PFS	B-T081
were	O
35.6	O
and	O
12.8	O
months	B-T079
,	O
respectively	O
(	O
median	B-T081
follow-up	B-T058
,	O
22.3	O
months	B-T079
).	O
The	O
median	B-T081
OS	B-T081
of	O
group A	B-T078
(not	O
reached)	O
was	O
better	O
than	O
that	O
of	O
group B	B-T078
(34.4	O
months	B-T079
)	O
and	O
group C	B-T078
(15.2	O
months	B-T079
)	O
(P	O
=	O
.009).	O
On	O
multivariate analysis	B-T081
,	O
performance status	B-T201
0	O
to	O
1	O
(	O
hazard ratio	B-T081
[	O
HR	B-T081
],	O
0.026;	O
P	O
<	O
.001),	O
adenocarcinoma	B-T191
(	O
HR	B-T081
,	O
0.156;	O
P	O
=	O
.003),	O
and	O
group A	B-T078
(	O
HR	B-T081
,	O
0.199;	O
P	O
=	O
.033)	O
were	O
independent prognostic factors	B-T201
.	O
The	O
OS	B-T081
of	O
group B	B-T078
(	O
HR	B-T081
,	O
0.450;	O
95%	O
confidence interval	B-T081
,	O
0.118-1.717;	O
P	O
=	O
.243)	O
was	O
not	O
statistically different	B-T080
from	O
that	O
of	O
group C	B-T078
.	O
For	O
marginally operable	B-T080
stage IIIA NSCLC	B-T191
,	O
our	O
phased CCRT strategy	B-T061
may	O
optimize	B-T052
survival	B-T169
by	O
maximizing	O
operability	B-T169
and	O
maintain	O
an	O
acceptable	O
survival	B-T169
for	O
reassessed	B-T052
inoperable patients	B-T101
by	O
split-course CCRT	B-T061
boost	B-T169
following	O
maintenance chemotherapy	B-T033
.	O

Evaluation	O
of	O
Three	B-T081
Protein-Extraction Methods	B-T059
for	O
Proteome	B-T116
Analysis	B-T059
of	O
Maize	B-T002
Leaf	B-T002
Midrib	B-T185
,	O
a	O
Compound Tissue	B-T025
Rich	O
in	O
Sclerenchyma Cells	B-T025
Leaf	B-T002
morphology	B-T080
is	O
closely	O
related	O
to	O
the	O
growth and development	B-T040
of	O
maize (Zea mays L.) plants	B-T002
and	O
final	O
kernel	B-T168
production.	O
As	O
an	O
important	O
part	O
of	O
the	O
maize	B-T002
leaf	B-T002
,	O
the	O
midrib	B-T185
holds	O
leaf	B-T002
blades	O
in	O
the	O
aerial position	B-T002
for	O
maximum	O
sunlight	B-T070
capture.	O
Leaf	B-T002
midrib	B-T185
s	O
of	O
adult	B-T079
plants	B-T002
contain	O
substantial	O
sclerenchyma cells	B-T025
with	O
heavily thickened	B-T080
and	O
lignified	B-T109
secondary walls	B-T026
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	B-T109
,	O
making	O
protein extraction	B-T059
and	O
proteome	B-T116
analysis	B-T059
difficult	O
in	O
leaf	B-T002
midrib	B-T185
tissue.	O
In	O
the	O
present	O
study,	O
three	O
protein-extraction methods	B-T059
that	O
are	O
commonly	O
used	O
in	O
plant	B-T002
proteomics	B-T091
,	O
i.e.,	O
phenol	B-T109
extraction	B-T059
,	O
TCA	B-T109
/	O
acetone	B-T109
extraction	B-T059
,	O
and	O
TCA	B-T109
/	O
acetone	B-T109
/	O
phenol	B-T109
extraction	B-T059
,	O
were	O
qualitatively	B-T080
and	O
quantitatively evaluated	B-T081
based	O
on	O
2DE	O
maps	O
and	O
MS/MS analysis	B-T059
using	O
the	O
midribs	B-T185
of	O
the	O
10th	O
newly	O
expanded	O
leaves	B-T002
of	O
maize plants	B-T002
.	O
Microscopy	B-T059
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	B-T025
underneath	O
maize	B-T002
midrib	B-T185
epidermises	B-T002
(particularly	O
abaxial	B-T082
epidermises	B-T002
).	O
The	O
spot-number	O
order	O
obtained	O
via	O
2DE mapping	B-T059
was	O
as	O
follows:	O
phenol	B-T109
extraction	B-T059
(655)	O
>	O
TCA	B-T109
/	O
acetone	B-T109
extraction	B-T059
(589)	O
>	O
TCA	B-T109
/	O
acetone	B-T109
/	O
phenol	B-T109
extraction	B-T059
(545).	O
MS/MS analysis	B-T059
identified	O
a	O
total	O
of	O
17	O
spots	B-T077
that	O
exhibited	O
2-fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	B-T081
methods	O
(using	O
phenol	B-T109
extraction	B-T059
as	O
a	O
control	B-T096
).	O
Sixteen	O
of	O
the	O
proteins	B-T116
identified	O
were	O
hydrophilic	B-T080
,	O
with	O
GRAVY values	B-T081
ranging	O
from	O
-0.026	O
to	O
-0.487.	O
For	O
all	O
three	B-T081
methods,	O
we	O
were	O
able	O
to	O
obtain	O
high-quality	O
protein	B-T116
samples	O
and	O
good	O
2DE maps	B-T059
for	O
the	O
maize	B-T002
leaf	B-T002
midrib	B-T185
.	O
However,	O
phenol	B-T109
extraction	B-T059
produced	O
a	O
better	O
2DE map	B-T059
with	O
greater	O
resolution	B-T077
between	O
spots	B-T077
,	O
and	O
TCA	B-T109
/	O
acetone	B-T109
extraction	B-T059
produced	O
higher	O
protein	B-T116
yields	B-T081
.	O
Thus,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	B-T080
protein extraction	B-T059
among	O
the	O
three	B-T081
methods.	O
This	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein extraction	B-T059
methods	O
for	O
the	O
proteome	B-T116
analysis	B-T059
of	O
recalcitrant	O
plant tissues	B-T025
that	O
are	O
rich	O
in	O
sclerenchyma cells	B-T025
.	O

Dominant	B-T033
and	O
Non-	O
Dominant	B-T033
Frequency	B-T079
Structure	O
of	O
Evoked	B-T080
Ventricular Fibrillation	B-T047
in	O
Dogs	B-T015
with	O
Myocardial Ischemia	B-T047
The	O
first	O
10	O
min	O
of	O
electrically provoked	B-T061
ventricular fibrillation	B-T047
in	O
dogs	B-T015
with	O
ischemic heart disease	B-T047
were	O
characterized	B-T052
by	O
organized	B-T169
myocardial activity	B-T042
evidenced	O
by	O
the	O
dominant ECG frequency	B-T033
structure.	O
During	O
the	O
first	O
2	O
min	O
of	O
ventricular fibrillation	B-T047
,	O
low-frequency oscillations	B-T080
(4-7	O
Hz)	O
dominated,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	B-T047
,	O
the	O
dominant frequencies	B-T033
were	O
low	B-T080
and	O
medium	B-T081
(4-12	O
Hz).	O
After	O
10-min	O
fibrillation	B-T047
,	O
the	O
oscillations	B-T061
became	O
non-	O
dominant	B-T033
.	O
Thus,	O
ischemic myocardium	B-T033
maintains	B-T052
the	O
organized structure	B-T079
of	O
ventricular fibrillation	B-T047
for	O
the	O
first	O
10	O
min,	O
which	O
is	O
important	O
for	O
the	O
development	B-T169
of	O
automatic diagnostics	B-T060
of	O
abnormal cardiac activity	B-T033
in	O
humans	B-T016
.	O

Adverse events	B-T046
risk	B-T078
associated with	B-T080
angiogenesis inhibitors	B-T121
addition	O
to	O
therapy	B-T061
in	O
ovarian cancer	B-T191
:	O
a	O
meta-analysis	B-T062
of	O
randomized controlled trials	B-T062
Inhibition of angiogenesis	B-T043
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment strategy	B-T061
for	O
advanced	B-T191
or	O
recurrent ovarian cancer	B-T191
.	O
We	O
conduct	O
this	O
meta-analysis	B-T062
to	O
investigate	B-T169
the	O
risk	B-T078
of	O
adverse events	B-T046
of	O
special	O
interest	O
related	O
to	O
angiogenesis inhibitors	B-T121
(	O
AIs	B-T121
)	O
in	O
ovarian cancer	B-T191
.	O
Databases	B-T170
from	O
PubMed	B-T170
,	O
Web of Science	B-T170
and	O
Cochrane library	B-T073
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	B-T080
studies	B-T062
.	O
Eligible	O
studies	B-T062
included	O
prospective randomized controlled phase II/III clinical trials	B-T062
evaluating	B-T058
therapy	B-T061
with	O
or	O
without	O
AIs	B-T121
for	O
ovarian cancer	B-T191
.	O
Summary	O
relative risk	B-T081
(	O
RR	B-T081
)	O
and	O
95%	O
confidence intervals	B-T081
(	O
CIs	B-T081
)	O
were	O
calculated	B-T052
using	O
random-effects	B-T080
or	O
fixed-effects	B-T080
according	O
to	O
the	O
heterogeneity	B-T080
among	O
included	O
trials	B-T062
.	O
A	O
total	O
of	O
7,761	O
patients	B-T101
from	O
ten	O
clinical trials	B-T062
were	O
included	O
in	O
the	O
meta-analysis	B-T062
.	O
Pooled	B-T169
RR	B-T081
showed	O
that	O
the	O
use of	B-T169
AIs	B-T121
was	O
associated with	B-T080
a	O
statistically	O
increased	B-T081
risk	B-T078
in	O
four	O
of	O
the	O
adverse	B-T169
outcomes	B-T080
studied:	O
arterial thromboembolic	B-T046
events	B-T051
(	O
RR	B-T081
=	O
2.0),	O
gastrointestinal (GI) perforation	B-T047
(	O
RR	B-T081
=	O
3.86),	O
proteinuria	B-T033
(	O
RR	B-T081
=	O
2.44),	O
and	O
hypertension	B-T047
(	O
RR	B-T081
=	O
5.39).	O
No statistically significant	B-T033
differences	B-T080
were	O
found	O
for	O
hemorrhagic	B-T046
events	B-T051
(p	O
=	O
0.07),	O
venous thromboembolic	B-T047
events	B-T051
(p	O
=	O
0.13),	O
or	O
fatal	B-T080
adverse events	B-T046
(p	O
=	O
0.26).	O
The	O
addition	O
of	O
AIs	B-T121
to	O
therapy	B-T061
in	O
ovarian cancer	B-T191
did	O
significantly	O
increase	B-T169
the	O
risk	B-T078
of	O
arterial thromboembolic	B-T046
events	B-T051
,	O
GI perforation	B-T047
,	O
proteinuria	B-T033
and	O
hypertension	B-T047
,	O
but	O
not	O
for	O
venous thromboembolic	B-T047
events	B-T051
,	O
hemorrhagic	B-T046
events	B-T051
,	O
or	O
fatal	B-T080
adverse events	B-T046
.	O

Relationship	B-T080
between	O
LRRK2	B-T028
R1628P polymorphism	B-T086
and	O
Parkinson's disease	B-T047
in	O
Asian populations	B-T098
Although	O
the	O
leucine-rich repeat kinase 2	B-T028
(	O
LRRK2	B-T028
)	O
R1628P polymorphism	B-T086
has	O
been	O
associated with	B-T080
the	O
risk	B-T078
of	O
Parkinson's disease	B-T047
(	O
PD	B-T047
)	O
in	O
Taiwan	B-T083
,	O
China	B-T083
,	O
and	O
Singapore	B-T083
,	O
there	O
are	O
conflicting	O
findings	O
regarding	O
this	O
relationship	B-T080
.	O
Thus,	O
the	O
aim	O
of	O
the	O
present	O
meta-analysis	B-T062
was	O
to	O
evaluate	O
the	O
associations	B-T080
between	O
the	O
LRRK2	B-T028
R1628P polymorphism	B-T086
(	O
rs33949390	B-T086
)	O
and	O
PD	B-T047
in	O
Asian populations	B-T098
.	O
A	O
search	O
for	O
eligible	O
studies	B-T062
was	O
performed	O
in	O
PubMed	B-T170
,	O
Embase	B-T170
,	O
SinoMed	B-T170
,	O
and	O
the	O
China Knowledge Resource Integrated Database	B-T170
,	O
and	O
pooled	O
odds	O
ratios	O
and	O
95%	O
confidence intervals	B-T081
were	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
association	B-T080
between	O
the	O
R1628P polymorphism	B-T086
and	O
PD	B-T047
.	O
This	O
meta-analysis	B-T062
assessed	O
19	O
studies	B-T062
from	O
14	O
papers	O
that	O
involved	O
a	O
total	O
of	O
9,927	O
PD	B-T047
patients	B-T101
and	O
8,602	O
controls	B-T096
and	O
found	O
that	O
the	O
R1628P polymorphism	B-T086
was	O
significantly	O
associated with	B-T080
the	O
risk	B-T078
of	O
PD	B-T047
in	O
Asian populations	B-T098
.	O
Moreover,	O
stratification analyses	B-T062
indicated	O
that	O
the	O
R1628P polymorphism	B-T086
was	O
significantly	O
associated with	B-T080
an	O
increased	O
risk	B-T078
of	O
PD	B-T047
among	O
Chinese	B-T098
as	O
well	O
as	O
non-Chinese Asian populations	B-T098
and	O
an	O
increased	O
risk	B-T078
of	O
PD	B-T047
in	O
Chinese patients	B-T101
from	O
China	B-T083
,	O
Taiwan	B-T083
,	O
and	O
Singapore	B-T083
.	O
In	O
a	O
stratified analysis	B-T062
conducted	O
according	O
to	O
age	B-T032
,	O
significant	O
associations	B-T080
were	O
found	O
for	O
both	O
late-onset	O
PD	B-T047
and	O
early-onset	O
PD	B-T047
.	O
The	O
present	O
data	O
indicate	O
that	O
the	O
R1628P polymorphism	B-T086
of	O
the	O
LRRK2 gene	B-T028
contributes	O
to	O
PD	B-T047
susceptibility	B-T201
in	O
Asian	B-T098
,	O
especially	O
Chinese	B-T098
,	O
populations	B-T098
.	O

Efficacy	B-T080
and	O
safety	B-T080
of	O
cisplatin	B-T121
,	O
dexamethasone	B-T109
,	O
gemcitabine	B-T114
and	O
pegaspargase	B-T116
(	O
DDGP	B-T121
)	O
regimen	B-T061
in	O
newly diagnosed	B-T080
,	O
advanced-stage	B-T080
extranodal natural killer/T-cell lymphoma	B-T191
:	O
interim	B-T079
analysis	B-T062
of	O
a	O
phase 4	B-T079
study	B-T062
NCT01501149	O
To	O
explore	O
a	O
more	O
effective	B-T080
treatment	B-T169
for	O
newly diagnosed	B-T080
,	O
advanced-stage	B-T080
extranodal natural killer/T-cell lymphoma, nasal type	B-T191
(	O
ENKTL	B-T191
),	O
we	O
conducted	O
a	O
phase 4	B-T079
study	B-T062
of	O
the	O
cisplatin	B-T121
,	O
dexamethasone	B-T109
,	O
gemcitabine	B-T114
,	O
pegaspargase	B-T116
(	O
DDGP	B-T121
)	O
regimen	B-T061
.	O
The	O
primary	O
end point	B-T080
was	O
the	O
2-year	O
progression-free survival	B-T081
(	O
PFS	B-T081
)	O
after	O
the	O
protocol treatment	B-T061
.	O
Secondary	O
endpoints	B-T080
included	O
response rate	B-T079
(	O
RR	B-T079
),	O
overall survival	B-T081
(	O
OS	B-T081
)	O
and	O
median survival time	B-T079
(	O
MST	B-T079
).	O
The	O
interim	B-T079
analysis	B-T062
included	O
data	B-T078
only	O
from	O
March	O
2011	O
to	O
September	O
2013,	O
who	O
received	B-T080
six	O
cycles	O
of	O
DDGP	B-T121
chemotherapy	B-T061
.	O
A	O
total	O
of	O
25	O
eligible	B-T080
patients	B-T101
were	O
enrolled.	O
Seventeen	O
patients	B-T101
(17/24,	O
70.83%)	O
achieved	O
complete response	B-T033
(	O
CR	B-T033
)	O
and	O
four	O
(4/24,	O
16.67%)	O
achieved	O
partial response	B-T033
(	O
PR	B-T033
),	O
three	O
(3/24,	O
12.50%)	O
had	O
progressive disease	B-T047
(	O
PD	B-T047
).	O
The	O
RR	B-T079
after	O
treatment	B-T169
was	O
87.50%.	O
After	O
a	O
median	B-T081
follow-up	B-T058
duration	B-T079
of	O
24.67	O
months	B-T079
(range	O
4-48	O
months	B-T079
).	O
The	O
2-year	O
PFS	B-T081
and	O
OS rate	B-T081
were	O
61.80%	O
(95%	O
CI	B-T081
,	O
42.00%	O
to	O
81.60%)	O
and	O
68.50	O
%	O
(95%	O
CI	B-T081
,	O
48.70%	O
to	O
88.30%),	O
respectively.	O
The	O
MST	B-T079
was	O
36.55	O
months	B-T079
(95%	O
CI	B-T081
,	O
29.41	O
months	B-T079
to	O
43.70	O
months	B-T079
).	O
Grade	B-T185
3/4	O
leukopenia	B-T047
occurred	B-T079
in	O
fourteen	O
patients	B-T101
(58.33%)	O
and	O
grade	B-T185
3/4	O
thrombocytopenia	B-T047
occurred	B-T079
in	O
eleven	O
patients	B-T101
(45.83%).	O
Twelve	O
patients	B-T101
(50.00%)	O
experienced	O
Activated Partial Phromboplastin Ptime	B-T059
(	O
APTT	B-T059
)	O
elongation	B-T033
and	O
fourteen	O
patients	B-T101
(58.33%)	O
experienced	O
hypofibrinogenemia	B-T047
.	O
In	O
conclusion,	O
DDGP	B-T121
regimen	B-T061
is	O
an	O
effective	B-T080
and	O
tolerated	B-T033
treatment	B-T169
for	O
newly diagnosed	B-T080
,	O
advanced-stage	B-T080
ENKTL	B-T191
.	O
This	O
trial	B-T062
was	O
registered	B-T058
at	O
www.ClinicalTrials.gov	B-T170
as	O
#NCT01501149.	O

Effect	B-T080
of	O
Hepatitis C Virus Coinfection	B-T047
on	O
the	O
Content	O
of	O
CD4(+) and CD8(+)	B-T025
T Cell	B-T025
Subpopulations	B-T185
in	O
HIV	B-T005
-	O
Infected	B-T033
Patients	B-T101
Receiving	B-T080
Antiretroviral Therapy	B-T061
We	O
studied	O
the	O
effect	B-T080
of	O
hepatitis C virus coinfection	B-T047
on	O
T cell	B-T025
subpopulations	B-T185
in	O
HIV	B-T005
-	O
infected	B-T033
patients	B-T101
receiving	O
antiretroviral therapy	B-T061
.	O
Coinfection	B-T047
with	O
hepatitis C virus	B-T005
was	O
followed	O
by	O
a	O
decrease	B-T081
in	O
the	O
number	O
of	O
naive CD4(+) T cells	B-T025
and	O
an	O
increase	B-T169
in	O
the	O
count	B-T081
of	O
central	O
CD8(+) memory T cells	B-T025
in	O
these	O
patients	B-T101
.	O
Hepatitis C virus	B-T005
had	O
no effect	B-T080
on	O
the	O
number	O
of	O
CD4(+) memory T cells	B-T025
(main	O
target	O
for	O
HIV	B-T005
).	O
This	O
can	O
explain	O
the	O
absence	O
of	O
strong	O
negative	B-T033
effect	B-T080
of	O
hepatitis C virus	B-T005
on	O
the	O
course	B-T079
of	O
HIV	B-T005
infection	B-T046
.	O

Examining	B-T169
the	O
contribution	B-T052
of	O
motor movement	B-T169
and	O
language	B-T171
dominance	B-T078
to	O
increased	B-T081
left	B-T082
lateralization	B-T042
during	O
sign	B-T171
generation	B-T052
in	O
native	B-T169
signers	B-T098
The	O
neural systems	B-T022
supporting	O
speech	B-T040
and	O
sign	B-T078
processing	B-T041
are	O
very	O
similar	B-T080
,	O
although	O
not	O
identical.	O
In	O
a	O
previous	O
fTCD study	B-T062
of	O
hearing	B-T041
native	B-T169
signers	B-T098
(Gutierrez-Sigut,	O
Daws,	O
et	O
al.,	O
2015)	O
we	O
found	O
stronger	O
left	B-T082
lateralization	B-T042
for	O
sign	B-T078
than	O
speech	B-T040
.	O
Given	O
that	O
this	O
increased	B-T081
lateralization	B-T042
could	O
not	O
be	O
explained	O
by	O
hand	B-T023
movement	B-T040
alone,	O
the	O
contribution	O
of	O
motor movement	B-T169
versus	O
'	O
linguistic	B-T171
'	O
processes	B-T041
to	O
the	O
strength	B-T078
of	O
hemispheric	B-T082
lateralization	B-T042
during	O
sign	B-T078
production	B-T041
remains	O
unclear.	O
Here	O
we	O
directly	O
contrast	B-T080
lateralization	B-T042
strength	B-T078
of	O
covert	B-T078
versus	O
overt	B-T080
signing	B-T078
during	O
phonological	B-T169
and	O
semantic	B-T078
fluency	B-T080
tasks	B-T169
.	O
To	O
address	O
the	O
possibility	O
that	O
hearing	B-T041
native	B-T169
signers	B-T098
'	O
elevated	B-T080
lateralization indices	B-T081
(	O
LIs	B-T081
)	O
were	O
due	O
to	O
performing	O
a	O
task	B-T169
in	O
their	O
less	O
dominant	B-T169
language	B-T171
,	O
here	O
we	O
test	O
deaf	B-T101
native	B-T169
signers	B-T098
,	O
whose	O
dominant	B-T169
language	B-T171
is	O
British Sign Language	B-T171
(	O
BSL	B-T171
).	O
Signers	B-T098
were	O
more	O
strongly	O
left	B-T082
lateralized	B-T042
for	O
overt	B-T080
than	O
covert	B-T078
sign	B-T078
generation.	O
However,	O
the	O
strength	B-T078
of	O
lateralization	B-T042
was	O
not	O
correlated	B-T080
with	O
the	O
amount	O
of	O
time	O
producing	O
movements	B-T040
of	O
the	O
right hand	B-T023
.	O
Comparisons	B-T052
with	O
previous	O
data	B-T078
from	O
hearing	B-T041
native	B-T169
English	B-T171
speakers	B-T098
suggest	O
stronger	O
laterality indices	B-T081
for	O
sign	B-T078
than	O
speech	B-T040
in	O
both	O
covert	B-T078
and	O
overt	B-T080
tasks	B-T169
.	O
This	O
increased	B-T081
left	B-T082
lateralization	B-T042
may	O
be	O
driven	O
by	O
specific	O
properties	B-T080
of	O
sign	B-T078
production	B-T041
such	O
as	O
the	O
increased	B-T081
use	B-T169
of	O
self-monitoring	B-T055
mechanisms	B-T169
or	O
the	O
nature	B-T078
of	O
phonological encoding	B-T041
of	O
signs	B-T078
.	O

Hard ticks	B-T204
(	O
Acari: Ixodidae	B-T204
)	O
of	O
livestock	B-T008
in	O
Nicaragua	B-T083
,	O
with	O
notes	B-T170
about	O
distribution	B-T169
We	O
document	B-T170
the	O
species	B-T185
of	O
ticks	B-T204
that	O
parasitize	B-T047
livestock	B-T008
in	O
Nicaragua	B-T083
.	O
The	O
study	B-T062
was	O
based	O
on	O
tick	B-T204
collection	B-T169
on	O
cattle	B-T015
and	O
horses	B-T015
from	O
437	O
farms	B-T082
in	O
nine	O
departments	B-T092
.	O
Of	O
4841	O
animals	B-T008
examined	O
(4481	O
cows	B-T015
and	O
360	O
horses	B-T015
),	O
3299	O
were	O
parasitized	B-T047
,	O
which	O
represent	O
68	O
%	O
of	O
the	O
bovines	B-T015
and	O
67	O
%	O
of	O
the	O
equines	B-T015
in	O
study	B-T062
:	O
59	O
cows	B-T015
and	O
25	O
horses	B-T015
were	O
parasitized	B-T047
by	O
more	O
than	O
one	O
species	B-T185
.	O
In	O
addition,	O
280	O
specimens	B-T167
of	O
the	O
entomological	B-T090
museum	B-T073
in	O
León	B-T083
were	O
examined.	O
The	O
ticks	B-T204
found	O
on	O
cattle	B-T015
were	O
Rhipicephalus microplus	B-T204
(75.2	O
%	O
of	O
the	O
ticks	B-T204
collected	B-T169
),	O
Amblyomma mixtum	B-T204
(20.8	O
%),	O
A. parvum	B-T204
(2.6	O
%),	O
A. tenellum	B-T204
(0.7	O
%),	O
A. maculatum	B-T204
(0.7	O
%).	O
While	O
the	O
ticks	B-T204
collected	B-T169
from	O
the	O
horses	B-T015
were:	O
Dermacentor nitens	B-T204
(41.5	O
%),	O
A. mixtum	B-T204
(31.7	O
%),	O
R. microplus	B-T204
(13.8	O
%),	O
A. parvum	B-T204
(6.5	O
%),	O
A. tenellum	B-T204
(3.3	O
%),	O
D. dissimilis	B-T204
(2.4	O
%)	O
and	O
A. maculatum	B-T204
(0.8	O
%).	O

Assessment	B-T058
the	O
Exposure	B-T080
Level	B-T080
of	O
Rare Earth Elements	B-T196
in	O
Workers	B-T098
Producing	B-T057
Cerium	B-T109
,	O
Lanthanum Oxide	B-T197
Ultrafine	B-T109
and	O
Nanoparticles	B-T073
In	O
order	O
to	O
assess	B-T058
occupational	B-T169
exposure	B-T080
level	B-T080
of	O
15	O
rare earth elements	B-T196
(	O
REEs	B-T196
)	O
and	O
identify	B-T080
the	O
associated	B-T080
influence	B-T077
,	O
we	O
used	O
inductively coupled plasma mass spectrometry	B-T059
(	O
ICP-MS	B-T059
)	O
based	B-T169
on	O
closed	B-T169
-	O
vessel	B-T073
microwave	B-T070
-	O
assisted	B-T080
wet digestion procedure	B-T169
to	O
determinate	B-T059
the	O
concentration	B-T081
of	O
Y	B-T196
,	O
La	B-T197
,	O
Ce	B-T109
,	O
Pr	B-T196
,	O
Nd	B-T196
,	O
Sm	B-T121
,	O
Eu	B-T196
,	O
Gd	B-T130
,	O
Tb	B-T196
,	O
Dy	B-T196
,	O
Ho	B-T196
,	O
Er	B-T196
,	O
Tm	B-T196
,	O
Yb	B-T121
and	O
Lu	B-T196
in	O
urinary samples	B-T031
obtained	B-T169
from	O
workers	B-T098
producing	B-T057
ultrafine	B-T109
and	O
nanoparticles	B-T073
containing	O
cerium	B-T109
and	O
lanthanum oxide	B-T197
.	O
The	O
results	B-T034
suggest	B-T078
that	O
La	B-T197
and	O
Ce	B-T109
were	O
the	O
primary	B-T080
component	B-T077
,	O
together	O
accounting	B-UnknownType
for	O
97	O
%	O
of	O
total	O
REEs	B-T196
in	O
workers	B-T098
.	O
The	O
urinary	B-T031
levels	B-T080
of	O
La	B-T197
,	O
and	O
Ce	B-T109
among	O
the	O
workers	B-T098
(6.36,	O
15.32	O
μg.g(-1)	O
creatinine	B-T109
,	O
respectively)	O
were	O
significantly	B-T078
enriched	B-T080
compared	B-T052
to	O
those	O
levels	B-T080
measured	B-T080
in	O
the	O
control	B-T096
subjects	B-T096
(1.52,	O
4.04	O
μg.g(-1)	O
creatinine	B-T109
,	O
respectively)	O
(p	O
<	O
0.05).	O
This	O
study	B-T062
simultaneously	B-T079
identified	B-T080
the	O
associated	B-T080
individual	B-T098
factors	B-T169
,	O
the	O
results	B-T034
indicate	B-T078
that	O
the	O
concentrations	B-T081
in	O
over	O
5	O
years	O
group	B-T078
(11.64	O
±	O
10.93	O
for	O
La	B-T197
,	O
27.83	O
±	O
24.38	O
for	O
Ce	B-T109
)	O
were	O
significantly	B-T078
elevated	B-T080
compared	B-T052
to	O
1-5	O
years	O
group	B-T078
(2.58	O
±	O
1.51	O
for	O
La	B-T197
,	O
6.87	O
±	O
3.90	O
for	O
Ce	B-T109
)	O
(p	O
<	O
0.05).	O
Compared	B-T052
the	O
urinary	B-T031
levels	B-T080
of	O
La	B-T197
and	O
Ce	B-T109
at	O
the	O
separation	B-T169
and	O
packaging	B-T068
locations	B-T082
(9.10	O
±	O
9.51	O
for	O
La	B-T197
,	O
22.29	O
±	O
21.01	O
for	O
Ce	B-T109
)	O
with	O
the	O
other	O
locations	B-T082
(2.85	O
±	O
0.98	O
for	O
La	B-T197
,	O
6.37	O
±	O
2.12	O
for	O
Ce	B-T109
),	O
the	O
results	B-T034
show	O
urinary	B-T031
concentrations	B-T081
were	O
significantly	B-T078
higher	B-T080
in	O
workers	B-T098
at	O
separation	B-T169
and	O
packaging	B-T068
locations	B-T082
(p	O
<	O
0.01).	O
Inter	B-T079
-	O
individual	B-T098
variation	B-T080
in	O
levels	B-T080
of	O
La	B-T197
and	O
Ce	B-T109
in	O
urine	B-T031
is	O
the	O
result	B-T169
of	O
multi-factorial	B-T081
comprehensive	B-T080
action	B-T052
.	O
Further	O
researches	B-T097
should	O
focus	B-T169
on	O
the	O
multiple	B-T081
factors	B-T169
contributing	B-T052
to	O
the	O
REEs	B-T196
levels	B-T080
of	O
the	O
occupationally	B-T169
exposed	B-T080
workers	B-T098
.	O

Two	O
known	B-T080
and	O
one	O
new	B-T080
species	B-T185
of	O
Draconematidae	B-T204
and	O
Epsilonematida	B-T204
(	O
Nematoda	B-T204
,	O
Desmodorida	B-T204
)	O
from	O
the	O
White Sea	B-T083
,	O
North Russia	B-T083
Morphological	B-T082
descriptions	B-T170
of	O
three	O
"	O
walking nematode	B-T204
"	O
species	B-T185
found	O
for	O
the	O
first	O
time	O
in	O
the	O
White Sea	B-T083
are	O
presented.	O
Draconema ophicephalum	B-T204
(	O
Claparède	B-T170
,	O
1863)	O
(	O
Draconematidae	B-T204
)	O
and	O
Epsilonema steineri	B-T204
Chitwood	B-T170
,	O
1935	O
(	O
Epsilonematidae	B-T204
),	O
both	O
known	O
from	O
insufficient	B-T080
material	O
and	O
females	B-T032
only,	O
are	O
re-described	O
and	O
problems	B-T033
of	O
their	O
taxonomic	B-T169
identification	B-T080
as	O
well	O
as	O
species	B-T185
compositions	B-T201
of	O
respective	O
genera	B-T185
are	O
discussed.	O
The	O
new	B-T080
species	B-T185
Prochaetosoma marisalbi sp	B-T204
.	O
n.	O
(	O
Draconematidae	B-T204
)	O
differs	O
from	O
other	O
Prochaetosoma species	B-T204
except	O
P. longicapitatum	B-T204
(	O
Allgén	B-T170
,	O
1935)	O
in	O
that	O
the	O
pharyngeal	B-T023
bulb	B-T017
lumen	B-T030
is	O
not cuticularised	B-T033
,	O
from	O
P. longicapitatum	B-T204
by	O
shape of body	B-T017
and	O
rostrum	B-T026
,	O
greater	B-T081
number	O
of	O
cephalic	B-T082
adhesive tubes	B-T026
,	O
and	O
from	O
P. maertensi	B-T204
Decraemer	B-T170
,	O
1989	O
by	O
having	O
a	O
relatively	O
longer	B-T080
tail	B-T023
,	O
fewer	O
anterior	B-T082
adhesive tubes	B-T026
and	O
longer	B-T080
spicules	B-T077
,	O
besides	O
lacking	O
cuticular thickening	B-T042
in	O
the	O
pharyngeal	B-T023
bulb	B-T017
.	O
Draconema hoonsooi	B-T204
,	O
D. youngeouni	B-T204
,	O
P.rochaetosoma beomseomense	B-T204
,	O
P. brevicaudatum	B-T204
,	O
P. byungilli	B-T204
,	O
P. cracense	B-T204
,	O
P. saheungi	B-T204
,	O
P. sujungi	B-T204
,	O
P. supseomense	B-T204
erected	B-T080
by	O
Rho	B-T170
&	O
Min	B-T170
(2011)	O
are	O
considered	O
as	O
invalid	B-T080
species	B-T185
while	O
Prochaetosoma arcticum	B-T204
,	O
P. lugubre	B-T204
and	O
Epsilonema cygnoides	B-T204
are	O
assumed	O
as	O
species inquirenda	B-T185
.	O
From	O
a	O
phylogenetic tree	B-T062
based	O
on	O
the	O
18S rRNA gene	B-T028
,	O
all	O
three	O
White Sea	B-T083
species	B-T185
adjoin	B-T082
to	O
unidentified	B-T080
species	B-T185
of	O
their	O
respective	O
genera	B-T185
.	O

Differential	B-T080
effects of	B-T080
crude oil	B-T109
on	O
denitrification	B-T067
and	O
anammox	B-T044
,	O
and	O
the	O
impact	B-T080
on	O
N2O	B-T121
production	B-T070
Denitrification	B-T067
and	O
anammox	B-T044
are	O
key	O
processes	B-T067
for	O
reducing	B-T080
the	O
external	B-T082
nitrogen	B-T123
loads	O
delivered	B-T169
to	O
coastal	B-T082
ecosystems	B-T070
,	O
and	O
these	O
processes	B-T067
can	O
be	O
affected	B-T169
by	O
pollutants	B-T131
.	O
In	O
this	O
study	B-T062
,	O
we	O
investigated	B-T169
the	O
effect of	B-T080
crude oil	B-T109
on	O
denitrification	B-T067
and	O
anammox	B-T044
.	O
Controlled laboratory experiments	B-T062
were	O
performed	O
using	O
sediment	B-T167
slurries	B-T167
from	O
the	O
Lima	B-T083
Estuary	B-T070
(	O
NW	B-T082
Portugal	B-T083
).	O
Anammox	B-T044
and	O
denitrification	B-T067
rates	B-T081
were	O
measured	O
using	O
(15)N-labeled	B-T196
NO3(-)	B-T197
,	O
and	O
the	O
production	B-T070
of	O
(29)N2	B-T123
and	O
(30)N2	B-T123
quantified	O
by	O
membrane inlet mass spectrometry	B-T059
.	O
Results	O
revealed	O
that	O
while	O
denitrification	B-T067
rates	B-T081
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude oil	B-T109
amendment	B-T170
,	O
anammox	B-T044
activity	B-T052
was	O
partially	O
(between	O
2	O
and	O
5	O
times)	O
or	O
completely	B-T080
inhibited	B-T080
by	O
the	O
addition	B-T169
of	O
crude oil	B-T109
when	O
comparing	O
to	O
rates	B-T081
in	O
unamended controls	B-T077
.	O
Similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	B-T082
sediment	B-T167
types	B-T080
,	O
despite	O
their	O
different	O
physical-chemical characteristics	B-T080
.	O
Moreover,	O
N2O	B-T121
production	B-T070
was	O
reduced	B-T080
by	O
2-36	O
times	O
following	O
crude oil	B-T109
addition	B-T169
.	O
Further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism(s)	B-T169
of	O
the	O
observed	B-T169
reduction	B-T080
in	O
N2O	B-T121
production	B-T070
.	O
This	O
study	B-T062
represents	O
one	O
of	O
the	O
first	O
contributions	B-T052
to	O
the	O
understanding	O
of	O
the	O
impact	B-T080
of	O
crude oil	B-T109
pollution	B-T069
on	O
denitrification	B-T067
and	O
anammox	B-T044
,	O
with	O
profound	O
implications	O
for	O
the	O
management	B-T057
of	O
aquatic	B-T067
ecosystems	B-T070
regarding	O
eutrophication	B-T067
(	O
N-removal	B-T052
).	O

Shining	O
the	O
light	O
on	O
the	O
dark	O
side	O
of	O
medical	B-T169
leadership	B-T054
-	O
a	O
qualitative study	B-T062
in	O
Australia	B-T083
Purpose	O
The	O
paper	O
aims	B-T078
to	O
explore	O
the	O
beliefs	B-T078
of	O
doctors	B-T097
in	O
leadership	B-T054
roles	O
of	O
the	O
concept	B-T078
of	O
"the	O
dark	O
side",	O
using	O
data	B-T078
collected	O
from	O
interviews	B-T052
carried	O
out	O
with	O
45	O
doctors	B-T097
in	O
medical	B-T169
leadership	B-T054
roles	O
across	O
Australia	B-T083
.	O
The	O
paper	O
looks	O
at	O
the	O
beliefs	B-T078
from	O
the	O
perspectives	B-T078
of	O
doctors	B-T097
who	O
are	O
already	O
in	O
leadership	B-T054
roles	O
themselves;	O
to	O
identify	O
potential	O
barriers	B-T033
they	O
might	O
have	O
encountered	O
and	O
to	O
arrive	O
at	O
better-informed	O
strategies	O
to	O
engage	O
more	O
doctors	B-T097
in	O
the	O
leadership	B-T054
of	O
the	O
Australian	B-T098
health system	B-T064
.	O
The	O
research	B-T062
question	O
is:	O
"What	O
are	O
the	O
beliefs	B-T078
of	O
medical	B-T169
leaders	B-T097
that	O
form	O
the	O
key	O
themes	B-UnknownType
or	O
dimensions	B-T081
of	O
the	O
negative	O
perception	O
of	O
the	O
'dark	O
side'?".	O
Design/methodology/approach	O
The	O
paper	O
analysed	O
data	B-T078
from	O
two	O
similar	O
qualitative studies	B-T062
examining	O
medical	B-T169
leadership	B-T054
and	O
engagement	O
in	O
Australia	B-T083
by	O
the	O
same	O
author,	O
in	O
collaboration	B-T054
with	O
other	O
researchers	B-T097
,	O
which	O
used	O
in-depth	O
semi-structured interviews	B-UnknownType
with	O
45	O
purposively	O
sampled	O
senior	O
medical	B-T169
leaders	B-T097
in	O
leadership	B-T054
roles	O
across	O
Australia	B-T083
in	O
health services	B-T058
,	O
private	B-T073
and	O
public hospitals	B-T073
,	O
professional associations	B-T094
and	O
health departments	B-T093
.	O
The	O
data	B-T078
were	O
analysed	O
using	O
deductive	O
and	O
inductive	O
approaches	B-T082
through	O
a	O
coding	B-T057
framework	O
based	O
on	O
the	O
interview	B-T052
data	B-T078
and	O
literature review	B-T170
,	O
with	O
all	O
sections	O
of	O
coded	B-T057
data	B-T078
grouped	B-T078
into	O
themes	B-UnknownType
.	O
Findings	O
Medical	B-T169
leaders	B-T097
had	O
four	O
key	O
beliefs	B-T078
about	O
the	O
"dark	O
side"	O
as	O
perceived	O
through	O
the	O
eyes	B-T023
of	O
their	O
own	O
past	O
clinical experience	B-T080
and/or	O
their	O
clinical	B-T080
colleagues	B-T098
.	O
These	O
four	O
beliefs	B-T078
or	O
dimensions	B-T081
of	O
the	O
negative	O
perception	O
colloquially	O
known	O
as	O
"the	O
dark	O
side"	O
are	O
the	O
belief	B-T078
that	O
they	O
lack	O
both	O
managerial	B-T090
and	O
clinical	B-T080
credibility	B-T080
,	O
they	O
have	O
confused	O
identities,	O
they	O
may	O
be	O
in	O
conflict	B-T078
with	O
clinicians	B-T097
,	O
their	O
clinical	B-T080
colleagues	B-T098
lack	O
insight	O
into	O
the	O
complexities	O
of	O
medical	B-T169
leadership	B-T054
and,	O
as	O
a	O
result,	O
doctors	B-T097
are	O
actively	O
discouraged	O
from	O
making	O
the	O
transition	O
from	O
clinical practice	B-T080
to	O
medical	B-T169
leadership	B-T054
roles	O
in	O
the	O
first	O
place.	O
Research	O
limitations/implications	O
This	O
research	B-T062
was	O
conducted	O
within	O
the	O
Western	B-T082
developed-nation	B-T080
setting	O
of	O
Australia	B-T083
and	O
only	O
involved	O
interviews	B-T052
with	O
doctors	B-T097
in	O
medical	B-T169
leadership	B-T054
roles.	O
The	O
findings	O
are	O
therefore	O
limited	O
to	O
the	O
doctors	B-T097
'	O
own	O
perceptions	O
of	O
themselves	O
based	O
on	O
their	O
past	O
experiences	O
and	O
beliefs	B-T078
.	O
Future	O
research	B-T062
involving	O
doctors	B-T097
who	O
have	O
not	O
chosen	O
to	O
transition	B-T052
to	O
leadership	B-T054
roles,	O
or	O
other	O
health practitioners	B-T097
in	O
other	O
settings,	O
may	O
provide	O
a	O
broader	O
perspective	B-T078
.	O
Also,	O
this	O
research	B-T062
was	O
exploratory	O
and	O
descriptive	B-T033
in	O
nature	O
using	O
qualitative methods	B-T062
,	O
and	O
quantitative research	B-T062
can	O
be	O
carried	O
out	O
in	O
the	O
future	O
to	O
extend	O
this	O
research	B-T062
for	O
statistical generalisation	B-T062
.	O
Practical	O
implications	O
The	O
paper	O
includes	O
implications	O
for	O
health organisations	B-T073
,	O
training	O
providers,	O
medical	B-T169
employers	B-T097
and	O
health departments	B-T093
and	O
describes	O
a	O
multi-prong	O
strategy	O
to	O
address	O
this	O
important	O
issue.	O
Originality/value	O
This	O
paper	O
fulfils	O
an	O
identified	O
need	O
to	O
study	B-T062
the	O
concept	B-T078
of	O
"moving	O
to	O
the	O
dark	O
side"	O
as	O
a	O
negative	O
perception	O
of	O
medical	B-T169
leadership	B-T054
and	O
contributes	O
to	O
the	O
evidence	B-T078
in	O
this	O
under-	O
researched	B-T062
area.	O
This	O
paper	O
has	O
used	O
data	B-T078
from	O
two	O
similar	O
studies	B-T062
,	O
combined	O
together	O
for	O
the	O
first	O
time,	O
with	O
new	O
analysis	B-T062
and	O
coding	B-T057
,	O
looking	O
at	O
the	O
concept	B-T078
of	O
the	O
"dark	O
side"	O
to	O
discover	O
new	O
emergent	O
findings.	O

Erlotinib	B-T109
plus	O
gemcitabine	B-T114
versus	O
gemcitabine	B-T114
for	O
pancreatic cancer	B-T191
:	O
real	B-T080
-	O
world	B-T098
analysis	B-T062
of	O
Korean	B-T083
national	B-T092
database	B-T170
A	O
randomized clinical trial	B-T062
has	O
found	O
that	O
the	O
addition	B-T067
of	O
erlotinib	B-T109
to	O
gemcitabine	B-T114
(	O
GEM	B-T114
-	O
E	B-T109
)	O
for	O
pancreatic cancer	B-T191
led	O
to	O
a	O
modest	B-T080
increase	B-T169
in	O
survival	B-T052
.	O
The	O
aim	B-T078
of	O
this	O
national	B-T082
population	B-T098
-	O
based	B-T169
retrospective study	B-T062
was	O
to	O
compare	B-T052
the	O
effectiveness	B-T080
of	O
GEM	B-T114
-	O
E	B-T109
to	O
GEM	B-T114
alone	O
for	O
pancreatic cancer	B-T191
patients	B-T101
in	O
real clinical practice	B-T057
.	O
Patients	B-T101
with	O
pancreatic cancer	B-T191
(ICD-10	B-T170
:	O
C25)	O
with	O
prescription	B-T170
claims	O
of	O
gemcitabine	B-T114
or	O
erlotinib	B-T109
between	O
Jan	O
1,	O
2007	O
and	O
Dec	O
31,	O
2012	O
were	O
retrospectively	B-T080
identified	B-T080
from	O
the	O
Korean	B-T083
Health Insurance	B-T058
claims	O
database	B-T170
.	O
To	O
be	O
included	O
in	O
the	O
study	B-T062
population	B-T098
,	O
patients	B-T101
were	O
required	B-T169
to	O
have	O
had	O
a	O
histological	B-UnknownType
or	O
cytological diagnosis	B-T033
within	O
one	O
year	O
before	O
chemotherapy	B-T061
.	O
Patients	B-T101
treated with	B-T033
prior	O
radiotherapy	B-T061
,	O
surgery	B-T058
,	O
or	O
chemotherapy	B-T061
were	O
excluded	B-T078
to	O
reduce	B-T061
heterogeneity	B-T080
.	O
Overall	O
survival	B-T052
from	O
the	O
initiation	B-T169
of	O
therapy	B-T061
and	O
the	O
medical costs	B-T081
of	O
GEM	B-T114
-	O
E	B-T109
and	O
GEM	B-T114
were	O
compared	B-T052
.	O
A	O
total	O
of	O
4,267	O
patients	B-T101
were	O
included	O
in	O
the	O
analysis	B-T062
.	O
Overall	O
survival	B-T052
was	O
not	O
significantly	B-T078
longer	B-T080
in	O
patients	B-T101
treated	B-T033
with	O
GEM	B-T114
-	O
E	B-T109
(	O
median	B-T081
6.77	O
months	O
for	O
GEM	B-T114
-	O
E	B-T109
vs.	O
6.68	O
months	O
for	O
GEM	B-T114
,	O
p	O
=	O
0.0977).	O
There	O
was	O
also	O
no significant	B-T033
difference	B-T081
in	O
the	O
respective	O
one-year	O
survival rates	B-T081
(27.0	O
%	O
vs.	O
27.3	O
%;	O
p	O
=	O
0.5988).	O
Multivariate analysis	B-T081
using	O
age	B-T032
,	O
gender	B-T032
,	O
and	O
comorbidities	B-T078
as	O
covariates	B-UnknownType
did	O
not	O
reveal	B-T080
any	O
significant	B-T078
differences	B-T081
in	O
survival	B-T052
.	O
Based	B-T169
on	O
this	O
relative effectiveness	B-T081
,	O
the	O
incremental	B-T081
cost	B-T081
per	O
life	B-T078
year	B-T079
gained	B-T081
over	O
GEM	B-T114
was	O
estimated	B-T081
at	O
USD	B-T081
70,843.64	O
for	O
GEM	B-T114
-	O
E	B-T109
.	O
GEM	B-T114
-	O
E	B-T109
for	O
pancreatic cancer	B-T191
is	O
not	O
more	O
effective	B-T080
than	O
GEM	B-T114
in	O
a	O
real	B-T080
-	O
world	B-T098
setting	B-T078
,	O
and	O
it	O
does	O
not	O
provide	B-T052
reasonable	B-T033
cost-effectiveness	B-T081
over	O
GEM	B-T114
.	O

Development	O
of	O
a	O
Novel	O
Quantitative Structure-Activity Relationship	B-T081
Model	B-T170
to	O
Accurately	O
Predict	O
Pulmonary Absorption	B-T042
and	O
Replace	O
Routine	O
Use	O
of	O
the	O
Isolated	B-T169
Perfused	B-T169
Respiring	B-T039
Rat Lung	B-T023
Model	B-T170
We	O
developed	O
and	O
tested	O
a	O
novel	O
Quantitative Structure-Activity Relationship	B-T081
(	O
QSAR	B-T081
)	O
model	B-T170
to	O
better	O
understand	O
the	O
physicochemical	B-T070
drivers	O
of	O
pulmonary absorption	B-T042
,	O
and	O
to	O
facilitate	O
compound design	B-T090
through	O
improved	O
prediction	B-T078
of	O
absorption	B-T067
.	O
The	O
model	B-T170
was	O
tested	O
using	O
a	O
large	O
array	O
of	O
both	O
existing	O
and	O
newly	O
designed	O
compounds	B-T121
.	O
Pulmonary absorption	B-T042
data	O
was	O
generated	O
using	O
the	O
isolated	B-T169
perfused	B-T169
respiring	B-T039
rat lung	B-T023
(	O
IPRLu	B-T023
)	O
model	B-T170
for	O
82	O
drug discovery	B-T062
compounds	B-T121
and	O
17	O
marketed drugs	B-T121
.	O
This	O
dataset	O
was	O
used	O
to	O
build	O
a	O
novel	O
QSAR	B-T081
model	B-T170
based	O
on	O
calculated	O
physicochemical properties	B-T070
.	O
A	O
further	O
9	O
compounds	B-T121
were	O
used	O
to	O
test	O
the	O
model's	B-T170
predictive	O
capability	B-T080
.	O
The	O
QSAR	B-T081
model	B-T170
performed	O
well	O
on	O
the	O
9	O
compounds	B-T121
in	O
the	O
"	O
Test set	B-T170
"	O
with	O
a	O
predicted	O
versus	O
observed	O
correlation	B-T081
of	O
R(2)	O
=	O
0.85,	O
and	O
>65%	O
of	O
compounds	B-T121
correctly	O
categorised.	O
Calculated	O
descriptors	O
associated	O
with	O
permeability	B-T070
and	O
hydrophobicity	B-T080
positively	O
correlated	O
with	O
pulmonary absorption	B-T042
,	O
whereas	O
those	O
associated	O
with	O
charge	B-T080
,	O
ionisation	B-T067
and	O
size	B-T082
negatively	O
correlated.	O
The	O
novel	O
QSAR	B-T081
model	B-T170
described	O
here	O
can	O
replace	O
routine	O
generation	O
of	O
IPRLu	B-T023
model	B-T170
data	O
for	O
ranking	B-T170
and	O
classifying	B-T185
compounds	B-T121
prior	O
to	O
synthesis	B-T052
.	O
It	O
will	O
also	O
provide	O
scientists	O
working	O
in	O
the	O
field	O
of	O
inhaled drug discovery	B-T062
with	O
a	O
deeper	O
understanding	O
of	O
the	O
physicochemical	B-T070
drivers	O
of	O
pulmonary absorption	B-T042
based	O
on	O
a	O
relevant	O
respiratory	O
compound	B-T121
dataset	B-T170
.	O

The	O
EpiDerm™	B-T170
3D human reconstructed skin micronucleus (RSMN) assay	B-T059
:	O
Historical control	B-T062
data	B-T078
and	O
proof	B-T033
of	O
principle studies	B-T062
for	O
mechanistic assay	B-T059
adaptations	O
The	O
in vitro human reconstructed skin micronucleus (RSMN) assay	B-T059
in	O
EpiDerm™	B-T170
is	O
a	O
promising	O
novel	O
animal alternative	B-T062
for	O
evaluating	O
genotoxicity	B-T049
of	O
topically applied	B-T061
chemicals	B-T103
.	O
It	O
is	O
particularly	O
useful	O
for	O
assessing	B-T058
cosmetic ingredients	B-T120
that	O
can	O
no	O
longer	O
be	O
tested	B-T169
using	O
in vivo	B-T082
assays	B-T059
.	O
To	O
advance	O
the	O
use	O
of	O
this	O
test	B-T170
especially	O
for	O
regulatory	B-T089
decision-making	B-T041
,	O
we	O
have	O
established	O
the	O
RSMN assay	B-T059
in	O
our	O
laboratory	B-T073
according	O
to	O
Good Laboratory Practice	B-T185
and	O
following	O
the	O
principles	O
of	O
the	O
OECD	B-T093
test guideline 487	B-T170
in vitro	B-T080
mammalian cell	B-T025
micronucleus test	B-T059
.	O
Proficiency	O
with	O
the	O
assay	B-T059
was	O
established	O
by	O
correctly	O
identifying	O
direct-acting genotoxins	B-T131
and	O
genotoxins	B-T131
requiring	O
metabolism	B-T040
,	O
as	O
well	O
as	O
non-genotoxic	B-T033
/	O
non-carcinogenic	B-T033
chemicals	B-T103
.	O
We	O
also	O
report	B-T170
the	O
analysis	B-T062
of	O
our	O
historical control	B-T062
data	B-T078
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive control	B-T077
values	B-T081
for	O
%	O
micronuclei	B-T026
in	O
binucleated cells	B-T049
are	O
in	O
the	O
ranges	O
reported	O
previously.	O
Technical issues	B-T067
including	O
evaluating	O
various	O
solvents	B-T130
with	O
both	O
48h	O
and	O
72h	O
treatment regimens	B-T061
were	O
investigated	B-T169
.	O
For	O
the	O
first	O
time,	O
mechanistic studies	B-T089
using	O
CREST analysis	B-T062
revealed	O
that	O
the	O
RSMN assay	B-T059
is	O
suitable	O
for	O
distinguishing	O
aneugens	B-T120
and	O
clastogens	B-T131
.	O
Moreover,	O
the	O
assay	B-T059
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	B-T116
as	O
markers	B-T080
for	O
proliferative	B-T046
and	O
toxic effects	B-T037
of	O
chemicals	B-T103
.	O

Wnt-5a	B-T116
/	O
Frizzled9	B-T116
receptor signaling	B-T044
through	O
the	O
Gαo	B-T116
/	O
Gβγ complex	B-T116
regulates	B-T038
dendritic spine	B-T026
formation	B-T043
Wnt ligands	B-T116
play	O
crucial	O
roles	O
in	O
the	O
development	B-T042
and	O
regulation of synapse structure and function	B-T042
.	O
Specifically,	O
Wnt-5a	B-T116
acts	O
as	O
a	O
secreted growth factor	B-T116
that	O
regulates	B-T038
dendritic spine	B-T026
formation	B-T043
in	O
rodent	B-T015
hippocampal	B-T023
neurons	B-T025
,	O
resulting	O
in	O
postsynaptic	B-T026
development	B-T042
that	O
promotes	O
the	O
clustering of the postsynaptic density protein-95 (PSD-95)	B-T043
.	O
Here,	O
we	O
focused	O
on	O
the	O
early	B-T079
events	B-T051
occurring	O
after	O
the	O
interaction	B-T044
between	O
Wnt-5a	B-T116
and	O
its	O
Frizzled receptor	B-T116
at	O
the	O
neuronal	B-T025
cell surface	B-T026
.	O
Additionally,	O
we	O
studied	O
the	O
role	B-T077
of	O
heterotrimeric G proteins	B-T116
in	O
Wnt-5a	B-T116
-dependent	O
synaptic	B-T026
development	B-T042
.	O
We	O
report	O
that	O
Frizzled9	B-T116
(	O
FZD9	B-T116
),	O
a	O
Wnt	B-T116
receptor	B-T116
related	O
to	O
Williams' syndrome	B-T047
,	O
is	O
localized	O
in	O
the	O
postsynaptic region	B-UnknownType
,	O
where	O
it	O
interacts	B-T044
with	O
Wnt-5a	B-T116
.	O
Functionally,	O
FZD9	B-T116
is	O
required	O
for	O
the	O
Wnt-5a	B-T116
-mediated	O
increase	B-T169
in	O
dendritic spine density	B-T026
.	O
FZD9	B-T116
forms	O
a	O
pre-coupled complex	B-T026
with	O
Gαo	B-T116
under	O
basal conditions	B-T070
that	O
dissociates	B-T044
after	O
Wnt-5a	B-T116
stimulation	B-T044
.	O
Accordingly,	O
we	O
found	O
that	O
G-protein inhibition abrogates	B-T043
Wnt-5a	B-T116
-dependent	O
pathway	B-T044
in	O
hippocampal	B-T023
neurons	B-T025
.	O
In	O
particular,	O
the	O
activation	B-T052
of	O
Gαo	B-T116
appears	O
to	O
be	O
a	O
key	O
factor	O
controlling	B-T067
the	O
Wnt-5a	B-T116
-	O
induced	B-T169
dendritic spine density	B-T026
.	O
In	O
addition,	O
we	O
found	O
that	O
Gβγ	B-T116
is	O
required	O
for	O
the	O
Wnt-5a	B-T116
-mediated	O
increase	B-T169
in	O
cytosolic	B-T026
calcium	B-T121
levels	B-T080
and	O
spinogenesis	B-T043
.	O
Our	O
findings	B-T169
reveal	O
that	O
FZD9	B-T116
and	O
heterotrimeric G proteins	B-T116
regulate	B-T038
Wnt-5a	B-T116
signaling	B-T044
and	O
dendritic spines	B-T026
in	O
cultured	B-T025
hippocampal	B-T023
neurons	B-T025
.	O

A	O
Delayed	B-T079
Diagnosis	B-T033
of	O
Chronic Mesenteric Ischaemia	B-T047
:	O
The	O
Role	O
of	O
Clinicians	B-T097
'	O
Cognitive	B-T169
Errors	B-T080
Chronic	B-T079
diarrhoeal illnesses	B-T047
with	O
nausea	B-T184
and	O
weight loss	B-T033
are	O
a	O
common	B-T081
indication	B-T078
for	O
gastroenterology	B-T091
review	B-T078
.	O
While	O
many	O
such	O
cases	O
have	O
intra-luminal	B-T082
aetiologies	B-T169
,	O
such	O
as	O
inflammatory bowel disease	B-T047
,	O
coeliac disease	B-T047
or	O
other	O
malabsorptive conditions	B-T033
,	O
with	O
many	O
other	O
cases	O
due	O
to	O
functional	B-T169
gut	B-T023
disorders	B-T047
or	O
systemic	B-T169
malignancy	B-T191
,	O
clinicians	B-T097
must	O
also	O
keep	O
vascular disorders	B-T047
in	O
mind.	O
Here	O
we	O
report	O
a	O
patient	B-T101
with	O
a	O
delayed	B-T079
diagnosis	B-T033
of	O
chronic mesenteric ischaemia	B-T047
after	O
6	O
months	B-T079
of	O
gastrointestinal symptoms	B-T184
strongly	O
mimicking	O
an	O
alternative	B-T077
diagnosis	B-T033
such	O
as	O
inflammatory bowel disease	B-T047
due	O
an	O
atypical	B-T080
predominance	B-T169
of	O
nausea	B-T184
and	O
diarrhoea	B-T184
rather	O
than	O
pain	B-T184
.	O
We	O
briefly	O
review	B-T078
the	O
literature	B-T170
on	O
treatment	B-T169
of	O
this	O
condition	B-T047
but	O
also	O
discuss	O
with	O
particular	O
attention	O
the	O
sequence	B-T169
of	O
cognitive	B-T169
errors	B-T080
made	O
by	O
clinicians	B-T097
that	O
led	O
to	O
a	O
diagnostic	B-T033
delay	B-T079
,	O
inviting	O
readers	O
to	O
thus	O
reflect	O
on	O
how	O
such	O
errors	B-T080
can	O
be	O
minimised	B-T080
in	O
their	O
practice	B-T057
.	O

Evaluation	B-T058
of	O
Choroidal	B-T023
Thickness	B-T080
in	O
Patients	B-T101
with	O
Pseudoexfoliation Syndrome	B-T047
and	O
Pseudoexfoliation Glaucoma	B-T047
Purpose	B-T169
.	O
To	O
compare	B-T052
the	O
macular	B-T082
and	O
peripapillary	B-T082
choroidal	B-T023
thickness	B-T080
in	O
eyes	B-T023
with	O
pseudoexfoliation (PEX) syndrome	B-T047
and	O
PEX glaucoma	B-T047
with	O
the	O
normal	B-T080
eyes	B-T023
of	O
healthy	B-T080
controls	B-T096
.	O
Materials	O
and	O
Methods.	O
In	O
this	O
prospective study	B-T062
,	O
30	O
eyes	B-T023
of	O
30	O
patients	B-T101
with	O
PEX syndrome	B-T047
,	O
28	O
eyes	B-T023
of	O
28	O
patients	B-T101
with	O
PEX glaucoma	B-T047
,	O
and	O
30	O
eyes	B-T023
of	O
30	O
age	B-T032
-matched	O
healthy	B-T080
subjects	B-T096
were	O
enrolled.	O
Choroidal	B-T023
thicknesses	B-T080
in	O
the	O
macular	B-T082
and	O
peripapillary	B-T082
areas	B-T082
were	O
measured	B-T080
by	O
using	O
spectral domain optical coherence tomography	B-T074
.	O
Results.	O
Gender	B-T032
,	O
age	B-T032
,	O
and	O
axial length	B-T081
did	O
not significantly	B-T033
differ	O
between	O
the	O
groups	B-UnknownType
(all,	O
p	O
>	O
0.05).	O
The	O
mean values	B-T081
of	O
choroidal	B-T023
thickness	B-T080
in	O
the	O
macular	B-T082
and	O
peripapillary	B-T082
areas	B-T082
(	O
except	B-T169
the	O
superior	B-T082
quadrant	B-T082
)	O
in	O
the	O
patients	B-T101
with	O
PEX syndrome	B-T047
and	O
PEX glaucoma	B-T047
were	O
lower	B-T052
compared	B-T052
with	O
controls	B-T096
(all	O
p	O
<	O
0.05).	O
The	O
mean values	B-T081
of	O
the	O
macular	B-T082
and	O
peripapillary	B-T082
choroidal	B-T023
thickness	B-T080
in	O
the	O
PEX glaucoma	B-T047
group	B-UnknownType
were	O
lower	B-T052
compared	B-T052
with	O
PEX syndrome	B-T047
group	B-UnknownType
;	O
however	O
this	O
difference	B-T080
was	O
not significant	B-T033
.	O
Conclusions.	O
The	O
findings	B-T033
of	O
this	O
study	B-T062
revealed	B-T080
that	O
macular	B-T082
and	O
peripapillary	B-T082
choroidal	B-T023
thicknesses	B-T080
were	O
decreased	B-T081
in	O
PEX syndrome	B-T047
and	O
PEX glaucoma	B-T047
cases	B-T169
.	O
The	O
role	O
of	O
choroid	B-T023
in	O
the	O
development	B-T169
of	O
glaucomatous	B-T047
damage	B-T169
in	O
patients	B-T101
with	O
PEX syndrome	B-T047
remains	O
unclear	B-T033
.	O

Clinical Features	B-T184
and	O
Complications	B-T046
of	O
the	O
HLA-B27	B-T116
-associated	O
Acute Anterior Uveitis	B-T047
:	O
A	O
Metanalysis	B-T062
In	O
this	O
article	B-T170
,	O
we	O
report	O
a	O
literature-based	B-T170
metanalysis	B-T062
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical features	B-T184
of	O
the	O
HLA-B27	B-T116
Acute Anterior Uveitis	B-T047
(	O
AAU	B-T047
).	O
The	O
examined	B-T033
material	O
was	O
based	O
on	O
observational studies	B-T062
in	O
which	O
participants	B-T098
were	O
affected	O
by	O
Acute Anterior Uveitis	B-T047
and	O
divided	O
into	O
HLA B27+	B-T034
and	O
HLA B27-	B-T034
.	O
We	O
performed	O
a	O
search	O
on	O
articles	B-T170
with	O
the	O
words	O
"	O
HLA B27 uveitis	B-T047
"	O
dated	O
before	O
May	O
2014.	O
Among	O
these,	O
29	O
articles	B-T170
were	O
selected	O
for	O
a	O
second	O
review	B-T078
.	O
After	O
a	O
further	O
evaluation,	O
22	O
articles	B-T170
were	O
analyzed	B-T062
.	O
The	O
clinical characteristics	B-T201
studied	O
in	O
the	O
metanalysis	B-T062
were:	O
(1)	O
systemic disease	B-T047
;	O
(2)	O
sex distribution	B-T081
;	O
(3)	O
laterality	B-T032
;	O
(4)	O
visual acuity	B-T201
;	O
(5)	O
hypopion	B-T047
;	O
(6)	O
anterior chamber's fibrin	B-T116
;	O
(7)	O
elevated intraocular pressure	B-T033
(	O
IOP	B-T042
)	O
during	O
inflammation	B-T046
;	O
(8)	O
glaucoma	B-T047
;	O
(9)	O
posterior synechiae	B-T047
;	O
(10)	O
cataract	B-T020
;	O
(11)	O
cystoid macular edema	B-T047
;	O
(12)	O
papillitis	B-T047
.	O
We	O
have	O
calculated	O
a	O
relative risk	B-T081
(	O
RR	B-T081
)	O
for	O
each	O
outcome measured	B-T081
.	O
The	O
results	B-T169
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA B27	B-T116
Acute Anterior Uveitis	B-T047
,	O
such	O
as	O
strong	O
association with	B-T080
ankylosing spondylitis	B-T047
(	O
RR	B-T081
=	O
6.80)	O
and	O
systemic diseases	B-T047
(	O
RR	B-T081
=	O
9.9),	O
male	B-T032
prevalence	B-T081
(	O
RR	B-T081
=	O
1.2),	O
unilateral	B-T082
(	O
RR	B-T081
=	O
1.1)	O
or	O
alternating	O
bilateral	B-T082
(	O
RR	B-T081
=	O
2.2)	O
involvement	B-T169
,	O
hypopion	B-T047
(	O
RR	B-T081
=	O
5.5),	O
fibrinous	B-T116
reaction	B-T169
and	O
even	O
papillitis	B-T047
(R	O
=	O
7.7).	O
Simultaneous	O
bilateral	B-T082
(	O
RR	B-T081
=	O
0.3)	O
AAU	B-T047
is	O
more	O
frequent	B-T079
in	O
HLA-B27	B-T116
negative	B-T033
form.	O
We	O
report	O
higher	O
risk	B-T078
of	O
elevated IOP	B-T033
and	O
glaucoma	B-T047
(	O
RR	B-T081
=	O
0.6)	O
in	O
B27- Acute Anterior Uveitis	B-T047
.	O
No	O
significant	O
difference	O
between	O
HLA B 27 positive	B-T033
and	O
negative	B-T033
AAU	B-T047
was	O
observed	B-T169
according	O
to	O
final	O
visual acuity	B-T201
and	O
complications	B-T046
such	O
as	O
posterior synechiae	B-T047
,	O
cataract	B-T020
,	O
and	O
maculare edema	B-T047
.	O
We	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical evaluation	B-T058
and	O
therapeutic	B-T169
decision	B-T041
in	O
addressing	O
a	O
still	O
ill-defined	O
ophthalmologic	B-T169
condition	B-T080
.	O

A	O
Case	O
Presenting	O
with	O
Splenic Infarct	B-T047
Diagnosed	B-T033
as	O
Primary Bone Marrow	B-T024
CD5 Positive	B-T025
DLBCL	B-T191
:	O
A	O
Clinicopathological Correlation	B-T080
De novo	B-T078
CD5+	B-T025
Diffuse large B cell lymphoma	B-T033
(	O
DLBCL	B-T191
)	O
is	O
a	O
rare	B-T080
and	O
aggressive subtype	B-T033
of	O
DLBCL	B-T191
.	O
It	O
is	O
a	O
distinct	O
clinicopathologic	B-T033
entity	B-T071
with	O
complex molecular profile	B-T169
and	O
poor prognosis	B-T033
.	O
A	O
59	O
year	B-T079
old	O
female	B-T032
presented with	B-T033
pyrexia of unknown origin	B-T184
since	O
1	O
month	B-T079
.	O
On	O
examination	B-T058
,	O
there	O
was	O
severe pallor	B-T033
,	O
hepatosplenomegaly	B-T184
and	O
no palpable	B-T080
lymphadenopathy	B-T047
.	O
Complete blood count	B-T059
revealed	B-T080
bicytopenia	B-T034
with	O
normal total leucocyte count	B-T033
.	O
Liver	B-T059
and	O
renal function tests	B-T059
were	O
normal	B-T080
.	O
Ultrasonography abdomen	B-T060
revealed	B-T080
splenic enlargement	B-T033
with	O
two focal lesions	B-T033
attributed	O
to	O
either	O
splenic abscess	B-T047
or	O
infarcts	B-T047
.	O
Patient	B-T101
was	O
being	O
managed	O
as	O
splenic infarct	B-T047
but	O
continued	O
to	O
have	O
bicytopenia	B-T034
.	O
Further	O
investigation	B-T058
showed	O
elevated serum ferritin	B-T033
,	O
triglycerides	B-T033
and	O
LDH	B-T034
.	O
With	O
a	O
clinical	B-T080
suspicion	B-T041
of	O
infection	B-T046
and	O
haemophagocytic lymphohistiocytosis	B-T047
bone marrow aspiration	B-T060
bone marrow aspiration (BMA) and biopsy (BMBx)	B-T060
BMA	B-T060
)	O
and	O
biopsy	B-T060
(BMBx)	O
was	O
done.	O
BMA	O
showed	O
extensive	B-T080
haemophagocytosis	B-T047
and	O
~7.4	O
%	O
large lymphoma-like cells	B-T191
.	O
On	O
this	O
basis	O
PET-CT	B-T060
was	O
suggested	O
which	O
showed	O
enlarged spleen	B-T033
with	O
diffuse uptake	B-T033
.	O
BMBx	B-T060
showed	O
nodular	B-T020
and	O
intrasinusoidal	B-T082
collection	O
of	O
abnormal lymphoid cells	B-T025
.	O
On	O
immunohistochemistry	B-T060
,	O
these	O
cells	B-T025
were	O
positive for CD20	B-T034
,	O
CD5	B-T116
,	O
MUM1	B-T116
,	O
BCL-2	B-T129
,	O
BCL-6	B-T129
and	O
negative	B-T033
for	O
CD3	B-T116
,	O
CD10	B-T116
and	O
CD23	B-T116
.	O
CD34	B-T116
highlighted	O
focal	B-T082
intrasinusoidal	B-T082
pattern	B-T082
.	O
The	O
complete	O
clinicopathological profile	B-T058
suggested	O
the	O
diagnosis	B-T033
of	O
de novo	B-T078
CD5+	B-T025
DLBCL	B-T191
,	O
with	O
primary hepatosplenic	B-T047
pattern	B-T082
of	O
involvement.	O
CD5+	B-T025
DLBCL	B-T191
presenting	O
as	O
splenic infarct	B-T047
is	O
very rare	B-T033
.	O
This	O
case	O
was	O
unusual	B-T080
as	O
the	O
diagnosis	B-T033
of	O
a	O
primary aggressive lymphoma	B-T191
with	O
haemophagocytosis	B-T047
was	O
established	B-T080
in	O
a	O
patient	B-T101
who	O
presented	O
with	O
fever	B-T184
and	O
splenic infarct	B-T047
without	O
lymphadenopathy	B-T047
.	O
This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	B-T082
assessment	B-T052
of	O
a	O
bone marrow aspirate	B-T031
and	O
biopsy	B-T060
to	O
make	O
a	O
correct diagnosis	B-T033
.	O

The	O
cost-effectiveness	B-T081
of	O
family	B-T099
/	O
family-based therapy	B-T061
for	O
treatment	B-T169
of	O
externalizing disorders	B-T048
,	O
substance use disorders	B-T048
and	O
delinquency	B-T048
:	O
a	O
systematic	O
review	B-T170
Family therapy	B-T061
and	O
family-based treatment	B-T169
has	O
been	O
commonly	O
applied	O
in	O
children	B-T100
and	O
adolescents	B-T100
in	O
mental health care	B-T061
and	O
has	O
been	O
proven	O
to	O
be	O
effective.	O
There	O
is	O
an	O
increased	O
interest	O
in	O
economic evaluations	B-T057
of	O
these,	O
often	O
expensive,	O
interventions	B-T061
.	O
The	O
aim	O
of	O
this	O
systematic	O
review	B-T170
is	O
to	O
summarize	O
and	O
evaluate	B-T058
the	O
evidence	O
on	O
cost-effectiveness	B-T081
of	O
family	B-T099
/	O
family-based therapy	B-T061
for	O
externalizing disorders	B-T048
,	O
substance use disorders	B-T048
and	O
delinquency	B-T048
.	O
A	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
PubMed	B-T170
,	O
Education Resource information Centre	B-T073
(	O
ERIC	B-T073
),	O
Psycinfo	B-T170
and	O
Cochrane	B-T170
reviews	B-T170
including	O
studies	B-T059
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
August	O
of	O
2013.	O
Full	O
economic evaluations	B-T057
investigating	O
family	B-T099
/	O
family-based interventions	B-T061
for	O
adolescents	B-T100
between	O
10	O
and	O
20	O
years	B-T079
treated	B-T169
for	O
substance use disorders	B-T048
,	O
delinquency	B-T048
or	O
externalizing disorders	B-T048
were	O
included.	O
Seven	O
hundred	O
thirty-one	O
articles	B-T170
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-T059
were	O
initially	O
selected.	O
The	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-T059
.	O
The	O
quality	B-T080
of	O
these	O
studies	B-T059
was	O
assessed	B-T052
.	O
Within	O
the	O
identified	O
studies	B-T059
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	B-T099
/	O
family-based interventions	B-T061
and	O
disorders	B-T047
.	O
According	O
to	O
the	O
outcomes	B-T057
of	O
the	O
checklists,	O
the	O
overall	O
quality	B-T080
of	O
the	O
economic evaluations	B-T057
was	O
low.	O
Results	O
varied	O
by	O
study	B-T059
.	O
Due	O
to	O
the	O
variations	O
in	O
setting,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta-analysis	B-T062
.	O
The	O
quality	B-T080
of	O
the	O
identified	O
economic evaluations	B-T057
of	O
family	B-T099
/	O
family-based therapy	B-T061
for	O
treatment	B-T169
of	O
externalizing disorders	B-T048
,	O
adolescent	B-T100
substance use disorders	B-T048
and	O
delinquency	B-T048
was	O
insufficient	O
to	O
determine	O
the	O
cost-effectiveness	B-T081
.	O
Although	O
commonly	O
applied,	O
family	B-T099
/	O
family-based therapy	B-T061
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	B-T080
is	O
needed.	O

Regulation	B-T045
of	O
ABCA1	B-T028
and	O
ABCG1	B-T028
gene expression	B-T045
in	O
the	O
intraabdominal adipose tissue	B-T024
Tissue specific expression of genes	B-T045
encoding	B-T052
cholesterol	B-T109
transporters	B-T116
ABCA1	B-T116
and	O
ABCG1	B-T116
as	O
well	O
as	O
genes	B-T028
encoding	B-T052
the	O
most	O
important	O
transcriptional	B-T045
regulators	B-T116
of	O
adipogenesis	B-T044
-	O
LXRa	B-T116
,	O
LXRb	B-T116
,	O
PPARg	B-T116
and	O
RORa	B-T116
has	O
been	O
investigated	B-T169
in	O
intraabdominal adipose tissue	B-T024
(	O
IAT	B-T024
)	O
samples	B-T167
.A	O
direct	O
correlation	B-T080
between	O
the	O
content	O
of	O
ABCA1	B-T116
and	O
ABCG1 proteins	B-T116
with	O
RORa protein	B-T116
level	B-T080
(r=0.480,	O
p<0.05;	O
r=0.435,	O
p<0.05,	O
respectively)	O
suggests	B-T078
the	O
role	O
of	O
the	O
transcription factor	B-T116
RORa	B-T116
in	O
the	O
regulation	B-T038
of	O
IAT	B-T024
ABCA1	B-T116
and	O
ABCG1 protein	B-T116
levels	B-T080
.	O
ABCA1	B-T028
and	O
ABCG1	B-T028
gene expression	B-T045
positively	O
correlated	B-T080
with	O
obesity	B-T047
indicators	B-T130
such	O
as	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
(r=0.522,	O
p=0.004;	O
r=0.594,	O
p=0.001,	O
respectively)	O
and	O
waist circumference	B-T201
(r=0.403,	O
p=0.033;	O
r=0.474,	O
p=0.013,	O
respectively).	O
The	O
development	B-T169
of	O
obesity	B-T047
is	O
associated with	B-T080
decreased	B-T081
IAT	B-T024
levels	B-T080
of	O
RORa	B-T028
and	O
LXRb	B-T028
mRNA	B-T114
(p=0.016	O
and	O
p=0.002,	O
respectively).	O
These	O
data	B-T078
suggest	B-T078
that	O
the	O
nuclear factor RORa	B-T116
can	O
play	O
a	O
significant	B-T078
role	O
in	O
the	O
regulation	B-T038
of	O
cholesterol metabolism	B-T044
and	O
control	B-T080
IAT	B-T024
expression	B-T045
of	O
ABCA1	B-T116
and	O
ABCG1	B-T116
,	O
while	O
the	O
level	B-T080
of	O
IAT	B-T024
LXRb	B-T028
gene expression	B-T045
may	O
be	O
an	O
important	O
factor	O
associated with	B-T080
the	O
development	B-T169
of	O
obesity	B-T047
.	O

Triterpenoids	B-T109
from	O
the	O
stems	B-T002
of	O
Tripterygium regelii	B-T002
Three	O
new	O
triterpenoids	B-T109
,	O
triregelolides	B-T109
A,	O
B	O
(1,	O
2),	O
and	O
triregeloic acid	B-T109
(3),	O
were	O
isolated	B-T169
from	O
the	O
stems	B-T002
of	O
Tripterygium regelii	B-T002
along	O
with	O
twenty	O
known	O
triterpene	B-T109
analogues	B-T104
(4-23).	O
The	O
structures	O
of	O
three	O
new	O
compounds	B-T109
were	O
identified	O
by	O
analyzing	O
their	O
NMR spectroscopic	B-T060
and	O
HRESIMS	B-T059
data.	O
Compounds	B-T109
4	B-T109
,	O
7	B-T109
,	O
8	B-T109
,	O
10	B-T109
,	O
13	B-T109
,	O
14	B-T109
,	O
17	B-T109
,	O
21-23	B-T109
were	O
isolated	B-T169
from	O
T. regelii	B-T002
for	O
the	O
first	O
time.	O
Compounds	B-T109
3	B-T109
,	O
5	B-T109
,	O
6	B-T109
,	O
8	B-T109
,	O
9	B-T109
,	O
10	B-T109
,	O
14	B-T109
and	O
16	B-T109
showed	O
inhibitory effects on the proliferation	B-T043
of	O
human breast cancer cells	B-T025
MCF-7	B-T025
by	O
24.1%,	O
69.6%,	O
72.8%,	O
21.6%,	O
23.1%,	O
43.3%,	O
25.5%	O
and	O
23.5%	O
(p<0.05)	O
at	O
a	O
concentration	B-T081
of	O
10μM,	O
respectively.	O

Biochemical	B-T169
evidence	O
for	O
a	O
mitochondrial	B-T026
genetic	B-T169
modifier	B-T028
in	O
the	O
phenotypic	B-T032
manifestation	B-T169
of	O
Leber's hereditary optic neuropathy	B-T047
-associated	O
mitochondrial DNA mutation	B-T019
Leber's hereditary optic neuropathy	B-T047
(	O
LHON	B-T047
)	O
is	O
the	O
most	O
common	O
mitochondrial disease	B-T047
.	O
Mitochondrial	B-T026
modifiers	B-T028
are	O
proposed	O
to	O
modify	O
the	O
phenotypic expression	B-T032
of	O
primary	O
LHON	B-T047
-associated	O
mitochondrial DNA	B-T114
(	O
mtDNA	B-T114
)	O
mutations	B-T019
.	O
In	O
this	O
study	B-T062
,	O
we	O
demonstrated	O
that	O
the	O
LHON	B-T047
susceptibility	B-T201
allele	B-T028
(	O
m.14502T > C	B-T028
,	O
p. 58I > V	B-T028
)	O
in	O
the	O
ND6 gene	B-T028
modulated	B-T082
the	O
phenotypic expression	B-T032
of	O
primary	O
LHON	B-T047
-associated	O
m.11778G > A mutation	B-T045
.	O
Twenty-two	O
Han Chinese	B-UnknownType
pedigrees	B-T170
carrying	O
m.14502T > C	B-T045
and	O
m.11778G > A mutations	B-T045
exhibited	O
significantly	O
higher	O
penetrance	B-T081
of	O
optic neuropathy	B-T047
than	O
those	O
carrying	O
only	O
m.11778G > A mutation	B-T045
.	O
We	O
performed	O
functional	B-T169
assays	B-T059
using	O
the	O
cybrid cell models	B-T025
,	O
generated	O
by	O
fusing	O
mtDNA-less ρ(o) cells	B-T025
with	O
enucleated cells	B-T025
from	O
LHON	B-T047
patients	B-T101
carrying	O
both	O
m.11778G > A	B-T045
and	O
m.14502T > C mutations	B-T045
,	O
only	O
m.14502T > C	B-T045
or	O
m.11778G > A mutation	B-T045
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtDNA	B-T114
haplogroup	B-T032
.	O
These	O
cybrids cell lines	B-T025
bearing	O
m.14502T > C mutation	B-T045
exhibited	O
mild	O
effects	B-T080
on	O
mitochondrial	B-T026
functions	B-T169
compared	O
with	O
those	O
carrying	O
only	O
m.11778G > A mutation	B-T045
.	O
However,	O
more	O
severe	O
mitochondrial	B-T026
dysfunctions	B-T077
were	O
observed	O
in	O
cell lines	B-T025
bearing	O
both	O
m.14502T > C	B-T045
and	O
m.11778G > A mutations	B-T045
than	O
those	O
carrying	O
only	O
m.11778G > A	B-T045
or	O
m.14502T > C mutation	B-T045
.	O
In	O
particular,	O
the	O
m.14502T > C mutation	B-T045
altered	O
assemble	O
of	O
complex I	B-T116
,	O
thereby	O
aggravating	O
the	O
respiratory	B-T169
phenotypes	B-T032
associated	O
with	O
m.11778G > A mutation	B-T045
,	O
resulted	O
in	O
a	O
more	O
defective	B-T169
complex I	B-T116
.	O
Furthermore,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	B-T026
ATP	B-T114
and	O
increasing	O
production	O
of	O
reactive oxygen species	B-T123
were	O
also	O
observed	O
in	O
mutant	B-T049
cells	B-T025
bearing	O
both	O
m.14502T > C	B-T045
and	O
m.11778G > A mutation	B-T045
than	O
those	O
carrying	O
only	O
11778G > A mutation	B-T045
.	O
Our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	B-T169
of	O
LHON	B-T047
that	O
were	O
manifested by	B-T080
interaction	O
between	O
primary	O
and	O
secondary	O
mtDNA	B-T114
mutations	B-T019
.	O

Improving	B-T080
Care Transitions	B-T058
Across	O
Healthcare	B-T058
Settings	B-T082
Through	O
a	O
Human Factors	B-T033
Approach	O
After	O
more	O
than	O
two	O
decades	B-T081
of	O
research	B-T062
focused	O
on	O
care transition	B-T058
improvement	B-T077
and	O
intervention	B-T061
development	B-T169
,	O
unfavorable outcome	B-T033
measures	B-T169
associated with	B-T080
care transitions	B-T058
across	O
healthcare	B-T058
settings	B-T082
persist.	O
Readmissions	B-UnknownType
rates	B-T081
remain	O
an	O
important	O
outcome	B-T169
to	O
target	B-T169
for	O
intervention	B-T061
,	O
adverse events	B-T046
associated with	B-T080
care transitions	B-T058
continue	O
to	O
be	O
an	O
issue	B-T033
,	O
and	O
patients	B-T101
are	O
often	O
dissatisfied	B-T041
with	O
the	O
quality	B-T080
of	O
their	O
care	B-T052
.	O
Currently,	O
interventions	B-T061
to	O
improve	O
care transitions	B-T058
are	O
disease	B-T047
specific	B-T080
,	O
require	O
substantial	B-T080
financial investments	B-T058
in	O
training	B-T065
allied healthcare professionals	B-T097
,	O
or	O
focus	O
primarily	O
on	O
hospital-based discharge planning	B-T058
with	O
mixed	O
results.	O
This	O
complex situation	B-T080
requires	O
a	O
method of evaluation	B-T062
that	O
can	O
provide	O
a	O
comprehensive	B-T080
,	O
in-depth	B-T082
,	O
and	O
context-driven	B-T078
investigation	B-T058
of	O
potential risks	B-T033
to	O
safe	O
care transitions	B-T058
across	O
healthcare	B-T058
settings	B-T082
,	O
which	O
can	O
lead	O
to	O
the	O
creation	B-T052
of	O
effective	B-T080
,	O
usable	B-T080
,	O
and	O
sustainable	B-T169
interventions	B-T061
.	O
A	O
systems'	O
approach	O
known	O
as	O
Human Factors and Ergonomics	B-T090
(	O
HFE	B-T090
)	O
evaluates	B-T170
the	O
factors	B-T169
in	O
a	O
system	O
that	O
affect	O
human performance	B-T052
.	O
This	O
article	B-T170
describes	O
how	O
HFE	B-T090
can	O
complement	O
and	O
further	O
strengthen	O
efforts	O
to	O
improve	B-T080
care transitions	B-T058
.	O

Adenosine	B-T114
and	O
the	O
adenosine A2A receptor agonist	B-T121
,	O
CGS21680	B-T109
,	O
upregulate	B-T044
CD39	B-T129
and	O
CD73	B-T116
expression	B-T045
through	O
E2F-1	B-T116
and	O
CREB	B-T116
in	O
regulatory T cells	B-T025
isolated	B-T169
from	O
septic	B-T169
mice	B-T015
The	O
number	O
of	O
regulatory T cells	B-T025
(	O
Treg cells	B-T025
)	O
and	O
the	O
expression	B-T045
of	O
ectonucleoside triphosphate diphosphohydrolase 1	B-T129
(	O
ENTPD1	B-T129
;	O
also	O
known	O
as	O
CD39	B-T129
)	O
and	O
5'-ectonucleotidase	B-T116
(	O
NT5E	B-T116
;	O
also	O
known	O
as	O
CD73	B-T116
)	O
on	O
the	O
Treg cell	B-T025
surface	B-T082
are	O
increased	B-T081
during	O
sepsis	B-T047
.	O
In	O
this	O
study,	O
to	O
determine	O
the	O
factors	B-T123
leading	O
to	O
the	O
high	B-T080
expression	B-T045
of	O
CD39	B-T129
and	O
CD73	B-T116
,	O
and	O
the	O
regulation of	B-T038
the	O
CD39	B-T129
/	O
CD73	B-T116
/	O
adenosine	B-T114
pathway	B-T077
in	O
Treg cells	B-T025
under	O
septic	B-T169
conditions,	O
we	O
constructed	O
a	O
mouse model	B-T050
of	O
sepsis	B-T047
and	O
separated	O
the	O
Treg cells	B-T025
using	O
a	O
flow cytometer	B-T074
.	O
The	O
Treg cells	B-T025
isolated	B-T169
from	O
the	O
peritoneal lavage	B-T058
and	O
splenocytes	B-T025
of	O
the	O
mice	B-T015
were	O
treated with	B-T061
adenosine	B-T114
or	O
the	O
specific	O
adenosine A2A receptor agonist	B-T121
,	O
CGS21680	B-T109
,	O
and	O
were	O
transfected	B-T063
with	O
specific	O
siRNA	B-T114
targeting	B-T169
E2F transcription factor 1	B-T116
(	O
E2F-1	B-T116
)	O
or	O
cyclic adenosine monophosphate (cAMP) response element-binding protein	B-T116
(	O
CREB	B-T116
),	O
which	O
are	O
predicted	O
transcription regulatory factors	B-T116
of	O
CD39	B-T129
or	O
CD73	B-T116
.	O
The	O
regulatory	B-T038
relationships	O
among	O
these	O
factors	B-T123
were	O
then	O
determined	O
by	O
western blot analysis	B-T059
and	O
dual-luciferase reporter assay	B-T059
.	O
In	O
addition,	O
changes	B-T169
in	O
adenosine metabolism	B-T044
were	O
measured	O
in	O
the	O
treated	B-T169
cells	B-T025
.	O
The	O
results	O
revealed	O
that	O
adenosine	B-T114
and	O
CGS21680	B-T109
significantly	O
upregulated	B-T044
CD39	B-T129
and	O
CD73	B-T116
expression	B-T045
(P<0.01).	O
E2F-1	B-T116
and	O
CREB	B-T116
induced	O
CD39	B-T129
and	O
CD73	B-T116
expression	B-T045
,	O
and	O
were	O
upregulated	B-T044
by	O
adenosine	B-T114
and	O
CGS21680	B-T109
.	O
Adenosine triphosphate (ATP) hydrolysis	B-T044
and	O
adenosine	B-T114
generation	B-T052
were	O
inhibited	B-T052
by	O
the	O
knockdown	B-T080
of	O
E2F-1	B-T116
or	O
CREB	B-T116
,	O
and	O
were	O
accelerated	B-T169
in	O
the	O
presence	O
of	O
CGS21680	B-T109
.	O
Based	O
on	O
these	O
results,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	B-T114
,	O
the	O
adenosine A2A receptor agonist	B-T121
,	O
E2F-1	B-T116
and	O
CREB	B-T116
are	O
the	O
possible	O
factors	B-T123
contributing	O
to	O
the	O
high	B-T080
expression	B-T045
of	O
CD39	B-T129
and	O
CD73	B-T116
on	O
the	O
Treg cell	B-T025
surface	B-T082
during	O
sepsis	B-T047
.	O
Adenosine	B-T114
and	O
its	O
A2A receptor agonist	B-T121
served	O
as	O
the	O
signal transducer	B-T044
factors	B-T123
of	O
the	O
CD39	B-T129
/	O
CD73	B-T116
/	O
adenosine	B-T114
pathway	B-T077
,	O
accelerating	B-T169
adenosine	B-T114
generation	B-T052
.	O
Our	O
study	O
may	O
benefit	O
further	O
research	B-T062
on	O
adenosine metabolism	B-T044
for	O
the	O
treatment	B-T061
of	O
sepsis	B-T047
.	O

Exploring	O
Consumer	B-T098
and	O
Patient	B-T101
Knowledge	B-T170
,	O
Behavior	B-T053
,	O
and	O
Attitude	B-T041
Toward	B-T078
Medicinal	B-T121
and	O
Lifestyle Products	B-T073
Purchased	B-T052
From	O
the	O
Internet	B-T073
:	O
A	O
Web	B-T073
-	O
Based	B-T169
Survey	B-T170
In	O
recent	O
years,	O
lifestyle products	B-T073
have	O
emerged	O
to	O
help	O
improve	B-T033
people's	B-T098
physical	B-T032
and	O
mental	B-T041
performance	B-T055
.	O
The	O
Internet	B-T073
plays	O
a	O
major	B-T080
role	B-T077
in	O
the	O
spread	B-T080
of	O
these	O
products	B-T071
.	O
However,	O
the	O
literature	B-T170
has	O
reported	O
issues	O
regarding	O
the	O
authenticity	B-T080
of	O
medicines	B-T121
purchased	B-T052
from	O
the	O
Internet	B-T073
and	O
the	O
impact	B-T080
of	O
counterfeit medicines	B-T131
on	O
public	B-T092
health	B-T078
.	O
Little	O
or	O
no data are available	B-T080
on	O
the	O
authenticity	B-T080
of	O
lifestyle products	B-T073
and	O
actual	O
toxicity	B-T080
associated with	B-T080
their	O
use	B-T169
and	O
misuse	B-T033
.	O
Our	O
aim	O
was	O
to	O
investigate	B-T169
consumer	B-T080
and	O
patient attitudes	B-T041
toward	B-T078
the	O
purchase	B-T052
of	O
lifestyle products	B-T073
from	O
the	O
Internet	B-T073
,	O
their	O
knowledge	B-T170
of	O
product	B-T071
authenticity	B-T080
and	O
toxicity	B-T080
,	O
and	O
their	O
experiences	B-T041
with	O
counterfeit	B-T080
lifestyle products	B-T073
.	O
A	O
Web	B-T073
-	O
based	B-T169
study	B-T062
was	O
performed	B-T169
between	O
May	O
2014	O
and	O
May	O
2015.	O
Uniform	B-T080
collection of data	B-T062
was	O
performed	B-T169
through	B-T169
an	O
anonymous	B-T080
online	B-T073
questionnaire	B-T170
.	O
Participants	B-T098
were	O
invited	O
worldwide	B-T082
via	O
email	B-T170
,	O
social media	B-T170
,	O
or	O
personal communication	B-T054
to	O
complete	B-T080
the	O
online	B-T073
questionnaire	B-T170
.	O
A	O
total	B-T080
of	O
320	O
participants	B-T098
completed	B-T080
the	O
questionnaire	B-T170
.	O
The	O
results	B-T169
of	O
the	O
questionnaire	B-T170
showed	O
that	O
208	O
(65.0%)	O
participants	B-T098
purchased	B-T052
lifestyle products	B-T073
from	O
the	O
Internet	B-T073
mainly	B-T080
due to	B-T169
convenience	B-T080
and	O
reduced	B-T080
cost	B-T081
.	O
More than	B-T081
half	B-T081
(55.6%,	O
178/320)	O
of	O
participants	B-T098
purchased	B-T052
cosmetic products	B-T073
,	O
whereas	O
only	O
a	O
minority	B-T080
purchased	B-T052
medicinal products	B-T121
.	O
Yet,	O
62.8%	O
(201/320)	O
of	O
participants	B-T098
were	O
aware	B-T041
of	O
the	O
presence	B-T033
of	O
counterfeit	B-T080
lifestyle products	B-T073
from	O
the	O
Internet	B-T073
,	O
and	O
11.9%	O
(38/320)	O
experienced	B-T041
counterfeit	B-T080
products	B-T071
.	O
In	O
only	O
0.9%	O
(3/320)	O
of	O
those	O
cases	B-T169
were	O
counterfeit	B-T080
lifestyle products	B-T073
reported	B-T058
to	O
authorities	B-T093
.	O
Moreover,	O
7.2%	O
(23/320)	O
of	O
the	O
participants	B-T098
experienced	B-T041
adverse effects	B-T046
due	O
to	O
counterfeit	B-T080
lifestyle products	B-T073
.	O
In	O
summary,	O
patients	B-T101
experienced	B-T041
counterfeit	B-T080
lifestyle products	B-T073
that	O
resulted in	B-T169
adverse effects	B-T046
on	O
their	O
health	B-T078
.	O
Although	O
certain	O
adverse effects	B-T046
were	O
reported	B-T058
in	O
this	O
study	B-T062
,	O
counterfeit	B-T080
products	B-T071
were	O
underreported	B-T058
to	O
authorities	B-T093
.	O
Further	O
public awareness campaigns	B-UnknownType
and	O
patient education	B-T065
are	O
needed	B-T080
.	O

It's	O
not	O
All	O
Doom	O
and	O
Gloom:	O
Prune Belly Syndrome	B-T047
Associated with VACTERL	B-T019
Prune belly syndrome	B-T047
is	O
a	O
rare	B-T080
abnormality	B-T033
;	O
its	O
association with VACTERL	B-T019
is	O
even	O
rarer	B-T080
.	O
This	O
association	B-T019
has	O
been	O
reported	B-T058
in	O
literature	B-T170
a	O
few	O
times	O
since	O
first	O
reported	B-T058
in	O
1993	O
and	O
so	O
far	O
the	O
majority	B-T054
have	O
either	O
been	O
stillbirths or died shortly after birth	B-T033
.	O
We	O
present	O
a	O
case	B-T077
of	O
Prune belly syndrome	B-T047
associated with VACTERL	B-T019
who	O
is	O
now	O
one	O
year	O
old.	O

Changes	B-T169
in	O
Cardiovascular	B-T029
Health Status	B-T080
and	O
the	O
Risk of	B-T078
New-Onset Hypertension	B-UnknownType
in	O
Kailuan	B-T098
Cohort Study	B-T081
American Heart Association	B-T093
cardiovascular	B-T029
health metrics	B-T170
are	O
intimately	O
related	O
to	O
cardiovascular diseases	B-T047
.	O
Acting	O
as	O
a	O
key	B-T080
independent	O
risk factor	B-T033
for	O
high	B-T080
morbidity	B-T081
and	O
mortality	B-T081
of	O
cardiovascular diseases	B-T047
,	O
hypertension	B-T047
and	O
its	O
relationship	B-T080
between	O
health status	B-T080
get	O
urgent	O
attention	B-T041
.	O
While	O
the	O
influence	B-T077
of	O
individual	B-T098
health status	B-T080
changes	B-T169
and	O
the	O
future	O
risk of	B-T078
new-onset hypertension	B-UnknownType
is	O
rarely	O
understood,	O
the	O
present	O
study	O
applied	O
this	O
construct	O
to	O
assess	B-T058
the	O
changes	B-T169
of	O
cardiovascular	B-T029
health status	B-T080
and	O
the	O
morbidity	B-T081
of	O
hypertension	B-T047
in	O
Kailuan	B-T098
cohort study	B-T081
in	O
north	B-T082
China	B-T083
.	O
The	O
Cardiovascular	B-T029
Health Score	B-T081
(	O
CHS	B-T081
)	O
was	O
evaluated	B-T058
by	O
the	O
follow-ups	B-T058
of	O
2006-2007,	O
2008-2009,	O
2010-2011	O
and	O
2012-2013.	O
The	O
study population	B-T098
(n	O
=	O
19381)	O
was	O
divided	B-T169
into	O
5	O
groups	B-T078
based	O
on	O
the	O
changes	B-T169
in	O
their	O
CHS score	B-T081
between	O
the	O
first	O
two	O
follow-ups	B-T058
(△CHS)	O
of	O
2006-2007	O
and	O
2008-2009	O
(≤-2,	O
-1,	O
0,	O
1,	O
≥2).	O
The	O
morbidity	B-T081
of	O
hypertension	B-T047
was	O
collected	B-T169
during	B-T079
2010-2011	O
and	O
2012-2013	O
follow-ups	B-T058
.	O
Data analysis	B-T057
showed	O
that	O
during	B-T079
a	O
median	B-T081
follow-up	B-T058
of	O
3.79±0.96	O
years,	O
morbidity	B-T081
of	O
hypertension	B-T047
had	O
a	O
graded	O
relationship	B-T080
with	O
△CHS.	O
As	O
△CHS	O
scored	O
from	O
low	O
to	O
high,	O
the	O
standardized	B-T058
morbidity	B-T081
of	O
hypertension	B-T047
for	O
all	O
participants	B-T098
were	O
81.40,	O
75.47,	O
68.37,	O
71.43	O
and	O
83.13	O
per	O
1000	O
person-year,	O
respectively.	O
An	O
increased	B-T081
△CHS	O
score	O
of	O
1	O
was	O
associated	O
with	O
a	O
10%	O
decrease	B-T081
in	O
the	O
future	B-T079
risk of	B-T078
new-onset hypertension	B-UnknownType
(HR:	O
0.90,	O
95%	O
CI	B-T081
:	O
0.88-0.92).	O
In	O
conclusion,	O
there	O
was	O
a	O
strong	O
inverse	O
relationship	B-T080
between	O
the	O
incidence	O
of	O
new-onset hypertension	B-UnknownType
and	O
elevation	B-T080
of	O
cardiovascular	B-T029
health metrics	B-T170
.	O
Population	B-T098
-wide	O
prevention	B-T080
,	O
especially	O
the	O
promotion	B-T058
of	O
lifestyle	B-T054
improvements	B-T077
,	O
is	O
critical	B-T080
to	O
reducing	B-T080
the	O
morbidity	B-T081
of	O
new-onset hypertension	B-UnknownType
.	O

An	O
HIV	B-T005
-	O
tailored	B-T058
quit	B-T052
-	O
smoking	B-T055
counselling	B-T058
pilot	B-T062
intervention	B-T061
targeting	B-T169
depressive symptoms	B-T184
plus	O
Nicotine Replacement Therapy	B-T061
Cardiovascular disease	B-T047
(	O
CVD	B-T047
)	O
rates	B-T081
among	O
people	B-T098
living with HIV/AIDS	B-T101
(	O
PHAs	B-T101
)	O
are	O
high	B-T080
.	O
Rates	B-T081
of	O
cigarette smoking	B-T055
,	O
a	O
leading	B-T169
contributor	B-T052
to	O
CVD	B-T047
among	O
PHAs	B-T101
,	O
are	O
40-70%	O
(2-3	O
times	O
higher	B-T080
than	O
the	O
general population	B-T098
).	O
Furthermore,	O
PHAs	B-T101
have	O
high	B-T080
rates	B-T081
of	O
depression	B-T048
(40-60%),	O
a	O
risk factor	B-T033
for	O
smoking	B-T055
cessation	B-T052
relapse	B-T067
.	O
The	O
current	O
pilot study	B-T062
examined	B-T033
the	O
effectiveness	B-T080
of	O
a	O
specifically	O
tailored	B-T058
5-	O
session	B-T051
smoking	B-T055
cessation	B-T052
counselling programme	B-T058
for	O
PHAs	B-T101
,	O
which	O
addressed	O
depression	B-T048
,	O
in	O
combination	O
with	O
Nicotine Replacement Therapy	B-T061
(	O
NRT	B-T061
)	O
in	O
a	O
cohort	B-T098
of	O
PHA	B-T101
smokers	B-T033
(n	O
=	O
50).	O
At	O
6-	O
month	B-T079
follow-up	B-T058
,	O
28%	O
of	O
participants	B-T098
demonstrated	O
biochemically	B-T169
verified	B-T169
abstinence	B-T061
from	O
smoking	B-T055
.	O
This	O
result	B-T033
compares	B-T052
favourably	O
to	O
other	O
quit	B-T052
-	O
smoking	B-T055
intervention	B-T061
studies	B-T062
,	O
particularly	O
given	O
the	O
high	B-T080
percentage	B-T081
of	O
HIV+	B-T034
smokers	B-T033
with	O
depression	B-T048
.	O
At	O
study	B-T062
baseline	B-T081
,	O
52%	O
of	O
HIV+	B-T034
smokers	B-T033
scored	O
above	O
the	O
clinical	B-T080
cut-off	B-T169
for	O
depression	B-T048
on	O
the	O
Centre for Epidemiological Studies - Depression (CES-D) scale	B-T170
.	O
HIV+	B-T034
smokers	B-T033
with	O
depression	B-T048
at	O
study	B-T062
baseline	B-T081
demonstrated	O
quantitatively	B-T081
lower	B-T052
depression	B-T048
at	O
6-	O
month	B-T079
follow-up	B-T058
with	O
a	O
large	B-T081
effect size	B-T081
(d	O
=	O
1),	O
though	O
it	O
did	O
not	O
reach	O
statistical significance	B-T081
(p	O
=	O
.058).	O
Furthermore,	O
those	O
with	O
depression	B-T048
were	O
no	O
more	O
likely	O
to	O
relapse	B-T067
than	O
those	O
without	O
depression	B-T048
(p	O
=	O
.33),	O
suggesting	O
that	O
our	O
counselling programme	B-T058
adequately	B-T080
addressed	O
this	O
significant	B-T078
barrier	B-T080
to	O
smoking	B-T055
cessation	B-T052
among	O
PHAs	B-T101
.	O
Our	O
pilot study	B-T062
indicates	O
the	O
importance	B-T080
of	O
tailored programmes	B-T058
to	O
help	O
PHAs	B-T101
quit	B-T052
smoking	B-T055
,	O
the	O
significance	B-T078
of	O
addressing	O
depressive symptoms	B-T184
,	O
and	O
the	O
need	O
for	O
tailored counselling programmes	B-T058
to	O
enhance	B-T052
quit	B-T052
rates	B-T081
among	O
PHAs	B-T101
.	O

Effects of	B-T080
complex	B-T080
life cycles	B-T079
on	O
genetic diversity	B-T070
:	O
cyclical parthenogenesis	B-T040
Neutral	O
patterns	O
of	O
population	B-T098
genetic diversity	B-T070
in	O
species	B-T185
with	O
complex	B-T080
life cycles	B-T079
are	O
difficult	O
to	O
anticipate	B-T078
.	O
Cyclical parthenogenesis	B-T040
(	O
CP	B-T040
),	O
in	O
which	O
organisms	B-T001
undergo	O
several	O
rounds	O
of	O
clonal	B-T024
reproduction	B-T040
followed	O
by	O
a	O
sexual event	B-T053
,	O
is	O
one	O
such	O
life cycle	B-T079
.	O
Many	O
species	B-T185
,	O
including	O
crop	B-T002
pests	B-T008
(	O
aphids	B-T204
),	O
human parasites	B-T204
(	O
trematodes	B-T204
)	O
or	O
models	B-T170
used	O
in	O
evolutionary science	B-T091
(	O
Daphnia	B-T204
),	O
are	O
cyclical parthenogens	B-T001
.	O
It	O
is	O
therefore	O
crucial	O
to	O
understand	O
the	O
impact	O
of	O
such	O
a	O
life cycle	B-T079
on	O
neutral	O
genetic diversity	B-T070
.	O
In	O
this	O
paper,	O
we	O
describe	O
distributions	B-T169
of	O
genetic diversity	B-T070
under	O
conditions	B-T080
of	O
CP	B-T040
with	O
various	O
clonal	B-T024
phase	B-T079
lengths	B-T081
.	O
Using	O
a	O
Markov chain model	B-T081
of	O
CP	B-T040
for	O
a	O
single	B-T081
locus	B-T082
and	O
individual-based	O
simulations	B-T062
for	O
two	B-T081
loci	B-T082
,	O
our	O
analysis	O
first	O
demonstrates	O
that	O
strong	O
departures	B-T052
from	O
full	O
sexuality	B-T053
are	O
observed	O
after	O
only	O
a	O
few	O
generations	B-T079
of	O
clonality	B-T080
.	O
The	O
convergence	B-T052
towards	O
predictions	B-T078
made	O
under	O
conditions	O
of	O
full	O
clonality	B-T080
during	O
the	O
clonal	B-T024
phase	B-T079
depends	O
on	O
the	O
balance	O
between	O
mutations	B-T045
and	O
genetic drift	B-T045
.	O
Second,	O
the	O
sexual event	B-T053
of	O
CP	B-T040
usually	O
resets	O
the	O
genetic diversity	B-T070
at	O
a	O
single	B-T081
locus	B-T082
towards	O
predictions	B-T078
made	O
under	O
full	O
sexuality	B-T053
.	O
However,	O
this	O
single	O
recombination	B-T045
event	O
is	O
insufficient	O
to	O
reshuffle	O
gametic phases	B-T043
towards	O
full-sexuality	B-T053
predictions	B-T078
.	O
Finally,	O
for	O
similar	O
levels	O
of	O
clonality	B-T080
,	O
CP	B-T040
and	O
acyclic	O
partial	B-T081
clonality	B-T080
(wherein	O
a	O
fixed	O
proportion	O
of	O
individuals	B-T098
are	O
clonally	B-T080
produced	O
within	O
each	O
generation	B-T079
)	O
differentially	O
affect	O
the	O
distribution	B-T169
of	O
genetic diversity	B-T070
.	O
Overall,	O
this	O
work	O
provides	O
solid	O
predictions	B-T078
of	O
neutral	O
genetic diversity	B-T070
that	O
may	O
serve	O
as	O
a	O
null model	B-T170
in	O
detecting	O
the	O
action	O
of	O
common	O
evolutionary	B-T045
or	O
demographic	B-T090
processes	B-T067
in	O
cyclical parthenogens	B-T001
(for	O
example,	O
selection	O
or	O
bottlenecks).	O

Recent	B-T079
advances	B-T078
in	O
chitosan	B-T109
-based	O
nanoparticulate	B-T073
pulmonary	B-T023
drug delivery	B-T074
The	O
advent	O
of	O
biodegradable polymer	B-T109
-	O
encapsulated	B-T080
drug	B-T121
nanoparticles	B-T073
has	O
made	O
the	O
pulmonary	B-T023
route of administration	B-T169
an	O
exciting	O
area	O
of	O
drug delivery	B-T074
research	B-T062
.	O
Chitosan	B-T109
,	O
a	O
natural	B-T169
biodegradable	B-T109
and	O
biocompatible	B-T122
polysaccharide	B-T109
has	O
received	B-T080
enormous	O
attention	O
as	O
a	O
carrier	B-T122
for	O
drug delivery	B-T074
.	O
Recently,	O
nanoparticles	B-T073
of	O
chitosan	B-T109
(	O
CS	B-T109
)	O
and	O
its	O
synthetic derivatives	B-T109
have	O
been	O
investigated	B-T169
for	O
the	O
encapsulation	B-T067
and	O
delivery	B-T169
of	O
many	O
drugs	B-T121
with	O
improved	B-T033
targeting	B-T169
and	O
controlled release	B-T079
.	O
Herein,	O
recent	B-T079
advances	B-T078
in	O
the	O
preparation	B-T052
and	O
use of	B-T169
micro-	B-T026
/	O
nanoparticles	B-T073
of	O
chitosan	B-T109
and	O
its	O
derivatives	B-T109
for	O
pulmonary	B-T023
delivery	B-T169
of	O
various	O
therapeutic agents	B-T073
(	O
drugs	B-T121
,	O
genes	B-T028
,	O
vaccines	B-T121
)	O
are	O
reviewed	B-T080
.	O
Although	O
chitosan	B-T109
has	O
wide	O
applications	B-T169
in	O
terms	O
of	O
formulations	B-T062
and	O
routes of drug delivery	B-T169
,	O
this	O
review	B-T170
is	O
focused	O
on	O
pulmonary	B-T023
delivery of drug-encapsulated nanoparticles	B-T058
of	O
chitosan	B-T109
and	O
its	O
derivatives	B-T109
.	O
In	O
addition,	O
the	O
controversial	B-T078
toxicological effects	B-T037
of	O
chitosan	B-T109
nanoparticles	B-T073
for	O
lung	B-T023
delivery	B-T169
will	O
also	O
be	O
discussed.	O

Form	B-T080
and	O
function	B-T169
in	O
gene regulatory networks	B-T044
:	O
the	O
structure	B-T082
of	O
network motifs	B-T080
determines	O
fundamental properties	B-T080
of	O
their	O
dynamical state space	B-T082
Network motifs	B-T080
have	O
been	O
studied	O
extensively	O
over	O
the	O
past	O
decade,	O
and	O
certain	O
motifs	B-T080
,	O
such	O
as	O
the	O
feed-forward loop	B-T080
,	O
play	O
an	O
important	O
role	O
in	O
regulatory networks	B-T044
.	O
Recent	B-T079
studies	B-T062
have	O
used	O
Boolean	B-T170
network	B-T169
motifs	B-T080
to	O
explore	O
the	O
link	O
between	O
form	B-T080
and	O
function	B-T169
in	O
gene regulatory networks	B-T044
and	O
have	O
found	O
that	O
the	O
structure	B-T082
of	O
a	O
motif	B-T080
does	O
not	O
strongly	O
determine	O
its	O
function	B-T169
,	O
if	O
this	O
is	O
defined	O
in	O
terms	O
of	O
the	O
gene expression	B-T045
patterns	B-T082
the	O
motif	B-T080
can	O
produce.	O
Here,	O
we	O
offer	O
a	O
different,	O
higher	B-T080
-	O
level	B-T080
definition	B-T170
of	O
the	O
'	O
function	B-T169
'	O
of	O
a	O
motif	B-T080
,	O
in	O
terms	O
of	O
two	O
fundamental properties	B-T080
of	O
its	O
dynamical state space	B-T082
as	O
a	O
Boolean	B-T170
network	B-T169
.	O
One	O
is	O
the	O
basin entropy	B-T081
,	O
which	O
is	O
a	O
complexity	B-T169
measure	B-T081
of	O
the	O
dynamics	B-T070
of	O
Boolean	B-T170
networks	B-T169
.	O
The	O
other	O
is	O
the	O
diversity	B-T080
of	O
cyclic attractor lengths	B-T081
that	O
a	O
given	O
motif	B-T080
can	O
produce.	O
Using	O
these	O
two	O
measures	B-T081
,	O
we	O
examine	O
all	O
104	O
topologically	O
distinct	O
three-node	B-T077
motifs	B-T080
and	O
show	O
that	O
the	O
structural	B-T082
properties	B-T080
of	O
a	O
motif	B-T080
,	O
such	O
as	O
the	O
presence	O
of	O
feedback loops	B-T080
and	O
feed-forward loops	B-T080
,	O
predict	O
fundamental characteristics	B-T080
of	O
its	O
dynamical state space	B-T082
,	O
which	O
in	O
turn	O
determine	O
aspects	O
of	O
its	O
functional versatility	B-T169
.	O
We	O
also	O
show	O
that	O
these	O
higher	B-T080
-	O
level	B-T080
properties	B-T080
have	O
a	O
direct	O
bearing	O
on	O
real	O
regulatory networks	B-T044
,	O
as	O
both	O
basin entropy	B-T081
and	O
cycle length	B-T081
diversity	B-T080
show	O
a	O
close	O
correspondence	O
with	O
the	O
prevalence	B-T081
,	O
in	O
neural	B-T040
and	O
genetic regulatory networks	B-T044
,	O
of	O
the	O
13	O
connected	O
motifs	B-T080
without	O
self-interactions	B-T169
that	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
literature	B-T170
.	O

Jak1	B-T116
-	O
STAT3	B-T116
Signals	B-T043
Are	O
Essential	B-T080
Effectors	B-T116
of	O
the	O
USP6	B-T116
/	O
TRE17 Oncogene	B-T116
in	O
Tumorigenesis	B-T191
Bone	B-T191
and	O
soft tissue tumors	B-T191
(	O
BSTT	B-T191
)	O
are	O
relatively	O
poorly	O
understood,	O
hampering	O
the	O
development	B-T169
of	O
effective	B-T080
therapies	B-T061
.	O
Here	O
we	O
report	B-T170
a	O
role	O
for	O
the	O
ubiquitin-specific protease 6	B-T116
(	O
USP6	B-T116
)/	O
TRE17 oncogene	B-T116
,	O
which	O
is	O
overexpressed	B-T045
upon	O
chromosome translocation	B-T049
in	O
various	O
human	B-T016
tumors	B-T191
,	O
including	O
aneurysmal bone cyst	B-T047
(	O
ABC	B-T047
),	O
and	O
the	O
related	O
benign	B-T080
lesion	B-T033
nodular fasciitis	B-T047
.	O
Ectopic expression	B-T045
of	O
USP6	B-T116
is	O
known	O
to	O
drive	O
formation	B-T169
of	O
tumors	B-T191
,	O
which	O
recapitulate	O
key features	B-T080
of	O
ABC	B-T047
and	O
nodular fasciitis	B-T047
;	O
however,	O
the	O
identity	B-T078
of	O
USP6's	B-T116
relevant	O
substrates	B-T120
has	O
been	O
obscure.	O
Here	O
we	O
report	B-T170
that	O
the	O
Jak1	B-T116
-	O
STAT3	B-T116
signaling pathway	B-T044
serves	O
as	O
an	O
essential	B-T080
effector	B-T116
of	O
USP6	B-T116
in	O
BSTT	B-T191
formation	B-T169
.	O
We	O
found	O
that	O
USP6	B-T116
directly	O
deubiquitinated	B-T044
Jak1	B-T116
,	O
leading	B-T169
to	O
its	O
stabilization	B-T033
and	O
activation	B-T045
of	O
STAT3	B-T116
.	O
The	O
tumorigenic	B-T191
potential	B-T080
of	O
USP6	B-T116
was	O
attenuated significantly by	B-T080
CRISPR	B-T114
-mediated	O
deletion	B-T045
of	O
Jak1	B-T028
or	O
STAT3	B-T028
,	O
or	O
by	O
administration	B-T169
of	O
a	O
Jak family	B-T116
inhibitor	B-T080
.	O
Analysis	B-T062
of	O
primary clinical samples	B-T077
of	O
nodular fasciitis	B-T047
confirmed	B-T033
the	O
activation	B-T045
of	O
a	O
Jak1	B-T116
-	O
STAT3	B-T116
gene signature	B-T169
in vivo	B-T062
Together,	O
our	O
studies	B-T059
highlight	O
Jak1	B-T116
as	O
the	O
first	O
identified	O
substrate	B-T120
for	O
USP6	B-T116
,	O
and	O
they	O
offer	O
a	O
mechanistic rationale	B-T078
for	O
the	O
clinical investigation	B-T058
of	O
Jak	B-T116
and	O
STAT3	B-T116
inhibitors	B-T080
as	O
therapeutics	B-T169
for	O
the	O
treatment	B-T061
of	O
bone	B-T191
and	O
soft tissue tumors	B-T191
along	O
with	O
other	O
neoplasms	B-T191
driven	O
by	O
USP6	B-T116
overexpression	B-T045
.	O
Cancer	O
Res;	O
76(18);	O
5337-47.	O
©2016	O
AACR.	O

The	O
Evidence	B-T078
Behind	O
Integrating	B-T052
Palliative Care	B-T091
Into	O
Oncology	B-T191
Practice	B-T057
Palliative care services	B-T093
provided	B-T052
alongside	O
traditional	B-T169
oncology care	B-T058
have	O
been	O
shown	O
to	O
be	O
beneficial	B-T080
to	O
patients	B-T101
and	O
families	B-T099
.	O
This	O
article	B-T170
provides	O
a	O
brief	B-T079
history	B-T090
of	O
palliative care	B-T091
,	O
a	O
pathway	O
to	O
implementing	B-T052
these	O
services	B-T057
into	O
currently	B-T079
established	B-T080
oncology programs	B-T058
,	O
and	O
a	O
brief	O
discussion	B-T054
of	O
common barriers	B-T080
.	O

Secondary Ossification Center	B-T023
Appearance	B-T080
and	O
Closure in the Pelvis	B-T061
and	O
Proximal Femur	B-T029
Variable	O
ossification	B-T042
patterns	B-T082
of	O
the	O
pelvis	B-T023
in	O
skeletally	B-T022
immature	B-T080
patients	B-T101
can	O
make	O
the	O
interpretation	O
of	O
pelvic	B-T023
radiographs	B-T060
challenging.	O
Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	B-T032
comparisons	B-T052
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary ossification centers	B-T023
.	O
This	O
study	O
evaluates	B-T058
the	O
chronology	B-T170
and	O
sex differences	B-T032
for	O
appearance	B-T080
and	O
closure of pelvic	B-T061
and	O
proximal femoral	B-T029
secondary ossification centers	B-T023
using	O
computed tomography	B-T060
(	O
CT	B-T060
).	O
Patients	B-T101
who	O
underwent	O
abdominal	B-T060
and	O
pelvic CT scans	B-T060
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma centers	B-T073
were	O
retrospectively	B-T080
reviewed	B-T080
.	O
Patients	B-T101
between	O
the	O
ages	B-T032
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-T060
of	O
the	O
pelvis	B-T023
and	O
proximal femurs	B-T029
were	O
included.	O
Patients	B-T101
with	O
a	O
history	O
of	O
orthopaedic trauma	B-T091
or	O
pathology	B-T091
affecting	B-T169
ossification	B-T042
were	O
excluded.	O
CT scans	B-T060
were	O
assessed	B-T052
for	O
the	O
appearance	B-T080
and	O
closure	B-T061
of	O
the	O
following	O
secondary ossification centers	B-T023
:	O
anterior inferior iliac spine	B-T023
(	O
AIIS	B-T023
),	O
anterior superior iliac spine	B-T023
(	O
ASIS	B-T023
),	O
femoral head	B-T023
(	O
FH	B-T023
),	O
greater trochanter	B-T023
(	O
GT	B-T023
),	O
iliac crest	B-T023
(	O
IC	B-T023
),	O
ischial tuberosity	B-T023
(	O
IT	B-T023
),	O
lesser trochanter	B-T023
(	O
LT	B-T023
),	O
posterior superior iliac spine	B-T023
(	O
PSIS	B-T023
),	O
symphysis pubis	B-T030
(	O
SP	B-T030
),	O
and	O
triradiate cartilage	B-T024
(	O
TRC	B-T024
).	O
Basic	O
descriptive	O
statistics	O
are	O
reported.	O
A	O
total	O
of	O
496	O
CT scans	B-T060
met	O
inclusion criteria	B-T080
(240	O
males	B-T032
and	O
256	O
females	B-T032
).	O
The	O
order	O
of	O
appearance	B-T080
of	O
the	O
secondary ossification centers	B-T023
was:	O
(	O
male	B-T032
)	O
GT	B-T023
,	O
LT	B-T023
,	O
AIIS	B-T023
,	O
IT	B-T023
,	O
ASIS	B-T023
,	O
PSIS	B-T023
,	O
IC	B-T023
,	O
and	O
SP	B-T030
;	O
(	O
female	B-T032
)	O
GT	B-T023
,	O
LT	B-T023
,	O
IT	B-T023
,	O
AIIS	B-T023
,	O
PSIS	B-T023
,	O
IC	B-T023
,	O
ASIS	B-T023
,	O
and	O
SP	B-T030
.	O
The	O
order	O
of	O
closure	B-T061
was	O
similar:	O
(	O
male	B-T032
)	O
TRC	B-T024
,	O
LT	B-T023
,	O
FH	B-T023
,	O
AIIS	B-T023
,	O
GT	B-T023
,	O
ASIS	B-T023
,	O
PSIS	B-T023
,	O
IT	B-T023
,	O
IC	B-T023
,	O
and	O
SP	B-T030
;	O
(	O
female	B-T032
)	O
LT	B-T023
,	O
TRC	B-T024
,	O
AIIS	B-T023
,	O
FH	B-T023
,	O
GT	B-T023
,	O
ASIS	B-T023
,	O
PSIS	B-T023
,	O
IT	B-T023
,	O
IC	B-T023
,	O
and	O
SP	B-T030
.	O
Female	B-T032
ossification centers	B-T023
appeared	O
~1	O
to	O
2	O
years	O
before	O
males	B-T032
in	O
all	O
locations	B-T029
.	O
Female	B-T032
ossification centers	B-T023
closed	O
~1	O
to	O
2	O
years	O
before	O
males	B-T032
in	O
all	O
locations	B-T029
except	O
TRC	B-T024
,	O
IC	B-T023
,	O
and	O
SP	B-T030
.	O
The	O
appearance	B-T080
and	O
closure of the pelvis	B-T061
and	O
proximal femur	B-T029
secondary ossification centers	B-T023
follow	O
a	O
predictable	O
pattern	O
of	O
development,	O
occurring	O
slightly	O
earlier	O
in	O
females	B-T032
than	O
males	B-T032
.	O
Knowledge	O
of	O
more	O
precise	O
ages of developmen	B-T033
t	O
and	O
sex differences	B-T032
better	O
characterize	O
this	O
complex	O
skeletal development	B-T040
.	O
Future	O
studies	O
may	O
use	O
secondary ossification centers	B-T023
to	O
further	O
evaluate	B-T058
skeletal maturity	B-T060
,	O
assess	O
pediatric	B-T091
pathology	B-T091
,	O
and	O
aid	O
surgical management	B-T058
.	O
Level	O
III.	O

Pediatric	B-T100
Orthopaedic	B-T022
Trauma	B-T037
and	O
Associated Injuries	B-T037
of	O
Snowmobile	B-T033
,	O
ATV	B-T067
,	O
and	O
Dirtbike Accidents	B-T067
:	O
A	O
19-Year	B-T079
Experience	O
at	O
a	O
Level	O
1	O
Pediatric	B-T100
Trauma Center	B-T073
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
type	B-T080
and	O
severity	B-T080
of	O
orthopaedic	B-T037
and	O
associated injuries	B-UnknownType
for	O
snowmobile	B-T033
,	O
All-terrain vehicles	B-T067
(	O
ATV	B-T067
)	O
and	O
motorized dirtbike accidents	B-T067
in	O
a	O
pediatric	B-T100
patient population	B-T101
.	O
A	O
total	O
of	O
758	O
patients	B-T101
who	O
presented	O
following	O
either	O
snowmobile	B-T037
(n=87),	O
ATV-related	B-T037
(n=308)	O
or	O
dirtbike (n=363)-related trauma	B-T037
at	O
our	O
institution	B-T093
between	O
1996	O
and	O
2015	O
were	O
retrospectively	O
reviewed	B-T080
.	O
A	O
total	O
of	O
441	O
axial	B-T037
and	O
appendicular fractures	B-T037
occurred	O
requiring	O
533	O
procedures	B-T169
.	O
Snowmobile	B-T033
and	O
dirtbike accidents	B-T067
were	O
associated with	B-T080
a	O
higher	O
rate	O
of	O
fractures	B-T037
(63%,	O
64%)	O
than	O
the	O
ATV group	B-T098
(50%)	O
(P=0.0008).	O
Snowmobile injuries	B-UnknownType
had	O
the	O
highest	O
rate	O
of	O
spinal	B-T037
(23%)	O
and	O
lower extremity fractures	B-T037
(53%)	O
(P=0.0004).	O
Snowmobile	B-T098
and	O
dirtbike cohorts	B-T098
had	O
higher	O
rate	O
of	O
femur fractures	B-T037
(22%,	O
17%,	O
P=0.001)	O
whereas	O
the	O
ATV cohort	B-T098
had	O
higher	O
rates	O
of	O
upper extremity	B-T023
(18%),	O
hand	B-T023
(11%),	O
scapula	B-T023
(4.6%),	O
and	O
open fractures	B-T037
(28.6%)	O
(P<0.01).	O
Head trauma	B-T037
was	O
the	O
most	O
commonly	O
associated injury	B-UnknownType
in	O
275	O
patients	B-T101
with	O
the	O
highest	O
rate	O
in	O
the	O
ATV group	B-T098
(44%)	O
who	O
also	O
had	O
the	O
highest	O
rate	O
of	O
no	O
helmet	O
use	O
(76%).	O
Snowmobile	B-T101
and	O
ATV patients	B-T101
had	O
higher	O
Injury Severity Score	B-T170
(11.3,	O
9.6)	O
than	O
dirtbike patients	B-T101
(7.8)	O
(P=0.001).	O
ATV patients	B-T101
were	O
found	O
to	O
be	O
younger	B-T079
(11.8	O
y)	O
compared	O
with	O
snowmobile	B-T101
(13.2	O
y)	O
and	O
dirtbike	B-T101
(13.5	O
y)	O
(P<0.01).	O
Pediatric	B-T100
snowmobile	B-T033
,	O
ATV	B-T067
and	O
dirtbike accidents	B-T067
result	O
in	O
severe	B-T080
orthopaedic	B-T037
and	O
associated injuries	B-UnknownType
with	O
each	O
vehicle	B-T073
demonstrating	O
significantly	O
different	O
injury	B-T037
patterns	B-T082
.	O
Injury prevention	B-T061
should	O
focus	O
on	O
improved	O
safety mechanisms	B-T058
,	O
protective gear	B-T073
,	O
safe	O
areas	O
for	O
off-road vehicle	B-T073
use	O
and	O
strict laws	B-T089
with	O
minimum	O
age	B-T032
requirements	O
LEVEL	O
OF	O
EVIDENCE::	O
Level	O
IV.	O

Hospitalist	B-T097
Co-management	B-T057
of	O
Pediatric	B-T080
Orthopaedic	B-T061
Surgical Patients	B-T101
at	O
a	O
Community Hospital	B-T073
The	O
benefits	O
of	O
hospitalist	B-T097
co-management	B-T057
of	O
pediatric	B-T080
surgical patients	B-T101
include	O
bettering	B-T080
patient safety	B-T058
,	O
decreasing	B-T033
negative	B-T080
patient outcomes	B-T078
,	O
providing	O
comprehensive medical care	B-T058
,	O
and	O
establishing	O
a	O
dedicated resource	B-T078
to	O
patients	B-T101
for	O
postoperative care	B-T058
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
characterize	B-T052
the	O
nature	B-T078
of	O
patients	B-T101
co-managed	O
by	O
a	O
pediatric	B-T080
hospitalist	B-T097
.	O
The	O
authors	B-T097
hypothesize	B-T078
that	O
hospitalist	B-T097
co-management	B-T057
is	O
safe	B-T033
and	O
efficacious	B-T080
in	O
pediatric	B-T080
orthopaedic	B-T061
surgical patients	B-T101
who	O
are	O
admitted	B-T058
to	O
a	O
community hospital	B-T073
.	O
A	O
retrospective review	B-T062
was	O
performed	O
of	O
all	O
pediatric	B-T080
orthopaedic	B-T061
surgical patients	B-T101
admitted	B-T058
to	O
a	O
community hospital	B-T073
who	O
were	O
co-managed	O
by	O
a	O
pediatric	B-T080
hospitalist	B-T097
.	O
Indications	O
for	O
hospitalization	B-T058
included	O
pain control	B-T061
,	O
antibiotic infusion	B-T061
,	O
and	O
need	O
for	O
neurovascular monitoring	B-T058
.	O
Parameters	B-T077
of	O
postoperative care	B-T058
and	O
co-management	B-T057
were	O
assessed	B-T052
,	O
including	O
presence	B-T033
of	O
complications	B-T078
,	O
medication introduction	B-T061
or	O
adjustment	O
by	O
the	O
hospitalist	B-T097
,	O
follow-up	B-T058
adherence	B-T169
,	O
and	O
readmission	B-T058
/	O
complication	B-T078
rates	B-T081
after	O
discharge	B-T058
.	O
Thirty-two	O
patients	B-T101
were	O
assessed	B-T052
with	O
an	O
average age	B-T032
of	O
8.8	O
years	B-T079
.	O
Twenty-five	O
percent	B-T081
of	O
patients	B-T101
had	O
an	O
associated comorbidity	B-T078
,	O
including	O
asthma	B-T047
,	O
attention deficit disorder	B-T048
,	O
and/or	O
autism	B-T048
.	O
The	O
pediatric	B-T080
hospitalist	B-T097
added	O
pain medication	B-T061
to	O
the	O
original	O
postoperative orders	B-T058
placed	O
by	O
the	O
orthopaedics team	B-T097
in	O
44	O
percent	B-T081
of	O
patients	B-T101
(14	O
of	O
the	O
32)	O
either	O
for	O
breakthrough pain	B-T184
or	O
better	O
long-term	O
coverage.	O
Additionally,	O
25	O
percent	B-T081
of	O
patients	B-T101
had	O
pain medication	B-T061
adjusted	O
from	O
the	O
original	O
dosing	B-T081
and	O
schedule	B-T058
.	O
The	O
hospitalist	B-T097
team	B-T096
contacted	O
the	O
surgeon	B-T097
about	O
the	O
four	O
patients	B-T101
(12.5	O
percent	B-T081
).	O
In	O
three	O
of	O
the	O
cases,	O
the	O
surgeon	B-T097
was	O
contacted	O
to	O
discuss	O
pain medication	B-T061
,	O
and	O
one	O
patient	B-T101
woke	O
up	O
agitated	O
from	O
anesthesia	B-T061
,	O
necessitating	O
a	O
visit	O
from	O
the	O
surgeon	B-T097
on	O
the	O
pediatrics	O
floor.	O
The	O
length	O
of	O
stay	O
was	O
one	O
day	O
for	O
all	O
patients	B-T101
.	O
The	O
hospitalists	B-T097
rounded	O
on	O
and	O
discharged patients	B-T058
the	O
subsequent	O
morning.	O
All	O
patients	B-T101
were	O
given	O
a	O
follow-up appointment and schedule	B-UnknownType
by	O
the	O
hospitalist	B-T097
team,	O
and	O
every patient	B-T101
followed up	B-T058
accordingly	O
within	O
ten	O
days	B-T079
of	O
discharge	B-T058
.	O
No	O
complications	B-T078
or	O
hospital readmissions	B-T058
occurred	O
within	O
thirty	O
days	B-T079
of	O
discharge	B-T058
.	O
Hospitalist	B-T097
co-management	B-T057
of	O
pediatric	B-T080
orthopaedic	B-T061
surgical patients	B-T101
patients	B-T101
in	O
a	O
community hospital	B-T073
allows	O
for	O
better	O
medical comorbidity	B-T078
and	O
medication management	B-T058
.	O
Hospitalist	B-T097
s	O
can	O
provide	O
closer	O
observation	O
during	O
the	O
inpatient stay	B-T169
and	O
help	B-T080
streamline communication	B-T054
between	O
providers	B-T097
and	O
patients	B-T101
while	O
allowing	O
the	O
surgeon	B-T097
the	O
ability	O
to	O
be	O
more	O
mobile.	O
Co-management	B-T057
is	O
safe	B-T033
and	O
efficacious	B-T080
in	O
pediatric	B-T080
orthopaedic	B-T061
surgical patients	B-T101
patients	B-T101
who	O
are	O
admitted	B-T058
to	O
a	O
community hospital	B-T073
.	O

Extra	O
carbohydrate binding module	B-T116
contributes	B-T052
to	O
the	O
processivity	B-T080
and	O
catalytic activity	B-T044
of	O
a	O
non-modular hydrolase	B-T116
family	O
5 endoglucanase	B-T116
from	O
Fomitiporia mediterranea MF3/22	B-T004
FmEG	B-T116
from	O
Fomitiporia mediterranea	B-T004
is	O
a	O
non-modular endoglucanase	B-T116
composed	O
of	O
a	O
24-amino acids	B-T116
extension	B-T169
and	O
13-amino acids	B-T116
linker-like peptide	B-T116
at	O
the	O
N-terminus	B-T087
and	O
a	O
312-amino acids	B-T116
GH5 catalytic domain	B-T087
(	O
CD	B-T087
)	O
at	O
the	O
C-terminus	B-T087
.	O
In	O
this	O
study,	O
six	O
FmEG	B-T116
derivatives	O
with	O
deletion	B-T052
of	O
N-terminal fragments	B-T116
or	O
fusion	B-T116
with	O
an	O
extra	O
family 1 carbohydrate-binding module	B-T116
(	O
CBM1	B-T116
)	O
was	O
constructed	O
in	O
order	O
to	O
evaluate	O
the	O
contribution	B-T052
of	O
CBM1	B-T116
to	O
FmEG	B-T116
processivity	B-T080
and	O
catalytic activity	B-T044
.	O
FmEG	B-T116
showed	O
a	O
weak	O
processivity	B-T080
and	O
released	O
cellobiose	B-T109
(	O
G2	B-T109
)	O
and	O
cellotriose	B-T109
(	O
G3	B-T109
)	O
as	O
main end products	B-T071
,	O
and	O
cellotriose	B-T109
(	O
G4	B-T109
)	O
as	O
minor end product	B-T071
from	O
filter paper	B-T074
(	O
FP	B-T074
),	O
but	O
more	O
amount	O
of	O
G4	B-T109
was	O
released	O
from	O
regenerated amorphous cellulose	B-T109
(	O
RAC	B-T109
).	O
All	O
derivatives	B-T109
had	O
similar	O
activity	O
on	O
carboxymethylcellulose	B-T109
(	O
CMC	B-T109
)	O
with	O
the	O
same optimal	B-T080
pH	B-T081
(7.0)	O
and	O
temperature	B-T081
(50°C).	O
However,	O
fusing	O
an	O
extra	O
CBM1	B-T116
to	O
FmEG△24	B-T116
or	O
FmEG△37	B-T116
with	O
flexible peptide	B-T116
significantly	O
improved	O
its	O
processivity	B-T080
and	O
catalytic activity	B-T169
to	O
FP	B-T074
and	O
RAC	B-T109
.	O
Overall,	O
1.79-	O
and	O
1.84-fold	O
increases	O
in	O
the	O
soluble	B-T080
/insoluble	O
product	O
ratio	B-T081
on	O
FP	B-T074
,	O
and	O
1.38-	O
and	O
1.39-fold	O
increases	O
on	O
RAC	B-T109
,	O
compared	O
to	O
FmEG△24	B-T116
,	O
were	O
recorded	O
for	O
CBM1	B-T116
-	O
FmEG△24	B-T116
and	O
CBM1	B-T116
-linker-	O
FmEG△24	B-T116
,	O
respectively.	O
Meanwhile,	O
they	O
displayed	O
2.64-	O
and	O
2.67-fold more activity	B-T033
on	O
RAC	B-T109
,	O
and	O
1.68-	O
and	O
1.77-fold	O
on	O
FP	B-T074
,	O
respectively.	O
Similar	O
improvement	O
was	O
also	O
obtained	O
for	O
CBM1	B-T116
-linker-	O
FmEG△37	B-T116
as	O
compared	O
with	O
FmEG△37	B-T116
.	O
Interestingly,	O
fusion	O
of	O
an	O
extra	O
CBM1	B-T116
with	O
FmEG	B-T116
also	O
caused	O
an	O
alteration	B-T078
of	O
cleavage pattern	B-T067
on	O
insoluble celluloses	B-T109
.	O
Our	O
results	O
suggest	O
that	O
such	O
improvements	O
in	O
processivity	B-T080
and	O
catalytic activity	B-T169
may	O
arise	O
from	O
CBM1	B-T116
binding affinity	B-T044
.	O
The	O
N-terminal 24- or 37-amino acids	B-T116
may	O
serve	O
as	O
linker	O
for	O
sufficient	O
spatial separation	B-T082
of	O
the	O
two domains	B-T087
required	O
for	O
processivity	B-T080
and	O
catalytic activity	B-T169
.	O
In	O
addition,	O
deletion	B-T052
of	O
the	O
N-terminal 24- or 37-amino acids	B-T116
led	O
to	O
significant reduction	B-T080
in	O
thermostability	B-T070
but	O
not	O
the	O
enzymatic activity	B-T044
.	O

Overnight	B-T079
switching	B-T058
from	O
oxcarbazepine	B-T109
to	O
eslicarbazepine acetate	B-T109
:	O
an	O
observational study	B-T062
There	O
are	O
clinical situations	B-T067
where	O
it	O
might	O
be	O
appropriate	B-T080
to	O
switch	B-T058
patients	B-T101
from	O
immediate-release	B-T122
oxcarbazepine	B-T109
(	O
OXC	B-T109
)	O
to	O
eslicarbazepine acetate	B-T109
(	O
ESL	B-T109
).	O
We	O
investigated	B-T169
the	O
effects of	B-T080
transitioning	O
patients	B-T101
overnight	B-T079
from	O
OXC	B-T109
to	O
ESL	B-T109
.	O
A	O
retrospective	B-T062
,	O
single-center study	B-T062
was	O
conducted	O
in	O
which	O
patients	B-T101
with	O
drug-resistant	B-T038
focal epilepsy	B-T047
on	O
a	O
stable	O
dose	B-T081
of	O
immediate-release	B-T122
OXC	B-T109
for	O
at	O
least	O
4 weeks	B-T079
were	O
switched	B-T058
overnight	B-T079
to	O
ESL	B-T109
.	O
Patients	B-T101
were	O
switched	B-T058
because	O
they	O
experienced	O
persistent	B-T079
seizures	B-T184
with	O
OXC	B-T109
but	O
were	O
unable	B-T033
to	O
tolerate	B-T080
increased	O
OXC	B-T109
dosing	B-T081
due	O
to	O
adverse events	B-T046
.	O
Tolerability	B-T080
was	O
assessed	B-T052
using	O
the	O
Adverse Events Profile	B-T170
(	O
AEP	B-T170
),	O
quality of life	B-T078
was	O
assessed	B-T052
using	O
the	O
Quality of Life in Epilepsy Inventory 10	B-T170
(	O
QOLIE-10	B-T170
),	O
and	O
alertness	B-T041
was	O
assessed	B-T052
as	O
reaction time	B-T079
using	O
a	O
subtest	O
of	O
the	O
Test Battery for Attention Performance version 2.3	B-T073
.	O
Assessments	B-T058
were	O
performed	B-T169
immediately	B-T079
prior to	B-T079
and	O
5 days	B-T079
after	O
switching	B-T058
from	O
OXC	B-T109
to	O
ESL	B-T109
(	O
days	B-T079
0	O
and	O
5,	O
respectively).	O
The	O
analysis	B-T062
included	O
21	O
patients	B-T101
(12	O
women	B-T098
,	O
9	O
men	B-T098
;	O
mean age 36 years	B-T033
).	O
After	O
switching	B-T058
from	O
OXC	B-T109
to	O
ESL	B-T109
,	O
there	O
were	O
significant	O
improvements	B-T077
in	O
mean scores	B-T081
for	O
AEP	B-T170
(P<.001),	O
QOLIE-10	B-T170
(P=.001),	O
and	O
alertness	B-T041
(P<.05).	O
Adverse Events Profile	B-T170
total scores	B-T081
improved	B-T033
for	O
21/21	O
(100.0%)	O
patients	B-T101
,	O
QOLIE-10	B-T170
total scores	B-T081
improved	B-T033
for	O
17/21	O
(81.0%)	O
patients	B-T101
,	O
and	O
alertness	B-T041
scores	B-T081
improved	B-T033
for	O
16/21	O
(76.2%)	O
patients	B-T101
.	O
In	O
this	O
short-term	B-T079
,	O
single-center study	B-T062
,	O
an	O
overnight	B-T079
switch	B-T058
from	O
twice-daily	B-T079
OXC	B-T109
to	O
once-daily	B-T079
ESL	B-T109
in	O
patients	B-T101
with	O
drug-resistant	B-T038
focal epilepsies	B-T047
resulted	B-T033
in	O
improvements	B-T077
in	O
side effects	B-T046
,	O
quality of life	B-T078
,	O
and	O
alertness	B-T041
.	O

Complete	B-T080
Genome	B-T028
Sequences	B-T086
of	O
Three	O
Outbreak	B-T067
-Associated	O
Legionella pneumophila	B-T007
Isolates	B-T123
We	O
report	O
here	O
the	O
complete	B-T080
genome	B-T028
sequences	B-T086
of	O
three	O
Legionella pneumophila	B-T007
isolates	B-T123
that	O
are	O
associated with	B-T080
a	O
Legionnaires' disease	B-T047
outbreak	B-T067
in	O
New York	B-T083
in	O
2012.	O
Two	O
clinical	B-T080
isolates	B-T123
(	O
D7630	B-T007
and	O
D7632	B-T007
)	O
and	O
one	O
environmental	B-T082
isolate	B-T123
(	O
D7631	B-T007
)	O
were	O
recovered	B-T080
from	O
this	O
outbreak	B-T067
.	O
A	O
single	O
isolate-specific	B-T123
virulence	B-T038
gene	B-T028
was	O
found	O
in	O
D7632	B-T007
.	O
These	O
isolates	B-T123
were	O
included	O
in	O
a	O
large	O
study	O
evaluating	B-T058
the	O
genomic	B-T028
resolution	B-T077
of	O
various	O
bioinformatics	B-T091
approaches	B-T169
for	O
L. pneumophila	B-T007
serogroup 1	B-T170
isolates	B-T123
.	O

Complete	O
Genome Sequence Analysis	B-T059
of	O
a	O
Naturally	O
Reassorted	O
Infectious Bursal Disease Virus	B-T005
from	O
India	B-T083
The	O
novel	O
infectious bursal disease virus	B-T005
(	O
IBDV	B-T005
)	O
isolate	B-T123
BGE14/ABT1/MVC/India	B-T005
is	O
a	O
very	O
virulent	B-T080
IBDV	B-T005
that	O
was	O
isolated	B-T123
from	O
broiler flocks	B-T012
in	O
southern	O
parts	O
of	O
India	B-T083
during	O
2014.	O
Here,	O
we	O
report,	O
for	O
the	O
first	O
time	O
in	O
India	B-T083
,	O
the	O
complete	O
genome sequence	B-T028
of	O
BGE14/ABT1/MVC/India	B-T005
,	O
a	O
reassortment	O
strain	B-T001
with	O
segments A and B	B-T028
derived	O
from	O
a	O
very	O
virulent	B-T080
IBDV	B-T005
strain	B-T001
and	O
an	O
attenuated	B-T052
IBDV	B-T005
,	O
respectively.	O
The	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic exchange	B-T045
between	O
attenuated	B-T052
and	O
very	O
virulent	B-T080
strains	B-T001
of	O
IBDV	B-T005
circulating	B-T169
in the field	B-T082
.	O

Patient Satisfaction	B-T080
With	O
Postpartum	B-T079
Teaching	B-T065
Methods	B-T170
Postpartum	B-T079
discharge instructions	B-T170
are	O
a	O
crucial	O
part	O
of	O
a	O
mother's	B-T099
birth	B-T040
experience	B-T041
.	O
Finding	B-T033
the	O
method	B-T170
to	O
provide	O
those	O
discharge instructions	B-T170
in	O
a	O
manner	O
that	O
increases	B-T169
the	O
mother's	B-T099
satisfaction	B-T041
with	O
her	O
hospital	B-T073
experience	B-T041
is	O
important.	O
This	O
quasi-experimental study	B-T062
examined	B-T033
the	O
relationship	B-T080
between	O
new	B-T080
mothers'	B-T099
interaction	B-T033
with	O
nurses	B-T097
providing	O
postpartum	B-T079
instructions	B-T170
by	O
the	O
traditional	B-T169
and	O
class	O
methods	B-T170
and	O
their	O
satisfaction	B-T041
with	O
discharge teaching	B-T065
.	O
The	O
results	O
indicated	O
new	B-T080
mothers	B-T099
were	O
satisfied	B-T041
with	O
both	O
methods	B-T170
of	O
discharge teaching	B-T065
;	O
however,	O
they	O
were	O
more	O
likely	O
to	O
report	O
stronger	O
agreement	B-T054
with	O
overall	O
satisfaction	B-T041
with	O
the	O
traditional	B-T169
method	B-T170
of	O
discharge teaching	B-T065
than	O
with	O
attending	B-T169
the	O
discharge class	B-T065
.	O

Splicing	B-T045
variants	O
of	O
ADAR2	B-T116
and	O
ADAR2	B-T116
-mediated	O
RNA editing	B-T045
in	O
glioma	B-T191
The	O
roles	O
of	O
alternative splicing	B-T045
and	O
RNA editing	B-T045
in	O
gene regulation	B-T045
and	O
transcriptome	B-T086
diversity	O
are	O
well	O
documented.	O
Adenosine deaminases	B-T116
acting	O
on	O
RNA	B-T114
(	O
ADARs	B-T116
)	O
are	O
responsible	O
for	O
adenosine-to-inosine (A-to-I) editing	B-T045
and	O
exemplify	O
the	O
complex	O
association	O
between	O
RNA editing	B-T045
and	O
alternative splicing	B-T045
.	O
The	O
self-editing	B-T045
activity	O
of	O
ADAR2	B-T116
,	O
which	O
acts	O
on	O
its	O
own	O
pre-mRNA	B-T114
,	O
leads	O
to	O
its	O
alternative splicing	B-T045
.	O
Alternative splicing	B-T045
occurs	O
independently	O
at	O
nine	O
splicing	B-T045
sites	O
on	O
ADAR2	B-T116
pre-mRNA	B-T114
,	O
generating	O
numerous	O
alternative splicing	B-T045
variants	O
with	O
various	O
catalytic activities	B-T044
.	O
A-to-I RNA editing	B-T045
is	O
important	O
in	O
a	O
range	O
of	O
physiological processes	B-T039
in	O
humans	B-T016
and	O
is	O
associated	O
with	O
several	O
diseases	B-T047
,	O
including	O
amyotrophic lateral sclerosis	B-T047
,	O
mood disorders	B-T048
,	O
epilepsy	B-T047
and	O
glioma	B-T191
.	O
Reduced	O
editing	B-T045
at	O
the	O
glutamine	B-T116
/	O
arginine	B-T116
site	O
of	O
the	O
AMPA receptor subunit GluA2	B-T116
in	O
glioma	B-T191
,	O
without	O
any	O
alteration	O
in	O
ADAR2	B-T116
expression	B-T045
,	O
is	O
a	O
notable	O
phenomenon.	O
Several	O
studies	O
have	O
tried	O
to	O
explain	O
this	O
alteration	B-T078
in	O
the	O
catalytic activity	B-T044
of	O
ADAR2	B-T116
;	O
however,	O
the	O
underlying	O
mechanism	O
remains	O
unclear.	O
The	O
present	O
review	B-T170
summarizes	O
the	O
relevant	O
literature	B-T170
and	O
shares	O
experimental results	B-T033
concerning	O
ADAR2	B-T116
alternative splicing	B-T045
.	O
In	O
particular,	O
the	O
present	O
review	B-T170
demonstrates	O
that	O
shifts	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
active	O
and	O
inactive	O
splicing	B-T045
variants	O
of	O
ADAR2	B-T116
may	O
reduce	O
the	O
ADAR2	B-T116
editing	B-T045
activity	O
in	O
glioma	B-T191
.	O
Dominant	O
expression	B-T045
of	O
ADAR2	B-T116
splicing	B-T045
variant	O
with	O
low	O
enzyme activity	B-T044
causes	O
reduced	O
RNA editing	B-T045
of	O
GluA2 subunit	B-T116
at	O
the	O
glutamine	B-T116
/	O
arginine	B-T116
site	O
in	O
glioma	B-T191
.	O

Heat-shock protein 60	B-T116
of	O
Porphyromonas gingivalis	B-T007
may	O
induce	O
dysfunction	B-T077
of	O
human umbilical endothelial cells	B-T025
via	O
regulation	B-T038
of	O
endothelial-nitric oxide synthase	B-T116
and	O
vascular endothelial-cadherin	B-T116
Accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	B-T047
was	O
an	O
independent	O
risk factor	B-T033
for	O
coronary heart disease	B-T047
(	O
CAD	B-T047
).	O
Porphyromonus gingivalis	B-T007
(	O
P. gingivalis	B-T007
),	O
a	O
major	O
periodontal	B-T080
pathogen	B-T001
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory response	B-T046
of	O
CAD	B-T047
in vivo	B-T082
.	O
The	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
identify	O
whether	O
P. gingivalis	B-T007
heat-shock protein 60	B-T116
(	O
HSP60	B-T116
)	O
induced	O
the	O
dysfunction	B-T077
of	O
human umbilical vein endothelial cells	B-T025
(	O
HUVECs	B-T025
)	O
in vitro	B-T080
.	O
HUVECs	B-T025
were	O
stimulated	B-T070
with	O
a	O
range	O
of	O
P. gingivalis	B-T007
HSP60	B-T116
concentrations	B-T081
(1,	O
10	O
and	O
100	O
ng/l)	O
at	O
different	O
time-points	B-T079
.	O
The	O
levels	B-T080
of	O
vascular endothelial (VE)-cadherin	B-T116
,	O
endothelial nitric oxide synthase	B-T116
(	O
eNOS	B-T116
)	O
and	O
cysteinyl aspartate-specific protease-3	B-T116
(	O
caspase-3	B-T116
)	O
were	O
measured	O
using	O
western blot	B-T059
analysis	B-T062
.	O
The	O
apoptotic	B-T043
rate	B-T081
of	O
HUVECs	B-T025
was	O
detected	O
using	O
flow cytometry	B-T059
.	O
P. gingivalis	B-T007
HSP60	B-T116
at	O
a	O
concentration	B-T081
of	O
10	O
ng/l	O
significantly	O
decreased	O
the	O
expression	B-T045
levels	B-T080
of	O
VE-cadherin	B-T116
and	O
eNOS protein	B-T116
at	O
24	O
h	B-T079
stimulation	B-T070
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	B-T116
was	O
identified	O
following	O
a	O
low dose	B-T081
of	O
P. gingivalis	B-T007
HSP60	B-T116
(1	O
ng/l).	O
P. gingivalis	B-T007
HSP60	B-T116
at	O
100	O
ng/l	O
significantly	O
downregulated	B-T044
the	O
expression	B-T045
levels	B-T080
of	O
VE-cadherin	B-T116
and	O
eNOS protein	B-T116
at	O
12	O
h	O
in	O
HUVECs	B-T025
.	O
However,	O
the	O
cleavage	B-T067
of	O
caspase-3	B-T116
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	B-T081
.	O
Consistently,	O
P. gingivalis	B-T007
HSP60	B-T116
induced	O
apoptosis	B-T043
of	O
HUVECs	B-T025
in	O
a	O
concentration	B-T081
-	O
dependent	B-T169
manner.	O
These	O
results	B-T169
indicated	O
that	O
P. gingivalis	B-T007
HSP60	B-T116
may	O
induce	O
dysfunction	B-T077
and	O
apoptosis	B-T043
in	O
HUVECs	B-T025
via	O
downregulating	B-T044
the	O
expression	B-T045
levels	B-T080
of	O
VE-cadherin	B-T116
and	O
eNOS	B-T116
,	O
and	O
promoting	O
the	O
cleavage	B-T067
of	O
caspase-3	B-T116
.	O

Estradiol	B-T109
prodrugs	B-T120
(	O
EP	B-T120
)	O
for	O
efficient	O
oral	B-T061
estrogen treatment	B-T169
and	O
abolished	O
effects	O
on	O
estrogen	B-T109
modulated	O
liver functions	B-T042
Oral	B-T061
compared	O
to	O
parenteral	B-T061
estrogen administration	B-T169
is	O
characterized	O
by	O
reduced	O
systemic	B-T169
but	O
prominent	O
hepatic	B-T029
estrogenic effects	B-T033
on	O
lipids	B-T109
,	O
hemostatic factors	B-T042
,	O
GH	B-T116
-/	O
IGF I	B-T116
axis,	O
angiotensinogen	B-T116
.	O
In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic effects	B-T039
of	O
oral treatment	B-T061
,	O
estradiol	B-T109
(	O
E2	B-T109
)	O
prodrugs	B-T120
(	O
EP	B-T120
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver tissue	B-T023
as	O
inactive	O
molecules.	O
Carbone17-OH sulfonamide [-O2-NH2] substituted esters	B-T104
of	O
E2	B-T109
(	O
EC508	B-T109
,	O
others)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic anhydrase II	B-T116
(	O
CA-II	B-T116
)	O
binding	B-T044
.	O
CA II	B-T116
in	O
erythrocytes	B-T025
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
EP	B-T120
from	O
portal vein blood	B-T024
during	O
liver	B-T023
passage	B-T082
.	O
Ovariectomized	B-T033
(	O
OVX	B-T033
,	O
day	O
minus	O
14)	O
rats	B-T015
were	O
orally treated	B-T061
once	O
daily	O
from	O
day	O
1-3.	O
Sacrifice	O
day	O
4.	O
Uteri	B-T023
were	O
dissected	B-T169
and	O
weighed	B-T059
.	O
Cholesterol fractions	B-T059
and	O
angiotensinogen	B-T059
were	O
determined	O
in	O
plasma	B-T031
.	O
Oral E2	B-T200
and	O
ethinyl estradiol	B-T109
(	O
EE	B-T109
)	O
generated	O
dose	O
related	O
uterine	B-T023
growth	B-T040
and	O
important	O
hepatic	B-T029
estrogenic effects	B-T033
.	O
EP	B-T120
induced	O
uterine growth	B-T042
at	O
about	O
hundred-fold	O
lower	O
doses.	O
This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	B-T031
cholesterol	B-T109
or	O
angiotensinogen	B-T116
.	O
Preliminary	O
pharmacokinetic studies	B-T062
with	O
EC508	B-T109
used	O
intravenous	B-T082
and	O
oral administration	B-T061
in	O
male	B-T032
rats	B-T015
.	O
Resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B-T061
bioavailability	B-T081
.	O
Further	O
high	O
blood	B-T031
-	O
but	O
low	O
plasma	B-T031
concentrations	O
indicated	O
erythrocyte	B-T025
binding	B-T052
of	O
EC508	B-T109
in vivo	B-T082
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B-T023
passage	B-T082
.	O
Very	O
high	O
systemic	B-T169
estrogenicity	B-T109
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	B-T029
estrogenic effects	B-T033
is	O
evidence	O
for	O
a	O
systemic	B-T169
release	O
of	O
E2	B-T109
from	O
sulfonamide EP	B-T120
.	O
In	O
conclusion,	O
tested	O
oral	B-T061
EP	B-T120
bypass	O
the	O
liver	B-T023
in	O
erythrocytes	B-T025
furnishing	O
systemic	B-T169
estradiol	B-T109
at	O
hydrolysis	B-T070
.	O
This	O
mechanism	O
avoids	O
the	O
hepatic	B-T029
estrogenic	B-UnknownType
impact	O
of	O
conventional	O
oral	B-T061
estrogen therapy	B-T061
.	O

Differences	B-T080
in	O
pain	B-T184
experience	B-T041
and	O
cooperation	B-T055
between	O
consecutive surgeries	B-T061
in	O
patients	B-T101
undergoing	O
phacoemulsification	B-T061
The	O
purpose	O
of	O
this	O
study	B-T062
is	O
to	O
compare	O
pain	B-T184
experience	B-T041
and	O
cooperation	B-T055
between	O
consecutive surgeries	B-T061
in	O
patients	B-T101
undergoing	O
phacoemulsification	B-T061
in	O
both	O
eyes	B-T023
,	O
using	O
sub-Tenon's local anesthesia	B-T061
without	O
sedation	B-T061
.	O
In	O
this	O
study	B-T062
,	O
268	O
patients	B-T101
with	O
bilateral senile cataracts	B-T047
were	O
recruited.	O
All	O
operations	B-T061
were	O
performed	O
without	O
sedation	B-T061
,	O
using	O
a	O
clear	O
corneal	B-T023
phacoemulsification technique	B-T061
and	O
sub-Tenon's local anesthesia	B-T061
,	O
by	O
one	O
of	O
four	O
surgeons	B-T097
.	O
The	O
first	O
surgery	B-T061
was	O
performed	O
on	O
the	O
eye	B-T023
with	O
the	O
higher	O
grade	O
cataract	B-T020
.	O
The	O
other	O
eye	B-T023
was	O
operated	B-T052
on	O
within	O
3 months	B-T079
by	O
the	O
same	O
surgeon	B-T097
(mean	O
interval	O
1.9	O
±	O
1.1	O
months	B-T079
).	O
All	O
patients	B-T101
were	O
asked	O
to	O
grade	O
their	O
pain	B-T184
experience	B-T041
during	O
induction	B-T061
and	O
maintenance	B-T052
of	O
anesthesia	B-T061
and	O
also	O
during	O
the	O
phacoemulsification surgery	B-T061
,	O
using	O
a	O
visual analogue scale	B-T060
(	O
VAS	B-T060
)	O
from	O
0	O
(	O
no pain	B-T033
)	O
to	O
10	O
(	O
unbearable pain	B-T184
)	O
administered	O
after	O
the	O
surgery	B-T061
.	O
The	O
cooperation	B-T055
of	O
the	O
patient	B-T101
was	O
graded	O
from	O
0	O
(no	O
event)	O
to	O
3	O
(	O
markedeye	B-T039
and	O
head movement	B-T040
and	O
lid squeezing	B-T184
)	O
by	O
the	O
attending	O
surgeon	B-T097
.	O
The	O
VAS scores	B-T081
and	O
cooperation	B-T055
scores	B-T081
of	O
the	O
patients	B-T101
were	O
the	O
outcome measurements	B-T081
.	O
The	O
mean pain score	B-T033
was	O
2.11	O
±	O
0.79	O
in	O
the	O
first	O
eye	B-T023
and	O
3.33	O
±	O
0.80	O
in	O
the	O
second	O
eye	B-T023
during	O
the	O
administration	B-T061
of	O
sub-Tenon's anesthesia	B-T061
,	O
and	O
1.50	O
±	O
0.60	O
in	O
the	O
first	O
eye	B-T023
and	O
2.10	O
±	O
0.57	O
in	O
the	O
second	O
eye	B-T023
during	O
the	O
phacoemulsification surgery	B-T061
.	O
The	O
patient cooperation	B-T055
score	B-T081
was	O
1.60	O
±	O
0.75	O
in	O
the	O
first	O
surgery	B-T061
and	O
2.08	O
±	O
0.72	O
in	O
the	O
second	O
surgery	B-T061
.	O
The	O
differences	B-T080
between	O
the	O
first	O
and	O
second	O
surgeries	B-T061
were	O
statistically	O
significant	O
for	O
all	O
outcome measures	B-T081
(p	O
<	O
0.01).	O
Patients	B-T101
who	O
previously	O
underwent	O
phaco surgery	B-T061
in	O
one	O
eye	B-T023
experienced	O
more	O
pain	B-T184
and	O
showed	O
worse	B-T033
cooperation	B-T055
during	O
the	O
phaco surgery	B-T061
in	O
the	O
second	O
eye	B-T023
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	B-T061
,	O
viz.,	O
less	O
than	O
3	O
months	B-T079
.	O
Therefore,	O
if	O
the	O
surgeon	B-T097
has	O
difficulty	B-T080
in	O
the	O
first	O
operation	B-T061
gaining	O
the	O
patient's cooperation	B-T055
,	O
the	O
surgeon	B-T097
must	O
be	O
careful:	O
if	O
contralateral eye surgery	B-T061
is	O
required,	O
the	O
addition	O
of	O
sedation	B-T061
/	O
analgesia	B-T061
should	O
be	O
considered	O
or	O
the	O
surgery	B-T061
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	B-T077
of	O
recent memory	B-T041
on	O
the	O
patient's	B-T101
subsequent	O
pain	B-T184
experience	B-T041
.	O

Co-ChIP	B-T059
enables	O
genome-wide mapping	B-T062
of	O
histone mark	B-T087
co-occurrence	B-T079
at	O
single-molecule resolution	B-T077
Histone modifications	B-T044
play	O
an	O
important	B-T080
role	B-T077
in	O
chromatin organization	B-T045
and	O
transcriptional regulation	B-T045
,	O
but	O
despite	O
the	O
large amount	B-T081
of	O
genome-wide	B-T028
histone modification	B-T044
data	B-T078
collected	B-T078
in	O
different	B-T080
cells	B-T025
and	O
tissues	B-T024
,	O
little	O
is	O
known	O
about	O
co-occurrence	B-T079
of	O
modifications	B-T044
on	O
the	O
same	O
nucleosome	B-T116
.	O
Here	O
we	O
present	B-T078
a	O
genome-wide quantitative method	B-T062
for	O
combinatorial indexed	B-T170
chromatin immunoprecipitation	B-T059
(	O
co-ChIP	B-T059
)	O
to	O
characterize	O
co-occurrence	B-T079
of	O
histone modifications	B-T044
on	O
nucleosomes	B-T116
.	O
Using	O
co-ChIP	B-T059
,	O
we	O
study	B-T062
the	O
genome-wide	B-T028
co-occurrence	B-T079
of	O
14	O
chromatin marks	B-T087
(70	O
pairwise combinations	B-T080
),	O
and	O
find	O
previously	O
undescribed	O
co-occurrence	B-T079
patterns	B-T082
,	O
including	O
the	O
co-occurrence	B-T079
of	O
H3K9me1	B-T028
and	O
H3K27ac	B-T028
in	O
super-enhancers	B-T086
.	O
Finally,	O
we	O
apply	B-T169
co-ChIP	B-T059
to	O
measure	B-T081
the	O
distribution	B-T169
of	O
the	O
bivalent	B-T081
H3K4me3	B-T028
-	O
H3K27me3	B-T028
domains	B-T087
in	O
two	O
distinct	O
mouse embryonic stem cell	B-T025
(	O
mESC	B-T025
)	O
states	O
and	O
in	O
four	O
adult tissues	B-T024
.	O
We	O
observe	B-T169
dynamic	B-T169
changes	B-T081
in	O
5,786	O
regions	O
and	O
discover	B-T052
both	O
loss	B-T081
and	O
de novo	B-T078
gain	B-T081
of	O
bivalency	B-T081
in	O
key	O
tissue-specific	B-T024
regulatory genes	B-T028
,	O
suggesting	B-T078
a	O
functional role	B-T077
for	O
bivalent	B-T081
domains	B-T087
during	O
different	O
stages	B-T079
of	O
development	B-T169
.	O
These	O
results	B-T033
show	O
that	O
co-ChIP	B-T059
can	O
reveal	B-T080
the	O
complex interactions	B-T169
between	O
histone modifications	B-T044
.	O

Hand-Assisted Laparoscopic	B-T061
Versus	O
Standard Laparoscopic Colectomy	B-T061
:	O
Are	O
Outcomes	B-T080
and	O
Operative Time	B-T079
Different?	O
HAL	B-T061
colectomy	B-T061
is	O
a	O
technique	B-T169
perceived	O
to	O
provide	O
the	O
benefits	O
of	O
laparoscopic surgery	B-T061
while	O
improving	O
tactile	O
feedback	O
and	O
operative time	B-T079
.	O
Published	O
data	B-T078
are	O
largely	O
limited	O
to	O
small,	O
single-institution studies	B-T062
.	O
The	O
2012-2013	O
National Surgical Quality Improvement Program Participant Data Use File	B-T170
was	O
queried	O
for	O
patients	B-T101
undergoing	O
elective	O
SL	B-T061
or	O
HAL	B-T061
colectomy	B-T061
.	O
Patients	B-T101
underwent	O
1:1	O
propensity	O
matching	O
and	O
had	O
outcomes	B-T080
compared.	O
An	O
additional	O
subgroup analysis	B-T062
was	O
performed	O
for	O
patients	B-T101
undergoing	O
segmental	B-T082
resections	B-T061
only.	O
13,949	O
patients	B-T101
were	O
identified,	O
of	O
whom	O
6084	O
(43.6	O
%)	O
underwent	O
HAL	B-T061
colectomy	B-T061
.	O
Patients	B-T101
undergoing	O
HAL	B-T061
versus	O
SL colectomy	B-T061
had	O
higher	O
rates	B-T081
of	O
postoperative ileus	B-T047
(8.7	O
vs.	O
6.3	O
%,	O
p	O
<	O
0.001),	O
wound complication	B-T037
(8.8	O
vs.	O
6.8	O
%,	O
p	O
=	O
0.006),	O
and	O
30-	O
day	B-T079
readmission	B-T058
(7.5	O
vs.	O
6.0	O
%,	O
p	O
=	O
0.002),	O
without	O
any	O
differences	O
in	O
operative time	B-T079
(156	O
vs.	O
157	O
min,	O
p	O
=	O
0.713).	O
Amongst	O
segmental	B-T082
colectomies	B-T061
,	O
HAL	B-T061
remained	O
associated	O
with	O
higher	O
rates	B-T081
of	O
wound complications	B-T037
(8.6	O
vs.	O
6.5	O
%,	O
p	O
=	O
0.016),	O
postoperative ileus	B-T047
(8.9	O
vs.	O
6.3	O
%,	O
p	O
<	O
0.001),	O
and	O
30-	O
day	B-T079
readmission	B-T058
(7.1	O
vs.	O
5.9	O
%,	O
p	O
=	O
0.041)	O
with	O
no	O
difference	O
in	O
operative time	B-T079
between	O
HAL	B-T061
and	O
SL	O
(145	O
vs.	O
145	O
min,	O
p	O
=	O
0.334).	O
Use	O
of	O
HAL	B-T061
colectomy	B-T061
is	O
associated	O
with	O
increased	O
risk	B-T058
of	O
wound complications	B-T037
,	O
postoperative ileus	B-T047
,	O
and	O
readmissions	B-T058
.	O
Importantly,	O
this	O
technique	B-T169
is	O
not	O
associated	O
with	O
any	O
decrease	O
in	O
operative time	B-T079
.	O

Safety	B-T068
and	O
immunogenecity	B-T062
of	O
a	O
live	O
attenuated	B-T121
Rift Valley fever vaccine	B-T121
(	O
CL13T	B-T121
)	O
in	O
camels	B-T015
Rift Valley fever	B-T047
is	O
an	O
emerging	O
zoonotic	B-T001
viral disease	B-T047
,	O
enzootic	B-T047
and	O
endemic	B-T047
in	O
Africa	B-T083
and	O
the	O
Arabian Peninsula	B-T083
,	O
which	O
poses	O
a	O
significant	B-T078
threat	B-T078
to	O
both	O
human	B-T016
and	O
animal	B-T008
health	B-T047
.	O
The	O
disease	B-T047
is	O
most	O
severe	B-T080
in	O
ruminants	B-T015
causing	B-T169
abortions	B-T046
in	O
pregnant	B-T040
animals	B-T008
,	O
especially	O
sheep animals	B-T015
and	O
high	O
mortality	B-T081
in	O
young	B-T079
populations	B-T098
.	O
High	O
mortality rates	B-T081
and	O
severe	B-T080
clinical	B-T080
manifestation	B-T080
have	O
also	O
been	O
reported	B-T170
among	O
camel	B-T015
populations	B-T098
in	O
Africa	B-T083
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	B-T079
available	B-T169
live vaccines	B-T121
against	O
RVF	B-T047
have	O
been	O
tested	B-T169
for	O
safety	B-T068
and	O
efficacy	B-T080
in	O
this	O
species	B-T185
.	O
In	O
this	O
study	B-T062
,	O
the	O
safety	B-T068
and	O
efficacy	B-T080
(through	O
a	O
neutralizing antibody	B-T116
response	B-T032
)	O
of	O
the	O
thermostable live attenuated	B-T121
RVF CL13T vaccine	B-T121
were	O
evaluated	B-T058
in	O
camels	B-T015
in	O
two	O
different	B-T080
preliminary	B-T079
experiments	B-T062
involving	O
16	O
camels	B-T015
,	O
(that	O
12	O
camels	B-T015
and	O
4	O
pregnant	B-T040
camels	B-T015
).	O
The	O
study	B-T062
revealed	B-T080
that	O
the	O
CL13T vaccine	B-T121
was	O
safe	B-T068
to	O
use	B-T169
in	O
camels	B-T015
and	O
no	O
abortions	B-T046
or	O
teratogenic effects	B-T046
were	O
observed	B-T169
.	O
The	O
single	O
dose	B-T081
of	O
the	O
vaccine	B-T121
stimulated	O
a	O
strong	B-T080
and	O
long-lasting	O
neutralizing antibody	B-T116
response	B-T032
for	O
up	O
to	O
12	O
months	B-T079
.	O
The	O
presence	B-T033
of	O
neutralization antibodies	B-T116
is	O
likely	O
to	O
correlate with	B-T080
protection	B-T033
;	O
however	O
protection	B-T033
would	O
need	O
to	O
be	O
confirmed by	B-T080
challenge	O
experiments	B-T062
using	O
the	O
virulent	B-T080
RVF virus	B-T005
.	O

Autoantibodies	B-T116
to	O
MOG	B-T116
in	O
a	O
distinct	O
subgroup	B-T185
of	O
adult	B-T100
multiple sclerosis	B-T047
To	O
evaluate	B-T058
the	O
presence	O
of	O
antibodies	B-T116
to	O
conformation	B-T082
-intact	O
myelin oligodendrocyte glycoprotein	B-T116
(	O
MOG	B-T116
)	O
in	O
a	O
subgroup	B-T185
of	O
adult	B-T100
patients	B-T101
with	O
clinically	B-T080
definite	O
multiple sclerosis	B-T047
(	O
MS	B-T047
)	O
preselected	O
for	O
a	O
specific	O
clinical	B-T080
phenotype	B-T032
including	O
severe	B-T080
spinal cord	B-T023
,	O
optic nerve	B-T023
,	O
and	O
brainstem	B-T023
involvement.	O
Antibodies	B-T116
to	O
MOG	B-T116
were	O
investigated	B-T169
using	O
a	O
cell-based assay	B-T059
in	O
3	O
groups	B-T098
of	O
patients	B-T101
:	O
104	O
preselected	O
patients	B-T101
with	O
MS	B-T047
(	O
group 1	B-T098
),	O
55	O
age	B-T032
-	O
and	O
sex	B-T032
-matched,	O
otherwise	O
unselected	O
patients	B-T101
with	O
MS	B-T047
(	O
group 2	B-T098
),	O
and	O
in	O
22	O
brain-biopsied	B-T060
patients	B-T101
with	O
demyelinating diseases	B-T047
of	O
the	O
CNS	B-T022
(n	O
=	O
19	O
with	O
MS	B-T047
),	O
4	O
of	O
whom	O
classified	B-T185
as	O
MS type II	B-T047
(	O
group 3	B-T098
).	O
Recognized	O
epitopes	B-T129
were	O
identified	O
with	O
mutated	B-T045
variants	B-T028
of	O
MOG	B-T028
.	O
Antibodies	B-T116
to	O
MOG	B-T116
were	O
found	O
in	O
about	O
5%	O
(5/104)	O
of	O
preselected	O
adult	B-T100
patients	B-T101
with	O
MS	B-T047
.	O
In	O
contrast,	O
in	O
groups 2	B-T098
and	O
3	B-T098
,	O
none	O
of	O
the	O
patients	B-T101
tested	B-T169
positive	O
for	O
MOG	B-T116
antibodies	B-T116
.	O
Patients	B-T101
with	O
MS	B-T047
with	O
antibodies	B-T116
to	O
MOG	B-T116
predominantly	O
manifested	B-T169
with	O
concomitant	B-T079
severe	B-T080
brainstem	B-T023
and	O
spinal cord	B-T023
involvement	O
and	O
had	O
a	O
severe	B-T080
disease course	B-T046
with	O
high	O
relapse	B-T067
rates	B-T081
and	O
failure	B-T033
to	O
several	O
disease-modifying therapies	B-T061
.	O
Three	O
of	O
them	O
had	O
been	O
treated with	B-T061
plasma exchange	B-T061
with	O
a	O
favorable response	B-UnknownType
.	O
All	O
anti-MOG	B-T129
-positive	O
patients	B-T101
with	O
MS	B-T047
showed	O
typical	O
MS	B-T047
lesions	B-T033
on	O
brain MRI	B-T060
.	O
Longitudinal analysis	B-UnknownType
up	O
to	O
9	O
years	B-T079
revealed	O
fluctuations	B-T184
and	O
reappearance	O
of	O
anti-MOG reactivity	B-T044
.	O
Epitope mapping	B-T059
indicated	O
interindividual heterogeneity	B-T080
,	O
yet	O
intraindividual stability	B-T080
of	O
the	O
antibody response	B-T038
.	O
Antibodies	B-T116
to	O
MOG	B-T116
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	B-T185
of	O
adult	B-T100
MS	B-T047
with	O
a	O
specific	O
clinical	B-T080
phenotype	B-T032
and	O
may	O
indicate	O
disease	B-T047
heterogeneity	B-T080
.	O

Acute Ph-negative lymphoblastic leukemias	B-T191
in	O
adults	B-T100
:	O
Risk factors	B-T033
in	O
the	O
use	O
of	O
the	O
ALL-2009 protocol	B-T170
to	O
analyze	O
well-known	O
risk factors	B-T033
(	O
RFs	B-T033
),	O
such	O
as	O
age	B-T032
,	O
immunophenotype	B-T059
,	O
baseline	B-T081
leukocytosis	B-T046
,	O
enhanced	B-T052
lactate dehydrogenase	B-T116
(	O
LDH	B-T116
)	O
activity	B-T044
,	O
time	O
to	O
achieve	O
complete	O
remission	B-T033
,	O
a	O
risk group	B-T098
,	O
and	O
cytogenetic abnormalities	B-T049
)	O
in	O
patients	B-T101
with	O
acute lymphoblastic leukemia	B-T191
(	O
ALL	B-T191
)	O
in	O
the	O
use	O
of	O
the	O
ALL-2009 protocol	B-T170
.	O
The	O
protocol	B-T170
covered	O
298	O
patients	B-T101
(137	O
women	B-T098
(	O
including	B-T169
13	O
pregnant women	B-T098
)	O
and	O
161	O
men	B-T098
)	O
aged	O
15	O
to	O
55	O
years	O
(median	O
age	O
28	O
years)	O
with	O
Ph-negative ALL	B-T191
.	O
The	O
phenotype	B-T032
was	O
unknown	O
in	O
6	O
patients	B-T101
.	O
Three	O
(1%)	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant.	O
182	O
(62.4%)	O
patients	B-T101
were	O
found	O
to	O
have	O
B-cell ALL	B-T191
(early	O
pre-B ALL	B-T191
(n=51);	O
common	O
ALL	B-T191
(n=92),	O
and	O
pre-B ALL	B-T191
(n=39);	O
107	O
(36.6%)	O
patients	B-T101
had	O
T-cell ALL	B-T191
(early	O
T-ALL	B-T191
(n=56);	O
thymic	B-T023
T-ALL	B-T191
(n=41),	O
and	O
mature	B-T079
T-ALL	B-T191
(n=10).	O
According	O
to	O
the	O
baseline	B-T081
clinical	B-T080
and	O
laboratory	B-T073
parameters	B-T033
(	O
leukocytosis	B-T046
of	O
30·109/l	O
and	O
more	O
for	O
B-ALL	B-T191
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T-ALL	B-T191
;	O
phenotype	B-T032
В-I	O
for	O
B-ALL	B-T191
,	O
phenotype	B-T032
Т-I-II-IV	O
for	O
T-ALL	B-T191
;	O
LDH	B-T116
activity	B-T044
was	O
more	O
than	O
twice	O
the	O
normal	O
values;	O
the	O
presence	B-T033
of	O
translocation t(4;11)	B-T049
),	O
the	O
high-risk group	B-T098
included	B-T169
most	O
patients	B-T101
with	O
B-ALL	B-T191
(n=110	O
(72.8%))	O
and	O
T-ALL	B-T191
(n=76	O
(76%)).	O
Thirty-five	O
patients	B-T101
with	O
T-ALL	B-T191
underwent	O
autologous bone marrow transplantation	B-T061
(	O
BMT	B-T061
).	O
Allogeneic BMT	B-T061
was	O
performed	B-T169
in	O
18	O
(7%)	O
of	O
the	O
258	O
patients	B-T101
who	O
had	O
undergone	O
an	O
induction phase	B-T062
.	O
Five-year	O
overall survival	B-T081
for	O
all	O
the	O
patients	B-T101
included	B-T169
in	O
the	O
investigation	B-T058
was	O
59%;	O
relapse-free	B-T061
survival	O
was	O
65%,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	B-T101
with	O
B-ALL	B-T191
and	O
in	O
those	O
with	O
T-ALL	B-T191
:	O
the	O
overall survival rates	B-T081
were	O
53.3	O
and	O
67.5%	O
(p=0.1);	O
the	O
relapse-free	O
survival	O
was	O
56	O
and	O
79%	O
(p=0.005),	O
respectively.	O
Multivariate analysis	B-T081
including	B-T169
the	O
well-known	O
RFs	B-T033
demonstrated	O
that	O
the	O
latter	O
for	O
T-ALL	B-T191
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient's	B-T101
age	B-T032
was	O
identified	O
for	O
B-ALL	B-T191
(p=0.013).	O
A	O
lower	O
chemotherapeutic	B-T121
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic BMTs	B-T061
did	O
not	O
affect	O
total	O
positive	O
treatment	B-T061
results	B-T034
in	O
adult	B-T100
patients	B-T101
with	O
ALL	B-T191
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B-T121
effects	B-T080
and	O
by	O
preserving	B-T169
the	O
total	O
cytostatic	B-T121
loading dose	B-T081
.	O
The	O
results	B-T034
of	O
the	O
Russian	B-T083
investigation	B-T058
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic BMTs	B-T061
in	O
adult	B-T100
patients	B-T101
with	O
ALL	B-T191
.	O

Multidetector CT	B-T060
of	O
expected	B-T170
findings	B-T033
and	O
complications	B-T046
after	O
contemporary	B-T079
inguinal hernia repair	B-T061
surgery	B-T061
Inguinal hernia repair	B-T061
(	O
IHR	B-T061
)	O
with	O
prosthetic	B-T074
mesh	B-T074
implantation	B-T061
is	O
the	O
most	O
common	O
procedure	B-T061
in	O
general surgery	B-T061
,	O
and	O
may	O
be	O
performed	B-T169
using	O
either	O
an	O
open	B-T082
or	O
laparoscopic approach	B-T082
.	O
This	O
paper	B-T073
provides	O
an	O
overview	B-T170
of	O
contemporary	B-T079
tension-free	O
IHR	B-T061
techniques	B-T169
and	O
materials	B-T167
,	O
and	O
illustrates	O
the	O
expected	B-T170
postoperative	B-T033
imaging findings	B-T034
and	O
iatrogenic injuries	B-T037
.	O
Emphasis	O
is	O
placed	O
on	O
multidetector CT	B-T060
,	O
which	O
represents	O
the	O
ideal	B-T080
modality	B-T078
to	O
comprehensively	O
visualize	O
the	O
operated	B-T169
groin region	B-T029
and	O
deeper	B-T082
intra-abdominal structures	B-T023
.	O
CT	B-T060
consistently	O
depicts	O
seroma	B-T046
,	O
mesh infections	B-T046
,	O
hemorrhages	B-T046
,	O
bowel	B-T023
complications	B-T046
and	O
urinary bladder	B-T023
injuries	B-T037
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	B-T078
basis	O
for	O
therapeutic	B-T169
choice	B-T052
.	O
Since	O
radiologists	B-T097
are	O
increasingly	B-T169
requested	O
to	O
investigate	B-T169
suspected	B-T078
iatrogenic	B-T080
complications	B-T046
,	O
this	O
paper	B-T073
aims	O
to	O
provide	O
an	O
increased	B-T081
familiarity	B-T041
with	O
early	B-T079
CT	B-T060
studies	B-T060
after	O
IHR	B-T061
,	O
including	O
complications	B-T046
and	O
normal	B-T080
postoperative	B-T033
appearances	B-T080
such	O
as	O
focal	B-T082
pseudolesions	B-T046
,	O
in	O
order	O
to	O
avoid misinterpretation	B-T058
and	O
inappropriate	B-T080
management	B-T058
.	O

The	O
transcription factors	B-T116
MS188	B-T116
and	O
AMS	B-T116
form	O
a	O
complex	B-T080
to	O
activate	B-T169
the	O
expression	B-T045
of	O
CYP703A2	B-T116
for	O
sporopollenin biosynthesis	B-T044
in	O
Arabidopsis thaliana	B-T002
The	O
sexine layer	B-T026
of	O
pollen grain	B-T002
is	O
mainly	O
composed	O
of	O
sporopollenins	B-T109
.	O
The	O
sporophytic secretory tapetum	B-T025
is	O
required	B-T169
for	O
the	O
biosynthesis of sporopollenin	B-T044
.	O
Although	O
several	O
enzymes	B-T116
involved	B-T169
in	O
sporopollenin biosynthesis	B-T044
have	O
been	O
reported,	O
the	O
regulatory mechanism	B-T044
of	O
these	O
enzymes	B-T116
in	O
tapetal layer	B-T025
remains	O
elusive.	O
ABORTED MICROSPORES	B-T116
(	O
AMS	B-T116
)	O
and	O
MALE STERILE 188	B-T116
/	O
MYB103	B-T116
/	O
MYB80	B-T116
(	O
MS188	B-T116
/	O
MYB103	B-T116
/	O
MYB80	B-T116
)	O
are	O
two	O
tapetal cell	B-T025
-specific	O
transcription factors	B-T116
required	B-T169
for	O
pollen wall formation	B-T042
.	O
AMS	B-T116
functions	B-T169
upstream	B-T082
of	O
MS188	B-T116
.	O
Here	O
we	O
report	O
that	O
AMS	B-T116
and	O
MS188	B-T116
target	B-T169
the	O
CYP703A2 gene	B-T028
,	O
which	O
is	O
involved	B-T169
in	O
sporopollenin biosynthesis	B-T044
.	O
We	O
found	O
that	O
AMS	B-T116
and	O
MS188	B-T116
were	O
localized	B-T082
in	O
tapetum	B-T025
while	O
CYP703A2	B-T116
was	O
localized	B-T082
in	O
both	O
tapetum	B-T025
and	O
locule	B-T002
.	O
Chromatin immunoprecipitation	B-T059
(	O
ChIP	B-T059
)	O
showed	O
that	O
MS188	B-T116
directly	O
bound	B-T052
to	O
the	O
promoter	B-T114
of	O
CYP703A2	B-T028
and	O
luciferase-inducible	B-T116
assay	B-T059
showed	O
that	O
MS188	B-T116
activated	B-T052
the	O
expression	B-T045
of	O
CYP703A2	B-T116
.	O
Yeast two-hybrid	B-T063
and	O
electrophoretic mobility shift assays	B-T059
(	O
EMSAs	B-T059
)	O
further	O
demonstrated	O
that	O
MS188	B-T116
complexed	B-T080
with	O
AMS	B-T116
.	O
The	O
expression	B-T045
of	O
CYP703A2	B-T028
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated levels	B-T080
of	O
MS188	B-T116
in	O
the	O
ams	B-T116
mutant	B-T049
.	O
Therefore,	O
our	O
data	B-T078
reveal	B-T080
that	O
MS188	B-T116
coordinates	B-T169
with	O
AMS	B-T116
to	O
activate	B-T169
CYP703A2	B-T116
in	O
sporopollenin biosynthesis	B-T044
of	O
plant	B-T002
tapetum	B-T025
.	O

Activation	B-T052
of	O
ephrinB-EphB receptor signalling	B-T169
in	O
rat spinal cord	B-T023
contributes	O
to	O
maintenance	B-T052
of	O
diabetic	B-T033
neuropathic pain	B-T033
Diabetic	B-T033
neuropathic pain	B-T033
(	O
DNP	B-T033
)	O
is	O
severe	B-T080
and	O
intractable	B-T169
in	O
clinic	B-T073
.	O
The	O
specific	B-T080
cellular	B-T043
and	O
molecular	B-T044
mechanisms	B-T169
underlying	O
DNP	B-T033
remain	O
elusive	O
and	O
its	O
treatment	B-T169
are	O
limited	B-T169
.	O
We	O
investigated	B-T169
roles	B-T077
of	O
EphB1 receptor	B-T116
in	O
the	O
development	O
of	O
DNP	B-T033
.	O
Diabetic	B-T033
neuropathic pain	B-T033
was	O
produced	O
in	O
male	B-T032
,	O
adult	B-T100
,	O
Sprague-Dawley rats	B-T015
by	O
a	O
single	O
i.p.	O
streptozotocin	B-T109
(	O
STZ	B-T109
)	O
or	O
alloxan	B-T109
.	O
Western blot analysis	B-T059
and	O
immunohistochemistry	B-T060
were	O
used	O
to	O
analyse	O
expression	B-T045
of	O
EphB1 receptor	B-T116
as	O
well	O
as	O
the	O
activation	B-T052
of	O
the	O
glial cells	B-T025
and	O
the	O
pro-inflammatory cytokines	B-T116
in	O
the	O
spinal cord	B-T023
.	O
DNP	B-T033
manifested	B-T169
as	O
mechanical allodynia	B-T184
,	O
which	O
was	O
determined	O
by	O
measuring	B-T080
incidence	B-T081
of	O
foot	B-T023
withdrawal	B-T052
in	O
response	B-T032
to	O
mechanical indentation	B-T082
of	O
the	O
hind	B-T082
paw	B-T023
by	O
an	O
electro von Frey filament	B-T073
.	O
Diabetic	B-T033
neuropathic pain	B-T033
and	O
high blood glucose	B-T033
were	O
exhibited	O
simultaneously	B-T079
in	O
around	O
70%	O
of	O
animals	B-T008
that	O
received	O
i.p.	O
STZ	B-T109
or	O
alloxan	B-T109
.	O
Phosphorylation	B-T044
of	O
EphB1	B-T116
,	O
activation	B-T052
of	O
the	O
astrocytes	B-T025
and	O
microglial cells	B-T025
,	O
and	O
level	B-T080
of	O
tumour necrosis factor	B-T116
(TNF)-α	B-T116
and	O
interleukin (IL)-1β	B-T116
in	O
the	O
spinal cord	B-T023
were	O
significantly	O
increased	O
in	O
rats	B-T015
with	O
DNP	B-T033
.	O
Spinal	B-T082
blocking	B-T169
EphB1 receptor	B-T116
activation	B-T052
in	O
the	O
late	O
phase	O
after	O
STZ	B-T109
injection	B-T061
significantly	O
suppressed	B-T169
the	O
established	O
mechanical allodynia	B-T184
as	O
well	O
as	O
activation	B-T052
of	O
the	O
astrocytes	B-T025
and	O
microglial cells	B-T025
and	O
activity	B-T052
of	O
TNF-α	B-T116
and	O
IL-1β	B-T116
.	O
However,	O
spinal	B-T082
treatment	B-T169
of	O
EphB1	B-T116
-	O
Fc	B-T116
in	O
the	O
early phase	B-UnknownType
after	O
STZ	B-T109
injection	B-T061
did	O
not	O
prevent	O
the	O
induction	B-T169
of	O
DNP	B-T033
.	O
EphB1 receptor	B-T116
activation	B-T052
in	O
the	O
spinal cord	B-T023
is	O
critical	B-T080
to	O
the	O
maintenance	B-T052
,	O
but	O
not	O
induction	B-T169
of	O
diabetic	B-T033
pain	B-T184
.	O
EphB1 receptor	B-T116
may	O
be	O
a	O
potential	B-T080
target	B-T169
for	O
relieving	B-T061
the	O
established	O
diabetic	B-T033
pain	B-T184
.	O
Activation	B-T052
of	O
EphB1 receptor	B-T116
in	O
the	O
spinal cord	B-T023
is	O
critical	B-T080
to	O
maintaining	B-T169
the	O
established	O
diabetic	B-T033
neuropathic pain	B-T033
,	O
but	O
not	O
to	O
diabetic	B-T033
pain	B-T184
induction	B-T169
.	O
Spinal	B-T082
blocking	B-T169
EphB1 receptor	B-T116
activation	B-T052
suppresses	B-T169
ongoing	O
diabetic	B-T033
neuropathic pain	B-T033
.	O

Conservation	B-T080
of	O
the	O
Red Kite	B-T012
Milvus milvus	B-T012
(	O
Aves	B-T012
:	O
Accipitriformes	B-T012
)	O
Is	O
Not	O
Affected	B-T169
by	O
the	O
Establishment	O
of	O
a	O
Broad	O
Hybrid	B-T001
Zone	B-T082
with	O
the	O
Black Kite	B-T012
Milvus migrans migrans	B-T012
in	O
Central Europe	B-T083
Among	O
Accipitriformes	B-T012
sensu	O
stricto,	O
only	O
a	O
few	O
species	B-T185
have	O
been	O
reported	B-T170
to	O
form	O
hybrid	B-T001
zones	B-T082
;	O
these	O
include	O
the	O
red kite	B-T012
Milvus milvus	B-T012
and	O
black kite	B-T012
Milvus migrans migrans	B-T012
.	O
M. milvus	B-T012
is	O
endemic	B-T169
to	O
the	O
western Palearctic	B-UnknownType
and	O
has	O
an	O
estimated	O
total	O
population	B-T081
of	O
20-24,000	O
breeding	B-T040
pairs	B-T080
.	O
The	O
species	B-T185
was	O
in	O
decline	O
until	O
the	O
1970s	O
due	O
to	O
persecution	B-T054
and	O
has	O
declined	O
again	O
since	O
the	O
1990s	O
due	O
to	O
ingestion	B-T038
of	O
rodenticide-treated baits	B-T131
,	O
illegal	B-T078
poisoning	B-T037
and	O
changes	O
in	O
agricultural practices	B-T090
,	O
particularly	O
in	O
its	O
core	B-T082
range	B-T081
.	O
Whereas	O
F1	B-T099
M. milvus	B-T012
×	O
M. migr. migrans	B-T012
hybrid	B-T001
offspring	B-T099
have	O
been	O
found,	O
F2	B-T099
and	O
F3	B-T099
hybrids	B-T001
have	O
only	O
rarely	O
been	O
reported	B-T170
,	O
with	O
low	O
nesting	B-T054
success	B-T054
rates	B-T081
of	O
F1	B-T099
hybrids	B-T001
and	O
partial	B-T081
hybrid	B-T001
sterility	O
likely	O
playing	O
a	O
role.	O
Here,	O
we	O
analyzed	B-T062
the	O
mitochondrial	B-T026
(	O
CO1	B-T028
and	O
CytB	B-T028
)	O
and	O
nuclear	B-T026
(	O
Myc	B-T028
)	O
DNA	B-T114
loci	B-T082
of	O
184	O
M. milvus	B-T012
,	O
124	O
M. migr. migrans	B-T012
and	O
3	O
F1	B-T099
hybrid	B-T001
individuals	O
collected	O
across	O
central Europe	B-T083
.	O
In	O
agreement	B-T170
with	O
previous	O
studies	B-T062
,	O
we	O
found	O
low	O
heterozygosity	B-T032
in	O
M. milvus	B-T012
regardless	O
of	O
locus	B-T082
.	O
We	O
found	O
that	O
populations	B-T081
of	O
both	O
examined	B-T033
species	B-T185
were	O
characterized	B-T052
by	O
a	O
high	O
gene flow	B-T045
within	O
populations	B-T081
,	O
with	O
all	O
of	O
the	O
major	O
haplotypes	B-T032
distributed	O
across	O
the	O
entire	O
examined	B-T033
area	B-T083
.	O
Few	O
haplotypes	B-T032
displayed	O
statistically significant	B-T081
aggregation	B-T169
in	O
one	O
region	B-T083
over	O
another.	O
We	O
did	O
not	O
find	O
mitochondrial DNA	B-T114
of	O
one	O
species	B-T185
in	O
individuals	O
with	O
the	O
plumage	B-T023
of	O
the	O
other	O
species	B-T185
,	O
except	O
in	O
F1	B-T099
hybrids	B-T001
,	O
which	O
agrees	O
with	O
Haldane´s Rule	B-T170
.	O
It	O
remains	O
to	O
be	O
investigated	B-T169
by	O
genomic	B-T028
methods	B-T169
whether	O
occasional	O
gene flow	B-T045
occurs	O
through	O
the	O
paternal	B-T080
line,	O
as	O
the	O
examined	B-T033
Myc gene	B-T028
displayed	O
only	O
marginal	O
divergence	B-T082
between	O
M. milvus	B-T012
and	O
M. migr. migrans	B-T012
.	O
The	O
central Europe	B-T083
an	O
population	B-T081
of	O
M. milvus	B-T012
is	O
clearly	O
subject	O
to	O
free	O
intraspecific	O
gene flow	B-T045
,	O
which	O
has	O
direct	O
implications	O
when	O
considering	O
the	O
origin	B-T079
of	O
individuals	O
in	O
M. milvus	B-T012
re-introduction	O
programs.	O

Extracellular	B-T026
Potassium	B-T123
and	O
Seizures	B-T184
:	O
Excitation	B-T052
,	O
Inhibition	B-T052
and	O
the	O
Role	O
of	O
Ih	B-T116
Seizure activity	B-T184
leads	O
to	O
increases	O
in	O
extracellular	B-T026
potassium	B-T123
concentration	B-T081
([	O
K	B-T121
[Formula:	O
see	O
text]]o),	O
which	O
can	O
result	O
in	O
changes	O
in	O
neuronal	B-T025
passive	B-T080
and	O
active	B-T169
membrane	B-T026
properties	O
as	O
well	O
as	O
in	O
population	B-T098
activities	B-T052
.	O
In	O
this	O
study	B-T062
,	O
we	O
examined	O
how	O
extracellular	B-T026
potassium	B-T123
modulates	O
seizure activities	B-T184
using	O
an	O
acute	O
4-AP	B-T109
induced	O
seizure	B-T184
model	B-T170
in	O
the	O
neocortex	B-T023
,	O
both	O
in vivo	B-T082
and	O
in vitro	B-T080
.	O
Moderately	O
elevated	O
[	O
K	B-T121
[Formula:	O
see	O
text]]o	O
up	O
to	O
9[Formula:	O
see	O
text]mM	O
prolonged	B-T079
seizure	B-T184
durations	B-T079
and	O
shortened interictal intervals	B-T079
as	O
well	O
as	O
depolarized	B-T046
the	O
neuronal	B-T025
resting membrane potential	B-T043
(	O
RMP	B-T043
).	O
However,	O
when	O
[	O
K	B-T121
[Formula:	O
see	O
text]]o	O
reached	O
higher	O
than	O
9[Formula:	O
see	O
text]mM,	O
seizure like events	B-T184
(	O
SLEs	B-T184
)	O
were	O
blocked	B-T169
and	O
neurons	B-T025
went	O
into	O
a	O
depolarization	B-T046
-	O
blocked	B-T169
state.	O
Spreading	B-T080
depression	B-T048
was	O
never	O
observed	O
as	O
the	O
blockade	O
of	O
ictal events	B-T184
could	O
be	O
reversed	O
within	O
1-2[Formula:	O
see	O
text]min	O
after	O
the	O
raised	O
[	O
K	B-T121
[Formula:	O
see	O
text]]o	O
was	O
changed	O
back	O
to	O
control	O
levels.	O
This	O
concentration	B-T081
-dependent	O
dual	O
effect	O
of	O
[	O
K	B-T121
[Formula:	O
see	O
text]]o	O
was	O
observed	O
using	O
in vivo	B-T082
and	O
in vitro	B-T080
mouse brain preparations	B-T024
as	O
well	O
as	O
in	O
human	B-T016
neocortical	B-T023
tissue	B-T024
resected	O
during	O
epilepsy	B-T047
surgery	B-T061
.	O
Blocking	B-T169
the	O
Ih	O
current,	O
mediated	O
by	O
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels	B-T116
,	O
modulated	O
the	O
elevated	O
[	O
K	B-T121
[Formula:	O
see	O
text]]o	O
influence	B-T077
on	O
SLEs	B-T184
by	O
promoting	O
the	O
high	O
[	O
K	B-T121
[Formula:	O
see	O
text]]o	O
inhibitory actions	B-T052
.	O
These	O
results	O
demonstrate	O
biphasic	O
actions	O
of	O
raised	O
[	O
K	B-T121
[Formula:	O
see	O
text]]o	O
on	O
neuronal	B-T025
excitability	B-T184
and	O
seizure activity	B-T184
.	O

Activation	B-T044
of	O
general control nonderepressible 2 kinase	B-T116
protects	B-T033
human	B-T016
glomerular endothelial cells	B-T025
from	O
harmful	O
high-glucose	B-T033
-	O
induced	B-T169
molecular pathways	B-T044
Considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	B-T116
restriction	B-T169
on	O
diabetic nephropathy	B-T047
(	O
DN	B-T047
)	O
and	O
the	O
role	O
of	O
renal	B-T023
endothelium	B-T024
in	O
its	O
pathogenesis	B-T046
,	O
we	O
evaluated	B-T058
the	O
effect	O
of	O
general control nonderepressible 2 (GCN2) kinase	B-T116
activation	B-T044
,	O
a	O
sensor	B-T075
of	O
amino acid	B-T116
deprivation	B-T080
,	O
on	O
known	O
detrimental	O
molecular pathways	B-T044
in	O
primary	O
human	B-T016
glomerular endothelial cells	B-T025
(	O
GEnC	B-T025
).	O
GEnC	B-T025
were	O
cultured	B-T059
under	O
normal	O
or	O
high	B-T080
high -glucose conditions	B-T047
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
GCN2 kinase	B-T116
activator	B-T044
,	O
tryptophanol	B-T116
.	O
Glucose transporter 1	B-T116
(	O
GLUT1	B-T116
)	O
expression	B-T045
was	O
assessed	B-T052
by	O
western blotting	B-T059
and	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
)	O
using	O
a	O
fluorogenic probe	B-T130
.	O
Activities	B-T044
of	O
glyceraldehyde 3-phosphate dehydrogenase	B-T116
(	O
GAPDH	B-T116
)	O
and	O
protein kinase C	B-T116
(	O
PKC	B-T116
)	O
were	O
assessed	B-T052
by	O
commercial activity assays	B-T059
,	O
sorbitol	B-T109
colorimetrically	B-T059
,	O
methylglyoxal	B-T109
by	O
ELISA	B-T059
and	O
O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins	B-T116
by	O
western blotting	B-T059
.	O
High glucose	B-T033
induced	B-T169
GLUT1	B-T116
expression	B-T045
,	O
increased	B-T081
ROS	B-T123
and	O
inhibited	B-T080
GAPDH	B-T116
.	O
Also	O
it	O
increased	B-T081
the	O
polyol	B-T109
pathway	B-T044
product	O
sorbitol	B-T109
,	O
PKC	B-T116
activity	B-T044
,	O
the	O
level	O
of	O
the	O
O-GlcNAc-modified proteins	B-T116
that	O
produced	O
by	O
the	O
hexosamine	B-T109
pathway	B-T044
and	O
the	O
advanced glycation endproducts'	B-T109
precursor	B-T078
methylglyoxal	B-T109
.	O
Co-treatment	B-T058
of	O
GEnC	B-T025
with	O
tryptophanol	B-T116
restored	O
the	O
above	O
high-glucose	B-T033
-	O
induced	B-T169
alterations.	O
Activation	B-T044
of	O
GCN2 kinase	B-T116
protects	O
GEnC	B-T025
from	O
high-glucose	B-T033
-	O
induced	B-T169
harmful	O
molecular pathways	B-T044
.	O
By	O
inhibiting	O
concurrently	B-T079
many	O
pathways	B-T044
involved	O
in	O
DN	B-T047
pathogenesis	B-T046
,	O
GCN2 kinase	B-T116
may	O
serve	O
as	O
a	O
pharmaceutical	B-T091
target	B-T169
for	O
the	O
treatment	B-T061
of	O
DN	B-T047
.	O

Juicer	B-T170
Provides	B-T052
a	O
One-Click	O
System	O
for	O
Analyzing	B-T062
Loop-Resolution Hi-C Experiments	B-T059
Hi-C experiments	B-T059
explore	O
the	O
3D structure	B-T082
of	O
the	O
genome	B-T028
,	O
generating	B-T052
terabases of data	B-T170
to	O
create	O
high-resolution	B-T059
contact maps	B-T170
.	O
Here,	O
we	O
introduce	O
Juicer	B-T170
,	O
an	O
open-source tool	B-T170
for	O
analyzing	O
terabase-scale	B-T081
Hi-C datasets	B-T170
.	O
Juicer	B-T170
allows	O
users	B-T098
without	B-T080
a	O
computational	B-T052
background	B-T077
to	O
transform	B-T062
raw sequence data	B-T170
into	O
normalized	O
contact maps	B-T170
with	O
one	O
click.	O
Juicer	B-T170
produces	O
a	O
hic file	B-T170
containing	O
compressed	B-T169
contact matrices	B-T082
at	O
many	O
resolutions	B-T081
,	O
facilitating	O
visualization	B-T041
and	O
analysis	B-T062
at	O
multiple scales	B-T081
.	O
Structural features	B-T082
,	O
such	O
as	O
loops	B-T026
and	O
domains	B-T044
,	O
are	O
automatically	B-T066
annotated	B-T080
.	O
Juicer	B-T170
is	O
available	O
as	O
open	B-T080
source	B-T081
software	B-T073
at	O
http://aidenlab.org/juicer/.	O

BJN Awards	B-T073
2016:	O
IV therapy	B-T061
Claire	O
Rickard	O
Professor	B-T097
of	O
Nursing	B-T097
,	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(NHMRC)	O
Centre of Research Excellence	B-T097
in	O
Nursing	B-T097
,	O
Griffith	O
University,	O
was	O
awarded	B-T073
second	O
place	O
in	O
the	O
BJN Awards	B-T073
2016	O
for	O
IV Therapy	B-T061
Nurse	B-T097
of	O
the	O
Year	B-T079
.	O
Here	O
she	O
talks	O
about	O
the	O
she	O
has	O
done	O
to	O
be	O
recognised	O
in	O
this	O
field	B-T058
.	O

Stressful	B-T169
life events	B-T032
and	O
leucocyte telomere length	B-T047
:	O
Do	O
lifestyle factors	B-T201
,	O
somatic	B-T080
and	O
mental health	B-T041
,	O
or	O
low grade inflammation	B-T046
mediate	O
this	O
relationship	B-T080
?	O
Results	O
from	O
a	O
cohort	B-T098
of	O
Danish men	B-T098
born	B-T040
in	O
1953	O
Exposure to	B-T080
psychosocial	B-T169
stress	B-T033
is	O
associated with	B-T080
increased	O
risk	B-T078
of	O
a	O
number	O
of	O
somatic	B-T080
and	O
mental disorders	B-T048
with	O
relation	B-T080
relation	B-T080
to	O
immune system	B-T022
functioning	B-T169
.	O
We	O
aimed	O
to	O
explore	O
whether	O
stressful events	B-T051
in	O
early	O
and	O
recent	O
life	B-T078
was	O
associated with	B-T080
leucocyte telomere length	B-T047
(	O
TL	B-T047
),	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	B-T033
burden	O
of	O
inflammation	B-T046
and	O
oxidative stress	B-T049
occurring	O
during	O
the	O
life course	B-T079
.	O
We	O
specifically	O
aimed	O
to	O
address	B-T078
whether	O
childhood	B-T079
constitutes	O
a	O
sensitive period	B-T079
and	O
how	O
much	O
of	O
the	O
relation	B-T080
between	O
stressful	B-T169
life	O
events	O
and	O
TL	B-T047
is	O
mediated	O
through	O
somatic	B-T080
and	O
mental health	B-T041
,	O
lifestyle	B-T054
,	O
and	O
markers	B-T201
of	O
low-grade inflammation	B-T046
.	O
A	O
cohort	B-T098
of	O
Danish men	B-T098
born	B-T040
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	B-T040
in	O
the	O
Metropolit Cohort	B-T098
.	O
These	O
men	B-T098
underwent	O
a	O
health examination	B-T058
including	O
blood sampling	B-T060
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative PCR-based measurement	B-T059
of	O
TL	B-T047
.	O
The	O
relation	B-T080
between	O
stressful	B-T169
life events	B-T032
and	O
TL	B-T047
was	O
analysed	O
using	O
structural equation modelling	B-T062
,	O
which	O
also	O
provided	O
an	O
estimate	B-T081
of	O
the	O
proportion	B-T081
of	O
the	O
total	O
effect	B-T080
mediated	O
by	O
somatic	B-T080
and	O
mental health	B-T041
(	O
cardiovascular disease	B-T047
,	O
body mass	B-T033
and	O
depressive mood	B-T033
),	O
lifestyle factors	B-T201
,	O
and	O
low grade inflammation	B-T046
(	O
C-reactive protein	B-T116
(	O
CRP	B-T116
),	O
interleukin (IL)-6	B-T116
and	O
IL-10	B-T116
).	O
Total number	B-T081
of	O
stressful events	B-T051
experienced	B-T067
during	B-T079
the	O
life course	B-T079
was	O
not	O
associated with	B-T080
TL	B-T047
.	O
In	O
terms	O
of	O
sensitive periods	B-T079
,	O
we	O
found	O
that	O
number	B-T081
of	O
stressful events	B-T051
in	O
childhood	B-T079
was	O
associated with	B-T080
shorter TL	B-T047
(βper	O
number	O
stressful events	B-T051
in	O
childhood	B-T079
=-0.02(SE=-0.02);	O
P=0.05).	O
This	O
relation	B-T080
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	B-T082
(β=-0.16;	O
P<0.000).	O
Thirty	O
percent	O
of	O
the	O
total	O
effect	B-T080
of	O
stressful events	B-T051
in	O
childhood	B-T079
on	O
TL	B-T047
was	O
mediated	O
by	O
the	O
included	O
variables	B-T081
,	O
with	O
the	O
largest	O
proportion	B-T081
being	O
mediated	O
through	O
depressive mood	B-T033
(16%)	O
and	O
CRP	B-T116
(9%).	O
This	O
study	O
suggests	O
that	O
stressful events	B-T051
in	O
childhood	B-T079
are	O
associated with	B-T080
shorter TL	B-T047
in	O
middle-aged men	B-T100
and	O
that	O
part	O
of	O
this	O
relation	B-T080
is	O
explained	O
by	O
depressive mood	B-T048
and	O
low grade inflammation	B-T046
.	O

Description	B-T170
of	O
Ancylomarina subtilis gen. nov., sp. nov.	B-T007
,	O
isolated	B-T169
from	O
coastal sediment	B-T082
,	O
proposal	B-T078
of	O
Marinilabiliales ord. nov.	B-T007
and	O
transfer	B-T078
of	O
Marinilabiliaceae	B-T007
,	O
Prolixibacteraceae	B-T007
and	O
Marinifilaceae	B-T007
to	O
the	O
order	B-T185
Marinilabiliales	B-T007
A	O
Gram-stain-negative	B-T007
,	O
facultatively anaerobic	B-T007
,	O
moderately halophilic	B-T194
,	O
filamentous	B-T080
,	O
non-motile bacterium	B-T007
,	O
designated	B-T169
FA102T	B-T007
,	O
was	O
isolated	B-T169
from	O
marine sediment	B-T070
of	O
the	O
coast	B-T082
of	O
Weihai, China	B-T083
.	O
Phylogenetic analysis	B-T062
based	B-T169
on	O
16S rRNA gene sequences	B-T114
showed	B-T169
that	O
strain	B-T080
FA102T	B-T007
formed	O
a	O
distinct	B-T080
evolutionary	B-T045
lineage	B-T077
within	O
the	O
family	B-T077
Marinifilaceae	B-T007
and	O
its	O
closest relative	B-T033
was	O
Marinifilum fragile JCM 15579T	B-T007
(93.2%	O
sequence similarity	B-T081
).	O
The	O
DNA	B-T114
G+C content	B-T081
of	O
the	O
novel	B-T080
strain	B-T080
was	O
36.5	O
mol%.	O
The	O
predominant	B-T080
cellular	B-T025
fatty acids	B-T109
and	O
respiratory	B-T169
quinone	B-T109
were	O
iso-C15:0	B-T109
and	O
iso-C15:0 3-OH	B-T116
,	O
and	O
MK-7	B-T109
,	O
respectively	B-T080
.	O
On	O
the	O
basis	B-T169
of	O
the	O
phylogenetic	B-UnknownType
,	O
phenotypic	B-T032
and	O
physiological	B-T169
data	B-T078
,	O
strain	B-T080
FA102T	B-T007
represents	B-T052
a	O
novel	B-T080
genus	B-T185
and	O
species	B-T185
,	O
for	O
which	O
the	O
name	O
Ancylomarina subtilis gen. nov., sp. nov.	B-T007
is	O
proposed	B-T080
.	O
The	O
type	B-T080
strain	B-T080
of	O
Ancylomarina subtilis	B-T007
is	O
FA102T	B-T007
(=	O
KCTC 42257T	B-T007
=	O
DSM 28825T	B-T007
=	O
CICC 10902T	B-T007
).	O
Furthermore,	O
a	O
new	B-T080
order	B-T185
named	O
Marinilabiliales	B-T007
is	O
proposed	B-T080
to	O
accommodate	B-T033
three	O
families	B-T077
previously	B-T079
classified	B-T185
in	O
the	O
order	B-T185
Bacteroidales	B-T007
.	O
Marinilabiliales ord. nov.	B-T007
encompasses	O
the	O
families	B-T077
Marinilabiliaceae	B-T007
,	O
Prolixibacteraceae	B-T007
and	O
Marinifilaceae	B-T007
.	O

Treatment	B-T061
for	O
Rheumatoid Arthritis	B-T047
and	O
Risk	B-T033
of	O
Alzheimer's Disease	B-T047
:	O
A	O
Nested Case-Control Analysis	B-T062
It	O
is	O
increasingly	B-T169
becoming	O
accepted	B-T080
that	O
inflammation	B-T046
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-T046
of	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
),	O
as	O
several	B-T081
immune	B-T022
-related	O
genes	B-T028
have	O
been	O
associated with	B-T080
AD	B-T047
.	O
Among	O
these	O
is	O
tumor necrosis factor (TNF)-α	B-T116
,	O
a	O
proinflammatory cytokine	B-T116
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune disorders	B-T047
,	O
including	O
rheumatoid arthritis	B-T047
(	O
RA	B-T047
).	O
Although	O
AD	B-T047
and	O
RA	B-T047
appear	O
to	O
involve	O
similar	B-T080
pathological mechanisms	B-T046
through	O
the	O
production	B-T038
of	O
TNF-α,	B-T116
the	O
relationship	B-T080
between	O
AD	B-T047
and	O
RA	B-T047
remains	O
unknown	B-T080
.	O
To	O
determine	O
the	O
relative risk	B-T081
of	O
AD	B-T047
among	O
RA	B-T047
patients	B-T101
and	O
non-	O
RA	B-T047
patients	B-T101
,	O
and	O
whether	O
anti-TNF therapy	B-T061
for	O
RA	B-T047
was	O
associated with	B-T080
a	O
lower	B-T080
risk	B-T033
of	O
AD	B-T047
in	O
RA	B-T047
patients	B-T101
.	O
We	O
performed	O
a	O
nested case-control study	B-T062
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	B-T170
adults	B-T100
(aged	O
≥18	O
years)	O
in	O
all	O
50	O
US states	B-T083
,	O
Puerto Rico	B-T083
,	O
and	O
US Virgin Islands	B-T083
in	O
the	O
Verisk Health claims database	B-T170
.	O
We	O
derived	O
a	O
sub-cohort	B-T098
of	O
subjects	O
with	O
a	O
diagnosis	B-T033
of	O
RA	B-T047
(	O
controls	B-T096
),	O
or	O
RA	B-T047
and	O
AD	B-T047
(	O
cases	B-T077
),	O
matching	B-T062
cases	B-T077
and	O
controls	O
based	O
on	O
age	B-T032
,	O
sex	B-T032
,	O
exposure assessment period	B-T058
,	O
and	O
methotrexate treatment	B-T061
.	O
We	O
also	O
assessed relative risk	B-T058
of	O
AD	B-T047
following	O
exposure to	B-T080
standard	B-T080
RA	B-T047
therapies	B-T061
,	O
including	O
anti-TNF agents	B-T121
(	O
infliximab	B-T116
,	O
adalimumab	B-T116
,	O
etanercept	B-T116
),	O
methotrexate	B-T109
,	O
prednisone	B-T109
,	O
sulfasalazine	B-T109
,	O
and	O
rituximab	B-T116
.	O
Odds ratios	B-T081
were	O
adjusted	O
for	O
comorbidities	B-T078
,	O
including	O
coronary artery disease	B-T047
,	O
diabetes mellitus	B-T047
,	O
and	O
peripheral vascular disease	B-T047
.	O
AD	B-T047
was	O
more	O
prevalent	B-T080
(p	O
<	O
0.0001)	O
among	O
RA	B-T047
patients	B-T101
(0.79	O
%)	O
than	O
among	O
those	O
without	B-T080
RA	B-T047
(0.11	O
%).	O
Chronic conditions	B-T033
such	O
as	O
coronary artery disease	B-T047
(	O
odds ratio	B-T081
[	O
OR	B-T081
]	O
1.48;	O
95	O
%	O
confidence interval	B-T081
[	O
CI	B-T081
]	O
1.04-2.05;	O
p	O
=	O
0.03),	O
diabetes	B-T047
(	O
OR	B-T081
1.86;	O
95	O
%	O
CI	B-T081
1.32-2.62;	O
p	O
=	O
0.0004),	O
and	O
peripheral vascular disease	B-T047
(	O
OR	B-T081
1.61;	O
95	O
%	O
CI	B-T081
1.06-2.43;	O
p	O
=	O
0.02)	O
significantly	O
increased	O
the	O
relative risk	B-T081
of	O
AD	B-T047
among	O
RA	B-T047
patients	B-T101
.	O
Exposure to	B-T080
anti-TNF agents	B-T121
as	O
a	O
class	B-T081
,	O
but	O
not	O
other	O
immunosuppressive drugs	B-T121
studied,	O
was	O
associated with	B-T080
lowered	B-T081
risk	B-T033
of	O
AD	B-T047
among	O
RA	B-T047
patients	B-T101
(unadjusted	O
OR	B-T081
0.44;	O
95	O
%	O
CI	B-T081
0.22-0.87;	O
p	O
=	O
0.02;	O
adjusted	O
OR	B-T081
0.45;	O
95	O
%	O
CI	B-T081
0.23-0.90;	O
p	O
=	O
0.02).	O
Sub-group analysis	B-T081
demonstrated	O
that	O
of	O
the	O
three	O
anti-TNF agents	B-T121
studied,	O
only	O
etanercept	B-T116
(unadjusted	O
OR	B-T081
,	O
0.33;	O
95	O
%	O
CI	B-T081
0.08-0.94;	O
p	O
=	O
0.03;	O
adjusted	O
OR	B-T081
0.30;	O
95	O
%	O
CI	B-T081
0.08-0.89;	O
p	O
=	O
0.02)	O
was	O
associated with	B-T080
a	O
decreased	B-T081
risk	B-T033
of	O
AD	B-T047
in	O
RA	B-T047
patients	B-T101
.	O
There	O
is	O
an	O
increased	B-T081
risk	B-T033
of	O
AD	B-T047
in	O
the	O
studied	O
RA	B-T047
population	B-T081
.	O
The	O
relative risk	B-T081
of	O
AD	B-T047
among	O
RA	B-T047
subjects	O
was	O
lowered	B-T081
in	O
those	O
exposed to	B-T080
etanercept	B-T116
.	O
Anti-TNF therapy	B-T061
with	O
etanercept	B-T116
shows	O
promise	B-T078
as	O
a	O
potential	B-T080
treatment	B-T061
for	O
AD	B-T047
.	O

Dimerization	B-T067
of	O
EGFR	B-T116
and	O
HER2	B-T116
induces	O
breast cancer	B-T191
cell motility	B-T040
through	O
STAT1	B-T116
-dependent	O
ACTA2	B-T116
induction	B-T169
The	O
dimerization	B-T067
of	O
EGFR	B-T116
and	O
HER2	B-T116
is	O
associated	O
with	O
poor	O
prognosis	B-T058
such	O
as	O
induction	B-T169
of	O
tumor growth	B-T191
and	O
cell invasion	B-T046
compared	B-T052
to	O
when	O
EGFR	B-T116
remains	O
as	O
a	O
homodimer	B-T104
.	O
However,	O
the	O
mechanism	B-T169
for	O
events	O
after	O
dimerization	B-T067
in	O
breast cancer	B-T191
models	B-T075
is	O
not	O
clear.	O
We	O
found	O
that	O
expressions	B-T045
of	O
alpha-smooth muscle actin	B-T116
(	O
ACTA2	B-T116
)	O
and	O
signal transducer and activator of transcription 1	B-T116
(	O
STAT1	B-T116
)	O
significantly	O
increased	B-T081
with	O
transient	O
or	O
stable	O
overexpression	B-T045
of	O
HER2	B-T116
in	O
EGFR	B-T116
-	O
positive	B-T033
breast cancer	B-T191
cells	B-T025
.	O
ACTA2	B-T116
and	O
STAT1	B-T116
expression	B-T045
was	O
also	O
increased	B-T081
in	O
HER2	B-T116
-	O
positive	B-T033
breast cancer	B-T191
patients	B-T101
.	O
In	O
contrast,	O
ACTA2	B-T116
expression	B-T045
was	O
decreased	B-T081
by	O
HER2 siRNA	B-T114
.	O
Next,	O
we	O
investigated	O
the	O
co-relation	O
between	O
STAT1	B-T116
and	O
ACTA2	B-T116
expression	B-T045
.	O
Basal	O
ACTA2	B-T116
expression	B-T045
was	O
significantly	O
decreased	B-T081
by	O
treatment	B-T061
with	O
the	O
STAT1 inhibitor	B-T121
fludarabine	B-T114
or	O
the	O
JAK2 inhibitor	B-T121
AG490	B-T109
.	O
In	O
contrast,	O
ACTA2	B-T116
expression	B-T045
was	O
increased	B-T081
by	O
STAT1	B-T116
overexpression	B-T045
.	O
Levels	O
of	O
ACTA2	B-T116
,	O
STAT1	B-T116
,	O
and	O
HER2	B-T116
were	O
increased	B-T081
and	O
relapse	O
free survival	B-T081
was	O
decreased	B-T081
in	O
high-risk	B-T033
breast cancer	B-T191
patients	B-T101
.	O
We	O
also	O
investigated	B-T169
the	O
effect	O
of	O
ACTA2	B-T116
on	O
cell motility	B-T040
,	O
which	O
was	O
suppressed	B-T169
by	O
ACTA2 shRNA	B-T114
overexpression	B-T045
in	O
MDA-MB231	B-T025
HER2	B-T116
and	O
4T1 mammary carcinoma cells	B-T025
.	O
The	O
number	O
of	O
lung metastatic nodules	B-T033
was	O
significantly	O
decreased	B-T081
in	O
ACTA2	B-T116
knockdown mice	B-T015
.	O
Taken	O
together,	O
these	O
results	O
demonstrated	O
that	O
induction	B-T169
of	O
ACTA2	B-T116
by	O
EGFR	B-T116
and	O
HER2	B-T116
dimerization	B-T067
was	O
regulated	O
through	O
a	O
JAK2	B-T116
/	O
STAT1	B-T116
signaling pathway	B-T044
,	O
and	O
aberrant	O
ACTA2	B-T116
expression	B-T045
expression	B-T045
accelerated	O
the	O
invasiveness	B-T046
and	O
metastasis	B-T191
of	O
breast cancer	B-T191
cells	B-T025
.	O

Intensive	O
social	B-T169
cognitive treatment	B-T061
(can	O
do	O
treatment	B-T169
)	O
with	O
participation	B-T169
of	O
support	O
partners	B-T098
in	O
persons	B-T098
with	O
relapsing remitting multiple sclerosis	B-T047
:	O
observation	B-T058
of	O
improved	B-T033
self-efficacy	B-T041
,	O
quality of life	B-T078
,	O
anxiety	B-T033
and	O
depression	B-T048
1	O
year	B-T079
later	O
In	O
persons	B-T098
with	O
multiple sclerosis	B-T047
(	O
MS	B-T047
)	O
self-efficacy	B-T041
positively	B-T033
affects	O
health-related quality of life	B-T078
(	O
HRQoL	B-T078
)	O
and	O
physical activity	B-T056
.	O
In	O
a	O
previous	O
study	O
we	O
observed	B-T169
that	O
6	O
months	B-T079
after	O
an	O
intensive	O
3-	O
day	B-T079
social	B-T169
cognitive treatment	B-T061
(Can	O
Do	O
treatment	B-T169
)	O
with	O
the	O
participation	B-T169
of	O
support	O
partners	B-T098
,	O
self-efficacy	B-T041
and	O
HRQoL	B-T078
had	O
improved	B-T033
in	O
persons	B-T098
with	O
relapsing remitting MS	B-T047
(	O
RRMS	B-T047
).	O
Given	O
the	O
chronic	B-T079
nature of the disease	B-T080
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
these	O
beneficial	B-T081
changes	B-T169
may	O
last.	O
Can	O
Do	O
treatment	B-T169
was	O
given	O
to	O
60	O
persons	B-T098
with	O
MS	B-T047
and	O
their	O
support	O
partners	B-T098
.	O
At	O
baseline	B-T081
and	O
12	O
months	B-T079
after	O
treatment	B-T061
self-efficacy	B-T041
control	B-T169
,	O
self-efficacy	B-T041
function	B-T169
,	O
physical	B-T169
and	O
mental	B-T041
HRQoL	B-T078
,	O
anxiety	B-T033
,	O
depression	B-T048
and	O
fatigue	B-T184
were	O
assessed	B-T052
via	O
self-report	B-T062
questionnaires	B-T170
.	O
Differences	B-T080
were	O
tested	B-T169
via	O
a	O
paired t test	B-T170
.	O
Of	O
the	O
57	O
persons	B-T098
with	O
MS	B-T047
that	O
completed	B-T080
the	O
baseline	B-T081
assessment	B-T052
and	O
the	O
3-	O
day	B-T079
treatment	B-T169
,	O
38	O
filled	O
in	O
the	O
12th	O
month	B-T079
questionnaires	B-T170
(	O
response	B-T033
rate	B-T081
66.7	O
%),	O
22	O
with	O
RRMS	B-T047
and	O
14	O
with	O
progressive	B-T169
MS	B-T047
.	O
In	O
the	O
RR	B-T047
group	B-T078
self-efficacy	B-T041
control	B-T169
had	O
increased	B-T081
by	O
20.2	O
%	O
and	O
physical	B-T169
HRQoL	B-T078
by	O
15.0	O
%,	O
and	O
depression	B-T048
and	O
anxiety	B-T033
had	O
decreased	B-T081
by	O
29.8	O
and	O
25.9	O
%,	O
respectively	O
(all	O
P	O
<	O
0.05);	O
the	O
changes	B-T169
in	O
mental	B-T041
HRQoL	B-T078
(+17	O
%)	O
and	O
fatigue	B-T184
(-20	O
%)	O
failed	B-T169
to	O
be	O
statistically significant	B-T081
(P	O
=	O
0.087,	O
P	O
=	O
0.080,	O
respectively).	O
In	O
the	O
progressive	B-T169
group	B-T078
no	O
changes	B-T169
suggestive of	B-T169
improvement	B-T077
were	O
seen.	O
The	O
findings	B-T169
suggest	B-T078
that	O
a	O
3-	O
day	B-T079
intensive	O
social	B-T169
cognitive treatment	B-T061
(Can	O
Do	O
treatment	B-T169
)	O
with	O
the	O
participation	B-T169
of	O
support	O
partners	B-T098
may	O
have	O
long lasting	B-T079
beneficial	B-T081
effects	B-T080
on	O
the	O
self-efficacy	B-T041
and	O
HRQoL	B-T078
in	O
persons	B-T098
with	O
RRMS	B-T047
;	O
and	O
that	O
improvements	B-T077
in	O
anxiety	B-T033
and	O
depression	B-T048
,	O
not	O
seen	O
in	O
the	O
6-	O
month	B-T079
study,	O
may	O
yet	O
develop	B-T169
at	O
12	O
months	B-T079
.	O

Perineal injuries	B-T037
and	O
birth positions	B-T033
among	O
2992	O
women	B-T098
with	O
a	O
low risk pregnancy	B-T033
who	O
opted	O
for	O
a	O
homebirth	B-T033
Whether	O
certain	O
birth positions	B-T033
are	O
associated with	B-T080
perineal injuries	B-T037
and	O
severe perineal trauma	B-UnknownType
(	O
SPT	B-UnknownType
)	O
is	O
still	O
unclear	B-T033
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
describe	O
the	O
prevalence	B-T081
of	O
perineal injuries	B-T037
of	O
different	O
severity	B-T080
in	O
a	O
low-risk	B-T081
population	B-T098
of	O
women	B-T098
who	O
planned	O
to	O
give	O
birth at home	B-T033
and	O
to	O
compare	O
the	O
prevalence	B-T081
of	O
perineal injuries	B-T037
,	O
SPT	B-UnknownType
and	O
episiotomy	B-T061
in	O
different	O
birth positions	B-T033
in	O
four	O
Nordic countries	B-T083
.	O
A	O
population	B-T098
-based	O
prospective cohort study	B-T062
of	O
planned	O
home births	B-T033
in	O
four	O
Nordic countries	B-T083
.	O
To	O
assess medical outcomes	B-T057
a	O
questionnaire	B-T170
completed	O
after	O
birth	B-T040
by	O
the	O
attending	O
midwife	B-T097
was	O
used.	O
Descriptive statistics	B-T062
,	O
bivariate analysis	B-UnknownType
and	O
logistic regression	B-T062
were	O
used	O
to	O
analyze	O
the	O
data	B-T078
.	O
Two	O
thousand	O
nine	O
hundred	O
ninety-two	O
women	B-T098
with	O
planned	O
home births	B-T033
,	O
who	O
birthed	O
spontaneously	O
at	O
home	B-T082
or	O
after	O
transfer to hospital	B-T058
,	O
between	O
2008	O
and	O
2013	O
were	O
included.	O
The	O
prevalence	B-T081
of	O
SPT	B-UnknownType
was	O
0.7	O
%	O
and	O
the	O
prevalence	B-T081
of	O
episiotomy	B-T061
was	O
1.0	O
%.	O
There	O
were	O
differences	O
between	O
the	O
countries	O
regarding	O
all	O
maternal	B-T033
characteristics	B-T080
.	O
No	O
association	O
between	O
flexible	B-T080
sacrum	B-T029
positions	B-T082
and	O
sutured	B-T169
perineal injuries	B-T037
was	O
found	O
(	O
OR	B-T081
1.02;	O
95	O
%	O
CI	B-T081
0.86-1.21)	O
or	O
SPT	B-UnknownType
(	O
OR	B-T081
0.68;	O
CI	B-T081
95	O
%	O
0.26-1.79).	O
Flexible	B-T080
sacrum	B-T029
positions	B-T082
were	O
associated with	B-T080
fewer	O
episiotomies	B-T061
(	O
OR	B-T081
0.20;	O
CI	B-T081
95	O
%	O
0.10-0.54).	O
A	O
low	O
prevalence	B-T081
of	O
SPT	B-UnknownType
and	O
episiotomy	B-T061
was	O
found	O
among	O
women	B-T098
opting	O
for	O
a	O
home birth	B-T033
in	O
four	O
Nordic countries	B-T083
.	O
Women	B-T098
used	O
a	O
variety	O
of	O
birth positions	B-T033
and	O
a	O
majority	O
gave	O
birth	B-T040
in	O
flexible	B-T080
sacrum	B-T029
positions	B-T082
.	O
No	O
associations	O
were	O
found	O
between	O
flexible	B-T080
sacrum	B-T029
positions	B-T082
and	O
SPT	B-UnknownType
.	O
Flexible	B-T080
sacrum	B-T029
positions	B-T082
were	O
associated with	B-T080
fewer	O
episiotomies	B-T061
.	O

Parallel-processing	B-T066
continuous-flow device	B-T074
for	O
optimization	B-T052
-	O
free	B-T169
polymerase chain reaction	B-T063
A	O
parallel-processing	B-T066
four-station polymerase chain reaction	B-T063
(	O
PCR	B-T063
)	O
device	B-T073
has	O
been	O
developed,	O
which	O
performs	B-T169
continuous-flow	B-T070
PCR	B-T063
without	O
optimization	B-T052
of	O
the	O
annealing	B-T045
temperature	B-T081
.	O
Since	O
the	O
annealing	B-T045
temperature	B-T081
of	O
each	O
station	B-T073
can	O
be	O
controlled	B-T169
independently	B-T169
,	O
the	O
device	B-T073
covers	B-T169
an	O
annealing	B-T045
temperature	B-T081
range	B-T081
of	O
50-68	O
°C,	O
which	O
is	O
wide	B-T082
enough	O
to	O
perform	B-T169
PCR	B-T063
for	O
any	O
DNA fragment	B-UnknownType
regardless	O
of	O
its	O
optimum	B-T080
annealing	B-T045
condition	B-T080
.	O
This	O
arrangement	B-T169
lets	O
us	O
continuously	B-T078
obtain	B-T169
an	O
amplified	B-T067
amount	B-T081
of	O
a	O
DNA fragment	B-UnknownType
at	O
least	O
from	O
one	O
of	O
the	O
stations	B-T073
.	O
The	O
device	B-T073
consists	O
of	O
four	O
identical	B-T080
cylindrical	B-T082
stations	B-T073
(	O
diameter	B-T081
20	O
mm,	O
height	B-T032
55	O
mm).	O
A	O
polytetrafluoroethylene	B-T109
capillary reactor	B-T074
(	O
length	B-T081
2	O
m,	O
I.D.	O
100	O
μm,	O
O.D.	O
400	O
μm)	O
is	O
wound helically	B-T082
up	B-T082
around	B-T078
each	O
station	B-T073
.	O
The	O
whole	O
assembly	B-T052
is	O
designed	B-T052
to	O
minimize	B-T080
the	O
number	B-T081
of	O
heating blocks	B-T074
(for	O
providing	B-T052
temperatures	B-T081
of	O
denaturation	B-T044
,	O
annealing	B-T045
,	O
and	O
extension	B-T169
)	O
to	O
be	O
seven	O
and	O
to	O
shape	B-T082
a	O
compact	B-T033
cube	B-T082
(	O
height	B-T032
55	O
mm,	O
base	B-T081
60	O
mm	O
×	O
60	O
mm).	O
The	O
reproducibility	B-T080
for	O
continuous-flow	B-T070
PCR	B-T063
is	O
reasonably	O
high	B-T080
(	O
run	B-T169
-to-	O
run	B-T169
and	O
station	B-T073
-to-	O
station	B-T073
relative	O
standard deviation	B-T081
of	O
their	O
amplification	B-T045
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%,	O
respectively).	O
Performance	B-T052
on	O
the	O
optimization	B-T052
-	O
free	B-T169
DNA amplification	B-T045
has	O
been	O
evaluated	B-T058
with	O
four	O
DNA samples	B-T026
with	O
different	B-T080
annealing	B-T045
conditions	B-T080
and	O
product	B-T071
sizes	B-T082
(323,	O
608,	O
828,	O
and	O
1101	O
bp),	O
which	O
has	O
demonstrated	B-T080
that	O
in	O
all	O
cases	B-T169
,	O
PCR	B-T063
is	O
successful	B-T080
at	O
least	O
on	O
one	O
station	B-T073
.	O
In	O
addition	B-T169
,	O
three	O
DNA fragment	B-UnknownType
s	O
with	O
different	B-T080
lengths	B-T081
(323,	O
1101,	O
and	O
2836	O
bp)	O
have	O
been	O
successfully	B-T080
amplified	B-T067
in	O
a	O
segmented	B-T082
-	O
flow	B-T070
mode	B-T169
without	O
the	O
carry-over	O
contamination	B-T078
between	O
segments	B-T082
.	O
This	O
result	B-T169
suggests	O
that	O
this	O
device	B-T073
could	O
serve	O
as	O
the	O
PCR	B-T063
module	B-T077
of	O
a	O
continuous-flow	B-T070
high-throughput on-line total DNA analysis	B-T060
system	B-T169
integrating	B-T080
all	O
necessary	O
modules	B-T077
from	O
cell	B-T025
lysis	B-T046
/	O
DNA extraction	B-T063
to	O
PCR	B-T063
product	B-T071
analysis	B-T062
.	O

Assessing	B-T052
sex-differences	B-T032
and	O
the	O
effect	B-T080
of	O
timing	B-T079
of	O
vaccination	B-T061
on	O
immunogenicity	B-T038
,	O
reactogenicity	B-T033
and	O
efficacy of vaccines	B-T033
in	O
young	B-T079
children	B-T100
:	O
study protocol	B-T170
for	O
an	O
individual	B-T098
participant	B-T098
data	B-T078
meta-analysis	B-T062
of	O
randomised controlled trials	B-T062
Disease	B-T047
incidence	B-T081
differs	O
between	O
males	B-T032
and	O
females	B-T032
for	O
some	O
infectious	B-T047
or	O
inflammatory diseases	B-T047
.	O
Sex-differences	B-T032
in	O
immune responses	B-T042
to	O
some	O
vaccines	B-T121
have	O
also	O
been	O
observed,	O
mostly	O
to	O
viral vaccines	B-T121
in	O
adults	B-T100
.	O
Little	O
evidence	B-T078
is	O
available	B-T169
on	O
whether	O
sex-differences	B-T032
occur	O
in	O
response	B-T033
to	O
immunisation	B-T061
in	O
infancy	B-T079
even	O
though	O
this	O
is	O
the	O
age group	B-T100
in	O
which	O
most	O
vaccines	B-T121
are	O
administered	B-T169
.	O
Factors	B-T169
other	O
than	O
sex	B-T032
,	O
such	O
as	O
timing	B-T079
or	O
coadministration	B-T061
of	O
other	O
vaccines	B-T121
,	O
can	O
also	O
influence	B-T077
the	O
immune response	B-T042
to	O
vaccination	B-T061
.	O
Individual	B-T098
participant	B-T098
data	B-T078
meta-analysis	B-T062
of	O
randomised controlled trials	B-T062
of	O
vaccines	B-T121
in	O
healthy	O
infants	B-T100
and	O
young	B-T079
children	B-T100
will	O
be	O
conducted.	O
Fully	O
anonymised	O
data	B-T078
from	O
∼170	O
randomised controlled trials	B-T062
of	O
v	O
accines	B-T121
for	O
diphtheria	B-T047
,	O
tetanus	B-T047
,	O
Bordetella pertussis	B-T007
,	O
polio	B-T047
,	O
Haemophilus influenzae type B	B-T007
,	O
hepatitis B	B-T047
,	O
Streptococcus pneumoniae	B-T007
,	O
Neisseria meningitidis	B-T007
,	O
measles	B-T047
,	O
mumps	B-T047
,	O
rubella	B-T047
,	O
varicella	B-T047
and	O
rotavirus	B-T005
will	O
be	O
combined	O
for	O
analysis	B-T062
.	O
Outcomes	B-T169
include	O
measures	B-T169
of	O
immunogenicity	B-T038
(	O
immunoglobulins	B-T116
),	O
reactogenicity	B-T033
,	O
safety	B-T068
and	O
disease	B-T047
-specific	O
clinical efficacy	B-T080
.	O
Data	B-T078
from	O
trials	B-T062
of	O
vaccines	B-T121
containing	O
similar	O
components	B-T073
will	O
be	O
combined	O
in	O
hierarchical	B-T169
models	B-T170
and	O
the	O
effect	B-T080
of	O
sex	B-T032
and	O
timing	B-T079
of	O
vaccinations	B-T061
estimated	O
for	O
each	O
outcome	B-T169
separately.	O
Systematic reviews	B-T170
of	O
published	B-T057
estimates	O
of	O
sex-differences	B-T032
cannot	O
adequately	O
answer questions	B-T061
in	O
this	O
field	B-T077
since	O
such	O
comparisons	B-T052
are	O
never	O
the	O
main	O
purpose	B-T169
of	O
a	O
clinical trial	B-T062
,	O
thus	O
a	O
large	B-T081
degree	B-T081
of	O
reporting	B-T058
bias	B-T078
exists	B-T077
in	O
the	O
published	B-T057
literature	B-T170
.	O
Recent	O
improvements	B-T077
in	O
the	O
widespread	B-T082
availability of	B-T169
individual	B-T098
participant	B-T098
data	B-T078
from	O
randomised controlled trials	B-T062
makes	O
it	O
feasible	O
to	O
conduct	O
extensive	B-T080
individual	B-T098
participant	B-T098
data	B-T078
meta-analyses	B-T062
which	O
were	O
previously	B-T079
impossible	B-T033
,	O
thereby	O
reducing	B-T080
the	O
effect	B-T080
of	O
publication	B-T073
or	O
reporting	B-T058
bias	B-T078
on	O
the	O
understanding	B-T041
of	O
the	O
infant	B-T100
immune response	B-T042
.	O
Preliminary results	B-T078
will	O
be	O
available	B-T169
in	O
2016	O
with	O
final	O
results	B-T169
available	B-T169
in	O
2019.	O
No	B-T169
ethics	B-T078
review	B-T170
is	O
required	O
for	O
secondary analyses	B-UnknownType
of	O
anonymised	O
data	B-T078
.	O

An	O
ultrasensitive	B-T169
electrochemiluminescence	B-T059
sensor	B-T073
based	O
on	O
reduced graphene oxide	B-T196
-	O
copper sulfide	B-T197
composite	B-T080
coupled	O
with	O
capillary electrophoresis	B-T059
for	O
determination	B-T059
of	O
amlodipine besylate	B-T109
in	O
mice	B-T015
plasma	B-T031
A	O
new	O
electrochemiluminescence	B-T059
(	O
ECL	B-T059
)	O
sensor	B-T073
based	O
on	O
reduced graphene oxide	B-T196
-	O
copper sulfide	B-T197
(	O
rGO	B-T196
-	O
CuS	B-T197
)	O
composite	B-T080
coupled	O
with	O
capillary electrophoresis	B-T059
(	O
CE	B-T059
)	O
was	O
constructed	O
for	O
the	O
ultrasensitive	B-T169
detection	B-T061
of	O
amlodipine besylate	B-T109
(	O
AML	B-T109
)	O
for	O
the	O
first	O
time.	O
In	O
this	O
work,	O
rGO	B-T196
-	O
CuS	B-T197
composite	B-T080
was	O
synthesized	O
by	O
one-pot	O
hydrothermal method	B-T169
and	O
used	O
for	O
electrode	B-T074
modification	B-T033
.	O
The	O
electrochemical	B-T059
and	O
ECL	B-T059
behaviors	O
of	O
the	O
sensor	B-T073
were	O
investigated	B-T169
.	O
More	O
than	O
5-fold	O
enhance	B-T052
in	O
ECL	B-T059
intensity	B-T081
was	O
observed	B-T169
after	O
modified	O
with	O
rGO	B-T196
-	O
CuS	B-T197
composite	B-T080
.	O
The	O
results	B-T034
can	O
be	O
ascribed	O
to	O
the	O
presence	B-T080
of	O
rGO	B-T196
-	O
CuS	B-T197
composite	B-T080
on	O
the	O
electrode	B-T074
surface	B-T082
that	O
facilitates	O
the	O
electron transfer rate	B-T081
between	O
the	O
electroactive	B-T169
center	B-T082
of	O
Ru(bpy)3(2+)	B-T104
and	O
the	O
electrode	B-T074
.	O
The	O
ECL	B-T059
sensor	B-T073
was	O
coupled	B-T169
with	O
CE	B-T059
to	O
improve	O
the	O
selectivity	B-T034
and	O
the	O
CE	B-T059
-	O
ECL	B-T059
parameters	B-T033
that	O
affect	O
separation	B-UnknownType
and	O
detection	B-T061
were	O
optimized.	O
Under	O
the	O
optimum	B-T080
conditions,	O
the	O
linear ranges	B-T081
for	O
AML	B-T109
was	O
0.008-5.0μg/mL	O
with	O
a	O
detection limit	B-T081
of	O
2.8ng/mL	O
(S/N=3).	O
The	O
method	B-T059
displayed	O
the	O
advantages	O
of	O
high sensitivity	B-T067
,	O
good selectivity	B-T034
,	O
wide	O
linear range	B-T081
,	O
low	O
detection limit	B-T081
and	O
fine reproducibility	B-T080
,	O
and	O
was	O
used	O
to	O
analyze	O
AML	B-T109
in	O
mice	B-T015
plasma	B-T031
with	O
a	O
satisfactory	O
result	B-T034
,	O
which	O
holds	O
a	O
great	O
potential	B-T080
in	O
the	O
field	O
of	O
pharmaceutical analysis	B-T062
.	O

Estrogen	B-T109
and	O
Progesterone	B-T109
hormone	B-T125
receptor expression	B-T045
in	O
oral cavity cancer	B-T191
Recent	O
studies	O
have	O
shown	O
an	O
increase	B-T169
in	O
the	O
incidence	B-T081
of	O
oral squamous cell carcinoma	B-T191
(	O
OSCC	B-T191
)	O
in	O
younger	B-T079
patients	B-T101
.	O
The	O
hypothesis	B-T078
that	O
tumors	B-T191
could	O
be	O
hormonally	B-T125
induced	B-T169
during	O
pregnancy	B-T040
or	O
in	O
young	B-T079
female	B-T032
patients	B-T101
without	O
the	O
well-known	O
risk factors	B-T033
alcohol	B-T048
or	O
tobacco abuse	B-T048
seems	O
to	O
be	O
plausible.	O
Estrogen Receptor alpha	B-T116
(	O
ERα	B-T116
)	O
and	O
Progesterone Receptor	B-T116
(	O
PR	B-T116
)	O
expression	B-T045
were	O
analyzed	B-T062
in	O
normal	O
oral mucosa	B-T023
(n=5),	O
oral precursor lesions	B-T033
(	O
simple hyperplasia	B-T047
,	O
n=11;	O
squamous intraepithelial neoplasia	B-T191
,	O
SIN I-III	B-T191
,	O
n=35),	O
and	O
OSCC	B-T191
specimen	B-T167
.	O
OSCCs	B-T191
were	O
stratified	B-T080
in	O
a	O
young	B-T079
female	B-T032
(n=7)	O
study	O
cohort	B-T098
and	O
older	B-T098
patients	B-T101
(n=46).	O
In	O
the	O
young	B-T079
female	B-T032
study	O
cohort	B-T098
three	O
patients	B-T101
(n=3/7)	O
developed	O
OSCC	B-T191
during	O
or	O
shortly	O
after	O
pregnancy	B-T040
.	O
Breast cancer	B-T191
tissues	B-T024
were	O
used	O
as	O
positive control	B-T077
for	O
ERα	B-T116
and	O
PR	B-T116
expression	B-T045
.	O
ERα	B-T116
expression	B-T045
was	O
found	O
in	O
four	O
oral precursor lesions	B-T033
(	O
squamous intraepithelial neoplasia	B-T191
,	O
SIN I-III	B-T191
,	O
n=4/35,	O
11%)	O
and	O
in	O
five	O
OSCC	B-T191
specimen	B-T167
(n=5/46,	O
11%).	O
The	O
five	O
ERα	B-T116
positive	B-T033
OSCC	B-T191
samples	B-T167
were	O
older	B-T098
male	B-T032
patients	B-T101
.	O
All	O
patients	B-T101
within	O
the	O
young	B-T079
female	B-T032
study	O
cohort	B-T098
were	O
negatively	B-T033
stained	O
for	O
both	O
ERα	B-T116
and	O
PR	B-T116
.	O
ER	B-T116
expression	B-T045
could	O
be	O
regarded	O
as	O
a	O
seldom	B-T080
risk factor	B-T033
for	O
OSCC	B-T191
.	O
PR	B-T116
expression	B-T045
seems	O
to	O
be	O
not	O
relevant	B-T080
for	O
the	O
development	B-T169
of	O
OSCC	B-T191
.	O

Studying	B-T062
neuroprotective effect	B-T169
of	O
Atorvastatin	B-T109
as	O
a	O
small molecule	B-T109
drug	B-T121
on	O
high glucose	B-T033
-	O
induced	B-T169
neurotoxicity	B-T037
in	O
undifferentiated	B-T080
PC12 cells	B-T025
:	O
role	B-T077
of	O
NADPH oxidase	B-T116
Overproduction	B-T080
of	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
)	O
by	O
NADPH oxidase	B-T116
(	O
NOX	B-T116
)	O
activation	B-T044
has	O
been	O
considered	B-T078
the	O
essential	B-T080
mechanism	B-T169
induced	B-T169
by	O
hyperglycemia	B-T047
in	O
various	O
tissues	B-T024
.	O
However,	O
there	O
is	O
no comprehensive	B-T080
study	B-T062
on	O
the	O
role	B-T077
of	O
NOXs	B-T116
in	O
high glucose	B-T033
(	O
HG	B-T033
)-	O
induced	B-T169
toxic effect	B-T037
in	O
neural tissues	B-T024
.	O
Recently,	O
a	O
therapeutic	B-T169
strategy	B-T041
in	O
oxidative	B-T169
related	B-T080
pathologies	B-T091
has	O
been	O
introduced	B-T169
by	O
blocking	B-T169
the	O
undesirable actions	B-T052
of	O
NOX enzymes	B-T116
by	O
small molecules	B-T109
.	O
The	O
protective	B-T033
roles	B-T077
of	O
Statins	B-T109
in	O
ameliorating	B-T080
oxidative stress	B-T049
by	O
NOX	B-T116
inhibition	B-T039
have	O
been	O
shown	O
in	O
some	O
tissues	B-T024
except	O
neural	B-T024
.	O
We	O
hypothesized	B-T078
then,	O
that	O
different	B-T080
NOXs	B-T116
may	O
have	O
role	B-T077
in	O
HG	B-T033
-	O
induced	B-T169
neural cell injury	B-T049
.	O
Furthermore,	O
we	O
postulate	B-T078
that	O
Atorvastatin	B-T109
as	O
a	O
small molecule	B-T109
may	O
modulate	B-T082
this	O
NOXs activity	B-T044
to	O
protect	B-T033
neural cells	B-T025
.	O
Undifferentiated	B-T080
PC12 cells	B-T025
were	O
treated with	B-T061
HG	B-T033
(140	O
mM/	O
24 h	B-T079
)	O
in	O
the	O
presence	B-T033
and	O
absence	B-T169
of	O
Atorvastatin	B-T109
(1	O
μM/	O
96 h	B-T079
).	O
The	O
cell viability	B-T043
was	O
measured	B-T080
by	O
MTT assay	B-T062
and	O
the	O
gene	B-T081
and	O
protein expressions profile	B-T034
of	O
NOX	B-T116
(1-4)	O
were	O
determined by	B-T080
RT-PCR	B-T063
and	O
western blotting	B-T059
,	O
respectively.	O
Levels	B-T080
of	O
ROS	B-T123
and	O
malondialdehyde	B-T109
(	O
MDA	B-T109
)	O
were	O
also	O
evaluated	B-T052
.	O
Gene	B-T045
and	O
protein expression	B-T045
levels	B-T080
of	O
NOX	B-T116
(1-4)	O
and	O
consequently	B-T033
ROS	B-T123
and	O
MDA	B-T109
levels	B-T080
were	O
elevated	B-T080
in	O
HG	B-T033
-	O
treated	B-T169
PC12 cells	B-T025
.	O
Atorvastatin	B-T109
could	O
significantly	B-T078
decrease	B-T081
HG	B-T033
-	O
induced	B-T169
NOXs	B-T116
,	O
ROS	B-T123
and	O
MDA	B-T109
elevation	B-T082
and	O
improve	B-T033
impaired	B-T169
cell viability	B-T043
.	O
It	O
can	O
be	O
concluded	B-T078
that	O
HG	B-T033
could	O
elevate	B-T080
NOXs activity	B-T044
,	O
ROS	B-T123
and	O
MDA	B-T109
levels	B-T080
in	O
neural tissues	B-T024
and	O
Atorvastatin	B-T109
as	O
a	O
small molecule	B-T109
NOX inhibitor drug	B-T121
may	O
prevent	B-T080
and	O
delay	B-T079
diabetic complications	B-T047
,	O
particularly	O
neuropathy	B-T047
.	O

Intravascular	B-T082
Inflammation	B-T046
Triggers	B-T080
Intracerebral	B-T082
Activated	B-T052
Microglia	B-T025
and	O
Contributes	O
to	O
Secondary Brain Injury	B-T037
After	O
Experimental	B-T080
Subarachnoid Hemorrhage	B-T047
(	O
eSAH	B-T047
)	O
Activation	B-T052
of	O
innate immunity	B-T032
contributes	O
to	O
secondary brain injury	B-T037
after	O
experimental	B-T080
subarachnoid hemorrhage	B-T047
(	O
eSAH	B-T047
).	O
Microglia	B-T025
accumulation	B-T033
and	O
activation	B-T052
within	O
the	O
brain	B-T023
has	O
recently	O
been	O
shown	O
to	O
induce	O
neuronal cell death	B-T043
after	O
eSAH	B-T047
.	O
In	O
isolated	B-T169
mouse	B-T015
brain	B-T023
capillaries	B-T023
after	O
eSAH	B-T047
,	O
we	O
show	O
a	O
significantly	O
increased	O
gene expression	B-T045
for	O
intercellular adhesion molecule-1	B-T028
(	O
ICAM-1	B-T028
)	O
and	O
P-selectin	B-T028
.	O
Hence,	O
we	O
hypothesized	B-T078
that	O
extracerebral	B-T082
intravascular	B-T082
inflammatory processes	B-T046
might	O
initiate	O
the	O
previously	O
reported	B-T058
microglia	B-T025
accumulation	B-T033
within	O
the	O
brain tissue	B-T023
.	O
We	O
therefore	O
induced	O
eSAH	B-T047
in	O
knockout mice	B-T015
for	O
ICAM-1	B-T028
(	O
ICAM-1(-/-)	B-T028
)	O
and	O
P-selectin glycoprotein ligand-1	B-T028
(	O
PSGL-1(-/-)	B-T028
)	O
to	O
find	O
a	O
significant	O
decrease	O
in	O
neutrophil	B-T025
-	O
endothelial	B-T025
interaction	B-T043
within	O
the	O
first	O
7	O
days	O
after	O
the	O
bleeding	B-T046
in	O
a	O
chronic	B-T079
cranial	B-T082
window model	B-T075
.	O
This	O
inhibition	B-T052
of	O
neutrophil recruitment	B-T039
to	O
the	O
endothelium	B-T025
results	O
in	O
significantly	O
ameliorated	B-T033
microglia	B-T025
accumulation	B-T033
and	O
neuronal cell death	B-T043
in	O
knockout animals	B-T008
in	O
comparison	O
to	O
controls.	O
Our	O
results	O
suggest	O
an	O
outside-in	O
activation	B-T052
of	O
the	O
CNS innate	B-T022
immune system	B-T022
at	O
the	O
vessel	B-T029
/	O
brain	B-T023
interface	O
following	O
eSAH	B-T047
.	O
Microglia	B-T025
cells	B-T025
,	O
as	O
part	O
of	O
the	O
brain's	B-T023
innate immune system	B-T032
,	O
are	O
triggered	B-T080
by	O
an	O
inflammatory reaction	B-T046
in	O
the	O
microvasculature	B-T042
after	O
eSAH	B-T047
,	O
thus	O
contributing	O
to	O
neuronal cell death	B-T043
.	O
This	O
finding	O
offers	O
a	O
whole	O
range	O
of	O
new	O
research	B-T062
targets	B-T169
,	O
as	O
well	O
as	O
possible	O
therapy	B-T169
options	O
for	O
patients	B-T101
suffering	O
from	O
eSAH	B-T047
.	O

Amphetamine Withdrawal	B-T048
Differentially	O
Increases	O
the	O
Expression	B-T045
of	O
Organic Cation Transporter 3	B-T116
and	O
Serotonin Transporter	B-T116
in	O
Limbic	B-T022
Brain Regions	B-T023
Amphetamine withdrawal	B-T048
increases	O
anxiety	B-T033
and	O
stress	B-T033
sensitivity	O
related	O
to	O
blunted	B-T080
ventral	B-T082
hippocampus	B-T023
(	O
vHipp	B-T023
)	O
and	O
enhances	O
the	O
central nucleus of the amygdala	B-T023
(	O
CeA	B-T023
)	O
serotonin	B-T109
responses	B-T032
.	O
Extracellular	B-T026
serotonin	B-T109
levels	B-T080
are	O
regulated	O
by	O
the	O
serotonin transporter	B-T116
(	O
SERT	B-T116
)	O
and	O
organic cation transporter 3	B-T116
(	O
OCT3	B-T116
),	O
and	O
vHipp	B-T023
OCT3	B-T116
expression	B-T045
is	O
enhanced	O
during	O
24 hours	B-T079
of	O
amphetamine withdrawal	B-T048
,	O
while	O
SERT	B-T116
expression	B-T045
is	O
unaltered.	O
Here,	O
we	O
tested	O
whether	O
OCT3	B-T116
and	O
SERT	B-T116
expression	B-T045
in	O
the	O
CeA	B-T023
is	O
also	O
affected	O
during	O
acute	O
withdrawal	B-T048
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	B-T022
serotonergic neurotransmission	B-T043
and	O
if	O
respective	O
changes	O
continued	O
with	O
two weeks	B-T079
of	O
withdrawal	B-T048
.	O
We	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	B-T116
expression	B-T045
were	O
confined	O
to	O
these	O
regions.	O
Male	B-T032
rats	B-T015
received	O
amphetamine	B-T109
or	O
saline	B-T167
for	O
two weeks	B-T079
followed	O
by	O
24 hours	B-T079
or	O
two weeks	B-T079
of	O
withdrawal	B-T048
,	O
with	O
transporter	B-T116
expression	B-T045
measured	O
using	O
Western immunoblot	B-T059
.	O
OCT3	B-T116
and	O
SERT	B-T116
expression	B-T045
increased	O
in	O
the	O
CeA	B-T023
at	O
both	O
withdrawal	B-T048
timepoints.	O
In	O
the	O
vHipp	B-T023
,	O
OCT3	B-T116
expression	B-T045
increased	O
only	O
at	O
24 hours	B-T079
of	O
withdrawal	B-T048
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial hypothalamus	B-T023
.	O
No changes	B-T033
were	O
evident	O
in	O
any	O
other	O
regions	B-T029
sampled.	O
These	O
regionally	O
specific	O
changes	O
in	O
limbic	B-T022
OCT3	B-T116
and	O
SERT	B-T116
expression	B-T045
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	B-T109
imbalance	B-T184
and	O
negative affect	B-T033
during	O
amphetamine withdrawal	B-T048
.	O

Nutritional aspects	B-T169
of	O
night	B-T079
eating	B-T040
and	O
its	O
association with	B-T080
weight	B-T032
status	B-T080
among	O
Korean	B-T098
adolescents	B-T100
A	O
growing	B-T169
body	O
of	O
research	B-T062
has	O
indicated	O
that	O
night	B-T079
eating	B-T040
could	O
be	O
associated with	B-T080
poor diet	B-T033
quality	B-T080
and	O
negative	B-T033
health outcomes	B-T170
.	O
This	O
study	B-T170
examined	O
the	O
nutritional aspects	B-T169
of	O
night	B-T079
eating	B-T040
,	O
its	O
related	O
factors	B-T169
,	O
and	O
the	O
association	B-T080
between	O
night	B-T079
eating	B-T040
and	O
body weight	B-T032
among	O
Korean	B-T098
adolescents	B-T100
.	O
This	O
study	B-T170
analysed	O
the	O
data	B-T078
from	O
a	O
one	O
day	B-T079
24-hour	O
dietary recall	B-T062
as	O
well	O
as	O
a	O
demographic survey	B-T062
of	O
1,738	O
Korean	B-T098
adolescents	B-T100
aged	O
12	O
to	O
18-	O
years	B-T079
-old	O
obtained	O
from	O
the	O
2010-2012	O
Korea	B-T083
National Health and Nutrition Examination Survey	B-T062
.	O
'	O
Night	B-T079
eating	B-T040
'	O
was	O
defined	O
as	O
consuming	O
25%	O
or	O
more	O
of	O
one's	O
daily energy intake	B-T081
between	O
21:00	O
and	O
06:00.	O
Subjects	B-T098
complying	O
with	O
the	O
preceding	O
condition	B-T080
were	O
classified	O
as	O
'	O
night	B-T079
eaters	B-T098
',	O
whereas	O
the	O
rest	O
were	O
considered	O
'	O
non-night eaters	B-T098
'.	O
Logistic regression analysis	B-UnknownType
examined	O
factors	B-T169
related	O
to	O
night	B-T079
eating	B-T040
.	O
Multiple linear regression analyses	B-T081
were	O
used	O
to	O
examine	O
the	O
relationship	B-T080
between	O
night	B-T079
eating	B-T040
and	O
BMI	B-T201
z-scores	B-T081
,	O
whereas	O
multinomial logistic regression analysis	B-UnknownType
was	O
used	O
to	O
examine	O
the	O
relationship	B-T080
between	O
night	B-T079
eating	B-T040
and	O
weight	B-T032
status	B-T080
.	O
About	O
21%	O
of	O
Korean	B-T098
adolescents	B-T100
appeared	O
to	O
be	O
night	B-T079
eaters	B-T098
.	O
Night	B-T079
eaters	B-T098
showed	O
increased	B-T081
breakfast	B-T056
skipping	B-T033
(P	O
=	O
0.001),	O
higher	O
energy intake	B-T081
from	O
snacks	B-T168
(P	O
<	O
0.001),	O
greater	O
proportion of energy intake from fat	B-T081
(P	O
=	O
0.029),	O
and	O
lower Dietary Diversity Scores	B-T081
(P	O
=	O
0.008)	O
than	O
non-night eaters	B-T098
.	O
Male	B-T032
adolescents	B-T100
presented	O
1.9	O
times	B-T081
higher	O
odds	O
of	O
being	O
night	B-T079
eaters	B-T098
than	O
females	B-T032
.	O
Adolescents	B-T100
whose	O
both	O
parents	B-T099
were	O
night	B-T079
eaters	B-T098
were	O
4.4	O
times	B-T081
as	O
likely	O
to	O
be	O
night	B-T079
eaters	B-T098
as	O
those	O
whose	O
neither	O
parents	B-T099
were.	O
Female	B-T032
adolescents	B-T100
showed	O
a	O
significant	O
relationship	B-T080
between	O
night	B-T079
eating	B-T040
and	O
BMI	B-T201
z-scores	B-T081
(β	O
=	O
0.28,	O
P	O
=	O
0.004).	O
However,	O
night	B-T079
eating	B-T040
did	O
not	O
increase	B-T169
odds	O
of	O
being	O
overweight	B-T184
or	O
obese	B-T047
in	O
adolescents	B-T100
.	O
Night	B-T079
eating	B-T040
in	O
Korean	B-T098
adolescents	B-T100
was	O
related	O
to	O
undesirable dietary behaviours	B-T033
and	O
low diet quality	B-T033
in	O
general	O
as	O
well	O
as	O
higher	O
BMI	B-T201
z-scores	B-T081
in	O
females	B-T032
.	O
Male	B-T032
gender	B-T032
and	O
parental	B-T099
night	B-T079
eating	B-T040
appeared	O
to	O
be	O
the	O
factors	B-T169
that	O
significantly	O
increased	B-T081
odds	O
of	O
night	B-T079
eating	B-T040
.	O
These	O
results	O
suggest	O
that	O
night	B-T079
eating	B-T040
should	O
be	O
considered	O
when	O
designing	O
nutrition education	B-T065
or	O
intervention programs	B-T061
targeting	O
adolescents	B-T100
.	O

A	O
randomized trial	B-T062
of	O
Plasma-Lyte A	B-T121
and	O
0.9 % sodium chloride	B-T121
in	O
acute pediatric gastroenteritis	B-T047
Compare	O
the	O
efficacy	B-T080
and	O
safety	O
of	O
Plasma-Lyte A	B-T121
(	O
PLA	B-T121
)	O
versus	O
0.9 % sodium chloride	B-T121
(	O
NaCl	B-T121
)	O
intravenous (IV) fluid replacement	B-T061
in	O
children	B-T100
with	O
moderate	O
to	O
severe dehydration	B-T047
secondary	O
to	O
acute gastroenteritis	B-T047
(	O
AGE	B-T047
).	O
Prospective	B-T062
,	O
randomized	B-T062
,	O
double-blind study	B-T062
conducted	O
at	O
eight	O
pediatric	B-T080
emergency departments	B-T073
(	O
EDs	B-T073
)	O
in	O
the	O
US	B-T083
and	O
Canada	B-T083
(NCT#01234883).	O
The	O
primary outcome measure	B-T080
was	O
serum bicarbonate level	B-T034
at	O
4	O
h.	O
Secondary outcomes	B-T080
included	O
safety	O
and	O
tolerability	B-T062
.	O
The	O
hypothesis	B-T078
was	O
that	O
PLA	B-T121
would	O
be	O
superior	O
to	O
0.9 % NaCl	B-T121
in	O
improvement of 4-h bicarbonate	B-T059
.	O
Patients	B-T101
(n	O
=	O
100)	O
aged	O
≥6	O
months	O
to	O
<11	O
years	O
with	O
AGE	B-T047
-induced	O
moderate-to-	O
severe dehydration	B-T047
were	O
enrolled.	O
Patients	B-T101
with	O
a	O
baseline	B-T081
bicarbonate level	B-T034
≤22	O
mEq/L	O
formed	B-T169
the	O
modified	B-T169
intent to treat	B-T169
(	O
mITT	B-T169
)	O
group	B-T098
.	O
At	O
baseline	B-T081
,	O
the	O
treatment	B-T061
groups	B-T098
were	O
comparable	O
except	O
that	O
the	O
PLA	B-T121
group	B-T098
was	O
older.	O
At	O
hour	O
4,	O
the	O
PLA	B-T121
group	B-T098
had	O
greater	O
increases in serum bicarbonate	B-T033
from	O
baseline	B-T081
than	O
did	O
the	O
0.9 % NaCl	B-T121
group	B-T098
(mean	O
±	O
SD	O
at	O
4	O
h:	O
18	O
±	O
3.74	O
vs	O
18.0	O
±	O
3.67;	O
change	O
from	O
baseline	B-T081
of	O
1.6	O
and	O
0.0,	O
respectively;	O
P	O
=	O
.004).	O
Both	O
treatment	B-T061
groups	B-T098
received	O
similar	O
fluid volumes	B-T081
.	O
The	O
PLA	B-T121
group	B-T098
had	O
less	O
abdominal pain	B-T184
and	O
better	O
dehydration	B-T047
scores	O
at	O
hour	O
2	O
(both	O
P	O
=	O
.03)	O
but	O
not	O
at	O
hour	O
4	O
(P	O
=	O
0.15	O
and	O
0.08,	O
respectively).	O
No	O
patient	B-T101
experienced	O
clinically relevant worsening	B-T078
of	O
laboratory findings	B-T034
or	O
physical examination	B-T058
,	O
and	O
hospital admission rates	B-T081
were	O
similar	B-T080
.	O
One	O
patient	B-T101
in	O
each	O
treatment	B-T061
group	B-T098
developed	O
hyponatremia	B-T047
.	O
Four	O
patients	B-T101
developed	O
hyperkalemia	B-T033
(	O
PLA	B-T121
:1,	O
0.9 % NaCl	B-T121
:3).	O
In	O
comparison	B-T052
with	O
0.9 % NaCl	B-T121
,	O
PLA	B-T121
for	O
rehydration	B-T061
in	O
children	B-T100
with	O
AGE	B-T047
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement in serum bicarbonate	B-T059
and	O
dehydration	B-T047
score.	O
NCT#01234883	O
(Registration	O
Date:	O
November	O
3,	O
2010).	O

The	O
relationships	B-T080
between	O
symptoms	B-T184
and	O
quality of life	B-T078
over	O
the	O
course	B-T079
of	O
cognitive-behavioral therapy	B-T061
for	O
panic disorder	B-T048
in	O
Japan	B-T083
This	O
study	B-T062
examined	B-T033
the	O
relationships	B-T080
between	O
changes	B-T169
in	O
symptoms	B-T184
and	O
changes	B-T169
in	O
quality of life	B-T078
(	O
QOL	B-T078
)	O
during	O
cognitive-behavioral therapy	B-T061
(	O
CBT	B-T061
)	O
for	O
panic disorder	B-T048
(	O
PD	B-T048
).	O
We	O
treated	B-T169
198	O
PD	B-T048
patients	B-T101
with	O
group	O
CBT	B-T061
in	O
Japan	B-T083
.	O
Using	O
multiple regression analysis	B-T170
,	O
we	O
examined	B-T033
the	O
associations	B-T080
between	O
changes	B-T169
in	O
QOL	B-T078
and	O
changes	B-T169
in	O
PD	B-T048
symptoms	B-T184
or	O
comorbid psychological symptoms	B-T184
during	O
CBT	B-T061
.	O
Changes	B-T169
in	O
anticipatory anxiety	B-T033
,	O
agoraphobic fear	B-T048
/	O
avoidance	B-T041
,	O
and	O
somatization	B-T048
were	O
significant	O
predictors	B-T078
of	O
changes	B-T169
in	O
some	O
aspects	O
of	O
QOL	B-T078
.	O
It	O
might	O
be	O
useful	O
to	O
decrease	O
somatization	B-T048
,	O
anticipatory anxiety	B-T033
,	O
and	O
agoraphobic fear	B-T048
to	O
improve	O
QOL	B-T078
in	O
CBT	B-T061
for	O
PD	B-T048
.	O

Coupling	B-T169
of	O
TRPV6	B-T116
and	O
TMEM16A	B-T116
in	O
epithelial principal cells	B-T025
of	O
the	O
rat epididymis	B-T023
The	O
epididymis	B-T023
establishes	O
a	O
congenial	B-T080
environment	B-T082
for	O
sperm maturation	B-T042
and	O
protection	B-T033
.	O
Its	O
fluid	B-T031
is	O
acidic	B-T081
,	O
and	O
the	O
calcium	B-T121
concentration	B-T081
is	O
low	B-T080
and	O
declines	O
along	O
the	O
length	B-T081
of	O
the	O
epididymal tubule	B-T023
.	O
However,	O
our	O
knowledge	O
of	O
ionic currents	B-T043
and	O
mechanisms	B-T169
of	O
calcium homeostasis	B-T043
in	O
rat epididymal	B-T023
epithelial cells	B-T025
remains	O
enigmatic.	O
In	O
this	O
study	B-T062
,	O
to	O
better	O
understand	O
calcium regulation	B-T043
in	O
the	O
epididymis	B-T023
,	O
we	O
use	O
the	O
patch-clamp method	B-T062
to	O
record	O
from	O
single	O
rat	B-T015
cauda epididymal	B-T023
principal cells	B-T025
.	O
We	O
detect	B-T033
a	O
constitutively	O
active	B-T169
Ca(2+)	B-T121
current	B-T043
with	O
characteristics	B-T080
that	O
match	O
the	O
epithelial	B-T024
calcium channel	B-T116
TRPV6	B-T116
.	O
Electrophysiological	B-T060
and	O
pharmacological data	B-T060
also	O
reveal	O
a	O
constitutively	O
active calcium-activated chloride conductance	B-T116
(	O
CaCC	B-T116
).	O
Removal	O
of	O
extracellular	B-T026
calcium	B-T121
attenuates	B-T052
not	O
only	O
the	O
TRPV6	B-T116
-like	O
conductance	B-UnknownType
,	O
but	O
also	O
the	O
CaCC	B-T116
.	O
Lanthanide	B-T196
block	B-T169
is	O
time	B-T079
dependent	B-T080
such	O
that	O
the	O
TRPV6	B-T116
-like	O
component	O
is	O
inhibited	B-T043
first,	O
followed	O
by	O
the	O
CaCC	B-T116
.	O
The	O
putative	O
CaCC	B-T116
blocker	B-T121
niflumic acid	B-T109
partially	O
inhibits	B-T043
whole-cell	B-T025
currents	B-T043
,	O
whereas	O
La(3+)	B-T197
almost	O
abolishes	O
whole-cell	B-T025
currents	B-T043
in	O
principal cells	B-T025
.	O
Membrane potential	B-T043
measurements	B-T169
reveal	O
an	O
interplay	O
between	O
La(3+)	B-T197
-	O
sensitive ion channels	B-T116
and	O
those	O
that	O
are	O
sensitive	B-T169
to	O
the	O
specific	B-T170
TMEM16A	B-T116
inhibitor	B-T120
tannic acid	B-T109
.	O
In vivo	B-T082
perfusion	B-T061
of	O
the	O
cauda epididymal tubule	B-T023
shows	O
a	O
substantial	O
rate	O
of	O
Ca(2+)	B-T121
reabsorption	B-T039
from	O
the	O
luminal side	B-T082
,	O
which	O
is	O
dose-dependently	O
suppressed	B-T169
by	O
ruthenium red	B-T130
,	O
a	O
putative	O
blocker	B-T121
of	O
epithelial	B-T024
Ca(2+) channels	B-T116
and	O
CaCC	B-T116
.	O
Finally,	O
we	O
discover	O
messenger RNA	B-T114
for	O
both	O
TRPV6	B-T116
and	O
TMEM16A	B-T116
in	O
the	O
rat epididymis	B-T023
and	O
show	O
that	O
their	O
proteins	B-T116
colocalize	B-T082
in	O
the	O
apical membrane	B-T026
of	O
principal cells	B-T025
.	O
Collectively,	O
these	O
data	B-T078
provide	O
evidence	B-T078
for	O
a	O
coupling	B-T169
mechanism	B-T169
between	O
TRPV6	B-T116
and	O
TMEM16A	B-T116
in	O
principal cells	B-T025
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation of calcium homeostasis	B-T043
in	O
the	O
epididymis	B-T023
.	O

Voices:	O
A	O
Conversation	B-T054
with	O
Allen J. Wilcox	B-T016
Allen James Wilcox	B-T016
was	O
born	O
on	O
30	O
September	O
1946	O
in	O
Columbus, OH	B-T083
.	O
He	O
studied	O
medicine	B-T091
at	O
the	O
University of Michigan	B-T073
,	O
graduated	O
in	O
1973,	O
and	O
after	O
a	O
rotating	O
internship	B-T065
,	O
he	O
completed a master's degree	B-T033
in	O
maternal and child health	B-T091
(1976)	O
and	O
a	O
PhD	B-T170
in	O
epidemiology	B-T091
(1979)	O
at	O
the	O
University of North Carolina	B-T073
in	O
Chapel Hill	B-T083
.	O
After	O
graduation	B-T065
,	O
he	O
went	O
to	O
work	B-T057
at	O
the	O
National Institute of Environmental Health Sciences	B-T093
(	O
NIEHS	B-T093
,	O
one	O
of	O
the	O
US National Institutes of Health	B-T093
)	O
in	O
Durham, NC	B-T083
,	O
where	O
he	O
has	O
spent	O
his	O
career	B-T057
.	O
He	O
developed	O
a	O
research program	B-T062
in	O
reproductive	O
and	O
perinatal epidemiology	B-T091
,	O
a	O
relatively	O
unexplored	O
area	O
at	O
the	O
time.	O
His	O
studies	O
include	O
the	O
early pregnancy	B-T047
study,	O
which	O
documented	B-T058
the	O
extent	O
of	O
subclinical	B-T080
pregnancy loss	B-T046
in	O
humans	B-T016
and	O
established	B-T080
the	O
fertile days	B-T079
of	O
a	O
woman's	B-T098
menstrual cycle	B-T040
.	O
He	O
served	O
as	O
the	O
Chief of	B-T097
the	O
Epidemiology	B-T091
Branch	B-T097
from	O
1991	O
to	O
2001,	O
and	O
as	O
Editor-in-Chief	B-T097
of	O
the	O
journal	B-T073
EPIDEMIOLOGY	B-T091
from	O
2001	O
to	O
2014.	O
His	O
textbook	B-T073
,	O
Fertility and Pregnancy-An Epidemiologic Perspective	B-T073
,	O
was	O
published	B-T057
by	O
Oxford University Press	B-T170
in	O
2010.	O
He	O
was	O
elected	B-UnknownType
to	O
the	O
American Epidemiological Society	B-T093
in	O
1989,	O
and	O
served	O
as	O
its	O
president	B-T090
in	O
2003.	O
He	O
also	O
served	O
as	O
president	B-T090
of	O
the	O
Society of Pediatric and Perinatal Epidemiological Research	B-T093
(1996)	O
and	O
the	O
president	B-T090
of	O
the	O
Society of Epidemiological Research	B-T093
(1998).	O
He	O
holds	O
adjunct	O
teaching	B-T065
appointments	B-T079
at	O
the	O
University of North Carolina	B-T073
,	O
Harvard University	B-T073
,	O
and	O
the	O
University of Bergen	B-T073
(	O
Norway	B-T083
),	O
which	O
awarded	B-T073
him	O
an	O
honorary	B-T080
doctoral degree	B-T170
in	O
2008.	O

Evaluation	B-T058
of	O
Spontaneous	B-T169
Bone Regeneration	B-T042
after	O
Enucleation	B-T061
of	O
Large	B-T081
Cysts	B-T047
of	O
the	O
Jaws	B-T023
using	O
Radiographic	B-T070
Computed	B-T059
Software	B-T073
Spontaneous	B-T169
regeneration of bone	B-T042
is	O
commonly	B-T081
seen	O
in	O
the	O
small	B-T081
surgical	B-T061
defects	B-T169
caused	O
by	O
enucleation	B-T061
of	O
cysts	B-T047
.	O
However,	O
in	O
case	O
of	O
large	B-T081
surgical	B-T061
defects	B-T169
caused	O
by	O
the	O
enucleation	B-T061
,	O
spontaneous	B-T169
regeneration of bone	B-T042
is	O
a	O
rare	B-T080
phenomenon	B-T067
and	O
it	O
depends	B-T080
on	O
factors	B-T169
,	O
such	O
as	O
age	B-T032
of	O
the	O
patient	B-T101
,	O
intact	B-T080
periosteum	B-T024
,	O
and	O
proper	O
stabilization	B-T061
.	O
The	O
study	B-T062
included	B-T169
16	O
patients	B-T101
,	O
who	O
reported	B-T058
to	O
the	O
department of oral and maxillofacial surgery	B-T073
with	O
the	O
complaint	B-T047
of	O
pain	B-T184
and	O
swelling	B-T033
in	O
the	O
jaws	B-T023
diagnosed	B-T033
as	O
cyst	B-T047
.	O
The	O
sample	B-T077
included	B-T169
equal	O
numbers	B-T081
of	O
male	B-T032
and	O
female	B-T032
subjects	B-T096
aged	B-T032
between	O
15	O
and	O
40	O
years.	O
Panoramic radiographs	B-T060
were	O
taken	O
pre-	B-T079
and	O
postoperatively	B-T079
on	O
day	O
2	O
of	O
the	O
enucleation	B-T061
.	O
The	O
dimensions	B-T081
of	O
the	O
cyst	B-T047
were	O
evaluated	B-T058
on	O
the	O
radiograph	B-T060
according	O
to	O
the	O
proforma	B-T169
.	O
Subsequent	B-T079
radiographs	B-T060
were	O
taken	O
at	O
regular	B-T080
intervals	B-T079
of	O
1.5,	O
3,	O
and	O
6	O
months	O
using	O
standard	B-T081
parameters	B-T077
and	O
were	O
analyzed	B-T062
using	O
MCID™ analysis	B-T170
software	B-T073
of	O
imaging research	B-T060
.	O
Mean	B-T081
reduction	B-T061
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60%	O
in	O
the	O
cystic	B-T080
cavity	B-T190
size	B-T082
and	O
increase	B-T169
in	O
the	O
mean	B-T081
density	B-T081
up	O
to	O
59	O
and	O
90.2%	O
at	O
3	O
and	O
6	O
months	O
intervals	B-T079
respectively.	O
Spontaneous	B-T169
bone regeneration	B-T042
was	O
seen	O
even	O
after	O
primary	B-T080
closure	B-T061
of	O
the	O
large	B-T081
cystic	B-T080
defect	B-T169
without	O
the	O
need	B-T080
for	O
placement	B-T058
of	O
foreign substances	B-T167
or	O
grafts	B-T122
and	O
it	O
also	O
eliminated	B-T080
the	O
complications	B-T046
resulting from	B-T169
placement	B-T058
of	O
foreign substance	B-T167
.	O
Further	O
studies	B-T062
are	O
required	B-T169
in	O
a	O
larger	B-T081
sample	B-T077
with	O
longer	B-T080
follow-up	B-T058
durations	B-T079
to	O
confirm	B-T080
the	O
outcome of the present work	B-T080
for	O
the	O
benefit	B-T081
of	O
patients	B-T101
.	O
The	O
present	B-T079
study	B-T062
depicted	O
that	O
spontaneous	B-T169
bone regeneration	B-T042
can	O
occur	O
with	O
accepted	B-T080
results	B-T033
after	O
simple	B-T080
enucleation	B-T061
of	O
jaw	B-T023
cyst	B-T047
without	O
the	O
aid	B-T080
of	O
any	O
graft material	B-T122
.	O
Hence,	O
simple	B-T080
enucleation	B-T061
may	O
be	O
considered	B-T078
as	O
a	O
first line of treatment	B-T061
modality	B-T078
for	O
cystic	B-T080
lesion	B-T033
of	O
the	O
jaws	B-T023
.	O
This	O
simplifies	O
the	O
surgical procedure	B-T061
,	O
decreases	B-T081
the	O
economic	B-T169
and	O
biologic	B-T080
costs	B-T081
,	O
and	O
reduces	B-T061
the	O
risk	B-T078
of	O
postoperative complications	B-T046
.	O
Follow-up	B-T058
is	O
necessary	O
along	O
with	O
patient's	B-T101
compliance	B-T055
for	O
the	O
success of treatment	B-T080
.	O

Membrane Protein Solubilization	B-T044
and	O
Composition	B-T070
of	O
Protein	B-T116
Detergent	B-T120
Complexes	B-T104
Membrane proteins	B-T116
are	O
typically expressed	B-T045
in	O
heterologous	B-T080
systems	B-T169
with	O
a	O
view	O
to	O
in vitro	B-T062
characterization	B-T052
.	O
A	O
critical step	B-T077
in	O
the	O
preparation	B-T052
of	O
membrane proteins	B-T116
after	O
expression	B-T045
in	O
any	O
system	B-T169
is	O
the	O
solubilization of the protein	B-T044
in	O
aqueous solution	B-T121
,	O
typically	O
using	O
detergents	B-T120
and	O
lipids	B-T109
,	O
to	O
obtain	O
the	O
protein	B-T116
in	O
a	O
form	O
suitable	B-T080
for	O
purification	B-T169
,	O
structural	B-T061
or	O
functional	B-T169
analysis	B-T062
.	O
This	O
process	B-T067
is	O
particularly	O
difficult	O
as	O
the	O
objective	O
is	O
to	O
prepare	O
the	O
protein	B-T116
in	O
an	O
unnatural	B-T080
environment	B-T082
,	O
a	O
protein	B-T116
detergent	B-T120
complex	B-T104
,	O
separating	O
it	O
from	O
its	O
natural	B-T169
lipid	B-T109
partners	O
while	O
causing	O
the	O
minimum	B-T080
destabilization	B-T043
or	O
modification	B-T033
of	O
the	O
structure	B-T082
.	O
Although	O
the	O
process	B-T067
is	O
difficult	B-T080
,	O
and	O
relatively	O
hard	O
to	O
master,	O
an	O
increasing	B-T169
number	O
of	O
membrane proteins	B-T116
have	O
been	O
successfully isolated	B-T169
after	O
expression	B-T045
in	O
a	O
wide	O
variety	O
of	O
systems	B-T169
.	O
In	O
this	O
chapter	O
we	O
give	O
a	O
general protocol	B-T170
for	O
preparing	O
protein	B-T116
detergent	B-T120
complexes	B-T104
that	O
is	O
aimed	O
at	O
guiding	O
the	O
reader	O
through	O
the	O
different	O
critical steps	B-T077
.	O
In	O
the	O
second	O
part	O
of	O
the	O
chapter	O
we	O
illustrate	O
how	O
to	O
analyze	B-T062
the	O
composition	B-T070
of	O
protein	B-T116
detergent	B-T120
complexes	B-T104
;	O
this	O
analysis	B-T062
is	O
important	O
as	O
it	O
has	O
been	O
found	O
that	O
compositional	B-T070
variation	B-T080
often	O
causes	O
irreproducible	O
results.	O

Can	O
We	O
Predict	B-T078
Burnout	B-T048
among	O
Student Nurses	B-T097
?	O
An	O
Exploration	O
of	O
the	O
ICWR-1 Model	B-T170
of	O
Individual	B-T098
Psychological Resilience	B-T055
The	O
nature	O
of	O
nursing work	B-T091
is	O
demanding	B-T061
and	O
can	O
be	O
stressful	B-T169
.	O
Previous	O
studies	O
have	O
shown	O
a	O
high	B-T080
rate	B-T081
of	O
burnout	B-T048
among	O
employed	B-T033
nurses	B-T097
.	O
Recently,	O
efforts	O
have	O
been	O
made	O
to	O
understand	O
the	O
role	O
of	O
resilience	B-T055
in	O
determining	O
the	O
psychological adjustment	B-T055
of	O
employed	B-T033
nurses	B-T097
.	O
A	O
theoretical model	B-T170
of	O
resilience	B-T055
was	O
proposed	O
recently	O
that	O
includes	B-T169
several	B-T081
constructs	B-T185
identified	O
in	O
the	O
literature	B-T170
related	O
to	O
resilience	B-T055
and	O
to	O
psychological functioning	B-T041
.	O
As	O
nursing students	B-T097
are	O
the	O
future	B-T079
of	O
the	O
nursing	B-T091
workforce	B-T097
it	O
is	O
important	B-T080
to	O
advance	B-T079
our	O
understanding	O
of	O
the	O
determinants	B-T169
of	O
resilience	B-T055
in	O
this	O
population	B-T098
.	O
Student nurses	B-T097
who	O
had	O
completed	B-T078
their	O
final	B-T079
practicum	B-T065
were	O
invited	O
to	O
participate	O
in	O
an	O
online survey	B-T170
measuring	B-T080
the	O
key	O
constructs	B-T185
of	O
the	O
ICWR-1 model	B-T170
.	O
422	O
students	B-T097
from	O
across	O
Australia	B-T083
and	O
Canada	B-T083
completed	B-T078
the	O
survey	B-T170
between	O
July	O
2014	O
and	O
July	O
2015.	O
As	O
well	O
as	O
several	B-T081
key	O
demographics	B-T078
,	O
trait negative affect	B-T033
,	O
mindfulness	B-T041
,	O
self-efficacy	B-T041
,	O
coping	B-T055
,	O
resilience	B-T055
,	O
and	O
burnout	B-T048
were	O
measured	B-T080
.	O
We	O
used	O
structural equation modeling	B-T062
and	O
found	O
support	O
for	O
the	O
major	B-T080
pathways	B-T077
of	O
the	O
model	B-T170
;	O
namely	O
that	O
resilience	B-T055
had	O
a	O
significant	B-T078
influence	B-T077
on	O
the	O
relationship	B-T080
between	O
mindfulness	B-T041
,	O
self-efficacy	B-T041
and	O
coping	B-T055
,	O
and	O
psychological adjustment	B-T055
(	O
burnout	B-T048
scores	B-T081
).	O
Furthermore,	O
as	O
predicted	B-T078
,	O
Neuroticism	B-T048
moderated	O
the	O
relationship	B-T080
between	O
coping	B-T055
and	O
burnout	B-T048
.	O
Results	O
are	O
discussed	O
in	O
terms	O
of	O
potential	B-T080
approaches	B-T169
to	O
supporting	O
nursing students	B-T097
who	O
may	O
be	O
at risk	B-T080
of	O
burnout	B-T048
.	O

Medication Intervention	B-T061
for	O
Chronic Kidney Disease	B-T047
Patients	B-T101
Transitioning	B-T052
from	O
Hospital	B-T073
to	O
Home	B-T082
:	O
Study Design	B-T062
and	O
Baseline	B-T081
Characteristics	B-T080
The	O
hospital readmission	B-T058
rate	B-T081
in	O
the	O
population	B-T098
with	O
chronic kidney disease	B-T047
(	O
CKD	B-T047
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	B-T078
are	O
urgently	O
needed	B-T080
.	O
The	O
CKD	B-T047
-	O
Medication Intervention Trial	B-T061
(	O
CKD	B-T047
-	O
MIT	B-T061
;	O
www.clinicaltrials.gov; NCTO1459770	B-T170
)	O
is	O
a	O
single-blind	B-T062
(	O
investigators	B-T097
),	O
randomized	B-T062
,	O
clinical trial	B-T062
conducted	O
at	O
Providence Health Care	B-T058
in	O
Spokane, Washington	B-T083
.	O
Study participants	B-T096
are	O
hospitalized patients	B-T101
with	O
CKD	B-T047
stages	B-T079
3-5	O
(not	O
treated with	B-T061
kidney replacement therapy	B-T061
)	O
and	O
acute illness	B-T046
.	O
The	O
study intervention	B-T170
is	O
a	O
pharmacist-led	B-T097
,	O
home-based	B-T058
,	O
medication management	B-T058
intervention	B-T061
delivered	B-T169
within	O
7	O
days	B-T079
after	O
hospital discharge	B-T058
.	O
The	O
primary outcome	B-T169
is	O
a	O
composite	O
of	O
hospital readmissions	B-T058
and	O
visits	O
to	O
emergency departments	B-T073
and	O
urgent care centers	B-T073
for	O
90	O
days	B-T079
following	O
hospital discharge	B-T058
.	O
Secondary outcomes	B-T169
are	O
achievements	B-UnknownType
of	O
guideline-based	B-T170
targets	B-T169
for	O
CKD	B-T047
risk factors	B-T033
and	O
complications	B-T046
.	O
Enrollment	B-T058
began	O
in	O
February	B-T080
2012	O
and	O
ended	O
in	O
May	B-T079
2015.	O
At	O
baseline	B-T081
,	O
the	O
age	B-T032
of	O
participants	B-T098
was	O
69	O
±	O
11	O
years	B-T079
(mean	O
±	O
SD),	O
50%	O
(77	O
of	O
155)	O
were	O
women	B-T098
,	O
83%	O
(117	O
of	O
141)	O
had	O
hypertension	B-T047
and	O
56%	O
(79	O
of	O
141)	O
had	O
diabetes	B-T047
.	O
At	O
baseline	B-T081
,	O
the	O
estimated glomerular filtration	B-T059
rate	B-T081
was	O
41	O
±	O
14	O
ml/min/1.73	O
m2	O
and	O
urine albumin-to-creatinine ratio	B-T059
was	O
43	O
mg/g	O
(	O
interquartile range	B-T081
8-528	O
mg/g).	O
The	O
most	O
frequent	O
diagnosis category	B-T185
for	O
the	O
index	O
hospital admission	B-T058
was	O
cardiovascular diseases	B-T047
at	O
34%	O
(53	O
of	O
155),	O
but	O
the	O
most	O
common	O
single diagnosis	B-T033
for	O
admission	B-T058
was	O
community-acquired	B-T080
acute kidney injury	B-T047
at	O
10%	O
(16	O
of	O
155).	O
Participants	B-T098
in	O
CKD	B-T047
-	O
MIT	B-T061
are	O
typical	O
of	O
acutely ill	B-T046
hospitalized patients	B-T101
with	O
CKD	B-T047
.	O
A	O
medication management	B-T058
intervention	B-T061
after	O
hospital discharge	B-T058
is	O
under	O
study	B-T062
to	O
reduce	B-T080
post	B-T079
-	O
hospitalization	B-T058
acute care	B-T058
utilization	B-T169
and	O
to	O
improve	O
CKD	B-T047
management	B-T058
.	O

Direct	B-T080
Repair	B-T058
of	O
Lumbar Pars Interarticularis	B-T023
Defects	B-T169
by	O
Utilizing	B-T169
Intraoperative O-Arm-Based Navigation	B-T074
and	O
Microendoscopic Techniques	B-T060
A	O
retrospective analysis	B-T062
of	O
the	O
clinical outcomes	B-T033
of	O
eight	O
patients	B-T101
with	O
the	O
lumbar pars interarticulars	B-T023
defects	B-T169
treated	B-T033
by	O
direct	B-T080
repair	B-T058
with	O
the	O
aid	B-T080
of	O
intraoperative O-arm based navigation	B-T074
and	O
microendoscopic techniques	B-T060
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
efficacy	B-T080
and	O
safety	B-T068
of	O
direct	B-T080
screw	B-T074
repair	B-T058
by	O
using	B-T169
minimally invasive surgery	B-T061
for	O
the	O
lumbar pars interarticulars	B-T023
defects	B-T169
in	O
a	O
pilot study	B-T062
.	O
Direct	B-T080
repair	B-T058
of	O
pars interarticulars	B-T023
defects	B-T169
has	O
been	O
used	B-T169
to	O
treat	B-T061
young adult	B-T100
patients	B-T101
.	O
Reports	B-T170
concerning	B-T078
direct	B-T080
repair	B-T058
by	O
minimally invasive techniques	B-T061
for	O
pars interarticulars	B-T023
defects	B-T169
are	O
quite	O
rare	B-T080
.	O
Review	B-T078
of	O
medical records	B-T170
identified	B-T080
eight	O
consecutive	B-T080
patients	B-T101
treated	B-T033
with	O
intraoperative O-arm based navigation	B-T074
and	O
microendoscopic techniques	B-T060
.	O
Debridement	B-T061
and	O
autograft	B-T061
of	O
pars interarticularis	B-T023
defects	B-T169
was	O
performed	B-T169
under	O
microendoscopic procedure	B-T060
.	O
Then,	O
percutaneous	B-T082
bilateral	B-T082
intralaminar	B-T082
screws	B-T074
were	O
inserted	B-T058
by	O
utilizing	B-T169
intraoperative navigation	B-T074
.	O
The	O
clinical	B-T170
and	O
radiological	B-T091
data	B-T078
were	O
collected	B-T078
and	O
analyzed	B-T062
retrospectively	B-T080
.	O
Eight	O
patients	B-T101
had	O
a	O
mean	B-T081
age	B-T032
of	O
28.4	O
years,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	B-T079
at	O
the	O
time	B-T079
of	O
treatment	B-T061
.	O
Symptoms	B-T184
included	B-T052
axial	B-T082
back pain	B-T184
in	O
100%	O
of	O
patients	B-T101
without	O
concomitant	B-T079
radiculopathy	B-T047
.	O
Autograft	B-T061
was	O
used	B-T169
in	O
all	O
cases	B-T077
.	O
The	O
average	B-T081
follow-up	B-T058
duration	B-T079
was	O
27.4	O
months	O
with	O
a	O
range	B-T081
of	O
20	O
to	O
33	O
months.	O
Symptoms	B-T184
resolved	B-T033
completely	B-T080
or	O
partially	B-T081
in	O
all	O
patients	B-T101
.	O
Low back pain	B-T184
visual analog scores	B-T201
decrease	B-T081
from	O
preoperative	B-T079
6.8	O
to	O
postoperative	B-T079
1.4	O
of	O
eight	O
cases	B-T077
.	O
Of	O
16	O
pars	B-T023
defects	B-T169
,	O
healing	B-T040
was	O
observed	B-T169
in	O
13	O
(81.3%)	O
at	O
last	O
radiological	B-T091
follow-up	B-T058
.	O
One	O
patient	B-T101
with	O
bilateral fusion failure	B-T019
refused	B-T052
revision surgery	B-T061
because	O
of	O
mild complaint	B-T033
.	O
No complications	B-T033
such	O
as	O
dural tear	B-T037
,	O
nerve root injury	B-T037
,	O
and	O
infection	B-T046
occurred	B-T052
.	O
Minimally invasive	B-T061
direct	B-T080
repair	B-T058
of	O
the	O
pars interarticularis	B-T023
defects	B-T169
with	O
intralaminar	B-T082
screws	B-T074
by	O
using	B-T169
microendoscopic system	B-T060
and	O
navigation procedure	B-T074
can	O
provide	B-T052
safe	O
and	O
effective	B-T080
treatment	B-T061
of	O
spondylolysis	B-T047
with	O
satisfactory	B-T080
clinical	B-T080
and	O
radiological	B-T091
outcomes	B-T169
,	O
which	O
need	B-T080
some	O
special tools	B-T074
with	O
steep	B-T080
learning curve	B-T041
.	O
4.	O

Evidence	B-T078
-Based	O
Review	B-T170
and	O
Survey	B-T170
of	O
Expert Opinion	B-T077
of	O
Reconstruction	B-T061
of	O
Metastatic Spine Tumors	B-T191
Systematic	B-T169
review	B-T170
and	O
consensus	B-T054
expert opinion	B-T077
.	O
To	O
provide	O
surgeons	B-T097
and	O
other	O
health care professionals	B-T097
with	O
guidelines	B-T170
for	O
surgical reconstruction	B-T061
of	O
metastatic	B-T191
spine disease	B-T047
based	O
on	O
evidence	B-T078
and	O
expert opinion	B-T077
.	O
The	O
surgical treatment	B-T061
of	O
spinal metastases	B-T191
is	O
controversial.	O
Specifically	O
two	O
aspects	O
of	O
surgical reconstruction	B-T061
are	O
addressed	O
in	O
this	O
study:	O
(i)	O
choice	O
of	O
bone graft	B-T061
used	O
during	B-T079
surgery	B-T061
for	O
metastatic spine tumors	B-T191
and	O
(ii)	O
the	O
design	B-T052
of	O
reconstruction	B-T061
or	O
construct	B-T122
to	O
stabilize	B-T033
.	O
A	O
systematic	B-T169
review	B-T170
of	O
the	O
available	B-T169
medical	B-T169
literature	B-T170
from	O
1980	O
to	O
2015	O
was	O
conducted,	O
and	O
combined	B-T080
with	O
consensus	B-T054
expert opinion	B-T077
from	O
a	O
recent	O
survey	B-T170
of	O
spine	B-T023
surgeons	B-T097
who	O
treat	B-T061
metastatic spine tumors	B-T191
.	O
There	O
is	O
very	O
little	O
evidence	B-T078
in	O
the	O
literature	B-T170
to	O
provide	O
guidance	B-T058
on	O
the	O
use of	B-T169
bone graft	B-T061
in	O
metastatic tumor	B-T191
reconstruction	B-T061
.	O
There	O
is	O
little	O
evidence	B-T078
in	O
the	O
literature	B-T170
to	O
support	O
the	O
preferential	O
use of	B-T169
one	O
graft type	B-T170
over	O
the	O
other.	O
Approximately,	O
41%	O
of	O
respondents	B-T098
said	O
they	O
used	O
bone graft	B-T061
or	O
bone graft	B-T061
substitutes	B-T122
to	O
accomplish	O
fusion	B-T061
.	O
There	O
were	O
17	O
studies	B-T062
that	O
described	O
the	O
use of	B-T169
a	O
prefabricated prosthetic	B-T074
,	O
10	O
studies	B-T062
describing	O
the	O
use of	B-T169
polymethyl methacrylate	B-T109
(	O
PMMA	B-T109
)	O
bone cement	B-T122
,	O
and	O
only	O
three	O
studies	B-T062
describing	O
the	O
use of	B-T169
bone graft	B-T061
for	O
anterior	B-T082
column	B-T023
reconstruction	B-T061
.	O
The	O
use of	B-T169
structural allograft	B-T061
was	O
most	O
popular	O
among	O
the	O
experts	B-T097
for	O
anterior	B-T082
reconstruction	B-T061
,	O
followed by	B-T079
cage	B-T074
reconstruction	B-T061
,	O
and	O
PMMA	B-T109
bone cement	B-T122
.	O
Achieving	O
bony union	B-T030
may	O
be	O
of	O
importance	B-T080
for	O
the	O
maintenance	B-T052
of	O
spinal	B-T023
stability	B-T080
in	O
the	O
long term	B-T079
after	O
reconstruction	B-T061
.	O
Whether	O
bony union	B-T030
is	O
required	B-T169
for	O
patients	B-T101
with	O
shorter	B-T081
life expectancies	B-T102
is	O
debatable.	O
The	O
literature	B-T170
supports	O
the	O
use of	B-T169
anterior	B-T082
reconstruction	B-T061
with	O
either	O
a	O
prefabricated prosthetic	B-T074
or	O
PMMA	B-T109
bone cement	B-T122
.	O
It	O
also	O
supports	O
the	O
use of	B-T169
an	O
anterior	B-T082
construct	B-T122
reinforced	O
with	O
bilateral	B-T082
posterior	B-T082
instrumentation	B-T080
when	O
performing	B-T061
a	O
three-column reconstruction	B-T061
.	O
N/A.	O

The	O
value	O
of	O
transesophageal echocardiography	B-T060
for	O
embolic strokes of undetermined source	B-T047
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic yield	B-T060
of	O
transesophageal echocardiography	B-T060
(	O
TEE	B-T060
)	O
in	O
consecutive	O
patients	B-T101
with	O
ischemic stroke	B-T047
(	O
IS	B-T047
)	O
fulfilling	O
the	O
diagnostic criteria	B-T170
of	O
embolic strokes of undetermined source	B-T047
(	O
ESUS	B-T047
).	O
We	O
prospectively	O
evaluated	O
consecutive	O
patients	B-T101
with	O
acute	O
IS	B-T047
satisfying	O
ESUS	B-T047
criteria	O
who	O
underwent	O
in-	O
hospital	B-T073
TEE examination	B-T060
in	O
3	O
tertiary care stroke centers	B-T073
during a 12-month period	B-T079
.	O
We	O
also	O
performed	O
a	O
systematic review	B-T170
and	O
meta-analysis estimating	B-T062
the	O
cumulative	O
effect	O
of	O
TEE	B-T060
findings	B-T033
on	O
therapeutic management	B-T169
for	O
secondary stroke prevention	B-T061
among	O
different	O
IS	B-T047
subgroups.	O
We	O
identified	O
61	O
patients	B-T101
with	O
ESUS	B-T047
who	O
underwent investigation	B-T058
with	O
TEE	B-T060
(mean	O
age	O
44	O
±	O
12	O
years,	O
49%	O
men	B-T098
,	O
median	O
NIH Stroke Scale score	B-T170
=	O
5	O
points	O
[	O
interquartile range	B-T081
:	O
3-8]).	O
TEE	B-T060
revealed	O
additional	O
findings	B-T033
in	O
52%	O
(95%	O
confidence interval	B-T081
[	O
CI	B-T081
]:	O
40%-65%)	O
of	O
the	O
study population	B-T098
.	O
TEE	B-T060
findings	B-T033
changed	O
management	O
(	O
initiation	B-T169
of	O
anticoagulation therapy	B-T061
,	O
administration	B-T061
of	O
IV antibiotic therapy	B-T061
,	O
and	O
patent foramen ovale closure	B-T061
)	O
in	O
10	O
(16%	O
[95%	O
CI	B-T081
:	O
9%-28%])	O
patients	B-T101
.	O
The	O
pooled rate	B-T081
of	O
reported	O
anticoagulation therapy	B-T061
attributed	O
to	O
abnormal	B-T033
TEE	B-T060
findings	B-T033
among	O
3,562	O
acute	O
IS	B-T047
patients	B-T101
included	O
in	O
the	O
meta-analysis	B-T062
(12	O
studies)	O
was	O
8.7%	O
(95%	O
CI	B-T081
:	O
7.3%-10.4%).	O
In	O
subgroup analysis	B-T062
,	O
the	O
rates	O
of	O
initiation	B-T169
of	O
anticoagulation therapy	B-T061
on	O
the	O
basis	O
of	O
TEE	B-T060
investigation	O
did	O
not	O
differ	O
(p	O
=	O
0.315)	O
among	O
patients	B-T101
with	O
cryptogenic stroke	B-T169
(6.9%	O
[95%	O
CI	B-T081
:	O
4.9%-9.6%]),	O
ESUS	B-T047
(8.1%	O
[95%	O
CI	B-T081
:	O
3.4%-18.1%]),	O
and	O
IS	B-T047
(9.4%	O
[95%	O
CI	B-T081
:	O
7.5%-11.8%]).	O
Abnormal	O
TEE	B-T060
findings	B-T033
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	B-T080
therapeutic strategy	B-T061
in	O
approximately	O
1	O
of	O
7	O
patients	B-T101
with	O
ESUS	B-T047
.	O

Simultaneous	B-T079
thrombosis	B-T046
of	O
multiple coronary arteries	B-T023
in	O
a	O
patient	B-T101
with	O
rheumatoid arthritis	B-T047
We	O
present	O
a	O
case	B-T169
of	O
simultaneous	B-T079
coronary thrombosis of the left main	B-T047
,	O
the	O
left anterior descending artery	B-T023
and	O
the	O
right coronary artery	B-T023
in	O
a	O
patient	B-T101
,	O
recently	O
diagnosed	B-T060
with	O
rheumatoid arthritis	B-T047
.	O

Unintentional Injuries	B-T037
in	O
Children	B-T100
Up	O
to	O
Six	O
Years	B-T079
of	O
Age	B-T032
and	O
Related	O
Parental	B-T099
Knowledge	B-T170
,	O
Attitudes	B-T041
,	O
and	O
Behaviors	B-T053
in	O
Italy	B-T083
To	O
describe	O
risk factors	B-T033
associated with	B-T080
unintentional injuries	B-T037
among	O
children	B-T100
aged	O
<6	O
years	B-T079
and	O
to	O
examine	O
parents	B-T099
'	O
level	O
of	O
knowledge	B-T170
,	O
attitudes	B-T041
,	O
and	O
behaviors	B-T053
about	O
pediatric	B-T080
injuries	B-T037
and	O
related	O
preventive measures	B-UnknownType
.	O
A	O
cross-sectional survey	B-T062
was	O
conducted	O
between	O
May	B-T079
and	O
July	B-T080
2015	O
on	O
a	O
random sample	B-T062
of	O
794	O
parents	B-T099
of	O
3-	O
to	O
6-year-old	O
children	B-T100
through	O
a	O
self-administered	B-T169
anonymous questionnaire	B-T170
.	O
A	O
total	O
of	O
409	O
parents	B-T099
participated.	O
Two-thirds	O
of	O
the	O
children	B-T100
had	O
experienced	O
at	O
least	O
1	O
unintentional injury	B-T037
in	O
the	O
previous	O
12	O
months	B-T079
.	O
More	O
than	O
one-half	O
of	O
these	O
children	B-T100
were	O
boys	B-T100
.	O
The	O
leading cause	B-T033
was	O
falls	B-T037
;	O
the	O
injuries	B-T037
occurred	O
mainly	O
at	O
home	B-T082
,	O
and	O
only	O
9.2%	O
were	O
brought	O
for	O
attention	O
to	O
an	O
emergency department	B-T073
.	O
Parents	B-T099
who	O
did	O
not	O
believe	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
unintentional injuries	B-T037
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
child	B-T100
injured	B-T169
.	O
Approximately	O
70%	O
of	O
respondents	B-T098
were	O
aware	B-T041
of	O
security measures	B-T089
to	O
prevent	O
pediatric	B-T080
injuries	B-T037
,	O
and	O
this	O
knowledge	B-T170
was	O
more	O
prevalent	O
in	O
older	O
parents	B-T099
and	O
in	O
those	O
with	O
at	O
least	O
a	O
college level of education	B-T065
compared	O
with	O
those	O
with	O
a	O
middle school education	B-T065
.	O
The	O
perceived	B-T041
utility	O
of	O
education	B-T065
about	O
preventive measures	B-UnknownType
of	O
pediatric	B-T080
injuries	B-T037
had	O
a	O
mean value	B-T081
of	O
8.9	O
on	O
a	O
Likert scale	B-T170
of	O
1-10	O
(1,	O
not	O
useful,	O
to	O
10,	O
very	O
useful)	O
and	O
was	O
significantly	O
higher	O
in	O
mothers	B-T099
.	O
This	O
study	O
highlights	O
a	O
clear	O
need	O
for	O
public health	B-T058
educational programs	B-T065
for	O
parents	B-T099
regarding	O
prevention	B-UnknownType
of	O
unintentional injuries	B-T037
in	O
children	B-T100
as	O
a	O
valuable	O
tool	O
to	O
increase	O
safety	B-T068
and	O
injury prevention	B-T061
and	O
to	O
reduce	B-T081
risks	B-T078
,	O
because	O
the	O
majority	O
of	O
such	O
injuries	B-T037
occur	O
at	O
home	B-T082
.	O

Truncated Bovine	B-T015
Integrin Alpha-v/Beta-6	B-T116
as	O
a	O
Universal Capture Ligand	B-T044
for	O
FMD	B-T047
Diagnosis	B-T033
Foot-and-mouth disease	B-T047
(	O
FMD	B-T047
)	O
is	O
endemic	B-T047
in	O
many	O
regions	B-T082
of	O
the	O
world	B-T098
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	B-T067
animal diseases	B-T047
.	O
FMD	B-T047
affects	O
livestock	B-T008
,	O
such	O
as	O
cattle	B-T015
,	O
sheep	B-T015
,	O
goats	B-T015
and	O
pigs	B-T015
,	O
and	O
causes	O
enormous economic losses	B-T081
due	O
to	O
reduced	O
productivity	B-T081
and	O
trade restrictions	B-T169
.	O
Preparedness	B-T033
and	O
early diagnosis	B-T060
are	O
essential	B-T080
for	O
effective control	B-T058
of	O
FMD	B-T047
.	O
Many	O
diagnostic assays	B-T059
are	O
dependent	B-T080
on	O
raising	O
high-affinity	B-T080
,	O
anti-FMD virus	B-T005
(	O
FMDV	B-T005
)	O
serotype-specific antibodies	B-T116
in	O
small	O
animals	B-T008
(	O
rabbits	B-T015
and	O
guinea pigs	B-T015
)	O
that	O
give	O
broad	O
virus	B-T005
coverage.	O
Here	O
we	O
show	O
that	O
soluble	B-T080
,	O
truncated forms	B-T080
of	O
bovine	B-T015
αvβ6	B-T116
bind	B-T044
FMDV	B-T005
in	O
an	O
authentic	O
RGD	B-T116
and	O
divalent cation dependent interaction	B-T044
and	O
can	O
be	O
used	O
as	O
the	O
trapping reagent	B-T130
in	O
a	O
FMDV	B-T005
sandwich ELISA	B-T059
.	O
In	O
addition,	O
inclusion	B-T080
of	O
FLAG	B-T116
or	O
His tags	B-T116
facilitates	O
simple	O
purification	B-T059
without	O
the	O
loss	B-T081
of	O
virus binding	B-T038
.	O
We	O
also	O
provide	O
evidence	B-T078
that	O
when	O
combined	B-T080
with	O
a	O
guinea pig	B-T015
polyclonal serum	B-T031
,	O
or	O
serotype-specific monoclonal antibodies	B-T116
,	O
the	O
integrin	B-T116
can	O
be	O
used	O
to	O
detect	B-T033
viruses	B-T005
representative	O
of	O
all	O
FMDV serotypes	B-T005
.	O
We	O
also	O
show	O
that	O
recombinant FMDV	B-T005
empty capsids	B-T017
,	O
with	O
stabilising disulphide bonds	B-T070
,	O
can	O
serve	O
as	O
an	O
antigen	B-T129
in	O
the	O
ELISA	B-T059
and	O
can	O
therefore	O
replace	O
inactivated virus antigen	B-T129
as	O
a	O
positive control	B-T077
for	O
the	O
assay	B-T059
.	O
Our	O
results	B-T034
demonstrate	O
the	O
potential	B-T080
use	O
of	O
bovine	B-T015
αvβ6	B-T116
and	O
FMDV	B-T005
empty capsids	B-T017
in	O
FMD	B-T047
diagnostic assays	B-T059
.	O

Stress	B-T048
and	O
binge drinking	B-T055
:	O
A	O
toxic	B-T037
combination	O
for	O
the	O
teenage	B-T079
brain	B-T023
Young adult	B-T100
university students	B-T080
frequently	O
binge	B-T055
on	O
alcohol	B-T055
and	O
have	O
high	B-T080
stress levels	B-T033
.	O
Based	O
on	O
findings	O
in	O
rodents	B-T015
,	O
we	O
predicted	O
that	O
heavy current alcohol use	B-T033
and	O
elevated	B-T080
stress	B-T048
and	O
depression scores	B-T033
would	O
be	O
associated with	B-T080
deficits	B-T080
on	O
high	B-T080
interference	B-T169
memory	B-T041
tasks	B-T057
,	O
while	O
early onset	B-T033
,	O
prolonged	O
binge	B-T055
patterns	B-T055
would	O
lead	O
to	O
broader	O
cognitive deficits	B-T048
on	O
tests	O
of	O
associative encoding	B-T041
and	O
executive functions	B-T041
.	O
We	O
developed	O
the	O
Concentration	B-T041
Memory	B-T041
Task	B-T057
,	O
a	O
novel	O
computerized version	B-T066
of	O
the	O
Concentration	B-T041
card game	B-T073
with	O
a	O
high	B-T080
degree	O
of	O
interference	B-T169
.	O
We	O
found	O
that	O
young adults	B-T100
with	O
elevated	B-T080
stress	B-T033
,	O
depression	B-T033
,	O
and	O
alcohol consumption scores	B-T081
were	O
impaired	B-T169
in	O
the	O
Concentration	B-T041
Memory	B-T041
Task	B-T057
.	O
We	O
also	O
analyzed data	B-T057
from	O
a	O
previous	O
study,	O
and	O
found	O
that	O
higher	B-T080
alcohol consumption scores	B-T081
were	O
associated with	B-T080
impaired	B-T169
performance	B-T055
on	O
another	O
high	B-T080
interference	B-T169
memory	B-T041
task	B-T057
,	O
based	O
on	O
Kirwan and Stark's Mnemonic Similarity Test	B-T170
.	O
On	O
the	O
other	O
hand,	O
adolescent	B-T100
onset	B-T081
of	O
binge drinking	B-T055
predicted	O
poorer	B-T080
performance	B-T055
on	O
broader	O
range	O
of	O
memory	B-T041
tests	B-T170
,	O
including	O
a	O
more	O
systematic test of spatial recognition memory	B-T170
,	O
and	O
an	O
associative learning	B-T041
task	B-T057
.	O
Our	O
results	B-T033
are	O
broadly	O
consistent with	B-T078
findings	O
in	O
rodents	B-T015
that	O
acute alcohol	B-T051
and	O
stress	B-T048
exposure	O
suppress	B-T169
neurogenesis	B-T040
in	O
the	O
adult	B-T100
hippocampus	B-T023
,	O
which	O
in	O
turn	O
impairs	B-T169
performance	B-T055
in	O
high	B-T080
interference	B-T169
memory	B-T041
tasks	B-T057
,	O
while	O
adolescent	B-T100
onset	B-T081
binge drinking	B-T055
causes	O
more	O
extensive	B-T080
brain damage	B-T037
and	O
cognitive deficits	B-T048
.	O

Of	O
Kindlins	B-T116
and	O
Cancer	B-T191
Kindlins	B-T116
are	O
4.1-ezrin-ridixin-moesin (FERM) domain	B-T087
containing	O
proteins	B-T116
.	O
There	O
are	O
three	O
kindlins	B-T116
in	O
mammals	B-T015
,	O
which	O
share	O
high	B-T080
sequence	B-T087
identity.	O
Kindlin-1	B-T116
is	O
expressed	B-T045
primarily	O
in	O
epithelial cells	B-T025
,	O
kindlin-2	B-T116
is	O
widely	O
distributed	B-T169
and	O
is	O
particularly	O
abundant	B-T080
in	O
adherent cells	B-T025
,	O
and	O
kindlin-3	B-T116
is	O
expressed	B-T045
primarily	O
in	O
hematopoietic cells	B-T025
.	O
These	O
distributions	B-T169
are	O
not	O
exclusive	B-T078
;	O
some	O
cells	B-T025
express	B-T045
multiple	B-T081
kindlins	B-T116
,	O
and	O
transformed cells	B-T025
often	B-T079
exhibit	O
aberrant	B-T080
expression	B-T045
,	O
both	O
in	O
the	O
isoforms	B-T116
and	O
the	O
levels	B-T080
of	O
kindlins	B-T116
.	O
Great	O
interest	O
in	O
the	O
kindlins	B-T116
has	O
emerged	O
from	O
the	O
recognition	O
that	O
they	O
play	O
major	B-T080
roles	B-T077
in	O
controlling	B-T067
integrin	B-T116
function	B-T044
.	O
In vitro studies	B-T062
,	O
in vivo studies	B-T062
of	O
mice	B-T015
deficient	B-T169
in	O
kindlins	B-T116
,	O
and	O
studies	B-T062
of	O
patients	B-T101
with	O
genetic	B-T169
deficiencies	B-T169
of	O
kindlins	B-T116
have	O
clearly	O
established	B-T080
that	O
they	O
regulate	O
the	O
capacity	B-T081
of	O
integrins	B-T116
to	O
mediate	B-T080
their	O
functions	B-T169
.	O
Kindlins	B-T116
are	O
adaptor proteins	B-T116
;	O
their	O
function	B-T169
emanate	B-T080
from	O
their	O
interaction	B-T169
with	O
binding	B-T044
partners,	O
including	O
the	O
cytoplasmic tails	B-T026
of	O
integrins	B-T116
and	O
components	O
of	O
the	O
actin cytoskeleton	B-T026
.	O
The	O
purpose	B-T169
of	O
this	O
review	B-T170
is	O
to	O
provide	O
a	O
brief	B-T079
overview	B-T170
of	O
kindlin	B-T116
structure	B-T116
and	O
function	B-T044
,	O
a	O
consideration	B-T033
of	O
their	O
binding	B-T044
partners,	O
and	O
then	O
to	O
focus	O
on	O
the	O
relationship	B-T080
of	O
each	O
kindlin	B-T116
family	B-T116
member	B-T096
with	O
cancer	B-T191
.	O
In	O
view	B-T082
of	O
many	O
correlations	B-T080
of	O
kindlin	B-T116
expression	B-T045
levels	B-T080
and	O
neoplasia	B-T191
and	O
the	O
known	O
association	B-T080
of	O
integrins	B-T116
with	O
tumor progression	B-T191
and	O
metastasis	B-T191
,	O
we	O
consider	B-T078
whether	O
regulation	O
of	O
kindlins	B-T116
or	O
their	O
function	B-T169
would	O
be	O
attractive	B-T080
targets	B-T169
for	O
treatment of cancer	B-T061
.	O

Preclinical	B-T080
fibrinolysis	B-T039
in	O
patients	B-T101
with	O
ST-segment elevation myocardial infarction	B-T047
in	O
a	O
rural region	B-T082
In	O
the	O
current guidelines	B-T170
for	O
the	O
treatment	B-T061
of	O
patients	B-T101
with	O
ST-segment elevation myocardial infarction	B-T047
(	O
STEMI	B-T047
),	O
the	O
European	O
Society	O
of	O
Cardiology	O
(ESC)	O
recommends	B-T078
preclinical	B-T080
fibrinolysis	B-T039
as	O
a	O
reperfusion therapy	B-T061
if,	O
due	O
to	O
long	O
transportation	B-T078
times	B-T079
,	O
no	O
cardiac catheterisation	B-T058
is	O
available	B-T169
within	O
90-120	O
min	B-T079
.	O
However,	O
there	O
is	O
little	O
remaining	B-T080
in-depth	O
expertise	B-T080
in	O
this	O
method	B-T169
because	O
fibrinolysis	B-T039
is	O
presently	B-T078
only	O
rarely	B-T080
indicated	B-T033
.	O
In	O
a	O
rural area	B-T082
in	O
southwestern	B-T082
Germany	B-T083
,	O
where	O
an	O
emergency primary percutaneous coronary intervention	B-T061
was	O
not	O
routinely	B-T080
available	B-T169
within	O
90-120	O
min	B-T079
,	O
156	O
STEMI	B-T047
patients	B-T101
underwent	O
fibrinolysis	B-T039
with	O
the	O
plasminogen activator reteplase	B-T116
,	O
performed by	B-T080
trained	O
emergency	B-T067
physicians	B-T097
.	O
The	O
practicality	B-T080
of	O
the	O
treatment	B-T061
,	O
as	O
well	O
as	O
complications	B-T046
and	O
the	O
mortality	B-T081
of	O
the	O
patients	B-T101
in	O
the	O
preclinical	B-T080
phase	B-T079
until	O
arrival	B-T052
at	O
the	O
hospital	B-T073
,	O
were	O
retrospectively studied	B-T062
.	O
The	O
mean time	B-T079
from	O
onset of	B-T080
the	O
symptoms	B-T184
to	O
first	O
medical contact	B-T058
was	O
114	O
±	O
116	O
min	B-T079
.	O
The	O
mean interval	B-T079
to	O
the	O
start	B-T079
of	O
fibrinolysis	B-T039
of	O
13.5	O
±	O
6.4	O
min	B-T079
was	O
within	O
the	O
30	O
min	B-T079
mandated	B-T089
by	O
the	O
ESC.	O
Patients	B-T101
with	O
inferior STEMI	B-T047
represented	B-T052
the	O
largest	B-T081
subgroup	B-T185
.	O
Occurring	O
in	O
39	O
cases	B-T096
(25	O
%),	O
complications	B-T046
due	O
to	O
infarction	B-T046
were	O
relatively	O
common	B-T081
during	O
the	O
prehospital	B-T058
phase	B-T079
,	O
including	O
15	O
cases	B-T096
(9.6	O
%)	O
of	O
cardiogenic shock	B-T046
,	O
but	O
in	O
all	O
cases	B-T096
the	O
complications	B-T046
were	O
manageable	B-T033
.	O
No	O
patient	B-T101
died	B-T033
before	O
arrival	B-T052
at	O
the	O
hospital	B-T073
.	O
As	O
lysis	B-T046
-	O
associated	B-T080
adverse effects	B-T046
,	O
merely	O
two	O
uncomplicated	B-T080
mucosal haemorrhages	B-T184
and	O
one	O
case	O
of	O
mild allergic skin reactions	B-T047
were	O
seen	B-T080
.	O
In	O
emergency situations	B-T067
with	O
long	O
transportation	B-T078
times	B-T079
to	O
the	O
nearest	O
suitable	B-T080
cardiac catheterisation	B-T058
laboratory	B-T073
,	O
preclinical	B-T080
fibrinolysis	B-T039
in	O
STEMI	B-T047
still	O
represents	O
a	O
workable method	B-T169
.	O
Success	B-T054
of	O
this	O
strategy	B-T041
requires	O
particularly	O
strong training	B-T065
of	O
the	O
emergency	B-T067
physicians	B-T097
in	O
ECG	B-T060
and	O
lysis	B-T046
therapy	B-T061
,	O
and	O
co-operation	B-T054
with	O
nearby	O
cardiac centres	B-T073
.	O

A	O
method	B-T169
of	O
providing	B-T052
engaging	O
formative feedback	B-T057
to	O
large	B-T081
cohort	B-T098
first-year	B-T079
physiology	B-T091
and	O
anatomy	B-T091
students	B-T098
A	O
growing	O
body	O
of	O
evidence	B-T078
demonstrates	B-T052
a	O
critical	B-T080
role	O
for	O
effective	B-T080
,	O
meaningful	B-T080
feedback	B-T041
to	O
enhance	B-T052
student	B-T098
learning	B-T041
.	O
Effective	B-T080
feedback	B-T041
can	O
become	O
part of	B-T082
the	O
learning	B-T041
cycle	B-T079
that	O
is	O
not	O
only	O
a	O
learning	B-T041
opportunity	B-T062
for	O
the	O
student	B-T098
but	O
can	O
also	O
be	O
used	O
to	O
inform	B-T057
the	O
teacher	B-T097
and	O
ongoing	B-T078
curriculum development	B-T065
.	O
Feedback	B-T041
is	O
considered	B-T078
particularly	O
important	B-T080
during	B-T079
the	O
first year	B-T079
of	O
university	B-T073
and	O
can	O
even	O
be	O
viewed	O
as	O
a	O
retention	B-T169
strategy	O
that	O
can	O
help	O
attenuate	B-T052
student	B-T098
performance anxieties	B-T048
and	O
solidify	B-T080
perceptions	B-T041
of	O
academic support	B-T065
.	O
Unfortunately,	O
the	O
provision	O
of	O
individualized	B-T080
,	O
timely	B-T080
feedback	B-T041
can	O
be	O
particularly	O
challenging	O
in	O
first-year	B-T079
courses	B-UnknownType
as	O
they	O
tend	O
to	O
be	O
large	B-T081
and	O
diverse	B-T080
cohort	B-T098
classes	B-T170
that	O
pose	O
challenges	O
of	O
time	B-T079
and	O
logistics	B-T057
.	O
Various	O
forms	O
of	O
generic	O
feedback	B-T041
can	O
provide	B-T052
rapid	B-T080
and	O
cost-effect	B-T081
feedback	B-T041
to	O
large	B-T081
cohorts	B-T098
but	O
may	O
be	O
of	O
limited	B-T169
benefit	B-T081
to	O
students	B-T098
other	O
than	O
signaling	O
weaknesses	B-T033
in	O
knowledge	B-T170
.	O
The	O
present	B-T033
study	B-T062
describes	B-T078
a	O
method	B-T169
that	O
was	O
used	O
to	O
provide	B-T052
formative task-related feedback	B-T057
to	O
a	O
large	B-T081
cohort	B-T098
of	O
first-year	B-T079
physiology	B-T091
and	O
anatomy	B-T091
students	B-T098
.	O
Based	O
on	O
student	B-T098
evaluations	B-T058
presented	B-T078
in	O
this	O
study	B-T062
,	O
this	O
method	B-T169
provided	B-T052
feedback	B-T041
in	O
a	O
manner	O
that	O
engaged	O
students	B-T098
,	O
uncovered	B-T169
underlying misconceptions	B-T033
,	O
facilitated	O
peer	B-T098
discussion	B-T054
,	O
and	O
provided	B-T052
opportunity	O
for	O
new	B-T080
instruction	B-T065
while	O
allowing	B-T054
the	O
lecturer	B-T097
to	O
recognize	B-T041
common	B-T081
gaps	B-T082
in	O
knowledge	B-T170
and	O
inform	O
ongoing	B-T078
curriculum development	B-T065
.	O

SIRT2	B-T116
Deacetylates	B-T044
and	O
Inhibits the Peroxidase Activity	B-T044
of	O
Peroxiredoxin-1	B-T116
to	O
Sensitize Breast Cancer Cells	B-T025
to	O
Oxidant Stress	B-T049
-	O
Inducing	B-T169
Agents	O
SIRT2	B-T116
is	O
a	O
protein deacetylase	B-T044
with	O
tumor suppressor activity	B-T043
in	O
breast	B-T191
and	O
liver tumors	B-T191
where	O
it	O
is	O
mutated	B-T049
;	O
however,	O
the	O
critical	O
substrates	B-T167
mediating	O
its	O
antitumor activity	B-T033
are	O
not	O
fully	O
defined.	O
Here	O
we	O
demonstrate	O
that	O
SIRT2	B-T116
binds	B-T044
,	O
deacetylates	B-T044
,	O
and	O
inhibits the peroxidase activity	B-T044
of	O
the	O
antioxidant protein peroxiredoxin	B-T116
(	O
Prdx-1	B-T116
)	O
in	O
breast cancer cells	B-T025
.	O
Ectopic	B-T082
overexpression	B-T045
of	O
SIRT2	B-T116
,	O
but	O
not	O
its	O
catalytically dead mutant	B-T049
,	O
increased	B-T081
intracellular levels	B-T082
of	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
)	O
induced by hydrogen peroxide,	B-T121
which	O
led	O
to	O
increased	B-T081
levels	B-T080
of	O
an	O
overoxidized and multimeric form of Prdx-1	B-T116
with	O
activity as a molecular chaperone	B-T116
.	O
Elevated	B-T080
levels	B-T080
of	O
SIRT2	B-T028
sensitized breast cancer cells	B-T025
to	O
intracellular DNA damage	B-T049
and	O
cell death induced by oxidative stress	B-T043
,	O
as	O
associated	O
with	O
increased	B-T081
levels	B-T080
of	O
nuclear FOXO3A	B-T116
and	O
the	O
proapoptotic BIM protein	B-T116
.	O
In	O
addition,	O
elevated	B-T080
levels	B-T080
of	O
SIRT2	B-T116
sensitized breast cancer cells	B-T025
to	O
arsenic trioxide	B-T121
,	O
an	O
approved	O
therapeutic agent	B-T073
,	O
along	O
with	O
other	O
intracellular ROS	B-T123
-	O
inducing agents	B-T121
.	O
Conversely,	O
antisense RNA	B-T114
-	O
mediated attenuation	B-T052
of	O
SIRT2	B-T116
reversed	B-T169
ROS	B-T123
-	O
induced toxicity	B-T037
as	O
demonstrated	O
in	O
a	O
zebrafish	B-T013
embryo model system	B-T018
.	O
Collectively,	O
our	O
findings	O
suggest	O
that	O
the	O
tumor suppressor activity	B-T043
of	O
SIRT2	B-T116
requires	O
its	O
ability	O
to	O
restrict	B-T169
the	O
antioxidant activity	B-T044
of	O
Prdx-1	B-T116
,	O
thereby	O
sensitizing breast cancer cells	B-T025
to	O
ROS	B-T123
-	O
induced DNA damage	B-T049
and	O
cell cytotoxicity	B-T049
.	O
Cancer	O
Res;	O
76(18);	O
5467-78.	O
©2016	O
AACR.	O

On	O
the	O
development	B-T169
of	O
conjunctival hyperemia	B-T047
computer-assisted diagnosis tools	B-T060
:	O
Influence	O
of	O
feature	B-T080
selection	B-T052
and	O
class imbalance	B-T170
in	O
automatic	O
gradings	O
The	O
sudden	O
increase	O
of	O
blood flow	B-T039
in	O
the	O
bulbar conjunctiva	B-T023
,	O
known	O
as	O
hyperemia	B-T047
,	O
is	O
associated	O
to	O
a	O
red hue	B-T070
of	O
variable	B-T080
intensity	B-T080
.	O
Experts	O
measure	O
hyperemia	B-T047
using	O
levels	O
in	O
a	O
grading scale	B-T170
,	O
a	O
procedure	O
that	O
is	O
subjective,	O
non-repeatable	O
and	O
time consuming	B-T080
,	O
thus	O
creating	O
a	O
need	O
for	O
its	O
automatisation	B-T066
.	O
However,	O
the	O
task	O
is	O
far	O
from	O
straightforward	B-T080
due	O
to	O
data	O
issues	O
such	O
as	O
class imbalance	B-T170
or	O
correlated	B-T080
features	B-T080
.	O
In	O
this	O
paper,	O
we	O
study	O
the	O
specific	O
features	B-T080
of	O
hyperemia	B-T047
and	O
propose	O
various	O
approaches	O
to	O
address	O
these	O
problems	O
in	O
the	O
context	O
of	O
an	O
automatic framework	B-T170
for	O
hyperemia	B-T047
grading	B-T033
.	O
Oversampling	B-T170
,	O
undersampling	B-T170
and	O
SMOTE approaches	B-T170
were	O
applied	O
in	O
order	O
to	O
tackle	O
the	O
problem	O
of	O
class imbalance	B-T170
.	O
25	O
features	O
were	O
computed	O
for	O
each	O
image	O
and	O
regression methods	B-T170
were	O
then	O
used	O
to	O
transform	O
them	O
into	O
a	O
value	O
on	O
the	O
grading scale	B-T170
.	O
The	O
values	O
and	O
relationships	O
among	O
features	B-T080
and	O
experts' values	B-T033
were	O
analysed,	O
and	O
five	O
feature	B-T080
selection	B-T052
techniques	O
were	O
subsequently	O
studied.	O
The	O
lowest mean square error	B-T081
(	O
MSE	B-T081
)	O
for	O
the	O
regression systems	B-T170
trained	O
with	O
individual	O
features	O
is	O
below	O
0.1	O
for	O
both	O
scales.	O
Multi-layer perceptron	B-T170
(	O
MLP	B-T170
)	O
obtains	O
the	O
best	O
values,	O
but	O
is	O
less	O
consistent	O
than	O
the	O
random forest (RF) method	B-T170
.	O
When	O
all	O
features	O
are	O
combined,	O
the	O
best	O
results	O
for	O
both	O
scales	O
are	O
achieved	O
with	O
MLP	B-T170
.	O
Correlation based feature selection	B-T170
(	O
CFS	B-T170
)	O
and	O
M5	O
provide	O
the	O
best	O
results,	O
MSE	B-T081
=0.108	O
and	O
MSE	B-T081
=0.061	O
respectively.	O
Finally,	O
the	O
class imbalance problem	B-T170
is	O
minimised	O
with	O
the	O
SMOTE approach	B-T170
for	O
both	O
scales	O
(	O
MSE	B-T081
<0.006).	O
Machine learning	B-T066
methods	O
are	O
able	O
to	O
perform	O
an	O
objective	O
assessment	O
of	O
hyperemia	B-T047
grading	B-T033
,	O
removing	O
both	O
intra- and inter-expert subjectivity	B-T080
while	O
providing	O
a	O
gain	O
in	O
computation	B-T052
time	B-T079
.	O
SMOTE	B-T170
and	O
oversampling approaches	B-T170
minimise	O
the	O
class imbalance problem	B-T170
,	O
while	O
feature	B-T080
selection	B-T052
reduces	O
the	O
number	O
of	O
features	B-T080
from	O
25	O
to	O
3-5	O
without	O
worsening	O
the	O
MSE	B-T081
.	O
As	O
the	O
differences	O
between	O
the	O
system	B-T073
and	O
a	O
human expert	B-T097
are	O
similar	O
to	O
the	O
differences	O
between	O
experts	B-T097
,	O
we	O
can	O
therefore	O
conclude	O
that	O
the	O
system	B-T073
behaves	O
like	O
an	O
expert	B-T097
.	O

Medication	B-T058
,	O
rehabilitation	B-T169
and	O
health care consumption	B-T055
in	O
adults	B-T100
with	O
cerebral palsy	B-T047
:	O
A	O
population based study	B-T062
To	O
evaluate	O
medication	B-T058
,	O
rehabilitation	B-T169
and	O
healthcare consumption	B-T055
in	O
adults	B-T100
with	O
CP	B-T047
as	O
a	O
function	B-T169
of	O
Gross Motor Function Classification System	B-T170
(	O
GMFCS	B-T170
)	O
level.	O
Questionnaire	B-T170
-based	O
cross-sectional study	B-T062
.	O
Brittany	B-T083
,	O
a	O
French county	B-T083
.	O
Adults	B-T100
with	O
cerebral palsy	B-T047
.	O
Questionnaires	B-T170
relating	O
to	O
drugs	B-T121
,	O
orthotic devices	B-T074
,	O
mobility aids	B-T074
,	O
rehabilitation	B-T169
and	O
medical input	B-T033
were	O
sent	B-T169
to	O
435	O
members	B-T098
of	O
a	O
unique	B-T080
regional French	B-T083
network	B-T169
dedicated	O
to	O
adults	B-T100
with	O
cerebral palsy	B-T047
.	O
The	O
questionnaire	B-T170
was	O
completed	B-T080
by	O
the	O
participant	B-T098
or	O
a	O
helper	B-UnknownType
if	O
necessary.	O
Of	O
the	O
282	O
responders	B-T033
,	O
7.8%	O
had	O
a	O
GMFCS level	B-T170
of	O
I,	O
14.2%	O
II,	O
17.7%	O
III,	O
29.1%	O
IV	O
and	O
31.2%	O
V.	O
Participants	B-T098
consumed	O
a	O
large amount of healthcare	B-T055
.	O
Almost three-quarters	B-T081
took	O
orally administered drugs	B-T121
,	O
of	O
which	O
antispastic	B-T121
and	O
antiepileptic drugs	B-T121
were	O
among	O
the	O
most frequent	B-T079
.	O
Nearly	O
all	O
patients	B-T101
had	O
at	O
least	O
one	O
type	O
of	O
rehabilitation	B-T169
,	O
87.2%	O
had	O
physiotherapy	B-T061
,	O
78%	O
used	O
at	O
least	O
one	O
mobility aid	B-T074
and	O
69.5%	O
used	O
at	O
least	O
one	O
orthotic device	B-T074
.	O
The	O
frequency	B-T079
of	O
numerous	O
inputs	O
increased	O
with	O
GMFCS level	B-T170
.	O
Specificities	B-T081
were	O
found	B-T033
for	O
each	O
GMFCS level	B-T170
,	O
e.g.	O
participants	B-T098
with	O
GMFCS level	B-T170
IV	O
and	O
V	O
had	O
a	O
high level	B-T080
of	O
medical input	B-T033
and	O
a	O
greater use of	B-T169
trunk-supporting devices	B-T074
,	O
antireflux	B-T061
and	O
laxative	B-T121
.	O
Profiles	B-T081
could	O
be	O
established	O
based	O
on	O
GMFCS levels	B-T170
.	O
Adults	B-T100
with	O
cerebral palsy	B-T047
use	O
a	O
large amount	B-T081
of	O
drugs	B-T121
,	O
mobility aids	B-T074
,	O
orthotic devices	B-T074
,	O
rehabilitation	B-T169
and	O
medical input	B-T033
.	O
Healthcare	B-T058
is	O
targeted	B-T169
at	O
cerebral palsy	B-T047
cerebral palsy -related issues	B-T033
.	O
GMFCS	B-T170
is	O
a	O
determinant	B-T169
of	O
healthcare consumption	B-T055
and	O
thus	O
a	O
useful	O
tool	O
for	O
clinical practice	B-T057
to	O
target	B-T169
care	B-T052
appropriately	B-T080
.	O

Transcriptome sequencing	B-T059
and	O
de novo	B-T078
characterization	B-T052
of	O
Korean	B-T083
endemic	O
land snail	B-T204
,	O
Koreanohadra kurodana	B-T204
for	O
functional	O
transcripts	B-T114
and	O
SSR	B-T114
markers	B-T045
The	O
Korean	B-T083
endemic	O
land snail	B-T204
Koreanohadra kurodana	B-T204
(	O
Gastropoda	B-T204
:	O
Bradybaenidae	B-T204
)	O
found	O
in	O
humid areas	B-T067
of	O
broadleaf forests	B-T070
and	O
shrubs	B-T002
have	O
been	O
considered	O
vulnerable	O
as	O
the	O
number	O
of	O
individuals	B-T098
are	O
declining	O
in	O
recent	O
years	B-T079
.	O
The	O
species	B-T204
is	O
poorly	O
characterized	O
at	O
the	O
genomic level	B-T028
that	O
limits	O
the	O
understanding	O
of	O
functions	B-T169
at	O
the	O
molecular	B-T080
and	O
genetics level	B-T169
.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
performed	O
de novo	B-T078
transcriptome sequencing	B-T059
to	O
produce	O
a	O
comprehensive	O
transcript	B-T114
dataset	B-T170
of	O
visceral mass tissue	B-T024
of	O
K. kurodana	B-T204
by	O
the	O
Illumina paired-end sequencing technology	B-T063
.	O
Over	O
234	O
million	O
quality	O
reads	O
were	O
assembled	O
to	O
a	O
total	O
of	O
315,924	O
contigs	B-T082
and	O
191,071	O
unigenes	B-T170
,	O
with	O
an	O
average	O
and	O
N50	B-T114
length	B-T081
of	O
585.6	O
and	O
715	O
bp	O
and	O
678	O
and	O
927	O
bp,	O
respectively.	O
Overall,	O
36.32	O
%	O
of	O
the	O
unigenes	B-T170
found	O
matches	O
to	O
known	O
protein	B-T087
/	O
nucleotide sequences	B-T086
in	O
the	O
public databases	B-T170
.	O
The	O
direction	B-T082
of	O
the	O
unigenes	B-T170
to	O
functional	O
categories	O
was	O
determined	O
using	O
COG	B-T170
,	O
GO	B-T170
,	O
KEGG	B-T170
,	O
and	O
InterProScan	B-T170
protein domain	B-T087
search	B-T052
.	O
The	O
GO	B-T170
analysis	B-T062
search	O
resulted	O
in	O
22,967	O
unigenes	B-T170
(12.02	O
%)	O
being	O
categorized	O
into	O
40	O
functional groups	B-T120
.	O
The	O
KEGG annotation	B-T170
revealed	O
that	O
metabolism pathway	B-T169
genes	B-T028
were	O
enriched.	O
The	O
most	O
prominent	O
protein motifs	B-T087
include	O
the	O
zinc finger	B-T087
,	O
ribonuclease H	B-T116
,	O
reverse transcriptase	B-T116
,	O
and	O
ankyrin repeat domains	B-T044
.	O
The	O
simple sequence repeats	B-T114
(	O
SSRs	B-T114
)	O
identified	O
from	O
>1	O
kb	O
length	B-T081
of	O
unigenes	B-T170
show	O
a	O
dominancy	O
of	O
dinucleotide repeat motifs	B-T114
followed	O
with	O
tri-	B-T114
and	O
tetranucleotide motifs	B-T114
.	O
A	O
number	O
of	O
unigenes	B-T170
were	O
putatively	O
assessed	O
to	O
belong	O
to	O
adaptation	B-T038
and	O
defense mechanisms	B-T041
including	O
heat shock proteins 70	B-T116
,	O
Toll-like receptor 4	B-T116
,	O
AMP-activated protein kinase	B-T116
,	O
aquaporin-2	B-T116
,	O
etc.	O
Our	O
data	O
provide	O
a	O
rich	O
source	O
for	O
the	O
identification	B-T080
and	O
functional	O
characterization	B-T052
of	O
new	O
genes	B-T028
and	O
candidate	O
polymorphic	B-T080
SSR	B-T114
markers	B-T045
in	O
K. kurodana	B-T204
.	O
The	O
availability	O
of	O
transcriptome	B-T086
information	O
(	O
http://bioinfo.sch.ac.kr/submission/	B-T170
)	O
would	O
promote	O
the	O
utilization	O
of	O
the	O
resources	O
for	O
phylogenetics study	B-T062
and	O
genetic diversity	B-T070
assessment	B-T052
.	O

Prediction	B-T078
of	O
Estrogenic	B-T109
Bioactivity	B-T052
of	O
Environmental Chemical	B-T103
Metabolites	B-T123
The	O
US Environmental Protection Agency's	B-T092
(	O
EPA	B-T092
)	O
Endocrine Disruptor Screening Program	B-T058
(	O
EDSP	B-T058
)	O
is	O
using	O
in vitro data	B-T078
generated	O
from	O
ToxCast	B-T170
/	O
Tox21	B-T170
high-throughput screening assays	B-T059
to	O
assess	O
the	O
endocrine	B-T022
activity	B-T052
of	O
environmental chemicals	B-T103
.	O
Considering	O
that	O
in vitro assays	B-T059
may	O
have	O
limited	O
metabolic capacity	B-T169
,	O
inactive chemicals	B-T103
that	O
are	O
biotransformed	B-T040
into	O
metabolites	B-T123
with	O
endocrine	B-T022
bioactivity	B-T052
may	O
be	O
missed	O
for	O
further	O
screening	B-T169
and	O
testing	B-T169
.	O
Therefore,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	B-T040
and	O
endocrine	B-T022
activity	B-T052
of	O
both	O
parent chemicals	B-T103
and	O
their	O
associated	O
metabolites	B-T123
.	O
We	O
used	O
commercially	O
available	O
software	B-T073
to	O
predict	O
metabolites	B-T123
of	O
50	O
parent compounds	B-T103
,	O
out	O
of	O
which	O
38	O
chemicals	B-T103
are	O
known	O
to	O
have	O
estrogenic	B-T109
metabolites	B-T123
,	O
and	O
12	O
compounds	B-T103
and	O
their	O
metabolites	B-T123
are	O
negative	O
for	O
estrogenic	B-T109
activity	B-T052
.	O
Three	O
ER	B-T116
QSAR	B-T081
models	B-T170
were	O
used	O
to	O
determine	O
potential	O
estrogen	B-T109
bioactivity	B-T052
of	O
the	O
parent compounds	B-T103
and	O
predicted	O
metabolites	B-T123
,	O
the	O
outputs	O
of	O
the	O
models	B-T170
were	O
averaged,	O
and	O
the	O
chemicals	B-T103
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	B-T169
of	O
the	O
parent chemical	B-T103
and	O
metabolites	B-T123
.	O
The	O
metabolite prediction software	B-T073
correctly	O
identified	O
known	O
estrogenic	B-T109
metabolites	B-T123
for	O
26	O
out	O
of	O
27	O
parent chemicals	B-T103
with	O
associated	O
metabolite	B-T123
data,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	B-T109
metabolites	B-T123
were	O
predicted	O
as	O
potential	O
biotransformation	B-T040
products	B-T121
derived	O
from	O
the	O
parent chemical	B-T103
.	O
The	O
QSAR	B-T081
models	B-T170
estimated	O
stronger	O
estrogenic	B-T109
activity	B-T052
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	B-T109
metabolites	B-T123
compared	O
to	O
their	O
parent chemicals	B-T103
.	O
Finally,	O
the	O
three	O
models	B-T170
identified	O
a	O
similar	O
set	O
of	O
parent compounds	B-T103
as	O
top	O
ranked	O
chemicals	B-T103
based	O
on	O
the	O
estrogenicity	B-T169
of	O
putative	O
metabolites	B-T123
.	O
This	O
proposed	O
in silico	B-T066
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	B-T033
of	O
chemicals	B-T103
with	O
estrogenic	B-T109
metabolites	B-T123
and	O
may	O
reduce	O
potential	O
false negative	B-T034
results	O
from	O
in vitro assays	B-T059
.	O

Effects of	B-T080
Application	B-T169
of	O
Social Marketing	B-T057
Theory	B-T078
and	O
the	O
Health Belief Model	B-T058
in	O
Promoting	B-T052
Cervical Cancer Screening	B-T061
among	O
Targeted	B-T169
Women	B-T098
in	O
Sisaket Province	B-T083
,	O
Thailand	B-T083
Cervical cancer	B-T191
is	O
a	O
major	B-T080
public health problem	B-T033
in	O
Thailand	B-T083
,	O
being	O
ranked	B-T170
second	O
only	O
to	O
breast cancer	B-T191
.	O
Thai	B-T098
women	B-T098
have	O
been	O
reported	B-T058
to	O
have	O
a	O
low	B-T080
rate	B-T081
of	O
cervical cancer screening	B-T061
(27.7%	O
of	O
the	O
80%	O
goal	B-T170
of	O
WHO	B-T093
).	O
We	O
therefore	O
aimed	B-T078
to	O
apply	B-T169
the	O
social marketing	B-T057
theory	B-T078
and	O
health belief model	B-T058
in	O
promoting	B-T052
cervical cancer screening	B-T061
in	O
Kanthararom District	B-T083
,	O
Sisaket Province	B-T083
.	O
A	O
total	B-T080
of	O
92	O
from	O
974	O
targeted	B-T169
women	B-T098
aged	B-T032
3060	O
years	B-T079
were	O
randomly	B-T062
divided	B-T169
into	O
two	O
groups	B-T078
.	O
The	O
experimental group	B-T098
underwent	O
application	B-T169
of	O
social marketing	B-T057
theory	B-T078
and	O
a	O
health belief model	B-T058
program	B-T169
promoting	B-T052
cervical cancer screening	B-T061
while	O
the	O
control group	B-T096
received	B-T080
normal services	B-T058
.	O
Two	O
research tools	B-T170
were	O
used:	O
(1)	O
application	B-T169
of	O
social marketing	B-T057
theory	B-T078
and	O
health belief model	B-T058
program	B-T169
and	O
(2)	O
questionnaire	B-T170
used	O
to	O
evaluate	B-T052
perceptions	B-T041
of	O
cervical cancer	B-T191
.	O
Descriptive	B-T170
and	O
inferential statistics	B-T081
including	B-T169
paired	B-T080
sample ttest	B-T170
and	O
independent	B-T169
ttest	B-T170
were	O
used	O
to	O
analyze the data	B-T057
.	O
After	O
the	O
program	B-T169
had	O
been	O
used,	O
the	O
mean score	B-T033
of	O
perception	B-T041
of	O
cervical cancer	B-T191
of	O
experimental group	B-T098
was	O
at	O
a	O
higher	B-T080
level	B-T080
(x=4.09;	O
S.D.	B-T081
=0.30),	O
than	O
in	O
the	O
control group	B-T096
(x=3.82;	O
S.D.	B-T081
=0.20)	O
with	O
statistical significance	B-T081
(p<0.001).	O
This	O
research	B-T062
demonstrated	O
an	O
appropriate	B-T080
communication	B-T054
process	B-T067
in	O
behavioral	B-T053
modification	B-T169
to	O
prevent	O
cervical cancer	B-T191
.	O
It	O
can	O
be	O
recommended	B-T078
that	O
this	O
program	B-T169
featuring	B-T080
social marketing	B-T057
and	O
the	O
health belief model	B-T058
be	O
used	O
to	O
promote	B-T052
cervical cancer screening	B-T061
in	O
targeted	B-T169
women	B-T098
and	O
it	O
can	O
be	O
promoted	B-T052
as	O
a	O
guideline	B-T170
for	O
other	O
health services	B-T058
,	O
especially	O
in	O
health promotion	B-T058
and	O
disease prevention	B-T061
.	O

Visualization	B-T060
of	O
the	O
Intimal Flap	B-T023
in	O
Intracranial Arterial Dissection	B-T190
Using	O
High-Resolution	B-T059
3T MRI	B-T060
Presence	B-T033
of	O
an	O
intimal flap	B-T023
is	O
a	O
critical	B-T080
imaging finding	B-T034
in	O
diagnosing	B-T033
intracranial artery dissection	B-T190
(	O
ICAD	B-T190
).	O
Recent	O
reports	B-T170
showed	O
that	O
high-resolution	B-T059
magnetic resonance imaging	B-T060
(	O
MRI	B-T060
)	O
was	O
better	B-T080
at	O
identifying	O
intimal flaps	B-T023
as	O
compared	B-T052
with	O
routine	O
MRI techniques	B-T060
used	O
in	O
clinical settings	B-T082
.	O
However,	O
no	O
current	O
standardized	O
sequence	B-T169
for	O
high-resolution	B-T059
MRI	B-T060
without	O
gadolinium	B-T130
enhancement	B-T052
produces	O
images	B-T078
of	O
satisfactory	O
quality	B-T080
with	O
clinically	O
tolerable	O
scanning	B-T060
times	B-T079
.	O
This	O
study	O
evaluated	B-T058
a	O
nonenhanced high-resolution fast spin echo (HR-FSE) MRI	B-T060
sequence	B-T169
for	O
visualizing	O
intimal flaps	B-T023
in	O
patients	B-T101
with	O
ICAD	B-T190
.	O
Three	O
patients	B-T101
with	O
ICAD	B-T190
underwent	O
plain	O
MRI	B-T060
examination	O
using	O
a	O
2-dimensional	B-T082
T2-weighted FSE imaging	B-T060
sequence	B-T169
optimized	O
for	O
our	O
3T system	B-T169
(in-plane	O
pixel	O
size,	O
.23	O
mm	O
×	O
.23	O
mm;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap),	O
as	O
well	O
as	O
scanning	B-T060
with	O
conventional	B-T080
modalities	B-T078
,	O
including	O
CT angiography	B-T060
,	O
magnetic resonance angiography	B-T060
,	O
and	O
digital subtraction angiography	B-T060
.	O
We	O
assessed	B-T052
whether	O
these	O
imaging methods	B-T169
could	O
visualize	O
an	O
intimal flap	B-T023
and/or	O
double lumen sign	B-T033
in	O
the	O
participants	B-T098
and	O
compared	B-T052
the	O
results	B-T033
between	O
HR-FSE	B-T060
and	O
the	O
other	O
modalities	B-T078
.	O
HR-FSE	B-T060
images	B-T078
clearly	O
showed	O
intimal flaps	B-T023
and	O
double lumen signs	B-T033
in	O
all	O
3	O
patients	B-T101
,	O
whereas	O
the	O
conventional	B-T080
modalities	B-T078
identified	B-T080
a	O
double lumen sign	B-T033
in	O
only	O
2	O
of	O
the	O
3	O
patients	B-T101
.	O
The	O
present	O
method	O
of	O
optimized	O
HR-FSE imaging	B-T060
with	O
a	O
3T system	B-T169
improved	B-T033
visualization	B-T060
of	O
intimal flaps	B-T023
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	B-T052
patients	B-T101
with	O
suspected	B-T078
ICAD	B-T190
that	O
cannot	O
be	O
definitively	O
diagnosed	B-T033
by	O
conventional	B-T080
imaging modalities	B-T169
.	O

Quantification	B-T081
of	O
intact	B-T080
plasma	B-T031
AGT	B-T116
consisting	O
of	O
oxidized	O
and	O
reduced conformations	B-T082
using	O
a	O
modified	O
ELISA	B-T059
The	O
pleiotropic actions	B-T052
of	O
the	O
renin-angiotensin system	B-T022
(	O
RAS	B-T022
)	O
depend	O
on	O
the	O
availability of	B-T169
angiotensinogen	B-T116
(	O
AGT	B-T116
)	O
which	O
generates	B-T052
angiotensin I	B-T116
(	O
ANG I	B-T116
)	O
when	O
cleaved	B-T082
by	O
renin	B-T116
.	O
Thus,	O
quantification	B-T081
of	O
the	O
intact	B-T080
AGT	B-T116
(	O
iAGT	B-T116
)	O
concentrations	B-T081
is	O
important	B-T080
to	O
evaluate	O
the	O
actual	B-T080
renin substrate	B-T116
available	B-T169
.	O
The	O
iAGT	B-T116
conformation	B-T082
exists	O
as	O
oxidized AGT	B-T116
(	O
oxi-AGT	B-T116
)	O
and	O
reduced AGT	B-T116
(	O
red-AGT	B-T116
)	O
in	O
a	O
disulfide bond	B-T087
,	O
and	O
oxi-AGT	B-T116
has	O
a	O
higher	B-T080
affinity	B-T070
for	O
renin	B-T116
,	O
which	O
may	O
exacerbate	O
RAS	B-T022
-	O
associated diseases	B-T046
.	O
Accordingly,	O
we	O
determined	B-T080
iAGT	B-T116
,	O
oxi-AGT	B-T116
,	O
and	O
red-AGT	B-T116
levels	B-T080
in	O
plasma	B-T031
from	O
rats	B-T015
and	O
mice	B-T015
.	O
Blood samples	B-T031
were	O
obtained	B-T169
by	O
cardiac puncture	B-T059
and	O
then	O
immediately	B-T079
mixed	B-T169
with	O
an	O
inhibitor	B-T120
solution	B-T167
containing	B-T169
a	O
renin inhibitor	B-T121
.	O
Total	B-T080
AGT	B-T116
(	O
tAGT	B-T116
)	O
levels	B-T080
were	O
measured	B-T080
by	O
tAGT	B-T116
ELISA	B-T059
which	O
detects	B-T033
both	O
cleaved	B-T082
and	O
iAGT	B-T116
.	O
iAGT	B-T116
levels	B-T080
were	O
determined by	B-T080
iAGT	B-T116
ELISA	B-T059
which	O
was	O
found	O
to	O
only	O
detect	B-T033
red-AGT	B-T116
.	O
Thus,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	B-T031
with	O
dithiothreitol	B-T109
,	O
a	O
reducing agent	B-T130
,	O
to	O
quantify	B-T081
total	B-T080
iAGT	B-T116
concentration	B-T081
.	O
tAGT	B-T116
levels	B-T080
in	O
rat	B-T015
and	O
mouse	B-T015
plasma	B-T031
were	O
1,839	O
±	O
139	O
and	O
1,082	O
±	O
77	O
ng/ml,	O
respectively.	O
iAGT	B-T116
levels	B-T080
were	O
53%	O
of	O
tAGT	B-T116
in	O
rat	B-T015
plasma	B-T031
but	O
only	O
22%	O
in	O
mouse	B-T015
plasma	B-T031
,	O
probably	O
reflecting	O
the	O
greater	B-T081
plasma	B-T031
renin	B-T116
activity	B-T044
in	O
mice	B-T015
.	O
The	O
ratios	B-T081
of	O
oxi-AGT	B-T116
and	O
red-AGT	B-T116
were	O
∼4:1	O
(	O
rat	B-T015
)	O
and	O
16:1	O
(	O
mouse	B-T015
).	O
Plasma	B-T031
iAGT	B-T116
consists	O
of	O
oxi-AGT	B-T116
and	O
red-AGT	B-T116
,	O
suggesting	B-T078
that	O
oxidative stress	B-T049
can	O
influence	B-T077
ANG I	B-T116
generation	B-T052
by	O
the	O
AGT	B-T116
conformation	B-T082
switch.	O
Furthermore,	O
the	O
lower	B-T052
availability of	B-T169
plasma	B-T031
iAGT	B-T116
in	O
mice	B-T015
suggests	B-T078
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	B-T169
factor	B-T169
in	O
ANG I	B-T116
formation	B-T169
in	O
this	O
species	B-T185
.	O

Carbon Monoxide	B-T131
Improves	B-T033
Efficacy	B-T080
of	O
Mesenchymal Stromal Cells	B-T025
During	B-T079
Sepsis	B-T047
by	O
Production	O
of	O
Specialized	B-T077
Proresolving	B-T033
Lipid Mediators	B-T123
Mesenchymal stromal cells	B-T025
are	O
being	O
investigated	B-T169
as	O
a	O
cell-based therapy	B-T061
for	O
a	O
number	O
of	O
disease processes	B-T046
,	O
with	O
promising	O
results	B-T033
in	O
animal models	B-T008
of	O
systemic inflammation	B-T047
and	O
sepsis	B-T047
.	O
Studies	B-T062
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	B-T033
the	O
therapeutic	B-T169
potential	B-T080
of	O
mesenchymal stromal cells	B-T025
.	O
A	O
gas	B-T104
molecule	B-T167
that	O
improves	B-T033
outcome	B-T169
in	O
experimental	B-T080
sepsis	B-T047
is	O
carbon monoxide	B-T131
.	O
We	O
hypothesized	O
that	O
preconditioning	B-T169
of	O
mesenchymal stromal cells	B-T025
with	O
carbon monoxide	B-T131
ex vivo	B-T169
would	O
promote	B-T052
further	O
therapeutic	B-T169
benefit	B-T081
when	O
cells	B-T025
are	O
administered	B-T169
in vivo	B-T082
after	O
the	O
onset of	B-T080
polymicrobial	B-T047
sepsis	B-T047
in	O
mice	B-T015
.	O
Animal study	B-T008
and	O
primary cell culture	B-T059
.	O
Laboratory	B-T073
investigation	B-T058
.	O
BALB/c mice	B-T015
.	O
Polymicrobial	B-T047
sepsis	B-T047
was	O
induced	B-T169
by	O
cecal	B-T023
ligation	B-T061
and	O
puncture	B-T058
.	O
Mesenchymal stromal cells	B-T025
,	O
mesenchymal stromal cells	B-T025
-	O
conditioned	B-T080
with	O
carbon monoxide	B-T131
,	O
fibroblasts	B-T025
,	O
or	O
fibroblasts	B-T025
-	O
conditioned	B-T080
with	O
carbon monoxide	B-T131
were	O
delivered	B-T169
by	O
tail vein	B-T023
injections	B-T061
to	O
septic	B-T169
mice	B-T015
.	O
The	O
mice	B-T015
were	O
assessed	B-T052
for	O
survival	B-T052
,	O
bacterial	B-T080
clearance	B-T080
,	O
and	O
the	O
inflammatory response	B-T046
during	B-T079
sepsis	B-T047
in	O
each	O
of	O
the	O
groups	B-T078
.	O
Mesenchymal stromal cells	B-T025
were	O
also	O
assessed	B-T052
for	O
their	O
ability	B-T032
to	O
promote	B-T052
bacterial	B-T080
phagocytosis	B-T043
by	O
neutrophils	B-T025
,	O
the	O
production	O
of	O
specialized	B-T077
proresolving	B-T033
lipid mediators	B-T123
,	O
and	O
their	O
importance	O
for	O
mesenchymal stromal cells	B-T025
function	B-T039
using	O
gene silencing	B-T045
.	O
Ex vivo	B-T169
preconditioning	B-T169
with	O
carbon monoxide	B-T131
allowed	O
mesenchymal stromal cells	B-T025
to	O
be	O
administered	B-T169
later	O
after	O
the	O
onset of	B-T080
sepsis	B-T047
(6	O
hr),	O
and	O
yet	O
maintain	O
their	O
therapeutic effect	B-T201
with	O
increased	B-T081
survival	B-T052
.	O
Carbon monoxide	B-T131
preconditioned	B-T081
mesenchymal stromal cells	B-T025
were	O
also	O
able	O
to	O
alleviate	O
organ injury	B-T037
,	O
improve	B-T033
bacterial	B-T080
clearance	B-T080
,	O
and	O
promote	B-T052
the	O
resolution	B-T046
of	O
inflammation	B-T046
.	O
Mesenchymal stromal cells	B-T025
exposed to	B-T080
carbon monoxide	B-T131
,	O
with	O
docosahexaenoic acid	B-T109
substrate	B-T167
,	O
produced	O
specialized	B-T077
proresolving	B-T033
lipid mediators	B-T123
,	O
particularly	O
D-series	B-T080
resolvins	B-T109
,	O
which	O
promoted	B-T052
survival	B-T052
.	O
Silencing	B-T045
of	O
lipoxygenase pathways	B-T044
(	O
5-lipoxygenase	B-T044
and	O
12	B-T044
/	O
15-lipoxygenase	B-T044
),	O
which	O
are	O
important	B-T080
enzymes	B-T116
for	O
specialized	B-T077
proresolving	B-T033
lipid mediator	B-T123
biosynthesis	B-T169
,	O
resulted	B-T169
in	O
a	O
loss	O
of	O
therapeutic	B-T169
benefit	B-T081
bestowed	O
on	O
mesenchymal stromal cells	B-T025
by	O
carbon monoxide	B-T131
.	O
Taken	O
together,	O
these	O
data	B-T078
suggest	O
that	O
production	O
of	O
specialized	B-T077
proresolving	B-T033
lipid mediators	B-T123
contribute	B-T052
to	O
improved	B-T033
mesenchymal stromal cell	B-T025
efficacy	B-T080
when	O
exposed to	B-T080
carbon monoxide	B-T131
,	O
resulting	O
in	O
an	O
improved	B-T033
therapeutic response	B-T201
during	B-T079
sepsis	B-T047
.	O

Effect	B-T080
of	O
primary health care	B-T058
reforms	B-T077
in	O
Turkey	B-T083
on	O
health service utilization	B-T058
and	O
user satisfaction	B-T033
Strengthening	B-T080
primary health care	B-T058
(	O
PHC	B-T058
)	O
is	O
considered	O
a	O
priority	O
for	O
efficient	B-T080
and	O
responsive	B-T169
health systems	B-T093
,	O
but	O
empirical	B-T080
evidence	B-T078
from	O
low-	O
and	O
middle-	O
income	B-T081
countries	B-T083
is	O
limited	B-T169
.	O
The	O
stepwise introduction	B-T061
of	O
family medicine	B-T091
across	O
all	O
81	O
provinces	B-T083
of	O
Turkey	B-T083
(a	O
middle-income	B-T080
country	B-T083
)	O
between	O
2005	O
and	O
2010,	O
aimed	O
at	O
PHC	B-T058
strengthening	B-T080
,	O
presents	O
a	O
natural experiment	B-T062
for	O
assessing	B-T052
the	O
effect	B-T080
of	O
family medicine	B-T091
on	O
health service utilization	B-T058
and	O
user satisfaction	B-T033
.The	O
effect	B-T080
of	O
health system	B-T093
reforms	B-T077
,	O
that	O
introduced	O
family medicine	B-T091
,	O
on	O
utilization	B-T169
was	O
assessed	B-T052
using	O
longitudinal	B-T062
,	O
province-level data	B-T062
for	O
12	O
years	B-T079
and	O
multivariate regression models	B-T075
adjusting	O
for	O
supply-side variables	B-T080
,	O
demographics	B-UnknownType
,	O
socio-economic development	B-T080
and	O
underlying	O
yearly	B-T079
trends	B-T079
.	O
User satisfaction	B-T033
with	O
primary	B-T058
and	O
secondary care	B-T058
services	B-T058
was	O
explored	O
using	O
data	B-T078
from	O
annual Life Satisfaction Surveys	B-T170
.	O
Trends	B-T079
in	O
preferred	O
first	O
point	O
of	O
contact	B-T169
(	O
primary	B-T058
vs	O
secondary	B-T058
,	O
public	B-T073
vs.	O
private	B-T073
),	O
reason for choice	B-T055
and	O
health services	B-T058
issues	B-UnknownType
,	O
were	O
described	B-T078
and	O
stratified	B-T080
by	O
patient characteristics	B-T201
,	O
provider type	B-T201
,	O
and	O
rural/urban settings	B-T083
.Between	O
2002	O
and	O
2013,	O
the	O
average number	B-T081
of	O
PHC	B-T058
consultations	B-T058
increased	B-T081
from	O
1.75	O
to	O
2.83	O
per	O
person	B-T098
per	O
year	B-T079
.	O
In	O
multivariate models	B-T075
,	O
family medicine	B-T091
introduction	B-T061
was	O
associated with	B-T080
an	O
increase	B-T169
of	O
0.37	O
PHC	B-T058
consultations	B-T058
per	O
person	B-T098
(P	O
<	O
0.001),	O
and	O
slower	B-T080
annual growth	B-T067
in	O
PHC	B-T058
and	O
secondary care	B-T058
consultations	B-T058
.	O
Following	O
family medicine	B-T091
introduction	B-T061
,	O
the	O
growth	B-T067
of	O
PHC	B-T058
and	O
secondary care	B-T058
consultations	B-T058
per	O
person	B-T098
was	O
0.08	O
and	O
0.30,	O
respectively,	O
a	O
year	B-T079
.	O
PHC	B-T058
increased	B-T081
as	O
preferred	O
provider	B-T201
by	O
9.5%	O
over	O
7	O
years	B-T079
with	O
the	O
reasons	O
of	O
proximity	B-T082
and	O
service satisfaction	B-T033
,	O
which	O
increased	B-T081
by	O
14.9%	O
and	O
11.8%,	O
respectively.	O
Reporting	B-T058
of	O
poor facility hygiene	B-T033
,	O
difficulty getting an appointment	B-T033
,	O
poor	B-T080
physician	B-T097
behaviour	B-T053
and	O
high	B-T080
costs of health care	B-T081
all	O
declined	B-T080
(P	O
<	O
0.001)	O
in	O
PHC	B-T058
settings	B-T083
,	O
but	O
remained	O
higher	B-T080
among	O
urban	B-T080
,	O
low-income	B-T033
and	O
working-age	B-T032
populations	B-T098
.	O

Laparoscopic	B-T060
radical lymph node dissection	B-T061
for	O
advanced colon cancer	B-T191
close	O
to	O
the	O
hepatic flexure	B-T029
Complete mesocolic excision	B-T061
is	O
currently	O
recognized	O
as	O
a	O
standard procedure	B-T061
for	O
colon cancer	B-T191
.	O
Gastroepiploic	B-T023
,	O
infrapyloric	B-T023
,	O
and	O
superficial pancreatic head lymph node	B-T023
metastases	B-T191
in	O
the	O
gastrocolic ligament	B-T023
have	O
been	O
reported	O
for	O
colon cancer	B-T191
close	O
to	O
the	O
hepatic flexure	B-T029
.	O
We	O
sought	O
to	O
investigate	O
metastases	B-T191
in	O
the	O
gastrocolic ligament	B-T023
in	O
colon cancer	B-T191
close	O
to	O
the	O
hepatic flexure	B-T029
.	O
This	O
was	O
a	O
single-center retrospective study	B-T062
.	O
All	O
patients	B-T101
with	O
T2	B-T033
or	O
deeper	O
invasive	B-T080
colon cancer	B-T191
in	O
the	O
relevant	O
tumor location	B-T082
who	O
underwent	O
laparoscopic right hemicolectomy	B-T061
or	O
extended right hemicolectomy	B-T061
at	O
our	O
institution	B-T073
between	O
1	O
April	B-T079
2011	O
and	O
31	O
March	B-T079
2015	O
were	O
included.	O
Lymph node dissection	B-T061
in	O
the	O
gastrocolic ligament	B-T023
was	O
performed	O
in	O
35	O
cases.	O
Complications	B-T046
occurred	O
in	O
11	O
patients	B-T101
(31%)	O
and	O
were	O
grades	O
I	O
and	O
II	O
according	O
to	O
the	O
Clavien-Dindo classification	B-T185
.	O
Lymph node metastases	B-T191
in	O
the	O
gastrocolic ligament	B-T023
were	O
found	O
in	O
only	O
three	O
patients	B-T101
(9%).	O
Each	O
metastasis	B-T191
was	O
larger	O
than	O
9	O
mm	B-T081
.	O
Metastases	B-T191
in	O
the	O
gastrocolic ligament	B-T023
occurred	O
in	O
9%	O
of	O
patients	B-T101
with	O
T2	B-T033
or	O
deeper	O
invasive	B-T080
colon cancer	B-T191
close	O
to	O
the	O
hepatic flexure	B-T029
.	O
Laparoscopy	B-T061
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic ligament resection	B-T061
.	O
This	O
study	B-T062
included	O
a	O
small	O
sample	B-T167
and	O
lacked	O
an	O
extended	B-T082
follow-up	B-T058
.	O
Further	O
studies	B-T062
are	O
needed	O
to	O
determine	O
the	O
clinical relevance	B-T080
of	O
this	O
finding	B-T033
,	O
particularly	O
in	O
terms	O
of	O
recurrence	B-T067
and	O
long-term	B-T079
survival	B-T052
.	O

Smartphone	B-T073
-Based	O
Psychotherapeutic	B-T061
Micro-Interventions	B-T061
to	O
Improve	O
Mood	B-T041
in	O
a	O
Real-World Setting	B-T079
Using	O
mobile	B-T073
communication technology	B-UnknownType
as	O
new	O
personalized	O
approach	B-T082
to	O
treat	B-T061
mental disorders	B-T048
or	O
to	O
more	O
generally	O
improve	O
quality of life	B-T078
is	O
highly	O
promising.	O
Knowledge	B-T170
about	O
intervention	B-T061
components	B-T073
that	O
target	O
key	O
psychopathological	B-T091
processes	B-T067
in	O
terms	O
of	O
transdiagnostic	O
psychotherapy	B-T061
approaches	B-T082
is	O
urgently	O
needed.	O
We	O
explored	O
the	O
use	O
of	O
smartphone	B-T073
-based	O
micro-interventions	B-T061
based	O
on	O
psychotherapeutic techniques	B-T170
,	O
guided	O
by	O
short	O
video-clips	B-T170
,	O
to	O
elicit	O
mood changes	B-T048
.	O
As	O
part	O
of	O
a	O
larger	O
neurofeedback	B-T061
study	B-T062
,	O
all	O
subjects	B-T098
-after	O
being	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
control	O
neurofeedback	B-T061
condition	B-T080
-underwent	O
daily	B-T079
smartphone	B-T073
-based	O
micro-interventions	B-T061
for	O
13	O
consecutive	O
days	B-T079
.	O
They	O
were	O
free	O
to	O
choose	O
out	O
of	O
provided	O
techniques	B-T169
,	O
including	O
viscerosensory	B-T080
attention	B-T041
,	O
emotional	B-T033
imagery	B-T041
,	O
facial expression	B-T033
,	O
and	O
contemplative	B-T080
repetition	B-T169
.	O
Changes	B-T169
in	O
mood	B-T041
were	O
assessed	O
in	O
real	O
world	O
using	O
the	O
Multidimensional Mood State Questionnaire	B-T170
(scales:	O
good	B-T080
-	O
bad	B-T080
,	O
GB;	O
awake	B-T033
-	O
tired	B-T184
,	O
AT;	O
and	O
calm	B-T041
-	O
nervous	B-T184
,	O
CN).	O
Twenty-seven	O
men	B-T098
participated	O
on	O
at	O
least	O
11	O
days	B-T079
and	O
were	O
thus	O
included	O
in	O
the	O
analyses	B-T062
.	O
Altogether,	O
they	O
underwent	O
335,	O
generally	O
well-tolerated,	O
micro-intervention sessions	B-UnknownType
,	O
with	O
viscerosensory	B-T080
attention	B-T041
(178	O
sessions	B-UnknownType
,	O
53.13%)	O
and	O
contemplative	B-T080
repetition	B-T169
(68	O
sessions	B-UnknownType
,	O
20.30%)	O
being	O
the	O
most	O
frequently	O
applied	O
techniques	B-T169
.	O
Mixed	O
models	B-T170
indicated	O
that	O
subjects	B-T098
showed	O
better	O
mood	B-T041
[GB:	O
b	O
=	O
0.464,	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
[0.068,	O
0.860],	O
t	O
(613.3)	O
=	O
2.298,	O
p	O
=	O
0.022]	O
and	O
became	O
more	O
awake	B-T033
[AT:	O
b	O
=	O
0.514,	O
95%	O
CI	B-T081
[0.103,	O
0.925],	O
t	O
(612.4)	O
=	O
2.456,	O
p	O
=	O
0.014]	O
and	O
calmer	B-T041
[CN:	O
b	O
=	O
0.685,	O
95%	O
CI	B-T081
[0.360,	O
1.010],	O
t	O
(612.3)	O
=	O
4.137,	O
p	O
<	O
0.001]	O
from	O
pre	B-T079
-	O
to	O
post-micro-intervention	B-T079
.	O
These	O
mood	B-T041
improvements	B-T077
from	O
pre	B-T079
-	O
to	O
post-micro-intervention	B-T079
were	O
associated	O
with	O
changes in mood	B-T048
from	O
the	O
1st	O
day	B-T079
until	O
the	O
last	O
day	B-T079
with	O
regard	O
to	O
GB mood	B-T041
(r	O
=	O
0.614,	O
95%	O
CI	B-T081
[0.297,	O
0.809],	O
p	O
<	O
0.001),	O
but	O
not	O
AT mood	B-T041
(r	O
=	O
0.279,	O
95%	O
CI	B-T081
[-0.122,	O
0.602],	O
p	O
=	O
0.167)	O
and	O
CN mood	B-T041
(r	O
=	O
0.277,	O
95%	O
CI	B-T081
[0.124,	O
0.601],	O
p	O
=	O
0.170).	O
Our	O
findings	B-T033
provide	O
evidence	O
for	O
the	O
applicability	O
of	O
smartphone	B-T073
-based	O
micro-interventions	B-T061
eliciting	O
short-term	B-T079
mood changes	B-T048
,	O
based	O
on	O
techniques	B-T169
used	O
in	O
psychotherapeutic	B-T061
approaches	B-T082
,	O
such	O
as	O
mindfulness	B-T041
-based	O
psychotherapy	B-T061
,	O
transcendental meditation	B-T041
,	O
and	O
other	O
contemplative	B-T080
therapies	B-T061
.	O
The	O
results	O
encourage	O
exploring	O
these	O
techniques	B-T169
'	O
capability	B-T080
to	O
improve	O
mood	B-T041
in	O
randomized	O
controlled studies	B-T062
and	O
patients	B-T101
.	O
Smartphone	B-T073
-based	O
micro-interventions	B-T061
are	O
promising	O
to	O
modify	O
mood	B-T041
in	O
real-world settings	B-T079
,	O
complementing	O
other	O
psychotherapeutic interventions	B-T061
,	O
in	O
line	O
with	O
the	O
precision	B-T079
medicine approach	B-UnknownType
.	O
The	O
here	O
presented	O
data	B-T078
were	O
collected	O
within	O
a	O
randomized trial	B-T062
,	O
registered	O
at	O
ClinicalTrials.gov	O
(Identifier:	O
NCT01921088)	O
https://clinicaltrials.gov/ct2/show/NCT01921088.	O

Primary	B-T080
pituitary	B-T023
diffuse large B-cell lymphoma	B-T191
with	O
somatotroph hyperplasia	B-T190
and	O
acromegaly	B-T047
:	O
case report	B-T170
Diffuse large B-cell lymphoma	B-T191
(	O
DLBCL	B-T191
)	O
is	O
the	O
most	O
common	B-T081
type	B-T080
of	O
non-Hodgkin lymphoma	B-T191
and	O
comprises	O
approximately	O
30%	O
of	O
all	O
lymphomas	B-T191
.	O
Patients	B-T101
typically	O
present	B-T033
with	O
a	O
nonpainful	B-T169
mass	B-T033
in	O
the	O
neck	B-T029
,	O
groin	B-T029
,	O
or	O
abdomen	B-T029
associated with	B-T080
constitutional symptoms	B-T184
.	O
In	O
this	O
report	B-T170
,	O
however,	O
the	O
authors	B-T097
describe	O
a	O
rare	B-T080
case	B-T169
of	O
a	O
61-	O
year	B-T079
-old	O
woman	B-T098
with	O
hyperprolactinemia	B-T047
,	O
hypothyroidism	B-T047
,	O
and	O
acromegaly	B-T047
(	O
elevation	B-T080
of	O
insulin-like growth factor-1	B-T116
[	O
IGF-1	B-T116
])	O
with	O
elevated	B-T080
growth hormone-releasing hormone	B-T116
(	O
GHRH	B-T116
)	O
in	O
whom	O
an	O
MRI	B-T060
demonstrated	B-T080
diffuse enlargement of the pituitary gland	B-T184
.	O
Despite	O
medical treatment	B-T061
,	O
the	O
patient	B-T101
had	O
persistent	B-T079
elevation	B-T080
of	O
IGF-1	B-T116
.	O
She	O
underwent	O
a	O
transsphenoidal biopsy	B-T060
,	O
which	O
yielded	B-T052
a	O
diagnosis	B-T033
of	O
DLBCL	B-T191
with	O
an	O
activated	B-T052
B-cell	B-T025
immunophenotype	B-T059
with	O
somatotroph hyperplasia	B-T190
.	O
After	O
stereo-tactic radiation therapy	B-T061
in	O
combination	B-T080
with	O
chemotherapy	B-T061
,	O
she	O
is	O
currently	B-T079
in	O
remission	B-T191
from	O
her	O
lymphoma	B-T191
and	O
has	O
normalized	B-T062
IGF-1	B-T116
levels	B-T080
without	O
medical therapy	B-T061
,	O
8	O
months	B-T079
after	O
her	O
histopathological	B-T169
diagnosis	B-T033
.	O
This	O
is	O
the	O
only	O
reported	B-T170
case	B-T169
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential diagnosis	B-T060
,	O
multidisciplinary evaluation	B-T060
,	O
and	O
critical	B-T080
intraoperative	B-T079
decision-making	B-T041
when	O
treating	B-T169
atypical	O
sellar	B-T023
lesions	B-T033
.	O

Doctor	B-T097
Competence	B-T080
and	O
the	O
Demand	B-T061
for	O
Healthcare	B-T058
:	O
Evidence	B-T078
from	O
Rural China	B-T083
The	O
agency	B-T092
problem	B-T033
between	O
patients	B-T101
and	O
doctors	B-T097
has	O
long	O
been	O
emphasised	O
in	O
the	O
health economics literature	B-T170
,	O
but	O
the	O
empirical	B-T080
evidence	B-T078
on	O
whether	O
patients	B-T101
can	O
evaluate	B-T052
and	O
respond	O
to	O
better	B-T080
quality care	B-T058
remains	O
mixed	B-T169
and	O
inconclusive	B-T080
.	O
Using	O
household	B-T099
data	B-T078
linked	O
to	O
an	O
assessment	B-T052
of	O
village	B-T083
doctors'	B-T097
clinical competence	B-T080
in	O
rural China	B-T083
,	O
we	O
show	O
that	O
there	O
is	O
no correlation	B-T080
between	O
doctor	B-T097
competence	B-T080
and	O
patients'	B-T101
healthcare	B-T058
utilisation	B-T169
,	O
with	O
confidence intervals	B-T081
reasonably	O
tight	O
around	O
zero.	O
Household	B-T099
perceptions	B-T041
of	O
quality	B-T080
are	O
an	O
important	B-T080
determinant	B-T169
of	O
care-seeking behaviour	B-T055
,	O
yet	O
patients	B-T101
appear	B-T080
unable	B-T033
to	O
recognise	B-T080
more	O
competent	B-T080
doctors	B-T097
-	O
there	O
is	O
no	O
relationship	B-T080
between	O
doctor	B-T097
competence	B-T080
and	O
perceptions	B-T041
of	O
quality	B-T080
.	O
Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons,	O
Ltd.	O
JOURNAL	O
ARTICLE	O

Unintentional	B-T169
insecticide poisoning	B-T037
by	O
age	B-T032
:	O
an	O
analysis	B-T062
of	O
Queensland	O
Poisons	O
Information	O
Centre	O
calls	B-T058
Data	B-T078
from	O
the	O
Queensland	O
Poisons	O
Information	O
Centre	O
(QPIC)	O
was	O
assessed	B-T052
to	O
determine	B-T078
mechanisms	B-T169
of	O
acute	O
insecticide poisoning	B-T037
in	O
young children	B-T100
(	O
<5 years	B-T079
)	O
and	O
whether	O
age	B-T032
affects	B-T041
insecticide-poisoning	B-T037
patterns	B-T082
.	O
Records	B-T170
of	O
all	O
insecticide-related calls	B-T058
placed	O
to	O
QPIC	O
in	O
2014	O
were	O
obtained	B-T169
.	O
A	O
stratified	B-T080
analysis	B-T062
of	O
call	B-T058
patterns	B-T082
by	O
age	B-T032
was	O
conducted	B-T169
.	O
Of	O
743	O
insecticide-related calls	B-T058
received by	B-T080
QPIC	O
364	O
(49.0%)	O
were	O
for	O
young children	B-T100
.	O
The	O
number	O
of	O
calls	B-T058
peaked	B-T080
in	O
children	B-T100
aged one	B-T079
.	O
Ant	B-T204
and	O
cockroach	B-T204
baits	B-T131
accounted	B-T081
for	O
39.0%	O
of	O
calls	B-T058
.	O
Sprays	B-T122
,	O
which	O
were	O
found	B-T033
to	O
contain	O
not	O
only	O
pyrethroids	B-T109
,	O
pyrethrins	B-T109
and/or	O
piperonly butoxide	B-T109
but	O
also	O
the	O
organophosphate diazinon	B-T109
,	O
accounted	B-T081
for	O
25.8%	O
of	O
calls	B-T058
.	O
Mouthing	B-T040
or	O
ingesting	B-T038
a	O
pest-control product	B-T131
and	O
consuming	B-T052
an	O
item/insect	O
after	O
treatment	B-T169
were	O
common	O
mechanisms	B-T169
for	O
children	B-T100
under	O
the	O
age of two	B-T079
.	O
Topical	B-T082
exposure to	B-T080
sprays	B-T122
,	O
via	O
direct	B-T080
application	B-T169
,	O
typically	O
by	O
the	O
child	B-T100
or	O
an	O
older sibling	B-T099
,	O
peaked	B-T080
in	O
children	B-T100
aged two	B-T079
.	O
In	O
12.3%	O
of	O
calls	B-T058
medical attention	B-T058
for	O
the	O
child	B-T100
was	O
already	O
sought	B-UnknownType
or	O
advised by	B-T058
QPIC.	O
Normal behaviours	B-T053
associated with	B-T080
child development	B-T040
,	O
particularly	O
mouthing	B-T040
behaviours	B-T053
,	O
explained	O
the	O
peak of exposure	B-T080
in	O
one-year	B-T079
-	O
olds	B-T100
.	O
This	O
finding	B-T033
should	O
guide	O
strategies	B-T041
to	O
minimise	B-T080
poisonings	B-T037
in	O
this	O
vulnerable population	B-T098
.	O

Investigating	O
Synthetic	B-T114
Oligonucleotide	B-T114
Targeting	O
of	O
Mir31	B-T114
in	O
Duchenne Muscular Dystrophy	B-T047
Exon-skipping	B-T045
via	O
synthetic	B-T114
antisense oligonucleotides	B-T114
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	B-T061
for	O
Duchenne muscular dystrophy	B-T047
(	O
DMD	B-T047
),	O
yet	O
this	O
approach	O
is	O
highly	O
sequence-specific	B-T045
and	O
thus	O
each	O
oligonucleotide	B-T114
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	B-T101
.	O
The	O
discovery	B-T052
that	O
dystrophin	B-T116
mRNA	B-T114
is	O
subject	O
to	O
translational suppression	B-T045
by	O
the	O
microRNA	B-T114
miR31	B-T114
,	O
and	O
that	O
miR31	B-T114
is	O
elevated	O
in	O
the	O
muscle	B-T024
of	O
DMD	B-T047
patients	B-T101
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	B-T114
chemistries	O
employed	O
for	O
exon skipping	B-T045
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational block	B-T045
.	O
This	O
approach	O
would	O
act	O
synergistically	B-T080
with	O
exon skipping	B-T045
where	O
possible,	O
but	O
by	O
targeting	O
the	O
3'UTR	B-T086
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
DMD	B-T047
patients	B-T101
who	O
express	O
low	O
levels	O
of	O
in-frame	B-T086
transcript	B-T114
.	O
We	O
here	O
present	O
investigations	B-T058
into	O
the	O
feasibility	O
of	O
combining	O
exon skipping	B-T045
with	O
several	O
different	O
strategies	O
for	O
miR31	B-T114
-	O
modulation	B-UnknownType
,	O
using	O
both	O
in vitro	B-T059
models	B-T075
and	O
the	O
mdx mouse	B-T015
(the	O
classical	O
animal model	B-T008
of	O
DMD	B-T047
),	O
and	O
monitoring	B-T058
effects	B-T080
on	O
dystrophin	B-T116
at	O
the	O
transcriptional	B-T045
and	O
translational	B-T045
level.	O
We	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell culture	B-T059
model	B-T075
,	O
our	O
in vivo	B-T082
data	B-T078
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	B-T052
of	O
dystrophin	B-T116
translation	B-T045
,	O
suggesting	O
that	O
miR31	B-T114
-	O
modulation	B-UnknownType
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	B-T114
approaches.	O
Possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	B-T080
are	O
discussed,	O
along	O
with	O
suggestions	O
for	O
future	O
investigations	B-T058
.	O

Undisclosed	B-T080
HIV infection	B-T047
and	O
art	B-T061
use	B-T169
in	O
the	O
kenya AIDS indicator survey 2012	B-T170
:	O
relevance	B-T080
to	O
targets	B-T169
for	O
HIV diagnosis	B-T060
and	O
treatment	B-T061
in	O
kenya	B-T083
To	O
assess	B-T058
the	O
impact	B-T080
of	O
undisclosed	B-T080
HIV infection	B-T047
and	O
antiretroviral (ARV) therapy	B-T061
(	O
ART	B-T061
)	O
on	O
national	B-T082
estimates	B-T081
of	O
diagnosed HIV	B-T033
and	O
ART	B-T061
coverage	B-T169
in	O
Kenya	B-T083
.	O
HIV-positive	B-T033
dried blood spot samples	B-T031
from	O
Kenya's second AIDS Indicator Survey	B-T170
were	O
tested	B-T169
for	O
an	O
ARV	B-T121
biomarker	B-T201
by	O
liquid chromatography-tandem mass spectrometry	B-T059
.	O
Estimates	B-T081
of	O
diagnosed HIV	B-T033
and	O
ART	B-T061
use	B-T169
based	O
on	O
self-report	B-T062
were	O
compared	B-T052
with	O
those	O
corrected	O
for	O
undisclosed	B-T080
HIV infection	B-T047
and	O
ART	B-T061
use	B-T169
based	O
on	O
ARV	B-T121
testing.	O
Multivariate analysis	B-T081
determined	B-T080
factors	B-T169
associated with	B-T080
undisclosed	B-T080
HIV infection	B-T047
and	O
ART	B-T061
use	B-T169
among	O
persons	B-T098
on	O
ART	B-T061
.	O
Among	O
559	O
HIV-positive	B-T033
samples	B-T031
,	O
the	O
ARV	B-T121
biomarker	B-T201
was	O
detected	B-T033
in	O
42.5%	O
(CI	O
37.4-47.7).	O
ARV drugs	B-T121
were	O
present	O
in	O
90.7%	O
(CI	O
86.1-95.2)	O
reporting HIV-positive	B-T033
status	O
and	O
receiving	B-T080
ART	B-T061
,	O
66.7%	O
(CI	O
59.9-73.4)	O
reporting HIV-positive	B-T033
status	O
irrespective	O
of	O
ART	B-T061
use	B-T169
,	O
21.0%	O
(CI	O
13.4-28.6)	O
reporting	B-T058
HIV-negative status	B-T034
,	O
and	O
19.3%	O
(CI	O
9.0-29.5)	O
reporting	B-T058
no	B-T033
previous	B-T079
HIV test	B-T059
.	O
After	O
correcting	O
for	O
undisclosed	B-T080
HIV infection	B-T047
and	O
ART	B-T061
use	B-T169
,	O
diagnosed HIV	B-T033
increased	B-T081
from	O
46.9%	O
to	O
57.2%	O
and	O
ART	B-T061
coverage	B-T169
increased	B-T081
from	O
31.8%	O
to	O
42.8%.	O
Undisclosed	B-T080
HIV infection	B-T047
on	O
ART	B-T061
was	O
associated with	B-T080
being	O
aged	B-T098
25-39	O
years	O
and	O
not	O
visiting	O
a	O
health provider	B-T097
in	O
the	O
past	O
year,	O
while	O
younger age	B-T033
and	O
higher wealth	B-T080
was	O
associated with	B-T080
undisclosed	B-T080
ART	B-T061
use	B-T169
.	O
Substantial	B-T078
levels	B-T080
of	O
undisclosed	B-T080
HIV infection	B-T047
and	O
ART	B-T061
use	B-T169
while	O
on	O
ART	B-T061
were	O
observed	B-T169
,	O
resulting in	B-T169
diagnosed HIV	B-T033
underestimated	O
by	O
112,000	O
persons	B-T098
and	O
ART	B-T061
coverage	B-T169
by	O
131,000	O
persons	B-T098
.	O
Supplementing	O
self-reported	B-T062
ART	B-T061
status	B-T080
with	O
objective measures	B-T170
of	O
ART	B-T061
use	B-T169
in	O
national	B-T082
population	B-T098
-based	O
sero-surveys	B-T058
can	O
improve	B-T033
monitoring	B-T058
of	O
treatment	B-T061
targets	B-T169
in	O
countries	B-T083
.	O

Differential	O
control	B-T080
and	O
function	B-T169
of	O
Arabidopsis	B-T002
ProDH1	B-T028
and	O
ProDH2 genes	B-T028
on	O
infection	B-T046
with	O
biotrophic	B-T033
and	O
necrotrophic	B-T033
pathogens	B-T001
Arabidopsis	B-T002
contains	O
two	O
proline dehydrogenase (ProDH) genes	B-T028
,	O
ProDH1	B-T028
and	O
ProDH2	B-T028
,	O
encoding	B-T052
for	O
homologous	B-T116
and	O
functional	B-T169
isoenzymes	B-T116
.	O
Although	O
ProDH1	B-T028
has	O
been	O
studied	O
extensively,	O
especially	O
under	O
abiotic stress	B-T046
,	O
ProDH2	B-T028
has	O
only	O
started	O
to	O
be	O
analysed	O
in	O
recent	O
years	B-T079
.	O
These	O
genes	B-T028
display	O
distinctive	O
expression	B-T045
patterns	B-T082
and	O
show	O
weak	B-T080
transcriptional co-regulation	B-T045
,	O
but	O
are	O
both	O
activated	B-T052
in	O
pathogen	B-T001
-	O
infected	B-T033
tissues	B-T024
.	O
We	O
have	O
demonstrated	O
previously	O
that	O
Arabidopsis plants	B-T002
with	O
silenced	B-T045
ProDH1	B-T028
/	O
2	B-T028
expression	B-T045
fail	B-T169
to	O
trigger	O
defences	B-T040
against	O
the	O
hemibiotrophic	B-T033
bacterial	B-T007
pathogen	B-T001
Pseudomonas syringae pv. tomato AvrRpm1	B-T007
(	O
Pst-AvrRpm1	B-T007
),	O
and	O
that	O
ProDH1	B-T028
and	O
ProDH2	B-T028
are	O
differentially	O
regulated	B-T064
by	O
salicylic acid	B-T109
(	O
SA	B-T109
).	O
In	O
the	O
current	O
work,	O
we	O
used	O
prodh1	B-T002
and	O
prodh2	B-T002
single-	O
mutant	B-T049
plants	B-T002
to	O
assess	O
the	O
particular	O
contribution	O
of	O
each	O
gene	B-T028
to	O
resistance	B-T169
against	O
Pst-AvrRpm1	B-T007
and	O
the	O
necrotrophic	B-T033
fungal pathogen	B-T004
Botrytis cinerea	B-T004
.	O
In	O
addition,	O
we	O
studied	O
the	O
sensitivity	B-T169
of	O
ProDH1	B-T028
and	O
ProDH2	B-T028
to	O
the	O
jasmonic acid	B-T109
(	O
JA	B-T109
)	O
defence	B-T040
pathway	B-T044
.	O
We	O
found	O
that	O
ProDH1	B-T116
and	O
ProDH2	B-T116
are	O
both	O
necessary	O
to	O
achieve	O
maximum	O
resistance	B-T169
against	O
Pst-AvrRpm1	B-T007
and	O
B. cinerea	B-T004
.	O
However,	O
ProDH2	B-T116
has	O
a	O
major	O
effect	O
on	O
early	O
restriction	B-T169
of	O
B. cinerea	B-T004
growth	B-T040
.	O
Interestingly,	O
ProDH1	B-T028
is	O
up-regulated	B-T044
by	O
SA	B-T109
and	O
JA	B-T109
,	O
whereas	O
ProDH2	B-T028
is	O
only	O
activated	B-T052
by	O
JA	B-T109
,	O
and	O
both	O
genes	B-T028
display	O
transcriptional inter-regulation	B-T045
at	O
basal	B-T082
and	O
infection	B-T046
conditions	B-T080
.	O
These	O
studies	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
contribution	O
of	O
ProDH2	B-T028
to	O
disease resistance	B-T040
,	O
and	O
describe	O
the	O
differential	O
regulation	B-T064
and	O
non-redundant	O
but	O
complementary function	B-T169
of	O
both	O
enzyme isoforms	B-T116
in	O
infected	B-T033
tissues	B-T024
,	O
providing	O
support	O
for	O
a	O
fundamental	O
role	O
of	O
ProDH	B-T028
in	O
the	O
control	O
of	O
biotrophic	B-T033
and	O
necrotrophic	B-T033
pathogens	B-T001
.	O

Effect	B-T080
of	O
Protein	B-T116
Repetitiveness	B-T169
on	O
Protein-Protein Interaction	B-T044
Prediction	B-T078
Results	B-T169
Using	O
Support Vector Machines	B-T081
There	O
are	O
many	O
computational approaches	B-T062
to	O
predict	O
the	O
protein-protein interactions	B-T044
using	O
support vector machines	B-T081
(	O
SVMs	B-T081
)	O
with	O
high	O
performance.	O
In	O
fact,	O
performance	O
of	O
currently	O
reported	O
methods	B-T170
are	O
significantly	O
over-estimated	O
and	O
affected	O
by	O
the	O
object	O
repetitiveness	B-T169
in	O
the	O
datasets	B-T170
used.	O
To	O
study	B-T062
the	O
effect	O
of	O
object	O
repetitiveness	B-T169
of	O
datasets	B-T170
on	O
predicting	B-T078
results	B-T169
.	O
We	O
present	O
novel	O
methods	B-T170
to	O
construct	O
different	O
positive	B-T033
datasets	B-T170
with	O
or	O
without	O
repeating	O
proteins	B-T116
using	O
graph	B-T170
maximum	O
matching	O
in	O
the	O
protein-protein interaction	B-T044
datasets	B-T170
and	O
corresponding	O
series	O
of	O
negative	B-T033
datasets	B-T170
with	O
different	O
proteins	B-T116
repetitiveness	B-T169
are	O
constructed	O
using	O
graph	B-T170
adjacency matrix	B-T082
.	O
The	O
relationship	B-T080
between	O
the	O
SVM	B-T081
prediction	B-T078
results	B-T169
and	O
the	O
repeated	B-T169
proteins	B-T116
(repeat	O
numbers	O
and	O
repeat	O
rates)	O
and	O
the	O
distributions	B-T169
of	O
repeated	B-T169
proteins	B-T116
in	O
the	O
datasets	B-T170
are	O
analyzed.	O
Protein	B-T116
repetitiveness	B-T169
of	O
positive	B-T033
and	O
negative	B-T033
datasets	B-T170
can	O
affect	O
the	O
prediction	B-T078
result	B-T169
:	O
high	O
protein	B-T116
repetitiveness	B-T169
of	O
positive	B-T033
or	O
negative	B-T033
datasets	B-T170
yield	O
high	O
performance	O
prediction	O
result	B-T169
.	O
This	O
indicate	O
that	O
dealing	O
with	O
object	O
repetitiveness	B-T169
of	O
datasets	B-T170
is	O
a	O
key	O
issue	O
in	O
protein-protein interactions	B-T044
prediction	B-T078
using	O
SVMs	B-T081
since	O
real	O
world	O
data	B-T078
contain	O
certain	O
degrees	O
of	O
repeat	B-T169
proteins	B-T116
.	O

From	O
'	O
sense of number	B-T041
'	O
to	O
'	O
sense of	B-T041
magnitude	B-T081
'	O
-	O
The	O
role	O
of	O
continuous	B-T078
magnitudes	B-T081
in	O
numerical	B-T081
cognition	B-T041
In	O
this	O
review,	O
we	O
are	O
pitting	B-T169
two	O
theories	B-T078
against	O
each	O
other:	O
the	O
more	O
accepted	O
theory	B-T078
-the	O
'	O
number sense	B-T041
'	O
theory	B-T078
-suggesting	O
that	O
a	O
sense of number	B-T041
is	O
innate	B-T055
and	O
non-symbolic numerosity	B-T041
is	O
being	O
processed	O
independently	O
of	O
continuous	B-T078
magnitudes	B-T081
(e.g.,	O
size	B-T082
,	O
area	B-T082
,	O
density	B-T081
);	O
and	O
the	O
newly	O
emerging	O
theory	B-T078
suggesting	O
that	O
(1)	O
both	O
numerosities	B-T041
and	O
continuous	B-T078
magnitudes	B-T081
are	O
processed	O
holistically	O
when	O
comparing	O
numerosities	B-T041
,	O
and	O
(2)	O
a	O
sense of number	B-T041
might	O
not	O
be	O
innate	B-T055
.	O
In	O
the	O
first	O
part	O
of	O
this	O
review,	O
we	O
discuss	O
the	O
'	O
number sense	B-T041
'	O
theory	B-T078
.	O
Against	O
this	O
background,	O
we	O
demonstrate	O
how	O
the	O
natural	O
correlation	B-T080
between	O
numerosities	B-T041
and	O
continuous	B-T078
magnitudes	B-T081
makes	O
it	O
nearly	O
impossible	O
to	O
study	O
non-symbolic numerosity processing	B-T041
in	O
isolation	O
from	O
continuous	B-T078
magnitudes	B-T081
,	O
and	O
therefore	O
the	O
results	O
of	O
behavioral	B-T062
and	O
imaging studies	B-T060
with	O
infants	B-T100
,	O
adults	B-T100
and	O
animals	B-T008
can	O
be	O
explained,	O
at	O
least	O
in	O
part,	O
by	O
relying	O
on	O
continuous	B-T078
magnitudes	B-T081
.	O
In	O
the	O
second	O
part,	O
we	O
explain	O
the	O
'	O
sense of	B-T041
magnitude	B-T081
'	O
theory	B-T078
theory	B-T078
and	O
review	O
studies	O
that	O
directly	O
demonstrate	O
that	O
continuous	B-T078
magnitudes	B-T081
are	O
more	O
automatic	O
and	O
basic	O
than	O
numerosities	B-T041
.	O
Finally,	O
we	O
present	O
outstanding	O
questions.	O
Our	O
conclusion	O
is	O
that	O
there	O
is	O
not	O
enough	O
convincing	O
evidence	O
to	O
support	O
the	O
number sense	B-T041
theory	B-T078
theory	B-T078
anymore.	O
Therefore,	O
we	O
encourage	O
researchers	O
not	O
to	O
assume	O
that	O
number sense	B-T041
is	O
simply	O
innate	B-T055
,	O
but	O
to	O
put	O
this	O
hypothesis	B-T078
to	O
the	O
test,	O
and	O
to	O
consider	O
if	O
such	O
an	O
assumption	O
is	O
even	O
testable	O
in	O
light	O
of	O
the	O
correlation	B-T080
of	O
numerosity	B-T041
and	O
continuous	B-T078
magnitudes	B-T081
.	O

How	O
Integrated Management Strategies	B-T059
Promote	B-T052
Protein	B-T116
Quality	B-T080
of	O
Cotton Embryos	B-T002
:	O
High	B-T080
Levels	B-T080
of	O
Soil	B-T167
Available	B-T169
N	B-T123
,	O
N	B-T123
Assimilation	B-T070
and	O
Protein	B-T116
Accumulation	B-T033
Rate	B-T081
Cottonseed	B-T002
is	O
widely	O
used	O
as	O
a	O
source	B-T033
of	O
ruminant	B-T015
feed	B-T168
and	O
for	O
industrial	B-T057
purposes	B-T169
.	O
Therefore,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	B-T033
the	O
nutritional value	B-T080
of	O
cotton embryos	B-T002
.	O
In	O
this	O
study	B-T062
,	O
a	O
conventional management	B-T059
(	O
CM	B-T059
)	O
and	O
two	O
integrated	O
cotton	B-T002
management strategies	B-T059
(	O
IMS1	B-T059
,	O
IMS2	B-T059
)	O
were	O
performed	B-T169
at	O
two	O
soil	B-T167
fertility	B-T033
levels	B-T080
to	O
study	B-T062
the	O
relationships	B-T080
among	O
soil	B-T167
N	B-T123
,	O
N	B-T123
assimilation	B-T070
,	O
embryonic	B-T002
protein	B-T116
accumulation	B-T033
and	O
protein	B-T116
quality	B-T080
.	O
The	O
levels of proteins	B-T059
,	O
essential amino acids	B-T059
,	O
and	O
semi-essential amino acids	B-T059
,	O
especially	O
those	O
of	O
glutamate	B-T059
,	O
lysine	B-T059
,	O
and	O
methionine	B-T059
,	O
were	O
higher	B-T080
in	O
IMS1	B-T059
and	O
IMS2	B-T059
embryos	B-T002
than	O
in	O
CM	B-T059
embryos	B-T002
.	O
These	O
changes	B-T169
were	O
significantly	O
positively	B-T033
correlated	B-T080
with	O
the	O
soil	B-T167
-	O
available	B-T169
N content	B-T059
,	O
glutamine synthetase activity	B-T044
and	O
peak	B-T080
value	O
of	O
protein	B-T116
accumulation	B-T033
rate	B-T081
and	O
were	O
negatively	B-T033
correlated	B-T080
with	O
the	O
free	B-T080
amino acid level	B-T059
.	O
These	O
results	B-T033
illustrated	O
that	O
integrated management strategies	B-T059
,	O
especially	O
the	O
rates	B-T081
and	O
timing	B-T079
of	O
N	B-T123
application	B-T169
,	O
raise	B-T169
the	O
level	B-T080
of	O
soil	B-T167
available	B-T169
N	B-T123
,	O
which	O
is	O
beneficial	O
for	O
N	B-T123
assimilation	B-T070
in	O
developing	O
cotton embryos	B-T002
.	O
The	O
protein content	B-T059
was	O
limited	B-T169
by	O
the	O
rate	B-T081
of	O
protein	B-T116
accumulation	B-T033
rather	O
than	O
by	O
the	O
free	B-T080
amino acid content	B-T059
.	O
The	O
combination	B-T080
of	O
target yield	B-T081
fertilization	B-T070
,	O
a	O
growth	B-T040
-driven	O
N	B-T123
application	B-T169
schedule,	O
a	O
high	B-T080
plant	B-T002
density	B-T081
and	O
the	O
seedling	B-T002
raising	O
with	O
bio-organic fertilizer	B-T167
can	O
substantially	O
improve	B-T033
protein	B-T116
quality	B-T080
in	O
cotton embryos	B-T002
,	O
especially	O
at	O
a	O
soil	B-T167
with	O
low	O
soil	B-T167
organic matter	B-T109
and	O
total	B-T080
nitrogen	B-T123
.	O

Help	O
end	O
the	O
HIV	B-T005
epidemic	B-T067
After	O
many	O
delays,	O
the	O
public consultation	B-T061
on	O
HIV prevention	B-T061
tool	B-T170
PrEP	B-T061
(	O
pre-exposure prophylaxis	B-T061
)	O
is	O
finally	O
here.	O
Now	O
is	O
the	O
time	O
to	O
mobilise	O
-	O
help	O
end	O
the	O
HIV	B-T005
epidemic	B-T067
by	O
responding	O
to	O
this	O
NHS England consultation	B-T058
before	O
23	O
September	B-T079
.	O

Osseointegration	B-T042
behavior	O
of	O
novel	B-T080
Ti-Nb-Zr-Ta-Si alloy	B-T122
for	O
dental implants	B-T074
:	O
an	O
in vivo	B-T082
study	B-T062
This	O
study	O
aimed	O
to	O
evaluate	B-T058
the	O
effects of	B-T080
Ti-Nb-Zr-Ta-Si alloy	B-T122
implants	B-T074
on	O
mineral apposition rate	B-T081
and	O
new	O
BIC contact	B-T081
in	O
rabbits	B-T015
.	O
Twelve	O
Ti-Nb-Zr-Ta-Si alloy	B-T122
implants	B-T074
were	O
fabricated	B-T169
and	O
placed	B-T058
into	O
the	O
right	B-T082
femur	B-T023
sites	B-T029
in	O
six	O
rabbits	B-T015
,	O
and	O
commercially	O
pure	O
titanium	B-T196
implants	B-T074
were	O
used	O
as	O
controls	B-T096
in	O
the	O
left	B-T082
femur	B-T023
.	O
Tetracycline	B-T109
and	O
alizarin red	B-T109
were	O
administered	O
3	O
weeks	B-T079
and	O
1	O
week	B-T079
before	O
euthanization	B-T058
,	O
respectively.	O
At	O
4	O
weeks	B-T079
and	O
8	O
weeks	B-T079
after	O
implantation	B-T061
,	O
animals	B-T008
were	O
euthanized	B-T058
,	O
respectively.	O
Surface	B-T082
characterization	B-T052
and	O
implant-bone contact	B-T081
surface	B-T082
analysis	B-T062
were	O
performed	B-T169
by	O
using	O
a	O
scanning electron microscope	B-T074
and	O
an	O
energy dispersive X-ray detector	B-T074
.	O
Mineral apposition rate	B-T081
was	O
evaluated	B-T058
using	O
a	O
confocal laser scanning microscope	B-T059
.	O
Toluidine blue staining	B-T059
was	O
performed	B-T169
on	O
undecalcified	B-T033
sections	B-T167
for	O
histology	B-T091
and	O
histomorphology	B-T080
evaluation.	O
Scanning electron microscope	B-T074
and	O
histomorphology	B-T080
observation	B-T078
revealed	B-T080
a	O
direct contact	B-T169
between	O
implants	B-T074
and	O
bone	B-T023
of	O
all	O
groups	B-T078
.	O
After	O
a	O
healing	B-T040
period	B-T079
of	O
4	O
weeks	B-T079
,	O
Ti-Nb-Zr-Ta-Si alloy	B-T122
implants	B-T074
showed	O
significantly	O
higher	O
mineral apposition rate	B-T081
compared	O
to	O
commercially	O
pure	O
titanium	B-T196
implants	B-T074
(P	O
<	O
0.05),	O
whereas	O
there	O
was	O
no significant	B-T033
difference	O
between	O
Ti-Nb-Zr-Ta-Si alloy	B-T122
implants	B-T074
and	O
commercially	O
pure	O
titanium	B-T196
implants	B-T074
(P	O
>	O
0.05)	O
at	O
8	O
weeks	B-T079
.	O
No significant	B-T033
difference	O
of	O
bone-to-implant contact	B-T081
was	O
observed	B-T169
between	O
Ti-Nb-Zr-Ta-Si alloy	B-T122
implants	B-T074
and	O
commercially	O
pure	O
titanium	B-T196
implants	B-T074
implants	B-T074
after	O
a	O
healing	B-T040
period	B-T079
of	O
4	O
weeks	B-T079
and	O
8	O
weeks	B-T079
.	O
This	O
study	O
showed	O
that	O
Ti-Nb-Zr-Ta-Si alloy	B-T122
implants	B-T074
could	O
establish	O
a	O
close direct contact	B-T169
comparedto	O
commercially	O
pure	O
titanium	B-T196
implants	B-T074
implants	B-T074
,	O
improved	B-T033
mineral matrix apposition rate	B-T081
,	O
and	O
may	O
someday	O
be	O
an	O
alternative	B-T077
as	O
a	O
material	B-T167
for	O
dental implants	B-T074
.	O

Simultaneous	B-T079
edited	B-T077
MRS	B-T060
of	O
GABA	B-T116
and	O
glutathione	B-T116
Edited	B-T077
MRS	B-T060
allows	O
the	O
detection	B-T061
of	O
low	B-T080
-	O
concentration	B-T081
metabolites	B-T123
,	O
whose	O
signals	B-T067
are	O
not	B-T169
resolved	B-T077
in	O
the	O
MR spectrum	B-T060
.	O
Tailored acquisitions	B-T052
can	O
be	O
designed	B-T090
to	O
detect	B-T061
,	O
for	O
example	B-T077
,	O
the	O
inhibitory	B-T052
neurotransmitter	B-T123
γ-aminobutyric acid	B-T116
(	O
GABA	B-T116
),	O
or	O
the	O
reduction-oxidation	B-T044
(	O
redox	B-T044
)	O
compound	O
glutathione	B-T116
(	O
GSH	B-T116
),	O
and	O
single	B-T081
-	O
voxel	B-T077
edited	B-T077
experiments	B-T062
are	O
generally	O
acquired	O
at	O
a	O
rate	B-T081
of	O
one	B-T081
metabolite	B-T123
-	O
per-experiment	B-T062
.	O
We	O
demonstrate	O
that	O
simultaneous	B-T079
detection	B-T061
of	O
the	O
overlapping	B-T079
signals	B-T067
of	O
GABA	B-T116
and	O
GSH	B-T116
is	O
possible	O
using	B-T169
Hadamard Encoding and Reconstruction of Mega-Edited Spectroscopy	B-T059
(	O
HERMES	B-T059
).	O
HERMES	B-T059
applies	B-T169
orthogonal editing encoding	B-T052
(	O
following	B-T079
a	O
Hadamard scheme	B-T170
),	O
such	O
that	O
GSH-	B-T116
and	O
GABA	B-T116
-	O
edited	B-T077
difference	B-T080
spectra	B-T077
can	O
be	O
reconstructed	O
from	O
a	O
single multiplexed experiment	B-T062
.	O
At	O
a	O
TE	B-T079
of	O
80ms,	O
20-ms	O
editing	B-T077
pulses	B-T067
are	O
applied	B-T169
at	O
4.56ppm	O
(on	O
GSH	B-T116
),1.9ppm	O
(on	O
GABA	B-T116
),	O
both	B-T080
offsets	B-T081
(using	O
a	O
dual-lobe cosine-modulated pulse	B-T067
)	O
or	O
neither.	O
Hadamard combinations	B-T170
of	O
the	O
four	O
sub-experiments	B-T062
yield	O
GABA	B-T116
and	O
GSH	B-T116
difference	B-T080
spectra	B-T077
.	O
It	O
is	O
shown	O
that	O
HERMES	B-T059
gives	O
excellent	B-T080
separation	B-T080
of	O
the	O
edited	B-T077
GABA	B-T116
and	O
GSH	B-T116
signals	B-T067
in	O
phantoms	B-T073
,	O
and	O
resulting	O
edited	B-T077
lineshapes	B-T080
agree	B-T033
well	B-T080
with	O
separate	B-T080
Mescher-Garwood Point-resolved Spectroscopy	B-T059
(	O
MEGA-PRESS	B-T059
)	O
acquisitions	B-T052
.	O
In vivo	B-T082
,	O
the	O
quality	B-T080
and	O
signal-to-noise ratio	B-T081
(	O
SNR	B-T081
)	O
of	O
HERMES	B-T059
spectra	B-T077
are	O
similar	B-T080
to	O
those	O
of	O
sequentially	B-T080
acquired	B-T080
MEGA-PRESS	B-T059
spectra	B-T077
,	O
with	O
the	O
benefit	B-T081
of	O
saving	O
half	O
the	O
acquisition	B-T052
time	B-T079
.	O

Chitosan	B-T109
-functionalised	O
poly(2-hydroxyethyl methacrylate)	B-T109
core-shell microgels	B-T122
as	O
drug delivery carriers	B-T074
:	O
salicylic acid	B-T109
loading and release	B-T169
This	O
work	O
presents	O
the	O
evaluation	O
of	O
chitosan	B-T109
-functionalised	O
poly(2-hydroxyethyl methacrylate)	B-T109
(	O
CS	B-T109
/	O
PHEMA	B-T109
)	O
core-shell microgels	B-T122
as	O
drug delivery carriers	B-T074
.	O
CS	B-T109
/	O
PHEMA	B-T109
microgels	B-T122
were	O
prepared	O
by	O
emulsifier-free emulsion polymerisation	B-T067
with	O
N,N '-methylenebisacrylamide	B-T109
(	O
MBA	B-T109
)	O
as	O
a	O
crosslinker	B-T109
.	O
The	O
study on drug loading	B-T062
,	O
using	O
salicylic acid	B-T109
(	O
SA	B-T109
)	O
as	O
a	O
model drug	B-T121
,	O
was	O
performed.	O
The	O
results	O
showed	O
that	O
the	O
encapsulation efficiency	B-T067
(	O
EE	B-T067
)	O
increased	O
as	O
drug	B-T121
-to-	O
microgel	O
ratio	B-T081
was	O
increased.	O
Higher	O
EE	B-T067
can	O
be	O
achieved	O
with	O
the	O
increase	O
in	O
degree	O
of	O
crosslinking	B-T067
,	O
by	O
increasing	O
the	O
amount	O
of	O
MBA	B-T109
from	O
0.01	O
g	O
to	O
0.03	O
g.	O
In	O
addition,	O
the	O
highest	O
EE	B-T067
(61.1%)	O
was	O
observed	O
at	O
pH	B-T081
3.	O
The	O
highest	O
release of SA	B-T070
(60%)	O
was	O
noticed	O
at	O
pH	B-T081
2.4,	O
while	O
the	O
lowest	O
one	O
(49.4%)	O
was	O
obtained	O
at	O
pH	B-T081
7.4.	O
Moreover,	O
the	O
highest	O
release of SA	B-T070
was	O
enhanced	O
by	O
the	O
presence	O
of	O
0.2	O
M	O
NaCl	B-T121
.	O
The	O
pH	B-T081
-	O
and	O
ionic-sensitivity	B-T080
of	O
CS	B-T109
/	O
PHEMA	B-T109
could	O
be	O
useful	O
as	O
a	O
sustained release delivery device	B-T121
,	O
especially	O
for	O
oral delivery	B-T074
.	O

Breast Augmentation	B-T061
after	O
Conservation Surgery	B-T061
and	O
Radiation Therapy	B-T061
There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
outcomes	O
for	O
patients	B-T101
undergoing	O
breast augmentation	B-T061
with	O
implants	B-T074
after	O
breast conservation surgery	B-T061
(	O
BCS	B-T061
)	O
and	O
radiotherapy	B-T061
.	O
This	O
retrospective study	B-T062
examined	O
outcomes	O
for	O
patients	B-T101
with	O
breast implant	B-T074
-only	O
augmentation	B-T061
after	O
BCS	B-T061
and	O
radiotherapy	B-T061
.	O
Between	O
June	O
1998	O
and	O
December	O
2010,	O
671	O
women	B-T098
underwent	O
prosthetic	B-T074
breast reconstruction	B-T061
.	O
Nineteen	O
patients	B-T101
(2.8%)	O
underwent	O
an	O
augmentation	B-T061
after	O
BCS	B-T061
and	O
radiotherapy	B-T061
.	O
The	O
mean	B-T081
age	B-T032
was	O
55.8	O
years	B-T079
(	O
range	B-T081
,	O
40-69	O
years	B-T079
).	O
Sixteen	O
of	O
these	O
patients	B-T101
underwent	O
one-stage implant	B-T061
-only	O
breast augmentation	B-T061
,	O
whereas	O
3	O
patients	B-T101
underwent	O
two-stage expander	B-T061
and	O
then	O
implant augmentation	B-T061
.	O
All	O
surgeries	B-T061
were	O
successful.	O
The	O
average	O
size	O
of	O
breast implant	B-T074
used	O
was	O
258.7�€‰g.	O
Seven	O
patients	B-T101
also	O
received	O
contralateral	B-T082
augmentation	B-T061
with	O
an	O
average	O
implant	O
size	O
of	O
232.2�€‰g.	O
One	O
patient	B-T101
received	O
oral	B-T169
antibiotics	B-T195
for	O
minor	O
wound infection	B-T046
.	O
Patients	B-T101
were	O
judged	O
to	O
have	O
an	O
excellent	O
(14/19;	O
73.7%),	O
good	O
(3/19;	O
15.8%),	O
or	O
fair	O
(2/19;	O
10.5%)	O
cosmetic	B-T033
result	B-T169
.	O
The	O
breasts	B-T023
of	O
selected	O
patients	B-T101
with	O
breast cancer	B-T191
after	O
BCS	B-T061
and	O
radiotherapy	B-T061
.	O
with	O
asymmetry	O
can	O
be	O
adequately	O
augmented	B-T081
with	O
breast implants	B-T074
alone.	O

Mitochondrial pyruvate dehydrogenase phosphatase 1	B-T028
regulates	O
the	O
early	O
differentiation of cardiomyocytes	B-T043
from	O
mouse embryonic stem cells	B-T025
Mitochondria	B-T026
are	O
crucial	O
for	O
maintaining	O
the	O
properties	O
of	O
embryonic stem cells	B-T025
(	O
ESCs	B-T025
)	O
and	O
for	O
regulating	O
their	O
subsequent	O
differentiation	B-T043
into	O
diverse	O
cell lineages	B-T078
,	O
including	O
cardiomyocytes	B-T025
.	O
However,	O
mitochondrial regulators	B-T123
that	O
manage	O
the	O
rate of differentiation	B-T081
or	O
cell fate	B-T043
have	O
been	O
rarely	O
identified.	O
This	O
study	O
aimed	O
to	O
determine	O
the	O
potential	O
mitochondrial factor	B-T116
that	O
controls	O
the	O
differentiation of ESCs	B-T043
into	O
cardiac myocytes	B-T025
.	O
We	O
induced	O
cardiomyocyte differentiation	B-T043
from	O
mouse ESCs	B-T025
(	O
mESCs	B-T025
)	O
and	O
performed	O
microarray assays	B-T059
to	O
assess	O
messenger RNA	B-T114
(	O
mRNA	B-T114
)	O
expression	B-T045
changes	O
at	O
differentiation day 8	B-T033
(	O
D8	B-T033
)	O
compared	O
with	O
undifferentiated	B-T080
mESCs	B-T025
(D0).	O
Among	O
the	O
differentially	O
expressed genes	B-T028
,	O
Pdp1	B-T028
expression	B-T045
was	O
significantly	O
decreased	O
(27-fold)	O
on	O
D8	B-T033
compared	O
to	O
D0	B-T080
,	O
which	O
was	O
accompanied	O
by	O
suppressed	B-T169
mitochondrial	B-T026
indices	B-T170
,	O
including	O
ATP	B-T114
levels,	O
membrane potential	B-T043
,	O
ROS	B-T044
and	O
mitochondrial Ca(2+)	B-T043
.	O
Notably,	O
Pdp1	B-T028
overexpression	B-T045
significantly	O
enhanced	O
the	O
mitochondrial	B-T026
indices	B-T170
and	O
pyruvate dehydrogenase activity	B-T044
and	O
reduced	O
the	O
expression	B-T045
of	O
cardiac differentiation	B-T043
marker mRNA	B-T045
and	O
the	O
cardiac differentiation	B-T043
rate	B-T081
compared	O
to	O
a	O
mock	O
control.	O
In	O
confirmation	O
of	O
this,	O
a	O
knockdown	B-T063
of	O
the	O
Pdp1 gene	B-T028
promoted	O
the	O
expression	B-T045
of	O
cardiac differentiation	B-T043
marker mRNA	B-T045
and	O
the	O
cardiac differentiation	B-T043
rate	B-T081
.	O
In	O
conclusion,	O
our	O
results	O
suggest	O
that	O
mitochondrial PDP1	B-T028
is	O
a	O
potential	O
regulator	O
that	O
controls	O
cardiac differentiation	B-T043
at	O
an	O
early	O
differentiation stage	B-T079
in	O
ESCs	B-T025
.	O

Thermo-reversible capture and release	B-T067
of	O
DNA	B-T114
by	O
zwitterionic surfactants	B-T120
The	O
thermo-reversible capture and release	B-T067
of	O
DNA	B-T114
were	O
studied	O
by	O
the	O
protonation	B-T067
and	O
deprotonation	B-T067
of	O
alkyldimethylamine oxide	B-T109
(	O
CnDMAO	B-T109
,	O
n	O
=	O
10,	O
12	O
and	O
14)	O
in	O
Tris-HCl	B-T130
buffer solution	B-T130
.	O
DNA	B-T114
/	O
C14DMAO	B-T109
in	O
Tris-HCl	B-T130
buffer solution	B-T130
with	O
pH	B-T081
=	O
7.2	O
is	O
transparent	B-T080
at	O
25	O
°C,	O
indicating	O
that	O
DNA	B-T114
molecules	B-T167
exist	O
mainly	O
in	O
individuals	B-T098
and	O
the	O
binding	B-T044
of	O
C14DMAO	B-T109
is	O
weak	B-T080
.	O
With	O
the	O
increase	B-T169
of	O
temperature	B-T081
,	O
the	O
pH	B-T081
of	O
the	O
buffer solution	B-T130
continuously	O
decreases	B-T081
,	O
which	O
leads	O
to	O
protonation	B-T067
of	O
C14DMAO	B-T109
(	O
C14DMAO	B-T109
+	O
H(+)	B-T196
→	O
C14DMAOH(+)	B-T109
)	O
and	O
an	O
obvious	O
increase of the turbidity	B-T033
of	O
the	O
samples	B-T167
.	O
This	O
indicates	O
a	O
stronger	O
binding	B-T044
of	O
the	O
protonated	B-T067
C14DMAOH(+)	B-T109
to	O
DNA	B-T114
.	O
Further	O
investigations	O
demonstrated	O
the	O
formation	B-T169
of	O
DNA	B-T114
/	O
C14DMAOH(+)	B-T109
complexes	B-T104
,	O
in	O
which	O
the	O
stretched	O
DNA	B-T114
molecules	B-T167
are	O
effectively	O
compacted	B-T033
as	O
evidenced	O
from	O
UV-vis	B-T070
UV-vis absorptions	B-T059
,	O
circular dichroism	B-T059
(	O
CD	B-T059
)	O
measurements	B-T169
,	O
atomic force microscopy	B-T059
(	O
AFM	B-T059
)	O
observations	B-T062
,	O
dynamic light scattering	B-T059
(	O
DLS	B-T059
)	O
measurements	B-T169
and	O
agarose gel electrophoresis	B-T059
(	O
AGE	B-T059
).	O
Interestingly,	O
when	O
the	O
temperature	B-T081
is	O
turned	O
back	O
to	O
25	O
°C,	O
the	O
compacted	B-T033
DNA	B-T114
molecules	B-T167
can	O
fully	O
recover	O
to	O
the	O
stretched	O
conformation.	O
This	O
cycle	B-T079
can	O
be	O
repeated	O
several	O
times	O
without	O
obvious	O
loss	B-T081
of	O
efficiency	B-T081
.	O
The	O
effect of	B-T080
the	O
chain length	B-T081
of	O
CnDMAO	B-T109
has	O
also	O
been	O
investigated.	O
When	O
C14DMAO	B-T109
was	O
replaced	O
by	O
C12DMAO	B-T109
,	O
similar	O
phenomena	B-T067
can	O
be	O
observed	O
with	O
a	O
slightly	O
higher	B-T080
critical	B-T080
surfactant	B-T120
concentration	B-T081
for	O
DNA	B-T114
compaction	B-T033
and	O
a	O
slightly	O
lower	B-T080
pH	B-T081
of	O
Tris-HCl	B-T130
buffer solution	B-T130
with	O
pH	B-T081
=	O
6.8.	O
For	O
the	O
DNA	B-T114
/	O
C10DMAO	B-T109
system,	O
however,	O
no	O
DNA	B-T114
compaction	B-T033
was	O
observed	O
even	O
in	O
Tris-HCl	B-T130
buffer solution	B-T130
with	O
a	O
much	O
lower	B-T080
pH	B-T081
and	O
a	O
much	O
higher	B-T080
C10DMAO	B-T109
concentration	B-T081
.	O
The	O
negative charges	B-T080
of	O
DNA	B-T114
molecules	B-T167
can	O
easily	O
be	O
neutralized	O
by	O
positive charges	B-T080
of	O
cationic CnDMAOH(+)	B-T109
(n	O
=	O
12	O
and	O
14)	O
micelles	B-T109
.	O
DNA	B-T114
was	O
compacted	B-T033
and	O
then	O
insoluble	O
DNA	B-T114
/	O
CnDMAOH(+)	B-T109
complexes	B-T104
were	O
formed.	O
Because	O
of	O
the	O
much	O
higher	B-T080
critical	B-T080
micelle	B-T109
concentration	B-T081
(	O
cmc	B-T081
)	O
of	O
the	O
shorter	O
chain length	B-T081
C10DMAOH(+)	B-T109
,	O
cationic C10DMAOH(+)	B-T109
micelles	B-T109
cannot	O
form	O
under	O
the	O
studied	O
condition	O
to	O
compact	B-T033
DNA	B-T114
.	O
The	O
strategy	O
may	O
provide	O
an	O
efficient	B-T080
and	O
alternative approach	B-T061
for	O
stimuli-responsive gene therapy	B-T061
and	O
drug release	B-T070
.	O

Collaborating	B-T054
for	O
Systems	B-T169
Change	B-T169
:	O
A	O
Social Science Framework	B-T170
for	O
Academic Roles	B-UnknownType
in	O
Community Partnerships	B-T054
Environmental health	B-T091
researchers	B-T097
,	O
government agencies	B-T092
,	O
and	O
community groups	B-UnknownType
have	O
endorsed	O
long-term	O
community	B-T096
-	O
academic	B-UnknownType
partnerships	B-T092
as	O
an	O
effective strategy	B-T041
to	O
support	B-T077
science	B-T090
-based	O
improvements	B-T077
in	O
environmental health	B-T091
.	O
Social sciences	B-T090
concepts	B-T078
,	O
approaches	B-T078
,	O
and	O
methods	B-T170
are	O
fundamental	O
to	O
these	O
translational partnerships	B-T092
.	O
However,	O
appropriate	B-T080
roles	B-T078
for	O
academic	B-UnknownType
partners	B-T098
vary	O
throughout	O
the	O
process	B-T067
of	O
changing	B-T169
systems	B-T169
(	O
policies	B-T170
,	O
practices	B-T057
,	O
programs	B-T169
,	O
etc.).	O
This	O
can	O
complicate	O
planning	B-T170
,	O
evaluating	B-T078
,	O
and	O
sustaining	B-T169
such	O
partnerships	B-T092
.	O
We	O
set	O
forth	O
a	O
conceptual framework	B-T078
for	O
academic	B-UnknownType
partners	B-T098
'	O
roles	O
at	O
different stages	B-T079
of	O
systems	B-T169
change	B-T169
.	O
We	O
apply	O
this	O
framework	B-T078
to	O
three	O
longstanding	O
academic	B-UnknownType
-	O
community	B-T096
partnerships	B-T092
involving	O
National Institute of Environmental Health Sciences	B-T093
Community Outreach and Engagement Cores	B-T097
.	O
We	O
conclude	O
by	O
discussing	O
how	O
the	O
framework	B-T078
can	O
help	O
academic	B-UnknownType
partners	B-T098
tap	O
appropriate	B-T080
expertise	B-T080
,	O
redefine	O
their	O
roles,	O
and	O
evaluate	O
their	O
contributions	O
to	O
community	B-T096
efforts	O
to	O
improve	B-T033
environmental health	B-T091
.	O

A	O
novel	B-T080
mechanical simulator	B-T074
for	O
cannulation	B-T061
and	O
sphincterotomy	B-T061
after	O
Billroth II	B-T061
or	O
Roux-en-Y reconstruction	B-T061
In	O
patients	B-T101
with	O
Billroth II	B-T061
(	O
B II	B-T061
)	O
or	O
Roux-en-Y	B-T061
anatomy	B-T017
,	O
endoscopic retrograde cholangiopancreatography	B-T060
(	O
ERCP	B-T060
)	O
is	O
demanding.	O
Here,	O
we	O
describe	O
a	O
novel	B-T080
simulator	B-T074
with	O
simulated	B-T062
fluoroscopy	B-T060
for	O
cannulation	B-T061
and	O
sphincterotomy	B-T061
training	B-T065
in	O
such	O
situations.	O
A	O
custom-made	O
simulation system	B-T074
was	O
built	B-T052
based	O
upon	O
a	O
common	B-T081
chassis	B-T073
of	O
a	O
series	B-T081
of	O
previously	B-T079
described	O
ERCP	B-T060
simulators	B-T074
.	O
The	O
papilla	B-T023
is	O
made	O
out	O
of	O
organic	B-T080
material	B-T167
and	O
can	O
be	O
cut	B-T067
by	O
high frequency	B-T079
current	B-T070
.	O
The	O
advancement	B-T169
of	O
guidewires	B-T073
and	O
other	O
instruments	B-T074
within	O
transparent	B-T080
mock	O
bile ducts	B-T023
can	O
be	O
viewed	O
in	O
the	O
window	B-T073
of	O
the	O
simulator	B-T074
without	O
the	O
need	O
for	O
fluoroscopy	B-T060
.	O
The	O
ERCP	B-T060
B II	B-T061
/	O
Roux-en-Y	B-T061
simulation system	B-T074
was	O
first	O
evaluated	B-T058
during	O
an	O
ERCP	B-T060
course	B-T079
.	O
There	O
were	O
no	O
technical problems	B-T067
related	O
to	O
the	O
novel	B-T080
simulator	B-T074
during	O
the	O
course	B-T079
.	O
After	O
sphincterotomy	B-T061
,	O
the	O
organic	B-T080
papillae	B-T023
could	O
easily	O
be	O
exchanged	B-T169
within	O
a	O
few	O
seconds	B-T079
.	O
Overall,	O
the	O
novel	B-T080
B II	B-T061
/	O
Roux-en-Y	B-T061
simulator	B-T074
achieved	O
favorable	B-T080
results	B-T169
by	O
trainees	B-T097
and	O
expert	B-T097
endoscopists	B-T097
in	O
all	O
categories	B-T170
assessed	B-T052
.	O
The	O
new	O
B II	B-T061
/	O
Roux-en-Y	B-T061
mechanical simulator	B-T074
is	O
simple	B-T080
and	O
practicable	B-T080
.	O
A	O
first	O
evaluation	B-T058
during	O
an	O
ERCP	B-T060
course	B-T079
showed	O
promising	O
results	B-T169
.	O

A	O
thermophilic	B-T001
-like	O
ene-reductase	B-T116
originating	O
from	O
an	O
acidophilic	B-T169
iron oxidizer	B-T007
Ene-reductases	B-T116
originating	O
from	O
extremophiles	B-T001
are	O
gaining	O
importance	O
in	O
the	O
field	O
of	O
biocatalysis	B-T070
due	O
to	O
higher	B-T080
-	O
stability	B-T080
properties	B-T080
.	O
The	O
genome	B-T028
of	O
the	O
acidophilic	B-T169
iron-oxidizing bacterium	B-T007
"	O
Ferrovum" sp. JA12	B-T007
was	O
found	O
to	O
harbor	O
a	O
thermophilic	B-T001
-like	O
ene-reductase	B-T116
(	O
FOYE-1	B-T116
).	O
The	O
foye-1 gene	B-T028
was	O
ligated	O
into	O
a	O
pET16bp	B-T114
expression	B-T045
vector system	B-T114
,	O
and	O
the	O
enzyme	B-T116
was	O
produced	O
in	O
Escherichia coli	B-T007
BL21 (DE3; pLysS) cells	B-T025
in	O
yields	O
of	O
10	O
mg	O
L(-1).	O
FOYE-1	B-T116
showed	O
remarkable	O
activity	B-T044
and	O
rates	B-T081
on	O
N-phenylmaleimide	B-T109
and	O
N-phenyl-2-methylmaleimide	B-T109
(up	O
to	O
89	O
U	O
mg(-1),	O
>97	O
%	O
conversion	B-T169
,	O
95	O
%	O
(R)-selective)	O
with	O
both	O
nicotinamide cofactors	B-T109
,	O
NADPH	B-T114
and	O
NADH	B-T114
.	O
The	O
catalytic	B-T070
efficiency	B-T081
with	O
NADPH	B-T114
was	O
27	O
times	O
higher	B-T080
compared	O
to	O
NADH	B-T114
.	O
At	O
the	O
temperature	B-T081
maximum	B-T081
(50	O
°C)	O
and	O
pH optimum	B-T081
(6.5),	O
activity	B-T044
was	O
almost	O
doubled	B-T052
to	O
160	O
U	O
mg(-1).	O
These	O
findings	B-T033
accomplish	O
FOYE-1	B-T116
for	O
a	O
valuable	O
biocatalyst	B-T067
in	O
the	O
synthesis	B-T052
of	O
succinimides	B-T109
.	O
The	O
appearance	O
of	O
a	O
thermophilic	B-T001
-like	O
ene-reductase	B-T116
in	O
an	O
acidic habitat	B-T082
is	O
discussed	O
with	O
respect	O
to	O
its	O
phylogenetic	O
placement	O
and	O
to	O
the	O
genomic	B-T028
neighborhood	B-T082
of	O
the	O
encoding	B-T052
gene	B-T028
,	O
awarding	O
FOYE-1	B-T116
a	O
putative	O
involvement	O
in	O
a	O
quorum-sensing	B-T043
process.	O

A	O
tanshinone I	B-T109
derivative	B-T169
enhances	O
the	O
activities	B-T038
of	O
antibiotics	B-T195
against	O
Staphylococcus aureus	B-T007
in vitro	B-T080
and	O
in vivo	B-T082
Infections	B-T046
caused	O
by	O
Staphylococcus aureus	B-T007
are	O
prevalent.	O
The	O
dramatically	O
reduced	O
discovery	B-T052
of	O
new	O
antibiotics	B-T195
,	O
as	O
well	O
as	O
the	O
persistent	O
emergence	O
of	O
resistant bacteria	B-T007
,	O
represents	O
a	O
major	O
health	B-T078
problem	B-T033
in	O
both	O
hospital	B-T073
and	O
community settings	B-T093
.	O
Using	O
antibiotic	B-T195
enhancers	O
to	O
rescue	O
existing	O
classes	O
of	O
antibiotics	B-T195
is	O
an	O
attractive	O
strategy.	O
In	O
this	O
study	B-T062
,	O
16-aldehyde tanshinone I	B-T121
(	O
ALT	B-T121
)	O
was	O
synthesized	B-T052
and	O
bacteriostatic activity	B-T038
was	O
explored.	O
In	O
addition,	O
synergistic	B-T080
or	O
additive	B-T080
activity	B-T038
between	O
ALT	B-T121
and	O
aminoglycoside antibiotics	B-T109
or	O
β-lactam antibiotics	B-T109
in vitro	B-T080
was	O
identified.	O
Moreover,	O
ALT	B-T121
was	O
documented	O
to	O
augment	O
clearance	O
of	O
streptomycin	B-T109
(	O
STR	B-T109
)	O
and	O
ampicillin	B-T109
(	O
AMP	B-T109
)	O
against	O
S. aureus	B-T007
in	O
a	O
murine infection model	B-T050
.	O
Primary	O
mechanistic insight	B-T044
indicated	O
that	O
ALT	B-T121
could	O
damage	B-T169
the	O
bacterial	B-T007
cell membrane	B-T026
,	O
leading	O
to	O
accumulation	B-T033
of	O
antibiotics	B-T195
inside	O
bacterial cells	B-T007
.	O
This	O
finding	O
might	O
be	O
useful	O
for	O
treating	B-T169
infections	B-T046
caused	O
by	O
S. aureus	B-T007
and	O
expand	O
the	O
scope	O
of	O
application	B-T169
of	O
tanshinones	B-T109
.	O

Investigation	O
of	O
argyrophilic	B-T025
nucleolar organizing region	B-T026
Ischemia/reperfusion (I/R) injury	B-T037
is	O
a	O
complex event	B-T051
frequently	O
observed	B-T169
in	O
vascular surgery	B-T061
and	O
can	O
cause	O
functional	B-T043
and	O
structural	B-T026
cell damage	B-T049
.	O
Nucleolar-organizing regions	B-T026
(	O
NORs	B-T026
)	O
are	O
sites	B-T082
of	O
the	O
ribosomal genes	B-T028
located	O
on	O
chromosomes	B-T026
and	O
can	O
be	O
stained	B-T059
with	O
silver	B-T196
when	O
they	O
are	O
active	B-T169
.	O
Thus	O
these	O
proteins	B-T116
are	O
named	O
as	O
argyrophilic-NOR (AgNOR)-associated proteins	B-T116
.	O
We	O
aimed	O
to	O
investigate	O
any	O
possible	O
effects of	B-T080
renal	B-T023
I/R injury	B-T037
on	O
the	O
NOR protein	B-T116
synthesis	B-T044
and	O
association	O
between	O
the	O
AgNOR proteins	B-T116
amount	B-T081
and	O
histopathological injuring score	B-T033
.	O
Nine	O
female	B-T032
wistar-albino rats	B-T015
with	O
weight	O
of	O
200-250g	O
were	O
included	O
into	O
the	O
study.	O
The	O
animals	B-T008
were	O
randomly	B-T080
divided	B-T169
in	O
two	O
groups	B-T078
,	O
a	O
Control Group	B-T096
and	O
an	O
I/R	B-T037
Group	B-T078
.	O
In	O
I/R	B-T037
group	B-T078
,	O
rats	B-T015
were	O
subjected	O
to	O
45	O
minutes	O
of	O
renal pedicle	B-T023
occlusion	B-T046
followed	O
by	O
24	O
hours	O
of	O
reperfusion	B-T038
.	O
In	O
the	O
control group	B-T096
no	O
drug injections	B-T061
or	O
ischemia reperfusion	B-T037
were	O
performed	B-T169
in	O
animals	B-T008
.	O
Then	O
histopathological injury score	B-T033
,	O
mean AgNOR number	B-T033
and	O
total AgNOR area	B-T033
/	O
nuclear area	B-T033
(	O
TAA	B-T033
/	O
NA	B-T033
)	O
were	O
detected	B-T033
for	O
each	O
rat	B-T015
.	O
The	O
differences	O
between	O
control	B-T096
and	O
I/R	B-T037
groups	B-T078
were	O
significant	B-T078
for	O
histopathological injury scores	B-T033
(p	O
=	O
0.016).	O
Also	O
the	O
differences	O
between	O
control group	B-T096
and	O
I/R	B-T037
group	B-T078
were	O
significant	B-T078
for	O
mean AgNOR number	B-T033
(p	O
=	O
0.000)	O
and	O
TAA/NA ratio	B-T081
(p	O
=	O
0.000).	O
Additionally,	O
there	O
was	O
a	O
positive correlation	B-T080
between	O
TAA/NA ratio	B-T081
and	O
histopathological injury score	B-T033
(r	O
=	O
0.728;	O
p	O
=	O
0.026)	O
and	O
between	O
mean AgNOR number	B-T033
and	O
histopathological injury score	B-T033
(r	O
=	O
0.670;	O
p	O
=	O
0.048).	O
The	O
detection	B-T061
of	O
AgNOR proteins	B-T116
amount	B-T081
may	O
be	O
used	O
as	O
an	O
indicator	B-T169
to	O
obtain	O
information	B-T078
about	O
the	O
cellular behaviour	B-T043
(	O
self-protective	B-T039
mechanism	O
of	O
tubular epithelial cells	B-T025
)	O
against	O
I/R injury	B-T037
and	O
cellular damage	B-T049
levels	B-T080
(Tab.	O
2,	O
Fig.	O
4,	O
Ref.	O
24).	O

When	O
emotion	B-T041
and	O
expression	B-T033
diverge:	O
The	O
social costs	B-UnknownType
of	O
Parkinson's disease	B-T047
Patients	B-T101
with	O
Parkinson's disease	B-T047
(	O
PD	B-T047
)	O
are	O
perceived	B-T041
more	O
negatively	B-T033
than	O
their	O
healthy	B-T080
peers	B-T098
,	O
yet	O
it	O
remains	O
unclear	O
what	O
factors	B-T169
contribute	B-T052
to	O
this	O
negative	B-T033
social perception	B-T041
.	O
Based	O
on	O
a	O
cohort	B-T098
of	O
17	O
PD	B-T047
patients	B-T101
and	O
20	O
healthy controls	B-T080
,	O
we	O
assessed	B-T052
how	O
naïve	O
raters	O
judge	O
the	O
emotion	B-T041
and	O
emotional	B-T033
intensity	B-T080
displayed	B-T169
in	O
dynamic	B-T169
facial expressions	B-T033
as	O
adults	B-T100
with	O
and	O
without	O
PD	B-T047
watched	B-T041
emotionally	B-T041
evocative	O
films	B-T170
(	O
Experiment	B-T062
1),	O
and	O
how	O
age	B-T032
-matched	O
peers	B-T098
naïve	O
to	O
patients	B-T101
'	O
disease	B-T047
status	O
judge	O
their	O
social desirability	B-T054
along	O
various	O
dimensions	B-T081
from	O
audiovisual	B-T170
stimuli	B-T067
(	O
interview excerpts	B-T097
)	O
recorded	O
after	O
certain	O
films	B-T170
(	O
Experiment	B-T062
2).	O
In	O
Experiment	B-T062
1,	O
participants	B-T098
with	O
PD	B-T047
were	O
rated	B-T052
as	O
significantly more	B-T081
facially expressive	B-T033
than	O
healthy controls	B-T080
;	O
moreover,	O
ratings	B-T052
demonstrated	O
that	O
PD	B-T047
patients	B-T101
were	O
routinely	O
mistaken	O
for	O
experiencing	B-T041
a	O
negative	B-T033
emotion	B-T041
,	O
whereas	O
controls	B-T080
were	O
rated	B-T052
as	O
displaying	B-T169
a	O
more	O
positive	B-T033
emotion	B-T041
than	O
they	O
reported	B-T058
feeling	B-T041
.	O
In	O
Experiment	B-T062
2,	O
results	B-T034
showed	O
that	O
age-peers	B-T098
rated	B-T052
PD	B-T047
patients	B-T101
as	O
significantly less	B-T081
socially desirable	B-T054
than	O
control	B-T080
participants	B-T098
.	O
Specifically,	O
PD	B-T047
patients	B-T101
were	O
rated	B-T052
as	O
less	O
involved	B-T169
,	O
interested	B-T041
,	O
friendly	B-T080
,	O
intelligent,	O
optimistic	B-T033
,	O
attentive,	O
and	O
physically attractive	B-T080
than	O
healthy controls	B-T080
.	O
Taken	O
together,	O
our	O
results	B-T034
point	O
to	O
a	O
disconnect	O
between	O
how	O
PD	B-T047
patients	B-T101
report	B-T058
feeling	B-T041
and	O
attributions	B-T041
that	O
others	O
make	O
about	O
their	O
emotions	B-T041
and	O
social characteristics	B-T055
,	O
underlining	O
significant	B-T078
social challenges	B-T080
of	O
the	O
disease	B-T047
.	O
In	O
particular,	O
changes	B-T169
in	O
the	O
ability	B-T032
to	O
modulate	B-T082
the	O
expression	B-T033
of	O
negative	B-T033
emotions	B-T041
may	O
contribute	B-T052
to	O
the	O
negative	B-T033
social	B-T169
impressions	B-T055
that	O
many	O
PD	B-T047
patients	B-T101
face.	O

Establishing	O
in-	O
hospital	B-T073
geriatrics services	B-T093
in	O
Africa	B-T083
:	O
Insights	O
from	O
the	O
University of Benin Teaching Hospital	B-T073
geriatrics	B-T091
project	B-T077
Unawareness	O
of	O
the	O
peculiar	O
healthcare	B-T058
needs	B-T080
of	O
the	O
elderly	B-T098
and	O
resource	B-T078
constraints	B-T169
may	O
be	O
some	O
reasons	O
why	O
until	O
recently,	O
Nigerian	B-T083
hospitals	B-T073
have	O
not	O
been	O
equipped	O
with	O
the	O
human	B-T081
and	O
infrastructural resources	B-T081
required	O
to	O
meet	O
older adults	B-T098
'	O
special	O
healthcare	B-T058
needs	B-T080
.	O
There	O
is	O
paucity	O
of	O
specialized	O
health services	B-T093
for	O
the	O
elderly	B-T098
in	O
Africa	B-T083
.	O
Nigeria	B-T083
,	O
with	O
a	O
population	B-T098
of	O
over	O
170	O
million,	O
did	O
not	O
have	O
any	O
healthcare facility	B-T073
with	O
dedicated	O
services	B-T058
for	O
the	O
elderly	B-T098
until	O
2012.	O
The	O
University of Benin Teaching Hospital	B-T073
(	O
UBTH	B-T073
)	O
in	O
Nigeria	B-T083
was	O
established	O
in	O
1973	O
and	O
created	O
its	O
geriatrics	B-T091
unit	O
in	O
October	O
2013.	O
A	O
prepared	O
environment	O
and	O
trained interdisciplinary teams	B-T058
are	O
pivotal	O
in	O
providing	O
effective	O
healthcare services	B-T093
for	O
the	O
elderly	B-T098
.	O
The	O
ongoing	O
UBTH	B-T073
geriatrics	B-T091
project	B-T077
aims	O
to	O
provide	O
specialized	O
interdisciplinary	B-T058
health services	B-T058
to	O
older adults	B-T098
and	O
to	O
provide	O
training	B-T065
and	O
continuing	O
professional development	B-T057
in	O
geriatrics	B-T091
for	O
healthcare staff	B-T097
.	O
In	O
developing	O
our	O
inpatient	B-T101
services	B-T058
,	O
we	O
adopted	O
the	O
acute care for elders	B-T058
(	O
ACE	B-T058
)	O
model	B-T170
and	O
worked	O
in	O
tandem	O
with	O
the	O
"ABCs"	O
of	O
implementing	O
ACE units	B-T170
.	O
In	O
the	O
face	O
of	O
limited	O
resources	B-T078
,	O
it	O
was	O
possible	O
to	O
establish	O
a	O
functional	O
geriatrics unit	B-T091
with	O
a	O
trained	O
interdisciplinary team	B-T058
.	O
Family	B-T099
participation	B-T169
is	O
central	O
in	O
our	O
practice	B-T091
.	O
Since	O
October	O
2013,	O
residents	B-T098
and	O
house officers	B-T097
in	O
internal medicine	B-T121
have	O
been	O
undertaking	O
4-	O
and	O
12-	O
weekly	B-T079
rotations	B-T169
,	O
respectively.	O
There	O
is	O
also	O
a	O
robust	O
academic program	B-T033
,	O
which	O
includes	O
once-	O
weekly	B-T079
geriatric	B-T080
pharmacotherapy	B-T061
seminars	B-T058
,	O
once-	O
weekly	B-T079
interdisciplinary	O
seminars	B-T058
,	O
and	O
2-	O
weekly	B-T079
journal club meetings	B-T052
alternating	O
with	O
seminars	B-T058
on	O
geriatric assessment tools	B-T170
.	O
It	O
is	O
possible	O
to	O
establish	O
geriatric services	B-T093
and	O
achieve	O
best	O
practices	B-T091
in	O
resource-limited	O
settings	O
by	O
investing	O
on	O
improving	O
available	O
human resources	B-T081
and	O
infrastructure	B-T185
.	O
We	O
also	O
make	O
recommendations	O
for	O
setting	O
up	O
similar	O
services	B-T093
in	O
other	O
parts	O
of	O
Africa	B-T083
.	O

Engaging	B-T033
adolescent girls	B-T100
in	O
transactional sex	B-T054
through	B-T169
compensated	B-T080
dating	B-T054
Transactional sex	B-T054
through	B-T169
so-called	O
compensated	B-T080
dating	B-T054
in	O
adolescent girls	B-T100
is	O
a	O
problem	B-T033
in	O
need	B-T080
of	O
public	B-T092
concern	B-T078
.	O
Compensated	B-T080
dating	B-T054
typically	O
involves	O
the	O
use of	B-T169
information communication technology	B-T170
to	O
advertise	B-T057
,	O
search	B-T052
,	O
bargain	B-T054
,	O
and	O
eventually	O
arrange	O
for	O
transactional sex	B-T054
.	O
The	O
technology	B-T170
enables	B-T041
the	O
sexual partners	B-T098
to	O
maintain	B-T052
privacy	B-T078
and	O
secrecy	B-T078
in	O
transactional sex	B-T054
.	O
Such	O
secrecy	B-T078
necessitates	B-T080
the	O
girls	B-T098
'	O
disclosure	B-T055
about	O
their	O
life experiences	B-T067
in	O
order	B-T080
to	O
address	O
the	O
concern	B-T078
.	O
The	O
disclosure	B-T055
is	O
the	O
focus	B-T169
of	O
the	O
present	O
qualitative study	B-T062
of	O
27	O
girls	B-T098
practicing	B-T041
the	O
dating	B-T054
in	O
Hong Kong	B-T083
,	O
China	B-T083
.	O
Based	B-T169
on	O
the	O
disclosure	B-T055
,	O
the	O
study	B-T062
presents	O
a	O
grounded theory	B-T170
that	O
epitomizes	O
engagement	B-T033
in	O
compensated	B-T080
dating	B-T054
by	O
referential choice	B-T055
.	O
Such	O
a	O
referential choice theory	B-T078
unravels	O
that	O
choice	B-T055
with	O
reference	B-T169
to	O
the	O
family	B-T099
push	B-T067
and	O
social norms	B-T078
sustains	B-T169
the	O
engagement	B-T033
.	O
Meanwhile,	O
the	O
choice	B-T055
rests	O
on	O
expectancy	B-T078
and	O
reinforcement	B-T169
from	O
experiential learning	B-T065
about	O
compensated	B-T080
dating	B-T054
.	O
The	O
theory	B-T078
thus	O
implies	O
ways	O
to	O
undercut	O
the	O
engagement	B-T033
through	B-T169
diverting	B-T080
the	O
referential choice	B-T055
of	O
the	O
dating	B-T054
.	O

Numerical simulation	B-T062
of	O
emitted particle	B-T104
characteristics	B-T080
and	O
airway	B-T023
deposition	B-T169
distribution	B-T039
of	O
Symbicort(®) Turbuhaler(®)	B-T109
dry powder	B-T122
fixed	O
combination	B-T121
aerosol drug	B-T122
One	O
of	O
the	O
most	O
widespread	O
dry powder	B-T122
fixed	O
combinations	B-T121
used	O
in	O
asthma	B-T047
and	O
chronic obstructive pulmonary disease	B-T047
(	O
COPD	B-T047
)	O
management	B-T058
is	O
Symbicort(®) Turbuhaler(®)	B-T109
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
simulate	B-T062
the	O
deposition	B-T169
distribution	B-T039
of	O
both	O
components	B-T185
of	O
this	O
drug	B-T121
within	O
the	O
airways	B-T023
based	O
on	O
realistic	O
airflow measurements	B-T060
.	O
Breathing	B-T040
parameters	B-T077
of	O
25	O
healthy adults	B-T033
(11	O
females	B-T032
and	O
14	O
males	B-T032
)	O
were	O
acquired	B-T080
while	O
inhaling	B-T040
through	O
Turbuhaler(®)	B-T074
.	O
Individual	B-T098
specific	O
emitted doses	B-T081
and	O
particle size	B-T081
distributions	B-T039
of	O
Symbicort(®) Turbuhaler(®)	B-T109
were	O
determined	B-T080
.	O
A	O
self-developed	O
particle	B-T104
deposition	B-T169
model	B-T170
was	O
adapted	B-T169
and	O
validated	B-T169
to	O
simulate	B-T062
the	O
deposition	B-T169
of	O
budesonide	B-T109
(	O
inhaled corticosteroid	B-T109
;	O
ICS	B-T109
)	O
and	O
formoterol	B-T109
(	O
long acting β2 agonist	B-T121
;	O
LABA	B-T121
)	O
in	O
the	O
upper airways	B-T030
and	O
lungs	B-T023
of	O
the	O
healthy volunteers	B-T098
.	O
Based	O
on	O
current	B-T079
simulations	B-T062
the	O
emitted doses	B-T081
varied	O
between	O
50.4%	O
and	O
92.5%	O
of	O
the	O
metered	O
dose	B-T081
for	O
the	O
ICS	B-T109
,	O
and	O
between	O
38%	O
and	O
96.1%	O
in	O
case	O
of	O
LABA	B-T121
component	B-T185
depending	O
on	O
the	O
individual	B-T098
inhalation flow rate	B-T201
.	O
This	O
variability	B-T077
induced	B-T169
a	O
notable	O
inter-	O
individual	B-T098
spread	B-T080
of	O
the	O
deposited	B-T169
lung	B-T023
doses	B-T081
(mean:	O
33.6%,	O
range	B-T081
:	O
20.4%-48.8%	O
for	O
budesonide	B-T109
and	O
mean:	O
29.8%,	O
range	B-T081
:	O
16.4%-42.9%	O
for	O
formoterol	B-T109
).	O
Significant	B-T078
inter-gender	B-T032
differences	B-T080
were	O
also	O
observed	B-T169
.	O
Average	O
lung	B-T023
dose	B-T081
of	O
budesonide	B-T109
was	O
29.2%	O
of	O
the	O
metered	O
dose	B-T081
for	O
females	B-T032
and	O
37%	O
for	O
males	B-T032
,	O
while	O
formoterol	B-T109
deposited	B-T169
with	O
26.4%	O
efficiency	B-T081
for	O
females	B-T032
and	O
32.5%	O
for	O
males	B-T032
.	O
Present	O
results	B-T169
also	O
highlighted	O
the	O
importance	B-T080
of	O
breath-holding	B-T033
after	O
inhalation	B-T040
of	O
the	O
drug	B-T121
.	O
About	O
a	O
half	O
of	O
the	O
total	O
lung	B-T023
deposition	B-T169
occurred	B-T052
during	O
breath-hold	B-T033
at	O
9.6s	O
average	O
breath-hold	B-T033
time	B-T079
.	O
Calculated	O
depositions	B-T169
confirmed	B-T080
appropriate	B-T080
lung	B-T023
deposition	B-T169
of	O
Symbicort(®) Turbuhaler(®)	B-T109
for	O
both	O
genders	B-T032
,	O
however	O
more	O
effort	O
for	O
optimal inhalation technique	B-T061
is	O
advised	B-T078
for	O
persons	B-T098
with	O
low vital capacity	B-T033
.	O
This	O
study	B-T062
demonstrated	O
the	O
possibility	O
of	O
personalized	B-T080
prediction	B-T078
of	O
airway	B-T023
deposition	B-T169
of	O
aerosol drugs	B-T122
by	O
numerical simulations	B-T062
.	O
The	O
methodology	B-T078
developed	O
in	O
this	O
study	B-T062
will	O
be	O
applicable	B-T080
also	O
to	O
other	O
marketed	B-T080
drugs	B-T121
in	O
the	O
future	B-T079
.	O

Nutrient intake	B-T058
of	O
infants	B-T100
and	O
toddlers	B-T100
in	O
the	O
United Arab Emirates	B-T083
:	O
the	O
Feeding	O
Infants	B-T100
and	O
Toddlers	B-T100
Study	O
This	O
descriptive	O
study	O
evaluated	O
the	O
nutrient adequacy	B-T081
of	O
the	O
diet	B-T168
of	O
infants	B-T100
(aged	O
6-11.9	O
months)	O
and	O
toddlers	B-T100
(aged	O
12-24	O
months)	O
in	O
the	O
United Arab Emirates	B-T083
.	O
A	O
random	O
sample	O
of	O
1000	O
infants	B-T100
and	O
toddlers	B-T100
was	O
recruited	O
from	O
2	O
cities	O
(	O
Al Ain	B-T083
and	O
Dubai	B-T083
)	O
from	O
March	B-T079
2011	O
to	O
February	B-T080
2012	O
and	O
their	O
usual	O
nutrient intake	B-T058
was	O
determined	O
using	O
24-hour	O
recall.	O
In	O
all,	O
54.2%	O
of	O
infants	B-T100
and	O
25.2%	O
of	O
toddlers	B-T100
were	O
breastfeeding	B-T040
.	O
Mean	O
energy intake	B-T081
of	O
infant girls	B-T100
in	O
Al Ain	B-T083
and	O
Dubai	B-T083
was	O
747	O
(SD	O
189)	O
kcal	B-T081
and	O
773	O
(SD	O
215)	O
kcal	B-T081
respectively	O
and	O
810.5	O
(SD	O
232.2)	O
kcal	B-T081
and	O
821.9	O
(SD	O
262)	O
kcal	B-T081
for	O
boys	B-T100
.	O
In	O
toddlers	B-T100
,	O
mean	O
energy intake	B-T081
for	O
girls	B-T100
in	O
Al	O
Ain	O
and	O
Dubai	O
was	O
1032.8	O
(SD	O
252)	O
kcal	B-T081
and	O
1013	O
(SD	O
339.1)	O
kcal	B-T081
respectively	O
and	O
1057.2	O
(SD	O
201.8)	O
kcal	B-T081
and	O
1030.3	O
(SD	O
341.7)	O
kcal	B-T081
for	O
boys	B-T100
.	O
Iron intake	B-T033
was	O
low	B-T080
in	O
both	O
groups.	O
Mean	O
body mass index	B-T201
and	O
body weight	B-T032
and	O
height	B-T032
were	O
similar	O
to	O
World Health Organization	B-T093
figures	O
but	O
significant	O
numbers	O
of	O
infants	B-T100
and	O
toddlers	B-T100
of	O
both	O
sexes	O
were	O
over	B-T184
-	O
or	O
underweight	B-T033
.	O
Although	O
mean	O
energy	O
and	O
macronutrient	B-T077
intakes	B-T058
were	O
comparable	O
to	O
the	O
RDA	B-T170
,	O
significant	O
numbers	O
were	O
over	B-T047
-	O
or	O
underfed	B-T047
.	O

Estimation	O
of	O
the	O
HIV-1	B-T005
backward	B-T082
mutation rate	B-T080
from	O
transmitted drug-resistant	B-T038
strains	B-T001
One	O
of	O
the	O
serious	O
threats	B-T078
facing	O
the	O
administration	O
of	O
antiretroviral therapy	B-T061
to	O
human immunodeficiency virus	B-T005
(	O
HIV-1	B-T005
)	O
infected	B-T047
patients	B-T101
is	O
the	O
reported	O
increasing prevalence	B-T081
of	O
transmitted drug resistance	B-T038
.	O
However,	O
given	O
that	O
HIV-1	B-T005
drug-resistant	B-T038
strains	B-T001
are	O
often	O
less	O
fit	O
than	O
the	O
wild-type	B-T028
strains	B-T001
,	O
it	O
is	O
expected	O
that	O
drug-resistant	B-T038
strains	B-T001
that	O
are	O
present	O
during	O
the	O
primary	B-T080
phase	B-T079
of	O
the	O
HIV-1 infection	B-T047
are	O
replaced	B-T169
by	O
the	O
fitter	O
wild-type	B-T028
strains	B-T001
.	O
This	O
replacement	B-T169
of	O
HIV-1 resistant	B-T033
mutations	B-T045
involves	O
the	O
emergence	O
of	O
wild-type	B-T028
strains	B-T001
by	O
a	O
process	B-T067
of	O
backward	B-T082
mutation	B-T045
.	O
How	O
quickly	O
the	O
replacement	B-T169
happens	O
is	O
dependent	B-T169
on	O
the	O
class	O
of	O
HIV-1	B-T005
mutation	B-T045
group	B-T078
.	O
We	O
estimate	O
the	O
backward	B-T082
mutation rates	B-T080
and	O
relative	O
fitness	O
of	O
various	O
mutational	B-T045
groups	B-T078
known	O
to	O
confer	O
HIV-1	B-T005
drug resistance	B-T038
.	O
We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic model	B-T062
to	O
data	B-T078
for	O
individuals	B-T098
who	O
were	O
originally	O
infected	B-T033
by	O
an	O
HIV-1	B-T005
strain	B-T001
carrying	O
any	O
one	O
of	O
the	O
known	O
drug resistance	B-T038
-conferring	O
mutations	B-T045
and	O
observed	O
over	O
a	O
period of time	B-T201
to	O
see	O
whether	O
the	O
resistant	B-T169
strain	B-T001
is	O
replaced	B-T169
.	O
To	O
do	O
this,	O
we	O
seek	O
a	O
distribution	B-T169
,	O
generated	O
from	O
simulations	B-T062
of	O
the	O
stochastic model	B-T062
,	O
that	O
best	O
describes	O
the	O
observed	B-T169
(	O
clinical data	B-T170
)	O
replacement	B-T169
times	B-T081
of	O
a	O
given	O
mutation	B-T045
.	O
We	O
found	O
that	O
Lamivudine/Emtricitabine	B-T109
-associated	O
mutations	B-T045
have	O
a	O
distinctly	O
higher,	O
backward	B-T082
mutation rate	B-T080
and	O
low	O
relative	B-T080
fitness	B-T056
compared	O
to	O
the	O
other	O
classes	B-T170
(as	O
has	O
been	O
reported	O
before)	O
while	O
protease inhibitors	B-T121
-associated	O
mutations	B-T045
have	O
a	O
slower	O
backward	B-T082
mutation rate	B-T080
and	O
high	O
relative	B-T080
fitness	B-T056
.	O
For	O
the	O
other	O
mutation	B-T045
classes	B-T170
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
estimates	B-T081
.	O

Modeling	B-T062
the	O
hospital	B-T073
safety	B-T068
partnership	B-T058
preferences of patients	B-T080
and	O
their	O
families	B-T099
:	O
a	O
discrete	B-T080
choice	B-T055
conjoint experiment	B-T062
Patients	B-T101
and	O
their	O
families	B-T099
play	O
an	O
important	O
role	B-T077
in	O
efforts	O
to	O
improve	B-T077
health service	B-T058
safety	B-T068
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
is	O
to	O
understand	O
the	O
safety	B-T068
partnership	B-T058
preferences of patients	B-T080
and	O
their	O
families	B-T099
.	O
We	O
used	O
a	O
discrete	B-T080
choice	B-T055
conjoint experiment	B-T062
to	O
model	O
the	O
safety	B-T068
partnership	B-T058
preferences	B-T080
of	O
1,084	O
patients	B-T101
or	O
those	O
such	O
as	O
parents	B-T099
acting	O
on	O
their	O
behalf.	O
Participants	B-T098
made	O
choices	B-T055
between	O
hypothetical	O
safety	B-T068
partnerships	B-T058
composed	O
by	O
experimentally	O
varying	O
15	O
four-level	O
partnership	B-T058
design	B-T052
attributes	B-T055
.	O
Participants	B-T098
preferred	B-T078
an	O
approach	B-T082
to	O
safety	B-T068
based	O
on	O
partnerships	B-T058
between	O
patients	B-T101
and	O
staff	B-T097
rather	O
than	O
a	O
model	O
delegating	O
responsibility	B-T055
for	O
safety	B-T068
to	O
hospital staff	B-T097
.	O
They	O
valued	O
the	O
opportunity to participate	B-UnknownType
in	O
point	O
of	O
service	O
safety	B-T068
partnerships	B-T058
,	O
such	O
as	O
identity	O
and	O
medication double checks	B-T058
,	O
that	O
might	O
afford	O
an	O
immediate	B-T079
risk reduction	B-T055
.	O
Latent	O
class	O
analysis	B-T062
yielded	O
two	O
segments.	O
Actively engaged participants	B-T098
(73.3%)	O
comprised	O
outpatients	B-T101
with	O
higher education	B-T065
,	O
who	O
anticipated	B-T033
more	O
benefits	B-T081
to	O
safety	B-T068
partnerships	B-T058
,	O
were	O
more confident	B-T033
in	O
their	O
ability	B-T032
to	O
contribute	B-T052
,	O
and	O
were	O
more	O
intent	B-T080
on	O
participating	B-T169
.	O
They	O
were	O
more	O
likely	O
to	O
prefer	B-T080
a	O
personal	O
engagement	B-T058
strategy	B-T041
,	O
valued	O
scientific evidence	B-T078
,	O
preferred	B-T078
a	O
more	O
active	O
approach	B-T082
to	O
safety education	B-T065
,	O
and	O
advocated	O
disclosure of errors	B-T080
.	O
The	O
passively	O
engaged	O
segment	O
(26.7%)	O
anticipated	B-T033
fewer	B-T081
benefits	B-T081
,	O
were	O
less	O
confident	B-T055
in	O
their	O
ability	B-T032
to	O
contribute	B-T052
,	O
and	O
were	O
less	O
intent	O
on	O
participating	B-T169
.	O
They	O
were	O
more	O
likely	O
to	O
prefer	O
an	O
engagement	B-T058
strategy	B-T041
based	O
on	O
signage	B-T073
.	O
They	O
preferred	B-T078
that	O
staff	B-T097
explain	O
why	O
they	O
thought	O
patients	B-T101
should	O
help	O
make	O
care	B-T058
safer	O
and	O
decide	O
whether	O
errors	B-T080
were	O
disclosed.	O
Inpatients	B-T101
,	O
those	O
with	O
immigrant backgrounds	B-T033
,	O
and	O
those	O
with	O
less education	B-T033
were	O
more	O
likely	O
to	O
be	O
in	O
this	O
segment.	O
Health services	B-T058
need	O
to	O
communicate	O
information	B-T078
regarding	O
risks	B-T078
,	O
ask	O
about	O
partnership	B-T058
preferences	B-T080
,	O
create	O
opportunities	B-UnknownType
respecting	O
individual differences	B-T054
,	O
and	O
ensure	O
a	O
positive response	B-T033
when	O
patients	B-T101
raise	O
safety	B-T068
concerns	B-T078
.	O

Influence	O
of	O
ozone	B-T103
and	O
paracetic acid	B-T109
disinfection	B-T061
on	O
adhesion of	B-T070
resilient liners	B-T122
to	O
acrylic resin	B-T122
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic acid	B-T109
(	O
PAA	B-T109
)	O
and	O
ozone	B-T103
disinfection	B-T061
on	O
the	O
tensile bond strength	B-T081
(	O
TBS	B-T081
)	O
of	O
silicone-based	B-T109
resilient liners	B-T122
to	O
acrylic resins	B-T122
.	O
One	O
hundred	O
and	O
twenty	O
dumbbell shaped	B-T082
heat-polymerized	B-T067
acrylic resins	B-T122
were	O
prepared.	O
From	O
the	O
mid	O
segment	O
of	O
the	O
specimens	B-T167
,	O
3	O
mm	O
of	O
acrylic	B-T122
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient liners	B-T122
.	O
The	O
specimens	B-T167
were	O
divided	O
into	O
2 control	B-T167
(	O
control1	B-T167
,	O
control7	B-T167
)	O
and	O
4	O
test	O
groups	O
of	O
PAA	B-T109
and	O
ozone	B-T103
disinfection	B-T061
(	O
PAA1	B-T109
,	O
PAA7	B-T109
,	O
ozone1	B-T103
and	O
ozone7	B-T103
;	O
n=10).	O
While	O
control	O
groups	O
were	O
immersed	O
in	O
distilled water	B-T121
for	O
10	O
min	O
(	O
control1	B-T167
)	O
and	O
7	O
days	O
(	O
control7	B-T167
),	O
test	O
groups	O
were	O
subjected	O
to	O
PAA	B-T109
(16	O
g/L)	O
or	O
ozone	B-T103
rich	O
water	B-T121
(4	O
mg/L)	O
for	O
1	O
cycle	O
(10	O
min	O
for	O
PAA	B-T109
and	O
60	O
min	O
for	O
ozone	B-T103
)	O
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	B-T081
tests	B-T059
.	O
Measurements	O
of	O
the	O
TBS	B-T081
were	O
analyzed	O
using	O
3-way	O
ANOVA	B-T081
and	O
Tukey's HSD test	B-T059
.	O
Adhesive	B-T073
strength	B-T078
of	O
Mollosil	B-T109
decreased	O
significantly	O
by	O
application	O
of	O
ozone	B-T103
disinfection	B-T061
.	O
PAA	B-T109
disinfection	B-T061
had	O
no	O
negative	O
effect	O
on	O
the	O
TBS	B-T081
values	O
of	O
Mollosil	B-T109
and	O
Molloplast B	B-T109
to	O
acrylic resin	B-T122
.	O
Single	O
application	O
of	O
ozone	B-T103
disinfection	B-T061
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
TBS	B-T081
values	O
of	O
Molloplast B	B-T109
,	O
but	O
prolonged	B-T079
exposure to ozone	B-T033
decreased	O
its	O
adhesive	B-T073
strength	B-T078
.	O
The	O
adhesion	B-T070
of	O
resilient liners	B-T122
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
PAA	B-T109
disinfection	B-T061
.	O
Immersion	O
in	O
ozonated	B-T052
water	B-T121
significantly	O
decreased	O
TBS	B-T081
of	O
Mollosil	B-T109
.	O
Prolonged	O
exposure	O
to	O
ozone	B-T103
negatively	O
affects	O
adhesion	B-T070
of	O
Molloplast B	B-T109
to	O
denture base materials	B-T074
.	O

The	O
construction	B-T052
of	O
three-dimensional	B-T082
composite	B-T122
fibrous	B-T080
macrostructures	B-T082
with nanotextures	B-T080
for	O
biomedical	B-T091
applications	B-T169
The	O
development	O
of	O
modern	O
biomedical	B-T091
nanotechnology	B-T090
requires	O
three-dimensional	B-T082
macrostructures	B-T082
with nanotextures	B-T080
to	O
meet	O
the	O
requirements	O
for	O
practical	O
applications	B-T169
in	O
intricate	O
biological systems	B-T022
.	O
Additionally,	O
the	O
restoration	B-UnknownType
and	O
regeneration	B-T040
of	O
some	O
specific	O
body tissues	B-T024
and	O
organs	B-T023
rely	O
on	O
the	O
function	O
of	O
conductive polymers	B-T104
,	O
which	O
can	O
provide	O
electrical	B-T169
cues	B-T078
for	O
cells	B-T025
.	O
In	O
this	O
study,	O
we	O
fabricated	O
three-dimensional	B-T082
composite	B-T122
nanofibre	B-T073
macrostructures	B-T082
of	O
polycaprolactone	B-T109
(	O
PCL	B-T109
)	O
with	O
different	O
concentrations	B-T081
of	O
polyaniline	B-T109
(	O
PANi	B-T109
)	O
by	O
employing	O
an	O
improved	O
electrospinning technology	B-T169
with	O
a	O
specially	O
designed	O
collector.	O
The	O
3D	B-T082
structures	B-T082
possessed	O
cap-like macrostructures	B-T082
with	O
centimetre-scale	B-T081
thickness	B-T080
and	O
interconnected	O
pore nanotextures	B-T080
with	O
nanometre-scale	B-T081
nanofibres	B-T073
.	O
To	O
estimate	O
the	O
biocompatibility	B-T044
of	O
the	O
3D	B-T082
PCL	B-T109
/	O
PANi	B-T109
composite	B-T122
nanofibre	B-T073
macrostructures	B-T082
,	O
mouse	B-T015
myoblasts	B-T025
(	O
C2C12 cells	B-T025
)	O
were	O
cultured	O
as	O
model	B-T050
cells	B-T025
.	O
The	O
initial	O
responses	O
of	O
C2C12 cells	B-T025
to	O
the	O
3D	B-T082
PCL	B-T109
/	O
PANi	B-T109
composite	B-T122
macrostructures	B-T082
were	O
significantly	O
superior	O
to	O
those	O
to	O
pure	O
PCL	B-T109
,	O
that	O
is,	O
the	O
cells	B-T025
exhibited	O
typical	O
myoblast-like morphologies	B-T080
with	O
obvious	O
pseudopodia	B-T026
and	O
the	O
moderate	O
incorporation	O
(less	O
than	O
2.0	O
wt%)	O
of	O
conductive	O
PANi	B-T109
facilitated	O
cell proliferation	B-T043
,	O
which	O
indicated	O
that	O
PANi	B-T109
has	O
appreciable	O
cell affinity	B-T038
.	O
Moreover,	O
the	O
addition	O
of	O
conductive	B-T080
PANi	B-T109
to	O
the	O
3D	B-T082
composite	B-T122
nanofibre	B-T073
macrostructures	B-T082
considerably	O
enhanced	O
myoblast differentiation	B-T043
and	O
myotube maturation	B-T043
.	O
These	O
results	O
suggest	O
that	O
electrospun	B-T080
3D	B-T082
PCL	B-T109
/	O
PANi	B-T109
composite	B-T122
nanofibre	B-T073
macrostructures	B-T082
macrostructures	B-T082
would	O
have	O
promising	O
applications	B-T169
in	O
tissue engineering	B-T061
.	O

Mechanisms	B-T169
of	O
replacement	B-T169
of	O
circulating	B-T169
viruses	B-T005
by	O
seasonal	B-T047
and	O
pandemic influenza A viruses	B-T005
Seasonal influenza	B-T047
causes	O
annual	O
epidemics	B-T067
by	O
the	O
accumulation	B-T033
of	O
antigenic changes	B-T044
.	O
Pandemic influenza	B-T047
occurs	O
through	O
a	O
major	O
antigenic change	B-T044
of	O
the	O
influenza A virus	B-T005
,	O
which	O
can	O
originate	B-T079
from	O
other	O
hosts	B-T001
.	O
Although	O
new	O
antigenic variants	B-T044
of	O
the	O
influenza A virus	B-T005
replace	O
formerly	O
circulating	B-T169
seasonal	B-T005
and	O
pandemic viruses	B-T005
,	O
replacement	B-T169
mechanisms	B-T169
remain	O
poorly	O
understood.	O
A	O
stochastic individual-based SEIR (susceptible-exposed-infectious-recovered) model	B-T170
with	O
two	O
viral strains	B-T001
(formerly	O
circulating	B-T169
old strain	B-T001
and	O
newly emerged strain	B-T001
)	O
was	O
developed	O
for	O
simulations	B-T062
to	O
elucidate	O
the	O
replacement	B-T169
mechanisms	B-T169
.	O
Factors	B-T169
and	O
conditions	B-T080
of	O
virus	B-T005
and	O
host	B-T001
populations	O
affecting	O
the	O
replacement	B-T169
were	O
identified.	O
Replacement	O
is	O
more	O
likely	O
to	O
occur	O
in	O
tropical regions	B-T083
than	O
temperate regions	B-T083
.	O
The	O
magnitude	B-T081
of	O
the	O
ongoing	O
epidemic	B-T067
by	O
the	O
old strain	B-T001
,	O
herd immunity	B-T039
against	O
the	O
old strain	B-T001
,	O
and	O
timing	B-T079
of	O
appearance	B-T080
of	O
the	O
new strain	B-T001
are	O
not	O
that	O
important	O
for	O
replacement	B-T169
.	O
It	O
is	O
probable	O
that	O
the	O
frequency	O
of	O
replacement	B-T169
by	O
a	O
pandemic virus	B-T005
is	O
higher	O
than	O
a	O
seasonal virus	B-T005
because	O
of	O
the	O
high	O
initial	O
susceptibility	B-T169
and	O
high	O
basic	O
reproductive	B-T040
number	O
of	O
the	O
pandemic virus	B-T005
.	O
The	O
findings	O
of	O
this	O
study	O
on	O
replacement	B-T169
mechanisms	B-T169
could	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
virus transmission	B-T043
dynamics	B-T070
and	O
may	O
possibly	O
be	O
helpful	O
in	O
establishing	O
an	O
effective	B-T080
strategy	O
to	O
mitigate	B-T067
the	O
impact	O
of	O
seasonal	B-T047
and	O
pandemic influenza	B-T047
.	O

Request	B-T052
and	O
fulfillment	B-T169
of	O
postpartum	B-T079
tubal ligation	B-T061
in	O
patients	B-T101
after	O
high-risk pregnancy	B-T046
Female sterilization	B-T061
is	O
one	O
of	O
the	O
most	O
prevalent	O
methods	B-T170
of	O
contraception	B-T061
in	O
the	O
United States	B-T083
.	O
Prior	O
studies	B-T062
have	O
shown	O
that	O
nearly	O
half	O
of	O
postpartum	B-T079
tubal ligation	B-T061
(	O
PPTL	B-T061
)	O
requests	B-T052
go	O
unfulfilled	B-T169
.	O
This	O
study	B-T062
seeks	O
to	O
establish	O
whether	O
obstetric	B-T169
or	O
medical risk	B-T078
status	B-T080
influences	O
patients	B-T101
'	O
request	B-T052
for	O
or	O
subsequent	O
completion	B-T080
of	O
PPTL	B-T061
.	O
This	O
study	B-T062
was	O
a	O
retrospective cohort study	B-T062
of	O
women	B-T098
delivering	B-T040
at	O
a	O
university hospital	B-T073
in	O
2009-2010	O
who	O
received	O
prenatal care	B-T058
in	O
the	O
faculty	B-T097
and	O
resident clinics	B-T073
.	O
High-risk	B-T033
status	B-T080
was	O
defined	O
by	O
Society for Maternal-Fetal Medicine guidelines	B-T170
.	O
Documentation	B-T170
of	O
contraceptive plan	B-T170
and	O
administration	B-T061
of	O
contraceptive methods	B-T061
was	O
abstracted	B-T079
from	O
patient records	B-T170
.	O
Subsequent	O
pregnancies	B-T040
through	O
March	O
1,	O
2013,	O
were	O
abstracted	B-T079
.	O
Of	O
3063	O
participants	B-T098
(2048	O
low risk	B-T081
and	O
1015	O
high risk	B-T033
),	O
231	O
requested	B-T052
PPTL	B-T061
(7.5%).	O
This	O
was	O
more	O
likely	O
among	O
high-risk	B-T033
patients	B-T101
than	O
low-risk	B-T081
patients	B-T101
(10.0%	O
vs.	O
6.3%,	O
p<.001),	O
those	O
with	O
public insurance	B-T078
(13.8%	O
vs.	O
3.2%,	O
p<.001)	O
and	O
those	O
with	O
an	O
unintended index pregnancy	B-T033
(13.8%	O
vs.	O
4.1%,	O
p<.001).	O
Of	O
the	O
patients	B-T101
requesting	B-T052
PPTL	B-T061
,	O
118	O
(51.1%)	O
underwent	O
the	O
procedure	B-T061
immediately	O
postpartum	B-T079
.	O
Completion	B-T080
was	O
not	O
associated	O
with	O
high-risk	B-T033
status	B-T080
(54.0%),	O
or	O
with	O
race	B-T098
,	O
insurance status	B-T078
or	O
parity	B-T033
.	O
Among	O
113	O
women	B-T098
with	O
an	O
unfulfilled	B-T169
PPTL	B-T061
request	B-T052
,	O
there	O
were	O
17	O
subsequent	O
pregnancies	B-T040
(15.0%)	O
during	O
the	O
27	O
months	B-T079
of	O
follow-up	B-T058
.	O
Though	O
women	B-T098
with	O
high-risk pregnancies	B-T046
were	O
more	O
likely	O
to	O
request	B-T052
PPTL	B-T061
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-T080
the	O
procedure	B-T061
.	O
Over	O
one	O
third	O
of	O
high-risk	B-T033
patients	B-T101
'	O
requests	B-T052
were	O
unfulfilled	B-T169
,	O
indicating	O
that	O
significant	O
barriers	O
may	O
remain.	O
Though	O
women	B-T098
with	O
high-risk pregnancies	B-T046
were	O
more	O
likely	O
to	O
request	B-T052
PPTL	B-T061
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-T080
the	O
procedure	B-T061
.	O
Providers	O
should	O
consider	O
these	O
procedures	B-T061
urgent	B-T079
,	O
especially	O
in	O
high-risk	B-T033
women	B-T098
,	O
and	O
advocate	O
for	O
their	O
patients	B-T101
'	O
access	O
to	O
this	O
procedure	B-T061
.	O

Gut microbiota	B-T001
after	O
Roux-en-Y gastric bypass	B-T061
and	O
sleeve gastrectomy	B-T061
in	O
a	O
diabetic	B-T047
rat	B-T015
model	B-T050
:	O
Increased	O
diversity	B-T080
and	O
associations	O
of	O
discriminant	B-T080
genera	B-T185
with	O
metabolic	B-T040
changes	B-T169
Recent	O
work	O
with	O
gut microbiota	B-T001
after	O
bariatric surgery	B-T061
is	O
limited,	O
and	O
the	O
results	O
have	O
not	O
been	O
in	O
agreement.	O
Given	O
the	O
role	O
of	O
the	O
gut microbiota	B-T001
in	O
regulating	O
host	B-T001
metabolism	B-T040
,	O
we	O
explored	O
the	O
effect	O
of	O
Roux-en-Y gastric bypass	B-T061
(	O
RYGB	B-T061
)	O
and	O
sleeve gastrectomy	B-T061
(	O
SG	B-T061
)	O
on	O
the	O
modifications	O
of	O
gut microbiota	B-T001
with	O
regard	O
to	O
the	O
potential	O
influence	O
of	O
food	B-T168
intake	B-T169
and/or	O
weight	B-T032
loss	B-T081
loss	B-T081
and	O
examined	O
their	O
links	O
with	O
host	B-T001
metabolism	B-T040
.	O
Zucker	O
diabetic	B-T047
fatty rats	B-T015
were	O
divided	O
into	O
the	O
following	O
groups	B-T078
:	O
RYGB	B-T061
;	O
sham-operated	B-T061
with	O
pair-fed	O
as	O
RYGB	B-T061
;	O
sham-operated	B-T061
fed	O
ad	O
libitum;	O
and	O
SG	B-T061
.	O
The	O
metabolic effects	B-T039
and	O
gut microbiota	B-T001
profile	B-T169
were	O
analyzed	B-T062
10	O
weeks	B-T079
postoperatively.	O
Associations	O
between	O
discriminating	B-T080
genera	B-T185
and	O
metabolic markers	B-T123
after	O
RYGB	B-T061
were	O
explored.	O
The	O
2	O
procedures	B-T061
induced	O
similar	O
glucose	B-T109
improvement	B-T077
and	O
increased	O
flora	B-T001
diversity	B-T080
after	O
10	O
weeks	B-T079
compared	B-T052
with	O
sham-operated	B-T061
groups.	O
RYGB	B-T061
induced	O
a	O
marked	O
higher	O
relative	O
abundance	O
of	O
Proteobacteria	B-T007
/	O
Gammaproteobacteria	B-T007
and	O
Betaproteobacteria	B-T007
and	O
increased	O
emergence	O
of	O
Fusobacteria	B-T007
and	O
Clostridium	B-T007
,	O
whereas	O
SG	B-T061
resulted	O
in	O
more	O
abundant	O
Actinobacteria	B-T007
compared	B-T052
with	O
other	O
groups.	O
Most	O
of	O
the	O
12	O
discriminant	B-T080
genera	B-T185
correlated	B-T080
with	O
changes	B-T169
in	O
metabolic	B-T040
phenotype	B-T032
,	O
but	O
only	O
28.6%	O
of	O
these	O
correlations	B-T080
were	O
independent	O
of	O
weight	B-T032
,	O
and	O
4	O
discriminant	B-T080
genera	B-T185
still	O
negatively	O
correlated	B-T080
with	O
serum insulin level	B-T034
independent	O
of	O
food	B-T168
intake	B-T169
and	O
weight	B-T032
loss	B-T081
after	O
RYGB	B-T061
.	O
These	O
data	B-T078
demonstrate	O
that	O
RYGB	B-T061
and	O
SG	B-T061
surgery	B-T169
produced	O
similar	O
diversity	B-T080
but	O
different	O
microbiota	B-T001
compositions	O
changes	O
in	O
Zucker	O
diabetic	B-T047
fatty rats	B-T015
.	O
These	O
findings	O
stimulate	O
deeper	O
explorations	O
of	O
functions	B-T040
of	O
the	O
discriminate	B-T080
microbiota	B-T001
and	O
the	O
mechanisms	B-T169
linking	O
postsurgical	B-T079
modulation	B-T082
of	O
gut microbiota	B-T001
and	O
improvements	B-T077
in	O
insulin resistance	B-T046
.	O

Ocular toxicity	B-T037
of	O
AUY922	B-T109
in	O
pigmented	B-T015
and	O
albino rats	B-T015
AUY922	B-T109
,	O
a	O
heat shock protein 90	B-T116
inhibitor	B-T080
is	O
associated	O
with	O
ocular	B-T023
adverse events	B-T046
(	O
AEs	B-T046
).	O
To	O
provide	O
a	O
better	O
understanding	O
of	O
ocular	B-T023
AEs	B-T046
in	O
patients	B-T101
,	O
4	O
investigative studies	B-T062
were	O
performed	O
in	O
a	O
step-wise approach	B-T082
to	O
assess	O
retinal structure	B-T023
and	O
function	O
in	O
pigmented	B-T015
(	O
Brown Norway	B-T015
)	O
and	O
albino (Wistar) rats	B-T015
Wistar	B-T015
)	O
rats.	O
In	O
rats	B-T015
administered	B-T169
30mg/kg	O
of	O
AUY922	B-T109
,	O
the	O
AUC	B-T081
0-24	O
h	B-T079
and	O
Cmax	B-T081
are	O
comparable	O
to	O
that	O
in	O
patients	B-T101
at	O
70mg/m(2).	O
AUY922	B-T109
at	O
≥30mg/kg	O
was	O
poorly	O
tolerated	O
by	O
rats	B-T015
with	O
morbidity	B-T081
or	O
mortality	B-T081
generally	O
after	O
the	O
third	O
weekly	B-T079
treatment	B-T061
.	O
Electroretinography	B-T060
(	O
ERG	B-T060
)	O
changes	B-T169
were	O
observed	O
at	O
doses	B-T081
≥30mg/kg.	O
The	O
ERG	B-T060
changes	B-T169
were	O
dose dependent	B-T081
,	O
consistent	B-T078
with	O
an	O
effect	O
on	O
the	O
photoreceptors	B-T025
,	O
and	O
fully	O
reversible	B-T169
.	O
The	O
ERG	B-T060
effects	O
could	O
not	O
be	O
minimized	O
by	O
decreasing	O
the	O
Cmax	B-T081
while	O
maintaining	O
AUC	B-T081
.	O
Histopathological	B-T169
changes	B-T169
were	O
seen	O
mainly	O
when	O
rats	B-T015
were	O
administered	B-T169
AUY922	B-T109
at	O
100mg/kg.	O
The	O
2-	O
hour	B-T079
infusion	B-T061
of	O
AUY922	B-T109
at	O
100mg/kg	O
caused	O
disorganization	B-T033
of	O
the	O
outer segment photoreceptor	B-T026
morphology	B-T080
in	O
male	B-T032
Brown Norway rats	B-T015
;	O
the	O
severity	O
of	O
the	O
disorganization	B-T033
increased	O
with	O
the	O
number	O
of	O
administrations	B-T061
,	O
but	O
was	O
reversible	B-T169
during	O
a	O
4-	O
week	B-T079
posttreatment period	B-T079
.	O
There	O
was	O
no	O
major	O
difference	O
in	O
ocular	B-T023
response	B-T032
between	O
Brown Norway	B-T015
and	O
Wistar rats	B-T015
.	O
No	O
changes	O
in	O
serum iron levels	B-T034
,	O
and	O
no	O
changes	O
in	O
rhodopsin	B-T116
,	O
PDE6α	B-T116
,	O
β-transducin	B-T116
concentrations	B-T081
,	O
or	O
retinal pigment epithelium-specific protein RPE65	B-T116
expression	B-T045
were	O
observed	O
after	O
single	O
and	O
multiple	O
infusions	B-T061
of	O
AUY922	B-T109
at	O
100mg/kg	O
compared	O
to	O
vehicle-treated controls	B-T096
.	O
AUY922	B-T109
retinal toxicity	B-T190
in	O
rats	B-T015
recapitulates	O
and	O
further	O
characterizes	O
that	O
reported	O
in	O
patients	B-T101
and	O
is	O
shown	O
to	O
be	O
reversible	B-T169
,	O
while	O
a	O
precise	O
molecular mechanism	B-T044
for	O
the	O
effect	O
was	O
not	O
determined.	O

Assessment	B-T058
of	O
cerebral	B-T023
blood perfusion	B-T042
reserve	O
with	O
acetazolamide	B-T109
using	O
3D spiral ASL MRI	B-T060
:	O
Preliminary	O
experience	O
in	O
pediatric	B-T080
patients	B-T101
To	O
demonstrate	O
the	O
clinical feasibility	B-T062
of	O
a	O
new	O
non-Cartesian cylindrically-distributed spiral 3D pseudo-continuous arterial spin labeling (pCASL) magnetic resonance imaging (MRI)	B-T060
pulse sequence	B-T082
in	O
pediatric	B-T080
patients	B-T101
in	O
quantifying	B-T081
cerebral blood flow	B-T033
(	O
CBF	B-T033
)	O
response	O
to	O
an	O
acetazolamide (ACZ) vasodilator	B-T121
challenge.	O
MRI exams	B-T060
were	O
performed	O
on	O
two	O
3 Tesla Philips Ingenia systems using 32 channel head coil arrays	B-T073
.	O
After	O
local	O
institutional review board approval	B-T170
,	O
the	O
3D spiral-based pCASL technique	B-T060
was	O
added	O
to	O
a	O
standard	O
brain MRI exam	B-T060
and	O
evaluated	O
in	O
13	O
pediatric	B-T080
patients	B-T101
(average	O
age:	O
11.7±6.4years,	O
range:	O
1.4-22.2years).	O
All	O
patients	B-T101
were	O
administered	B-T058
ACZ	B-T109
for	O
clinically indicated	B-T033
reasons.	O
Quantitative	O
whole-brain CBF measurements	B-T060
were	O
computed	O
pre	B-T079
-	O
and	O
post	B-T079
-	O
ACZ	B-T109
to	O
assess	O
cerebrovascular reserve	B-T042
.	O
3D spiral pCASL	B-T060
data	B-T078
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	B-T062
.	O
In	O
11	O
patients	B-T101
,	O
CBF	B-T033
increased	O
2.8%	O
to	O
93.2%	O
after	O
administration of	B-T058
ACZ	B-T109
.	O
In	O
the	O
two	O
remaining	O
patients	B-T101
,	O
CBF	B-T033
decreased	O
by	O
2.4	O
to	O
6.0%	O
after	O
ACZ	B-T109
.	O
The	O
group	O
average	O
change	O
in	O
CBF	B-T033
due	O
to	O
ACZ	B-T109
was	O
approximately	O
25.0%	O
and	O
individual	O
changes	O
were	O
statistically significant	B-T081
(p<0.01)	O
in	O
all	O
patients	B-T101
using	O
a	O
paired	O
t-test analysis	B-T170
.	O
CBF	B-T033
perfusion	B-T042
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR angiography	B-T060
and	O
clinical findings	B-T170
.	O
3D cylindrically-distributed spiral pCASL MRI	B-T060
provides	O
a	O
robust	O
approach	O
to	O
assess	B-T058
cerebral blood flow	B-T033
and	O
reserve	O
in	O
pediatric	B-T080
patients	B-T101
.	O

Assessing	B-T058
the	O
learning	B-T041
potential	B-T080
of	O
an	O
interactive	B-T065
digital game	B-T073
versus	O
an	O
interactive-style	B-T065
didactic	B-T080
lecture	B-T170
:	O
the	O
continued	O
importance	O
of	O
didactic	B-T080
teaching	B-T065
in	O
medical student	B-T097
education	B-T065
Games	B-T056
with	O
educational	B-T065
intent	O
offer	O
a	O
possible	B-T033
advantage	O
of	O
being	O
more	O
interactive	B-T065
and	O
increasing	B-T081
learner	B-T098
satisfaction	B-T041
.	O
We	O
conducted	O
a	O
two-armed experiment	B-T062
to	O
evaluate	B-T058
student	B-T098
satisfaction	B-T041
and	O
content	B-T077
mastery	B-T041
for	O
an	O
introductory	O
pediatric radiology	B-T091
topic	B-T170
,	O
taught	B-T080
by	O
either	O
an	O
interactive	B-T065
digital game	B-T073
or	O
with	O
a	O
traditional	B-T169
didactic	B-T080
lecture	B-T170
.	O
Medical students	B-T097
participating	B-T169
in	O
a	O
fourth-year	O
radiology	B-T091
elective	B-T079
were	O
invited	O
to	O
participate	B-T169
.	O
Student	B-T098
cohorts	B-T098
were	O
alternatively	B-T077
given	O
a	O
faculty	B-T097
-	O
supervised	B-T065
1h	O
session	B-T077
playing	B-T056
a	O
simple	O
interactive	B-T065
digital	B-T080
Tic-tac-toe	B-T056
quiz module	B-T077
on	O
pediatric gastrointestinal radiology	B-T060
or	O
a	O
1h	O
didactic	B-T080
introductory	O
lecture	B-T170
on	O
the	O
same	O
topic	B-T170
.	O
Survey	B-T170
questions	B-T170
assessed	B-T052
the	O
learners'	B-T098
perceived	B-T041
ability to recall	B-T201
the	O
material	B-T167
as	O
well	O
as	O
their	O
satisfaction	B-T041
with	O
the	O
educational	B-T065
experience	B-T041
.	O
Results	O
of	O
an	O
end-of-rotation	B-T079
exam	B-T169
were	O
reviewed	B-T080
to	O
evaluate	B-T058
a	O
quantitative measure	B-T081
of	O
learning	B-T041
between	O
groups	B-T078
.	O
Survey	B-T170
responses	B-T041
were	O
analyzed	B-T062
with	O
a	O
chi-squared test	B-T170
.	O
Exam	B-T169
results	O
for	O
both	O
groups	B-T078
were	O
analyzed	B-T062
with	O
a	O
paired	O
Student's t-test	B-T081
.	O
Students	B-T098
in	O
the	O
lecture	B-T170
group	B-T078
had	O
higher	B-T080
test scores	B-T080
compared	B-T052
to	O
students	B-T098
in	O
the	O
game	B-T056
group	B-T078
(4.0/5	O
versus	O
3.6/5,	O
P	O
=	O
0.045).	O
Students	B-T098
in	O
the	O
lecture	B-T170
group	B-T078
reported	B-T058
greater	B-T081
understanding	B-T041
and	O
recall	B-T041
of	O
the	O
material	B-T167
than	O
students	B-T098
in	O
the	O
game	B-T056
group	B-T078
(P	O
<	O
0.001	O
and	O
P	O
=	O
0.004,	O
respectively).	O
Students	B-T098
in	O
the	O
lecture	B-T170
group	B-T078
perceived	B-T041
the	O
lecture	B-T170
to	O
be	O
more	O
enjoyable	B-T033
and	O
a	O
better	O
use	O
of	O
their	O
time	B-T079
compared	B-T052
to	O
those	O
in	O
the	O
game	B-T056
group	B-T078
(P	O
=	O
0.04	O
and	O
P	O
<	O
0.001,	O
respectively).	O
There	O
was	O
no	O
statistically significant	B-T081
difference	B-T033
between	O
the	O
lecture	B-T170
and	O
game	B-T056
group	B-T078
in	O
ability	B-T032
to	O
maintain	O
interest	B-T054
(P	O
=	O
0.187).	O
In	O
comparison	O
to	O
pre-survey	B-T079
results,	O
there	O
was	O
a	O
statistically significant	B-T081
decrease	B-T081
in	O
interest	B-T054
for	O
further	O
digital	B-T080
interactive	B-T065
materials	B-T167
reported	B-T058
by	O
students	B-T098
in	O
the	O
game	B-T056
group	B-T078
(P	O
=	O
0.146).	O
Our	O
experience	B-T041
supported	O
the	O
use	O
of	O
a	O
traditional	B-T169
lecture	B-T170
over	O
a	O
digital game	B-T073
module.	O
While	O
these	O
results	O
might	O
be	O
affected	B-T169
by	O
the	O
specific	B-T080
lecture	B-T170
and	O
digital	B-T080
content	B-T077
in	O
any	O
given	O
comparison	B-T052
,	O
a	O
digital	B-T080
module	B-T077
is	O
not	O
always	O
the	O
superior	O
option.	O

Predictors	B-T078
of	O
30-	O
day	B-T079
mortality	B-T081
in	O
patients	B-T101
with	O
spontaneous	B-T169
primary	B-T080
intracerebral hemorrhage	B-T033
Intracerebral hemorrhage	B-T033
(	O
ICH	B-T033
)	O
is	O
a	O
life threatening	B-T033
entity,	O
and	O
an	O
early outcome assessment	B-T058
is	O
mandatory	O
for	O
optimizing	O
therapeutic efforts	B-T061
.	O
We	O
retrospectively	B-T080
analyzed	B-T062
data	B-T078
from	O
342	O
patients	B-T101
with	O
spontaneous	B-T169
primary	B-T080
ICH	B-T033
to	O
evaluate	O
possible	O
predictors	B-T078
of	O
30-	O
day	B-T079
mortality	B-T081
considering	O
clinical	B-T080
,	O
radiological	B-T169
,	O
and	O
therapeutical	B-T169
parameters	B-T077
.	O
We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome grading scoring systems	B-T170
[(	O
ICH score	B-T081
,	O
FUNC score	B-T081
and	O
intracerebral hemorrhage grading scale	B-T170
(	O
ICH-GS	B-T170
)]	O
on	O
our	O
population	B-T098
to	O
evaluate	O
the	O
correlation	B-T080
of	O
these	O
scores	B-T081
with	O
the	O
30-	O
day	B-T079
mortality	B-T081
in	O
our	O
study	B-T062
.	O
We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome grading scoring systems	B-T170
[(	O
ICH score	B-T081
,	O
FUNC score	B-T081
and	O
intracerebral hemorrhage grading scale	B-T170
(	O
ICH-GS	B-T170
)]	O
on	O
our	O
population	B-T098
to	O
evaluate	O
the	O
correlation	B-T080
of	O
these	O
scores	B-T081
with	O
the	O
30-	O
day	B-T079
mortality	B-T081
in	O
our	O
study	B-T062
.	O
From	O
342	O
patients	B-T101
(mean	O
age	B-T032
:	O
67	O
years	B-T079
,	O
mean	O
Glasgow Coma Scale	B-T170
[	O
GCS	B-T170
]	O
on	O
admission	B-T058
:	O
9,	O
mean	O
ICH	B-T033
volume	B-T081
:	O
62.19	O
ml,	O
most	O
common	O
hematoma	B-T046
location	B-T029
:	O
basal ganglia	B-T023
[43.9%]),	O
102	O
received	O
surgical	B-T061
and	O
240	O
conservative treatment	B-T061
.	O
The	O
30-	O
day	B-T079
mortality	B-T081
was	O
25.15%.	O
In	O
a	O
multivariate analysis	B-T081
,	O
GCS	B-T170
(	O
Odds ratio	B-T081
[	O
OR	B-T081
]	O
=0.726,	O
95%	O
confidence interval	B-T081
[	O
CI	B-T081
]	O
=0.661-0.796,	O
P	O
<	O
0.001),	O
bleeding	B-T046
volume	B-T081
(	O
OR	B-T081
=	O
1.012	O
per	O
ml,	O
95%	O
CI	B-T081
=	O
1.007	O
-	O
1.017,	O
P	O
<	O
0.001),	O
and	O
infratentorial	B-T082
hematoma	B-T046
location	B-T029
(	O
OR	B-T081
=	O
5.381,	O
95%	O
CI	B-T081
=	O
2.166-13.356,	O
P	O
=	O
0.009)	O
were	O
significant	O
predictors	B-T078
for	O
the	O
30-	O
day	B-T079
mortality	B-T081
.	O
After	O
receiver operating characteristics	B-T081
analysis	B-T062
,	O
we	O
defined	O
a	O
"	O
high-risk group	B-T098
"	O
for	O
an	O
unfavorable	O
short-term	B-T079
outcome	B-T169
with	O
GCS	B-T170
<11	O
and	O
ICH	B-T033
volume	B-T081
>32	O
ml	O
supratentorially	B-T082
or	O
21	O
ml	O
infratentorially	B-T082
.	O
Using	O
Pearson correlation	B-T170
,	O
we	O
found	O
a	O
correlation	B-T080
of	O
0.986	O
between	O
ICH score	B-T081
and	O
30-	O
day	B-T079
mortality	B-T081
(P	O
<	O
0.001),	O
0.853	O
between	O
FUNC score	B-T081
and	O
30-	O
day	B-T079
mortality	B-T081
(P	O
=	O
0.001),	O
and	O
0.924	O
between	O
ICH-GS	B-T170
and	O
30-	O
day	B-T079
mortality	B-T081
(P	O
=	O
0.001).	O
GCS	B-T170
score	B-T081
on	O
admission	B-T058
together	O
with	O
the	O
baseline	B-T081
volume	B-T081
and	O
localization	B-T169
of	O
the	O
hemorrhage	B-T046
are	O
strong	O
predictors	B-T078
for	O
30-	O
day	B-T079
mortality	B-T081
in	O
patients	B-T101
with	O
spontaneous	B-T169
primary	B-T080
intracerebral hemorrhage	B-T033
,	O
and	O
by	O
relying	O
on	O
them	O
it	O
is	O
possible	O
to	O
identify	O
high-risk	B-T033
patients	B-T101
with	O
poor	O
short-term	B-T079
outcome	B-T169
.	O
The	O
ICH score	B-T081
and	O
the	O
ICH-GS	B-T170
accurately	B-T080
predict	B-T078
the	O
30-	O
day	B-T079
mortality	B-T081
.	O

Gga-miR-21	B-T114
inhibits	B-T080
chicken	B-T012
pre-adipocyte	B-T025
proliferation	B-T043
in	O
part	O
by	O
down-regulating	B-T044
Kruppel-like factor 5	B-T028
Gga-miR-21	B-T114
is	O
abundantly	O
expressed	B-T045
in	O
chicken	B-T012
pre-adipocytes	B-T025
,	O
but	O
its	O
role	O
is	O
unclear.	O
The	O
present	O
study	O
investigated	B-T169
the	O
role	O
of	O
gga-miR-21	B-T114
in	O
chicken	B-T012
pre-adipocyte	B-T025
proliferation	B-T043
.	O
Cell proliferation assay	B-T062
and	O
gene expression analysis	B-T063
of	O
proliferating cell nuclear antigen	B-T028
(	O
PCNA	B-T028
)	O
showed	O
that	O
the	O
gga-miR-21	B-T114
mimic	B-T052
inhibited	B-T080
pre-adipocyte	B-T025
proliferation	B-T043
.	O
In	O
contrast,	O
the	O
gga-miR-21	B-T114
inhibitor	B-T080
enhanced	B-T052
pre-adipocyte	B-T025
proliferation	B-T043
.	O
The	O
subsequent	O
investigation	B-T169
identified	O
Kruppel-like factor 5	B-T028
(	O
KLF5	B-T028
)	O
mRNA	B-T114
as	O
a	O
target	B-T169
of	O
gga-miR-21	B-T114
.	O
The	O
gga-miR-21	B-T114
mimic	B-T052
inhibited	B-T080
KLF5	B-T028
3(')UTR	B-T086
reporter	B-T028
activity	B-T052
and	O
decreased	B-T081
endogenous	B-T169
KLF5	B-T028
expression	B-T045
in	O
primary	B-T080
pre-adipocytes	B-T025
.	O
KLF5	B-T028
knockdown	B-T063
using	O
RNAi	B-T045
had	O
a	O
similar	O
effect	B-T080
to	O
that	O
of	O
the	O
gga-miR-21	B-T114
mimic	B-T052
on	O
cell proliferation	B-T043
.	O
The	O
promoting	B-T052
effect	B-T080
of	O
the	O
gga-miR-21	B-T114
inhibitor	B-T080
on	O
pre-adipocyte	B-T025
proliferation	B-T043
was	O
partially	O
attenuated	B-T080
by	O
KLF5	B-T028
knockdown	B-T063
.	O
Taken	O
together,	O
our	O
results	O
demonstrated	O
that	O
miR-21	B-T114
inhibits	O
chicken	B-T012
pre-adipocyte	B-T025
proliferation	B-T043
,	O
at	O
least	O
in	O
part,	O
by	O
targeting	B-T063
KLF5	B-T028
.	O

The	O
application	B-T169
of	O
heterogeneous cluster grouping	B-T081
to	O
reflective writing	B-T090
for	O
medical humanities	B-T090
literature study	B-T062
to	O
enhance	B-T052
students'	B-T098
empathy	B-T055
,	O
critical thinking	B-T041
,	O
and	O
reflective writing	B-T090
To	O
facilitate	O
interdisciplinary collaboration	B-T058
and	O
to	O
make	O
connections	B-T082
between	O
patients'	B-T101
diseases	B-T047
and	O
their	O
social	B-T169
/	O
cultural contexts	B-T169
,	O
the	O
study	B-T062
examined	B-T033
whether	O
the	O
use	O
of	O
heterogeneous cluster grouping	B-T081
in	O
reflective writing	B-T090
for	O
medical humanities	B-T090
literature	O
acquisition	B-T052
could	O
have	O
positive effects	B-T080
on	O
medical university	B-T073
students	B-T098
in	O
terms	O
of	O
empathy	B-T055
,	O
critical thinking	B-T041
,	O
and	O
reflective writing	B-T090
.	O
A	O
15-week	B-T079
quasi-experimental design	B-UnknownType
was	O
conducted	O
to	O
investigate	B-T169
the	O
learning outcomes	B-T169
.	O
After	O
conducting	O
cluster algorithms	B-T170
,	O
heterogeneous learning clusters	B-T081
(	O
experimental group	B-UnknownType
;	O
n	O
=	O
43)	O
and	O
non-heterogeneous learning clusters	B-T081
(	O
control group	B-T096
;	O
n	O
=	O
43)	O
were	O
derived	O
for	O
a	O
medical humanities	B-T090
literature study	B-T062
.	O
Before	O
and	O
after	O
the	O
intervention	B-T061
,	O
an	O
Empathy Scale	B-T170
in	O
Patient Care	B-T058
(	O
ES	B-T170
-	O
PC	B-T058
),	O
a	O
critical thinking disposition assessment	B-T058
(	O
CTDA-R	B-T058
),	O
and	O
a	O
reflective writing test	B-T058
were	O
administered	B-T169
to	O
both	O
groups	B-T078
.	O
The	O
findings	O
showed	O
that	O
on	O
the	O
empathy scale	B-T170
,	O
significant	O
differences	O
in	O
the	O
"	O
behavioral empathy	B-T055
,"	O
"	O
affective empathy	B-T055
,"	O
and	O
overall	O
sections	O
existed	O
between	O
the	O
post-test mean scores	B-T033
of	O
the	O
experimental group	B-UnknownType
and	O
those	O
of	O
the	O
control group	B-T096
,	O
but	O
such	O
differences	O
did	O
not	O
exist	O
in	O
"	O
intelligent empathy	B-T055
."	O
Regarding	O
critical thinking	B-T041
,	O
there	O
were	O
significant	O
differences	O
in	O
"	O
systematicity	B-T169
and	O
analyticity	B-T062
,"	O
"	O
skepticism	B-T041
and	O
well-informed	B-T058
,"	O
"	O
maturity	B-T080
and	O
skepticism	B-T041
,"	O
and	O
overall	O
sections.	O
As	O
for	O
reflective writing	B-T090
,	O
significant	O
differences	O
existed	O
in	O
"	O
ideas	B-T078
,"	O
"	O
voice	B-T040
and	O
point of view	B-T078
,"	O
"	O
critical thinking	B-T041
and	O
representation	B-T052
,"	O
"	O
depth of reflection	B-T041
on	O
personal growth	B-T055
,"	O
and	O
overall	O
sections,	O
but	O
not	O
in	O
"	O
focus	B-T169
and	O
context structure	B-T078
"	O
and	O
"	O
language	B-T171
and	O
conventions	B-T068
."	O
This	O
study	B-T062
outlined	O
an	O
alternative	O
for	O
using	O
heterogeneous cluster grouping	B-T081
in	O
reflective writing	B-T090
about	O
medical humanities	B-T090
literature	O
to	O
facilitate	O
interdisciplinary cooperation	B-T054
to	O
provide	O
more	O
humanizing	O
medical care	B-T033
.	O

The	O
Usefulness	O
of	O
Employing	B-T033
an	O
Electronic Traction Table	B-T074
to	O
Determine	O
Flexibility	B-T080
in	O
Adolescent Idiopathic Scoliosis	B-T190
The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
develop	B-T169
new	O
equipment	B-T073
for	O
the	O
assessment	B-T058
of	O
the	O
flexibility	B-T080
of	O
the	O
spine	B-T023
with	O
different	O
forces	B-T067
.	O
This	O
new	O
system	B-T169
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent idiopathic scoliosis	B-T190
(	O
AIS	B-T190
)	O
for	O
the	O
selection	B-T052
of	O
fusion levels	B-T080
and	O
surgical	B-T061
success	B-T080
.	O
Eighteen	O
patients	B-T101
suffering	O
from	O
AIS	B-T190
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	B-T082
instrumented spinal fusion	B-T061
in	O
our	O
clinic	B-T073
were	O
recruited	O
in	O
this	O
study	B-T062
.	O
The	O
Electronic Traction Table	B-T074
(	O
ETT	B-T074
)	O
that	O
was	O
designed	O
in	O
our	O
clinic	B-T073
was	O
used	O
to	O
evaluate	O
the	O
radiogical	B-T077
and	O
clinical	B-T080
parameters	B-T077
of	O
the	O
spine	B-T023
.	O
The	O
significant	O
prescriptive angle	B-T080
of	O
major	O
Cobb angles	B-T033
between	O
postoperative angles	B-T080
were	O
longitudinal	B-T082
traction	B-T061
and	O
lateral pushing Cobb angles	B-T033
.	O
Longitudinal	B-T082
traction	B-T061
and	O
lateral pushing angles	B-T033
were	O
more	O
correlated	O
with	O
correction ratios	B-T081
.	O
There	O
was	O
a	O
significant	B-T078
difference	O
between	O
longitudinal	B-T082
traction	B-T061
minor	O
Cobb angle	B-T033
,	O
longitudinal	B-T082
traction	B-T061
lateral pushing minor Cobb angle	B-T033
and	O
postoperative minor Cobb angles	B-T033
.	O
The	O
deformity	B-T190
is	O
needed	O
to	O
balance	O
both	O
tractional	B-T061
and	O
rotational	B-T169
rotational forces	B-T067
and	O
useful	O
technique	B-T169
to	O
evaluate	O
curve	O
flexibility	B-T080
before	O
the	O
operation	B-T061
.	O
Electronic traction table	B-T074
is	O
a	O
new	O
device	B-T074
for	O
determining	O
preoperative flexibility	B-T080
with	O
longitudinal	B-T082
traction	B-T061
and	O
lateral pushing radiographs	B-T060
.	O
It	O
can	O
be	O
useful	O
for	O
choosing	B-T052
selective	O
fusion levels	B-T080
at	O
the	O
proximal	B-T082
and	O
distal	B-T082
end	O
of	O
the	O
vertebral column	B-T023
.	O

The	O
MEssaging for Diabetes	B-T058
Intervention	B-T061
Reduced	O
Barriers	B-T080
to	O
Medication Adherence	B-T033
Among	O
Low-Income	B-T033
,	O
Diverse	O
Adults	B-T100
With	O
Type 2	B-T047
Nonadherence	B-T033
to	O
diabetes	B-T047
medication	B-T058
is	O
prevalent	O
and	O
costly.	O
MEssaging for Diabetes	B-T058
(	O
MED	B-T058
),	O
a	O
mobile health	B-T058
(	O
mHealth	B-T058
)	O
intervention	B-T061
,	O
identified	O
and	O
addressed	O
user	B-T098
-specific	O
barriers	B-T080
to	O
medication adherence	B-T033
.	O
We	O
assessed	O
whether	O
MED	B-T058
reduced	O
users	B-T098
'	O
targeted	O
barriers	B-T080
and	O
if	O
barrier	B-T080
reductions	O
were	O
associated	O
with	O
within-participant	B-T098
improvements	O
in	O
adherence	B-T169
or	O
glycemic control	B-T080
(	O
HbA1c	B-T116
).	O
Adults	B-T100
(N	O
=	O
80)	O
with	O
type 2 diabetes	B-T047
completed	O
self-report	O
measures	O
identifying	O
barriers	B-T080
to	O
adherence	B-T169
at	O
baseline	O
and	O
monthly	B-T079
for	O
3	O
months	B-T079
.	O
At	O
each	O
assessment	B-T058
,	O
17	O
barriers	B-T080
were	O
assessed	O
and	O
ranked	O
for	O
each	O
user	B-T098
.	O
Each	O
subsequent	O
month	B-T079
,	O
users	B-T098
received	O
daily	O
text messages	B-T170
addressing	O
their	O
3	O
highest	O
ranked	O
barriers	B-T080
.	O
Targeted	O
barriers	B-T080
were	O
different	O
for	O
each	O
participant	B-T098
and	O
could	O
change	O
monthly	B-T079
.	O
Paired	O
t-tests	B-T170
assessed	O
within-participant	B-T098
improvement	O
in	O
targeted	O
barriers	B-T080
each	O
month	B-T079
,	O
and	O
nested	O
regression models	B-T170
assessed	O
if	O
changes	O
in	O
a	O
participant's	B-T098
barrier	O
scores	O
were	O
associated	O
with	O
improvements	O
in	O
adherence	B-T169
and	O
HbA1c	B-T116
.	O
Participants	B-T098
were	O
69%	O
non-white	O
and	O
82%	O
had	O
incomes	O
<$25K.	O
Average	O
HbA1c	B-T116
was	O
8.2	O
±	O
2.0%.	O
Assessment	O
completion	O
rates	O
were	O
100%	O
at	O
baseline,	O
59%	O
at	O
1	O
month	B-T079
,	O
30%	O
at	O
2	O
months	B-T079
,	O
and	O
65%	O
at	O
3	O
months	B-T079
.	O
The	O
most	O
commonly	O
reported	O
barriers	B-T080
were	O
the	O
cost	B-T081
of	O
medications	B-T058
(76%),	O
believing	O
medications	B-T058
are	O
harmful	O
(58%),	O
and	O
lacking	O
information	O
about	O
medications	B-T058
(53%).	O
Participants	B-T098
'	O
barrier	B-T080
scores	O
improved	O
each	O
month	B-T079
and	O
barrier	B-T080
improvement	O
predicted	O
adherence	B-T169
assessed	O
via	O
nightly	O
adherence	B-T169
assessment	O
text messages	B-T170
(P	O
<	O
.001).	O
Among	O
participants	B-T098
who	O
completed	O
assessments	O
each	O
month	B-T079
,	O
barrier	B-T080
improvement	O
in	O
months	B-T079
2	O
and	O
3	O
(P	O
<	O
.05)	O
predicted	O
HbA1c	B-T116
improvement.	O
Iterative,	O
individual	O
tailoring	O
may	O
overcome	O
users	B-T098
'	O
barriers	B-T080
to	O
adherence	B-T169
.	O
Attrition	O
is	O
a	O
challenge	O
for	O
mHealth	B-T058
interventions	B-T061
among	O
low-income	B-T033
patients	B-T101
.	O

Macular	B-T082
Ganglion Cell	B-T025
-	O
Inner Plexiform Layer	B-T023
Thickness	B-T080
Is	O
Associated with	B-T080
Clinical Progression	B-T046
in	O
Mild Cognitive Impairment	B-T047
and	O
Alzheimers Disease	B-T047
We	O
investigated	O
the	O
association	O
of	O
the	O
macular	B-T082
ganglion cell	B-T025
-	O
inner plexiform layer	B-T023
(	O
GCIPL	B-T023
)	O
and	O
peripapillary retinal nerve fiber layer	B-T023
(	O
RNFL	B-T023
)	O
thicknesses	B-T080
with	O
disease progression	B-T046
in	O
mild cognitive impairment	B-T047
(	O
MCI	B-T047
)	O
and	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
).	O
We	O
recruited	O
42	O
patients	B-T101
with	O
AD	B-T047
,	O
26	O
with	O
MCI	B-T047
,	O
and	O
66	O
normal	O
elderly controls	B-T096
.	O
The	O
thicknesses	B-T080
of	O
the	O
RNFL	B-T023
and	O
GCIPL	B-T023
were	O
measured	O
via	O
spectral-domain optic coherent tomography	B-T074
in	O
all	O
participants	B-T098
at	O
baseline	B-T081
.	O
The	O
patients	B-T101
with	O
MCI	B-T047
or	O
AD	B-T047
underwent	O
clinical	B-T080
and	O
neuropsychological tests	B-T060
at	O
baseline	B-T081
and	O
once every year thereafter for 2 years	B-T079
.	O
The	O
Clinical Dementia Rating scale-Sum of Boxes	B-T170
(	O
CDR-SB	B-T170
)	O
score	B-T081
exhibited	O
significant	O
negative	B-T033
relationships	B-T080
with	O
the	O
average GCIPL	B-T023
thickness	B-T080
(β	O
=	O
-0.15,	O
p	O
<	O
0.05)	O
and	O
the	O
GCIPL	B-T023
thickness	B-T080
in	O
the	O
superotemporal	B-T029
,	O
superonasal	B-T029
,	O
and	O
inferonasal sectors	B-T029
.	O
The	O
composite memory score	B-T081
exhibited	O
significant	O
positive	B-T033
associations	B-T080
with	O
the	O
average GCIPL	B-T023
thickness	B-T080
and	O
the	O
GCIPL	B-T023
thickness	B-T080
in	O
the	O
superotemporal	B-T029
,	O
inferonasal	B-T029
,	O
and	O
inferotemporal sectors	B-T029
.	O
The	O
temporal RNFL	B-T023
thickness	B-T080
,	O
the	O
average	O
and	O
minimum	O
GCIPL	B-T023
thicknesses	B-T080
,	O
and	O
the	O
GCIPL	B-T023
thickness	B-T080
in	O
the	O
inferonasal	B-T029
,	O
inferior	B-T029
,	O
and	O
inferotemporal sectors	B-T029
at	O
baseline	B-T081
were	O
significantly	O
reduced	B-T080
in	O
MCI	B-T047
patients	B-T101
who	O
were	O
converted	O
to	O
AD	B-T047
compared	O
to	O
stable	O
MCI	B-T047
patients	B-T101
.	O
The	O
change	O
of	O
CDR-SB	B-T170
from	O
baseline	B-T081
to	O
2	O
years	B-T079
exhibited	O
significant	O
negative	B-T033
associations	B-T080
with	O
the	O
average	O
(β	O
=	O
-0.150,	O
p	O
=	O
0.006)	O
and	O
minimum GCIPL	B-T023
thicknesses	B-T080
as	O
well	O
as	O
GCIPL	B-T023
thickness	B-T080
in	O
the	O
superotemporal	B-T029
,	O
superior	B-T029
,	O
superonasal	B-T029
,	O
and	O
inferonasal sectors	B-T029
at	O
baseline	B-T081
.	O
Our	O
data	O
suggest	O
that	O
macular	O
GCIPL	B-T023
thickness	B-T080
represents	O
a	O
promising	O
biomarker	B-T201
for	O
monitoring	O
the	O
progression	B-T046
of	O
MCI	B-T047
and	O
AD	B-T047
.	O

Green	B-T057
and	O
rapid	B-T080
synthesis	B-T052
of	O
silver	B-T196
nanoparticles	B-T073
using	O
Borago officinalis	B-T002
leaf	B-T002
extract	B-T123
:	O
anticancer	B-T033
and	O
antibacterial activities	B-T033
This	O
study	O
highlights	O
the	O
facile,	O
reliable,	O
cost	B-T081
effective	B-T080
,	O
and	O
ecofriendly	B-T057
synthesis	B-T052
of	O
silver	B-T196
nanoparticles	B-T073
(	O
AgNPs	B-T073
)	O
using	O
Borago officinalis	B-T002
leaves	B-T002
extract	B-T123
efficiently	B-T080
.	O
The	O
biosynthesis	B-T052
of	O
AgNPs	B-T073
was	O
verified	B-T078
by	O
UV-Vis spectrum	B-T070
which	O
showed	O
the	O
surface plasmon resonance	B-T063
(	O
SPR	B-T063
)	O
band	O
at	O
422	O
nm.	O
Transmission electron microscope (TEM) analysis	B-T059
revealed	O
that	O
the	O
particles	B-T073
were	O
spherical	B-T082
,	O
hexagonal	B-T082
,	O
and	O
irregular	B-T080
in	O
shape	B-T082
and	O
had	O
size	B-T081
ranging	B-T081
from	O
30	O
to	O
80	O
nm.	O
The	O
energy dispersive X-ray spectroscopy	B-T059
(	O
EDX	B-T059
)	O
and	O
elemental mapping	B-T059
have	O
displayed	O
the	O
purity	B-T081
and	O
maximum	B-T081
distribution	B-T169
of	O
silver	B-T196
in	O
the	O
AgNPs	B-T196
.	O
The	O
crystalline	B-T104
nature	O
of	O
AgNPs	B-T196
had	O
been	O
identified	B-T080
using	O
X-ray diffraction	B-T059
(	O
XRD	B-T059
)	O
and	O
selected area diffraction pattern	B-T059
(SAED).	O
The	O
particle size	B-T081
analysis	B-T169
revealed	O
that	O
the	O
Z-average	B-T081
diameter	B-T081
of	O
the	O
AgNPs	B-T196
was	O
50.86	O
nm	O
with	O
polydispersity index	B-T077
(	O
PDI	B-T077
)	O
0.136.	O
Zeta potential	B-T067
analysis	B-T169
displayed	O
the	O
colloidal stability	B-T080
of	O
AgNPs	B-T196
.	O
This	O
work	O
also	O
showed	O
the	O
efficacy	B-T080
of	O
AgNPs	B-T073
against	O
lung	B-T023
cancer cell lines	B-T025
(	O
A549	B-T025
)	O
and	O
cervical	B-T023
cancer cell line	B-T025
(	O
HeLa	B-T025
),	O
in vitro	B-T080
.	O
The	O
AgNPs	B-T073
showed	O
cytotoxicity	B-T049
to	O
the	O
A549	B-T025
and	O
HeLa	B-T025
cancer cell line	B-T025
at	O
the	O
concentrations	B-T081
5	O
and	O
2	O
μg/ml.	O
The	O
AgNPs	B-T196
were	O
also	O
explored	O
for	O
the	O
antibacterial activity	B-T033
including	O
biofilm	B-T007
inhibition	B-T052
against	O
pathogenic	B-T033
bacteria	B-T007
.	O
The	O
B. officinalis	B-T002
leaves	B-T002
extract	B-T123
can	O
be	O
used	O
efficiently	B-T080
for	O
green	O
synthesis	B-T052
AgNPs	B-T196
.	O
The	O
biosynthesized	O
AgNPs	B-T196
demonstrated	O
potentials	B-T080
as	O
anticancer	B-T109
and	O
antibacterial agents	B-T195
.	O
This	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	B-T169
of	O
new	O
anticancer	B-T109
and	O
antimicrobial agents	B-T121
.	O

Genotyping	B-T059
of	O
Staphylococcus aureus	B-T007
in	O
bovine mastitis	B-T047
and	O
correlation	O
to	O
phenotypic	B-T032
characteristics	B-T080
Reducing	O
the	O
prevalence	O
of	O
mastitis	B-T047
caused	O
by	O
Staphylococcus aureus	B-T007
(	O
S. aureus	B-T007
)	O
is	O
essential	O
to	O
improve	O
animal	B-T008
health	B-T078
and	O
reduce	O
economic	O
losses	O
for	O
farmers	B-T097
.	O
The	O
clinical	O
outcome	O
of	O
acute mastitis	B-T047
and	O
risk	B-T078
of	O
progression	O
to	O
persistent	B-T079
mastitis	B-T047
can,	O
at	O
least	O
to	O
some	O
extent,	O
be	O
related	O
to	O
genetic variants	B-T028
of	O
the	O
strain	B-T001
causing	O
the	O
infection	B-T046
.	O
In	O
the	O
present	O
study	B-T062
we	O
have	O
used	O
microarrays	B-T073
to	O
investigate	O
the	O
presence	O
of	O
virulence	B-T038
genes	B-T028
in	O
S. aureus	B-T007
isolates	O
from	O
dairy cows	B-T015
with	O
acute clinical mastitis	B-T047
(n=70)	O
and	O
correlated	O
the	O
findings	B-T033
to	O
other	O
genotypic	B-T032
and	O
phenotypic	B-T032
characteristics	B-T080
.	O
Among	O
the	O
most	O
commonly	O
found	O
virulence factors	B-T109
were	O
genes	B-T028
encoding	B-T052
several	O
hemolysin	B-T123
types	B-T080
,	O
leukocidins D	B-T116
and	O
lukM	B-T116
/	O
lukF-P83	B-T116
,	O
clumping factors A	B-T116
and	O
B	B-T116
,	O
fibrinogen binding protein	B-T116
and	O
fibronectin-binding protein A	B-T116
.	O
Some	O
virulence factors	B-T109
e.g.	O
fibronectin-binding protein B	B-T116
and	O
Staphylococcus aureus	B-T007
surface protein G	B-T116
were	O
less	O
common.	O
Genes	B-T028
coding	O
for	O
several	O
staphylococcal enterotoxins	B-T123
and	O
toxic shock syndrome toxin-1	B-T116
(	O
TSST-1	B-T116
)	O
were	O
commonly	O
found,	O
especially	O
in	O
one	O
major	O
pulsotype	B-T001
.	O
No	B-T033
beta-lactamase genes	B-T028
were	O
found	O
in	O
any	O
common	O
pulsotype	B-T001
,	O
while	O
present	O
in	O
some	O
rare	O
pulsotypes	B-T001
,	O
indicated	O
to	O
be	O
of	O
human origin	B-T077
.	O
Production	O
of	O
TSST-1	B-T116
,	O
enterotoxins	B-T116
,	O
hemolysins	B-T123
and	O
beta-lactamase	B-T116
could	O
all	O
be	O
positively	O
correlated	O
to	O
presence	O
of	O
the	O
corresponding	O
genes	B-T028
.	O
This	O
study	B-T062
reveals	O
a	O
number	O
of	O
genotypic	B-T032
differences	B-T080
and	O
similarities	B-T080
among	O
common	O
and	O
rare	O
pulsotypes	B-T001
of	O
S. aureus	B-T007
from	O
cases	O
of	O
mastitis	B-T047
in	O
Sweden	B-T083
.	O
The	O
results	O
could	O
help	O
the	O
design	O
of	O
diagnostic tools	B-T063
to	O
guide	O
on-farm	O
interventions	O
according	O
to	O
the	O
expected	O
impact	O
on	O
udder	B-T023
health	B-T078
from	O
a	O
specific	O
S. aureus	B-T007
genotype	B-T032
.	O

Uveitis	B-T047
in	O
spondyloarthritis	B-T047
patients	B-T101
and	O
its	O
association with	B-T080
HLA-B27 histocompatibility antigen	B-T116
:	O
prospective study	B-T062
T	O
o	O
perform	O
a	O
prospective study	B-T062
of	O
clinical presentation	B-T170
and	O
course	B-T079
of	O
uveitis	B-T047
in	O
spondyloarthritis	B-T047
(	O
SpA	B-T047
)	O
patients	B-T101
as	O
well	O
as	O
its	O
association with	B-T080
the	O
HLA-B27 histocompatibility antigen	B-T116
.	O
The	O
study	B-T062
included	O
219	O
patients	B-T101
with	O
uveitis	B-T047
,	O
all	O
tested	B-T169
for	O
HLA-B27 antigen	B-T116
and	O
various	O
infections	B-T046
(	O
viral	B-T047
,	O
bacterial	B-T047
,	O
and	O
parasitic	B-T047
)	O
as	O
well	O
as	O
examined	B-T033
for	O
locomotive system	B-T022
involvement	B-T169
.	O
The	O
presence	B-T033
of	O
the	O
HLA-B27 antigen	B-T116
was	O
determined	B-T080
in	O
142	O
(64.8%)	O
out	O
of	O
219	O
patients	B-T101
,	O
of	O
them	O
87	O
were	O
diagnosed	B-T033
with	O
an	O
entity	B-T071
of	O
the	O
SpA	B-T047
group	B-T078
.	O
The	O
remaining	B-T080
77	O
(35.2%)	O
patients	B-T101
appeared	O
to	O
be	O
HLA-B27	B-T116
-	O
negative	B-T033
,	O
but	O
13	O
were	O
still	O
diagnosed	B-T033
with	O
an	O
entity	B-T071
of	O
the	O
SpA	B-T047
group	B-T078
.	O
There	O
were	O
10	O
(4.6%)	O
patients	B-T101
with	O
2	O
or	O
more	O
diseases	B-T047
from	O
the	O
SpA	B-T047
group	B-T078
(«clinical	O
decussation»).	O
When	O
comparing	B-T052
the	O
two	O
groups	B-T078
of	O
HLA-B27-positive	B-T034
and	O
negative	B-T033
patients	B-T101
having	O
both	O
SpA	B-T047
and	O
uveitis	B-T047
,	O
no	O
statistically significant	B-T081
difference	B-T080
was	O
found	O
as	O
to	O
the	O
age of onset	B-T081
,	O
site	B-T029
,	O
frequency of attacks	B-T079
,	O
and	O
uni	B-T082
-	O
or	O
bilateral	B-T082
involvement	B-T169
(p>0.05).	O
We	O
also	O
performed	B-T169
a	O
comparison	B-T052
of	O
HLA-B27-positive	B-T034
and	O
negative	B-T033
patients	B-T101
with	O
no	O
account	O
to	O
their	O
SpA	B-T047
status	B-T080
and	O
revealed	B-T080
a	O
higher	B-T080
complication	B-T046
rate	B-T081
in	O
those	O
that	O
were	O
«	O
negative	B-T033
»	O
(p<0.0001),	O
which	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
HLA-B27	B-T116
-	O
negative	B-T033
patients	B-T101
often	O
have	O
autoimmune	B-T047
or	O
infectious uveitis	B-T047
of	O
different	B-T080
origin	O
notable	O
for	O
long	B-T080
attacks	O
and	O
short	B-T081
remissions	B-T033
.	O
Assessing	B-T058
the	O
site	B-T029
and	O
course	B-T079
of	O
uveitis	B-T047
as	O
well	O
as	O
HLA-B27	B-T116
testing	B-T169
of	O
uveitis	B-T047
patients	B-T101
has	O
proved	O
important	B-T080
for	O
etiological	B-T169
diagnosis	B-T033
.	O
Diseases	B-T047
of	O
the	O
SpA	B-T047
group	B-T078
have	O
been	O
shown	O
to	O
be	O
6.7	O
times	B-T081
more	O
common	O
in	O
HLA-B27-positive	B-T034
patients	B-T101
as	O
compared	B-T052
to	O
HLA-B27	B-T116
-	O
negative	B-T033
ones.	O
Clinical presentation	B-T170
of	O
uveitis	B-T047
in	O
the	O
presence	B-T033
of	O
SpA	B-T047
in	O
both	O
HLA-B27-positive	B-T034
and	O
negative	B-T033
patients	B-T101
resembles	O
that	O
of	O
idiopathic uveitis	B-T047
-	O
an	O
independent	O
HLA-B27	B-T116
-	O
associated	B-T080
syndrome	B-T047
(р>0.05).	O
Cases	O
of	O
«decussation»	O
between	O
entities	B-T071
of	O
the	O
SpA	B-T047
group	B-T078
are	O
usually	O
more	O
severe	B-T080
in	O
terms	O
of	O
clinical presentation	B-T170
and	O
course	B-T079
of	O
uveitis	B-T047
and	O
are	O
associated with	B-T080
a	O
worse prognosis	B-T033
.	O
Complications	B-T046
of	O
uveitis	B-T047
are	O
more	O
likely	O
to	O
be	O
found	O
in	O
non-SpA	B-T033
HLA-B27	B-T116
-	O
negative	B-T033
patients	B-T101
(р<0.0001).	O

Human	B-T016
brucellosis	B-T047
in	O
South Africa	B-T083
:	O
Public health	B-T170
and	O
diagnostic pitfalls	B-UnknownType
Human	B-T016
brucellosis	B-T047
in	O
South Africa	B-T083
(	O
SA	B-T083
)	O
is	O
under-diagnosed	B-UnknownType
and	O
under-reported	B-T033
.	O
This	O
is	O
because	O
many	O
clinicians	B-T097
have	O
little	O
or	O
no	O
experience	O
in	O
managing	O
affected patients	B-T080
,	O
and	O
in	O
part	O
because	O
of	O
the	O
nonspecific	B-T078
and	O
insidious	B-T080
nature of the disease	B-T080
.	O
A	O
case	B-T169
of	O
human	B-T016
brucellosis	B-T047
caused	O
by	O
Brucella melitensis	B-T007
in	O
a	O
patient	B-T101
from	O
the	O
Western Cape Province	B-UnknownType
of	O
SA	B-T083
is	O
described	B-T078
,	O
and	O
the	O
resulting	B-T169
exposure	O
of	O
staff members	B-T097
at	O
two	O
medical microbiology laboratories	B-T073
,	O
as	O
well	O
as	O
the	O
public health investigation	B-T058
that	O
was	O
conducted,	O
are	O
discussed.	O
This	O
article	B-T170
aims	B-T078
to	O
highlight	O
the	O
need	O
for	O
strengthening	O
integration	B-T169
between	O
public health	B-T170
,	O
medical	B-T058
and	O
veterinary	B-T091
services	B-T057
and	O
exposing deficiencies	B-T169
in	O
public health	B-T170
,	O
veterinary	B-T091
and	O
laboratory	B-T073
practices.	O

Survey	B-T170
of	O
Trichinella infection	B-T047
from	O
domestic pigs	B-T015
in	O
the	O
historical	B-T033
endemic areas	B-T082
of	O
Henan province	B-T083
,	O
central China	B-T083
The	O
aim	B-T078
of	O
this	O
work	B-T057
was	O
to	O
investigate	B-T169
the	O
current situation	B-T033
of	O
Trichinella infection	B-T047
from	O
domestic pigs	B-T015
in	O
the	O
historical	B-T033
endemic areas	B-T082
of	O
Henan province	B-T083
,	O
central China	B-T083
.	O
A	O
total	O
of	O
823	O
diaphragm samples	B-T031
from	O
the	O
indoor-raised pigs	B-T015
were	O
collected	B-T169
in	O
five	B-T081
cities	B-T083
of	O
Henan	B-T083
during	O
2014-2015	O
and	O
examined	B-T033
by	O
artificial digestion method	B-T169
.	O
The	O
overall prevalence	B-T081
of	O
Trichinella infection	B-T047
in	O
pigs	B-T015
was	O
0.61	O
%	O
(5/823).	O
Trichinella larvae	B-T204
were	O
detected	B-T033
in	O
0.91	O
%	O
(5/550)	O
of	O
pigs	B-T015
from	O
Nanyang city	B-T083
of	O
Henan	B-T083
.	O
The	O
larval	B-T204
burden	B-T078
in	O
infected animals	B-T033
was	O
0.03	O
larvae	B-T204
per	O
gram	O
(lpg)	O
of	O
muscles	B-T024
with	O
a	O
range	B-T081
from	O
0.02	O
to	O
0.05	O
lpg.	O
The	O
larvae	B-T204
were	O
identified	B-T080
as	O
Trichinella spiralis	B-T204
by	O
multiple PCR	B-T063
.	O
Our	O
study	B-T062
confirms	B-T080
the	O
existence	B-T077
of	O
swine	B-T015
trichinellosis	B-T047
in	O
Henan	B-T083
,	O
but	O
the	O
infection	B-T046
level	B-T080
was	O
under	O
the	O
minimum level	B-T080
for	O
defining	O
infectious sources	B-T001
for	O
humans	B-T016
.	O
However,	O
the	O
prevalence	B-T081
of	O
swine	B-T015
Trichinella infection	B-T047
in	O
Henan	B-T083
need	O
to	O
be	O
further	O
evaluated	B-T058
with	O
a	O
large scale	B-T081
of	O
pork samples	B-T167
for	O
ensuring	O
meat	B-T168
food safety	B-T057
.	O

Voriconazole	B-T109
metabolism	B-T044
is	O
influenced	B-T077
by	O
severe	B-T080
inflammation	B-T046
:	O
a	O
prospective study	B-T062
During	O
an	O
infection	B-T046
or	O
inflammation	B-T046
,	O
several	B-T081
drug	B-T121
-	O
metabolizing	B-T044
enzymes	B-T116
in	O
the	O
liver	B-T023
are	O
down-regulated	B-T044
,	O
including	O
cytochrome P450 iso-enzymes	B-T116
.	O
Since	O
voriconazole	B-T109
is	O
extensively	B-T080
metabolized	B-T044
by	O
cytochrome P450 iso-enzymes	B-T116
,	O
the	O
metabolism	B-T044
of	O
voriconazole	B-T109
can	O
be	O
influenced	B-T077
during	O
inflammation	B-T046
via	O
reduced	B-T080
clearance of the drug	B-T039
,	O
resulting	O
in	O
higher	B-T080
voriconazole	B-T109
trough concentrations	B-T081
.	O
To	O
investigate	O
prospectively	O
the	O
influence	B-T077
of	O
inflammation	B-T046
on	O
voriconazole	B-T109
metabolism	B-T044
and	O
voriconazole	B-T109
trough concent ratio ns	B-T081
ratio	B-T081
ns.	O
A	O
prospective observational study	B-T062
was	O
performed	O
at	O
the	O
University Medical Center	B-T073
Groningen	B-T083
.	O
Patients	B-T101
were	O
eligible	B-T080
for	O
inclusion	B-T080
if	O
they	O
were	O
≥18	O
years	O
old	O
and	O
treated with	B-T061
voriconazole	B-T109
.	O
Voriconazole	B-T109
and	O
voriconazole-N-oxide	B-T109
concentrations	B-T081
were	O
determined	O
in	O
discarded	O
blood samples	B-T031
.	O
To	O
determine	O
the	O
degree	B-T081
of	O
inflammation	B-T046
,	O
C-reactive protein (CRP) concentrations	B-T059
were	O
used.	O
Subsequently,	O
a	O
longitudinal data analysis	B-T062
was	O
performed	O
to	O
assess	B-T058
the	O
effect	B-T080
of	O
inflammation	B-T046
on	O
the	O
metabolic	B-T044
ratio	B-T081
and	O
voriconazole	B-T109
trough concentration	B-T081
.	O
Thirty-four	O
patients	B-T101
were	O
included.	O
In	O
total	O
489	O
voriconazole	B-T109
trough concentrations	B-T081
were	O
included	O
in	O
the	O
longitudinal data analysis	B-T062
.	O
This	O
analysis	B-T062
showed	O
that	O
inflammation	B-T046
,	O
reflected	O
by	O
CRP concentrations	B-T059
,	O
significantly	O
influence	B-T077
d	O
the	O
metabolic	B-T044
ratio	B-T081
,	O
voriconazole	B-T109
trough concentration	B-T081
and	O
voriconazole-N-oxide	B-T109
concentration	B-T081
(all	O
P	O
<	O
0.001),	O
when	O
corrected	O
for	O
other	O
factors	B-T169
that	O
could	O
influence	B-T077
voriconazole	B-T109
metabolism	B-T044
.	O
The	O
metabolic	B-T044
ratio	B-T081
was	O
decreased	B-T081
by	O
0.99229(N)	O
and	O
the	O
voriconazole-N-oxide	B-T109
concentration	B-T081
by	O
0.99775(N),	O
while	O
the	O
voriconazole	B-T109
trough concentration	B-T081
was	O
increased	B-T081
by	O
1.005321(N),	O
where	O
N	O
is	O
the	O
difference	O
in	O
CRP	B-T116
units	O
(in	O
mg/L).	O
This	O
study	O
shows	O
that	O
voriconazole	B-T109
metabolism	B-T044
is	O
decreased	B-T081
during	O
inflammation	B-T046
,	O
resulting	O
in	O
higher	B-T080
voriconazole	B-T109
trough concentration	B-T081
s.	O
Therefore,	O
frequent	B-T079
monitoring	B-T058
of	O
voriconazole	B-T109
serum concentrations	B-T081
is	O
recommended	O
during	O
and	O
following	O
severe	B-T080
inflammation	B-T046
.	O

Neoadjuvant Chemotherapy	B-T061
of	O
Ovarian Cancer	B-T191
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor-Infiltrating Lymphocyte	B-T025
Response	B-T039
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	B-T061
Purpose:	O
Some	O
forms	O
of	O
chemotherapy	B-T061
can	O
enhance	O
antitumor	B-T080
immunity	B-T039
through	O
immunogenic	B-T169
cell death	B-T043
,	O
resulting	O
in	O
increased	O
T-cell activation	B-T043
and	O
tumor infiltration	B-T191
.	O
Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	B-T191
to	O
immunotherapies	B-T061
,	O
including	O
checkpoint blockade	B-T043
.	O
We	O
investigated	O
whether	O
platinum	B-T196
-	O
and	O
taxane	B-T109
-based	O
chemotherapy	B-T061
for	O
ovarian cancer	B-T191
induces	O
immunologic	B-T169
changes	O
consistent	O
with	O
this	O
possibility.	O
Experimental Design	B-T062
:	O
Matched	O
pre	B-T079
-	O
and	O
post	B-T079
-	O
neoadjuvant chemotherapy	B-T061
tumor samples	B-T024
from	O
26	O
high-grade serous carcinoma	B-T191
(	O
HGSC	B-T191
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-T060
(	O
IHC	B-T060
)	O
for	O
a	O
large	O
panel	O
of	O
immune cells	B-T025
and	O
associated	O
factors.	O
The	O
prognostic	O
significance	O
of	O
post	B-T079
-	O
chemotherapy	B-T061
TIL	B-T025
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	B-T098
(n	O
=	O
90).Results:	O
Neoadjuvant chemotherapy	B-T061
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	B-T116
(+),	O
CD8	B-T129
(+),	O
CD8	B-T129
(+)	O
TIA-1	B-T116
(+),	O
PD-1	B-T116
(+)	O
and	O
CD20	B-T116
(+)	O
TIL	B-T025
.	O
Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged,	O
including	O
CD79a	B-T116
(+)	O
CD138	B-T116
(+)	O
plasma cells	B-T025
,	O
CD68	B-T116
(+)	O
macrophages	B-T025
,	O
and	O
MHC class I	B-T116
on	O
tumor cells	B-T025
.	O
Immunosuppressive	B-T047
cell	B-T025
types	O
were	O
also	O
unchanged,	O
including	O
FoxP3	B-T116
(+)	O
PD-1	B-T116
(+)	O
cells	B-T025
(putative	O
regulatory T cells	B-T025
),	O
IDO-1	B-T116
(+)	O
cells,	O
and	O
PD-L1	B-T129
(+)	O
cells	O
(both	O
macrophages	B-T025
and	O
tumor cells	B-T025
).	O
Hierarchical clustering	B-T062
revealed	O
three	O
response	O
patterns:	O
(i)	O
TIL	B-T025
(high)	O
tumors	B-T191
showed	O
increases	O
in	O
multiple	O
immune markers	B-T080
after	O
chemotherapy	B-T061
;	O
(ii)	O
TIL	B-T025
(low)	O
tumors	O
underwent	O
similar	O
increases,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group;	O
and	O
(iii)	O
TIL	B-T025
(	O
negative	B-T033
)	O
cases	O
generally	O
remained	O
negative	B-T033
.	O
Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns,	O
post-	O
chemotherapy	B-T061
TIL	B-T025
showed	O
limited	O
prognostic	O
significance.Conclusions:	O
Chemotherapy	B-T061
augments	O
pre-existing	O
TIL	B-T025
responses	B-T039
but	O
fails	O
to	O
relieve	O
major	O
immune-suppressive mechanisms	B-T047
or	O
confer	O
significant	O
prognostic	O
benefit.	O
Our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	B-T061
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor microenvironment	B-T070
.	O
Clin	O
Cancer	O
Res;	O
23(4);	O
925-34.	O
©2016	O
AACR.	O

The	O
adder	B-T014
(	O
Vipera berus	B-T014
)	O
in	O
Southern Altay Mountains	B-T083
:	O
population characteristics	B-T102
,	O
distribution	B-T082
,	O
morphology	B-T080
and	O
phylogenetic position	B-T080
As	O
the	O
most	O
widely	O
distributed	B-T082
snake	B-T014
in	O
Eurasia	B-T083
,	O
the	O
adder	B-T014
(	O
Vipera berus	B-T014
)	O
has	O
been	O
extensively	B-T080
investigated	B-T169
in	O
Europe	B-T083
but	O
poorly	O
understood	O
in	O
Asia	B-T083
.	O
The	O
Southern Altay Mountains	B-T083
represent	O
the	O
adder's	B-T014
southern	B-T082
distribution	B-T082
limit	B-T169
in	O
Central Asia	B-T083
,	O
whereas	O
its	O
population status	B-T081
has	O
never	O
been	O
assessed	B-T052
.	O
We	O
conducted,	O
for	O
the	O
first	O
time,	O
field surveys	B-T062
for	O
the	O
adder	B-T014
at	O
two	O
areas	B-T082
of	O
Southern Altay Mountains	B-T083
using	O
a	O
combination	B-T080
of	O
line transects	B-T062
and	O
random	B-T080
searches	B-T052
.	O
We	O
also	O
described	O
the	O
morphological characteristics	B-T080
of	O
the	O
collected specimens	B-T059
and	O
conducted	O
analyses	B-T062
of	O
external	B-T082
morphology	B-T080
and	O
molecular phylogeny	B-T078
.	O
The	O
results	B-T033
showed	O
that	O
the	O
adder	B-T014
distributed	B-T082
in	O
both	O
survey	B-T062
sites	B-T082
and	O
we	O
recorded	B-T170
a	O
total	O
of	O
34	O
sightings	B-T053
.	O
In	O
Kanas river valley	B-T082
,	O
the	O
estimated	B-T081
encounter	B-T053
rate	B-T081
over	O
a	O
total	O
of	O
137	O
km	O
transects	B-T062
was	O
0.15	O
±	O
0.05	O
sightings	B-T053
/km.	O
The	O
occurrence	B-T079
of	O
melanism	B-T047
was	O
only	O
17%.	O
The	O
small size	B-T033
was	O
typical	B-T080
for	O
the	O
adders	B-T014
in	O
Southern Altay Mountains	B-T083
in	O
contrast	O
to	O
other	O
geographic populations	B-T081
of	O
the	O
nominate	B-T052
subspecies	B-T185
.	O
A	O
phylogenetic tree	B-T080
obtained	B-T169
by	O
Bayesian Inference	B-T081
based	O
on	O
DNA sequences	B-T086
of	O
the	O
mitochondrial cytochrome b	B-T116
(1,023	O
bp)	O
grouped	B-T082
them	O
within	O
the	O
Northern clade	B-T081
of	O
the	O
species	B-T185
but	O
failed	O
to	O
separate	B-T080
them	O
from	O
the	O
subspecies	B-T185
V. b. sachalinensis	B-T014
.	O
Our	O
discovery	B-T052
extends	O
the	O
distribution	B-T082
range	B-T081
of	O
V. berus	B-T014
and	O
provides	O
a	O
basis	B-T169
for	O
further	O
researches	B-T062
.	O
We	O
discuss	O
the	O
hypothesis	B-T078
that	O
the	O
adder	B-T014
expands	B-T082
its	O
distribution	B-T082
border	B-T185
to	O
the	O
southwest	B-T082
along	O
the	O
mountains	B-T083
'	O
elevation	B-T082
gradient	B-T081
,	O
but	O
the	O
population	B-T098
abundance	B-T080
declines	B-T081
gradually	B-T080
due	O
to	O
a	O
drying climate	B-T070
.	O

Binding	B-T052
of	O
Pollutants	B-T131
to	O
Biomolecules	B-T123
:	O
A	O
Simulation Study	B-T062
A	O
number	O
of	O
cases	B-T169
around	O
the	O
world	B-T098
have	O
been	O
reported	O
where	O
animals	B-T008
were	O
found dead	B-T033
or	O
dying	B-T040
with	O
symptoms	B-T184
resembling	O
a	O
thiamine	B-T047
(vitamin B) deficiency	B-T047
,	O
and	O
for	O
some	O
of	O
these,	O
a	O
link	O
to	O
pollutants	B-T131
has	O
been	O
suggested.	O
Here,	O
we	O
investigate	B-T058
whether	O
biomolecules	B-T123
involved	O
in	O
thiamin binding	B-T044
and	O
transport	B-T043
could	O
be	O
blocked	B-T169
by	O
a	O
range	O
of	O
different	O
pollutants	B-T131
.	O
We	O
used	O
in silico	B-T066
docking	B-T044
of	O
five	O
compound	B-T123
classes	B-T170
(25	O
compounds	B-T123
in	O
total)	O
to	O
each	O
of	O
five	O
targets	O
(	O
prion protein	B-T116
,	O
ECF-type ABC transporter	B-T026
,	O
thi-box riboswitch receptor	B-T114
,	O
thiamin pyrophosphokinase	B-T116
,	O
and	O
YKoF protein	B-T116
)	O
and	O
subsequently	O
performed	O
molecular dynamics (MD) simulations	B-T066
to	O
assess	O
the	O
stability	B-T080
of	O
the	O
complexes	B-T104
.	O
The	O
compound	B-T123
classes	B-T170
were	O
thiamin	B-T109
analogues	B-T104
(	O
control	B-T167
),	O
pesticides	B-T131
,	O
veterinary	B-T080
medicines	B-T121
,	O
polychlorinated biphenyls	B-T109
,	O
and	O
dioxins	B-T109
,	O
all	O
of	O
which	O
are	O
prevalent	B-T081
in	O
the	O
environment	B-T082
to	O
some	O
extent.	O
A	O
few	O
anthropogenic	O
compounds	B-T123
were	O
found	O
to	O
bind	B-T044
the	O
ECF-type ABC transporter	B-T026
,	O
but	O
none binds stably	B-T033
to	O
prion protein	B-T116
.	O
For	O
the	O
riboswitch	B-T114
,	O
most	O
compounds	B-T123
remained	O
in	O
their	O
binding pockets	B-T120
during	O
50	O
ns	O
of	O
MD simulation	B-T066
,	O
indicating	O
that	O
RNA	B-T114
provides	O
a	O
promiscuous	O
binding site	B-T192
.	O
In	O
both	O
YKoF	B-T116
and	O
thiamin pyrophosphokinase	B-T116
(	O
TPK	B-T116
),	O
most	O
compounds	B-T123
remain	O
tightly bound	B-T052
.	O
However,	O
TPK	B-T116
biomolecules	B-T123
undergo	O
pollutant	B-T131
-	O
induced	B-T169
conformational changes	B-T044
.	O
Although	O
most	O
compounds	B-T123
are	O
found	O
to	O
bind	O
to	O
some	O
of	O
these	O
targets,	O
a	O
larger	O
data	O
set	O
is	O
needed	O
along	O
with	O
more	O
quantitative methods	B-T062
like	O
free energy perturbation	B-UnknownType
calculations	B-T052
before	O
firm	O
conclusions	B-T078
can	O
be	O
drawn.	O
This	O
study	B-T062
is	O
in	O
part	O
a	O
test	O
bed	O
for	O
large-scale	O
quantitative	B-T081
computational screening	B-T059
of	O
interactions	B-T169
between	O
biological entities	B-T123
and	O
pollutant molecules	B-T131
.	O

Characterisation	B-T052
of	O
methicillin-resistant Staphylococcus aureus	B-T007
clinical	B-T080
isolates	B-T123
from	O
animals	B-T008
in	O
New Zealand	B-T083
,	O
2012-2013,	O
and	O
subclinical	B-T080
colonisation	B-T033
in	O
dogs	B-T015
and	O
cats	B-T015
in	O
Auckland	B-UnknownType
To	O
characterise	B-T052
methicillin-resistant Staphylococcus aureus	B-T007
(	O
MRSA	B-T007
)	O
isolates	B-T123
from	O
infection sites	B-T047
in	O
animals	B-T008
in	O
New Zealand	B-T083
and	O
assess	O
the	O
prevalence	B-T081
of	O
subclinical	B-T080
MRSA colonisation	B-T033
in	O
dogs	B-T015
and	O
cats	B-T015
attending	O
veterinary clinics	B-T073
in	O
Auckland	B-UnknownType
.	O
MRSA	B-T007
isolates	B-T123
from	O
clinical	B-T080
specimens	B-T167
obtained	O
by	O
the	O
main	O
New Zealand	B-T083
veterinary diagnostic laboratories	B-T073
between	O
June	B-T079
2012	O
and	O
June	B-T079
2013,	O
were	O
genotypically characterised	B-T052
by	O
DNA microarray hybridisation analysis	B-T063
and	O
spa	B-T116
typing	B-T059
.	O
In	O
addition,	O
nasal	B-T023
or	O
perineal skin	B-T023
swabs	B-T167
collected	O
from	O
a	O
cross-sectional sample	B-T167
of	O
dogs	B-T015
(n=361)	O
and	O
cats	B-T015
(n=225)	O
attending	O
29	O
veterinary clinics	B-T073
in	O
Auckland	B-UnknownType
during	O
the	O
same	O
period	B-T079
were	O
analysed	B-T062
for	O
MRSA	B-T007
by	O
culture	B-T059
.	O
Eight	O
MRSA	B-T007
clinical	B-T080
isolates	B-T123
were	O
submitted	O
for	O
characterisation	B-T052
by	O
the	O
participating	O
laboratories	B-T073
.	O
The	O
isolates	B-T123
originated	O
from	O
five	O
dogs	B-T015
,	O
including	O
two	O
isolates	B-T123
from	O
the	O
same	O
dog	B-T015
,	O
one	O
foal	B-T015
,	O
and	O
one	O
isolate	B-T123
had	O
no	O
identification	O
of	O
the	O
source	B-T033
.	O
The	O
strain	B-T001
-	O
types	B-T080
identified	B-T080
were	O
AK3 (ST-5 SCCmecIV	B-T007
t045;	O
n=1),	O
USA500 (ST8 SCCmecIV	B-T007
t064;	O
n=1),	O
WSPP (ST30 SCCmecIV	B-T007
t019;	O
n=1),	O
Rhine Hesse (ST5 SCCmecII	B-T007
t002;	O
n=2),	O
and	O
EMRSA-15 (ST22 SCCmecIV	B-T007
t032;	O
n=3).	O
No	O
MRSA	B-T007
were	O
isolated	B-T169
from	O
586	O
cultured swabs	B-T167
.	O
Methicillin-susceptible S. aureus	B-T007
were	O
detected	B-T033
in	O
9/257	O
(3.5%)	O
swabs	B-T167
and	O
non-aureus staphylococci	B-T007
in	O
22/257	O
(8.5%)	O
swabs	B-T167
.	O
The	O
estimated	O
true	O
MRSA	B-T007
subclinical	B-T080
colonisation	B-T033
prevalence	B-T081
was	O
0%,	O
with	O
an	O
upper	O
95%	O
CI	B-T081
boundary	O
of	O
1.9%	O
for	O
cats	B-T015
and	O
1.4%	O
for	O
dogs	B-T015
.	O
The	O
modest number	B-T081
of	O
MRSA	B-T007
isolates	B-T123
submitted	O
for	O
this	O
study	B-T170
by	O
the	O
participating	O
laboratories	B-T073
suggests	O
clinical	B-T080
MRSA infection	B-T047
in	O
animals	B-T008
in	O
New Zealand	B-T083
continues	O
to	O
be	O
sporadic	B-T079
.	O
The	O
wide	O
variety	O
of	O
strain	B-T001
-	O
types	B-T080
found	O
mirrored	O
the	O
evolving	O
strain	B-T001
-	O
type	B-T080
diversity	B-T080
observed	O
in	O
humans	B-T016
.	O
We	O
cannot	O
rule	O
out	O
bias	B-T078
due	O
to	O
the	O
non-random sampling	B-T062
of	O
dogs	B-T015
and	O
cats	B-T015
,	O
but	O
the	O
apparent	O
colonisation	B-T033
prevalence	B-T081
of	O
0%	O
was	O
consistent with	B-T078
the	O
low	O
prevalence	B-T081
of	O
subclinical	B-T080
colonisation	B-T033
in	O
humans	B-T016
in	O
New Zealand	B-T083
.	O
These	O
similarities	B-T080
indicate	O
the	O
epidemiology	B-T091
of	O
animal	B-T008
and	O
human	B-T016
MRSA infections	B-T047
are	O
linked.	O
In	O
the	O
last	O
decade	B-T081
,	O
the	O
prevalence	B-T081
of	O
human	B-T016
MRSA infections	B-T047
in	O
New Zealand	B-T083
has	O
steadily	O
increased	B-T081
.	O
This	O
is	O
the	O
second	O
published	O
study	B-T170
of	O
MRSA	B-T007
in	O
animals	B-T008
in	O
New Zealand	B-T083
.	O
The	O
results	O
indicate	O
clinical	B-T080
MRSA infection	B-T047
in	O
animals	B-T008
remains	O
sporadic	B-T079
,	O
but	O
the	O
diversification	B-T057
of	O
the	O
strain	B-T001
-	O
types	B-T080
may	O
pose	O
new	O
therapeutic	B-T169
challenges	O
to	O
veterinarians	B-T097
,	O
due	O
to	O
their	O
diverse	O
resistome	B-T028
.	O

Cloud-based MOTIFSIM	B-T170
:	O
Detecting	B-T033
Similarity	B-T080
in	O
Large	O
DNA Motif	B-T086
Data Sets	B-T170
We	O
developed	O
the	O
cloud-based MOTIFSIM	B-T170
on	O
Amazon Web Services	B-T066
(	O
AWS	B-T066
)	O
cloud	B-T066
.	O
The	O
tool	B-T170
is	O
an	O
extended	O
version	B-T170
from	O
our	O
web-based tool version 2.0	B-T170
,	O
which	O
was	O
developed	O
based	O
on	O
a	O
novel	O
algorithm	B-T170
for	O
detecting	B-T033
similarity	B-T080
in	O
multiple	O
DNA motif	B-T086
data sets	B-T170
.	O
This	O
cloud	B-T066
-based	O
version	B-T170
further	O
allows	O
researchers	B-T097
to	O
exploit	O
the	O
computing resources	B-T078
available	O
from	O
AWS	B-T066
to	O
detect	B-T033
similarity	B-T080
in	O
multiple	O
large-scale	O
DNA motif	B-T086
data sets	B-T170
resulting	O
from	O
the	O
next-generation sequencing technology	B-T063
.	O
The	O
tool	B-T170
is	O
highly	O
scalable	O
with	O
expandable	O
AWS	B-T066
.	O

Utilization	B-T169
and	O
Outcomes	B-T062
of	O
Sentinel Lymph Node Biopsy	B-T060
for	O
Vulvar Cancer	B-T191
To	O
examine	O
the	O
use	O
and	O
predictors	O
of	O
sentinel node biopsy	B-T060
in	O
women	B-T098
with	O
vulvar cancer	B-T191
.	O
The	O
Perspective database	B-T170
,	O
an	O
all-payer database	B-T170
that	O
collects data	B-T062
from	O
more	O
than	O
500	O
hospitals	B-T073
,	O
was	O
used	O
to	O
perform	O
a	O
retrospective cohort study	B-T062
of	O
women	B-T098
with	O
vulvar cancer	B-T191
who	O
underwent	O
vulvectomy	B-T061
and	O
lymph node assessment	B-T060
from	O
2006	O
to	O
2015.	O
Multivariable models	B-T075
were	O
used	O
to	O
determine	O
factors	B-T169
associated	O
with	O
sentinel node biopsy	B-T060
.	O
Length of stay	B-T079
and	O
cost	B-T081
were	O
compared	O
between	O
women	B-T098
who	O
underwent	O
sentinel node biopsy	B-T060
and	O
lymphadenectomy	B-T061
.	O
Among	O
2,273	O
women	B-T098
,	O
sentinel node biopsy	B-T060
was	O
utilized	O
in	O
618	O
(27.2%)	O
and	O
1,655	O
(72.8%)	O
underwent	O
inguinofemoral lymphadenectomy	B-T061
.	O
Performance	O
of	O
sentinel node biopsy	B-T060
increased	O
from	O
17.0%	O
(95%	O
confidence interval	B-T081
[	O
CI	B-T081
]	O
12.0-22.0%)	O
in	O
2006	O
to	O
39.1%	O
(95%	O
CI	B-T081
27.1-51.0%)	O
in	O
2015.	O
In	O
a	O
multivariable model	B-T075
,	O
women	B-T098
treated	B-T169
more	O
recently	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
sentinel node biopsy	B-T060
,	O
whereas	O
women	B-T098
with	O
more	O
comorbidities	B-T078
and	O
those	O
treated	B-T169
at	O
rural hospitals	B-T093
were	O
less	O
likely	O
to	O
have	O
undergone	O
the	O
procedure	B-T060
.	O
The	O
median	B-T082
length of stay	B-T079
was	O
shorter	O
for	O
those	O
undergoing	O
sentinel node biopsy	B-T060
(	O
median	B-T082
2	O
days,	O
interquartile range	B-T081
1-3)	O
compared	O
with	O
women	B-T098
who	O
underwent	O
inguinofemoral lymphadenectomy	B-T061
(median	O
3	O
days,	O
interquartile range	B-T081
2-4).	O
The	O
cost	O
of	O
sentinel node biopsy	B-T060
was	O
$7,599	O
(	O
interquartile range	B-T081
$5,739-9,922)	O
compared	O
with	O
$8,095	O
(	O
interquartile range	B-T081
$5,917-11,281)	O
for	O
lymphadenectomy	B-T061
.	O
The	O
use	O
of	O
sentinel node biopsy	B-T060
for	O
vulvar cancer	B-T191
has	O
more	O
than	O
doubled	O
since	O
2006.	O
Sentinel lymph node biopsy	B-T060
is	O
associated	O
with	O
a	O
shorter hospital stay	B-T079
and	O
decreased cost	B-T081
compared	O
with	O
inguinofemoral lymphadenectomy	B-T061
.	O

Condition	B-T080
-	O
dependent	B-T080
co-regulation	B-T038
of	O
genomic clusters	B-T028
of	O
virulence factors	B-T109
in	O
the	O
grapevine trunk	B-T047
pathogen	B-T001
Neofusicoccum parvum	B-T004
The	O
ascomycete	B-T004
Neofusicoccum parvum	B-T004
,	O
one	O
of	O
the	O
causal agents	B-T033
of	O
Botryosphaeria dieback	B-T004
,	O
is	O
a	O
destructive	O
wood	B-T167
-	O
infecting	B-T033
fungus	B-T004
and	O
a	O
serious	O
threat	B-T078
to	O
grape	B-T168
production	O
worldwide	B-T098
.	O
The	O
capability	B-T080
of	O
colonizing	B-T033
woody tissue	B-T025
combined	B-T080
with	O
the	O
secretion	B-T038
of	O
phytotoxic	B-T080
compounds	B-T103
is	O
thought	O
to	O
underlie	O
its	O
pathogenicity	B-T032
and	O
virulence	B-T038
.	O
Here,	O
we	O
describe	O
the	O
repertoire	O
of	O
virulence factors	B-T109
and	O
their	O
transcriptional	B-T045
dynamics	B-T070
as	O
the	O
fungus	B-T004
feeds	B-T168
on	O
different	O
substrates	B-T167
and	O
colonizes	B-T033
the	O
woody stem	B-T002
.	O
We	O
assembled	B-T052
and	O
annotated	B-T080
a	O
highly	B-T080
contiguous	B-T082
genome	B-T028
using	O
single molecule real-time DNA sequencing	B-UnknownType
.	O
Transcriptome profiling	B-T059
by	O
RNA-sequencing	B-T059
determined	O
the	O
genome	B-T028
-wide	O
patterns	B-T082
of	O
expression	B-T045
of	O
virulence factors	B-T109
both	O
in vitro	B-T062
(	O
potato	B-T168
dextrose agar	B-T130
or	O
medium	B-T130
amended	B-T080
with	O
grape	B-T168
wood	B-T167
as	O
substrate	B-T167
)	O
and	O
in	O
planta	B-T002
.	O
Pairwise statistical testing	B-T170
of	O
differential	B-T080
expression	B-T045
followed	O
by	O
co-expression network analysis	B-T063
revealed	O
that	O
physically	B-T169
clustered genes	B-T028
coding	B-T085
for	O
putative	O
virulence	B-T038
functions	B-T169
were	O
induced	O
depending	O
on	O
substrate	B-T167
or	O
stage	B-T079
of	O
plant	B-T002
infection	B-T046
.	O
Co-expressed	B-T045
gene clusters	B-T028
were	O
significantly	O
enriched	O
not	O
only	O
in	O
genes	B-T028
associated with	B-T080
secondary metabolism	B-T044
,	O
but	O
also	O
with	O
cell wall degradation	B-T043
,	O
suggesting	O
that	O
dynamic	B-T169
co-regulation	B-T038
of	O
transcriptional networks	B-T044
contribute	O
to	O
multiple	O
aspects	O
of	O
N. parvum	B-T004
virulence	B-T038
.	O
In	O
most	O
of	O
the	O
co-expressed	B-T045
clusters	B-T028
,	O
all	O
genes	B-T028
shared	O
at	O
least	O
a	O
common	O
motif	O
in	O
their	O
promoter region	B-T114
indicative	O
of	O
co-regulation	B-T038
by	O
the	O
same	O
transcription factor	B-T116
.	O
Co-expression analysis	B-T063
also	O
identified	O
chromatin	B-T116
regulators	B-T077
with	O
correlated	B-T080
expression	B-T045
with	O
inducible	B-T169
clusters	B-T028
of	O
virulence factors	B-T109
,	O
suggesting	O
a	O
complex,	O
multi-layered	O
regulation	B-T038
of	O
the	O
virulence	B-T038
repertoire	O
of	O
N. parvum	B-T004
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Congenital anomalies	B-T019
following	O
use	O
of	O
isotretinoin	B-T109
:	O
Emphasis	O
on	O
its	O
legal aspects	B-T064
We	O
described	O
a	O
neonate	B-T100
with	O
severe	B-T080
and	O
multiple abnormalities	B-T019
following	O
use	O
of	O
isotretinoin	B-T109
,	O
in	O
spite	O
of	O
the	O
mother	B-T099
's	O
previous	O
knowledge	B-T170
of	O
drug complications	B-T046
.	O
Initial	O
physical examination	B-T058
after	O
delivery	B-T061
showed	O
congenital absence	B-T019
of	O
both eyes	B-T023
and	O
both	O
auricles	B-T023
as	O
well	O
as	O
anal atresia	B-T019
and	O
a	O
cleft palate	B-T019
.	O
Due	O
to	O
severe	B-T080
respiratory distress	B-T184
and	O
atresia	B-T019
of	O
the	O
anus	B-T023
,	O
the	O
neonate	B-T100
was	O
admitted	O
to	O
a	O
neonatal	B-T100
intensive care unit	B-T073
and	O
underwent	O
reconstructive surgery	B-T061
.	O
The	O
drug	B-T121
should	O
not	O
have	O
been	O
used	O
during	O
pregnancy	B-T040
.	O
Using	O
this	O
drug	B-T121
within	O
pregnancy	B-T040
with	O
awareness	O
of	O
its	O
side effects	B-T046
may	O
have	O
legal	B-T169
consequences	B-T169
.	O

Functional adaptation	B-T038
of	O
crustacean	B-T204
exoskeletal	B-T023
elements	B-T196
through	O
structural	B-T082
and	O
compositional	B-T032
diversity	B-T080
:	O
a	O
combined	B-T080
experimental	B-T062
and	O
theoretical study	B-T062
The	O
crustacean	B-T204
cuticle	B-T002
is	O
a	O
composite	B-T080
material	B-T167
that	O
covers	O
the	O
whole	O
animal	B-T008
and	O
forms	O
the	O
continuous exoskeleton	B-T023
.	O
Nano-fibers	B-T073
composed	O
of	O
chitin	B-T109
and	O
protein molecules	B-T116
form	O
most	O
of	O
the	O
organic	B-T080
matrix	B-T109
of	O
the	O
cuticle	B-T002
that,	O
at	O
the	O
macroscale	B-T081
,	O
is	O
organized	O
in	O
up	O
to	O
eight	O
hierarchical	B-T169
levels	B-T080
.	O
At	O
least	O
two	O
of	O
them,	O
the	O
exo-	B-T002
and	O
endocuticle	B-T002
,	O
contain	O
a	O
mineral phase	B-T197
of	O
mainly	O
Mg	B-T123
-	O
calcite	B-T197
,	O
amorphous	B-T080
calcium carbonate	B-T121
and	O
phosphate	B-T121
.	O
The	O
high	O
number	O
of	O
hierarchical	B-T169
levels	B-T080
and	O
the	O
compositional	B-T032
diversity	B-T080
provide	O
a	O
high	O
degree of freedom	B-T080
for	O
varying	B-T169
the	O
physical	B-T201
,	O
in	O
particular	O
mechanical	B-T169
,	O
properties	B-T080
of	O
the	O
material	B-T167
.	O
This	O
makes	O
the	O
cuticle	B-T002
a	O
versatile material	B-T167
ideally	O
suited	O
to	O
form	O
a	O
variety	O
of	O
skeletal	B-T082
elements	B-T196
that	O
are	O
adapted	B-T038
to	O
different	O
functions	B-T169
and	O
the	O
eco-physiological strains	B-T001
of	O
individual species	B-T185
.	O
This	O
review	B-T170
presents	O
our	O
recent	O
analytical	B-T170
,	O
experimental	B-T062
and	O
theoretical studies	B-T062
on	O
the	O
cuticle	B-T002
,	O
summarising	O
at	O
which	O
hierarchical	B-T169
levels	B-T080
structure	B-T082
and	O
composition	B-T032
are	O
modified	O
to	O
achieve	O
the	O
required	O
physical properties	B-T201
.	O
We	O
describe	O
our	O
multi-scale hierarchical modeling approach	B-T075
based	O
on	O
the	O
results	B-T169
from	O
these	O
studies	B-T062
,	O
aiming	O
at	O
systematically	B-T169
predicting	B-T078
the	O
structure	B-T082
-	O
composition	B-T032
-	O
property	B-T080
relations	B-T080
of	O
cuticle	B-T002
composites	B-T080
from	O
the	O
molecular	B-T080
level	B-T080
to	O
the	O
macro-scale	B-T081
.	O
This	O
modeling approach	B-T075
provides	O
a	O
tool	O
to	O
facilitate	O
the	O
development	B-T169
of	O
optimized	O
biomimetic materials	B-T073
within	O
a	O
knowledge-based design approach	B-T075
.	O

Draft Genome Sequences	B-T085
of	O
15	O
Isolates	B-T123
of	O
Listeria monocytogenes Serotype 1/2a	B-T007
,	O
Subgroup	B-T185
ST204	B-T001
Listeria monocytogenes	B-T007
sequence type 204 (ST204) strains	B-T001
have	O
been	O
isolated	B-T169
from	O
a	O
range of food	B-T168
,	O
environmental	B-T082
,	O
and	O
clinical	B-T080
sources	B-T033
in	O
Australia	B-T083
.	O
This	O
study	O
describes	O
the	O
draft genome sequences	B-T085
of	O
15	O
isolates	O
collected	O
from	O
meat	B-T168
and	O
dairy associated sources	B-T168
.	O

High	O
Transferability	B-T080
of	O
Homoeolog-Specific Markers	B-T045
between	O
Bread	B-T168
Wheat	B-T168
and	O
Newly	O
Synthesized	B-T052
Hexaploid Wheat Lines	B-T168
Bread	B-T168
wheat	B-T168
(	O
Triticum aestivum	B-T002
,	O
2n	O
=	O
6x	O
=	O
42,	O
AABBDD)	O
has	O
a	O
complex	O
allohexaploid genome	B-T028
,	O
which	O
makes	O
it	O
difficult	O
to	O
differentiate	B-T169
between	O
the	O
homoeologous sequences	B-T085
and	O
assign	O
them	O
to	O
the	O
chromosome A	B-T026
,	O
B	B-T026
,	O
or	O
D	B-T026
subgenomes	B-T028
.	O
The	O
chromosome	B-T026
-based	O
draft	O
genome	B-T028
sequence	B-T086
of	O
the	O
'	O
Chinese Spring	B-T168
'	O
common	O
wheat cultivar	B-T168
enables	O
the	O
large-scale	O
development	B-T169
of	O
polymerase chain reaction	B-T063
(	O
PCR	B-T063
)-based	O
markers	B-T045
specific	O
for	O
homoeologs.	O
Based	O
on	O
high-confidence	O
'	O
Chinese Spring	B-T168
'	O
genes	B-T028
with	O
known	O
functions,	O
we	O
developed	O
183	O
putative	O
homoeolog-specific markers	B-T045
for	O
chromosomes 4B	B-T026
and	O
7B	B-T026
.	O
These	O
markers	B-T045
were	O
used	O
in	O
PCR assays	B-T063
for	O
the	O
4B	B-T026
and	O
7B	B-T026
nullisomes	O
and	O
their	O
euploid	O
synthetic hexaploid wheat (SHW) line	B-T168
that	O
was	O
newly	O
generated	O
from	O
a	O
hybridization	B-T070
between	O
Triticum turgidum	B-T002
(AABB)	O
and	O
the	O
wild	O
diploid species	B-T025
Aegilops tauschii	B-T002
(DD).	O
Up	O
to	O
64%	O
of	O
the	O
markers	B-T045
for	O
chromosomes 4B	B-T026
or	O
7B	B-T026
in	O
the	O
SHW	B-T168
background	O
were	O
confirmed	O
to	O
be	O
homoeolog-specific.	O
Thus,	O
these	O
markers	B-T045
were	O
highly	O
transferable	O
between	O
the	O
'	O
Chinese Spring	B-T168
'	O
bread	B-T168
wheat	B-T168
and	O
SHW lines	B-T168
.	O
Homoeolog-specific markers	B-T045
designed	O
using	O
genes	B-T028
with	O
known	O
functions	O
may	O
be	O
useful	O
for	O
genetic investigations	B-T059
involving	O
homoeologous	O
chromosome	B-T026
tracking	O
and	O
homoeolog	O
expression	B-T045
and	O
interaction	O
analyses.	O

Participation	B-T169
in	O
and	O
adherence	B-T169
to	O
physical exercise	B-T056
after	O
completion	B-T080
of	O
primary cancer	B-T191
treatment	B-T061
The	O
purpose	B-T169
of	O
this	O
study	B-T062
was	O
to	O
identify	B-T041
demographic	B-T078
,	O
clinical	B-T080
,	O
psychosocial	B-T169
,	O
physical	B-T169
and	O
environmental	B-T082
factors	B-T169
that	O
are	O
associated with	B-T080
participation	B-T169
in	O
and	O
adherence	B-T169
to	O
a	O
combined	B-T080
resistance	B-T169
and	O
endurance exercise	B-T061
program	B-T169
among	O
cancer survivors	B-T101
,	O
shortly	O
after	O
completion	B-T080
of	O
primary cancer	B-T191
treatment	B-T061
.	O
Data	B-T078
from	O
the	O
randomized	B-T033
controlled	B-T169
Resistance and Endurance exercise After ChemoTherapy	B-T170
(	O
REACT	B-T170
)	O
study	B-T062
were	O
used	O
for	O
this	O
study	B-T062
.	O
The	O
participants	B-T098
of	O
the	O
REACT	B-T170
study	B-T062
were	O
randomly	B-T080
allocated	B-T052
to	O
either	O
a	O
high intensity	B-T185
(	O
HI	B-T185
)	O
or	O
low	B-T080
-to-	O
moderate intensity	B-T185
(	O
LMI	B-T080
)	O
exercise	B-T056
program	B-T169
.	O
Patients	B-T101
'	O
participation	B-T169
rate	B-T081
was	O
defined	O
as	O
the	O
cancer survivors	B-T101
'	O
decision	O
to	O
participate	B-T169
in	O
the	O
REACT	B-T170
study	B-T062
.	O
Exercise	B-T056
adherence	B-T169
reflected	B-T041
participants	B-T098
'	O
attendance	B-T052
to	O
the	O
scheduled	B-T080
exercise	B-T056
sessions	B-T051
and	O
their	O
compliance	B-T055
to	O
the	O
prescribed	B-T058
exercises	B-T056
.	O
High	B-T080
session	B-T051
attendance	B-T052
rates	B-T081
were	O
defined	O
as	O
attending	B-T169
at	O
least	O
80	O
%	O
of	O
the	O
sessions	B-T051
.	O
High	B-T080
compliance	B-T055
rates	B-T081
were	O
defined	O
as	O
performing	B-T169
at	O
least	O
of	O
90	O
%	O
of	O
the	O
prescribed	B-T058
exercise	B-T056
across	O
all	O
sessions	B-T051
.	O
Correlates	B-T080
of	O
exercise	B-T056
adherence	B-T169
were	O
studied	B-T062
separately	B-T080
for	O
HI	B-T185
and	O
LMI	B-T080
exercise	B-T056
.	O
Demographic	B-T078
,	O
clinical	B-T080
,	O
and	O
physical	B-T169
factors	B-T169
were	O
assessed	B-T052
using	O
self-reported	B-T062
questionnaires	B-T170
.	O
Relevant	B-T080
clinical information	B-T170
was	O
extracted	B-T169
from	O
medical records	B-T170
.	O
Multivariable logistic regression analyses	B-UnknownType
were	O
applied	B-T169
to	O
identify	B-T041
correlates	B-T080
that	O
were	O
significantly	B-T078
associated with	B-T080
participation	B-T169
,	O
high	B-T080
session	B-T051
attendance	B-T052
,	O
high	B-T080
compliance	B-T055
with	O
resistance	B-T169
and	O
high	B-T080
compliance	B-T055
with	O
endurance exercises	B-T061
.	O
Participants	B-T098
were	O
more likely	B-T033
to	O
have	O
higher education	B-T170
,	O
be	O
non-smokers	B-T033
,	O
have	O
lower	B-T080
psychological distress	B-T048
,	O
higher	B-T080
outcome	B-T080
expectations	B-T078
,	O
and	O
perceive	B-T041
more	B-T081
exercise	B-T056
barriers	B-T080
than	O
non-participants	B-T098
.	O
In	O
HI	B-T185
exercise	B-T056
,	O
higher	B-T080
self-efficacy	B-T041
was	O
significantly	B-T078
associated with	B-T080
high	B-T080
session	B-T051
attendance	B-T052
and	O
high	B-T080
compliance	B-T055
with	O
endurance exercises	B-T061
,	O
and	O
lower	B-T080
psychological distress	B-T048
was	O
significantly	B-T078
associated with	B-T080
high	B-T080
compliance	B-T055
with	O
resistance	B-T169
exercise	B-T056
s.	O
In	O
LMI	B-T080
exercise	B-T056
,	O
being	O
a	O
non-smoker	B-T033
was	O
significantly	B-T078
associated with	B-T080
high	B-T080
compliance	B-T055
with	O
resistance	B-T169
exercises	B-T056
and	O
higher	B-T080
BMI	B-T201
was	O
significantly	B-T078
associated with	B-T080
high	B-T080
compliance	B-T055
with	O
resistance	B-T169
and	O
endurance exercises	B-T061
.	O
Furthermore,	O
breast cancer survivors	B-T101
were	O
less	B-T081
likely	B-T078
to	O
report	B-T058
high	B-T080
compliance	B-T055
with	O
resistance	B-T169
and	O
endurance exercises	B-T061
in	O
LMI	B-T080
exercise	B-T056
compared	B-T052
to	O
survivors	B-T101
of	O
other	O
types	O
of	O
cancer	B-T191
.	O
The	O
discriminative	B-T041
ability	B-T032
of	O
the	O
multivariable	B-T080
models	B-T170
ranged	B-T081
from	O
0.62	O
to	O
0.75.	O
Several	O
demographic	B-T078
,	O
clinical	B-T080
and	O
psychosocial	B-T169
factors	B-T169
were	O
associated with	B-T080
participation	B-T169
in	O
and	O
adherence	B-T169
to	O
exercise	B-T056
among	O
cancer survivors	B-T101
.	O
Psychosocial	B-T169
factors	B-T169
were	O
more	B-T081
strongly	B-T080
associated with	B-T080
adherence	B-T169
in	O
HI	B-T185
than	O
LMI	B-T080
exercise	B-T056
.	O
This	O
study	B-T062
was	O
registered	B-T170
at	O
the	O
Netherlands Trial Register	B-T170
[	O
NTR2153	B-T170
]	O
on	O
the	O
5(th)	O
of	O
January	O
2010.	O

In situ	B-T082
stabilization	B-T080
of	O
heavy metals	B-T196
in	O
multiple-	O
metal	B-T197
contaminated	B-T169
paddy	B-T002
soil	B-T167
using	O
different	O
steel	B-T122
slag	B-T197
-based	O
silicon	B-T196
fertilizer	B-T073
Steel	B-T122
slag	B-T197
has	O
been	O
widely	O
used	O
as	O
amendment	O
and	O
silicon	B-T196
fertilizer	B-T073
to	O
alleviate	O
the	O
mobility	B-T033
and	O
bioavailability	B-T081
of	O
heavy metals	B-T196
in	O
soil	B-T167
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
influence	B-T077
of	O
particle size	B-T081
,	O
composition	B-T070
,	O
and	O
application	O
rate	O
of	O
slag	B-T197
on	O
metal	B-T197
immobilization	B-T169
in	O
acidic	B-T103
soil	B-T167
,	O
metals	B-T197
uptake	B-T039
by	O
rice	B-T002
and	O
rice	B-T002
growth	B-T039
.	O
The	O
results	O
indicated	O
that	O
application	O
of	O
slag	B-T197
increased	O
soil	B-T167
pH	B-T081
,	O
plant	B-T002
-available	O
silicon	B-T196
concentrations	B-T081
in	O
soil	B-T167
,	O
and	O
decreased	B-T081
the	O
bioavailability	B-T081
of	O
metals	B-T197
compared	O
with	O
control treatment	B-T080
,	O
whereas	O
pulverous slag	B-T197
(	O
S1	B-T197
)	O
was	O
more effective	B-T080
than	O
granular	B-T080
slag	B-T197
(S2	O
and	O
S3).	O
The	O
acid	B-T103
-	O
extractable fraction of	B-T081
Cd	B-T131
in	O
the	O
spiked	O
soil	B-T167
was	O
significantly	O
decreased	B-T081
with	O
application	O
of	O
S1	B-T197
at	O
rates	O
of	O
1	O
and	O
3	O
%,	O
acid-extractable	O
fractions	O
of	O
Cu	B-T121
and	O
Zn	B-T121
were	O
decreased	B-T081
when	O
treated	B-T169
at	O
3	O
%.	O
Use	O
of	O
S1	B-T197
at	O
both	O
rates	O
resulted	O
in	O
significantly lower	B-T081
Cd	B-T131
,	O
Cu	B-T121
,	O
and	O
Zn	B-T121
concentrations	B-T081
in	O
rice	B-T002
tissues	B-T025
than	O
in	O
controls	B-T096
by	O
82.6-92.9,	O
88.4-95.6,	O
and	O
67.4-81.4	O
%,	O
respectively.	O
However,	O
use	O
of	O
pulverous slag	B-T197
at	O
1	O
%	O
significantly	O
promotes	B-T052
rice	B-T002
growth	B-T039
,	O
restricted	O
rice	B-T002
growth	B-T039
when	O
treated	B-T169
at	O
3	O
%.	O
Thus,	O
the	O
results	O
explained	O
that	O
reduced	B-T080
particle size	B-T081
and	O
suitable	O
application	O
rate	O
of	O
slag	B-T197
could	O
be	O
beneficial	O
to	O
rice	B-T002
growth	B-T039
and	O
metals	B-T197
stabilization	B-T080
.	O

Plasmodium falciparum	B-T204
Choline Kinase	B-T116
Inhibition	B-T052
Leads	O
to	O
a	O
Major	O
Decrease	B-T081
in	O
Phosphatidylethanolamine	B-T109
Causing	O
Parasite	B-T204
Death	B-T040
Malaria	B-T047
is	O
a	O
life-threatening	B-T033
disease	B-T047
caused	O
by	O
different	O
species	B-T185
of	O
the	O
protozoan parasite	B-T204
Plasmodium	B-T204
,	O
with	O
P. falciparum	B-T204
being	O
the	O
deadliest.	O
Increasing	B-T169
parasitic	B-T169
resistance	B-T169
to	O
existing	O
antimalarials	B-T121
makes	O
the	O
necessity	O
of	O
novel	B-T080
avenues	O
to	O
treat	B-T061
this	O
disease	B-T047
an	O
urgent	O
priority.	O
The	O
enzymes	B-T116
responsible	O
for	O
the	O
synthesis	B-T052
of	O
phosphatidylcholine	B-T109
and	O
phosphatidylethanolamine	B-T109
are	O
attractive	O
drug targets	B-T169
to	O
treat	B-T061
malaria	B-T047
as	O
their	O
selective	O
inhibition	B-T052
leads	O
to	O
an	O
arrest	O
of	O
the	O
parasite's	B-T204
growth	B-T040
and	O
cures	B-T033
malaria	B-T047
in	O
a	O
mouse model	B-T050
.	O
We	O
present	O
here	O
a	O
detailed	O
study	B-T062
that	O
reveals	O
a	O
mode of action	B-T169
for	O
two	O
P. falciparum	B-T204
choline kinase	B-T116
inhibitors	B-T120
both	O
in vitro	B-T080
and	O
in vivo	B-T082
.	O
The	O
compounds	B-T080
present	O
distinct	O
binding	B-T044
modes	O
to	O
the	O
choline	B-T109
/	O
ethanolamine	B-T109
-	O
binding site	B-T192
of	O
P. falciparum	B-T204
choline kinase	B-T116
,	O
reflecting	O
different	O
types	O
of	O
inhibition	B-T052
.	O
Strikingly,	O
these	O
compounds	B-T080
primarily	O
inhibit	O
the	O
ethanolamine kinase activity	B-T044
of	O
the	O
P. falciparum	B-T204
choline kinase	B-T116
,	O
leading	O
to	O
a	O
severe	O
decrease	B-T081
in	O
the	O
phosphatidylethanolamine	B-T109
levels	B-T080
within	O
P. falciparum	B-T204
,	O
which	O
explains	O
the	O
resulting	O
growth phenotype	B-T032
and	O
the	O
parasites	B-T204
death	B-T040
.	O
These	O
studies	O
provide	O
an	O
understanding	O
of	O
the	O
mode of action	B-T169
,	O
and	O
act	O
as	O
a	O
springboard	O
for	O
continued	O
antimalarial development	B-T039
efforts	O
selectively	O
targeting	O
P. falciparum	B-T204
choline kinase	B-T116
.	O

Anti-CD45RB	B-T116
and	O
donor-specific spleen cells transfusion	B-T169
inhibition	B-T052
allograft skin rejection	B-T046
mediated	O
by	O
memory T cells	B-T025
Donor-reactive	O
memory T (Tm)cells	B-T025
mediate	O
accelerated	O
rejection	B-T042
,	O
which	O
is	O
known	O
as	O
a	O
barrier	O
to	O
the	O
survival	O
of	O
transplanted organs	B-T023
.	O
Selective	O
interference	O
with	O
the	O
anti-CD45RB monoclonal antibody (α-CD45RB)	B-T116
reliably	O
induces	O
donor	B-T098
-	O
specific	B-T080
tolerance	B-T040
.	O
In	O
this	O
study	B-T062
,	O
pre-sensitization	B-T079
to	O
female	B-T032
C57BL/6 mice	B-T015
with	O
the	O
skin	B-T022
of	O
female	B-T032
BLAB/c mice	B-T015
generated	O
a	O
large	O
number	O
of	O
Tm cells	B-T025
and	O
resulted	O
in	O
rapid	O
rejection	B-T042
of	O
the	O
secondly	B-T081
transplanted	B-T169
allografts	B-T122
.	O
α-CD45RB	B-T116
did	O
induce	O
the	O
tolerance	B-T040
to	O
skin allograft	B-T122
primarily	B-T080
transplanted	B-T169
but	O
failed	O
to	O
induce	O
tolerance	B-T040
in	O
the	O
pre-sensitized mice	B-T015
.	O
Donor-specific spleen cell transfusion	B-T169
(	O
DST	B-T169
)	O
alone	O
also	O
failed	O
to	O
induce	O
the	O
tolerance	B-T040
in	O
the	O
pre-sensitized	B-T079
recipients	B-T101
.	O
Interestingly,	O
combination	O
of	O
α-CD45RB	B-T116
with	O
DST	B-T169
inhibited	O
the	O
rejection	B-T042
induced	O
by	O
memory T cells	B-T025
in	O
the	O
pre-sensitized mice	B-T015
.	O
CD25+ T-cell	B-T025
depletion	B-T061
in	O
α-CD45RB	B-T116
combined	O
with	O
DST	B-T169
therapy	B-T061
recipients	B-T101
could	O
prevent	O
skin allograft	B-T122
tolerance	B-T040
from	O
establishing.	O
In	O
addition,	O
adoptive transfer	B-T061
of	O
donor	B-T098
-primed	O
memory T cells	B-T025
into	O
the	O
tolerant	B-T040
recipients	B-T101
markedly	O
broke	O
the	O
established	O
tolerance	B-T040
.	O
Our	O
findings	B-T033
indicate	O
that	O
α-CD45RB	B-T116
and	O
DST	B-T169
can	O
synergistically	O
inhibit	O
the	O
accelerated	O
rejection	B-T042
mediated	O
by	O
memory T cells	B-T025
and	O
induce	O
long-term	O
skin allograft	B-T122
acceptance	B-T039
in	O
mice	B-T015
.	O

Recruitment	B-T052
of	O
Minority	B-T098
Adolescents	B-T100
and	O
Young Adults	B-T100
into	O
Randomised Clinical Trials	B-T062
:	O
Testing	B-T169
the	O
Design	B-T052
of	O
the	O
Technology Enhanced Community Health Nursing	B-T058
(	O
TECH-N	B-T058
)	O
Pelvic Inflammatory Disease	B-T047
Trial	O
Pelvic inflammatory disease	B-T047
(	O
PID	B-T047
)	O
disproportionately	B-T080
affects	O
adolescent	B-T100
and	O
young adult	B-T100
(	O
AYA	B-T100
)	O
women	B-T098
and	O
can	O
negatively	O
influence	B-T077
reproductive health	B-T091
trajectories.	O
Few	O
randomized controlled trials	B-T062
(	O
RCTs	B-T062
)	O
have	O
focused	O
on	O
strategies	O
to	O
improve	B-T033
outpatient	B-T101
adherence	B-T169
or	O
to	O
reduce	B-T080
reproductive	B-T040
morbidity	B-T081
in	O
this	O
population	B-T098
.	O
This	O
paper	O
describes	O
the	O
research methods	B-T062
and	O
preliminary	B-T079
effectiveness	B-T080
of	O
recruitment	B-T052
,	O
retention	B-UnknownType
,	O
and	O
intervention	B-T058
strategies	O
employed	O
in	O
a	O
novel	O
RCT	B-T062
designed	O
to	O
test	O
a	O
technology-enhanced community-health nursing	B-T058
(	O
TECH-N	B-T058
)	O
intervention	B-T058
among	O
urban	O
AYA	B-T100
with	O
PID	B-T047
.	O
AYA	B-T100
women	B-T098
aged	B-T032
13-25	O
years	B-T079
were	O
recruited	B-T052
during	O
acute PID	B-T047
visits	B-T058
in	O
outpatient clinics	B-T073
and	O
emergency departments	B-T073
(	O
ED	B-T073
)	O
to	O
participate	B-T058
in	O
this	O
IRB-approved	B-T170
trial.	O
Participants	B-T098
completed	B-T080
an	O
audio-computerized self-interview	B-T052
(	O
ACASI	B-T052
),	O
provided	O
vaginal specimens	B-T024
,	O
and	O
were	O
randomized	B-T062
to	O
standard	B-T080
treatment	B-T061
or	O
the	O
intervention	B-T058
.	O
Intervention	B-T058
participants	B-T098
received	B-T080
text-messaging	B-T052
support	B-T077
for	O
30	O
days	B-T079
and	O
a	O
community health nurse (CHN) interventionist	B-T097
performed	B-T169
a	O
home visit with clinical assessment	B-T058
within	O
5	O
days	B-T079
after	O
enrollment	B-T058
.	O
All	O
patients	B-T101
received	O
a	O
full	O
course	B-T079
of	O
medications	B-T058
and	O
completed	B-T080
research	O
visits	B-T058
at	O
14-	O
days	B-T079
(	O
adherence	B-T169
),	O
30	O
days	B-T079
and	O
90	O
days	B-T079
with	O
by	O
an	O
outreach worker	B-T097
.	O
STI	B-T047
testing	B-T169
performed	B-T169
at	O
the	O
30-and	O
90-	O
day	B-T079
visits	B-T058
.	O
Exploratory analyses	B-T062
using	O
descriptive statistics	B-T062
were	O
conducted	O
to	O
examine	O
recruitment	B-T052
,	O
retention	B-UnknownType
,	O
and	O
follow-up	B-T058
data	B-T078
to	O
test	O
the	O
overall	O
design	B-T052
of	O
the	O
intervention	B-T058
.	O
In	O
the	O
first	O
48	O
months	B-T079
,	O
64%	O
of	O
463	O
patients	B-T101
were	O
eligible	B-T080
for	O
the	O
study	O
and	O
81.2%	O
of	O
293	O
eligible	B-T080
patients	B-T101
were	O
recruited	B-T052
for	O
the	O
study	O
(63.3%);	O
238	O
(81.2%)	O
of	O
eligible	B-T080
patients	B-T101
were	O
enrolled	B-T058
.	O
Most	O
participants	B-T098
were	O
African American	B-T098
(95.6%)	O
with	O
a	O
mean	B-T081
age	B-T032
of	O
18.6	O
(2.3).	O
Ninety-four	O
percent	O
of	O
individuals	B-T098
assigned	O
to	O
the	O
TECH-N intervention	B-T058
completed	B-T080
the	O
nursing visits	B-T058
.	O
All	O
completed	B-T080
visits	B-T058
have	O
been	O
within	O
the	O
5-	O
day	B-T079
window	B-T079
and	O
over	O
90%	O
of	O
patients	B-T101
in	O
both	O
arms	O
have	O
been	O
retained	B-T169
over	O
the	O
3-	O
month	B-T079
follow-up	B-T058
period	B-T079
.	O
Biological	B-T080
data	B-T078
suggests	O
a	O
shift in the biological milieu	B-T070
with	O
the	O
predominance	O
of	O
Chlamydia trachomatis	B-T047
,	O
Mycoplasma genitalium	B-T047
,	O
and	O
Trichomonas vaginalis infections	B-T047
.	O
Preliminary	B-T079
data	B-T078
from	O
the	O
TECH-N	B-T058
study	O
demonstrated	O
that	O
urban	B-T083
,	O
low-income	B-T033
,	O
minority	B-T098
AYA	B-T100
with	O
PID	B-T047
can	O
effectively	O
be	O
recruited	B-T052
and	O
retained	B-T169
to	O
participate	B-T058
in	O
sexual	B-T032
and	O
reproductive health	B-T091
RCTs	B-T062
with	O
sufficient	B-T080
investment	B-T073
in	O
the	O
design	B-T052
and	O
infrastructure of the study	B-T185
.	O
Community	B-T096
-based	O
sexual health	B-T032
interventions	B-T061
appear	O
to	O
be	O
both	O
feasible	B-T080
and	O
acceptable	B-T080
in	O
this	O
population	B-T098
.	O

Extended	O
use	O
of	O
Prostate Health Index	B-T059
and	O
percentage	O
of	O
[-2]pro-prostate-specific antigen	B-T116
in	O
Chinese	B-T098
men	B-T098
with	O
prostate specific antigen	B-T116
10-20	O
ng/mL	O
and	O
normal	B-T080
digital rectal examination	B-T060
We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate Health Index	B-T059
(	O
PHI	B-T059
)	O
and	O
percentage	O
of	O
[-2]pro-prostate-specific antigen	B-T116
(	O
%p2PSA	B-T116
)	O
in	O
Chinese	B-T098
men	B-T098
with	O
prostate-specific antigen	B-T116
(	O
PSA	B-T116
)	O
10-20	O
ng/mL	O
and	O
normal	B-T080
digital rectal examination	B-T060
(	O
DRE	B-T060
).	O
All	O
consecutive	O
Chinese	B-T098
men	B-T098
with	O
PSA	B-T116
10-20	O
ng/mL	O
and	O
normal	B-T080
DRE	B-T060
who	O
agreed	O
for	O
transrectal ultrasound	B-T060
(	O
TRUS	B-T060
)-guided	O
10-core	O
prostate biopsy	B-T060
were	O
recruited.	O
Blood samples	B-T031
were	O
taken	O
immediately	O
before	O
TRUS	B-T060
-guided	O
prostate biopsy	B-T060
.	O
The	O
performances	O
of	O
total PSA	B-T059
(	O
tPSA	B-T059
),	O
%	O
free-to-total PSA	B-T059
(%	O
fPSA	B-T059
),	O
%p2PSA	B-T116
,	O
and	O
PHI	B-T059
were	O
compared	O
using	O
logistic regression	B-T062
,	O
receiver operating characteristic	B-T081
,	O
and	O
decision curve analyses	B-T062
(	O
DCA	B-T062
).	O
From	O
2008	O
to	O
2015,	O
312	O
consecutive	O
Chinese	B-T098
men	B-T098
were	O
included.	O
Among	O
them,	O
53	O
out	O
of	O
312	O
(17.0%)	O
men	B-T098
were	O
diagnosed	B-T033
to	O
have	O
prostate cancer	B-T191
on	O
biopsy	B-T060
.	O
The	O
proportions	O
of	O
men	B-T098
with	O
positive biopsies	B-T033
biopsies	B-T060
were	O
6.7%	O
in	O
PHI	B-T059
<35,	O
22.8%	O
in	O
PHI	B-T059
35-55,	O
and	O
54.5%	O
in	O
PHI	B-T059
>55	O
(	O
chi-square test	B-T170
,	O
p<0.001).	O
The	O
area under curves	B-T081
(	O
AUC	B-T081
)	O
of	O
the	O
base model	B-T170
including	O
age	B-T032
,	O
tPSA	B-T059
and	O
status	O
of	O
initial/repeated	O
biopsy	B-T060
was	O
0.64.	O
Adding	O
%p2PSA	B-T116
and	O
PHI	B-T059
to	O
the	O
base model	B-T170
improved	B-T033
the	O
AUC	B-T081
to	O
0.79	O
(p<0.001)	O
and	O
0.78	O
(p<0.001),	O
respectively,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
DCA	B-T062
.	O
The	O
positive biopsy	B-T033
biopsy	B-T060
rates	O
of	O
Gleason 7 or above	B-T185
prostate cancers	B-T191
were	O
2.2%	O
for	O
PHI	B-T059
<35,	O
7.9%	O
for	O
PHI	B-T059
35-55,	O
and	O
36.4%	O
for	O
PHI	B-T059
>55	O
(	O
chi-square test	B-T170
,	O
p<0.001).	O
By	O
utilizing	O
the	O
PHI	B-T059
cutoff	O
of	O
35	O
to	O
men	B-T098
with	O
PSA	B-T116
10-20	O
ng/mL	O
and	O
normal	B-T080
DRE	B-T060
,	O
57.1%	O
(178	O
of	O
312)	O
biopsies	B-T060
could	O
be	O
avoided	B-T078
.	O
Both	O
PHI	B-T059
and	O
%p2PSA	B-T116
performed	O
well	O
in	O
predicting	O
prostate cancer	B-T191
and	O
high grade prostate cancer	B-T191
.	O
The	O
use	O
of	O
PHI	B-T059
and	O
%p2PSA	B-T116
should	O
be	O
extended	O
to	O
Chinese	B-T098
men	B-T098
with	O
PSA	O
10-20	O
ng/mL	O
and	O
normal	B-T080
DRE	B-T060
.	O

A	O
pilot study	B-T062
exploring	O
the	O
relationship	B-T080
between	O
self	B-T078
-	O
compassion	B-T054
,	O
self	B-T078
-	O
judgement	B-T041
,	O
self	B-T078
-	O
kindness	B-T041
,	O
compassion	B-T054
,	O
professional quality of life	B-T078
and	O
wellbeing	B-T033
among	O
UK	B-T083
community nurses	B-T097
Compassion fatigue	B-T048
and	O
burnout	B-T048
can	O
impact	B-T080
on	O
performance	B-T052
of	O
nurses	B-T097
.	O
This	O
paper	O
explores	O
the	O
relationship	B-T080
between	O
self	B-T078
-	O
compassion	B-T054
,	O
self	B-T078
-	O
judgement	B-T041
,	O
self	B-T078
-	O
kindness	B-T041
,	O
compassion	B-T054
,	O
professional quality of life	B-T078
,	O
and	O
wellbeing	B-T033
among	O
community nurses	B-T097
.	O
To	O
measure	B-T081
associations	B-T080
between	O
self	B-T078
-	O
compassion	B-T054
,	O
compassion fatigue	B-T048
,	O
wellbeing	B-T033
,	O
and	O
burnout	B-T048
in	O
community nurses	B-T097
.	O
Quantitative	B-T081
data	B-T078
were	O
collected	B-T169
using	O
standardised	B-T080
psychometric questionnaires	B-T170
:	O
(1)	O
Professional Quality of Life Scale	B-T170
;	O
(2)	O
Self-Compassion Scale	B-T081
;	O
(3)	O
short Warwick Edinburgh Mental Wellbeing Scale	B-T170
;	O
(4)	O
Compassion For Others Scale	B-T081
,	O
used	O
to	O
measure	B-T081
relationships	B-T080
between	O
self	B-T078
-	O
compassion	B-T054
,	O
compassion fatigue	B-T048
,	O
wellbeing	B-T033
,	O
and	O
burnout	B-T048
.	O
A	O
cross sectional	B-T062
sample	O
of	O
registered community nurses	B-T097
(n=37)	O
studying	O
for	O
a	O
postgraduate	B-T077
diploma	B-T033
at	O
a	O
University	B-T073
in	O
the	O
North of England	B-T083
took	O
part	O
in	O
this	O
study	B-T062
.	O
Results	B-T169
show	O
that	O
community nurses	B-T097
who	O
score	B-T081
high	B-T080
on	O
measures	B-T081
of	O
self	B-T078
-	O
compassion	B-T054
and	O
wellbeing	B-T033
,	O
also	O
report	O
less	B-T080
burnout	B-T048
.	O
Greater	B-T081
compassion	B-T054
satisfaction	B-T041
was	O
also	O
positively	B-T033
associated with	B-T080
compassion	B-T054
for	O
others,	O
and	O
wellbeing	B-T033
,	O
whilst	O
also	O
being	O
negatively	B-T033
correlated	B-T080
with	O
burnout	B-T048
.	O
High	B-T080
levels	B-T080
of	O
self	B-T078
-	O
compassion	B-T054
were	O
linked	O
with	O
lower	B-T052
levels	B-T080
of	O
burnout	B-T048
.	O
Furthermore	O
when	O
community nurses	B-T097
have	O
greater	B-T081
compassion	B-T054
satisfaction	B-T041
they	O
also	O
report	O
more	O
compassion	B-T054
for	O
others,	O
increased	B-T081
wellbeing	B-T033
,	O
and	O
less	B-T080
burnout	B-T048
.	O
The	O
implications	B-T169
of	O
this	O
are	O
discussed	O
alongside	O
suggestions	B-T078
for	O
the	O
promotion	B-T052
of	O
greater	B-T081
compassion	B-T054

CD169	B-T116
identifies	B-T033
an	O
activated	B-T025
CD8(+) T cell	B-T025
subset	B-T185
in	O
regional lymph nodes	B-T023
that	O
predicts	B-T078
favorable	B-T080
prognosis	B-T058
in	O
colorectal cancer	B-T191
patients	B-T101
CD169	B-T116
was	O
first	O
identified	O
on	O
macrophages	B-T025
(	O
Mϕ	B-T025
)	O
and	O
linked	O
to	O
antigen presentation	B-T043
.	O
Here,	O
we	O
showed	O
CD169 expression	B-T045
on	O
some	O
CD8(+) T lymphocytes	B-T025
in	O
regional lymph nodes	B-T023
(	O
LNs	B-T023
)	O
and	O
investigated	B-T169
the	O
function	B-T039
and	O
clinical relevance	B-T033
of	O
CD169(+)CD8(+) T cells	B-T025
in	O
tumor-draining LNs	B-T023
of	O
colorectal cancer	B-T191
(	O
CRC	B-T191
)	O
patients	B-T101
.	O
Fresh tumor-draining LN tissues	B-T024
from	O
39	O
randomly	B-T080
enrolled patients	B-T033
were	O
assessed	B-T052
by	O
flow cytometry	B-T059
for	O
activation	B-T025
and	O
differentiation	B-T043
of	O
CD169(+)CD8(+) T cells	B-T025
and	O
T cell-mediated killing of tumor cells	B-T043
.	O
In	O
total,	O
114	O
tumor-draining LN	B-T023
paraffin	O
sections	O
from	O
CRC	B-T191
patients	B-T101
were	O
analyzed	O
by	O
multiple-color immunofluorescence	B-T059
for	O
CD169(+)CD8(+) T cell	B-T025
distribution	B-T169
and	O
clinical	O
values.	O
The	O
prognostic	B-T170
significance	B-T080
of	O
CD169(+)CD8(+) T cells	B-T025
was	O
evaluated	B-T058
by	O
Kaplan-Meier analysis	B-T081
.	O
A	O
fraction of	B-T081
CD8(+) T cells	B-T025
in	O
regional LNs	B-T023
,	O
but	O
not	O
peripheral blood	B-T031
,	O
tonsils	B-T023
,	O
or	O
tumors	B-T191
,	O
expressed surface CD169	B-T116
.	O
In situ	B-T082
detection	B-T061
of	O
draining LNs	B-T023
revealed	B-T080
preferential	O
localization	B-T169
of	O
CD169(+)CD8(+) T cells	B-T025
to	O
subcapsular sinus	B-T024
and	O
interfollicular regions	B-T029
,	O
closely	O
associated with	B-T080
CD169(+) Mϕ	B-T025
.	O
CD169(+)CD8(+) T cell	B-T025
ratios	B-T081
were	O
significantly	O
lower	O
in	O
peri-tumor	B-T082
LNs	B-T023
than	O
distant-tumor	B-T082
LNs	B-T023
.	O
CD169(+)CD8(+) T cells	B-T025
predominantly	B-T080
expressed	O
activation markers	B-T201
(	O
CD69	B-T116
,	O
HLA-DR	B-T116
,	O
PD-1	B-T116
)	O
with	O
slightly	O
lower	O
CD45RA	B-T116
and	O
CD62L	B-T116
levels	B-T080
.	O
They	O
produced	O
high	B-T080
granzyme B	B-T116
,	O
perforin	B-T116
,	O
TNF-α	B-T116
,	O
and	O
IFNγ	B-T116
levels	B-T080
,	O
and	O
promoted	O
tumor-killing efficiency	B-T061
ex vitro	B-T082
.	O
Moreover,	O
CD169(+)CD8(+) T cells	B-T025
infiltrating	B-T046
tumor-draining LNs	B-T023
decreased	B-T081
with	O
disease progression	B-T046
and	O
were	O
strongly	O
associated with	B-T080
CRC	B-T191
patient	B-T101
survival	B-T052
.	O
We	O
identified	B-T080
novel	O
activated	B-T025
/	O
cytolytic CD169(+)CD8(+) T cells	B-T025
selectively	O
present	O
in	O
regional LNs	B-T023
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic factor	B-T201
and	O
indicator	B-T169
for	O
selecting	B-T052
patients	B-T101
for	O
immunotherapy	B-T061
.	O

Appearance	B-T080
Differences	B-T080
Between	O
Lots	B-T170
and	O
Brands	B-T170
of	O
Similar	O
Shade	B-T080
Designations	B-T170
of	O
Dental Composite Resins	B-T109
The	O
purposes	B-T169
of	O
this	O
study	B-T062
were	O
to	O
investigate	B-T169
differences	B-T080
in	O
two	O
inherent	B-T080
appearance	B-T080
characteristics	B-T080
between	O
lots	B-T170
of	O
an	O
enamel dental composite resin	B-T109
of	O
the	O
same	O
shade	B-T080
and	O
brand	B-T170
,	O
and	O
to	O
further	O
compare	B-T052
these	O
differences	B-T080
to	O
those	O
of	O
similar	O
shade	B-T080
designation	B-T170
of	O
a	O
different	B-T080
brand	B-T170
of	O
dental composite resins	B-T109
.	O
Appearance	B-T080
analyses	B-T062
proceeded	B-T079
for	O
three	O
different	O
lots	B-T170
of	O
shades	B-T080
A1	B-T185
,	O
B2	B-T185
,	O
and	O
D3	B-T185
manufactured	B-T057
by	O
one	O
company	B-T073
and	O
for	O
one	O
lot	B-T170
of	O
shade	B-T080
EA1	B-T185
manufactured	B-T057
by	O
another.	O
Samples	B-T167
were	O
measured	B-T080
on	O
black	B-T080
,	O
white	B-T080
,	O
and	O
gray	B-T080
backings	B-T077
using	O
spectroradiometry	B-T059
.	O
Kubelka-Munk theory	B-T078
was	O
used	O
to	O
determine	O
reflectivity	B-T081
of	O
each	O
lot	B-T170
studied	B-T062
.	O
CIELAB values	B-T080
and	O
color	B-T080
differences	B-T080
between	O
shades	B-T080
and	O
lots	B-T170
were	O
analyzed	B-T062
.	O
Translucency	B-T080
indicators	B-T130
were	O
compared	B-T052
between	O
lots	B-T170
over	O
thicknesses	B-T080
from	O
0.5	O
to	O
3.0	O
mm.	O
Differences	B-T080
in	O
inherent	B-T080
color	B-T080
between	O
some	O
lots	B-T170
of	O
same	O
shade	B-T080
designations	B-T170
within	O
a	O
brand	B-T170
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	B-T080
threshold	B-T080
.	O
Color	B-T080
difference	B-T080
between	O
an	O
enamel composite resin	B-T109
of	O
shade	B-T080
A1	B-T185
and	O
a	O
composite resin	B-T109
of	O
shade	B-T080
EA1	B-T185
was	O
also	O
above	O
the	O
acceptability	B-T080
threshold	B-T080
.	O
Statistically significant	B-T081
differences	B-T080
in	O
the	O
translucency	B-T080
were	O
found	O
between	O
some	O
lots	B-T170
of	O
one	O
shade	B-T080
over	O
the	O
entire	O
range	B-T081
of	O
thicknesses	B-T080
studied	B-T062
.	O
Appearance	B-T080
analyses	B-T062
indicate	B-T078
substantial	O
variation	B-T080
between	O
lots	B-T170
of	O
same	O
shade	B-T080
designations	B-T170
as	O
well	O
as	O
between	O
brands	B-T170
of	O
similar	O
shade	B-T080
designations	B-T170
.	O
Optical	B-T090
principles	O
applied	B-T169
to	O
important	B-T080
clinical	B-T080
appearance	B-T080
attributes	O
are	O
described	O
which	O
characterize	B-T052
inherent	B-T080
appearance	B-T080
attributes	O
and	O
provide	O
aid	B-T080
in	O
the	O
appearance	B-T080
matching	B-T080
process	B-T067
for	O
dental composite resins	B-T109
used	O
in	O
restorative	B-T061
and	O
operative dental procedures	B-T061
.	O
(J	O
Esthet	O
Restor	O
Dent	O
29:E6-E14,	O
2017).	O

Patient Preferences	B-T080
in	O
Treatment	B-T061
Choices	B-T052
for	O
Early-Stage	B-T079
Lung Cancer	B-T191
Decision-making	B-T041
for	O
lung cancer	B-T191
treatment	B-T061
can	O
be	O
complex	B-T080
because	O
it	O
involves	O
both	O
provider	B-T097
recommendations	B-T078
based	O
on	O
the	O
patient's	B-T101
clinical	B-T080
condition	B-T080
and	O
patient preferences	B-T080
.	O
This	O
study	B-T062
describes	O
the	O
relative	O
importance	O
of	O
several	O
considerations	B-T033
in	O
lung cancer	B-T191
treatment	B-T061
from	O
the	O
patient's	B-T101
perspective	B-T041
.	O
A	O
conjoint preference experiment	B-T062
began	O
by	O
asking	O
respondents	B-T098
to	O
imagine	O
that	O
they	O
had	O
just	O
been	O
diagnosed	B-T033
with	O
lung cancer	B-T191
.	O
Respondents	B-T098
then	O
chose	B-T052
among	O
procedures	B-T061
that	O
differed	O
regarding	O
treatment	B-T061
modalities	B-T077
,	O
the	O
potential	O
for	O
treatment	B-T061
-related	O
complications	B-T046
,	O
the	O
likelihood	B-T081
of	O
recurrence	B-T067
,	O
provider	B-T097
case	B-T169
volume	B-T081
,	O
and	O
distance	B-T081
needed	B-T169
to	O
travel	B-T056
for	O
treatment	B-T061
.	O
Conjoint analysis	B-T062
derived	O
relative	O
weights	O
for	O
these	O
attributes	B-T080
.	O
A	O
total	O
of	O
225	O
responses	B-T170
were	O
analyzed	B-T062
.	O
Respondents	B-T098
were	O
most	O
willing	O
to	O
accept	O
minimally	B-T080
invasive operations	B-T061
for	O
treatment	B-T061
of	O
their	O
hypothetical	O
lung cancer	B-T191
,	O
followed	O
by	O
stereotactic body radiation therapy	B-T061
(	O
SBRT	B-T061
);	O
they	O
were	O
least	O
willing	O
to	O
accept	O
thoracotomy	B-T061
.	O
Treatment	B-T061
type	O
and	O
risk of recurrence	B-T081
were	O
the	O
most	O
important	O
attributes	B-T080
from	O
the	O
conjoint experiment	B-T062
(each	O
with	O
a	O
relative	O
weight	O
of	O
0.23),	O
followed	O
by	O
provider	B-T097
volume	B-T081
(relative	O
weight	O
of	O
0.21),	O
risk	B-T078
of	O
major	O
complications	B-T046
(relative	O
weight	O
of	O
0.18),	O
and	O
distance	B-T081
needed	B-T169
to	O
travel	B-T056
for	O
treatment	B-T061
(relative	O
weight	O
of	O
0.15).	O
Procedural	B-T061
and	O
treatment	B-T061
preferences	B-T078
did	O
not	O
vary	O
with	O
demographics	B-T080
,	O
self-reported	B-T062
health status	B-T080
,	O
or	O
familiarity	B-T041
with	O
the	O
procedures	B-T061
.	O
Survey	B-T170
respondents	B-T098
preferred	O
minimally	B-T080
invasive operations	B-T061
over	O
SBRT	B-T061
or	O
thoracotomy	B-T061
for	O
treatment	B-T061
of	O
early-stage	B-T079
non-small cell lung cancer	B-T191
.	O
Treatment	B-T061
modality	B-T077
and	O
risk	B-T078
of	O
cancer recurrence	B-T191
were	O
the	O
most	O
important	O
factors	O
associated	O
with	O
treatment	B-T061
preferences	B-T078
.	O
Provider	B-T097
experience	B-T041
outweighed	O
the	O
potential	O
need	B-T169
to	O
travel	B-T056
for	O
lung cancer	B-T191
treatment	B-T061
.	O

Suppressed	B-T169
translation	B-T044
and	O
ULK1	B-T116
degradation	B-T044
as	O
potential	B-T080
mechanisms	B-T169
of	O
autophagy	B-T043
limitation	O
under	O
prolonged	B-T079
starvation	B-T033
Macroautophagy	B-T043
/	O
autophagy	B-T043
is	O
a	O
well-organized	O
process	O
of	O
intracellular degradation	B-T043
,	O
which	O
is	O
rapidly	O
activated	B-T052
under	O
starvation	B-T033
conditions.	O
Recent	O
data	B-T078
demonstrate	O
a	O
transcriptional	B-T045
upregulation	B-T044
of	O
several	O
autophagy	B-T043
genes	B-T028
as	O
a	O
mechanism	B-T169
that	O
controls	B-T169
autophagy	B-T043
in	O
response	O
to	O
starvation	B-T033
.	O
Here	O
we	O
report	O
that	O
despite	O
the	O
significant	O
upregulation	B-T044
of	O
mRNA	B-T114
of	O
the	O
essential	O
autophagy	B-T043
initiation gene	B-T028
ULK1	B-T028
,	O
its	O
protein	B-T116
level	B-T080
is	O
rapidly	O
reduced	B-T080
under	O
starvation	B-T033
.	O
Although	O
both	O
autophagic	B-T043
and	O
proteasomal systems	B-T116
contribute	O
to	O
the	O
degradation	B-T044
of	O
ULK1	B-T116
,	O
under	O
prolonged	B-T079
nitrogen	B-T123
deprivation	B-T080
,	O
its	O
level	B-T080
was	O
still	O
reduced	B-T080
in	O
ATG7	B-T028
knockout cells	B-T025
,	O
and	O
only	O
initially	O
stabilized	O
in	O
cells	B-T025
treated	B-T169
with	O
the	O
lysosomal	B-T026
or	O
proteasomal inhibitors	B-T121
.	O
We	O
demonstrate	O
that	O
under	O
starvation	B-T033
,	O
protein translation	B-T044
is	O
rapidly	O
diminished	B-T081
and,	O
similar	O
to	O
treatments	B-T061
with	O
the	O
proteosynthesis inhibitors	B-T121
cycloheximide	B-T109
or	O
anisomycin	B-T109
,	O
is	O
associated	O
with	O
a	O
significant	O
reduction	B-T080
of	O
ULK1	B-T116
.	O
Furthermore,	O
it	O
was	O
found	O
that	O
inhibition	B-T052
of	O
the	O
mitochondrial	B-T026
respiratory complexes	B-T026
or	O
the	O
mitochondrial	B-T026
ATP synthase function	B-T044
that	O
could	O
also	O
take	O
place	O
in	O
the	O
absence	B-T169
of	O
substrates	B-T167
,	O
promote	O
upregulation	B-T044
of	O
ULK1 mRNA	B-T114
and	O
protein expression	B-T045
in	O
an	O
AMPK	B-T116
-	O
dependent	B-T169
manner	O
in	O
U1810 lung cancer cells	B-T025
growing	O
in	O
complete	O
culture medium	B-T130
.	O
These	O
inhibitors	B-T080
could	O
also	O
drastically	O
increase	B-T169
the	O
ULK1 protein	B-T116
in	O
U1810 cells	B-T025
with	O
knockout	O
of	O
ATG13	B-T028
,	O
where	O
the	O
ULK1	B-T116
expression	B-T045
is	O
significantly	O
diminished	B-T081
.	O
However,	O
such	O
upregulation	B-T044
of	O
ULK1 protein	B-T116
is	O
negligible	O
under	O
starvation	B-T033
conditions,	O
further	O
signifying	O
the	O
contribution	O
of	O
translation	B-T044
and	O
suggesting	O
that	O
transcriptional	B-T045
upregulation	B-T044
of	O
ULK1 protein	B-T116
will	O
be	O
diminished	B-T081
under	O
such	O
conditions.	O
Thus,	O
we	O
propose	O
a	O
model	B-T075
where	O
inhibition	B-T052
of	O
protein translation	B-T044
,	O
together	O
with	O
the	O
degradation	B-T044
systems,	O
limit	O
autophagy	B-T043
during	O
starvation	B-T033
.	O

Neuroprotective Role	B-T169
of	O
MicroRNA-22	B-T028
in	O
a	O
6-Hydroxydopamine	B-T109
-	O
Induced	B-T169
Cell	B-T025
Model	B-T050
of	O
Parkinson's Disease	B-T047
via	O
Regulation	B-T045
of	O
Its	O
Target	B-T169
Gene	B-T028
TRPM7	B-T028
Parkinson's disease	B-T047
(	O
PD	B-T047
),	O
the	O
second	O
most	O
prevalent	B-T082
neurodegenerative disorder	B-T047
with	O
only	O
symptomatic	B-T169
treatment	B-T061
available	B-T169
,	O
is	O
characterized	B-T052
by	O
a	O
progressive	B-T169
loss	B-T081
of	O
dopaminergic neurons	B-T025
in	O
the	O
midbrain	B-T023
.	O
Ample	O
evidence	O
indicated	O
that	O
microRNAs	B-T114
(	O
miRs	B-T114
)	O
could	O
regulate post-transcriptional	B-T045
gene expression	B-T045
and	O
neuronal disease	B-T047
.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
have	O
evaluated	O
the	O
effects	B-T080
and	O
mechanism	B-T169
of	O
miR-22	B-T028
in	O
PC12 pheochromocytoma cells	B-T025
treated	B-T169
with	O
6-hydroxydopamine	B-T109
(	O
6-OHDA	B-T109
)	O
to	O
mimic	O
PD	B-T047
.	O
RT-PCR	B-T063
results	B-T169
showed	O
that	O
the	O
expression	B-T045
of	O
miR-22	B-T028
is	O
downregulated	B-T044
in	O
6-OHDA	B-T109
-	O
treated	B-T169
PC12 cells	B-T025
,	O
and	O
the	O
overexpression	B-T045
of	O
miR-22	B-T028
significantly	O
promoted	B-T052
the	O
survival	B-T043
and	O
proliferation	B-T043
of	O
6-OHDA	B-T109
-	O
induced	B-T169
PC12 cells	B-T025
,	O
whereas	O
miR-22	B-T028
inhibitor	B-T080
reversed	B-T169
these	O
effects	B-T080
.	O
In	O
addition,	O
PC12 cells	B-T025
were	O
treated	B-T169
with	O
miR-22 mimics	B-T028
or	O
inhibitor	B-T080
following	B-T079
6-OHDA	B-T109
administration	B-T061
,	O
which	O
medicated	O
ROS	B-T123
production	B-T044
and	O
upregulation	B-T044
or	O
downregulation	B-T044
of	O
caspase-3 activity	B-T044
,	O
respectively.	O
A	O
luciferase	B-T116
reporter	O
assay	B-T059
revealed	B-T080
that	O
transient receptor potential melastatin 7	B-T028
(	O
TRPM7	B-T028
)	O
is	O
a	O
direct	B-T080
target	B-T169
gene	B-T028
of	O
miR-22	B-T028
,	O
and	O
miR-22	B-T028
overexpression	B-T045
markedly	O
downregulated	B-T044
the	O
level	B-T080
of	O
TRPM7	B-T028
.	O
Strikingly,	O
further	O
analysis	B-T062
showed	O
that	O
miR-22	B-T028
mediated	O
6-OHDA	B-T109
-	O
induced	B-T169
PC12	B-T025
cell survival	B-T043
and	O
proliferation	B-T043
by	O
targeting	B-T169
TRPM7	B-T028
.	O
Taken	O
together,	O
the	O
present	O
study	B-T062
showed	O
that	O
miR-22	B-T028
overexpression	B-T045
exhibited	O
neuroprotective	B-T169
and	O
reversal	B-T169
effects	B-T080
on	O
the	O
6-OHDA	B-T109
-	O
induced	B-T169
PC12	B-T025
cell growth	B-T043
and	O
apoptosis	B-T043
by	O
targeting	B-T169
TRPM7	B-T028
.	O

Obstacle course runs	B-T056
:	O
review	B-T170
of	O
acquired	O
injuries	B-T037
and	O
illnesses	B-T184
at	O
a	O
series	B-T081
of	O
Canadian	B-T033
events	B-T051
(	O
RACE	B-T056
)	O
The	O
growing	O
popularity	O
of	O
obstacle course runs	B-T056
(	O
OCRs	B-T056
)	O
has	O
led	O
to	O
significant	B-T078
concerns	B-T078
regarding	O
their	O
safety	B-T068
.	O
The	O
influx	O
of	O
injuries	B-T037
and	O
illnesses	B-T184
in	O
rural areas	B-T082
where	O
OCRs	B-T056
are	O
often	O
held	O
can	O
impose	O
a	O
large	O
burden	O
on	O
emergency medical services	B-T058
(	O
EMS	B-T058
)	O
and	O
local	O
EDs.	O
Literature	B-T170
concerning	B-T078
the	O
safety	B-T068
of	O
these	O
events	B-T051
is	O
minimal	B-T080
and	O
mostly	O
consists	O
of	O
media	B-T170
reports	B-T170
.	O
We	O
sought	O
to	O
characterise	B-T052
the	O
injury	B-T037
and	O
illness	B-T184
profile	O
of	O
OCRs	B-T056
and	O
the	O
level	B-T080
of	O
medical care	B-T061
required.	O
This	O
study	B-T062
analysed	B-T062
OCR	B-T056
events	B-T051
occurring	O
in	O
eight	O
locations	O
across	O
Canada	B-T083
from	O
May	O
to	O
August	O
2015	O
(total	O
45	O
285	O
participants	B-T098
).	O
Data	B-T078
were	O
extracted	B-UnknownType
from	O
event	B-T051
medical charts	B-T074
of	O
patients	B-T101
presenting	O
to	O
the	O
onsite	B-T082
medical team	B-T058
,	O
including	O
injury	B-T037
or	O
illness	B-T184
type,	O
onsite	O
treatment	B-T061
and	O
disposition	B-T078
.	O
There	O
were	O
557	O
race participants	B-T098
treated	B-T169
at	O
eight	O
OCR	B-T056
events	B-T051
(1.2%	O
of	O
all	O
participants	B-T098
).	O
There	O
were	O
609	O
medical complaints	B-T170
in	O
total.	O
Three	O
quarters	O
of	O
injuries	B-T037
were	O
musculoskeletal	B-T169
in	O
nature.	O
Eighty-nine	O
per	O
cent	O
returned	O
to	O
the	O
event	B-T051
with	O
no	O
need	O
for	O
further	O
medical care	B-T061
.	O
The	O
majority	O
of	O
treatments	B-T061
were	O
completed	O
with	O
first aid	B-T061
and	O
basic	O
medical equipment	B-T074
.	O
Eleven	O
patients	B-T101
(2%	O
of	O
patients	B-T101
)	O
required	O
transfer	O
to	O
hospital	B-T073
by	O
EMS	B-T058
for	O
presentations	O
including	O
fracture	B-T037
,	O
dislocation	B-T037
,	O
head injury	B-T037
,	O
chest pain	B-T184
,	O
fall from height	B-T067
,	O
and	O
abdominal pain	B-T184
.	O
We	O
found	O
that	O
1.2%	O
of	O
race participants	B-T098
presented	O
to	O
onsite	O
medical services	B-T058
.	O
The	O
majority	O
of	O
complaints	O
were	O
minor	B-T037
and	O
musculoskeletal	B-T037
in	O
nature.	O
Only	O
2%	O
of	O
those	O
treated	B-T169
were	O
transferred	O
to	O
hospital	B-T073
through	O
EMS	B-T058
.	O
This	O
is	O
consistent with	B-T078
other	O
types	O
of	O
mass gathering	B-T033
events	B-T051
.	O

Is	O
Modern	B-T079
Medical Management	B-T058
Changing	B-T169
Ultimate	O
Patient Outcomes	B-T078
in	O
Inflammatory Bowel Disease	B-T047
?	O
The	O
impact	B-T080
of	O
modern	B-T079
medical management	B-T058
of	O
inflammatory bowel disease	B-T047
(	O
IBD	B-T047
)	O
on	O
surgical necessity	B-T058
and	O
outcomes	B-T169
remains	O
unclear	B-T033
.	O
We	O
hypothesized	O
that	O
surgery	B-T061
rates	B-T081
have	O
decreased	B-T081
while	O
outcomes	B-T169
have	O
worsened	B-T033
due	O
to	O
operating	B-T061
on	O
"	O
sicker	B-T184
"	O
patients	B-T101
since	O
the	O
introduction	B-T169
of	O
biologic medications	B-T061
.	O
The	O
Nationwide	O
Inpatient	B-T101
Sample	B-T167
and	O
ICD-9-CM codes	B-T170
were	O
used	O
to	O
identify	O
inpatient	B-T101
admissions	B-T058
for	O
Crohn's disease	B-T047
and	O
ulcerative colitis	B-T047
.	O
Trends	B-T079
in	O
IBD	B-T047
nutrition	B-T033
,	O
surgeries	B-T061
,	O
and	O
postoperative complications	B-T046
were	O
determined.	O
There	O
were	O
191,743	O
admissions	B-T058
for	O
IBD	B-T047
during	O
the	O
study	B-T062
period	B-T079
.	O
Surgery	B-T061
rates	B-T081
were	O
largely	O
unchanged	B-T033
over	O
the	O
study	B-T062
period	B-T079
,	O
ranging	O
from	O
9	O
to	O
12	O
%	O
of	O
admissions	B-T058
in	O
both	O
Crohn's disease	B-T047
and	O
ulcerative colitis	B-T047
.	O
The	O
rate	B-T081
of	O
poor nutrition	B-T047
increased	B-T081
by	O
67	O
%	O
in	O
ulcerative colitis	B-T047
and	O
by	O
83	O
%	O
in	O
Crohn's disease	B-T047
.	O
Rates	B-T081
of	O
postoperative	B-T079
anastomotic leak	B-T046
(10.2-13.9	O
%)	O
were	O
unchanged	B-T033
over	O
the	O
years.	O
Postoperative infection	B-T046
rates	B-T081
decreased	B-T081
by	O
17	O
%	O
in	O
Crohn's disease	B-T047
(18	O
%	O
in	O
2003	O
to	O
15	O
%	O
in	O
2012;	O
P	O
<	O
0.001)	O
but	O
did	O
not	O
show	O
a	O
trend	B-T033
in	O
any	O
direction	O
in	O
ulcerative colitis	B-T047
.	O
Rates	B-T081
of	O
IBD	B-T047
surgery	B-T091
have	O
remained	O
stable	B-T080
while	O
postoperative infectious complications	B-T046
have	O
remained	O
stable	B-T080
or	O
decreased	B-T081
since	O
the	O
implementation	B-T058
of	O
biologic therapies	B-T061
.	O
We	O
identified	O
an	O
increase	B-T169
in	O
poor nutrition	B-T047
in	O
surgical patients	B-T101
.	O

Clinical	B-T080
Experience	B-T067
With	O
the	O
Subcutaneous Implantable Cardioverter-Defibrillator	B-T074
in	O
Adults	B-T100
With	O
Congenital Heart Disease	B-T019
Sudden cardiac death	B-T046
is	O
a	O
major	O
contributor	O
to	O
mortality	B-T081
for	O
adults	B-T100
with	O
congenital heart disease	B-T019
.	O
The	O
subcutaneous	B-T082
implantable cardioverter-defibrillator	B-T074
(	O
ICD	B-T074
)	O
has	O
emerged	O
as	O
a	O
novel	B-T080
tool	B-T073
for	O
prevention	B-T080
of	O
sudden cardiac death	B-T046
,	O
but	O
clinical performance	B-T033
data	B-T078
for	O
adults	B-T100
with	O
congenital heart disease	B-T019
are	O
limited.	O
A	O
retrospective study	B-T062
involving	O
7	O
centers	O
over	O
a	O
5-	O
year	B-T079
period	B-T079
beginning	O
in	O
2011	O
was	O
performed	B-T169
.	O
Twenty-one	O
patients	B-T101
(	O
median	B-T081
33.9	O
years	B-T079
)	O
were	O
identified.	O
The	O
most	O
common	O
diagnosis	B-T033
was	O
single ventricle	B-T019
physiology	B-T039
(52%),	O
9	O
palliated	B-T061
by	O
Fontan operation	B-T061
and	O
2	O
by	O
aortopulmonary shunts	B-T061
:	O
d-transposition of the great arteries	B-T019
after	O
Mustard	B-T061
/	O
Senning	B-T061
(n=2),	O
tetralogy of Fallot	B-T019
(n=2),	O
aortic valve disease	B-T047
(n=2),	O
and	O
other	O
biventricular	B-T082
surgery	B-T061
(n=4).	O
A	O
prior	O
cardiac device	B-T074
had	O
been	O
implanted	B-T061
in	O
7	O
(33%).	O
The	O
ICD	B-T074
indication	B-T078
was	O
primary prevention	B-T061
in	O
67%	O
and	O
secondary	B-T061
in	O
33%	O
patient s	B-T101
.	O
The	O
most	O
common	O
reason	O
for	O
subcutaneous	B-T082
ICD	B-T074
placement	B-T058
was	O
limited	O
transvenous access	B-T082
for	O
ventricular lead	B-T074
placement	B-T058
(n=10)	O
followed	O
by	O
intracardiac right-to-left shunt	B-T033
(n=5).	O
Ventricular arrhythmia	B-T047
was	O
induced	B-T169
in	O
17	O
(81%)	O
and	O
was	O
converted	O
with	O
≤80	O
Joules	B-T081
in	O
all.	O
There	O
was	O
one	O
implant complication related to infection	B-T046
,	O
not	B-T080
requiring	O
device removal	B-T061
.	O
Over	O
a	O
median	B-T081
follow-up	B-T058
of	O
14	O
months	B-T079
,	O
4	O
patients	B-T101
(21%)	O
received	O
inappropriate	B-T047
and	O
1	O
(5%)	O
patient	B-T101
received	O
appropriate shocks	B-T046
.	O
There	O
was	O
one	O
arrhythmic death	B-T033
related	O
to	O
asystole	B-T047
in	O
a	O
single ventricle	B-T019
patient	B-T101
.	O
Subcutaneous	B-T082
ICD	B-T074
implantation	B-T061
is	O
feasible	O
for	O
adults	B-T100
with	O
congenital heart disease	B-T019
patients	B-T101
.	O
Most	O
candidates	B-T101
have	O
single ventricle	B-T019
heart disease	B-T047
and	O
limited	O
transvenous options	B-T082
for	O
ICD	B-T074
placement	B-T058
.	O
Despite	O
variable	B-T080
anatomy	B-T080
,	O
this	O
study	B-T062
demonstrates	O
successful	B-T080
conversion	B-T169
of	O
induced	B-T169
ventricular arrhythmia	B-T047
and	O
reasonable	B-T033
rhythm	B-T042
discrimination	B-T042
during	O
follow-up	B-T058
.	O

Interaction	B-T169
of	O
multiple	B-T081
gene variants	B-T028
and	O
their	O
effects	B-T080
on	O
schizophrenia	B-T048
phenotypes	B-T032
Schizophrenia	B-T048
is	O
a	O
clinically	B-T080
heterogeneous disorder	B-T033
and	O
may	O
be	O
explained	O
by	O
its	O
complex	O
genetic architecture	B-T169
.	O
Many	O
schizophrenia	B-T048
susceptibility	B-T201
genes	B-T028
were	O
identified	B-T080
but	O
the	O
picture	O
remains	O
unclear	O
due	O
to	O
inconsistent	B-T080
or	O
contradictory	B-T080
genetic association studies	B-T063
.	O
This	O
confusion	O
may,	O
in	O
part,	O
be	O
because	O
symptoms	B-T184
result	O
from	O
the	O
combined	O
interaction	B-T169
of	O
many	O
genes	B-T028
and	O
these	O
interacting	B-T169
genes	B-T028
are	O
associated with	B-T080
specific	B-T080
sub-phenotypes	B-T032
of	O
schizophrenia	B-T048
rather	O
than	O
schizophrenia	B-T048
as	O
a	O
whole.	O
This	O
study	O
investigates	B-T169
the	O
relationship	B-T080
between	O
schizophrenia	B-T048
susceptibility	B-T201
genes	B-T028
and	O
schizophrenia	B-T048
sub-phenotypes	B-T032
by	O
identifying	B-T080
multiple	B-T081
gene variant	B-T028
interactions	B-T169
.	O
Fifty	O
SNPs	B-T086
from	O
21	O
genes	B-T028
were	O
genotyped	B-T059
in	O
235	O
Australian	B-T098
participants	B-T098
with	O
schizophrenia	B-T048
screened	B-T058
for	O
various	O
phenotypes	B-T032
.	O
Schizophrenia	B-T048
participants	B-T098
were	O
grouped	O
into	O
relevant	B-T080
phenotype	B-T032
clusters	B-T081
using	O
cluster analysis	B-T062
and	O
normalized	B-T062
phenotype	B-T032
cluster	B-T081
scores	B-T081
were	O
calculated	O
for	O
each	O
patient	B-T101
.	O
The	O
relationship	B-T080
between	O
genotypes	B-T032
and	O
normalized	B-T062
phenotype	B-T032
cluster	B-T081
scores	B-T081
were	O
analyzed	O
by	O
linear regression analysis	B-T170
.	O
Three	O
phenotype	B-T032
clusters	B-T081
were	O
identified	B-T080
.	O
There	O
was	O
some	O
overlap	O
in	O
symptoms	B-T184
between	O
phenotype	B-T032
clusters	B-T081
,	O
particularly	O
for	O
depression	B-T048
.	O
However,	O
cluster 1	B-T081
appears	O
to	O
be	O
characterized	O
by	O
speech disorder	B-T047
and	O
affective	O
behavior symptoms	B-T184
,	O
cluster 2	B-T081
has	O
predominantly	O
hallucination	B-T048
symptoms	B-T184
and	O
cluster 3	B-T081
has	O
mainly	O
delusion	B-T048
symptoms	B-T184
.	O
Interaction	B-T169
of	O
five	O
SNPs	B-T086
was	O
found	O
to	O
have	O
an	O
effect	O
on	O
cluster 1	B-T081
symptoms	B-T184
;	O
ten	O
SNPs	B-T086
on	O
cluster 2	B-T081
symptoms	B-T184
;	O
and	O
eight	O
SNPs	B-T086
on	O
cluster 3	B-T081
symptoms	B-T184
.	O
The	O
interaction	B-T169
of	O
specific	B-T080
susceptibility	B-T201
genes	B-T028
is	O
likely	O
to	O
lead	O
to	O
specific	B-T080
clinical	B-T080
sub-phenotypes	B-T032
of	O
schizophrenia	B-T048
.	O
Larger	O
patient	B-T101
cohorts	B-T098
with	O
more	O
extensive	O
clinical	B-T080
data	B-T078
will	O
improve	O
the	O
detection	B-T033
of	O
gene interactions	B-T045
and	O
the	O
resultant	O
schizophrenia	B-T048
clinical	B-T080
phenotypes	B-T032
.	O

Evaluation	O
of	O
DNMT1	B-T028
gene expression profile	B-T081
and	O
methylation	B-T044
of	O
its	O
promoter region	B-T114
in	O
patients	B-T101
with	O
ankylosing spondylitis	B-T047
Ankylosing spondylitis	B-T047
(	O
AS	B-T047
)	O
is	O
an	O
autoimmune disease	B-T047
with	O
a	O
chronic inflammatory arthritis	B-T047
.	O
The	O
critical	O
role	O
of	O
methylation	B-T044
in	O
the	O
biology	B-T091
of	O
immunocytes	B-T025
has	O
increasingly	O
been	O
surveyed	B-T170
to	O
discover	O
disease	B-T047
etiology	B-T169
.	O
DNA methyltransferase 1	B-T116
(	O
DNMT1	B-T116
)	O
is	O
an	O
enzyme	B-T116
,	O
which	O
establishes	O
and	O
regulates	B-T038
patterns	B-T082
of	O
methylated cytosine	B-T109
residues.	O
The	O
aim	B-T078
of	O
the	O
current	O
investigation	B-T058
was	O
to	O
unveil	O
if	O
methylation	B-T044
circumstances	O
of	O
CpG	B-T114
sites	B-T082
in	O
DNMT1	B-T028
promoter	B-T114
could	O
affect	O
the	O
mRNA expression	B-T045
level	B-T080
of	O
this	O
gene	B-T028
in	O
peripheral blood mononuclear cells	B-T025
(	O
PBMCs	B-T025
)	O
from	O
AS	B-T047
patients	B-T101
.	O
PBMCs	B-T025
were	O
isolated	O
from	O
whole blood	B-T031
of	O
40	O
AS	B-T047
patients	B-T101
and	O
40	O
healthy	B-T080
individuals	B-T098
.	O
Total	O
RNA	B-T114
and	O
DNA	B-T114
contents	O
of	O
leukocytes	B-T025
were	O
extracted	B-T061
.	O
Afterward,	O
quantitative analysis	B-T081
was	O
carried	O
out	O
by	O
real-time PCR	B-T063
using	O
the	O
SYBR Green PCR Master Mix	B-T170
.	O
Finally,	O
to	O
determine	O
the	O
methylation	B-T044
level	B-T080
,	O
PCR	B-T063
products	B-T114
of	O
bisulfite-treated DNA	B-T114
from	O
patients	B-T101
and	O
controls	B-T096
were	O
sequenced	B-T059
.	O
Compared	O
with	O
healthy	B-T080
controls	B-T096
,	O
expression level	B-T045
of	O
DNMT1	B-T028
in	O
AS	B-T047
patients	B-T101
was	O
significantly	O
downregulated	B-T044
.	O
Methylation	B-T044
of	O
DNMT1	B-T028
promoter	B-T114
was	O
significantly	O
higher	O
in	O
AS	B-T047
patients	B-T101
in	O
comparison	O
to	O
controls	B-T096
.	O
While	O
a	O
negative	B-T033
correlation	B-T080
between	O
methylation	B-T044
and	O
expression level	B-T045
of	O
DNMT1	B-T028
was	O
observed	O
in	O
AS	B-T047
patients	B-T101
,	O
both	O
methylation	B-T044
and	O
expression level	B-T045
of	O
DNMT1	B-T028
did	O
not	O
correlate	B-T080
with	O
clinical	B-T080
manifestations	B-T169
.	O
Considering	O
the	O
observation	O
that	O
decreased	B-T081
expression level	B-T045
of	O
DNMT1	B-T028
was	O
associated	O
with	O
hypermethylation	B-T045
of	O
DNMT1	B-T028
promoter	B-T114
in	O
PBMCs	B-T025
from	O
AS	B-T047
patients	B-T101
,	O
this	O
survey	B-T170
suggests	O
that	O
dysregulation	O
of	O
DNMT1	B-T028
expression	B-T045
through	O
altered	B-T169
methylation	B-T044
level	B-T080
of	O
other	O
target	B-T169
genes	B-T028
would	O
probably	O
contribute	O
to	O
AS	B-T047
development.	O

Antibacterial	B-T195
Activity	B-T052
of	O
Polyaniline	B-T109
Coated	B-T080
Silver	B-T196
Nanoparticles	B-T073
Synthesized	B-T052
from	O
Piper Betle Leaves Extract	B-T109
Plants	B-T002
or	O
natural resources	B-T078
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	B-T077
method	B-T169
for	O
nanoparticles	B-T073
synthesis	B-T052
.	O
In	O
this	O
study	B-T062
,	O
polyaniline	B-T109
coated	B-T080
silver	B-T196
nanoparticles	B-T073
(	O
AgNPs	B-T073
)	O
synthesized	B-T052
from	O
Piper betle leaves extract	B-T109
were	O
investigated	O
for	O
their	O
antibacterial	B-T195
activity	B-T052
activity	B-T052
.	O
Silver	B-T196
nanoparticles	B-T073
were	O
prepared	O
from	O
the	O
reduction	B-T080
of	O
silver nitrate	B-T121
and	O
NaBH4	B-T130
was	O
used	O
as	O
reducing agent	B-T130
.	O
Silver	B-T196
nanoparticles	B-T073
and	O
extracts	B-T123
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	B-T080
by	O
polyaniline	B-T109
.	O
Prepared	O
nanoparticles	B-T073
were	O
characterized	B-T052
by	O
Visual inspection	B-T169
,	O
Ultraviolet-visible spectroscopy	B-T059
(	O
UV	B-T059
),	O
Fourier transform infrared Spectroscopy	B-T062
(	O
FT-IR	B-T062
),	O
Transmission Electron Microscopy (TEM) techniques	B-T059
.	O
Antibacterial	B-T195
activities	B-T052
of	O
the	O
synthesized	B-T052
silver	B-T196
nanoparticles	B-T073
were	O
tested	B-T169
against	O
Staphylococcus aureus ATCC 25923	B-T007
,	O
Salmonella typhi ATCC 14028	B-T007
,	O
Escherichia coli ATCC 25922	B-T007
and	O
Pseudomonas aeruginosa ATCC 27853	B-T007
.	O
UV-Vis spectrum	B-T059
of	O
reaction mixture	B-T167
showed	O
strong absorption peak	B-T080
with	O
centering	O
at	O
400	O
nm.	O
The	O
FT-IR	B-T062
results	B-T034
imply	O
that	O
Ag-NPs	B-T073
were	O
successfully	O
synthesized	B-T052
and	O
capped with bio-compounds	B-T080
present	O
in	O
P. betle	B-T109
.	O
TEM	B-T059
image	O
showed	O
that	O
Ag-NPs	B-T073
formed	O
were	O
well	O
dispersed	B-T082
with	O
a	O
spherical structures	B-T082
and	O
particle size	B-T081
ranging	O
from	O
10	O
to	O
30	O
nm.	O
The	O
result	B-T169
revealed	B-T080
that	O
Ag-Extract NPs	B-T073
showed	O
32.78±0.64	O
mm	O
zone	O
of	O
inhibition	B-T052
against	O
S. aureus	B-T007
,	O
whereas	O
norfloxacin	B-T109
(	O
positive control	B-T077
)	O
showed	O
maximum	O
32.15±0.40	O
mm	O
zone	O
of	O
inhibition	B-T052
for	O
S. aureus	B-T007
.	O
Again,	O
maximum zone	B-T082
of	O
inhibition	B-T052
29.55±0.45	O
mm	O
was	O
found	O
for	O
S. typhi	B-T007
,	O
27.12±0.38	O
mm	O
for	O
E. coli	B-T007
and	O
21.95±0.45	O
mm	O
for	O
P. aeruginosa	B-T007
.	O
The	O
results	B-T169
obtained	O
by	O
this	O
study	B-T062
can't	O
be	O
directly	O
extrapolated	B-T081
to	O
human	B-T016
;	O
so	O
further studies	B-T062
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	B-T121
activity	B-T052
of	O
Ag-Extract NPs	B-T073
for	O
drug development program	B-T091
.	O

Clinical Pearls	B-T170
in	O
Tremor	B-T184
and	O
Other	O
Hyperkinetic Movement	B-T048
Disorders	B-T048
Hyperkinetic movements	B-T048
,	O
such	O
as	O
tremor	B-T184
,	O
myoclonus	B-T184
,	O
chorea	B-T047
,	O
and	O
dystonia	B-T184
,	O
occur	O
in	O
many	O
neurologic	B-T047
and	O
medical conditions	B-T047
.	O
Accurate	O
clinical evaluation	B-T058
is	O
the	O
important	O
first	O
step	O
for	O
the	O
proper	O
diagnosis	B-T062
and	O
treatment	B-T061
of	O
patients	B-T101
with	O
abnormal movements	B-T047
.	O

Tracking	O
children	B-T100
with	O
acute lymphoblastic leukemia	B-T191
who	O
abandoned	B-T080
therapy	B-T061
:	O
Experience	B-T041
,	O
challenges	B-T058
,	O
parental	B-T099
perspectives	B-T082
,	O
and	O
impact	O
of	O
treatment	B-T061
subsidies	B-T058
and	O
intensified counseling	B-T058
Refusal for treatment	B-T055
and	O
therapy	B-T061
abandonment	B-T033
are	O
important	O
reasons	O
for	O
unfavorable	O
outcome	O
of	O
childhood	B-T079
acute lymphoblastic leukemia	B-T191
(	O
ALL	B-T191
)	O
in	O
resource	B-T078
-poor	O
countries	B-T083
.	O
The	O
present	O
study	B-T062
,	O
conducted	O
on	O
children	B-T100
with	O
ALL	B-T191
whose	O
treatment	B-T061
was	O
abandoned	B-T080
,	O
attempted	O
to	O
track	O
all	O
these	O
children	B-T100
to	O
ascertain	O
the	O
causes	O
and	O
outcome	B-T169
of	O
therapy	B-T061
abandonment	B-T033
/	O
refusal	B-T055
.	O
In	O
order	O
to	O
improve	O
outcome	B-T169
of	O
ALL	B-T191
,	O
measures	O
to	O
prevent	O
abandonment	B-T033
were	O
introduced	O
in	O
the	O
form	O
of	O
treatment	B-T061
subsidies	B-T058
and	O
intensified multistage counseling	B-T058
.	O
Of	O
the	O
77	O
(of	O
418)	O
children	B-T100
abandoning	O
therapy	B-T061
,	O
17	O
(22%)	O
refused upfront	B-T052
,	O
whereas	O
the	O
rest	O
abandoned	B-T080
during	O
various	O
phases	O
of	O
chemotherapy	B-T061
.	O
Only	O
39	O
(50.6%)	O
of	O
these	O
77	O
families	B-T099
could	O
be	O
subsequently	O
contacted.	O
Financial problems	B-T033
,	O
too	O
many	O
dependents	B-T098
at	O
home	B-T082
,	O
and	O
wrong	O
perceptions	B-T041
about	O
cancer	B-T191
led	O
to	O
abandonment	B-T033
in	O
majority.	O
Children abandoning treatment	B-T033
before	O
completion	O
of	O
induction	B-T061
had	O
a	O
significantly	O
shorter	O
survival	B-T052
than	O
who	O
abandoned	B-T080
post induction	B-T079
(P	O
<	O
.0001).	O
Intensified preabandonment counseling	B-T058
and	O
subsidized	O
treatment	B-T061
led	O
to	O
significant	O
reduction	B-T080
in	O
abandonment rates	B-T081
(P	O
<	O
.0001).	O

Effect	B-T080
of	O
New-Onset	B-T033
Left Bundle Branch Block	B-T047
After	O
Transcatheter Aortic Valve Implantation	B-T061
(	O
CoreValve	B-T074
)	O
on	O
Mortality	B-T081
,	O
Frequency	B-T079
of	O
Re-Hospitalization	B-T058
,	O
and	O
Need	O
for	O
Pacemaker	B-T074
New-onset	B-T033
conduction disturbances	B-T046
are	O
common	O
after	O
transcatheter aortic valve implantation	B-T061
(	O
TAVI	B-T061
).	O
The	O
most	O
common	O
complication	B-T046
is	O
left bundle branch block	B-T047
(	O
LBBB	B-T047
).	O
The	O
clinical	B-T080
impact	B-T080
of	O
new-onset	B-T033
LBBB	B-T047
after	O
TAVI	B-T061
remains	O
controversial	B-T054
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	B-T080
impact	B-T080
of	O
new-onset	B-T033
LBBB	B-T047
in	O
terms	O
of	O
mortality	B-T081
and	O
morbidity	B-T081
(need	O
for	O
pacemakers	B-T074
and	O
admissions	B-T058
for	O
heart failure	B-T047
)	O
at	O
long-term follow-up	B-T058
.	O
From	O
April	O
2008	O
to	O
December	O
2014,	O
220	O
patients	B-T101
who	O
had	O
severe	O
aortic stenosis	B-T047
were	O
treated with	B-T061
the	O
implantation	B-T061
of	O
a	O
CoreValve prosthesis	B-T074
.	O
Sixty-seven	O
of	O
these	O
patients	B-T101
were	O
excluded	O
from	O
the	O
analysis	B-T062
,	O
including	O
22	O
patients	B-T101
with	O
pre-existing	B-T080
LBBB	B-T047
and	O
45	O
with	O
a	O
permanent pacemaker	B-T074
,	O
implanted	B-T074
previously	O
or	O
within	O
72	O
hours	B-T079
of	O
implantation	B-T061
.	O
The	O
remaining	O
153	O
patients	B-T101
were	O
divided	O
into	O
2	O
groups	B-T078
:	O
group	B-T078
1	O
(n	O
=	O
80),	O
those	O
with	O
persistent	B-T079
new-onset	B-T033
LBBB	B-T047
,	O
and	O
group	B-T078
2	O
(n	O
=	O
73),	O
those	O
without	O
conduction disturbances	B-T046
after	O
treatment	B-T061
.	O
Both	O
groups	B-T078
were	O
followed up	B-T058
at	O
1	O
month	B-T079
,	O
6	O
months	B-T079
,	O
12	O
months	B-T079
,	O
and	O
yearly	B-T079
thereafter.	O
Persistent	B-T079
new-onset	B-T033
LBBB	B-T047
occurred	O
in	O
80	O
patients	B-T101
(36%)	O
immediately	O
after	O
TAVI	B-T061
;	O
73	O
patients	B-T101
(33%)	O
did	O
not	O
develop	O
conduction disturbances	B-T046
.	O
The	O
mean	O
follow-up	B-T058
time	B-T079
of	O
both	O
groups	B-T078
was	O
32	O
±	O
22	O
months	B-T079
(range	O
3	O
to	O
82	O
months	B-T079
),	O
and	O
there	O
were	O
no	O
differences	O
in	O
time	B-T079
between	O
the	O
groups	B-T078
.	O
There	O
were	O
no	O
differences	O
in	O
mortality	B-T081
between	O
the	O
groups	B-T078
(39%	O
vs	O
48%,	O
p	O
=	O
0.58).	O
No	O
differences	O
were	O
observed	O
between	O
the	O
groups	B-T078
in	O
re-hospitalizations	B-T058
for	O
heart failure	B-T047
(11%	O
vs	O
16%,	O
p	O
=	O
0.55).	O
Group	B-T078
1	O
did	O
not	O
require	O
pacemaker implantation	B-T061
more	O
often	O
at	O
follow-up	B-T058
(10%	O
vs	O
13%,	O
p	O
=	O
0.38)	O
than	O
group	B-T078
2.	O
In	O
conclusion,	O
new-onset	B-T033
LBBB	B-T047
was	O
not	O
associated with	B-T080
a	O
higher	B-T080
incidence	B-T081
of	O
late	O
need	O
for	O
a	O
permanent pacemaker	B-T074
after	O
CoreValve	B-T074
implantation	B-T061
.	O
In	O
addition,	O
it	O
was	O
not	O
associated with	B-T080
a	O
higher	O
risk	O
of	O
late	O
mortality	B-T081
or	O
re-hospitalization	B-T058
.	O

The	O
relationship	B-T080
between	O
polymorphisms	B-T045
of	O
BDNFOS	B-T028
and	O
BDNF genes	B-T028
and	O
heroin addiction	B-T048
in	O
the	O
Han Chinese population	B-UnknownType
The	O
number	O
of	O
heroin	B-T109
addicts	B-T101
is	O
increasing	B-T169
in	O
the	O
world	B-T098
.	O
Both	O
environmental	B-T080
and	O
genetic factors	B-T080
both	O
play	O
critical	B-T080
roles	O
in	O
the	O
process	B-T067
of	O
heroin addiction	B-T048
.	O
We	O
aimed	B-T078
to	O
investigate	B-T169
the	O
associations	B-T080
between	O
single nucleotide polymorphisms	B-T086
(	O
SNPs	B-T086
)	O
in	O
LIN7C	B-T028
,	O
BDNFOS	B-T028
and	O
BDNF genes	B-T028
and	O
drug addiction	B-T048
in	O
the	O
Han Chinese population	B-UnknownType
.	O
We	O
conducted	O
a	O
case-control study	B-T062
among	O
692	O
cases	B-T169
and	O
700	O
healthy controls	B-T080
from	O
Xi'an	B-UnknownType
,	O
China	B-T083
.	O
Eight	O
SNPs	B-T086
were	O
selected	B-T052
and	O
genotyped	B-T059
using	O
MassARRAY technology	B-T170
(	O
Sequenom	B-T073
,	O
San Diego, CA	B-T083
,	O
USA	B-T083
).	O
Odds ratios	B-T081
(	O
OR	B-T081
)	O
and	O
95%	O
confidence intervals	B-T081
(	O
CIs	B-T081
)	O
were	O
calculated	B-T052
by	O
unconditional logistic regression	B-T062
adjusting	O
for	O
age	B-T032
and	O
sex	B-T032
.	O
Using	O
the	O
chi-squared test	B-T170
,	O
we	O
found	O
that	O
rs7481311	B-T028
(	O
OR	B-T081
=1.275,	O
95%	O
CI	B-T081
=	O
1.087-1.497,	O
p	O
=	O
0.009)	O
and	O
rs11030096	B-T028
(	O
OR	B-T081
=1.227,	O
95%	O
CI	B-T081
=	O
1.049-1.436,	O
p	O
=	O
0.011)	O
in	O
the	O
BNDFOS	B-T028
were	O
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
of	O
heroin addiction	B-T048
.	O
By	O
contrast,	O
rs988712	B-T028
located	O
in	O
BDNFOS	B-T028
showed	O
a	O
decreased	B-T081
risk	B-T078
of	O
heroin addiction	B-T048
(	O
OR	B-T081
=0.734,	O
95%	O
CI	B-T081
=	O
0.582-0.925,	O
p	O
=	O
0.003).	O
By	O
genetic model	B-T170
analysis	B-T062
,	O
we	O
found	O
that	O
the	O
'T' allele	B-T028
of	O
rs988712	B-T028
in	O
BDNFOS	B-T028
had	O
a	O
protective	O
role	O
for	O
heroin addiction	B-T048
in	O
the	O
additive model	B-T170
and	O
dominant model	B-T170
(p	O
<	O
0.05).	O
By	O
contrast,	O
the	O
allele 'T'	B-T028
of	O
rs7481311	B-T028
in	O
BDNFOS	B-T028
significantly	O
elevated	B-T080
the	O
risk	B-T078
of	O
heroin addiction	B-T048
in	O
the	O
additive model	B-T170
,	O
recessive model	B-T170
and	O
dominant model	B-T170
(p	O
<	O
0.05).	O
We	O
also	O
found	O
that	O
allele 'C	B-T028
'	O
of	O
rs11030096	B-T028
was	O
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
of	O
addiction	B-T048
in	O
the	O
dominant model	B-T170
and	O
additive model	B-T170
(p	O
<	O
0.05).	O
Additionally,	O
we	O
found	O
that	O
rs6265	B-T028
,	O
rs11030104	B-T028
and	O
rs10767664	B-T028
in	O
BDNF	B-T028
were	O
associated with	B-T080
a	O
decreased	B-T081
risk	B-T078
of	O
heroin addiction	B-T048
(p	O
<	O
0.05).	O
However,	O
only	O
rs7481311	B-T028
in	O
BDNFOS	B-T028
remained	O
significant	B-T078
after	O
Bonferroni correction	B-T081
(p	O
<	O
0.00625).	O
These	O
results	B-T033
suggest	O
that	O
polymorphisms	B-T045
of	O
BDNFOS	B-T028
play	O
an	O
important	B-T080
role	O
in	O
heroin addiction	B-T048
susceptibility	B-T169
in	O
the	O
Chinese Han population	B-UnknownType
.	O

Risk and protective factors	B-T201
associated with	B-T080
adolescent girls'	B-T100
substance use	B-T048
:	O
Data	B-T078
from	O
a	O
nationwide	O
Facebook	B-T170
sample	O
Despite	O
overall	O
reductions	B-T081
in	O
teenage	B-T079
substance use	B-T048
,	O
adolescent girls	B-T100
'	O
rates	B-T081
of	O
substance use	B-T048
remain	O
unacceptably high	B-T080
.	O
This	O
article	B-T170
examines	O
whether	O
girls	B-T098
'	O
substance use	B-T048
is	O
associated with	B-T080
general	O
risk and protective factors	B-T201
(	O
goal setting	B-T041
,	O
problem solving	B-T041
,	O
refusal skills	B-T055
,	O
peer use	B-T054
,	O
and	O
self-efficacy	B-T041
)	O
and	O
gender	B-T032
-	O
specific	B-T080
risk and protective factors	B-T201
(	O
communication style	B-T054
,	O
coping skills	B-T055
,	O
self-esteem	B-T041
,	O
body image	B-T041
,	O
perceived stress	B-T048
,	O
anxiety	B-T048
,	O
and	O
depression	B-T048
).	O
Cross-sectional data	B-T062
were	O
collected	O
in	O
2013	O
via	O
online surveys	B-T062
from	O
a	O
nationwide	O
sample	O
of	O
adolescent girls	B-T100
(N	O
=	O
788),	O
aged	O
13	O
and	O
14	O
years,	O
who	O
were	O
recruited	O
through	O
Facebook	B-T170
.	O
In	O
multivariate analyses	B-T081
,	O
controlling	O
for	O
correlates	B-T041
of	O
adolescent	B-T100
substance use	B-T048
,	O
11	O
of	O
the	O
13	O
general	O
and	O
gender	B-T032
-	O
specific	B-T080
risk and protective factors	B-T201
were	O
consistently	O
associated with	B-T080
past-month	O
alcohol	B-T055
,	O
cigarette	B-T055
,	O
and	O
other	O
drug use	B-T048
in	O
the	O
expected	O
direction;	O
past-month marijuana use	B-T048
was	O
associated with	B-T080
8	O
of	O
the	O
13	O
factors	B-T169
.	O
Refusal skill	B-T055
s,	O
peer use	B-T054
,	O
coping	B-T055
,	O
and	O
depressive mood	B-T033
were	O
most	O
consistently	O
and	O
strongly	O
associated with	B-T080
substance use	B-T048
.	O
Substance abuse prevention	B-T058
programs	B-T058
targeting	O
adolescent girls	B-T100
should	O
focus	O
on	O
such	O
general	O
risk and protective factors	B-T201
as	O
problem solving	B-T041
,	O
refusal skill	B-T055
s,	O
peer influences	B-T054
,	O
and	O
self-efficacy	B-T041
,	O
as	O
well	O
as	O
such	O
gender	B-T032
-	O
specific	B-T080
risk and protective factors	B-T201
as	O
communication style	B-T054
,	O
coping	B-T055
,	O
self-esteem	B-T041
,	O
body image	B-T041
,	O
perceived stress	B-T048
,	O
and	O
mood management	B-T061
.	O

Ethics	B-T078
Hype	B-T080
?	O
There	O
has	O
been	O
growing	O
concern	B-T078
about	O
the	O
phenomenon	B-T067
of	O
science	B-T090
hype	B-T080
,	O
the	O
tendency	O
to	O
exaggerate	B-T080
the	O
value	O
or	O
near	B-T080
-	O
future	B-T079
application	B-T169
of	O
research results	B-T033
.	O
Although	O
this	O
is	O
a	O
problem	B-T033
that	O
touches	O
every	O
area of biomedicine	B-T091
,	O
the	O
topic	B-T170
of	O
genetics	B-T091
seems	O
to	O
be	O
particularly	O
prone	O
to	O
enthusiastic	B-T041
predictions	B-T078
.	O
The	O
world	B-T098
has	O
been	O
told	O
for	O
over	O
two	O
decades	B-T079
-by	O
the	O
media	B-T170
,	O
researchers	B-T097
,	O
politicians	B-T097
,	O
and	O
the	O
biotech	B-T091
industry	B-T057
-that	O
a	O
genome	B-T028
-driven	O
health care	B-T058
revolution	B-T068
is	O
just	O
around	O
the	O
corner.	O
And	O
while	O
the	O
revolution	B-T068
never	O
seems	O
to	O
arrive,	O
the	O
hopeful	O
rhetoric	B-T169
continues.	O
It	O
has	O
been	O
suggested	O
that	O
this	O
unrelenting	O
"	O
genohype	B-T080
"	O
is	O
having	O
a	O
range	O
of	O
adverse	B-T033
social consequences	B-T054
,	O
including	O
misleading	O
the	O
public	B-T098
and	O
hurting	B-T184
the	O
long-term	B-T079
legitimacy	B-T089
of	O
the	O
field	B-T077
.	O
While	O
we	O
need	O
more	O
good	O
data	B-T078
on	O
the	O
nature	B-T078
and	O
magnitude	B-T081
of	O
these	O
possible	O
harms	B-UnknownType
,	O
few	O
would	O
argue	O
with	O
the	O
proposition	B-T170
that	O
sustained	B-T169
science	B-T090
hype	B-T080
is	O
a	O
bad	O
thing.	O
We	O
all	O
benefit	B-T081
from	O
robust	B-T080
science	B-T090
and	O
accurate	B-T080
public	B-T098
representations	B-T052
of	O
biomedical research	B-T062
.	O
But,	O
to	O
date,	O
there	O
has	O
been	O
very	O
little	O
consideration	B-T033
of	O
the	O
degree	B-T081
to	O
which	O
the	O
scholarship	B-T078
on	O
the	O
related	O
ethical	B-T078
,	O
legal	B-T089
,	O
and	O
social issues	B-T054
has	O
been	O
hyped.	O
Are	O
the	O
conclusions	B-T078
from	O
ELSI scholarship	B-T078
also	O
exaggerated	B-T080
?	O

Lubiprostone	B-T109
Accelerates	B-T169
Intestinal Transit	B-T042
and	O
Alleviates	B-T169
Small Intestinal Bacterial Overgrowth	B-T047
in	O
Patients	B-T101
With	O
Chronic Constipation	B-T184
Lubiprostone	B-T109
is	O
an	O
effective	B-T080
treatment	B-T169
for	O
chronic constipation	B-T184
(	O
CC	B-T184
).	O
The	O
mechanism of action	B-T169
of	O
lubiprostone	B-T109
is	O
through	O
increasing	B-T169
fluid secretion	B-T043
and	O
lubrication	B-T067
of	O
the	O
intestinal lumen	B-T030
.	O
The	O
effects	B-T080
of	O
lubiprostone	B-T109
on	O
gastrointestinal transit	B-T042
and	O
small intestinal bacterial overgrowth	B-T047
(	O
SIBO	B-T047
)	O
have	O
not	O
been	O
adequately	O
explored.	O
The	O
current	O
study	B-T062
was	O
designed	O
to	O
investigate	B-T169
whether	O
lubiprostone	B-T109
(1)	O
alters	O
gastrointestinal transit	B-T042
and	O
(2)	O
affects	O
SIBO	B-T047
in	O
patients	B-T101
with	O
constipation	B-T184
.	O
A	O
total	O
of	O
29	O
female patients	B-T032
(	O
mean age	B-T032
=	O
39	O
years	B-T079
;	O
range	B-T081
:	O
19-64)	O
with	O
CC	B-T184
received	B-T080
2	O
weeks	B-T079
of	O
lubiprostone	B-T109
(24mcg	O
b.i.d.,	O
P.O.).	O
Stool consistency	B-T033
based	O
on	O
Bristol stool scale	B-T170
and	O
the	O
frequency of bowel movements	B-T033
(	O
BMs	B-T040
)	O
were	O
recorded.	O
Gastric emptying time	B-T079
,	O
small bowel transit time	B-T042
,	O
colon	B-T023
transit time	B-T042
(	O
CTT	B-T042
),	O
combined	O
small and large bowel transit time	B-T042
(	O
SLBTT	B-T042
)	O
and	O
whole	O
gut	B-T023
transit time	B-T042
were	O
measured	B-T080
using	O
wireless motility capsule	B-T060
.	O
The	O
SIBO	B-T047
status	B-T080
was	O
assessed	O
by	O
the	O
lactulose breath test	B-T060
.	O
Data	B-T078
were	O
analyzed	B-T062
using	O
Wilcoxon rank	B-T081
,	O
Mann-Whitney U	B-T081
,	O
Spearman׳s rank correlation	B-T081
and	O
Chi-square tests	B-T170
.	O
Lubiprostone	B-T109
significantly	O
softened	B-T067
the	O
stool	B-T031
and	O
increased	B-T081
the	O
frequency of BM	B-T033
from	O
median	B-T081
of	O
2	O
to	O
4	O
times	B-T081
per	O
week	B-T079
.	O
The	O
CTT	B-T042
and	O
SLBTT	B-T042
were	O
significantly	O
shorter	B-T080
in	O
responders	B-T098
to	O
lubiprostone	B-T109
(i.e.,	O
those	O
with	O
≥	O
2	O
times	B-T081
increase	B-T169
in	O
the	O
number	B-T081
of	O
their	O
weekly	B-T079
BM	B-T040
)	O
compared	B-T052
with	O
nonresponders	B-T098
.	O
The	O
higher	B-T080
frequency of BM	B-T033
after	O
treatment	B-T169
was	O
significantly	O
correlated	B-T080
with	O
the	O
acceleration	B-T067
of	O
CTT	B-T042
,	O
SLBTT	B-T042
and	O
whole	O
gut	B-T023
transit time	B-T042
.	O
In	O
all,	O
17	O
out	O
of	O
25	O
(68%)	O
patients	B-T101
,	O
who	O
were	O
tested	B-T169
for	O
SIBO	B-T047
at	O
baseline	B-T081
,	O
were	O
positive	B-T033
.	O
In	O
addition,	O
7	O
out	O
of	O
17	O
(41%)	O
SIBO	B-T047
-	O
positive	B-T033
patients	B-T101
became	O
SIBO	B-T047
-	O
negative	B-T033
after	O
lubiprostone	B-T109
treatment	B-T169
(P	O
<	O
0.05).	O
In	O
CC	B-T184
,	O
lubiprostone	B-T109
improves	O
the	O
frequency of BMs	B-T033
,	O
softens	B-T067
the	O
stool	B-T031
,	O
accelerates	B-T169
intestinal transit	B-T042
and	O
decreases	B-T081
accompanying	O
SIBO	B-T047
.	O
The	O
improvement	B-T077
of	O
SIBO	B-T047
could	O
be	O
explained	O
by	O
the	O
cleansing	B-T052
effect	B-T080
of	O
increased	B-T081
intestinal fluid	B-T042
and	O
mucus	B-T031
combined	O
with	O
enhanced	B-T052
intestinal motility	B-T042
with	O
lubiprostone	B-T109
.	O

Minimally invasive treatment	B-T061
of	O
difficult	O
bleeding	B-T046
lesions	B-T033
of	O
the	O
small bowel	B-T023
Bleeding	B-T046
lesions	B-T033
of	O
the	O
small bowel	B-T023
are	O
often	O
difficult	O
to	O
identify	B-T080
due	O
to	O
the	O
obscure	B-T033
symptomatology	B-T184
.	O
Localizing	B-T082
these	O
lesions	B-T033
requires	O
specific	B-T080
techniques	B-T169
.	O
The	O
Double-balloon enteroscopy	B-T060
(	O
DBE	B-T060
)	O
could	O
be	O
used	O
to	O
precisely	O
localize	B-T082
and	O
mark	O
lesions	B-T033
,	O
so	O
that	O
a	O
minimally invasive surgical treatment	B-T061
could	O
be	O
performed.	O
Twenty	O
robot	B-T073
-	O
assisted	B-T080
small bowel procedures	B-T061
are	O
presented	O
using	O
a	O
combination	B-T080
of	O
DBE	B-T060
for	O
localization	B-T082
and	O
robotic resection	B-T061
.	O
There	O
were	O
10	O
jejunal resections	B-T061
and	O
10	O
ileal resections	B-T061
.	O
Mean	O
age	B-T032
was	O
58.7	O
years	B-T079
.	O
Mean	O
operative time	B-T079
was	O
153.4	O
minutes	B-T079
,	O
mean	O
blood loss	B-T033
of	O
46	O
mL.	O
No	O
conversion-to-open	B-T061
and	O
there	O
were	O
4	O
post-operative	B-T079
complications	B-T046
.	O
The	O
90-	O
day	B-T079
mortality	B-T081
was	O
nil	O
and	O
the	O
median	O
length of stay	B-T079
was	O
4.1	O
days	B-T079
.	O
Final	O
pathology	B-T170
was	O
consistent with	B-T078
malignancy	B-T191
in	O
10	O
cases	B-T169
.	O
The	O
combination	B-T080
of	O
double-balloon enteroscopy	B-T060
and	O
robotic technology	B-T061
allows	O
accurate	B-T080
identification	B-T080
and	O
selective	O
treatment	B-T169
of	O
lesions	B-T033
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	B-T169
in	O
a	O
minimally invasive fashion	B-T061
.	O

Kinematic	B-T091
and	O
EMG	B-T060
Responses	B-T032
to	O
Pelvis	B-T023
and	O
Leg	B-T023
Assistance	B-T077
Force	B-T070
during	O
Treadmill Walking	B-T056
in	O
Children	B-T100
with	O
Cerebral Palsy	B-T047
Treadmill training	B-T061
has	O
been	O
used	O
for	O
improving	O
locomotor function	B-T040
in	O
children	B-T100
with	O
cerebral palsy	B-T047
(	O
CP	B-T047
),	O
but	O
the	O
functional	O
gains	O
are	O
relatively	O
small,	O
suggesting	O
a	O
need	O
to	O
improve	O
current	O
paradigms	B-T062
.	O
The	O
understanding	O
of	O
the	O
kinematic	B-T091
and	O
EMG	B-T060
responses	B-T032
to	O
force	B-T070
s	O
applied	O
to	O
the	O
body	B-T017
of	O
subjects	O
during	O
treadmill walking	B-T056
is	O
crucial	O
for	O
improving	O
current	O
paradigms	B-T062
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
kinematic	B-T091
s	O
and	O
EMG	B-T060
responses	B-T032
to	O
the	O
pelvis	B-T023
and/or	O
leg	B-T023
assistance	B-T077
force	B-T070
.	O
Ten	O
children	B-T100
with	O
spastic CP	B-T019
were	O
recruited	O
to	O
participate	B-T058
in	O
this	O
study	B-T062
.	O
A	O
controlled	O
assistance	B-T077
force	B-T070
was	O
applied	O
to	O
the	O
pelvis	B-T023
and/or	O
legs	B-T023
during	O
stance	B-T033
and	O
swing phase of gait	B-T033
through	O
a	O
custom	O
designed	O
robotic system	B-T170
during	O
walking	B-T056
.	O
Muscle	B-T024
activities	B-T052
and	O
spatial	B-T082
-	O
temporal	B-T079
gait parameters	B-T033
were	O
measured	O
at	O
different	O
loading conditions	B-T032
during	O
walking	B-T056
.	O
In	O
addition,	O
the	O
spatial-temporal gait parameters	B-T033
during	O
overground	O
walking	B-T056
before	O
and	O
after	O
treadmill training	B-T061
were	O
also	O
collected.	O
Applying	O
pelvis	B-T023
assistance	B-T077
improved	B-T033
step height	B-T033
and	O
applying	O
leg	B-T023
assistance	B-T077
improved	B-T033
step length	B-T033
during	O
walking	B-T056
,	O
but	O
applying	O
leg	B-T023
assistance	B-T077
also	O
reduced	B-T080
muscle	B-T024
activation	B-T052
of	O
ankle flexor	B-T023
during	O
the	O
swing phase of gait	B-T033
.	O
In	O
addition,	O
step length	B-T033
and	O
self-selected	O
walking speed	B-T032
significantly	O
improved	B-T033
after	O
one	O
session	B-T051
of	O
treadmill training	B-T061
with	O
combined	O
pelvis	B-T023
and	O
leg	B-T023
assistance	B-T077
.	O

Outlining	O
a	O
Population "at Risk"	B-T098
of	O
Parkinson's Disease	B-T047
:	O
Evidence	B-T078
from	O
a	O
Case-Control Study	B-T062
The	O
multifactorial pathogenesis	B-T046
of	O
Parkinson's Disease	B-T047
(	O
PD	B-T047
)	O
requires	O
a	O
careful	O
identification	O
of	O
populations "at risk"	B-T098
of	O
developing	O
the	O
disease	B-T047
.	O
In	O
this	O
case-control study	B-T062
we	O
analyzed	B-T062
a	O
large	O
Italian	B-T083
population	B-T098
,	O
in	O
an	O
attempt	O
to	O
outline	O
general criteria	B-T078
to	O
define	O
a	O
population "at risk"	B-T098
of	O
PD	B-T047
.	O
We	O
enrolled	O
300	O
PD	B-T047
patients	B-T101
and	O
300	O
controls	B-T096
,	O
gender	B-T032
and	O
age	B-T032
matched	B-T096
,	O
from	O
the	O
same	O
urban	B-T080
geographical area	B-UnknownType
.	O
All	O
subjects	B-T098
were	O
interviewed	B-T052
on	O
demographics	B-T090
,	O
family history	B-T033
of	O
PD	B-T047
,	O
occupational and environmental toxicants exposure	B-T033
,	O
smoking status	B-T201
,	O
and	O
alcohol consumption	B-T055
.	O
A	O
sample	O
of	O
65	O
patients	B-T101
and	O
65	O
controls	B-T096
also	O
underwent	O
serum	B-T031
dosing	B-T081
of	O
iron	B-T059
,	O
copper	B-T059
,	O
mercury	B-T059
,	O
and	O
manganese	B-T059
by	O
means	O
of	O
Inductively Coupled-Plasma-Mass-Spectrometry	B-T059
(	O
ICP-MS	B-T059
).	O
Positive	B-T033
family history	B-T033
,	O
toxicants exposure	B-T033
,	O
non-current-smoker	B-T033
,	O
and	O
alcohol nonconsumer status	B-T033
occurred	O
as	O
significant	O
risk factors	B-T033
in	O
our	O
population	B-T098
.	O
The	O
number	O
of	O
concurring risk factors	B-T033
overlapping	B-T079
in	O
the	O
same subject	B-T098
impressively	O
increased	B-T081
the	O
overall risk	B-T080
.	O
No significant differences	B-T033
were	O
measured	B-T080
in	O
the	O
metal	B-T197
serum	B-T031
levels	B-T080
.	O
Our	O
findings	B-T033
indicate	O
that	O
combination	O
of	O
three	O
to	O
four	O
concurrent	B-T079
PD	B-T047
-	O
risk factors	B-T033
defines	O
a	O
condition	O
"	O
at risk	B-T080
"	O
of	O
PD	B-T047
.	O
A	O
simple	O
stratification	B-T062
,	O
based	O
on	O
these	O
questionnaires	B-T170
,	O
might	O
be	O
of	O
help	O
in	O
identifying subjects	B-T062
suitable	O
for	O
neuroprotective strategies	B-T041
.	O

Work	B-T057
process	B-T067
,	O
performance	B-T033
and	O
professional profile	B-T097
of	O
a	O
Hearing Health Network	B-T058
:	O
reference	B-T170
for	O
satisfaction	B-T041
To	O
analyze	B-T062
the	O
correlation	B-T080
between	O
the	O
satisfaction	B-T041
of	O
professionals	B-T097
from	O
the	O
Hearing Health Care network	B-T058
in	O
two	O
micro	B-T077
-	O
regions	B-T082
of	O
Minas Gerais state	B-UnknownType
and	O
the	O
sociodemographic profile	B-T169
,	O
work	B-T057
process	B-T067
,	O
and	O
work performance	B-T033
in	O
the	O
health service	B-T058
.	O
This	O
is	O
a	O
cross-sectional	B-T062
,	O
observational	B-T062
,	O
analytic study	B-T081
with	O
a	O
non-probabilistic sample	B-T062
including	O
34	O
professionals	B-T097
from	O
the	O
Hearing Health Care services	B-T058
.	O
Data collection	B-T062
occurred	O
through	O
individual	B-T098
interviews	B-T052
in	O
the	O
municipality	B-T083
of	O
professional practice	B-T057
.	O
Associations	B-T080
between	O
the	O
Professional Satisfaction	B-T041
variable	B-T080
and	O
the	O
explanatory	B-T170
variables	B-T080
Sociodemographic Data	B-T078
,	O
Work Routine	B-T080
,	O
and	O
Developed	B-T169
Actions	B-T052
were	O
conducted.	O
Professionals	B-T097
with	O
graduate studies	B-T065
were	O
more	O
satisfied	B-T170
with	O
the	O
human resources policy	B-T170
and	O
the	O
activities	B-T052
developed	B-T169
,	O
whereas	O
health	B-T058
civil servants	B-T097
showed	O
more	O
satisfaction	B-T041
with	O
the	O
wage	B-T081
policy	B-T170
and	O
the	O
work schedule	B-T079
.	O
The	O
correlation analysis	B-T062
between	O
work	B-T057
process	B-T067
and	O
satisfaction	B-T041
revealed	B-T080
a	O
moderate	B-T081
positive	B-T033
correlation	B-T080
between	O
items	O
such	O
as	O
Health Promotion	B-T058
Actions	B-T052
,	O
Satisfaction	B-T041
with	O
Diagnostic Equipment	B-T074
,	O
and	O
Satisfaction	B-T041
with	O
Maintenance Equipment	B-T033
.	O
The	O
present	O
study	B-T062
revealed	O
a	O
higher	B-T080
level	B-T080
of	O
satisfaction	B-T041
among	O
professionals	B-T090
with	O
graduate studies	B-T065
(	O
human resources policy	B-T170
and	O
activities	B-T052
developed	B-T169
)	O
and	O
civil servants	B-T097
(	O
wage	B-T081
policy	B-T170
and	O
work schedule	B-T079
).	O
The	O
relevance	B-T080
of	O
this	O
study	B-T062
lies	O
on	O
the	O
important	O
role	O
that	O
health professionals	B-T097
play	O
on	O
the	O
Health Care Network	B-T058
.	O
Additionally,	O
the	O
study	B-T062
of	O
satisfaction	B-T041
level	B-T080
can	O
provide	O
a	O
search	O
for	O
improvements	B-T077
,	O
considering	O
that	O
satisfied	B-T170
professionals	B-T090
not	O
only	O
improve	B-T033
service quality	B-T080
,	O
but	O
also	O
show greater creativity	B-T033
,	O
commitment	B-T041
,	O
and	O
performance	B-T033
.	O

Application	B-T058
of	O
Laparoscopic	B-T060
Lumbar Discectomy	B-T061
and	O
Artificial Disc Replacement	B-T061
:	O
At	O
Least	O
Two	O
Years	O
of	O
Follow-Up	B-T058
This	O
prospective	B-T062
observational study	B-T062
included	O
22	O
patients	B-T101
who	O
were	O
diagnosed	B-T033
with	O
symptomatic	B-T169
degenerative disc disease	B-T047
treated	O
via	O
artificial disc replacement	B-T061
(	O
ADR	B-T061
)	O
with	O
a	O
laparoscopic	B-T060
technique	B-T169
.	O
The	O
current	O
study	B-T062
aimed	B-T078
to	O
assess	B-T052
the	O
safety	B-T068
and	O
efficacy	B-T080
of	O
ADR	B-T061
using	O
a	O
laparoscopic	B-T060
technique	B-T169
for	O
lumbar disc herniation	B-T020
.	O
Symptomatic	B-T169
degenerative disc disease	B-T047
is	O
the	O
major	O
cause	O
of	O
low back pain	B-T184
with	O
lumbar	B-T029
segmental	B-T082
instability	B-T033
.	O
ADR	B-T061
has	O
increased	B-T081
in	O
popularity	B-T054
as	O
an	O
alternative treatment	B-UnknownType
for	O
lumbar disc herniation	B-T020
.	O
However,	O
the	O
traditional	B-T169
approach	B-T082
to	O
spinal surgery	B-T061
carries	O
the	O
risk	B-T078
of	O
catastrophic	B-T047
bleeding	B-T046
from	O
injury	B-T037
to	O
major	O
vessels	B-T023
,	O
as	O
well	O
as	O
iatrogenic	B-T080
injury	B-T037
to	O
the	O
viscera	B-T023
and	O
associated structures	B-T023
.	O
Therefore,	O
laparoscopic	B-T060
lumbar discectomy	B-T061
and	O
ADR	B-T061
may	O
represent	B-T052
a	O
useful	O
alternative	B-T077
.	O
Twenty-two	O
patients	B-T101
(8	O
males	B-T032
and	O
14	O
females	B-T032
)	O
who	O
were	O
diagnosed	B-T033
with	O
symptomatic	B-T169
degenerative disc disease	B-T047
were	O
included	O
in	O
this	O
study	B-T062
.	O
Seven	O
cases	B-T169
involved	O
the	O
L4/5	O
level,	O
and	O
15	O
cases	B-T169
involved	O
the	O
L5/S1	O
level.	O
All	O
patients	B-T101
were	O
ineffective	B-T078
after	O
at	O
least	O
6	O
months	O
of	O
conservative treatments	B-T061
;	O
all	O
patients	B-T101
were	O
informed	O
of	O
the	O
surgery	B-T061
before	O
the	O
operation	B-T061
and	O
provided	O
consent	B-T169
.	O
Three-dimensional	B-T082
computed tomographic angiography	B-T060
(	O
3D	B-T082
-	O
CTA	B-T060
)	O
of	O
the	O
iliac	B-T023
great	O
blood vessels	B-T023
was	O
completed	B-T080
before	O
the	O
surgery	B-T061
.	O
All	O
surgical procedures	B-T061
were	O
performed	O
under	O
a	O
laparoscope	B-T074
.	O
All	O
patients	B-T101
were	O
followed up	B-T058
.	O
All	O
surgeries	B-T061
were	O
successfully	B-T080
completed	B-T080
.	O
The	O
average	B-T081
operation	B-T061
time	B-T079
was	O
120	O
minutes	O
(	O
range	B-T081
110-150	O
min),	O
and	O
the	O
average	B-T081
hemorrhage	B-T046
was	O
145	O
mL	O
(	O
range	B-T081
80-360	O
mL).	O
All	O
cases	B-T169
underwent	O
X-rays	B-T060
at	O
3	O
days,	O
3	O
months,	O
6	O
months,	O
1	O
year,	O
and	O
the	O
final	O
postoperative	B-T058
follow-up	B-T058
.	O
The	O
outcome	B-T169
indicated	O
that	O
there	O
was	O
no	O
mobilization	B-T169
,	O
displacement	B-T067
,	O
or	O
subsidence	B-T067
in	O
all	O
patients	B-T101
with	O
the	O
exception	B-T077
of	O
one	O
case	B-T169
with	O
prosthesis migration	B-T067
.	O
The	O
follow-up	B-T058
time	O
was	O
43.8	O
months	O
(	O
range	B-T081
24-64	O
months).	O
The	O
mean	B-T081
visual analog scale	B-T201
(	O
VAS	B-T201
)	O
and	O
Oswestry scores	B-T033
were	O
decreased	B-T081
postoperatively	B-T079
.	O
The	O
mean	B-T081
improvement	B-T077
rate	B-T081
of	O
the	O
VAS score	B-T201
was	O
73.5%.	O
Lumbar	B-T029
ADR	B-T061
using	O
a	O
laparoscope	B-T074
represents	O
a	O
novel,	O
minimally invasive	B-T169
treatment	B-T169
for	O
symptomatic	B-T169
degenerative disc disease	B-T047
and	O
severe	B-T080
lumbar discogenic pain	B-T047
.	O

Low literacy	B-T033
and	O
written drug information	B-T170
:	O
information-seeking	B-T033
,	O
leaflet	B-T170
evaluation	B-T078
and	O
preferences	B-T078
,	O
and	O
roles	O
for	O
images	B-T170
Background	O
Low-literate	B-T098
patients	B-T101
are	O
at	O
risk	B-T078
to	O
misinterpret	O
written drug information	B-T170
.	O
For	O
the	O
(co-)	O
design	O
of	O
targeted	O
patient information	B-T170
,	O
it	O
is	O
key	O
to	O
involve	O
this	O
group	B-T098
in	O
determining	O
their	O
communication barriers	B-T078
and	O
information	B-T078
needs.	O
Objective	O
To	O
gain	O
insight	O
into	O
how	O
people	B-T098
with	O
low literacy	B-T033
use	O
and	O
evaluate	O
written drug information	B-T170
,	O
and	O
to	O
identify	O
ways	O
in	O
which	O
they	O
feel	O
the	O
patient	B-T101
leaflet	B-T170
can	O
be	O
improved,	O
and	O
in	O
particular	O
how	O
images	B-T170
could	O
be	O
used.	O
Setting	O
Food banks	B-T092
and	O
an	O
education institution	B-T073
for	O
Dutch language	B-T171
training	B-T065
in	O
the	O
Netherlands	B-T083
.	O
Method	O
Semi-structured	O
focus groups	B-T096
and	O
individual	B-T098
interviews	B-T052
were	O
held	O
with	O
low-literate participants	B-T098
(n	O
=	O
45).	O
The	O
thematic framework approach	B-T077
was	O
used	O
for	O
analysis	O
to	O
identify	O
themes	O
in	O
the	O
data	B-T078
.	O
Main	O
outcome	B-T169
measure	O
Low-literate people's	B-T098
experience	B-T078
with	O
patient information	B-T170
leaflets	B-T170
,	O
ideas	B-T078
for	O
improvements	B-T077
,	O
and	O
perceptions	B-T041
on	O
possible	O
uses	O
for	O
visuals	B-T169
.	O
Results	O
Patient information	B-T170
leaflets	B-T170
were	O
considered	O
discouraging	O
to	O
use,	O
and	O
information	B-T078
difficult	O
to	O
find	O
and	O
understand	B-T041
.	O
Many	O
rely	O
on	O
alternative	O
information sources	B-T033
.	O
The	O
leaflet	B-T170
should	O
be	O
shorter,	O
and	O
improved	O
in	O
terms	O
of	O
organisation	B-T169
,	O
legibility	B-T033
and	O
readability	B-T080
.	O
Participants	B-T098
thought	O
images	B-T170
could	O
increase	O
the	O
leaflet's	B-T170
appeal,	O
help	O
ask	O
questions	B-T170
,	O
provide	O
an	O
overview	B-T170
,	O
help	O
understand	O
textual	B-T170
information	B-T078
,	O
aid	O
recall	B-T041
,	O
reassure,	O
and	O
even	O
lead	O
to	O
increased	O
confidence	B-T041
,	O
empowerment	B-T054
and	O
feeling	O
of	O
safety	B-T068
.	O
Conclusion	O
Already	O
at	O
the	O
stages	O
of	O
paying	O
attention	O
to	O
the	O
leaflet	B-T170
and	O
maintaining	O
interest	O
in	O
the	O
message,	O
low-literate patients	B-T098
experience	B-T041
barriers in the communication	B-T078
process	O
through	O
written drug information	B-T170
.	O
Short,	O
structured,	O
visual	B-T169
/	O
textual	B-T170
explanations	B-T170
can	O
lower	O
the	O
motivational	O
threshold	O
to	O
use	O
the	O
leaflet	B-T170
,	O
improve	B-T033
understanding	B-T041
,	O
and	O
empower	O
the	O
low-literate target group	B-T098
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow cytometry	B-T059
-based	O
method	B-T170
for	O
detecting	B-T033
histone acetylation	B-T044
levels	B-T080
Histone deacetylase inhibitors	B-T116
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	B-T047
and	O
other	O
diseases	B-T047
,	O
are	O
a	O
new	O
class	O
of	O
anticancer drugs	B-T109
developed	O
in	O
recent	O
years.	O
However,	O
there	O
is	O
still	O
a	O
lack	B-T080
of	O
a	O
unified	B-T080
and	O
reliable	B-T170
method	B-T170
for	O
detecting	B-T033
histone acetylation	B-T044
levels	B-T080
in	O
basic	B-T062
and	O
clinical research	B-T062
.	O
In	O
this	O
study	B-T062
,	O
we	O
developed	O
a	O
flow cytometry	B-T059
-based	O
method	B-T170
to	O
detect	B-T061
detect	B-T033
histone acetylation	B-T044
levels	B-T080
by	O
comparing	B-T052
different	O
sample	B-T167
processing	B-T052
temperature	B-T081
(on	O
ice	B-T197
vs.	O
room temperature	B-T033
room temperature	B-T033
),	O
permeabilization	B-T043
method	B-T170
(	O
intracellular	B-T026
vs.	O
nuclear	B-T026
),	O
antibody	B-T116
dose	B-T081
(	O
antibody titration	B-T059
)	O
and	O
antibody	B-T116
incubation time	B-T079
(	O
time gradient	B-T081
)	O
using	O
whole blood	B-T031
and	O
peripheral blood mononuclear cells	B-T025
.	O
In	O
addition,	O
we	O
applied	O
this	O
optimized	B-T052
method	B-T170
in	O
in vitro	B-T080
experiment	B-T062
and	O
clinical trial	B-T062
of	O
Chidamide	B-T109
(the	O
only	O
China	B-T083
FDA approved HDACi	B-T170
),	O
the	O
result	B-T169
of	O
which	O
confirmed	B-T033
that	O
the	O
flow cytometry	B-T059
-based	O
method	B-T170
for	O
detecting	B-T033
histone acetylation	B-T044
levels	B-T080
is	O
a	O
reliable	B-T170
,	O
fast	B-T080
and	O
convenient	B-T080
method	B-T170
which	O
can	O
be	O
used	O
in	O
basic	B-T062
and	O
clinical research	B-T062
.	O

Performance	B-T052
and	O
safety	B-T080
of	O
collagenated xenogeneic bone block	B-T122
for	O
lateral alveolar ridge augmentation	B-T061
and	O
staged implant placement	B-T061
.	O
A	O
monocenter, prospective single-arm clinical study	B-T062
To	O
assess	B-T058
the	O
clinical safety	B-T080
and	O
performance	B-T052
of	O
collagenated xenogeneic bone block	B-T122
(	O
CXBB	B-T122
)	O
for	O
lateral alveolar ridge augmentation	B-T061
and	O
two-stage	B-T079
implant placement	B-T061
.	O
In	O
ten	O
patients	B-T101
exhibiting	B-T078
a	O
single	B-T081
-	O
tooth	B-T023
gap	B-T082
,	O
the	O
surgical procedure	B-T061
included	B-T052
the	O
preparation	B-T052
of	O
mucoperiosteal flaps	B-T017
,	O
a	O
rigid fixation	B-T061
of	O
CXBB	B-T122
(	O
Geistlich Bio-Graft(®)	B-T170
)	O
using	O
an	O
osteosynthesis screw	B-T074
,	O
and	O
contour	B-T082
augmentation	B-T061
.	O
After	O
24	O
weeks	O
of	O
submerged healing	B-T040
,	O
the	O
primary endpoint	B-T130
was	O
defined	O
as	O
the	O
final	B-T079
ridge	B-T029
width	B-T081
sufficient	B-T080
to	O
place	O
an	O
adequately	B-T080
dimensioned	B-T081
titanium implant	B-T061
at	O
the	O
respective	O
sites	B-T082
.	O
Secondary outcomes	B-T080
included	B-T052
,	O
for	O
example,	O
the	O
gain	B-T081
in	O
ridge	B-T029
width	B-T081
(mm).	O
Clinical parameters	B-T062
(e.g.,	O
bleeding on probing	B-T033
-	O
BOP	B-T033
,	O
probing depth	B-T081
-	O
PD	B-T081
,	O
mucosal recession	B-T190
-	O
MR	B-T190
)	O
were	O
assessed	B-T052
immediately	O
after	O
the	O
cementation of the crown	B-T061
and	O
at	O
the	O
final visit	B-T061
.	O
At	O
24	O
weeks,	O
implant placement	B-T061
could	O
be	O
achieved	B-T052
in	O
8	O
of	O
10	O
patients	B-T101
exhibiting	B-T078
a	O
mean	B-T081
gain	B-T081
in	O
ridge	B-T029
width	B-T081
(	O
mean	B-T081
±	O
SD	B-T081
)	O
of	O
3.88	O
±	O
1.75	O
mm.	O
Histological	B-T080
analysis	B-T062
has	O
pointed	O
to	O
a	O
homogeneous	B-T082
osseous	B-T023
organization	B-T169
of	O
CXBB	B-T122
.	O
The	O
changes	B-T169
of	O
mean	B-T081
BOP	B-T033
,	O
PD	B-T081
,	O
and	O
MR	B-T190
values	B-T081
at	O
the	O
final visit	B-T061
amounted	B-T081
to	O
16.62	O
±	O
32.02%,	O
0.04	O
±	O
0.21	O
mm,	O
and	O
-0.04	O
±	O
0.12	O
mm,	O
respectively.	O
CXBB	B-T122
may	O
be	O
successfully	B-T080
used	O
to	O
support	B-T077
lateral alveolar ridge augmentation	B-T061
and	O
two-stage	B-T079
implant placement	B-T061
.	O

The	O
link	O
between	O
self-perceptions	B-T041
of	O
aging	B-T040
,	O
cancer	B-T191
view	O
and	O
physical	B-T169
and	O
mental health	B-T041
of	O
older people	B-T098
with	O
cancer	B-T191
:	O
A cross-sectional study	B-T062
Older people	B-T098
may	O
suffer	O
from	O
stigmas	B-T048
linked	O
to	O
cancer	B-T191
and	O
aging	B-T040
.	O
Although	O
some	O
studies	B-T062
suggested	O
that	O
a	O
negative	B-T033
view	B-T082
of	O
cancer	B-T191
may	O
increase	O
the	O
level of depression	B-T033
,	O
such	O
an	O
association	O
has	O
never	O
been	O
studied	B-T062
in	O
the	O
elderly population	B-T098
.	O
Similarly,	O
even	O
though	O
it	O
is	O
established	O
that	O
a	O
negative	B-T033
self-perception	B-T041
of	O
aging	B-T040
has	O
deleterious	O
consequences	B-T169
on	O
mental	B-T041
and	O
physical health	B-T033
in	O
normal	O
aging	B-T040
,	O
the	O
influence	O
in	O
pathological	B-T169
contexts	B-T078
,	O
such	O
as	O
oncology	B-T191
,	O
has	O
not	O
been	O
studied.	O
The	O
main	O
aim	O
of	O
this	O
study	O
is	O
thus	O
to	O
analyze	B-T062
the	O
effect	O
of	O
these	O
two	O
stigmas	B-T048
on	O
the	O
health	B-T078
of	O
elderly	B-T098
oncology	B-T191
patients	B-T101
.	O
101	O
patients	B-T101
suffering	O
from	O
a	O
cancer	B-T191
(	O
breast	B-T191
,	O
gynecological	B-T047
,	O
lung	B-T191
or	O
hematological	B-T047
)	O
were	O
seen	O
as	O
soon	O
as	O
possible	O
after	O
their	O
diagnosis	B-T033
.	O
Their	O
self-perception	B-T041
of	O
age	B-T032
,	O
cancer	B-T191
view	O
and	O
health	B-T078
(	O
physical	B-T033
and	O
mental	B-T041
)	O
was	O
assessed.	O
Multiple	O
regressions	B-T041
showed	O
that	O
patients	B-T101
with	O
a	O
more	O
negative	B-T033
self-perception	B-T041
of	O
aging	B-T040
and/or	O
more	O
negative	B-T033
cancer	B-T191
view	O
reported	O
poorer	B-T080
global health	B-T091
.	O
We	O
also	O
observed	O
that	O
negative	B-T033
self-perception	B-T041
of	O
aging	B-T040
was	O
associated with	B-T080
worse	O
physical	B-T033
and	O
mental health	B-T041
,	O
whereas	O
negative	B-T033
cancer	B-T191
views	O
were	O
only	O
linked	O
to	O
worse	O
mental health	B-T041
.	O
No	O
interaction	O
was	O
observed	O
between	O
these	O
two	O
stigmas	B-T048
,	O
suggesting	O
that	O
their	O
action	O
is	O
independent	B-T078
.	O
Older	O
patients	B-T101
with	O
cancer	B-T191
face	O
double	O
stigmatization	B-T078
,	O
due	O
to	O
negative	B-T033
self-perception	B-T041
of	O
aging	B-T040
and	O
cancer	B-T191
,	O
and	O
these	O
stigmas	B-T048
have	O
impacts	O
on	O
global	O
and	O
mental health	B-T041
.	O
Self-perception	B-T041
of	O
aging	B-T040
is	O
also	O
linked	O
to	O
physical health	B-T033
.	O
Longitudinal studies	B-T062
will	O
be	O
necessary	O
to	O
analyze	B-T062
the	O
direction	O
of	O
the	O
association	O
between	O
this	O
double	O
stigmatization	B-T078
and	O
health	B-T078
.	O

The	O
Aortic Root	B-T029
:	O
Natural History	B-T090
After	O
Root-Sparing Ascending Replacement	B-T061
in	O
Nonsyndromic	B-T033
Aneurysmal Patients	B-T101
Leaving	O
native	B-T169
aortic tissue	B-T024
in situ	B-T082
in	O
root-sparing ascending aortic replacement	B-T061
raises	O
concern	B-T078
regarding	O
potential	B-T080
later	B-T079
need	B-T080
for	O
root	B-T029
reoperation	B-T061
or	O
for	O
the	O
potential	B-T080
occurrence	B-T079
of	O
localized	B-T082
dissections	B-T047
or	O
rupture	B-T037
in	O
the	O
residual	B-T080
root	B-T029
.	O
The	O
purpose of this study	B-UnknownType
was	O
to	O
evaluate	B-T058
the	O
natural growth	B-T040
of	O
the	O
aortic root	B-T029
after	O
root-sparing aortic replacement	B-T061
.	O
In	O
all,	O
102	O
consecutive	B-T080
patients	B-T101
(	O
mean	B-T081
age	B-T032
61.8	O
±	O
12.5	O
years	B-T079
;	O
60%	O
male	B-T098
)	O
who	O
had	O
undergone	O
root-sparing aortic replacement	B-T061
had	O
sufficient	B-T080
retrievable information	B-T078
regarding	O
their	O
aortic root	B-T029
diameter	B-T081
at	O
postoperative	B-T079
baseline	B-T081
and	O
follow-up	B-T058
imaging	B-T060
by	O
computed tomography	B-T060
or	O
echocardiography	B-T060
.	O
The	O
annual	B-T079
growth rate	B-T079
was	O
evaluated	B-T052
and	O
also	O
compared	B-T052
according	O
to	O
the	O
influence	B-T077
of	O
valve morphology	B-T080
and	O
concomitant	B-T079
aortic valve replacement	B-T061
.	O
Furthermore,	O
the	O
years	B-T079
of	O
natural history	B-T090
that	O
would	O
require	B-T169
for	O
root	B-T029
enlargement	B-T190
to	O
meet	O
a	O
50	O
mm	B-T081
threshold	B-T080
of	O
the	O
root	B-T029
diameter	B-T081
were	O
calculated	B-T052
.	O
The	O
estimated	B-T081
growth rate	B-T079
of	O
the	O
aortic root	B-T029
after	O
root-sparing aortic replacement	B-T061
is	O
between	O
0.27	O
and	O
0.51	O
mm	B-T081
per year	B-T079
(	O
mean	B-T081
0.41	O
mm	B-T081
,	O
varying	O
according	O
to	O
the	O
underlying diameter	B-T081
)	O
and	O
therefore	O
fivefold	O
less than	B-T081
other	O
aortic regions	B-T029
.	O
Accordingly,	O
a	O
root aneurysm	B-T047
indicating	O
reoperation	B-T061
would	O
not	O
be	O
expected	B-T170
for	O
29.1	O
years	B-T079
on	O
average	B-T081
.	O
Only	O
patients	B-T101
with	O
a	O
diameter	B-T081
of	O
45	O
mm	B-T081
or	O
more	O
are	O
at risk	B-T080
for	O
reoperation	B-T061
,	O
and	O
not	O
until	B-T170
at	O
least	O
after	B-T079
10.4	O
years	B-T079
have passed	B-T033
.	O
Neither	B-T080
the	O
valve morphology	B-T080
(p	O
=	O
0.62)	O
nor	O
concomitant	B-T079
aortic valve replacement	B-T061
(p	O
=	O
0.86)	O
influenced	B-T077
rate	B-T081
of	O
root dilation	B-T047
.	O
In	O
nonsyndromic	B-T033
patients	B-T101
,	O
the	O
aortic root	B-T029
is	O
the	O
slowest	B-T080
growing	B-T040
portion	B-T082
of	O
the	O
thoracic aorta	B-T023
.	O
Leaving	O
the	O
native	B-T169
root	B-T029
,	O
as	O
in	O
root-sparing ascending aortic replacement	B-T061
,	O
is	O
a	O
safe approach	B-T082
regarding	O
secondary root	B-T029
intervention	B-T061
for	O
aortic root	B-T029
diameters	B-T081
of	O
45	O
mm	B-T081
or	O
less.	O

Physical Exercise	B-T056
for	O
Late-Life	B-T079
Depression	B-T048
:	O
Effects	B-T080
on	O
Heart Rate	B-T201
Variability	B-T077
Late-life	B-T079
major depression	B-T048
is	O
associated with	B-T080
increased	B-T081
cardiovascular risk	B-T033
and	O
impaired autonomic control of the heart	B-T047
,	O
as	O
evident	O
from	O
reduced	B-T080
heart rate	B-T201
variability	B-T077
(	O
HRV	B-T077
).	O
Moreover,	O
antidepressant drug	B-T121
therapy	B-T061
also	O
might	O
be	O
associated with	B-T080
further	O
reductions	B-T080
of	O
HRV	B-T077
.	O
In	O
the	O
SEEDS study	B-T062
,	O
we	O
investigated	O
whether	O
sertraline	B-T109
associated with	B-T080
physical exercise	B-T056
protocols	O
led	O
to	O
improvements	B-T077
of	O
HRV	B-T077
,	O
compared	O
with	O
antidepressant drug	B-T121
therapy	B-T061
alone.	O
Single-blind	B-T062
randomized controlled trial	B-T062
.	O
Psychiatric consultation	B-T073
-liaison	O
program	O
for	O
primary care	B-T058
.	O
Patients	B-T101
aged	O
65-85	O
years	O
with	O
major depression	B-T048
,	O
recruited	O
from	O
primary care	B-T058
.	O
Sertraline	B-T109
plus	O
structured,	O
tailored group	B-UnknownType
physical exercise	B-T056
(	O
S + EX	B-UnknownType
)	O
versus	O
sertraline	B-T109
alone	O
(S)	O
for	O
24	O
weeks	B-T079
.	O
HRV	B-T077
indices	B-T170
(RR,	O
percentage of NN intervals greater than 50 msec	B-T081
[	O
pNN50	B-T081
],	O
square root of the mean squared differences of successive NN intervals	B-T081
[	O
RMSSD	B-T081
],	O
standard deviation	B-T081
of	O
heart rate	B-T201
[	O
SDHR	B-T081
],	O
standard deviation of the NN interval	B-T081
[	O
SDNN	B-T081
],	O
high-frequency band	B-T081
[	O
HF	B-T081
],	O
low-frequency band	B-T081
[	O
LF	B-T081
],	O
and	O
their	O
ratio	B-T081
[	O
LF/HF	B-T081
])	O
were	O
measured	B-T080
at	O
baseline	B-T081
,	O
week	B-T079
12,	O
and	O
week	B-T079
24.	O
Psychiatric	B-T060
and	O
medical assessments	B-T058
.	O
Participants	B-T098
displayed	O
significant	O
improvements	B-T077
of	O
most	O
HRV	B-T077
indices	B-T170
over	O
time,	O
irrespective	O
of	O
the	O
group	O
assignment	O
(	O
pNN50	B-T081
,	O
RMSSD	B-T081
,	O
SDHR	B-T081
,	O
SDNN	B-T081
,	O
HF	B-T081
,	O
LF	B-T081
,	O
and	O
LF/HF	B-T081
).	O
Moreover,	O
patients	B-T101
in	O
the	O
S + EX group	B-UnknownType
displayed	O
greater	O
increases	B-T169
of	O
different	O
HRV	B-T077
indices	B-T170
(	O
RR	B-T081
,	O
pNN50	B-T081
,	O
RMSSD	B-T081
,	O
SDHR	B-T081
,	O
SDNN	B-T081
,	O
HF	B-T081
,	O
and	O
LF	B-T081
)	O
compared	O
with	O
those	O
in	O
the	O
S group	B-UnknownType
.	O
The	O
combination	B-T080
of	O
structured	O
physical exercise	B-T056
and	O
sertraline	B-T109
might	O
exert	O
positive	B-T033
effects	B-T080
on	O
the	O
autonomic control of the heart	B-T042
among	O
older	O
patients	B-T101
with	O
major depression	B-T048
.	O

Genome-Wide SNP Linkage Mapping	B-T059
and	O
QTL	B-T028
Analysis	B-T059
for	O
Fiber	B-T002
Quality	B-T080
and	O
Yield	B-T081
Traits	B-T032
in	O
the	O
Upland Cotton	B-T002
Recombinant Inbred Lines	B-T008
Population	O
It	O
is	O
of	O
significance	O
to	O
discover	O
genes	B-T028
related	O
to	O
fiber	B-T002
quality	B-T080
and	O
yield	B-T081
traits	B-T032
and	O
tightly	O
linked	O
markers	B-T045
for	O
marker-assisted selection	B-T062
(	O
MAS	B-T062
)	O
in	O
cotton	B-T002
breeding	B-T040
.	O
In	O
this	O
study,	O
188 F8	B-T002
recombinant inbred lines	B-T008
(	O
RILs	B-T008
),	O
derived	O
from	O
a	O
intraspecific	B-T080
cross	B-T040
between	O
HS46	B-T002
and	O
MARCABUCAG8US-1-88	B-T002
were	O
genotyped	B-T032
by	O
the	O
cotton	B-T002
63K	O
single nucleotide polymorphism (SNP) assay	B-T059
.	O
Field trials	B-T062
were	O
conducted	O
in	O
Sanya, Hainan Province	B-UnknownType
,	O
during	O
the	O
2014-2015	O
cropping	B-T090
seasons	B-T079
under	O
standard	B-T080
conditions	B-T080
.	O
Results	O
revealed	O
significant	B-T081
differences	B-T080
(P	O
<	O
0.05)	O
among	O
RILs	B-T008
,	O
environments	B-T082
and	O
replications	B-T080
for	O
fiber	B-T002
quality	B-T080
and	O
yield	B-T081
traits	B-T032
.	O
Broad-sense	O
heritabilities	B-T169
of	O
all	O
traits	B-T032
including	O
fiber	B-T002
length	B-T081
,	O
fiber	B-T002
uniformity	B-T080
,	O
micronaire	B-T080
,	O
fiber	B-T002
elongation	B-T040
,	O
fiber	B-T002
strength	B-T081
,	O
boll	B-T002
weight	B-T081
,	O
and	O
lint	B-T167
percentage	B-T081
ranged	O
from	O
0.26	O
to	O
0.66.	O
A	O
1784.28	O
cM	B-T081
(	O
centimorgans	B-T081
)	O
linkage map	B-T059
,	O
harboring	O
2618	O
polymorphic	B-T080
SNP	B-T086
markers	B-T045
,	O
was	O
constructed,	O
which	O
had	O
0.68	O
cM	B-T081
per	O
marker	B-T045
density.	O
Seventy-one	O
quantitative trait locus	B-T028
(	O
QTLs	B-T028
)	O
for	O
fiber	B-T002
quality	B-T080
and	O
yield	B-T081
traits	B-T032
were	O
detected	O
on	O
21	O
chromosomes	B-T026
,	O
explaining	O
4.70~32.28%	O
phenotypic	B-T032
variance	B-T080
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	B-T080
QTLs	B-T028
across	O
two	O
environments	B-T082
.	O
Meanwhile,	O
12	O
certain	O
regions	B-T026
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
(	O
hotspot	B-T086
)	O
or	O
more	O
(	O
cluster	B-T028
)	O
traits	B-T032
,	O
mainly	O
focused	O
on	O
Chr05	B-T026
,	O
Chr09	B-T026
,	O
Chr10	B-T026
,	O
Chr14	B-T026
,	O
Chr19	B-T026
,	O
and	O
Chr20	B-T026
.	O
Nineteen	O
pairs	O
of	O
epistatic	B-T028
QTLs	B-T028
(	O
e-QTLs	B-T028
)	O
were	O
identified,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	B-T080
QTLs	B-T028
.	O
These	O
additive	B-T080
QTLs	B-T028
,	O
e-QTLs	B-T028
,	O
and	O
QTL	B-T028
clusters	B-T028
were	O
tightly	O
linked	O
to	O
SNP	B-T086
markers	B-T045
,	O
which	O
may	O
serve	O
as	O
target	B-T169
regions	B-T026
for	O
map-based cloning	B-T059
,	O
gene discovery	B-T063
,	O
and	O
MAS	B-T062
in	O
cotton	B-T002
breeding	B-T040
.	O

Effects	B-T080
of	O
an	O
early	O
intervention	B-T061
using	O
human	B-T016
amniotic	B-T018
epithelial cells	B-T025
in	O
a	O
COPD	B-T047
rat	B-T015
model	B-T075
The	O
study	B-T062
aimed	O
to	O
investigate	B-T169
the	O
effect	B-T080
of	O
an	O
early	O
intervention	B-T061
using	O
human	B-T016
amniotic	B-T018
epithelial cell	B-T025
(	O
hAEC	B-T025
)	O
in	O
a	O
rat	B-T015
model	B-T075
of	O
chronic obstructive pulmonary disease	B-T047
(	O
COPD	B-T047
).	O
Twenty-four	O
specific pathogen-free	B-T001
Wistar rats	B-T015
were	O
randomized	B-T062
to	O
the	O
control	B-T096
,	O
COPD	B-T047
,	O
and	O
COPD	B-T047
+	O
hAEC	B-T025
groups	B-T078
.	O
COPD	B-T047
was	O
established	O
by	O
intratracheal	B-T169
LPS	B-T109
injection	O
combined	O
with	O
smoke	B-T131
fumigation	B-T068
over	O
30	O
days	B-T079
.	O
On	O
the	O
first	O
day	B-T079
of	O
model	B-T075
establishment	O
rats	B-T015
in	O
the	O
AEC	B-T025
group	B-T078
also	O
received	O
intratracheal instillation	B-T169
of	O
500,000	O
hAECs	B-T025
isolated	O
from	O
the	O
placenta	B-T018
of	O
healthy	B-T080
donors	B-T098
.	O
The	O
mean linear intercept	B-T081
(	O
MLI	B-T081
)	O
and	O
mean alveolar number	B-T081
(	O
MAN	B-T081
)	O
were	O
used	O
to	O
assess	O
the	O
degree	O
of	O
lung emphysema	B-T047
.	O
IL-8	B-T116
was	O
measured	O
using	O
a	O
radioimmunoassay	B-T059
,	O
surfactant protein D	B-T116
(	O
SP-D	B-T116
)	O
was	O
measured	O
by	O
ELISA	B-T059
,	O
and	O
matrix metalloproteinase (MMP)2	B-T116
and	O
MMP8	B-T116
expression	B-T045
was	O
assessed	O
by	O
PCR	B-T063
.	O
Smoke	B-T131
fumigation	B-T068
combined	O
to	O
LPS	B-T109
injection	O
successfully	O
established	O
a	O
COPD	B-T047
rat	B-T015
model	B-T075
with	O
significant	O
emphysema	B-T047
and	O
airway inflammation	B-T046
,	O
elevated	B-T080
MLI	B-T081
and	O
MAN	B-T081
,	O
elevated	B-T080
systemic	B-T169
and	O
lung	B-T023
tissue	B-T024
levels	B-T080
of	O
IL-8	B-T116
and	O
SP-D	B-T116
(P<0.05),	O
and	O
high	O
expression	B-T045
of	O
MMP2	B-T116
and	O
MMP8	B-T116
.	O
Rats	B-T015
in	O
the	O
COPD	B-T047
+	O
hAEC	B-T025
group	B-T078
exhibited	O
alleviated	B-T080
lung	B-T023
damage	B-T037
,	O
MLI	B-T081
and	O
MAN	B-T081
(P<0.05),	O
reduced	B-T080
systemic	B-T169
and	O
lung	B-T023
tissue	B-T024
levels	B-T080
of	O
IL-8	B-T116
and	O
SP-D	B-T116
(P<0.05)	O
and	O
MMP2	B-T116
and	O
MMP8	B-T116
expression	B-T045
(P<0.05).	O
Early	O
intervention	B-T061
using	O
hAECs	B-T025
could	O
delay	O
disease progression	B-T046
in	O
rats	B-T015
with	O
COPD	B-T047
.	O

Systematic	B-T169
Identification	B-T041
of	O
Pharmacological	B-T038
Targets	B-T169
from	O
Small-Molecule	B-T109
Phenotypic Screens	B-T059
Phenotypic	B-T032
drug discovery	B-T062
offers	O
some	O
advantages	B-UnknownType
over	O
target	B-T169
-	O
based	B-T169
methods	B-T170
,	O
mainly	O
because	O
it	O
allows	O
drug leads	B-T121
to	O
be	O
tested	B-T169
in	O
systems	B-T169
that	O
more	B-T081
closely	B-T033
model	B-T075
distinct	B-T080
disease states	B-T033
.	O
However,	O
a	O
potential	B-T080
disadvantage	B-T080
is	O
the	O
difficulty	B-T080
of	O
linking	B-T052
the	O
observed	B-T169
phenotype	B-T032
to	O
a	O
specific	B-T080
cellular	B-T025
target	B-T169
.	O
To	O
address	O
this	O
problem	B-T033
,	O
we	O
developed	B-T169
DePick	B-T170
,	O
a	O
computational	B-T052
target	O
de-convolution	B-T066
tool	B-T073
to	O
determine	B-T059
targets	B-T169
specifically	B-T080
linked	B-T052
to	O
small-molecule	B-T109
phenotypic screens	B-T059
.	O
We	O
applied	B-T169
DePick	B-T170
to	O
eight	O
publicly	B-T092
available	O
screens	B-T074
and	O
predicted	B-T078
59	O
drug	B-T121
target	B-T169
-	O
phenotype	B-T032
associations	B-T080
.	O
In	O
addition	O
to	O
literature	B-T170
-	O
based	B-T169
evidence	B-T078
for	O
our	O
predictions	B-T078
,	O
we	O
provide	B-T052
experimental	B-T080
support	B-T077
for	O
seven	O
predicted	B-T078
associations	B-T080
.	O
Interestingly	B-T041
,	O
our	O
analysis	B-T062
led	O
to	O
the	O
discovery	B-T052
of	O
a	O
previously	B-T079
unrecognized	B-T080
connection	B-T082
between	O
the	O
Wnt signaling pathway	B-T044
and	O
an	O
aromatase	B-T116
,	O
CYP19A1	B-T116
.	O
These	O
results	B-T033
demonstrate	B-T080
that	O
the	O
DePick	B-T170
approach	O
can	O
not	O
only	O
accelerate	B-T169
target	B-T169
de-convolution	B-T066
but	O
also	O
aid	B-T080
in	O
discovery	B-T052
of	O
new	O
functionally	B-T169
relevant	B-T080
biological	B-T080
relationships	B-T080
.	O

'	O
Yarn	B-T058
with	O
me':	O
applying	O
clinical yarning	B-T058
to	O
improve	O
clinician	B-T097
-	O
patient	B-T101
communication	B-T054
in	O
Aboriginal	B-T098
health care	B-T058
Although	O
successful	O
communication	B-T054
is	O
at	O
the	O
heart	O
of	O
the	O
clinical consultation	B-T058
,	O
communication	B-T054
between	O
Aboriginal	B-T098
patients	B-T101
and	O
practitioners	B-T097
such	O
as	O
doctors	B-T097
,	O
nurses	B-T097
and	O
allied health professionals	B-T097
,	O
continues	O
to	O
be	O
problematic	B-T033
and	O
is	O
arguably	O
the	O
biggest	O
barrier	O
to	O
the	O
delivery	O
of	O
successful	O
health care	B-T058
to	O
Aboriginal people	B-T098
.	O
This	O
paper	O
presents	O
an	O
overarching framework	B-T170
for	O
practitioners	B-T097
to	O
help	O
them	O
reorientate	O
their	O
communication	B-T054
with	O
Aboriginal	B-T098
patients	B-T101
using	O
'	O
clinical yarning	B-T058
'.	O
Clinical yarning	B-T058
is	O
a	O
patient	B-T101
-centred	O
approach	O
that	O
marries	O
Aboriginal	B-T098
cultural communication	B-T054
preferences	O
with	O
biomedical	B-T091
understandings	O
of	O
health and disease	B-T070
.	O
Clinical yarning	B-T058
consists	O
of	O
three	O
interrelated	O
areas:	O
the	O
social	B-T169
yarn	B-T058
,	O
in	O
which	O
the	O
practitioner	B-T097
aims	O
to	O
find	O
common	O
ground	O
and	O
develop	O
the	O
interpersonal relationship	B-T054
;	O
the	O
diagnostic	B-T169
yarn	B-T058
,	O
in	O
which	O
the	O
practitioner	B-T097
facilitates	O
the	O
patient's	B-T101
health story	B-T078
while	O
interpreting	O
it	O
through	O
a	O
biomedical	B-T091
or	O
scientific lens	B-T059
;	O
and	O
the	O
management	O
yarn	B-T058
,	O
that	O
employs stories	B-T078
and	O
metaphors	B-T078
as	O
tools	O
for	O
patients	B-T101
to	O
help	O
them	O
understand	O
a	O
health issue	B-T033
so	O
a	O
collaborative management approach	B-T062
can	O
be	O
adopted.	O
There	O
is	O
cultural	B-T169
and	O
research	B-T062
evidence	B-T078
that	O
supports	O
this	O
approach.	O
Clinical yarning	B-T058
has	O
the	O
potential	O
to	O
improve	O
outcomes	B-T169
for	O
patients	B-T101
and	O
practitioners	B-T097
.	O

Effect	O
of	O
single-dose	B-T201
carbapenem	B-T109
exposure	B-T033
on	O
transcriptional expression	B-T045
of	O
blaNDM-1	B-T028
and	O
mexA	B-T028
in	O
Pseudomonas aeruginosa	B-T007
The	O
therapeutic option	B-T169
of	O
a	O
carbapenem antibiotic	B-T109
is	O
compromised	O
in	O
Pseudomonas aeruginosa	B-T007
owing	O
both	O
to	O
acquired	B-T040
and	O
intrinsic resistance	B-T032
mechanisms.	O
In	O
recent	O
years,	O
New Delhi metallo-β-lactamase	B-T116
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem resistance determinant	B-T032
.	O
However,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
P. aeruginosa	B-T007
strain	B-T001
possessing	O
both	O
blaNDM-1	B-T028
and	O
an	O
overexpressed	B-T045
MexAB-OprM	B-T028
system	O
during	O
carbapenem	B-T109
therapy	B-T061
.	O
This	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical isolates	B-T123
of	O
P. aeruginosa	B-T007
when	O
exposed	O
to	O
meropenem	B-T109
.	O
Five	O
strains	B-T001
were	O
used:	O
(i)	O
strain overexpressing	B-T045
MexAB-OprM	B-T028
but	O
with	O
no	B-T169
blaNDM-1	B-T028
;	O
(ii)	O
strain	O
harbouring	O
blaNDM-1	B-T028
but	O
expressing	B-T045
MexAB-OprM	B-T028
at	O
basal	O
level;	O
(iii)	O
strain	B-T001
possessing	O
blaNDM-1	B-T028
and	O
overexpressing	B-T045
MexAB-OprM	B-T028
;	O
(iv)	O
P. aeruginosa PAO1	B-T007
;	O
and	O
(v)	O
P. aeruginosa K2733-PAO1	B-T007
(	O
ΔMexAB-OprM	B-T028
ΔMexCD-OprJ	B-T028
ΔMexEF-OprN	B-T028
ΔMexXY-OprM	B-T028
)	O
into	O
which	O
blaNDM-1	B-T028
was	O
cloned	B-T059
.	O
Strains	B-T001
were	O
incubated	O
in	O
Luria-Bertani broth	B-T130
with	O
and	O
without	O
1μg/mL	O
meropenem	B-T109
.	O
Total RNA	B-T059
was	O
isolated	O
at	O
45-min	O
intervals	O
and	O
was	O
immediately	O
reverse transcribed	B-T045
to	O
cDNA	B-T114
.	O
This	O
was	O
repeated	O
for	O
6h.	O
Quantitative real-time PCR	B-T063
was	O
performed	O
for	O
both	O
resistance mechanisms	B-T062
.	O
Meropenem	B-T109
exposure	B-T033
did	O
not	O
significantly	O
elevate transcription	B-T045
of	O
either	O
the	O
blaNDM-1	B-T028
or	O
mexA gene	B-T028
.	O
However,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single-dose	B-T201
exposure to carbapenem	B-T033
,	O
the	O
efflux pump system	B-T024
played	O
a	O
major	O
role in bacterial survival	B-T169
compared	O
with	O
NDM-1	B-T116
.	O
This	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial response to carbapenem antibiotic	B-T040
when	O
two	O
different	O
resistance mechanisms	B-T062
coexist.	O
This	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
antimicrobials	B-T121
.	O

Inducible	B-T169
Expression	B-T045
of	O
both	O
ermB	B-T028
and	O
ermT	B-T028
Conferred	O
High	B-T080
Macrolide Resistance	B-T033
in	O
Streptococcus gallolyticus subsp. pasteurianus	B-T007
Isolates	B-T001
in	O
China	B-T083
Streptococcus gallolyticus subsp. pasteurianus	B-T007
is	O
an	O
under-recognized	O
pathogen	B-T001
and	O
zoonotic agent	B-T007
causing	O
opportunistic infections	B-T047
in	O
humans	B-T016
.	O
Despite	O
increasing	O
recognition	B-T080
of	O
this	O
subspecies	B-T007
as	O
a	O
cause	O
for	O
human	B-T016
infectious diseases	B-T047
,	O
limited	O
information	O
is	O
known	O
about	O
its	O
antibiotic resistance	B-T032
mechanism	B-T169
.	O
In	O
this	O
study	B-T062
,	O
we	O
aim	O
to	O
identify	O
the	O
molecular mechanism	B-T044
underlying	O
the	O
high	O
macrolide resistance	B-T033
of	O
six	O
S. gallolyticus subsp. pasteurianus	B-T007
isolates	B-T001
from	O
dead	B-T033
ducklings	B-T012
collected	O
in	O
several	O
natural	O
outbreaks	O
in	O
China	B-T083
during	O
2010-2013.	O
All	O
isolates	B-T001
exhibited	O
multi-drug resistance	B-T032
including	O
high	O
macrolide resistance	B-T033
(	O
MIC	B-T034
MIC	B-T034
≥	O
1024	O
mg/L	O
for	O
erythromycin	B-T109
,	O
and	O
512	O
mg/L	O
for	O
clarithromycin	B-T109
).	O
Efflux-encoding mefA	B-T028
and	O
mefE genes	B-T028
were	O
not	O
detectable	O
in	O
these	O
isolates	B-T001
.	O
The	O
presence	O
of	O
23S rRNA	B-T114
mutations	B-T045
in	O
specific	O
isolates	B-T001
did	O
not	O
significantly	O
change	O
macrolide	B-T109
MIC	B-T034
s.	O
No	O
nucleotide	B-T114
substitutions	B-T052
were	O
found	O
in	O
genes	B-T028
encoding	O
ribosomal proteins L4	B-T116
or	O
L22	B-T116
.	O
The	O
ermB	B-T028
and	O
ermT genes	B-T028
were	O
found	O
in	O
the	O
genomes	B-T028
of	O
all	O
isolates	B-T001
.	O
These	O
two	O
genes	B-T028
were	O
acquired	O
independently	B-T169
in	O
one	O
highly	O
virulent isolate AL101002	B-T001
,	O
and	O
clustered	O
with	O
Tn916	B-T001
and	O
IS1216	B-T001
,	O
respectively.	O
The	O
expression	B-T045
of	O
both	O
ermB	B-T028
and	O
ermT	B-T028
in	O
all	O
isolates	B-T001
was	O
erythromycin	B-T109
inducible	B-T169
and	O
yielded	O
comparable	O
macrolide	B-T109
MICs	B-T034
in	O
all	O
six	O
isolates	B-T001
.	O
Taken	O
together,	O
inducible	B-T169
expression	B-T045
of	O
both	O
ermB	B-T028
and	O
ermT	B-T028
conferred	O
high	O
macrolide resistance	B-T033
in	O
these	O
S. gallolyticus subsp. pasterianus	B-T007
isolates	B-T001
.	O
Our	O
findings	B-T033
reveal	O
new	O
macrolide resistance	B-T033
features	O
in	O
S. gallolyticus subsp. pasteurianus	B-T007
by	O
both	O
ermB	B-T028
and	O
ermT	B-T028
.	O

Bilateral	B-T082
C1 laminar hooks	B-T074
combined	O
with	O
C2 pedicle screw	B-T074
fixation	B-T061
in	O
the	O
treatment	B-T061
of	O
atlantoaxial subluxation	B-T037
after	O
Grisel syndrome	B-T047
Many	O
etiologies	B-T169
can	O
lead	O
to	O
atlantoaxial subluxaion	B-T037
.	O
In	O
Grisel syndrome	B-T047
(	O
GS	B-T047
),	O
this	O
subluxation	B-T037
occurs	O
spontaneously	B-T169
after	O
inflammatory	B-T169
processes	B-T067
of	O
the	O
head	B-T029
and	O
neck	B-T029
.	O
Diagnosis	B-T033
is	O
typically	O
based	O
on	O
clinical history	B-T033
and	O
a	O
strong	O
suspicion	B-T041
of	O
this	O
syndrome	B-T047
.	O
Nonsurgical treatment	B-T061
most	O
often	O
resolves	B-T077
the	O
symptoms	B-T184
;	O
however,	O
in	O
some	O
cases	B-T169
surgical treatment	B-T061
is	O
necessary	O
to	O
repair	B-T061
the	O
subluxation	B-T037
.	O
Various	O
surgical techniques	B-T060
and	O
instrumentation systems	B-T074
have	O
been	O
used	O
to	O
treat	B-T061
atlantoaxial subluxation	B-T037
,	O
although	O
there	O
is	O
no	O
consensus	B-T054
regarding	O
the	O
best	O
treatment method	B-T061
for	O
the	O
pediatric	B-T080
population	B-T098
.	O
To	O
describe	O
a	O
case	B-T169
of	O
atlantoaxial subluxation	B-T037
in	O
a	O
child	B-T100
with	O
GS	B-T047
treated	B-T033
surgically	B-T061
with	O
an	O
alternative	B-T077
construct	B-T074
.	O
This	O
is	O
a	O
case report	B-T170
and	O
literature review	B-T170
.	O
Our	O
case study	B-T170
involves	O
a	O
5-	O
year	B-T079
-old	O
girl	B-T100
with	O
a	O
6-	O
month	B-T079
history	B-T033
of	O
unresolved	B-T080
Fielding type II atlantoaxial subluxation	B-T037
caused	O
by	O
GS	B-T047
.	O
Despite	O
conservative treatment	B-T061
,	O
the	O
patient's	B-T101
symptoms	B-T184
continued	B-T078
to	O
progress	B-T169
.	O
After	O
two	O
failed	B-T169
closed reduction	B-T061
attempts	B-T051
,	O
open reduction	B-T061
and	O
C1-C2 fusion	B-T061
were	O
performed	B-T169
with	O
atlas laminar hook	B-T074
and	O
axis pedicle polyaxial screws	B-T074
.	O
A	O
literature review	B-T170
of	O
the	O
surgical treatment	B-T061
of	O
GS	B-T047
was	O
also	O
performed	B-T169
.	O
After	O
surgery	B-T169
,	O
the	O
patient	B-T101
exhibited	O
full	O
clinical	B-T080
and	O
functional recovery	B-T184
with	O
complete resolution	B-T077
of	O
symptoms	B-T184
.	O
At	O
the	O
36-	O
month	B-T079
follow-up	B-T058
examination	B-T058
,	O
there	O
was	O
continual	B-T079
evidence	B-T078
of	O
satisfactory	B-T033
reduction	B-T061
and	O
fusion	B-T061
.	O
No	O
complications	B-T046
were	O
observed	B-T169
.	O
Upon	O
completion	B-T080
of	O
the	O
literature review	B-T170
,	O
eight	O
GS	B-T047
cases	B-T169
were	O
found	O
to	O
have	O
been	O
treated	B-T169
surgically	B-T061
with	O
the	O
minimum	O
patient	B-T101
age	B-T032
being	O
9	O
years	B-T079
.	O
Conservative management	B-T061
of	O
GS	B-T047
is	O
the	O
most	O
common	B-T081
and	O
effective	B-T080
treatment	B-T061
;	O
however,	O
a	O
few	O
surgical cases	B-T169
have	O
been	O
reported	B-T058
in	O
the	O
literature	B-T170
with	O
good	O
results	B-T169
.	O
Satisfactory	B-T033
clinical results	B-T033
and	O
fusion	B-T061
at	O
36	O
months	B-T079
post surgery	B-T033
were	O
seen	O
in	O
a	O
pediatric	B-T080
patient	B-T101
with	O
atlantoaxial subluxation	B-T037
and	O
instability	B-T033
using	O
atlas laminar hook	B-T074
and	O
axis pedicle polyaxial screws	B-T074
.	O

Caries	B-T047
with	O
Dental Fluorosis	B-T047
and	O
Oral Health Behaviour	B-T201
Among	O
12-Year	B-T079
School Children	B-T100
in	O
Moderate-Fluoride Drinking Water Community	B-T096
in	O
Quetta	B-T083
,	O
Pakistan	B-T083
To	O
determine	O
the	O
prevalence	B-T081
of	O
dental caries	B-T047
and	O
its	O
relationship	B-T080
with	O
dental fluorosis	B-T047
,	O
oral health behaviour	B-T201
and	O
dietary behaviour	B-T033
among	O
12-year	B-T079
school children	B-T100
in	O
moderate-fluoride drinking water community	B-T096
in	O
Quetta	B-T083
,	O
Pakistan	B-T083
.	O
Cross-sectional study	B-T062
.	O
Government	B-T073
and	O
private schools	B-T073
of	O
Quetta	B-T083
,	O
from	O
November	B-T079
2012	O
to	O
February	B-T080
2013.	O
Atotal	O
of	O
349	O
children	B-T100
aged	O
12-year	B-T079
from	O
14	O
randomly	O
selected	O
schools	B-T073
were	O
included.	O
The	O
data collection	B-T062
was	O
done	O
on	O
questionnaire	B-T170
designed	O
for	O
children	B-T100
.	O
Dental caries	B-T047
status	B-T080
status	B-T080
was	O
examined	B-T033
by	O
using	O
WHO	B-T093
criteria.	O
Dental caries	B-T047
was	O
found	O
in	O
81	O
children	B-T100
(23.2%)	O
with	O
mean	O
DMFT	B-T081
0.61.	O
Boys	B-T100
had	O
1.6	O
times	O
more	O
chance	O
to	O
have	O
dental caries	B-T047
than	O
girls	B-T100
.	O
Dental fluorosis	B-T047
was	O
found	O
in	O
63.6%	O
of	O
children	B-T100
with	O
majority	O
of	O
moderate	B-T080
degree	O
(50.5%).	O
Dental fluorosis	B-T047
status	B-T080
was	O
found	O
significantly	O
associated with	B-T080
dental caries	B-T047
status	B-T080
in	O
children	B-T100
.	O
The	O
children	B-T100
who	O
had	O
mild	B-T080
,	O
moderate	B-T080
and	O
severe	B-T080
fluorosis	B-T047
,	O
had	O
4	O
times	O
more	O
chances	O
to	O
develop	B-T169
caries	B-T047
than	O
those	O
who	O
did	O
not	O
have	O
fluorosis	B-T047
.	O
There	O
was	O
no	O
significant	O
association	B-T080
between	O
children's	B-T100
caries	B-T047
status	B-T080
and	O
use	O
of	O
paste	B-T122
,	O
brushing habit	B-T061
,	O
miswak	B-T122
,	O
and	O
visit	B-T053
to	O
the	O
dentist	B-T097
.	O
The	O
use	O
of	O
pastries	B-T168
and	O
juices	B-T168
had	O
a	O
direct	O
relation	O
with	O
the	O
children's	B-T100
dental caries	B-T047
status	B-T080
.	O
Dental caries	B-T047
in	O
children	B-T100
of	O
Quetta	B-T083
is	O
not	O
so	O
much	O
frequent	O
as	O
compared	O
to	O
the	O
fluoride	B-T121
deficient	B-T169
countries	B-T083
.	O
However,	O
the	O
high	O
prevalence	B-T081
of	O
moderate	O
dental fluorosis	B-T047
and	O
consumption	B-T052
of	O
pastries	B-T168
and	O
juices	B-T168
resulted	O
in	O
dental caries	B-T047
.	O

Proteomics	B-T116
analysis	B-T059
of	O
the	O
endogenous	B-T169
,	O
constitutive,	O
leaf	B-T002
SUMOylome	B-T044
SUMOylation	B-T044
is	O
a	O
post-translational modification	B-T044
which	O
regulates	B-T038
a	O
number	O
of	O
critical	B-T080
biological processes	B-T038
in,	O
for	O
example	O
mammals	B-T015
,	O
yeast	B-T004
and	O
plants	B-T002
.	O
In	O
order	O
to	O
fully	O
understand	B-T041
the	O
functional effects	B-T033
of	O
SUMOylation	B-T044
an	O
essential	B-T080
first	O
step	O
is	O
the	O
identification	B-T041
of	O
endogenous	B-T169
targets	B-T169
for	O
SUMOylation	B-T044
.	O
Here	O
we	O
report	B-T170
the	O
results	B-T169
of	O
using	O
a	O
recently	O
developed	O
proteomic approach	B-T091
based	O
on	O
the	O
use	O
of	O
3D	B-T082
gels	B-T122
to	O
identify	O
the	O
endogenous	B-T169
SUMO	B-T116
targets	B-T169
in	O
leaves	B-T002
of	O
Solanum tuberosum	B-T002
.	O
By	O
using	O
3D	B-T082
gels	B-T122
we	O
avoid	O
the	O
problem	O
of	O
co-migration	B-T067
of	O
proteins	B-T116
,	O
which	O
is	O
a	O
major	B-T080
limitation	B-T169
of	O
2D	B-T082
gels	B-T122
,	O
and	O
we	O
enable	O
the	O
use	O
of	O
the	O
highly sensitive	B-T080
CyDye DIGE fluor saturation dyes	B-T130
.	O
Using	O
this	O
new	O
method	O
we	O
have	O
identified	B-T080
39	O
individual proteins	B-T116
as	O
probable	B-T081
SUMO	B-T116
targets	B-T169
in	O
leaves	B-T002
of	O
Solanum tuberosum	B-T002
.	O
The	O
advantages	O
of	O
this	O
method	B-T059
compared	O
with	O
other	O
approaches	B-T169
are	O
discussed,	O
and	O
possible	B-T033
future	B-T079
developments	B-T169
are	O
outlined.	O
The	O
authors	B-T097
have	O
no	O
conflicts of interest	B-T078
to	O
declare.	O
All	O
authors	B-T097
have	O
approved	B-T080
the	O
manuscript	B-T073
and	O
agree	B-T033
with	O
submission	B-T169
to	O
Journal of Proteomics	B-T073
.	O

Antenatal	B-T079
consultation	B-T058
following	B-T079
limb malformation	B-T019
discovery	B-T052
using	O
ultrasound scan	B-T060
Our	O
unit	B-T073
has	O
been	O
providing	B-T052
antenatal	B-T079
consultations	B-T058
for	O
30	O
years	O
following	B-T079
the	O
discovery	B-T052
of	O
limb malformation	B-T019
with	O
the	O
fetus	B-T018
.	O
Each	O
of	O
these	O
consultations	B-T058
is	O
specific	B-T080
and	O
carried out	B-T058
by	O
a	O
multi-professional team	B-T058
.	O
It	O
requires	B-T169
a	O
physical	O
and	O
rehabilitation	B-T091
doctor	B-T097
,	O
an	O
orthopedic surgeon	B-T097
,	O
an	O
occupational therapist	B-T097
for	O
upper limb malformation	B-T019
,	O
a	O
physiotherapist	B-T097
for	O
lower malformation	B-T019
and	O
a	O
psychologist	B-T097
.	O
This	O
multidisciplinary	B-T057
consultation	B-T058
is	O
unique	B-T080
because	O
of	O
each	O
pregnancy	B-T040
story,	O
because	O
of	O
each	O
patient	B-T101
life story	B-T170
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	B-T097
when	O
announcing	O
the	O
diagnosis	B-T033
.	O
We	O
deal	O
with	O
couples	B-T099
shocked	B-T033
by	O
the	O
prenatal diagnosis	B-T060
.	O
We	O
help	O
them	O
get	O
acceptance	B-T055
of	O
the	O
child	B-T100
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	B-T041
child	B-T100
.	O
Medical information	B-T058
is	O
often	O
perceived	B-T041
as	O
being	O
"a	O
surfeit	B-T080
of	O
information	B-T078
"	O
difficult	B-T080
to	O
handle	O
by	O
the	O
couple	B-T099
stunned	B-T033
by	O
the	O
overwhelming	B-T080
diagnosis	B-T033
.	O
We	O
must	O
stress	O
that	O
it	O
is	O
critical	B-T080
to	O
not	O
only	O
have	O
a	O
good	O
medical description	B-T033
of	O
the	O
malformations	B-T019
and	O
potential treatments	B-T061
but	O
also	O
a	O
good	O
psychological support	B-T058
(	O
parents	B-T099
personal	B-T032
life story	B-T170
,	O
self-defense mechanism	B-T041
,	O
guilt feeling	B-T041
).	O
The	O
ethical aspect	B-T078
of	O
this	O
consultation	B-T058
is	O
also	O
important	B-T080
.	O
Team	B-T058
members	B-T098
must	O
be	O
as	O
neutral	B-T170
as	O
possible	B-T033
in	O
their	O
assessments	B-T058
in	O
order	O
to	O
let	O
the	O
couple	B-T099
take	O
the	O
final	O
decision	B-T041
:	O
the	O
continuation	B-T033
of	O
the	O
pregnancy	B-T040
or	O
a	O
request	B-T052
of	O
voluntary	B-T055
termination of pregnancy	B-T061
.	O
These	O
prenatal	B-T100
consultations	B-T058
highlight	O
the	O
importance	B-T080
of	O
the	O
multidisciplinary	B-T080
global	B-T080
care	B-T058
.	O

Bending rules	B-T170
:	O
the	O
shape	B-T082
of	O
the	O
perceptual	B-T041
generalisation	B-T041
gradient	B-T081
is	O
sensitive	B-T169
to	O
inference rules	B-T170
Generalising	B-T041
what	O
is	O
learned	B-T041
about	O
one	O
stimulus	B-T067
to	O
other	O
but	O
perceptually	B-T041
related	O
stimuli	B-T067
is	O
a	O
basic	O
behavioural	B-T053
phenomenon	B-T067
.	O
We	O
evaluated	B-T058
whether	O
a	O
rule	B-T170
learning	B-T041
mechanism	B-T169
may	O
serve	O
to	O
explain	O
such	O
generalisation	B-T041
.	O
To	O
this	O
end,	O
we	O
assessed	B-T052
whether	O
inference rules	B-T170
communicated	B-T033
through	O
verbal instructions	B-T058
affect	O
generalisation	B-T041
.	O
Expectancy	B-T078
ratings	B-T052
,	O
but	O
not	O
valence	O
ratings	B-T052
,	O
proved	O
sensitive	B-T169
to	O
this	O
manipulation	B-T053
.	O
In	O
addition	O
to	O
revealing	O
a	O
role	B-T170
for	O
inference rules	B-T170
in	O
generalisation	B-T041
,	O
our	O
study	B-T062
has	O
clinical	B-T080
implications	B-T169
as	O
well.	O
More	O
specifically,	O
we	O
argue	O
that	O
targeting	B-T169
inference rules	B-T170
might	O
prove	O
to	O
be	O
an	O
effective	O
strategy	B-T041
to	O
affect	O
the	O
excessive	B-T080
generalisation	B-T041
that	O
is	O
often	O
observed	O
in	O
psychopathology	B-T091
.	O

Neuroticism	B-T048
and	O
Fatigue	B-T184
3 Months	B-T079
After	O
Ischemic Stroke	B-T047
:	O
A	O
Cross-Sectional Study	B-T062
To	O
examine	B-T033
the	O
relation	O
between	O
neuroticism	B-T048
and	O
fatigue	B-T184
in	O
Chinese	B-T083
patients	B-T101
with	O
stroke	B-T047
.	O
Cross-sectional study	B-T062
.	O
Acute	B-T079
stroke unit	B-T093
.	O
Survivors	B-T101
of	O
ischemic stroke	B-T047
(N=191)	O
recruited	O
from	O
the	O
acute	B-T079
stroke unit	B-T093
between	O
May	O
1,	O
2010,	O
and	O
September	O
1,	O
2011.	O
Not	O
applicable.	O
The	O
personality trait	B-T033
of	O
neuroticism	B-T048
was	O
measured	B-T080
with	O
the	O
neuroticism	B-T048
subscale	B-T081
of	O
the	O
Chinese	B-T083
version	B-T170
of	O
the	O
NEO Five-Factor Inventory	B-T060
.	O
The	O
level	B-T080
of	O
fatigue	B-T184
was	O
measured	B-T080
with	O
the	O
Fatigue Assessment Scale	B-T170
.	O
The	O
National Institutes of Health Stroke Scale	B-T170
,	O
Geriatric Depression Scale	B-T170
,	O
Barthel Index	B-T170
,	O
and	O
Mini-Mental State Examination	B-T060
were	O
administered	B-T169
to	O
obtain	O
demographic	B-T090
and	O
clinical information	B-T170
.	O
Fatigue severity	B-T170
3 months	B-T079
after	O
stroke	B-T047
positively	O
correlated	B-T080
with	O
Geriatric Depression Scale	B-T170
and	O
NEO Five-Factor Inventory	B-T060
neuroticism	B-T048
scores	B-T081
and	O
negatively	B-T033
correlated	B-T080
with	O
the	O
Barthel Index score	B-T081
.	O
Neuroticism	B-T048
,	O
independent	B-T033
of	O
depressive symptoms	B-T184
,	O
is	O
a	O
predictor	O
of	O
fatigue severity	B-T170
3 months	B-T079
after	O
stroke	B-T047
.	O
Interventions	O
such	O
as	O
psychological	B-T169
screening programs	B-T169
are	O
warranted	O
for	O
early	O
detection	B-T061
of	O
patients	B-T101
at	O
high risk of	B-T033
poststroke depression	B-T047
.	O

Hematological	B-T033
,	O
biochemical	B-T033
,	O
and	O
toxicopathic effects	B-T033
of	O
subchronic	B-T080
acetamiprid	B-T109
toxicity	B-T037
in	O
Wistar rats	B-T015
Acetamiprid	B-T109
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	B-T131
.	O
This	O
study	O
investigates	B-T169
toxic effects	B-T037
of	O
repeated	O
oral administration	B-T169
of	O
three	O
doses	B-T081
of	O
acetamiprid	B-T109
(1/20,	O
1/10,	O
and	O
1/5	O
of	O
LD50	B-T081
)	O
during	O
60	O
days	B-T079
.	O
For	O
this,	O
male	B-T032
Wistar rats	B-T015
were	O
divided	O
into	O
four	O
different	O
groups	B-T078
.	O
Hematological	B-T033
,	O
biochemical	B-T033
,	O
and	O
toxicopathic effects	B-T033
of	O
acetamiprid	B-T109
were	O
evaluated	B-T058
.	O
According	O
to	O
the	O
results,	O
a	O
significant	O
decrease	B-T081
in	O
the	O
body weight gain	B-T033
at	O
the	O
highest	O
dose	B-T081
1/5	O
of	O
LD50	B-T081
of	O
acetamiprid	B-T109
was	O
noticed.	O
An	O
increase	B-T169
in	O
the	O
relative	O
liver	B-T023
weight	B-T081
was	O
also	O
observed	O
at	O
this	O
dose	B-T081
level	B-T080
.	O
The	O
hematological constituents	B-T167
were	O
affected.	O
A	O
significant	O
decrease	B-T081
in	O
RBC	B-T025
,	O
HGB	B-T116
,	O
and	O
HCT	B-T033
in	O
rats	B-T015
treated	B-T169
with	O
higher	O
doses	B-T081
of	O
acetamiprid	B-T109
(1/10	O
and	O
1/5	O
of	O
LD50	B-T081
)	O
was	O
noted.	O
However,	O
a	O
significant	O
increase	B-T169
in	O
WBC	B-T025
and	O
PLT	B-T025
were	O
observed	O
at	O
the	O
same	O
doses	B-T081
.	O
Furthermore,	O
acetamiprid	B-T109
induced liver toxicity	B-T047
measured	O
by	O
the	O
increased	B-T081
activities	B-T044
of	O
aspartate aminotransferase	B-T116
(	O
AST	B-T116
),	O
alanine aminotransferase	B-T116
(	O
ALT	B-T116
),	O
alkaline phosphates	B-T116
(	O
ALPs	B-T116
),	O
and	O
lactate dehydrogenase	B-T116
(	O
LDH	B-T116
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	B-T081
of	O
hepatic membrane architecture	B-T026
and	O
hepatocellular damage	B-T046
.	O
In	O
addition,	O
exposure to	B-T080
acetamiprid	B-T109
resulted	O
in	O
a	O
significant	O
decrease	B-T081
in	O
the	O
levels	B-T080
of	O
superoxide dismutase	B-T116
and	O
catalase	B-T116
activities	B-T044
(p	O
≤	O
0.01)	O
with	O
concomitant	B-T079
increase	B-T169
in	O
lipid peroxidation	B-T044
in	O
rat	B-T015
liver	B-T023
.	O
These	O
findings	B-T033
highlight	O
the	O
subchronic	B-T080
hepatotoxicity	B-T037
of	O
acetamiprid	B-T109
.	O

Sustained delivery	B-T122
of	O
vincristine	B-T109
inside	O
an	O
orthotopic	B-T082
mouse sarcoma	B-T191
model	O
decreases	B-T081
tumor growth	B-T191
Sarcoma	B-T191
accounts	O
for	O
20%	O
of	O
solid tumors	B-T191
in	O
children	B-T100
.	O
Surgery	B-T061
has	O
significant	O
morbidity	B-T081
.	O
We	O
hypothesized	O
that	O
delivering	O
chemotherapy	B-T061
directly	O
into	O
tumors	B-T191
through	O
sustained release	B-T122
silk	B-T116
systems	O
could	O
slow	O
tumor growth	B-T191
.	O
Human	B-T016
Ewing sarcoma	B-T191
cells A673	B-T025
were	O
cultured	B-T059
with	O
vincristine	B-T109
and	O
doxorubicin	B-T109
to	O
determine	O
half maximal inhibitory concentration	B-T081
(	O
IC50	B-T081
).	O
Cells	B-T025
were	O
injected	O
into	O
mouse	B-T015
hind leg	B-T023
to	O
create	O
orthotopic	B-T082
tumors	B-T191
.	O
Tumor volumes	B-T081
were	O
measured	O
using	O
ultrasound	B-T060
.	O
When	O
volume	O
reached	O
>250mm(3,)	O
interventions	B-T061
included:	O
implantation	B-T061
of	O
drug-free	B-UnknownType
silk	B-T116
foam	O
(	O
Control	B-T096
-F),	O
doxorubicin	B-T109
400μg	O
foam	O
(Dox400	B-T109
-F),	O
vincristine	B-T109
50μg	O
foam	O
(	O
Vin50	B-T109
-F),	O
drug-free	B-UnknownType
silk	B-T116
gel	B-T167
(	O
Control	B-T096
-G),	O
vincristine	B-T109
50μg	O
gel	B-T167
(	O
Vin50	B-T109
-G),	O
or	O
single	O
dose	O
intravenous	B-T082
vincristine	B-T109
50μg	O
(	O
Vin50	B-T109
-IV).	O
End-point	B-T080
was	O
volume>1000mm(3).	O
Kaplan Meier	B-T081
and	O
ANOVA	B-T081
were	O
used.	O
IC50	B-T081
for	O
vincristine	B-T109
and	O
doxorubicin	B-T109
was	O
0.5ng/mL	O
and	O
200ng/mL,	O
respectively.	O
There	O
was	O
no	O
difference	O
between	O
Dox400	B-T109
-F	O
[6±	O
1days	B-T079
to	O
end point	B-T080
(	O
DTEP	B-T080
)]	O
and	O
Control	B-T096
-F	O
(5±1.3	O
DTEP	B-T080
).	O
Vin50	B-T109
-F	O
(12.4±3.5	O
DTEP	B-T080
)	O
had	O
slower growth	B-T033
compared	O
to	O
Control	B-T096
-F	O
(p<0.001),	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	B-T109
-F	O
and	O
Vin50	B-T109
-IV	O
(14±0	O
DTEP	B-T080
).	O
Growth was slowest	B-T033
with	O
Vin50	B-T109
-G,	O
28±10.3	O
DTEP	B-T080
compared	O
to	O
all	O
other	O
treatment	O
groups	O
(p<0.05).	O
Sustained delivery	B-T122
of	O
vincristine	B-T109
inside	O
the	O
sarcoma	B-T191
tumor	B-T191
with	O
silk	B-T116
gel	B-T167
decreased	B-T081
tumor growth	B-T191
.	O
Applying	O
this	O
intratumoral treatment	B-T061
strategy	O
may	O
potentially	O
decrease	B-T081
the	O
extent	O
of	O
surgical excision	B-T061
.	O

Spinal	B-T023
load	B-T032
in	O
nurses	B-T097
during	O
emergency	B-T067
lifting	B-T052
of	O
obese	B-T047
patients	B-T101
:	O
preliminary results	B-T078
Nurses	B-T097
are	O
exposed	O
to	O
the	O
risk	B-T078
of	O
injury	B-T037
while	O
handling	B-T033
patients	B-T101
.	O
This	O
is	O
particularly	O
true	O
for	O
obese	B-T047
patients	B-T101
.	O
The	O
goal	B-T170
of	O
this	O
paper	O
is	O
to	O
estimate	B-T081
the	O
spinal	B-T023
loads	B-T032
and	O
the	O
related	O
risk	B-T078
of	O
injury	B-T037
to	O
nurses	B-T097
while	O
lifting	B-T052
obese	B-T047
patients	B-T101
from	O
the	O
floor	B-T073
with	O
a	O
bariatric sheet	B-T074
during	O
a	O
hospital	B-T073
emergency	B-T067
.	O
Six	O
male	B-T032
nurses	B-T097
participated	O
in	O
this	O
study	B-T062
.	O
The	O
biomechanical analysis	B-T060
focused	O
on	O
the	O
lifting	B-T052
strategy.	O
Thirty	O
obese	B-T047
in-patients	B-T101
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental study	B-T062
and	O
divided	O
into	O
three	O
groups	B-T078
according	O
to	O
their	O
Body Mass Index	B-T201
(	O
BMI	B-T201
).	O
Three-dimensional motion analysis	B-T060
was	O
conducted	O
using	O
an	O
optoelectronic system	B-T074
.	O
The	O
trunk	B-T029
kinematics	B-T091
and	O
the	O
loading	B-T032
on	O
the	O
spines	B-T023
of	O
the	O
operating	O
nurses	B-T097
were	O
computed	B-T059
.	O
Our	O
data	B-T078
showed	O
that	O
when	O
the	O
nurse	B-T097
was	O
operating	O
from	O
the	O
central	O
handle,	O
his	O
trunk	B-T029
was	O
more	O
flexed	B-T042
at	O
the	O
end	O
of	O
the	O
lift	B-T052
with	O
a	O
reduced	B-T080
range of motion	B-T201
.	O
The	O
values	B-T081
were	O
higher	B-T080
when	O
the	O
nurse	B-T097
lifted	O
patients	B-T101
with	O
higher	B-T080
BMIs	B-T201
.	O
All	O
kinetic parameters	B-T081
and	O
tension	B-T042
in	O
the	O
lumbar muscles	B-T023
at	O
the	O
end	O
of	O
the	O
movement	B-T040
were	O
characterised	O
by	O
lower	B-T080
values	B-T081
for	O
the	O
nurse	B-T097
placed	O
beside	O
the	O
patient's	B-T101
head	B-T029
or	O
feet	B-T023
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient groups	B-T101
.	O
Our	O
preliminary	O
data	B-T078
suggest	O
that	O
only	O
the	O
reaction	O
load	B-T032
on	O
the	O
spine	B-T023
of	O
the	O
nurse	B-T097
holding	O
the	O
central	O
handle,	O
closest	O
to	O
the	O
patient's	B-T101
centre	O
of	O
mass,	O
seems	O
to	O
exceed	O
the	O
recommended	B-T078
safety	B-T068
limits	B-T169
.	O

Expectations	B-T078
for	O
the	O
methodology	B-T078
and	O
translation	B-T062
of	O
animal research	B-T062
:	O
a	O
survey	B-T170
of	O
the	O
general public	B-T098
,	O
medical students	B-T097
and	O
animal	B-T008
researchers	B-T097
in	O
North America	B-T083
To	O
determine	O
what	O
are	O
considered	O
acceptable	B-T080
standards	B-T170
for	O
animal research	B-T062
(	O
AR	B-T062
)	O
methodology	B-T078
and	O
translation rate	B-T081
to	O
humans	B-T016
,	O
a	O
validated	O
survey	B-T170
was	O
sent	O
to:	O
a)	O
a	O
sample	O
of	O
the	O
general public	B-T098
,	O
via	O
Sampling Survey International	B-T170
(	O
SSI	B-T170
;	O
Canada	B-T083
),	O
Amazon Mechanical Turk	B-T170
(	O
AMT	B-T170
;	O
USA	B-T083
),	O
a	O
Canadian city	B-T083
festival	B-T052
(	O
CF	B-T052
)	O
and	O
a	O
Canadian	B-T083
children's hospital	B-T093
(	O
CH	B-T093
);	O
b)	O
a	O
sample	O
of	O
medical students	B-T097
(two	O
first-year	O
classes);	O
and	O
c)	O
a	O
sample	O
of	O
scientists	B-T097
(corresponding	O
authors	B-T097
and	O
academic	B-T092
paediatricians	B-T097
).	O
There	O
were	O
1379	O
responses	B-T032
from	O
the	O
general public	B-T098
sample	O
(	O
SSI	B-T170
,	O
n	O
=	O
557;	O
AMT	B-T170
,	O
n	O
=	O
590;	O
CF	B-T052
,	O
n	O
=	O
195;	O
CH	B-T093
,	O
n	O
=	O
102),	O
205/330	O
(62%)	O
medical student	B-T097
responses	B-T032
,	O
and	O
23/323	O
(7%,	O
too	O
few	O
to	O
report)	O
scientist	B-T097
responses	B-T032
.	O
Asked	O
about	O
methodological quality	B-UnknownType
,	O
most	O
of	O
the	O
general public	B-T098
and	O
medical student	B-T097
respondents	B-T098
expect	O
that:	O
AR	B-T062
is	O
of	O
high quality	B-T080
(e.g.	O
anaesthesia	B-T061
and	O
analgesia	B-T061
are	O
monitored,	O
even	O
overnight,	O
and	O
'humane'	O
euthanasia	B-T058
,	O
optimal	B-T080
statistical design	B-UnknownType
,	O
comprehensive	B-T080
literature review	B-T170
,	O
randomisation	B-T062
and	O
blinding	B-T062
,	O
are	O
performed),	O
and	O
costs	B-T081
and	O
difficulty	O
are	O
not	O
acceptable	B-T080
justifications	B-T078
for	O
lower quality	B-T080
(e.g.	O
costs	B-T081
of	O
expert	O
consultation	B-T058
,	O
or	O
more	O
laboratory staff	B-T097
).	O
Asked	O
about	O
their	O
expectations	B-T078
of	O
translation	B-T062
to	O
humans	B-T016
(of	O
toxicity	B-T037
,	O
carcinogenicity	B-T191
,	O
teratogenicity	B-T046
and	O
treatment	B-T169
findings	B-T169
),	O
most	O
expect	O
translation	B-T062
more	O
than	O
60%	O
of	O
the	O
time.	O
If	O
translation	B-T062
occurred	O
less	O
than	O
20%	O
of	O
the	O
time,	O
a	O
minority	B-T098
disagreed	O
that	O
this	O
would	O
"significantly	O
reduce	O
your	O
support	O
for	O
AR	B-T062
".	O
Medical students	B-T097
were	O
more	O
supportive	B-T077
of	O
AR	B-T062
,	O
even	O
if	O
translation	B-T062
occurred	O
less	O
than	O
20%	O
of	O
the	O
time.	O
Expectations	B-T078
for	O
AR	B-T062
are	O
much	O
higher	O
than	O
empirical data	B-T078
show	O
to	O
have	O
been	O
achieved.	O

Predicting	B-T078
violence	B-T048
and	O
recidivism	B-T055
in	O
a	O
large	O
sample	O
of	O
males	B-T032
on	O
probation	B-T089
or	O
parole	B-T089
This	O
study	B-T062
evaluated	B-T078
the	O
utility	O
of	O
items	O
and	O
scales	O
from	O
the	O
Iowa	B-T083
Violence	B-T048
and	O
Victimization	B-T068
Instrument	B-T170
in	O
a	O
sample	O
of	O
1961	O
males	B-T032
from	O
the	O
state	O
of	O
Iowa	B-T083
who	O
were	O
on	O
probation	B-T089
or	O
released from prison	B-T033
to	O
parole	B-T089
supervision	B-T057
.	O
This	O
is	O
the	O
first	O
study	B-T062
to	O
examine	O
the	O
potential	B-T080
of	O
the	O
Iowa	B-T083
Violence	B-T048
and	O
Victimization	B-T068
Instrument	B-T170
to	O
predict	B-T078
criminal offenses	B-UnknownType
.	O
The	O
males	B-T032
were	O
followed	O
for	O
30	O
months	B-T079
immediately	O
following	O
their	O
admission	B-T079
to	O
probation	B-T089
or	O
parole	B-T089
.	O
AUC	B-T081
analyses	B-T062
indicated	O
fair	O
to	O
good	O
predictive	B-T080
power	O
for	O
the	O
Iowa	B-T083
Violence	B-T048
and	O
Victimization	B-T068
Instrument	B-T170
for	O
charges	O
of	O
violence	B-T048
and	O
victimization	B-T068
,	O
but	O
chance	O
predictive	B-T080
power	O
for	O
drug offenses	B-UnknownType
.	O
Notably,	O
both	O
scales	O
of	O
the	O
instrument	B-T170
performed	O
equally	O
well	O
at	O
the	O
30-	O
month	B-T079
follow-up	B-T058
.	O
Items	O
on	O
the	O
Iowa	B-T083
Violence	B-T048
and	O
Victimization	B-T068
Instrument	B-T170
not	O
only	O
predicted	B-T078
violence	B-T048
,	O
but	O
are	O
straightforward	O
to	O
score.	O
Violence	B-T048
management	O
strategies	O
are	O
discussed	O
as	O
they	O
relate	O
to	O
the	O
current	B-T079
findings	B-T169
,	O
including	O
the	O
potential	B-T080
to	O
expand	B-T082
the	O
measure	O
to	O
other	O
jurisdictions	B-T170
and	O
populations	B-T098
.	O

Prognostic significance	B-T201
of	O
non-HPV16 genotypes	B-T032
in	O
oropharyngeal squamous cell carcinoma	B-T191
Recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal squamous cell carcinoma	B-T191
(	O
OPSCC	B-T191
)	O
positive	B-T034
for	O
HPV16 genotype	B-T114
have	O
better	B-T080
overall survival	B-T081
compared	B-T052
with	O
cases	O
positive	O
for	O
other	O
HPV genotypes	B-T114
.	O
We	O
sought	O
to	O
further	O
replicate	B-T080
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified by	B-T080
expression	B-T045
of	O
p16 tumor suppressor protein	B-T116
.	O
We	O
identified	O
238	O
OPSCC	B-T191
cases	O
from	O
the	O
Carolina Head and Neck Cancer Study	B-T062
(	O
CHANCE	B-T062
)	O
study,	O
a	O
population based case-control study	B-T062
.	O
Tumors	B-T191
that	O
tested	O
positive solely	B-T034
for	O
HPV16 genotype	B-T114
and	O
no	O
other	O
genotypes	B-T032
with	O
PCR	B-T063
were	O
classified	B-T185
as	O
HPV16-positive	B-T034
.	O
Tumors	B-T191
positive for	B-T034
any	O
other	O
high-risk	B-T033
HPV genotype	B-T114
were	O
classified	B-T185
as	O
non-HPV16-positive	B-T034
.	O
Expression	B-T045
of	O
p16	B-T116
in	O
the	O
tumor	B-T191
was	O
determined	B-T080
with	O
immunohistochemistry	B-T060
.	O
Follow-up	O
time	O
was	O
calculated	O
from	O
the	O
date of diagnosis	B-T079
to	O
date of death	B-T079
or	O
December	O
31,	O
2013.	O
Overall survival	B-T081
was	O
compared	O
with	O
the	O
Kaplan-Meier curves	B-T081
and	O
log-rank test	B-T081
.	O
Hazard ratios	B-T081
(	O
HR	B-T081
)	O
adjusted	O
for	O
smoking	B-T055
,	O
alcohol use	B-T055
,	O
sex	B-T032
,	O
race	B-T098
,	O
and	O
age	B-T032
was	O
calculated	O
with	O
the	O
Cox proportional hazard regression	B-T081
.	O
Cases	O
with	O
HPV16-positive	B-T034
OPSCC	B-T191
had	O
better	B-T080
overall survival	B-T081
than	O
cases	O
with	O
non-HPV16-positive	B-T034
OPSCC	B-T191
(log-rank	O
p-value:	O
0.010).	O
When	O
restricted	O
to	O
OPSCC	B-T191
cases	O
positive	B-T033
for	O
p16 expression	B-T045
,	O
the	O
same	O
trend	B-T079
continued	O
(log-rank	O
p-value:	O
0.002).	O
In	O
the	O
adjusted	O
model,	O
cases	O
with	O
non-HPV16-positive	B-T034
OPSCC	B-T191
had	O
greater risk of	B-T033
death	B-T033
compared	O
to	O
cases	O
with	O
HPV16-positive	B-T034
tumors	B-T191
(	O
HR	B-T081
:	O
1.92;	O
95%	O
CI:	O
1.03,	O
3.60).	O
This	O
finding	B-T033
indicates	B-T033
that	O
HPV	B-T005
genotyping	B-T059
carries	O
valuable prognostic significance	B-T201
in	O
addition	O
to	O
p16	B-T116
status	B-T080
and	O
future	O
survival	O
studies	O
of	O
OPSCC	B-T191
should	O
take	O
into	O
account	O
differing	O
HPV genotypes	B-T114
.	O

Randomized Trials	B-T062
of	O
the	O
Teen	B-T100
Outreach Program	B-T095
in	O
Louisiana	B-T083
and	O
Rochester	B-T083
,	O
New York	B-T083
To	O
evaluate	B-T058
the	O
Teen	B-T100
Outreach Program	B-T095
,	O
a	O
pregnancy prevention	B-T061
program	B-T170
,	O
in	O
2	O
community	B-T096
-based	O
settings.	O
We	O
evaluated	B-T058
the	O
Teen	B-T100
Outreach Program	B-T095
,	O
a	O
9-month	O
positive youth development program	B-T077
,	O
in	O
3	O
cohorts	B-T098
of	O
youths	B-T100
from	O
2012	O
to	O
2015	O
in	O
2	O
states	B-T083
.	O
In	O
Louisiana	B-T083
,	O
7	O
agencies	B-T092
participated	O
in	O
an	O
individualized	B-T080
randomized controlled trial	B-T062
,	O
with	O
youths	B-T100
randomly	O
assigned	O
to	O
a	O
treatment	B-T061
or	O
control condition	B-T096
.	O
Fourteen	O
agencies	B-T092
in	O
Rochester	B-T083
,	O
New York	B-T083
,	O
participated	O
in	O
a	O
cluster	B-T081
randomized controlled trial	B-T062
.	O
We	O
found	O
no differences	B-T033
between	O
the	O
intervention	B-T061
and	O
control youths	B-T096
on	O
delay	B-T079
of	O
sexual	B-T053
onset	B-T080
in	O
Louisiana	B-T083
(	O
adjusted odds ratio	B-T081
[	O
AOR	B-T081
]	O
=	O
0.80;	O
95%	O
confidence interval	B-T081
[	O
CI	B-T081
]	O
=	O
0.62,	O
1.03)	O
or	O
in	O
Rochester	B-T083
,	O
New York	B-T083
(	O
AOR	B-T081
=	O
0.89;	O
95%	O
CI	B-T081
=	O
0.45,	O
1.77),	O
or	O
for	O
sex	B-T040
with	O
no	O
effective	O
means	O
of	O
birth control	B-T121
(	O
Louisiana	B-T083
,	O
AOR	B-T081
=	O
1.18;	O
95%	O
CI	B-T081
=	O
0.78,	O
1.78;	O
Rochester	B-T083
,	O
AOR	B-T081
=	O
0.41;	O
95%	O
CI	B-T081
=	O
0.13,	O
1.27)	O
after	O
controlling	B-T067
for	O
relevant	O
covariates	B-T081
.	O
We	O
found	O
no	B-T033
short-term	B-T079
effects	B-T080
for	O
the	O
offer	O
of	O
the	O
intervention	B-T061
.	O
Research	B-T062
might	O
be	O
needed	O
for	O
the	O
long-term	B-T067
and	O
intermediate impacts	B-T080
of	O
youth development programs	B-T077
on	O
these	O
and	O
other	O
adolescent	B-T100
risk behaviors	B-T055
.	O

A	O
single session	B-T051
of	O
exhaustive exercise	B-T056
markedly	O
decreases	B-T081
circulating	B-T169
levels	O
of	O
guanidinoacetic acid	B-T109
in	O
healthy	B-T080
men	B-T098
and	O
women	B-T098
We	O
evaluated	B-T058
the	O
effects of	B-T080
exercise	B-T056
on	O
circulating	B-T169
concentrations	B-T081
of	O
guanidinoacetic acid	B-T109
(	O
GAA	B-T109
)	O
and	O
creatine	B-T116
in	O
23	O
healthy volunteers	B-T098
subjected	O
to	O
running	B-T056
to	O
exhaustion	B-T184
and	O
free-weight bench-press	B-T056
to	O
volitional failure	B-T056
.	O
Blood	B-T031
was	O
taken	O
before	O
and	O
following	O
each	O
exercise	B-T056
session	B-T051
.	O
Running	B-T056
induced	B-T169
a	O
significant	O
decrease	B-T081
in	O
serum	B-T031
GAA	B-T109
by	O
20.1%	O
(P	O
<	O
0.001),	O
while	O
free-weight exercise	B-T056
reduced	B-T080
GAA	B-T109
by	O
11.7%	O
(P	O
<	O
0.001),	O
suggesting	O
the	O
possible	O
use	O
of	O
serum	B-T031
GAA	B-T109
as	O
a	O
novel	O
biomarker	B-T201
of	O
exhaustion	B-T184
.	O

Anti-helminthic	B-T121
activity	B-T169
of	O
Momordica charantia L	B-T002
.	O
against	O
Fasciola hepatica eggs	B-T204
after	O
twelve	O
days	B-T079
of	O
incubation	B-T059
in vitro	B-T080
Fasciolosis	B-T047
,	O
a	O
parasitic disease	B-T047
caused	O
by	O
the	O
trematode	B-T204
Fasciola hepatica	B-T204
underreported	O
is	O
expanding	O
both	O
in	O
human	B-T016
and	O
animal population	B-T008
,	O
throughout	O
the	O
world	B-T098
.	O
The	O
constant	O
use	O
of	O
synthetic drugs	B-T121
to	O
treat	B-T061
this	O
condition	B-T047
has	O
led	O
to	O
the	O
natural selection	B-T070
of	O
resistant	B-T169
strains	B-T001
of	O
the	O
parasite	B-T204
.	O
Hence,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti-helminthic	B-T121
properties	B-T169
of	O
medicinal plants	B-T002
and	O
phytopharmaceuticals	B-T109
.	O
The	O
current	O
study	B-T062
assessed	O
the	O
potential	O
anti-fasciolicide	B-T169
action	B-T052
of	O
Momordica charantia	B-T002
leaf	B-T002
extracts	B-T123
and	O
fractions	B-T081
on	O
the	O
eggs of F. hepatica parasites	B-T204
.	O
The	O
lyophilized	B-T080
crude extract	B-T103
(	O
CE	B-T103
)	O
of	O
M. charantia leaves	B-T002
and	O
its	O
sub-fractions	B-T081
,	O
obtained	O
from	O
liquid-liquid partitioning	B-T059
with	O
organic solvents	B-T109
,	O
were	O
analysed	B-T062
by	O
High Performance Liquid Chromatography	B-T059
(	O
HPLC	B-T059
),	O
suspended	B-T078
in	O
1%	O
DMSO	B-T109
and	O
used	O
in	O
in vitro	B-T080
tests	B-T059
.	O
Quadruplicates	B-T081
of	O
50	O
F. hepatica eggs	B-T204
were	O
incubated	B-T059
at	O
23°C	O
with	O
M. charantia	B-T002
leaf	B-T002
CE	B-T103
in	O
different	O
concentrations	B-T081
.	O
After	O
12	O
days	B-T079
no	O
larvae	B-T204
were	O
formed	O
in	O
eggs	B-T204
incubated	B-T059
with	O
CE	B-T103
concentrations	B-T081
above	O
12.5mg/mL.	O
Eggs	B-T204
incubated	B-T059
with	O
CE	B-T103
sub-fractions	B-T081
at	O
concentrations	B-T081
of	O
1000,	O
100,	O
10,	O
1,	O
0.1,	O
0.01μg/mL	O
affected	B-T169
embryonic development	B-T042
,	O
with	O
n-butanol	B-T109
presenting	O
the	O
strongest	O
inhibition	B-T052
of	O
miracidia	B-T204
formation	B-T169
.	O
In	O
contrast,	O
on	O
the	O
12th	O
day,	O
90%	O
of	O
the	O
miracidia	B-T204
hatched	B-T040
in	O
the	O
control experiments	B-T096
using	O
0.03%	O
DMSO	B-T109
whereas	O
embryogenesis	B-T042
was	O
completely	O
abolished	B-T079
with	O
any	O
concentration	B-T081
of	O
albendazole sulphoxide	B-T109
ABZ(SO)	B-T109
.	O
Chemical analysis	B-T059
of	O
the	O
CE	B-T103
and	O
sub-fractions	B-T081
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	B-T109
.	O
HPLC-MS	B-T059
confirmed	O
Quercetin	B-T109
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	B-T109
present	O
in	O
the	O
CE	B-T103
and	O
the	O
n-butanol	B-T109
subfraction	B-T081
.	O
This	O
is	O
the	O
first	O
study	B-T062
to	O
analyse	B-T062
the	O
potential	O
anti-fasciolicide	B-T169
action	B-T052
of	O
M. charantia	B-T002
leaf	B-T002
CE	B-T103
and	O
subfractions	B-T081
.	O

Dabigatran	B-T109
:	O
A	O
new	O
oral anticoagulant	B-T109
.	O
Guidelines	B-T170
to	O
follow	O
in	O
oral surgery procedures	B-T061
.	O
A	O
systematic	O
review of the literature	B-T170
Dabigatran	B-T109
is	O
a	O
newly	O
commercialized	O
drug	B-T121
that	O
is	O
replacing	O
other	O
anticoagulants	B-T121
in	O
the	O
prevention	O
of	O
venous thromboembolism	B-T047
,	O
stroke	B-T047
and	O
systemic arterial valve embolism	B-UnknownType
.	O
It	O
acts	O
directly	O
on	O
thrombin	B-T116
presenting	O
in	O
a	O
dynamic	O
and	O
predictable	O
way,	O
which	O
does	O
not	O
require	O
monitoring	O
these	O
patients	B-T101
.	O
Therefore,	O
we	O
consider	O
the	O
need	O
to	O
assess	O
whether	O
their	O
use	O
increases	B-T169
the	O
risk of bleeding	B-T033
involved	O
before	O
any	O
dental treatment	B-T061
.	O
We	O
performed	O
a	O
systematic	O
review	O
with	O
a	O
bibliographic search	B-UnknownType
in	O
PubMed	B-T170
/	O
Medline	B-T170
along	O
with	O
the	O
Cochrane Library	B-T073
.	O
We	O
excluded	O
articles	O
dealing	O
with	O
all	O
anticoagulants	B-T121
other	O
than	O
dabigatran	B-T109
,	O
and	O
works	O
about	O
surgical treatments	B-T061
in	O
anatomical locations	B-T029
other	O
than	O
the	O
oral cavity	B-T030
.	O
We	O
included	O
a	O
total	O
of	O
13	O
papers	O
of	O
which	O
1	O
was	O
a	O
randomized clinical trial	B-T062
,	O
9	O
narrative literature reviews	B-UnknownType
,	O
1	O
case series	B-T062
,	O
2	O
clinical cases	B-T077
and	O
1	O
expert opinion	B-T077
.	O
Because	O
we	O
did	O
not	O
obtain	O
any	O
properly	O
designed	O
clinical trials	B-T062
,	O
we	O
were	O
unable	O
to	O
conduct	O
a	O
meta-analysis	B-T062
.	O
Currently,	O
there	O
is	O
no	O
consensus	B-T054
on	O
the	O
procedure	B-T061
to	O
be	O
followed	O
in	O
patients	B-T101
taking	O
dabigatran	B-T109
.	O
However,	O
all	O
authors	O
agree	O
to	O
treat	O
each	O
case	O
individually	O
in	O
accordance	O
to	O
the	O
risk	B-T078
of	O
embolism	B-T046
,	O
postoperative bleeding	B-T046
and	O
renal function	B-T042
.	O
Also,	O
it	O
is	O
necessary	O
to	O
perform	O
minimally	O
invasive interventions	B-T061
,	O
and	O
take	O
the	O
appropriate	O
local	O
anti-hemolytic measures	B-T061
.	O

Did	O
FIDELIS	B-T170
projects	B-T077
contribute	B-T052
to	O
the	O
detection	B-T033
of	O
new	O
smear	B-T059
-	O
positive	B-T033
pulmonary tuberculosis	B-T047
cases	O
in	O
China	B-T083
?	O
Setting:	O
The	O
first phase of the Fund for Innovative DOTS Expansion through Local Initiatives to Stop TB	B-T170
(	O
FIDELIS	B-T170
)	O
projects	B-T077
in	O
China	B-T083
started	O
in	O
2003.	O
Objective:	O
To	O
determine	O
whether	O
the	O
FIDELIS	B-T170
projects	B-T077
contribute	B-T052
d	O
to	O
the	O
increased	B-T081
case	B-T169
detection	B-T033
rate	B-T081
for	O
new	O
smear	B-T059
-	O
positive	B-T033
pulmonary tuberculosis	B-T047
(	O
PTB	B-T047
)	O
in	O
China	B-T083
.	O
Methods:	O
We	O
compared	B-T052
the	O
case notification rates	B-T081
(	O
CNRs	B-T081
)	O
in	O
the	O
intervention year	B-T079
with	O
those	O
of	O
the	O
previous	B-T079
year	B-T079
in	O
the	O
FIDELIS	B-T170
areas	B-T083
,	O
then	O
compared	B-T052
the	O
difference	B-T080
between	O
the	O
CNRs	B-T081
of	O
the	O
intervention year	B-T079
and	O
the	O
previous	B-T079
year	B-T079
in	O
the	O
FIDELIS	B-T170
areas	B-T083
with	O
those	O
in	O
the	O
non-FI-DELIS	B-T033
areas	B-T083
within	O
the	O
province	B-T083
.	O
Results:	O
There	O
was	O
an	O
increase	B-T169
in	O
the	O
CNR	B-T081
in	O
the	O
intervention year	B-T079
compared	B-T052
with	O
the	O
previous	B-T079
year	B-T079
for	O
all	O
the	O
project	B-T077
sites.	O
The	O
differences	B-T080
between	O
the	O
CNR	B-T081
in	O
the	O
intervention year	B-T079
and	O
the	O
previous	B-T079
year	B-T079
ranged	B-T081
from	O
6.4	O
to	O
31.1	O
per	O
100	O
000	O
population	B-T098
in	O
the	O
FIDELIS	B-T170
areas	B-T083
and	O
from	O
2.9	O
to	O
20.4/100	O
000	O
in	O
the	O
non-FIDELIS	B-T033
areas	B-T083
.	O
Differences	B-T080
-in-	O
differences	B-T080
analysis	B-T062
shows	O
that	O
the	O
differences	B-T080
in	O
the	O
CNRs	B-T081
in	O
the	O
FIDELIS	B-T170
areas	B-T083
were	O
not	O
statistically significantly	B-T081
different	B-T080
from	O
those	O
in	O
the	O
non-	O
FIDELIS	B-T170
areas	B-T083
(P	O
=	O
0.393).	O
Conclusion:	O
The	O
FIDELIS	B-T170
projects	B-T077
may	O
have	O
contributed	B-T052
to	O
the	O
increase	B-T169
in	O
case	B-T169
detection	B-T033
of	O
new	O
smear	B-T059
-	O
positive	B-T033
PTB	B-T047
in	O
China	B-T083
,	O
but	O
the	O
level	B-T080
of	O
evidence	B-T078
is	O
low	B-T080
.	O

Liver Fatty Acid Binding Protein	B-T116
Deficiency	B-T169
Provokes	O
Oxidative Stress	B-T049
,	O
Inflammation	B-T046
,	O
and	O
Apoptosis	B-T043
-Mediated	O
Hepatotoxicity	B-T037
Induced	B-T169
by	O
Pyrazinamide	B-T109
in	O
Zebrafish	B-T013
Larvae	B-T204
Pyrazinamide	B-T109
(	O
PZA	B-T109
)	O
is	O
an	O
essential	B-T080
antitubercular drug	B-T121
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	B-T037
potential	B-T080
.	O
This	O
study	O
examined	O
the	O
effects of	B-T080
PZA	B-T109
exposure	B-T080
on	O
zebrafish	B-T013
(	O
Danio rerio	B-T013
)	O
larvae	B-T204
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	B-T037
.	O
A	O
transgenic line	B-T028
of	O
zebrafish	B-T013
larvae	B-T204
that	O
expressed	B-T045
enhanced green fluorescent protein	B-T116
(	O
EGFP	B-T116
)	O
in	O
the	O
liver	B-T023
was	O
incubated	B-T059
with	O
1,	O
2.5,	O
and	O
5	O
mM	O
PZA	B-T109
from	O
72	O
h	O
postfertilization	B-T040
(hpf).	O
Different	O
endpoints	B-T080
such	O
as	O
mortality	B-T081
,	O
morphology	B-T033
changes	B-T169
in	O
the	O
size	B-T032
and	O
shape	B-T082
of	O
the	O
liver	B-T023
,	O
histological	B-T091
changes	B-T169
,	O
transaminase analysis	B-T059
and	O
apoptosis	B-T043
,	O
markers	B-T201
of	O
oxidative	B-T049
and	O
genetic damage	B-T049
,	O
as	O
well	O
as	O
the	O
expression	B-T045
of	O
certain	O
genes	B-T028
were	O
selected	O
to	O
evaluate	B-T058
PZA	B-T109
-	O
induced	B-T169
hepatotoxicity	B-T037
.	O
Our	O
results	O
confirm	B-T033
the	O
manner	O
of	O
PZA	B-T109
dose-dependent	B-T081
hepatotoxicity	B-T037
.	O
PZA	B-T109
was	O
found	O
to	O
induce	B-T169
marked	B-T080
injury	B-T037
in	O
zebrafish	B-T013
larvae	B-T204
,	O
such	O
as	O
liver atrophy	B-T047
,	O
elevations of transaminase levels	B-T033
,	O
oxidative stress	B-T049
,	O
and	O
hepatocyte apoptosis	B-T043
.	O
To	O
further	O
understand	O
the	O
mechanism	O
behind	O
PZA	B-T109
-	O
induced	B-T169
hepatotoxicity	B-T037
,	O
changes	B-T169
in	O
gene expression levels	B-T081
in	O
zebrafish	B-T013
larvae	B-T204
exposed to	B-T080
PZA	B-T109
for	O
72	O
h	O
postexposure	B-T080
(hpe)	O
were	O
determined.	O
The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
PZA	B-T109
decreased	B-T081
the	O
expression levels	B-T081
of	O
liver fatty acid binding protein	B-T116
(	O
L-FABP	B-T116
)	O
and	O
its	O
target gene	B-T028
,	O
peroxisome proliferator-activated receptor α	B-T116
(	O
PPAR-α	B-T116
),	O
and	O
provoked	O
more	O
severe	B-T080
oxidative stress	B-T049
and	O
hepatitis	B-T047
via	O
the	O
upregulation	B-T044
of	O
inflammatory cytokines	B-T043
such	O
as	O
tumor necrosis factor alpha	B-T116
(	O
TNF-α	B-T116
)	O
and	O
transforming growth factor β	B-T116
(	O
TGF-β	B-T116
).	O
These	O
findings	O
suggest	O
that	O
L-FABP	B-T116
-mediated	O
PPAR-α	B-T116
downregulation	B-T044
appears	O
to	O
be	O
a	O
hepatotoxic response	B-T043
resulting	O
from	O
zebrafish	B-T013
larva	B-T204
liver cell	B-T025
apoptosis	B-T043
,	O
and	O
L-FABP	B-T116
can	O
be	O
used	O
as	O
a	O
biomarker	B-T201
for	O
the	O
early detection	B-T060
of	O
PZA	B-T109
-	O
induced	B-T169
liver damage	B-T046
in	O
zebrafish	B-T013
larvae	B-T204
.	O

Smooth	B-T080
versus	O
Textured	B-T080
Surfaces	B-T082
:	O
Feature	B-T080
-Based	O
Category	B-T170
Selectivity	B-T052
in	O
Human	B-T016
Visual Cortex	B-T023
In	O
fMRI studies	B-T060
,	O
human	B-T016
lateral occipital (LO) cortex	B-T023
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	B-T170
of	O
objects	B-T072
,	O
compared	B-T052
with	O
nonobjects	B-T071
.	O
However,	O
it	O
remains	O
unresolved	B-T080
whether	O
all	O
objects	B-T072
evoke	O
equivalent	B-T080
levels	B-T080
of	O
activity	B-T052
in	O
LO	B-T023
,	O
and,	O
if	O
not,	O
which	O
image features	B-T080
produce	O
stronger	B-T080
activation	B-T052
.	O
Here,	O
we	O
used	O
an	O
unbiased parametric texture model	B-T170
to	O
predict	B-T078
preferred	B-T067
versus	O
nonpreferred stimuli	B-T067
in	O
LO	B-T023
.	O
Observation	B-T062
and	O
psychophysical results	B-T169
showed	O
that	O
predicted	B-T078
preferred	B-T078
stimuli	B-T067
(both	O
objects	B-T072
and	O
nonobjects	B-T071
)	O
had	O
smooth	B-T080
(rather	O
than	O
textured	B-T080
)	O
surfaces	B-T082
.	O
These	O
predictions	B-T078
were	O
confirmed	B-T080
using	O
fMRI	B-T060
,	O
for	O
objects	B-T072
and	O
nonobjects	B-T071
.	O
Similar	O
preferences	B-T078
were	O
also	O
found	O
in	O
the	O
fusiform face area	B-T022
(	O
FFA	B-T022
).	O
Consistent with	B-T078
this:	O
(1)	O
FFA	B-T022
and	O
LO	B-T023
responded	O
more	O
strongly	O
to	O
nonfreckled	B-T080
(	O
smooth	B-T080
)	O
faces	B-T082
,	O
compared	B-T052
with	O
otherwise	O
identical	O
freckled	B-T033
(	O
textured	B-T080
)	O
faces	B-T082
;	O
and	O
(2)	O
strong	O
functional	B-T169
connections	B-T082
were	O
found	O
between	O
LO	B-T023
and	O
FFA	B-T022
.	O
Thus,	O
LO	B-T023
and	O
FFA	B-T022
may	O
be	O
part	O
of	O
an	O
information	B-T078
-	O
processing	B-T052
stream	O
distinguished	O
by	O
feature	B-T080
-based	O
category	B-T170
selectivity	B-T052
(	O
smooth	B-T080
>	O
textured	B-T080
).	O

High-fructose diet	B-T061
is	O
as	O
detrimental	O
as	O
high-fat diet	B-T061
in	O
the	O
induction	B-T061
of	O
insulin resistance	B-T046
and	O
diabetes	B-T047
mediated	O
by	O
hepatic	B-T029
/	O
pancreatic	B-T023
endoplasmic reticulum (ER) stress	B-T049
In	O
the	O
context	B-T078
of	O
high	B-T080
human	B-T016
consumption	B-T169
of	O
fructose	B-T109
diets	B-T168
,	O
there	O
is	O
an	O
imperative	O
need	B-T080
to	O
understand	B-T041
how	O
dietary	B-T169
fructose intake	B-T033
influence	B-T077
cellular	B-T025
and	O
molecular	B-T080
mechanisms	B-T169
and	O
thereby	O
affect	B-T080
β-cell dysfunction	B-T033
and	O
insulin resistance	B-T046
.	O
While	O
evidence	B-T078
exists	B-T077
for	O
a	O
relationship	B-T080
between	O
high	B-T080
-	O
fat	B-T109
-	O
induced	B-T169
insulin resistance	B-T046
and	O
metabolic disorders	B-T047
,	O
there	O
is	O
lack of	B-T080
studies	B-T062
in	O
relation	O
to	O
high-fructose diet	B-T061
.	O
Therefore,	O
we	O
attempted	O
to	O
study	B-T062
the	O
effect	B-T080
of	O
different	B-T080
diets	B-T168
viz.,	O
high-fat diet	B-T061
(	O
HFD	B-T061
),	O
high-fructose diet	B-T061
(	O
HFS	B-T061
),	O
and	O
a	O
combination	B-T080
(	O
HFS	B-T061
+	O
HFD	B-T061
)	O
diet	B-T168
on	O
glucose homeostasis	B-T039
and	O
insulin sensitivity	B-T046
in	O
male	B-T032
Wistar rats	B-T015
compared	B-T052
to	O
control animals	B-T008
fed	B-T052
with	O
normal	B-T080
pellet	B-T081
diet	B-T168
.	O
Investigations	B-T169
include	O
oral glucose tolerance test	B-T060
,	O
insulin tolerance test	B-T059
,	O
histopathology	B-T059
by	O
H&E	B-T059
and	O
Masson's trichrome staining	B-T059
,	O
mRNA expression	B-T045
by	O
real-time PCR	B-T063
,	O
protein expression	B-T059
by	O
Western blot	B-T059
,	O
and	O
caspase-3 activity	B-T044
by	O
colorimetry	B-T059
.	O
Rats	B-T015
subjected	O
to	O
high-fat	B-T061
/	O
fructose diets	B-T061
became	O
glucose	B-T109
intolerant	B-T169
,	O
insulin-resistant	B-T046
,	O
and	O
dyslipidemic	B-T033
.	O
Compared	B-T052
to	O
control animals	B-T008
,	O
rats	B-T015
subjected	O
to	O
different	B-T080
combination	B-T080
of	O
fat	B-T061
/	O
fructose diets	B-T061
showed	O
increased	B-T081
mRNA	B-T045
and	O
protein expression	B-T045
of	O
a	O
battery	O
of	O
ER stress	B-T049
markers	B-T080
both	O
in	O
pancreas	B-T023
and	O
liver	B-T023
.	O
Transcription factors	B-T116
of	O
β-cell function	B-T043
(	O
INSIG1	B-T116
,	O
SREBP1c	B-T116
and	O
PDX1	B-T116
)	O
as	O
well	O
as	O
hepatic	B-T029
gluconeogenesis	B-T044
(	O
FOXO1	B-T116
and	O
PEPCK	B-T116
)	O
were	O
adversely affected	B-T046
in	O
diet	B-T168
-	O
induced	B-T169
insulin-resistant	B-T046
rats	B-T015
.	O
The	O
convergence	B-T052
of	O
chronic	B-T079
ER stress	B-T049
towards	O
apoptosis	B-T043
in	O
pancreas	B-T023
/	O
liver	B-T023
was	O
also	O
indicated	B-T033
by	O
increased	B-T081
levels	B-T080
of	O
CHOP mRNA	B-T114
&	O
increased	B-T081
activity	O
of	O
both	O
JNK	B-T044
and	O
Caspase-3	B-T044
in	O
rats	B-T015
subjected	O
to	O
high-fat	B-T061
/	O
fructose diets	B-T061
.	O
Our	O
study	B-T062
exposes	O
the	O
experimental	B-T080
support	B-T077
in	O
that	O
high-fructose diet	B-T061
is	O
equally	B-T080
detrimental	O
in	O
causing	B-T169
metabolic disorders	B-T047
.	O

Immature	B-T080
stages	B-T079
and	O
larval	B-T204
chaetotaxy	B-T090
of	O
Notofairchildia stenygros	B-T204
(Quate	O
&	O
Alexander)	O
(	O
Diptera	B-T204
:	O
Psychodidae	B-T204
:	O
Bruchomyiinae	B-T204
)	O
Some	O
authors	O
have	O
hypothesized	O
that	O
Bruchomyiinae	B-T204
is	O
"the	O
most	O
plesiomorphic subfamily	B-T185
of	O
Psychodidae	B-T204
"	O
and	O
its	O
members	B-T071
"are	O
among	O
the	O
most	O
primitive	B-T080
living	B-T078
Diptera	B-T204
".	O
Although	O
Bruchomyiinae	B-T204
is	O
of	O
no	B-T033
medical	B-T169
importance	B-T080
,	O
it	O
is	O
of	O
great	O
evolutionary	B-T045
significance	B-T078
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister group	B-T169
of	O
Phlebotominae	B-T204
.	O
In	O
general,	O
species	B-T185
of	O
this	O
subfamily	B-T185
are	O
rarely	O
collected	O
in	O
their	O
natural environment	B-T082
;	O
therefore,	O
adults	B-T204
and,	O
even	O
more	O
so,	O
the	O
immature	B-T080
stages	B-T079
of	O
these	O
flies	B-T204
are	O
poorly	O
known.	O
We	O
describe	O
the	O
egg	B-T204
,	O
larvae	B-T204
and	O
pupae	B-T204
of	O
Notofairchildia stenygros	B-T204
and	O
provide	O
nomenclatural notes	B-T170
on	O
larval	B-T204
chaetotaxy	B-T090
based	O
on	O
analyses	O
using	O
scanning electron microscopy	B-T059
(	O
SEM	B-T059
)	O
and	O
optic microscopy	B-T059
.	O
The	O
morphology	B-T080
of	O
immature	B-T080
Nt. stenygros	B-T204
is	O
compared	O
with	O
other	O
Bruchomyiinae	B-T204
and	O
Psychodidae	B-T204
species	B-T185
,	O
especially	O
with	O
species	B-T185
of	O
Phlebotominae	B-T204
that	O
are	O
superficially	O
similar	B-T080
to	O
Bruchomyiinae	B-T204
.	O
Results	B-T033
of	O
this	O
study	B-T062
revealed	O
striking	O
morphological	B-T082
differences	B-T080
between	O
the	O
immature	B-T080
stages	B-T079
of	O
Bruchomyiinae	B-T204
and	O
Phlebotominae	B-T204
;	O
the	O
former	O
are	O
lacking	O
abdominal	B-T029
pseudopods	B-T026
and	O
microtrichia	B-T023
on	O
the	O
cephalic	B-T082
integument	B-T022
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	B-T204
of	O
Phlebotominae	B-T204
.	O
These	O
morphological	B-T082
differences	B-T080
observed	O
in	O
the	O
immature	B-T080
stages	B-T079
between	O
members	B-T071
of	O
the	O
two	O
subfamilies	B-T185
support	O
the	O
findings	B-T033
of	O
recent	O
molecular studies	B-T059
indicating	O
that	O
Bruchomyiinae	B-T204
and	O
Phlebtominae	B-T204
are	O
evolutionarily	B-T045
not closely related	B-T078
.	O
Notofairchildia stenygros	B-T204
is	O
now	O
the	O
fourth	B-T081
species	B-T185
of	O
Bruchomyiinae	B-T204
for	O
which	O
the	O
immature	B-T080
stages	B-T079
are	O
described.	O

Initial	O
clinical results	B-T034
with	O
the	O
ThermoCool® SmartTouch® Surround Flow catheter	B-T074
The	O
Biosense Webster ThermoCool(®) SmartTouch(®) Surround Flow (STSF) catheter	B-T074
is	O
a	O
recently	O
developed	O
ablation	B-T061
catheter	B-T074
incorporating	O
Surround Flow	B-T042
(	O
SF	B-T042
)	O
technology	B-T090
to	O
ensure	O
efficient	O
cooling	O
and	O
force	O
sensing	O
to	O
quantify	B-T081
tissue	B-T024
contact	B-T169
.	O
In	O
our	O
unit,	O
it	O
superseded	O
the	O
ThermoCool(®) SF catheter	B-T074
from	O
the	O
time	O
of	O
its	O
introduction	O
in	O
May	O
2015.	O
Procedure	B-T061
-related	O
data	B-T078
were	O
collected	O
prospectively	O
for	O
the	O
first	O
100	O
ablation procedures	B-T061
performed	O
in	O
our	O
department	O
using	O
the	O
STSF catheter	B-T074
.	O
From	O
a	O
database	B-T170
of	O
654	O
procedures	B-T061
performed	O
in	O
our	O
unit	O
using	O
the	O
SF catheter	B-T074
,	O
we	O
selected	O
one	O
to	O
match	O
each	O
STSF procedure	B-T061
,	O
matching	O
for	O
procedure type	B-T185
,	O
operator	B-T098
experience	B-T041
,	O
patient age	B-T032
,	O
and	O
gender	B-T032
.	O
The	O
groups	B-UnknownType
were	O
well	O
matched	O
for	O
patient age	B-T032
,	O
gender	B-T032
,	O
and	O
procedure type	B-T185
.	O
Procedure duration	B-T079
was	O
similar	O
in	O
both	O
groups	B-UnknownType
(mean	O
225.5	O
vs.	O
221.4	O
min,	O
IQR	B-T081
106.5	O
vs.	O
91.5,	O
P	O
=	O
0.55),	O
but	O
fluoroscopy duration	B-T079
was	O
shorter	B-T081
in	O
the	O
STSF group	B-UnknownType
(mean	O
25.8	O
vs.	O
30.0,	O
IQR	B-T081
19.6	O
vs.	O
18.5,	O
P	O
=	O
0.03).	O
No complication	B-T033
occurred	O
in	O
the	O
STSF group	B-UnknownType
.	O
Complications	B-T046
occurred	O
in	O
two	O
cases	B-T077
in	O
the	O
SF group	B-UnknownType
(one	O
pericardial effusion	B-T047
requiring	O
drainage	B-T061
and	O
one	O
need	O
for	O
permanent	B-T079
pacing	B-T061
).	O
Complete procedural success	B-T033
was	O
achieved	O
in	O
98	O
cases	B-T077
in	O
the	O
STSF group	B-UnknownType
and	O
94	O
cases	B-T077
in	O
the	O
SF group	B-UnknownType
(P	O
=	O
0.15).	O
The	O
composite	O
endpoint	O
of	O
procedure	O
failure	B-T066
or	O
acute	B-T079
complication	B-T046
was	O
less	O
common	O
in	O
the	O
STSF group	B-UnknownType
(2	O
vs.	O
8,	O
P	O
=	O
0.05).	O
The	O
STSF catheter	B-T074
is	O
safe	O
and	O
effective	B-T080
in	O
treating	B-T169
a	O
range	O
of	O
arrhythmias	B-T033
.	O
Compared	O
with	O
the	O
SF catheter	B-T074
,	O
it	O
shows	O
a	O
trend	O
towards	O
improved	O
safety	B-T068
-	O
efficacy	B-T080
balance.	O

Low birth weight	B-T033
and	O
features	B-T080
of	O
neuroticism	B-T048
and	O
mood disorder	B-T048
in	O
83	O
545	O
participants	B-T098
of	O
the	O
UK	B-T083
Biobank	B-T093
cohort	B-T098
Low birth weight	B-T033
has	O
been	O
inconsistently	O
associated	O
with	O
risk	B-T078
of	O
developing	O
affective disorders	B-T048
,	O
including	O
major depressive disorder	B-T048
(	O
MDD	B-T048
).	O
To	O
date,	O
studies	B-T062
investigating	B-T169
possible	O
associations	B-T080
between	O
birth weight	B-T032
and	O
bipolar disorder	B-T048
(	O
BD	B-T048
),	O
or	O
personality traits	B-T033
known	O
to	O
predispose	B-T032
to	O
affective disorders	B-T048
such	O
as	O
neuroticism	B-T048
,	O
have	O
not	O
been	O
conducted	O
in	O
large	O
cohorts	B-T098
.	O
To	O
assess	B-T052
whether	O
very low birth weight	B-T184
(<1500	O
g)	O
and	O
low birth weight	B-T033
(1500-2490	O
g)	O
were	O
associated with	B-T080
higher neuroticism	B-T033
scores	B-T081
assessed	B-T052
in	O
middle age	B-T079
,	O
and	O
lifetime history	B-T032
of	O
either	O
MDD	B-T048
or	O
BD	B-T048
.	O
We	O
controlled	O
for	O
possible	O
confounding factors	B-T169
.	O
Retrospective	B-T080
cohort study	B-T081
using	O
baseline	B-T081
data	B-T078
on	O
the	O
83	O
545	O
UK	B-T083
Biobank	B-T093
participants	B-T098
with	O
detailed	O
mental health	B-T041
and	O
birth weight	B-T032
data	B-T078
.	O
Main	O
outcomes	B-T169
were	O
prevalent	O
MDD	B-T048
and	O
BD	B-T048
,	O
and	O
neuroticism	B-T048
assessed	B-T052
using	O
the	O
Eysenck Personality Inventory Neuroticism scale - Revised	B-T170
(	O
EPIN-R	B-T170
).	O
Referent	O
to	O
normal birth weight	B-T033
,	O
very low	B-T184
/	O
low birth weight	B-T033
were	O
associated	O
with	O
higher neuroticism	B-T033
scores	B-T081
,	O
increased	B-T081
MDD	B-T048
and	O
BD	B-T048
.	O
The	O
associations	B-T080
between	O
birth weight	B-T032
category	B-T170
and	O
MDD	B-T048
were	O
partially	O
mediated	O
by	O
higher neuroticism	B-T033
.	O
These	O
findings	B-T033
suggest	O
that	O
intrauterine	B-T029
programming	B-T038
may	O
play	O
a	O
role	B-T077
in	O
lifetime	B-T079
vulnerability	B-T033
to	O
affective disorders	B-T048
.	O
None.	O
©	O
The	O
Royal	O
College	O
of	O
Psychiatrists	O
2016.	O
This	O
is	O
an	O
open	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Non-Commercial,	O
No	O
Derivatives	O
(CC	O
BY-NC-ND)	O
licence.	O

DNA annealing	B-T045
by	O
Redβ	B-T116
is	O
insufficient	O
for	O
homologous recombination	B-T045
and	O
the	O
additional	O
requirements	O
involve	O
intra- and inter-molecular interactions	B-UnknownType
Single strand annealing proteins	B-T116
(	O
SSAPs	B-T116
)	O
like	O
Redβ	B-T116
initiate	O
homologous recombination	B-T045
by	O
annealing complementary DNA strands	B-T114
.	O
We	O
show	O
that	O
C-terminally truncated	B-T044
Redβ	B-T116
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	B-T045
and	O
nucleoprotein filament formation	B-T045
,	O
is	O
unable	O
to	O
mediate	O
homologous recombination	B-T045
.	O
Mutations	B-T045
of	O
the	O
C-terminal domain	B-T087
were	O
evaluated	O
using	O
both	O
single	B-T114
-	O
and	O
double stranded	B-T114
(	O
ss	B-T114
and	O
ds	B-T114
)	O
substrates	O
in	O
recombination	B-T045
assays	B-T059
.	O
Mutations	B-T059
of	O
critical amino acids	B-T116
affected	O
either	O
dsDNA	B-T114
recombination	B-T043
or	O
both	O
ssDNA	B-T114
and	O
dsDNA recombination	B-T043
indicating	O
two	O
separable	O
functions,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsDNA recombination	B-T043
and	O
the	O
second	O
for	O
recombination	B-T043
per	O
se.	O
As	O
evaluated	O
by	O
co-immunoprecipitation experiments	B-T059
,	O
the	O
dsDNA recombination function	B-T043
relates	O
to	O
the	O
Redα	B-T116
-	O
Redβ	B-T116
protein-protein interaction	B-T044
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
C-terminal domain	B-T087
but	O
also	O
a	O
region	O
near	O
the	O
N-terminus	B-T087
.	O
Because	O
the	O
nucleoprotein filament formed	B-T045
with	O
C-terminally truncated	B-T044
Redβ	B-T116
has	O
altered	O
properties,	O
the	O
second	O
C-terminal function	B-T044
could	O
be	O
due	O
to	O
an	O
interaction	B-T045
required	O
for	O
functional	B-T169
filaments	B-T026
.	O
Alternatively	O
the	O
second	O
C-terminal function	B-T044
could	O
indicate	O
a	O
requirement	O
for	O
a	O
Redβ	B-T116
-	O
host factor interaction	B-T043
.	O
These	O
data	O
further	O
advance	O
the	O
model	O
for	O
Red recombination	B-T045
and	O
the	O
proposition	O
that	O
Redβ	B-T116
and	O
RAD52	B-T116
SSAPs	B-T116
share	O
ancestral	O
and	O
mechanistic	O
roots.	O

Multi-drug-resistant	B-T032
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	B-T007
infection	B-T046
outbreak	B-T067
in	O
dogs	B-T015
and	O
cats	B-T015
in	O
a	O
veterinary hospital	B-T073
Members	O
of	O
the	O
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	B-T007
cause	O
severe	B-T080
outbreaks	B-T067
in	O
humans	B-T016
,	O
and	O
are	O
increasingly	B-T169
reported	B-T058
in	O
animals	B-T008
.	O
A	O
retrospective study	B-T062
,	O
describing	O
a	O
severe	B-T080
outbreak	B-T067
in	O
dogs	B-T015
and	O
cats	B-T015
caused	O
by	O
a	O
multidrug resistant member	B-T007
of	O
the	O
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	B-T007
in	O
a	O
veterinary hospital	B-T073
,	O
between	O
July	O
2010	O
and	O
November	O
2012.	O
The	O
study	B-T062
included	B-T169
19	O
dogs	B-T015
and	O
4	O
cats	B-T015
.	O
Acinetobacter calcoaceticus-Acinetobacter baumannii complex bacteria	B-T007
were	O
isolated	B-T169
from	O
urine	B-T031
(9	O
animals	B-T008
),	O
respiratory tract	B-T022
(11),	O
tissues	B-T024
(3)	O
and	O
blood	B-T031
(1).	O
The	O
most	B-T081
common	B-T081
infection	B-T046
-	O
associated findings	B-T033
included	B-T169
fever	B-T184
,	O
purulent discharge	B-T184
from	O
endotracheal tubes	B-T074
,	O
hypotension	B-T033
,	O
and	O
neutropaenia	B-T047
.	O
Infection	B-T046
s	O
led	O
to	O
pneumonia	B-T047
,	O
urinary tract infection	B-T047
,	O
cellulitis	B-T046
and	O
sepsis	B-T047
.	O
Infection	B-T046
was	O
transmitted	B-T046
in	O
the	O
intensive care unit	B-T073
,	O
where	O
22	O
of	O
23	O
animals	B-T008
were	O
initially	B-T079
hospitalised	B-T058
.	O
The	O
mortality rate	B-T081
was	O
70%	O
(16	O
of	O
23	O
animals	B-T008
),	O
and	O
was	O
higher	B-T080
in	O
cases	O
of	O
respiratory infection	B-T047
compared	B-T052
to	O
other	O
infections	B-T046
.	O
Aggressive	O
environmental	B-T082
cleaning	B-T052
and	O
disinfection	B-T061
,	O
with	O
staff education	B-T065
for	O
personal hygiene	B-T056
and	O
antisepsis	B-T061
,	O
sharply	O
decreased	B-T081
the	O
infection	B-T046
incidence	B-T081
.	O
Health care	B-T078
-	O
associated	B-T080
outbreaks	B-T067
with	O
multidrug resistant	B-T032
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	B-T007
in	O
dogs	B-T015
and	O
cats	B-T015
are	O
potentially	O
highly	B-T080
fatal	B-T080
and	O
difficult	B-T080
to	O
eradicate	B-T061
,	O
warranting	O
monitoring	B-T058
,	O
antiseptic	B-T121
techniques	B-T169
and	O
judicious	O
antibiotic	B-T195
use	B-T169
.	O

Manipulation	O
of	O
an	O
existing	O
crystal form	B-T104
unexpectedly results	B-T033
in	O
interwoven packing networks	B-T116
with	O
pseudo-translational symmetry	B-T082
Nonribosomal peptide synthetases	B-T116
(	O
NRPSs	B-T116
)	O
are	O
multimodular enzymes	B-T116
that	O
synthesize	B-T052
a	O
myriad	B-T081
of	O
diverse molecules	B-T167
.	O
Tailoring domains	B-T087
have	O
been	O
co-opted	O
into	O
NRPSs	B-T116
to	O
introduce	O
further	O
variety	O
into	O
nonribosomal peptide products	B-T116
.	O
Linear gramicidin synthetase	B-T116
contains	B-T052
a	O
unique	O
formylation	B-T044
-	O
tailoring domain	B-T087
in	O
its	O
initiation module	B-T077
(	O
F-A	B-T044
-	O
PCP	B-T087
).	O
The	O
structure	O
of	O
the	O
F-A	B-T044
di-domain	B-T087
has	O
previously	O
been	O
determined	O
in	O
a	O
crystal form	B-T104
which	O
had	O
large	O
solvent	B-T130
channels	B-T082
and	O
no density	B-T081
for	O
the	O
minor	O
Asub subdomain	B-T087
.	O
An	O
attempt	O
was	O
made	O
to	O
take	O
advantage	O
of	O
this	O
packing	B-T052
by	O
removing	B-T052
the	O
Asub subdomain	B-T087
from	O
the	O
construct	O
(	O
F-A	B-T044
Δ	O
sub	B-T087
)	O
in	O
order	O
to	O
produce	O
a	O
crystal	B-T104
that	O
could	O
accommodate	O
the	O
PCP domain	B-T087
.	O
In	O
the	O
resulting	O
crystal	B-T104
the	O
original packing network	B-T116
was	O
still	O
present,	O
but	O
a	O
second network	B-T116
with	O
the	O
same	O
packing	B-T052
and	O
almost	O
no	O
contact	O
with	O
the	O
original network	B-T116
took	O
the	O
place	O
of	O
the	O
solvent	B-T130
channels	B-T082
and	O
changed	O
the	O
space group of the crystal	B-T104
.	O

Folate	B-T109
-based	O
single cell screening	B-T059
using	O
surface enhanced Raman microimaging	B-T059
Recent	O
progress	O
in	O
nanotechnology	B-T090
and	O
its	O
application	O
to	O
biomedical settings	B-T062
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early cancer diagnosis	B-T060
.	O
The	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer cells	B-T025
,	O
such	O
as	O
the	O
expression	B-T045
of	O
particular	O
plasma membrane	B-T026
molecular receptors	B-T091
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing the stage of development of the disease	B-T058
.	O
Here	O
we	O
report	O
a	O
single cell screening	B-T059
approach	O
based	O
on	O
Surface Enhanced Raman Scattering (SERS) microimaging	B-T059
SERS	B-T059
)	O
microimaging.	O
We	O
fabricated	O
a	O
SERS-labelled	B-T059
nanovector	B-T090
based	O
on	O
the	O
biofunctionalization	B-T078
of	O
gold nanoparticles	B-T073
with	O
folic acid	B-T109
.	O
After	O
treating the cells	B-T025
with	O
the	O
nanovector	B-T090
,	O
we	O
were	O
able	O
to	O
distinguish three different cell populations	B-T059
from	O
different cell lines	B-T025
(	O
cancer HeLa	B-T025
and	O
PC-3	B-T050
,	O
and	O
normal HaCaT lines	B-T025
),	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	B-T045
of	O
folate binding proteins	B-T116
.	O
The	O
nanovector	B-T090
,	O
indeed,	O
binds much more efficiently	B-T052
on	O
cancer cell lines	B-T025
than	O
on	O
normal	O
ones,	O
resulting	O
in	O
a	O
higher	O
SERS	B-T059
signal	O
measured	O
on	O
cancer cells	B-T025
.	O
These	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single cell diagnostics	B-T059
and,	O
potentially	B-T080
,	O
in	O
theranostics	B-T091
.	O

Self-reported	B-T062
occupational injuries	B-T037
among	O
industrial	B-T057
beef	B-T015
slaughterhouse	B-T073
workers	B-T098
in	O
the	O
Midwestern United States	B-T083
Although	O
workers	B-T098
in	O
meatpacking facilities	B-T092
in	O
the	O
United States	B-T083
experience	O
high rates	B-T081
of	O
occupational injury	B-T037
,	O
their	O
injury	B-T037
experiences	O
have	O
received	O
limited	O
research	B-T062
attention.	O
Prior	O
research indicates	B-T062
underreporting	B-T058
in	O
injury rates	B-T033
in	O
this	O
industry	B-T057
as	O
well	O
significant	O
variation	O
in	O
injury rates	B-T033
among	O
facilities.	O
To	O
add	O
detail	O
to	O
the	O
rates	O
and	O
circumstances	O
surrounding	O
occupational injury	B-T037
among	O
meatpacking	B-T092
workers	B-T098
,	O
we	O
conducted	O
a	O
cross-sectional study	B-T062
of	O
workers	B-T098
employed	O
at	O
an	O
industrial beefpacking plant	B-T092
in	O
Nebraska	B-T083
,	O
United States	B-T083
(n	O
=	O
137)	O
and	O
interviewed	O
workers	B-T098
about	O
recent	O
injury	B-T037
experiences.	O
We	O
assessed	O
frequency,	O
cause	O
and	O
nature	O
of	O
self-reported	B-T062
injury	B-T037
.	O
We	O
estimated	O
annual incidence rates	B-T081
of	O
self-reported	B-T062
injuries	B-T037
using	O
the	O
OSHA	B-T093
formula	B-T170
and	O
compared	O
these	O
rates	O
to	O
industry-wide data	B-T078
.	O
We	O
also	O
evaluated	O
psychological distress	B-T048
in	O
this	O
workforce	O
as	O
measured	O
by	O
the	O
Kessler-6 scale	B-T170
to	O
assess	O
whether	O
distress	B-T033
was	O
associated with	B-T080
recent	O
occupational injury	B-T037
injury	B-T037
.	O
In	O
this	O
study,	O
15.1%	O
of	O
workers	B-T098
experienced	O
occupational injuries	B-T037
that	O
required	O
time	O
off	O
work,	O
job transfer	B-UnknownType
,	O
or	O
restriction during	B-T079
the	O
past	O
three	O
months.	O
The	O
estimated	O
annual incidence rate	B-T081
was	O
15.2	O
injuries	B-T037
per	O
100	O
full-time	O
workers	B-T098
for	O
these	O
injuries	B-T037
at	O
this	O
plant	B-T073
.	O
Rushing	O
was	O
identified	O
as	O
the	O
cause	O
of	O
nearly	O
50%	O
of	O
injuries	B-T037
,	O
and	O
repetitive	O
work	O
as	O
the	O
cause	O
of	O
an	O
additional	O
20%	O
of	O
injuries	B-T037
.	O
Use	O
of	O
metal mesh	B-T074
sleeves	B-T074
(POR:	O
0.10	O
(p	O
=	O
0.008))	O
and	O
metal mesh	B-T074
gloves	B-T073
(POR:	O
0.41	O
(p	O
=	O
0.05)	O
were	O
associated with	B-T080
reduced	O
risk	O
of	O
injury	B-T037
.	O
Use	O
of	O
a	O
carbon	B-T196
steel	B-T122
for	O
knife	B-T073
sharpening	O
(POR:	O
5.2	O
(p	O
=	O
0.02))	O
was	O
associated with	B-T080
elevated	O
risk	O
of	O
moderate and severe	B-T080
injury	B-T037
.	O
There	O
were	O
no	O
associations	O
between	O
self-reported	B-T062
occupational injury	B-T037
and	O
overall	O
measures	O
of	O
psychological distress	B-T048
.	O
Self-reported	B-T062
incidence rate	B-T081
of	O
severe	B-T080
injury	B-T037
in	O
this	O
plant	O
was	O
more	O
than	O
twice	O
official	O
industry estimates	B-T081
.	O
Worker	O
self-reports	B-T062
may	O
illustrate	O
key	O
areas	O
for	O
injury prevention	B-T061
.	O

The	O
Effect	B-T080
of	O
l-Arginine	B-T116
on	O
Dural Healing	B-T040
After	O
Experimentally	O
Induced	B-T169
Dural	B-T023
Defect	B-T169
in	O
a	O
Rat	B-T015
Model	B-T075
Incomplete	B-T080
repair	B-T040
of	O
the	O
dura mater	B-T023
may	O
result	B-T169
in	O
numerous	B-T081
complications	B-T046
such	O
as	O
cerebrospinal fluid leakage	B-T047
and	O
meningitis	B-T047
.	O
For	O
this	O
reason,	O
accurate	B-T080
repair	B-T040
of	O
the	O
dura mater	B-T023
is	O
essential	B-T080
.	O
In	O
this	O
study,	O
the	O
effect	B-T080
of	O
systemic	B-T169
and	O
local	B-T082
supplementation	B-T169
of	O
l-arginine	B-T116
on	O
dural healing	B-T040
was	O
evaluated.	O
Thirty	O
male	B-T032
Wistar rats	B-T015
were	O
used	O
and	O
divided	B-T169
into	O
control	B-T096
,	O
local	B-T082
,	O
and	O
systemic	B-T169
l-arginine	B-T116
groups	B-T078
,	O
with	O
10	O
rats	B-T015
in	O
each.	O
In	O
each	O
group	B-T078
,	O
a	O
5-mm	O
experimental incision	B-T061
was	O
made	O
at	O
the	O
lumbar segment of the dura mater	B-T029
and	O
cerebrospinal fluid leakage	B-T047
was	O
induced	B-T169
.	O
Each	O
group	B-T078
was	O
divided	B-T169
into	O
2	O
subgroups	B-T185
and	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-T079
,	O
the	O
rats	B-T015
were	O
killed	B-T058
and	O
the	O
damaged	B-T169
segments	B-T082
of	O
the	O
dura	B-T023
were	O
separated	B-T080
,	O
histologically	B-T169
evaluated	O
and	O
the	O
dural healing	B-T040
indicators	B-T169
including	O
cell types	B-T025
,	O
granulation tissue	B-T024
formation	B-T169
,	O
collagen	B-T116
deposit	B-T169
,	O
and	O
vascularization	B-T169
were	O
compared	B-T052
between	O
groups	B-T078
.	O
The	O
systematic	B-T169
supplementation	B-T169
of	O
l-arginine	B-T116
showed	O
a	O
significant	B-T078
effect	B-T080
in	O
dural healing	B-T040
compared	B-T052
with	O
the	O
control group	B-T096
.	O
After	O
the	O
first	O
week	B-T079
,	O
granulation	B-T024
formation	B-T169
increased	B-T081
considerably	O
(P	O
<	O
0.031),	O
and	O
after	O
6	O
weeks	B-T079
,	O
collagen	B-T116
deposition	B-T169
and	O
neovascularization	B-T046
were	O
significantly	O
different	B-T080
compared	B-T052
with	O
the	O
control group	B-T096
(P	O
<	O
0.030;	O
P	O
<	O
0.009).	O
In	O
comparison	B-T052
between	O
different	B-T080
groups	B-T078
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-T079
,	O
maximum	B-T081
changes	B-T169
in	O
healing	B-T040
indicators	B-T169
were	O
observed	B-T169
in	O
the	O
systemic	B-T169
group	B-T078
and	O
the	O
least	O
variations	B-T080
were	O
related	O
to	O
the	O
control group	B-T096
.	O
The	O
systemic	B-T169
supplementation	B-T169
of	O
l-arginine	B-T116
may	O
accelerate	B-T169
dural healing	B-T040
by	O
increasing	B-T169
the	O
level	B-T080
of	O
granulation tissue	B-T024
formation	B-T169
,	O
collagen	B-T116
deposition	B-T169
,	O
and	O
vascularization	B-T169
.	O

Birth Preparedness and Complication Readiness Practice	B-T058
and	O
Associated	B-T080
Factors	B-T169
among	O
Pregnant Women	B-T098
,	O
Northwest Ethiopia	B-T083
Background.	O
Little	O
is	O
known	O
about	O
birth preparedness and complication readiness	B-T058
(	O
BPCR	B-T058
)	O
plan	B-T169
in	O
resource	O
limited	O
settings	O
to	O
decrease	O
maternal mortality	B-T081
.	O
Therefore,	O
this	O
study	B-T062
was	O
done	O
to	O
assess	B-T058
the	O
status	B-T080
of	O
BPCR	B-T058
and	O
associated	B-T080
factors	B-T169
among	O
pregnant women	B-T098
in	O
South Wollo	B-T083
,	O
Northwest Ethiopia	B-T083
,	O
by	O
involving	O
819	O
pregnant women	B-T098
from	O
March	O
to	O
April,	O
2014.	O
Data	B-T078
were	O
collected	O
by	O
using	O
pretested	O
interviewer	B-T097
administered questionnaire	B-T170
and	O
analyzed	B-T062
using	O
a	O
computer program	B-T073
of	O
SPSS version 20.00	B-T170
.	O
Results	B-T169
.	O
Pregnant women	B-T098
who	O
were	O
prepared	B-T033
for	O
at	O
least	O
three	O
elements	B-T077
of	O
BPCR	B-T058
were	O
24.1%.	O
Pregnant women	B-T098
knowing	O
at	O
least	O
three	O
key	O
danger signs	B-T184
during	O
pregnancy	B-T040
,	O
delivery	B-T040
,	O
and	O
postnatal period	B-T079
were	O
23.2%,	O
22.6%,	O
and	O
9.6%,	O
respectively.	O
Women	B-T098
having	O
secondary education	B-T170
and	O
higher	O
were	O
6.20	O
(95%	O
CI	B-T081
=	O
[1.36,	O
28.120])	O
times	O
more	O
likely	O
to	O
be	O
prepared	B-T033
than	O
illiterates	B-T033
.	O
Women	B-T098
having	O
a	O
lifetime history	B-T032
of	O
stillbirth	B-T033
[5.80	O
(1.13,	O
29.63)],	O
attending	B-T169
ANC	B-T058
for	O
last	O
child	B-T100
pregnancy	B-T040
[5.44	O
(2.07,	O
14.27)],	O
participating	B-T169
in	O
community	B-T096
BPCR	B-T058
group discussion	B-T054
[4.36	O
(1.17,	O
16.26)],	O
and	O
having	O
their	O
male	B-T032
partner	B-T099
involved	O
in	O
BPCR	B-T058
counseling	B-T058
during	O
ANC	B-T058
follow-up	B-T058
[4.45	O
(1.95,	O
10.16)]	O
were	O
more	O
likely	O
to	O
be	O
prepared	B-T033
.	O
Conclusions	B-T078
.	O
BPCR	B-T058
was	O
very	O
low	O
and	O
should	O
be	O
strengthened	O
through	O
health communication	B-T058
by	O
involving	O
partner	B-T099
in	O
BPCR	B-T058
counseling	B-T058
.	O

Fluoranthene	B-T109
degradation	B-T070
and	O
binding	B-T044
mechanism	B-T169
study	B-T062
based	O
on	O
the	O
active-site	B-T169
structure	B-T082
of	O
ring-hydroxylating dioxygenase	B-T116
in	O
Microbacterium paraoxydans JPM1	B-T007
In	O
this	O
study	B-T062
,	O
a	O
gram-positive fluoranthene-degrading bacterial	B-T007
strain	B-T001
was	O
isolated	B-T169
from	O
crude oil	B-T109
in	O
Dagang Oilfield	B-T070
and	O
identified	B-T080
as	O
Microbacterium paraoxydans JPM1	B-T007
by	O
the	O
analysis	B-T062
of	O
16S rDNA	B-T114
sequence	B-T086
.	O
After	O
25	O
days	B-T079
of	O
incubation	B-T059
,	O
the	O
strain	B-T001
JPM1	B-T007
could	O
degrade	O
91.78	O
%	O
of	O
the	O
initial	B-T079
amount	B-T081
of	O
fluoranthene	B-T109
.	O
Moreover,	O
four	O
metabolites	B-T123
9-fluorenone-1-carboxylic acid	B-T123
,	O
9-fluorenone	B-T109
,	O
phthalic acid	B-T109
,	O
and	O
benzoic acid	B-T109
were	O
detected	O
in	O
the	O
culture solution	B-T130
.	O
The	O
gene sequence	B-T086
encoding	B-T052
the	O
aromatic-ring-hydroxylating dioxygenase	B-T116
was	O
amplified	B-T045
in	O
the	O
strain	B-T001
JPM1	B-T007
by	O
PCR	B-T063
.	O
Based	O
on	O
the	O
translated	O
protein sequence	B-T087
,	O
a	O
homology modeling method	B-T063
was	O
applied	O
to	O
build	O
the	O
crystal structure	B-T104
of	O
dioxygenase	B-T116
.	O
Subsequently,	O
the	O
interaction	B-T169
mechanism	B-T169
between	O
fluoranthene	B-T109
and	O
the	O
active site	B-T169
of	O
dioxygenase	B-T116
was	O
simulated	B-T062
and	O
analyzed	B-T062
by	O
molecular docking	B-T063
.	O
Consequently,	O
a	O
feasible	O
degrading	B-T070
pathway	B-T044
of	O
fluoranthene	B-T109
in	O
the	O
strain	B-T001
JPM1	B-T007
was	O
proposed	O
based	O
on	O
the	O
metabolites	B-T123
and	O
the	O
interaction analyses	B-T081
.	O
Additionally,	O
the	O
thermodynamic analysis	B-T062
showed	O
that	O
the	O
strain	B-T001
JPM1	B-T007
had	O
high	B-T080
tolerance	B-T080
for	O
fluoranthene	B-T109
,	O
and	O
the	O
influence	B-T077
of	O
fluoranthene	B-T109
for	O
the	O
bacterial	B-T007
growth	B-T040
activity	O
was	O
negligible	B-T080
under	O
100	O
to	O
400	O
mg	O
L(-1)	O
concentrations	B-T081
.	O
Taken	O
together,	O
this	O
study	B-T062
indicates	O
that	O
the	O
strain	B-T001
JPM1	B-T007
has	O
high	O
potential	B-T080
for	O
further	O
study	B-T062
in	O
bioremediation	B-T069
of	O
polycyclic aromatic hydrocarbon	B-T109
(	O
PAH	B-T109
)-	O
contaminated	B-T169
sites	B-T082
.	O

Ultrasonography	B-T060
for	O
acute appendicitis	B-T047
-	O
the	O
way	O
it	O
looks	O
today	O
Despite	O
sophisticated	O
physical examination	B-T058
and	O
laboratory support	B-T059
,	O
diagnosis	B-T033
of	O
acute appendicitis	B-T047
remained	O
challenging	O
in	O
clinical practice	B-T057
with	O
a	O
negative appendectomy	B-T061
rate	B-T081
of	O
15	O
-	O
30	O
%.	O
As	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986,	O
ultrasonography	B-T060
(	O
US	B-T060
)	O
has	O
been	O
proven	O
a	O
reliable	B-T170
diagnostic method	B-T060
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	B-T080
presentation	B-T078
and	O
enables	O
to	O
rule out	B-T169
many	O
differential diagnoses	B-T060
.Recent	O
publications	B-T073
emphasized	O
the	O
role	O
of	O
multidetector computed tomography	B-T060
(	O
CT	B-T060
)	O
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false negative findings	B-T034
at	O
operation	B-T061
.	O
Extensive	B-T080
as	O
well	O
as	O
uncritical application	B-T061
of	O
this	O
method	O
even	O
in	O
children	B-T100
inevitably	O
causes	O
substantial	O
radiation exposure	B-T037
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified/	O
inadequate	B-T080
performance	B-T052
of	O
US	B-T060
in	O
this	O
particular	O
situation,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	B-T033
or	O
economic	B-T169
preponderance	B-T081
.Recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
US	B-T060
(and	O
CT	B-T060
)	O
in	O
acute appendicitis	B-T047
.	O
Therefore,	O
1	O
generation	O
after	O
US with graded compression	B-T060
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	B-T033
acute appendicitis	B-T047
(Puylaert),	O
a	O
visual	B-T169
arousal	B-T041
fostering	B-T056
its	O
role	O
and	O
performance	O
in	O
clinical medicine	B-T091
appears	O
justified.	O

Mesenchymal stem cells	B-T025
enhance	B-T052
the	O
oncolytic	B-T080
effect	B-T080
of	O
Newcastle disease virus	B-T005
in	O
glioma	B-T191
cells	B-T025
and	O
glioma	B-T191
stem cells	B-T025
via	O
the	O
secretion	B-T038
of	O
TRAIL	B-T116
Newcastle disease virus	B-T005
(	O
NDV	B-T005
)	O
is	O
an	O
avian paramyxovirus	B-T005
,	O
which	O
selectively	O
exerts	B-T040
oncolytic	B-T080
effects	B-T080
in	O
cancer cells	B-T025
.	O
Mesenchymal stem cells	B-T025
(	O
MSCs	B-T025
)	O
have	O
been	O
reported	O
to	O
affect	O
tumor growth	B-T191
and	O
deliver	B-T169
anti-tumor agents	B-T109
to	O
experimental	B-T080
glioblastoma	B-T191
(	O
GBM	B-T191
).	O
Here,	O
we	O
explored	O
the	O
effects of	B-T080
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T025
derived	O
from	O
different	O
sources	B-T033
,	O
on	O
glioma	B-T191
cells	B-T025
and	O
glioma	B-T191
stem cells	B-T025
(	O
GSCs	B-T025
)	O
and	O
the	O
mechanisms	B-T169
involved	O
in	O
their	O
effects	B-T080
.	O
The	O
glioma	B-T191
cell lines	B-T025
(	O
A172	B-T025
and	O
U87	B-T025
)	O
and	O
primary	B-T080
GSCs	B-T025
that	O
were	O
generated	B-T052
from	O
GBM	B-T191
tumors	B-T191
were	O
used	O
in	O
this	O
study	B-T062
.	O
MSCs	B-T025
derived	B-T080
from	O
bone marrow	B-T024
,	O
adipose tissue	B-T024
or	O
umbilical cord	B-T018
were	O
infected	B-T033
with	O
NDV	B-T005
(	O
MTH-68/H	B-T061
).	O
The	O
ability	B-T032
of	O
these	O
cells	B-T025
to	O
deliver	B-T169
the	O
virus	B-T005
to	O
glioma	B-T191
cell lines	B-T025
and	O
GSCs	B-T025
and	O
the	O
effects of	B-T080
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T025
on	O
cell death	B-T043
and	O
on	O
the	O
stemness	B-T080
and	O
self-renewal	B-T043
of	O
GSCs	B-T025
were	O
examined	B-T033
.	O
The	O
mechanisms	B-T169
involved	B-T169
in	O
the	O
cytotoxic	B-T169
effects of	B-T080
the	O
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T025
and	O
their	O
influence	B-T077
on	O
the	O
radiation sensitivity	B-T032
of	O
GSCs	B-T025
were	O
examined	B-T033
as	O
well.	O
NDV	B-T005
induced	B-T169
a	O
dose-dependent	B-T081
cell death	B-T043
in	O
glioma	B-T191
cells	B-T025
and	O
a	O
low	B-T080
level	B-T080
of	O
apoptosis	B-T043
and	O
inhibition	B-T052
of	O
self-renewal	B-T043
in	O
GSCs	B-T025
.	O
MSCs	B-T025
derived	B-T080
from	O
bone marrow	B-T024
,	O
adipose	B-T024
and	O
umbilical cord	B-T018
that	O
were	O
infected	B-T033
with	O
NDV	B-T005
delivered	B-T169
the	O
virus	B-T005
to	O
co-cultured	B-T059
glioma	B-T191
cells	B-T025
and	O
GSCs	B-T025
.	O
Conditioned medium	B-T130
of	O
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T025
induced	B-T169
higher	B-T080
level	B-T080
of	O
apoptosis	B-T043
in	O
the	O
tumor cells	B-T025
compared	B-T052
with	O
the	O
apoptosis	B-T043
induced	B-T169
by	O
their	O
direct infection	B-T047
with	O
similar	B-T080
virus titers	B-T081
.	O
These	O
results	B-T033
suggest	B-T078
that	O
factor(s)	B-T169
secreted	B-T043
by	O
the	O
infected	B-T033
MSCs	B-T025
sensitized	B-T025
the	O
glioma	B-T191
cells	B-T025
to	O
the	O
cytotoxic	B-T169
effects of	B-T080
NDV	B-T005
.	O
We	O
identified	B-T080
TRAIL	B-T116
as	O
a	O
mediator	B-T080
of	O
the	O
cytotoxic	B-T169
effects of	B-T080
the	O
infected	B-T033
MSCs	B-T025
and	O
demonstrated	B-T080
that	O
TRAIL	B-T116
synergized	O
with	O
NDV	B-T005
in	O
the	O
induction	B-T169
of	O
cell death	B-T043
in	O
glioma	B-T191
cells	B-T025
and	O
GSCs	B-T025
.	O
Moreover,	O
conditioned	B-T080
medium	B-T081
of	O
infected	B-T033
MSCs	B-T025
enhanced	B-T052
the	O
sensitivity	O
of	O
GSCs	B-T025
to	O
γ-radiation	B-T070
.	O
NDV	B-T005
-	O
infected	B-T033
umbilical cord	B-T018
-	O
derived	B-T080
MSCs	B-T025
may	O
provide	O
a	O
novel	B-T080
effective	B-T080
therapeutic	B-T169
approach	B-T082
for	O
targeting	B-T169
GSCs	B-T025
and	O
GBM	B-T191
and	O
for	O
sensitizing	O
these	O
tumors	B-T191
to	O
γ-radiation	B-T070
.	O

Importance	B-T080
of	O
Ecological Factors	B-T077
and	O
Colony	B-T078
Handling	B-T033
for	O
Optimizing	B-T052
Health Status	B-T080
of	O
Apiaries	B-T073
in	O
Mediterranean	B-T098
Ecosystems	B-T070
We	O
analyzed	B-T062
six	O
apiaries	B-T073
in	O
several	O
natural environments	B-T082
with	O
a	O
Mediterranean	B-T098
ecosystem	B-T070
in	O
Madrid	B-T083
,	O
central Spain	B-T083
,	O
in	O
order	O
to	O
understand	B-T041
how	O
landscape	B-T082
and	O
management	B-T170
characteristics	B-T080
may	O
influence	B-T077
apiary	B-T073
health	B-T078
and	O
bee	B-T204
production	O
in	O
the	O
long term	B-T079
.	O
We	O
focused	B-T169
on	O
five	O
criteria	B-T078
(	O
habitat	B-T082
quality	B-T080
,	O
landscape	B-T082
heterogeneity	B-T080
,	O
climate	B-T070
,	O
management	B-T170
and	O
health	B-T078
),	O
as	O
well	O
as	O
30	O
subcriteria	B-T078
,	O
and	O
we	O
used	O
the	O
analytic hierarchy process	B-T062
(	O
AHP	B-T062
)	O
to	O
rank	B-T170
them	O
according	O
to	O
relevance	B-T080
.	O
Habitat	B-T082
quality	B-T080
proved	O
to	O
have	O
the	O
highest	O
relevance	B-T080
,	O
followed	O
by	O
beehive	B-T073
management	B-T170
.	O
Within	O
habitat	B-T082
quality	B-T080
,	O
the	O
following	O
subcriteria	B-T078
proved	O
to	O
be	O
most	O
relevant	B-T080
:	O
orographic diversity	B-T080
,	O
elevation	B-T082
range	B-T081
and	O
important	B-T080
plant	B-T002
species	B-T185
located	B-T082
1.5	O
km	O
from	O
the	O
apiary	B-T073
.	O
The	O
most	O
important	B-T080
subcriteria	B-T078
under	O
beehive	B-T073
management	B-T170
were	O
honey	B-T168
production	B-T057
,	O
movement	O
of	O
the	O
apiary	B-T073
to	O
a	O
location	B-T082
with	O
a	O
higher	O
altitude	B-T081
and	O
wax	B-T122
renewal	B-T169
.	O
Temperature	B-T081
was	O
the	O
most	O
important	O
subcriterion	B-T078
under	O
climate	B-T070
,	O
while	O
pathogen	B-T001
and	O
Varroa	B-T204
loads	B-T033
were	O
the	O
most	O
significant	B-T078
under	O
health	B-T078
.	O
Two	O
of	O
the	O
six	O
apiaries	B-T073
showed	O
the	O
best values	B-T081
in	O
the	O
AHP	B-T062
analysis	B-T062
and	O
showed	O
annual	B-T079
honey	B-T168
production	B-T057
of	O
70	O
and	O
28	O
kg/	O
colony	B-T078
.	O
This	O
high	O
productivity	B-T081
was	O
due	O
primarily	O
to	O
high	O
elevation	B-T082
range	B-T081
and	O
high	O
orographic diversity	B-T080
,	O
which	O
favored	O
high	O
habitat	B-T082
quality	B-T080
.	O
In	O
addition,	O
one	O
of	O
these	O
apiaries	B-T073
showed	O
the	O
best value	B-T081
for	O
beehive	B-T073
management	B-T170
,	O
while	O
the	O
other	O
showed	O
the	O
best value	B-T081
for	O
health	B-T078
,	O
reflected	O
in	O
the	O
low	B-T080
pathogen	B-T001
load	B-T033
and	O
low	B-T080
average	B-T081
number	B-T081
of	O
viruses	B-T005
.	O
These	O
results	B-T169
highlight	O
the	O
importance	B-T080
of	O
environmental factors	B-T077
and	O
good	O
sanitary practices	B-T169
to	O
maximize	O
apiary	B-T073
health	B-T078
and	O
honey	B-T168
productivity	B-T081
.	O

Chordoma dedifferentiation	B-T191
after	O
proton beam therapy	B-T061
:	O
a	O
case report	B-T170
and	O
review of the literature	B-T170
Chordoma	B-T191
is	O
a	O
rare	B-T080
invasive	B-T080
bone tumor	B-T191
that	O
may	O
occur	O
anywhere	O
along	O
the	O
neuraxis	B-T082
.	O
A	O
total	O
of	O
three	O
primary	B-T080
histological varieties	B-T191
have	O
been	O
identified	B-T080
:	O
conventional	B-T191
,	O
chondroid	B-T191
,	O
and	O
dedifferentiated	B-T191
.	O
We	O
report	B-T170
a	O
case	B-T077
of	O
an	O
8-year-old	O
white	B-T098
girl	B-T100
who	O
presented	O
with	O
conventional chordoma	B-T191
,	O
was	O
treated	B-T033
with	O
surgical resection	B-T061
and	O
mixed	B-T169
proton	B-T070
and	O
photon beam therapy	B-T061
,	O
and	O
had	O
a	O
recurrence	B-T067
in	O
the	O
resection cavity	B-T020
2.5	O
years	O
later	O
with	O
dedifferentiated morphology	B-T191
.	O
The	O
recurrent tumor	B-T191
did	O
not	O
express	B-T045
brachyury	B-T116
,	O
a	O
recently	B-T079
identified	B-T080
protein	B-T116
specific	B-T080
to	O
tissue	B-T024
of	O
notochordal	B-T018
origin	B-T079
.	O
The	O
short	B-T081
time period	B-T079
between	O
radiation therapy	B-T061
and	O
dedifferentiation	B-T043
,	O
low dose	B-T081
of	O
photons	B-T167
,	O
and	O
rarity	B-T080
of	O
dedifferentiated skull base chordomas	B-T191
in	O
pediatric	B-T080
patients	B-T101
should	O
alert	B-T169
clinicians	B-T097
to	O
the	O
possibility	B-T033
of	O
chordoma dedifferentiation	B-T191
after	O
proton beam therapy	B-T061
.	O

Volumetric absorptive microsampling	B-T060
at	O
home	B-T082
as	O
an	O
alternative	B-T077
tool	B-T073
for	O
the	O
monitoring	B-T058
of	O
HbA1c	B-T116
in	O
diabetes	B-T047
patients	B-T101
Microsampling techniques	B-T169
have	O
several	O
advantages	O
over	O
traditional	O
blood collection	B-T060
.	O
Dried blood spot (DBS) sampling	B-T059
and	O
blood collection	B-T060
with	O
heparinized capillaries	B-T074
are	O
the	O
standard	B-T080
techniques	B-T059
.	O
Volumetric absorptive microsampling	B-T060
(	O
VAMS	B-T060
)	O
is	O
a	O
novel	O
technique	B-T059
that	O
collects	O
a	O
fixed	O
volume	B-T081
of	O
blood	B-T031
by	O
applying	O
an	O
absorbent	O
tip	B-T080
to	O
a	O
blood drop	B-T031
.	O
In	O
the	O
present	O
study	B-T062
we	O
explored	O
the	O
feasibility	O
of	O
HbA1c	B-T116
monitoring	B-T058
with	O
VAMS sampling	B-T060
at	O
home	B-T082
and	O
analysis	B-T062
in	O
the	O
laboratory	B-T073
.	O
Diabetic	B-T047
patients	B-T101
were	O
enrolled	O
in	O
this	O
study	B-T062
during	O
consultation	B-T058
with	O
the	O
endocrinologist	B-T097
.	O
A	O
venous	B-T031
(	O
adults	B-T100
)	O
or	O
capillary (children) sample	B-T031
was	O
taken	O
for	O
immediate	O
HbA1c	B-T116
analysis	B-T062
.	O
DBS	B-T059
(n=1)	O
and	O
dried VAMS	B-T060
(n=2)	O
were	O
collected	O
at	O
home	B-T082
and	O
sent	O
to	O
the	O
laboratory	B-T073
.	O
For	O
25	O
pediatric	B-T080
patients	B-T101
one	O
VAMS	B-T060
was	O
collected	O
during	O
consultation	B-T058
for	O
immediate	O
analysis	B-T062
(without	O
drying),	O
referred	O
to	O
as	O
"	O
wet VAMS	B-T060
".	O
HbA1c	B-T116
analyses	B-T062
were	O
performed	O
on	O
a	O
Tosoh HLC-723 G8 high-performance liquid chromatography (HPLC) analyzer	B-T074
.	O
The	O
median	O
time	O
between	O
sampling	B-T060
at	O
home	B-T082
and	O
analysis	B-T062
was	O
3	O
days	B-T079
.	O
Results	B-T169
of	O
HbA1c	B-T116
in	O
dried	O
VAMS	B-T060
showed	O
a	O
poor	O
agreement	O
with	O
venous	B-T031
/	O
capillary blood	B-T031
collected	O
in	O
hospital	B-T073
(	O
concordance correlation coefficient	B-T081
CCC	B-T081
=0.72).	O
Similar	O
observations	O
were	O
found	O
with	O
standard	B-T080
DBS	B-T059
.	O
An	O
excellent	O
agreement	O
was	O
obtained	O
between	O
HbA1c	B-T116
results	B-T169
on	O
wet VAMS	B-T060
(	O
CCC	B-T081
=0.996)	O
and	O
standard	B-T080
blood samples	B-T031
.	O
Patients	B-T101
experienced	O
VAMS	B-T060
and	O
DBS	B-T059
as	O
easy	B-T033
and	O
convenient	B-T080
to	O
use	B-T169
.	O
Utilizing	O
equipment	B-T073
standard	B-T080
available	O
in	O
the	O
clinical	B-T080
laboratory	B-T073
,	O
the	O
use	O
of	O
home	B-T082
-sampled	O
dried VAMS	B-T060
and	O
DBS	B-T059
is	O
not	O
a	O
reliable	O
tool	O
for	O
the	O
monitoring	B-T058
of	O
HbA1c	B-T116
.	O
However,	O
perfect	O
agreement	O
between	O
HbA1c	B-T116
measured	O
on	O
wet VAMS	B-T060
and	O
capillary microsamples	B-T031
was	O
obtained.	O

Are	O
Eyes	B-T023
a	O
Mirror	B-T070
of	O
the	O
Soul	B-T078
?	O
What	O
Eye	B-T023
Wrinkles	B-T190
Reveal	B-T080
about	O
a	O
Horse's	B-T015
Emotional State	B-T041
Finding	O
valid	B-T080
indicators	B-T169
of	O
emotional states	B-T041
is	O
one	O
of	O
the	O
biggest	O
challenges	O
in	O
animal welfare science	B-T052
.	O
Here,	O
we	O
investigated	B-T169
in	O
horses	B-T015
whether	O
variation	B-T080
in	O
the	O
expression	B-T080
of	O
eye	B-T023
wrinkles	B-T190
caused	O
by	O
contraction	B-T046
of	O
the	O
inner eyebrow	B-T023
raiser	O
reflects	B-T041
emotional valence	B-T033
.	O
By	O
confronting	O
horses	B-T015
with	O
positive	B-T033
and	O
negative	B-T033
conditions	B-T080
,	O
we	O
aimed	O
to	O
induce	B-T169
positive	B-T033
and	O
negative	B-T033
emotional states	B-T041
,	O
hypothesising	B-T078
that	O
positive	B-T033
emotions	B-T041
would	O
reduce	B-T080
whereas	O
negative	B-T033
emotions	B-T041
would	O
increase	B-T169
eye	B-T023
wrinkle	B-T190
expression	B-T080
.	O
Sixteen	O
horses	B-T015
were	O
individually	O
exposed	B-T080
in	O
a	O
balanced	B-T169
order	O
to	O
two	O
positive	B-T033
(	O
grooming	B-T055
,	O
food anticipation	B-T041
)	O
and	O
two	O
negative	B-T033
condition	B-T080
s	O
(	O
food	B-T168
competition	B-T054
,	O
waving	B-T052
a	O
plastic bag	B-T073
).	O
Each	O
condition	B-T080
lasted	O
for	O
60	O
seconds	B-T079
and	O
was	O
preceded	O
by	O
a	O
60	O
second	B-T079
control phase	B-T079
.	O
Throughout	O
both	O
phases	B-T079
,	O
pictures	B-T073
of	O
the	O
eyes	B-T023
were	O
taken,	O
and	O
for	O
each	O
horse	B-T015
four	O
pictures	B-T073
per	O
condition	B-T080
and	O
phase	B-T079
were	O
randomly selected	B-T052
.	O
Pictures	B-T073
were	O
scored	O
in	O
random order	B-T080
and	O
by	O
two	O
experimenters	B-T097
blind	B-T062
to	O
condition	B-T080
and	O
phase	B-T079
for	O
six	O
outcome measures	B-T081
:	O
qualitative	B-T080
impression	B-T080
,	O
eyelid	B-T023
shape	B-T082
,	O
markedness	B-T080
of	O
the	O
wrinkles	B-T190
,	O
presence	B-T033
of	O
eye white	B-T023
,	O
number	B-T081
of	O
wrinkles	B-T190
,	O
and	O
the	O
angle	B-T082
between	O
the	O
line	O
through	O
the	O
eyeball	B-T023
and	O
the	O
highest	B-T080
wrinkle	B-T190
.	O
The	O
angle	B-T082
decreased	B-T081
during	O
grooming	B-T055
and	O
increased	B-T081
during	O
food	B-T168
competition	B-T054
compared	B-T052
to	O
control phase	B-T079
s,	O
whereas	O
the	O
two	O
phases	B-T079
did	O
not	O
differ	O
during	O
food anticipation	B-T041
and	O
the	O
plastic bag	B-T073
condition	B-T080
.	O
No effects	B-T080
on	O
the	O
other	O
outcome measures	B-T081
were	O
detected	B-T033
.	O
Taken	O
together,	O
we	O
have	O
defined	O
a	O
set	O
of	O
measures	B-T081
to	O
assess	B-T052
eye	B-T023
wrinkle	B-T190
expression	B-T080
reliably,	O
of	O
which	O
one	O
measure	B-T081
was	O
affected	B-T169
by	O
the	O
conditions	B-T080
the	O
horses	B-T015
were	O
exposed to	B-T080
.	O
Variation	B-T080
in	O
eye	B-T023
wrinkle	B-T190
expression	B-T080
might	O
provide	B-T168
valuable	O
information	B-T078
on	O
horse	B-T015
welfare	B-T052
but	O
further	O
validation	B-T062
of	O
specific	B-T080
measures	B-T081
across	O
different	B-T080
conditions	B-T080
is	O
needed.	O

Effective	B-T080
mercury(II)	B-T131
bioremoval	B-T052
from	O
aqueous solution	B-T121
,	O
and	O
its	O
electrochemical determination	B-UnknownType
This	O
work	O
proposed	O
mercury	B-T131
elimination	B-T052
using	O
agricultural	B-T090
waste	B-T167
(	O
Allium Cepa L	B-T002
.).	O
The	O
biomass	B-T081
removed	B-T080
99.4%	O
of	O
mercury	B-T131
,	O
following	O
a	O
pseudo-second order kinetics	B-T070
(r(2)	O
=	O
0.9999).	O
The	O
Langmuir model	B-T170
was	O
adequately	B-T080
fitted	O
to	O
the	O
adsorption isotherm	B-T067
,	O
thereby	O
obtaining	O
the	O
maximum	B-T081
mercury	B-T131
adsorption	B-T059
capacity	B-T081
of	O
111.1	O
±	O
0.3	O
mg	O
g(-1).	O
The	O
biomass	B-T081
showed	O
high	B-T080
density	B-T081
of	O
strong	B-T080
mercury	B-T131
chelating groups	B-T121
,	O
thus	O
making	O
it	O
economically	B-T169
attractive	B-T080
.	O
Also,	O
the	O
implementation	B-T052
of	O
a	O
mercury	B-T131
-	O
selective electrode	B-T059
for	O
continuous	B-T078
determination	B-T059
in	O
real time	B-T079
is	O
proposed	B-T080
;	O
this	O
electrode	B-T073
replaces	B-T078
techniques	B-T169
like	O
atomic absorption spectroscopy	B-T059
,	O
thus	O
it	O
can	O
be	O
applied	O
to	O
real time	B-T079
studies	B-T062
.	O
This	O
work	O
therefore	O
presents	O
a	O
new	O
perspective	B-T169
for	O
removing	B-T052
mercury(II)	B-T131
from	O
contaminated water	B-T069
for	O
environmental remediation	B-T069
.	O

Modeling	B-T062
nurse-patient assignments	B-T057
considering	O
patient acuity	B-T080
and	O
travel	B-T056
distance	B-T081
metrics	B-T169
Balancing	B-T169
workload	B-T081
among	O
nurses	B-T097
on	O
a	O
hospital unit	B-T073
is	O
important	O
for	O
the	O
satisfaction	B-T041
and	O
safety	B-T068
of	O
nurses	B-T097
and	O
patients	B-T101
.	O
To	O
balance	B-T169
nurse	B-T097
workloads	B-T081
,	O
direct	B-T080
patient care activities	B-T058
,	O
indirect	B-T080
patient care activities	B-T058
,	O
and	O
non-patient care activities	B-T058
that	O
occur	O
throughout	O
a	O
shift	B-T169
must	O
be	O
considered.	O
The	O
layout	O
of	O
a	O
hospital unit	B-T073
and	O
the	O
location	B-T082
of	O
a	O
nurse's	B-T097
assigned	B-T169
patients	B-T101
relative	B-T080
to	O
other	O
resources	B-T078
on	O
the	O
unit	B-T073
are	O
also	O
important factors	B-T169
in	O
achieving	B-T033
workload	B-T081
balance	B-T169
.	O
In	O
most	O
hospitals	B-T073
,	O
a	O
unit	O
charge	O
nurse	B-T097
is	O
responsible	B-T033
for	O
the	O
shift	B-T169
assignment	B-T169
of	O
patients	B-T101
to	O
nurses	B-T097
based	O
on	O
experience	B-T041
and	O
past practices	B-T041
.	O
The	O
nurse-patient assignment	B-T057
process	B-T067
is	O
also	O
often	O
a	O
manual process	B-T067
in	O
which	O
the	O
charge	O
nurse	B-T097
must	O
sort	B-T052
through	O
multiple decision criteria	B-T078
in	O
a	O
limited	O
amount	O
of	O
time	B-T079
.	O
In	O
this	O
paper,	O
a	O
methodology	B-T078
for	O
the	O
construction	O
of	O
balanced	B-T169
nurse-patient workload assignments	B-T057
is	O
proposed	B-T080
.	O
Through	O
the	O
illustration	O
of	O
this	O
methodology	B-T078
new	O
scoring	B-T081
metrics	B-T169
are	O
developed	B-T169
using	O
measures	B-T081
currently	O
available	B-T169
on,	O
or	O
from,	O
the	O
hospital unit	B-T073
.	O
It	O
was	O
demonstrated	B-T169
that	O
the	O
complex scheduling	B-T080
problem	B-T033
can	O
be	O
captured.	O
While	O
the	O
methodology	B-T078
was	O
illustrated	O
for	O
a	O
scheduling	B-T080
problem	B-T033
commonly	O
encountered	O
on	O
a	O
hospital unit	B-T073
,	O
the	O
approach	B-T082
can	O
be	O
adapted	O
to	O
other	O
workforce	B-T169
scheduling	B-T080
problems	B-T033
in	O
which	O
measures	B-T081
of	O
workload	B-T081
are	O
required	B-T169
and	O
composed	O
of	O
elements	B-T077
imposed	O
by	O
the	O
work environment	B-T082
,	O
variability	B-T077
within	O
the	O
required	B-T169
tasks	B-T057
,	O
and	O
a	O
measurable	B-T169
perception	B-T041
of	O
the	O
relative	B-T080
intensity	B-T080
of	O
the	O
work elements	B-T077
.	O

Effect of	B-T080
alpha lipoic acid	B-T109
on	O
in vitro	B-T080
development	B-T040
of	O
bovine	B-T015
secondary preantral follicles	B-T023
The	O
present	O
study	B-T062
aimed	O
to	O
evaluate	B-T058
the	O
in vitro	B-T080
effect of	B-T080
alpha lipoic acid	B-T109
(	O
ALA	B-T109
)	O
addition	O
to	O
the	O
culture medium	B-T130
on	O
the	O
development	B-T040
of	O
the	O
bovine	B-T015
secondary preantral follicles	B-T023
.	O
Bovine	B-T015
secondary preantral follicles	B-T023
were	O
collected	B-T169
and	O
divided	B-T169
into	O
two	O
groups	B-T078
depending	O
on	O
their	O
size	B-T082
(80-100	O
μm	O
and	O
100-110	O
μm).	O
They	O
were	O
cultured	O
in vitro	B-T080
for	O
15	O
days	O
(D)	O
using	O
different	O
media	B-T130
including	O
at	O
three	O
different	O
doses	B-T081
of	O
ALA	B-T109
.	O
The	O
genes expression	B-T045
levels	B-T080
of	O
follicle-stimulating hormone beta-subunit	B-T028
(	O
FSHR	B-T028
),	O
insulin-like growth factor	B-T028
(	O
IGF-1	B-T028
),	O
Activin	B-T028
,	O
luteinizing hormone/choriogonadotropin receptor	B-T028
,	O
bone morphogenetic protein receptor type IA	B-T028
,	O
transforming growth factor beta receptor 1	B-T028
,	O
growth differentiation factor 9	B-T028
,	O
BCL2-associated X protein	B-T028
(	O
BAX	B-T028
),	O
and	O
C-Myc	B-T028
were	O
studied	O
using	O
real-time polymerase chain reaction	B-T063
.	O
The	O
protein expression	B-T045
levels	B-T080
of	O
FSHR	B-T116
,	O
IGF-1	B-T116
,	O
and	O
BAX	B-T116
were	O
measured	O
using	O
Western blot analysis	B-T059
.	O
The	O
results	B-T034
of	O
the	O
present	O
work	O
revealed	O
that	O
in vitro	B-T080
addition	O
of	O
ALA	B-T109
-	O
induced	B-T169
significant	B-T078
increase in the growth	B-T042
and	O
development	B-T040
of	O
secondary preantral follicles	B-T023
throughout	O
the	O
culture	B-T059
period	B-T079
as	O
compared	B-T052
to	O
control	B-T096
.	O
The	O
FSHR	B-T028
,	O
IGF-1	B-T028
,	O
luteinizing hormone/choriogonadotropin receptor	B-T028
,	O
bone morphogenetic protein receptor type IA	B-T028
,	O
transforming growth factor beta receptor 1	B-T028
,	O
growth differentiation factor 9	B-T028
,	O
and	O
Activin A genes	B-T028
were	O
upregulated	B-T044
in	O
ALA	B-T109
-	O
treated	B-T169
follicles	B-T023
as	O
compared	B-T052
to	O
the	O
control	B-T096
.	O
On	O
contrary,	O
preapoptotic genes	B-T028
BAX	B-T028
and	O
C-Myc	B-T028
were	O
downregulated	B-T044
in	O
treated	B-T169
follicles	B-T023
compared	B-T052
to	O
control	B-T096
ones.	O
The	O
protein levels	B-T034
of	O
FSHR	B-T116
and	O
IGF-1	B-T116
were	O
highly	O
expressed	B-T045
in	O
treated	B-T169
follicles	B-T023
compared	B-T052
to	O
control	B-T096
;	O
however,	O
BAX protein	B-T116
was	O
downregulated	B-T044
in	O
the	O
treated	B-T169
follicles	B-T023
groups	B-T078
.	O
The	O
addition	O
of	O
ALA	B-T109
to	O
the	O
culture medium	B-T130
enhances	B-T052
secondary preantral follicles	B-T023
development	B-T040
and	O
growth	B-T042
.	O

How	O
should	O
proxies	B-T169
of	O
cognitive reserve	B-T041
be	O
evaluated	B-T058
in	O
a	O
population	B-T098
of	O
healthy	B-T080
older adults	B-T098
?	O
While	O
some	O
tools	B-T170
have	O
been	O
developed	O
to	O
estimate	B-T081
an	O
individual's	B-T098
cognitive reserve	B-T041
(	O
CR	B-T041
),	O
no	O
study	O
has	O
assessed	B-T052
the	O
adequacy	B-T080
of	O
the	O
method	O
used	O
for	O
assessing	O
these	O
CR	B-T041
proxy	B-T169
indicators.	O
Therefore,	O
we	O
aimed	O
to	O
determine	O
the	O
most	O
appropriate	B-T080
method	O
to	O
estimate	B-T081
CR	B-T041
by	O
comparing	O
two	O
approaches:	O
(1)	O
the	O
common	B-T081
assessment	B-T058
of	O
CR	B-T041
proxies	B-T169
in	O
the	O
literature	B-T170
(e.g.	O
years of education	B-T081
)	O
and	O
(2)	O
the	O
calculation	B-T052
of	O
a	O
comprehensive	B-T080
index	B-T170
based	O
on	O
most significant	B-T080
parameters	B-T033
used	O
in	O
the	O
estimation	B-T041
of	O
CR	B-T041
.	O
Data	O
on	O
CR	B-T041
proxies	B-T169
(i.e.	O
education	B-T065
,	O
occupation	B-T090
,	O
and	O
leisure activities	B-T056
)	O
were	O
obtained	O
in	O
a	O
sample	O
of	O
204	O
older adults	B-T098
.	O
Regression analyses	B-T170
were	O
used	O
to	O
develop	O
the	O
two	O
indices	B-T170
of	O
CR	B-T041
(i.e.	O
ICR-standard	B-T170
and	O
ICR-detailed	B-T170
)	O
and	O
to	O
determine	O
which	O
index	B-T170
best	O
represented	O
the	O
level	O
of	O
one's	O
CR	B-T041
.	O
The	O
ICR-standard	B-T170
was	O
calculated	B-T052
using	O
a	O
combination	B-T080
of	O
the	O
three	O
most	O
common	B-T081
measures	B-T081
of	O
reserve	B-T041
in	O
the	O
literature	B-T170
:	O
number of schooling years	B-T081
,	O
complexity	B-T080
of	O
the	O
primary	O
occupation	B-T090
,	O
and	O
amount	O
of	O
current	B-T079
participation	B-T169
in	O
stimulating	B-T070
activities	B-T052
.	O
The	O
ICR-detailed	B-T170
was	O
calculated	B-T052
using	O
the	O
most significant	B-T080
parameters	B-T033
(established	O
in	O
initial	B-T079
analyses	B-T062
)	O
of	O
CR	B-T041
:	O
highest level of education	B-T033
combined	B-T080
with	O
the	O
number	O
of	O
training courses	B-T065
,	O
last	B-T080
occupation	B-T090
,	O
and	O
amount	B-T081
of	O
current	O
participation	B-T169
in	O
social	B-T054
and	O
intellectual activities	B-T065
.	O
The	O
comparison	B-T052
of	O
both	O
indices	B-T170
showed	O
that	O
higher	O
levels	O
of	O
ICR-standard	B-T170
and	O
ICR-detailed	B-T170
were	O
associated with	B-T080
a	O
greater	B-T081
minimization	B-T080
of	O
the	O
effects of	B-T080
age	B-T032
on	O
cognition	B-T041
.	O
However,	O
the	O
ICR-detailed	B-T170
was	O
more	O
strongly	O
associated	B-T080
to	O
this	O
minimization	B-T080
than	O
the	O
ICR-standard	B-T170
,	O
suggesting	O
that	O
the	O
ICR-detailed	B-T170
best	O
reflect	O
one's	O
CR	B-T041
.	O
This	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
it	O
is	O
of	O
great	B-T081
importance	B-T080
to	O
question	O
methods	O
measuring	B-T080
CR	B-T041
proxies	B-T169
in	O
order	O
to	O
develop	O
a	O
clinical tool	B-T170
allowing	O
a	O
comprehensive	B-T080
and	O
accurate	B-T080
estimation	B-T041
of	O
CR	B-T041
.	O

Discordance	B-T077
in	O
pathology report	B-T170
after	O
central pathology review	B-T060
:	O
Implications	O
for	O
breast cancer	B-T191
adjuvant treatment	B-T061
Pathological	B-T169
predictive factors	B-T170
are	O
the	O
most	O
important	O
markers	B-T201
when	O
selecting	O
early	O
breast cancer	B-T191
adjuvant therapy	B-T061
.	O
In	O
randomized clinical trials	B-T062
the	O
variability	B-T077
in	O
pathology report	B-T170
after	O
central pathology review	B-T060
is	O
noteworthy.	O
We	O
evaluated	O
the	O
discordance	B-T077
rate	B-T081
(	O
DR	B-T081
)	O
and	O
inter-rater agreement	B-T081
between	O
local	B-T082
and	O
central	B-T082
histopathological report	B-T170
and	O
the	O
clinical	B-T080
implication	O
on	O
treatment decision	B-T033
.	O
A	O
retrospective analysis	B-T062
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast cancer tumors	B-T191
diagnosed	O
by	O
local pathologists	B-T097
and	O
subsequently	O
reviewed	B-T080
at	O
the	O
Pathology Division	B-T093
of	O
European Institute of Oncology	B-T093
.	O
The	O
inter-rater agreement	B-T081
(k)	O
between	O
local	O
and	O
central pathology	B-T091
was	O
calculated	O
for	O
Ki-67	B-T116
,	O
grading	B-T170
,	O
hormone receptors	B-T116
(	O
ER	B-T116
/	O
PgR	B-T116
)	O
and	O
HER2/neu	B-T201
.	O
The	O
Bland-Altman plots	B-T062
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	B-T116
,	O
ER	B-T116
and	O
PgR	B-T116
.	O
DR	B-T081
was	O
calculated	O
for	O
ER	B-T116
/	O
PgR	B-T116
and	O
HER2	B-T116
.	O
From	O
2007	O
to	O
2013,	O
187	O
pathology specimens	B-T031
from	O
10	O
Cancer Centers	B-T093
were	O
reviewed	B-T080
.	O
Substantial	O
agreement	O
was	O
observed	O
for	O
ER	B-T116
(k0.612;	O
95%	O
CI	B-T081
,	O
0538-0.686),	O
PgR	B-T116
(k0.659;	O
95%	O
CI	B-T081
,	O
0580-0.737),	O
Ki-67	B-T116
(k0.609;	O
95%	O
CI	B-T081
,	O
0.534-0.684)	O
and	O
grading	B-T170
(k0.669;	O
95%	O
CI	B-T081
,	O
0.569-0.769).	O
Moderate	O
agreement	O
was	O
found	O
for	O
HER2	B-T116
(k0.546;	O
95%	O
CI	B-T081
,	O
0444-0.649).	O
DR	B-T081
was	O
9.5%	O
(negativity	O
to	O
positivity)	O
and	O
31.7%	O
(positivity	O
to	O
negativity)	O
for	O
HER2	B-T116
and	O
26.2%	O
(negativity	O
to	O
positivity)	O
and	O
12.5%	O
(positivity	O
to	O
negativity)	O
for	O
ER	B-T116
/	O
PgR	B-T116
.	O
According	O
to	O
changes	O
in	O
Her2	B-T116
and	O
ER	B-T116
/	O
PgR	B-T116
status,	O
23	O
(12.2%)	O
and	O
33	O
(17.6%)	O
systemic	B-T169
prescription	B-T058
were	O
respectively	O
modified.	O
In	O
our	O
retrospective analysis	B-T062
,	O
central pathological review	B-T060
has	O
a	O
significant	O
impact	O
in	O
the	O
decision-making process	B-T058
in	O
early	O
breast cancer	B-T191
,	O
as	O
shown	O
in	O
clinical trials	B-T062
.	O
Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
provocative	O
results.	O

Implementing	B-T052
Non-Invasive	B-T169
Prenatal Diagnosis	B-T060
(	O
NIPD	B-T060
)	O
in	O
a	O
National Health Service Laboratory	B-T073
;	O
From	O
Dominant	B-T169
to	O
Recessive	B-T045
Disorders	B-T047
Our	O
UK National Health Service regional genetics laboratory	B-T073
offers	O
NIPD	B-T060
for	O
autosomal dominant	B-T045
and	O
de novo	B-T078
conditions	B-T080
(	O
achondroplasia	B-T019
,	O
thanataphoric dysplasia	B-T019
,	O
Apert syndrome	B-T019
),	O
paternal	B-T080
mutation	B-T045
exclusion	B-T169
for	O
cystic fibrosis	B-T047
and	O
a	O
range	O
of	O
bespoke tests	B-T060
.	O
NIPD	B-T060
avoids	O
the	O
risks	B-T033
associated with	B-T080
invasive testing	B-T060
,	O
making	O
prenatal diagnosis	B-T060
more	B-T081
accessible	O
to	O
families	B-T099
at	O
high	B-T080
genetic risk	B-T081
.	O
However,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	B-T079
diagnosis	B-T033
for	O
autosomal recessive diseases	B-T047
,	O
which	O
is	O
complicated	B-T169
by	O
the	O
predominance	B-T080
of	O
the	O
maternal	B-T099
mutant	B-T049
allele	B-T028
in	O
the	O
cell-free DNA	B-T114
sample	B-T077
and	O
thus	O
requires	O
a	O
variety	B-T077
of	O
different	B-T080
approaches	B-T082
.	O
Validation	B-T062
and	O
diagnostic	B-T169
implementation	B-T052
for	O
NIPD	B-T060
of	O
congenital adrenal hyperplasia	B-T047
(	O
CAH	B-T047
)	O
is	O
further	O
complicated	B-T169
by	O
presence	B-T033
of	O
a	O
pseudogene	B-T028
that	O
requires	O
a	O
different	B-T080
approach	B-T082
.	O
We	O
have	O
used	O
an	O
assay	B-T059
targeting	B-T169
approximately	B-T080
6700	O
heterozygous	B-T032
SNPs	B-T086
around	O
the	O
CAH gene	B-T028
(	O
CYP21A2	B-T028
)	O
to	O
construct	O
the	O
high-risk	B-T033
parental	B-T099
haplotypes	B-T032
and	O
tested	O
this	O
approach	B-T082
in	O
five	O
cases,	O
showing	O
that	O
inheritance	B-T081
of	O
the	O
parental	B-T099
alleles	B-T028
can	O
be	O
correctly	O
identified	B-T080
using	O
NIPD	B-T060
.	O
We	O
are	O
evaluating	O
various	O
measures	B-T081
of	O
the	O
fetal	B-T018
fraction	O
to	O
help	O
determine	O
inheritance	B-T081
of	O
parental	B-T099
mutations	B-T045
.	O
We	O
are	O
currently	O
exploring	O
the	O
utility	B-T080
of	O
an	O
NIPD	B-T060
multi-disorder panel	B-T059
for	O
autosomal recessive disease	B-T047
,	O
to	O
make	O
testing	B-T169
more	O
widely	O
applicable	B-T080
to	O
families	B-T099
with	O
a	O
variety	O
of	O
serious	B-T080
genetic conditions	B-T047
.	O

Silk fibroin	B-T121
based	O
carrier system	B-T122
for	O
delivery	B-T169
of	O
fibrinogen	B-T116
and	O
thrombin	B-T116
as	O
coagulant	B-T121
supplements	B-T169
The	O
control	B-T169
of	O
bleeding	B-T046
is	O
one	O
of	O
the	O
most	O
important	O
interventions	B-T061
after	O
a	O
traumatic injury	B-T037
.	O
Hemostatic devices	B-T121
delivering	B-UnknownType
blood clotting	B-T046
accelerating	O
agents	B-T121
such	O
as	O
fibrinogen	B-T116
are	O
increasingly	B-T169
used	O
due	O
to	O
their	O
efficacy	B-T080
and	O
their	O
ease	O
of	O
application	B-T058
.	O
In	O
the	O
present	O
study,	O
we	O
describe	O
a	O
method	B-T170
to	O
incorporate	B-T169
the	O
coagulant	B-T121
supplements	B-T169
fibrinogen	B-T116
and	O
thrombin	B-T116
in	O
silk protein	B-T121
sponges	B-T074
by	O
mixing	O
the	O
coagulants	B-T121
with	O
an	O
aqueous	B-T121
silk	B-T116
solution,	O
followed	O
by	O
molding	B-T059
,	O
freeze-drying	B-T059
and	O
water annealing	B-T059
.	O
In	O
this	O
combination	B-T080
system	B-T169
we	O
demonstrate	O
the	O
delivery	B-T169
of	O
fibrinogen	B-T116
while	O
maintaining	O
its	O
hemostatic potential	B-T042
.	O
Concentration ratios	B-T081
of	O
silk	B-T116
to	O
fibrinogen	B-T116
of	O
1.0%/2.8%,	O
2.3%/1.5%	O
and	O
3.0%/0.8%	O
were	O
used.	O
The	O
thrombin	B-T116
-induced	O
fibrin	B-T116
polymeric	B-T104
network	B-T169
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	B-T116
spongy structure	B-T082
but	O
also	O
remained	O
interconnected	B-UnknownType
to	O
the	O
silk	B-T116
,	O
providing	O
an	O
intact	B-T080
network	B-T169
.	O
The	O
mechanical characterization	B-T052
of	O
the	O
fibrinogen-releasing	B-T169
silk	B-T116
sponges	B-T074
before	O
and	O
after	O
the	O
induction	B-T169
of	O
the	O
fibrinogen	B-T116
polymerization	B-T067
demonstrated	O
that	O
the	O
fibrin	B-T116
network	B-T169
resulted	O
in	O
reduced	B-T080
permanent	B-T079
deformation	B-T169
from	O
21.1%	O
to	O
6.5%,	O
19.6%	O
to	O
5.7%	O
and	O
12.7%	O
to	O
9.4%	O
for	O
the	O
2.8%,	O
1.5%	O
and	O
0.8%	O
fibrinogen	B-T116
-containing	O
silk	B-T116
sponges	B-T074
,	O
respectively.	O
Moreover,	O
the	O
fibrin	B-T116
formation	B-T169
lead	O
to	O
a	O
more	O
linear	B-T082
elastic behavior	B-T070
over	O
longer	O
strain	O
ranges.	O
In	O
combination,	O
the	O
Calcein-AM	B-T109
/	O
PI	B-T109
stainings	B-T130
and	O
MTT assay	B-T062
results	O
indicate	O
uniform	B-T080
cell adhesion	B-T043
on	O
the	O
surface	B-T082
and	O
cytocompatibility	B-T080
of	O
the	O
silk	B-T116
/	O
fibrin	B-T116
sponges	B-T074
,	O
respectively.	O
Moreover,	O
the	O
co-delivery	B-T169
of	O
thrombin	B-T116
with	O
fibrinogen	B-T116
via	O
silk	B-T116
as	O
carrier material	B-T122
is	O
described,	O
offering	O
a	O
more	O
mechanically	B-T169
robust	B-T080
and	O
durable system	B-T080
while	O
preserving	B-T169
hemostatic features	B-T042
of	O
the	O
coagulant substances	B-T121
for	O
the	O
generation	B-T052
of	O
hemostatic devices	B-T121
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Adoptively	O
transferred	O
natural killer cells	B-T025
maintain	O
long-term	O
antitumor activity	B-T033
by	O
epigenetic imprinting	B-T045
and	O
CD4(+) T cell	B-T025
help	O
Natural killer (NK) cell	B-T025
infusions	B-T061
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	B-T101
with	O
different	O
types	O
of	O
cancer	B-T191
.	O
The	O
optimal	O
strategies	O
for	O
NK cell	B-T025
activation	B-T043
prior	O
to	O
infusion	B-T061
are	O
still	O
under	O
debate.	O
There	O
is	O
recent	O
evidence	O
that	O
NK cells	B-T025
can	O
acquire	O
long-term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	B-T116
IL-12	B-T116
/	O
15	B-T116
/	O
18	B-T116
.	O
The	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long-term	O
NK cell	B-T025
antitumor activity	B-T033
are	O
incompletely	O
under-stood.	O
Here,	O
we	O
show	O
that	O
NK cells	B-T025
preactivated	O
in vitro	B-T059
with	O
IL-12	B-T116
/	O
15	B-T116
/	O
18	B-T116
,	O
but	O
not	O
with	O
IL-15	B-T116
alone,	O
maintained	O
high	O
antitumor activity	B-T033
even	O
1 mo	B-T079
after	O
transfer	O
into	O
lymphopenic	B-T047
RAG-2(-/-)	B-T028
γc(-/-)	O
mice	B-T015
.	O
The	O
NK cell	B-T025
intrinsic	O
ability	O
for	O
IFNγ	B-T116
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding sequence	B-T114
(	O
CNS	B-T114
)	O
1	O
in	O
the	O
Ifng	B-T028
locus	B-T082
,	O
previously	O
shown	O
to	O
enhance	O
transcription	B-T045
of	O
Ifng	B-T028
.	O
In	O
a	O
xenograft melanoma mouse model	B-T050
,	O
human	B-T016
IL-12	B-T116
/	O
15	B-T116
/	O
18	B-T116
-preactivated	O
NK cells	B-T025
rejected	O
tumors	B-T191
more	O
efficiently.	O
In	O
RAG-2(-/-)	B-T028
γc(-/-)	O
mice	B-T015
,	O
co-transfer	O
of	O
CD4(+) T cells	B-T025
further	O
improved	O
the	O
long-term	O
competence	O
of	O
NK cells	B-T025
for	O
IFNγ	B-T116
production	O
that	O
was	O
dependent	O
on	O
IL-2	B-T116
.	O
CD4(+) T cell	B-T025
activation	B-T043
during	O
homeostatic proliferation	B-T043
required	O
macrophages	B-T025
and	O
further	O
promoted	O
the	O
long-term	O
NK cell	B-T025
antitumor activity	B-T033
.	O
Thus,	O
NK cells	B-T025
can	O
"remember"	O
a	O
previous	O
exposure	O
to	O
cytokines	B-T116
by	O
epigenetic imprinting	B-T045
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFNγ	B-T116
-producing	O
phenotype	B-T032
after	O
adoptive	O
transfer.	O
In	O
addition,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	B-T116
-preactivated	O
NK cells	B-T025
with	O
CD4(+) T cell	B-T025
activation	B-T043
upon	O
lymphopenic	B-T047
conditioning	O
to	O
achieve	O
long-term	O
NK cell	B-T025
effector	O
function	O
for	O
cancer immunotherapy	B-T061
.	O

Survey	B-T062
of	O
Neonatal Intensive Care Unit	B-T073
Nurse	B-T097
Attitudes	B-T041
Toward	O
Therapeutic Hypothermia Treatment	B-T061
The	O
traumatic	B-T169
experiences	O
of	O
parent	B-T099
s	O
of	O
babies	B-T100
treated with	B-T061
therapeutic hypothermia	B-T061
(	O
TH	B-T061
)	O
have	O
been	O
described.	O
No	O
research	B-T062
has	O
assessed	B-T052
neonatal intensive care unit	B-T073
(	O
NICU	B-T073
)	O
nurse	B-T097
experience	O
in	O
providing	O
care	O
to	O
hypothermic	B-T033
babies	B-T100
and	O
emotional	O
support	O
to	O
their	O
parents	B-T099
.	O
To	O
assess	O
NICU	B-T073
nurse	B-T097
attitudes	B-T041
to	O
the	O
provision	O
of	O
TH	B-T061
with	O
respect	O
to	O
perceptions	B-T041
about	O
baby	B-T100
pain	B-T184
/	O
sedation	B-T061
,	O
need	O
for	O
nurse	B-T097
and	O
parent	B-T099
education	B-T065
,	O
decision making	B-T041
about	O
initiation	B-T169
of	O
TH	B-T061
,	O
and	O
barriers	O
to	O
best	O
care.	O
A	O
survey	B-T062
was	O
electronically	O
sent	O
to	O
219	O
nurses	B-T097
at	O
2	O
affiliated	O
academic	O
level	O
III	O
NICUs	B-T073
:	O
1	O
rural	O
and	O
1	O
urban	O
location.	O
There	O
were	O
17	O
questions	O
where	O
responses	B-T170
were	O
selected	O
from	O
a	O
preset	O
list	O
and	O
7	O
opportunities	O
for	O
nurses	B-T097
to	O
provide	O
free	O
text	O
responses	B-T170
.	O
The	O
response	B-T170
rate	O
was	O
38%	O
(N	O
=	O
83).	O
Overwhelming	B-T080
similarities	O
between	O
the	O
urban	B-T093
and	O
rural institutions	B-T093
were	O
found	O
with	O
NICU	B-T073
nurses	B-T097
expressing	O
understanding	O
of	O
the	O
indications	O
for	O
initiating	O
TH	B-T061
,	O
agreement	O
that	O
TH	B-T061
improves	O
long-term	B-T079
outcomes	B-T080
and	O
that	O
the	O
benefits	O
of	O
TH	B-T061
outweigh	O
the	O
risks.	O
Nurses	B-T097
at	O
the	O
urban institution	B-T093
more	O
frequently	O
expressed	O
concerns	O
surrounding	O
inadequate	O
treatment	B-T061
of	O
baby	B-T100
pain	B-T184
/	O
sedation	B-T061
,	O
and	O
nurses	B-T097
at	O
both	O
institutions	B-UnknownType
strongly	O
emphasized	O
the	O
need	O
for	O
more	O
nurse	B-T097
and	O
parent	B-T099
education	B-T065
about	O
TH	B-T061
and	O
improved	O
timeliness	O
of	O
decision making	B-T041
for	O
initiation	B-T169
of	O
TH	B-T061
.	O
NICU	B-T073
nurses	B-T097
specifically	O
want	O
to	O
learn	O
more	O
about	O
outcomes	B-T080
of	O
babies	B-T100
after	O
treatment	B-T061
with	O
TH	B-T061
and	O
feel	O
that	O
parents	B-T099
need	O
more	O
education	B-T065
about	O
TH	B-T061
.	O
Research	B-T062
is	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
implications	O
of	O
TH treatment	B-T061
for	O
parent	B-T099
-	O
baby	B-T100
bonding.	O

Pharmacological Venous Thromboembolism Prophylaxis	B-T061
in	O
Meningioma	B-T191
Patients	B-T101
:	O
Should	O
It	O
Be	O
Earlier	O
Than	O
Clinical Practice	B-T061
?	O
We	O
read	O
the	O
report	B-T170
by	O
Çeltikçi	O
et	O
al	O
in	O
the	O
Turkish Neurosurgery	B-T073
with	O
great	O
interest.	O
In	O
this	O
single-center	O
retrospective study	B-T062
,	O
they	O
analysed	O
449	O
intracranial meningioma	B-T191
patients	B-T101
underwent	O
open surgery	B-T061
.	O
They	O
stated	O
that	O
venous thromboembolism	B-T047
(	O
VTE	B-T047
)	O
had	O
been	O
seen	O
in	O
21	O
(4.6%)	O
of	O
their	O
patients	B-T101
.	O
This	O
is	O
an	O
important	O
issue	O
because	O
VTE	B-T047
,	O
including	O
deep vein thrombosis	B-T047
(	O
DVT	B-T047
)	O
and	O
pulmonary embolism	B-T047
(	O
PE	B-T047
),	O
is	O
the	O
most	O
common	O
overall	O
complication	B-T046
in	O
meningioma surgery	B-T061
and	O
is	O
fatal	O
in	O
up	O
to	O
one	O
third	O
of	O
patients	B-T101
(2).	O
We	O
suppose	O
that	O
prophylaxis	B-T061
of	O
VTE	B-T047
is	O
most	O
effective	O
when	O
mechanical	O
and	O
pharmacological prophylaxis	B-T061
are	O
combined.	O
We	O
consider	O
that	O
there	O
key	O
some	O
practical	O
questions	O
to	O
be	O
answered	O
for	O
a	O
proper	O
clinical extrapolation	B-T169
.	O

BEST	B-T170
:	O
Next-Generation	B-T079
Biomedical Entity Search Tool	B-T170
for	O
Knowledge	B-T170
Discovery	B-T052
from	O
Biomedical Literature	B-T078
As	O
the	O
volume	B-T080
of	O
publications	B-T073
rapidly	B-T080
increases	B-T081
,	O
searching	B-T052
for	O
relevant	B-T080
information	B-T078
from	O
the	O
literature	B-T170
becomes	O
more	O
challenging	B-T033
.	O
To	O
complement	O
standard	B-T080
search engines	B-T170
such	O
as	O
PubMed	B-T170
,	O
it	O
is	O
desirable	B-T080
to	O
have	O
an	O
advanced search tool	B-T170
that	O
directly	B-T080
returns	B-T080
relevant	B-T080
biomedical	B-T080
entities	B-T071
such	O
as	O
targets	B-T074
,	O
drugs	B-T121
,	O
and	O
mutations	B-T045
rather	O
than	O
a	O
long	O
list	O
of	O
articles.	O
Some	O
existing	B-T033
tools	B-T170
submit	B-T169
a	O
query	B-T170
to	O
PubMed	B-T170
and	O
process	B-T067
retrieved	O
abstracts	B-T170
to	O
extract	O
information	B-T078
at	O
query	B-T170
time	B-T079
,	O
resulting	B-T169
in	O
a	O
slow	B-T080
response	O
time	B-T079
and	O
limited	B-T169
coverage	B-T169
of	O
only	O
a	O
fraction of	B-T081
the	O
PubMed corpus	B-T170
.	O
Other	O
tools	B-T170
preprocess	B-T066
the	O
PubMed corpus	B-T170
to	O
speed	O
up	O
the	O
response	O
time	B-T079
;	O
however,	O
they	O
are	O
not	O
constantly	B-T080
updated	B-T079
,	O
and	O
thus	O
produce	B-T169
outdated	B-T170
results	B-T169
.	O
Further,	O
most	O
existing	O
tools	B-T170
cannot	O
process	B-T067
sophisticated	B-T080
queries	B-T170
such	O
as	O
searches	B-T052
for	O
mutations	B-T045
that	O
co-occur	B-T052
with	O
query	B-T170
terms	O
in	O
the	O
literature	B-T170
.	O
To	O
address	O
these	O
problems	B-T033
,	O
we	O
introduce	B-T169
BEST	B-T170
,	O
a	O
biomedical entity search tool	B-T170
.	O
BEST	B-T170
returns	B-T080
,	O
as	O
a	O
result	B-T169
,	O
a	O
list	O
of	O
10	O
different	B-T080
types	O
of	O
biomedical	B-T080
entities	B-T071
including	B-T169
genes	B-T028
,	O
diseases	B-T047
,	O
drugs	B-T121
,	O
targets	B-T074
,	O
transcription factors	B-T116
,	O
miRNAs	B-T114
,	O
and	O
mutations	B-T045
that	O
are	O
relevant	B-T080
to	O
a	O
user's	O
query	B-T170
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	B-T170
,	O
BEST	B-T170
is	O
the	O
only	O
system	B-T169
that	O
processes	B-T067
free	O
text	B-T170
queries	B-T170
and	O
returns	B-T080
up-to-date	B-T033
results	B-T169
in	O
real time	B-T079
including	B-T169
mutation	B-T045
information	B-T078
in	O
the	O
results	B-T169
.	O
BEST	B-T170
is	O
freely	O
accessible	O
at	O
http://best.korea.ac.kr.	O

Alanine	B-T116
to	O
Serine	B-T116
Variant	B-T080
at	O
Position	O
986	O
of	O
Calcium Sensing Receptor	B-T116
and	O
Colorectal Cancer	B-T191
Risk	B-T078
With	O
regard	O
to	O
the	O
effect	B-T080
of	O
calcium	B-T121
against	O
colorectal cancer	B-T191
(	O
CRC	B-T191
)	O
and	O
considering	O
the	O
key	O
role	B-T077
of	O
calcium sensing receptor	B-T116
(	O
CaSR	B-T116
)	O
in	O
calcium homeostasis	B-T121
,	O
this	O
study	O
investigated	B-T169
whether	O
CaSR gene	B-T028
rs1801725	B-T028
or	O
A986S variant	B-T028
was	O
associated with	B-T080
susceptibility	B-T169
to	O
CRC	B-T191
risk	B-T078
.	O
This	O
study	O
was	O
conducted	O
as	O
a	O
case-control study	B-T062
and	O
303	O
cases	B-T169
with	O
CRC	B-T191
and	O
354	O
controls	B-T096
were	O
enrolled.	O
All	O
657	O
subjects	B-T096
were	O
genotyped	B-T032
for	O
CaSR gene	B-T028
A986S variant	B-T028
using	O
PCR	B-T063
-	O
RFLP method	B-T059
.	O
No significant	B-T033
difference	B-T080
was	O
observed	B-T169
for	O
the	O
A986S variant	B-T028
of	O
CaSR gene	B-T028
in	O
either	O
genotype	B-T032
or	O
allele frequencies	B-T081
between	O
the	O
cases	B-T169
and	O
the	O
controls	B-T096
and	O
this	O
lack	B-T080
of	O
difference	B-T080
remained	O
non-significant	O
even	O
after	O
adjustment	B-T169
for	O
age	B-T032
,	O
BMI	B-T201
,	O
sex	B-T032
,	O
smoking status	B-T201
,	O
and	O
family history	B-T033
of	O
CRC	B-T191
.	O
No evidence	B-T080
for	O
the	O
effect	B-T080
modification	B-T033
of	O
the	O
association	B-T080
A986S variant	B-T028
and	O
CRC	B-T191
by	O
BMI	B-T201
,	O
sex	B-T032
,	O
or	O
tumor site	B-T082
was	O
also	O
observed	B-T169
.	O
Furthermore,	O
the	O
risk	B-T078
of	O
obesity	B-T047
in	O
relation	B-T080
to	O
the	O
A986S variant	B-T028
in	O
the	O
controls	B-T096
and	O
the	O
cases	B-T169
was	O
separately	O
analyzed	B-T062
and	O
we	O
observed	O
no significant difference	B-T033
between	O
normal weight	B-T033
(	O
BMI	B-T201
<	O
25kg/m(2))	O
and	O
overweight	B-T184
/	O
obese	B-T047
(	O
BMI	B-T201
≥	O
25kg/m(2))	O
subjects	B-T096
.	O
Our	O
findings	B-T033
do	O
not	O
support	O
a	O
role	O
for	O
effect	B-T080
of	O
the	O
CaSR gene	B-T028
A986S variant	B-T028
on	O
CRC	B-T191
risk	B-T078
;	O
nevertheless,	O
this	O
finding	B-T033
requires	O
confirmation	B-T033
and	O
the	O
role	B-T077
of	O
the	O
gene variant	B-T028
in	O
carcinogenesis	B-T191
needs	O
to	O
be	O
further	O
investigated	B-T169
.	O

Treatment	B-T061
of	O
erythematotelangiectatic rosacea	B-T047
with	O
the	O
fractionation	B-T061
of	O
high-fluence	B-T079
,	O
long-pulsed	O
595-nm	O
pulsed dye laser	B-T074
Various	O
lasers	B-T073
have	O
been	O
used	O
for	O
the	O
treatment	B-T061
of	O
erythematotelangiectatic rosacea	B-T047
(	O
ETR	B-T047
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	B-T061
or	O
topical therapy	B-T061
.	O
The	O
pulsed dye lasers	B-T074
(	O
PDLs	B-T074
)	O
are	O
an	O
effective	O
option	O
for	O
ETR	B-T047
,	O
and	O
the	O
purpuragenic	B-T047
fluence	B-T079
proved	O
to	O
be	O
superior	O
until	O
now.	O
Given	O
that	O
purpura	B-T047
and	O
subsequent	O
possible	O
postinflammatory hyperpigmentation	B-T046
(	O
PIH	B-T046
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	B-T101
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	B-T033
fluence	B-T079
were	O
reported.	O
To	O
deliver	O
the	O
sufficient	O
high fluence	B-T079
of	O
a	O
PDL	B-T074
without	O
generating	O
purpura	B-T047
,	O
we	O
designed	O
the	O
fractionation	B-T061
of	O
high fluence	B-T079
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(6	O
milliseconds)	O
of	O
a	O
PDL	B-T074
in	O
succession.	O
A	O
total	O
of	O
eight	O
patients	B-T101
with	O
ETR	B-T047
were	O
enrolled	O
in	O
this	O
study;	O
all	O
patients	B-T101
were	O
treated	O
with	O
PDL	B-T074
10	O
times	O
at	O
2-week	O
intervals.	O
Erythema	B-T047
and	O
telangiectasia	B-T047
scores,	O
as	O
well	O
as	O
improvement,	O
were	O
assessed	O
by	O
two	O
physicians	B-T097
using	O
the	O
digital photographs	B-T170
.	O
Moderate-to-marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	B-T101
,	O
and	O
erythema	B-T047
and	O
telangiectasia	B-T047
scores	O
were	O
significantly	O
decreased.	O
Purpura	B-T047
and	O
PIH	B-T046
were	O
not	O
reported	O
in	O
all	O
patients	B-T101
.	O
The	O
fractionation	B-T061
of	O
high-fluence	B-T079
,	O
long-pulsed	O
595	O
nm	O
PDL	B-T074
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	B-T061
for	O
ETR	B-T047
.	O

Propulsion strategy	B-T041
in	O
the	O
gait	B-T033
of	O
primary school	B-T073
children	B-T100
;	O
the	O
effect	B-T080
of	O
age	B-T032
and	O
speed	B-T081
The	O
strategy	B-T041
used	O
to	O
generate	B-T052
power	B-T081
for	O
forward	O
propulsion	B-T040
in	O
walking	B-T056
and	O
running	B-T056
has	O
recently	O
been	O
highlighted	O
as	O
a	O
marker	B-T201
of	O
gait	B-T033
maturation	B-T040
and	O
elastic energy	B-T081
recycling	B-T169
.	O
This	O
study	B-T062
investigated	B-T058
ankle	B-T029
and	O
hip	B-T023
power	B-T081
generation	B-T052
as	O
a	O
propulsion strategy	B-T041
(	O
PS	B-T041
)	O
during	O
the	O
late stance	B-T033
/	O
early swing phases	B-T033
of	O
walking	B-T056
and	O
running	B-T056
in	O
typically developing	B-T067
(	O
TD	B-T067
)	O
children	B-T100
(15:	O
six	O
to	O
nine	O
years	B-T079
;	O
17:	O
nine	O
to	O
13	O
years	B-T079
)	O
using	O
three-dimensional	B-T082
gait analysis	B-T060
.	O
Peak	B-T080
ankle	B-T029
power	B-T081
generation	B-T052
at	O
push-off	B-T080
(	O
peakA2	B-T080
),	O
peak	B-T080
hip	B-T023
power	B-T081
generation	B-T052
in	O
early swing	B-T033
(	O
peakH3	B-T080
)	O
and	O
propulsion strategy	B-T041
(PS)	B-T041
[	O
peakA2	B-T080
/	O
(peakA2+peakH3	B-T080
)]	O
were	O
calculated	B-T169
to	O
provide	O
the	O
relative	O
contribution	O
of	O
ankle	B-T029
power	B-T081
to	O
total	O
propulsion	B-T040
.	O
Mean	B-T081
PS	B-T041
values	B-T080
decreased	B-T081
as	O
speed	B-T081
increased	B-T081
for	O
comfortable walking	B-T056
(p<0.001),	O
fast	B-T080
walking	B-T056
(p<0.001)	O
and	O
fast	B-T080
running	B-T056
(p<0.001),	O
and	O
less	O
consistently	O
during	O
jogging	B-T056
(p=0.054).	O
PS	B-T041
varied	O
with	O
age	B-T032
(p<0.001)	O
only	O
during	O
fast	B-T080
walking	B-T056
.	O
At	O
any	O
speed	B-T081
of	O
fast	B-T080
walking	B-T056
,	O
older children	B-T100
generated	B-T052
more	O
peakA2	B-T080
(p=0.001)	O
and	O
less	O
peakH3	B-T080
(p=0.001)	O
than	O
younger children	B-T100
.	O
While	O
the	O
kinetics	B-T070
of	O
running	B-T056
propulsion	B-T040
appear	O
to	O
be	O
developed	O
by	O
age	B-T032
six	O
years	B-T079
,	O
the	O
skills	B-T055
of	O
fast	B-T080
walking	B-T056
appeared	O
to	O
require	O
additional	O
neuromuscular	B-T080
maturity	B-UnknownType
.	O
These	O
findings	B-T033
support	O
the	O
concept	O
that	O
running	B-T056
is	O
a	O
skill	B-T055
that	O
matures	B-T040
early	B-T079
for	O
TD	B-T067
children	B-T100
.	O

The	O
relationship	B-T080
between	O
anthropometry	B-T062
and	O
body composition	B-T032
from	O
computed tomography	B-T060
:	O
The	O
Mediators	O
of	O
Atherosclerosis	B-T047
in	O
South Asians	B-T098
Living	B-T078
in	O
America	B-T083
Study	O
Few	O
studies	O
examine	O
the	O
relationships	B-T080
between	O
anthropometry	B-T062
and	O
the	O
body composition	B-T032
measures	O
they	O
approximate,	O
or	O
whether	O
they	O
differ	O
by	O
sex	B-T032
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	B-T080
in	O
South Asians	B-T098
living	O
in	O
the	O
US	B-T083
.	O
We	O
conducted	O
a	O
cross-sectional study	B-T062
of	O
871	O
participants	B-T098
in	O
the	O
Mediators	O
of	O
Atherosclerosis	B-T047
in	O
South Asians	B-T098
Living	B-T078
in	O
America	B-T083
(MASALA) Study	B-T062
who	O
had	O
BMI	B-T201
<	O
40	O
kg/m(2)	O
and	O
underwent	O
abdominal CT scans	B-T060
for	O
measurement	B-T169
of	O
visceral	B-T024
and	O
subcutaneous fat	B-T024
.	O
Linear regression	B-T081
was	O
used	O
to	O
model	B-T170
the	O
associations	O
between	O
anthropometric measures	B-T170
and	O
naturally	O
log-transformed	O
body composition	B-T032
measures.	O
All	O
measures	O
of	O
anthropometry	B-T062
,	O
except	O
height	B-T032
,	O
were	O
significantly	O
associated with	B-T080
visceral fat	B-T024
and	O
had	O
a	O
significant	B-T078
non-linear	O
component	O
(p	O
<	O
.05).	O
The	O
only	O
associations	O
for	O
visceral fat	B-T024
that	O
exhibited	O
significant	B-T078
heterogeneity	B-T080
by	O
sex	B-T032
were	O
waist circumference	B-T201
(%	O
difference	O
in	O
visceral fat	B-T024
slope:	O
women	B-T098
1.92,	O
men	B-T098
2.74,	O
p	O
=	O
.007	O
for	O
interaction)	O
and	O
waist-to-hip ratio	B-T032
(	O
women	B-T098
25.9,	O
men	B-T098
717.4,	O
p	O
<	O
.001).	O
Except	O
for	O
height	B-T032
,	O
all	O
measures	O
of	O
anthropometry	B-T062
were	O
significantly	O
associated with	B-T080
subcutaneous fat	B-T024
,	O
had	O
a	O
significant	B-T078
quadratic	O
component,	O
and	O
significant	B-T078
heterogeneity	B-T080
by	O
sex	B-T032
(	O
weight	B-T032
(kg):	O
2.74	O
for	O
women	B-T098
,	O
4.08	O
for	O
men	B-T098
;	O
BMI	B-T201
(kg/m(2)):	O
10.3,	O
14.0;	O
waist circumference	B-T201
(cm):	O
1.51,	O
3.36;	O
hip circumference	B-T201
(cm):	O
2.53,	O
4.50)	O
with	O
p	O
<	O
.001	O
for	O
each.	O
In	O
MASALA	O
participants	B-T098
,	O
the	O
relationships	B-T080
of	O
anthropometric measures	B-T170
with	O
visceral	B-T024
and	O
subcutaneous fat	B-T024
appear	O
similar	O
to	O
other	O
race	B-T098
/	O
ethnic groups	B-T098
,	O
but	O
with	O
weaker	B-T080
non-linearity	O
and	O
heterogeneity	B-T080
by	O
sex	B-T032
.	O
Given	O
these	O
results,	O
researchers	B-T097
should	O
consider	O
separate	O
models	O
by	O
sex	B-T032
for	O
US	O
South Asians	B-T098
when	O
approximating	O
subcutaneous fat	B-T024
or	O
when	O
using	O
waist circumference	B-T201
to	O
approximate	O
visceral fat	B-T024
.	O

Active	B-T169
packaging	B-T068
of	O
chicken meats	B-T168
with	O
modified	B-T169
atmosphere	B-T070
including	O
oxygen	B-T121
scavengers	B-T120
The	O
effects of	B-T080
modified	B-T169
atmosphere	B-T070
packaging	B-T068
(	O
MAP	B-T070
-70%	O
CO2	B-T123
/30%	O
N2	B-T123
)	O
and	O
iron	B-T121
-based	O
oxygen	B-T121
scavengers	B-T120
(	O
OS	B-T120
)	O
with	O
various	O
absorption	O
capacities	O
(Ageless(®)	O
ss100,	O
ss300,	O
and	O
ss500)	O
as	O
an	O
active	O
packaging system	B-T073
on	O
microbiological	B-T170
and	O
oxidative	B-T169
changes	B-T169
in	O
chicken thigh meats	B-T168
were	O
evaluated	O
during	O
refrigerated storage	B-T169
(4°C)	O
for	O
19	O
d	O
at	O
3-	O
day	B-T079
intervals	B-T079
.	O
Total aerobic mesophilic bacteria counts	B-T081
exceeded	O
the	O
acceptability limit	B-T081
at	O
d	O
7	O
in	O
the	O
control group	B-T096
without	O
MAP	B-T070
(	O
AIR	B-T167
),	O
and	O
at	O
d	O
19	O
in	O
MAP	B-T070
and	O
OS	B-T120
containing	O
samples	B-T167
.	O
OS	B-T120
utilization	B-T169
resulted	O
in	O
around	O
1.5	O
and	O
1.0	O
log	O
unit	O
reductions	B-T080
in	O
Pseudomonas spp.	B-T007
counts	B-T081
at	O
d	O
7	O
and	O
d	O
10	O
of	O
storage	B-T169
,	O
respectively,	O
as	O
compared	O
with	O
AIR	B-T167
and	O
MAP	B-T070
groups	B-T078
(P	O
<	O
0.05).	O
MAP	B-T070
and	O
OS	B-T120
groups	B-T078
had	O
fewer	O
(P	O
<	O
0.05)	O
coliform counts	B-T081
than	O
did	O
the	O
AIR	B-T167
group	B-T078
,	O
with	O
an	O
approximately	O
1.0	O
log	O
reduction	B-T080
observed	O
at	O
d	O
10.	O
Although	O
in	O
some	O
cases	B-T169
OS	B-T120
utilization	B-T169
resulted	O
in	O
lower	O
TBARS	B-T109
values	B-T081
and	O
carbonyl	B-T077
and	O
sulphydryl contents	B-T077
,	O
particularly	O
during	O
later	O
stages	B-T079
of	O
refrigerated storage	B-T169
as	O
compared	O
to	O
AIR	B-T167
and	O
MAP	B-T070
groups	B-T078
,	O
in	O
general,	O
these	O
effects	B-T080
were	O
not	O
always	O
apparent.	O
The	O
results	O
of	O
this	O
study	O
suggested	O
that	O
MAP	B-T070
suppressed	B-T169
microbiological growth	B-T067
and	O
retarded	O
lipid	B-T044
and	O
protein oxidation	B-T044
in	O
chicken thigh meats	B-T168
,	O
with	O
a	O
9-	O
day	B-T079
shelf-life	B-T070
extention	O
with	O
insignificant	O
effects of	B-T080
OS	B-T120
.	O

Multidrug Resistance	B-T032
of	O
Acinetobacter Baumannii	B-T007
in	O
Ladoke Akintola University Teaching Hospital	B-T073
,	O
Osogbo, Nigeria	B-T083
Acinetobacter baumannii	B-T007
is	O
a	O
ubiquitous	O
pathogen	B-T001
that	O
has	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
healthcare-associated infections	B-T046
at	O
Ladoke Akintola University Teaching Hospital	B-T073
.	O
Isolates	B-T123
were	O
assayed	B-T059
according	O
to	O
standard protocol	B-T170
.	O
The	O
isolates	B-T123
were	O
subjected	O
to	O
molecular techniques	B-T063
to	O
detect	O
blaOXA, blaTEM, blaCTX-M, and blaSHV genes	B-T028
in	O
strains	B-T007
of	O
the	O
A. baumannii	B-T007
isolates	B-T123
.	O
The	O
prevalence	O
of	O
A. baumannii	B-T007
was	O
8.5%	O
and	O
was	O
most	O
prevalent	O
among	O
patients	B-T101
in	O
the	O
age group	B-T100
51-60	O
(36%);	O
the	O
male	B-T032
patients	B-T101
(63.6%)	O
were	O
more	O
infected	B-T033
than	O
their	O
female	B-T032
counterparts.	O
Patients	B-T101
(72.7%)	O
in	O
the	O
intensive care unit	B-T073
(	O
ICU	B-T073
)	O
were	O
most	O
infected	B-T033
with	O
this	O
organism	B-T001
.	O
The	O
isolates	B-T123
showed	O
100%	O
resistance	B-T169
to	O
both	O
amikacin	B-T109
and	O
ciprofloxacin	B-T109
and	O
90.9%	O
to	O
both	O
ceftriaxone	B-T109
and	O
ceftazidime	B-T109
,	O
while	O
resistance	B-T169
to	O
the	O
other	O
antibiotics	B-T195
used	O
in	O
this	O
study	B-T062
were:	O
piperacillin	B-T109
(81.8%),	O
imipenem	B-T109
(72.7%),	O
gentamycin	B-T109
(72.2%),	O
and	O
meropenem	B-T109
(63.6%).	O
None	O
of	O
the	O
isolates	B-T123
was,	O
however,	O
resistant	B-T169
to	O
colistin	B-T109
.	O
PCR	B-T063
results	B-T034
showed	O
that	O
blaOXA, blaTEM, and blaCTX-M genes	B-T028
were	O
positive	B-T033
in	O
some	O
isolates	B-T123
,	O
while	O
blaSHV	B-T028
was	O
not detected	B-T033
in	O
any	O
of	O
the	O
isolates	B-T123
.	O
This	O
study	B-T062
has	O
revealed	B-T080
that	O
the	O
strains	B-T007
of	O
A. baumannii	B-T007
isolated	B-T169
are	O
multiple drug resistant	B-T032
.	O
Regular	O
monitoring	B-T058
,	O
judicious	O
prescription	B-T058
,	O
and	O
early	O
detection	B-T061
of	O
resistance	B-T169
to	O
these	O
antibiotics	B-T195
are,	O
therefore,	O
necessary	O
to	O
check	O
further	O
dissemination	O
of	O
the	O
organism	B-T001
.	O

Dataset	B-T170
of	O
the	O
molecular dynamics simulations	B-T066
of	O
bilayers	B-T080
consisting	O
of	O
short	O
amyloidogenic peptide	B-T116
VDSWNVLVAG	B-T087
from	O
Bgl2p-glucantransferase	B-T116
of	O
S. cerevisiae	B-T004
cell wall	B-T026
The	O
amyloidogenic peptide	B-T116
VDSWNVLVAG	B-T087
from	O
Bgl2p-glucantransferase	B-T116
of	O
Saccharomyces cerevisiae	B-T004
cell wall	B-T026
and	O
its	O
modifying	O
analog	B-T104
VESWNVLVAG	B-T087
were	O
taken	O
for	O
the	O
construction	O
of	O
four	B-T081
types	O
of	O
bilayers	B-T080
which	O
differ	O
by	O
orientation	B-T082
of	O
the	O
peptides	B-T116
in	O
the	O
layers	B-T080
and	O
of	O
the	O
layers	B-T080
relative	O
to	O
each	O
other.	O
These	O
bilayers	B-T080
were	O
used	O
as	O
starting	O
models	B-T170
for	O
the	O
molecular dynamics	B-T044
(	O
MD	B-T044
)	O
at	O
three	O
charge	O
states	O
(neutral,	O
pH3,	O
and	O
pH5).	O
The	O
changes	B-T169
of	O
the	O
fraction	O
of	O
secondary structure	B-T082
during	O
1	O
ns	O
simulations	B-T062
were	O
received	O
for	O
96	O
MD	O
trajectories.	O
The	O
data	B-T078
article	B-T170
contains	O
the	O
necessary	O
information	B-T078
for	O
the	O
construction	O
of	O
models	B-T170
of	O
β-strands	B-T082
organization	B-T169
in	O
the	O
oligomer	B-T087
structure	B-T082
.	O
These	O
results	B-T169
were	O
used	O
in	O
the	O
associated	O
research article	B-T170
"	O
Structural model	B-T073
of	O
amyloid fibrils	B-T116
for	O
amyloidogenic peptide	B-T116
from	O
Bgl2p-glucantransferase	B-T116
of	O
S. cerevisiae	B-T004
cell wall	B-T026
and	O
its	O
modifying	O
analog	B-T104
.	O
New	O
morphology	B-T080
of	O
amyloid fibrils	B-T116
"	O
(Selivanova	O
et	O
al.,	O
2016)	O
[1].	O

Straight configuration saphenous vein	B-T023
transposition	B-T061
to	O
popliteal artery	B-T023
for	O
vascular access	B-T074
The	O
saphenous vein	B-T023
is	O
commonly	O
used	O
as	O
a	O
vascular graft	B-T023
in	O
peripheral artery	B-T023
surgery	B-T061
but	O
rarely	B-T080
used	O
for	O
vascular access	B-T074
.	O
The	O
literature	B-T170
on	O
straight configuration saphenous vein	B-T023
transposition	B-T061
to	O
the	O
popliteal artery	B-T023
is	O
scarce	B-T080
.	O
Here	O
we	O
present	O
two	O
cases	O
of	O
straight configuration saphenous vein	B-T023
transposition	B-T061
to	O
the	O
popliteal artery	B-T023
for	O
vascular access	B-T074
,	O
the	O
surgical technique	B-T060
and	O
respective	O
follow-up	B-T058
.	O
Two	O
young	B-T100
men	B-T098
,	O
aged	O
29	O
and	O
36	O
years	B-T079
,	O
were	O
chosen	O
for	O
lower-limb vascular access	B-T061
for	O
hemodialysis	B-T061
.	O
The	O
first	O
patient	B-T101
was	O
paraplegic	B-T047
since	O
birth.	O
He	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper extremity vascular access	B-UnknownType
was	O
avoided.	O
The	O
second	O
patient	B-T101
presented	O
with	O
an	O
infected	B-T033
upper extremity arteriovenous graft	B-UnknownType
(AVG	B-UnknownType
)	O
and	O
after	O
multiple	O
closed	B-T169
AVFs	B-T190
he	O
had	O
no	O
more	O
available	O
arm veins	B-T023
.	O
Both	O
patients	B-T101
received	B-T080
autologous	B-T080
lower extremity	B-T023
straight configuration saphenous vein	B-T023
transpositions	B-T061
to	O
the	O
popliteal artery	B-T023
under	O
spinal anesthesia	B-T061
in	O
May	O
and	O
October	O
2012,	O
respectively.	O
Cannulation	B-T061
of	O
the	O
fistula	B-T190
was	O
allowed	O
after	O
one	O
month	B-T079
.	O
There	O
were	O
no early complications	B-T184
.	O
Slight swelling	B-T033
on	O
the	O
leg	B-T023
appeared	B-T080
in	O
one	O
of	O
the	O
patients	B-T101
.	O
Both	O
fistulas	B-T190
were	O
still	O
functional	B-T169
after	O
36	O
and	O
32	O
months	B-T079
,	O
respectively.	O
The	O
straight configuration saphenous vein	B-T023
transposition	B-T061
to	O
popliteal artery	B-T023
is	O
simple	O
to	O
perform,	O
offers	O
a	O
long and straight segment	B-T082
for	O
cannulation	B-T061
and	O
may	O
be	O
a	O
suitable	O
autologous	B-T080
vascular access	B-T074
in	O
selected	O
patients	B-T101
.	O

Inhibited	B-T080
Temperament	B-T041
and	O
Hippocampal	B-T023
Volume	B-T081
in	O
Offspring	B-T099
of	O
Parents	B-T099
with	O
Bipolar Disorder	B-T048
Prior	O
studies	O
have	O
suggested	B-T078
that	O
inhibited	B-T080
temperament	B-T041
may	O
be	O
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
for	O
developing	O
anxiety	B-T048
or	O
mood disorder	B-T048
,	O
including	O
bipolar disorder	B-T048
.	O
However,	O
the	O
neurobiological	O
basis	O
for	O
this	O
increased	B-T081
risk	B-T078
is	O
unknown	B-T080
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-T033
temperament	B-T041
in	O
symptomatic	B-T169
and	O
asymptomatic	B-T033
child	B-T100
offspring	B-T099
of	O
parents	B-T099
with	O
bipolar disorder	B-T048
(	O
OBD	B-T048
)	O
and	O
to	O
investigate	B-T169
whether	O
inhibited	B-T080
inhibited	B-T080
temperament	B-T041
is	O
associated with	B-T080
aberrant	B-T080
hippocampal	B-T023
volumes	B-T081
compared	B-T052
with	O
healthy control	B-T080
(	O
HC	B-T080
)	O
youth	B-T100
.	O
The	O
OBD	B-T048
group	B-UnknownType
consisted	O
of	O
45	O
youth	B-T100
,	O
24	O
of	O
whom	O
had	O
current	B-T079
psychiatric symptoms	B-T184
(OBD(+)s)	B-T048
and	O
21	O
without	B-T080
any	O
psychiatric symptoms	B-T184
(OBD(-)s),	O
and	O
were	O
compared	B-T052
with	O
24	O
HC	B-T080
youth	B-T100
.	O
Temperament	B-T041
characteristics	B-T080
were	O
measured	B-T080
by	O
using	O
the	O
Revised Dimensions of Temperament Survey	B-T060
.	O
Magnetic resonance imaging	B-T060
was	O
used	O
to	O
measure	B-T081
hippocampal	B-T023
volumes	B-T081
.	O
The	O
association	B-T080
between	O
temperament	B-T041
and	O
hippocampal	B-T023
volumes	B-T081
was	O
tested	B-T169
by	O
using	O
multiple regression analysis	B-T080
.	O
Compared	B-T052
with	O
the	O
OBD(-)s group	B-UnknownType
,	O
the	O
OBD(+)s	B-T048
group	B-UnknownType
had	O
significantly more	B-T081
inhibited	B-T080
inhibited	B-T080
temperament	B-T041
traits	B-T032
,	O
less	B-T080
flexibility	B-T080
,	O
more	B-T081
negative	B-T033
mood	B-T041
,	O
and	O
less	B-T080
regular	B-T080
rhythm	B-T033
in	O
their	O
daily	B-T079
routines	B-T080
.	O
In	O
contrast,	O
the	O
OBD(-)s group	B-UnknownType
was	O
more	O
likely	O
to	O
approach	O
novel	B-T080
situations	B-T080
compared	B-T052
with	O
OBD(+)s	B-T048
or	O
HC	B-T080
groups	B-UnknownType
.	O
Within	O
the	O
OBD(+)s	B-T048
group	B-UnknownType
,	O
a	O
more	O
inhibited	B-T080
inhibited	B-T080
temperament	B-T041
was	O
associated with	B-T080
smaller	O
right	B-T082
hippocampal	B-T023
volumes	B-T081
.	O
In	O
this	O
study,	O
symptomatic	B-T169
OBD	B-T048
were	O
characterized	B-T052
by	O
an	O
inhibited	B-T080
inhibited	B-T080
temperament	B-T041
that	O
was	O
inversely	B-T080
correlated	B-T080
with	O
hippocampal	B-T023
volume	B-T081
.	O
Additional	O
longitudinal studies	B-T062
are	O
needed	B-T080
to	O
determine	O
whether	O
inverse	B-T080
correlations	B-T080
between	O
hippocampal	B-T023
volume	B-T081
and	O
inhibited	B-T080
inhibited	B-T080
temperament	B-T041
represent	O
early	O
markers	B-T201
of	O
risk	B-T078
for	O
later	O
developing	O
bipolar disorder	B-T048
.	O

Dynamic	B-T169
disorder	B-T080
can	O
explain	O
non-exponential	B-T081
kinetics	B-T070
of	O
fast	O
protein mechanical unfolding	B-T043
Protein unfolding	B-T043
often	O
does	O
not	O
obey	O
a	O
simple	O
two-state	O
behavior.	O
Previous	O
single molecule force spectroscopy	B-T059
studies	B-T059
demonstrated	O
stretched exponential	B-T080
kinetics	B-T070
of	O
protein unfolding	B-T043
under	O
a	O
constant pulling force	B-T067
,	O
the	O
molecular	B-T080
origin	B-T079
of	O
which	O
remains	O
subject	O
to	O
debate.	O
We	O
here	O
set	O
out	O
to	O
extensively	O
sample	O
the	O
mechanical unfolding	B-T043
of	O
ubiquitin	B-T116
and	O
NuG2	B-T116
by	O
Molecular Dynamics (MD) simulations	B-T066
.	O
Both	O
proteins	B-T116
show	O
kinetics	B-T070
best	O
fit	O
by	O
stretched exponentials	B-T080
,	O
with	O
stretching exponents	B-T081
similar	O
to	O
those	O
found	O
in	O
experiments	B-T062
,	O
even	O
though	O
static	O
disorder	O
is	O
absent	B-T169
in	O
our	O
short	O
MD simulations	B-T066
.	O
Instead,	O
we	O
can	O
ascribe	O
non-exponential	B-T081
kinetics	B-T070
to	O
dynamic	B-T169
disorder	B-T080
,	O
due	O
to	O
conformational	B-T082
fluctuations	B-T079
on	O
the	O
nanosecond timescale	B-T079
.	O
Our	O
study	B-T062
highlights	O
the	O
general	O
role	O
of	O
dynamic	B-T169
disorder	B-T080
in	O
protein kinetics	B-T070
on	O
a	O
broad	O
range	O
of	O
time scales	B-T079
even	O
including	O
those	O
probed	O
in	O
MD simulations	B-T066
.	O

Identification	O
and	O
functional	O
analysis	O
of	O
the	O
GTPV	B-T005
bidirectional	B-T080
promoter region	B-T114
The	O
goat pox chick embryo-attenuated virus	B-T005
(	O
GTPV	B-T005
)	O
has	O
been	O
developed	O
as	O
an	O
effective	O
vaccine	B-T121
that	O
can	O
elicit	O
protective	O
immune responses	B-T042
.	O
It	O
possesses	O
a	O
large	O
genome	B-T028
and	O
a	O
robust	O
ability	O
to	O
express	B-T045
exogenous	B-T169
genes	B-T028
.	O
Thus,	O
this	O
virus	B-T005
is	O
an	O
ideal	B-T080
vector	B-T114
for	O
recombinant live vaccines	B-T116
for	O
infectious diseases	B-T047
in	O
ruminant animals	B-T015
.	O
In	O
this	O
study,	O
we	O
identified	O
a	O
novel	O
bidirectional	B-T080
promoter region	B-T114
of	O
GTPV	B-T005
through	O
screening	O
named	O
PbVV(±)	B-T114
.	O
PbVV(±)	B-T114
is	O
located	O
between	O
ETF-l	B-T116
and	O
VITF-3	B-T116
,	O
which	O
are	O
transcribed	B-T045
in	O
opposite	B-T082
directions	B-T082
.	O
A	O
new	O
recombinant goat pox virus	B-T005
(	O
rGTPV	B-T005
)	O
was	O
constructed,	O
in	O
which	O
duplicate	O
PbVV(+)	B-T114
was	O
used	O
as	O
a	O
promoter	B-T114
element	O
to	O
enhance	B-T052
Brucella OMP31	B-T116
expression	B-T045
,	O
and	O
duplicate	O
PbVV	B-T114
(-)	O
was	O
used	O
as	O
a	O
promoter element	B-T114
to	O
regulate	O
enhanced green fluorescent protein	B-T116
(	O
EGFP	B-T116
)	O
at	O
the	O
same	O
time	O
as	O
the	O
selection	O
marker.	O
PbVV(-) promoter	B-T114
activity	O
was	O
compared	O
to	O
that	O
of	O
the	O
P7.5 promoter	B-T114
of	O
vaccinia virus	B-T005
,	O
as	O
measured	O
by	O
EGFP	B-T116
expression	B-T045
;	O
the	O
fluorescence intensity	B-T059
of	O
EGFP	B-T116
expressed	B-T045
in	O
cells	B-T025
was	O
confirmed	O
by	O
fluorescence microscopy	B-T059
and	O
flow cytometry	B-T059
.	O
PbVV(+) promoter	B-T114
activity	O
was	O
measured	O
by	O
Brucella OMP31	B-T116
expression	B-T045
.	O
Interaction	O
with	O
the	O
anti-Brucella-OMP31 monoclonal antibody	B-T116
was	O
confirmed	O
by	O
western blotting	B-T059
,	O
and	O
OMP31	B-T116
mRNA expression	B-T045
was	O
assessed	O
by	O
qRT-PCR	B-T063
.	O
The	O
results	O
of	O
this	O
study	O
will	O
be	O
useful	O
for	O
the	O
further	O
study	O
of	O
effective	B-T080
multivalent vaccines	B-T121
based	O
on	O
rGTPV	B-T005
.	O
This	O
study	O
also	O
provides	O
a	O
theoretical	O
basis	O
for	O
overcoming	O
the	O
problem	O
of	O
low	O
expression	B-T045
of	O
exogenous	B-T169
genes	B-T028
.	O

Psychometric analysis	B-T060
of	O
the	O
Patient Health Questionnaire	B-T170
in	O
Danish	B-T083
patients	B-T101
with	O
an	O
implantable cardioverter defibrillator	B-T074
(The	O
DEFIB-WOMEN study	B-T062
)	O
To	O
assess	O
the	O
psychometric properties	B-T060
of	O
the	O
Patient Health Questionnaire	B-T170
(	O
PHQ-9	B-T170
),	O
a	O
measure	B-T081
of	O
depressive symptoms	B-T184
,	O
in	O
a	O
large	B-T081
Danish	B-T083
national cohort	B-T098
of	O
patients	B-T101
with	O
heart disease	B-T047
,	O
implanted	B-T061
with	O
an	O
implantable cardioverter defibrillator	B-T074
(	O
ICD	B-T074
),	O
using	O
item response theory	B-T062
.	O
A	O
prospective cohort	B-T098
of	O
patients	B-T101
implanted	B-T061
with	O
an	O
ICD	B-T074
(n=1531;	O
80.4%	O
men	B-T098
)	O
completed	O
the	O
PHQ-9	B-T170
at	O
the	O
time	O
of	O
implant	B-T061
.	O
Data	B-T078
were	O
analyzed	B-T062
using	O
two	O
item response theory models	B-T062
,	O
the	O
partial credit model	B-T081
and	O
the	O
generalized partial credit model	B-T081
.	O
The	O
analysis	B-T062
showed	O
disordered response	B-T170
thresholds	B-T080
in	O
eight	O
of	O
nine	O
items	B-T080
for	O
the	O
partial credit model	B-T081
and	O
five	O
of	O
nine	O
items	B-T080
for	O
the	O
generalized partial credit model	B-T081
,	O
indicating	O
that	O
respondents	B-T098
have	O
difficulty	B-T080
discriminating	B-T041
between	O
response	B-T170
options.	O
When	O
collapsing	O
response	B-T170
options	B-T169
2	O
and	O
3,	O
the	O
rescored	B-T081
PHQ-9	B-T170
had	O
a	O
better	O
fit	O
to	O
both	O
models	B-T081
.	O
The	O
unidimensionality	B-T080
and	O
the	O
precision	B-T080
of	O
the	O
rescored	B-T081
PHQ-9	B-T170
were	O
confirmed.	O
Items	B-T062
did	O
not	O
have	O
any	O
differential functioning	B-T169
(	O
DIF	B-T169
)	O
across	O
educational level	B-T033
,	O
age	B-T032
,	O
indication	B-T078
for	O
ICD	B-T074
implantation	B-T061
,	O
and	O
severity	B-T080
of	O
heart failure	B-T047
that	O
influence	B-T077
depression	B-T048
outcomes	B-T169
in	O
patients	B-T101
with	O
an	O
ICD	B-T074
.	O
One	O
item	O
exhibited	O
DIF	B-T169
by	O
gender	B-T032
.	O
Three	O
items	B-T062
did	O
not	O
fit	O
the	O
partial credit model	B-T081
,	O
but	O
the	O
generalized partial credit model	B-T081
could	O
be	O
fitted	O
to	O
the	O
full	O
item set	B-T062
.	O
The	O
unidimensionality	B-T080
and	O
reliability	B-T081
of	O
the	O
Danish version	B-T171
of	O
the	O
PHQ-9	B-T170
were	O
confirmed	B-T033
.	O
However,	O
the	O
associated	B-T080
consequences	B-T169
of	O
the	O
number	O
of	O
response	B-T170
options	B-T169
(3-point	O
versus	O
4-point	O
Likert scale	B-T170
)	O
need	O
to	O
be	O
further	O
examined	B-T033
for	O
the	O
PHQ-9	B-T170
both	O
as	O
a	O
screening	B-T058
tool	B-T170
and	O
outcome measure	B-T081
.	O

Geographical variations	B-T033
in	O
incidence	B-T081
,	O
management	B-T058
and	O
survival	B-T081
of	O
hepatocellular carcinoma	B-T191
in	O
a	O
Western country	B-T083
Information	B-T078
on	O
the	O
incidence	B-T081
,	O
management	B-T058
,	O
and	O
prognosis	B-T058
of	O
hepatocellular carcinoma	B-T191
(	O
HCC	B-T191
)	O
is	O
derived	O
from	O
population samples	B-T098
,	O
regional	B-T082
data	B-T078
,	O
or	O
registries	B-T170
.	O
Comprehensive	B-T080
national	B-T092
evaluations	B-T058
within	O
a	O
given	O
country	B-T083
are	O
lacking	B-T080
.	O
This	O
study	B-T062
aimed	O
to	O
investigate	B-T169
regional	B-T082
variations	B-T080
in	O
HCC	B-T191
care	B-T052
within	O
France	B-T083
.	O
This	O
observational study	B-T062
analysed	O
data	B-T078
from	O
French	B-T098
administrative databases	B-T170
for	O
more	O
than	O
30,000	O
patients	B-T101
with	O
HCC	B-T191
diagnosed	B-T033
between	O
2009	O
and	O
2012,	O
and	O
followed-up	O
until	O
2013.	O
The	O
incidence	B-T081
of	O
HCC	B-T191
,	O
access	B-T082
to	O
surgery	B-T061
,	O
and	O
survival	B-T081
,	O
at	O
both	O
the	O
national level	B-T082
and	O
two	O
geographical levels	B-UnknownType
(the	O
21	O
French regions	B-T083
and	O
95	O
French	B-T098
departments	B-T092
into	O
which	O
France	B-T083
is	O
divided administratively	B-T092
),	O
were	O
determined.	O
The	O
influence	B-T077
on	O
outcome	B-T169
of	O
the	O
structure	O
of	O
the	O
hospital	B-T073
where	O
HCC	B-T191
was	O
first	O
managed	B-T057
was	O
assessed	B-T052
.	O
At	O
the	O
national level	B-T082
,	O
the	O
median survival	B-T079
was	O
9.4	O
months	B-T079
and	O
only	O
22.8%	O
of	O
patients	B-T101
had	O
curative treatment	B-T033
.	O
There	O
were	O
marked	O
variations	O
between	O
regions	B-T083
and	O
departments	B-T092
in	O
incidence	B-T081
,	O
access	B-T082
to	O
curative treatment	B-T033
(range	O
1.3-28.8%	O
and	O
8.1-32.3%	O
respectively),	O
and	O
in	O
median survival	B-T079
(	O
range	B-T081
5.7-12.1	O
and	O
4.3-16.5	O
months	B-T079
respectively).	O
The	O
administrative type	B-T057
and	O
annual	B-T079
HCC	B-T191
-	O
caseload	B-T081
of	O
the	O
hospital	B-T073
where	O
patients	B-T101
were	O
first	O
admitted	B-T058
also	O
had	O
an	O
independent	B-T078
influence	B-T077
on	O
treatment	B-T061
and	O
survival	B-T081
.	O
Despite	O
full	O
insurance coverage	B-T078
for	O
all	O
citizens	B-T098
,	O
national	B-T092
measures	B-T081
to	O
reduce inequities	B-T080
in	O
the	O
management	B-T058
of	O
cancer patients	B-T101
,	O
standardised	O
recommendations	B-T078
for	O
HCC	B-T191
surveillance	B-T061
and	O
management	B-T058
,	O
the	O
percentage	B-T081
of	O
patients	B-T101
undergoing	O
curative treatment	B-T033
and	O
their	O
survival	B-T081
may	O
vary	O
four-fold	O
depending	O
on	O
their	O
postcode	B-T033
.	O
The	O
hospital	B-T073
in	O
which	O
patients	B-T101
are	O
first	O
managed	B-T057
has	O
a	O
clear	O
influence	B-T077
on	O
accessibility	B-T080
to	O
both	O
good care	B-T052
and	O
survival	B-T081
.	O
Population-based studies	B-T062
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	B-T083
in	O
the	O
survival	B-T081
of	O
patients	B-T101
with	O
malignancy	B-T191
.	O
As	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	B-T080
of	O
health systems	B-T064
,	O
in	O
addition	O
to	O
the	O
incidence	B-T081
of	O
the	O
cancer	B-T191
or	O
quality	B-T080
of	O
registration	B-T058
,	O
variations	O
within	O
a	O
given	O
country	B-T083
should	O
be	O
minimal	B-T080
.	O
However,	O
similar	O
to	O
between	O
countries	B-T083
differences,	O
this	O
study	B-T062
shows	O
differences	O
within	O
the	O
same	O
country	B-T083
in	O
the	O
incidence	B-T081
,	O
curative treatment	B-T033
rate	B-T081
,	O
and	O
survival	B-T081
of	O
patients	B-T101
with	O
HCC	B-T191
.	O
Evidence	B-T078
that	O
access	O
to	O
care	B-T052
and	O
survival	B-T081
varies	O
within	O
a	O
country	B-T083
can	O
strengthen the impetus	B-T080
for	O
government	B-T092
and	O
clinicians	B-T097
to	O
address	O
these	O
disparities	B-T080
.	O

Identification	B-T080
of	O
potential	O
predictive	B-T080
markers	B-T080
of	O
dexamethasone	B-T109
resistance	B-T038
in	O
childhood	B-T079
acute lymphoblastic leukemia	B-T191
Response	B-T040
to	O
dexamethasone	B-T109
(	O
DEXA	B-T109
),	O
as	O
a	O
hallmark drug	B-T121
in	O
the	O
treatment	B-T169
of	O
childhood	B-T079
acute lymphoblastic leukemia	B-T191
(	O
ALL	B-T191
),	O
is	O
one	O
of	O
the	O
pivotal	O
prognostic factors	B-T201
in	O
the	O
prediction of outcome	B-T058
in	O
ALL	B-T191
.	O
Identification	B-T080
of	O
predictive	B-T080
markers	B-T080
of	O
chemoresistance	B-T038
is	O
beneficial	O
to	O
selecting	O
of	O
the	O
best	O
therapeutic protocol	B-T061
with	O
the	O
lowest	O
effect adverse	B-T046
.	O
Hence,	O
we	O
aimed	O
to	O
find	O
drug targets	B-T074
using	O
the	O
2DE	B-T059
/	O
MS	B-T059
proteomics study	B-T059
of	O
a	O
DEXA	B-T109
-	O
resistant cell line	B-T025
(	O
REH	B-T025
)	O
as	O
a	O
model	B-T075
for	O
poor	O
DEXA	B-T109
responding	O
patients	B-T101
before	O
and	O
after	O
drug treatment	B-T061
.	O
Using	O
the	O
proteomic methods	B-T059
,	O
three	O
differentially	O
expressed	B-T045
proteins	B-T116
were	O
detected	B-T033
,	O
including	O
voltage dependent anion channel 1	B-T116
(	O
VDAC1	B-T116
),	O
sorting Nexin 3	B-T116
(	O
SNX3	B-T116
),	O
and	O
prefoldin subunit 6	B-T116
(	O
PFDN6	B-T116
).	O
We	O
observed	O
low	O
expression	B-T045
of	O
three	O
proteins	B-T116
after	O
DEXA	B-T109
treatment	B-T169
in	O
REH cells	B-T025
.	O
We	O
subsequently	O
verified	O
low	O
expression	B-T045
of	O
resulted	O
proteins	B-T116
at	O
the	O
mRNA	B-T114
level	B-T080
using	O
the	O
quantitative PCR method	B-T059
.	O
These	O
proteins	B-T116
are	O
promising	O
proteins	B-T116
because	O
of	O
their	O
important	O
roles	B-T077
in	O
drug resistance	B-T038
and	O
regulation of apoptosis	B-T043
(	O
VDAC1	B-T116
),	O
protein trafficking	B-T043
(	O
SNX3	B-T116
),	O
and	O
protein folding	B-T044
(	O
PFDN6	B-T116
).	O
Additionally,	O
mRNA	B-T114
expression level	B-T081
of	O
these	O
proteins	B-T116
was	O
assessed	B-T052
in	O
17	O
bone marrow samples	B-T031
from	O
children	B-T100
with	O
newly diagnosed	B-T080
ALL	B-T191
and	O
7	O
non-cancerous samples	B-T167
as	O
controls	B-T096
.	O
The	O
results	O
indicated	O
that	O
independent	O
of	O
the	O
molecular subtypes	B-T185
of	O
leukemia	B-T191
,	O
mRNA	B-T114
expression	B-T045
of	O
VDAC1	B-T116
,	O
SNX3	B-T116
,	O
and	O
PFDN6	B-T116
decreased	O
in	O
ALL	B-T191
samples	B-T167
compared	O
with	O
non-cancerous samples	B-T167
particularly	O
in	O
VDAC1	B-T116
(p	O
<	O
0.001).	O
Additionally,	O
mRNA	B-T114
expression	B-T045
of	O
three	O
proteins	B-T116
was	O
also	O
declined	O
in	O
high-risk	B-T033
samples	B-T167
compared	O
with	O
standard	B-T080
risk	B-T078
cases	B-T169
.	O
These	O
results	O
demonstrated	O
diagnostic	B-T169
and	O
prognostic	B-T170
value	B-T080
of	O
these	O
proteins	B-T116
in	O
childhood	B-T079
ALL	B-T191
.	O
Furthermore,	O
investigation	B-T058
of	O
protein-protein interaction	B-T044
using	O
STRING	B-T170
database	B-T170
indicated	O
that	O
these	O
proteins	B-T116
involved	O
in	O
the	O
signaling pathway	B-T044
of	O
NR3C1	B-T116
as	O
dexamethasone	B-T109
target	B-T033
.	O
In	O
conclusion,	O
our	O
proteomic study	B-T059
in	O
DEXA	B-T109
resistant	B-T038
leukemic cells	B-T025
revealed	O
VDAC1	B-T116
,	O
SNX3	B-T116
,	O
and	O
PFDN6	B-T116
are	O
promising	O
proteins	B-T116
that	O
might	O
serve	O
as	O
potential	O
biomarkers	B-T201
of	O
prognosis	B-T058
and	O
chemotherapy	B-T061
in	O
childhood	B-T079
ALL	B-T191
.	O

Benthic injury dose-response models	B-T170
for	O
polychlorinated biphenyl	B-T109
-	O
contaminated	B-T169
sediment	B-T167
using	O
equilibrium partitioning	B-T170
The	O
study	B-T062
goal	O
was	O
to	O
develop	O
a	O
sediment	B-T167
polychlorinated biphenyl	B-T109
(	O
PCB	B-T109
)	O
dose-response model	B-T170
based	O
on	O
benthic invertebrate	B-T001
effects	O
to	O
PCBs	B-T109
.	O
The	O
authors	O
used	O
an	O
equilibrium partitioning (EqP) approach	B-T170
to	O
generate	O
predicted	O
PCB	B-T109
sediment	B-T167
effect	O
concentrations	B-T081
(largely	O
Aroclor 1254	B-T109
)	O
associated	O
with	O
a	O
gradient	B-T081
of	O
toxic effects	B-T037
in	O
benthic organisms	B-T001
from	O
effects	O
observed	O
in	O
aquatic	B-T067
toxicity	B-T037
studies	B-T062
.	O
The	O
present	O
study	B-T062
differs	O
from	O
all	O
other	O
EqP	B-T170
collective	O
sediment	B-T167
investigations	O
in	O
that	O
the	O
authors	O
examined	O
a	O
common	O
dose-response	B-T038
gradient	B-T081
of	O
effects	O
for	O
PCBs	B-T109
rather	O
than	O
a	O
single,	O
protective	O
value.	O
The	O
authors	O
reviewed	O
the	O
chronic	B-T079
aquatic	B-T067
toxicity	B-T037
literature	B-T170
to	O
identify	O
measured	O
aqueous	B-T080
PCB	B-T109
concentrations	B-T081
and	O
associated	O
benthic invertebrate	B-T001
effects.	O
The	O
authors	O
control-normalized	O
the	O
aquatic	B-T067
toxic effect	B-T037
data	B-T078
and	O
expressed	O
results	O
from	O
various	O
studies	B-T062
as	O
a	O
common metric	B-T081
,	O
percent injury	B-T081
.	O
Then,	O
they	O
calculated	O
organic carbon	B-T109
-normalized	O
sediment	B-T167
PCB	B-T109
concentrations	B-T081
(mg/kg	O
organic carbon	B-T109
)	O
from	O
the	O
aqueous	B-T080
PCB	B-T109
toxicity	B-T037
data set	B-T170
using	O
EqP	B-T170
theory	O
based	O
on	O
the	O
US Environmental Protection Agency's	B-T092
(	O
EPIWEB 4.1	B-T073
)	O
derivation	O
of	O
the	O
water-organic carbon partition coefficient	B-T081
(	O
KOC	B-T081
).	O
Lastly,	O
the	O
authors	O
constructed	O
a	O
nonlinear	O
dose-response numerical model	B-T170
for	O
these	O
synoptic	O
sediment	B-T167
PCB	B-T109
concentrations	B-T081
and	O
biological effects	B-T070
:	O
Y	O
=	O
100/1	O
+	O
10(([logEC50-logX]	O
×	O
[Hill	O
slope]))	O
(EC50	O
=	O
median effective concentration	B-T081
).	O
These	O
models	B-T170
were	O
used	O
to	O
generate	O
"look-up"	O
tables	B-T170
reporting	O
percent injury	B-T081
in	O
benthic biota	B-T070
for	O
a	O
range	O
of	O
Aroclor	B-T109
-specific	O
sediment	B-T167
concentrations	B-T081
.	O
For	O
example,	O
the	O
model	B-T170
using	O
the	O
EPIWEB	B-T073
KOC	B-T081
estimate	O
predicts	O
mean benthic injury	B-T081
of	O
23.3%,	O
46.0%,	O
70.6%,	O
87.1%,	O
and	O
95%	O
for	O
hypothetical	O
sediment	B-T167
concentrations	B-T081
of	O
1	O
mg/kg,	O
2	O
mg/kg,	O
4	O
mg/kg,	O
8	O
mg/kg,	O
and	O
16	O
mg/kg	O
dry	O
weight	O
of	O
Aroclor 1254	B-T109
,	O
respectively	O
(at	O
1%	O
organic carbon	B-T109
).	O
The	O
authors	O
recommend	O
the	O
model	B-T170
presented	O
for	O
screening	O
but	O
suggest,	O
when	O
possible,	O
determining	O
a	O
site-specific	B-T082
KOC	B-T081
that,	O
along	O
with	O
the	O
tables	B-T170
and	O
equations	B-T077
,	O
allows	O
users	O
to	O
create	O
their	O
own	O
protective	O
dose-response	B-T038
sediment	B-T167
concentration	B-T081
.	O
Environ	O
Toxicol	O
Chem	O
2017;36:1311-1329.	O
©	O
2016	O
SETAC.	O

Extract of Caulis Spatholobi	B-T123
Caulis Spatholobi	B-T002
,	O
a	O
novel	O
blocker	B-T121
targeting	O
tumor cell	B-T025
tumor cell ‑induced platelet aggregation	B-T043
,	O
inhibits	O
breast cancer	B-T191
metastasis	B-T191
Metastasis	B-T191
of	O
breast cancer	B-T191
is	O
the	O
vital	O
step	O
for	O
malignant progression	B-T191
.	O
During	O
such	O
a	O
process,	O
hematogenous metastasis	B-T191
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer cells	B-T025
.	O
A	O
platelet	B-T025
,	O
contributes	O
to	O
hypercoagulable state	B-T047
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	B-T169
in	O
the	O
coagulation	B-T042
system	B-T169
for	O
supporting	O
metastasis	B-T191
.	O
Therefore,	O
the	O
relationship	O
of	O
a	O
platelet	B-T025
and	O
a	O
tumor cell	B-T025
plays	O
a	O
critical	O
role	O
in	O
tumor cell	B-T025
metastasis	B-T191
.	O
Consequently,	O
inhibiting	O
tumor cell	B-T025
tumor cell ‑induced platelet aggregation	B-T043
(	O
TCIPA	B-T043
)	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	B-T044
of	O
tumor metastasis	B-T191
such	O
as	O
aspirin	B-T109
(	O
ASA	B-T109
).	O
Under	O
such	O
circumstance,	O
here	O
we	O
report	O
that,	O
through	O
dissociating	O
the	O
tumor‑platelet (T‑P) complex,	B-T026
80%	O
ethanol	B-T109
extracts of Caulis Spatholobi	B-T123
Caulis Spatholobi	B-T002
(	O
SET	B-T123
)	O
successfully	O
alleviated	O
the	O
hypercoagulation state	B-T047
,	O
thereby	O
reducing	O
tumor metastasis	B-T191
and	O
improving	O
the	O
prospects	O
of	O
survival	B-T052
in	O
breast	B-T023
cancer cell	B-T025
model	B-T075
.	O
Through	O
MTT	B-T059
and	O
anti‑aggregation assay stimulated by ADP	B-T059
,	O
we	O
detected	O
the	O
optimum treatment time	B-T079
and	O
the	O
optimum dose	B-T081
of	O
SET	B-T123
.	O
By	O
using	O
confocal microscopy	B-T059
,	O
we	O
observed	O
that	O
SET	B-T123
can	O
strongly	O
block	O
the	O
formation	B-T169
of	O
T‑P complex	B-T026
i	O
n vitro	B-T080
.	O
The	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
FACS analysis	B-T059
.	O
The	O
fluorescent value	B-T081
of	O
T‑P complex	B-T026
was	O
obviously	O
decreased	O
in	O
the	O
drug‑treated groups.	B-T078
In vivo	B-T082
,	O
4T1 cells	B-T025
were	O
injected	B-T061
through	O
the	O
mouse	B-T015
tail vein	B-T023
for	O
dynamic visualization	B-T060
by	O
small animal imaging system	B-T073
.	O
The	O
metastatic intensity	B-T081
was	O
quantified	O
and	O
the	O
survival curve	B-T081
was	O
analyzed	B-T062
.	O
Additionally,	O
general	O
observation	O
and	O
hematoxylin and eosin (H&E) staining	B-T059
of	O
lung	B-T023
tissue	B-T024
was	O
performed.	O
SET	B-T123
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	B-T052
of	O
metastasis	B-T191
and	O
increasing	O
the	O
survival rate	B-T081
of	O
mice	B-T015
.	O
For	O
the	O
molecular mechanism	B-T044
study	B-T062
of	O
anti‑TCIPA	B-T059
,	O
zymography	B-T062
and	O
R	O
T‑PCR assay	B-T063
preliminarily	O
revealed	O
the	O
molecular mechanism	B-T044
of	O
SET	B-T123
in	O
the	O
regulation	O
of	O
P	O
‑T interaction	B-T043
.	O
Collectively,	O
through	O
drug efficacy	B-T080
identification	O
and	O
pharmacological	B-T169
revealing,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	B-T023
metastasis	B-T191
by	O
suppressing	O
TCIPA	B-T043
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	B-T080
cancer treatment	B-T061
.	O

Generalized Epilepsy	B-T047
and	O
Myoclonic Seizures	B-T047
in	O
22q11.2 Deletion Syndrome	B-T047
Prompted	O
by	O
the	O
observations	O
of	O
juvenile myoclonic epilepsy	B-T047
(	O
JME	B-T047
)	O
in	O
22q11.2 deletion syndrome	B-T047
(	O
22q11DS	B-T047
)	O
and	O
recurrent copy number variants	B-T086
in	O
genetic	B-T169
generalized epilepsy	B-T047
(	O
GGE	B-T047
),	O
we	O
searched	O
for	O
further	O
evidence	O
supporting	O
a	O
possible	O
correlation	B-T080
of	O
22q11DS	B-T047
with	O
GGE	B-T047
and	O
with	O
myoclonic seizures	B-T047
.	O
Through	O
routine diagnostics	B-T060
,	O
we	O
identified	O
3	O
novel	O
individuals	B-T098
with	O
the	O
seemingly	O
uncommon	B-T080
combination	B-T080
of	O
22q11DS	B-T047
and	O
JME	B-T047
.	O
We	O
subsequently	O
screened	B-T058
the	O
literature	B-T170
for	O
reports	B-T170
focussing	O
on	O
the	O
epilepsy phenotype	B-T032
in	O
22q11DS	B-T047
.	O
We	O
additionally	O
screened	B-T058
a	O
database	B-T170
of	O
173	O
22q11DS	B-T047
patients	B-T101
and	O
identified	O
a	O
fourth	O
individual	B-T098
with	O
JME	B-T047
as	O
well	O
as	O
2	O
additional	O
cases	B-T169
with	O
GGE	B-T047
.	O
We	O
describe	O
6	O
novel	B-T080
and	O
22	O
published	B-T057
cases	B-T169
with	O
co-occurrence	B-T033
of	O
22q11DS	B-T047
and	O
GGE	B-T047
.	O
In	O
many	O
patients	B-T101
,	O
GGE	B-T047
was	O
associated with	B-T080
myoclonic seizures	B-T047
allowing	O
for	O
a	O
diagnosis	B-T033
of	O
JME	B-T047
in	O
at	O
least	O
6	O
individuals	B-T098
.	O
Seventeen	O
of	O
the	O
173	O
22q11DS	B-T047
cases	B-T169
(10%)	O
had	O
a	O
diagnosis	B-T033
of	O
either	O
focal	B-T047
or	O
generalized epilepsy	B-T047
.	O
In	O
these	O
cases	B-T169
,	O
focal epilepsy	B-T047
could	O
often	O
be	O
attributed	O
to	O
syndrome-associated hypocalcaemia	B-T047
,	O
cerebral bleeds	B-T033
,	O
or	O
structural brain anomalies	B-T033
.	O
However,	O
the	O
cause	O
of	O
GGE	B-T047
remained	O
unclear.	O
In	O
this	O
study	B-T062
,	O
we	O
describe	O
and	O
review	O
28	O
individuals	B-T098
with	O
22q11DS	B-T047
and	O
GGE	B-T047
(especially	O
JME	B-T047
),	O
showing	O
that	O
both	O
disorders	B-T047
frequently co-occur	B-T033
.	O
Compared	O
to	O
the	O
reported prevalence	B-T081
of	O
15-21%,	O
in	O
our	O
case series	B-T062
only	O
10%	O
of	O
22q11DS	B-T047
individuals	B-T098
were	O
found	O
to	O
have	O
epilepsy	B-T047
,	O
often	O
GGE	B-T047
.	O
Since	O
22q11.2	B-T026
does	O
not	O
contain	O
convincing	O
GGE	B-T047
candidate genes	B-T028
,	O
we	O
discuss	O
the	O
possibility	O
of	O
an	O
aetiological	B-T169
correlation	B-T080
through	O
a	O
possibly	O
disturbed	O
interaction	O
with	O
the	O
GABAB receptor	B-T116
.	O

Normal Levels	B-T080
of	O
Urinary	B-T031
CC16 Protein	B-T116
.	O
Comments on Beamer et al. Association	B-T170
of	O
Children's	B-T100
Urinary	B-T031
CC16	B-T116
Levels	B-T059
with	O
Arsenic Concentrations	B-T059
in	O
Multiple Environmental Media	B-T077
.	O
Int.	O
J.	O
Environ.	O
Res.	O
Public	O
Health	O
2016,	O
13,	O
521	O
In	O
1937,	O
Max Clara	B-T016
described	O
a	O
new	O
type	O
of	O
cell	B-T025
in	O
the	O
human	B-T016
lung	B-T023
,	O
which	O
was	O
later	O
determined	O
to	O
be	O
an	O
exocrine secretory cell type containing granules	B-T026
composed	O
of	O
proteins	B-T116
[1].[...].	O

Diverse	O
Colletotrichum species	B-T004
cause	O
anthracnose	B-T047
of	O
tea plants	B-T002
(	O
Camellia sinensis (L.) O. Kuntze	B-T002
)	O
in	O
China	B-T083
Anthracnose	B-T047
caused	O
by	O
Colletotrichum	B-T004
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	B-T047
that	O
can	O
afflict	O
Camellia sinensis	B-T002
.	O
However,	O
research	B-T062
on	O
the	O
diversity	B-T080
and	O
geographical distribution	B-T079
of	O
Colletotrichum	B-T004
in	O
China	B-T083
remain	O
limited.	O
In	O
this	O
study	B-T062
,	O
106	O
Colletotrichum	B-T004
isolates	B-T123
were	O
collected	B-T169
from	O
diseased	B-T047
leaves	B-T002
of	O
Ca. sinensis	B-T002
cultivated	O
in	O
the	O
15	O
main	O
tea production	B-T090
provinces	B-T083
in	O
China	B-T083
.	O
Multi-locus phylogenetic analysis	B-T062
coupled	O
with	O
morphological identification	B-T059
showed	O
that	O
the	O
collected	B-T169
isolates	B-T123
belonged	O
to	O
11	O
species	B-T185
,	O
including	O
6	O
known	O
species	B-T185
(	O
C. camelliae	B-T004
,	O
C. cliviae	B-T004
,	O
C. fioriniae	B-T004
,	O
C. fructicola	B-T004
,	O
C. karstii	B-T004
,	O
and	O
C. siamense	B-T004
),	O
3	O
new	O
record species	B-T185
(	O
C. aenigma	B-T004
,	O
C. endophytica	B-T004
,	O
and	O
C. truncatum	B-T004
),	O
1	O
novel	O
species	B-T185
(	O
C. wuxiense	B-T004
),	O
and	O
1	O
indistinguishable	O
strain	B-T001
,	O
herein	O
described	O
as	O
Colletotrichum sp.	B-T004
Of	O
these	O
species	B-T185
,	O
C. camelliae	B-T004
and	O
C. fructicola	B-T004
were	O
the	O
dominant	O
species	B-T185
causing	O
anthracnose	B-T047
in	O
Ca. sinensis	B-T002
.	O
In	O
addition,	O
our	O
study	B-T062
provided	O
further	O
evidence	B-T078
that	O
phylogenetic analysis	B-T062
using	O
a	O
combination	O
of	O
ApMat and GS sequences	B-T086
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	B-T169
relationships	B-T080
within	O
the	O
C. gloeosporioides	B-T004
species complex	B-T185
.	O
Finally,	O
pathogenicity	B-T032
tests	B-T059
suggested	O
that	O
C. camelliae	B-T004
,	O
C. aenigma	B-T004
,	O
and	O
C. endophytica	B-T004
are	O
more	O
invasive	B-T080
than	O
other	O
species	B-T185
after	O
the	O
inoculation	B-T061
of	O
the	O
leaves	B-T002
of	O
Ca. sinensis	B-T002
.	O

ATP	B-T114
release	B-T169
from	O
bladder urothelium	B-T024
and	O
serosa	B-T024
in	O
a	O
rat	O
model	B-T050
of	O
partial bladder outlet obstruction	B-T047
Overactive bladder	B-T047
is	O
one	O
of	O
the	O
major	O
health problem	B-T033
especially	O
in	O
elderly people	B-T098
.	O
Adenosine triphosphate	B-T114
(	O
ATP	B-T114
)	O
is	O
released	B-T169
from	O
urinary bladder cells	B-T025
and	O
acts	O
as	O
a	O
smooth muscle contraction	B-T042
and	O
sensory signal	B-T041
in	O
micturition	B-T040
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
ATP	B-T114
release	O
in	O
the	O
pathophysiology	B-T046
of	O
overactive bladder	B-T047
.	O
To	O
assess	O
the	O
relationship	O
between	O
ATP	B-T114
and	O
overactive bladder	B-T047
,	O
we	O
used	O
a	O
partial bladder outlet obstruction	B-T047
(	O
pBOO	B-T047
)	O
model	B-T050
in	O
rats	B-T015
.	O
The	O
bladder	B-T023
caused	O
several	O
changes	O
by	O
pBOO	B-T047
:	O
An	O
increase	B-T169
in	O
bladder	B-T023
weight	B-T081
,	O
hypertrophy	B-T046
of	O
sub-urothelium	B-T024
and	O
sub-serosal area	B-T024
,	O
and	O
frequent	O
non	B-T169
-	O
voiding bladder contraction	B-T042
during	O
urine	B-T031
storage.	O
Basal	B-T082
ATP	B-T114
release	O
from	O
urothelium	B-T024
and	O
serosa	B-T024
of	O
pBOO	B-T047
rats	B-T015
was	O
significantly	O
higher	O
than	O
that	O
of	O
normal	O
rats	B-T015
.	O
Distention	B-T033
induced	O
ATP	B-T114
release	B-T169
from	O
urothelium	B-T024
of	O
normal	O
and	O
pBOO	B-T047
rats	B-T015
had	O
no	O
significant	O
change.	O
However,	O
distention	B-T033
-	O
induced	B-T169
ATP	B-T114
release	B-T169
from	O
serosa	B-T024
of	O
pBOO	B-T047
rats	B-T015
was	O
higher	O
than	O
that	O
of	O
normal.	O
These	O
findings	O
may	O
identify	O
ATP	B-T114
especially	O
released	B-T169
from	O
serosa	B-T024
as	O
one	O
of	O
causes	O
of	O
non	B-T169
-	O
voiding contractions	B-T042
and	O
overactive bladder	B-T047
symptoms	B-T184
.	O

Determining	O
putative vectors	B-T008
of	O
the	O
Bogia Coconut Syndrome	B-T047
phytoplasma	B-T007
using	O
loop-mediated isothermal amplification	B-T059
of	O
single-insect feeding media	B-T168
Phytoplasmas	B-T007
are	O
insect vectored mollicutes	B-T007
responsible	O
for	O
disease	B-T047
in	O
many	O
economically	O
important	O
crops	B-T002
.	O
Determining	O
which	O
insect species	B-T204
are	O
vectors	B-T008
of	O
a	O
given	O
phytoplasma	B-T007
is	O
important	O
for	O
managing	O
disease	B-T047
but	O
is	O
methodologically	O
challenging	O
because	O
disease-free plants	B-T002
need	O
to	O
be	O
exposed	O
to	O
large	O
numbers	O
of	O
insects	B-T204
,	O
often	O
over	O
many	O
months	B-T079
.	O
A	O
relatively	O
new	O
method	O
to	O
detect	O
likely	O
transmission	B-T070
involves	O
molecular testing	B-T059
for	O
phytoplasma	B-T007
DNA	B-T114
in	O
sucrose	B-T109
solution	B-T167
that	O
insects	B-T204
have	O
fed	B-T052
upon.	O
In	O
this	O
study	B-T062
we	O
combined	O
this	O
feeding medium method	B-T059
with	O
a	O
loop-mediated isothermal amplification (LAMP) assay	B-T059
to	O
study	O
627	O
insect	B-T204
specimens	B-T077
of	O
11	O
Hemiptera taxa	B-T204
sampled	O
from	O
sites	O
in	O
Papua New Guinea	B-T083
affected	O
by	O
Bogia coconut syndrome	B-T047
(	O
BCS	B-T047
).	O
The	O
LAMP assay	B-T059
detected	O
phytoplasma	B-T007
DNA	B-T114
from	O
the	O
feeding solution	B-T168
and	O
head	B-T029
tissue	B-T024
of	O
insects	B-T204
from	O
six	O
taxa	B-T077
belonging	O
to	O
four	O
families:	O
Derbidae	B-T204
,	O
Lophopidae	B-T204
,	O
Flatidae	B-T204
and	O
Ricaniidae	B-T204
.	O
Two	O
other	O
taxa	B-T077
yielded	O
positives	O
only	O
from	O
the	O
heads	B-T029
and	O
the	O
remainder	O
tested	O
negative.	O
These	O
results	O
demonstrate	O
the	O
utility	O
of	O
combining	O
single-insect feeding medium tests	B-T059
with	O
LAMP assays	B-T059
to	O
identify	O
putative vectors	B-T008
that	O
can	O
be	O
the	O
subject	O
of	O
transmission	B-T070
tests	B-T169
and	O
to	O
better	O
understand	O
phytoplasma	B-T007
pathosystems	B-T091
.	O

Non-toxigenic	B-T169
environmental	B-T082
Vibrio cholerae O1	B-T007
strain	B-T001
from	O
Haiti	B-T083
provides	B-T052
evidence	B-T078
of	O
pre-pandemic	B-T067
cholera	B-T047
in	O
Hispaniola	B-T083
Vibrio cholerae	B-T007
is	O
ubiquitous	B-T080
in	O
aquatic environments	B-T067
,	O
with	O
environmental	B-T082
toxigenic	B-T170
V. cholerae O1	B-T007
strains	B-T001
serving	B-T081
as	O
a	O
source	B-T033
for	O
recurrent	B-T079
cholera epidemics	B-T047
and	O
pandemic	B-T067
disease	B-T047
.	O
However,	O
a	O
number	O
of	O
questions	O
remain	O
about	O
long-term	B-T079
survival	B-T169
and	O
evolution	O
of	O
V. cholerae	B-T007
strains	B-T001
within	O
these	O
aquatic environmental	B-T067
reservoirs	B-T083
.	O
Through	O
monitoring	B-T057
of	O
the	O
Haitian	B-T083
aquatic environment	B-T067
following	O
the	O
2010	O
cholera epidemic	B-T047
,	O
we	O
isolated	B-T169
two	B-T081
novel	B-T080
non-toxigenic	B-T169
(	O
ctxA/B	B-T028
-	O
negative	B-T033
)	O
Vibrio cholerae O1	B-T007
.	O
These	O
two	B-T081
isolates	B-T123
underwent	O
whole-genome sequencing	B-T063
and	O
were	O
investigated	B-T169
through	B-T169
comparative	B-T052
genomics	B-T091
and	O
Bayesian coalescent analysis	B-T081
.	O
These	O
isolates	B-T123
cluster	O
in	O
the	O
evolutionary	O
tree	B-T002
with	O
strains	B-T001
responsible	O
for	O
clinical	B-T080
cholera	B-T047
,	O
possessing	B-T078
genomic components	B-T028
of	O
6(th)	O
and	O
7(th)	O
pandemic	B-T067
lineages	B-T077
,	O
and	O
diverge	B-T080
from	O
"	O
modern	B-T079
"	O
cholera	B-T047
strains	B-T001
around	O
1548	O
C.E.	O
[95%	O
HPD:	O
1532-1555].	O
Vibrio Pathogenicity Island	B-T028
(VPI)-1	B-T028
was	O
present	B-T033
;	O
however,	O
SXT/R391-family ICE	B-T028
and	O
VPI-2	B-T028
were	O
absent	B-T169
.	O
Rugose phenotype	B-T032
conversion	B-T169
and	O
vibriophage	B-T005
resistance	B-T169
evidenced	B-T169
adaption	O
for	O
persistence	B-T041
in	O
aquatic environments	B-T067
.	O
The	O
identification	B-T080
of	O
V. cholerae O1	B-T007
strains	B-T001
in	O
the	O
Haitian	B-T083
environment	B-T067
,	O
which	O
predate	O
the	O
first	O
reported	B-T062
cholera	B-T047
pandemic	B-T067
in	O
1817,	O
broadens	O
our	O
understanding	B-T041
of	O
the	O
history	B-T169
of	O
pandemics	B-T067
.	O
It	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
and	O
similar	B-T080
environmental	B-T067
strains	B-T001
could	O
acquire	B-T052
virulence	B-T080
genes	B-T028
from	O
the	O
2010	O
Haitian	B-T083
epidemic	B-T067
clone	B-T024
,	O
including	O
the	O
cholera toxin	B-T116
producing	B-T169
CTXϕ	B-T116
.	O

The	O
Pre-Eclampsia	B-T046
Ontology	B-T077
:	O
A	O
Disease Ontology	B-T077
Representing	O
the	O
Domain	O
Knowledge	O
Specific	O
to	O
Pre-Eclampsia	B-T046
Pre-eclampsia	B-T046
(	O
PE	B-T046
)	O
is	O
a	O
clinical syndrome	B-T185
characterized	O
by	O
new-onset hypertension	B-UnknownType
and	O
proteinuria	B-T033
at	O
≥20 weeks of gestation	B-T033
,	O
and	O
is	O
a	O
leading	O
cause	B-T169
of	O
maternal	B-T033
and	O
perinatal morbidity	B-T046
and	O
mortality	B-T081
.	O
Previous	O
studies	O
have	O
gathered	O
abundant	B-T080
data	B-T078
about	O
PE	B-T046
such	O
as	O
risk factors	B-T033
and	O
pathological findings	B-T169
.	O
However,	O
most	O
of	O
these	O
data	B-T078
are	O
not	O
semantically	O
structured.	O
Clinical data	B-T170
on	O
PE	B-T046
patients	B-T101
are	O
often	O
generated	O
with	O
semantic	B-T078
heterogeneity	B-T080
such	O
as	O
using	O
disparate terminology	B-T170
to	O
describe	O
the	O
same	O
phenomena	B-T067
.	O
In	O
clinical studies	B-T062
,	O
interoperability	O
of	O
heterogenic	B-T078
clinical data	B-T170
is	O
required	O
in	O
various	O
situations	B-T169
.	O
In	O
such	O
a	O
situation	B-T169
,	O
it	O
is	O
necessary	O
to	O
develop	O
an	O
interoperable	O
and	O
standardized	O
semantic	B-T078
framework	B-T077
to	O
research	B-T062
the	O
pathology	B-T169
of	O
PE	B-T046
more	O
comprehensively	O
and	O
to	O
achieve	O
interoperability	O
of	O
heterogenic	B-T078
clinical data	B-T170
of	O
PE	B-T046
patients	B-T101
.	O
In	O
this	O
study,	O
we	O
developed	O
an	O
ontology	B-T077
representing	O
clinical features	B-T201
,	O
treatments	B-T061
,	O
genetic factors	B-T080
,	O
environmental factors	B-T080
,	O
and	O
other	O
aspects	B-T080
of	O
the	O
current	O
knowledge	O
in	O
the	O
domain	O
of	O
PE	B-T046
.	O
We	O
call	O
this	O
pre-eclampsia	B-T046
ontology	B-T077
"	O
PEO	B-T077
".	O
To	O
achieve	O
interoperability	O
with	O
other	O
ontologies	B-T077
,	O
the	O
core	O
structure	O
of	O
PEO	B-T077
was	O
compliant	O
with	O
the	O
hierarchy	O
of	O
the	O
Basic Formal Ontology	B-T090
(	O
BFO	B-T090
).	O
The	O
PEO	B-T077
incorporates	O
a	O
wide	O
range	O
of	O
key	O
concepts	B-T078
and	O
terms	B-T079
of	O
PE	B-T046
from	O
clinical	B-T062
and	O
biomedical research	B-T062
in	O
structuring	O
the	O
knowledge	O
base	O
that	O
is	O
specific	O
to	O
PE	B-T046
;	O
therefore,	O
PEO	B-T077
is	O
expected	O
to	O
enhance	B-T052
PE	B-T046
-specific	O
information retrieval	B-T057
and	O
knowledge	O
discovery	O
in	O
both	O
clinical	B-T062
and	O
biomedical research	B-T062
fields	B-UnknownType
.	O

Predictors	B-T078
and	O
Moderators	B-T080
of	O
Spontaneous	B-T169
Pretend Play	B-T041
in	O
Children	B-T100
with	O
and	O
without	O
Autism Spectrum Disorder	B-T048
Although	O
pretend play	B-T041
has	O
long	O
been	O
linked	O
to	O
children's	B-T100
normative	B-T080
cognitive development	B-T041
,	O
inconsistent	B-T080
findings	B-T033
call	O
for	O
greater	O
rigor	O
in	O
examining	B-T169
this	O
relation	B-T080
(Lillard	O
et	O
al.,	O
2013).	O
Spontaneous	B-T169
pretend play	B-T041
is	O
often	O
impacted	O
in	O
atypical	B-T080
development	B-T039
,	O
notably	O
in	O
autism spectrum disorder	B-T048
(	O
ASD	B-T048
).	O
Since	O
ASD	B-T048
traits	B-T032
exist	O
along	O
a	O
continuum	B-T082
in	O
the	O
general population	B-T098
,	O
investigating	B-T169
how	O
pretend play	B-T041
varies	O
across	O
the	O
range	O
of	O
ASD	B-T048
symptoms	B-T184
by	O
indexing	O
variations	B-T080
in	O
ASD	B-T048
traits	B-T032
in	O
both	O
typically	O
developing	O
and	O
ASD	B-T048
populations	B-T098
may	O
provide	O
insight	O
into	O
how	O
ASD	B-T048
symptoms	B-T184
may	O
influence	O
the	O
relation	B-T080
between	O
pretend play	B-T041
and	O
associated	O
processes	O
in	O
cognitive development	B-T041
.	O
This	O
study	B-T062
used	O
rigorous observational methods	B-T062
to	O
assess	O
spontaneous	B-T169
pretend play	B-T041
.	O
Specifically,	O
5-	O
min	B-T079
free-play sessions	B-T058
with	O
two	O
discrete	B-T080
toy	B-T073
sets	O
were	O
double-coded	O
by	O
blinded coders	B-T073
(coder	O
assignment	O
counterbalanced).	O
Key	O
facets	O
of	O
pretense development	B-T041
[	O
attribution of pretend properties	B-T080
(	O
APP	B-T080
),	O
object substitution	B-T052
(	O
OS	B-T052
),	O
imaginary objects	B-T041
]	O
were	O
examined	B-T169
.	O
These	O
facets	O
of	O
pretend play	B-T041
production	B-T041
were	O
then	O
analyzed	B-T062
in	O
relation	B-T080
to	O
ASD	B-T048
symptoms	B-T184
,	O
as	O
well	O
as	O
plausible,	O
long-theorized	O
correlates	O
[	O
theory of mind	B-T078
(	O
ToM	B-T078
),	O
verbal ability	B-T041
,	O
familiarity	B-T041
,	O
and	O
interest	B-T041
in	O
specific	B-T080
toys	B-T073
].	O
Forty	O
children	B-T100
(Mage	O
=	O
6;5,	O
SDage	O
=	O
1.45;	O
29	O
males	B-T032
),	O
six	O
of	O
whom	O
met	O
the	O
threshold	B-T080
for	O
ASD	B-T048
diagnosis	B-T033
via	O
parent	B-T099
-reported	O
ASD	B-T048
symptoms	B-T184
,	O
participated	O
in	O
play sessions	B-T058
and	O
completed	O
measures	B-T081
of	O
verbal IQ	B-T032
and	O
ToM	B-T078
.	O
Besides	O
the	O
measure	B-T081
of	O
child	B-T100
ASD	B-T048
symptoms	B-T184
,	O
parents	B-T099
completed	O
a	O
survey	B-T170
of	O
their	O
child's	B-T100
interest	B-T041
in	O
and	O
familiarity	B-T041
with	O
the	O
play session	B-T058
toys	B-T073
.	O
Overall,	O
greater	O
ToM	B-T078
predicted	B-T078
more	O
APP	B-T080
,	O
and	O
more	O
interest	B-T041
in	O
the	O
toys	B-T073
presented	O
predicted	B-T078
more	O
OS	B-T052
.	O
In	O
terms	O
of	O
overall	O
pretend play	B-T041
production	B-T041
,	O
two	O
results	O
were	O
counterintuitive.	O
First,	O
among	O
children	B-T100
with	O
more	O
ASD	B-T048
symptoms	B-T184
,	O
verbal ability	B-T041
marginally	O
negatively	O
predicted	B-T078
pretend play	B-T041
production	B-T041
.	O
Second,	O
among	O
children	B-T100
with	O
fewer	O
ASD	B-T048
symptoms	B-T184
,	O
ToM	B-T078
negatively	O
predicted	B-T078
pretend play	B-T041
production	B-T041
.	O
Further	O
probing	O
revealed	O
that	O
the	O
negative	O
effect	O
of	O
ASD	B-T048
symptoms	B-T184
on	O
pretend play	B-T041
was	O
simultaneously	O
moderated	O
by	O
both	O
variables:	O
low	O
ToM	B-T078
and	O
high	O
verbal ability	B-T041
both	O
related	O
to	O
less	O
pretend play	B-T041
production	O
among	O
children	B-T100
with	O
more	O
ASD	B-T048
symptoms	B-T184
.	O
Implications	O
for	O
assessment	O
and	O
subsequent	O
treatment	B-T061
for	O
pretend ability	B-T032
among	O
children	B-T100
with	O
varying	O
degrees	O
of	O
ASD	B-T048
symptoms	B-T184
,	O
as	O
well	O
as	O
for	O
future	O
research,	O
are	O
discussed.	O

Allelic	B-T028
diversity	B-T080
in	O
an	O
NLR gene	B-T028
BPH9	B-T028
enables	O
rice	B-T002
to	O
combat	O
planthopper	B-T204
variation	B-T070
Brown planthopper	B-T204
(	O
BPH	B-T204
),	O
Nilaparvata lugens Stål	B-T204
,	O
is	O
one	O
of	O
the	O
most	O
devastating	O
insect	B-T204
pests	B-T008
of	O
rice	B-T002
(	O
Oryza sativa L.	B-T002
).	O
Currently,	O
30	O
BPH	B-T204
-	O
resistance genes	B-T028
have	O
been	O
genetically	O
defined,	O
most	O
of	O
which	O
are	O
clustered	O
on	O
specific	O
chromosome regions	B-T026
.	O
Here,	O
we	O
describe	O
molecular cloning	B-T059
and	O
characterization	B-T052
of	O
a	O
BPH	B-T204
-	O
resistance gene	B-T028
,	O
BPH9	B-T028
,	O
mapped	O
on	O
the	O
long arm of rice chromosome 12	B-T026
(12L).	O
BPH9	B-T028
encodes	O
a	O
rare	O
type	O
of	O
nucleotide-binding	B-T044
and	O
leucine-rich repeat	B-T087
(	O
NLR	B-T087
)-containing	O
protein	B-T116
that	O
localizes	O
to	O
the	O
endomembrane system	B-T026
and	O
causes	O
a	O
cell death	B-T043
phenotype	B-T032
.	O
BPH9	B-T028
activates	O
salicylic acid	B-T109
-	O
and	O
jasmonic acid	B-T109
-	O
signaling pathways	B-T044
in	O
rice	B-T002
plants	B-T002
and	O
confers	O
both	O
antixenosis	B-T070
and	O
antibiosis	B-T070
to	O
BPH	B-T204
.	O
We	O
further	O
demonstrated	O
that	O
the	O
eight	O
BPH	B-T204
-	O
resistance genes	B-T028
that	O
are	O
clustered	O
on	O
chromosome 12L	B-T026
,	O
including	O
the	O
widely	O
used	O
BPH1	B-T028
,	O
are	O
allelic	O
with	O
each	O
other.	O
To	O
honor	O
the	O
priority	O
in	O
the	O
literature	B-T170
,	O
we	O
thus	O
designated	O
this	O
locus	B-T082
as	O
BPH1/9	B-T028
These	O
eight	O
genes	B-T028
can	O
be	O
classified	O
into	O
four	O
allelotypes	B-T028
,	O
BPH1/9-1	B-T028
,	O
-2	B-T028
,	O
-7	B-T028
,	O
and	O
-9	B-T028
These	O
allelotypes	B-T028
confer	O
varying	O
levels	B-T080
of	O
resistance	B-T039
to	O
different	O
biotypes	B-T170
of	O
BPH	B-T204
.	O
The	O
coding region	B-T028
of	O
BPH1/9	B-T028
shows	O
a	O
high	O
level	O
of	O
diversity	B-T080
in	O
rice germplasm	B-T002
.	O
Homologous	O
fragments	O
of	O
the	O
nucleotide-binding	B-T044
(	O
NB	B-T044
)	O
and	O
leucine-rich repeat	B-T087
(	O
LRR	B-T087
)	O
domains	B-T087
exist,	O
which	O
might	O
have	O
served	O
as	O
a	O
repository	B-T073
for	O
generating	O
allele	B-T028
diversity	B-T080
.	O
Our	O
findings	O
reveal	O
a	O
rice	B-T002
plant	B-T002
strategy	O
for	O
modifying	O
the	O
genetic information	B-T169
to	O
gain	O
the	O
upper	O
hand	O
in	O
the	O
struggle	O
against	O
insect	B-T204
herbivores	B-T008
.	O
Further	O
exploration	O
of	O
natural	O
allelic variation	B-T070
and	O
artificial shuffling	B-T062
within	O
this	O
gene	B-T028
may	O
allow	O
breeding	B-T040
to	O
be	O
tailored	O
to	O
control	O
emerging	O
biotypes	B-T170
of	O
BPH	B-T204
.	O

Nontoxic	B-T080
Formulations	B-T167
of	O
Scintillation	B-T070
Nanocrystals	B-T073
for	O
Use	O
as	O
X-ray Computed Tomography	B-T060
Contrast Agents	B-T130
X-ray computed tomography	B-T060
(	O
CT	B-T060
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful,	O
noninvasive	B-T185
,	O
clinical	B-T080
in vivo	B-T082
imaging techniques	B-T060
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X-ray device	B-T074
and	O
contrast	B-T080
enhancement technologies	B-T061
.	O
The	O
present	O
study	B-T062
demonstrates,	O
for	O
the	O
first	O
time,	O
that	O
metal tungstates	B-T130
(such	O
as	O
CaWO4	B-T130
)	O
are	O
promising	O
contrast agents	B-T130
for	O
X-ray	B-T060
,	O
radiation	B-T070
,	O
and	O
CT imaging	B-T060
,	O
because	O
of	O
the	O
high	O
X-ray	B-T060
mass attenuation	B-T052
of	O
tungsten	B-T196
(	O
W	B-T196
).	O
We	O
have	O
developed	O
a	O
method	O
of	O
formulation	B-T167
,	O
in	O
which	O
CaWO4	B-T130
(	O
CWO	B-T130
)	O
nanoparticles	B-T073
(	O
NPs	B-T073
)	O
are	O
encapsulated	B-T080
within	O
a	O
biocompatible	O
poly(ethylene glycol-b-d,l-lactic acid) (PEG-PLA) block copolymer (BCP) capsule	B-T109
.	O
We	O
show	O
that	O
these	O
PEG-PLA	B-T109
-	O
encapsulated	B-T080
CWO NPs	B-T073
(170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter)	O
produce	O
a	O
higher	O
CT	B-T060
contrast	B-T080
(by	O
a	O
factor	O
of	O
about	O
2)	O
than	O
commercial	O
iodine	B-T121
-based	O
radiocontrast agents	B-T130
(e.g.,	O
Iohexol	B-T109
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	B-T196
or	O
I	B-T121
atoms	B-T196
.	O
PEG-PLA	B-T109
-	O
coated	B-T080
CWO NPs	B-T073
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	B-T080
.	O
It	O
was	O
confirmed	O
that	O
the	O
maximum tolerated dose	B-T081
(	O
MTD	B-T081
)	O
of	O
this	O
material	B-T167
in	O
mice	B-T015
is	O
significantly	O
higher	O
(250	O
±	O
50	O
mg	O
per	O
kg	O
body weight	B-T032
following	O
a	O
single	O
intravenous (IV) administration	B-T082
)	O
than,	O
for	O
instance,	O
commercially	O
available	O
dextran	B-T109
-	O
coated	B-T080
iron oxide	B-T121
nanoparticles	B-T073
that	O
are	O
currently	O
used	O
clinically	B-T080
as	O
MRI	B-T060
contrast agents	B-T130
(	O
MTD	B-T081
in	O
mice	B-T015
≈	O
168	O
mg/kg	O
per	O
dose	B-T081
IV).	O
IV-	O
injected	B-T169
PEG-PLA	B-T109
/	O
CWO NPs	B-T073
caused	O
no	B-T033
histopathologic	B-T091
damage	B-T169
in	O
major	O
excretory organs	B-T023
(	O
heart	B-T023
,	O
liver	B-T023
,	O
lungs	B-T023
,	O
spleen	B-T023
,	O
and	O
kidney	B-T023
).	O
When	O
an	O
IV	O
dose	B-T081
of	O
100	O
mg/kg	O
was	O
given	O
to	O
mice	B-T015
,	O
the	O
blood circulation	B-T039
half-life	B-T079
was	O
measured	O
to	O
be	O
about	O
4	O
h,	O
and	O
more	O
than	O
90%	O
of	O
the	O
NPs	B-T073
were	O
cleared	O
from	O
the	O
mice	B-T015
within	O
24	O
h	O
via	O
the	O
renal	B-T023
and	O
hepatobiliary systems	B-T022
.	O
When	O
intratumorally administered	B-T169
,	O
PEG-PLA	B-T109
-	O
coated	B-T080
CWO NPs	B-T073
showed	O
complete	O
retention	O
in	O
a	O
tumor-bearing mouse model	B-T050
(measurements	O
were	O
made	O
up	O
to	O
1	O
week	B-T079
).	O
These	O
results	O
suggest	O
that	O
PEG-PLA	B-T109
-	O
coated	B-T080
CWO NPs	B-T073
are	O
promising	O
materials	B-T167
for	O
use	O
in	O
CT	B-T060
contrast	B-T080
.	O

Albumin	B-T116
-Bioinspired	O
Gd	B-T130
:	O
CuS	B-T197
Nanotheranostic Agent	B-T073
for	O
In Vivo	B-T082
Photoacoustic	B-T060
Photoacoustic / Magnetic Resonance Imaging -Guided Tumor -Targeted Photothermal Therapy	B-T061
Magnetic Resonance Imaging	B-T060
-Guided	O
Tumor	B-T191
-Targeted	O
Photothermal	O
Therapy	O
Photothermal therapy	B-T061
(	O
PTT	B-T061
)	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	B-T022
skin cancer therapy	B-T061
in	O
the	O
clinic	B-T073
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	B-T080
and	O
low systemic adverse effects	B-T046
.	O
However,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible PTT agents	B-T073
,	O
which	O
enable	O
accurate	B-T080
imaging	B-T060
,	O
monitoring	B-T058
,	O
and	O
diagnosis	B-T033
.	O
Herein,	O
a	O
biocompatible Gd -integrated CuS nanotheranostic agent	B-T073
Gd	B-T130
-integrated	O
CuS	B-T197
nanotheranostic	O
agent	O
(	O
Gd	B-T130
:	O
CuS	B-T197
@	O
BSA	B-T116
)	O
was	O
synthesized	B-T052
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic strategy	B-T041
,	O
using	O
bovine serum albumin	B-T116
(	O
BSA	B-T116
)	O
as	O
a	O
biotemplate	B-T078
at	O
physiological temperature	B-T081
.	O
The	O
as-prepared	O
Gd	B-T130
:	O
CuS	B-T197
@	O
BSA	B-T116
nanoparticles	B-T073
(	O
NPs	B-T073
)	O
with	O
ultrasmall sizes	B-T033
(ca.	O
9	O
nm)	O
exhibited	O
high	O
photothermal conversion efficiency	B-T033
and	O
good	O
photostability	B-T033
under	O
near-infrared (NIR) laser	B-T070
irradiation	B-T070
.	O
With	O
doped Gd species	B-T130
and	O
strong	O
tunable NIR absorbance	B-T080
,	O
Gd	B-T130
:	O
CuS	B-T197
@	O
BSA	B-T116
NPs	B-T073
demonstrate	O
prominent	O
tumor-contrasted imaging	B-T060
performance	O
both	O
on	O
the	O
photoacoustic	B-T060
photoacoustic and magnetic resonance imaging modalities	B-T169
magnetic resonance imaging	B-T060
modalities.	O
The	O
subsequent	O
Gd	B-T130
Gd: CuS @ BSA -mediated PTT	B-T061
CuS	B-T197
@	O
BSA	B-T116
-mediated	O
PTT	O
result	O
shows	O
high	O
therapy efficacy	B-T033
as	O
a	O
result	O
of	O
their	O
potent	O
NIR absorption	B-T033
and	O
high	O
photothermal conversion efficiency	B-T033
.	O
The	O
immune response	B-T042
triggered by	B-T080
Gd	B-T130
Gd: CuS @ BSA -mediated PTT	B-T061
CuS	B-T197
@	O
BSA	B-T116
-mediated	O
PTT	O
is	O
preliminarily	O
explored.	O
In	O
addition,	O
toxicity studies	B-T060
in vitro	B-T080
and	O
in vivo	B-T082
verify	O
that	O
Gd	B-T130
:	O
CuS	B-T197
@	O
BSA	B-T116
NPs	B-T073
qualify	O
as	O
biocompatible agents	B-T073
.	O
A	O
biodistribution study	B-T062
demonstrated	O
that	O
the	O
NPs	B-T073
can	O
undergo	O
hepatic clearance	B-UnknownType
from	O
the	O
body	B-T016
.	O
This	O
study	O
highlights	O
the	O
practicality	B-T080
and	O
versatility	B-T080
of	O
albumin	B-T116
albumin -mediated biomimetic mineralization	B-T067
of	O
a	O
nanotheranostic agent	B-T073
and	O
also	O
suggests	O
that	O
bioinspired	O
Gd	B-T130
:	O
CuS	B-T197
@	O
BSA	B-T116
NPs	B-T073
possess	O
promising	O
imaging guidance	B-T061
and	O
effective	O
tumor ablation properties	B-T061
,	O
with	O
high	O
spatial resolution	B-T080
and	O
deep tissue penetration	B-T080
tissue	B-T024
penetration.	O

Family	B-T099
and	O
healthcare professionals	B-T097
'	O
perceptions	B-T041
of	O
a	O
pilot	O
hospice	B-T058
at	O
home	B-T082
programme	B-T058
for	O
children	B-T100
:	O
a	O
qualitative	O
study	B-T062
Parents	B-T099
commonly	O
report	O
a	O
significant	O
improvement	B-T077
in	O
quality of life	B-T078
following	O
the	O
provision	B-T058
of	O
hospice	B-T058
and	O
supportive care	B-T061
and	O
have	O
identified	O
a	O
need	O
for	O
such	O
a	O
service	B-T058
in	O
the	O
home	B-T082
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
understand	O
the	O
experiences	O
of	O
families	B-T099
receiving	O
a	O
nurse	B-T097
led	O
pilot	O
hospice	B-T058
at	O
home	B-T082
programme	B-T058
and	O
the	O
experiences	B-T041
of	O
healthcare professionals	B-T097
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-T058
.	O
An	O
exploratory,	O
qualitative	O
study	B-T062
was	O
conducted,	O
including	O
telephone interviews	B-T062
with	O
parents	B-T099
and	O
focus groups	B-T096
and	O
individual	B-T098
interviews	B-T052
with	O
healthcare professionals	B-T097
.	O
All	O
parents	B-T099
of	O
families	B-T099
who	O
received	O
the	O
programme	B-T058
of	O
care	B-T058
between	O
June	O
2014	O
and	O
September	O
2015	O
and	O
healthcare professionals	B-T097
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-T058
were	O
invited	O
to	O
participate.	O
Seven	O
parents	B-T099
participated	O
in	O
telephone interviews	B-T062
.	O
Four	O
focus groups	B-T096
took	O
place,	O
two	O
with	O
external stakeholders	B-T098
(18	O
participants	B-T098
in	O
total),	O
one	O
with	O
in-patient	B-T101
hospice staff	B-T097
(13	O
participants	B-T098
)	O
and	O
one	O
with	O
the	O
hospice	B-T058
at	O
home	O
team	O
(8	O
participants	B-T098
).	O
Two	O
additional	O
interviews	B-T052
took	O
place	O
with	O
individual	B-T098
stakeholders	B-T098
who	O
were	O
unable	O
to	O
attend	O
a	O
scheduled	O
focus group	B-T096
.	O
Themes	O
from	O
interviews	B-T052
with	O
parents	B-T099
focused	O
on	O
the	O
value	O
of	O
having	O
consistent	O
and	O
expert	O
care	B-T058
.	O
The	O
findings	O
from	O
healthcare professionals	B-T097
centred	O
on	O
communication	B-T054
within	O
and	O
across	O
services	B-T058
,	O
education and training	B-T065
and	O
lone working	B-T057
.	O
The	O
pilot	O
hospice	B-T058
at	O
home	B-T082
programme	B-T058
was	O
welcomed	O
by	O
all	O
those	O
who	O
took	O
part	O
in	O
the	O
study	B-T062
.	O
The	O
programme	B-T058
may	O
be	O
improved	O
by	O
enhanced	O
clarification	B-T052
of	O
roles,	O
enhanced	O
access	O
to	O
multi-disciplinary	O
services	B-T058
,	O
greater	O
communication	B-T054
across	O
services	B-T058
and	O
improved	O
information	O
provision	O
to	O
families	B-T099
.	O

Functional	B-T169
1,3a,6a-triazapentalene	B-T109
scaffold	B-T104
:	O
Design	B-T052
of	O
fluorescent probes	B-T130
for	O
kinesin spindle protein	B-T116
(	O
KSP	B-T116
)	O
1,3a,6a-Triazapentalene	B-T109
is	O
a	O
compact	O
fluorescent	B-T130
chromophore	B-T120
.	O
In	O
this	O
study	B-T062
,	O
triazapentalene	B-T109
was	O
used	O
to	O
modify	O
a	O
series	O
of	O
biphenyl-type	B-T109
inhibitors	B-T121
of	O
kinesin spindle protein	B-T116
(	O
KSP	B-T116
)	O
to	O
develop	O
fluorescent probes	B-T130
for	O
the	O
intracellular	B-T082
visualization	B-T169
of	O
this	O
protein	B-T116
.	O
Microscopic	B-T080
studies	B-T062
demonstrated	O
that	O
these	O
novel	B-T080
triazapentalene	B-T109
-	O
labeled	B-T080
compounds	B-T103
exhibited	O
inhibitory	B-T052
activity	B-T169
towards	O
KSP	B-T116
in	O
cultured cells	B-T025
and	O
provided	O
important	O
information	B-T078
concerning	O
the	O
intracellular	B-T082
distribution	B-T169
.	O

C4b binding protein	B-T116
negatively regulates	B-T044
TLR1	B-T116
/	O
2	B-T116
response	B-T032
TLR2	B-T116
associates with	B-T080
TLR1	B-T116
and	O
recognizes	O
microbial	B-T001
lipoproteins	B-T116
.	O
Pam3CSK4	B-T116
,	O
a	O
triacylated lipoprotein	B-T116
,	O
is	O
anchored	B-T044
to	O
the	O
extracellular domain	B-T082
of	O
TLR1	B-T116
and	O
TLR2	B-T116
and	O
induces	B-T169
pro-inflammatory	B-T046
signals	B-T038
.	O
Here	O
we	O
show	O
that	O
C4b binding protein	B-T116
(	O
C4BP	B-T116
),	O
which	O
is	O
a	O
complement pathway	B-T044
inhibitor	B-T080
,	O
is	O
a	O
TLR2	B-T116
-associated	O
molecule.	O
Immunoprecipitation assay	B-T059
using	O
anti-TLR2 mAb	B-T129
shows	O
that	O
C4BP	B-T116
binds to	B-T044
TLR2	B-T116
.	O
In	O
C4BP-deficient	B-T028
mice	B-T015
,	O
Pam3CSK4	B-T116
-	O
induced	B-T169
IL-6	B-T116
levels	B-T080
were	O
increased	B-T081
compared	B-T052
with	O
wild type mice	B-T015
.	O
In	O
C4BP	B-T116
-	O
expressing	B-T045
cells	B-T025
,	O
Pam3CSK4	B-T116
-	O
induced	B-T169
IL-8 production	B-T040
was	O
reduced	B-T080
depending	O
on	O
the	O
C4BP	B-T116
expression levels	B-T081
.	O
These	O
results	O
reveal	B-T080
the	O
important	O
role	O
of	O
C4BP	B-T116
in	O
negative regulation	B-T044
of	O
TLR1	B-T116
/	O
2	B-T116
-	O
dependent	B-T116
pro-inflammatory	B-T046
cytokine production	B-T040
.	O
Furthermore,	O
using	O
a	O
fluorescent conjugated	B-T130
Pam3CSK4	B-T116
,	O
we	O
show	O
that	O
C4BP	B-T116
blocks	B-T169
the	O
binding of	B-T044
Pam3CSK4	B-T116
to	O
TLR1	B-T116
/	O
2	B-T116
.	O
Finally,	O
we	O
show	O
that	O
exogenous	B-T169
C4BP	B-T116
also	O
inhibits	B-T052
Pam3CSK4	B-T116
-	O
induced signaling	B-T044
leading	O
to	O
IL-8 production	B-T040
.	O
Our	O
results	O
indicate	O
C4BP	B-T116
binding to	B-T044
TLR2	B-T116
and	O
consequent	B-T033
neutralization	B-T169
of	O
its	O
activity	B-T044
otherwise	O
inducing	O
pro-inflammatory	B-T046
cytokine production	B-T040
.	O
C4BP	B-T116
is	O
a	O
negative regulator	B-T044
of	O
TLR1	B-T116
/	O
2	B-T116
activity	B-T044
.	O

Effect	B-T080
of	O
emodin	B-T109
on	O
mobility signal transduction system	B-T043
of	O
gallbladder	B-T023
smooth muscle	B-T024
in	O
Guinea pig	B-T015
with	O
cholelithiasis	B-T047
To	O
study	B-T062
the	O
effect	B-T080
of	O
emodin	B-T109
on	O
protein	B-T045
and	O
gene expressions	B-T045
of	O
the	O
massagers	B-UnknownType
in	O
mobility signal transduction system	B-T043
of	O
cholecyst	B-T023
smooth muscle cells	B-T025
in	O
guinea pig	B-T015
with	O
cholesterol calculus	B-T031
.	O
The	O
guinea pigs	B-T015
were	O
randomly	O
divided	O
into	O
4	O
groups	B-T078
,	O
such	O
as	O
control group	B-T096
,	O
gall-stone	B-T047
(	O
GS	B-T047
)	O
group	B-T078
,	O
emodin	B-T109
group	B-T078
and	O
ursodeoxycholic acid	B-T109
(	O
UA	B-T109
)	O
group	B-T078
.	O
Cholesterol calculus	B-T031
models	B-T075
were	O
induced	O
in	O
guinea pigs	B-T015
of	O
GS	B-T047
,	O
emodin	B-T109
and	O
UA	B-T109
groups	B-T078
by	O
lithogenic diet	B-T168
,	O
while	O
emodin	B-T109
or	O
UA	B-T109
were	O
given	O
to	O
the	O
corresponding	O
group	B-T078
for	O
7	O
weeks	B-T079
.	O
The	O
histomorphological	B-T080
and	O
ultrastructure	B-T078
change	B-T169
of	O
gallbladder	B-T023
were	O
detected	B-T033
by	O
microscope	B-T074
and	O
electron microscope	B-T074
,	O
the	O
content	O
of	O
plasma	B-T031
cholecystokinin	B-T116
(	O
CCK	B-T116
)	O
and	O
[Ca(2+)]i	B-T121
were	O
analyzed	B-T062
successively	O
by	O
radioimmunoassay	B-T059
and	O
flow cytometry	B-T059
.	O
The	O
protein	B-T116
and	O
mRNA	B-T114
of	O
Gsα	B-T116
,	O
Giα	B-T116
and	O
Cap	B-T116
in	O
cholecyst	B-T023
cells	B-T025
were	O
determined by	B-T080
western blotting	B-T059
and	O
real time polymerase chain reaction	B-T063
(	O
RT-PCR	B-T063
).	O
Emodin	B-T109
or	O
UA	B-T109
can	O
relieve	O
pathogenic	B-T033
changes	B-T169
in	O
epithelial cells	B-T025
and	O
muscle cells	B-T025
in	O
gallbladder	B-T023
of	O
guinea pig	B-T015
with	O
cholesterol calculus	B-T031
by	O
microscope	B-T074
and	O
transmission electron microscope	B-T074
.	O
In	O
the	O
cholecyst	B-T023
cells	B-T025
of	O
GS	B-T047
group	B-T078
,	O
CCK	B-T116
levels	B-T080
in	O
plasma	B-T031
and	O
[Ca(2+)]i	B-T121
decreased	B-T081
,	O
the	O
protein	B-T116
and	O
mRNA	B-T114
of	O
GS	B-T047
were	O
down-regulated	B-T044
,	O
the	O
protein	B-T116
and	O
mRNA	B-T114
of	O
Gi	B-T116
and	O
Cap	B-T116
were	O
up-regulated	B-T044
.	O
Emodin	B-T109
significantly	B-T078
decreased	B-T081
the	O
formative	B-T169
rate	B-T081
of	O
gallstone	B-T047
,	O
improved	O
the	O
pathogenic	B-T033
change	B-T169
in	O
epithelial cells	B-T025
and	O
muscle cells	B-T025
,	O
increased	O
CCK	B-T116
levels	B-T080
in	O
plasma	B-T031
and	O
[Ca(2+)]i	B-T121
in	O
cholecyst	B-T023
cells	B-T025
,	O
enhanced	O
the	O
protein	B-T116
and	O
mRNA	B-T114
of	O
Gs	B-T116
in	O
cholecyst	B-T023
cells	B-T025
,	O
reduced	B-T080
the	O
protein	B-T116
and	O
mRNA	B-T114
of	O
Gi	B-T116
and	O
Cap	B-T116
in	O
cholecyst	B-T023
cells	B-T025
in	O
guinea pig	B-T015
with	O
cholesterol calculus	B-T031
.	O
The	O
dysfunction	B-T077
of	O
gallbladder contraction	B-T042
gives	O
rise	O
to	O
the	O
disorders	B-T047
of	O
mobility signal transduction system	B-T043
in	O
cholecyst	B-T023
smooth muscle cells	B-T025
,	O
including	B-T169
low	O
content	O
of	O
plasma	B-T031
CCK	B-T116
and	O
[Ca(2+)]i	B-T121
in	O
cholecyst	B-T023
cells	B-T025
,	O
abnormal protein	B-T116
and	O
mRNA	B-T114
of	O
Gs	B-T116
,	O
Gi	B-T116
and	O
Cap	B-T116
.	O
Emodin	B-T109
can	O
enhance	B-T052
the	O
contractibility of gallbladder	B-T042
and	O
alleviate	B-T081
cholestasis	B-T047
by	O
regulating	B-T038
plasma	B-T031
CCK	B-T116
levels	B-T080
,	O
[Ca(2+)]i	B-T121
in	O
cholecyst	B-T023
cells	B-T025
and	O
the	O
protein	B-T116
and	O
mRNA	B-T114
of	O
Gs	B-T116
,	O
Gi	B-T116
and	O
Cap	B-T116
.	O

Quantification	B-T081
of	O
urinary	B-T080
mono-hydroxylated metabolites	B-T123
of	O
polycyclic aromatic hydrocarbons	B-T109
by	O
on-line solid phase extraction	B-T059
-	O
high performance liquid chromatography-tandem mass spectrometry	B-T059
Human	B-T016
exposure to	B-T080
polycyclic aromatic hydrocarbons	B-T109
(	O
PAHs	B-T109
)	O
can	O
be	O
assessed	B-T052
through	O
monitoring	B-T058
of	O
urinary	B-T080
mono-hydroxylated PAHs	B-T109
(	O
OH-PAHs	B-T109
).	O
Gas chromatography	B-T059
(	O
GC	B-T059
)	O
has	O
been	O
widely	O
used	O
to	O
separate	B-T080
OH-PAHs	B-T109
before	O
quantification	B-T081
by	O
mass spectrometry	B-T059
in	O
biomonitoring	B-T057
studies	B-T062
.	O
However,	O
because	O
GC	B-T059
requires	O
derivatization	B-T169
,	O
it	O
can	O
be	O
time consuming	B-T080
.	O
We	O
developed	B-T169
an	O
on-line solid phase extraction	B-T059
coupled	B-T169
to	O
isotope	B-T196
dilution	B-T169
-	O
high performance liquid chromatography-tandem mass spectrometry	B-T059
(	O
on-line-SPE	B-T059
-	O
HPLC-MS	B-T059
/	O
MS	B-T059
)	O
method	B-T170
for	O
the	O
quantification	B-T081
in	O
urine	B-T031
of	O
1-OH-naphthalene	B-T109
,	O
2-OH-naphthalene	B-T109
,	O
2-OH-fluorene	B-T109
,	O
3-OH-fluorene	B-T109
,	O
1-OH-phenanthrene	B-T109
,	O
the	O
sum	O
of	O
2-OH	B-T109
and	O
3-OH-phenanthrene	B-T109
,	O
4-OH-phenanthrene	B-T109
,	O
and	O
1-OH-pyrene	B-T109
.	O
The	O
method	B-T170
,	O
which	O
employed	B-T033
a	O
96-	O
well plate platform	B-T082
and	O
on-line SPE	B-T059
,	O
showed	O
good sensitivity	B-T067
(i.e.,	O
limits	B-T169
of	O
detection	B-T061
ranged	B-T081
from	O
0.007	O
to	O
0.09	O
ng/mL)	O
and	O
used	O
only	O
100	O
μL	O
of	O
urine	B-T031
.	O
Accuracy	B-T080
,	O
calculated	B-T059
from	O
the	O
recovery	B-T052
percentage	B-T081
at	O
three	O
spiking	B-T082
levels	B-T080
,	O
varied	B-T080
from	O
94	O
to	O
113	O
%,	O
depending	B-T080
on	O
the	O
analyte	B-T167
.	O
The	O
inter	B-T079
-	O
and	O
intra	B-T079
-	O
day precision	B-T078
,	O
calculated	B-T059
from	O
20	O
repeated	B-T169
measurements	B-T169
of	O
two	O
quality control	B-T169
materials	B-T167
,	O
varied	B-T080
from	O
5.2	O
to	O
16.7	O
%.	O
Adequate	B-T080
method	B-T170
performance	B-T052
was	O
also	O
confirmed by	B-T080
acceptable	B-T080
recovery	B-T052
(83-102	O
%)	O
of	O
two	O
NIST	B-T092
standard reference	B-T081
materials	B-T167
(3672	O
and	O
3673).	O
This	O
high-throughput	B-T170
on-line-SPE	B-T059
-	O
HPLC-MS	B-T059
/	O
MS	B-T059
method	B-T170
can	O
be	O
applied	O
in	O
large	B-T081
-	O
scale	B-T077
epidemiological studies	B-T062
.	O
Graphical abstract	B-T170
Example	O
LC-MS chromatogram	B-T169
of	O
urinary	B-T080
mono-hydroxylated PAH	B-T109
metabolites	B-T123
.	O

Utility	B-T169
and	O
applicability	B-T169
of	O
the	O
"Childhood Obesity Risk Evaluation" (CORE)-index	B-T170
in	O
predicting	O
obesity	B-T047
in	O
childhood	B-T079
and	O
adolescence	B-T079
in	O
Greece	B-T083
from	O
early	B-T079
life	B-T078
:	O
the	O
"	O
National	O
Action	O
Plan	O
for	O
Public	O
Health	O
"	O
Early	B-T079
identification	B-T058
of	O
infants	B-T100
being	O
at	O
high risk	B-T033
to	O
become	O
obese	B-T047
at	O
their	O
later	B-T079
childhood	B-T079
or	O
adolescence	B-T079
can	O
be	O
of	O
vital	O
importance	O
in	O
any	O
obesity	B-T047
prevention	B-T080
initiative	B-T033
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
utility	B-T169
and	O
applicability	B-T169
of	O
the	O
"Childhood Obesity Risk Evaluation (CORE)" index	B-T170
as	O
a	O
screening	B-T058
tool	B-T073
for	O
the	O
early	B-T079
prediction	B-T078
of	O
obesity	B-T047
in	O
childhood	B-T079
and	O
adolescence	B-T079
.	O
Anthropometric	B-T078
,	O
socio-demographic data	B-T078
were	O
collected	B-T078
cross-sectionally	B-T080
and	O
retrospectively	B-T080
from	O
a	O
representative	O
sample	B-T167
of	O
5946	O
children	B-T100
,	O
and	O
adolescents	B-T100
and	O
were	O
combined	O
for	O
calculating	B-T052
the	O
CORE-index score	B-T170
.	O
Logistic regression analyses	B-UnknownType
were	O
performed	O
to	O
examine	O
the	O
associations	B-T080
of	O
the	O
CORE-index score	B-T170
with	O
obesity	B-T047
by	O
gender	B-T032
and	O
age group	B-T100
,	O
and	O
cut-off point analysis	B-T062
was	O
also	O
applied	O
to	O
identify	O
the	O
optimal	B-T080
value	B-T081
of	O
the	O
CORE-index score	B-T170
that	O
differentiates	B-T080
obese	B-T047
from	O
non-obese children	B-T100
.	O
Mean CORE-index score	B-T170
in	O
the	O
total	B-T080
sample	B-T167
was	O
3.06	O
(	O
sd	B-T081
1.92)	O
units	O
(range	O
0-11	O
units).	O
Each	O
unit	O
increase	B-T169
in	O
the	O
CORE-index score	B-T170
was	O
found	O
to	O
be	O
associated with	B-T080
a	O
30	O
%	O
(95	O
%	O
C.I.	B-T081
1.24-1.36)	O
increased	B-T081
likelihood	B-T081
for	O
obesity	B-T047
in	O
childhood	B-T079
or	O
adolescence	B-T079
,	O
while	O
the	O
optimal	B-T080
cut-off value	B-T081
of	O
the	O
CORE-index score	B-T170
that	O
predicted	B-T078
obesity	B-T047
with	O
the	O
highest	B-T080
possible	O
sensitivity and specificity	B-T081
was	O
found	O
to	O
be	O
3.5.	O
The	O
present	O
study	O
supports	O
the	O
utility	B-T169
and	O
applicability	B-T169
of	O
the	O
CORE-index	B-T170
as	O
a	O
screening	B-T058
tool	B-T073
for	O
the	O
early	B-T079
identification	B-T058
of	O
infants	B-T100
that	O
are	O
potentially	O
at	O
a	O
higher risk	B-T033
for	O
becoming	O
obese	B-T047
at	O
their	O
childhood	B-T079
and	O
adolescence	B-T079
.	O
This	O
tool	B-T073
could	O
be	O
routinely	O
used	O
by	O
health professionals	B-T097
to	O
identify	O
infants	B-T100
at	O
high risk	B-T033
and	O
provide	O
appropriate	O
counselling	B-T058
to	O
their	O
parents	B-T099
and	O
caregivers	B-T097
so	O
as	O
to	O
maximize	O
the	O
effectiveness	B-T080
of	O
early	B-T079
obesity	B-T047
prevention	B-T080
initiatives	B-T033
.	O
What	O
is	O
known?	O
•	O
Childhood	B-T079
obesity	B-T047
has	O
reached	O
epidemic proportions	B-T081
worldwide.	O
•	O
Certain	O
perinatal	B-T033
and	O
socio-demographic indices	B-T033
that	O
were	O
previously	O
identified	B-T080
as	O
correlates	O
of	O
childhood	B-T079
obesity	B-T047
in	O
children	B-T100
were	O
combined	O
to	O
develop	O
the	O
CORE-index	B-T170
,	O
a	O
screening	B-T058
tool	B-T073
that	O
estimates	O
obesity	B-T047
risk	B-T078
in	O
9-13	O
year-old	B-T079
children	B-T100
.	O
What	O
is	O
new?	O
•	O
The	O
utility	B-T169
and	O
applicability	B-T169
of	O
the	O
CORE-index	B-T170
as	O
screening	B-T058
tool	B-T073
can	O
be	O
extended	O
to	O
the	O
age	B-T032
range	O
of	O
6-15	O
years	B-T079
.	O
•	O
The	O
CORE-index	B-T170
is	O
a	O
cost-effective	B-T080
screening	B-T058
tool	B-T073
that	O
can	O
assist	O
health professionals	B-T097
in	O
initiating	O
obesity	B-T047
preventive measures	B-T170
from	O
early	B-T079
life	B-T078
.	O

Methodology	B-T078
development	B-T169
on	O
aquatic environmental	B-T067
assessment	B-T058
The	O
Water Framework Directive	B-T170
aims	B-T078
at	O
reaching	O
the	O
good	O
ecological	B-T070
status	B-T080
of	O
the	O
surface	B-T082
and	O
ground water bodies	B-T082
(László	O
et	O
al.	O
Microchem	O
J	O
85(1):65-71,	O
2007).	O
The	O
paper	O
deals	O
with	O
quality	B-T080
evaluation	B-T058
of	O
waters	B-T121
with	O
special	B-T080
focus	O
on	O
the	O
water	B-T121
chemistry	B-T169
parameters	B-T077
as	O
defined	O
in	O
the	O
Water Framework Directive	B-T170
and	O
pertaining	O
legal regulations	B-T089
.	O
The	O
purpose	B-T169
of	O
this	O
paper	O
is	O
to	O
devise	O
a	O
quantitative	B-T081
type	O
of	O
water	B-T121
quality	B-T080
assessment	B-T058
method	B-T170
which	O
could	O
provide	B-T052
rapid	B-T080
,	O
accurate	B-T080
,	O
and	O
reliable	B-T170
information	B-T078
on	O
the	O
quality	B-T080
of	O
the	O
surface	B-T082
waters	B-T121
by	O
using	O
water	B-T121
chemistry	B-T169
parameters	B-T077
.	O
Quality	B-T080
classes	B-T170
have	O
been	O
defined	B-T080
for	O
every	O
water	B-T121
chemistry	B-T169
parameter	B-T077
in	O
light	O
of	O
the	O
legal limit values	B-T089
of	O
the	O
water	B-T121
parameters	B-T077
.	O
In	O
addition	O
to	O
this,	O
weight indices	B-T081
were	O
calculated	B-T059
on	O
the	O
basis	O
of	O
the	O
outcome	B-T169
of	O
the	O
paired comparison	B-T081
of	O
water	B-T121
chemistry	B-T169
parameters	B-T077
and	O
normalized	B-T062
matrix	B-T082
.	O
This	O
was	O
followed	O
by	O
the	O
parametric level analysis	B-UnknownType
of	O
the	O
water	B-T121
chemistry	B-T169
parameters	B-T077
,	O
and	O
finally,	O
the	O
aquatic environment index	B-T170
(	O
AEI	B-T170
)	O
was	O
calculated	B-T059
,	O
which	O
provided	B-T052
general information	B-T185
on	O
the	O
quality	B-T080
of	O
water	B-T121
regarding	O
the	O
water	B-T121
chemistry	B-T169
parameters	B-T077
.	O
The	O
method	B-T170
was	O
illustrated	O
on	O
Lake	B-T083
Balaton	B-T083
,	O
Hungary	B-T083
in	O
which	O
case	O
water	B-T121
samples	B-T167
taken	O
from	O
Balatonfüred City	B-T083
lake	B-T083
area	B-T083
were	O
analyzed	B-T062
and	O
evaluated	B-T058
with	O
the	O
method	B-T170
devised.	O

WDR26	B-T116
promotes	B-T052
mitophagy	B-T043
of	O
cardiomyocytes	B-T025
induced	B-T169
by	O
hypoxia	B-T046
through	O
Parkin	B-T116
translocation	B-T043
Myocardial ischemia	B-T047
is	O
a	O
heart	B-T023
condition	B-T080
caused	O
by	O
reduction	B-T080
of	O
blood flow	B-T039
to	O
the	O
heart	B-T023
,	O
preventing	O
heart	B-T023
from	O
receiving	B-T080
enough	O
oxygen	B-T121
.	O
Myocardial ischemia	B-T047
is	O
the	O
most	O
common	O
cause of death	B-T033
globally	B-T082
.	O
Heart	B-T023
ischemic preconditioning	B-T061
(	O
IPC	B-T061
)	O
has	O
a	O
protective effect	B-T080
against	O
myocardial cell	B-T025
death	B-T043
induced	B-T169
by	O
ischemia	B-T046
and	O
ischemia-reperfusion injury	B-T037
.	O
WDR26	B-T116
has	O
recently	O
been	O
identified	B-T080
as	O
a	O
protein	B-T116
that	O
is	O
increased	B-T081
following	O
rat	B-T015
cardiac	B-T023
IPC	B-T061
.	O
WDR26	B-T116
can	O
promote	B-T052
the	O
proliferation	B-T043
of	O
H9c2 cells	B-T025
and	O
protect	O
cardiomyocytes	B-T025
against	O
oxidative stress	B-T049
through	O
inhibiting	B-T052
apoptosis	B-T043
.	O
However,	O
its	O
role	B-T077
in	O
myocardial ischemia	B-T047
is	O
unclear.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
explore	O
the	O
role	O
of	O
WDR26	B-T116
in	O
myocardial ischemia	B-T047
and	O
H9c2 cell	B-T025
hypoxia	B-T046
.	O
Our	O
results	B-T169
showed	O
that	O
WDR26	B-T116
is	O
induced	B-T169
by	O
myocardial ischemia	B-T047
and	O
H9c2 cell	B-T025
hypoxia	B-T046
.	O
WDR26	B-T116
protects	O
H9c2 cells	B-T025
against	O
hypoxia	B-T046
injury	B-T037
through	O
inhibiting	B-T052
LDH	B-T116
release	O
and	O
increasing	O
cell viability	B-T043
.	O
WDR26	B-T116
promotes	B-T052
hypoxia	B-T046
-	O
induced	B-T169
autophagy	B-T043
in	O
hypoxia	B-T046
of	O
H9c2 cells	B-T025
.	O
We	O
further	O
demonstrated	O
that	O
in	O
H9c2 cell	B-T025
hypoxia	B-T046
,	O
WDR26	B-T116
increases	B-T169
mitochondrial membrane potential	B-T043
,	O
thereby	O
increases	B-T169
Parkin	B-T116
translocation	B-T043
of	O
mitochondria	B-T026
.	O
After	O
Parkin	B-T116
is	O
translocated	B-T043
at	O
mitochondria	B-T026
,	O
WDR26	B-T116
can	O
increase	B-T169
mitochondria	B-T026
l	O
protein ubiquitination	B-T044
in	O
hypoxia	B-T046
of	O
H9c2 cells	B-T025
.	O
WDR26	B-T116
is	O
a	O
mediator	O
of	O
response	O
to	O
hypoxia	B-T046
,	O
and	O
WDR26	B-T116
plays	O
an	O
important	O
role	O
in	O
hypoxia	B-T046
-mediated	O
autophagy	B-T043
and	O
mitophagy	B-T043
.	O
This	O
study	B-T062
provides	O
novel	B-T080
insights	O
into	O
the	O
protective	O
role	O
of	O
WDR26	B-T116
in	O
cardiomyocyte	B-T025
injury	B-T037
during	O
hypoxia	B-T046
.	O
WDR26	B-T116
may	O
serve	O
as	O
a	O
potential	O
target	B-T169
for	O
the	O
treatment	B-T061
of	O
myocardial ischemia	B-T047
.	O

Impact	B-T080
of	O
antibiotic	B-T195
de-escalation	B-T061
on	O
clinical outcomes	B-T169
in	O
community-acquired	B-T080
pneumococcal pneumonia	B-T047
Although	O
antibiotic	B-T195
de-escalation	B-T061
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	B-T080
selection	O
pressure,	O
adverse drug effects	B-T046
and	O
costs	B-T081
,	O
evidence	B-T078
supporting	O
this	O
practice	O
in	O
community-acquired pneumococcal pneumonia	B-T047
(	O
CAPP	B-T047
)	O
is	O
lacking	B-T080
.	O
We	O
carried	O
out	O
a	O
retrospective	B-T080
analysis	B-T062
of	O
prospectively	O
collected	O
data	B-T078
of	O
a	O
cohort	B-T098
of	O
hospitalized adults	B-T101
with	O
CAPP	B-T047
.	O
Pneumococcal	B-T047
aetiology	B-T169
was	O
established	B-T080
in	O
patients	B-T101
with	O
one	O
or	O
more	O
positive cultures	B-T033
for	O
Streptococcus pneumoniae	B-T007
obtained	O
from	O
blood	B-T031
,	O
sterile fluids	B-T031
or	O
sputum	B-T031
,	O
and/or	O
a	O
positive	B-T033
urinary antigen test	B-T059
.	O
De-escalation therapy	B-T061
was	O
considered	O
when	O
the	O
initial	O
antibiotic therapy	B-T061
was	O
narrowed	O
to	O
penicillin	B-T109
,	O
amoxicillin	B-T109
or	O
amoxicillin/clavulanate	B-T121
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-T058
.	O
The	O
primary	O
outcomes	B-T169
were	O
30	O
day	B-T079
mortality	B-T081
and	O
length of hospital stay	B-T079
(	O
LOS	B-T079
).	O
Adjustment	B-T169
for	O
confounders	O
was	O
performed	B-T169
with	O
multivariate	B-T081
and	O
propensity score	B-T081
analyses	B-T062
.	O
Of	O
1410	O
episodes	O
of	O
CAPP	B-T047
,	O
antibiotic	B-T195
de-escalation	B-T061
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-T058
was	O
performed	B-T169
in	O
166	O
cases	B-T169
.	O
After	O
adjustment	B-T169
,	O
antibiotic	B-T195
de-escalation	B-T061
was	O
not	O
associated with	B-T080
a	O
higher	O
risk	B-T078
of	O
mortality	B-T081
(	O
OR	B-T081
=	O
0.83,	O
95%	O
CI	B-T081
=	O
0.24-2.81),	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective factor	B-T055
for	O
prolonged	B-T079
LOS	B-T079
(above	O
the	O
median	B-T081
)	O
(	O
OR	B-T081
=	O
0.46,	O
95%	O
CI	B-T081
=	O
0.30-0.70).	O
Similar	O
results	B-T169
were	O
found	O
in	O
patients	B-T101
classified	O
into	O
high-risk	B-T033
pneumonia	B-T047
severity	O
index	O
classes	O
(IV-V),	O
those	O
with	O
clinical instability	B-T033
and	O
those	O
with	O
bacteraemia	B-T047
.	O
No significant differences	B-T033
were	O
documented	B-T058
in	O
adverse drug reactions	B-T046
or	O
readmission	B-T058
(<30	O
days	B-T079
).	O
Antibiotic	B-T195
de-escalation	B-T061
seems	O
to	O
be	O
safe	O
and	O
effective	B-T080
in	O
reducing	B-T080
the	O
duration	B-T079
of	O
LOS	B-T079
,	O
and	O
did	O
not	O
adversely affect	B-T046
outcomes	B-T169
of	O
patients	B-T101
with	O
CAPP	B-T047
,	O
even	O
those	O
with	O
bacteraemia	B-T047
and	O
severe disease	B-T047
,	O
and	O
those	O
who	O
were	O
clinically unstable	B-T033
.	O

Radiation	B-T070
-	O
induced	B-T169
Parotid Gland Atrophy	B-T046
in	O
Patients	B-T101
with	O
Head and Neck Cancer	B-T191
After	O
Carbon-ion Radiotherapy	B-T061
This	O
study	B-T062
aimed	O
to	O
clarify	B-T052
the	O
relationship	B-T080
between	O
dosimetric	B-T059
factors	B-T169
and	O
parotid gland (PG) atrophy	B-T046
after	O
carbon ion radiotherapy	B-T061
(	O
C-ion RT	B-T061
).	O
Fifty-four	O
patients	B-T101
with	O
head and neck tumours	B-T191
were	O
enrolled	O
and	O
93	O
irradiated	O
PGs	B-T023
were	O
analyzed.	O
Thirty	O
and	O
24	O
patients	B-T101
were	O
treated with	B-T061
total doses	B-T081
[	O
relative biological effectiveness	B-T081
(	O
RBE	B-T081
)]	O
of	O
57.6	O
Gy	O
and	O
64.0	O
Gy,	O
respectively,	O
in	O
16	O
fractions.	O
PG	B-T023
volumes	B-T081
were	O
measured	B-T059
using	O
computed tomographic images	B-T078
obtained	O
before	O
C-ion RT	B-T061
and	O
every	O
3-6	O
months	B-T079
thereafter.	O
The	O
median	B-T081
follow-up	B-T058
period	B-T079
was	O
46.4	O
months	B-T079
(	O
range	B-T081
=24.0-123.0	O
months	B-T079
).	O
Univariate analysis	B-T062
showed	O
that	O
PG	B-T023
volumes	B-T081
receiving	O
more	O
than	O
5,	O
10,	O
15,	O
and	O
20	O
Gy	O
RBE	B-T081
(	O
V5	B-T081
,	O
V10	B-T081
,	O
V15	B-T081
and	O
V20	B-T081
,	O
respectively),	O
mean	B-T081
dose	B-T081
,	O
and	O
maximum	B-T081
dose	B-T081
were	O
significantly	O
associated with	B-T080
PG atrophy	B-T046
.	O
Multivariate analysis	B-T081
indicated	O
that	O
only	O
V5	B-T081
was	O
significantly	O
associated with	B-T080
atrophy	B-T046
.	O
Increasing	B-T169
V5	B-T081
was	O
a	O
significant	O
risk factor	B-T033
for	O
PG atrophy	B-T046
after	O
C-ion RT	B-T061
.	O

IL-27	B-T116
Is	O
Essential	O
for	O
Suppression	B-T061
of	O
Experimental	B-T080
Allergic Asthma	B-T047
by	O
the	O
TLR7	B-T116
/	O
8	B-T116
Agonist	B-T121
R848	B-T109
(	O
Resiquimod	B-T109
)	O
Different	O
models of experimental	B-T050
allergic asthma	B-T047
have	O
shown	O
that	O
the	O
TLR7	B-T116
/	O
8	B-T116
agonist	B-T121
resiquimod	B-T109
(	O
R848	B-T109
)	O
is	O
a	O
potential	O
inhibitor	B-T080
of	O
type 2 helper cell	B-T025
-driven	O
inflammatory responses	B-T046
.	O
However,	O
the	O
mechanisms	O
mediating	O
its	O
therapeutic effects	B-T201
are	O
not	O
fully	O
understood.	O
Using	O
a	O
model of experimental	B-T050
allergic asthma	B-T047
,	O
we	O
show	O
that	O
induction	B-T061
of	O
IL-27	B-T116
by	O
R848	B-T109
is	O
critical	O
for	O
the	O
observed	O
ameliorative	B-T080
effects.	O
R848	B-T109
significantly	O
inhibited	B-T080
all	O
hallmarks	B-T025
of	O
experimental	B-T080
allergic asthma	B-T047
,	O
including	O
airway hyperreactivity	B-T047
,	O
eosinophilic	B-T169
airway	B-T023
inflammation	B-T046
,	O
mucus hypersecretion	B-T047
,	O
and	O
Ag	B-T129
-	O
specific Ig	B-T116
production	B-T038
.	O
Whereas	O
R848	B-T109
significantly	O
reduced	O
IL-5	B-T116
,	O
IL-13	B-T116
,	O
and	O
IL-17	B-T116
,	O
it	O
induced	O
IFN-γ	B-T116
and	O
IL-27	B-T116
.	O
Neutralization	B-T169
of	O
IL-27	B-T116
completely	O
reversed	O
the	O
therapeutic effect	B-T201
of	O
R848	B-T109
in	O
the	O
experimental	B-T080
asthma	B-T047
model	B-T050
,	O
demonstrating	O
dependence	O
of	O
R848	B-T109
-mediated	O
suppression	B-T061
on	O
IL-27	B-T116
.	O
In vitro	B-T080
,	O
R848	B-T109
induced	B-T061
production	O
of	O
IL-27	B-T116
by	O
murine	B-T015
alveolar macrophages	B-T025
and	O
dendritic cells	B-T025
and	O
enhanced	B-T052
expression	B-T045
of	O
programmed death-ligand 1	B-T129
,	O
whose	O
expression	B-T045
on	O
monocytes	B-T025
and	O
dendritic cells	B-T025
has	O
been	O
shown	O
to	O
regulate	B-T038
peripheral tolerance	B-T042
in	O
both	O
murine	B-T015
and	O
human	B-T016
studies.	O
Moreover,	O
in vitro	B-T080
IL-27	B-T116
enhanced	B-T052
secretion	B-T043
of	O
IFN-γ	B-T116
whereas	O
it	O
inhibited	B-T080
IL-5	B-T116
and	O
IL-13	B-T116
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	B-T025
responses.	O
Taken	O
together,	O
our	O
study	O
proves	O
that	O
R848	B-T109
-mediated	O
suppression	B-T061
of	O
experimental	B-T080
asthma	B-T047
is	O
dependent	O
on	O
IL-27	B-T116
.	O
These	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
IL-27	B-T116
for	O
the	O
control	O
of	O
Th2	B-T025
-mediated	O
allergic diseases	B-T047
.	O

A	O
comparison	O
of	O
functional	B-T169
outcomes	O
in	O
patients	B-T101
undergoing	O
revision arthroscopic repair	B-T061
of	O
massive	O
rotator cuff tears	B-T047
with	O
and	O
without	B-T080
arthroscopic	B-T082
suprascapular nerve release	B-T061
This	O
study	O
was	O
designed	O
to	O
compare	O
functional	B-T169
outcomes	O
in	O
patients	B-T101
undergoing	O
revision repair	B-T061
of	O
massive	O
rotator cuff tears	B-T047
(	O
retracted medial	B-T082
to	O
the	O
glenoid	B-T030
)	O
with	O
Goutallier Grade 4 atrophy	B-T046
and	O
concomitant	O
release of the suprascapular nerve	B-T061
to	O
a	O
similar	O
group	O
of	O
patients	B-T101
with	O
Grade 3 atrophy	B-T046
undergoing	O
revision rotator cuff repair	B-T061
(	O
RTCR	B-T061
)	O
without	O
nerve release	B-T061
.	O
We	O
hypothesized	O
that	O
patients	B-T101
undergoing	O
nerve release	B-T061
would	O
have	O
more	O
favorable	O
functional	B-T169
outcomes	O
as	O
measured	O
by	O
the	O
Modified	O
University of California	B-T092
at	O
Los Angeles	B-T083
shoulder rating scale	B-T081
(	O
UCLA	B-T081
).	O
Twenty-two	O
patients	B-T101
underwent	O
revision repair	B-T061
of	O
massive	O
rotator cuff tears	B-T047
with	O
release of the suprascapular nerve	B-T061
at	O
the	O
suprascapular notch	B-T029
.	O
We	O
compared	O
total	O
preoperative	B-T079
,	O
postoperative	B-T079
,	O
and	O
change	O
in	O
UCLA score	B-T080
in	O
these	O
patients	B-T101
to	O
a	O
similar	O
group	B-T098
of	O
22	O
patients	B-T101
undergoing	O
revision RTCR	B-T061
without	B-T080
suprascapular nerve release	B-T061
.	O
Additionally,	O
UCLA	O
subscores	O
between	O
the	O
two	O
groups	B-T098
were	O
compared	O
preoperatively	B-T079
and	O
at	O
final	O
follow-up	B-T058
.	O
The	O
average	O
preoperative	B-T079
UCLA score	B-T080
in	O
the	O
nerve-release group	B-T098
was	O
7.91,	O
and	O
final	O
follow-up	B-T058
average	O
was	O
27.86;	O
average	O
3.05	O
grades	O
of	O
strength	O
were	O
recovered.	O
In	O
the	O
comparison	O
group	B-T098
,	O
average	O
preoperative	B-T079
UCLA score	B-T080
was	O
11.77,	O
and	O
final	O
follow-up	B-T058
average	O
was	O
29.09;	O
average	O
1.32	O
grades	O
of	O
strength	O
were	O
recovered.	O
The	O
average	O
preoperative	B-T079
UCLA score	B-T080
was	O
significantly	O
worse	O
in	O
the	O
nerve-release group	B-T098
(P=0.007).	O
The	O
average	O
postoperative	B-T079
UCLA score	B-T080
was	O
not	O
significantly	O
different	O
(P=0.590)	O
between	O
the	O
groups	B-T098
,	O
indicating	O
a	O
better	O
improvement	O
in	O
the	O
nerve-release group	B-T098
with	O
significantly	O
greater	O
improvement	O
in	O
active	O
forward	O
flexion	B-T042
,	O
strength	B-T042
,	O
and	O
pain relief	B-T061
.	O
Patients	B-T101
who	O
underwent	O
concomitant	O
release of the suprascapular nerve	B-T061
during	O
revision RTCR	B-T061
had	O
greater	O
overall	O
improvement	O
as	O
noted	O
in	O
pain relief	B-T061
,	O
active forward flexion	B-T042
,	O
and	O
strength	B-T042
,	O
than	O
a	O
comparable	O
group	B-T098
without	B-T080
nerve release	B-T061
.	O

Fading	B-T081
With Time	B-T079
of	O
PD-L1	B-T129
Immunoreactivity	B-T044
in	O
Non-Small Cells Lung Cancer	B-T191
Tissues	B-T024
:	O
A	O
Methodological Study	B-T057
Blockade	B-T169
of	O
inhibitory immune checkpoints	B-T043
is	O
currently	O
arising	O
as	O
a	O
potential	O
immunologic	B-T169
option	B-T169
for	O
tumor therapy	B-T061
.	O
Inhibition	B-T052
of	O
programmed cell death protein 1	B-T116
and/or	O
its	O
specific	O
ligand	B-T103
programmed death-ligand 1	B-T129
(	O
PD-L1	B-T129
)	O
was	O
effective	O
in	O
clinical trials	B-T062
in	O
advanced	B-T080
melanoma	B-T191
,	O
non-small cell lung cancer	B-T191
(	O
NSCLC	B-T191
)	O
bladder	B-T191
and	O
kidney cancer	B-T191
.	O
The	O
predictive	O
role	O
of	O
the	O
immunohistochemical	B-T059
(	O
IHC	B-T059
)	O
expression	B-T045
of	O
PD-L1	B-T129
is	O
highly	O
debated.	O
Different	O
reagents	B-T130
,	O
clones	B-T024
,	O
cutoffs	O
of	O
cell	B-T025
expression	B-T045
and	O
subjective	B-T080
interpretation	B-T033
of	O
PD-L1	B-T129
immunoreactivity	B-T044
in	O
epithelial cells	B-T025
and	O
lymphocytes	B-T025
are	O
the	O
main	O
issue	B-T033
.	O
In	O
this	O
study	O
we	O
selected	O
58	O
consecutive	O
NSCLC	B-T191
surgical specimens	B-T024
that	O
underwent	O
pathologic examination	B-T060
from	O
January	B-T080
2014	O
to	O
July	B-T080
2015.	O
Using	O
a	O
tissue	O
microarray approach	B-T059
we	O
evaluated	O
the	O
IHC expression	B-T059
of	O
PD-L1	B-T129
in	O
tumor-infiltrating lymphocytes	B-T025
and	O
tumor cells	B-T025
(	O
TCs	B-T025
)	O
and	O
compared	O
the	O
ICH staining	B-T059
with	O
tumor histology	B-T091
,	O
grade	B-T185
and	O
the	O
age	O
of	O
the	O
tissue blocks	B-T024
.	O
The	O
main	O
new	O
finding	B-T033
was	O
the	O
fading	B-T081
of	O
PD-L1	B-T129
IHC expression	B-T059
in	O
TCs	B-T025
in	O
tissues	B-T024
processed	O
in	O
2014	O
compared	O
with	O
2015.	O
PD-L1	B-T129
expression	B-T045
in	O
tumor-infiltrating lymphocytes	B-T025
in	O
the	O
2	O
years	B-T079
was	O
similar	B-T080
.	O
We	O
also	O
found	O
a	O
significant higher	B-T080
immunoreactivity	B-T044
of	O
TCs	B-T025
in	O
high grade	B-T080
NSCLC	B-T191
and	O
in	O
the	O
squamous carcinoma	B-T191
histotype	B-T201
compared	O
with	O
low grade	B-T080
tumors	B-T091
and	O
the	O
adenocarcinoma	B-T191
histology	B-T091
(P=0.013).	O
We	O
demonstrated	O
that	O
the	O
IHC evaluation	B-T059
of	O
PD-L1	B-T129
in	O
NSCLC	B-T191
archival tissues	B-T024
is	O
feasible	O
and	O
can	O
be	O
implemented	O
in	O
a	O
routine	O
pathology setting	B-T091
,	O
but	O
it	O
should	O
be	O
carefully	O
assessed	O
in	O
tissue blocks	B-T024
older	O
than	O
1	O
year	B-T079
.	O

Differential	B-T080
transcriptome	B-T086
expression	B-T045
in	O
human	B-T016
nucleus accumbens	B-T023
as	O
a	O
function	O
of	O
loneliness	B-T033
Loneliness	B-T033
is	O
associated with	B-T080
impaired	B-T046
mental	B-T041
and	O
physical health	B-T078
.	O
Studies	O
of	O
lonely individuals	B-T098
reported	O
differential expression	B-T045
of	O
inflammatory	B-T169
genes	B-T028
in	O
peripheral	B-T082
leukocytes	B-T025
and	O
diminished	B-T081
activation	B-T045
in	O
brain	B-T023
reward regions	B-T029
such	O
as	O
nucleus accumbens	B-T023
,	O
but	O
could	O
not	O
address	O
gene expression	B-T045
in	O
the	O
human	B-T016
brain	B-T023
.	O
Here,	O
we	O
examined	O
genome-wide RNA expression	B-T045
in	O
post-mortem	B-T060
nucleus accumbens	B-T023
from	O
donors	B-T098
(N=26)	O
with	O
known	O
loneliness	B-T033
measures	B-T081
.	O
Loneliness	B-T033
was	O
associated with	B-T080
1710	O
differentially expressed transcripts	B-T114
and	O
genes	B-T028
from	O
1599	O
genes	B-T028
(	O
DEGs	B-T028
;	O
false discovery rate	B-T081
P<0.05,	O
fold	O
change	O
⩾|2|,	O
controlling	O
for	O
confounds)	O
previously	O
associated with	B-T080
behavioral processes	B-T053
,	O
neurological disease	B-T047
,	O
psychological disorders	B-T048
,	O
cancer	B-T191
,	O
organismal	B-T001
injury	B-T037
and	O
skeletal	B-T047
and	O
muscular disorders	B-T047
,	O
as	O
well	O
as	O
networks	B-T169
of	O
upstream	B-T082
RNA regulators	B-T028
.	O
Furthermore,	O
a	O
number	O
of	O
DEGs	B-T028
were	O
associated with	B-T080
Alzheimer's disease	B-T047
(	O
AD	B-T047
)	O
genes	B-T028
(that	O
was	O
correlated	B-T080
with	O
loneliness	B-T033
in	O
this	O
sample	B-T167
,	O
although	O
gene expression analyses	B-T063
controlled	O
for	O
AD	B-T047
diagnosis	B-T033
).	O
These	O
results	O
identify	O
novel	O
targets	B-T169
for	O
future	O
mechanistic studies	B-T062
of	O
gene	B-T028
networks	O
in	O
nucleus accumbens	B-T023
and	O
gene regulatory mechanisms	B-T045
across	O
a	O
variety	O
of	O
diseases	B-T047
exacerbated	O
by	O
loneliness	B-T033
.	O
Molecular Psychiatry advance online publication	B-T073
,	O
1	O
November	B-T079
2016;	O
doi:10.1038/mp.2016.186.	O

Overall	O
Quality Properties	B-T080
of	O
Kiwifruit	B-T168
Treated by	B-T061
Cinnamaldehyde	B-T109
and	O
Citral	B-T109
:	O
Microbial	B-T001
,	O
Antioxidant Capacity	B-T044
during	O
Cold Storage	B-T059
This	O
work	O
was	O
undertaken	O
to	O
evaluate	B-T058
the	O
microbiological	B-T170
characteristics	B-T080
and	O
antioxidant	B-T044
and	O
physiological activities	B-T039
in	O
kiwifruits	B-T168
(	O
Actinida deliciosa	B-T002
var.	O
Qinmei)	O
with/without	O
cinnamaldehyde	B-T109
(C1)	O
and	O
citral	B-T109
(C2)	O
fumigation	B-T068
treatments	B-T169
(5	O
μL/L)	O
during	O
0,	O
3,	O
6,	O
9,	O
and	O
12	O
d	O
of	O
storage	B-T169
at	O
4	O
°C.	O
Essential oils	B-T109
(	O
EOs	B-T109
)	O
treatment	B-T169
lowered	O
the	O
total	O
viable counts	B-T081
,	O
yeast	B-T004
,	O
and	O
mold	B-T004
to	O
1.54,	O
2.36,	O
and	O
2.05	O
log	O
CFU/g,	O
respectively.	O
Moreover,	O
EOs	B-T109
improved	O
the	O
antioxidant activities	B-T044
of	O
kiwifruit	B-T168
.	O
They	O
enhanced	B-T052
phenolics	B-T109
and	O
flavonoids	B-T109
content	O
in	O
fruit	B-T168
tissue	B-T025
by	O
49.48%	O
at	O
day	O
3	O
and	O
56.93%	O
at	O
day	O
6,	O
respectively.	O
In	O
addition,	O
ascorbic acid	B-T109
in	O
treated	B-T169
groups	B-T078
had	O
the	O
lower	O
losing	O
rate	B-T081
.	O
Similarly,	O
MDA	B-T109
(	O
malondialdehyde	B-T109
),	O
H2 O2	B-T121
(	O
hydrogen peroxide	B-T121
),	O
and	O
(•)	O
O2(-)	B-T196
(	O
superoxide anion	B-T196
)	O
production	O
were	O
effectively	B-T080
decreased	B-T081
in	O
the	O
range	O
of	O
27.27%	O
to	O
54.38%.	O
Physicochemical characteristics	B-T080
showed	O
that	O
kiwifruits	B-T168
from	O
treated	B-T169
group	B-T078
maintained	O
higher	O
levels	O
of	O
flesh luminosity	B-T080
and	O
firmness	B-T080
.	O
EOs	B-T109
also	O
decreased	B-T081
the	O
levels	O
of	O
reducing sugar	B-T109
by	O
45.97%	O
at	O
day	O
3,	O
and	O
increased	B-T081
the	O
content	O
of	O
soluble protein	B-T116
and	O
hydrolyzed	O
amino acid	B-T116
.	O
Therefore,	O
postharvest	O
EOs	B-T109
treatment	B-T169
has	O
positive effects	B-T080
on	O
delaying	O
senescence	B-T038
and	O
enhancing	B-T052
antioxidant capacities	B-T044
in	O
kiwifruit	B-T168
.	O

Anti-inflammatory effect	B-T080
of	O
Yu-Ping-Feng-San	B-T109
via	O
TGF-β1	B-T116
signaling suppression	B-T038
in	O
rat	B-T015
model	B-T050
of	O
COPD	B-T047
Yu-Ping-Feng-San	B-T109
(	O
YPFS	B-T109
)	O
is	O
a	O
classical	O
traditional	O
Chinese medicine	B-T121
that	O
is	O
widely	O
used	O
for	O
treatment	B-T169
of	O
the	O
diseases	B-T047
in	O
respiratory systems	B-T022
,	O
including	O
chronic obstructive pulmonary disease	B-T047
(	O
COPD	B-T047
)	O
recognized	O
as	O
chronic inflammatory disease	B-T047
.	O
However,	O
the	O
molecular mechanism	B-T044
remains	O
unclear.	O
Here	O
we	O
detected	O
the	O
factors	O
involved	O
in	O
transforming growth factor beta 1	B-T116
(	O
TGF-β1	B-T116
)/	O
Smad2	B-T116
signaling pathway	B-T044
and	O
inflammatory cytokines	B-T116
,	O
to	O
clarify	O
whether	O
YPFS	B-T109
could	O
attenuate	B-T052
inflammatory response	B-T046
dependent	O
on	O
TGF-β1	B-T116
/	O
Smad2	B-T116
signaling	B-T038
in	O
COPD	B-T047
rats	B-T015
or	O
cigarette smoke extract	B-T131
(	O
CSE	B-T131
)-	O
treated	B-T169
human	B-T016
bronchial epithelial (Beas-2B) cells	B-T025
.	O
The	O
COPD	B-T047
rat	B-T015
model	B-T050
was	O
established	O
by	O
exposure	B-T080
to	O
cigarette smoke	B-T131
and	O
intratracheal instillation	B-T169
of	O
lipopolysaccharide	B-T109
,	O
YPFS	B-T109
was	O
administered	O
to	O
the	O
animals	B-T008
.	O
The	O
efficacy	B-T080
of	O
YPFS	B-T109
was	O
evaluated	O
by	O
comparing	O
the	O
severity	B-T080
of	O
pulmonary pathological damage	B-T046
,	O
pro-inflammation cytokines	B-T116
,	O
collagen related genes	B-T028
and	O
the	O
activation	B-T052
of	O
TGF-β1	B-T116
/	O
Smad2	B-T116
signaling pathway	B-T044
.	O
Furthermore,	O
CSE	B-T131
-	O
treated	B-T169
cells	B-T025
were	O
employed	O
to	O
confirm	O
whether	O
the	O
effect	B-T080
of	O
YPFS	B-T109
was	O
dependent	O
on	O
the	O
TGF-β1	B-T116
/	O
Smad2	B-T116
signaling	B-T038
via	O
knockdown	B-T063
Smad2	B-T028
(	O
Si-RNA	B-T114
),	O
or	O
pretreatment	B-T052
with	O
the	O
inhibitor	B-T080
of	O
TGF-β1	B-T116
.	O
Administration	O
of	O
YPFS	B-T109
effectively	O
alleviated	O
injury of lung	B-T037
,	O
suppressed	B-T169
releasing	O
of	O
pro-inflammatory cytokines	B-T116
and	O
collagen deposition	B-T046
in	O
COPD	B-T047
animals	B-T008
(P<0.05),	O
whereas	O
exogenous TGF-β1	B-T116
promoted	O
releasing	O
of	O
IL-1β	B-T116
,	O
IL-6	B-T116
,	O
TNFα	B-T116
(P<0.05).	O
Administration	O
YPFS	B-T109
reduced	O
inflammatory response	B-T046
significantly,	O
also	O
down-regulated	B-T044
TGF-β1	B-T116
/	O
Smad2	B-T116
signaling	B-T038
in vivo	B-T082
and	O
in vitro	B-T080
.	O
Unexpectedly,	O
knockdown	B-T063
Smad2	B-T028
or	O
inhibition	B-T052
of	O
TGF-β1	B-T116
abolished	O
anti-inflammatory effect	B-T080
of	O
YPFS	B-T109
in	O
CSE	B-T131
-	O
treated	B-T169
cells	B-T025
.	O
YPFS	B-T109
accomplished	O
anti-inflammatory effects	B-T080
mainly	O
by	O
suppressing	B-T169
phosphorylation	B-T044
of	O
Smad2	B-T116
,	O
TGF-β1	B-T116
/	O
Smad2	B-T116
signaling pathway	B-T044
was	O
required	O
for	O
YPFS	B-T109
-mediated	O
anti-inflammation	B-T080
in	O
COPD	B-T047
rats	B-T015
or	O
CSE	B-T131
-	O
treated	B-T169
Beas-2B cells	B-T025
.	O

The	O
association	B-T080
between	O
maternal	B-T033
hydronephrosis	B-T047
and	O
acute	B-T079
flank pain	B-T184
during	O
pregnancy	B-T040
:	O
a	O
prospective	B-T062
pilot-study	B-T062
Maternal	B-T033
hydronephrosis	B-T047
may	O
cause	O
flank pain	B-T184
during	O
pregnancy	B-T040
.	O
We	O
aimed	B-T078
to	O
investigate	B-T169
the	O
association	O
between	O
maternal	B-T033
hydronephrosis	B-T047
and	O
flank pain	B-T184
intensity	B-T201
.	O
From	O
2014	O
to	O
2015,	O
all	O
consecutive	B-T080
women	B-T098
with	O
singleton pregnancies	B-T040
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	B-T079
flank pain	B-T184
,	O
were	O
prospectively	B-T062
evaluated	B-T058
by	O
renal	B-T023
ultrasonography	B-T060
and	O
pain	B-T184
questionnaires	B-T170
.	O
A	O
visual analogue scale	B-T060
was	O
used	O
to	O
assess	O
pain intensity	B-T201
.	O
The	O
study	B-T062
had	O
90%	O
power	O
to	O
detect	O
a	O
significant	B-T078
correlation	B-T080
between	O
hydronephrosis	B-T047
and	O
flank pain	B-T184
(	O
Spearman's test	B-T170
).	O
A	O
total	O
of	O
51	O
consecutive	B-T080
women	B-T098
with	O
left-sided	B-T082
(13.7%),	O
right-sided	B-T082
(64.7%)	O
or	O
bilateral	B-T082
(21.6%)	O
pain	B-T184
were	O
enrolled.	O
The	O
mean	B-T081
gestational age	B-T032
of	O
these	O
women	B-T098
,	O
who	O
presented	O
due	O
to	O
their	O
pain	B-T184
,	O
was	O
27.5	O
±	O
6.8	O
weeks	B-T079
at	O
the	O
time	O
of	O
consultation	B-T058
.	O
The	O
mean	B-T081
VAS score	B-T201
was	O
7.6	O
±	O
2.2.	O
In	O
43/51	O
(84.3%)	O
women	B-T098
,	O
hydronephrosis	B-T047
was	O
found	O
on	O
renal	B-T023
sonograms.	O
No	O
correlation	B-T080
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	B-T047
and	O
pain intensity	B-T201
(p	O
=	O
0.466;	O
r=	O
-0.28).	O
Women	B-T098
delivered	O
at	O
a	O
mean	B-T081
gestational age	B-T032
of	O
38.1	O
±	O
2.4	O
weeks	B-T079
and	O
their	O
infants	B-T100
had	O
a	O
mean	B-T081
birthweight	B-T032
of	O
3138	O
±	O
677	O
g.	O
Hydronephrosis	B-T047
is	O
a	O
common	O
finding	B-T033
among	O
pregnant women	B-T098
with	O
acute	B-T079
flank pain	B-T184
.	O
The	O
grade	O
of	O
hydronephrosis	B-T047
does	O
not	O
affect	O
pain intensity	B-T201
.	O
This	O
study	B-T062
suggests	O
normal pregnancy	B-T033
outcomes	B-T033
in	O
these	O
women	B-T098
.	O

Simulating	B-T062
the	O
potential	B-T080
role	B-T077
of	O
media coverage	B-T057
and	O
infected	B-T033
bats	B-T015
in	O
the	O
2014	O
Ebola	B-T047
outbreak	B-T067
Multiple	O
epidemiological	B-T169
models	B-T075
have	O
been	O
developed	B-T169
to	O
model	O
the	O
transmission dynamics	B-T078
of	O
Ebola virus (EBOV) disease	B-T047
in	O
West Africa	B-T083
in	O
2014	O
because	O
the	O
severity	B-T080
of	O
the	O
epidemic	B-T067
is	O
commonly	O
overestimated.	O
A	O
compartmental model	B-T170
that	O
incorporates	O
the	O
media impact	B-T080
and	O
the	O
effect	B-T080
of	O
infected	B-T033
bats	B-T015
was	O
constructed	O
and	O
calibrated	B-T081
using	O
data	B-T078
reported	O
until	O
the	O
end	O
of	O
2014.	O
The	O
final	O
cumulative	B-T080
number of deaths	B-T081
and	O
confirmed	B-T033
cases	B-T077
were	O
estimated	B-T081
to	O
be	O
1.0921×10(4)	O
(95%	O
CI	B-T081
9.7706×10(3)-1.2072×10(4))	O
and	O
1.5193×10(4)	O
(95%	O
CI	B-T081
1.3593×10(4)-1.6795×10(4)),	O
respectively.	O
The	O
epidemic	B-T067
was	O
estimated	B-T081
to	O
end	O
on	O
June	O
2015,	O
which	O
was	O
similar	B-T080
to	O
the	O
data	B-T078
reported	B-T058
by	O
the	O
World Health Organization	B-T093
.	O
A	O
sensitivity analysis	B-T062
indicated	B-T033
that	O
an	O
increase	B-T169
of	O
either	O
the	O
media impact	B-T080
or	O
the	O
number	B-T081
of	O
infectious	B-T080
bats	B-T015
that	O
are	O
captured	O
daily	B-T079
can	O
increase	B-T169
the	O
cumulative	B-T080
number	B-T081
of	O
confirmed	B-T033
cases	B-T077
/	O
deaths	B-T081
.	O
Of	O
the	O
considered	O
epidemiological parameters	B-T169
,	O
only	O
the	O
media coverage	B-T057
can	O
significantly	O
reduce	O
both	O
the	O
peak time	B-T033
and	O
the	O
value	B-T081
of	O
the	O
cumulative	B-T080
confirmed	B-T033
cases	B-T077
/	O
deaths	B-T081
.	O
Thus,	O
we	O
propose	O
'the	O
cumulative	B-T080
confirmed	B-T033
cases	B-T077
and	O
deaths	B-T081
'	O
as	O
another	O
media	B-T170
mechanism	B-T169
.	O
In	O
conclusion,	O
the	O
media impact	B-T080
contributed	O
to	O
the	O
control	B-T080
of	O
the	O
2014	O
Ebola	B-T047
outbreak	B-T067
,	O
and	O
infectious	B-T080
bats	B-T015
may	O
be	O
a	O
potential	B-T080
source	B-T033
of	O
the	O
epidemic	B-T067
.	O

Body	B-T016
Diffusion Weighted Imaging	B-T060
Using	O
Non-CPMG Fast Spin Echo	B-T060
SS-FSE	B-T060
is	O
a	O
fast	B-T080
technique	B-T060
that	O
does	O
not	O
suffer	O
from	O
off-resonance	B-T033
distortions	B-T080
to	O
the	O
degree	O
that	O
EPI	B-T060
does.	O
Unlike	O
EPI	B-T060
,	O
SS-FSE	B-T060
is	O
ill-suited	O
to	O
diffusion weighted imaging	B-T060
(	O
DWI	B-T060
)	O
due	O
to	O
the	O
Carr-Purcell-Meiboom-Geill (CPMG) condition	B-T033
.	O
Non-CPMG	B-T033
phase	B-T079
cycling	B-T079
does	O
accommodate	O
SS-FSE	B-T060
and	O
DWI	B-T060
but	O
places	B-T082
constraints	B-T169
on	O
reconstruction	B-T169
,	O
which	O
are	O
resolved	B-T033
here	O
through	O
parallel imaging	B-T060
.	O
Additionally,	O
improved	B-T033
echo stability	B-T080
can	O
be	O
achieved	O
by	O
using	O
short duration	B-T080
and	O
highly	O
selective	O
DIVERSE	B-T080
radiofrequency	B-T070
pulses	B-T067
.	O
Here,	O
signal-to-noise ratio	B-T081
(	O
SNR	B-T081
)	O
comparisons	O
between	O
EPI	B-T060
and	O
nCPMG	B-T033
SS-FSE	B-T060
acquisitions	B-T066
and	O
reconstruction techniques	B-T169
give	O
similar	B-T080
values	B-T080
.	O
Diffusion imaging	B-T060
with	O
nCPMG	B-T033
SS-FSE	B-T060
gives	O
similar	B-T080
SNR	B-T081
to	O
an	O
EPI	B-T060
acquisition	B-T066
,	O
though	O
apparent diffusion coefficient	B-T077
values	B-T080
are	O
higher	B-T080
than	O
seen	O
with	O
EPI	B-T060
.	O
In vivo	B-T082
images	B-T170
have	O
good	O
image quality	B-T080
with	O
little	O
distortion	B-T080
.	O
This	O
method	O
has	O
the	O
ability	O
to	O
capture	O
distortion	B-T080
-	O
free	B-T169
DWI	B-T060
images	B-T170
near	O
areas	B-T082
of	O
significant	B-T078
off-resonance	B-T033
as	O
well	O
as	O
preserve	O
adequate	O
SNR	B-T081
.	O
Parallel imaging	B-T060
and	O
DIVERSE	B-T080
refocusing	O
RF	B-T070
pulses	B-T066
allow	O
shorter ETL	B-T079
compared	O
to	O
previous	O
implementations	B-T052
and	O
thus	O
reduces	B-T080
phase	B-T079
encode	B-T052
direction	B-T082
blur	B-T080
and	O
SAR	B-T040
accumulation	B-T033
.	O

Modification	B-T169
of	O
Mechanical Properties	B-T080
,	O
Polymerization	B-T067
Temperature	B-T081
,	O
and	O
Handling Time	B-T079
of	O
Polymethylmethacrylate	B-T109
Cement	B-T122
for	O
Enhancing	O
Applicability	B-T169
in	O
Vertebroplasty	B-T061
Polymethylmethacrylate	B-T109
(	O
PMMA	B-T109
)	O
bone cement	B-T122
is	O
a	O
popular	O
bone	B-T023
void	B-T030
filler	B-T122
for	O
vertebroplasty	B-T061
.	O
However,	O
the	O
use	O
of	O
PMMA	B-T109
has	O
some	O
drawbacks,	O
including	O
the	O
material's	B-T122
excessive	O
stiffness	B-T080
,	O
exothermic polymerization	B-T067
,	O
and	O
short	B-T081
handling time	B-T079
.	O
This	O
study	B-T062
aimed	O
to	O
create	O
an	O
ideal	O
modified	B-T169
bone cement	B-T122
to	O
solve	O
the	O
above-mentioned	O
problems	B-T033
.	O
Modified	B-T169
bone cements	B-T122
were	O
prepared	B-T052
by	O
combining	O
PMMA	B-T109
with	O
three	O
different	O
volume fractions	B-T081
of	O
castor oil	B-T109
(5%,	O
10%,	O
and	O
15%).	O
The	O
peak	B-T080
polymerization	B-T067
temperatures	B-T081
,	O
times	O
to	O
achieve	O
the	O
peak	B-T080
polymerization	B-T067
temperature	B-T081
,	O
porosities	B-T080
,	O
densities	B-T081
,	O
modulus	B-T081
and	O
maximum	B-T081
compression strengths	B-T081
of	O
standard	B-T080
(without	O
castor oil	B-T109
),	O
and	O
modified	B-T169
cements	B-T122
were	O
investigated	B-T169
following	O
storage	O
at	O
ambient temperature	B-T070
(22°C)	O
or	O
under	O
precooling	B-T070
conditions	B-T080
(3°C).	O
Six	O
specimens	B-T167
were	O
tested	O
in	O
each	O
group	O
of	O
the	O
aforementioned	O
parameters	B-T077
.	O
Increasing	B-T081
castor oil	B-T109
content	O
and	O
precooling	B-T070
treatment	B-T169
effectively	O
decreased	B-T081
the	O
peak	B-T080
polymerization	B-T067
temperatures	B-T081
and	O
increased	B-T081
the	O
duration	B-T079
to	O
achieve	O
the	O
peak	B-T080
polymerization	B-T067
temperature	B-T081
(P	O
<	O
0.05).	O
Furthermore,	O
the	O
mechanical properties	B-T080
of	O
the	O
material	B-T122
,	O
including	O
density	B-T081
,	O
modulus	B-T081
,	O
and	O
maximum	B-T081
compression strength	B-T081
,	O
decreased	B-T081
with	O
increasing	B-T081
castor oil	B-T109
content	B-T077
.	O
However,	O
preparation	B-T052
temperature	B-T081
(	O
room temperature	B-T070
versus	O
precooling	B-T070
)	O
had	O
no	O
significant	O
effect	O
(P	O
>	O
0.05)	O
on	O
these	O
mechanical properties	B-T080
.	O
In	O
conclusion,	O
the	O
addition	O
of	O
castor oil	B-T109
to	O
PMMA	B-T109
followed	O
by	O
precooling	B-T070
created	O
an	O
ideal	O
modified	B-T169
bone cement	B-T122
with	O
a	O
low	O
modulus	B-T081
,	O
low	O
polymerization	B-T067
temperature	B-T081
,	O
and	O
long	O
handling time	B-T079
,	O
enhancing	O
its	O
applicability	B-T169
and	O
safety	B-T068
for	O
vertebroplasty	B-T061
.	O

A	O
case	B-T169
of	O
retrograde intussusception	B-T020
at	O
Roux-en-Y anastomosis	B-T061
10	O
years	O
after	O
total gastrectomy	B-T061
:	O
review of the literature	B-T170
A	O
63-year-	O
old man	B-T032
,	O
who	O
had	O
undergone	O
total gastrectomy	B-T061
and	O
Roux-en-Y reconstruction	B-T061
for	O
gastric cancer	B-T191
10	O
years	O
previously,	O
was	O
admitted	B-T058
to	O
our	O
hospital	B-T073
with	O
complaints	B-T184
of	O
abdominal pain	B-T184
,	O
palpable	B-T080
abdominal tumor	B-T191
,	O
and	O
hematemesis	B-T033
.	O
On admission	B-T058
,	O
the	O
abdominal tenderness	B-T184
was	O
improving	B-T080
and	O
no	O
abdominal tumor	B-T191
was	O
palpable	B-T080
.	O
Mild inflammatory	B-T046
changes	O
and	O
anemia	B-T047
were	O
noted	O
on	O
blood examination	B-T059
.	O
Abdominal	B-T029
computed tomography	B-T060
revealed	O
a	O
tumor	B-T191
with	O
a	O
layered structure	B-T080
in	O
the	O
left abdomen	B-T029
.	O
The	O
patient	B-T101
was	O
diagnosed	B-T033
with	O
intestinal obstruction	B-T047
secondary	O
to	O
intussusception	B-T047
,	O
and	O
surgery	B-T061
was	O
performed	B-T169
.	O
Retrograde intussusception	B-T020
was	O
found	O
at	O
the	O
site	O
of	O
the	O
Y anastomosis	B-T061
.	O
We	O
conducted	O
manual reduction	B-T061
using	O
the	O
Hutchinson procedure	B-T061
.	O
The	O
intestinal	B-T023
color	B-T080
after	O
the	O
reduction	B-T061
was	O
good,	O
and	O
no	O
intestinal resection	B-T061
was	O
required	B-T169
.	O
Postoperative recovery	B-T033
was	O
uneventful,	O
and	O
the	O
patient	B-T101
was	O
discharged	B-T058
12	O
days	O
after	O
surgery	B-T061
.	O
Reports	B-T170
of	O
jejunal	B-T023
intussusception	B-T047
after	O
total gastrectomy	B-T061
with	O
Roux-en-Y reconstruction	B-T061
are	O
relatively	O
rare.	O
Here,	O
we	O
report	O
a	O
case	O
of	O
jejunal	B-T023
intussusception	B-T047
after	O
total gastrectomy	B-T061
with	O
Roux-en-Y reconstruction	B-T061
.	O

Brassinosteroid	B-T109
-	O
induced	B-T169
changes	B-T169
of	O
lipid	B-T109
composition	B-T070
in	O
leaves	B-T002
of	O
Pisum sativum L.	B-T002
during	O
senescence	B-T040
The	O
effect of	B-T080
steroid	B-T109
phytohormone	B-T116
24-epibrassinolide	B-T109
(	O
EBR	B-T109
)	O
on	O
the	O
composition	B-T070
of	O
some	O
lipid	B-T109
classes	B-T170
(	O
free fatty acids	B-T109
,	O
triacylglycerols	B-T109
and	O
galactolipids	B-T109
)	O
in	O
detached	B-T169
pea	B-T002
leaves	B-T002
was	O
studied	O
for	O
the	O
first	O
time.	O
EBR	B-T109
(0.1μM)	O
promoted	O
senescence	B-T040
and	O
increased	B-T081
the	O
content	B-T077
of	O
14:0,	O
16:0	O
and	O
18:1	O
free fatty acids	B-T109
as	O
well	O
as	O
18:2	O
and	O
18:3	O
bound	O
to	O
triacylglycerols	B-T109
in	O
the	O
detached	B-T169
leaves	B-T002
in	O
contrast	O
to	O
mock-treated leaves	B-T002
.	O
The	O
content	B-T077
of	O
all	O
identified	B-T080
fatty acids	B-T109
bound	O
to	O
galactolipids	B-T109
decreased	B-T081
in	O
the	O
detached	B-T169
leaves	B-T002
treated	B-T169
with	O
EBR	B-T109
compared	O
to	O
that	O
in	O
mock-treated leaves	B-T002
.	O
These	O
findings	B-T169
suggest	O
that	O
free fatty acids	B-T109
are	O
liberated	O
from	O
polar	B-T081
lipids	B-T109
and	O
then	O
undergo	O
esterification	B-T044
to	O
neutral lipids	B-T109
in	O
the	O
detached	B-T169
leaves	B-T002
upon	O
EBR	B-T109
treatment	B-T169
.	O
We	O
propose	O
that	O
steroid	B-T109
phytohormones	B-T116
may	O
be	O
involved	O
into	O
regulation	B-T038
of	O
leaf	B-T002
senescence	B-T040
via	O
alteration	B-T078
of	O
cell	B-T025
lipid	B-T109
composition	B-T070
.	O

Posterior dislocation	B-T037
of	O
the	O
sternoclavicular joint	B-T030
:	O
report	B-T170
of	O
two	O
cases	B-T169
The	O
authors	O
report	B-T170
the	O
cases	B-T169
of	O
two	O
young	B-T079
patients	B-T101
who	O
had	O
suffered	O
a	O
sporting accident	B-T037
with	O
posterior traumatic dislocation	B-T037
of	O
sternoclavicular joint	B-T030
.	O
In	O
one	O
of	O
the	O
patients	B-T101
closed reduction	B-T061
was	O
accomplished	O
by	O
keeping	O
the	O
limb	B-T023
in	O
a	O
sling	B-T074
.	O
The	O
second	O
patient	B-T101
,	O
after	O
reduction	B-T061
was	O
done,	O
presented	O
recurrence	B-T067
of	O
the	O
dislocation	B-T037
,	O
thus	O
requiring	O
surgical treatment	B-T061
.	O
It	O
is	O
important	O
to	O
observe	O
the	O
relevance	B-T080
of	O
computed tomography	B-T060
to	O
help	O
diagnosing	B-T062
,	O
as	O
well	O
as	O
monitoring	O
the	O
reduction procedure	B-T061
.	O
The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
demonstrate	O
two	O
different	O
types	O
of	O
treatment	B-T061
in	O
a	O
rare	B-T080
injury	B-T037
such	O
as	O
the	O
posterior dislocation	B-T037
of	O
sternoclavicular joint	B-T030
.	O

Using	O
a	O
graphical risk tool	B-T058
to	O
examine	O
willingness to take	B-T033
migraine	B-T047
prophylactic	B-T061
medications	B-T121
Many	O
migraine	B-T047
sufferers	B-T101
use	O
daily	B-T079
prophylactic therapy	B-T061
to	O
reduce	O
the	O
frequency	B-T079
of	O
their	O
headache	B-T184
attacks.	O
The	O
Food and Drug Administration	B-T093
has	O
approved	B-T080
several	B-T081
different	O
medications	B-T121
for	O
migraine	B-T047
prophylaxis	B-T061
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	B-T101
perceive	O
these	O
treatments	B-T061
to	O
provide	O
clinically significant	B-T078
benefits	B-T081
given	O
their	O
side effect	B-T046
profiles	B-T059
.	O
Three	O
hundred	O
headache	B-T184
sufferers	B-T101
were	O
recruited	O
from	O
the	O
community	B-T096
and	O
local	B-T082
headache	B-T184
clinics	B-T073
using	O
print	B-T057
and	O
television	B-T073
advertising	B-T057
.	O
Participants	B-T098
reported	O
experiencing	O
problematic	O
headache	B-T184
attacks	O
with	O
a	O
median	B-T081
(IQR)	O
frequency	B-T079
of	O
7.0	O
(4-13)	O
headache	B-T184
days per month	B-T079
.	O
These	O
sufferers	B-T101
participated	O
in	O
a	O
cross-sectional, single-site, study	B-T062
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task.	O
Participants	B-T098
were	O
instructed	O
on	O
the	O
probability	B-T081
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side effects	B-T046
for	O
several	B-T081
blinded	B-T062
medication	B-T121
profiles	B-T059
:	O
divalproex sodium	B-T109
,	O
venlafaxine	B-T109
,	O
gabapentin	B-T109
,	O
propranolol	B-T109
,	O
and	O
topiramate	B-T109
.	O
After	O
learning	O
the	O
likelihood	B-T081
of	O
experiencing	O
side effect	B-T046
profiles	B-T059
of	O
each	O
medication	B-T121
,	O
participants	B-T098
were	O
asked	O
whether	O
they	O
would	O
be	O
willing to take	B-T033
the	O
medication	B-T121
for	O
a	O
given	O
headache	B-T184
reduction	B-T080
level	B-T080
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days per month	B-T079
.	O
The	O
side effect	B-T046
profile	B-T059
for	O
divalproex sodium	B-T109
was	O
associated with	B-T080
the	O
smallest willingness to take	B-T033
,	O
with	O
gabapentin	B-T109
,	O
propranolol	B-T109
,	O
and	O
topiramate	B-T109
perceived	O
to	O
be	O
much	O
more	O
agreeable.	O
However,	O
<60%	O
of	O
participants	B-T098
reported	O
willingness to take	B-T033
any	O
of	O
these	O
medications	B-T121
even	O
if	O
they	O
provided	O
a	O
50%	O
reduction	B-T080
in	O
headache	B-T184
frequency	B-T079
.	O
Several	B-T081
general	O
predictors	B-T078
of	O
willingness to take	B-T033
were	O
observed	O
including	O
high	B-T080
headache	B-T184
-related	O
disability	B-T033
,	O
depressive symptoms	B-T184
,	O
and	O
pain medication	B-T109
concerns	B-T078
including	O
fear	B-T041
of	O
tolerance	B-T041
.	O
These	O
findings	B-T033
suggest	O
that	O
if	O
properly	O
informed	B-T080
of	O
the	O
side effect	B-T046
profiles	B-T059
of	O
these	O
medications	B-T121
,	O
many	O
patients	B-T101
might	O
opt	O
for	O
other	O
treatments	B-T061
.	O

Genome-Wide Detection	B-T063
of	O
Selective Signatures	B-T045
in	O
Chicken	B-T012
through	O
High Density SNPs	B-T086
Chicken	B-T012
is	O
recognized	O
as	O
an	O
excellent	O
model	B-T075
for	O
studies	O
of	O
genetic	B-T169
mechanism	B-T169
of	O
phenotypic	B-T032
and	O
genomic	B-T028
evolution	B-T045
,	O
with	O
large	O
effective	O
population size	B-T081
and	O
strong	O
human	B-T016
-driven	O
selection	B-T052
.	O
In	O
the	O
present	O
study,	O
we	O
performed	O
Extended Haplotype Homozygosity	B-UnknownType
(	O
EHH	B-UnknownType
)	O
tests	O
to	O
identify	O
significant	O
core regions	B-T086
employing	O
600K	O
SNP	B-T086
Chicken	B-T012
chip	B-T063
in	O
an	O
F2 population	B-T078
of	O
1,534	O
hens	B-T012
,	O
which	O
was	O
derived	O
from	O
reciprocal crosses	B-T059
between	O
White Leghorn	B-T012
and	O
Dongxiang chicken	B-T012
.	O
Results	O
indicated	O
that	O
a	O
total	O
of	O
49,151	O
core regions	B-T086
with	O
an	O
average	O
length	B-T081
of	O
9.79	O
Kb	O
were	O
identified	B-T080
,	O
which	O
occupied	O
approximately	O
52.15%	O
of	O
genome	B-T028
across	O
all	O
autosomes	B-T026
,	O
and	O
806	O
significant	O
core regions	B-T086
attracted	O
us	O
mostly.	O
Genes	B-T028
in	O
candidate regions	B-T086
may	O
experience	O
positive selection	B-T059
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic traits	B-T080
.	O
A	O
panel	B-T078
of	O
genes	B-T028
including	O
AASDHPPT	B-T028
,	O
GDPD5	B-T028
,	O
PAR3	B-T028
,	O
SOX6	B-T028
,	O
GPC1	B-T028
and	O
a	O
signal pathway	B-T044
of	O
AKT1	B-T028
were	O
detected	B-T033
with	O
the	O
most	O
extreme	O
P-values	B-T081
.	O
Further	O
enrichment analyses	B-T062
indicated	O
that	O
these	O
genes	B-T028
were	O
associated with	B-T080
immune function	B-T042
,	O
sensory organ development	B-T042
and	O
neurogenesis	B-T040
,	O
and	O
may	O
have	O
experienced	O
positive selection	B-T059
in	O
chicken	B-T012
.	O
Moreover,	O
some	O
of	O
core regions	B-T086
exactly	O
overlapped	O
with	O
genes	B-T028
excavated	O
in	O
our	O
previous	O
GWAS	B-T063
,	O
suggesting	O
that	O
these	O
genes	B-T028
have	O
undergone	O
positive selection	B-T059
may	O
affect	O
egg	B-T168
production	B-T052
.	O
Findings	B-T169
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome-wide map	B-T062
of	O
selection signature	B-T045
in	O
the	O
chicken	B-T012
genome	B-T028
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	B-T169
mechanisms	B-T169
of	O
phenotypic	B-T032
diversity	B-T080
in	O
poultry	B-T012
breeding	B-T040
.	O

High-Throughput	O
Genotyping	B-T059
with	O
TaqMan Allelic Discrimination	B-T059
and	O
Allele-Specific Genotyping Assays	B-T059
Real-time PCR	B-T063
-based	O
genotyping methods	B-T059
,	O
such	O
as	O
TaqMan allelic discrimination assays	B-T059
and	O
allele-specific genotyping	B-T059
,	O
are	O
particularly	O
useful	B-T080
when	O
screening	B-T060
a	O
handful	O
of	O
single nucleotide polymorphisms	B-T086
in	O
hundreds	O
of	O
samples	B-T167
;	O
either	O
derived	O
from	O
different	B-T080
individuals	B-T098
,	O
tissues	B-T024
,	O
or	O
pre	B-T079
-	O
amplified DNA	B-T045
.	O
Although	O
real-time PCR	B-T063
-	O
based	B-T169
methods	B-T170
such	O
as	O
TaqMan	B-T059
are	O
well-established	B-T080
,	O
alternative	B-T077
methods	B-T170
,	O
like	O
allele-specific genotyping	B-T059
,	O
are	O
powerful	O
alternatives	B-T077
,	O
especially	O
for	O
genotyping	B-T059
short tandem repeat	B-T114
(STR)	B-T114
length	B-T081
polymorphisms	B-T045
.	O
Here,	O
we	O
describe	O
all	O
relevant	B-T080
aspects	B-T080
when	O
developing	B-T169
an	O
assay	B-T059
for	O
a	O
new	O
SNP	B-T086
or	O
STR	B-T114
using	O
either	O
TaqMan	B-T059
or	O
allele-specific genotyping	B-T059
,	O
respectively,	O
such	O
as	O
primer	B-T114
and	O
probe	B-T114
design,	O
optimization	B-T052
of	O
reaction	B-T169
conditions	B-T080
,	O
the	O
experimental procedure for typing	B-T059
hundreds	O
of	O
samples	B-T167
,	O
and	O
finally	O
the	O
data	B-T078
evaluation	B-T058
.	O
Our	O
goal	B-T170
is	O
to	O
provide	B-T052
a	O
guideline	B-T170
for	O
developing	B-T169
genotyping assays	B-T059
using	O
these	O
two	O
approaches	B-T169
that	O
render	O
reliable	O
and	O
reproducible	B-T080
genotype calls	B-T059
involving	B-T169
minimal	B-T080
optimization	B-T052
.	O

The	O
role	O
of	O
P2X7 receptors	B-T116
in	O
a	O
rodent	B-T015
PCP	B-T109
-	O
induced	B-T169
schizophrenia	B-T048
model	B-T050
P2X7 receptors	B-T116
(	O
P2X7Rs	B-T116
)	O
are	O
ligand-gated ion channels	B-T116
sensitive	B-T169
to	O
extracellular	B-T026
ATP	B-T114
.	O
Here	O
we	O
examined	B-T033
for	O
the	O
first	O
time	O
the	O
role	O
of	O
P2X7R	B-T116
in	O
an	O
animal model	B-T008
of	O
schizophrenia	B-T048
.	O
Using	O
the	O
PCP	B-T109
induced	B-T169
schizophrenia	B-T048
model	B-T050
we	O
show	O
that	O
both	O
genetic deletion	B-T045
and	O
pharmacological	B-T169
inhibition	B-T052
of	O
P2X7Rs	B-T116
alleviate	B-T169
schizophrenia-like	B-T033
behavioral	B-T053
alterations	B-T078
.	O
In	O
P2rx7+/+	B-T028
mice	B-T015
,	O
PCP	B-T109
induced	B-T169
hyperlocomotion	B-T033
,	O
stereotype behavior	B-T048
,	O
ataxia	B-T184
and	O
social withdrawal	B-T033
.	O
In	O
P2X7 receptor	B-T028
deficient	B-T169
mice	B-T015
(	O
P2rx7-/-	B-T028
),	O
the	O
social interactions	B-T033
were	O
increased	B-T081
,	O
whereas	O
the	O
PCP	B-T109
induced	B-T169
hyperlocomotion	B-T033
and	O
stereotype behavior	B-T048
were	O
alleviated	B-T169
.	O
The	O
selective	O
P2X7 receptor antagonist	B-T121
JNJ-47965567	B-T121
partly	O
replicated	O
the	O
effect of	B-T080
gene deficiency	B-T045
on	O
PCP	B-T109
-	O
induced	B-T169
behavioral changes	B-T055
and	O
counteracted	O
PCP	B-T109
-	O
induced	B-T169
social withdrawal	B-T033
.	O
We	O
also	O
show	O
that	O
PCP	B-T109
treatment	B-T169
upregulates	B-T044
and	O
increases	B-T169
the	O
functional	B-T169
responsiveness	B-T169
of	O
P2X7Rs	B-T116
in	O
the	O
prefrontal cortex	B-T023
of	O
young adult	B-T100
animals	B-T008
.	O
The	O
amplitude	B-UnknownType
of	O
NMDA	B-T116
evoked	B-T080
currents	B-T070
recorded	O
from	O
layer V pyramidal neurons	B-T025
of	O
cortical	B-T023
slices	O
were	O
slightly	O
decreased	B-T081
by	O
both	O
genetic deletion	B-T045
of	O
P2rx7	B-T028
and	O
by	O
JNJ-47965567	B-T121
.	O
PCP	B-T109
induced	B-T169
alterations	B-T078
in	O
mRNA expression	B-T045
encoding	O
schizophrenia-related	B-T048
genes	B-T028
,	O
such	O
as	O
NR2A	B-T028
,	O
NR2B	B-T028
,	O
neuregulin 1	B-T116
,	O
NR1	B-T192
and	O
GABA α1	B-T116
subunit	O
were	O
absent	B-T169
in	O
the	O
PFC	O
of	O
young adult	B-T100
P2rx7-/-	B-T028
animals	B-T050
.	O
Our	O
findings	B-T033
point	O
to	O
P2X7R	B-T116
as	O
a	O
potential	B-T080
therapeutic	B-T169
target	B-T169
in	O
schizophrenia	B-T048
.	O

The	O
flavor	B-T168
and	O
nutritional	B-T080
characteristic	B-T080
of	O
four	O
strawberry	B-T168
varieties	B-T077
cultured	B-T090
in	O
soilless system	B-T167
Strawberry fruits	B-T168
(	O
cv. Benihoppe	B-T168
,	O
Tochiotome	B-T168
,	O
Sachinoka	B-T168
,	O
and	O
Guimeiren	B-T168
)	O
were	O
harvested	O
and	O
evaluated	O
the	O
flavor	B-T168
and	O
nutritional	B-T080
parameters	B-T077
.	O
By	O
principal component analysis	B-T081
and	O
hierarchical clustering analysis	B-T062
,	O
differences	O
were	O
observed	O
based	O
on	O
the	O
volatile compounds	B-T109
composition	B-T070
,	O
sugar	B-T109
and	O
acid	B-T109
concentration	B-T081
,	O
sweetness	B-T080
,	O
and	O
total soluble sugars	B-T109
/	O
total organic acids	B-T109
of	O
the	O
four	O
varieties	B-T077
.	O
A	O
total	O
of	O
37,	O
48,	O
65,	O
and	O
74	O
volatile compounds	B-T109
were	O
identified	B-T080
and	O
determined	B-T080
in	O
cv. Benihoppe	B-T168
,	O
Tochiotome	B-T168
,	O
Sachinoka	B-T168
,	O
and	O
Guimeiren strawberry fruits	B-T168
extracted	B-T061
by	O
head-space solid-phase microextraction	B-T059
(	O
HS-SPME	B-T059
),	O
respectively.	O
Esters	B-T109
significantly	O
dominated	O
the	O
chemical composition	B-T070
of	O
the	O
four	O
varieties	B-T077
.	O
Furaneol	B-T109
was	O
detected	O
in	O
cultivars	B-T002
of	O
Sachinoka	B-T168
and	O
Guimeiren	B-T168
,	O
but	O
mesifuran	B-T168
was	O
only	O
found	O
in	O
cv. Tochiotome	B-T168
.	O
Tochiotome	B-T168
and	O
Sachinoka	B-T168
showed	O
higher	O
content	B-T081
of	O
linalool	B-T109
and	O
(E)-nerolidol	B-T109
.	O
Sachinoka	B-T168
showed	O
the	O
highest	B-T080
content	B-T081
of	O
total sugars	B-T109
and	O
total acids	B-T109
.	O
Guimeiren	B-T168
showed	O
higher	O
sweetness	B-T080
index	B-T170
than	O
the	O
other	O
three	O
cultivars	B-T002
.	O
Firmness	B-T080
of	O
Tochiotome	B-T168
was	O
highest	B-T080
among	O
all	O
the	O
varieties	B-T077
.	O
The	O
highest	B-T080
total soluble solids TSS value	B-T081
was	O
found	O
in	O
cv. Sachinoka	B-T168
,	O
followed	O
by	O
the	O
Guimeiren	B-T168
and	O
Tochiotome	B-T168
varieties	B-T077
.	O
Sachinoka	B-T168
had	O
the	O
highest	B-T080
titratable acidity TA value	B-T034
.	O
The	O
content	B-T081
of	O
ascorbic acid	B-T109
(	O
AsA	B-T109
)	O
of	O
cv. Tochiotome	B-T168
was	O
higher	B-T080
than	O
the	O
others,	O
but	O
there	O
was	O
no significant	B-T033
difference	B-T081
in	O
cultivars	B-T002
of	O
Benihoppe	B-T168
,	O
Tochiotome	B-T168
,	O
and	O
Sachinoka	B-T168
.	O
Fructose	B-T109
and	O
glucose	B-T109
were	O
the	O
major	O
sugars	B-T109
in	O
all	O
cultivars	B-T002
.	O
Citric acid	B-T109
was	O
the	O
major	O
organic acid	B-T109
in	O
cv. Tochiotome	B-T168
,	O
cv. Sachinoka	B-T168
,	O
and	O
cv. Guimeiren	B-T168
.	O
Tochiotome	B-T168
had	O
higher	B-T080
ratios	B-T081
of	O
TSS	B-T109
/	O
TA	B-T034
and	O
total sugars	B-T109
/	O
total organic acids	B-T109
than	O
others,	O
arising	O
from	O
its	O
lower	O
acid	B-T109
content	B-T081
.	O
The	O
order	O
of	O
the	O
comprehensive evaluation score	B-T081
was	O
Sachinoka	B-T168
>	O
Guimeiren	B-T168
>	O
Tochiotome	B-T168
>	O
Benihoppe	B-T168
.	O

Prognostic value	B-T081
of	O
GLUT-1	B-T116
expression	B-T045
in	O
oral squamous cell carcinoma	B-T191
:	O
A	O
prisma-compliant meta-analysis	B-T170
A	O
variety	O
of	O
studies	B-T062
have	O
evaluated	B-T058
the	O
correlation	B-T080
between	O
glucose transporter-1	B-T116
(	O
GLUT-1	B-T116
)	O
expression	B-T045
and	O
prognosis	B-T058
of	O
oral squamous cell carcinoma	B-T191
(	O
OSCC	B-T191
);	O
however,	O
the	O
results	B-T169
were	O
inconsistent	B-T080
and	O
inconclusive	B-T080
.	O
A	O
meta-analysis	B-T062
was	O
performed	O
to	O
assess	B-T058
the	O
prognostic	B-T170
significance	B-T078
of	O
GLUT-1	B-T116
in	O
OSCC	B-T191
.	O
Electronic databases	B-T170
of	O
PubMed	B-T170
,	O
Embase	B-T170
,	O
and	O
Web of Science	B-T170
were	O
searched	O
for	O
relevant studies	B-T062
.	O
The	O
last	O
search	O
was	O
updated	O
on	O
July	B-T080
2016.	O
Odds ratio	B-T081
(	O
OR	B-T081
)	O
and	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
were	O
pooled	O
to	O
evaluate	B-T058
the	O
relationship	B-T078
between	O
GLUT-1	B-T116
and	O
clinical features	B-T033
and	O
hazard ratio	B-T081
(	O
HR	B-T081
)	O
and	O
95%	O
CI	B-T081
were	O
combined	O
to	O
measure	B-T081
the	O
effect	B-T080
of	O
GLUT-1	B-T116
on	O
overall survival	B-T081
(	O
OS	B-T081
).	O
P	O
value	O
<	O
0.05	O
was	O
considered	O
as	O
statistically significant	B-T081
.	O
A	O
total	O
of	O
13	O
studies	B-T062
with	O
1301	O
subjects	B-T098
were	O
included	O
for	O
meta-analysis	B-T062
.	O
The	O
pooled data	B-T078
showed	O
that	O
high	O
GLUT-1	B-T116
expression	B-T045
was	O
associated with	B-T080
advanced tumor stages	B-T201
(n	O
=	O
7,	O
OR	B-T081
=	O
2.99,	O
95%	O
CI	B-T081
:	O
2.01-4.46,	O
P	O
<	O
0.001),	O
higher tumor grade	B-T185
(n	O
=	O
5,	O
OR	B-T081
=	O
3.34,	O
95%	O
CI	B-T081
:	O
1.12-9.94,	O
P	O
=	O
0.031),	O
tumor size	B-T082
(n	O
=	O
5,	O
OR	B-T081
=	O
3.36,	O
95%	O
CI	B-T081
:	O
2.04-5.51,	O
P	O
<	O
0.001),	O
lymph node metastasis	B-T033
(n	O
=	O
5,	O
OR	B-T081
=	O
3.15,	O
95%	O
CI	B-T081
:	O
1.89-5.25,	O
P	O
<	O
0.001),	O
tobacco use	B-T055
(n	O
=	O
3,	O
OR	B-T081
=	O
2.18,	O
95%	O
CI	B-T081
:	O
1.18-4.01,	O
P	O
=	O
0.013),	O
and	O
distant metastasis	B-T201
(n	O
=	O
2,	O
OR	B-T081
=	O
3.06,	O
95%	O
CI	B-T081
:	O
1.19-7.9,	O
P	O
=	O
0.02).	O
Furthermore,	O
increased	B-T081
GLUT-1	B-T116
expression	B-T045
was	O
also	O
correlated	B-T080
with	O
shorter OS	B-T081
(n	O
=	O
8,	O
HR	B-T081
=	O
1.88,	O
95%	O
CI	B-T081
:	O
1.51-2.33,	O
P	O
<	O
0.001).	O
No	O
significant publication bias	B-T080
was	O
detected	B-T033
in	O
this	O
meta-analysis	B-T062
.	O
GLUT-1	B-T116
overexpression	B-T045
was	O
in	O
connection	O
with	O
aggressive clinical features	B-T033
and	O
worse OS	B-T081
in	O
OSCC	B-T191
.	O
However,	O
further	O
studies	B-T062
are	O
still	O
needed	O
to	O
verify	O
whether	O
GLUT-1	B-T116
could	O
serve	O
as	O
a	O
prognostic	B-T170
biomarker	B-T201
for	O
OSCC	B-T191
.	O

Biogeography	B-T090
and	O
Character	O
Evolution	B-T038
of	O
the	O
Ciliate	B-T204
Genus	B-T185
Euplotes	B-T204
(	O
Spirotrichea	B-T204
,	O
Euplotia	B-T204
),	O
with	O
Description	B-T170
of	O
Euplotes curdsi sp. nov	B-T204
Ciliates	B-T204
comprise	O
a	O
diverse	B-T080
and	O
ecologically	B-T077
important	B-T080
phylum	B-T185
of	O
unicellular protists	B-T001
.	O
One	O
of	O
the	O
most	O
specious	O
and	O
best-defined	O
genera	B-T185
is	O
Euplotes	B-T204
,	O
which	O
constitutes	O
more	O
than	O
70	O
morphospecies	B-T185
,	O
many	O
of	O
which	O
have	O
never	O
been	O
molecularly tested	B-T169
.	O
The	O
increasing	O
number	O
of	O
described	O
Euplotes	B-T204
taxa	B-T077
emphasizes	O
the	O
importance	O
for	O
detailed	O
characterizations	B-T052
of	O
new	O
ones,	O
requiring	O
standardized	O
morphological	B-T082
observations	B-T062
,	O
sequencing	B-T169
of	O
molecular markers	B-T201
and	O
careful	O
comparison	B-T052
with	O
previous	O
literature	B-T170
.	O
Here	O
we	O
describe	O
Euplotes curdsi sp. nov	B-T204
.,	O
distinguishable	B-T080
by	O
the	O
combination	B-T080
of	O
the	O
following	O
features	B-T080
:	O
45-65	O
μm	O
length	B-T081
,	O
oval or elongated shape	B-T080
with	O
both	O
ends	O
rounded,	O
narrow peristome	B-T080
with	O
25-34	O
adoral membranelles	B-T080
,	O
conspicuous paroral membrane	B-T026
,	O
double-eurystomus dorsal argyrome type	B-T080
,	O
6-7	O
dorsolateral kineties	B-T080
and	O
10	O
frontoventral cirri	B-T080
.	O
Three	O
populations	B-T081
of	O
the	O
novel	O
species	B-T185
have	O
been	O
found	O
in	O
brackish	B-T131
and	O
marine samples	B-T083
in	O
the	O
Mediterranean	B-T083
and	O
the	O
White Sea	B-T083
.	O
We	O
provide	O
the	O
SSU rRNA gene	B-T028
sequences	B-T028
of	O
these	O
populations	B-T081
,	O
and	O
an	O
updated	O
phylogeny	B-T078
of	O
the	O
genus	B-T185
Euplotes	B-T204
.	O
Using	O
the	O
molecular	B-T080
phylogenetic tree	B-T080
,	O
we	O
inferred	O
aspects	B-T080
of	O
the	O
biogeographical history	B-T169
of	O
the	O
genus	B-T185
and	O
the	O
evolution	B-T038
of	O
its	O
most	O
important	O
taxonomic	B-T169
characters	B-T080
in	O
order	O
to	O
provide	O
a	O
frame	O
for	O
future	O
descriptions	B-T170
.	O
Ultimately,	O
these	O
data	B-T078
reveal	O
recurrent	B-T079
trends	B-T079
of	O
freshwater	B-T167
invasion	O
and	O
highlight	O
the	O
dynamic,	O
yet	O
convergent,	O
morphological	B-T082
evolution	B-T038
of	O
Euplotes	B-T204
.	O

Comparative Effectiveness	B-T062
of	O
Treatments	B-T061
for	O
Chronic Low Back Pain	B-T047
:	O
A	O
Multiple Treatment Comparison Analysis	B-T062
A	O
systematic review	B-T170
and	O
network meta-analysis	B-T062
.	O
To	O
determine	O
current treatment options	B-T061
of	O
chronic low back pain	B-T047
(	O
LBP	B-T047
)	O
as	O
defined	O
by	O
randomized controlled trials	B-T062
(	O
RCTs	B-T062
)	O
and	O
to	O
compare	B-T052
effectiveness	B-T080
of	O
those	O
treatments	B-T061
using	O
a	O
mixed-treatment comparison	B-T062
(	O
MTC	B-T062
).	O
It	O
is	O
important	O
to	O
provide	O
an	O
evidence-based	B-T078
assessment	B-T058
of	O
the	O
treatment options	B-T061
that	O
exist	O
for	O
LBP	B-T047
.	O
A	O
systematic search	B-T062
of	O
RCTs	B-T062
was	O
conducted	O
in	O
MEDLINE	B-T170
and	O
the	O
Cochrane Collaboration Library	B-T073
from	O
1990	O
to	O
2014.	O
From	O
the	O
selected studies	B-T062
,	O
we	O
extracted	O
preoperative	B-T079
and	O
postoperative	B-T079
ODI	B-T033
and	O
VAS back pain scores	B-T081
,	O
additional surgeries	B-T058
,	O
and	O
complications	B-T046
.	O
Standard and network meta-analytic techniques	B-T062
were	O
used.	O
Twelve	O
RCTs	B-T062
were	O
included	O
in	O
the	O
analysis	B-T062
:	O
5	O
total disk replacement	B-T061
(	O
TDR	B-T061
)	O
versus	O
fusion	B-T061
;	O
1	O
TDR	B-T061
versus	O
exercise	B-T061
and	O
cognitive behavioral therapy	B-T061
(	O
CBT	B-T061
);	O
5	O
fusion	B-T061
versus	O
exercise	B-T061
and	O
CBT	B-T061
;	O
and	O
1	O
fusion	B-T061
versus	O
physical therapy	B-T061
(	O
PT	B-T061
).	O
On	O
the	O
basis	O
of	O
MTC	B-T062
,	O
with	O
respect	O
to	O
ODI change scores	B-T033
,	O
the	O
pooled mean difference	B-T081
favoring	O
fusion	B-T061
over	O
exercise	B-T061
and	O
CBT	B-T061
was	O
2.0	O
points	O
(95%	O
CI,	O
-1.2	O
to	O
4.8).	O
The	O
pooled mean difference	B-T081
favoring	O
TDR	B-T061
over	O
exercise	B-T061
and	O
CBT	B-T061
was	O
6.4	O
points	O
(95%	O
CI,	O
3.2-9.3).	O
The	O
pooled mean difference	B-T081
favoring	O
fusion	B-T061
over	O
PT	B-T061
was	O
8.8	O
points	O
(95%	O
CI,	O
4.1-13.6).	O
The	O
pooled mean differences	B-T081
favoring	O
TDR	B-T061
over	O
fusion	B-T061
was	O
4.4	O
points	O
(95%	O
CI,	O
2.37-6.63).	O
For	O
PT	B-T061
versus	O
structured exercise	B-T061
with	O
CBT	B-T061
,	O
the	O
pooled mean difference	B-T081
favoring	O
exercise	B-T061
with	O
CBT	B-T061
over	O
PT	B-T061
was	O
6.8	O
points	O
(95%	O
CI,	O
1.5-12.8).	O
For	O
TDR	B-T061
versus	O
PT	B-T061
,	O
the	O
pooled mean difference	B-T081
favoring	O
TDR	B-T061
over	O
PT	B-T061
was	O
13.2	O
points	O
(95%	O
CI,	O
8.0-18.4).	O
Additional	O
surgery rates	B-T081
were	O
similar	O
between	O
treatment options	B-T061
.	O
All	O
4	O
treatments	B-T061
provided	O
some	O
benefit	B-T081
to	O
patients	B-T101
with	O
chronic LBP	B-T047
.	O
According	O
to	O
the	O
MTC analysis	B-T062
,	O
TDR	B-T061
may	O
be	O
the	O
most effective	B-T080
treatment	B-T061
and	O
PT	B-T061
the	O
least effective	B-T080
treatment	B-T061
for	O
chronic LBP	B-T047
.	O
This	O
review	B-T170
is	O
based	O
on	O
a	O
limited number	B-T081
of	O
RCT studies	B-T062
and	O
does	O
not	O
support	O
any	O
1	O
treatment	B-T061
modality	B-T078
for	O
all	O
patients	B-T101
.	O

A	O
Novel	O
Selective	O
Inhibitor	B-T121
of	O
Delta-5 Desaturase	B-T116
Lowers	O
Insulin Resistance	B-T046
and	O
Reduces Body Weight	B-T033
in	O
Diet	B-T168
-Induced	O
Obese	B-T047
C57BL/6J Mice	B-T015
Obesity	B-T047
is	O
now	O
recognized	O
as	O
a	O
state	O
of	O
chronic	O
low-grade	O
inflammation	B-T046
and	O
is	O
called	O
as	O
metabolic	B-T169
inflammation	B-T046
.	O
Delta-5 desaturase	B-T116
(	O
D5D	B-T116
)	O
is	O
an	O
enzyme	B-T116
that	O
metabolizes	O
dihomo-γ-linolenic acid	B-T109
(	O
DGLA	B-T109
)	O
to	O
arachidonic acid	B-T109
(	O
AA	B-T109
).	O
Thus,	O
D5D	B-T116
inhibition	B-T039
increases	O
DGLA	B-T109
(precursor	O
to	O
anti-inflammatory	B-T080
eicosanoids	B-T109
)	O
while	O
decreasing	O
AA	B-T109
(precursor	O
to	O
pro-inflammatory	O
eicosanoids	B-T109
),	O
and	O
could	O
result	O
in	O
synergistic	B-T080
improvement	B-T077
in	O
the	O
low-grade	O
inflammatory	O
state.	O
Here,	O
we	O
demonstrate	O
reduced	B-T080
insulin resistance	B-T046
and	O
the	O
anti-obesity	B-T121
effect	O
of	O
a	O
D5D	B-T116
selective	O
inhibitor	O
(	O
compound-326	B-T121
),	O
an	O
orally	B-T082
active	O
small-molecule	B-T109
,	O
in	O
a	O
high-fat diet	B-T168
-induced	O
obese (DIO) mouse	B-T015
model	B-T050
.	O
In	O
vivo	O
D5D	B-T116
inhibition	B-T039
was	O
confirmed	O
by	O
determining	O
changes	O
in	O
blood	B-T031
AA	B-T109
/	O
DGLA	B-T109
profiles	B-T059
.	O
In	O
DIO mice	B-T015
,	O
chronic	O
treatment	O
with	O
compound-326	B-T121
lowered	O
insulin resistance	B-T046
and	O
caused	O
body weight loss	B-T033
without	O
significant	O
impact	O
on	O
cumulative	O
calorie intake	B-T081
.	O
Decreased	O
macrophage infiltration into adipose tissue	B-T033
was	O
expected	O
from	O
mRNA analysis	B-T059
.	O
Increased	O
daily	O
energy expenditure	B-T039
was	O
also	O
observed	O
following	O
administration	B-T061
of	O
compound-326	B-T121
,	O
in	O
line	O
with	O
sustained	O
body weight loss	B-T033
.	O
These	O
data	O
indicate	O
that	O
the	O
novel	O
D5D	B-T116
selective	O
inhibitor	B-T121
,	O
compound-326	B-T121
,	O
will	O
be	O
a	O
new	O
class	O
of	O
drug	O
for	O
the	O
treatment	O
of	O
obese	B-T047
and	O
diabetic	B-T047
patients	B-T101
.	O

Blood Collection Tubes	B-T074
and	O
Storage Temperature	B-T080
Should	O
Be	O
Evaluated	O
when	O
Using	O
the	O
Siemens ADVIA Centaur XP	B-T073
for	O
Measuring 25-Hydroxyvitamin D	B-T059
A	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
Siemens ADVIA Centaur XP	B-T073
system	O
for	O
measurement of 25-hydroxyvitamin D	B-T059
(	O
25OHD	B-T109
)	O
with	O
VACUETTE® tubes with Serum Clot Activator and Gel	B-T074
.	O
Here,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	B-T074
or	O
temperatures	B-T081
affected	O
25OHD results	B-T059
obtained	O
with	O
the	O
Siemens ADVIA Centaur XP	B-T073
system.	O
Serum	B-T031
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum blood collection tubes	B-T074
from	O
three	O
manufacturers,	O
and	O
25OHD was analyzed	B-T059
using	O
the	O
Siemens ADVIA Centaur XP	B-T073
system	O
and	O
liquid chromatography tandem mass spectrometry	B-T059
(	O
LC-MS/MS	B-T059
)	O
immediately	O
or	O
after	O
storage	O
at	O
4°C	O
or	O
-80°C	O
for	O
48	O
h.	O
Significantly higher	B-T081
25OHD values	B-T059
were	O
found	O
when	O
using	O
the	O
Siemens ADVIA Centaur XP	B-T073
system	O
with	O
VACUETTE® tubes with serum clot activator and gel	B-T074
and	O
VACUETTE® tubes with clot activator	B-T074
but	O
no	O
gel	O
compared	O
with	O
VACUETTE® tubes	B-T074
with	O
no	O
additives.	O
The	O
25OHD values	B-T059
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
LC-MS/MS	B-T059
.	O
Moreover,	O
after	O
storage	O
at	O
-80°C	O
for	O
48	O
h,	O
the	O
values	O
obtained	O
in	O
IMPROVEVACUTER® tubes with serum clot activator and ge	B-T074
l	O
significantly increased	B-T081
,	O
with	O
a	O
mean	O
bias	O
of	O
74.6%	O
compared	O
with	O
the	O
values	O
before	O
storage,	O
on	O
analysis	O
with	O
the	O
Siemens ADVIA Centaur XP	B-T073
system.	O
VACUETTE® tubes	B-T074
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25OHD results	B-T059
obtained	O
using	O
the	O
Siemens ADVIA Centaur XP	B-T073
system.	O
Additionally,	O
the	O
composition	O
of	O
serum	B-T031
collected	O
in	O
IMPROVEVACUTER® tubes	B-T074
was	O
affected	O
by	O
freezing	B-T070
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
Siemens	O
25OHD	B-T109
assay platform	B-T073
.	O

Evolution	B-T045
of	O
Fitness	B-T045
Cost-Neutral	B-T033
Mutant	B-T049
PfCRT	B-T116
Conferring	O
P. falciparum	B-T204
4-Aminoquinoline	B-T109
Drug Resistance	B-T038
Is	O
Accompanied	O
by	O
Altered	B-T169
Parasite	B-T204
Metabolism	B-T040
and	O
Digestive Vacuole	B-T026
Physiology	B-T091
Southeast Asia	B-T083
is	O
an	O
epicenter	O
of	O
multidrug-resistant	B-T032
Plasmodium falciparum strains	B-T204
.	O
Selective	O
pressures	O
on	O
the	O
subcontinent	O
have	O
recurrently	O
produced	O
several	O
allelic	B-T028
variants	B-T028
of	O
parasite	B-T204
drug resistance	B-T038
genes	B-T028
,	O
including	O
the	O
P. falciparum chloroquine resistance transporter	B-T028
(	O
pfcrt	B-T028
).	O
Despite	O
significant	O
reductions	B-T061
in	O
the	O
deployment	B-T052
of	O
the	O
4-aminoquinoline	B-T109
drug	B-T121
chloroquine	B-T109
(	O
CQ	B-T109
),	O
which	O
selected	O
for	O
the	O
mutant	B-T028
pfcrt	B-T028
alleles	B-T028
that	O
halted	O
CQ	B-T109
efficacy	B-T080
decades	O
ago,	O
the	O
parasite	B-T204
pfcrt	B-T028
locus	B-T082
is	O
continuously	O
evolving.	O
This	O
is	O
highlighted	O
by	O
the	O
presence	O
of	O
a	O
highly	B-T080
mutated	B-T045
allele	B-T028
,	O
Cam734 pfcrt	B-T028
,	O
which	O
has	O
acquired	O
the	O
singular	O
ability	O
to	O
confer	O
parasite	B-T204
CQ	B-T109
resistance	B-T038
without	O
an	O
associated	O
fitness	B-T045
cost	B-T080
.	O
Here,	O
we	O
used	O
pfcrt	B-T028
-specific	O
zinc-finger nucleases	B-T116
to	O
genetically dissect	B-T169
this	O
allele	B-T028
in	O
the	O
pathogenic	B-T033
setting	O
of	O
asexual blood-stage infection	B-T046
.	O
Comparative analysis	B-T062
of	O
drug resistance	B-T038
and	O
growth	B-T040
profiles	O
of	O
recombinant parasites	B-T204
that	O
express	B-T045
Cam734	B-T028
or	O
variants	B-T028
thereof,	O
Dd2	B-T028
(the	O
most	O
common	O
Southeast Asian	B-T083
variant	B-T028
),	O
or	O
wild-type	B-T028
pfcrt	B-T028
,	O
revealed	O
previously	O
unknown	O
roles	O
for	O
PfCRT	B-T116
mutations	B-T045
in	O
modulating	O
parasite	B-T204
susceptibility	O
to	O
multiple	O
antimalarial agents	B-T121
.	O
These	O
results	O
were	O
generated	O
in	O
the	O
GC03	B-T028
strain	B-T001
,	O
used	O
in	O
multiple	O
earlier	O
pfcrt	B-T028
studies	B-T062
,	O
and	O
might	O
differ	O
in	O
natural	O
isolates	O
harboring	O
this	O
allele	B-T028
.	O
Results	O
presented	O
herein	O
show	O
that	O
Cam734	B-T028
-mediated	O
CQ	B-T109
resistance	B-T038
is	O
dependent	O
on	O
the	O
rare	O
A144F	B-T045
mutation	B-T045
that	O
has	O
not	O
been	O
observed	O
beyond	O
Southeast Asia	B-T083
,	O
and	O
reveal	O
distinct	O
impacts	B-T080
of	O
this	O
and	O
other	O
Cam734	B-T028
-specific	O
mutations	B-T045
on	O
CQ	B-T109
resistance	B-T038
and	O
parasite	B-T204
growth rates	B-T079
.	O
Biochemical assays	B-T059
revealed	O
a	O
broad	O
impact	B-T080
of	O
mutant	B-T049
PfCRT	B-T116
isoforms	B-T116
on	O
parasite	B-T204
metabolism	B-T040
,	O
including	O
nucleoside triphosphate	B-T114
levels	B-T080
,	O
hemoglobin catabolism	B-T044
and	O
disposition	O
of	O
heme	B-T109
,	O
as	O
well	O
as	O
digestive vacuole	B-T026
volume	B-T081
and	O
pH	B-T081
.	O
Results	O
from	O
our	O
study	O
provide	O
new	O
insights	O
into	O
the	O
complex molecular basis	B-T170
and	O
physiological	B-T169
impact	B-T080
of	O
PfCRT	B-T116
-mediated	O
antimalarial	B-T121
drug resistance	B-T038
,	O
and	O
inform	O
ongoing	O
efforts	O
to	O
characterize	O
novel	O
pfcrt	B-T028
alleles	B-T028
that	O
can	O
undermine	O
the	O
efficacy	B-T080
of	O
first-line	O
antimalarial drug	B-T121
regimens	B-T061
.	O

Effect	B-T080
of	O
nutritionally induced	B-T033
hyperlipidaemia	B-T047
on	O
in vitro	B-T080
bovine	B-T015
embryo	B-T018
quality	O
depends	O
on	O
the	O
type	O
of	O
major	O
fatty acid	B-T109
in	O
the	O
diet	B-T168
The	O
present	O
study	B-T062
examined	B-T033
whether	O
the	O
effects of	B-T080
dietary	B-T168
-induced	O
hyperlipidaemia	B-T047
on	O
preimplantation embryo development	B-T039
depend	O
on	O
the	O
predominant	O
fatty acid	B-T109
(	O
FA	B-T109
)	O
type	O
in	O
the	O
diet	B-T168
.	O
In	O
a	O
combined	O
in vivo	B-T082
-	O
in vitro	B-T080
bovine	B-T015
model	B-T008
,	O
two	O
groups	O
of	O
cows	B-T015
(n=3	O
in	O
each	O
group)	O
were	O
fed	B-T052
with	O
three	O
diets	B-T168
consecutively	O
(4	O
weeks	O
feeding	B-T052
for	O
each):	O
(1)	O
a	O
maintenance control diet	B-T168
(	O
CONT	B-T168
);	O
(2)	O
a	O
high	B-T080
-	O
starch	B-T168
diet	B-T168
rich	O
in	O
saturated fat	B-T168
(	O
SAT	B-T168
);	O
and	O
(3)	O
a	O
high	B-T080
-	O
starch	B-T168
diet	B-T168
rich	O
in	O
omega-3	B-T109
unsaturated fat	B-T109
(	O
UNSAT	B-T109
).	O
Two	O
feeding	B-T052
sequences	B-T169
were	O
used	O
to	O
test	O
for	O
carry-over	O
effects:	O
Group	O
A	O
was	O
fed	B-T052
CONT	B-T168
,	O
SAT1	B-T168
and	O
then	O
UNSAT2	B-T109
,	O
whereas	O
Group	O
B	O
was	O
fed	B-T052
CONT	B-T168
,	O
UNSAT1	B-T109
and	O
then	O
SAT2	B-T168
.	O
Serum	B-T031
was	O
collected	O
after	O
each	O
dietary	B-T168
period	B-T079
,	O
analysed	B-T062
and	O
tested	B-T169
in	O
bovine	B-T015
in vitro	B-T080
embryo culture	B-T059
.	O
Introducing	O
SAT	B-T168
and	O
UNSAT	B-T109
diets	B-T168
induced	O
hyperlipidaemia	B-T047
(specifically	O
hypercholesterolaemia	B-T047
and	O
elevated	O
free FAs	B-T109
)	O
and	O
reduced	O
insulin sensitivity	B-T046
.	O
Carry-over	O
effects	O
in	O
serum	B-T031
metabolites	B-T123
and	O
FA profile	B-T059
were	O
dependent	O
on	O
the	O
diet	B-T168
and	O
feeding	B-T052
sequence	B-T169
.	O
SAT1	B-T168
and	O
SAT2	B-T168
serum	B-T031
decreased	O
blastocyst	B-T018
rates	O
and	O
altered	O
blastocyst	B-T018
mRNA expression	B-T045
related	O
to	O
apoptosis	B-T043
and	O
oxidative stress	B-T049
.	O
UNSAT1	B-T109
and	O
UNSAT2	B-T109
serum	B-T031
resulted	O
in	O
normal	O
embryo	B-T018
development	O
and	O
quality	B-T080
.	O
Other	O
in vitro	B-T080
effects	O
depended	O
on	O
the	O
sequence	B-T169
of	O
feeding	B-T052
.	O
In	O
conclusion,	O
substitution	B-T052
of	O
saturated fat	B-T168
with	O
omega-3 fat	B-T109
in	O
a	O
high-caloric diet	B-T061
induced	O
hyperlipidaemia	B-T047
with	O
an	O
FA profile	B-T059
yielding	O
similar	O
rates	O
and	O
quality	O
of	O
blastocysts	B-T018
compared	O
with	O
normolipidaemic controls	B-T096
.	O

Draft Genome Sequence	B-T085
of	O
the	O
Soil	B-T167
Isolate	B-T123
Lysinibacillus fusiformis M5	B-T007
,	O
a	O
Potential	B-T080
Hypoxanthine	B-T109
Producer	O
Lysinibacillus fusiformis strain M5	B-T007
is	O
a	O
potential	B-T080
hypoxanthine	B-T109
producer	O
that	O
was	O
isolated	B-T123
from	O
clay	B-T197
soil	B-T167
.	O
Here,	O
we	O
present	O
the	O
draft genome sequence	B-T085
that	O
was	O
annotated	B-T063
in	O
order	O
to	O
facilitate	O
future	O
studies	B-T062
of	O
L. fusiformis M5.	B-T007

Impact	B-T080
of	O
Clinical Trial	B-T062
Results	B-T034
on	O
the	O
Temporal	B-T079
Trends	B-T079
of	O
Carotid Endarterectomy	B-T061
and	O
Stenting	B-T061
From	O
2002	O
to	O
2014	O
Randomized trials	B-T062
provide	O
conflicting	B-T080
data	B-T078
for	O
the	O
efficacy	B-T080
of	O
carotid-artery stenting	B-T061
compared	O
with	O
endarterectomy	B-T061
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	B-T080
of	O
conflicting	B-T080
clinical trial publications	B-T170
on	O
the	O
utilization	B-UnknownType
utilization rates	B-T081
of	O
carotid revascularization procedures	B-T061
.	O
We	O
conducted	O
a	O
population-level time-series analysis	B-T062
of	O
all	O
individuals	B-T098
who	O
underwent	O
carotid endarterectomy	B-T061
and	O
stenting	B-T061
in	O
Ontario	B-T083
,	O
Canada	B-T083
(2002-2014).	O
The	O
primary analysis	B-T062
examined	O
temporal	B-T079
changes	B-T081
in	O
the	O
rates	B-T081
of	O
carotid revascularization procedures	B-T061
after	O
publications	B-T073
of	O
major	O
randomized trials	B-T062
.	O
Secondary analyses	B-UnknownType
examined	O
changes	B-T081
in	O
overall	B-T080
and	O
age	B-T032
,	O
sex	B-T032
,	O
carotid-artery symptom	B-T184
,	O
and	O
operator specialty-specific procedure rates	B-T081
.	O
A	O
total	O
of	O
16	O
772	O
patients	B-T101
were	O
studied	O
(14	O
394	O
endarterectomy	B-T061
[86%];	O
2378	O
stenting	B-T061
[14%]).	O
The	O
overall	O
rate	O
of	O
carotid revascularization	B-T061
decreased	O
from	O
6.0	O
procedures	B-T061
per	O
100	O
000	O
individuals	B-T098
≥40	O
years	O
old	O
in	O
April	O
2002	O
to	O
4.3	O
procedures	B-T061
in	O
the	O
first	O
quarter	O
of	O
2014	O
(29%	O
decrease;	O
P<0.001).	O
The	O
rate	B-T081
of	O
endarterectomy	B-T061
decreased	B-T081
by	O
36%	O
(P<0.001),	O
whereas	O
the	O
rate	B-T081
of	O
carotid-artery stenting	B-T061
increased	B-T081
by	O
72%	O
(P=0.006).	O
We	O
observed	O
a	O
marked increase	B-T169
(P=0.01)	O
in	O
stenting	B-T061
after	O
publication	B-T073
of	O
the	O
SAPPHIRE trial	B-T062
(	O
Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy	B-T062
)	O
in	O
2004,	O
whereas	O
stenting	B-T061
remained	O
relatively	O
unchanged	B-T033
after	O
subsequent	O
randomized trials	B-T062
published	O
in	O
2006	O
(P=0.11)	O
and	O
2010	O
(P=0.34).	O
In	O
contrast,	O
endarterectomy	B-T061
decreased	B-T081
after	O
trials	B-T062
published	O
in	O
2006	O
(P=0.04)	O
and	O
2010	O
(P=0.005).	O
Although	O
the	O
overall rates	B-T081
of	O
carotid revascularization	B-T061
and	O
endarterectomy	B-T061
have	O
fallen	O
since	O
2002,	O
the	O
rate	B-T081
of	O
carotid-artery stenting	B-T061
has	O
risen	B-T081
since	O
the	O
publication	B-T073
of	O
stenting	B-T061
-favorable	O
SAPPHIRE trial	B-T062
.	O
Subsequent	O
conflicting	B-T080
randomized trials	B-T062
were	O
associated with	B-T080
a	O
decreasing rate	B-T033
of	O
carotid endarterectomy	B-T061
.	O

Electronic tongues	B-T073
to	O
assess	O
wine	B-T168
sensory	B-T080
descriptors	B-T170
This	O
work	B-T057
reports	B-T170
the	O
application	B-T169
of	O
an	O
electronic tongue	B-T073
as	O
a	O
tool	B-T073
towards	O
the	O
analysis	B-T062
of	O
wine	B-T168
in	O
tasks	O
such	O
as	O
its	O
discrimination	B-T078
based	O
on	O
the	O
maturing	B-T079
in	O
barrels	B-T073
or	O
the	O
prediction	B-T078
of	O
the	O
global	B-T080
scores	B-T081
assigned	O
by	O
a	O
sensory panel	B-T097
.	O
To	O
this	O
aim,	O
red wine	B-T168
samples	B-T167
were	O
first	O
analysed	B-T062
with	O
the	O
voltammetric sensor array	B-T073
,	O
without	O
performing	O
any	O
sample	B-T167
pretreatment	B-T052
.	O
Afterwards,	O
obtained	O
responses	B-T169
were	O
preprocessed	B-T067
employing	O
fast Fourier transform	B-T170
(	O
FFT	B-T170
)	O
for	O
the	O
compression	B-T070
and	O
reduction	B-T080
of	O
signal	B-T067
complexity	B-T080
,	O
and	O
obtained	O
coefficients	B-T081
were	O
then	O
used	O
as	O
inputs	B-T077
to	O
build	O
the	O
qualitative	B-T080
and	O
quantitative	B-T081
models	B-T075
employing	O
either	O
linear discriminant analysis	B-T062
(	O
LDA	B-T062
)	O
or	O
partial least squares regression	B-T170
(	O
PLS	B-T170
),	O
respectively.	O
Satisfactory	O
results	B-T033
were	O
obtained	O
overall,	O
with	O
a	O
classification	B-T185
rate	B-T081
of	O
100%	O
in	O
the	O
discrimination	B-T078
of	O
the	O
type	O
of	O
barrel	B-T073
used	O
during	O
wine	B-T168
maturing	B-T079
,	O
a	O
normalized NRMSE	B-T081
of	O
0.077	O
in	O
the	O
estimation	O
of	O
ageing	B-T040
time	B-T079
(	O
months	B-T079
)	O
or	O
0.11	O
in	O
the	O
prediction	B-T078
of	O
the	O
scores	B-T081
(0-10)	O
from	O
a	O
trained sensory panel	B-T097
(all	O
for	O
the	O
external	O
test	B-T169
subset	B-T185
).	O

Toward	O
optimizing	B-T052
dental implant	B-T074
performance:	O
Surface	B-T082
characterization	B-T052
of	O
Ti	B-T196
and	O
TiZr	B-T197
implant materials	B-T122
Targeting	B-T169
understanding	O
enhanced	B-T052
osseointegration	B-T042
kinetics	B-T070
,	O
the	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
characterize	B-T052
the	O
surface	B-T082
morphology	B-T080
and	O
composition	B-T201
of	O
Ti	B-T196
and	O
TiZr	B-T197
dental implant	B-T074
substrates	B-T167
subjected	O
to	O
one	O
of	O
two	O
surface	B-T082
treatments	B-T169
developed	O
by	O
Straumann.	O
These	O
two	O
treatments	B-T169
are	O
typically	O
known	O
as	O
SLA	B-T074
and	O
SLActive	B-T074
,	O
with	O
the	O
latter	O
resulting	O
in	O
more	O
rapid	B-T080
osseointegration	B-T042
.	O
A	O
range	O
of	O
techniques	B-T169
was	O
applied	B-T169
to	O
characterize	B-T052
four	O
different	B-T080
substrate	B-T082
/	O
surface	B-T082
treatment	B-T169
combinations	B-T080
(	O
TiSLA	B-T074
,	O
TiSLActive	B-T074
,	O
TiZrSLA	B-T074
,	O
and	O
TiZrSLActive	B-T074
).	O
Contact	B-T169
angle	B-T082
measurements	B-T169
establish	O
establish	O
their	O
hydrophilic	B-T080
/	O
hydrophobic	B-T080
nature.	O
Surface	B-T082
morphology	B-T080
was	O
probed	O
with	O
scanning electron microscopy	B-T059
.	O
X-ray diffraction	B-T059
,	O
Raman μ-spectroscopy	B-T059
,	O
and	O
X-ray photoelectron spectroscopy	B-T059
were	O
used	O
to	O
elucidate	O
the	O
composition	B-T201
of	O
the	O
near-	O
surface	B-T082
region.	O
Consistent with	B-T078
previous	B-T079
work,	O
surface	B-T082
morphology	B-T080
was	O
found	O
to	O
differ	B-T080
only	O
at	O
the	O
nanoscale	B-T081
,	O
with	O
both	O
SLActive	B-T074
substrates	B-T167
displaying	B-T169
nano	B-T081
-	O
protrusions	B-T190
.	O
Spectroscopic	B-T059
data	B-T078
indicate	O
that	O
all	O
substrates	B-T167
exhibit	O
surface	B-T082
films	B-T080
of	O
titanium oxide	B-T121
displaying	O
near	O
TiO2	B-T121
stoichiometry	B-T081
.	O
Raman μ-spectroscopy	B-T059
reveals	B-T080
that	O
amorphous	B-T080
TiO2	B-T121
is	O
most	O
likely	O
the	O
only	O
phase	B-T079
present	B-T033
on	O
TiSLA	B-T074
,	O
whilst	O
rutile	B-T121
-	O
TiO2	B-T121
is	O
also	O
evidenced	B-T078
on	O
TiSLActive	B-T074
,	O
TiZrSLA	B-T074
,	O
and	O
TiZrSLActive	B-T074
.	O
For	O
TiZr	B-T197
alloy	B-T122
substrates	B-T167
,	O
there	O
is	O
no	O
evidence	B-T078
of	O
discrete	B-T080
phases	B-T079
of	O
oxidized	B-T044
Zr	B-T196
.	O
X-ray photoelectron spectra	B-T059
demonstrate	O
that	O
all	O
samples	B-T167
are	O
terminated	B-T078
by	O
adventitious	B-T080
carbon	B-T196
,	O
with	O
it	O
being	O
somewhat	O
thicker	B-T080
(∼1nm)	O
on	O
TiSLA	B-T074
and	O
TiZrSLA	B-T074
.	O
Given	O
previous	B-T079
in vivo studies	B-T062
,	O
acquired	B-T080
data	B-T078
suggest	O
that	O
both	O
nanoscale	B-T081
protrusions	B-T190
,	O
and	O
a	O
thinner	B-T080
layer	B-T080
of	O
adventitious	B-T080
carbon	B-T196
contribute	B-T052
to	O
the	O
more	O
rapid	B-T080
osseointegration	B-T042
of	O
SLActive	B-T074
dental implants	B-T074
.	O
Composition	B-T201
of	O
the	O
surface	B-T082
oxide	B-T197
layer	B-T080
is	O
apparently	O
less	B-T080
important	B-T080
in	O
determining	O
osseointegration	B-T042
kinetics	B-T070
.	O

Cocaine	B-T109
Use	B-T169
Reverses	B-T169
Striatal Plasticity	B-T042
Produced	B-T169
During	B-T079
Cocaine	B-T109
Seeking	O
Relapse	B-T067
is	O
a	O
two	B-T081
-	O
component	B-T077
process	B-T067
consisting	O
of	O
a	O
highly	B-T080
motivated	B-T041
drug-seeking	O
phase	B-T079
that,	O
if	O
successful,	O
is	O
followed by	B-T079
a	O
drug-using	B-T048
phase	B-T079
resulting in	B-T169
temporary	B-T079
satiation	B-T041
.	O
In	O
rodents	B-T015
,	O
cue-induced	O
drug	O
seeking	O
requires	B-T169
transient synaptic potentiation	B-T042
(	O
t-SP	B-T042
)	O
of	O
cortical glutamatergic synapses	B-T030
on	O
nucleus accumbens	B-T023
core	B-T082
medium spiny neurons	B-T025
,	O
but	O
it	O
is	O
unknown	B-T080
how	O
achieving	O
drug use	B-T048
affects	B-T041
this	O
plasticity	B-T042
.	O
We	O
modeled	B-T077
the	O
two	O
phases	B-T079
of	O
relapse	B-T067
after	O
extinction	B-T041
from	O
cocaine	B-T109
self-administration	B-T061
to	O
assess	B-T052
how	O
cocaine	B-T109
use	O
affects	B-T041
t-SP	B-T042
associated with	B-T080
cue-induced	O
drug	O
seeking.	O
Rats	B-T015
were	O
trained	O
to	O
self-administer	B-T061
cocaine	B-T109
(n	O
=	O
96)	O
or	O
were	O
used	O
as	O
yoked	B-T073
-	O
saline	B-T167
control animals	B-T008
(n	O
=	O
21).	O
After	O
extinction	B-T041
,	O
reinstatement	B-T079
was	O
initiated	B-T169
by	O
10	O
minutes	B-T079
of	O
cue-induced	O
drug	O
seeking,	O
followed by	B-T079
45	O
minutes	B-T079
with	O
contingent	B-T080
cocaine	B-T109
access	B-T169
,	O
after	O
which	O
cocaine	B-T109
was	O
discontinued	B-T033
and	O
unreinforced lever pressing ensued	B-T033
.	O
Three	B-T081
measures	B-T081
of	O
t-SP	B-T042
were	O
assayed	B-T059
during	B-T079
reinstatement	B-T079
:	O
dendritic spine	B-T026
morphology	B-T080
,	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid	B-T109
(	O
AMPA	B-T109
)	O
to	O
N-methyl-D-aspartate	B-T116
(	O
NMDA	B-T116
)	O
ratios	B-T081
,	O
and	O
matrix metalloproteinase	B-T116
activity	B-T044
.	O
We	O
found	B-T033
that	O
cocaine	B-T109
use	O
for	O
10	O
minutes	B-T079
collapsed	B-T169
all	O
three	B-T081
measures	B-T081
of	O
cue-potentiated	O
t-SP	B-T042
back	O
to	O
baseline	B-T081
.	O
Moreover,	O
when	O
cocaine	B-T109
use	O
was	O
discontinued	B-T033
45	O
minutes	B-T079
later,	O
dendritic spine	B-T026
morphology	B-T080
and	O
AMPA	B-T109
to	O
NMDA	B-T116
ratios	B-T081
were	O
restored	O
as	O
animals	B-T008
became	O
motivated	B-T041
to	O
engage	O
unrewarded	O
lever pressing	B-T033
.	O
Nonreinforced	O
drug	O
seeking	O
was	O
positively	B-T033
correlated	B-T080
with	O
changes	B-T169
in	O
spine	B-T026
morphology	B-T080
,	O
and	O
cocaine	B-T109
access	B-T169
reversed	B-T169
this	O
relationship	B-T080
.	O
Using	O
a	O
novel	B-T080
modification	B-T169
of	O
the	O
reinstatement	B-T079
paradigm	B-T062
,	O
we	O
show	O
that	O
achieving	O
cocaine	B-T109
use	O
reversed	B-T169
the	O
synaptic plasticity	B-T042
underpinning	O
the	O
motivation	B-T041
to	O
seek	O
the	O
drug	B-T121
.	O

Delicaflavone	B-T121
induces	B-T169
autophagic cell death	B-T043
in	O
lung cancer	B-T191
via	O
Akt	B-T044
/	O
mTOR	B-T044
/	O
p70S6K	B-T116
signaling pathway	B-T044
Searching	O
for	O
potential	B-T080
anticancer agents	B-T109
from	O
natural sources	B-T033
is	O
an	O
effective	B-T080
strategy	O
for	O
developing	O
novel	B-T080
chemotherapeutic agents	B-T121
.	O
In	O
this	O
study	B-T062
,	O
data	B-T078
supporting	O
the	O
in vitro	B-T080
and	O
in vivo	B-T082
anticancer effects	B-T033
of	O
delicaflavone	B-T121
,	O
a	O
rarely	O
occurring	O
biflavonoid	B-T109
from	O
Selaginella doederleinii	B-T002
,	O
were	O
reported.	O
Delicaflavone	B-T121
exhibited	O
favorable	B-T080
anticancer	B-T033
properties	B-T070
,	O
as	O
shown	O
by	O
the	O
MTT assay	B-T062
and	O
xenograft model	B-T050
of	O
human	B-T016
non-small cell lung cancer	B-T191
in	O
male	B-T032
BALB/c nude mice	B-T015
without	O
observable	O
adverse effect	B-T046
.	O
By	O
transmission electron microscopy	B-T059
with	O
acridine orange	B-T109
and	O
Cyto-ID®Autophagy	B-T043
detection	O
dyes	B-T130
,	O
Western blot	B-T059
analysis	B-T062
,	O
and	O
RT-PCR assay	B-T063
,	O
we	O
confirmed	O
that	O
delicaflavone	B-T121
induces	B-T169
autophagic cell death	B-T043
by	O
increasing	B-T169
the	O
ratio	O
of	O
LC3-II	B-T116
to	O
LC3-I	B-T116
,	O
which	O
are	O
autophagy-related proteins	B-T116
,	O
and	O
promoting	B-T052
the	O
generation	B-T052
of	O
acidic vesicular organelles	B-T026
and	O
autolysosomes	B-T026
in	O
the	O
cytoplasm	B-T026
of	O
human	O
lung cancer	B-T191
A549	B-T025
and	O
PC-9 cells	B-T025
in	O
a	O
time	B-T079
-	O
and	O
dose-dependent	B-T081
manner.	O
Delicaflavone	B-T121
downregulated	B-T044
the	O
expression of phospho-Akt	B-T033
,	O
phospho-mTOR	B-T116
,	O
and	O
phospho-p70S6K	B-T116
in	O
a	O
time	B-T079
-	O
and	O
dose-dependent	B-T081
manner,	O
suggesting	B-T078
that	O
it	O
induced	B-T169
autophagy	B-T043
by	O
inhibiting	B-T052
the	O
Akt	B-T044
/	O
mTOR	B-T044
/	O
p70S6K	B-T116
pathway	B-T044
in	O
A549	B-T025
and	O
PC-9 cells	B-T025
.	O
Delicaflavone	B-T121
is	O
a	O
potential	B-T080
anticancer agent	B-T109
that	O
can	O
induce	B-T169
autophagic cell death	B-T043
in	O
human	B-T016
non-small cell lung cancer	B-T191
via	O
the	O
Akt	B-T044
/	O
mTOR	B-T044
/	O
p70S6K	B-T116
signaling pathway	B-T044
.	O
Delicaflavone	B-T121
showed	O
anti-lung cancer effects	B-T033
in vitro	B-T080
and	O
in vivo	B-T082
.	O
Delicaflavone	B-T121
induced	B-T169
autophagic cell death	B-T043
via	O
Akt	B-T044
/	O
mTOR	B-T044
/	O
p70S6K	B-T116
signaling pathway	B-T044
.	O
Delicaflavone	B-T121
did	O
not	O
show	O
observable	O
side effects	B-T046
in	O
a	O
xenograft mouse model	B-T050
.	O
Delicaflavone	B-T121
may	O
represent	O
a	O
potential	B-T080
therapeutic agent	B-T073
for	O
lung cancer	B-T191
.	O
Delicaflavone	B-T121
showed	O
anti-lung cancer effects	B-T033
in vitro	B-T080
and	O
in vivo	B-T082
.	O
Delicaflavone	B-T121
induced	O
autophagic cell death	B-T043
via	O
Akt	B-T044
/	O
mTOR	B-T044
/	O
p70S6K	B-T116
signaling pathway	B-T044
.	O
Delicaflavone	B-T121
did	O
not	O
show	O
observable	O
side effects	B-T046
in	O
a	O
xenograft mouse model	B-T050
.	O
Delicaflavone	B-T121
may	O
represent	O
a	O
potential	B-T080
therapeutic agent	B-T073
for	O
lung cancer	B-T191
.	O

Determinants	B-T169
of	O
On-Road	B-T073
Driving	B-T056
in	O
Multiple Sclerosis	B-T047
To	O
investigate	B-T169
the	O
cognitive	B-T169
,	O
visual	B-T169
,	O
and	O
motor deficits	B-T033
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	B-T033
of	O
on-road	B-T073
driving	B-T056
in	O
individuals	B-T098
with	O
multiple sclerosis	B-T047
(	O
MS	B-T047
).	O
Prospective	O
cross-sectional study	B-T062
.	O
MS clinic	B-T073
and	O
driving	B-T056
simulator	B-T062
lab	B-T073
.	O
Active drivers	B-T098
(N=102)	O
with	O
various	O
types	O
of	O
MS	B-T047
.	O
Not	O
applicable.	O
Off-road	B-T073
cognitive	B-T169
,	O
visual	B-T169
,	O
and	O
motor functions	B-T038
,	O
as	O
well	O
as	O
13	O
specific	B-T080
driving skills	B-UnknownType
.	O
These	O
skills	B-UnknownType
were	O
categorized	B-T052
into	O
hierarchic clusters	B-T062
of	O
operational	B-T052
,	O
tactical	B-UnknownType
,	O
visuo-integrative	B-T169
,	O
and	O
mixed driving	B-UnknownType
.	O
Stepwise regression analysis	B-T170
was	O
used	O
to	O
determine	O
the	O
off-road	B-T073
functions	O
influencing	O
performance	O
on	O
the	O
on-road	B-T073
test	B-T169
and	O
each	O
cluster	B-T081
.	O
Visuospatial function	B-T041
(P=.002),	O
inhibition	B-T041
(P=.008),	O
binocular acuity	B-T033
(P=.04),	O
vertical visual field	B-T060
(P=.02),	O
and	O
stereopsis	B-T041
(P=.03)	O
best	O
determined	O
variance	B-T080
in	O
total	O
on-road	B-T073
score	B-T081
(unadjusted	O
R(2)=.37).	O
Attentional shift	B-T033
(P=.0004),	O
stereopsis	B-T041
(P=.007),	O
glare recovery	B-T060
(P=.047),	O
and	O
use	O
of	O
assistive devices	B-T074
(P=.03)	O
best	O
predicted	O
the	O
operational cluster	B-T062
(unadjusted	O
R(2)=.28).	O
Visuospatial function	B-T041
(P=.002),	O
inhibition	B-T041
(P=.002),	O
reasoning	B-T041
(P=.003),	O
binocular acuity	B-T033
(P=.04),	O
and	O
stereopsis	B-T041
(P=.005)	O
best	O
determined	O
the	O
tactical cluster	B-T062
(unadjusted	O
R(2)=.41).	O
The	O
visuo-integrative mode	B-T170
l	O
(unadjusted	O
R(2)=.12)	O
comprised	O
binocular acuity	B-T033
(P=.007)	O
and	O
stereopsis	B-T041
(P=.045).	O
Inhibition	B-T041
(P=.0001)	O
and	O
binocular acuity	B-T033
(P=.001)	O
provided	O
the	O
best	O
model	B-T081
of	O
the	O
mixed cluster	B-T062
(unadjusted	O
R(2)=.25).	O
Our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	B-T169
that	O
influence	O
different	O
dimensions	O
of	O
on-road	B-T073
driving	B-T056
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	B-T169
driving	B-T056
intervention programs	B-T061
in	O
MS	B-T047
.	O

Netarsudil	B-T121
Increases	B-T169
Outflow Facility	B-T060
in	O
Human	B-T016
Eyes	B-T023
Through	O
Multiple	B-T081
Mechanisms	B-T169
Netarsudil	B-T121
is	O
a	O
Rho kinase/norepinephrine transporter inhibitor	B-T121
currently	O
in	O
phase 3 clinical development	B-T062
for	O
glaucoma	B-T047
treatment	B-T061
.	O
We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	B-T123
,	O
netarsudil-M1	B-T121
,	O
on	O
outflow facility	B-T060
(	O
C	B-T060
),	O
outflow	B-T039
hydrodynamics	B-T070
,	O
and	O
morphology	B-T080
of	O
the	O
conventional	B-T080
outflow pathway	B-T077
in	O
enucleated human eyes	B-T037
.	O
Paired	B-T080
human	B-T016
eyes	B-T023
(n	O
=	O
5)	O
were	O
perfused	B-T061
with	O
either	O
0.3	O
μM	O
netarsudil-M1	B-T121
or	O
vehicle solution	B-T122
at	O
constant pressure	B-T067
(15	O
mm	O
Hg).	O
After	O
3	O
hours	B-T079
,	O
fluorescent microspheres	B-T074
were	O
added	O
to	O
perfusion	B-T061
media	B-T130
to	O
trace	B-T081
the	O
outflow patterns	B-T039
before	O
perfusion	B-T061
-	O
fixation	B-T061
.	O
The	O
percentage effective filtration length	B-T081
(	O
PEFL	B-T081
)	O
was	O
calculated	O
from	O
the	O
measured	B-T080
lengths	B-T081
of	O
tracer	B-T130
distribution	B-T169
in	O
the	O
trabecular meshwork	B-T023
(	O
TM	B-T023
),	O
episcleral veins	B-T023
(	O
ESVs	B-T023
),	O
and	O
along	O
the	O
inner wall	B-T082
(	O
IW	B-T082
)	O
of	O
Schlemm's canal	B-T030
after	O
global	B-T080
and	O
confocal imaging	B-T059
.	O
Morphologic changes	B-T190
along	O
the	O
trabecular	B-T023
outflow pathway	B-T077
were	O
investigated	O
by	O
confocal	B-T059
,	O
light	B-T059
,	O
and	O
electron microscopy	B-T059
.	O
Perfusion	B-T061
with	O
netarsudil-M1	B-T121
significantly	B-T078
increased	B-T081
C	B-T060
when	O
compared	O
to	O
baseline	O
(51%,	O
P	O
<	O
0.01)	O
and	O
to	O
paired	B-T080
controls	O
(102%,	O
P	O
<	O
0.01),	O
as	O
well	O
as	O
significantly	B-T078
increased	B-T081
PEFL	B-T081
in	O
both	O
IW	B-T082
(P	O
<	O
0.05)	O
and	O
ESVs	B-T023
(P	O
<	O
0.01).	O
In	O
treated	O
eyes	B-T023
,	O
PEFL	B-T081
was	O
significantly	B-T078
higher	O
in	O
ESVs	B-T023
than	O
in	O
the	O
IW	B-T082
(P	O
<	O
0.01)	O
and	O
was	O
associated with	B-T080
increased	B-T081
cross-sectional area	B-T082
of	O
ESVs	B-T023
(P	O
<	O
0.01).	O
Percentage effective filtration length	B-T081
in	O
ESVs	B-T023
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	B-T060
(R2	O
=	O
0.58,	O
P	O
=	O
0.01).	O
A	O
significant	B-T078
increase	B-T169
in	O
juxtacanalicular connective tissue	B-T024
(	O
JCT	B-T024
)	O
thickness	B-T080
(P	O
<	O
0.05)	O
was	O
found	O
in	O
treated	O
eyes	B-T023
compared	O
to	O
controls.	O
Netarsudil	B-T121
acutely	B-T079
increased	B-T081
C	B-T060
by	O
expansion	O
of	O
the	O
JCT	B-T024
and	O
dilating	O
the	O
ESVs	B-T023
,	O
which	O
led	O
to	O
redistribution	B-T169
of	O
aqueous	O
outflow	B-T039
through	O
a	O
larger area	B-T082
of	O
the	O
IW	B-T082
and	O
ESVs	B-T023
.	O

Geographical	B-UnknownType
Factors	B-T169
Associated With	B-T080
Health Disparities	B-T033
in	O
Prostate Cancer	B-T191
Treatment	B-T061
variation	B-T080
in	O
prostate cancer	B-T191
is	O
common,	O
and	O
it	O
is	O
driven	O
by	O
clinical	B-T080
and	O
clinician	B-T097
factors	B-T169
,	O
patient preferences	B-T080
,	O
availability of	B-T169
resources	B-T078
,	O
and	O
access	B-T082
to	O
physicians	B-T097
and	O
treating facilities	B-T073
.	O
Most	O
research	B-T062
on	O
treatment	B-T061
disparities	B-T080
in	O
men	B-T098
with	O
prostate cancer	B-T191
has	O
focused	O
on	O
race	B-T098
and	O
socioeconomic factors	B-T102
.	O
However,	O
the	O
geography	B-T077
of	O
disparities	B-T080
-	O
capturing	O
racial	B-T033
and	O
socioeconomic differences	B-T033
based	O
on	O
where	O
patients	B-T080
live	B-T052
-	O
can	O
provide	O
insight	O
into	O
barriers	B-T080
to	O
care	B-T058
and	O
help	O
identify	O
outlier	O
areas	B-UnknownType
in	O
which	O
access	B-T082
to	O
care	B-T058
,	O
health resources	B-T078
,	O
or	O
both	O
are	O
more	O
pronounced.	O
Research	B-T062
regarding	O
treatment	B-T061
patterns	B-T082
and	O
disparities	B-T080
in	O
prostate cancer	B-T191
using	O
the	O
Geographical Information System	B-T170
(	O
GIS	B-T170
)	O
was	O
searched	B-T052
.	O
Studies	B-T062
were	O
limited	O
to	O
English-language	B-T171
articles	B-T170
and	O
research	B-T062
focused	O
on	O
US	B-T083
populations	B-T098
.	O
A	O
total	O
of	O
43	O
articles	B-T170
were	O
found;	O
of	O
those,	O
30	O
provided	O
information	B-T078
about	O
or	O
used	O
spatial	B-T082
or	O
geographical	B-UnknownType
analyses	B-T062
to	O
assess	B-T052
and	O
describe	O
differences	B-T080
or	O
disparities	B-T080
in	O
prostate cancer	B-T191
and	O
its	O
treatment	B-T061
.	O
Two	O
additional	O
GIS	B-T170
resources	O
were	O
included.	O
The	O
research	B-T062
on	O
geographical	B-UnknownType
and	O
spatial determinants	B-T169
of	O
prostate cancer	B-T191
disparities	B-T080
was	O
reviewed	B-T080
.	O
We	O
also	O
examined	O
geographical	B-UnknownType
analyses	B-T062
at	O
the	O
state level	B-UnknownType
,	O
focusing	O
on	O
Florida	B-T083
.	O
Overall,	O
we	O
described	O
a	O
geographical	B-UnknownType
framework	O
to	O
disparities	B-T080
that	O
affect	O
men	B-T098
with	O
prostate cancer	B-T191
and	O
reviewed	B-T080
existing	O
published	O
evidence	B-T078
supporting	O
the	O
interplay	O
of	O
geographical	B-UnknownType
factors	B-T169
and	O
disparities	B-T080
in	O
prostate cancer	B-T191
.	O
Disparities	B-T080
in	O
prostate cancer	B-T191
are	O
common	B-T081
and	O
persistent	B-T079
,	O
and	O
notable	O
differences	O
in	O
treatment	B-T061
are	O
observable	O
across	O
racial	O
and	O
socioeconomic	O
strata.	O
Geographical	B-UnknownType
analysis	B-T062
provides	O
additional	O
information	B-T078
about	O
where	O
disparate	B-T080
groups	B-T098
live	B-T052
and	O
also	O
helps	O
to	O
map	B-T073
access	B-T082
to	O
care	B-T058
.	O
This	O
information	B-T078
can	O
be	O
used	O
by	O
public health officials	B-T097
,	O
health-systems administrators	B-T097
,	O
clinicians	B-T097
,	O
and	O
policymakers	B-T097
to	O
better	O
understand	O
and	O
respond	O
to	O
geographical	B-UnknownType
barriers	B-T080
that	O
contribute	O
to	O
disparities in care	B-T080
.	O

The	O
Novel	O
miR-9600	B-T114
Suppresses	B-T169
Tumor Progression	B-T191
and	O
Promotes	O
Paclitaxel	B-T109
Sensitivity	B-T080
in	O
Non-small-cell Lung Cancer	B-T191
Through	O
Altering	B-T078
STAT3	B-T028
Expression	B-T045
MicroRNAs	B-T114
have	O
been	O
identified	B-T080
to	O
be	O
involved	O
in	O
center stage	B-T201
of	O
cancer biology	B-T091
.	O
They	O
accommodate	O
cell proliferation	B-T043
and	O
migration	B-T043
by	O
negatively	B-T033
regulate gene expression	B-T045
either	O
by	O
hampering	O
the	O
translation	B-UnknownType
of	O
targeted mRNAs	B-T114
or	O
by	O
promoting	O
their	O
degradation	B-T169
.	O
We	O
characterized	B-T052
and	O
identified	B-T080
the	O
novel	O
miR-9600	B-T114
and	O
its	O
target	B-T169
in	O
human	B-T016
non-small-cell lung cancer	B-T191
(	O
NSCLC	B-T191
).	O
Our	O
results	O
demonstrated	O
that	O
the	O
miR-9600	B-T114
were	O
downregulated	B-T044
in	O
NSCLC	B-T191
tissues	B-T024
and	O
cells	B-T025
.	O
It	O
is	O
confirmed	O
that	O
signal transducer and activator of transcription 3	B-T028
(	O
STAT3	B-T028
),	O
a	O
putative target gene	B-T028
,	O
is	O
directly	O
inhibited	B-T080
by	O
miR-9600	B-T114
.	O
The	O
miR-9600	B-T114
markedly	O
suppressed	B-T169
the	O
protein expression	B-T045
of	O
STAT3	B-T028
,	O
but	O
with	O
no significant	B-T033
influence	B-T077
in	O
corresponding	O
mRNA	B-T114
levels	B-T080
,	O
and	O
the	O
direct	O
combination	O
of	O
miR-9600	B-T114
and	O
STAT3	B-T028
was	O
confirmed	O
by	O
a	O
luciferase	O
reporter	O
assay.	O
miR-9600	B-T114
inhibited	B-T080
cell growth	B-T043
,	O
hampered	O
expression	B-T045
of	O
cell cycle	B-T043
-related	O
proteins	B-T116
and	O
inhibited	B-T080
cell migration	B-T043
and	O
invasion	B-T046
in	O
human	B-T016
NSCLC	B-T191
cell lines	B-T025
.	O
Further,	O
miR-9600	B-T114
significantly	O
suppressed	B-T169
tumor growth	B-T191
in	O
nude mice	B-T015
.	O
Similarly,	O
miR-9600	B-T114
impeded	O
tumorigenesis	B-T191
and	O
metastasis	B-T046
through	O
directly	O
targeting	B-T044
STAT3	B-T028
.	O
Furthermore,	O
we	O
identified	B-T080
that	O
miR-9600	B-T114
augmented	O
paclitaxel	B-T109
and	O
cisplatin	B-T121
sensitivity	B-T080
by	O
downregulating	B-T044
STAT3	B-T028
and	O
promoting	O
chemotherapy	B-T061
-	O
induced	B-T169
apoptosis	B-T043
.	O
These	O
data	O
demonstrate	O
that	O
miR-9600	B-T114
might	O
be	O
a	O
useful	O
and	O
novel	O
therapeutic	B-T169
target	B-T169
for	O
NSCLC	B-T191
.	O

Beneficial effects	B-UnknownType
of	O
natural eggshell membrane	B-T109
(	O
NEM	B-T109
)	O
on	O
multiple	O
indices	O
of	O
arthritis	B-T047
in	O
collagen-induced arthritic	B-T050
rats	B-T015
This	O
study	B-T062
was	O
performed	O
to	O
evaluate	B-T058
the	O
potential efficacy	B-T080
of	O
natural eggshell membrane	B-T109
(	O
NEM	B-T109
)	O
in	O
collagen-induced arthritic	B-T050
rats	B-T015
,	O
a	O
well-established	O
rodent model of inflammation	B-T050
and	O
rheumatoid arthritis	B-T047
.	O
Rats	B-T015
with	O
developing	O
type II collagen-induced arthritis	B-T050
(	O
CIA	B-T050
)	O
were	O
treated	O
once	O
daily	B-T079
by	O
oral gavage	B-T169
on	O
study days	B-T079
-14	O
to	O
17	O
with	O
vehicle	B-T122
or	O
NEM	B-T109
(52	O
mg/kg	O
body weight	B-T032
).	O
Rats	B-T015
were	O
euthanized	B-T062
on	O
study day	B-T079
17.	O
Efficacy	B-T080
was	O
assessed	B-T052
by	O
daily	B-T079
ankle	B-T029
caliper	B-T074
measurements	B-T169
measurements	B-T169
,	O
ankle	B-T029
diameter	B-T081
expressed	O
as	O
area under the curve	B-T081
(	O
AUCd0-17	B-T081
),	O
and	O
histopathologic evaluation	B-T091
of	O
ankles	B-T029
and	O
knees	B-T023
.	O
Serum	B-T031
biomarkers	B-T201
of	O
cartilage function	B-T042
and	O
inflammation	B-T046
[	O
collagen type II C-telopeptide	B-T059
(	O
CTXII	B-T059
),	O
cartilage oligomeric matrix protein	B-T059
(	O
COMP	B-T059
),	O
and	O
alpha-2-macroglobulin	B-T059
(	O
A2M	B-T059
)]	O
were	O
measured	B-T080
by	O
ELISA	B-T059
.	O
Treatment	B-T169
with	O
NEM	B-T109
resulted	O
in	O
significant beneficial effects	B-UnknownType
on	O
the	O
daily	B-T079
ankle	B-T029
diameter	B-T081
measurements	B-T169
and	O
ankle	B-T029
diameter	B-T081
AUC	B-T081
.	O
Ankle	B-T029
and	O
knee	B-T023
histopathology scores	B-T034
were	O
significantly reduced	B-T080
(36%	O
and	O
43%	O
reduction	B-T080
of	O
summed	O
individual	O
histopathology scores	B-T034
for	O
ankle	B-T029
and	O
knee	B-T023
,	O
respectively;	O
p	O
<	O
0.05)	O
toward	O
normal	O
for	O
rats	B-T015
given	O
NEM	B-T109
compared	O
to	O
vehicle	O
controls.	O
The	O
percent	O
reduction	O
of	O
serum	B-T031
CTXII	B-T059
,	O
COMP	B-T059
,	O
and	O
A2M	B-T059
in	O
NEM	B-T109
-	O
treated	B-T169
rats	B-T015
ranged	O
from	O
30%	O
to	O
72%	O
(p	O
<	O
0.05).	O
NEM	B-T109
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory arthritis	B-T047
including	O
inflammation	B-T046
,	O
pannus	B-T046
,	O
cartilage damage	B-T037
,	O
bone resorption	B-T042
,	O
and	O
periosteal bone formation	B-T042
.	O
This	O
study	B-T062
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
CTXII	B-T116
,	O
COMP	B-T116
,	O
and	O
A2M	B-T116
as	O
relevant	O
biomarkers	B-T201
that	O
were	O
responsive	O
to	O
NEM	B-T109
.	O

Mimicking	O
the	O
cell membrane	B-T026
:	O
bio-inspired	B-T090
simultaneous	B-T079
functions	O
with	O
monovalent	B-UnknownType
anion	B-T196
selectivity	B-T052
and	O
antifouling properties	B-T070
of	O
anion	B-T196
exchange	O
membrane	B-T074
A	O
new	O
bio-inspired method	B-T090
was	O
applied	O
in	O
this	O
study	O
to	O
simultaneously	B-T079
improve	O
the	O
monovalent	B-UnknownType
anion	B-T196
selectivity	B-T052
and	O
antifouling properties	B-T070
of	O
anion	B-T196
exchange	O
membranes	B-T074
(AEMs).	O
Three-layer	O
architecture	O
was	O
developed	O
by	O
deposition	O
of	O
polydopamine	B-T109
(	O
PDA	B-T109
)	O
and	O
electro-deposition	O
of	O
N-O-sulfonic acid benzyl chitosan	B-T109
(	O
NSBC	B-T109
).	O
The	O
innermost	B-T082
and	O
outermost	B-T082
layers	B-T167
were	O
PDA	B-T109
with	O
different	O
deposition	O
time.	O
The	O
middle	B-T082
layer	B-T167
was	O
prepared	O
by	O
NSBC	B-T109
.	O
Fourier transform infrared spectroscopy	B-T062
and	O
scanning electron microscopy	B-T059
confirmed	O
that	O
PDA	B-T109
and	O
NSBC	B-T109
were	O
successfully	O
modified	O
on	O
the	O
surfaces	O
of	O
AEMs.	O
The	O
contact	O
angle	O
of	O
the	O
membranes	B-T074
indicated	O
an	O
improved	O
hydrophilicity	B-T080
of	O
the	O
modified	O
membranes	B-T074
.	O
A	O
series	O
of	O
electrodialysis experiments	B-UnknownType
in	O
which	O
Cl(-)	B-T196
/	O
SO4(2-)	B-T196
separation	O
was	O
studied,	O
demonstrating	O
the	O
monovalent	B-UnknownType
anion	B-T196
selectivity	B-T052
of	O
the	O
samples.	O
The	O
Cl(-)	B-T196
/	O
SO4(2-)	B-T196
permselectivity	B-T070
of	O
the	O
modified	O
membranes	B-T074
can	O
reach	O
up	O
to	O
2.20,	O
higher	O
than	O
that	O
of	O
the	O
commercial membrane	B-T074
(only	O
0.78)	O
during	O
90	O
minutes	O
in	O
electrodialysis	B-UnknownType
(	O
ED	B-UnknownType
).	O
The	O
increase	O
value	O
of	O
the	O
resistance	O
of	O
the	O
membranes	B-T074
was	O
also	O
measured	O
to	O
evaluate	O
the	O
antifouling properties	B-T070
.	O
Sodium dodecyl benzene sulfonate	B-T109
(	O
SDBS	B-T109
)	O
was	O
used	O
as	O
the	O
fouling	B-T070
material	O
in	O
the	O
ED	B-UnknownType
process	O
and	O
the	O
membrane	B-T074
area	O
resistance	O
of	O
modified membrane	B-T074
increase	O
value	O
of	O
was	O
only	O
0.08	O
Ωcm(2)	O
30	O
minutes	O
later.	O

The	O
Loop 2 Region	B-T087
of	O
Ribosomal Protein uS5	B-T116
Influences	O
Spectinomycin	B-T109
Sensitivity	B-T033
,	O
Translational Fidelity	B-T044
,	O
and	O
Ribosome Biogenesis	B-T043
Ribosomal protein uS5	B-T116
is	O
an	O
essential component	B-T077
of	O
the	O
small ribosomal subunit	B-T026
that	O
is	O
involved	O
in	O
subunit assembly	B-T043
,	O
maintenance of translational fidelity	B-T044
,	O
and	O
the	O
ribosome's	B-T026
response	B-T032
to	O
the	O
antibiotic spectinomycin	B-T109
.	O
While	O
many	O
of	O
the	O
characterized	O
uS5 mutations	B-T045
that	O
affect	O
decoding	B-T044
map	O
to	O
its	O
interface	B-T044
with	O
uS4	B-T116
,	O
more	O
recent	O
work	O
has	O
shown	O
that	O
residues	B-T077
distant	O
from	O
the	O
uS4-uS5 interface	B-T044
can	O
also	O
affect	O
the	O
decoding process	B-T067
.	O
We	O
targeted	O
one	O
such	O
interface-remote area	B-T082
,	O
the	O
loop 2 region	B-T087
(	O
residues	B-T077
20	O
to	O
31),	O
for	O
mutagenesis	B-T044
in	O
Escherichia. coli	B-T007
and	O
generated	O
21	O
unique mutants	B-T049
.	O
A	O
majority	O
of	O
the	O
loop 2	B-T087
alterations	O
confer	O
resistance	B-T169
to	O
spectinomycin	B-T109
and	O
affect	O
the	O
fidelity of translation	B-T044
.	O
However,	O
only	O
a	O
minority	O
show	O
altered	O
rRNA	B-T114
processing	O
or	O
ribosome biogenesis	B-T043
defects	B-T169
.	O

Multiplex	B-T080
social	B-T169
ecological	B-T082
network analysis	B-T062
reveals	B-T080
how	O
social changes	B-T054
affect	B-T169
community	B-T096
robustness	B-T080
more	O
than	O
resource	B-T081
depletion	B-T080
Network analysis	B-T062
provides	B-T052
a	O
powerful	O
tool	O
to	O
analyze	O
complex	B-T080
influences	B-T077
of	O
social	B-T102
and	O
ecological structures	B-T082
on	O
community	B-T096
and	O
household	B-T099
dynamics.	O
Most	O
network studies	B-T062
of	O
social	B-T169
-	O
ecological systems	B-T070
use	O
simple	B-T080
,	O
undirected,	O
unweighted networks	B-T169
.	O
We	O
analyze	O
multiplex	B-T080
,	O
directed	B-T082
,	O
and	O
weighted networks	B-T169
of	O
subsistence	B-T052
food	B-T168
flows	O
collected	B-T078
in	O
three	O
small	O
indigenous	B-T102
communities	B-T096
in	O
Arctic	B-T083
Alaska	B-T083
potentially	O
facing	O
substantial	O
economic	B-T169
and	O
ecological	B-T082
changes	B-T169
.	O
Our	O
analysis	O
of	O
plausible	O
future	B-T079
scenarios	B-T169
suggests	O
that	O
changes	B-T169
to	O
social	B-T169
relations	B-T080
and	O
key	O
households	B-T099
have	O
greater	O
effects	B-T080
on	O
community	B-T096
robustness	B-T080
than	O
changes	B-T169
to	O
specific	B-T080
wild food resources	B-T081
.	O

Heavy Resistance Training	B-T061
in	O
Hypoxia	B-T046
Enhances	B-T052
1RM	B-T081
Squat	B-T033
Performance	B-T055
Purpose:	O
To	O
determine	O
if	O
heavy resistance training	B-T061
in	O
hypoxia	B-T046
(	O
IHRT	B-T061
)	O
is	O
more	O
effective	B-T080
at	O
improving	B-T080
strength	B-T081
,	O
power	B-T033
,	O
and	O
increasing	B-T169
lean mass	B-T201
than	O
the	O
same	O
training	B-T080
in	O
normoxia.	O
Methods:	O
A	O
pair-matched	B-T080
,	O
placebo-controlled study	B-T062
design	B-T052
included	O
20	O
resistance-trained	B-T061
participants	B-T098
assigned	O
to	O
IHRT	B-T061
(	O
FIO2	B-T061
0.143)	O
or	O
placebo	B-T096
(	O
FIO2	B-T061
0.20),	O
(n	O
=	O
10	O
per	O
group	B-UnknownType
).	O
Participants	B-T098
were	O
matched	B-T080
for	O
strength	B-T081
and	O
training	B-T061
.	O
Both	B-T080
groups	B-UnknownType
performed	B-T169
20	O
sessions	B-T051
over	O
7	O
weeks	B-T079
either	O
with	O
IHRT	B-T061
or	O
placebo	B-T096
.	O
All	O
participants	B-T098
were	O
tested	B-T169
for	O
1RM	B-T081
,	O
20-m	B-T081
sprint	B-T061
,	O
body composition	B-T032
,	O
and	O
countermovement jump	B-T056
pre	B-T079
-,	O
mid	B-T079
-,	O
and	O
post	B-T079
-	O
training	B-T061
and	O
compared	B-T052
via	O
magnitude	B-T081
-	O
based	B-T169
inferences	B-T041
.	O
Presentation	O
of	O
Results:	O
Groups	B-UnknownType
were	O
not clearly	B-T033
different	B-T080
for	O
any	O
test	B-T169
at	O
baseline	B-T081
.	O
Training	B-T061
improved	B-T033
both	B-T080
absolute	B-T080
(	O
IHRT	B-T061
:	O
13.1	O
±	O
3.9%,	O
effect size	B-T081
(	O
ES	B-T081
)	O
0.60,	O
placebo	B-T096
9.8	O
±	O
4.7%,	O
ES	B-T081
0.31)	O
and	O
relative	B-T080
1RM	B-T081
(	O
IHRT	B-T061
:	O
13.4	O
±	O
5.1%,	O
ES	B-T081
0.76,	O
placebo	B-T096
9.7	O
±	O
5.3%,	O
ES	B-T081
0.48)	O
at	O
mid.	O
Similarly,	O
at	O
post	B-T079
both	B-T080
groups	B-UnknownType
increased	B-T081
absolute	B-T080
(	O
IHRT	B-T061
:	O
20.7	O
±	O
7.6%,	O
ES	B-T081
0.74,	O
placebo	B-T096
14.1	O
±	O
6.0%,	O
ES	B-T081
0.58)	O
and	O
relative	B-T080
1RM	B-T081
(	O
IHRT	B-T061
:	O
21.6	O
±	O
8.5%,	O
ES	B-T081
1.08,	O
placebo	B-T096
13.2	O
±	O
6.4%,	O
ES	B-T081
0.78).	O
Importantly,	O
the	O
change	B-T169
in	O
IHRT	B-T061
was	O
greater	B-T081
than	O
placebo	B-T096
at	O
mid	O
for	O
both	B-T080
absolute	B-T080
[4.4%	O
greater	B-T081
change	B-T169
,	O
90%	O
Confidence Interval	B-T081
(	O
CI	B-T081
)	O
1.0:8.0%,	O
ES	B-T081
0.21,	O
and	O
relative	B-T080
strength	B-T081
(5.6%	O
greater	B-T081
change	B-T169
,	O
90%	O
CI	B-T081
1.0:9.4%,	O
ES	B-T081
0.31	O
(	O
relative	B-T080
)].	O
There	O
was	O
also	O
a	O
greater	B-T081
change	B-T169
for	O
IHRT	B-T061
at	O
post	O
for	O
both	B-T080
absolute	B-T080
(7.0%	O
greater	B-T081
change	B-T169
,	O
90%	O
CI	B-T081
1.3:13%,	O
ES	B-T081
0.33),	O
and	O
relative	B-T080
1RM	B-T081
(9.2%	O
greater	B-T081
change	B-T169
,	O
90%	O
CI	B-T081
1.6:14.9%,	O
ES	B-T081
0.49).	O
Only	O
IHRT	B-T061
increased	B-T081
countermovement jump	B-T056
peak	B-T080
power	B-T033
at	O
Post	B-T079
(4.9%,	O
ES	B-T081
0.35),	O
however	O
the	O
difference	B-T080
between	O
IHRT	B-T061
and	O
placebo	B-T096
was	O
unclear	B-T033
(2.7,	O
90%	O
CI	B-T081
-2.0:7.6%,	O
ES	B-T081
0.20)	O
with	O
no clear	B-T033
differences	B-T080
in	O
speed	B-T081
or	O
body composition	B-T032
throughout.	O
Conclusion:	O
Heavy resistance training	B-T061
in	O
hypoxia	B-T046
is	O
more	O
effective	B-T080
than	O
placebo	B-T096
for	O
improving	B-T080
absolute	B-T080
and	O
relative	B-T080
strength	B-T081
.	O

Ultrasonography	B-T060
and	O
magnetic resonance imaging	B-T060
evaluation	B-T058
of	O
pediatric	B-T080
spinal anomalies	B-T019
Spinal dysraphisms	B-T019
are	O
congenital abnormalities	B-T019
of	O
the	O
spine	B-T023
due	O
to	O
imperfect	O
fusion	B-T169
of	O
midline	B-T082
mesenchymal	B-T080
,	O
bony	B-T169
and	O
neural	B-T169
structures	B-T082
.	O
Imaging	B-T060
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	B-T058
as	O
significant	O
portion	O
of	O
patients	B-T101
may	O
present	O
with	O
concurrent	B-T079
anomalies	B-T019
that	O
need	O
to	O
be	O
corrected	B-T080
simultaneously	B-T079
to	O
avoid	O
repeat surgeries	B-T061
.	O
The	O
aims	O
of	O
the	O
study	B-T062
were	O
to	O
evaluate	B-T058
Spinal dysraphisms	B-T019
using	O
USG	B-T060
and	O
MRI	B-T060
and	O
to	O
correlate	B-T080
imaging	B-T060
findings	B-T169
with	O
operative	B-T079
findings	B-T169
in	O
patients	B-T101
undergoing	O
surgery	B-T061
.	O
Hospital	B-T073
based	O
observational study	B-T062
conducted	O
over	O
a	O
period	B-T079
of	O
year	B-T079
.	O
38	O
cases	B-T077
of	O
both	O
sexes	B-T032
and	O
below	O
12	O
years	B-T079
of	O
age	B-T032
with	O
spinal dysraphism	B-T019
were	O
studied.	O
USG	B-T060
was	O
performed	O
in	O
29	O
cases	B-T077
where	O
acoustic window	B-T082
was	O
available	O
for	O
proper	O
evaluation	B-T058
.	O
MRI	B-T060
was	O
performed	O
in	O
all	O
cases	B-T077
.	O
USG	B-T060
findings	B-T169
were	O
compared	O
with	O
MRI	B-T060
findings	B-T169
and	O
operative	B-T079
follow up	B-T058
was	O
taken	O
in	O
23	O
cases	B-T077
who	O
underwent	O
operative management	B-T058
.	O
Results	O
were	O
analysed	B-T062
using	O
percentage	B-T081
and	O
arithmetic mean	B-T081
.	O
39.47	O
%	O
cases	B-T077
were	O
male	B-T032
and	O
60.53	O
%	O
cases	B-T077
were	O
female	B-T032
.	O
Neonatal period	B-T079
was	O
the	O
most	O
common	O
presenting	O
age group	B-T100
.	O
Closed	B-T169
spinal dysraphism	B-T019
(63.16%)	O
was	O
more	O
common	O
than	O
open	B-T082
(36.84%).	O
79.31%	O
cases	B-T077
showed	O
full	O
agreement	O
between	O
spinal	B-T082
USG	B-T060
and	O
MRI	B-T060
examinations	B-T058
and	O
6	O
out	O
of	O
20.69%	O
showed	O
partial	O
agreement.	O
On	O
operative	B-T079
correlation	B-T080
,	O
USG	B-T060
findings	B-T169
were	O
confirmatory	B-T033
in	O
91.30%	O
cases	B-T077
and	O
MRI	B-T060
findings	B-T169
were	O
confirmatory	B-T033
in	O
100%	O
cases	B-T077
.	O
USG	B-T060
can	O
be	O
used	O
as	O
the	O
initial	O
modality	B-T169
for	O
evaluation	B-T058
of	O
spinal dysraphism	B-T019
as	O
well	O
as	O
for	O
screening	B-T058
of	O
suspected	B-T078
cases	B-T077
.	O
MRI	B-T060
is	O
indicated	O
to	O
confirm	O
abnormal	B-T033
USG	B-T060
findings	B-T169
,	O
which	O
shows	O
all	O
concurrent	B-T079
abnormalities	B-T019
and	O
also	O
provides	O
additional	O
anatomical	B-T080
details	B-T080
relevant	O
to	O
surgical planning	B-T170
.	O

BORA	B-T028
-dependent	O
PLK1	B-T116
regulation	B-T043
:	O
A	O
new	O
weapon	O
for	O
cancer therapy	B-T061
?	O
The	O
mitotic kinase polo like kinase 1	B-T116
(	O
PLK1	B-T116
)	O
is	O
overexpressed	B-T045
in	O
many	O
cancers and its inhibition	B-T043
slows down proliferation	B-T043
and	O
increases apoptosis	B-T043
in	O
cancer cell lines	B-T025
.	O
Understanding	O
how	O
PLK1 is activated	B-T043
is	O
therefore	O
crucial	O
for	O
the	O
development	O
of	O
novel	O
PLK1 inhibitors	B-T116
with	O
anticancer properties	B-T109
.	O
We	O
recently	O
identified	O
a	O
conserved	O
regulatory loop	B-UnknownType
leading	O
to	O
PLK1 activation	B-T043
that	O
involves	O
cyclin-dependent kinase 1	B-T116
(	O
CDK1	B-T116
).	O

Activation of transcription	B-T045
enforces	O
the	O
formation	O
of	O
distinct	O
nuclear bodies	B-T026
in	O
zebrafish	B-T013
embryos	B-T018
Nuclear bodies	B-T026
are	O
cellular compartments	B-T030
that	O
lack	B-T080
lipid bilayers	B-T026
and	O
harbor	O
specific	B-T080
RNAs	B-T114
and	O
proteins	B-T116
.	O
Recent	O
proposals	O
that	O
nuclear bodies	B-T026
form	O
through	O
liquid-liquid	O
phase	O
separation	O
leave	O
the	O
question	O
of	O
how	O
different	O
nuclear bodies	B-T026
maintain	O
their	O
distinct	O
identities	O
unanswered.	O
Here	O
we	O
investigate	B-T169
Cajal bodies	B-T026
(	O
CBs	B-T026
),	O
histone locus bodies	B-T026
(	O
HLBs	B-T026
)	O
and	O
nucleoli	B-T026
-	O
involved	O
in	O
assembly	O
of	O
the	O
splicing machinery	B-T045
,	O
histone mRNA 3' end processing	B-T045
,	O
and	O
rRNA processing	B-T045
,	O
respectively	O
-	O
in	O
the	O
embryos	B-T018
of	O
the	O
zebrafish	B-T013
,	O
Danio rerio	B-T013
.	O
We	O
take	O
advantage	O
of	O
the	O
transcriptional	O
silence	O
of	O
the	O
1-cell	O
embryo	B-T018
and	O
follow	O
nuclear body	B-T026
appearance	O
as	O
zygotic	B-T018
transcription	B-T045
becomes	O
activated	B-T052
.	O
CBs	B-T026
are	O
present	O
from	O
fertilization	B-T040
onwards,	O
while	O
HLB	B-T026
and	O
nucleolar	B-T026
components	B-T026
formed	O
foci	B-T082
several	O
hours	O
later	O
when	O
histone	B-T116
genes	B-T028
and	O
rDNA	B-T114
became	O
active	B-T169
.	O
HLB	B-T026
formation	O
was	O
blocked	B-T169
by	O
transcription inhibition	B-T045
,	O
suggesting	O
nascent histone transcripts	B-T114
recruit	O
HLB	B-T026
components	B-T026
like	O
U7 snRNP	B-T114
.	O
Surprisingly,	O
we	O
found	O
that	O
U7	O
base-pairing	B-T044
with	O
nascent histone transcripts	B-T114
was	O
not	O
required	O
for	O
localization	B-T043
to	O
HLBs	B-T026
.	O
Rather,	O
the	O
type	O
of	O
Sm	O
ring	O
assembled	O
on	O
U7	O
determined	O
its	O
targeting	O
to	O
HLBs	B-T026
or	O
CBs	B-T026
;	O
the	O
spliceosomal	O
Sm	O
ring	O
targeted	O
snRNAs	B-T114
to	O
CBs	B-T026
while	O
the	O
specialized	O
U7	O
Sm-ring	O
localized	O
to	O
HLBs	B-T026
,	O
demonstrating	O
the	O
contribution	B-T052
of	O
protein	B-T116
constituents	B-T167
to	O
the	O
distinction	O
among	O
nuclear bodies	B-T026
.	O
Thus,	O
nucleolar	B-T026
,	O
HLB	B-T026
,	O
and	O
CB	B-T026
components	B-T026
can	O
mix	O
in	O
early	B-T079
embryogenesis	B-T042
when	O
transcription	B-T045
is	O
naturally	O
or	O
artificially	O
silenced.	O
These	O
data	O
support	O
a	O
model	O
in	O
which	O
transcription	B-T045
of	O
specific	B-T080
gene loci	B-T082
nucleates	O
nuclear body	B-T026
components	B-T026
with	O
high	O
specificity	B-T081
and	O
fidelity	O
to	O
perform	O
distinct	O
regulatory	B-T077
functions	B-T039
.	O

Variation in the age	B-T100
of	O
first reproduction	B-T040
:	O
different strategies	B-T080
or	O
individual quality	B-T080
?	O
Although	O
age	B-T032
at	O
first reproduction	B-T040
is	O
a	O
key	O
demographic parameter	B-T078
that	O
is	O
probably	O
under	O
high selective pressure	B-T033
,	O
it	O
is	O
highly	O
variable	B-T080
and	O
the	O
cause	O
of	O
this	O
variability	B-T077
is	O
not	O
well	O
understood.	O
Two	O
non-exclusive	O
hypotheses	B-T078
may	O
explain	O
such	O
variability	B-T077
.	O
It	O
could	O
be	O
the	O
expression	B-T055
of	O
different	O
individual strategies	B-T080
,	O
i.e.,	O
different	O
allocation strategies	B-T052
in	O
fitness components	B-T078
,	O
or	O
the	O
consequences	O
of	O
individual difference	B-T054
in	O
intrinsic quality	B-T082
,	O
i.e.,	O
some	O
individuals	B-T098
always	O
doing	O
better	O
than	O
others	O
in	O
all	O
fitness components	B-T078
.	O
We	O
tested	B-T169
these	O
hypotheses	B-T078
in	O
the	O
Wandering Albatross	B-T012
investigating	O
relationships	B-T080
between	O
the	O
age	B-T032
at	O
first reproduction	B-T040
and	O
subsequent	O
adult	B-T100
demographic	B-T090
traits	B-T032
.	O
Using	O
finite mixture capture recapture modeling	B-T062
,	O
we	O
demonstrate	O
that	O
the	O
age	B-T032
at	O
first reproduction	B-T040
is	O
negatively	B-T033
related	O
to	O
both	O
reproductive	B-T040
performances	B-T055
and	O
adult	B-T100
survival	B-T052
,	O
suggesting	O
that	O
individual quality	B-T080
was	O
an	O
important	O
factor	O
explaining	O
variation	B-T077
in	O
the	O
age	B-T032
at	O
first reproduction	B-T040
.	O
Our	O
results	O
suggest	O
that	O
age	B-T032
at	O
first breeding	B-T040
is	O
a	O
good	O
predictor	B-T078
of	O
quality	B-T080
in	O
this	O
long-lived	O
seabird species	B-T012
.	O

Heterogeneity	B-T080
of	O
colorectal cancer	B-T191
risk	B-T078
by	O
tumour	B-T191
characteristics	B-T080
:	O
Large	O
prospective study	B-T062
of	O
UK	B-T083
women	B-T098
Associations	B-T080
between	O
behavioural	B-T053
and	O
other	O
personal	B-T032
factors	B-T169
and	O
colorectal cancer	B-T191
risk	B-T078
have	O
been	O
reported	O
to	O
vary	O
by	O
tumour	B-T191
characteristics	B-T080
,	O
but	O
evidence	O
is	O
inconsistent.	O
In	O
a	O
large	O
UK	B-T083
-based	O
prospective study	B-T062
we	O
examined	O
associations	O
of	O
14	O
postulated	O
risk factors	B-T033
with	O
colorectal cancer	B-T191
risk	B-T078
overall,	O
and	O
across	O
three	O
anatomical sites	B-T029
and	O
four	O
morphological	B-T082
subtypes	B-T185
.	O
Among	O
1.3	O
million	O
women	B-T098
,	O
18,518	O
incident	O
colorectal cancers	B-T191
were	O
identified	O
during	O
13.8	O
(SD	O
3.4)	O
years	O
follow-up	B-T058
via	O
record	O
linkage	O
to	O
national cancer registry	B-T170
data	B-T078
.	O
Cox regression	B-T081
yielded	O
adjusted	O
relative risks	B-T081
.	O
Statistical significance	B-T081
was	O
assessed	O
using	O
correction	O
for	O
multiple	O
testing.	O
Overall,	O
colorectal cancer	B-T191
risk	B-T078
was	O
significantly	O
associated with	B-T080
height	B-T032
,	O
body mass index	B-T201
(	O
BMI	B-T201
),	O
smoking	B-T055
,	O
alcohol intake	B-T055
,	O
physical activity	B-T056
,	O
parity	B-T033
and	O
menopausal hormone therapy	B-T061
use.	O
For	O
smoking	B-T055
there	O
was	O
substantial	O
heterogeneity	B-T080
across	O
morphological	B-T082
types	B-T080
;	O
relative risks	B-T081
around	O
two	O
or	O
greater	O
were	O
seen	O
in	O
current	O
smokers	B-T033
both	O
for	O
signet ring cell	B-T025
and	O
for	O
neuroendocrine tumours	B-T191
.	O
Obese	B-T047
women	B-T098
were	O
also	O
at higher risk	B-T033
for	O
signet ring cell	B-T025
tumours	B-T191
.	O
For	O
adenocarcinomas	B-T191
,	O
the	O
large	O
majority	O
of	O
colorectal cancers	B-T191
in	O
the	O
cohort	B-T098
,	O
all	O
risk factor	B-T033
associations	B-T080
were	O
weak.	O
There	O
was	O
little	O
or	O
no	O
heterogeneity	B-T080
in	O
risk	B-T078
between	O
tumours	B-T191
of	O
the	O
right colon	B-T023
,	O
left colon	B-T023
and	O
rectum	B-T023
for	O
any	O
of	O
the	O
14	O
factors	B-T033
examined.	O
These	O
epidemiological	B-T091
findings	B-T033
complement	O
an	O
emerging	O
picture	O
from	O
molecular studies	B-T063
of	O
possible	O
different	O
developmental	B-T080
pathways	B-T077
for	O
different	O
tumour	B-T191
types	B-T080
.	O

Impact	B-T080
of	O
alcohol use	B-T055
on	O
EEG dynamics	B-T060
of	O
response inhibition	B-T041
:	O
a	O
cotwin control analysis	B-T062
Research	O
indicates	O
that	O
alcohol misuse	B-UnknownType
is	O
associated with	B-T080
behavioral disinhibition	B-T048
,	O
but	O
the	O
neurophysiological mechanisms	B-T040
governing	O
this	O
relationship	B-T080
remain	O
largely	O
unknown.	O
Recent	O
work	O
suggests	O
that	O
successful	O
inhibition	B-T041
and	O
cognitive control	B-T041
involve	O
electrophysiological theta-band dynamics	B-T060
,	O
including	O
medial frontal cortex	B-T024
(	O
MFC	B-T024
)	O
power enhancement	B-T042
and	O
functional connectivity	B-T042
between	O
the	O
MFC	B-T024
and	O
dorsal prefrontal cortex	B-T023
(	O
dPFC	B-T023
)	O
regions,	O
which	O
may	O
be	O
disrupted	O
by	O
alcohol misuse	B-UnknownType
.	O
In	O
addition,	O
research	O
suggests	O
that,	O
compared	O
to	O
men	B-T098
,	O
women	B-T098
are	O
at	O
heightened	O
risk	B-T078
of	O
experiencing	O
the	O
negative	O
physical	B-T039
and	O
neurocognitive correlates	B-T041
of	O
drinking	B-T055
.	O
The	O
present	O
study	B-T062
tested	O
the	O
hypothesis	O
that	O
alcohol misuse	B-UnknownType
has	O
a	O
deleterious effect	B-T046
on	O
theta-band	B-T061
response inhibition	B-T041
EEG dynamics	B-T060
in	O
a	O
sample	B-T098
of	O
300	O
24-year-old	O
same-sex	O
twins	B-T099
.	O
A	O
cotwin control (CTC) design	B-T062
was	O
used	O
to	O
disentangle	O
premorbid	O
risk	B-T078
for	O
alcohol use	B-T055
from	O
the	O
causal effects	B-T080
of	O
alcohol exposure	B-T051
.	O
Drinking	B-T055
was	O
negatively	O
associated with	B-T080
theta-band	B-T061
MFC power	B-T042
and	O
MFC	B-T024
-	O
dPFC	B-T023
connectivity	B-T030
during	O
response inhibition	B-T041
,	O
and	O
this	O
effect	B-T080
was	O
stronger	O
among	O
women	B-T098
.	O
The	O
CTC analysis	B-T062
suggested	O
that,	O
for	O
women	B-T098
,	O
reduced	O
nogo-related	O
theta-band	B-T061
MFC power	B-T042
and	O
MFC	B-T024
-	O
dPFC	B-T023
connectivity	B-T030
were	O
both	O
consistent	O
with	O
the	O
potential	O
deleterious causal effects	B-T046
of	O
alcohol exposure	B-T051
.	O
These	O
findings	O
suggest	O
that	O
diminished	B-T081
theta-band	B-T061
MFC power	B-T042
and	O
MFC	B-T024
-	O
dPFC	B-T023
connectivity	B-T030
may	O
be	O
neurophysiological mechanisms	B-T040
underlying	O
alcohol-related disinhibition	B-T048
.	O
Although	O
preliminary,	O
these	O
results	O
suggest	O
that	O
normative levels	B-T033
of	O
alcohol use	B-T055
during	O
emerging	O
adulthood	B-T079
have	O
potential	O
sex-specific	O
causal effects	B-T080
on	O
response inhibition	B-T041
EEG dynamics	B-T060
,	O
and	O
thus	O
have	O
potentially	O
significant	O
public	O
health	O
implications.	O

Neutrophil	B-T025
and	O
Monocyte	B-T025
Function	B-T043
in	O
Patients	B-T101
with	O
Chronic Hepatitis C	B-T047
Undergoing	O
Antiviral Therapy	B-T061
with	O
Regimens	B-T061
Containing	O
Protease Inhibitors	B-T121
with	O
and	O
without	O
Interferon	B-T116
Real-life data	B-T078
showed	O
an	O
increased	B-T081
incidence	B-T081
of	O
bacterial infections	B-T047
in	O
patients	B-T101
with	O
advanced	O
liver disease	B-T047
receiving	B-T080
a	O
protease inhibitor	B-T121
(	O
PI	B-T121
)-containing	O
antiviral regimen	B-T061
against	O
hepatitis C	B-T005
(	O
HCV	B-T005
).	O
However,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown.	O
We	O
hypothesized	O
that	O
PIs	B-T121
might	O
impair	O
innate immune responses	B-T032
through	O
the	O
inhibition of proteases	B-T039
participating	O
in	O
the	O
anti-bacterial functions	B-T039
of	O
neutrophils	B-T025
and	O
monocytes	B-T025
.	O
The	O
aims	O
of	O
the	O
study	B-T077
were	O
to	O
assess	B-T058
phagocytic and oxidative burst	B-T043
capacity	B-T081
in	O
neutrophils	B-T025
and	O
monocytes	B-T025
obtained	O
from	O
patients	B-T101
receiving	B-T080
a	O
PI	B-T121
containing-	O
antiviral regimen	B-T061
,	O
and	O
to	O
determine	O
cytokine secretion	B-T043
after	O
neutrophil	B-T025
stimulation	B-T043
with	O
flagellin	B-T116
.	O
Forty	O
patients	B-T101
with	O
chronic HCV	B-T047
(80%	O
with	O
cirrhosis	B-T047
)	O
were	O
enrolled	O
in	O
the	O
study	B-T077
,	O
28	O
received	B-T080
triple therapy	B-T061
(	O
Group A	B-T185
)	O
with	O
pegylated-interferon	B-T116
and	O
ribavirin	B-T114
for	O
4	O
weeks	B-T079
followed	O
by	O
the	O
addition	O
of	O
a	O
PI	B-T121
(	O
telaprevir	B-T116
,	O
boceprevir	B-T116
or	O
simeprevir	B-T109
),	O
and	O
12	O
patients	B-T101
received	B-T080
an	O
interferon	B-T116
interferon -free regimen	B-T061
(	O
Group B	B-T185
)	O
with	O
simeprevir	B-T109
and	O
sofosbuvir	B-T114
.	O
Phagocytosis and oxidative burst	B-T043
capacity	B-T081
were	O
analyzed	O
by	O
flow cytometry	B-T059
at	O
baseline	B-T081
,	O
week	B-T079
4,	O
and	O
week	B-T079
8	O
of	O
therapy	B-T061
.	O
In	O
neutrophils	B-T025
from	O
Group A	B-T185
patients	B-T101
,	O
oxidative burst	B-T043
rate	B-T081
and	O
oxidative	B-T169
enzymatic activity per cell	B-T044
significantly	O
decreased	B-T081
throughout	O
the	O
study period	B-T079
(p	O
=	O
0.014	O
and	O
p	O
=	O
0.010,	O
respectively).	O
Pairwise comparisons	B-T081
showed	O
a	O
decrease	B-T081
between	O
baseline	B-T081
and	O
week	B-T079
4	O
and	O
8	O
of	O
therapy	B-T061
.	O
No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	B-T061
of	O
the	O
PI	B-T121
.	O
The	O
oxidative	B-T169
enzymatic activity per cell	B-T044
in	O
monocytes	B-T025
significantly	O
decrease	B-T081
during	O
the	O
study period	B-T079
(p	O
=	O
0.042)	O
due	O
to	O
a	O
decrease	B-T081
from	O
baseline	B-T081
to	O
week	B-T079
8	O
of	O
therapy	B-T061
(p	O
=	O
0.037)	O
in	O
patients	B-T101
from	O
Group A	B-T185
.	O
None	O
of	O
these	O
findings	B-T169
were	O
observed	O
in	O
Group B	B-T185
patients	B-T101
.	O
Cytokine secretion	B-T043
did	O
not	O
significantly	O
change	O
during	O
the	O
study	B-T077
in	O
both	O
groups	B-T078
.	O
In	O
conclusion,	O
our	O
data	B-T078
suggest	O
that	O
the	O
use	O
interferon	B-T116
(rather	O
than	O
the	O
PI	B-T121
)	O
has	O
a	O
deleterious effect	B-T080
on	O
neutrophil	B-T025
and	O
monocyte	B-T025
phagocytic and oxidative burst	B-T043
capacity	B-T081
in	O
this	O
cohort	B-T098
of	O
patients	B-T101
with	O
HCV	B-T005
-related	O
advanced liver fibrosis	B-T047
.	O

Child death	B-T033
and	O
maternal	B-T033
psychosis-like experiences	B-T048
in	O
44	O
low-	B-T098
and	O
middle-income	B-T080
countries	B-T083
:	O
The	O
role	O
of	O
depression	B-T048
Studies	O
on	O
the	O
effect	O
of	O
child death	B-T033
on	O
the	O
mental wellbeing	B-T041
of	O
women	B-T098
in	O
low-	B-T098
and	O
middle-income	B-T080
countries	B-T083
(	O
LMICs	B-T083
)	O
are	O
scarce	O
despite	O
the	O
high	O
child mortality	B-T081
rates.	O
Thus,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	B-T080
between	O
child death	B-T033
and	O
psychosis-like experiences	B-T048
(	O
PLEs	B-T048
),	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	B-T048
in	O
this	O
association	B-T080
.	O
Data	B-T081
from	O
44	O
LMICs	B-T083
which	O
participated	O
in	O
the	O
World Health Survey	B-T062
(	O
WHS	B-T062
)	O
were	O
analyzed.	O
A	O
total	O
of	O
59,444	O
women	B-T098
who	O
ever	O
gave	O
birth	B-T040
,	O
aged	O
18-49	O
years	B-T079
,	O
without	O
a	O
self-reported	B-T062
lifetime	B-T079
psychosis diagnosis	B-T060
,	O
were	O
included	O
in	O
the	O
analysis.	O
The	O
World Mental Health Survey	B-T170
version	O
of	O
the	O
Composite International Diagnostic Interview	B-T170
(	O
CIDI	B-T170
)	O
was	O
used	O
to	O
establish	O
the	O
diagnosis	B-T062
of	O
past	O
12-	O
month	B-T079
DSM-IV	B-T170
depression	B-T048
,	O
and	O
assess	O
four	O
positive psychotic symptoms	B-T184
.	O
Depression	B-T048
was	O
defined	O
as	O
self-reported	B-T062
lifetime	B-T079
depression diagnosis	B-T060
and/or	O
past	O
12-	O
month	B-T079
depression	B-T048
.	O
Multivariable	O
logistic regression analyses	B-UnknownType
were	O
performed.	O
After	O
adjustment	O
for	O
potential confounders	B-T169
,	O
women	B-T098
who	O
experienced	O
child death	B-T033
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
PLEs	B-T048
(when	O
unadjusted	O
for	O
depression	B-T048
)	O
(	O
OR	B-T081
1.20-1.71;	O
p<0.05)	O
and	O
depression	B-T048
(	O
OR	B-T081
=1.64;	O
95%	O
CI	B-T081
=1.39-1.93).	O
When	O
adjusted	O
for	O
depression	B-T048
,	O
only	O
delusion of control	B-T048
was	O
strongly	O
associated with	B-T080
child death	B-T033
(	O
OR	B-T081
=1.54;	O
95%	O
CI	B-T081
=1.20-1.97).	O
Child death	B-T033
may	O
be	O
an	O
important	O
determinant	O
of	O
mental wellbeing	B-T041
among	O
women	B-T098
in	O
LMICs	B-T083
.	O
Given	O
the	O
known	O
adverse health outcomes	B-T057
associated with	B-T080
PLEs	B-T048
and	O
depression	B-T048
,	O
as	O
well	O
as	O
the	O
co-occurrence	O
of	O
these	O
symptoms	B-T184
,	O
mental health care	B-T061
may	O
be	O
particularly	O
important	O
for	O
mothers	B-T099
who	O
have	O
experienced	O
child loss	B-T033
in	O
LMICs	B-T083
.	O

Prednisolone	B-T109
is	O
associated with	B-T080
a	O
worse lipid profile	B-T033
than	O
hydrocortisone	B-T109
in	O
patients	B-T101
with	O
adrenal insufficiency	B-T047
Prednisolone	B-T109
is	O
used	O
as	O
glucocorticoid	B-T109
replacement therapy	B-T061
for	O
adrenal insufficiency	B-T047
(	O
AI	B-T047
).	O
Recent	O
data	B-T078
indicate	O
that	O
its	O
use	O
in	O
AI	B-T047
is	O
associated with	B-T080
low	O
bone mineral density	B-T201
.	O
Data	B-T078
on	O
risk factors	B-T033
for	O
cardiovascular disease	B-T047
in	O
patients	B-T101
with	O
AI	B-T047
treated	B-T169
with	O
prednisolone	B-T109
are	O
scarce,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	B-T033
of	O
excess	O
mortality	B-T081
.	O
We	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real-world	O
data	B-T078
from	O
the	O
European Adrenal Insufficiency Registry	B-T170
(	O
EU-AIR	B-T170
).	O
EU-AIR	B-T170
,	O
comprising	O
of	O
19	O
centres	B-T073
across	O
Germany	B-T083
,	O
the	O
Netherlands	B-T083
,	O
Sweden	B-T083
and	O
the	O
UK	B-T083
,	O
commenced	O
enrolling	O
patients	B-T101
with	O
AI	B-T047
in	O
August	O
2012.	O
Patients	B-T101
receiving	O
prednisolone	B-T109
(3-6	O
mg/day,	O
n	O
=	O
50)	O
or	O
hydrocortisone	B-T109
(15-30	O
mg/day,	O
n	O
=	O
909)	O
were	O
identified	B-T080
and	O
grouped	B-T082
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	B-T109
:	O
hydrocortisone	B-T109
)	O
by	O
matching	O
for	O
gender	B-T032
,	O
age	B-T032
,	O
duration	B-T079
and	O
type of disease	B-T170
.	O
Data	B-T078
from	O
baseline	B-T081
and	O
follow-up	B-T058
visits	B-T058
were	O
analysed.	O
Data	B-T078
from	O
patients	B-T101
with	O
congenital adrenal hyperplasia	B-T047
were	O
excluded	B-T052
.	O
Significantly	O
higher	O
mean ± s.d. total	B-T081
(6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol/L;	O
P	O
=	O
0.003)	O
and	O
low-density lipoprotein (LDL) cholesterol	B-T109
LDL	B-T109
)	O
cholesterol	O
levels	B-T080
(3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol/L;	O
P	O
=	O
0.013)	O
were	O
identified	B-T080
in	O
47	O
patients	B-T101
on	O
prednisolone	B-T109
vs	O
141	O
receiving	O
hydrocortisone	B-T109
at	O
baseline	B-T081
and	O
at	O
follow-up	B-T058
(P	O
=	O
0.005	O
and	O
P	O
=	O
0.006,	O
respectively).	O
HbA1c	B-T116
,	O
high-density lipoprotein	B-T116
and	O
triglyceride levels	B-T034
,	O
body mass index	B-T201
,	O
systolic	B-T047
and	O
diastolic blood pressure	B-T047
and	O
waist circumference	B-T201
were	O
not	O
significantly	O
different.	O
This	O
is	O
the	O
first	O
matched	B-T080
analysis	B-T062
of	O
its	O
kind.	O
Significantly	O
higher	O
LDL levels	B-T034
in	O
patients	B-T101
receiving	O
prednisolone	B-T109
relative	O
to	O
hydrocortisone	B-T109
could	O
predict	O
a	O
higher	O
relative	O
risk	B-T078
of	O
cardiovascular disease	B-T047
in	O
the	O
former	O
group	B-T078
.	O

Oxytocin	B-T116
Reduces	B-T080
Face	B-T029
Processing	B-T052
Time	B-T079
but	O
Leaves	B-T080
Recognition	B-T041
Accuracy	B-T080
and	O
Eye	B-T023
-	O
Gaze	B-T033
Unaffected	B-T077
Previous	B-T079
studies	B-T062
have	O
found	O
that	O
oxytocin	B-T116
(	O
OXT	B-T116
)	O
can	O
improve	B-T033
the	O
recognition	B-T041
of	O
emotional	B-T033
facial expressions	B-T033
;	O
it	O
has	O
been	O
proposed	B-T080
that	O
this	O
effect	B-T080
is	O
mediated	B-T054
by	O
an	O
increase	B-T169
in	O
attention	B-T041
to	O
the	O
eye-region	B-T029
of	O
faces	B-T029
.	O
Nevertheless,	O
evidence	B-T078
in	O
support	O
of	O
this	O
claim	O
is	O
inconsistent	B-T080
,	O
and	O
few	B-T081
studies	B-T062
have	O
directly	B-T080
tested	B-T169
the	O
effect	B-T080
of	O
oxytocin	B-T116
on	O
emotion	B-T041
recognition	B-T041
via	O
altered	B-T169
eye	B-T023
-	O
gaze	B-T033
Methods	B-T170
:	O
In	O
a	O
double-blind	B-T062
,	O
within	B-T082
-	O
subjects	B-T098
,	O
randomized control experiment	B-T062
,	O
40	O
healthy	B-T080
male participants	B-T098
received	B-T080
24	O
IU	B-T081
intranasal	B-T061
OXT	B-T116
and	O
placebo	B-T122
in	O
two	O
identical	B-T080
experimental	B-T080
sessions	B-T051
separated	B-T080
by	O
a	O
2-	O
week	B-T079
interval	B-T079
.	O
Visual attention	B-T041
to	O
the	O
eye-region	B-T029
was	O
assessed	B-T052
on	O
both	O
occasions	O
while	O
participants	B-T098
completed	B-T080
a	O
static	B-T080
facial	B-T029
emotion	B-T041
recognition	B-T041
task	B-T057
using	O
medium intensity	B-T080
facial expressions	B-T033
.	O
Although	O
OXT	B-T116
had	O
no effect	B-T080
on	O
emotion	B-T041
recognition	B-T041
accuracy	B-T080
,	O
recognition	B-T041
performance	B-T052
was	O
improved	B-T033
because	O
face	B-T029
processing	B-T052
was	O
faster	B-T080
across	O
emotions	B-T041
under	O
the	O
influence	B-T077
of	O
OXT	B-T116
.	O
This	O
effect	B-T080
was	O
marginally	B-T080
significant	B-T078
(p<.06).	O
Consistent with	B-T078
a	O
previous	B-T079
study	B-T062
using	O
dynamic stimuli	B-T067
,	O
OXT	B-T116
had	O
no effect	B-T080
on	O
eye	B-T023
-	O
gaze	B-T033
patterns	B-T082
when	O
viewing	B-T082
static	B-T080
emotional	B-T033
faces	B-T029
and	O
this	O
was	O
not	O
related	O
to	O
recognition	B-T041
accuracy	B-T080
or	O
face	B-T029
processing	B-T052
time	B-T079
.	O
These	O
findings	B-T033
suggest	B-T078
that	O
OXT	B-T116
-	O
induced	B-T169
enhanced	B-T052
facial	B-T029
emotion	B-T041
recognition	B-T041
is	O
not	O
necessarily	O
mediated	B-T054
by	O
an	O
increase	B-T169
in	O
attention	B-T041
to	O
the	O
eye-region	B-T029
of	O
faces	B-T029
,	O
as	O
previously	B-T079
assumed	B-T170
.	O
We	O
discuss	O
several	B-T081
methodological	B-T078
issues	B-T033
which	O
may	O
explain	O
discrepant findings	B-T033
and	O
suggest	B-T078
the	O
effect	B-T080
of	O
OXT	B-T116
on	O
visual attention	B-T041
may	O
differ	O
depending	O
on	O
task	B-T057
requirements	B-T169
.	O
(JINS,	O
2017,	O
23,	O
23-33).	O

New	O
directions	O
for	O
psychiatric rehabilitation	B-T061
in	O
the	O
USA	B-T083
American	B-T098
researchers	B-T097
have	O
led	O
the	O
world	B-T098
in	O
developing	B-T169
,	O
evaluating	B-T058
,	O
and	O
disseminating	B-T082
evidence	B-T078
-based	O
psychiatric rehabilitation	B-T061
practices	B-T169
for	O
people	B-T098
with	O
serious	B-T080
mental illness	B-T048
.	O
Paradoxically,	O
however,	O
the	O
USA	B-T083
lags	O
behind	O
most	O
industrialized nations	B-T080
in	O
providing	O
access	B-T080
to	O
high-quality	B-T058
mental health	B-T058
and	O
psychiatric services	B-T058
.	O
This	O
essay	B-T170
examines	O
several	O
evidence-based practices	B-T169
developed	O
in	O
the	O
USA	B-T083
,	O
the	O
spread	O
of	O
these	O
practices	B-T058
,	O
the	O
barriers	B-T033
to	O
ensuring	O
availability	B-T080
to	O
people	B-T098
who	O
could	O
benefit	B-T081
from	O
these	O
services	B-T058
,	O
and	O
some	O
promising	O
directions	O
for	O
overcoming	B-T052
the	O
barriers	B-T033
.	O
Factors	B-T169
influencing	O
the	O
growth	O
and	O
sustainment	B-T052
of	O
effective	B-T080
client	B-T096
-centred	O
practices	B-T058
include	O
the	O
availability	B-T169
of	O
adequate and stable funding	B-T081
,	O
committed leadership	B-T054
,	O
and	O
the	O
influence	B-T077
of	O
vested	O
interests.	O
Two	O
strategies	O
for	O
promoting	B-T052
the	O
spread	B-T080
and	O
sustainment	B-T052
of	O
well-implemented evidence-based practices	B-T169
are	O
the	O
adoption	B-T052
of	O
fidelity scales	B-T054
and	O
learning	B-T041
communities	B-T096
.	O

Modifiable	B-T169
Healthy Lifestyle Behaviors	B-T055
:	O
10-Year	O
Health Outcomes	B-T170
From	O
a	O
Health Promotion Program	B-T058
Previous	O
studies	O
have	O
examined	O
the	O
impact of	B-T080
healthy lifestyle choices	B-T055
on	O
health-related outcomes	B-T170
;	O
however,	O
given	O
their	O
fragmented	B-T080
,	O
often	O
cross-sectional nature	B-T062
,	O
assessing the relative impact	B-T058
of	O
daily	O
modifiable	B-T169
behaviors	B-T053
on	O
overall	O
long-term	B-T079
outcomes	B-T170
,	O
particularly	O
for	O
a	O
diverse	O
working adult population	B-T098
,	O
remains challenging	B-T080
.	O
Relationships	O
between	O
ten	O
self-reported	B-T062
healthy lifestyle behaviors	B-T055
and	O
health outcomes	B-T170
during	O
the	O
subsequent	O
9	O
years	O
in	O
a	O
cohort	B-T098
of	O
10,248	O
participants	B-T098
enrolled	O
during	O
2003	O
in	O
a	O
voluntary	B-T055
workplace	B-T082
wellness program	B-T058
were	O
assessed.	O
Cox proportional-hazards models	B-T081
computed hazard ratios	B-T081
(	O
HRs	B-T081
)	O
for	O
lifestyle characteristics	B-T054
associated	O
with	O
time	B-T079
to	O
one	O
of	O
seven	O
self-reported	B-T062
chronic diseases	B-T047
or	O
death	B-T040
.	O
Data were collected	B-T033
between	O
2003	O
and	O
2012	O
and	O
analyzed	O
between	O
2014	O
and	O
2016.	O
Behaviors	B-T053
that	O
most	O
significantly	O
affected	O
future outcomes	B-T081
were	O
low-fat diet	B-T061
,	O
aerobic exercise	B-T061
,	O
nonsmoking	B-T058
,	O
and	O
adequate sleep	B-T033
.	O
A	O
dose-response effect	B-T062
was	O
seen	O
between	O
dietary fat intake	B-T033
and	O
hypertension	B-T047
,	O
obesity	B-T047
,	O
diabetes	B-T047
,	O
heart disease	B-T047
,	O
and	O
hypercholesterolemia	B-T047
.	O
After	O
dietary fat intake	B-T033
,	O
aerobic exercise	B-T061
was	O
the	O
next	O
most	O
significant	O
behavior	B-T053
associated	O
with	O
development of outcomes	B-T062
.	O
Compared	O
with	O
sedentary	B-T080
participants	B-T098
,	O
those	O
who	O
exercised	B-T056
4	O
days	O
per	O
week	O
were	O
less	O
likely	O
to	O
develop	O
new-onset diabetes	B-UnknownType
(	O
HR	B-T081
=0.31,	O
95%	O
CI	B-T081
=0.20,	O
0.48);	O
heart disease	B-T047
(	O
HR	B-T081
=0.46,	O
95%	O
CI	B-T081
=0.27,	O
0.80);	O
and	O
hypercholesterolemia	B-T047
(	O
HR	B-T081
=0.61,	O
95%	O
CI	B-T081
=0.50,	O
0.74).	O
Low-fat diet	B-T061
and	O
adequate sleep	B-T033
were	O
more	O
significant	O
than	O
commonly	O
promoted	O
healthy behaviors	B-T055
,	O
such	O
as	O
eating a daily breakfast	B-T055
.	O
Modifiable	B-T169
lifestyle behaviors	B-T054
targeted	O
in	O
health promotion programs	B-T058
should	O
be	O
prioritized	O
in	O
an	O
evidence-based manner	B-T169
.	O
Top	O
priorities	O
for	O
workplace	B-T082
health promotion	B-T058
should	O
include	O
low-fat diet	B-T061
,	O
aerobic exercise	B-T061
,	O
nonsmoking	B-T058
,	O
and	O
adequate sleep	B-T033
.	O

Diazoxide	B-T109
prevents	B-T169
reactive oxygen species	B-T123
and	O
mitochondrial damage	B-T046
,	O
leading	O
to	O
anti-hypertrophic effects	B-T033
Pathological	B-T169
cardiac hypertrophy	B-T046
is	O
characterized	B-T052
by	O
wall	B-T023
thickening	B-T033
or	O
chamber	B-T023
enlargement	B-T046
of	O
the	O
heart	B-T023
in	O
response	O
to	O
pressure	B-T081
or	O
volume	B-T081
overload,	O
respectively.	O
This	O
condition	B-T080
will,	O
initially,	O
improve	B-T033
the	O
organ	B-T023
contractile function	B-T042
,	O
but	O
if	O
sustained	B-T169
will	O
render	O
dysfunctional	B-T077
mitochondria	B-T026
and	O
oxidative stress	B-T049
.	O
Mitochondrial ATP-sensitive K(+) channels	B-T116
(	O
mitoKATP	B-T116
)	O
modulate	B-T082
the	O
redox status	B-T044
of	O
the	O
cell	B-T025
and	O
protect	B-T033
against	O
several	O
cardiac	B-T023
insults	B-T169
.	O
Here,	O
we	O
tested	O
the	O
hypothesis	B-T078
that	O
mitoKATP	B-T116
opening	B-T082
(using	O
diazoxide	B-T109
)	O
will	O
avoid	O
isoproterenol	B-T109
-	O
induced	B-T169
cardiac hypertrophy	B-T046
in vivo	B-T082
by	O
decreasing	O
reactive oxygen species	B-T123
(ROS	B-T123
)	O
production	O
and	O
mitochondrial	B-T026
Ca(2+)	B-T121
-	O
induced	B-T169
swelling	B-T033
.	O
To	O
induce	B-T169
cardiac hypertrophy	B-T046
,	O
Swiss mice	B-T015
were	O
treated	B-T169
intraperitoneally	B-T082
with	O
isoproterenol	B-T109
(30	O
mg/kg/	O
day	B-T079
)	O
for	O
8	O
days	B-T079
.	O
Diazoxide	B-T109
(5	O
mg/kg/	O
day	B-T079
)	O
was	O
used	O
to	O
open	O
mitoKATP	B-T116
and	O
5-hydroxydecanoate	B-T109
(5	O
mg/kg/	O
day	B-T079
)	O
was	O
administrated	O
as	O
a	O
mitoKATP	B-T116
blocker	B-T121
.	O
Isoproterenol	B-T109
-	O
treated	B-T169
mice	B-T015
had	O
elevated	B-T080
heart	B-T023
weight	B-T081
/	O
tibia	B-T023
length	B-T081
ratios	B-T081
and	O
increased	B-T081
myocyte	B-T025
cross-sectional areas	B-T033
.	O
Additionally,	O
hypertrophic	B-T169
hearts	B-T023
produced	O
higher	B-T080
levels	B-T080
of	O
H2O2	B-T121
and	O
had	O
lower	O
glutathione peroxidase activity	B-T044
.	O
In	O
contrast,	O
mitoKATP	B-T116
opening	B-T082
with	O
diazoxide	B-T109
blocked	B-T169
all	O
isoproterenol	B-T109
effects	B-T080
in	O
a	O
manner	O
reversed	B-T169
by	O
5-hydroxydecanoate	B-T109
.	O
Isolated	B-T169
mitochondria	B-T026
from	O
Isoproterenol	B-T109
-	O
induced	B-T169
hypertrophic	B-T169
hearts	B-T023
had	O
increased	B-T081
susceptibility	B-T169
to	O
Ca(2+)	B-T121
-	O
induced	B-T169
swelling	B-T033
secondary	O
to	O
mitochondrial permeability transition pore	B-T116
opening	B-T082
.	O
MitokATP	B-T116
opening	B-T082
was	O
accompanied	O
by	O
lower	O
Ca(2+)	B-T121
-	O
induced	B-T169
mitochondrial swelling	B-T049
,	O
an	O
effect	B-T080
blocked	B-T169
by	O
5-hydroxydecanoate	B-T109
.	O
Our	O
results	O
suggest	O
that	O
mitoKATP	B-T116
opening	B-T082
negatively	B-T033
regulates	B-T038
cardiac hypertrophy	B-T046
by	O
avoiding	O
oxidative	B-T169
impairment	B-T169
and	O
mitochondrial damage	B-T046
.	O

Anticholinergic	B-T121
premedication	B-T061
to	O
prevent	O
bradycardia	B-T046
in	O
combined	O
spinal anesthesia	B-T061
and	O
dexmedetomidine	B-T109
sedation	B-T061
:	O
a	O
randomized	B-T062
,	O
double-blind	B-T062
,	O
placebo-controlled study	B-T062
When	O
dexmedetomidine	B-T109
is	O
used	O
in	O
patients	B-T101
undergoing	O
spinal anesthesia	B-T061
,	O
high	O
incidence	B-T169
of	O
bradycardia	B-T046
in	O
response	O
to	O
parasympathetic	B-T022
activation	B-T052
is	O
reported.	O
Therefore,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	B-T080
of	O
atropine	B-T109
premedication	B-T061
for	O
preventing	B-T169
the	O
incidence	B-T169
of	O
bradycardia	B-T046
and	O
the	O
hemodynamic effect	B-T042
on	O
patients	B-T101
undergoing	O
spinal anesthesia	B-T061
with	O
sedation	B-T061
by	O
dexmedetomidine	B-T109
.	O
Randomized	B-T062
,	O
double-blind	B-T062
,	O
placebo-controlled study	B-T062
.	O
Operating room	B-T073
.	O
One	O
hundred	O
fourteen	O
patients	B-T109
(age	O
range,	O
2-65	O
years	B-T079
;	O
American Society of Anesthesiology class I-II	B-T094
)	O
participated	O
in	O
this	O
study	B-T062
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal anesthesia	B-T061
.	O
The	O
patients	B-T109
were	O
divided	O
into	O
2	O
groups	B-UnknownType
:	O
group A	B-UnknownType
and	O
group C	B-UnknownType
.	O
After	O
performing	O
spinal anesthesia	B-T061
,	O
dexmedetomidine	B-T109
was	O
infused	B-T061
at	O
a	O
loading dose	B-UnknownType
of	O
0.6	O
μg/kg	O
for	O
10	O
minutes	B-T079
,	O
followed	O
by	O
an	O
infusion	B-T061
at	O
0.25	O
μg/(kg	O
h).	O
Simultaneously	O
with	O
the	O
loading dose	B-UnknownType
of	O
dexmedetomidine	B-T109
,	O
patients	B-T109
in	O
group A	B-UnknownType
received	O
an	O
intravenous bolus	B-T169
of	O
0.5	O
mg	O
atropine	B-T109
,	O
whereas	O
patients	B-T109
in	O
group C	B-UnknownType
received	O
an	O
intravenous normal saline	B-T061
bolus	B-T061
.	O
Data	B-T078
on	O
administration	B-T061
of	O
atropine	B-T109
and	O
ephedrine	B-T109
were	O
collected.	O
Hemodynamic	B-T059
data	B-T078
including	O
heart rate	B-T201
,	O
systolic blood pressure	B-T201
,	O
diastolic blood pressure	B-T201
(	O
DBP	B-T201
),	O
and	O
mean blood pressure	B-T033
(	O
MBP	B-T033
)	O
were	O
also	O
recorded.	O
The	O
incidence	B-T169
of	O
bradycardia	B-T046
requiring	O
atropine	B-T109
treatment	B-T061
was	O
significantly higher	B-T081
in	O
group C	B-UnknownType
than	O
group A	B-UnknownType
(P=.035).	O
However,	O
the	O
incidence	B-T169
of	O
hypotension	B-T033
needing	O
ephedrine	B-T109
treatment	B-T061
showed	O
no significant difference	B-T033
between	O
the	O
2	O
groups	B-UnknownType
(P=.7).	O
Systolic blood pressure	B-T201
and	O
heart rate	B-T201
showed	O
no significant differences	B-T033
between	O
the	O
2	O
groups	B-UnknownType
(P=.138	O
and	O
.464,	O
respectively).	O
However,	O
group A	B-UnknownType
showed	O
significant	O
increases	B-T081
in	O
DBP	B-T201
and	O
MBP	B-T033
,	O
and	O
group C	B-UnknownType
did	O
not	O
(P=.014	O
and	O
.008,	O
respectively).	O
Prophylactic	B-T061
atropine	B-T109
reduces	O
the	O
incidence	B-T169
of	O
bradycardia	B-T046
in	O
patients	B-T109
undergoing	O
spinal anesthesia	B-T061
with	O
dexmedetomidine	B-T109
sedation	B-T061
.	O
However,	O
DBP	B-T201
and	O
MBP	B-T033
showed	O
significant	O
increases	B-T081
in	O
patients	B-T109
when	O
prophylactic	B-T061
atropine	B-T109
was	O
administrated	B-T061
.	O
Therefore,	O
atropine	B-T109
premedication	B-T061
should	O
be	O
administered	B-T061
cautiously.	O

Downregulation	B-T044
of	O
Endothelial Transient Receptor Potential Vanilloid Type 4 Channel	B-T116
and	O
Small-Conductance of Ca2+-Activated K+ Channels	B-T116
Underpins	O
Impaired	B-T169
Endothelium-Dependent Hyperpolarization	B-T123
in	O
Hypertension	B-T047
Endothelium-dependent hyperpolarization	B-T123
(	O
EDH	B-T123
)-mediated	O
responses	B-T033
are	O
impaired	B-T169
in	O
hypertension	B-T047
,	O
but	O
the	O
underlying	O
mechanisms	B-T169
have	O
not	O
yet	O
been	O
determined.	O
The	O
activation	B-T052
of	O
small-	B-T116
and	O
intermediate-conductance of Ca(2+)-activated K(+) channels	B-T116
(	O
SKCa	B-T116
and	O
IKCa	B-T116
)	O
underpins	O
EDH	B-T123
-mediated	O
responses	B-T033
.	O
It	O
was	O
recently	O
reported	B-T170
that	O
Ca(2+) influx	B-T043
through	O
endothelial transient receptor potential vanilloid type 4 channel	B-T116
(	O
TRPV4	B-T116
)	O
is	O
a	O
prerequisite	B-T078
for	O
the	O
activation	B-T052
of	O
SKCa	B-T116
/	O
IKCa	B-T116
in	O
endothelial cells	B-T025
in	O
specific	O
beds.	O
Here,	O
we	O
attempted	B-T051
to	O
determine	O
whether	O
the	O
impairment	B-T169
of	O
EDH	B-T123
in	O
hypertension	B-T047
is	O
attributable	O
to	O
the	O
dysfunction	B-T077
of	O
TRPV4	B-T116
and	O
S	B-T116
/	O
IKCa	B-T116
,	O
using	O
isolated	O
superior mesenteric arteries	B-T023
of	O
20-week-old	O
stroke-prone spontaneously hypertensive rats	B-T015
(	O
SHRSP	B-T015
)	O
and	O
age-matched	O
Wistar-Kyoto (WKY) rats	B-T015
.	O
In	O
the	O
WKY	B-T015
arteries	B-T023
,	O
EDH	B-T123
-mediated	O
responses	B-T033
were	O
reduced	B-T080
by	O
a	O
combination	B-T080
of	O
SKCa	B-T116
/	O
IKCa	B-T116
blockers	B-T121
(	O
apamin	B-T116
plus	O
TRAM-34	B-T109
;	O
1-[(2-chlorophenyl)diphenylmethl]-1H-pyrazole	B-T109
)	O
and	O
by	O
the	O
blockade	B-T169
of	O
TRPV4	B-T116
with	O
the	O
selective	O
antagonist	B-T120
RN-1734	B-T109
or	O
HC-067047	B-T109
.	O
In	O
the	O
SHRSP	B-T015
arteries	B-T023
,	O
EDH-mediated hyperpolarization	B-T123
and	O
relaxation	B-T052
were	O
significantly	B-T078
impaired	B-T169
when	O
compared	O
with	O
WKY	B-T015
.	O
GSK1016790A	B-T109
,	O
a	O
selective	O
TRPV4	B-T116
activator	B-T121
,	O
evoked	O
robust	O
hyperpolarization	B-T043
and	O
relaxation	B-T052
in	O
WKY	B-T015
arteries	B-T023
.	O
In	O
contrast,	O
in	O
SHRSP	B-T015
arteries	B-T023
,	O
the	O
GSK1016790A	B-T109
-evoked	O
hyperpolarization	B-T043
was	O
small	O
and	O
relaxation	B-T052
was	O
absent	B-T169
.	O
Hyperpolarization	B-T043
and	O
relaxation	B-T052
to	O
cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine	B-T109
,	O
a	O
selective	O
SKCa	B-T116
activator	B-T121
,	O
were	O
marginally	B-T080
decreased	B-T081
in	O
SHRSP	B-T015
arteries	B-T023
compared	O
with	O
WKY	B-T015
arteries	B-T023
.	O
The	O
expression	B-T045
of	O
endothelial TRPV4	B-T116
and	O
SKCa	B-T116
protein	O
was	O
significantly decreased	B-T081
in	O
the	O
SHRSP	B-T015
mesenteric arteries	B-T023
compared	O
with	O
those	O
of	O
WKY	B-T015
,	O
whereas	O
function	B-T169
and	O
expression	B-T045
of	O
IKCa	B-T116
were	O
preserved	O
in	O
SHRSP	B-T015
arteries	B-T023
.	O
These	O
findings	B-T033
suggest	O
that	O
EDH	B-T123
-mediated	O
responses	B-T033
are	O
impaired	B-T169
in	O
superior mesenteric arteries	B-T023
of	O
SHRSP	B-T015
because	O
of	O
a	O
reduction	B-T061
in	O
both	O
TRPV4	B-T116
and	O
SKCa	B-T116
input	B-T077
to	O
EDH	B-T123
.	O

Bioavailability	B-T062
and	O
health risk assessment	B-T061
of	O
potentially	B-T080
toxic elements	B-T131
in	O
Thriasio Plain, near Athens	B-T083
,	O
Greece	B-T083
Elevated	O
concentrations	B-T081
of	O
potentially	B-T080
toxic elements	B-T131
(	O
PTEs	B-T131
)	O
are	O
usually	O
found	O
in	O
areas of intense industrial activity	B-T033
.	O
Thriasio Plain	B-T083
is	O
a	O
plain near Athens	B-T083
,	O
Greece	B-T083
,	O
where	O
most	O
of	O
the	O
heavy industry	B-T090
of	O
the	O
country	O
has	O
been	O
situated	O
for	O
decades,	O
but	O
it	O
also	O
is	O
a	O
residential	B-T082
and	O
horticultural	B-UnknownType
area	B-T082
.	O
We	O
aimed	O
at	O
measuring	O
the	O
levels	O
of	O
PTEs	B-T131
in	O
soils	B-T167
soils	B-T167
and	O
indigenous	B-T169
plant species	B-T002
and	O
assessing the health risk	B-T061
associated with	B-T080
direct	O
soil	B-T167
ingestion	B-T038
.	O
Samples of soils	B-T167
at	O
roadsides	B-T073
and	O
growing	O
plants	B-T002
were	O
collected	O
from	O
31	O
sites	O
of	O
that	O
area	B-T082
.	O
Concentrations	B-T081
of	O
Al	B-T196
,	O
As	B-T121
,	O
Cd	B-T131
,	O
Co	B-T123
,	O
Cr	B-T131
,	O
Cu	B-T121
,	O
Fe	B-T121
,	O
Mn	B-T123
,	O
Mo	B-T123
,	O
Ni	B-T123
,	O
Pb	B-T131
,	O
V	B-T131
and	O
Zn	B-T121
were	O
measured	O
in	O
both	O
soils	B-T167
(as	O
pseudo-total)	O
and	O
aerial	O
plant tissues	B-T025
.	O
We	O
found	O
that	O
As	B-T121
,	O
Cd	B-T131
,	O
Cr	B-T131
,	O
Cu	B-T121
,	O
Ni	B-T123
,	O
Pb	B-T131
and	O
Zn	B-T121
were	O
higher	O
than	O
maximum	O
regulatory	B-T089
limits	B-T078
.	O
Element	B-T196
concentrations	B-T081
in	O
plants	B-T002
were	O
rather	O
lower	O
than	O
expected,	O
probably	O
because	O
indigenous	B-T169
plants	B-T002
have	O
developed	O
excluder	B-T169
behaviour	O
over	O
time.	O
Copper	B-T121
and	O
Zn	B-T121
soil	B-T167
-to-	O
plant	B-T002
coefficients	B-T081
were	O
highest	O
among	O
the	O
other	O
elements	B-T196
;	O
for	O
Cu	B-T121
this	O
was	O
unexpected,	O
and	O
probably	O
associated with	B-T080
recent	O
Cu	B-T121
-	O
releasing	B-T169
industrial	B-T057
activity	B-T052
.	O
Risk assessment analysis	B-T058
indicated	O
that	O
As	B-T121
was	O
the	O
element	B-T196
contributing	O
more	O
than	O
50	O
%	O
of	O
the	O
health	B-T078
risk	B-T078
related	O
to	O
direct	O
soil	B-T167
ingestion	B-T038
,	O
followed	O
by	O
Cr	B-T131
,	O
Pb	B-T131
,	O
and,	O
surprisingly,	O
Mn	B-T123
.	O
We	O
concluded	O
that	O
in	O
a	O
multi	B-T081
-	O
element	B-T196
contamination	B-T068
situation,	O
elevated	O
risk	O
of	O
PTEs	B-T131
(such	O
as	O
As	B-T121
,	O
Cr	B-T131
and	O
Pb	B-T131
)	O
may	O
reduce	O
the	O
tolerance	B-T080
limits	B-T169
of	O
exposure to	B-T080
less-	O
toxic elements	B-T131
(here,	O
Mn	B-T123
).	O

Nutrients	B-T168
influence	O
the	O
thermal ecophysiology	B-T039
of	O
an	O
intertidal	B-T082
macroalga	B-T204
:	O
multiple stressors	B-T078
or	O
multiple drivers	B-T078
?	O
Urbanization	B-T068
of	O
coastlines	B-UnknownType
is	O
leading	O
to	O
increased	O
introduction	O
of	O
nutrients	B-T168
from	O
the	O
terrestrial environment	B-T082
to	O
nearshore habitats	B-T082
.	O
While	O
such	O
nutrient	B-T168
influxes	O
can	O
be	O
detrimental	O
to	O
coastal	B-UnknownType
marine organisms	B-T001
due	O
to	O
increased	O
eutrophication	B-T067
and	O
subsequent	O
reduced	B-T080
oxygen	B-T121
,	O
they	O
could	O
also	O
have	O
positive effects	B-T080
(i.e.,	O
increased	O
food	B-T168
availability	B-T169
)	O
on	O
species	B-T185
that	O
are	O
nitrogen-limited	B-T123
such	O
as	O
macroalgae	B-T204
.	O
Nutrient	B-T168
enrichment	B-T067
in	O
this	O
environment	B-T082
thus	O
has	O
the	O
potential	B-T080
to	O
counteract	O
some	O
of	O
the	O
negative impacts	B-T080
of	O
increasing	B-T169
temperatures	B-T081
,	O
at	O
least	O
for	O
some	O
species	B-T185
.	O
Characterizing	O
the	O
physiological response	B-T039
of	O
organisms	B-T001
to	O
simultaneous	B-T079
changes	B-T169
in	O
multiple drivers	B-T078
such	O
as	O
these	O
is	O
an	O
important	O
first	O
step	O
in	O
predicting	O
how	O
global	B-T080
climate change	B-T070
may	O
lead	O
to	O
ecological	B-T070
responses	B-T032
at	O
more	O
local levels	B-UnknownType
.	O
We	O
evaluated	O
how	O
nutrient	B-T168
enrichment	B-T067
(i.e.,	O
nitrogen	B-T123
availability	B-T169
)	O
affected	O
the	O
growth	B-T040
of	O
Fucus vesiculosus	B-T002
,	O
a	O
foundational	O
macroalgal	B-T204
species	B-T204
in	O
the	O
North Atlantic rocky intertidal zone	B-T083
,	O
and	O
found	O
that	O
nutrient	B-T168
-enriched	O
algal blades	B-T185
showed	O
a	O
significant	O
increase	O
in	O
tissue growth	B-T042
compared	O
to	O
individuals	B-T078
grown	O
under	O
ambient	B-T080
conditions.	O
We	O
further	O
quantified	O
net	O
photosynthesis	B-T070
by	O
ambient	O
and	O
nutrient	B-T168
-enriched	O
tissues	B-T025
at	O
saturating irradiance	B-T070
over	O
a	O
range	O
of	O
temperature	B-T081
conditions	O
(6-30°C).	O
Respiration	B-T039
was	O
unaffected	O
by	O
nutrient	B-T168
treatment	B-T169
;	O
however,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
photosynthetic	B-T070
oxygen	B-T121
production	O
for	O
nutrient	B-T168
-enriched	O
tissue	B-T025
compared	O
to	O
ambient	B-T080
,	O
but	O
only	O
at	O
elevated	B-T080
(≥18°C)	O
temperatures	B-T081
.	O
This	O
study	B-T062
contributes	O
to	O
a	O
growing	O
body	O
of	O
literature	B-T170
showing	O
the	O
complexity	O
of	O
responses to changes	B-T032
in	O
multiple drivers	B-T078
,	O
and	O
highlights	O
the	O
importance	O
of	O
studying	B-T062
the	O
impacts	B-T067
of	O
global	B-T080
climate change	B-T070
within	O
the	O
context	O
of	O
more	O
local	O
environmental	B-T082
conditions	B-T080
.	O

A	O
trial	B-T062
to	O
determine	O
whether	O
septic shock	B-T046
-	O
reversal	B-T169
is	O
quicker	B-T080
in	O
pediatric	B-T080
patients	B-T101
randomized	B-T062
to	O
an	O
early	B-T079
goal-directed fluid-sparing strategy	B-T061
versus	O
usual care	B-T058
(	O
SQUEEZE	B-T062
):	O
study protocol	B-T170
for	O
a	O
pilot randomized controlled trial	B-T062
Current	B-T079
pediatric	B-T080
septic shock	B-T046
resuscitation	B-T061
guidelines	B-T170
from	O
the	O
American College of Critical Care Medicine	B-T093
focus	O
on	O
the	O
early	B-T079
and	O
goal-directed administration	B-T061
of	O
intravascular	B-T082
fluid	B-T031
followed	O
by	O
vasoactive	B-T080
medication	B-T121
infusions	B-T061
for	O
persistent	B-T079
and	O
fluid-refractory shock	B-T047
.	O
However,	O
accumulating	B-T033
adult	B-T100
and	O
pediatric	B-T080
data	B-T078
suggest	O
that	O
excessive	B-T080
fluid administration	B-T061
is	O
associated	O
with	O
worse	B-T033
patient	B-T101
outcomes	B-T169
and	O
even	O
increased risk of death	B-T033
.	O
The	O
optimal amount	B-T081
of	O
intravascular	B-T082
fluid	B-T031
required	O
in	O
early	B-T079
pediatric	B-T080
septic shock	B-T046
resuscitation	B-T061
prior	O
to	O
the	O
initiation	B-T169
of	O
vasoactive support	B-T080
remains	O
unanswered.	O
The	O
SQUEEZE Pilot Trial	B-T062
is	O
a	O
pragmatic	B-T054
,	O
two-arm	B-T062
,	O
parallel-group	B-T062
,	O
open-label	B-T062
,	O
prospective pilot randomized controlled trial	B-T062
.	O
Participants	B-T098
are	O
children	B-T100
aged	B-T032
29	O
days	B-T079
to	O
under	O
18	O
years	B-T079
with	O
suspected	B-T078
or	O
confirmed	B-T033
septic shock	B-T046
and	O
a	O
need	O
for	O
ongoing	O
resuscitation	B-T061
.	O
Eligible	O
participants	B-T098
are	O
enrolled	B-T058
under	O
an	O
exception	B-T077
to	O
consent	B-T169
process	B-T067
and	O
randomly	B-T080
assigned	B-T169
via	O
concealed	B-T080
allocation	B-T052
to	O
either	O
the	O
Usual Care	B-T058
(	O
control	B-T096
)	O
or	O
Fluid Sparing (intervention) resuscitation strategy	B-T061
.	O
The	O
primary	B-T080
objective	B-T170
of	O
this	O
pilot trial	B-T062
is	O
to	O
determine	O
feasibility	B-T062
,	O
based	O
on	O
the	O
ability	O
to	O
enroll	B-T058
participants	B-T098
and	O
to	O
adhere	O
to	O
the	O
study protocol	B-T170
.	O
The	O
primary outcome measure	B-T080
by	O
which	O
success	B-T080
will	O
be	O
determined	O
is	O
participant	B-T098
enrollment	B-T058
rate	B-T081
("pass"	O
defined	O
as	O
at	O
least	O
two	O
participants	B-T098
/	O
site	B-T082
/	O
month	B-T079
,	O
recognizing	O
that	O
enrollment	B-T058
may	O
be	O
slower	O
during	O
the	O
run-in	O
phase).	O
Secondary	O
objectives	B-T170
include	O
assessing	O
(1)	O
appropriateness	B-T080
of	O
eligibility criteria	B-T080
,	O
and	O
(2)	O
completeness	B-T080
of	O
clinical outcomes	B-T169
to	O
inform	O
the	O
endpoints	B-T080
for	O
the	O
planned	B-T169
multisite trial	B-T062
.	O
To	O
support	O
the	O
nested translational study	B-T062
,	O
SQUEEZE-D	B-T062
,	O
we	O
will	O
also	O
evaluate	O
the	O
feasibility	B-T062
of	O
describing	O
cell-free DNA	B-T114
(a	O
procoagulant molecule	B-T116
with	O
prognostic utility	B-T170
)	O
in	O
blood samples	B-T031
obtained	O
from	O
children	B-T100
enrolled	B-T058
into	O
the	O
SQUEEZE Pilot Trial	B-T062
at	O
baseline	B-T081
and	O
at	O
24	O
h.	O
The	O
optimal	O
degree	B-T081
of	O
fluid	B-T031
resuscitation	B-T061
and	O
the	O
timing	B-T079
of	O
initiation	B-T169
of	O
vasoactive support	B-T080
in	O
order	O
to	O
achieve	O
recommended	O
therapeutic	B-T169
targets	B-T169
in	O
children	B-T100
with	O
septic shock	B-T046
remains	O
unanswered.	O
No	O
prospective study	B-T062
to	O
date	B-T079
has	O
examined	O
this	O
important	O
question	B-T170
for	O
children	B-T100
in	O
developed countries	B-T080
including	O
Canada	B-T083
.	O
Recruitment	B-T052
for	O
the	O
SQUEEZE Pilot Trial	B-T062
opened	B-T033
on	O
6	O
January	O
2014.	O
Findings	B-T033
will	O
inform	O
the	O
feasibility	B-T062
of	O
the	O
planned	B-T169
multicenter trial	B-T062
to	O
answer	O
our	O
overall	B-T080
research question	B-T078
.	O
ClinicalTrials.gov	O
Identifier	O
NCT01973907,	O
registered	O
on	O
23	O
October	O
2013.	O

Entropy-driven reactions	B-T169
in	O
living	B-T078
cells	B-T025
for	O
assay	B-T059
let-7a microRNA	B-T114
Imaging	B-T060
of	O
microRNA	B-T114
(	O
miRNA	B-T114
)	O
in	O
living	B-T078
cells	B-T025
could	O
facilitate	O
the	O
monitoring	B-T057
of	O
the	O
expression	B-T045
and	O
distribution	B-T169
of	O
miRNA	B-T114
and	O
research	B-T062
on	O
miRNA	B-T114
-related	O
diseases	B-T047
.	O
Given	O
the	O
low	O
expression levels	B-T081
and	O
even	O
down-regulation	B-T044
of	O
cellular	B-T025
miRNA	B-T114
that	O
is	O
associated with	B-T080
some	O
diseases	B-T047
,	O
enzyme	B-T116
-	O
free	B-T169
amplification strategies	B-T063
are	O
imperative	O
for	O
intracellular	B-T082
miRNA	B-T114
assay	B-T059
.	O
In	O
this	O
work,	O
we	O
report	O
an	O
entropy-driven reaction	B-T169
for	O
amplification	B-T063
assay	B-T059
miRNA	B-T114
with	O
a	O
detection limit	B-T081
of	O
0.27	O
pM.	O
The	O
resulting	O
signal	B-T067
amplification	B-T067
provides	O
excellent	O
recognition	O
and	O
signal	B-T067
enhancement	B-T052
of	O
specific	B-T080
miRNA	B-T114
s	O
in	O
living	B-T078
cells	B-T025
.	O
This	O
method	O
supplies	O
accurate	B-T080
information	B-T078
regarding	O
cellular	B-T025
miRNA	B-T114
-related	O
biological events	B-T038
and	O
provides	O
a	O
new	O
tool	O
for	O
highly sensitive	B-T080
and	O
simultaneous	B-T079
imaging	B-T060
of	O
multiple	B-T081
low-level	O
biomarkers	B-T201
,	O
thereby	O
improving	O
the	O
accuracy	B-T080
of	O
early disease diagnosis	B-T060
.	O

Iterative	B-T033
Development	B-T169
and	O
Evaluation	B-T058
of	O
a	O
Pharmacogenomic	B-T091
-Guided	O
Clinical Decision Support System	B-T170
for	O
Warfarin Dosing	B-T081
Pharmacogenomic	B-T091
-guided	O
dosing	B-T081
has	O
the	O
potential	O
to	O
improve	O
patient	B-T101
outcomes	O
but	O
its	O
implementation	B-T052
has	O
been	O
met	O
with	O
clinical	B-T080
challenges	B-T058
.	O
Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	B-T058
a	O
clinical decision support system	B-T170
(	O
CDSS	B-T170
)	O
for	O
pharmacogenomic	B-T091
-guided	O
warfarin dosing	B-T081
designed	B-T052
for	O
physicians	B-T097
and	O
pharmacists	B-T097
.	O
Twelve	O
physicians	B-T097
and	O
pharmacists	B-T097
completed	O
6	O
prescribing	B-T058
tasks	B-T057
using	O
simulated patient	B-T065
scenarios	B-T169
in	O
two	O
iterations	B-T033
(	O
development	B-T169
and	O
validation	B-T062
phases	B-T079
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	B-T091
-driven	O
CDSS	B-T170
prototype	B-T080
.	O
For	O
each	O
scenario	B-T169
,	O
usability	B-T170
was	O
measured	B-T080
via	O
efficiency	B-T081
,	O
recorded	B-T170
as	O
time to task completion	B-T201
,	O
and	O
participants	B-T098
'	O
perceived	B-T041
satisfaction	B-T041
which	O
were	O
compared	O
using	O
Kruskal-Wallis and Mann Whitney U tests	B-T170
,	O
respectively.	O
Debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively analyzed	B-T059
.	O
Usability	B-T170
findings	O
from	O
the	O
first	O
(i.e.	O
development	B-T169
)	O
iteration	B-T033
were	O
incorporated	O
into	O
the	O
CDSS	B-T170
design	B-T052
for	O
the	O
second	B-T079
(i.e.	O
validation	B-T062
)	O
iteration	B-T033
.	O
During	O
the	O
CDSS	B-T170
validation	B-T062
iteration	B-T033
,	O
participants	B-T098
took	O
more	O
time to complete tasks	B-T201
with	O
a	O
median	B-T082
(IQR)	O
of	O
183	O
(124-247)	O
seconds	B-T079
versus	O
101	O
(73.5-197)	O
seconds	B-T079
in	O
the	O
development	B-T169
iteration	B-T033
(p=0.01).	O
This	O
increase	B-T169
in	O
time on task	B-T079
was	O
due	O
to	O
the	O
increase	B-T169
in	O
time	B-T079
spent	O
in	O
the	O
CDSS	B-T170
corresponding	O
to	O
several	O
design	B-T052
changes.	O
Efficiency	B-T081
differences	O
that	O
were	O
observed	O
between	O
pharmacists	B-T097
and	O
physicians	B-T097
in	O
the	O
development	B-T169
iteration	B-T033
were	O
eliminated	O
in	O
the	O
validation	B-T062
iteration	B-T033
.	O
The	O
increased	B-T081
use	O
of	O
the	O
CDSS	B-T170
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
CDSS	B-T170
recommended	O
doses	B-T081
in	O
the	O
validation	B-T062
iteration	B-T033
(4%	O
in	O
the	O
first	O
iteration	B-T033
vs.	O
37.5%	O
in	O
the	O
second	B-T079
iteration	B-T033
,	O
p<0.001).	O
Overall	O
satisfaction	B-T041
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	B-T033
but	O
the	O
qualitative analysis	B-T059
revealed	O
greater	O
trust	O
in	O
the	O
second	B-T079
prototype	B-T080
.	O
A	O
pharmacogenomic	B-T091
-guided	O
CDSS	B-T170
has	O
been	O
developed	O
using	O
warfarin	B-T109
as	O
the	O
test	O
drug	B-T121
.	O
The	O
final	O
CDSS	B-T170
prototype	B-T080
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	B-T081
the	O
time	B-T079
using	O
the	O
tool	B-T033
and	O
acceptance	O
of	O
the	O
recommended	O
doses	B-T081
.	O
This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	B-T091
into	O
CDSS	B-T170
design	B-T052
for	O
clinical testing	B-T062
.	O

Pedicle Screw	B-T074
Combined	B-T080
With	O
Lateral Mass Screw	B-T074
Fixation	B-T061
in	O
the	O
Treatment	B-T061
of	O
Basilar Invagination	B-T019
and	O
Congenital C2-C3 Fusion	B-T019
Clinical evaluation	B-T058
of	O
a	O
surgical	B-T061
fixation	B-T061
technique	B-T169
featuring	O
combined	B-T080
use	O
of	O
pedicle screw	B-T074
and	O
lateral mass screw	B-T074
(	O
LMS	B-T074
).	O
Introduction	O
of	O
a	O
novel	O
technique	B-T169
for	O
the	O
treatment	B-T061
of	O
congenital C2-C3 fusion	B-T019
and	O
basilar invagination	B-T019
(	O
BI	B-T019
).	O
Posterior	B-T082
occipitocervical	B-T029
fixation	B-T061
using	O
C2 pedicle screw	B-T074
was	O
widely	O
used	O
for	O
BI	B-T019
.	O
However,	O
in	O
cases	B-T169
where	O
BI	B-T019
is	O
concurrent	B-T079
with	O
congenital C2-C3 fusion	B-T019
,	O
the	O
C2 pedicles	B-T023
tend	O
to	O
be	O
thinner	B-T080
than	O
that	O
in	O
normal	B-T080
population	B-T098
and	O
hence	O
more	O
likely	O
to	O
fail	B-T169
.	O
We	O
prompted	O
to	O
tackle	O
the	O
issue	B-T033
by	O
combining	B-T080
the	O
pedicle screw	B-T074
with	O
the	O
additional	O
use	O
of	O
LMS	B-T074
in	O
attempt	O
to	O
strengthen	B-T078
the	O
fixation	B-T061
.	O
Twenty-five	O
patients	B-T101
who	O
underwent	O
combined	B-T080
pedicle screw	B-T074
with	O
LMS	B-T074
fixation	B-T061
were	O
retrospectively studied	B-T062
.	O
The	O
instrument	B-T074
position	B-T082
,	O
fusion	B-T169
status	B-T080
,	O
and	O
complications	B-T046
were	O
analyzed	B-T062
.	O
None	O
had	O
spinal cord	B-T037
or	O
vertebral artery injury	B-T037
.	O
The	O
average	O
follow-up	B-T058
time	B-T079
was	O
20	O
months	B-T079
.	O
Solid	O
fusion	B-T169
was	O
achieved	O
in	O
23	O
patients	B-T101
(92%)	O
as	O
detected	O
radiologically	B-T060
.	O
Two	O
cases	B-T169
suffered	O
from	O
recurred	B-T067
BI	B-T019
and	O
instrument	B-T074
failure	B-T033
but	O
eventually	O
achieved	O
solid	O
fusion	B-T169
between	O
the	O
occiput	B-T029
and	O
C2	B-T023
was	O
after	O
revision	B-T061
.	O
Among	O
all	O
25	O
patients	B-T101
,	O
4	O
suffered	O
from	O
complications	B-T046
including	O
instrument	B-T074
s	O
failure	B-T033
,	O
cerebrospinal fluid leakage	B-T047
,	O
and	O
intracranial	B-T029
infection	B-T046
.	O
The	O
clinical	B-T080
outcome	B-T169
indicates	O
that	O
the	O
technique	B-T169
is	O
reliable	O
for	O
the	O
treatment	B-T061
of	O
BI	B-T019
with	O
congenital C2-C3 fusion	B-T019
.	O

Co-occurrence	B-T079
and	O
clustering	B-T081
of	O
health	B-T078
conditions	B-T080
at	O
age	B-T032
11:	O
cross-sectional	B-T062
findings	B-T169
from	O
the	O
Millennium Cohort Study	B-T081
To	O
identify	O
patterns	O
of	O
co-occurrence	B-T079
and	O
clustering	B-T081
of	O
6	O
common	O
adverse	B-T046
health	B-T078
conditions	B-T080
in	O
11-	O
year	B-T079
-old	O
children	B-T100
and	O
explore	O
differences	B-T080
by	O
sociodemographic factors	B-T078
.	O
Nationally	O
representative	O
prospective cohort study	B-T062
.	O
Children	B-T100
born	O
in	O
the	O
UK	B-T083
between	O
2000	O
and	O
2002.	O
11	O
399	O
11-	O
year	B-T079
-old	O
singleton	B-T099
children	B-T100
for	O
whom	O
data	B-T078
on	O
all	O
6	O
health	B-T078
conditions	B-T080
and	O
sociodemographic information	B-T078
were	O
available	O
(	O
complete	B-T080
cases	B-T169
).	O
Prevalence	B-T081
,	O
co-occurrence	B-T079
and	O
clustering	B-T081
of	O
6	O
common	O
health	B-T078
conditions	B-T080
:	O
wheeze	B-T184
;	O
eczema	B-T047
;	O
long-standing illness	B-T184
(excluding	O
wheeze	B-T184
and	O
eczema	B-T047
);	O
injury	B-T037
;	O
socioemotional difficulties	B-T048
(measured	O
using	O
Strengths and Difficulties Questionnaire	B-T170
)	O
and	O
unfavourable weight	B-T032
(	O
thin	B-T033
/	O
overweight	B-T184
/	O
obese	B-T047
vs	O
normal	B-T032
).	O
42.4%	O
of	O
children	B-T100
had	O
2	O
or	O
more	O
adverse	B-T046
health	B-T078
conditions	B-T080
(	O
co-occurrence	B-T079
).	O
Co-occurrence	B-T079
was	O
more	O
common	O
in	O
boys	B-T100
and	O
children	B-T100
from	O
lower	O
income	B-T081
households	B-T099
.	O
Latent class analysis	B-T062
identified	O
6	O
classes	B-T170
:	O
'	O
normative	B-T080
'	O
(57.4%):	O
'	O
atopic	B-T046
burdened	B-T078
'	O
(14.0%);	O
'	O
socioemotional burdened	B-T048
'	O
(11.0%);	O
'	O
unfavourable weight	B-T032
/	O
injury	B-T037
'	O
(7.7%);	O
'	O
eczema	B-T047
/	O
injury	B-T037
'	O
(6.0%)	O
and	O
'	O
eczema	B-T047
/	O
unfavourable weight	B-T032
'	O
(3.9%).	O
As	O
with	O
co-occurrence	B-T079
,	O
class	B-T170
membership	B-T055
differed	O
by	O
sociodemographic factors	B-T078
:	O
boys	B-T100
,	O
children	B-T100
of	O
mothers	B-T099
with	O
lower	O
educational attainment	B-T033
and	O
children	B-T100
from	O
lower	O
income	B-T081
households	B-T099
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
socioemotional burdened	B-T048
'	O
class	B-T170
.	O
Children	B-T100
of	O
mothers	B-T099
with	O
higher	O
educational attainment	B-T033
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
normative	B-T080
'	O
and	O
'	O
eczema	B-T047
/	O
unfavourable weight	B-T032
'	O
classes	B-T170
.	O
Co-occurrence	B-T079
of	O
adverse	B-T046
health	B-T078
conditions	B-T080
at	O
age	B-T032
11	O
is	O
common	O
and	O
is	O
associated with	B-T080
adverse	B-T046
socioeconomic	B-T077
circumstances	B-T077
.	O
Holistic	B-T078
,	O
child	B-T100
focused	O
care	B-T052
,	O
particularly	O
in	O
boys	B-T100
and	O
those	O
in	O
lower	O
income	B-T081
groups	B-T078
,	O
may	O
help	O
to	O
prevent	B-T080
and	O
reduce	B-T080
co-occurrence	B-T079
in	O
later	B-T079
childhood	B-T079
and	O
adolescence	B-T079
.	O

Genomic	B-T028
characterization	B-T052
of	O
a	O
wild-bird	B-T012
-	O
origin	B-T033
pigeon	B-T012
paramyxovirus type 1	B-T005
(	O
PPMV-1	B-T005
)	O
first	O
isolated	B-T169
in	O
the	O
northwest region of China	B-T083
Pigeon	B-T012
paramyxovirus type-1	B-T005
(	O
PPMV-1	B-T005
)	O
is	O
an	O
enzootic	B-T169
in	O
pigeon	B-T012
flocks	B-T096
and	O
causes	O
severe	B-T080
economic losses	B-T081
in	O
the	O
poultry	B-T012
industry	B-T057
in	O
many	O
countries	B-T083
.	O
A	O
PPMV-1	B-T005
isolate	B-T123
,	O
abbreviated	O
as	O
PPMV-1/QL-01/CH/15	B-T005
,	O
was	O
isolated	B-T169
from	O
a	O
great	O
spotted	O
woodpecker	B-T012
in	O
the	O
northwest region of China	B-T083
in	O
2015.	O
The	O
complete	O
genome	B-T028
was	O
sequenced	B-T059
,	O
and	O
the	O
results	B-T169
showed	O
that	O
the	O
virus	B-T005
genome	B-T028
was	O
15,192	O
nt	O
in	O
length	B-T081
,	O
in	O
the	O
gene arrangement 3'-NP-P-M-F-HN-L-5'	B-T044
.	O
Several	O
amino acid	B-T116
mutations	B-T045
were	O
identified	B-T080
in	O
the	O
functional domains	B-T087
of	O
the	O
F	B-T116
and	O
HN proteins	B-T116
.	O
The	O
pathogenicity index	B-T032
of	O
the	O
isolate	B-T123
was	O
evaluated	B-T058
,	O
and	O
the	O
mean death time	B-T079
(	O
MDT	B-T079
)	O
was	O
72	O
h	O
and	O
the	O
intracerebral pathogenicity index	B-T032
(	O
ICPI	B-T032
)	O
was	O
0.925,	O
indicating	O
that	O
this	O
isolate	B-T123
was	O
mesogenic	B-T080
.	O
Sequencing	B-T059
results	B-T169
showed	O
that	O
it	O
had	O
a	O
virulent	B-T080
Newcastle disease virus	B-T005
cleavage motif (112)R-R-Q-K-R-F(117)	B-T087
at	O
the	O
fusion protein	B-T116
cleavage site	B-T087
.	O
Morbidity	B-T081
and	O
mortality	B-T081
were	O
70%	O
and	O
50%,	O
after	O
inoculation	B-T061
of	O
pigeons	B-T012
,	O
whereas	O
this	O
virus	B-T005
was	O
nonpathogenic	B-T033
in	O
chickens	B-T012
.	O
Different	O
immune responses	B-T042
of	O
pigeons	B-T012
and	O
chickens	B-T012
were	O
induced	B-T169
in vivo	B-T082
,	O
which	O
led	O
to	O
different	O
HI serum antibody titers	B-T059
.	O
The	O
results	B-T169
of	O
phylogenetic	B-T062
and	O
evolutionary distance analysis	B-T062
showed	O
that	O
this	O
PPMV-1	B-T005
strain	B-T001
belonged	O
to	O
sub-genotype VIa	B-T170
in	O
class II	B-T170
.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
identification	B-T059
and	O
analysis	B-T062
of	O
PPMV-1	B-T005
co-circulation	B-T033
among	O
wild birds	B-T012
and	O
domestic pigeon	B-T012
flocks	B-T096
in	O
China	B-T083
.	O
The	O
data	B-T078
from	O
this	O
study	B-T062
highlight	O
the	O
important	O
role	O
of	O
wild birds	B-T012
in	O
the	O
dissemination	B-T082
of	O
PPMV-1	B-T005
and	O
provide	O
useful	O
references	B-T170
for	O
improving	B-T080
our	O
understanding	O
of	O
the	O
distribution	B-T082
and	O
evolution	B-T045
of	O
PPMV-1	B-T005
in	O
China	B-T083
.	O

Memory consolidation	B-T041
effects	B-T080
on	O
memory stabilization	B-T041
and	O
item integration	B-T041
in	O
older adults	B-T098
This	O
study	B-T062
examined	O
the	O
differential effects	B-T169
of	O
aging	B-T040
on	O
consolidation processes	B-T041
that	O
strengthen	O
newly	O
acquired	O
memory traces	B-T041
in	O
veridical	O
form	O
(	O
memory stabilization	B-T041
)	O
versus	O
consolidation processes	B-T041
that	O
are	O
responsible	O
for	O
integrating	B-T041
these	O
memory traces	B-T041
into	O
an	O
existing	O
body	O
of	O
knowledge	B-T170
(	O
item integration	B-T041
).	O
Older adults	B-T098
learned	B-T041
13	O
nonwords	B-T170
and	O
were	O
tested	O
on	O
their	O
memory	B-T041
for	O
the	O
nonwords	B-T170
,	O
and	O
on	O
whether	O
these	O
nonwords	B-T170
impacted	O
upon	O
processing	O
of	O
similar-sounding	O
English	B-T171
words	B-T170
immediately	O
and	O
24	O
hours	B-T079
later.	O
Participants	B-T098
accurately	O
recognized	O
the	O
nonwords	B-T170
immediately,	O
but	O
showed	O
significant	O
decreases	O
in	O
delayed	O
recognition	B-T041
and	O
recall	B-T041
.	O
In	O
comparison,	O
the	O
nonwords	B-T170
impacted	O
upon	O
processing	B-T052
of	O
similar-sounding words	B-T170
only	O
in	O
the	O
delayed test	B-T170
.	O
Together,	O
these	O
findings	O
suggest	O
that	O
memory consolidation processes	B-T041
may	O
be	O
more	O
evident	O
in	O
item integration	B-T041
than	O
memory stabilization processes	B-T041
for	O
new	O
declarative	O
memories	B-T041
in	O
older adults	B-T098
.	O

Mucosa	B-T031
-	O
associated	B-T080
biohydrogenating microbes	B-T001
protect	O
the	O
simulated	O
colon	B-T204
microbiome	B-T001
from	O
stress	B-T033
associated with	B-T080
high concentrations	B-T081
of	O
poly-unsaturated fat	B-T109
Polyunsaturated fatty acids	B-T109
(	O
PUFAs	B-T109
)	O
may	O
affect	O
colon	B-T204
microbiome	B-T001
homeostasis	B-T038
by	O
exerting	B-T040
(	O
specific	B-T080
)	O
antimicrobial	B-T195
effects	B-T080
and/or	O
interfering	O
with	O
mucosal	B-T031
biofilm	B-T167
formation	B-T169
at	O
the	O
gut mucosal interface	B-T023
.	O
We	O
used	O
standardized batch incubations	B-T059
and	O
the	O
Mucosal-Simulator of the Human Microbial Intestinal Ecosystem	B-T170
(	O
M-SHIME	B-T170
)	O
to	O
show	O
the	O
in vitro	B-T080
luminal	B-T030
and	O
mucosal	B-T031
effects of	B-T080
the	O
main	O
PUFA	B-T109
in	O
the	O
Western diet	B-T061
,	O
linoleic acid	B-T109
(	O
LA	B-T109
).	O
High concentrations	B-T081
of	O
LA	B-T109
were	O
found	O
to	O
decrease	B-T081
butyrate	B-T109
production	B-T169
and	O
Faecalibacterium prausnitzii	B-T007
numbers	O
dependent	O
on	O
LA	B-T109
biohydrogenation	B-T070
to	O
vaccenic acid	B-T109
(	O
VA	B-T109
)	O
and	O
stearic acid	B-T109
(	O
SA	B-T109
).	O
In	O
faecal	B-T031
batch incubations	B-T059
,	O
LA	B-T109
biohydrogenation	B-T070
and	O
butyrate	B-T109
production	B-T169
were	O
positively correlated	B-T080
and	O
SA	B-T109
did	O
not	O
inhibit	B-T052
butyrate	B-T109
production	B-T169
.	O
In	O
the	O
M-SHIME	B-T170
,	O
addition	O
of	O
a	O
mucosal	B-T031
environment	B-T082
stimulated	B-T070
biohydrogenation	B-T070
to	O
SA	B-T109
and	O
protected	O
F. prausnitzii	B-T007
from	O
inhibition	B-T052
by	O
LA	B-T109
.	O
This	O
was	O
probably	O
due	O
to	O
the	O
preference	B-T078
of	O
two	O
biohydrogenating	B-T070
genera	B-T185
Roseburia	B-T007
and	O
Pseudobutyrivibrio	B-T007
for	O
the	O
mucosal	B-T031
niche.	O
Co-culture	B-T059
batch incubations	B-T059
using	O
Roseburia hominis	B-T007
and	O
F. prausnitzii	B-T007
validated	B-T062
these	O
observations	B-T062
.	O
Correlations	B-T080
networks	B-T169
further	O
uncovered	O
the	O
central	O
role	O
of	O
Roseburia	B-T007
and	O
Pseudobutyrivibrio	B-T007
in	O
protecting	O
luminal	B-T030
and	O
mucosal SHIME microbiota	B-T059
from	O
LA	B-T109
-	O
induced stress	B-T033
.	O
Our	O
results	B-T169
confirm	O
how	O
cross-shielding interactions	B-T169
provide	O
resilience	O
to	O
the	O
microbiome	B-T001
and	O
demonstrate	O
the	O
importance	B-T080
of	O
biohydrogenating	B-T070
,	O
mucosal	B-T031
bacteria	B-T007
for	O
recovery	B-T052
from	O
LA	B-T109
stress	B-T033
.	O

Genetic	B-T169
parameters	B-T033
for	O
tick count	B-T081
and	O
udder	B-T023
health	B-T078
in	O
commercial	B-T170
and	O
indigenous	B-T102
ewes	B-UnknownType
in	O
South Africa	B-T083
The	O
genetics	B-T169
of	O
tick infestation	B-T047
in	O
sheep	B-T015
need	O
study,	O
as	O
host resistance	B-T169
often	O
forms	O
part	O
of	O
integrated	O
pest control programs	B-T057
.	O
Repeated	O
udder	B-T023
health scores	B-T170
,	O
site-specific	B-T082
tick count	B-T081
,	O
mating	B-T040
weight	B-T081
and	O
reproduction	B-T040
records	B-T170
(N=879-1204)	O
were	O
recorded	O
annually	O
from	O
2010	O
to	O
2015	O
on	O
ewes	B-UnknownType
of	O
the	O
indigenous	B-T102
Namaqua Afrikaner	B-T015
(	O
NA	B-T015
)	O
fat-tailed breed	B-T185
,	O
as	O
well	O
as	O
the	O
commercial	B-T170
Dorper	B-T015
and	O
SA Mutton Merino (SAMM) breeds	B-T015
.	O
Udder	B-T023
s	O
were	O
scored	B-T081
subjectively	O
on	O
a	O
1-5	O
scale	O
(1	O
-	O
udder	B-T023
intact	B-T080
and	O
5	O
-	O
udder	B-T023
damaged severely	B-T037
)	O
and	O
ticks	B-T047
were	O
counted	B-T081
on	O
three locations	B-T029
.	O
The	O
body sites	B-T029
counted	B-T081
were	O
the	O
head and thoracic limb	B-T023
(	O
HTLTC	B-T023
),	O
udder-pelvic limb	B-T023
(	O
UPLTC	B-T023
)	O
and	O
perineum-breech-tail	B-T023
(	O
PBTTC	B-T023
).	O
These	O
counts	B-T081
were	O
also	O
totaled	O
for	O
a	O
total tick count	B-T081
(	O
TTC	B-T081
).	O
Reproduction	B-T040
traits	B-T032
were	O
number	O
of	O
lambs	B-T015
weaned	B-T033
per	O
ewe lambed	B-T033
and	O
total	O
weight	O
of	O
lamb weaned	B-T033
per	O
ewe lambed	B-T033
.	O
Udder	B-T023
health scores	B-T170
of	O
NA	B-T015
ewes	B-UnknownType
were	O
lower	O
than	O
those	O
of	O
Dorpers	B-T015
,	O
which	O
in	O
turn	O
had	O
lower	O
scores	O
than	O
SAMM	B-T015
ewes	B-UnknownType
.	O
NA	B-T015
ewes	B-UnknownType
had	O
lower	O
values	O
for	O
HTLTC	B-T023
,	O
UPLTC	B-T023
and	O
TTC	B-T081
than	O
the	O
commercial	B-T170
breeds	B-T185
,	O
but	O
higher	O
values	O
for	O
PBTTC	B-T023
than	O
Dorpers	B-T015
.	O
Heritability	B-T033
estimates	B-T081
amounted	O
to	O
0.26±0.04	O
for	O
HTLTC	B-T023
,	O
0.53±0.04	O
for	O
UPLTC	B-T023
,	O
0.07±0.06	O
for	O
PBTTC	B-T023
,	O
0.44±0.06	O
for	O
TTC	B-T081
and	O
0.61±0.03	O
for	O
udder	B-T023
health score	B-T170
.	O
Animal permanent environment	B-T082
also	O
affected	O
PBTTC	B-T023
(0.14±0.07).	O
Significant genetic correlations	B-UnknownType
were	O
found	O
between	O
the	O
HTLTC	B-T023
and	O
UPLTC	B-T023
(0.47±0.10),	O
UPLTC	B-T023
and	O
udder	B-T023
health score	B-T170
(0.52±0.07),	O
HTLTC	B-T023
and	O
UPLTC	B-T023
(0.24±0.11)	O
as	O
well	O
as	O
UPLTC	B-T023
and	O
PBTTC	B-T023
(-0.44±0.11).	O
Heavier	O
ewes	B-UnknownType
had	O
higher	O
UPLTC	B-T023
(0.38±0.09),	O
TTC	B-T081
(0.33±0.09)	O
and	O
impaired	B-T169
udder	B-T023
health	B-T078
(0.21±0.08).	O
Udder	B-T023
health score	B-T170
s	O
and	O
tick counts	B-T081
at	O
all	O
sites	O
were	O
not	O
related	O
to	O
reproduction	B-T040
traits	B-T032
.	O
The	O
indigenous	B-T102
NA	B-T015
breed	B-T185
outperformed	O
the	O
commercial	B-T170
breeds	B-T185
with	O
lower	O
values	O
for	O
HTLTC	B-T023
,	O
UPLTC	B-T023
,	O
TTC	B-T081
and	O
a	O
better	O
udder	B-T023
health score	B-T170
.	O
Mechanisms	O
contributing	O
to	O
the	O
better	O
performance	O
of	O
the	O
NA	B-T015
breed	B-T185
under	O
pastoral conditions	B-T058
and	O
the	O
scope	O
for	O
selection	O
for	O
tick	B-T047
tolerance	B-T080
within	O
breeds	B-T185
should	O
be	O
studied	O
further.	O

Starvation	B-T033
-	O
and	O
antibiotics	B-T195
-induced	O
formation	B-T043
of	O
persister cells	B-T007
in	O
Pseudomonas aeruginosa	B-T007
Planktonic	B-T007
stationary and exponential cultures	B-T059
of	O
Pseudomonas aeruginosa	B-T007
are	O
highly resistant	B-T169
to	O
killing	B-T033
by	O
bactericidal antimicrobials	B-T195
because	O
of	O
the	O
presence	O
of	O
persisters	B-T007
,	O
cells	B-T007
that	O
are	O
multidrug tolerant	B-T033
and	O
play	O
a	O
key	O
role	O
in	O
the	O
recalcitrance	B-T169
of	O
biofilm	B-T007
infections	B-T046
.	O
The	O
aim	O
of	O
this	O
study	B-T170
was	O
to	O
investigate	B-T169
the	O
formation	B-T043
of	O
persister cells	B-T007
in	O
P. aeruginosa	B-T007
stationary	B-T059
vs.	O
exponential cultures	B-T059
using	O
different	B-T080
class	B-T170
antimicrobials	B-T195
.	O
The	O
susceptibilities	B-T169
of	O
P. aeruginosa PAO1 wild-type	B-T007
and	O
mutant strains	B-T001
to	O
antimicrobials	B-T195
were	O
determined	O
by	O
standard microtiter broth dilution method	B-T059
.	O
In	O
order	O
to	O
determine	O
persister	B-T007
formation	B-T043
,	O
dose	B-T081
-	O
and	O
time	B-T079
-dependent	O
killing experiments	B-T059
were	O
performed	B-T169
with	O
antibiotics	B-T195
.	O
Ceftazidime	B-T109
(	O
Cephalosporin	B-T109
)	O
showed	O
little	O
efficacy	B-T080
against	O
either	O
culture	B-T059
.	O
Stationary-phase cells	B-T007
were	O
more	O
tolerant	B-T033
to	O
imipenem	B-T109
(	O
Carbapenem	B-T109
)	O
than	O
exponential cells	B-T007
,	O
leaving	O
a	O
small	O
fraction of	B-T081
persisters	B-T007
at	O
high	B-T080
imipenem	B-T109
concentration	B-T081
in	O
both	O
populations	B-T098
.	O
Polymyxin B	B-T116
(	O
Polymyxin	B-T116
)	O
appeared	O
to	O
be	O
ineffective	O
at	O
low concentrations	B-T081
against	O
both	O
cell populations	B-T098
.	O
Very	O
high	O
polymyxin B	B-T116
concentration	B-T081
completely	O
eradicated	O
exponential cells	B-T007
and	O
regrowth	B-T169
was	O
seen	O
in	O
a	O
stationary population	B-T098
.	O
Stationary cells	B-T007
were	O
more	O
tolerant	B-T033
to	O
tobramycin	B-T109
(	O
Aminoglycoside	B-T109
)	O
than	O
exponential cells	B-T007
but	O
a	O
higher concentration	B-T081
of	O
tobramycin	B-T109
completely	O
eliminated	B-T080
survivors	B-T078
.	O
Ciprofloxacin	B-T109
(	O
Fluoroquinolone	B-T109
)	O
at	O
a	O
low concentration	B-T081
resulted	O
in	O
killing	B-T033
of	O
both	O
cultures	B-T059
of	O
P. aeruginosa	B-T007
,	O
producing	O
persisters	B-T007
that	O
were	O
invulnerable	O
to	O
killing	B-T033
.	O
Stationary cells	B-T007
appear	O
to	O
be	O
somewhat	O
more	O
tolerant	B-T033
than	O
exponential cells	B-T007
in	O
all	O
of	O
these	O
assays	B-T059
.	O
We	O
also	O
showed	O
that	O
nutrient	B-T168
deprivation	B-T080
(	O
serine	B-T116
starvation	B-T033
)	O
regulated	O
by	O
stringent and general stress response	B-T039
,	O
contribute	O
to	O
the	O
increased tolerance	B-T033
of	O
P. aeruginosa	B-T007
exponential and stationary planktonic cells	B-T007
via	O
production	B-T043
of	O
persisters	B-T007
.	O

Chaetomium thermophilum	B-T004
formate dehydrogenase	B-T116
has	O
high	O
activity	O
in	O
the	O
reduction	B-T070
of	O
hydrogen carbonate	B-T197
(	O
HCO3 -	B-T197
)	O
to	O
formate	B-T109
While	O
formate dehydrogenases	B-T116
(	O
FDHs	B-T116
)	O
have	O
been	O
used	O
for	O
cofactor	B-T123
recycling	B-T068
in	O
chemoenzymatic synthesis	B-T044
,	O
the	O
ability	O
of	O
FDH	B-T116
to	O
reduce	O
CO2	B-T123
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	B-T169
of	O
CO2	B-T123
to	O
useful	O
products	B-T071
via	O
formate	B-T109
(	O
HCOO(-)	B-T109
).	O
In	O
this	O
study,	O
we	O
investigated	B-T169
the	O
reduction	B-T070
of	O
CO2	B-T123
in	O
the	O
form	O
of	O
hydrogen carbonate	B-T197
(	O
HCO3(-)	B-T197
)	O
to	O
formate	B-T109
by	O
FDHs	B-T116
from	O
Candida methylica	B-T004
(	O
CmFDH	B-T116
)	O
and	O
Chaetomium thermophilum	B-T004
(	O
CtFDH	B-T116
)	O
in	O
a	O
NADH	B-T114
-dependent	O
reaction	B-T169
.	O
The	O
catalytic performance	B-T044
with	O
HCO3(-)	B-T197
as	O
a	O
substrate	B-T167
was	O
evaluated	O
by	O
measuring	B-T080
the	O
kinetic rates	B-T079
and	O
conducting	O
productivity assays	B-T059
.	O
CtFDH	B-T116
showed	O
a	O
higher	O
efficiency	B-T081
in	O
converting	B-T169
HCO3(-)	B-T197
to	O
formate	B-T109
than	O
CmFDH	B-T116
,	O
whereas	O
CmFDH	B-T116
was	O
better	O
in	O
the	O
oxidation	B-T044
of	O
formate	B-T109
.	O
The	O
pH	B-T081
optimum	O
of	O
the	O
reduction	B-T070
was	O
at	O
pH	B-T081
7-8.	O
However,	O
the	O
high concentrations	B-T081
of	O
HCO3(-)	B-T197
reduced	O
the	O
reaction rate	B-T079
.	O
CtFDH	B-T116
was	O
modeled	O
in	O
the	O
presence	O
of	O
HCO3(-)	B-T197
showing	O
that	O
it	O
fits	O
to	O
the	O
active site	B-T169
.	O
The	O
active site	B-T169
setting	O
for	O
hydride transfer	B-T044
in	O
CO2	B-T123
reduction	B-T070
was	O
modeled.	O
The	O
hydride donated	B-T044
by	O
NADH	B-T114
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon atom	B-T196
of	O
HCO3(-)	B-T197
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	B-T196
within	O
the	O
molecule	B-T167
.	O
This	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen carbonate	B-T197
and	O
the	O
hydride	B-T196
to	O
break	O
into	O
formate	B-T109
and	O
hydroxide ions	B-T196
.	O

Evaluation	B-T170
of	O
an	O
international	B-T078
educational programme	B-T065
for	O
health care professionals	B-T097
on	O
best	O
practice	O
in	O
the	O
management	B-T057
of	O
a	O
perinatal	B-T079
death	B-T040
:	O
IMproving Perinatal mortality Review and Outcomes Via Education	B-T065
(	O
IMPROVE	B-T065
)	O
Stillbirths	B-T033
and	O
neonatal deaths	B-T033
are	O
devastating events	B-T051
for	O
both	O
parents	B-T099
and	O
clinicians	B-T080
and	O
are	O
global public health	B-T091
concerns	B-T078
.	O
Careful	O
clinical management	B-T058
after	O
these	O
deaths	B-T040
is	O
required,	O
including	O
appropriate	O
investigation	B-T058
and	O
assessment	B-T058
to	O
determine	O
cause	O
(s)	O
to	O
prevent	O
future	O
losses,	O
and	O
to	O
improve	O
bereavement care	B-T058
for	O
families	B-T099
.	O
An	O
educational programme	B-T065
for	O
health care professionals	B-T097
working	O
in	O
maternal	B-T033
and	O
child health	B-T058
has	O
been	O
designed	O
to	O
address	O
these	O
needs	O
according	O
to	O
the	O
Perinatal Society of Australia and New Zealand Guideline for Perinatal Mortality	B-T170
:	O
IMproving Perinatal mortality Review and Outcomes Via Education	B-T065
(	O
IMPROVE	B-T065
).	O
The	O
programme	B-T065
has	O
a	O
major	O
focus	O
on	O
stillbirth	B-T033
and	O
is	O
delivered	O
as	O
six	O
interactive skills	B-T065
-based	O
stations	B-T073
.	O
We	O
aimed	O
to	O
determine	O
participants	B-T098
'	O
pre-	B-T065
and	O
post-programme	B-T065
knowledge	B-T170
of	O
and	O
confidence	B-T041
in	O
the	O
management	B-T057
of	O
perinatal	B-T079
deaths	B-T040
,	O
along	O
with	O
satisfaction	B-T041
with	O
the	O
programme	B-T065
.	O
We	O
also	O
aimed	O
to	O
determine	O
suitability	O
for	O
international	B-T078
use.	O
The	O
IMPROVE programme	B-T065
was	O
delivered	O
to	O
health professionals	B-T097
in	O
maternity hospitals	B-T093
in	O
all	O
seven	O
Australian	B-T083
states	B-T083
and	O
territories	B-UnknownType
and	O
modified	O
for	O
use	O
internationally	B-T078
with	O
piloting	O
in	O
Vietnam	B-T083
,	O
Fiji	B-T083
,	O
and	O
the	O
Netherlands	B-T083
(with	O
the	O
assistance	B-T058
of	O
the	O
International Stillbirth Alliance	B-T093
,	O
ISA	B-T093
).	O
Modifications	O
were	O
made	O
to	O
programme materials	B-T170
in	O
consultation	B-T058
with	O
local	O
teams	O
and	O
included	O
translation	B-T170
for	O
the	O
Vietnam programme	B-T065
.	O
Participants	B-T098
completed	O
pre-	B-T065
and	O
post-programme	B-T065
evaluation	B-T170
questionnaires	B-T170
on	O
knowledge	B-T170
and	O
confidence	B-T041
on	O
six	O
key	O
components	O
of	O
perinatal	B-T079
death	B-T040
management	B-T057
as	O
well	O
as	O
a	O
satisfaction questionnaire	B-T170
.	O
Over	O
the	O
period	O
May	O
2012	O
to	O
May	O
2015,	O
30	O
IMPROVE	B-T065
workshops	B-T065
were	O
conducted,	O
including	O
26	O
with	O
758	O
participants	B-T098
in	O
Australia	B-T083
and	O
four	O
with	O
136	O
participants	B-T098
internationally	B-T078
.	O
Evaluations	B-T170
showed	O
a	O
significant	B-T078
improvement	B-T057
between	O
pre-	B-T065
and	O
post-programme	B-T065
knowledge	B-T170
and	O
confidence	B-T041
in	O
all	O
six	O
stations	B-T073
and	O
overall,	O
and	O
a	O
high	O
degree	O
of	O
satisfaction	B-T041
in	O
all	O
settings	B-T082
.	O
The	O
IMPROVE programme	B-T065
has	O
been	O
well	O
received	O
in	O
Australia	B-T083
and	O
in	O
three	O
different	O
international	B-T078
settings	B-T082
and	O
is	O
now	O
being	O
made	O
available	O
through	O
ISA	B-T093
.	O
Future	O
research	B-T062
is	O
required	O
to	O
determine	O
whether	O
the	O
immediate	O
improvements	B-T057
in	O
knowledge	B-T170
are	O
sustained	B-T169
with	O
less	O
causes	O
of	O
death	B-T040
being	O
classified	O
as	O
unknown,	O
changes in clinical practice	B-T057
and	O
improvement	B-T057
in	O
parents'	B-T099
experiences	O
with	O
care	B-T052
.	O
The	O
suitability	O
for	O
this	O
programme	B-T065
in	O
low-income	B-T033
countries	B-T083
also	O
needs	O
to	O
be	O
established.	O

Experiences	O
of	O
support	O
in	O
working	O
toward	O
personal	B-T032
recovery	B-T040
goals	B-T170
:	O
a	O
collaborative	B-T062
,	O
qualitative study	B-T062
Recovery	B-T040
can	O
be	O
understood	O
as	O
a	O
subjective process	B-T067
guided	O
by	O
personal	B-T032
expectations	B-T078
,	O
goals	B-T170
and	O
hopes	B-T041
.	O
The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
explore	O
how	O
persons	B-T098
using	O
a	O
Community Mental Health Centre	B-T073
(	O
CMHC	B-T073
)	O
experienced	O
that	O
their	O
expectations	B-T078
for	O
treatment	B-T061
,	O
and	O
goals	B-T170
and	O
hopes	B-T041
for	O
recovery	B-T040
were	O
supported	O
by	O
the	O
health professionals	B-T097
during	O
treatment	B-T061
.	O
Employing	O
a	O
hermeneutic	B-T078
-phenomenological	O
approach,	O
eight	O
service users	B-T101
were	O
interviewed	O
about	O
their	O
expectations	B-T078
for	O
treatment	B-T061
and	O
their	O
goals	B-T170
and	O
hopes	B-T041
for	O
recovery	B-T040
at	O
the	O
start	O
of	O
their	O
contact	O
with	O
health professionals	B-T097
at	O
a	O
CMHC	B-T073
.	O
Two	O
years	B-T079
later,	O
they	O
were	O
re-interviewed	O
about	O
their	O
experiences	O
of	O
treatment	B-T061
and	O
support	O
from	O
the	O
health professionals	B-T097
in	O
their	O
work	O
towards	O
these	O
goals	B-T170
and	O
hopes	B-T041
.	O
A	O
collaborative approach	B-T054
was	O
adopted.	O
A	O
co-researcher	B-T097
with	O
lived	O
experience	O
took	O
part	O
in	O
all	O
stages	O
of	O
the	O
study	B-T062
.	O
Data	B-T078
were	O
analysed	O
by	O
means	O
of	O
a	O
data	B-T078
-driven	O
stepwise	O
approach	O
in	O
line	O
with	O
thematic analysis	B-T062
.	O
Five	O
themes	O
reflecting	O
how	O
participants	B-T098
experienced	O
support	O
from	O
health professionals	B-T097
at	O
the	O
CMHC	B-T073
in	O
their	O
work	O
towards	O
their	O
recovery	B-T040
goals	B-T170
were	O
elicited,	O
as	O
follows:	O
developing an understanding of oneself	B-T080
and	O
one's	O
mental health problems	B-T033
;	O
learning	O
how	O
to	O
change	O
feelings	B-T041
and	O
behaviours	B-T053
;	O
being 'pushed' into social arenas	B-T033
;	O
finding helpful medication	B-T033
;	O
and	O
counselling	B-T058
in	O
family	B-T033
,	O
practical	B-T033
and	O
financial issues	B-T033
.	O
The	O
participants	B-T098
'	O
expectations	B-T078
about	O
counselling	B-T058
with	O
regard	O
to	O
longer-term	O
family	B-T033
,	O
practical	B-T033
,	O
and	O
financial challenges	B-T033
were	O
insufficiently	O
met	O
by	O
the	O
CMHC	B-T073
.	O
In	O
the	O
experience	O
of	O
the	O
service users	B-T101
,	O
recovery	B-T040
occurred	O
within	O
the	O
context	O
of	O
their	O
everyday life	B-T078
with	O
or	O
without	O
the	O
support	O
of	O
their	O
professional	B-T097
helpers	B-T097
.	O
To	O
facilitate	O
recovery	B-T040
,	O
health professionals	B-T097
should	O
acknowledge	O
the	O
service user's	B-T101
personal	B-T032
goals	B-T170
and	O
hopes	B-T041
and	O
take	O
a	O
more	O
comprehensive	O
and	O
longer-term	O
approach	O
to	O
his	O
or	O
her	O
needs	B-T080
and	O
desires	B-T041
.	O
Acknowledging	O
and	O
facilitating	O
recovery	B-T040
goals	B-T170
by	O
offering	O
counselling	B-T058
with	O
regard	O
to	O
family	B-T033
,	O
practical	B-T033
and	O
financial issues	B-T033
seems	O
particularly	O
important.	O

Pathogenesis	B-T046
of	O
COPD	B-T047
and	O
Asthma	B-T047
Asthma	B-T047
and	O
COPD	B-T047
remain	O
two	O
diseases of the respiratory tract	B-T047
with	O
unmet	B-T052
medical	B-T169
needs	B-T080
.	O
This	O
review	B-T170
considers	O
the	O
current	O
state	O
of	O
play	O
with	O
respect	O
to	O
what	O
is	O
known	O
about	O
the	O
underlying	O
pathogenesis	B-T046
of	O
these	O
two	O
chronic inflammatory diseases	B-T047
of	O
the	O
lung	B-T023
.	O
The	O
review	B-T170
highlights	O
why	O
they	O
are	O
different	O
conditions	B-T080
requiring	O
different	O
approaches	O
to	O
treatment	B-T061
and	O
provides	O
a	O
backdrop	O
for	O
the	O
subsequent	O
chapters	O
in	O
this	O
volume	O
discussing	O
recent	O
advances	O
in	O
the	O
pharmacology	B-T091
and	O
treatment	B-T061
of	O
asthma	B-T047
and	O
COPD	B-T047
.	O

Antigen specificity	B-T044
determines	O
anti-red blood cell IgG-Fc alloantibody	B-T116
glycosylation	B-T070
and	O
thereby	O
severity	B-T080
of	O
haemolytic disease of the fetus and newborn	B-T047
Haemolytic disease of the fetus and newborn	B-T047
(	O
HDFN	B-T047
)	O
is	O
a	O
severe	O
disease	B-T047
in	O
which	O
fetal	B-T018
red blood cells	B-T025
(	O
RBC	B-T025
)	O
are	O
destroyed	B-T052
by	O
maternal anti-RBC IgG alloantibodies	B-T116
.	O
HDFN	B-T047
is	O
most	O
often	O
caused	O
by	O
anti-D	B-T116
but	O
may	O
also	O
occur	O
due to	B-T169
anti-K	B-T116
,	O
-c	B-T116
-	O
or	O
-E	B-T116
.	O
We	O
recently	O
found	O
N-linked glycosylation	B-T044
of	O
anti-D	B-T116
to	O
be	O
skewed	O
towards	O
low	B-T080
fucosylation	B-T044
,	O
thereby	O
increasing	B-T169
the	O
affinity	B-T044
to	O
IgG-Fc receptor IIIa	B-T116
and	O
IIIb	B-T116
,	O
which	O
correlated	B-T080
with	O
HDFN	B-T047
disease	B-T047
severity	B-T080
.	O
Here,	O
we	O
analysed	O
230	O
pregnant women	B-T098
with	O
anti-c	B-T116
,	O
-E	B-T116
or	O
-K	B-T116
alloantibodies	B-T129
from	O
a	O
prospective	O
screening cohort	B-T058
and	O
investigated	B-T169
the	O
type	O
of	O
Fc-tail glycosylation	B-T044
of	O
these	O
antibodies	B-T116
in	O
relation	O
to	O
the	O
trigger	B-T080
of	O
immunisation	B-T061
and	O
pregnancy outcome	B-T033
.	O
Anti-c	B-T116
,	O
-E	B-T116
and	O
-K	B-T116
show	O
-	O
independent of	B-T169
the	O
event	B-T051
that	O
had	O
led	O
to	O
immunisation	B-T061
-	O
a	O
different	B-T080
kind	O
of	O
Fc-glycosylation	B-T044
compared	O
to	O
that	O
of	O
the	O
total	O
IgG	B-T116
IgG fraction	B-T116
,	O
but	O
with	O
less	O
pronounced	O
differences	O
compared	O
to	O
anti-D	B-T116
.	O
High	O
Fc-galactosylation	B-T044
and	O
sialylation	B-T043
of	O
anti-c	B-T116
correlated	O
with	O
HDFN	B-T047
disease	B-T047
severity	B-T080
,	O
while	O
low	O
anti-K	B-T116
Fc-fucosylation	B-T044
correlated	B-T080
with	O
severe	B-T080
fetal anaemia	B-T047
.	O
IgG-Fc glycosylation	B-T044
of	O
anti-RBC antibodies	B-T116
is	O
shaped	O
depending	O
on	O
the	O
antigen	B-T129
.	O
These	O
features	B-T080
influence	O
their	O
clinical potency	B-T080
and	O
may	O
therefore	O
be	O
used	O
to	O
predict	B-T078
severity	B-T080
and	O
identify	O
those	O
needing	O
treatment	B-T169
.	O

Shout	O
louder	O
about	O
poor pay	B-T081
It	O
seems	O
increasingly	O
clear	O
to	O
me	O
that	O
the	O
NHS	B-T058
pay	B-T081
campaign	B-UnknownType
is	O
not	O
making	O
waves	O
either	O
in	O
the	O
NHS	B-T058
or	O
with	O
the	O
public	B-T098
.	O

SARS	B-T047
-	O
CoV	B-T005
fusion	O
peptides	B-T116
induce	O
membrane	B-T026
surface	B-T082
ordering	B-T082
and	O
curvature	B-T082
Viral membrane fusion	B-T038
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane-anchored	B-T026
viral fusion glycoproteins	B-T116
.	O
The	O
S2	B-T116
subunit	B-T116
of	O
the	O
spike glycoprotein	B-T116
from	O
severe acute respiratory syndrome	B-T047
(	O
SARS	B-T047
)	O
coronavirus	B-T005
(	O
CoV	B-T005
)	O
contains	O
internal domains	B-T087
called	O
fusion peptides	B-T116
(	O
FP	B-T116
)	O
that	O
play	O
essential	O
roles	O
in	O
virus entry	B-T038
.	O
Although	O
membrane fusion	B-T044
has	O
been	O
broadly	O
studied	B-T062
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	B-T080
details	O
of	O
lipid	B-T109
rearrangements	B-T067
in	O
the	O
bilayer	B-T026
during	O
fusion peptide	B-T116
-	O
membrane	B-T026
interactions	B-T169
.	O
Here	O
we	O
employed	O
differential scanning calorimetry	B-T059
(	O
DSC	B-T059
)	O
and	O
electron spin resonance	B-T059
(	O
ESR	B-T059
)	O
to	O
gather	O
information	O
on	O
the	O
membrane fusion	B-T044
mechanism	B-T169
promoted	B-T052
by	O
two	O
putative	O
SARS	B-T047
FPs	B-T116
.	O
DSC	B-T059
data	B-T078
showed	O
the	O
peptides	B-T116
strongly	O
perturb	O
the	O
structural	B-T082
integrity	B-T080
of	O
anionic vesicles	B-T026
and	O
support	O
the	O
hypothesis	B-T078
that	O
the	O
peptides	B-T116
generate	O
opposing	O
curvature	B-T082
stresses	O
on	O
phosphatidylethanolamine	B-T109
membranes	B-T026
.	O
ESR	B-T059
showed	O
that	O
both	O
FPs	B-T116
increase	O
lipid	B-T109
packing	B-T052
and	O
head	O
group	O
ordering	B-T082
as	O
well	O
as	O
reduce	O
the	O
intramembrane	B-T026
water content	B-T081
for	O
anionic membranes	B-T026
.	O
Therefore,	O
bending	O
moment	O
in	O
the	O
bilayer	B-T026
could	O
be	O
generated,	O
promoting	O
negative	O
curvature	B-T082
.	O
The	O
significance	B-T078
of	O
the	O
ordering effect	B-T080
,	O
membrane	B-T026
dehydration	B-T033
,	O
changes	O
in	O
the	O
curvature	B-T082
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	B-T109
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
SARS	B-T047
-	O
CoV	B-T005
-mediated	O
membrane fusion	B-T044
are	O
discussed.	O

Elucidating	O
a	O
chemical	O
defense mechanism	B-T040
of	O
Antarctic	B-T083
sponges	B-T204
:	O
A	O
computational study	B-T059
In	O
2000,	O
a	O
novel	O
secondary metabolite	B-T123
(	O
erebusinone	B-T123
,	O
Ereb	B-T123
)	O
was	O
isolated	O
from	O
the	O
Antarctic	B-T083
sea sponge	B-T204
,	O
Isodictya erinacea	B-T204
.	O
The	O
bioactivity	B-T070
of	O
Ereb	B-T123
was	O
investigated,	O
and	O
it	O
was	O
found	O
to	O
inhibit	B-T052
molting	B-T040
when	O
fed	O
to	O
the	O
arthropod species	B-T204
Orchomene plebs	B-T204
.	O
Xanthurenic acid	B-T109
(	O
XA	B-T109
)	O
is	O
a	O
known	O
endogenous	B-T169
molt regulator	B-T077
present	O
in	O
arthropods	B-T204
.	O
Experimental	O
studies	O
have	O
confirmed	O
that	O
XA	B-T109
inhibits	B-T052
molting	B-T040
by	O
binding	B-T044
to	O
either	O
(or	O
both)	O
of	O
two	O
P450 enzymes	B-T116
(	O
CYP315a1	B-T116
or	O
CYP314a1	B-T116
)	O
that	O
are	O
responsible	O
for	O
the	O
final	O
two	O
hydroxylations	B-T070
in	O
the	O
production	O
of	O
the	O
molt-inducing hormone	B-T125
,	O
20-hydroxyecdysone	B-T109
(	O
20E	B-T109
).	O
The	O
lack	O
of	O
crystal structures	B-T104
and	O
biochemical assays	B-T059
for	O
CYP315a1	B-T116
or	O
CYP314a1	B-T116
,	O
has	O
prevented	O
further	O
experimental	O
exploration	B-T062
of	O
XA	B-T109
and	O
Ereb's	B-T123
molt	B-T040
inhibition	B-T052
mechanisms	B-T169
.	O
Herein,	O
a	O
wide	O
array	O
of	O
computational techniques	B-T062
-	O
homology modeling	B-T063
,	O
molecular dynamics simulations	B-T066
,	O
binding site	B-T044
bioinformatics	B-T091
,	O
flexible receptor-flexible ligand docking	B-T044
,	O
and	O
molecular	O
mechanics-generalized	O
Born surface area calculations	B-T170
-	O
have	O
been	O
employed	O
to	O
elucidate	O
the	O
structure-function relationships	B-T080
between	O
the	O
aforementioned	O
P450s	B-T116
and	O
the	O
two	O
described	O
small	O
molecule	O
inhibitors	B-T120
(	O
Ereb	B-T123
and	O
XA	B-T109
).	O
Results	O
indicate	O
that	O
Ereb	B-T123
likely	O
targets	O
CYP315a1	B-T116
by	O
interacting	O
with	O
a	O
network	O
of	O
aromatic residues	B-T104
in	O
the	O
binding site	B-T044
,	O
while	O
XA	B-T109
may	O
inhibit	O
both	O
CYP315a1	B-T116
and	O
CYP314a1	B-T116
because	O
of	O
its	O
aromatic	B-T104
,	O
as	O
well	O
as	O
charged nature	B-T196
.	O

The	O
anatomical mummies	B-T015
of	O
Mombello	B-UnknownType
:	O
detection	B-T033
of	O
cocaine	B-T109
,	O
nicotine	B-T109
,	O
and	O
caffeine	B-T109
in	O
the	O
hair	B-T023
of	O
psychiatric patients	B-T101
of	O
the	O
early	O
20th	O
century	O
The	O
Mombello Psychiatric Hospital	B-T073
in	O
Limbiate	B-UnknownType
,	O
near	O
Milan	B-UnknownType
,	O
replaced	O
the	O
old	O
Senavra Hospital	B-T073
as	O
the	O
Psychiatric Hospital	B-T073
for	O
the	O
Province of Milan	B-UnknownType
in	O
the	O
19th	O
century.	O
During	O
the	O
early	O
20th	O
century,	O
bodies	B-T016
of	O
several	O
Mombello patients	B-T101
were	O
dissected	B-T169
and	O
preserved	B-T059
by	O
Giuseppe Paravicini	B-T016
,	O
an	O
anatomist	B-T097
who	O
operated	O
within	O
the	O
asylum	B-T073
.	O
The	O
aim	B-T078
of	O
the	O
present	O
study	B-T062
was	O
to	O
examine	O
and	O
memorialize	O
this	O
important	O
assemblage	B-T062
.	O
To	O
this	O
end,	O
we	O
were	O
allowed	O
to	O
sample	B-T077
the	O
head hair	B-T023
of	O
six	O
such	O
preparations	B-T052
for	O
toxicological	B-T169
analysis	B-T062
.	O
By	O
means	O
of	O
high performance liquid chromatography	B-T059
,	O
cocaine	B-T109
and	O
its	O
main	O
metabolite	B-T123
,	O
benzoylecgonine	B-T109
,	O
were	O
detected	B-T033
in	O
two	O
out	O
of	O
six	O
hair samples	B-T077
.	O
The	O
concentrations	B-T081
for	O
cocaine	B-T109
were	O
0.151	O
and	O
0.09ng/mg	O
and	O
for	O
benzoylecgonine	B-T109
0.103	O
and	O
0.147ng/mg,	O
respectively.	O
Given	O
that	O
cocaine	B-T109
was	O
a	O
commonly	O
used	O
medicine	B-T121
,	O
beginning	O
in	O
the	O
mid-19th	O
century	O
and	O
persisting	O
into	O
the	O
20th	O
century,	O
it	O
is	O
not	O
surprising	O
that	O
some	O
patients	B-T073
may	O
have	O
ingested	B-T038
this	O
drug	B-T121
.	O
In	O
addition	O
to	O
the	O
detection	B-T033
of	O
cocaine	B-T109
,	O
these	O
analyses	B-T062
also	O
provided	O
evidence	O
of	O
nicotine	B-T109
and	O
caffeine	B-T109
intake	B-T169
.	O

Terahertz identification	B-T059
and	O
quantification	B-T081
of	O
neurotransmitter	B-T123
and	O
neurotrophy mixture	B-T116
Terahertz spectroscopy	B-T059
has	O
been	O
widely	O
used	O
for	O
investigating	B-T169
the	O
fingerprint spectrum	B-T059
of	O
different	O
substances	B-T167
.	O
For	O
cancerous	B-T191
tissues	B-T024
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	B-T067
peaks	O
of	O
various	O
substances	B-T167
contained	O
in	O
tissues	B-T024
overlap	B-T079
with	O
each	O
other,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	B-T081
analyze	B-T062
.	O
As	O
a	O
result,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer cell	B-T025
and	O
then	O
to	O
diagnose	B-T033
accurately	B-T080
.	O
In	O
this	O
paper,	O
we	O
select	O
three	O
typical	O
neurotransmitters	B-T123
(	O
γ-aminobutyric acid	B-T116
,	O
L-glutamic acid	B-T116
,	O
dopamine hydrochloride	B-T109
)	O
and	O
two	O
typical	O
metabolites	B-T123
(	O
inositol	B-T109
and	O
creatine	B-T116
)	O
in	O
neurons	B-T025
to	O
measure	O
their	O
terahertz spectra	B-T059
with	O
different	O
mixture ratios	B-T081
.	O
By	O
choosing	O
characteristic	B-T080
absorption	B-T067
peaks,	O
removing	O
baseline	B-T081
and	O
using	O
the	O
least square method	B-T081
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	B-T081
of	O
each	O
mixture,	O
where	O
the	O
goodness of fit	B-T080
to	O
practical	O
situation	O
is	O
up	O
to	O
94%.	O
These	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve substances	B-T123
and	O
obtaining	O
exact	O
quantitative	B-T081
analysis	B-T062
.	O

Comparing	O
the	O
bulking	O
effect	O
of	O
calcium hydroxyapatite	B-T121
and	O
Deflux	B-T109
injection	B-T061
into	O
the	O
bladder neck	B-T023
for	O
improvement	B-T077
of	O
urinary incontinence	B-T046
in	O
bladder exstrophy-epispadias complex	B-T047
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
efficacy	B-T080
of	O
the	O
endoscopic injection	B-T061
of	O
calcium hydroxyapatite	B-T121
(	O
CaHA	B-T121
)	O
into	O
the	O
bladder neck	B-T023
(	O
BN	B-T023
)	O
region	O
of	O
patients	B-T101
with	O
urinary incontinence	B-T046
and	O
bladder exstrophy-epispadias complex	B-T047
(	O
BEEC	B-T047
).	O
We	O
designed	O
a	O
retrospective cohort study	B-T062
in	O
which	O
we	O
retrospectively studied	B-T062
medical charts	B-UnknownType
of	O
female	B-T032
and	O
male	B-T032
patients	B-T101
of	O
BEEC	B-T047
who	O
had	O
undergone	O
CaHA	B-T121
or	O
Deflux	B-T109
injection	B-T061
for	O
continence improvement	B-T061
between	O
2009	O
and	O
2014.	O
Sixteen	O
incontinent	B-T047
patients	B-T101
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
8.09	O
±	O
3.5	O
years	O
received	O
an	O
endoscopic submucosal injection	B-T061
of	O
5.4	O
ml	O
of	O
pure	O
CaHA	B-T121
powder	O
with	O
autologous	B-T080
plasma	B-T031
(group	O
A).	O
Patients	B-T101
in	O
group	O
B	O
(N	O
=	O
21),	O
control group	B-T096
,	O
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
7.51	O
±	O
2.8	O
years	O
received	O
Deflux	B-T109
injection	B-T061
(5.1	O
ml).	O
The	O
mean	O
follow-up	B-T058
after	O
injection	B-T061
was	O
38	O
±	O
5.2	O
and	O
33	O
±	O
4.1	O
months	O
in	O
groups	O
A	O
and	O
B,	O
respectively.	O
No	O
post-injection complication	B-T046
was	O
detected	B-T033
in	O
none	O
of	O
the	O
patients	B-T101
during	O
the	O
follow-up	B-T058
.	O
Eleven	O
patients	B-T101
(68.75%)	O
in	O
group	O
A	O
became	O
socially	O
dry	B-T080
following	O
1-2	O
injections	B-T061
,	O
the	O
degree	O
of	O
incontinence	B-T047
was	O
improved	O
in	O
4	O
patients	B-T101
(25%),	O
and	O
there	O
was	O
no change	B-T033
in	O
one	O
patient	B-T101
(6.25%).	O
However,	O
Deflux	B-T109
injection	B-T061
resulted	O
in	O
complete dryness	B-T080
in	O
14	O
(66.66%),	O
improvement	B-T077
in	O
the	O
degree	O
of	O
incontinence	B-T047
in	O
5	O
(23.81%)	O
and	O
no change	B-T033
in	O
2	O
patients	B-T101
(9.52%),	O
leading	O
to	O
no significant difference	B-T033
in	O
continence achievement	B-T061
between	O
CaHA	B-T121
and	O
Deflux	B-T109
groups	O
(p	O
=	O
0.9).	O
The	O
statistical analysis	B-T062
was	O
not significantly different	B-T033
in	O
terms	O
of	O
bladder capacity	B-T033
(p	O
=	O
0.7)	O
or	O
Q	O
max	O
(p	O
=	O
0.8).	O
The	O
preliminary results	B-T078
of	O
this	O
study	B-T062
revealed	B-T080
that	O
CaHA	B-T121
may	O
be	O
applied	O
as	O
an	O
affordable	O
bulking agent	B-T121
in	O
treatment	B-T061
of	O
urinary incontinence	B-T046
in	O
BEEC	B-T047
.	O

Opportunities	B-T062
for	O
genomic	B-T028
prediction	B-T078
for	O
fertility	B-T040
using	O
endocrine	B-T022
and	O
classical	B-T169
fertility	B-T040
traits	B-T032
in	O
dairy cattle	B-T015
Endocrine	B-T022
fertility	B-T040
traits	B-T032
,	O
defined	O
from	O
progesterone	B-T109
concentration	B-T081
levels	B-T080
in	O
milk	B-T031
,	O
have	O
been	O
suggested	O
as	O
alternative	B-T077
indicators	B-T169
for	O
fertility	B-T040
in	O
dairy cows	B-T015
because	O
they	O
are	O
less	O
biased	O
by	O
farm	B-T082
management	B-T057
decisions	B-T041
and	O
more	O
directly	O
reflect	O
a	O
cow	B-T015
's	O
reproductive	B-T040
physiology	B-T039
than	O
classical	B-T169
traits	B-T032
derived	O
from	O
insemination	B-T042
and	O
calving	O
data	B-T078
.	O
To	O
determine	O
the	O
potential	O
use of	B-T169
endocrine	B-T022
fertility	B-T040
traits	B-T032
in	O
genomic	B-T028
evaluations	B-T062
,	O
the	O
improvement	B-T077
in	O
accuracy	B-T080
from	O
using	O
endocrine	B-T022
fertility	B-T040
traits	B-T032
concurrent	B-T079
with	O
classical	B-T169
traits	B-T032
in	O
the	O
genomic	B-T028
prediction	B-T078
of	O
fertility	B-T040
was	O
quantified	B-T081
.	O
The	O
impact	B-T080
of	O
recording	O
all	O
traits	B-T032
on	O
all	O
training	O
animals	B-T008
was	O
also	O
investigated	B-T169
.	O
Endocrine	B-T022
and	O
classical	B-T169
fertility	B-T040
records	O
were	O
available	O
on	O
5,339	O
lactations	B-T042
from	O
2,447	O
Holstein cows	B-T015
in	O
Ireland	B-T083
,	O
the	O
Netherlands	B-T083
,	O
Sweden	B-T083
,	O
and	O
the	O
United Kingdom	B-T083
.	O
The	O
endocrine	B-T022
traits	B-T032
were	O
commencement of luteal activity	B-T042
(	O
C-LA	B-T042
)	O
and	O
proportion	B-T081
of	O
samples	B-T167
with	O
luteal activity	B-T042
(	O
PLA	B-T167
);	O
the	O
classical	B-T169
trait	B-T032
was	O
the	O
interval	B-T079
from	O
calving	O
to	O
first	O
service	O
(CFS).	O
The	O
interval	B-T079
from	O
C-LA	B-T042
to	O
first	O
service	O
(C-LAFS),	O
which	O
is	O
a	O
combination	O
of	O
an	O
endocrine	B-T022
trait	B-T032
and	O
a	O
classical	B-T169
trait	B-T032
,	O
was	O
also	O
investigated	B-T169
.	O
The	O
target	B-T169
(	O
breeding goal	B-T169
)	O
trait	B-T032
for	O
fertility	B-T040
was	O
CFS	O
or	O
C-LAFS,	O
whereas	O
C-LA	B-T042
and	O
PLA	B-T167
served	O
as	O
predictor	B-T078
traits	B-T032
.	O
Genomic EBV	B-T028
(	O
GEBV	B-T028
)	O
for	O
fertility	B-T040
were	O
derived	O
using	O
genomic BLUP	B-T062
in	O
bivariate models	B-T075
with	O
85,485	O
SNP	B-T086
.	O
Genomic	O
EBV	O
for	O
the	O
separate	O
fertility	B-T040
traits	B-T032
were	O
also	O
computed,	O
in	O
univariate models	B-T075
.	O
The	O
accuracy	B-T080
of	O
GEBV	B-T028
was	O
evaluated	O
by	O
5-fold	O
cross-validation	B-T062
.	O
The	O
highest	O
accuracy	B-T080
of	O
GEBV	B-T028
was	O
achieved	O
using	O
bivariate	B-UnknownType
predictions	B-T078
,	O
where	O
both	O
an	O
endocrine	B-T022
fertility	B-T040
trait	B-T032
and	O
the	O
classical	B-T169
fertility	B-T040
trait	B-T032
were	O
used.	O
Accuracy	B-T080
of	O
GEBV	B-T028
for	O
predicting	B-T078
adjusted	O
phenotypes	B-T032
for	O
CFS	O
in	O
the	O
univariate model	B-T075
was	O
0.04,	O
but	O
when	O
predicting	B-T078
CFS	O
using	O
a	O
bivariate model	B-T075
with	O
C-LA	B-T042
,	O
the	O
accuracy	B-T080
increased	B-T081
to	O
0.14	O
when	O
all	O
training animals	B-T008
were	O
phenotyped	B-T032
for	O
C-LA	B-T042
and	O
(or	O
not)	O
for	O
CFS.	O
On	O
phenotyping	B-T032
all	O
training animals	B-T008
for	O
both	O
C-LA	B-T042
and	O
CFS,	O
accuracy	B-T080
for	O
CFS	O
increased	B-T081
to	O
0.18;	O
however,	O
when	O
validation	B-T062
animals	B-T008
were	O
also	O
phenotyped	B-T032
for	O
C-LA	B-T042
,	O
there	O
was	O
no	B-T033
substantial increase	B-T169
in	O
accuracy	B-T080
.	O
When	O
predicting	B-T078
CFS	O
in	O
bivariate analysis	B-UnknownType
with	O
PLA	B-T167
,	O
accuracy	B-T080
ranged	O
from	O
0.07	O
to	O
0.14.	O
This	O
first	O
study	B-T062
on	O
genomic	B-T028
predictions	B-T078
for	O
fertility	B-T040
using	O
endocrine	B-T022
traits	B-T032
suggests	O
some	O
improvement	B-T077
in	O
the	O
accuracy	B-T080
of	O
prediction	B-T078
over	O
using	O
only	O
the	O
classical	B-T169
traits	B-T032
.	O
Further	O
studies	B-T062
with	O
larger	B-T081
training populations	B-T098
may	O
show	O
greater	B-T081
improvements	B-T077
.	O

A	O
Microfluidic	B-T090
Platform	O
to	O
design	B-T052
crosslinked Hyaluronic Acid Nanoparticles	B-T073
(	O
cHANPs	B-T073
)	O
for	O
enhanced MRI	B-T060
Recent	B-T079
advancements	B-T079
in	O
imaging diagnostics	B-T060
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	B-T073
that	O
entrap	O
Magnetic Resonance Imaging	B-T060
(	O
MRI	B-T060
)	O
Contrast Agents	B-T130
(	O
CAs	B-T130
),	O
without	O
the	O
need	O
to	O
chemically	B-T103
modify	B-T169
the	O
clinically	B-T080
approved	B-T080
compounds	B-T103
.	O
Nevertheless,	O
the	O
exploitation	O
of	O
microfluidic platforms	B-T090
for	O
their	O
controlled	B-T169
and	O
continuous	B-T078
production	B-T052
is	O
still	O
missing.	O
Here,	O
a	O
microfluidic platform	B-T090
is	O
used	O
to	O
synthesize	B-T052
crosslinked Hyaluronic Acid NanoParticles	B-T073
(	O
cHANPs	B-T073
)	O
in	O
which	O
a	O
clinically	B-T080
relevant	B-T080
MRI	B-T060
-	O
CAs	B-T130
,	O
gadolinium diethylenetriamine penta-acetic acid	B-T109
(	O
Gd-DTPA	B-T109
),	O
is	O
entrapped.	O
This	O
microfluidic	B-T090
process	B-T067
facilitates	O
a	O
high	O
degree	B-T080
of	O
control	B-T169
over	O
particle	B-T073
synthesis	B-T052
,	O
enabling	O
the	O
production	B-T052
of	O
monodisperse particles	B-T073
as	O
small	O
as	O
35	O
nm.	O
Furthermore,	O
the	O
interference	B-T169
of	O
Gd-DTPA	B-T109
during	O
polymer	B-T104
precipitation	B-T070
is	O
overcome	O
by	O
finely	O
tuning	O
process	B-T067
parameters	B-T077
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic-lipophilic balance	B-T081
(	O
HLB	B-T081
)	O
of	O
surfactants	B-T120
and	O
pH	B-T081
conditions	B-T080
.	O
For	O
both	O
production	B-T052
strategies	O
proposed	O
to	O
design	B-T052
Gd	B-T109
-loaded	O
cHANPs	B-T073
,	O
a	O
boosting	O
of	O
the	O
relaxation rate T1	B-T081
is	O
observed	O
since	O
a	O
T1	B-T081
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	B-T109
-loaded	O
cHANPs	B-T073
while	O
a	O
similar	O
value	B-T081
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	B-T080
clinical	B-T080
Gd-DTPA	B-T109
in	O
solution	B-T167
.	O
The	O
advanced	O
microfluidic	B-T090
platform	O
to	O
synthesize	O
intravascularly	B-T082
-	O
injectable	B-T122
and	O
completely	O
biocompatible hydrogel	B-T109
nanoparticles	B-T073
entrapping	O
clinically	B-T080
approved	B-T080
CAs	B-T130
enables	O
the	O
implementation	B-T052
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	B-T080
and	O
therapy	B-T061
applications	B-T169
.	O

Arthrobacter ginkgonis sp. nov.	B-T007
,	O
an	O
actinomycete	B-T007
isolated	B-T169
from	O
rhizosphere	B-T070
of	O
Ginkgo biloba L	B-T002
A	O
Gram-stain-positive	B-T034
,	O
aerobic	B-T080
actinobacterial strain	B-T007
(designated	O
SYP-A7299T	B-T007
),	O
which	O
displayed	O
a	O
rod-coccus growth lifecycle	B-T007
,	O
was	O
isolated	B-T169
from	O
the	O
rhizosphere	B-T070
of	O
Ginkgo biloba L	B-T002
.	O
Phylogenetic analyses	B-T062
based	O
on	O
16S rRNA gene sequences	B-T028
indicated	O
that	O
strain SYP-A7299T	B-T007
belongs	O
to	O
the	O
genus	B-T185
Arthrobacter	B-T007
and	O
is	O
most	O
closely	O
related	O
to	O
Arthrobacter halodurans JSM 078085T	B-T007
(97.4	O
%	O
16S rRNA gene sequence	B-T028
similarity	B-T080
).	O
The	O
DNA	B-T114
-	O
DNA	B-T114
relatedness value	B-T081
between	O
strain SYP-A7299T	B-T007
and	O
A. halodurans JSM 078085T	B-T007
was	O
37	O
%	O
±2.9.	O
The	O
cell-wall	B-T026
peptidoglycan	B-T109
was	O
A4α	B-T109
,	O
and	O
glucose	B-T109
and	O
galactose	B-T109
were	O
whole-cell sugars	B-T109
.	O
The	O
polar lipids	B-T109
consisted	O
of	O
diphosphatidylglycerol	B-T123
,	O
phosphatidylglycerol	B-T109
,	O
phosphatidylinositol	B-T109
,	O
two	O
glycolipids	B-T109
and	O
an	O
unknown	O
polar lipid	B-T109
.	O
The	O
major	O
menaquinone	B-T109
were	O
MK-8(H2)	B-T109
(72	O
%)	O
and	O
MK-9(H2)	B-T109
(28	O
%),	O
and	O
the	O
predominant	O
cellular fatty acids	B-T109
were	O
anteiso-C15: 0	B-T109
,	O
iso-C15: 0	B-T109
and	O
anteiso-C17: 0	B-T109
.	O
The	O
DNA	B-T114
G+C content	B-T081
was	O
68.9	O
mol%.	O
Based	O
on	O
the	O
morphological	B-T082
,	O
physiological	B-T169
,	O
biochemical	B-T169
and	O
chemotaxonomic characters	B-T169
presented	O
in	O
this	O
study,	O
strain SYP-A7299T	B-T007
represents	O
a	O
novel	O
species	B-T185
of	O
the	O
genus	B-T185
Arthrobacter	B-T007
,	O
for	O
which	O
the	O
name	O
Arthrobacter ginkgonis sp. nov.	B-T007
is	O
proposed.	O
The	O
type strain	B-T001
is	O
SYP-A7299T	B-T007
(	O
=DSM 100491T=KCTC 39 592T	B-T007
).	O

Decoding	B-T041
the	O
Interactions	B-T043
Regulating	B-T080
the	O
Active State	B-T033
Mechanics	B-T070
of	O
Eukaryotic	B-T204
Protein Kinases	B-T116
Eukaryotic	B-T204
protein kinases	B-T116
regulate	B-T080
most	O
cellular functions	B-T043
by	O
phosphorylating	B-T044
targeted	B-T169
protein	B-T116
substrates	B-T167
through	B-T169
a	O
highly	B-T080
conserved	B-T169
catalytic core	B-T026
.	O
In	O
the	O
active state	B-T033
,	O
the	O
catalytic core	B-T026
oscillates	B-T061
between	O
open	B-T082
,	O
intermediate	B-T082
,	O
and	O
closed	B-T082
conformations	B-T082
.	O
Currently	B-T079
,	O
the	O
intramolecular interactions	B-T043
that	O
regulate	B-T080
the	O
active state	B-T033
mechanics	B-T070
are	O
not well understood	B-T080
.	O
Here,	O
using	O
cAMP-dependent protein kinase	B-T116
as	O
a	O
representative	B-T052
model	B-T075
coupled	B-T169
with	O
biochemical	B-T169
,	O
biophysical	B-T038
,	O
and	O
computational techniques	B-T062
,	O
we	O
define	O
a	O
set	O
of	O
highly	B-T080
conserved	B-T080
electrostatic	B-UnknownType
and	O
hydrophobic interactions	B-T044
working	O
harmoniously	B-T054
to	O
regulate	B-T080
these	O
mechanics	B-T070
.	O
These	O
include	B-T169
the	O
previously	B-T079
identified	B-T080
salt bridge	B-T044
between	O
a	O
lysine	B-T116
from	O
the	O
β3-strand	B-T082
and	O
a	O
glutamate	B-T116
from	O
the	O
αC-helix	B-T082
as	O
well	O
as	O
an	O
electrostatic interaction	B-UnknownType
between	O
the	O
phosphorylated	B-T044
activation	B-T052
loop	B-T082
and	O
αC-helix	B-T082
and	O
an	O
ensemble	B-T081
of	O
hydrophobic	B-T080
residues	B-T077
of	O
the	O
Regulatory	O
spine	O
and	O
Shell.	O
Moreover,	O
for	O
over	O
three	O
decades	B-T081
it	O
was	O
thought	O
that	O
the	O
highly	B-T080
conserved	B-T169
β3	B-T082
β3 -lysine	B-T116
was	O
essential	B-T080
for	O
phosphoryl transfer	B-T044
,	O
but	O
our	O
findings	B-T169
show	O
that	O
the	O
β3	B-T082
β3 -lysine	B-T116
is	O
not	O
required	O
for	O
phosphoryl transfer	B-T044
but	O
is	O
essential	B-T080
for	O
the	O
active state	B-T033
mechanics	B-T070
.	O

Acute	B-T079
clinical	B-T080
adverse radiation effects	B-T037
after	O
Gamma Knife surgery	B-T061
for	O
vestibular schwannomas	B-T191
OBJECTIVE	O
Vestibular schwannomas	B-T191
(	O
VSs	B-T191
)	O
represent	O
a	O
common	O
indication	O
of	O
Gamma Knife surgery	B-T061
(	O
GKS	B-T061
).	O
While	O
most	O
studies	B-T062
focus	O
on	O
the	O
long-term	B-T079
morbidity	B-T081
and	O
adverse radiation effects	B-T037
(	O
AREs	B-T037
),	O
none	O
describe	O
the	O
acute	B-T079
clinical	B-T080
AREs	B-T037
that	O
might	O
appear	O
on	O
a	O
short-term	B-T079
basis.	O
These	O
types	O
of	O
events	O
are	O
investigated	B-T169
,	O
and	O
their	O
incidence	B-T081
,	O
type	B-T080
,	O
and	O
outcomes	B-T062
are	O
reported	B-T170
in	O
the	O
present	O
paper.	O
METHODS	O
The	O
included	O
patients	B-T101
were	O
treated	B-T169
between	O
July	O
2010	O
and	O
March	O
2016,	O
underwent	O
at	O
least	O
6	O
months	B-T079
of	O
follow-up	B-T058
,	O
and	O
presented	O
with	O
a	O
disabling	B-T047
symptom	B-T184
during	O
the	O
first	O
6	O
months	B-T079
after	O
GKS	B-T061
that	O
affected	B-T169
their	O
quality of life	B-T078
.	O
The	O
timing	O
of	O
appearance,	O
as	O
well	O
as	O
the	O
type	O
of	O
main	O
symptom	B-T184
and	O
outcome	B-T062
,	O
were	O
noted.	O
The	O
prescribed	B-T058
dose	B-T081
was	O
12	O
Gy	O
at	O
the	O
margin.	O
RESULTS	O
Thirty-five	O
(22%)	O
of	O
159	O
patients	B-T101
who	O
fulfilled	O
the	O
inclusion	B-T080
criteria	O
had	O
acute	B-T079
clinical	B-T080
AREs	B-T037
.	O
The	O
mean	B-T081
followup	B-T058
period	O
was	O
30	O
months	B-T079
(	O
range	B-T081
6-49.2	O
months	B-T079
).	O
The	O
mean	B-T081
time	O
of	O
appearance	O
was	O
37.9	O
days	B-T079
(	O
median	B-T081
31	O
days	B-T079
;	O
range	B-T081
3-110	O
days	B-T079
).	O
In	O
patients	B-T101
with	O
de novo	B-T078
symptoms	B-T184
,	O
the	O
more	O
frequent	O
symptoms	B-T184
were	O
vertigo	B-T184
(n	O
=	O
4;	O
11.4%)	O
and	O
gait disturbance	B-T033
(n	O
=	O
3;	O
8.6%).	O
The	O
exacerbation	B-T033
of	O
a	O
preexisting	O
symptom	B-T184
was	O
more	O
frequently	O
related	O
to	O
hearing loss	B-T033
(n	O
=	O
10;	O
28.6%),	O
followed	O
by	O
gait disturbance	B-T033
(n	O
=	O
7;	O
20%)	O
and	O
vertigo	B-T184
(n	O
=	O
3,	O
8.6%).	O
In	O
the	O
univariate	B-T062
logistic regression analysis	B-UnknownType
,	O
the	O
following	O
factors	B-T169
were	O
statistically significant	B-T081
:	O
age	B-T032
(p	O
=	O
0.002;	O
odds ratio	B-T081
[	O
OR	B-T081
]	O
0.96),	O
hearing	O
at	O
baseline	B-T081
by	O
Gardner-Robertson	B-T170
(	O
GR	B-T170
)	O
class	O
(p	O
=	O
0.006;	O
OR	B-T081
0.21),	O
pure tone average	B-T081
at	O
baseline	B-T081
(p	O
=	O
0.006;	O
OR	B-T081
0.97),	O
and	O
Koos grade	B-T170
at	O
baseline	B-T081
(with	O
Koos Grade I	B-T170
used	O
as	O
a	O
reference)	O
(for	O
Koos Grade II	B-T170
,	O
OR	B-T081
0.17	O
and	O
p	O
=	O
0.002;	O
for	O
Koos Grade III	B-T170
,	O
OR	B-T081
0.42	O
and	O
p	O
=	O
0.05).	O
The	O
following	O
were	O
not	O
statistically significant	B-T081
but	O
showed	O
a	O
tendency	O
toward	O
significance:	O
the	O
number	O
of	O
isocenters	B-T082
(p	O
=	O
0.06;	O
OR	B-T081
0.94)	O
and	O
the	O
maximal	B-T081
dose	B-T081
received	O
by	O
the	O
cochlea	B-T047
(p	O
=	O
0.07;	O
OR	B-T081
0.74).	O
Fractional polynomial regression analysis	B-T170
showed	O
a	O
nonlinear	O
relationship	O
between	O
the	O
outcome	B-T062
and	O
the	O
radiation dose rate	B-T081
(minimum	O
reached	O
at	O
a	O
cutoff	O
of	O
2.5	O
Gy/minute)	O
and	O
the	O
maximal	B-T081
vestibular	B-T030
dose	B-T081
(maximum	O
reached	O
at	O
a	O
cutoff	O
of	O
8	O
Gy),	O
but	O
the	O
small	O
sample size	B-T081
precludes	B-T169
a	O
detailed	O
analysis	B-T062
of	O
the	O
former.	O
The	O
clinical	B-T080
acute	B-T079
AREs	B-T037
disappeared	O
in	O
32	O
(91.4%)	O
patients	B-T101
during	O
the	O
first	O
6	O
months	B-T079
after	O
appearance.	O
Permanent	O
and	O
somewhat	O
disabling	B-T047
morbidity	B-T081
was	O
found	O
in	O
3	O
cases	B-T077
(1.9%	O
from	O
the	O
whole	O
series):	O
1	O
each	O
with	O
complete hearing loss	B-T033
(	O
GR Class I	B-T170
before	O
and	O
V	B-T170
after),	O
hemifacial spasm	B-T033
(	O
persistent	B-T079
but	O
alleviated),	O
and	O
dysgeusia	B-T033
.	O
CONCLUSIONS	O
Acute	B-T079
effects	B-T080
after	O
radiosurgery	B-T061
for	O
VS	B-T191
are	O
not	O
rare.	O
They	O
concern	O
predominantly	O
de novo	B-T078
vertigo	B-T184
and	O
gait disturbance	B-T033
and	O
the	O
exacerbation	B-T033
of	O
preexistent	O
hearing loss	B-T033
.	O
In	O
de novo	B-T078
vestibular	B-T030
symptom	B-T184
s,	O
a	O
vestibular	B-T030
dose	B-T081
of	O
more	O
than	O
8	O
Gy	O
is	O
thought	O
to	O
play	O
a	O
role.	O
In	O
most	O
cases	B-T077
,	O
none	O
of	O
these	O
effects	B-T080
are	O
permanent,	O
and	O
they	O
will	O
ultimately	O
improve	O
or	O
disappear	O
with	O
steroid therapy	B-T061
.	O
Permanent	O
AREs	B-T037
remain	O
very	O
rare	B-T080
.	O

Long-chain n-3 PUFA	B-T109
supplied	B-T052
by	O
the	O
usual	B-T080
diet	B-T168
decrease	B-T081
plasma stearoyl-CoA desaturase	B-T116
index	B-T170
in	O
non-hypertriglyceridemic	B-T033
older adults	B-T098
at	O
high	O
vascular	B-T023
risk	B-T078
The	O
activity	B-T044
of	O
stearoyl-CoA desaturase-1	B-T116
(	O
SCD1	B-T116
),	O
the	O
central enzyme	B-T116
in	O
the	O
synthesis	B-T052
of	O
monounsaturated fatty acids	B-T109
(	O
MUFA	B-T109
),	O
has	O
been	O
associated with	B-T080
de novo	B-T078
lipogenesis	B-T040
.	O
In	O
experimental models	B-T170
SCD1	B-T116
is	O
down-regulated	B-T044
by	O
polyunsaturated fatty acids	B-T109
(	O
PUFA	B-T109
),	O
but	O
clinical studies	B-T062
are	O
scarce.	O
The	O
effect	B-T080
of	O
long-chain n-3 PUFA	B-T109
(	O
LCn-3PUFA	B-T109
)	O
supplied	B-T052
by	O
the	O
regular diet	B-T168
,	O
in	O
the	O
absence	B-T169
of	O
fatty fish	B-T168
or	O
fish oil	B-T168
supplementation,	B-T168
remains	O
to	O
be	O
explored.	O
We	O
related	B-T080
1-y	O
changes	B-T169
in	O
plasma SCD1	B-T116
index	B-T170
,	O
as	O
assessed	B-T052
by	O
the	O
C16:1n-7	B-T109
/	O
C16:0	B-T109
ratio	B-T081
,	O
to	O
both	O
adiposity	B-T032
traits	B-T032
and	O
nutrient intake	B-T033
changes	B-T169
in	O
a	O
sub-cohort	B-T098
(n	O
=	O
243)	O
of	O
non-hypertriglyceridemic	B-T033
subjects	B-T098
of	O
the	O
PREDIMED (PREvención con DIeta MEDiterranea) trial	B-T062
.	O
After	O
adjustment	O
for	O
confounders,	O
including	O
changes	B-T169
in	O
fasting	B-T033
triglycerides	B-T109
,	O
plasma SCD1	B-T116
index	B-T170
increased	B-T081
in	O
parallel	O
with	O
body weight	B-T032
(0.221	O
[95%	O
confidence interval	B-T081
,	O
0.021	O
to	O
0.422],	O
P	O
=	O
0.031)	O
and	O
BMI	B-T201
(0.115	O
[0.027	O
to	O
0.202],	O
P	O
=	O
0.011).	O
Additionally,	O
dietary	B-T168
LCn-3PUFA	B-T109
(but	O
not	O
MUFA	B-T109
or	O
plant-derived PUFA	B-T109
)	O
were	O
associated with	B-T080
decreased	B-T081
plasma SCD1	B-T116
index	B-T170
(-0.544	O
[-1.044	O
to	O
-0.043],	O
P	O
=	O
0.033,	O
for	O
each	O
1	O
g/d-	O
increase	B-T169
in	O
LCn-3PUFA	B-T109
).	O
No	O
associations	B-T080
were	O
found	O
for	O
other	O
food	B-T168
groups	B-T078
,	O
but	O
there	O
was	O
a	O
trend	O
for	O
fatty fish	B-T168
intake	B-T169
(-0.083	O
[-0.177	O
to	O
0.012],	O
P	O
=	O
0.085,	O
for	O
each	O
10	O
g/d-	O
increase	B-T169
).	O
Our	O
data	B-T078
add	O
clinical	B-T080
evidence	B-T078
on	O
the	O
down-regulation	B-T044
of	O
plasma SCD1	B-T116
index	B-T170
by	O
LCn-3PUFA	B-T109
in	O
the	O
context	B-T078
of	O
realistic	O
changes	B-T169
in	O
fish	B-T013
consumption	B-T052
in	O
the	O
customary	B-T080
,	O
non-supplemented	B-T033
diet	B-T168
.	O
http://www.Controlled-trials.com/ISRCTN35739639.	O

Distinct cortical and sub-cortical neurogenic domains	B-T025
for	O
GABAergic	B-T043
interneuron	B-T025
precursor	B-T078
transcription factors	B-T116
NKX2.1	B-T116
,	O
OLIG2	B-T116
and	O
COUP-TFII	B-T116
in	O
early	O
fetal	B-T169
human	B-T016
telencephalon	B-T018
The	O
extent	O
of	O
similarities	B-T080
and	O
differences	B-T080
between	O
cortical GABAergic interneuron generation	B-T043
in	O
rodent	B-T015
and	O
primate	B-T015
telencephalon	B-T018
remains	O
contentious.	O
We	O
examined	O
expression	B-T045
of	O
three	O
interneuron	B-T025
precursor	B-T078
transcription factors	B-T116
,	O
alongside	O
other	O
markers	B-T201
,	O
using	O
immunohistochemistry	B-T060
on	O
8-12	O
post-conceptional weeks	B-T032
(	O
PCW	B-T032
)	O
human	B-T016
telencephalon	B-T018
sections.	O
NKX2.1	B-T116
,	O
OLIG2	B-T116
,	O
and	O
COUP-TFII	B-T116
expression	B-T045
occupied	O
distinct	O
(although	O
overlapping)	O
neurogenic domains	B-T025
which	O
extended	O
into	O
the	O
cortex	B-T023
and	O
revealed	O
three	O
CGE compartments	B-T018
:	O
lateral	B-T082
,	O
medial	B-T082
,	O
and	O
ventral	B-T082
.	O
NKX2.1	B-T116
expression	B-T045
was	O
very	O
largely	O
confined	O
to	O
the	O
MGE	B-T018
,	O
medial	B-T082
CGE	B-T018
,	O
and	O
ventral	B-T082
septum	B-T023
confirming	O
that,	O
at	O
this	O
developmental stage	B-T079
,	O
interneuron	B-T025
generation	O
from	O
NKX2.1	B-T116
+	O
precursor	B-T078
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	B-T015
.	O
OLIG2	B-T116
immunoreactivity	B-T044
was	O
observed	O
in	O
GABAergic cells	B-T025
of	O
the	O
proliferative	B-T043
zones	B-T082
of	O
the	O
MGE	B-T018
and	O
septum	B-T023
,	O
but	O
not	O
necessarily	O
co-expressed	O
with	O
NKX2.1	B-T116
,	O
and	O
OLIG2	B-T116
expression	B-T045
was	O
also	O
extensively	O
seen	O
in	O
the	O
LGE	B-T018
,	O
CGE	B-T018
,	O
and	O
cortex	B-T023
.	O
At	O
8	O
PCW	B-T032
,	O
OLIG2	B-T116
+	O
cells	B-T025
were	O
only	O
present	O
in	O
the	O
medial	B-T082
and	O
anterior	B-T082
cortical wall	B-T023
suggesting	O
a	O
migratory	B-T169
pathway	B-T077
for	O
interneuron	B-T025
precursor	B-T078
s	O
via	O
the	O
septum	B-T023
into	O
the	O
medial	B-T082
cortex	B-T023
.	O
By	O
12	O
PCW	B-T032
,	O
OLIG2	B-T116
+	O
cells	B-T025
were	O
present	O
throughout	O
the	O
cortex	B-T023
and	O
many	O
were	O
actively	O
dividing	B-T169
but	O
without	O
co-expressing	O
cortical	B-T023
progenitor	B-T025
markers	B-T201
.	O
Dividing	O
COUP-TFII	B-T116
+	O
progenitor cells	B-T025
were	O
localized	B-T082
to	O
ventral	B-T082
CGE	B-T018
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	B-T082
cortex	B-T023
;	O
in	O
both	O
the	O
cases,	O
COUP-TFII	B-T116
was	O
co-expressed	O
with	O
PAX6	B-T116
in	O
proliferative	B-T043
zones	B-T082
and	O
TBR1	B-T116
or	O
calretinin	B-T116
in	O
post-	O
mitotic	B-T080
cortical neurons	B-T025
.	O
Thus	O
COUP-TFII	B-T116
+	O
progenitors	B-T025
gave	O
rise	O
to	O
pyramidal cells	B-T025
,	O
but	O
also	O
interneurons	B-T025
which	O
not	O
only	O
migrated	B-T169
posteriorly	O
into	O
the	O
cortex	B-T023
from	O
ventral	B-T082
CGE	B-T018
but	O
also	O
anteriorly	B-T082
via	O
the	O
LGE	B-T018
.	O

Primary neuroendocrine carcinoma	B-T191
of	O
the	O
breast	B-T023
A	O
single Center experience	B-T041
and	O
review of the literature	B-T170
Neuroendocrine carcinoma	B-T191
of	O
the	O
breast	B-T023
is	O
an	O
extremely	B-T080
rare	B-T080
tumor	B-T191
.	O
A	O
standard	B-T080
treatment	B-T061
has	O
yet	O
to	O
be	O
established	B-T080
because	O
only	O
a	O
few	O
cases	B-T077
have	O
been	O
reported	O
in	O
literature	B-T170
.	O
The	O
authors	B-T097
report	O
five	O
cases	B-T077
observed	O
from	O
January	B-T080
2007	O
to	O
December	B-T080
2014	O
and	O
a	O
review of literature	B-T170
.	O
Four	O
patients	B-T101
underwent	O
quadrantectomy	B-T061
and	O
in	O
two	O
cases	B-T077
axillary nodal dissection	B-T061
and	O
only	O
one	O
to	O
mastectomy	B-T061
with	O
axillary nodal dissection	B-T061
.	O
Tumor size	B-T082
was	O
from	O
T1	B-T033
to	O
T2	B-T033
with	O
N0	B-T033
to	O
N1	B-T033
,	O
according	O
TNM classification	B-T185
.	O
Pathological specimens	B-T031
were	O
stained	B-T080
with	O
hematoxylin	B-T109
and	O
eosin	B-T130
and	O
an	O
immunohistochemical	B-T059
panel	B-T078
of	O
antibodies	B-T130
(	O
Neuron-specific enolase	B-T129
,	O
Chromogranin	B-T116
,	O
Synaptophysin	B-T116
,	O
Estrogen	B-T116
and	O
Progesterone receptors	B-T116
,	O
c-erb	B-T129
and	O
Ki-67	B-T116
).	O
All	O
cases	B-T077
showed	O
markers	B-T080
positivity	O
to	O
Neuron-specific enolase	B-T129
,	O
Chromogranin	B-T116
,	O
Synaptophysin	B-T116
and	O
Estrogen	B-T116
and	O
Progesterone receptors	B-T116
were	O
found.	O
Ki-67	B-T116
was	O
higher	O
than	O
40%	O
in	O
four	O
patients	B-T101
.	O
Adjuvant chemotherapy	B-T061
was	O
administrated	B-T061
in	O
patients	B-T101
with	O
Ki-67	B-T116
>10%;	O
every	O
patients	B-T101
were	O
treated	B-T169
with	O
radiotherapy	B-T061
and	O
with	O
hormonal therapy	B-T061
too.	O
Although	O
Neuroendocrine breast tumor	B-T191
is	O
considered	O
a	O
distinct	O
entity	B-T071
,	O
the	O
best	O
treatment	B-T061
seems	O
to	O
be	O
correlate	B-T080
to	O
the	O
size of tumor	B-T082
and	O
to	O
the	O
lymph node	B-T023
status	B-T080
and	O
to	O
Ki-67	B-T116
index	B-T170
like	O
the	O
common	O
breast cancer	B-T191
.	O
Diagnosis	B-T033
,	O
Neuroendocrine breast carcinoma	B-T191
.	O

A	O
new	O
parametric model	B-T170
to	O
assess	B-T052
delay	B-T079
and	O
compression	B-T080
of	O
mortality	B-T081
A	O
decrease	B-T081
in	O
mortality	B-T081
across	O
all	O
ages	B-T032
causes	O
a	O
shift	O
of	O
the	O
age	B-T032
pattern	B-T082
of	O
mortality	B-T081
,	O
or	O
mortality	B-T081
delay	B-T079
,	O
while	O
differences	B-T080
in	O
the	O
rate	B-T081
of	O
decrease	B-T081
across	O
ages	B-T032
cause	O
a	O
change	O
in	O
the	O
shape	B-T082
of	O
the	O
age-at-death	B-T033
distribution	B-T169
,	O
mortality	B-T081
compression	B-T080
or	O
expansion	B-T169
.	O
Evidence	B-T078
exists	O
for	O
both	O
compression	B-T080
and	O
delay	B-T079
of	O
mortality	B-T081
.	O
Existing	O
parametric models	B-T170
to	O
describe	O
the	O
full	O
age	B-T032
pattern	B-T082
of	O
mortality	B-T081
are	O
not	O
able	O
to	O
capture	O
mortality	B-T081
delay	B-T079
versus	O
mortality	B-T081
compression	B-T080
.	O
More	O
recent	O
models	B-T170
that	O
assess	O
delay	B-T079
versus	O
compression	B-T080
mostly	O
focused	O
on	O
the	O
adult	B-T100
or	O
old ages	B-T098
alone	O
and	O
did	O
not	O
distinguish	O
mortality	B-T081
compression	B-T080
below	O
and	O
above	O
the	O
modal age	B-T032
at	O
death	B-T033
,	O
although	O
they	O
represent	O
different	B-T080
mechanisms	B-T169
.	O
This	O
paper	B-T170
presents	O
a	O
new	O
parametric model	B-T170
that	O
describes	O
the	O
full	O
age	B-T032
pattern	B-T082
of	O
mortality	B-T081
and	O
assesses	O
compression	B-T080
-	O
at	O
different	B-T080
stages of life	B-T079
-	O
and	O
delay	B-T079
of	O
mortality	B-T081
:	O
the	O
CoDe model	B-T170
.	O
The	O
model	B-T170
includes	O
10	O
parameters	B-T077
,	O
of	O
which	O
five	O
are	O
constant	B-T080
over	O
time	B-T079
.	O
The	O
five	O
time	B-T079
-varying	O
parameters	B-T077
reflect	O
delay	B-T079
of	O
mortality	B-T081
and	O
compression	B-T080
of	O
mortality	B-T081
in	O
infancy	B-T079
,	O
adolescence	B-T079
,	O
young adulthood	B-T100
,	O
late adulthood	B-T079
,	O
and	O
old age	B-T098
.	O
The	O
model	B-T170
describes	O
infant	B-T100
and	O
background	O
mortality	B-T081
by	O
two	O
simple	O
functions	B-T169
,	O
uses	O
a	O
mixed logistic model	B-T081
with	O
different	B-T080
slopes	B-T081
in	O
adult	B-T100
,	O
middle	B-T079
,	O
and	O
old age	B-T098
,	O
and	O
includes	O
the	O
modal age	B-T032
at	O
death	B-T033
as	O
a	O
parameter	B-T077
to	O
account	O
for	O
the	O
delay	B-T079
in	O
mortality	B-T081
.	O
Applying	O
the	O
CoDe model	B-T170
to	O
age	B-T032
-	O
specific	B-T080
probabilities	B-T081
of	O
death	B-T033
for	O
Japanese	B-T098
,	O
French	B-T098
,	O
American	B-T098
,	O
and	O
Danish	B-T098
men	B-T098
and	O
women	B-T098
between	O
1950	O
and	O
2010	O
showed	O
a	O
very	O
good	O
fit	O
of	O
the	O
full	O
age	B-T032
pattern	B-T082
of	O
mortality	B-T081
.	O
Delay	B-T079
of	O
mortality	B-T081
explained	O
about	O
two-thirds	O
of	O
the	O
increase	B-T169
in	O
life expectancy	B-T102
at	O
birth	B-T040
,	O
whereas	O
compression	B-T080
of	O
mortality	B-T081
due	O
to	O
mortality declines	B-T081
in	O
young age	B-T033
explained	O
about	O
one-third.	O
No	O
strong	O
compression	B-T080
of	O
mortality	B-T081
in	O
late adulthood age	B-T079
was	O
observed.	O
Mortality	B-T081
compression	B-T080
in	O
old age	B-T098
has	O
had	O
a	O
small	O
negative	O
impact	O
on	O
life expectancy	B-T102
.	O
The	O
CoDe model	B-T170
proved	O
a	O
valid	O
instrument	O
for	O
describing	O
the	O
full	O
age	B-T032
pattern	B-T082
of	O
mortality	B-T081
and	O
for	O
disentangling	O
the	O
effects	O
of	O
mortality	B-T081
delay	B-T079
and	O
compression	B-T080
-	O
at	O
different	B-T080
stages of life	B-T079
-	O
on	O
the	O
increase	B-T169
in	O
life expectancy	B-T102
.	O

Prevalence	B-T081
of	O
Hypothyroidism	B-T047
in	O
Andalusia, Spain,	B-T083
Determined	O
by	O
Thyroid Hormone	B-T116
Comsumption	B-UnknownType
Hypothyroidism	B-T047
is	O
the	O
most	O
common	O
condition	O
linked	O
to	O
a	O
hormone deficiency	B-T047
,	O
nevertheless	O
data	O
on	O
its	O
prevalence	B-T081
are	O
scarce	O
in	O
Spain	B-T083
.	O
For	O
that	O
reason,	O
we	O
have	O
estimated	O
its	O
prevalence	B-T081
through	O
the	O
registration	B-T058
of	O
patients	B-T101
who	O
had	O
used	O
thyroid hormones	B-T116
in	O
Andalusia (South Spain)	B-T083
.	O
Data	O
of	O
patients	B-T101
who	O
had	O
withdrawn	O
levothyroxine	B-T109
under	O
the	O
public	O
system	O
during	O
2014	O
from	O
the	O
base	O
of	O
the	O
Andalusian Health Service	B-T058
were	O
considered.	O
Prevalence	B-T081
were	O
calculated	O
with	O
confidence intervals	B-T081
of	O
95%	O
for	O
each	O
management area	B-UnknownType
,	O
stratified	O
by	O
sex	B-T032
and	O
age groups	B-T100
,	O
and	O
differences	O
between	O
them	O
were	O
evaluated	B-T058
.	O
321,368	O
people	B-T098
(98%	O
older	O
than	O
18	O
years	O
and	O
83%	O
female	B-T032
)	O
were	O
identified	O
as	O
levothyroxine	B-T109
users	O
and	O
a	O
prevalence	B-T081
of	O
hypothyroidism	B-T047
of	O
3.95%	O
(95%	O
CI	B-T081
:3.94-3.96)	O
was	O
estimated	O
for	O
the	O
general	O
population	B-T098
.	O
The	O
condition	O
was	O
more	O
common	O
in	O
females	B-T032
,	O
in	O
the	O
older	O
18	O
years	O
7.81%	O
(95%	O
CI	B-T081
:7.80	O
to	O
7.82)	O
compared	O
to	O
males	B-T032
1.75%	O
(95%	O
CI	B-T081
:1.73-1.77)	O
with	O
a	O
ratio	O
of	O
4.5-fold	B-T079
.	O
It	O
increases	O
in	O
the	O
population	B-T098
of	O
women	B-T098
older	O
than	O
45	O
years,	O
10.32%	O
(95%	O
CI	B-T081
:10.30-0.32)	O
and	O
in	O
the	O
over	O
60	O
years	O
11.37%	O
(95%	O
CI	B-T081
:	O
11.35-11.40).	O
The	O
prevalence	B-T081
in	O
adult	B-T100
women	B-T098
in	O
the	O
western provinces	B-T083
is	O
7.38%	O
(95%	O
CI	B-T081
:7.36-7.40),	O
in	O
the	O
eastern provinces	B-T083
8.59%	O
(95%	O
CI	B-T081
:8.57-8.62)	O
and	O
in	O
coastal areas	B-T083
6.70%	O
(95%	O
CI	B-T081
:	O
6.68-6.72)	O
compared	O
to	O
the	O
mountainous ones	B-T098
,	O
which	O
is	O
8.91%	O
(95%	O
CI	B-T081
:8.88-8.94).	O
The	O
results	O
denote	O
a	O
high prevalence	B-T081
of	O
hypothyroidism	B-T047
in	O
the	O
adult	B-T100
population	B-T098
of	O
Andalusia	B-T083
compared	O
to	O
the	O
nearby	O
countries	B-T083
,	O
with	O
a	O
clear	O
increased	O
associated with	B-T080
females	B-T032
and	O
age	B-T032
.	O
Furthermore,	O
the	O
prevalence	B-T081
of	O
the	O
illness	B-T184
presents	O
also	O
a	O
geographically-related	B-UnknownType
variability	B-T077
.	O

Disease Activity	B-T047
and	O
Increased Risk of	B-T033
Cardiovascular Death	B-T046
among	O
Patients	B-T101
with	O
Psoriatic Arthritis	B-T047
Recent	O
studies	O
indicate	O
increased	O
cardiovascular (CV) morbidity	B-T047
and	O
mortality	B-T046
in	O
patients	B-T101
with	O
psoriatic arthritis	B-T047
(	O
PsA	B-T047
),	O
but	O
results	O
are	O
inconsistent.	O
This	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality rate	B-T081
,	O
cause of death	B-T033
,	O
and	O
incidence	O
of	O
acute	O
CV events	B-T033
in	O
patients	B-T101
from	O
northern	B-T082
Sweden	B-T083
with	O
PsA	B-T047
.	O
Patients	B-T101
with	O
established	O
PsA	B-T047
(464)	O
were	O
included.	O
To	O
calculate	O
standardized mortality ratio	B-T081
(	O
SMR	B-T081
)	O
and	O
standardized incidence ratio	B-T081
(	O
SIR	B-T081
)	O
for	O
CV events	B-T033
,	O
data	O
were	O
extracted	O
from	O
the	O
National Causes of Death Register	B-T170
and	O
the	O
National Inpatient Care Register	B-T170
in	O
Sweden	B-T083
,	O
and	O
compared	O
with	O
the	O
general population	B-T098
.	O
The	O
study	O
period	O
was	O
1995-2011.	O
To	O
study	O
the	O
effect	O
of	O
inflammatory	B-T169
activity,	O
a	O
composite	O
disease activity index	B-T060
(	O
DAI	B-T060
)	O
was	O
used.	O
The	O
SMR	B-T081
(95%	O
CI)	O
for	O
overall mortality	B-T081
and	O
diseases of the circulatory system	B-T047
(	O
International Classification of Diseases	B-T170
,	O
10th	O
edition;	O
I00-I99)	O
was	O
1.22	O
(0.89-1.63)	O
and	O
1.64	O
(1.02-2.52),	O
respectively.	O
In	O
regression analysis	B-T170
,	O
DAI	B-T060
was	O
significantly	O
associated	O
with	O
death	B-T033
(OR	O
1.99,	O
95%	O
CI	O
1.41-2.80)	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
(p	O
<	O
0.001),	O
and	O
remained	O
significant	O
after	O
stratifying	B-T080
patients	B-T101
into	O
the	O
2	O
major	O
causes of death	B-T033
:	O
diseases of the circulatory system	B-T047
and	O
malignant neoplasms	B-T191
.	O
Peripheral	B-T047
and	O
axial disease	B-T033
was	O
associated	O
with	O
death	B-T033
(OR	O
4.02,	O
95%	O
CI	O
1.84-8.84,	O
p	O
<	O
0.001)	O
compared	O
with	O
peripheral disease	B-T047
only.	O
The	O
SIR	B-T081
(95%	O
CI)	O
for	O
a	O
CV event	B-T033
(	O
myocardial infarction	B-T047
or	O
stroke	B-T037
)	O
was	O
0.597	O
(0.40-0.86);	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	B-T098
.	O
Patients	B-T101
with	O
PsA	B-T047
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
SMR	B-T081
for	O
death	B-T033
due	O
to	O
diseases of the circulatory system	B-T047
compared	O
with	O
the	O
general population	B-T098
.	O
Among	O
patients	B-T101
,	O
death	B-T033
was	O
associated	O
with	O
DAI	B-T060
,	O
as	O
well	O
as	O
axial involvement	B-T033
in	O
combination	O
with	O
peripheral disease	B-T047
,	O
indicating	O
more	O
aggressive	O
disease phenotypes	B-T032
.	O

Histomorphometric	B-T059
and	O
transcriptome	B-T086
evaluation	B-T058
of	O
early	O
healing bone	B-T033
treated with	B-T061
a	O
novel	B-T080
human particulate dentin	B-T031
powder	B-T122
Human particulate dentin	B-T031
(	O
HPD	B-T031
)	O
shows	O
potential	B-T080
as	O
an	O
alternative	B-T077
bone grafting	B-T061
material	B-T122
.	O
However,	O
the	O
mechanism	B-T169
of	O
bone healing	B-T033
at	O
the	O
molecular	B-T080
level	B-T080
after	O
grafting	B-T061
with	O
HPD	B-T031
is	O
unclear.	O
This	O
study	B-T062
assessed	B-T052
the	O
histological	B-T169
and	O
global	B-T080
gene expression	B-T045
of	O
bone tissues	B-T024
grafted	B-T169
with	O
HPD	B-T031
.	O
The	O
HPD	B-T031
was	O
prepared	B-T033
to	O
250-500	O
µm	O
in	O
size.	O
X-ray diffraction	B-T059
(	O
XRD	B-T059
)	O
and	O
energy dispersive x-ray spectroscopy	B-T059
(	O
EDX	B-T059
)	O
were	O
performed	B-T169
to	O
confirm	B-T080
the	O
crystal structure	B-T104
,	O
organic compound	B-T109
residues	B-T077
,	O
and	O
surface morphology	B-T080
,	O
respectively.	O
Bony	B-T169
defects	B-T169
were	O
created	B-T052
on	O
the	O
heads	B-T029
of	O
24	O
New Zealand White rabbits	B-T015
.	O
Sterilized	B-T080
HPD	B-T031
was	O
used	O
as	O
the	O
grafting material	B-T122
.	O
The	O
quality	B-T080
and	O
quantity	B-T081
of	O
new bone formation	B-T042
was	O
evaluated	B-T058
using	O
micro-CT	B-T060
and	O
histologic	B-T169
analyses	B-T062
during	B-T079
the	O
8	O
week	O
experimental	B-T080
periods	B-T079
.	O
For	O
microarray assay	B-T059
,	O
bone tissue	B-T024
and	O
blood samples	B-T031
were	O
taken	O
at	O
3,	O
5	O
and	O
7	O
d	O
post-implantation	B-T079
.	O
The	O
results	B-T034
of	O
XRD	B-T059
and	O
EDX	B-T059
showed	O
that	O
HPD	B-T031
exhibited	O
physical	B-T070
and	O
chemical properties	B-T070
similar	B-T080
to	O
natural	B-T169
hydroxyapatite	B-T197
.	O
New bone formation	B-T042
was	O
observed	B-T169
after	O
HPD	B-T031
implantation	B-T061
compared	B-T052
to	O
the	O
controls	B-T096
,	O
as	O
shown	O
on	O
hematoxylin and eosin staining	B-T059
and	O
micro-CT	B-T060
.	O
The	O
bone volume	B-T032
of	O
HPD	B-T031
treated	B-T169
animals	B-T008
was	O
higher	B-T080
than	O
that	O
of	O
the	O
control group	B-T096
at	O
all	O
observation	B-T062
times	B-T081
.	O
Microarray analysis	B-T059
showed	O
that	O
vascular development	B-T042
coupled	O
with	O
immune	B-T169
and	O
inflammatory	B-T169
related	O
genes	B-T028
were	O
expressed	B-T045
in	O
the	O
early	B-T079
healing	B-T040
stage	B-T079
.	O
The	O
gene coding	B-T028
for	O
the	O
IL-1 antagonist	B-T121
,	O
IL1RN	B-T028
,	O
was	O
expressed	B-T045
to	O
inhibit	B-T044
the	O
inflammatory response	B-T046
,	O
and	O
at	O
the	O
same	O
time,	O
the	O
CCL2 gene	B-T028
was	O
activated	B-T052
to	O
2.3	O
times	O
the	O
normal	B-T080
level	B-T080
.	O
BMP2	B-T028
,	O
RUNX2	B-T028
,	O
COL1A	B-T028
,	O
and	O
OPN	B-T028
expression	B-T045
were	O
also	O
up-regulated	B-T044
.	O
CCL2	B-T028
predominated	B-T080
in	O
osteoblastogenesis	B-T043
of	O
the	O
HPD	B-T031
-	O
treated	B-T169
bony	B-T169
defect	B-T169
in	O
the	O
early stage	B-T079
of	O
healing	B-T040
.	O
HPD	B-T031
accelerated	B-T169
bone regeneration	B-T042
and	O
augmentation	B-T033
.	O
These	O
results	B-T034
suggested	B-T078
that	O
HPD	B-T031
provided	B-T052
potential	B-T080
as	O
a	O
bone graft	B-T061
resource	B-T078
during	B-T079
the	O
bone	B-T023
healing process	B-T040
.	O

'You	O
can't	O
be	O
a	O
person	B-T098
and	O
a	O
docto	B-T097
r':	O
the	O
work-life balance	B-T056
of	O
doctors	B-T097
in	O
training	B-T065
-a	O
qualitative study	B-T062
Investigate	B-T169
the	O
work-life balance	B-T056
of	O
doctors	B-T097
in	O
training	B-T065
in	O
the	O
UK	B-T083
from	O
the	O
perspectives	O
of	O
trainers	B-T073
and	O
trainees.	O
Qualitative	B-T080
semistructured	O
focus	O
groups	O
and	O
interviews	B-T052
with	O
trainees	O
and	O
trainers	B-T073
.	O
Postgraduate medical training	B-T065
in	O
London	B-T083
,	O
Yorkshire	B-T083
and	O
Humber	B-T083
,	O
Kent	B-T083
,	O
Surrey	B-T083
and	O
Sussex	B-T083
,	O
and	O
Wales	B-T083
during	O
the	O
junior doctor	B-T097
contract	B-T170
dispute	B-T054
at	O
the	O
end	O
of	O
2015.	O
Part	O
of	O
a	O
larger	O
General Medical Council	B-T092
study	B-T062
about	O
the	O
fairness	O
of	O
postgraduate medical training	B-T065
.	O
96	O
trainees	O
and	O
41	O
trainers	B-T073
.	O
Trainees	O
comprised	O
UK	B-T083
graduates	B-T098
and	O
International Medical Graduates	B-T097
,	O
across	O
all	O
stages	O
of	O
training	B-T065
in	O
6	O
specialties	B-T091
(	O
General Practice	B-T091
,	O
Medicine	B-T091
,	O
Obstetrics and Gynaecology	B-T091
,	O
Psychiatry	B-T091
,	O
Radiology	B-T091
,	O
Surgery	B-T091
)	O
and	O
Foundation	B-T092
.	O
Postgraduate training	B-T065
was	O
characterised	O
by	O
work-life imbalance	B-T056
.	O
Long	B-T080
hours	B-T079
at	O
work	B-T057
were	O
typically	O
supplemented	O
with	O
revision	B-T079
and	O
completion	B-T080
of	O
the	O
e-portfolio	B-T080
.	O
Trainees	O
regularly	O
moved	O
workplaces	B-T082
which	O
could	O
disrupt	B-T080
their	O
personal lives	B-UnknownType
and	O
sometimes	O
led	O
to	O
separation	B-T068
from	O
friends	B-T098
and	O
family	B-T099
.	O
This	O
made	O
it	O
challenging	O
to	O
cope	B-T055
with	O
personal	O
pressures,	O
the	O
stresses	B-T048
of	O
which	O
could	O
then	O
impinge	O
on	O
learning	B-T041
and	O
training	B-T065
,	O
while	O
also	O
leaving	B-T052
trainees	O
with	O
a	O
lack	B-T080
of	O
social support	B-T054
outside	O
work	O
to	O
buffer	O
against	O
the	O
considerable	O
stresses	B-T048
of	O
training	B-T065
.	O
Low	B-T080
morale	B-T033
and	O
harm	B-T033
to	O
well-being	B-T033
resulted	O
in	O
some	O
trainees	O
feeling	B-T041
dehumanised	B-T054
.	O
Work-life imbalance	B-T056
was	O
particularly	O
severe	B-T080
for	O
those	O
with	O
children	B-T100
and	O
especially	O
women	B-T098
who	O
faced	O
a	O
lack	B-T080
of	O
less-than	B-T081
-	O
full-time positions	B-T056
and	O
discriminatory	B-T041
attitudes	B-T041
.	O
Female	B-T032
trainees	O
frequently	O
talked	B-T056
about	O
having	O
to	O
choose	B-T052
a	O
specialty	B-T091
they	O
felt	O
was	O
more	O
conducive	O
to	O
a	O
work-life balance	B-T056
such	O
as	O
General Practice	B-T091
.	O
The	O
proposed	O
junior doctor	B-T097
contract	B-T170
was	O
felt	O
to	O
exacerbate	B-T033
existing	B-T080
problems	B-T033
.	O
A	O
lack	B-T080
of	O
work-life balance	B-T056
in	O
postgraduate medical training	B-T065
negatively	B-T080
impacted	B-T169
on	O
trainees	O
'	O
learning	B-T041
and	O
well-being	B-T033
.	O
Women	B-T098
with	O
children	B-T100
were	O
particularly	O
affected	B-T169
,	O
suggesting	O
this	O
group	B-T078
would	O
benefit	B-T081
the	O
greatest	B-T081
from	O
changes	B-T169
to	O
improve	B-T033
the	O
work-life balance	B-T056
of	O
trainees.	O

Reappraisal	B-T058
Modulates	O
Attentional Bias	B-T041
to	O
Angry	B-T041
Angry Faces	B-T033
Heightened	O
attentional bias	B-T041
to	O
emotional	B-T033
information	B-T078
is	O
one	O
of	O
the	O
main	O
characteristics	O
of	O
disorders	B-T047
related	O
to	O
emotion	B-T041
dysregulation	B-T048
such	O
as	O
anxiety	B-T048
,	O
depression	B-T048
,	O
and	O
substance abuse	B-T048
.	O
Although	O
reappraisal	B-T058
,	O
an	O
emotion regulation	B-T041
strategy	B-T041
,	O
is	O
known	O
to	O
effectively	O
modulate	O
subjective experience	B-T041
of	O
emotions	B-T041
,	O
it	O
remains	O
unknown	O
whether	O
reappraisal	B-T058
can	O
alter	O
attentional biases	B-T041
to	O
emotional	B-T033
information	B-T078
.	O
In	O
the	O
current	O
research	B-T062
,	O
we	O
investigated	B-T169
the	O
influence	O
of	O
instruction-induced state reappraisal	B-T058
(	O
Study 1	B-T062
)	O
and	O
trait reappraisal	B-T058
(	O
Study 2	B-T062
)	O
on	O
attentional biases	B-T041
to	O
happy	B-T033
and	O
angry	B-T041
angry faces	B-T033
.	O
In	O
Study 1	B-T062
,	O
healthy	B-T080
young women	B-T098
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
groups	B-T078
:	O
up	B-T078
-,	O
down	B-T078
-,	O
and	O
no-regulation	B-T078
.	O
Participants	B-T098
were	O
instructed	O
to	O
reappraise	B-T058
their	O
emotions	B-T041
to	O
increase	O
and	O
decrease	O
emotional	B-T033
experience	B-T041
while	O
viewing	O
an	O
emotionally negative film clip	B-T170
.	O
Attentional bias	B-T041
was	O
assessed	O
with	O
a	O
dot-probe task	B-T061
with	O
pictures	B-T073
of	O
angry	B-T041
and	O
happy	B-T041
facial expressions	B-T033
.	O
In	O
Study 2	B-T062
,	O
a	O
separate	O
group	B-T078
of	O
healthy	B-T080
young men	B-T098
and	O
women	B-T098
participated.	O
Participants	B-T098
'	O
trait reappraisal	B-T058
and	O
suppression	B-T041
as	O
well	O
as	O
state	B-T048
and	O
trait anxiety	B-T033
were	O
assessed.	O
A	O
dot-probe task	B-T061
was	O
completed	O
by	O
all	O
participants	B-T098
.	O
Statistical tests	B-T170
in	O
Study 1	B-T062
revealed	O
that	O
participants	B-T098
who	O
reappraised	B-T058
to	O
decrease	O
negative emotions	B-T041
while	O
viewing	O
an	O
emotionally negative film clip	B-T170
had	O
reduced	O
attentional bias	B-T041
to	O
subsequently	O
presented	O
angry	B-T041
angry faces	B-T033
compared	B-T052
to	O
participants	B-T098
who	O
reappraised	B-T058
to	O
increase	O
negative emotions	B-T041
.	O
Multiple regression analyses	B-T170
in	O
Study 2	B-T062
revealed	O
that	O
trait reappraisal	B-T058
predicted	O
slower	O
orienting	O
toward	O
angry	B-T041
angry faces	B-T033
,	O
whereas	O
state anxiety	B-T048
predicted	O
slower	O
disengagement	B-T052
from	O
angry	B-T041
angry faces	B-T033
.	O
Interestingly,	O
trait suppression	B-T041
predicted	O
slower	O
disengagement	B-T052
from	O
happy faces	B-T033
.	O
Taken	O
together,	O
these	O
results	O
suggest	O
that	O
both	O
instruction-induced state reappraisal	B-T058
and	O
trait reappraisal	B-T058
are	O
linked	O
to	O
reduced	O
attentional bias	B-T041
to	O
negative	B-T033
information	B-T078
and	O
contribute	O
to	O
better	O
understanding	O
of	O
how	O
everyday	O
emotion regulation	B-T041
styles	O
contribute	O
to	O
attentional	O
processing	O
of	O
emotional	B-T033
information	B-T078
.	O

Graded Structure	B-T185
in	O
Sexual	B-T053
Definitions	B-T170
:	O
Categorizations	B-T185
of	O
Having	O
"	O
Had Sex	B-T033
"	O
and	O
Virginity	B-T055
Loss	B-T169
Among	O
Homosexual	B-T098
and	O
Heterosexual	B-T098
Men	B-T098
and	O
Women	B-T098
Definitions	B-T170
of	O
sexual behavior	B-T053
display	O
a	O
robust	O
hierarchy	B-T080
of	O
agreement	O
regarding	O
whether	O
or	O
not	O
acts	B-T052
should	O
be	O
classed	O
as,	O
for	O
example,	O
sex	B-T040
or	O
virginity	B-T055
loss	B-T169
.	O
The	O
current	O
research	B-T062
offers	O
a	O
theoretical	B-T078
explanation	B-T170
for	O
this	O
hierarchy	B-T080
,	O
proposing	O
that	O
sexual	B-T053
definitions	B-T170
display	O
graded categorical structure	B-T185
,	O
arising	O
from	O
goodness	O
of	O
membership	B-T055
judgments	B-T041
.	O
Moderation	B-T080
of	O
this	O
graded structure	B-T185
is	O
also	O
predicted,	O
with	O
the	O
focus	O
here	O
on	O
how	O
sexual orientation	B-T032
identity	B-T041
affects	O
sexual	B-T053
definitions	B-T170
.	O
A	O
total	O
of	O
300	O
18-	O
to	O
30-	O
year	B-T079
-old	O
participants	B-T098
completed	O
an	O
online survey	B-T170
,	O
rating	B-T052
18	O
behaviors	B-T053
for	O
how	O
far	O
each	O
constitutes	O
having	O
"	O
had sex	B-T033
"	O
and	O
virginity	B-T055
loss	B-T169
.	O
Participants	B-T098
fell	O
into	O
one	O
of	O
four	O
groups	B-UnknownType
:	O
heterosexual	B-T098
male	B-T098
or	O
female	B-T098
,	O
gay male	B-T098
or	O
lesbian	B-T098
.	O
The	O
predicted	O
ratings	B-T052
hierarchy	B-T080
emerged,	O
in	O
which	O
bidirectional genital acts	B-T053
were	O
rated	B-T052
significantly	O
higher	B-T080
than	O
unidirectional	B-T053
or	O
nonpenetrative contact	B-T033
,	O
which	O
was	O
in	O
turn	O
rated	B-T052
significantly	O
higher	B-T080
than	O
acts	B-T052
involving	O
no genital contact	B-T033
.	O
Moderation	B-T080
of	O
graded structure	B-T185
was	O
also	O
in	O
line	O
with	O
predictions	B-T078
.	O
Compared	O
to	O
the	O
other	O
groups	B-UnknownType
,	O
the	O
lesbian group	B-UnknownType
significantly	O
upgraded	O
ratings	B-T052
of	O
genital contact	B-T053
that	O
was	O
either	O
unidirectional	B-T053
or	O
nonpenetrative	B-T033
.	O
There	O
was	O
also	O
evidence	B-T078
of	O
upgrading	O
by	O
the	O
gay male	B-T098
sample	O
of	O
anal intercourse	B-T054
ratings	B-T052
.	O
These	O
effects	B-T080
are	O
theorized	O
to	O
reflect	O
group	B-UnknownType
-level	O
variation	B-T080
in	O
experience	B-T041
,	O
contextual perspective	B-T041
,	O
and	O
identity	B-T041
-management.	O
The	O
implications	B-T078
of	O
the	O
findings	B-T033
in	O
relation	O
to	O
previous	O
research	B-T062
are	O
discussed.	O
It	O
is	O
suggested	O
that	O
a	O
graded structure	B-T185
approach	O
can	O
greatly	O
benefit	B-T081
future	O
research	B-T062
into	O
sexual	B-T053
definitions	B-T170
,	O
by	O
permitting	O
variable	O
definitions	B-T170
to	O
be	O
predicted	O
and	O
explained,	O
rather	O
than	O
merely	O
identified.	O

Effects	O
of	O
soybean isoflavone	B-T109
on	O
intestinal	B-T023
antioxidant capacity	B-T044
and	O
cytokines	B-T116
in	O
young	O
piglets	B-T015
fed	B-T052
oxidized	B-T044
fish oil	B-T109
To	O
investigate	O
the	O
effect	O
of	O
glycitein	B-T109
,	O
a	O
synthetic	B-T052
soybean isoflavone	B-T109
(	O
ISF	B-T109
),	O
on	O
the	O
intestinal	B-T023
antioxidant capacity	B-T044
,	O
morphology	B-T080
,	O
and	O
cytokine	B-T116
content	O
in	O
young	O
piglets	B-T015
fed	B-T052
oxidized	B-T044
fish oil	B-T109
,	O
72	O
4-d-old	O
male	O
piglets	B-T015
were	O
assigned	O
to	O
three	O
treatments	B-T061
.	O
The	O
control group	B-T096
was	O
fed	B-T052
a	O
basal diet	B-T168
containing	O
fresh	B-T080
fish oil	B-T109
,	O
and	O
the	O
other	O
two	O
groups	O
received	O
the	O
same	O
diet	O
except	O
for	O
the	O
substitution	O
with	O
the	O
same	O
dosage	B-T081
of	O
oxidized	B-T044
fish oil	B-T109
alone	O
or	O
with	O
ISF	B-T109
(	O
oxidized	B-T044
fish oil	B-T109
plus	O
ISF	B-T109
).	O
After	O
21	O
d	O
of	O
feeding	B-T052
,	O
supplementation	B-T061
of	O
oxidized	B-T044
fish oil	B-T109
increased	O
the	O
levels	O
of	O
malondialdehyde	B-T109
(	O
MDA	B-T109
),	O
oxidized glutathione	B-T116
(	O
GSSG	B-T116
),	O
interleukin-1β	B-T116
(	O
IL-1β	B-T116
),	O
tumor necrosis factor-α	B-T116
(	O
TNF-α	B-T116
),	O
interleukin-2	B-T116
(	O
IL-2	B-T116
),	O
nuclear factor κ B	B-T116
(NF-κB	B-T116
),	O
inducible nitric oxide synthase	B-T116
(	O
iNOS	B-T116
),	O
NO	B-T121
,	O
and	O
Caspase-3	B-T116
in	O
jejunal mucosa	B-T023
,	O
and	O
decreased	O
the	O
villous	B-T023
height	B-T032
in	O
duodenum	B-T023
and	O
the	O
levels	O
of	O
secretory immunoglobulin A	B-T116
(sIgA	B-T116
)	O
and	O
IL-4	B-T116
in	O
the	O
jejunal mucosa	B-T023
compared	O
with	O
supplementation	B-T061
with	O
fresh	B-T080
oil	B-T109
.	O
The	O
addition	O
of	O
oxidized	B-T044
fish oil	B-T109
plus	O
ISF	B-T109
partially	O
alleviated	O
this	O
negative	O
effect.	O
The	O
addition	O
of	O
oxidized	B-T044
fish oil	B-T109
plus	O
ISF	B-T109
increased	O
the	O
villous	B-T023
height	B-T032
and	O
levels	O
of	O
sIgA	B-T116
and	O
IL-4	B-T116
in	O
jejunal mucosa	B-T023
,	O
but	O
decreased	O
the	O
levels	O
of	O
IL-1β	B-T116
and	O
IL-2	B-T116
in	O
jejunal mucosa	B-T023
(P<0.05)	O
compared	O
with	O
oxidized	B-T044
fish oil	B-T109
.	O
Collectively,	O
these	O
results	O
show	O
that	O
dietary supplementation	B-T061
of	O
ISF	B-T109
could	O
partly	O
alleviate	O
the	O
negative	O
effect	O
of	O
oxidized	B-T044
fish oil	B-T109
by	O
improving	O
the	O
intestinal morphology	B-T023
as	O
well	O
as	O
the	O
antioxidant capacity	B-T044
and	O
immune function	B-T042
in	O
young	O
piglets	B-T015
piglets	B-T015
.	O

Evolution	B-T045
:	O
Enhanced	B-T052
Footing	B-T169
for	O
Snake	B-T014
Limb Development	B-T042
Two	O
groups	O
have	O
studied	O
the	O
loss	B-T081
of	O
limbs	B-T023
in	O
snake	B-T014
evolution	B-T045
by	O
focusing	O
on	O
a	O
long-distance	B-T033
cis-acting enhancer	B-T086
of	O
Sonic Hedgehog	B-T028
.	O
They	O
find	O
a	O
progressive	B-T169
degeneration	B-T169
of	O
binding sites	B-T087
for	O
key	O
transcription factors	B-T116
,	O
mirroring	O
the	O
progressive	B-T169
limblessness	B-T080
occurring	B-T052
in	O
these	O
reptiles	B-T014
.	O

Dynamin-related protein 1	B-T116
mediates	B-T169
low glucose	B-T109
-	O
induced	B-T169
endothelial dysfunction	B-T047
in	O
human	B-T016
arterioles	B-T023
Intensive	O
glycemic regulation	B-T038
has	O
resulted	O
in	O
an	O
increased	B-T081
incidence	B-T081
of	O
hypoglycemia	B-T047
.	O
Hypoglycemic	B-T047
burden	B-T078
correlates	O
with	O
adverse	B-T169
cardiovascular complications	B-T046
and	O
contributes	O
acutely	B-T079
and	O
chronically	B-T079
to	O
endothelial dysfunction	B-T047
.	O
Prior	O
data	B-T078
indicate	O
that	O
mitochondrial dysfunction	B-T033
contributes	O
to	O
hypoglycemia	B-T047
-	O
induced	B-T169
endothelial dysfunction	B-T047
,	O
but	O
the	O
mechanisms	B-T169
behind	O
this	O
linkage	B-T169
remain	O
unknown	B-T080
.	O
We	O
attempt	O
to	O
determine	O
whether	O
clinically	B-T080
relevant	B-T080
low-glucose	B-T109
(	O
LG	B-T109
)	O
exposures	B-T080
acutely	B-T079
induce	B-T169
endothelial dysfunction	B-T047
through	O
activation	B-T052
of	O
the	O
mitochondrial fission process	B-T043
.	O
Characterization	B-T052
of	O
mitochondrial morphology	B-T033
was	O
carried	O
out	O
in	O
cultured	B-T169
endothelial cells	B-T025
by	O
using	O
confocal microscopy	B-T059
.	O
Isolated	B-T169
human	B-T016
arterioles	B-T023
were	O
used	O
to	O
explore	O
the	O
effect	B-T080
LG	B-T109
-	O
induced	B-T169
mitochondrial fission	B-T043
has	O
on	O
the	O
formation	B-T169
of	O
detrimental reactive oxygen species	B-T123
(	O
ROS	B-T123
),	O
bioavailability	B-T081
of	O
nitric oxide	B-T121
(	O
NO	B-T121
),	O
and	O
endothelial-dependent vascular relaxation	B-T042
.	O
Fluorescence microscopy	B-T059
was	O
employed	O
to	O
visualize	O
changes	B-T169
in	O
mitochondrial	B-T026
ROS	B-T123
and	O
NO	B-T121
levels	B-T080
and	O
videomicroscopy	B-T059
applied	O
to	O
measure	B-T081
vasodilation	B-T042
response	B-T169
.	O
Pharmacological	B-T169
disruption	B-T169
of	O
the	O
profission protein	B-T116
Drp1	B-T116
with	O
Mdivi-1	B-T109
during	O
LG	B-T109
exposure	B-T080
reduced	B-T080
mitochondrial fragmentation	B-T043
among	O
vascular endothelial cells	B-T025
(	O
LG	B-T109
:	O
0.469;	O
LG	B-T109
+	O
Mdivi-1	B-T109
:	O
0.276;	O
P	O
=	O
0.003),	O
prevented	B-T169
formation	B-T169
of	O
vascular	B-T023
ROS	B-T123
(	O
LG	B-T109
:	O
2.036;	O
LG	B-T109
+	O
Mdivi-1	B-T109
:	O
1.774;	O
P	O
=	O
0.005),	O
increased	B-T081
the	O
presence	B-T033
of	O
NO	B-T121
(	O
LG	B-T109
:	O
1.352;	O
LG	B-T109
+	O
Mdivi-1	B-T109
:	O
1.502;	O
P	O
=	O
0.048),	O
and	O
improved	B-T033
vascular dilation	B-T042
response	B-T169
to	O
acetylcholine	B-T109
(	O
LG	B-T109
:	O
31.6%;	O
LG	B-T109
+	O
Mdivi-1	B-T109
;	O
78.5%	O
at	O
maximum	B-T081
dose	B-T081
;	O
P	O
<	O
0.001).	O
Additionally,	O
decreased	B-T081
expression	B-T045
of	O
Drp1	B-T116
via	O
siRNA	B-T114
knockdown	B-T063
during	O
LG	B-T109
conditions	B-T080
also	O
improved	B-T033
vascular relaxation	B-T042
.	O
Exposure to	B-T080
LG	B-T109
imparts	O
endothelial dysfunction	B-T047
coupled	B-T169
with	O
altered	B-T169
mitochondrial	B-T026
phenotypes	B-T032
among	O
isolated	B-T169
human	B-T016
arterioles	B-T023
.	O
Disruption	B-T169
of	O
Drp1	B-T116
and	O
subsequent	B-T079
mitochondrial fragmentation	B-T043
events	O
prevents	B-T169
impaired	B-T169
vascular dilation	B-T042
,	O
restores	B-T169
mitochondrial	B-T026
phenotype	B-T032
,	O
and	O
implicates	O
mitochondrial fission	B-T043
as	O
a	O
primary	B-T080
mediator	B-T080
of	O
LG	B-T109
-	O
induced	B-T169
endothelial dysfunction	B-T047
.NEW	O
&	O
NOTEWORTHY	O
Acute	B-T079
low-glucose	B-T109
exposure	B-T080
induces	B-T169
mitochondrial fragmentation	B-T043
in	O
endothelial cells	B-T025
via	O
Drp1	B-T116
and	O
is	O
associated with	B-T080
impaired	B-T169
endothelial	B-T025
function	B-T043
in	O
human	B-T016
arterioles	B-T023
.	O
Targeting	B-T043
of	O
Drp1	B-T116
prevents	B-T169
fragmentation	B-T043
,	O
improves	O
vasofunction	B-T042
,	O
and	O
may	O
provide	O
a	O
therapeutic	B-T169
target	B-T169
for	O
improving	O
cardiovascular complications	B-T046
among	O
diabetics	B-T033
.Listen	O
to	O
this	O
article's	O
corresponding	O
podcast	O
@	O
http://ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/	B-T170
.	O

A	O
16	O
Yin Yang	B-T028
gene expression	B-T045
ratio	B-T081
signature	B-T169
for	O
ER+	B-T191
/	O
node- breast cancer	B-T191
Breast cancer	B-T191
is	O
one	O
of	O
the	O
leading	O
causes	B-T169
of	O
cancer	B-T191
death	B-T040
in	O
women	B-T098
.	O
It	O
is	O
a	O
complex	B-T080
and	O
heterogeneous	B-T080
disease	B-T047
with	O
different	O
clinical	B-T080
outcomes	B-T080
.	O
Stratifying	B-T080
patients	B-T101
into	O
subgroups	B-T185
with	O
different	O
outcomes	B-T080
could	O
help	O
guide	O
clinical decision making	B-T060
.	O
In	O
this	O
study	B-T062
,	O
we	O
used	O
two	O
opposing	O
groups	B-T078
of	O
genes	B-T028
,	O
Yin and Yang	B-T028
,	O
to	O
develop	O
a	O
prognostic	B-T201
expression	B-T045
ratio	B-T081
signature	B-T169
.	O
Using	O
the	O
METABRIC	B-T170
cohort	B-T062
we	O
identified	O
a16-	O
gene signature	B-T169
capable	O
of	O
stratifying	B-T080
breast cancer	B-T191
patients	B-T101
into	O
four	O
risk levels	B-T080
with	O
intention	O
that	O
low-risk	B-T081
patients	B-T101
would	O
not	O
undergo	O
adjuvant	B-T169
systemic therapy	B-T061
,	O
intermediate	B-T082
-	O
low-risk	B-T081
patients	B-T101
will	O
be	O
treated with	B-T061
hormonal therapy	B-T061
only,	O
and	O
intermediate	B-T082
-high-	O
and	O
high-risk groups	B-T098
will	O
be	O
treated	B-T061
by	O
chemotherapy	B-T061
in	O
addition	O
to	O
the	O
hormonal therapy	B-T061
.	O
The	O
16-	O
gene signature	B-T169
for	O
four	O
risk level	B-T080
stratifications	B-T185
of	O
breast cancer	B-T191
patients	B-T101
has	O
been	O
validated	B-T062
using	O
14	O
independent	O
datasets	B-T170
.	O
Notably,	O
the	O
low-risk	B-T081
group	B-T098
(n	O
=	O
51)	O
of	O
205	O
estrogen receptor-positive	B-T191
and	O
node negative	B-T191
(	O
ER+	B-T191
/	O
node-	B-T191
)	O
patients	B-T101
from	O
three	O
different	O
datasets	B-T170
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant therapy	B-T061
had	O
100%	O
15-	O
year	B-T079
disease-specific survival rate	B-T081
.	O
The	O
Concordance Index	B-T170
of	O
YMR	B-T060
for	O
ER+	B-T191
/	O
node negative	B-T191
patients	B-T101
is	O
close	O
to	O
the	O
commercially	B-T170
available	O
signatures	B-T169
.	O
However,	O
YMR	B-T060
showed	O
more	O
significance	B-T078
(	O
HR	B-T081
=	O
3.7,	O
p	O
=	O
8.7e-12)	O
in	O
stratifying	B-T080
ER+	B-T191
/	O
node-	B-T191
subgroup	B-T185
than	O
OncotypeDx	B-T060
(	O
HR	B-T081
=	O
2.7,	O
p	O
=	O
1.3e-7),	O
MammaPrint	B-T059
(	O
HR	B-T081
=	O
2.5,	O
p	O
=	O
5.8e-7),	O
rorS	B-T060
(	O
HR	B-T081
=	O
2.4,	O
p	O
=	O
1.4e-6),	O
and	O
NPI	B-T060
(	O
HR	B-T081
=	O
2.6,	O
p	O
=	O
1.2e-6).	O
YMR	B-T060
signature	B-T169
may	O
be	O
developed	O
as	O
a	O
clinical	B-T080
tool	B-T170
to	O
select	O
a	O
subgroup	B-T185
of	O
low-risk	B-T081
ER+	B-T191
/	O
node-	B-T191
patients	B-T101
who	O
do	O
not	O
require	O
any	O
adjuvant	B-T169
hormonal therapy	B-T061
(	O
AHT	B-T061
).	O

Risk Factors	B-T033
Associated With	B-T080
Repeated	B-T169
HIV Testing	B-T059
Among	O
Internet	B-T073
-Using	O
Men Who Have Sex With Men	B-T098
Men who have sex with men	B-T098
(	O
MSM	B-T098
)	O
represent	B-T052
a	O
disproportionately	B-T080
impacted	B-T169
risk group	B-T098
for	O
HIV	B-T005
incidence	B-T081
among	O
at-risk	B-T080
U.S	B-T083
.	O
Few	O
studies	B-T062
have	O
identified	B-T080
risk factors	B-T033
associated with	B-T080
HIV testing	B-T059
frequency	B-T081
both	O
within	B-T082
and	O
outside	B-T082
of	O
traditional	O
health care settings	B-T058
.	O
MSM	B-T098
enrolled	O
in	O
a	O
prospective cohort	B-T062
were	O
mailed	B-T073
at-home specimen collection kits	B-T074
and	O
followed	B-T079
for	O
a	O
year	B-T079
.	O
Incidence density rate ratios	B-T081
(	O
IDRR	B-T081
)	O
of	O
testing	B-T169
were	O
calculated	B-T052
,	O
and	O
generalized	B-T082
estimating	B-T081
equations	B-T077
were	O
used	O
to	O
analyze	O
the	O
association	B-T080
between	O
HIV testing	B-T059
and	O
behavioral	B-T053
factors	B-T169
.	O
The	O
incidence rate	B-T081
of	O
testing	B-T169
was	O
higher	B-T080
among	O
Black	B-T098
MSM	B-T098
than	O
White	B-T098
MSM	B-T098
(	O
IDRR	B-T081
:	O
1.3,	O
95%	O
confidence interval	B-T081
CI	B-T081
[1.1,	O
1.5])	O
and	O
higher	B-T080
among	O
MSM	B-T098
who	O
reported	O
3+	O
condomless	B-T033
condomless anal intercourse partners	B-T098
anal	B-T023
intercourse	O
partners	O
(	O
CAI	B-T098
)	O
than	O
MSM	B-T098
who	O
reported	O
no	B-T033
CAI	B-T098
(	O
IDRR	B-T081
:	O
1.6,	O
95%	O
CI	B-T081
[1.3,	O
2.0]).	O
Increasing	B-T169
availability of	B-T169
HIV testing	B-T059
outside	B-T082
traditional	O
health care settings	B-T058
,	O
including	O
at-home testing kits	B-T074
,	O
in	O
conjunction	B-T078
with	O
targeted	B-T169
behavioral	B-T053
interventions	B-T169
and	O
biomedical	B-T091
treatment preventions	B-T061
is	O
needed.	O

nursingstandard.com	B-T170
1	O
Nurse	B-T097
Donna	O
Wood	O
has	O
been	O
suspended	B-T169
for	O
2	O
months	B-T079
by	O
the	O
Nursing and Midwifery Council	B-T094
(	O
NMC	B-T094
)	O
for	O
concealing	B-T080
the	O
high temperature	B-T184
of	O
colleague	B-T097
Pauline	O
Cafferkey,	O
who	O
later	O
developed	O
Ebola	B-T047
.	O
Read	O
more:	O
rcni.com/donna-wood	B-T170
.	O

Theory of Mind	B-T078
in	O
Adolescents	B-T100
with	O
Bipolar Disorder	B-T048
in	O
Euthymic Phase	B-T048
:	O
‎Using	O
the	O
Strange Stories Test	B-T170
Objective:	O
This	O
study	O
evaluated	B-T058
the	O
theory of mind	B-T078
(	O
ToM	B-T078
)	O
in	O
adolescents	B-T100
diagnosed	B-T033
with	O
bipolar disorder	B-T048
‎‎(	O
BD	B-T048
)	O
during	O
their	O
euthymic period	B-T048
compared	O
to	O
a	O
typically developing (TD) group	B-T078
.‎	O
Method:	O
The	O
BD	B-T048
group	B-T078
consisted	O
of	O
thirty	O
11-18	O
year	O
old	O
inpatients	B-T101
in	O
euthymic phase	B-T048
.	O
The	O
TD ‎group	B-T078
included	O
30	O
age	B-T032
,	O
gender	B-T032
,	O
and	O
IQ	B-T032
matched	O
volunteer	O
students	B-T098
.	O
To	O
assess	O
the	O
diagnosis	B-T033
and	O
‎comorbid disorders	B-T047
,	O
we	O
performed	O
the	O
semi-structured interview	B-UnknownType
of	O
the	O
Kiddie Schedule for Affective Disorders ‎and Schizophrenia-Present and Lifetime Version	B-UnknownType
(	O
K-SADS-PL	B-UnknownType
)	O
for	O
the	O
BD	B-T048
adolescents	B-T100
.	O
To	O
‎evaluate	B-T058
the	O
severity	O
of	O
attention deficit hyperactivity disorder	B-T048
(	O
ADHD	B-T048
)	O
and	O
mania	B-T048
,	O
Conner's ‎Parent Rating Scale-Revised version (CPRS-R)	B-T081
,	O
and	O
Young Mania Rating Scale	B-T170
(	O
YMRS	B-T170
)	O
were	O
‎used,	O
respectively.	O
Ravens Progressive Matrices	B-T170
was	O
conducted	O
to	O
evaluate	B-T058
intellectual ability	B-T033
in	O
‎the	O
both	O
groups	B-T078
.	O
Happe Strange Stories test	B-T170
was	O
performed	O
to	O
assess	O
ToM	B-T078
in	O
the	O
participants	B-T098
.	O
Data	B-T078
were	O
‎analyzed	O
using	O
the	O
independent	O
t-test	B-T170
,	O
analysis of covariance	B-T081
,	O
and	O
Pearson Correlation analysis	B-T062
.‎	O
Results:	O
The	O
two	O
groups	B-T078
did	O
not	O
show	O
any	O
differences	O
in	O
comprehending	O
the	O
stories;	O
however,	O
the	O
BD	B-T048
‎	O
group's	B-T078
mentalizing scores	B-T053
were	O
significantly	O
weaker	O
than	O
the	O
TD group	B-T078
(p<0.05).‎‎	O
Conclusion:	O
The	O
ToM	B-T078
impairments	B-T169
in	O
adolescents	B-T100
with	O
BD	B-T048
may	O
be	O
explained	O
as	O
a	O
trait marker	B-T045
which	O
may	O
lead	O
‎to	O
continuation	O
of	O
social problems	B-T033
even	O
during	O
remission‏	B-T046
.‏.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
TYW3	B-T116
/	O
Taw3	B-T116
class	O
of	O
SAM-dependent methyltransferases	B-T116
S-adenosylmethionine (SAM)-dependent methyltransferases	B-T116
regulate	B-T038
a	O
wide	O
range	O
of	O
biological processes	B-T038
through	O
the	O
modification	B-T044
of	O
proteins	B-T116
,	O
nucleic acids	B-T114
,	O
polysaccharides	B-T109
,	O
as	O
well	O
as	O
various	O
metabolites	B-T123
.	O
TYW3	B-T116
/	O
Taw3	B-T116
is	O
a	O
SAM-dependent methyltransferase	B-T116
responsible	O
for	O
the	O
formation	O
of	O
a	O
tRNA modification	B-T045
known	O
as	O
wybutosine	B-T114
and	O
its	O
derivatives	O
that	O
are	O
required	O
for	O
accurate	O
decoding	B-T045
in	O
protein synthesis	B-T044
.	O
Here,	O
we	O
report	O
the	O
crystal structure	B-T026
of	O
Taw3	B-T116
,	O
a	O
homolog	O
of	O
TYW3	B-T116
from	O
Sulfolobus solfataricus	B-T194
,	O
which	O
revealed	O
a	O
novel	O
α/β fold	B-T044
.	O
The	O
sequence	O
motif	O
(	O
S/T)xSSCxGR	B-T087
and	O
invariant	O
aspartate	B-T116
and	O
histidine	B-T116
,	O
conserved	O
in	O
TYW3	B-T116
/	O
Taw3	B-T116
,	O
cluster	B-T081
to	O
form	O
the	O
catalytic	B-T067
center.	O
These	O
structural	B-T116
and	O
sequence	B-T087
features	O
indicate	O
that	O
TYW3	B-T116
/	O
Taw3	B-T116
proteins	O
constitute	O
a	O
distinct	O
class	O
of	O
SAM-dependent methyltransferases	B-T116
.	O
Using	O
site-directed mutagenesis	B-T045
along	O
with	O
in vivo complementation assays	B-T059
combined	O
with	O
mass spectrometry	B-T059
as	O
well	O
as	O
ligand docking	B-T044
and	O
cofactor binding	B-T044
assays	B-T059
,	O
we	O
have	O
identified	O
the	O
active site	B-T169
of	O
TYW3	B-T116
and	O
residues	O
essential	O
for	O
cofactor binding	B-T044
and	O
methyltransferase activity	B-T044
.	O

Developmental	B-T080
Profile	B-T059
and	O
Diagnoses	B-T062
in	O
Children	B-T100
Presenting	O
with	O
Motor Stereotypies	B-T033
Motor stereotypies	B-T033
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	B-T080
in	O
distinguishing	O
non-clinical behaviors	B-T053
(	O
physiological	B-T039
and	O
transient	B-T079
)	O
from	O
symptoms	B-T184
or	O
among	O
different	O
disorders	B-T047
["	O
primary stereotypies	B-T048
,"	O
associated with	B-T080
autistic spectrum disorder	B-T048
(	O
ASD	B-T048
),	O
intellectual disabilities	B-T048
,	O
genetic syndromes	B-T047
,	O
and	O
sensory impairment	B-T033
].	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
obtain	B-T169
an	O
accurate	O
assessment	B-T058
on	O
the	O
relationship	B-T080
between	O
stereotypies	B-T048
and	O
neurodevelopmental disorders	B-T048
.	O
We	O
studied	B-T062
23	O
children	B-T100
(3	O
girls	B-T100
),	O
aged	B-T032
36-95	O
months	B-T079
,	O
who	O
requested	O
a	O
consultation	B-T058
due	O
to	O
the	O
persistence	B-T033
or	O
increased	B-T081
severity	B-T080
of	O
motor stereotypies	B-T033
.	O
None	O
of	O
the	O
patients	B-T101
had	O
a	O
previous	O
diagnosis	B-T062
of	O
ASD	B-T048
.	O
The	O
assessment	B-T058
included	O
the	O
Motor Severity Stereotypy Scale	B-T170
(	O
MSSS	B-T170
),	O
the	O
Repetitive Behavior Scale-Revised	B-T170
(	O
RBS-R	B-T170
),	O
the	O
Raven's Colored Progressive Matrices	B-T033
,	O
the	O
Child Behavior CheckList	B-T060
for	O
ages	B-T032
1½-5	O
or	O
4-18	O
(	O
CBCL	B-T060
),	O
the	O
Social Responsiveness Scale	B-T170
(SRS)	B-T170
,	O
and	O
the	O
Autism Diagnostic Observation Schedule-second edition	B-T170
(	O
ADOS 2	B-T170
).	O
All	O
patients	B-T101
were	O
showing	O
motor stereotypies	B-T033
for	O
periods of time	B-T079
varying	O
from	O
6	O
to	O
77	O
months	B-T079
.	O
The	O
MSSS	B-T170
showed	O
that	O
each	O
child	B-T100
had	O
a	O
limited	B-T169
number	B-T081
of	O
stereotypies	B-T048
;	O
their	O
frequency	B-T081
and	O
intensity	B-T080
were	O
mild	B-T080
.	O
The	O
interference	B-T169
of	O
stereotypies	B-T048
was	O
variable	B-T080
;	O
the	O
impairment	B-T169
in	O
daily	O
life	B-T078
was	O
mild	B-T080
.	O
The	O
RBS-R	B-T170
scores	B-T081
were	O
positive	O
for	O
the	O
subscale	O
of	O
"	O
stereotypic behaviors	B-T048
"	O
in	O
all	O
children	B-T100
.	O
Moreover,	O
several	O
children	B-T100
presented	O
other	O
repetitive behaviors	B-T033
,	O
mainly	O
"	O
ritualistic behavior	B-T184
"	O
and	O
"	O
sameness behavior	B-T033
."	O
All	O
patients	B-T101
showed	O
a	O
normal cognitive level	B-T033
.	O
The	O
CBCL	B-T060
evidenced	B-T078
behavioral problems	B-T048
in	O
22%	O
of	O
the	O
children	B-T100
:	O
internalizing problems	B-T184
,	O
attention	B-T041
,	O
and	O
withdrawn	B-T048
were	O
the	O
main	O
complaints.	O
On	O
the	O
SRS	B-T170
,	O
all	O
but	O
one	O
of	O
the	O
tested	B-T169
patients	B-T101
obtained	B-T169
clinical scores	B-T033
in	O
the	O
clinical	B-T080
range	B-T081
for	O
at	O
least	O
one	O
area.	O
On	O
the	O
ADOS 2	B-T170
,	O
4	O
patients	B-T101
obtained	B-T169
scores	B-T081
indicating	O
a	O
moderate	B-T080
level	B-T080
of	O
ASD	B-T048
symptoms	B-T184
,	O
4	O
had	O
a	O
mild	B-T080
level	B-T080
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	B-T184
of	O
ASD	B-T048
.	O
Motor stereotypies	B-T033
in	O
children	B-T100
with	O
normal cognitive level	B-T033
represent	O
a	O
challenging	O
diagnostic	B-T169
issue	B-T033
for	O
which	O
a	O
finely	O
tailored	B-T170
assessment	B-T058
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	B-T080
profile	B-T169
.	O
Thus,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized tests	B-T170
is	O
warranted	O
to	O
avoid	O
misdiagnosis	B-T033
.	O
Furthermore,	O
it	O
is	O
hard	O
to	O
consider	O
motor stereotypies	B-T033
,	O
even	O
the	O
primary	O
ones,	O
exclusively	O
as	O
a	O
movement disorder	B-T047
.	O

Left ventricular	B-T023
rotational	B-T082
mechanics	B-T070
in	O
infants	B-T100
with	O
hypoxic ischemic encephalopathy	B-T047
and	O
preterm infants	B-T100
at	O
36	O
weeks	B-T079
postmenstrual age	B-T032
:	O
A	O
comparison	B-T052
with	O
healthy	B-T080
term controls	B-T096
There	O
is	O
a	O
paucity	O
of	O
data	B-T078
on	O
left ventricle	B-T023
(	O
LV	B-T023
)	O
rotational physiology	B-T091
in	O
neonates	B-T100
.	O
We	O
aimed	O
to	O
assess	O
rotational	B-T082
mechanics	B-T070
in	O
infants	B-T100
with	O
hypoxic ischemic encephalopathy	B-T047
(	O
HIE	B-T047
)	O
and	O
premature infants	B-T100
(<32	O
weeks	B-T079
)	O
at	O
36	O
weeks	B-T079
postmenstrual age	B-T032
(	O
PMA	B-T032
)	O
(	O
preterm group	B-T098
)	O
and	O
compare	B-T052
them	O
with	O
healthy	B-T080
term controls	B-T096
(	O
term controls	B-T096
).	O
We	O
also	O
compared	B-T052
the	O
parameters	B-T077
in	O
preterm infants	B-T100
with	O
and	O
without	O
chronic lung disease	B-T047
(	O
CLD	B-T047
).	O
Echocardiography	B-T060
was	O
performed	O
within	O
48	O
hours	B-T079
of	O
birth	B-T040
or	O
at	O
36	O
weeks	B-T079
PMA	B-T032
.	O
LV	B-T023
basal	B-T082
and	O
apical	O
rotation	B-T169
,	O
twist	B-T082
(and	O
torsion	O
=	O
twist	B-T082
/	O
LV length	B-T081
),	O
twist rate	B-T081
(	O
LVTR	B-T081
),	O
and	O
untwist rate	B-T081
(	O
LVUTR	B-T081
)	O
were	O
measured.	O
One-way ANOVA	B-T081
was	O
used	O
to	O
compare	B-T052
values	B-T080
.	O
There	O
was	O
no	O
difference	O
in	O
gestation	B-T040
(40.0	O
[39.1-40.3]	O
vs	O
39.9	O
[39.0-40.9],	O
P>.05)	O
or	O
birthweight	B-T032
(3.7	O
[3.4-4.1]	O
vs	O
3.5	O
[3.2-3.9],	O
P>.05)	O
between	O
the	O
HIE	B-T047
group	B-T098
(n=16)	O
and	O
term controls	B-T096
(n=30).	O
The	O
preterm group	B-T098
(n=35)	O
had	O
a	O
gestation	B-T040
and	O
weight	B-T081
of	O
36.0	O
[34.6-36.3]	O
weeks	B-T079
and	O
2.3	O
[2.0-2.4]	O
kg.	O
The	O
HIE	B-T047
group	O
had	O
lower	O
twist	B-T082
,	O
torsion,	O
LVTR	B-T081
,	O
and	O
LVUTR	B-T081
than	O
the	O
other	O
two	O
groups.	O
The	O
preterm group	B-T098
had	O
a	O
more	O
negative	O
(	O
clockwise	B-T169
)	O
basal	B-T082
rotation	B-T169
while	O
the	O
term group	B-T098
had	O
a	O
more	O
positive	O
(	O
counterclockwise	B-T169
)	O
apical	B-T082
rotation	B-T169
.	O
Preterm infants	B-T100
with	O
CLD	B-T047
had	O
higher	O
apical	B-T082
rotation	B-T169
,	O
twist	B-T082
,	O
and	O
torsion	O
when	O
compared	B-T052
to	O
infants	B-T100
without	O
CLD	B-T047
.	O
Infants	B-T100
with	O
HIE	B-T047
have	O
reduced	O
rotational	B-T082
mechanics	B-T070
.	O
Preterm infants	B-T100
at	O
36	O
weeks	B-T079
PMA	B-T032
have	O
comparable	B-T052
measurements	B-T169
of	O
twist	B-T082
to	O
term infants	B-T100
.	O
This	O
is	O
achieved	O
by	O
predominant	O
basal	B-T082
basal	B-T082
rather	O
than	O
apical	B-T082
rotation	B-T169
.	O
Infants	B-T100
with	O
CLD	B-T047
have	O
increased	O
apical	B-T082
rotation	B-T169
.	O

Comparing	B-T052
the	O
effects of	B-T080
different	B-T080
dynamic sitting strategies	B-T061
in	O
wheelchair seating	B-T074
on	O
lumbar-pelvic angle	B-T029
Prolonged	B-T079
static sitting	B-T033
in	O
a	O
wheelchair	B-T074
is	O
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
of	O
lower back pain	B-T184
.	O
The	O
wheelchair seating system	B-T074
is	O
a	O
key factor	B-T169
of	O
this	O
risk	B-T078
because	O
it	O
affects	O
spinal	B-T082
loading	B-T169
in	O
the	O
sitting position	B-T033
.	O
In	O
this	O
study	B-T062
,	O
7	O
dynamic sitting strategies	B-T061
(	O
DSSs	B-T061
)	O
are	O
examined	B-T033
:	O
lumbar prominent dynamic sitting	B-T061
(	O
LPDS	B-T061
),	O
back reclined dynamic sitting	B-T061
(	O
BRDS	B-T061
),	O
femur upward dynamic sitting	B-T061
(	O
FUDS	B-T061
),	O
lumbar prominent with back reclined dynamic sitting	B-T061
(	O
LBDS	B-T061
),	O
lumbar prominent with femur upward dynamic sitting	B-T061
(	O
LFDS	B-T061
),	O
back reclined with femur upward dynamic sitting	B-T061
(	O
BFDS	B-T061
),	O
and	O
lumbar prominent with back reclined with femur upward dynamic sitting	B-T061
(	O
LBFDS	B-T061
).	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
analyze	B-T062
the	O
biomechanical	B-T070
effects of	B-T080
these	O
sitting strategies	B-T061
on	O
lumbar-pelvic angles	B-T029
.	O
Twenty	O
able-bodied	B-T033
participants	B-T098
were	O
recruited	B-T169
for	O
the	O
study	B-T062
.	O
All	O
participants	B-T098
performed	B-T169
LPDS	B-T061
,	O
BRDS	B-T061
,	O
FUDS	B-T061
,	O
LBDS	B-T061
,	O
LFDS	B-T061
,	O
BFDS	B-T061
,	O
and	O
LBFDS	B-T061
in	O
a	O
random	B-T080
order	B-T080
.	O
All	O
lumbar-pelvic angle	B-T029
parameters	B-T077
,	O
including	O
the	O
static	B-T080
lumbar angle	B-T029
,	O
static	B-T080
pelvic angle	B-T023
,	O
lumbar range of motion	B-T033
,	O
and	O
pelvic range of motion	B-T033
were	O
measured	B-T080
and	O
compared	B-T052
.	O
Results	B-T169
show	O
that	O
LBDS	B-T061
and	O
LBFDS	B-T061
enabled	B-T041
the	O
most	O
beneficial	B-T080
lumbar movements	B-T201
,	O
although	O
the	O
difference	B-T080
between	O
the	O
2	O
strategies	B-T041
was	O
nonsignificant	B-T033
.	O
BRDS	B-T061
and	O
BFDS	B-T061
enabled	B-T041
the	O
most	O
beneficial	B-T080
pelvic movements	B-T061
,	O
although	O
the	O
difference	B-T080
between	O
the	O
2	O
strategies	B-T041
was	O
nonsignificant	B-T033
.	O
Among	O
all	O
the	O
upright	O
DSSs	B-T061
,	O
LPDS	B-T061
and	O
LFDS	B-T061
enabled	B-T041
the	O
most	O
beneficial	B-T080
lumbar	B-T201
and	O
pelvic movements	B-T061
,	O
although	O
no significant	B-T033
difference	B-T080
was	O
observed	B-T169
between	O
these	O
2	O
strategies	B-T041
.	O
We	O
identified	B-T080
the	O
effects	B-T080
and	O
differences	B-T080
among	O
7	O
DSSs	B-T061
on	O
lumbar-pelvic angles	B-T029
.	O
Wheelchair users	B-T101
can	O
choose	B-T052
the	O
most	O
suitable	B-T080
DSS	B-T061
that	O
meets	B-T067
their	O
needs	B-T080
.	O
These	O
findings	B-T033
may	O
serve	O
as	O
a	O
reference	B-T077
for	O
practicing physicians	B-T097
or	O
wheelchair users	B-T101
to	O
choose	B-T052
an	O
appropriate	B-T080
dynamic	O
wheelchair seating	B-T074
system.	O
ISRCTN12389808,	O
18th	O
November	O
2016,	O
retrospectively	O
registered.	O

Source	O
apportionment	O
and	O
heavy metal	B-T196
health risk	B-T061
(	O
HMHR	B-T061
)	O
quantification	B-T081
from	O
sources	B-T033
in	O
a	O
southern	B-T082
city	B-T083
in	O
China	B-T083
,	O
using	O
an	O
ME2	B-T073
-	O
HMHR	B-T061
model	B-T170
Heavy metals	B-T196
(	O
Cr	B-T131
,	O
Co	B-T123
,	O
Ni	B-T123
,	O
As	B-T121
,	O
Cd	B-T131
,	O
and	O
Pb	B-T131
)	O
can	O
be	O
bound	O
to	O
PM	B-T167
adversely affecting	B-T046
human	B-T016
health	B-T078
.	O
Quantifying	O
the	O
source	B-T033
impacts	O
on	O
heavy metals	B-T196
can	O
provide	O
source	B-T033
-	O
specific	B-T080
estimates	O
of	O
the	O
heavy metal	B-T196
health risk	B-T061
(	O
HMHR	B-T061
)	O
to	O
guide	O
effective	B-T080
development	O
of	O
strategies	O
to	O
reduce	O
such	O
risks	B-T078
from	O
exposure to	B-T080
heavy metals	B-T196
in	O
PM2.5	B-T167
(	O
particulate matter	B-T167
(	O
PM	B-T167
)	O
with	O
aerodynamic diameter	B-T081
less	O
than	O
or	O
equal	O
to	O
2.5	O
μm).	O
In	O
this	O
study,	O
a	O
method	O
combining	O
Multilinear Engine 2	B-T073
(	O
ME2	B-T073
)	O
and	O
a	O
risk assessment	B-T058
model	B-T170
is	O
developed	O
to	O
more	O
effectively	O
quantify	B-T081
source	B-T033
contributions	B-T052
to	O
HMHR	B-T061
,	O
including	O
heavy metal	B-T196
non-cancer risk	B-T033
(	O
non-HMCR	B-T033
)	O
and	O
cancer risk	B-T081
(	O
HMCR	B-T081
).	O
The	O
combined	O
model	B-T170
(called	O
ME2-HMHR	B-T170
)	O
has	O
two	O
steps:	O
step1,	O
source	B-T033
contributions	B-T052
to	O
heavy metals	B-T196
are	O
estimated	O
by	O
employing	O
the	O
ME2	B-T073
model	B-T170
;	O
step2,	O
the	O
source	B-T033
contributions	B-T052
in	O
step	O
1	O
are	O
introduced	O
into	O
the	O
risk assessment	B-T058
model	B-T170
to	O
calculate	O
the	O
source	B-T033
contributions	B-T052
to	O
HMHR	B-T061
.	O
The	O
approach	O
was	O
applied	O
to	O
Huzou	B-T083
,	O
China	B-T083
and	O
five	O
significant	O
sources	B-T033
were	O
identified.	O
Soil	B-T167
dust	B-T167
is	O
the	O
largest	O
source	B-T033
of	O
non-HMCR	B-T033
.	O
For	O
HMCR	B-T081
,	O
the	O
source	B-T033
contributions	B-T052
of	O
soil	B-T167
dust	B-T167
,	O
coal	B-T109
combustion	B-T073
,	O
cement dust	B-T033
dust	B-T167
,	O
vehicle	B-T131
,	O
and	O
secondary	O
sources	B-T033
are	O
1.0	O
×	O
10(-4),	O
3.7	O
×	O
10(-5),	O
2.7	O
×	O
10(-6),	O
1.6	O
×	O
10(-6)	O
and	O
1.9	O
×	O
10(-9),	O
respectively.	O
The	O
soil	B-T167
dust	B-T167
is	O
the	O
largest	O
contributor	B-T052
to	O
HMCR	B-T081
,	O
being	O
driven	O
by	O
the	O
high	O
impact	B-T080
of	O
soil	B-T167
dust	B-T167
on	O
PM2.5	B-T167
and	O
the	O
abundance	B-T080
of	O
heavy metals	B-T196
in	O
soil	B-T167
dust	B-T167
.	O

Aspirin	B-T109
Suppresses	B-T169
Growth	B-T040
in	O
PI3K	B-T028
-	O
Mutant	B-T028
Breast Cancer	B-T191
by	O
Activating	B-T045
AMPK	B-T116
and	O
Inhibiting	B-T052
mTORC1	B-T116
Signaling	O
Despite	O
the	O
high	O
incidence	B-T081
of	O
oncogenic	B-T028
mutations	B-T045
in	O
PIK3CA	B-T028
,	O
the	O
gene encoding	B-T028
the	O
catalytic subunit	B-T087
of	O
PI3K	B-T116
,	O
PI3K	B-T116
inhibitors	B-T121
have	O
yielded	O
little	O
clinical benefit	B-T033
for	O
breast cancer	B-T191
patients	B-T101
.	O
Recent	B-T079
epidemiologic studies	B-T062
have	O
suggested	B-T078
a	O
therapeutic	B-T169
benefit	B-T081
from	O
aspirin	B-T109
intake	O
in	O
cancers	B-T191
harboring	O
oncogenic PIK3CA	B-T116
Here,	O
we	O
show	O
that	O
mutant	B-T028
PIK3CA	B-T116
-	O
expressing	B-T045
breast cancer cells	B-T025
have	O
greater	O
sensitivity	B-T169
to	O
aspirin	B-T109
-mediated	O
growth	B-T043
suppression	B-T043
than	O
their	O
wild-type	B-T028
counterparts.	O
Aspirin	B-T109
decreased	B-T081
viability	B-T043
and	O
anchorage-independent growth	B-T059
of	O
mutant	B-T028
PIK3CA	B-T116
breast cancer cells	B-T025
independently	B-T033
of	O
its	O
effects	B-T080
on	O
COX-2	B-T116
and	O
NF-κB	B-T116
.	O
We	O
ascribed	O
the	O
effects of	B-T080
aspirin	B-T109
to	O
AMP-activated protein kinase	B-T116
(	O
AMPK	B-T116
)	O
activation	B-T045
,	O
mTORC1	B-T116
inhibition	B-T043
,	O
and	O
autophagy	B-T043
induction.	O
In	O
vivo,	O
oncogenic	B-T028
PIK3CA	B-T116
-driven	O
mouse	B-T015
mammary tumors	B-T191
treated	B-T169
daily	O
with	O
aspirin	B-T109
resulted	O
in	O
decreased	B-T081
tumor growth	B-T191
kinetics	B-T070
,	O
whereas	O
combination	B-T080
therapy	B-T061
of	O
aspirin	B-T109
and	O
a	O
PI3K	B-T116
inhibitor	B-T080
further	O
attenuated	B-T052
tumor growth	B-T191
.	O
Our	O
study	O
supports	O
the	O
evaluation	B-T058
of	O
aspirin	B-T109
and	O
PI3K	B-T116
pathway	O
inhibitors	B-T121
as	O
a	O
combination	B-T080
therapy	B-T061
for	O
targeting	B-T169
breast cancer	B-T191
.	O
Cancer	O
Res;	O
77(3);	O
790-801.	O
©2016	O
AACR.	O

Prevalence	B-T081
of	O
Psychiatric Disorders	B-T048
among	O
Female	B-T032
Juvenile Offenders	B-T098
Inmates	B-T098
of	O
Juvenile Developmental Centers	B-T093
are	O
the	O
special	B-T080
group	B-T098
of	O
youth	B-T100
population	B-T098
who	O
are	O
in	O
conflict	B-T055
with	O
law	B-T089
.	O
They	O
are	O
vulnerable	B-T169
to	O
psychiatric illness	B-T048
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
see	O
the	O
prevalence	B-T081
and	O
type	B-T080
of	O
psychiatric disorders	B-T048
in	O
institutionalized	B-T033
female	B-T032
juvenile offenders	B-T098
and	O
non-offenders	B-T098
of	O
same	B-T080
age	B-T032
,	O
sex	B-T032
and	O
socioeconomic group	B-T080
in	O
the	O
community	B-T096
.	O
The	O
association	B-T041
of	O
mental disorders	B-T048
was	O
examined	B-T033
in	O
43	O
female	B-T032
inmates	B-T098
of	O
Juvenile Development Centers	B-T093
and	O
43	O
randomly	B-T080
selected	B-T052
comparison	B-T052
subjects	B-T096
in	O
community	B-T096
.	O
One stage-structured assessment	B-T058
of	O
psychopathology	B-T091
was	O
carried	O
out	O
by	O
using	O
a	O
structured	B-T169
and	O
valid	B-T080
Bangla	B-T171
version	B-T170
of	O
the	O
Development and Well-Being Assessment	B-T058
(	O
DAWBA	B-T058
).	O
Development and Well-Being Assessment	B-T058
generated	O
psychiatric	B-T169
diagnosis	B-T033
was	O
assigned	O
based	O
on	O
ICD-10	B-T170
diagnostic criteria	B-T170
for	O
research	B-T062
.	O
The	O
result	B-T033
revealed	B-T080
that,	O
of	O
those	O
who	O
were	O
in	O
conflict	B-T055
with	O
law	B-T089
,	O
93%	O
had	O
mental disorder	B-T048
,	O
whereas	O
14%	O
of	O
non-offenders	B-T098
had	O
psychiatric disorder	B-T048
.	O
Among	O
the	O
offenders	B-T098
with	O
psychiatric disorders	B-T048
,	O
most	O
of	O
them	O
(32.6%)	O
suffered	O
from	O
Major Depressive Disorder	B-T048
(	O
MDD	B-T048
),	O
followed	O
by	O
combined	B-T080
MDD	B-T048
&	O
Post Traumatic Stress Disorder	B-T048
(	O
PTSD	B-T048
).	O
On	O
the	O
other	O
hand,	O
among	O
the	O
non-offenders	B-T098
with	O
psychiatric disorder	B-T048
9.3%	O
suffered	O
from	O
MDD	B-T048
.	O
It	O
can	O
be	O
concluded	B-T078
that	O
considerable	B-T080
psychiatric disorders	B-T048
are	O
prevalent	B-T081
among	O
the	O
female	B-T032
juvenile offenders	B-T098
with	O
comparison	B-T052
to	O
non-offenders	B-T098
.	O
Broad	B-T082
-based	O
replication study	B-UnknownType
could	O
confirm	B-T080
these	O
findings	B-T033
.	O

Association	B-T080
between	O
neutrophil	B-T025
-to-	O
lymphocyte	B-T025
ratio	B-T081
and	O
differentiated thyroid cancer	B-T191
:	O
a	O
meta-analysis	B-T062
The	O
association	B-T080
between	O
neutrophil	B-T025
-to-	O
lymphocyte	B-T025
ratio	B-T081
(	O
NLR	B-T081
)	O
and	O
differentiated thyroid cancer	B-T191
(	O
DTC	B-T191
)	O
is	O
undecided.	O
To	O
rectify	O
this	O
question,	O
we	O
conducted	B-T169
a	O
systematic	B-T169
meta-analysis	B-T062
based	O
on	O
7	O
prospective cohort studies	B-T062
published	B-T170
between	O
2013	O
and	O
2015,	O
comprising	O
7349	O
patients	B-T101
.	O
Six	O
of	O
these	O
cohorts	B-T098
included	O
pretreatment	B-T052
(	O
baseline	B-T081
)	O
NLR	B-T081
data	B-T078
for	O
patients	B-T101
with	O
thyroid nodules	B-T191
.	O
The	O
meta-analysis	B-T062
of	O
these	O
6	O
cohorts	B-T098
showed	O
that	O
the	O
NLR	B-T081
of	O
patients	B-T101
with	O
DTC	B-T191
(4617	O
cases	B-T077
)	O
was	O
statistically	B-T081
similar	O
to	O
patients	B-T101
with	O
benign nodules	B-T191
only	O
(1666	O
cases	B-T077
),	O
with	O
a	O
mean	O
difference	O
(MD)	O
of	O
0.19	O
(95%	O
CI	B-T081
:	O
-0.09	O
to	O
0.46;	O
I(2)	O
=	O
93%;	O
P	B-T081
<	O
0.001).	O
No	O
significant	O
difference	O
in	O
NLR	B-T081
was	O
found	O
between	O
patients	B-T101
with	O
DTC	B-T191
and	O
patients	B-T101
with	O
benign nodules	B-T191
.	O
Two	O
studies	B-T059
addressed	O
an	O
association	B-T080
between	O
NLR	B-T081
and	O
papillary thyroid carcinoma	B-T191
in	O
patients	B-T101
stratified	B-T080
by	O
age	B-T032
<45	O
and	O
≥45	O
years	B-T079
(496	O
and	O
891	O
cases	B-T077
,	O
respectively);	O
the	O
pooled	O
MD	O
was	O
0.09	O
(95%	O
CI	B-T081
:	O
-0.37	O
to	O
0.55;	O
I(2)	O
=	O
92.2%,	O
P	B-T081
<	O
0.001).	O
An	O
elevated	B-T080
NLR	B-T081
seems	O
not	O
a	O
reliable	B-T170
indicator	B-T169
of	O
progressing	B-T169
DTC	B-T191
in	O
patients	B-T101
with	O
goiters	B-T046
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
NLR	B-T081
between	O
patients	B-T101
aged	B-T032
<45	O
years	B-T079
and	O
those	O
aged	B-T032
≥45	O
years	B-T079
.	O
Well-designed	O
and	O
large-scale	O
investigations	B-T058
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
NLR	B-T081
in	O
the	O
prognosis	B-T033
of	O
DTC	B-T191
.	O

Transcriptomic	B-T086
insights	O
into	O
the	O
allelopathic	B-T070
effects of	B-T080
the	O
garlic	B-T168
allelochemical	B-T103
diallyl disulfide	B-T109
on	O
tomato	B-T168
roots	B-T002
Garlic	B-T168
is	O
an	O
allelopathic	B-T070
crop	B-T002
that	O
can	O
alleviate	O
the	O
obstacles	O
to	O
continuous	B-T078
cropping	B-T090
of	O
vegetable crops	B-T002
.	O
Diallyl disulfide	B-T109
(	O
DADS	B-T109
),	O
one	O
of	O
the	O
most	O
important	O
allelochemicals	B-T103
in	O
garlic	B-T168
,	O
promotes	B-T052
tomato	B-T168
root growth	B-T040
.	O
Therefore,	O
the	O
global	B-T080
transcriptome	B-T086
profiles	B-T081
of	O
DADS	B-T109
-	O
treated	B-T169
tomato	B-T168
roots	B-T002
over	O
time	O
were	O
investigated	B-T169
to	O
reveal	O
the	O
potential	B-T080
growth-promoting mechanisms	B-UnknownType
.	O
We	O
detected	B-T033
1828,	O
1296	O
and	O
1190	O
differentially expressed	B-T045
genes	B-T028
(	O
DEGs	B-T028
)	O
in	O
the	O
4,	O
24	O
and	O
48	O
h	O
samples,	O
respectively.	O
Most	O
DEGs	B-T028
involved	O
in	O
assimilatory sulfate reduction	B-T044
and	O
glutathione metabolism	B-T044
were	O
up-regulated	B-T044
after	O
short-term	B-T079
(4	O
h)	O
DADS	B-T109
treatment	B-T169
.	O
In	O
addition,	O
increased activity of defensive enzymes	B-T033
and	O
up-regulation	B-T044
of	O
six	O
peroxidase genes	B-T028
were	O
observed	B-T169
,	O
suggesting	O
that	O
DADS	B-T109
could	O
induce	B-T169
tomato	B-T168
resistance	B-T169
.	O
In	O
plant-pathogen interactions	B-T040
,	O
DEGs	B-T028
related	O
to	O
calcium signaling	B-T043
were	O
primarily	O
inhibited	B-T080
,	O
while	O
those	O
encoding	B-T052
pathogenesis-related proteins	B-T116
were	O
primarily	O
up-regulated	B-T044
.	O
Although	O
plant	B-T002
hormone synthesis	B-T044
and	O
signal transduction	B-T043
were	O
both	O
significantly affected	B-T169
by	O
DADS	B-T109
,	O
the	O
expression	B-T045
trends	B-T079
of	O
the	O
genes	B-T028
in	O
these	O
two	O
pathways	B-T044
were	O
conflicting.	O
This	O
research	B-T062
provides	O
comprehensive	B-T080
information	B-T078
concerning	O
the	O
changes	B-T169
in	O
the	O
tomato	B-T168
root	B-T002
transcriptome	B-T086
affected	B-T169
by	O
DADS	B-T109
and	O
may	O
help	O
direct	O
further	O
studies	B-T062
on	O
DADS	B-T109
-	O
responsive	B-T169
genes	B-T028
to	O
enhance	B-T052
the	O
current	B-T079
understanding	O
of	O
the	O
mechanisms	B-T044
by	O
which	O
DADS	B-T109
alleviates	O
the	O
obstacles	O
to	O
continuous	B-T078
cropping	B-T090
.	O

Mitotic	B-T080
phosphotyrosine	B-T116
network analysis	B-T170
reveals	O
that	O
tyrosine phosphorylation	B-T044
regulates	O
Polo-like kinase 1	B-T116
(	O
PLK1	B-T116
)	O
Tyrosine phosphorylation	B-T044
is	O
closely	O
associated with	B-T080
cell proliferation	B-T043
.	O
During	O
the	O
cell cycle	B-T043
,	O
serine and threonine phosphorylation	B-T044
plays	O
the	O
leading	O
role,	O
and	O
such	O
phosphorylation	B-T044
events	O
are	O
most	O
dynamic	B-T169
during	O
the	O
mitotic phase	B-T043
of	O
the	O
cell cycle	B-T043
.	O
However,	O
mitotic	B-T080
phosphotyrosine	B-T116
is	O
not	O
well	O
characterized.	O
Although	O
a	O
few	O
functionally	B-T169
-	O
relevant	B-T080
mitotic	B-T080
phosphotyrosine	B-T116
sites	B-T082
have	O
been	O
characterized	B-T052
,	O
evidence	O
suggests	O
that	O
this	O
modification	B-T169
may	O
be	O
more	O
prevalent	B-T081
than	O
previously	O
appreciated.	O
Here,	O
we	O
examined	B-T033
tyrosine phosphorylation	B-T044
in	O
mitotic human cells	B-T025
including	O
those	O
on	O
spindle-associated proteins	B-T116
.?	O
Database mining	B-T066
confirmed	O
~2000	O
mitotic	B-T080
phosphotyrosine	B-T116
sites	B-T082
,	O
and	O
network analysis	B-T170
revealed	O
a	O
number	O
of	O
subnetworks	O
that	O
were	O
enriched	O
in	O
tyrosine-phosphorylated proteins	B-T116
,	O
including	O
components	O
of	O
the	O
kinetochore	B-T026
or	O
spindle	B-T026
and	O
SRC family kinases	B-T116
.	O
We	O
identified	O
Polo-like kinase 1	B-T116
(	O
PLK1	B-T116
),	O
a	O
major	O
signaling	B-T038
hub	O
in	O
the	O
spindle	B-T026
subnetwork	B-T169
,	O
as	O
phosphorylated	B-T116
at	O
the	O
conserved	O
Tyr(217)	B-T116
in	O
the	O
kinase domain	B-T087
.	O
Substitution	B-T045
of	O
Tyr(217)	B-T116
with	O
a	O
phosphomimetic residue	B-T104
eliminated	O
PLK1	B-T116
activity	B-T044
in vitro	B-T080
and	O
in	O
cells	B-T025
.	O
Further	O
analysis	B-T062
showed	O
that	O
Tyr(217)	B-T116
phosphorylation	B-T044
reduced	O
the	O
phosphorylation of Thr(210)	B-T044
in	O
the	O
activation loop	B-T082
,	O
a	O
phosphorylation	B-T044
event	O
necessary	O
for	O
PLK1	B-T116
activity	B-T044
.	O
Our	O
data	O
indicate	O
that	O
mitotic	B-T080
tyrosine phosphorylation	B-T044
regulated	O
a	O
key	O
serine/threonine kinase	B-T116
hub	O
in	O
mitotic cells	B-T025
and	O
suggested	O
that	O
spatially	O
separating	O
tyrosine phosphorylation	B-T044
events	O
can	O
reveal	O
previously	O
unrecognized	B-T080
regulatory events	B-T169
and	O
complexes	B-T080
associated	O
with	O
specific	O
structures	B-T026
of	O
the	O
cell cycle	B-T043
.	O

Divided	B-T169
and	O
Sliding	B-T169
Superficial Temporal Artery	B-T023
Flap	B-T023
for	O
Primary	B-T080
Donor-site	B-T029
Closure	B-T061
Superficial temporal artery	B-T023
(	O
STA	B-T023
)	O
flaps	B-T023
are	O
often	O
used	O
for	O
reconstruction	B-T061
of	O
hair-bearing areas	B-T029
.	O
However,	O
primary closure	B-T061
of	O
the	O
donor site	B-T029
is	O
not	O
easy	O
when	O
the	O
size	B-T082
of	O
the	O
necessary	O
skin island	B-T022
is	O
relatively	O
large	B-T081
.	O
In	O
such	O
cases,	O
skin grafts	B-T023
are	O
needed	O
at	O
the	O
donor site	B-T029
,	O
resulting	O
in	O
baldness	B-T047
.	O
We	O
have	O
solved	O
this	O
issue	O
by	O
applying	O
the	O
divided	B-T169
and	O
sliding	B-T169
flap	B-T023
technique	B-T169
,	O
which	O
was	O
first	O
reported	O
for	O
primary donor-site closure	B-T061
of	O
a	O
latissimus dorsi musculocutaneous	B-T023
flap	B-T023
.	O
We	O
applied	O
this	O
technique	B-T169
to	O
the	O
hair-bearing STA	B-T023
flap	B-T023
,	O
where	O
primary donor-site closure	B-T061
is	O
extremely	O
beneficial	O
for	O
preventing	B-T080
baldness	B-T047
consequent	O
to	O
skin grafting	B-T061
.	O
The	O
STA	B-T023
flap	B-T023
was	O
divided	B-T169
into	O
3,	O
and	O
creation	B-T052
of	O
large	O
flap	B-T023
was	O
possible.	O
Therefore,	O
we	O
concluded	O
that	O
the	O
divided	B-T169
and	O
sliding	B-T169
STA	B-T023
flap	B-T023
could	O
at	O
least	O
partially	O
solve	O
the	O
donor-site	B-T029
problem	B-T033
.	O
Although	O
further	O
investigation	B-T058
is	O
necessary	O
to	O
validate	B-T062
the	O
maximum	B-T081
possible	B-T033
flap	B-T023
size	B-T082
,	O
this	O
technique	B-T169
may	O
be	O
applicable	O
to	O
at	O
least	O
small	B-T081
defects	B-T169
that	O
are	O
common	O
after	O
skin cancer	B-T191
ablation	B-T061
or	O
trauma	B-T037
.	O

Influence	B-T077
of	O
Surface Properties	B-T070
on	O
Adhesion Forces	B-T067
and	O
Attachment	B-T052
of	O
Streptococcus mutans	B-T007
to	O
Zirconia	B-T121
In Vitro	B-T080
Zirconia	B-T121
is	O
becoming	O
a	O
prevalent material	B-T167
in	O
dentistry	B-T091
.	O
However,	O
any	O
foreign bodies	B-T037
inserted	B-T058
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	B-T007
in	O
oral cavity	B-T030
.	O
The	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	B-T080
of	O
surface properties	B-T070
including	O
surface roughness	B-T033
and	O
hydrophobicity	B-T080
on	O
the	O
adhesion	B-T070
and	O
biofilm formation	B-T043
of	O
Streptococcus mutans	B-T007
(	O
S. mutans	B-T007
)	O
to	O
zirconia	B-T121
.	O
Atomic force microscopy	B-T059
was	O
employed	O
to	O
determine	O
the	O
zirconia	B-T121
surface	B-T082
morphology	B-T080
and	O
the	O
adhesion forces	B-T067
between	O
the	O
S. mutans	B-T007
and	O
zirconia	B-T121
.	O
The	O
results	B-T169
showed	O
that	O
the	O
surface roughness	B-T033
was	O
nanoscale	B-T081
and	O
significantly	O
different	B-T080
among	O
tested groups	B-T078
(P	O
<	O
0.05):	O
Coarse	B-T080
(23.94	O
±	O
2.52	O
nm)	O
>	O
Medium	B-T081
(17.00	O
±	O
3.81	O
nm)	O
>	O
Fine	B-T080
(11.89	O
±	O
1.68	O
nm).	O
The	O
contact angles	B-T082
of	O
the	O
Coarse group	B-T078
were	O
the	O
highest,	O
followed	O
by	O
the	O
Medium	B-T081
and	O
the	O
Fine groups	B-T078
.	O
Increasing	O
the	O
surface roughness	B-T033
and	O
hydrophobicity	B-T080
resulted	O
in	O
an	O
increase	O
of	O
adhesion forces	B-T067
and	O
early	O
attachment	B-T052
(2	O
h	O
and	O
4	O
h)	O
of	O
S. mutans	B-T007
on	O
the	O
zirconia	B-T121
but	O
no	O
influence	B-T077
on	O
the	O
further	O
development	B-T169
of	O
biofilm	B-T007
(6	O
h~24	O
h).	O
Our	O
findings	O
suggest	O
that	O
the	O
surface roughness	B-T033
in	O
nanoscale	B-T081
and	O
hydrophobicity	B-T080
of	O
zirconia	B-T121
had	O
influence	B-T077
on	O
the	O
S. mutans	B-T007
initial	O
adhesion force	B-T067
and	O
early	O
attachment	B-T052
instead	O
of	O
whole	O
stages	O
of	O
biofilm formation	B-T043
.	O

The	O
relationship	O
between	O
thiamine	B-T109
and	O
two	O
symbioses	B-T070
:	O
Root nodule	B-T002
symbiosis	B-T070
and	O
arbuscular mycorrhiza	B-T004
Lotus japonicus	B-T002
THIC	B-T028
is	O
expressed	B-T045
in	O
all	O
organs	B-T002
,	O
and	O
the	O
encoded protein	B-T116
catalyzes	B-T070
thiamine biosynthesis	B-T044
.	O
Loss of function	B-T033
produces	O
chlorosis	B-T047
,	O
a	O
typical	O
thiamine	B-T109
-deficiency	O
phenotype	B-T032
,	O
and	O
mortality	B-T081
.	O
To	O
investigate	O
thiamine's	B-T109
role	O
in	O
symbiosis	B-T070
,	O
we	O
focused	O
on	O
THI1	B-T028
,	O
a	O
thiamine-biosynthesis gene	B-T028
expressed	B-T045
in	O
roots	B-T002
,	O
nodules	B-T002
,	O
and	O
seeds	B-T002
.	O
The	O
thi1 mutant	B-T028
had	O
green leaves	B-T002
,	O
but	O
formed	O
small	B-T081
nodules	B-T002
and	O
immature	B-T080
seeds	B-T002
.	O
These	O
phenotypes	B-T032
were	O
rescued	O
by	O
THI1	B-T028
complementation	B-T045
and	O
by	O
exogenous	B-T169
thiamine	B-T109
.	O
Thus,	O
THI1	B-T028
is	O
required	O
for	O
nodule	B-T002
enlargement	B-T169
and	O
seed maturation	B-T039
.	O
On	O
the	O
other	O
hand,	O
colonization	B-T033
by	O
arbuscular mycorrhiza	B-T004
(	O
AM	B-T004
)	O
fungus	B-T004
Rhizophagus irregularis	B-T004
was	O
not	O
affected	O
in	O
the	O
thi1 mutant	B-T028
or	O
by	O
exogenous	B-T169
thiamine	B-T109
.	O
However,	O
spores	B-T004
of	O
R. irregularis	B-T004
stored	O
more	O
thiamine	B-T109
than	O
the	O
source	O
(	O
host plants	B-UnknownType
),	O
despite	O
lacking	O
thiamine biosynthesis genes	B-T028
.	O
Therefore,	O
disturbance	O
of	O
the	O
thiamine	B-T109
supply	O
would	O
affect	O
progeny	B-T099
phenotypes	B-T032
such	O
as	O
spore formation	B-T043
and	O
hyphal growth	B-T043
.	O
Further	O
investigation	O
will	O
be	O
required	O
to	O
elucidate	O
thiamine's	B-T109
effect	O
on	O
AM	B-T004
.	O

Bilateral	B-T082
sternal	B-T023
infusion	B-T061
of	O
ropivacaine	B-T109
and	O
length of stay	B-T079
in	O
ICU	B-T073
after	O
cardiac surgery	B-T061
with	O
increased	B-T081
respiratory risk	B-UnknownType
:	O
A	O
randomised controlled trial	B-T062
The	O
continuous	O
bilateral	B-T082
infusion	B-T061
of	O
a	O
local anaesthetic	B-T109
solution	B-T122
around	O
the	O
sternotomy	B-T061
wound	B-T037
(	O
bilateral	B-T082
sternal	B-T023
)	O
is	O
an	O
innovative	O
technique	B-T169
for	O
reducing	B-T080
pain	B-T184
after	O
sternotomy	B-T061
.	O
To	O
assess	O
the	O
effects	B-T080
of	O
the	O
technique	B-T169
on	O
the	O
need	O
for	O
intensive care	B-T058
in	O
cardiac patients	B-T101
at	O
increased	B-T081
risk	B-T078
of	O
respiratory complications	B-T046
.	O
Randomised, observer-blind controlled trial	B-T062
.	O
Single	O
centre,	O
French University Hospital	B-T073
.	O
In	O
total,	O
120	O
adults	B-T100
scheduled	O
for	O
open-heart surgery	B-T061
,	O
with	O
one	O
of	O
the	O
following	O
conditions:	O
age	B-T032
more	O
than	O
75	O
years	B-T079
,	O
BMI	B-T201
>30	O
kg	O
m,	O
chronic obstructive pulmonary disease	B-T047
,	O
active smoking habit	B-T169
.	O
Either	O
a	O
bilateral	B-T082
sternal	B-T023
infusion	B-T061
of	O
0.2%	O
ropivacaine	B-T109
(3	O
ml	O
h	O
through	O
each	O
catheter	B-T074
;	O
'intervention' group	B-T098
),	O
or	O
standardised care	B-T052
only	O
(	O
'control' group	B-T096
).	O
Analgesia	B-T061
was	O
provided	O
with	O
paracetamol	B-T109
and	O
self-administered	B-T169
intravenous	B-T169
morphine	B-T109
.	O
The	O
length of time	B-T079
to	O
readiness	B-T033
for	O
discharge	B-T058
from	O
ICU	B-T073
,	O
blindly	O
assessed	B-T052
by	O
a	O
committee	B-T096
of	O
experts	B-T097
.	O
No effect	B-T080
was	O
found	O
between	O
groups	B-T078
for	O
the	O
primary outcome	B-T080
(P	O
=	O
0.680,	O
intention to treat	B-T062
);	O
the	O
median values	B-T080
were	O
42.4	O
and	O
37.7	O
h,	O
respectively	O
for	O
the	O
control	B-T096
and	O
intervention groups	B-T098
(P	O
=	O
0.873).	O
Similar	O
nonsignificant	O
trends	O
were	O
noted	O
for	O
other	O
postoperative	B-T033
delays	B-T079
.	O
Significant	O
effects	B-T080
favouring	O
the	O
intervention	B-T061
were	O
noted	O
for	O
dynamic pain	B-T184
,	O
patient satisfaction	B-T080
,	O
occurrence of nausea	B-T184
and	O
vomiting	B-T184
,	O
occurrence	B-T079
of	O
delirium	B-T048
or	O
mental confusion	B-T048
and	O
occurrence	B-T079
of	O
pulmonary complications	B-T046
.	O
In	O
12	O
patients	B-T101
,	O
although	O
no	O
symptoms	B-T184
actually	O
occurred,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological symptoms	B-T184
have	O
been	O
observed	O
in	O
healthy volunteers	B-T098
.	O
Because	O
of	O
a	O
small size effect	B-T081
,	O
and	O
despite	O
significant	O
analgesic effects	B-T033
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	B-T079
spent	O
in	O
ICU	B-T073
.	O
EudraCT	B-T077
(N°:	O
2012-005225-69);	O
ClinicalTrials.gov	B-T170
(NCT01828788).	O

Pupil Sizes	B-T201
Scale	B-T170
with	O
Attentional Load	B-T170
and	O
Task	B-T057
Experience	B-T041
in	O
a	O
Multiple	B-T081
Object	B-T072
Tracking	B-T082
Task	B-T057
Previous	O
studies	O
have	O
related	O
changes	B-T169
in	O
attentional load	B-T170
to	O
pupil size	B-T201
modulations	B-T082
.	O
However,	O
studies	O
relating	O
changes	B-T169
in	O
attentional load	B-T170
and	O
task	B-T057
experience	B-T041
on	O
a	O
finer	O
scale	B-T170
to	O
pupil size	B-T201
modulations	B-T082
are	O
scarce.	O
Here,	O
we	O
investigated	B-T169
how	O
these	O
changes	B-T169
affect	B-T041
pupil sizes	B-T201
.	O
To	O
manipulate	B-T053
attentional load	B-T170
,	O
participants	B-T098
covertly	O
tracked	B-T082
between	O
zero	B-T081
and	O
five	B-T081
objects	B-T072
among	O
several	O
randomly	B-T080
moving	O
objects	B-T072
on	O
a	O
computer	B-T073
screen	B-T073
.	O
To	O
investigate	B-T169
effects of	B-T080
task	B-T057
experience	B-T041
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	B-T081
consecutive	B-T080
days	B-T079
.	O
We	O
found	O
that	O
pupil sizes	B-T201
increased	O
with	O
each	O
increment	B-T081
in	O
attentional load	B-T170
.	O
Across	O
days	B-T079
,	O
we	O
found	O
systematic	B-T169
pupil size	B-T201
reductions	B-T080
.	O
We	O
compared	O
the	O
model fit	B-T080
for	O
predicting	O
pupil size	B-T201
modulations	B-T082
using	O
attentional load	B-T170
,	O
task	B-T057
experience	B-T041
,	O
and	O
task performance	B-T061
as	O
predictors	B-T078
.	O
We	O
found	O
that	O
a	O
model	B-T170
which	O
included	O
attentional load	B-T170
and	O
task	B-T057
experience	B-T041
as	O
predictors	B-T078
had	O
the	O
best	O
model fit	B-T080
while	O
adding	O
performance	B-T061
as	O
a	O
predictor	B-T078
to	O
this	O
model	B-T170
reduced	O
the	O
overall	O
model fit	B-T080
.	O
Overall,	O
results	B-T169
suggest	O
that	O
pupillometry	B-T060
provides	O
a	O
viable	B-T080
metric	B-T081
for	O
precisely	O
assessing	O
attentional load	B-T170
and	O
task	B-T057
experience	B-T041
in	O
visuospatial	B-T041
tasks	B-T057
.	O

Back	O
to	O
the	O
Roots:	O
Deep	O
View	O
into	O
the	O
Evolutionary	B-T038
History	B-T169
of	O
ADP-Ribosylation	B-T067
Opened	O
by	O
the	O
DNA	B-T114
-	O
Targeting	B-T169
Toxin	B-T123
-	O
Antitoxin	B-T121
Module DarTG	B-T077
In	O
this	O
issue	O
of	O
Molecular Cell	B-T091
,	O
Jankevicius	O
et	O
al.	O
(2016)	O
characterize	O
the	O
DarTG	B-T077
toxin	B-T123
-	O
antitoxin	B-T121
module	B-T077
in	O
which	O
the	O
DarT	B-T116
toxin	B-T123
ADP-ribosylates	B-T067
single-stranded DNA	B-T114
and	O
the	O
DarG	B-T116
antitoxin	B-T121
counteracts	B-T169
DarT	B-T116
by	O
direct	O
binding	B-T044
and	O
by	O
enzymatic	B-T116
remova	B-T052
l	O
of	O
the	O
ADP-ribosylation	B-T067
.	O

Growth differentiation factor 15	B-T116
is	O
a	O
myomitokine	B-T123
governing systemic energy homeostasis	B-T039
Reduced	B-T080
mitochondrial electron transport chain	B-T026
activity	B-T052
promotes	B-T052
longevity	B-T079
and	O
improves	B-T033
energy homeostasis	B-T038
via	O
cell-autonomous	B-T043
and	O
-	O
non-autonomous factors	B-T043
in	O
multiple model systems	B-T075
.	O
This	O
mitohormetic	B-T040
effect	B-T080
is	O
thought	O
to	O
involve	O
the	O
mitochondrial unfolded protein response	B-T044
(	O
UPR(mt)	B-T044
),	O
an	O
adaptive stress-response	B-T039
pathway	B-T077
activated	B-T052
by	O
mitochondrial	B-T026
proteotoxic stress	B-T046
.	O
Using	O
mice	B-T015
with	O
skeletal muscle-specific	B-T024
deficiency	B-T169
of	O
Crif1	B-T116
(	O
muscle-specific	B-T024
knockout	B-T015
[	O
MKO	B-T015
]),	O
an	O
integral protein	B-T116
of	O
the	O
large mitoribosomal subunit	B-T026
(	O
39S	B-T026
),	O
we	O
identified	O
growth differentiation factor 15	B-T116
(	O
GDF15	B-T116
)	O
as	O
a	O
UPR(mt)	B-T044
-associated	O
cell-non-autonomous	B-T043
myomitokine	B-T123
that	O
regulates systemic energy homeostasis	B-T039
.	O
MKO mice	B-T015
were	O
protected	B-T033
against	O
obesity	B-T047
and	O
sensitized	B-T040
to	O
insulin	B-T116
,	O
an	O
effect	O
associated with	B-T080
elevated	B-T080
GDF15	B-T116
secretion	B-T043
after	O
UPR(mt)	B-T044
activation	B-T052
.	O
In	O
ob/ob mice	B-T015
,	O
administration	O
of	O
recombinant	B-T116
GDF15	B-T116
decreased	B-T081
body weight	B-T032
and	O
improved	B-T033
insulin sensitivity	B-T046
,	O
which	O
was	O
attributed	O
to	O
elevated	B-T080
oxidative metabolism	B-T043
and	O
lipid mobilization	B-T042
in	O
the	O
liver	B-T023
,	O
muscle	B-T024
,	O
and	O
adipose tissue	B-T024
.	O
Thus,	O
GDF15	B-T116
is	O
a	O
potent	B-T080
mitohormetic	B-T040
signal	B-T038
that	O
safeguards	O
against	O
the	O
onset of obesity	B-T033
and	O
insulin resistance	B-T046
.	O

Synthesis	B-T052
and	O
characterization	B-T052
of	O
acetylated amylose	B-T109
and	O
development	B-T169
of	O
inclusion complexes	B-T104
with	O
rifampicin	B-T109
Amylose	B-T109
(	O
AM	B-T109
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion complexes	B-T104
with	O
suitable	O
agents	B-T120
.	O
These	O
complexes	B-T104
are	O
considered	B-T078
promising	O
biomaterial	B-T122
carrier	O
since	O
the	O
guest molecules	B-T167
can	O
be	O
released	B-T169
later	B-T079
,	O
leading	O
to	O
many	O
applications	B-T169
,	O
especially	O
in	O
the	O
pharmaceutical industry	B-T093
.	O
Rifampicin	B-T109
(	O
RIF	B-T109
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	B-T169
drug	B-T121
against	O
Mycobacterium tuberculosis	B-T007
,	O
however,	O
the	O
administration	B-T061
of	O
RIF	B-T109
in	O
high	O
dosages	B-T081
can	O
originate	O
unwanted	O
side-effects	B-T169
.	O
Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	B-T169
amylose	B-T109
(	O
AM	B-T109
)	O
in	O
the	O
formation	B-T169
of	O
complexes	B-T104
is	O
limited	O
by	O
their	O
low	O
water solubility	B-T081
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	B-T081
of	O
substitution	B-T052
(	O
DS	B-T052
),	O
allowing	O
solubilizing	B-T080
(0.5gL(-1))	O
acetylated amylose	B-T109
(	O
AMA	B-T109
)	O
in	O
water	B-T121
at	O
neutral pH	B-T080
,	O
in	O
opposition	O
to	O
that	O
observed	B-T169
with	O
native	B-T169
amylose	B-T109
(	O
trace	B-T081
solubility	B-T080
).	O
The	O
resulting	O
acetylated amylose	B-T109
was	O
characterized	B-T052
by	O
means	O
of	O
Fourier Transform Infrared (FT-IR) spectroscopy	B-T062
and	O
Scanning Electron Microscopy	B-T059
(	O
SEM	B-T059
).	O
FT-IR	B-T062
results	B-T169
indicated	B-T033
that	O
the	O
acetylation	B-T044
of	O
anhydroglucose	B-T109
units	B-T081
of	O
amylose	B-T109
corresponds	O
to	O
a	O
low	B-T080
DS	B-T052
,	O
whereas	O
SEM	B-T059
results	B-T169
suggested	O
that	O
the	O
smooth surfaces	B-T082
of	O
amylose	B-T109
granules	B-T167
were	O
changed	B-T169
into	O
rougher	O
surfaces	B-T082
after	O
acetylation	B-T044
.	O
Ultraviolet absorption spectroscopy	B-T059
(	O
UV-vis	B-T059
)	O
analysis	B-T062
confirmed	B-T080
the	O
formation	B-T169
and	O
allowed	O
the	O
quantification	B-T081
of	O
both	O
native	B-T169
(	O
AM	B-T109
-	O
RIF	B-T109
)	O
and	O
acetylated	O
(	O
AMA	B-T109
-	O
RIF	B-T109
)	O
amylose	B-T109
inclusion complexes	B-T104
.	O
Their	O
characterization	B-T052
in	O
solution	B-T167
was	O
performed	B-T169
by	O
dynamic light scattering	B-T059
(	O
DLS	B-T059
)	O
and	O
zeta potential	B-T067
(	O
ZP	B-T067
)	O
measurements	B-T169
.	O
The	O
average size	B-T082
of	O
inclusion complexes	B-T104
as	O
determined by	B-T080
DLS	B-T059
,	O
ranged	B-T081
between	O
70	O
and	O
100nm.	O
Besides,	O
ZP	B-T067
analysis	B-T062
showed	O
that	O
both	O
complexes	B-T104
are	O
more	O
stable	B-T080
in	O
the	O
presence	B-T033
of	O
RIF	B-T109
.	O
This	O
study	O
may	O
lead	O
to	O
the	O
development	B-T169
of	O
an	O
effective	B-T080
method	O
for	O
the	O
preparation	B-T052
of	O
amylose	B-T109
inclusion complexes	B-T104
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	B-T082
application	B-T169
in	O
drug delivery systems	B-T074
.	O

Selective	B-T052
reaching	B-T040
in	O
macaques	B-T015
:	O
evidence	B-T078
for	O
action	B-T052
-centred	O
attention	B-T041
When	O
a	O
monkey	B-T015
selects	B-T052
a	O
piece	O
of	O
food	B-T168
lying	O
on	O
the	O
ground	O
from	O
among	O
other	B-T080
viable	B-T080
objects	B-T072
in	O
the	O
near	B-T080
vicinity	B-T082
,	O
only	O
the	O
desired	B-T041
item	B-T168
governs	B-T080
the	O
particular	O
pattern	B-T082
and	O
direction	B-T082
of	O
the	O
animal's	B-T008
reaching	B-T040
action	B-T052
.	O
It	O
would	O
seem	O
then	O
that	O
selection	B-T052
is	O
an	O
important	B-T080
component	B-T078
controlling	B-T169
the	O
animal's	B-T008
action	B-T052
.	O
But,	O
we	O
may	O
ask,	O
is	O
the	O
selection	B-T052
process	B-T067
in	O
such	O
cases	B-T169
impervious	O
to	O
the	O
presence	B-T080
of	O
other	B-T080
objects	B-T072
that	O
could	O
constitute	B-T169
potential	B-T080
obstacles	B-T072
to	O
or	O
constraints	B-T169
on	O
movement	B-T040
execution	B-T052
?	O
And	O
if	O
it	O
is,	O
in	O
fact,	O
pervious	B-T169
to	O
other	B-T080
objects	B-T072
,	O
do	O
they	O
have	O
a	O
direct	B-T080
influence	B-T077
on	O
the	O
organization	B-T039
of	O
the	O
response	B-T032
?	O
The	O
kinematics	B-T091
of	O
macaques	B-T015
'	O
reaching	B-T040
movements	B-T040
were	O
examined	B-T033
by	O
the	O
current	B-T079
study	B-T062
that	O
analysed	B-T062
some	O
exemplars	O
as	O
they	O
selectively	B-T052
reached	B-T040
to	O
grasp	B-T040
a	O
food item	B-T168
in	O
the	O
absence	B-T169
as	O
well	O
as	O
in	O
the	O
presence	B-T080
of	O
potential	B-T080
obstacles	B-T072
(i.e.,	O
stones	B-T072
)	O
that	O
could	O
affect	B-T041
the	O
arm	B-T029
trajectory	B-T082
.	O
Changes	B-T169
in	O
movement	B-T040
parameterization	B-UnknownType
were	O
noted	B-T080
in	O
temporal	B-T079
measures	B-T081
,	O
such	O
as	O
movement	B-T040
time	B-T079
,	O
as	O
well	O
as	O
in	O
spatial ones	B-T082
,	O
such	O
as	O
paths	O
of	O
trajectory	B-T082
.	O
Generally	O
speaking,	O
the	O
presence	B-T080
of	O
stones	B-T072
in	O
the	O
vicinity	B-T082
of	O
the	O
acting	B-T055
hand	B-T023
stalled	B-T052
the	O
reaching	B-T040
movement	B-T040
and	O
affected	B-T041
the	O
arm	B-T029
trajectory	B-T082
as	O
the	O
hand	B-T023
veered away	B-T033
from	O
the	O
stone	B-T072
even	O
when	O
it	O
was	O
not	B-T169
a	O
physical	B-T169
obstacle	B-T072
.	O
We	O
concluded	O
that	O
nearby	B-T080
objects	B-T072
evoke	O
a	O
motor response	B-T201
in	O
macaques	B-T015
,	O
and	O
the	O
attentional	B-T041
mechanisms	B-T169
that	O
allow	O
for	O
a	O
successful	B-T080
action	B-T052
selection	B-T052
are	O
revealed	B-T080
in	O
the	O
reaching	B-T040
path	B-T082
.	O
The	O
data	B-T078
outlined	O
here	O
concur	O
with	O
human	B-T016
studies	B-T062
indicating	B-T078
that	O
potential	B-T080
obstacles	B-T072
are	O
internally	B-T082
represented	B-T052
,	O
a	O
finding	B-T033
implying	O
basic	B-T169
cognitive	B-T169
operations	B-T052
allowing	O
for	O
action	B-T052
selection	B-T052
in	O
macaques	B-T015
.	O

A	O
novel	B-T080
method	B-T170
for	O
interactive	B-T169
multi-objective	B-T080
dose-guided patient positioning	B-T058
In	O
intensity-modulated radiation therapy	B-T061
(	O
IMRT	B-T061
),	O
3D	O
in-room	O
imaging	B-T060
data	B-T078
is	O
typically	O
utilized	O
for	O
accurate	B-T080
patient alignment	B-UnknownType
on	O
the	O
basis	O
of	O
anatomical landmarks	B-T029
.	O
In	O
the	O
presence	O
of	O
non-rigid	O
anatomical changes	B-T169
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient position	B-T033
is	O
most	O
suitable.	O
Thus,	O
dose	B-T081
-guided	O
patient alignment	B-UnknownType
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in-room	O
imaging	B-T060
data	B-T078
for	O
up-to-date	O
dose	B-T081
calculation	B-T052
,	O
aimed	O
at	O
finding	B-T033
the	O
position	O
that	O
yields	O
the	O
optimal	B-T080
dose	B-T081
distribution	B-T169
.	O
This	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	B-T081
-guided	O
patient alignment	B-UnknownType
as	O
multi-criteria	O
optimization	O
problem.	O
User-defined	O
clinical	B-T080
objectives	B-T170
are	O
employed	O
for	O
setting	O
up	O
a	O
multi-objective	B-T080
problem.	O
Using	O
pre-calculated	O
dose	B-T081
distributions	B-T169
at	O
a	O
limited	O
number	O
of	O
patient shifts	B-T058
and	O
dose	B-T081
interpolation	B-T062
,	O
a	O
continuous	O
space	O
of	O
Pareto-efficient patient shifts	B-T058
becomes	O
accessible.	O
Pareto	O
sliders	O
facilitate	O
interactive	B-T169
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real-time	O
dose	B-T081
display	O
to	O
the	O
user.	O
Dose	B-T081
interpolation	B-T062
accuracy	B-T080
is	O
validated	O
and	O
the	O
potential	O
of	O
multi-objective	B-T080
dose-guided positioning	B-T058
demonstrated	O
for	O
three	O
head and neck	B-T191
(	O
H&N	B-T191
)	O
and	O
three	O
prostate cancer	B-T191
patients	B-T101
.	O
Dose-guided positioning	B-T058
is	O
compared	B-T052
to	O
replanning	O
for	O
all	O
cases.	O
A	O
delineated	O
replanning	O
CT	B-T060
served	O
as	O
surrogate	O
for	O
in-room	O
imaging	B-T060
data	B-T078
.	O
Dose	B-T081
interpolation	B-T062
accuracy	B-T080
was	O
high	B-T080
.	O
Using	O
a	O
[Formula:	O
see	O
text]	O
dose	B-T081
difference	O
criterion,	O
a	O
median	O
pass-rate	O
of	O
95.7%	O
for	O
H&N	B-T191
and	O
99.6%	O
for	O
prostate cases	B-T191
was	O
determined	O
in	O
a	O
comparison	B-T052
to	O
exact	O
dose	B-T081
calculations	B-T052
.	O
For	O
all	O
patients	B-T101
,	O
dose-guided positioning	B-T058
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	B-T081
distribution	B-T169
compared	B-T052
to	O
bony anatomy based alignment	B-T081
.	O
For	O
all	O
H&N	B-T191
cases,	O
mean	O
dose	B-T081
to	O
the	O
spared	O
parotid glands	B-T023
was	O
below	O
[Formula:	O
see	O
text]	O
(up	O
to	O
[Formula:	O
see	O
text]	O
with	O
bony alignment	B-T081
)	O
and	O
clinical target volume	B-T081
(	O
CTV	B-T081
)	O
[Formula:	O
see	O
text]	O
above	O
99.1%	O
(	O
compared	B-T052
to	O
95.1%).	O
For	O
all	O
prostate	B-T191
patients	B-T101
,	O
CTV	B-T081
[Formula:	O
see	O
text]	O
was	O
above	O
98.9%	O
(	O
compared	B-T052
to	O
88.5%)	O
and	O
[Formula:	O
see	O
text]	O
to	O
the	O
rectum	O
below	O
[Formula:	O
see	O
text]	O
(	O
compared	B-T052
to	O
56.1%).	O
Replanning	O
yielded	O
improved	O
results	O
for	O
the	O
H&N	B-T191
cases.	O
For	O
the	O
prostate cases	B-T191
,	O
differences	O
to	O
dose-guided positioning	B-T058
were	O
minor.	O

Clinical	B-T033
and	O
radiological	B-T060
outcome	B-T169
following	O
pneumothorax	B-T047
after	O
endoscopic lung volume reduction	B-T061
with	O
valves	B-T074
Valve	B-T074
implantation	B-T061
has	O
evolved	O
as	O
a	O
therapy	B-T061
for	O
patients	B-T101
with	O
advanced	B-T080
emphysema	B-T047
.	O
Although	O
it	O
is	O
a	O
minimally invasive treatmen	B-T061
t,	O
it	O
is	O
associated with	B-T080
complications	B-T046
,	O
the	O
most	O
common	B-T081
being	O
pneumothorax	B-T047
.	O
Pneumothorax	B-T047
occurs	O
due	O
to	O
the	O
rapid	B-T080
target	B-T169
lobe	B-T023
volume reduction	B-T061
and	O
may	O
be	O
a	O
predictor	B-T078
of	O
clinical	B-T080
benefit	B-T081
despite	O
this	O
complication	B-T046
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
conduct	O
an	O
exploratory data analysis	B-T080
of	O
patients	B-T101
who	O
developed	O
a	O
pneumothorax	B-T047
following	O
endoscopic valve therapy	B-T061
for	O
emphysema	B-T047
.	O
This	O
study	B-T062
performed	B-T169
a	O
retrospective evaluation	B-T062
of	O
pneumothorax	B-T047
management	B-T058
and	O
the	O
impact	B-T080
of	O
pneumothorax	B-T047
on	O
clinical outcomes	B-T033
in	O
70	O
patients	B-T101
following	O
valve therapy	B-T061
in	O
381	O
consecutive	B-T080
patients	B-T101
.	O
Pneumothorax	B-T047
rate	B-T081
following	O
valve therapy	B-T061
was	O
18%.	O
Pneumothorax	B-T047
management	B-T058
consisted	O
of	O
chest tube insertion	B-T061
,	O
valve	B-T074
removal	B-T061
,	O
and	O
surgical intervention	B-T033
in	O
87%	O
(61/70),	O
44%	O
(31/70),	O
and	O
19%	O
(13/70)	O
of	O
the	O
patients	B-T101
,	O
respectively.	O
Despite	O
pneumothorax	B-T047
,	O
patients	B-T101
experienced	O
modest	B-T080
but	O
significant	B-T078
improvements	B-T077
in	O
lung function	B-T042
parameters	B-T077
(	O
forced expiratory volume	B-T042
in	O
1	O
second:	O
55±148	O
mL,	O
residual volume	B-T201
:	O
-390±964	O
mL,	O
total lung capacity	B-T033
:	O
-348±876;	O
all	O
P<0.05).	O
Persistent	B-T079
lobar atelectasis	B-T046
3	O
months	O
after	O
recovering	B-T077
from	O
pneumothorax	B-T047
,	O
which	O
was	O
associated with	B-T080
relevant	B-T080
clinical	B-T080
improvement	B-T077
,	O
was	O
observed	B-T169
in	O
only	O
21%	O
(15/70)	O
of	O
the	O
patients	B-T101
.	O
Pneumothorax	B-T047
is	O
a	O
frequent	B-T079
severe	B-T080
complication	B-T046
following	O
valve therapy	B-T061
that	O
requires	O
further	O
intervention	B-T061
.	O
Nevertheless,	O
the	O
pneumothorax	B-T047
does	O
not	O
impair	B-T169
the	O
clinical status	B-T080
in	O
the	O
majority	O
of	O
patients	B-T101
.	O
Patients	B-T101
with	O
lobar atelectasis	B-T046
benefit	B-T081
after	O
recovering	B-T077
from	O
pneumothorax	B-T047
in	O
terms	O
of	O
lung function	B-T042
parameters	B-T077
.	O

3Mo	B-T075
:	O
A	O
Model	B-T075
for	O
Music	B-T170
-	O
Based	B-T169
Biofeedback	B-T061
In	O
the	O
domain	B-T169
of	O
sports	B-T056
and	O
motor	B-T038
rehabilitation	B-T169
,	O
it	O
is	O
of	O
major	B-T080
importance	B-T080
to	O
regulate	B-T038
and	O
control	B-T169
physiological processes	B-T039
and	O
physical motion	B-T070
in	O
most	B-T081
optimal	B-T080
ways.	O
For	O
that	O
purpose	B-T169
,	O
real-time	B-T079
auditory feedback	B-T041
of	O
physiological	B-T169
and	O
physical	B-T169
information	B-T078
based	B-T169
on	O
sound signals	B-T070
,	O
often	O
termed	O
"	O
sonification	B-T169
,"	O
has	O
been	O
proven	B-T080
particularly	O
useful	B-T080
.	O
However,	O
the	O
use	B-T169
of	O
music	B-T170
in	O
biofeedback	B-T061
systems	B-T169
has	O
been	O
much	O
less	B-T081
explored	B-T061
.	O
In	O
the	O
current	B-T079
article	B-T170
,	O
we	O
assert	O
that	O
the	O
use	B-T169
of	O
music	B-T170
,	O
and	O
musical	B-T170
principles	B-T078
,	O
can	O
have	O
a	O
major	B-T080
added	O
value	B-T170
,	O
on	O
top	O
of	O
mere	B-T080
sound signals	B-T070
,	O
to	O
the	O
benefit	B-T081
of	O
psychological	B-T169
and	O
physical	B-T169
optimization	B-T052
of	O
sports	B-T056
and	O
motor	B-T038
rehabilitation	B-T169
tasks	B-T057
.	O
In	O
this	O
article	B-T170
,	O
we	O
present	B-T078
the	O
3Mo model	B-T075
to	O
describe	O
three	O
main	B-T080
functions	B-T169
of	O
music	B-T170
that	O
contribute	B-T052
to	O
these	O
benefits	B-T081
.	O
These	O
functions	B-T169
relate	O
the	O
power	B-T078
of	O
music	B-T170
to	O
Motivate	B-T041
,	O
and	O
to	O
Monitor	B-T058
and	O
Modify	B-T169
physiological	B-T169
and	O
physical	B-T169
processes	B-T067
.	O
The	O
model	B-T075
brings	O
together	O
concepts	B-T078
and	O
theories	B-T078
related	O
to	O
human	B-T016
sensorimotor interaction	B-T040
with	O
music	B-T170
,	O
and	O
specifies	B-T080
the	O
underlying	O
psychological	B-T169
and	O
physiological	B-T169
principles	B-T078
.	O
This	O
3Mo model	B-T075
is	O
intended	B-T080
to	O
provide	B-T052
a	O
conceptual framework	B-T077
that	O
guides	B-T170
future	B-T079
research	B-T062
on	O
musical	B-T170
biofeedback	B-T061
systems	B-T169
in	O
the	O
domain	B-T169
of	O
sports	B-T056
and	O
motor	B-T038
rehabilitation	B-T169
.	O
Journal	O

Analysis	B-T059
of	O
tilianin	B-T109
and	O
acacetin	B-T109
in	O
Agastache rugosa	B-T002
by	O
high-performance liquid chromatography	B-T059
with	O
ionic liquids	B-T103
-	O
ultrasound	B-T169
based	O
extraction	B-T059
Ionic liquid	B-T103
1-butyl-3-methylimidazolium bromide	B-T109
-	O
methanol	B-T109
-based	O
ultrasonic	B-T169
-assisted	O
extraction	B-T059
(	O
ILUAE	B-T059
)	O
was	O
used	O
to	O
extract	B-T059
tilianin	B-T109
and	O
acacetin	B-T109
from	O
the	O
aerial parts	B-T002
of	O
Agastache rugose	B-T002
(	O
A. rugose	B-T002
),	O
and	O
simultaneously	O
determined	O
by	O
reversed phase high performance liquid chromatographic	B-T059
(	O
RP-HPLC	B-T059
)	O
method	O
with	O
ultraviolet detection	B-T170
(	O
RP-HPLC-UV)	B-T170
.	O
An	O
InertSustain RP-C18 column	B-T075
was	O
used	O
with	O
the	O
mobile phase	B-T130
consisting	O
of	O
methanol	B-T109
and	O
0.2%	O
acetic acid	B-T109
as	O
gradient	B-T081
elution	B-T059
at	O
the	O
detection wavelength	B-T081
of	O
332	O
nm.	O
The	O
flow rate	B-T081
was	O
0.8	O
mL/min,	O
and	O
the	O
column	B-T075
temperature	B-T081
was	O
30	O
°C.	O
Under	O
the	O
optimized	B-T052
conditions	B-T080
,	O
tilianin	B-T109
and	O
acacetin	B-T109
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595-4.76	O
and	O
0.0585-4.68	O
μg/mL,	O
respectively,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88%,	O
respectively.	O
The	O
method	B-T169
of	O
ILUAE	B-T059
was	O
compared	O
with	O
the	O
traditional methods	B-T169
,	O
it	O
exhibited	O
higher	B-T080
efficiency	B-T081
,	O
higher	B-T080
reproducibility	B-T080
and	O
environmental friendly	B-T082
in	O
analyzing	O
the	O
active	B-T169
compounds	B-T103
in	O
traditional Chinese medicines	B-T091
(	O
TCMs	B-T091
).	O

Evaluation	B-T058
of	O
MIF -173 G/C	B-T028
Polymorphism	B-T045
in	O
Turkish	B-T098
Patients	B-T101
with	O
Ankylosing Spondylitis	B-T047
Ankylosing spondylitis	B-T047
(	O
AS	B-T047
)	O
is	O
a	O
chronic inflammatory disease	B-T047
mainly	O
affecting	O
the	O
spine	B-T023
and	O
sacroiliac joints	B-T030
.	O
Macrophage migration inhibitory (MIF) factor	B-T116
is	O
a	O
regulatory	B-T077
cytokine	B-T116
that	O
inhibits	B-T052
random	O
immune cell migration	B-T043
.	O
MIF gene	B-T028
promoter	B-T028
polymorphisms	B-T045
play	O
a	O
role	O
in	O
the	O
progression	B-T046
of	O
several	O
inflammatory disorders	B-T047
.	O
To	O
investigate	B-T169
the	O
relationship	O
between	O
the	O
MIF gene -173 G/C	B-T028
single-nucleotide polymorphism	B-T086
(	O
SNP	B-T086
)	O
and	O
AS	B-T047
.	O
Cross-sectional study	B-T062
.	O
In	O
this	O
study	B-T062
,	O
a	O
total	O
of	O
161	O
AS	B-T047
and	O
194	O
normal	B-T080
controls	B-T096
were	O
recruited.	O
The	O
MIF gene -173 G/C	B-T028
SNP	B-T086
was	O
analyzed	B-T062
by	O
polymerase chain reaction	B-T063
using	O
the	O
restriction fragment length polymorphism method	B-T059
.	O
There	O
was	O
no	O
significant	B-T078
difference	O
between	O
groups	B-T098
in	O
terms	O
of	O
genotype	B-T032
distribution	O
(p>0.05).	O
When	O
wild-type	B-T028
G/G	B-T032
and	O
G/C+C/C genotypes	B-T032
are	O
compared	O
in	O
terms	O
of	O
clinical characteristics	B-T201
,	O
there	O
is	O
a	O
significant	B-T078
difference	O
between	O
the	O
average	O
age	B-T032
and	O
the	O
duration of disease	B-T079
in	O
AS	B-T047
patients	B-T101
(p<0.05).	O
No	O
significant	B-T078
relationship	O
between	O
AS	B-T047
disease	B-T047
and	O
MIF -173 G/C	B-T028
polymorphism	B-T045
was	O
found.	O
MIF -173 G/C	B-T028
polymorphism	B-T045
(	O
C allele	B-T028
)	O
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration of disease	B-T079
in	O
AS	B-T047
patients	B-T101
.	O

Mechanisms	O
of	O
Global	B-T080
Cerebral Edema	B-T046
Formation	O
in	O
Aneurysmal Subarachnoid Hemorrhage	B-T046
A	O
growing	O
body	O
of	O
clinical	B-T080
literature	B-T170
emphasizes	O
the	O
impact	O
of	O
cerebral edema	B-T046
in	O
early brain injury	B-T037
following	O
aneurysmal subarachnoid hemorrhage	B-T046
(	O
aSAH	B-T046
).	O
Aneurysm rupture	B-T047
itself	O
initiates	O
global	B-T080
cerebral edema	B-T046
in	O
up	O
to	O
two	O
thirds	O
of	O
cases.	O
Although	O
cerebral edema	B-T046
is	O
not	O
a	O
universal	O
feature	O
of	O
aSAH	B-T046
,	O
it	O
portends	O
a	O
poor	O
clinical course	B-T079
,	O
with	O
quantitative analysis	B-T081
revealing	O
a	O
direct	O
correlation	O
between	O
cerebral edema	B-T046
and	O
poor outcome	B-T033
,	O
including	O
mortality	O
and	O
cognitive	O
deficits.	O
Mechanistically,	O
global	B-T080
cerebral edema	B-T046
has	O
been	O
linked	O
to	O
global	B-T080
ischemia	B-T046
at	O
the	O
time	O
of	O
aneurysm rupture	B-T047
,	O
dysfunction	B-T077
of	O
autoregulation	B-T038
,	O
blood breakdown	B-T043
products	B-T071
,	O
neuroinflammation	B-T046
,	O
and	O
hyponatremia	B-T047
/	O
endocrine abnormalities	B-T190
.	O
At	O
a	O
molecular	B-T080
level	B-T080
,	O
several	O
culprits	O
have	O
been	O
identified,	O
including	O
aquaporin-4	B-T116
,	O
matrix metalloproteinase-9	B-T116
,	O
SUR1	B-T116
-	O
TRPM4 cation channels	B-T116
,	O
vascular endothelial growth factor	B-T116
,	O
bradykinin	B-T116
,	O
and	O
others.	O
Here,	O
we	O
review	O
these	O
cellular	B-T025
and	O
molecular	B-T080
mechanisms	O
of	O
global	B-T080
cerebral edema	B-T046
formation	O
in	O
aSAH	B-T046
.	O
Given	O
the	O
importance	O
of	O
edema	B-T184
to	O
the	O
outcome	O
of	O
patients	B-T101
with	O
aSAH	B-T046
and	O
its	O
status	B-T080
as	O
a	O
highly	O
modifiable	O
pathological process	B-T046
,	O
a	O
better	O
understanding	O
of	O
cerebral edema	B-T046
in	O
aSAH	B-T046
promises	O
to	O
hasten	O
the	O
development	O
of	O
medical therapies	B-T061
to	O
improve	O
outcomes	O
in	O
this	O
frequently	O
devastating	B-T169
disease	B-T047
.	O

Biliary	B-T023
Phospholipids	B-T109
Sustain	B-T169
Enterocyte	B-T025
Proliferation	B-T043
and	O
Intestinal Tumor	B-T191
Progression	B-T191
via	O
Nuclear Receptor	B-T116
Lrh1	B-T116
in	O
mice	B-T015
The	O
proliferative-	O
crypt compartment	B-T023
of	O
the	O
intestinal epithelium	B-T024
is	O
enriched	O
in	O
phospholipids	B-T109
and	O
accumulation	B-T033
of	O
phospholipids	B-T109
has	O
been	O
described	O
in	O
colorectal tumors	B-T191
.	O
Here	O
we	O
hypothesize	O
that	O
biliary	B-T023
phospholipid	B-T109
flow	B-T070
could	O
directly	O
contribute	O
to	O
the	O
proliferative power	B-T169
of	O
normal	B-T025
and	O
dysplastic enterocytes	B-T025
.	O
We	O
used	O
Abcb4	B-T028
(-/-)	O
mice	B-T015
which	O
lack	O
biliary	B-T023
phospholipid	B-T109
secretion	B-T038
.	O
We	O
first	O
show	O
that	O
Abcb4	B-T028
(-/-)	O
mice	B-T015
are	O
protected	B-T033
against	O
intestinal	B-T023
tumorigenesis	B-T191
.	O
At	O
the	O
molecular	B-T080
level	B-T080
,	O
the	O
transcriptional activity	B-T045
of	O
the	O
nuclear receptor	B-T116
Liver Receptor Homolog-1	B-T116
(	O
Lrh1	B-T116
)	O
is	O
reduced	B-T080
in	O
Abcb4	B-T028
(-/-)	O
mice	B-T015
and	O
its	O
re-activation	B-T052
re-establishes	O
a	O
tumor	B-T191
burden	B-T078
comparable	O
to	O
control	B-T096
mice	B-T015
.	O
Feeding	B-T052
Abcb4	B-T028
(-/-)	O
mice	B-T015
a	O
diet supplemented	B-T168
with	O
phospholipids	B-T109
completely	O
overcomes	B-T052
the	O
intestinal tumor	B-T191
protective	O
phenotype	B-T032
,	O
thus	O
corroborating	O
the	O
hypothesis	O
that	O
the	O
absence	B-T169
of	O
biliary	B-T023
phospholipids	B-T109
and	O
not	O
lack	O
of	O
Abcb4 gene	B-T028
per	O
se	O
is	O
responsible	O
for	O
the	O
protection	B-T033
.	O
In	O
turn,	O
phospholipids	B-T109
cannot	O
re-establish	O
intestinal	B-T023
tumorigenesis	B-T191
in	O
Abcb4	B-T028
(-/-)	O
mice	B-T015
crossed	O
with	O
mice	B-T015
with	O
intestinal	B-T023
specific	B-T080
ablation	B-T061
of	O
Lrh1	B-T116
,	O
a	O
nuclear hormone receptor	B-T116
that	O
is	O
activates	B-T052
by	O
phospholipids	B-T109
.	O
Our	O
data	B-T078
identify	O
the	O
key	O
role	O
of	O
biliary	B-T023
phospholipids	B-T109
in	O
sustaining	O
intestinal mucosa	B-T024
proliferation	B-T169
and	O
tumor progression	B-T191
through	O
the	O
activation	B-T052
of	O
nuclear receptor	B-T116
Lrh1	B-T116
.	O

Metalloproteinase	B-T116
meprin α	B-T116
regulates	O
migration	B-T043
and	O
invasion	B-T033
of	O
human	B-T016
hepatocarcinoma	B-T191
cells	B-T025
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	B-T116
Reptin	B-T116
Hepatocellular carcinoma	B-T191
is	O
associated with	B-T080
a	O
high	B-T080
rate	B-T081
of	O
intra-hepatic	B-T029
invasion	B-T033
that	O
carries	O
a	O
poor prognosis	B-T033
.	O
Meprin alpha	B-T116
(	O
Mep1A	B-T116
)	O
is	O
a	O
secreted	B-T043
metalloproteinase	B-T116
with	O
many	O
substrates	O
relevant	O
to	O
cancer invasion	B-T033
.	O
We	O
found	O
that	O
Mep1A	B-T116
was	O
a	O
target	B-T169
of	O
Reptin	B-T116
,	O
a	O
protein that is oncogenic	B-T116
in	O
HCC	B-T191
.	O
We	O
studied	O
Mep1A	B-T116
regulation	B-T038
by	O
Reptin	B-T116
,	O
its	O
role	O
in	O
HCC	B-T191
,	O
and	O
whether	O
it	O
mediates	O
Reptin	B-T116
oncogenic	B-T131
effects	B-T080
.	O
MepA	B-T116
and	O
Reptin	B-T116
expression	B-T045
was	O
measured	O
in	O
human	B-T016
HCC	B-T191
by	O
qRT-PCR	B-T063
and	O
in	O
cultured cells	B-T025
by	O
PCR	B-T063
,	O
western blot	B-T059
and	O
enzymatic activity measurements	B-T062
.	O
Cell growth	B-T043
was	O
assessed	B-T052
by	O
counting	B-T059
and	O
MTS assay	B-T062
.	O
Cell migration	B-T043
was	O
measured	O
in	O
Boyden chambers	B-T074
and	O
wound healing	B-T040
assays	B-T059
,	O
and	O
cell invasion	B-T033
in	O
Boyden chambers	B-T074
.	O
Silencing	B-T045
Reptin	B-T028
decreased	B-T081
Mep1A	B-T116
expression	B-T045
and	O
activity	B-T052
,	O
without	O
affecting	O
meprin β	B-T116
.	O
Mep1A	B-T116
,	O
but	O
not	O
meprin β	B-T116
,	O
was	O
overexpressed	B-T045
in	O
a	O
series	O
of	O
242	O
human	B-T016
HCC	B-T191
(2.04	O
fold,	O
p	O
<	O
0.0001),	O
and	O
a	O
high	B-T080
expression	B-T045
correlated	B-T080
with	O
a	O
poor prognosis	B-T033
.	O
Mep1A	B-T116
and	O
Reptin	B-T116
expressions	B-T045
were	O
positively	O
correlated	B-T080
(r	O
=	O
0.39,	O
p	O
<	O
0.0001).	O
Silencing	B-T045
Mep1A	B-T028
had	O
little	O
effect	O
on	O
cell proliferation	B-T043
,	O
but	O
decreased	B-T081
cell migration	B-T043
and	O
invasion	B-T033
of	O
HuH7	B-T025
and	O
Hep3B cells	B-T025
.	O
Conversely,	O
overexpression	B-T045
of	O
Mep1A	B-T116
or	O
addition	O
of	O
recombinant	B-T001
Mep1A	B-T116
increased	B-T081
migration	B-T043
and	O
invasion	B-T033
.	O
Finally,	O
overexpression	B-T045
of	O
Mep1A	B-T116
restored	O
a	O
normal	B-T080
cell migration	B-T043
in	O
cells	B-T025
where	O
Reptin	B-T116
was	O
depleted	B-T169
.	O
Mep1A	B-T116
is	O
overexpressed	B-T045
in	O
most	O
HCC	B-T191
and	O
induces	B-T169
HCC	B-T191
cell migration	B-T043
and	O
invasion	B-T033
.	O
Mep1A	B-T116
expression	B-T045
is	O
regulated	O
by	O
Reptin	B-T116
,	O
and	O
Mep1A	B-T116
mediates	O
Reptin	B-T116
-	O
induced	B-T169
migration	B-T043
.	O
Overall,	O
we	O
suggest	O
that	O
Mep1A	B-T116
may	O
be	O
a	O
useful	O
target	B-T169
in	O
HCC	B-T191
.	O

Psychosocial impact	B-T080
on	O
families	B-T099
with	O
an	O
infant	B-T100
with	O
a	O
hypoplastic left heart syndrome	B-T047
during and after the interstage monitoring period	B-T079
-	O
a	O
prospective mixed-method study	B-T062
To	O
investigate	O
parents' experiences	B-T041
,	O
coping ability	B-T055
and	O
quality of life	B-T078
while	O
monitoring	B-T058
their	O
sick child	B-T101
with	O
hypoplastic left heart syndrome	B-T047
at	O
home	B-T082
.	O
Interstage home monitoring	B-T058
for	O
children	B-T100
with	O
hypoplastic left heart syndrome	B-T047
reduces	O
interstage	O
mortality	B-T081
between	O
Norwood stages I and II	B-T061
.	O
Little	O
is	O
known	O
about	O
the	O
psychosocial impact	B-T080
of	O
interstage home monitoring	B-T058
.	O
Prospective mixed-method study	B-T062
.	O
This	O
study	O
assessed	O
the	O
psychosocial impact	B-T080
on	O
parents	B-T099
during	O
interstage home monitoring	B-T058
.	O
This	O
contains	O
for	O
quantitative assessment	B-T081
the	O
Short Form Health Survey questionnaire	B-T170
and	O
the	O
Impact	O
of	O
Family Scale administered	B-T033
one	O
and	O
five	O
weeks	O
following	O
discharge	B-T058
before and after stage II	B-T079
.	O
For	O
qualitative assessment	B-T080
,	O
semi-structured interviews	B-UnknownType
focussing	O
on	O
the	O
postdischarge	B-T033
coping strategies	B-T061
were	O
conducted	O
twice,	O
five	O
weeks	O
after hospital discharge	B-T033
before and after stage II	B-T079
.	O
Ten	O
infants	B-T100
(eight	O
males	B-T032
)	O
with	O
hypoplastic left heart syndrome	B-T047
(n	O
=	O
7)	O
or	O
other	O
types	O
of	O
univentricular heart malformations	B-T019
(n	O
=	O
3),	O
and	O
their	O
parents	B-T099
(nine	O
mother/father	B-T099
two-	O
parent	B-T099
households	B-T099
,	O
one	O
single mother	B-T099
)	O
were	O
included.	O
There	O
were	O
no interstage deaths	B-T033
.	O
Mental Health	B-T041
Composite Summary scores	B-T081
were	O
low	O
in	O
both	O
parents	B-T099
(	O
mothers	B-T099
:	O
40·45	O
±	O
9·07;	O
fathers	B-T099
:	O
40·58	O
±	O
9·69)	O
and	O
lowest	O
for	O
the	O
item	O
'	O
vitality	B-T033
'	O
(	O
mothers	B-T099
:	O
37·0	O
±	O
19·46;	O
fathers	B-T099
:	O
43·12	O
±	O
25·9)	O
before and after stage II	B-T079
.	O
Impact	O
of	O
Family Scale values	B-T033
showed	O
higher	O
daily	O
and	O
social burdens	B-T078
for	O
mothers	B-T099
.	O
'Becoming	O
a	O
family'	O
was	O
the	O
most	O
important	O
task	O
as	O
coping strategy	B-T061
to	O
equilibrate	O
the	O
fragile emotional balance	B-T048
.	O
The	O
parents	B-T099
judged	O
interstage home monitoring	B-T058
as	O
a	O
protective intervention	B-T061
.	O
Although	O
psychosocial burden	B-T080
before and after stage II	B-T079
remains	O
high,	O
becoming	O
a	O
family	B-T099
is	O
an	O
essential	O
experience	O
for	O
parents	B-T099
and	O
confirms	O
their	O
parenthood	B-T054
.	O
Healthcare professionals	B-T097
must	O
be	O
aware	O
of	O
parents	B-T099
'	O
needs	O
during	O
this	O
vulnerable interstage period	B-T079
and	O
to	O
provide	O
psychosocial	B-T169
and	O
nursing support	B-T061
.	O

Rates	B-T081
and	O
predictors	B-T078
of	O
injury	B-T037
in	O
a	O
population	B-T081
-	O
based	B-T169
cohort	B-T098
of	O
people	B-T098
living	B-T078
with	O
HIV	B-T047
Injuries	B-T037
are	O
responsible	O
for	O
10%	O
of	O
the	O
global	B-T080
burden	B-T078
of	O
disease	B-T047
;	O
however,	O
the	O
epidemiology	B-T169
of	O
injury	B-T037
among	O
people living with HIV	B-T047
(	O
PLHIV	B-T047
)	O
has	O
not been well	B-T033
elucidated	B-T052
.	O
This	O
study	B-T062
seeks	O
to	O
characterize	B-T052
rates	B-T081
and	O
predictors	B-T078
of	O
injury	B-T037
among	O
PLHIV	B-T047
compared	B-T052
to	O
the	O
general population	B-T098
in	O
British Columbia	B-T083
(	O
BC	B-T083
),	O
Canada	B-T083
.	O
A	O
population	B-T081
-	O
based	B-T169
dataset	B-T170
was	O
created	B-T080
via	O
linkage	B-T062
between	B-T082
the	O
BC Centre for Excellence in HIV/AIDS	B-T093
and	O
PopulationDataBC	B-T078
.	O
PLHIV	B-T047
aged	B-T032
20 years	B-T079
and	O
older	B-T079
were	O
compared	B-T052
to	O
a	O
random	B-T080
10%	O
sample	B-T167
of	O
the	O
adult	B-T100
general population	B-T098
.	O
The	O
International	B-T078
Classification	B-T185
of	O
Diseases	B-T047
9	O
and	O
10	O
codes	O
were	O
used	B-T169
to	O
classify	B-T185
unintentional	B-T037
and	O
intentional injuries	B-T037
based	B-T169
on	O
the	O
external cause	B-T033
of	O
the	O
injury	B-T037
from	O
1996	O
to	O
2013.	O
Generalized estimating equation	B-T081
(	O
GEE	B-T081
)	O
Poisson regression models	B-T081
were	O
fit	O
to	O
estimate	B-T081
the	O
effect	B-T080
of	O
HIV	B-T047
status	B-T080
on	O
rates	B-T081
of	O
unintentional	B-T037
and	O
intentional injury	B-T037
,	O
and	O
to	O
identify	B-T080
correlates	B-T080
of	O
injury	B-T037
among	O
PLHIV	B-T047
.	O
The	O
crude	O
incidence rate	B-T081
of	O
unintentional injury	B-T037
was	O
18.56/1000	O
person	B-T098
-	O
years	B-T079
[95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
17.77-19.39]	O
among	O
PLHIV	B-T047
and	O
8.51/1000	O
person	B-T098
-	O
years	B-T079
(95%	O
CI	B-T081
8.42-8.59)	O
in	O
the	O
general population	B-T098
.	O
Among	O
PLHIV	B-T047
,	O
13.45%	O
of	O
deaths	B-T033
were	O
due to	B-T169
injury	B-T037
,	O
compared	B-T052
to	O
5.52%	O
of	O
deaths	B-T033
in	O
the	O
general population	B-T098
.	O
In	O
adjusted	O
models	B-T081
,	O
PLHIV	B-T047
were	O
more	O
likely	O
to	O
report	B-T058
unintentional	B-T037
(	O
incidence rate	B-T081
ratio	B-T081
1.42,	O
95%	O
CI	B-T081
1.32-1.52)	O
and	O
intentional injury	B-T037
(	O
incidence rate	B-T081
ratio	B-T081
1.93,	O
95%	O
CI	B-T081
1.70-2.18)	O
compared	B-T052
to	O
the	O
general population	B-T098
.	O
We	O
identified	B-T080
elevated	B-T080
rates	B-T081
of	O
intentional	B-T037
and	O
unintentional injury	B-T037
among	O
PLHIV	B-T047
.	O
Injuries	B-T037
are	O
largely	B-T081
preventable	B-T170
;	O
as	O
such,	O
targeted	B-T169
efforts	O
are	O
needed	B-T080
to	O
decrease	B-T081
the	O
burden	B-T078
of	O
injury	B-T037
-	O
related	B-T080
disability	B-T033
and	O
death	B-T033
among	O
PLHIV	B-T047
.	O

TREK-1 (K2P2.1) K(+) channels	B-T116
are	O
suppressed	B-T169
in	O
patients	B-T101
with	O
atrial fibrillation	B-T047
and	O
heart failure	B-T047
and	O
provide	B-T052
therapeutic targets	B-T169
for	O
rhythm control	B-T080
Atrial fibrillation	B-T047
(	O
AF	B-T047
)	O
is	O
the	O
most	O
common	O
cardiac arrhythmia	B-T033
.	O
Concomitant heart failure	B-T047
(	O
HF	B-T047
)	O
poses	O
a	O
particular	O
therapeutic	B-T169
challenge	B-T059
and	O
is	O
associated	O
with	O
prolonged	B-T079
atrial electrical refractoriness	B-T040
compared	O
with	O
non-failing hearts	B-T023
.	O
We	O
hypothesized	O
that	O
downregulation	B-T044
of	O
atrial repolarizing	B-T042
TREK-1 (K2P2.1) K(+) channels	B-T116
contributes	B-T052
to	O
electrical remodeling	B-T046
during	O
AF	B-T047
with	O
HF	B-T047
,	O
and	O
that	O
TREK-1 gene transfer	B-T063
would	O
provide	O
rhythm control	B-T080
via	O
normalization	B-T062
of	O
atrial effective refractory periods	B-T033
in	O
this	O
AF	B-T047
subset	B-T062
.	O
In	O
patients	B-T101
with	O
chronic AF	B-T047
and	O
HF	B-T047
,	O
atrial TREK-1	B-T116
mRNA	B-T114
levels	B-T080
were	O
reduced	O
by	O
82%	O
(	O
left atrium	B-T023
)	O
and	O
81%	O
(	O
right atrium	B-T023
)	O
compared	O
with	O
sinus rhythm	B-T033
(	O
SR	B-T033
)	O
subjects	B-T098
.	O
Human	B-T016
findings	B-T033
were	O
recapitulated	O
in	O
a	O
porcine model	B-T075
of	O
atrial tachypacing-induced AF	B-T047
and	O
reduced	B-T080
left ventricular function	B-T042
.	O
TREK-1	B-T116
mRNA	B-T114
(-66%)	O
and	O
protein	B-T116
(-61%)	O
was	O
suppressed	B-T169
in	O
AF	B-T047
animals	B-T008
at	O
14-day	O
follow-up	O
compared	B-T052
with	O
SR	B-T033
controls.	O
Downregulation	B-T044
of	O
repolarizing	B-T042
TREK-1 channels	B-T116
was	O
associated	O
with	O
prolongation	B-T079
of	O
atrial effective refractory periods	B-T033
versus	O
baseline	B-T081
conditions,	O
consistent with	B-T078
prior	B-T079
observations	B-T062
in	O
humans	B-T016
with	O
HF	B-T047
.	O
In	O
a	O
preclinical	B-T080
therapeutic approach	B-T169
,	O
pigs	B-T015
were	O
randomized	B-T062
to	O
either	O
atrial Ad-TREK-1 gene therapy	B-T061
or	O
sham treatment	B-T061
.	O
Gene transfer	B-T063
effectively	B-T080
increased	B-T081
TREK-1 protein	B-T116
levels	B-T080
and	O
attenuated	B-T052
atrial effective refractory period	B-T033
prolongation	B-T079
in	O
the	O
porcine AF model	B-T075
.	O
Ad-TREK-1	B-T116
increased	O
the	O
SR	B-T033
prevalence	B-T081
to	O
62%	O
during	O
follow-up	O
in	O
AF	B-T047
animals	B-T008
,	O
compared	B-T052
to	O
35%	O
in	O
the	O
untreated	O
AF	B-T047
group.	O
In	O
conclusion	B-T078
,	O
TREK-1	B-T116
downregulation	B-T044
and	O
rhythm control	B-T080
by	O
Ad-TREK-1 transfer	B-T063
suggest	B-T078
mechanistic and potential therapeutic	B-T061
significance	B-T078
of	O
TREK-1 channels	B-T116
in	O
a	O
subgroup	B-T185
of	O
AF	B-T047
patients	B-T101
with	O
HF	B-T047
and	O
prolonged	B-T079
atrial effective refractory periods	B-T033
.	O
Functional correction	B-T169
of	O
ionic	O
remodeling	O
through	O
TREK-1 gene therapy	B-T061
represents	O
a	O
novel	B-T080
paradigm	B-T062
to	O
optimize	O
and	O
specify	O
AF	B-T047
management.	O

A	O
Rasch Rating Scale	B-T062
Analysis	B-T062
of	O
the	O
Presence	B-T033
of	O
Nursing	B-T091
Scale	B-T081
-	O
RN	B-T097
The	O
phenomenon	B-T067
of	O
nursing	B-T091
presence	B-T033
encompasses	O
the	O
emotional	B-T033
connection	B-T082
between	O
nurse	B-T097
and	O
patient	B-T101
,	O
and	O
technical skills	B-T169
performed	B-T169
by	O
the	O
nurse	B-T097
.	O
The	O
Presence	B-T033
of	O
Nursing	B-T091
Scale	B-T081
-	O
RN	B-T097
version	B-T170
(	O
PONS	B-T081
-	O
RN	B-T097
)	O
was	O
developed	B-T169
to	O
measure	B-T081
nurses'	B-T097
perceptions	B-T041
of	O
their	O
ability	B-T032
to	O
be	O
present	B-T033
to	O
their	O
patients	B-T101
.	O
This	O
study	B-T062
summarizes	B-T170
the	O
process	B-T067
of	O
re-evaluation	B-T062
of	O
the	O
psychometric properties	B-T060
of	O
the	O
PONS	B-T081
-	O
RN	B-T097
instrument.	O
A	O
sample	B-T098
of	O
76	O
registered nurses	B-T097
providing	B-T052
direct	B-T080
patient care	B-T058
responded	B-T041
to	O
the	O
31-	O
item	B-T071
questionnaire	B-T170
.	O
The	O
Rasch rating scale model	B-T062
was	O
used	O
for	O
assessing	B-T058
construct validity	B-T080
of	O
PONS	B-T081
-	O
RN	B-T097
data	B-T078
.	O
A	O
principal component analysis	B-T081
(	O
PCA	B-T081
)	O
of	O
residuals	B-T080
supported	B-T077
appropriateness	B-T080
of	O
the	O
subscales	B-T081
defined	O
by	O
a	O
2-dimensional	B-T082
structure	B-T082
.	O
The	O
results	B-T033
of	O
item	B-T071
and	O
person	B-T098
fit	B-T052
analysis	B-T062
,	O
rating scale	B-T081
functioning	B-T169
analysis	B-T062
and	O
reliability analysis	B-UnknownType
have	O
demonstrated	B-T080
that	O
the	O
thirty-one	O
item	B-T071
Presence	B-T033
of	O
Nursing	B-T091
Scale	B-T081
-	O
RN	B-T097
instrument	O
yielded	O
measures	B-T081
with	O
high	B-T080
validity and reliability	B-UnknownType
as	O
two	O
sub-scales	B-T081
.	O
Jou	O
rn	B-T097

Elastin	B-T116
Is	O
Differentially Regulated	B-T045
by	O
Pressure Therapy	B-T061
in	O
a	O
Porcine	B-T015
Model	B-T008
of	O
Hypertrophic Scar	B-T020
Beneficial effects	B-T080
of	O
pressure therapy	B-T061
for	O
hypertrophic scars	B-T020
have	O
been	O
reported,	O
but	O
the	O
mechanisms	B-T169
of	O
action	O
are	O
not	O
fully	O
understood.	O
This	O
study	B-T062
evaluated	O
elastin	B-T116
and	O
its	O
contribution	O
to	O
scar	B-T020
pliability	B-T080
.	O
The	O
relationship	B-T080
between	O
changes	O
in	O
Vancouver Scar Scale	B-T170
(	O
VSS	B-T170
)	O
scores	B-T081
of	O
pressure-treated	B-T061
scars	B-T020
and	O
differential	O
regulation	O
of	O
elastin	B-T116
was	O
assessed.	O
Hypertrophic scars	B-T020
were	O
created	O
and	O
assessed	O
weekly	B-T079
using	O
VSS	B-T170
and	O
biopsy	B-T060
procurement	B-T033
.	O
Pressure treatment	B-T061
began	O
on	O
day	B-T079
70	O
postinjury	B-T079
.	O
Treated	B-T061
scars	B-T020
were	O
compared	B-T052
with	O
untreated	O
shams	B-T061
.	O
Treatment	B-T061
lasted	O
2	O
weeks	B-T079
,	O
through	O
day	B-T079
84,	O
and	O
scars	B-T020
were	O
assessed	O
weekly	B-T079
through	O
day	B-T079
126.	O
Transcript	B-T114
and	O
protein levels	B-T034
of	O
elastin	B-T116
were	O
quantified	B-T081
.	O
Pressure treatment	B-T061
resulted	O
in	O
lower	O
VSS	B-T170
scores	B-T081
compared	B-T052
with	O
sham-treated	B-T061
scars	B-T020
.	O
Pliability	B-T080
(	O
VSSP	B-T080
)	O
was	O
a	O
key	O
contributor	O
to	O
this	O
difference.	O
At	O
day	B-T079
70	O
pretreatment	B-T052
,	O
VSSP	B-T080
=	O
2.	O
Without treatment	B-T061
,	O
sham-treated	B-T061
scars	B-T020
became	O
less	O
pliable	B-T080
,	O
while	O
pressure-treated	B-T061
scars	B-T020
became	O
more	O
pliable	B-T080
.	O
The	O
percentage	O
of	O
elastin	B-T116
in	O
scars	B-T020
at	O
day	B-T079
70	O
was	O
higher	O
than	O
in	O
uninjured skin	B-T022
.	O
Following	O
treatment	B-T061
,	O
the	O
percentage	O
of	O
elastin	B-T116
increased	B-T081
and	O
continued	O
to	O
increase	B-T169
through	O
day	B-T079
126.	O
Untreated	O
sham	B-T061
scars	B-T020
did	O
not	O
show	O
a	O
similar	O
increase	B-T169
.	O
Quantification	B-T081
of	O
Verhoeff-Van Gieson staining	B-T059
corroborated	O
the	O
findings	B-T033
and	O
immunofluorescence	B-T059
revealed	O
the	O
alignment	B-T081
of	O
elastin fibers	B-T116
.	O
Pressure treatment	B-T061
results	O
in	O
increased	B-T081
protein level expression	B-T045
of	O
elastin	B-T116
compared	B-T052
with	O
sham	B-T061
-untreated	O
scars	B-T020
.	O
These	O
findings	B-T033
further	O
characterize	O
the	O
extracellular matrix's	B-T024
response	O
to	O
the	O
application	O
of	O
pressure	B-T067
as	O
a	O
scar	B-T020
treatment	B-T061
,	O
which	O
will	O
contribute	O
to	O
the	O
refinement	O
of	O
rehabilitation	B-T169
practices	O
and	O
ultimately	O
improvements	B-T077
in	O
functional	B-T169
and	O
psychosocial	B-T169
outcomes	B-T169
for	O
patients	B-T101
.	O

Epigenome-wide analysis	B-T063
links	O
SMAD3	B-T028
methylation	B-T044
at	O
birth	B-T040
to	O
asthma in children	B-T047
of	O
asthmatic	B-T047
mothers	B-T099
The	O
timing	O
and	O
mechanisms	B-T169
of	O
asthma	B-T047
inception	B-T169
remain	O
imprecisely	O
defined.	O
Although	O
epigenetic	B-T045
mechanisms	B-T169
likely	O
contribute	O
to	O
asthma	B-T047
pathogenesis	B-T046
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
asthma	B-T047
inception	B-T169
.	O
We	O
sought	O
to	O
assess	B-T058
whether	O
the	O
trajectory	O
to	O
asthma	B-T047
begins	O
already	O
at	O
birth	B-T040
and	O
whether	O
epigenetic	B-T045
mechanisms	B-T169
,	O
specifically	O
DNA methylation	B-T044
,	O
contribute	O
to	O
asthma	B-T047
inception	B-T169
.	O
We	O
used	O
the	O
Methylated CpG Island Recovery Assay chip	B-T059
to	O
survey	B-T170
DNA methylation	B-T044
in	O
cord blood	B-T031
mononuclear cells	B-T025
from	O
36	O
children	B-T100
(18	O
nonasthmatic	B-T098
and	O
18	O
asthmatic	B-T047
subjects	B-T098
by	O
age	B-T032
9	O
years	B-T079
)	O
from	O
the	O
Infant	B-T100
Immune	B-T169
Study	B-T062
(	O
IIS	B-T062
),	O
an	O
unselected	O
birth	B-T040
cohort	B-T098
closely	O
monitored	O
for	O
asthma	B-T047
for	O
a	O
decade.	O
SMAD3	B-T028
methylation	B-T044
in	O
IIS	B-T062
(n	O
=	O
60)	O
and	O
in	O
2	O
replication	B-T045
cohorts	B-T098
(the	O
Manchester	B-UnknownType
Asthma	B-T047
and	O
Allergy Study	B-T059
[n	O
=	O
30]	O
and	O
the	O
Childhood Origins of Asthma	B-T047
Study	B-T062
[n	O
=	O
28])	O
was	O
analyzed	B-T062
by	O
using	O
bisulfite sequencing	B-T063
or	O
Illumina 450K arrays	B-T059
.	O
Cord blood	B-T031
mononuclear cell	B-T025
-derived	O
IL-1β	B-T116
levels	B-T080
were	O
measured	B-T080
by	O
means	O
of	O
ELISA	B-T059
.	O
Neonatal	B-T100
immune	B-T169
cells	B-T025
harbored	O
589	O
differentially	O
methylated regions	B-T086
that	O
distinguished	O
IIS	B-T062
children	B-T098
who	O
did	O
and	O
did	O
not	O
have	O
asthma	B-T047
by	O
age	B-T032
9	O
years	B-T079
.	O
In	O
all	O
3	O
cohorts	B-T098
methylation	B-T044
in	O
SMAD3	B-T028
,	O
the	O
most	O
connected	O
node	O
within	O
the	O
network	O
of	O
asthma	B-T047
-	O
associated	B-T080
,	O
differentially	O
methylated regions	B-T086
,	O
was	O
selectively	O
increased	B-T081
in	O
asthmatic	B-T047
children	B-T100
of	O
asthmatic	B-T047
mothers	B-T099
and	O
was	O
associated with	B-T080
childhood asthma	B-T047
risk	B-T078
.	O
Moreover,	O
SMAD3	B-T028
methylation	B-T044
in	O
IIS	B-T062
neonates	B-T100
with	O
maternal	B-T099
asthma	B-T047
was	O
strongly	O
and	O
positively	O
associated with	B-T080
neonatal	B-T100
production	O
of	O
IL-1β	B-T116
,	O
an	O
innate inflammatory mediator	B-T121
.	O
The	O
trajectory	O
to	O
childhood asthma	B-T047
begins	O
at	O
birth	B-T040
and	O
involves	O
epigenetic	B-T045
modifications	B-T169
in	O
immunoregulatory	B-T040
and	O
proinflammatory	B-T169
pathways	B-T044
.	O
Maternal	B-T099
asthma	B-T047
influences	O
epigenetic	B-T045
mechanisms	B-T169
that	O
contribute	O
to	O
the	O
inception	B-T169
of	O
this	O
trajectory.	O

Clinical	B-T080
correlates	B-T080
of	O
faecal incontinence	B-T047
in	O
systemic sclerosis	B-T047
:	O
identifying	O
therapeutic avenues	B-UnknownType
The	O
aim	O
was	O
to	O
establish	O
the	O
prevalence	B-T081
and	O
severity	B-T080
of	O
faecal incontinence	B-T047
(	O
FI	B-T047
)	O
in	O
SSc	B-T047
,	O
its	O
association	B-T080
with	O
other	O
intestinal	B-T023
manifestations	B-T169
and	O
potential	B-T080
predictors	B-T078
of	O
FI	B-T047
,	O
and	O
its	O
impact	B-T080
on	O
quality of life	B-T078
.	O
A	O
multicentre,	O
cross-sectional study	B-T062
of	O
298	O
SSc	B-T047
subjects	B-T101
followed	O
in	O
the	O
Canadian Scleroderma Research Group	B-T093
cohort	B-T098
was	O
performed	O
using	O
validated	O
questionnaires	B-T170
:	O
Jorge-Wexner score	B-T170
(an	O
FI	B-T047
severity scale	B-T170
),	O
Bristol stool scale	B-T170
(a	O
visual	O
scale	O
of	O
stool consistency	B-T033
)	O
and	O
FI	B-T047
Quality-of-Life scale	B-T170
.	O
Constipation	B-T184
was	O
defined	O
by	O
the	O
Rome III criteria	B-T170
.	O
Associations	B-T080
between	O
the	O
Jorge-Wexner score	B-T170
and	O
other	O
clinical variables	B-T033
were	O
determined	O
using	O
multivariate regression analyses	B-T170
.	O
Eighty-one	O
(27.2%)	O
subjects	B-T101
had	O
FI	B-T047
,	O
which	O
was	O
mild	B-T080
in	O
37	O
(12.4%)	O
and	O
moderate to severe	B-T080
in	O
44	O
(14.8%).	O
Most	O
patients	B-T101
had	O
well-formed	O
stools	B-T031
,	O
111	O
(38.8%)	O
reported	O
constipation	B-T184
and	O
38	O
(13.4%)	O
had	O
been	O
previously	B-T079
treated	B-T169
for	O
small intestinal bacterial overgrowth	B-T047
(	O
SIBO	B-T047
).	O
Variables	B-T080
independently	B-T078
associated with	B-T080
FI	B-T047
were:	O
loose	B-T184
vs	O
well-formed	O
stools	B-T031
[	O
odds ratio	B-T081
(	O
OR	B-T081
)	O
=	O
7.01,	O
95%	O
CI	B-T081
:	O
2.09,	O
23.51)],	O
constipation	B-T184
(	O
OR	B-T081
=	O
3.64,	O
95%	O
CI	B-T081
:	O
1.61,	O
8.27,	O
P	B-T081
=	O
0.002),	O
history	B-T033
of	O
SIBO	B-T047
(	O
OR	B-T081
=	O
2.97,	O
95%	O
CI	B-T081
:	O
1.06,	O
8.27)	O
and	O
urinary incontinence	B-T046
(	O
OR	B-T081
=	O
2.45,	O
95%	O
CI	B-T081
:	O
1.14,	O
5.27).	O
Quality of life	B-T078
measured	B-T080
with	O
the	O
FI	B-T047
Quality-of-Life scale	B-T170
was	O
inversely	B-T080
correlated	B-T080
with	O
FI	B-T047
severity	B-T080
(	O
correlation	B-T080
coefficients	B-T081
between	O
-0.602	O
and	O
-0.702,	O
P	B-T081
<	O
0.001).	O
FI	B-T047
was	O
common	B-T081
and	O
often	O
severe	B-T080
in	O
SSc	B-T047
.	O
Loose stools	B-T184
,	O
SIBO	B-T047
,	O
constipation	B-T184
and	O
urinary incontinence	B-T046
were	O
strongly	B-T080
associated with	B-T080
FI	B-T047
.	O
Other	O
than	O
targeting	B-T169
anorectal	B-T030
dysfunction	B-T046
,	O
concomitant	B-T079
treatment	B-T061
of	O
clinical	B-T080
correlates	B-T080
could	O
lead	O
to	O
improvement	B-T077
in	O
FI	B-T047
and	O
quality of life	B-T078
in	O
SSc	B-T047
.	O

From	O
training	B-T065
to	O
practice	B-T057
:	O
the	O
impact	B-T080
of	O
ENGAGE	B-T093
,	O
Ireland's	B-T083
national men's health training programme	B-T065
Ireland's	B-T083
National Men's Health Policy	B-T170
recommended	B-T078
developing	O
training programmes	B-T065
tailored	B-T058
to	O
the	O
needs	B-T080
of	O
those	O
working	B-T057
in	O
health	B-T097
and	O
allied health professionals	B-T097
and	O
ENGAGE	B-T093
was	O
developed	O
to	O
meet	O
that	O
recommendation	B-T078
.	O
This	O
study	B-T062
evaluated	B-T058
the	O
impact	B-T080
of	O
ENGAGE	B-T093
on	O
frontline service providers'	B-T058
self-reported knowledge	B-T033
,	O
skills	B-T055
,	O
capacity	B-T081
and	O
practice	B-T057
up	O
to	O
5-months	O
post	B-T079
training	B-T065
.	O
Between	O
2012	O
and	O
2015,	O
ENGAGE	B-T093
Trainers	B-T073
(n	O
=	O
57)	O
delivered	O
62	O
1-day	O
training programmes	B-T065
to	O
810	O
participants	B-T098
.	O
This	O
study	B-T062
was	O
conducted	O
on	O
a	O
subset	B-T185
of	O
those	O
training	B-T065
days	O
(n	O
=	O
26)	O
and	O
participants	B-T098
.	O
Quantitative	B-T081
methodologies	B-T062
were	O
used	O
to	O
collect	O
pre	O
(n	O
=	O
295),	O
post	B-T079
(n	O
=	O
295)	O
and	O
5-month	O
post	B-T079
(n	O
=	O
128)	O
training	B-T065
questionnaire	B-T170
data.	O
Overall	B-T080
,	O
participants	B-T098
were	O
highly	O
satisfied	B-T170
with	O
the	O
training	B-T065
immediately	B-T079
post	B-T079
training	B-T065
(8.60	O
±	O
1.60	O
out	O
of	O
10)	O
and	O
at	O
5-month	O
follow up	B-T033
(8.06	O
±	O
1.43	O
out	O
of	O
10).	O
Participants'	B-T098
self-reported level of knowledge	B-T033
,	O
skill	B-T055
and	O
capacity	B-T081
in	O
identifying	O
priorities	B-T079
,	O
engaging	O
men	B-T098
and	O
influencing	B-T077
practice	B-T057
beyond	O
their	O
own	O
organisation	B-T057
increased	B-T081
immediately	B-T079
following	O
training	B-T065
(P	O
<	O
0.001)	O
and,	O
with	O
the	O
exception	B-T077
of	O
improving	B-T080
capacity	B-T081
to	O
engage	O
men	B-T098
and	O
influencing	B-T077
practice	B-T057
beyond	O
their	O
organisation	B-T057
,	O
these	O
improvements	B-T057
were	O
sustained	B-T169
at	O
5-month	O
post	B-T079
training	B-T065
(P	O
<	O
0.001).	O
The	O
vast	O
majority	B-T054
of	O
service providers	B-T058
(93.4%)	O
reported	B-T058
that	O
ENGAGE	B-T093
had	O
impacted	B-T080
their	O
work	B-T057
practice	B-T057
up	O
to	O
5-month	O
post	B-T079
training	B-T065
.	O
The	O
findings	B-T033
suggest	B-T078
that	O
ENGAGE	B-T093
has	O
succeeded	B-T033
in	O
improving	B-T080
service providers'	B-T058
capacity	B-T081
to	O
engage	O
and	O
work	B-T057
with	O
men	B-T098
;	O
improving	B-T080
gender	B-T032
competency	B-T080
in	O
the	O
delivery	O
of	O
health	B-T078
and	O
health related services	B-T058
may	O
increase	B-T081
the	O
utilisation	B-T058
of	O
such	O
services	B-T058
by	O
men	B-T098
and	O
thereby	O
improve	B-T033
health outcomes	B-T057
for	O
men	B-T098
.	O

Double strand break	B-T049
induction	B-T169
and	O
kinetics	B-T070
indicate	O
preserved	O
hypersensitivity	B-T046
in	O
keratinocytes	B-T025
to	O
subtherapeutic	B-T169
doses	B-T081
for	O
7	O
weeks	B-T079
of	O
radiotherapy	B-T061
Previously	O
we	O
reported	O
that	O
hyper-radiosensitivity	B-T032
(	O
HRS	B-T032
)	O
was	O
evidenced	O
by	O
quantifying	B-T081
DNA double strand break (DSB) foci	B-T026
in	O
epidermis	B-T024
biopsies	B-T060
collected	O
after	O
delivering	O
radiotherapeutic	B-T170
one	O
and	O
five	O
dose fractions	B-T081
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
determine	O
whether	O
HRS	B-T032
was	O
preserved	O
throughout	O
a	O
7-	O
week	B-T079
radiotherapy	B-T061
treatment	B-T061
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	B-T026
decline	O
and	O
foci	B-T026
persistence	O
between	O
dose fractions	B-T081
.	O
42	O
patients	B-T101
with	O
prostate cancer	B-T191
received	O
7-	O
week	B-T079
fractionated	O
radiotherapy treatment	B-T061
(	O
RT	B-T061
)	O
with	O
daily	O
dose fractions	B-T081
of	O
0.05-1.10Gy	O
to	O
the	O
skin	B-T022
.	O
Before	O
RT	B-T061
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	B-T061
,	O
skin biopsies	B-T060
(n=452)	O
were	O
collected	O
at	O
30min,	O
and	O
2,	O
3,	O
24,	O
and	O
72h	O
after	O
dose fractions	B-T081
.	O
DSB-foci	B-T026
markers	B-T086
,	O
γH2AX	B-T028
and	O
53BP1	B-T028
,	O
were	O
labelled	O
in	O
epidermal	B-T024
keratinocytes	B-T025
with	O
immunofluorescence	B-T059
and	O
immunohistochemical staining	B-T059
.	O
Foci	O
were	O
counted	O
both	O
with	O
digital image analysis	B-T060
and	O
manually.	O
HRS	B-T032
in	O
keratinocytes	B-T025
was	O
evidenced	O
by	O
the	O
dose-response relationships	B-T038
of	O
DSB foci	B-T026
,	O
observed	O
throughout	O
the	O
treatment course	B-T079
,	O
independent of	B-T169
sampling	B-T060
time	B-T079
and	O
quantification	B-T081
method	B-T170
.	O
Foci	B-T026
observed	O
at	O
24h	O
after	O
dose fractions	B-T081
indicated	O
considerable	O
DSB	B-T049
persistence.	O
Accordingly,	O
foci	B-T026
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose fractions	B-T081
.	O
For	O
doses	B-T081
below	O
0.3Gy,	O
persistent	O
foci	B-T026
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	B-T049
induction	B-T169
.	O
A	O
comparison	B-T052
of	O
γH2AX	B-T028
and	O
53BP1	B-T028
quantifications	B-T081
in	O
double-staine	B-T080
d	O
biopsies	B-T060
showed	O
similar	O
HRS	B-T032
dose-response relationships	B-T038
.	O
These	O
results	O
represented	O
the	O
first	O
evidence	B-T078
of	O
preserved	O
HRS	B-T032
,	O
assessed	B-T052
by	O
γH2AX	B-T028
-	O
and	O
53BP1	B-T028
-labelled	O
DSB foci	B-T026
,	O
throughout	O
a	O
7-	O
week	B-T079
treatment course	B-T079
with	O
daily	B-T079
repeated	O
subtherapeutic	B-T169
dose fractions	B-T081
.	O

CT angiography	B-T060
for	O
planning	B-T169
transcatheter aortic valve replacement	B-T061
using	O
automated tube voltage selection	B-T081
:	O
Image quality	B-T080
and	O
radiation	B-T070
exposure	B-T080
To	O
assess	B-T058
image quality	B-T080
and	O
accuracy	B-T080
of	O
CT angiography	B-T060
(	O
CTA	B-T060
)	O
for	O
transcatheter aortic valve replacement	B-T061
(	O
TAVR	B-T061
)	O
planning	B-T169
performed	O
with	O
3rd generation dual-source CT	B-T060
(	O
DSCT	B-T060
).	O
We	O
evaluated	O
125	O
patients	B-T101
who	O
underwent	O
TAVR	B-T061
-	O
planning	B-T169
CTA	B-T060
on	O
3rd generation DSCT	B-T060
.	O
A	O
two-part protocol	B-T061
was	O
performed	O
including	O
retrospectively	B-T080
ECG-gated coronary CTA	B-T060
(	O
CCTA	B-T060
)	O
and	O
prospectively	B-T080
ECG-triggered aortoiliac CTA	B-T060
using	O
60mL	O
of	O
contrast medium	B-T130
.	O
Automated tube voltage selection	B-T081
and	O
advanced iterative reconstruction	B-T060
were	O
applied.	O
Effective dose	B-T081
(	O
ED	B-T081
),	O
signal-to-noise	B-T081
(	O
SNR	B-T081
)	O
and	O
contrast-to-noise ratios	B-T081
(	O
CNR	B-T081
)	O
were	O
calculated.	O
Five-point scales	B-T170
were	O
used	O
for	O
subjective	B-T080
image quality analysis	B-T060
.	O
In	O
patients	B-T101
who	O
underwent	O
TAVR	B-T061
,	O
sizing parameters	B-T033
were	O
obtained.	O
Image quality	B-T080
was	O
rated	O
good	O
to	O
excellent	O
in	O
97.6%	O
of	O
CCTA	B-T060
and	O
100%	O
of	O
aortoiliac CTAs	B-T060
.	O
CTA	B-T060
studies	B-T062
at	O
>100kV	O
showed	O
decreased	B-T081
objective	B-T080
image quality	B-T080
compared	O
to	O
70-100kV	O
(	O
SNR	B-T081
,	O
all	O
p≤0.0459;	O
CNR	B-T081
,	O
all	O
p≤0.0462).	O
Mean	B-T081
ED	B-T081
increased	B-T081
continuously	O
from	O
70	O
to	O
>100kV	O
(	O
CCTA	B-T060
:	O
4.5±1.7mSv-13.6±2.9mSv,	O
all	O
p≤0.0233;	O
aortoiliac CTA	B-T060
:	O
2.4±0.9mSv-6.8±2.7mSv,	O
all	O
p≤0.0414).	O
In	O
39	O
patients	B-T101
TAVR	B-T061
was	O
performed	O
and	O
annulus	B-T023
diameter	B-T081
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	B-T101
.	O
No	B-T033
severe	B-T080
cardiac	B-T046
or	O
vascular complications	B-T046
were	O
noted.	O
3rd generation DSCT	B-T060
provides	O
diagnostic	B-T169
image quality	B-T080
in	O
TAVR	B-T061
-	O
planning	B-T169
CTA	B-T060
and	O
facilitates	O
reliable	O
assessment	B-T058
of	O
TAVR	B-T061
device	B-T074
and	O
delivery	B-T169
option	O
while	O
reducing	B-T080
radiation dose	B-T081
.	O

A	O
Giant	B-T025
Aneurysmal Bone Cyst	B-T047
in	O
the	O
Mandibular Condyle	B-T023
Aneurysmal bone cyst	B-T047
(	O
ABC	B-T047
)	O
is	O
a	O
rare	B-T080
,	O
rapidly	B-T080
expanding	B-T082
,	O
locally	B-T082
destructive	B-T052
,	O
and	O
easily	B-T033
misdiagnosed	B-T033
lesion	B-T033
.	O
An	O
ABC	B-T047
of	O
the	O
condyle	B-T023
is	O
rare	B-T080
.	O
This	O
report	O
presents	O
a	O
25-	O
year	B-T079
-	O
old	B-T079
female	B-T032
with	O
a	O
giant	B-T025
ABC	B-T047
in	O
the	O
left mandibular condyle	B-T082
mandibular condyle	B-T023
.	O
This	O
patient	B-T101
was	O
treated with	B-T061
surgical resection	B-T061
of	O
the	O
affected	B-T169
bone	B-T023
and	O
immediate	O
mandibular reconstruction	B-T061
using	O
autologous	B-T080
bone	B-T023
.	O
Follow-up to date	B-T058
showed	O
no	O
signs	B-T033
of	O
recurrence	B-T067
.	O
The	O
clinical	B-T080
feature	B-T080
,	O
imaging finding	B-T034
,	O
pathogenesis	B-T046
,	O
and	O
treatment methods	B-T061
of	O
ABCs	B-T047
are	O
discussed.	O

Association	B-T080
between	O
postpartum depression	B-T048
and	O
the	O
practice	B-T041
of	O
exclusive breastfeeding	B-T055
in	O
the	O
first	O
three	O
months	B-T079
of	O
life	B-T078
To	O
investigate	B-T169
the	O
association	B-T080
between	O
postpartum depression	B-T048
and	O
the	O
occurrence	B-T079
of	O
exclusive breastfeeding	B-T055
.	O
This	O
is	O
a	O
cross-sectional study	B-T062
conducted	O
in	O
the	O
states	B-T083
of	O
the	O
Northeast region	B-T083
,	O
during	O
the	O
vaccination campaign	B-T058
in	O
2010.	O
The	O
sample	O
consisted	O
of	O
2583	O
mother	B-T099
-	O
child	B-T100
pairs	B-T080
,	O
with	O
children	B-T100
aged	B-T032
from	O
15	O
days	B-T079
to	O
3	O
months	B-T079
.	O
The	O
Edinburgh Postnatal Depression Scale	B-T170
was	O
used	O
to	O
screen	B-T058
for	O
postpartum depression	B-T048
.	O
The	O
outcome	B-T169
was	O
lack	B-T080
of	O
exclusive breastfeeding	B-T055
,	O
defined	O
as	O
the	O
occurrence	B-T079
of	O
this	O
practice	B-T078
in	O
the	O
24h	O
preceding	B-T079
the	O
interview	B-T052
.	O
Postpartum depression	B-T048
was	O
the	O
explanatory variable	B-UnknownType
of	O
interest	O
and	O
the	O
covariates	B-UnknownType
were:	O
socioeconomic	B-T102
and	O
demographic conditions	B-T078
;	O
maternal health care	B-T058
;	O
prenatal	B-T058
,	O
delivery	B-T061
,	O
and	O
postnatal care	B-T058
;	O
and	O
the	O
child's biological factors	B-T080
.	O
Multivariate logistic regression analysis	B-T081
was	O
conducted	O
to	O
control	O
for	O
possible	O
confounding factors	B-T169
.	O
Exclusive breastfeeding	B-T055
was	O
observed	B-T169
in	O
50.8%	O
of	O
the	O
infants	B-T100
and	O
11.8%	O
of	O
women	B-T098
had	O
symptoms	B-T184
of	O
postpartum depression	B-T048
.	O
In	O
the	O
multivariate logistic regression analysis	B-T081
,	O
a	O
higher	O
chance	O
of	O
exclusive breastfeeding	B-T055
absence	B-T169
was	O
found	O
among	O
mothers	B-T099
with	O
symptoms	B-T184
of	O
postpartum depression	B-T048
(OR=1.67;	O
p<0.001),	O
among	O
younger subjects	B-T098
(OR=1.89;	O
p<0.001),	O
those	O
who	O
reported	O
receiving	O
benefits	B-T081
from	O
the	O
Bolsa Família Program	B-UnknownType
(OR=1.25;	O
p=0.016),	O
and	O
those	O
started	O
antenatal care	B-T058
later	O
during	O
pregnancy	B-T040
(OR=2.14;	O
p=0.032).	O
Postpartum depression	B-T048
contributed	O
to	O
reducing	B-T080
the	O
practice	B-T078
of	O
exclusive breastfeeding	B-T055
.	O
Therefore,	O
this	O
disorder	B-T047
should	O
be	O
included	O
in	O
the	O
prenatal	B-T058
and	O
early postpartum	B-T079
support guidelines	B-T170
for	O
breastfeeding	B-T040
,	O
especially	O
in	O
low socioeconomic status	B-T081
women	B-T098
.	O

Evidence of	B-T169
toothpick	B-T073
groove	B-T030
formation	B-T169
in	O
Neandertal	B-T015
anterior	B-T082
and	O
posterior	B-T082
teeth	B-T023
During	O
the	O
microscopic examination	B-T059
of	O
the	O
Neandertal	B-T015
dentitions	B-T023
from	O
El Sidrón	B-T083
(	O
Spain	B-T083
)	O
and	O
Hortus	B-T083
(	O
France	B-T083
),	O
we	O
found	O
unusual	B-T080
fine	O
parallel	O
microstriations	B-T070
on	O
the	O
mesial	B-T029
and	O
distal sides	B-T082
of	O
all	O
tooth	B-T023
types,	O
near	O
the	O
cervix	B-T029
.	O
As	O
its	O
appearance	O
was	O
similar	B-T080
to	O
toothpick	B-T073
grooves	B-T030
described	O
in	O
other	O
Homo species	B-T015
,	O
it	O
could	O
correspond	O
to	O
early stages	B-T079
on	O
its	O
formation	B-T169
.	O
To	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental replication	B-T062
of	O
a	O
groove	B-T030
using	O
grass	B-T002
stalks	B-T002
.	O
Comparisons	B-T052
between	O
204	O
isolated	B-T169
Neandertal	B-T015
teeth	B-T023
and	O
the	O
two	O
experimental	B-T080
dental	B-T080
specimens	B-T167
corroborate	O
that	O
the	O
marks	B-T184
correspond	O
to	O
initial stages	B-T079
of	O
toothpick	B-T073
groove	B-T030
formation	B-T169
,	O
and	O
we	O
propose	O
a	O
five-grade recording scale	B-T170
that	O
summarized	O
the	O
groove	B-T030
formation process	B-T169
.	O
Using	O
this	O
new	O
recording	O
procedure,	O
we	O
found	O
that	O
Hortus	B-T083
individuals	B-T098
have	O
higher	O
incidence	B-T081
of	O
this	O
trait	O
(eight	O
individuals	B-T098
out	O
of	O
nine)	O
than	O
the	O
El Sidrón	B-T083
individuals	B-T098
(nine	O
out	O
of	O
11).	O
Toothpick	B-T073
grooves	B-T030
from	O
El Sidrón	B-T083
show	O
the	O
earliest stages	B-T079
of	O
development	B-T169
,	O
whereas	O
the	O
grooves	B-T030
found	O
on	O
Hortus	B-T083
Neandertals	B-T015
were	O
well-developed	B-T080
.	O
Toothpick	B-T073
grooves	B-T030
were	O
also	O
found	O
in	O
21	O
incisors	B-T023
and	O
canines	B-T023
.	O
These	O
differences	B-T080
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	B-T029
dental wear	B-T037
in	O
Hortus	B-T083
individuals	B-T098
,	O
maybe	O
age	B-T032
-related	O
and	O
with	O
a	O
more	O
meat	B-T168
-based	O
diet	B-T168
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	B-T168
debris	B-T167
and	O
thus	O
probing	B-T169
as	O
the	O
cleaning methodology	B-T052
.	O
Our	O
results	O
allow	O
the	O
identification	B-T080
and	O
characterization	B-T052
of	O
incipient	B-T079
toothpick	B-T073
grooves	B-T030
on	O
the	O
human	B-T016
fossil	B-T167
record	B-T170
and	O
contribute	B-T052
to	O
increase	B-T169
our	O
knowledge	B-T170
on	O
Neandertals	B-T015
behavioral	B-T055
and	O
oral care habits	B-T033
.	O

THSD7A	B-T116
expression	B-T045
in	O
human	B-T016
cancer	B-T191
We	O
recently	O
described	O
a	O
case	O
of	O
a	O
Thrombospondin Type-1 Domain containing 7A	B-T116
(	O
THSD7A	B-T116
)	O
associated	O
membranous nephropathy	B-T047
in	O
a	O
female patient	B-T032
who	O
was	O
synchronously	B-T079
suffering	B-T184
from	O
a	O
THSD7A	B-T116
-	O
positive	B-T033
malignancy	B-T080
.	O
We	O
here	O
investigated	O
the	O
role	O
of	O
THSD7A	B-T116
as	O
a	O
new	O
potential	O
tumor antigen	B-T116
by	O
evaluating	O
over	O
20	O
000	O
tissue spots	B-T024
in	O
more	O
than	O
70	O
different	O
tumor entities	B-T033
by	O
immunohistochemistry	B-T060
using	O
tissue microarrays	B-T075
.	O
THSD7A	B-T116
expression	B-T045
was	O
highly	O
variable	O
in	O
different neoplasias	B-T191
with	O
differing	O
staining patterns	B-T082
.	O
Both	O
gain and loss	B-T033
of	O
THSD7A	B-T116
expression	B-T045
compared	O
to	O
expression status	B-T045
in	O
non-tumor tissue	B-T024
were	O
linked	O
to	O
tumor-specific markers	B-T123
in	O
the	O
different	O
tumor entities	B-T033
and	O
were	O
of	O
prognostic value	B-T081
.	O
The	O
potential	O
role	O
of	O
THSD7A	B-T116
in	O
tumor development	B-T033
and	O
therapy	B-T061
needs	O
further	O
investigation.	O

Civil Society	B-UnknownType
-Driven	O
Drug Policy Reform	B-UnknownType
for	O
Health	B-T078
and	O
Human Welfare	B-T095
-	O
India	B-T083
The	O
lack	B-T080
of	O
adequate	B-T080
access	O
to	O
opioids	B-T109
in	O
India	B-T083
as	O
analgesics	B-T109
and	O
for	O
agonist	B-T121
therapies	B-T061
,	O
forces	O
millions	O
to	O
live	O
with	O
severe	B-T080
unalleviated pain	B-T184
,	O
or	O
languish	B-T080
with	O
suffering	B-T048
associated	O
with	O
drug dependence	B-T048
.	O
Although	O
India	B-T083
is	O
a	O
major	O
opium	B-T109
exporter	B-T097
,	O
the	O
excessively	O
prohibitive	B-T054
1985	O
narcotics law	B-T089
formulated	O
to	O
control	B-T080
harmful use of drugs	B-T048
,	O
impeded	O
the	O
availability	B-T169
and	O
access	B-T082
to	O
opioids	B-T109
for	O
medical	B-UnknownType
and	O
scientific	B-T062
purposes	B-T169
.	O
Amendment	B-T170
of	O
this	O
law	B-T170
in	O
2014	O
established	O
a	O
new	O
national regulatory framework	B-T089
for	O
improved	O
access	B-T082
to	O
essential	B-T080
opioid analgesics	B-T109
.	O
This	O
article	O
reflects	O
on	O
key	O
elements	O
and	O
processes	O
that	O
led	O
to	O
this	O
landmark	O
achievement	B-T053
.	O
Unlike	O
quick	O
timelines	O
associated	O
with	O
effecting	O
policy reforms	B-UnknownType
for	O
law enforcement	B-T064
,	O
realizing	O
the	O
2014	O
drug policy	B-UnknownType
change	O
primarily	O
to	O
mitigate	B-T067
human suffering,	B-T048
was	O
a	O
22-year-long	O
process.	O
The	O
most	O
exacting	O
challenges	O
included	O
recognizing	O
the	O
multilayered complexities	B-T033
of	O
the	O
prior	O
policy framework	B-T170
and	O
understanding	O
their	O
adverse	B-T080
impact	B-UnknownType
on	O
field	O
practices	O
to	O
chart	O
an	O
appropriate	O
and	O
viable	O
path	O
for	O
reform	B-T064
.	O
The	O
evolution	O
of	O
an	O
informal	O
civil society movement	B-T054
involving	O
health care professionals	B-T097
,	O
lawyers	B-T097
,	O
media	B-T097
,	O
policy analysts	B-T097
,	O
government officials	B-T097
,	O
and	O
the	O
public	B-T098
was	O
pivotal	O
in	O
addressing	O
these	O
challenges	B-T058
and	O
garnering	O
momentum	O
for	O
reform	B-UnknownType
.	O
The	O
success	B-T054
of	O
the	O
effort	O
for	O
improving	O
access	B-T080
to	O
opioid	B-T109
medications	B-T058
was	O
underpinned	O
by	O
a	O
three-pronged	O
strategy	O
of	O
1)	O
persuading	O
the	O
executive arm of the government	B-T097
to	O
take	O
interim	B-T079
enabling	O
measures	B-T170
;	O
2)	O
leveraging	O
judicial intervention	B-T064
through	O
public	B-T098
interest	B-T098
litigation	B-T068
;	O
and	O
3)	O
crafting a viable policy document	B-T064
for	O
legislative approval	B-T064
and	O
implementation	B-T052
.	O
We	O
hope	O
our	O
findings	O
are	O
useful	O
for	O
realizing	O
drug policy reforms	B-UnknownType
,	O
given	O
the	O
current	O
transformed	O
global	B-T080
policy	B-T170
mandates	B-UnknownType
emphasizing	O
humanitarian	B-T095
,	O
healthcare	B-T058
,	O
and	O
quality-of-life	B-T078
considerations	B-T033
.	O

Efficacy	B-T080
of	O
Synbiotics	B-T168
for	O
Treatment	B-T061
of	O
Bacillary Dysentery	B-T047
in	O
Children	B-T100
:	O
A	O
Double-Blind	B-T062
,	O
Randomized	B-T062
,	O
Placebo-Controlled Study	B-T062
Bacillary dysentery	B-T047
is	O
a	O
major	O
cause	O
of	O
children's	B-T100
admission to hospitals	B-T058
.	O
To	O
assess	B-T058
the	O
probiotic	B-T007
and	O
prebiotic	B-T109
(	O
synbiotics	B-T168
)	O
effects	B-T080
in	O
children	B-T100
with	O
dysentery	B-T047
in	O
a	O
randomized clinical trial	B-T062
,	O
200	O
children	B-T100
with	O
dysentery	B-T047
were	O
studied	O
in	O
2	O
groups	B-T078
:	O
the	O
synbiotic	B-T168
group	B-T078
received	O
1	O
tablet	B-T122
/day	B-T079
of	O
synbiotic	B-T168
for	O
3-5	O
days	B-T079
and	O
the	O
placebo	B-T122
group	B-T078
received	O
placebo	B-T122
tablets	B-T122
(identical	O
tablet	B-T122
form	O
like	O
probiotics	B-T007
).	O
The	O
standard	B-T080
treatment	B-T061
was	O
administered	B-T169
for	O
all	O
patients	B-T101
.	O
Duration	B-T079
of	O
hospitalization	B-T058
,	O
dysentery	B-T047
,	O
fever	B-T184
,	O
and	O
the	O
weight loss	B-T033
were	O
assessed	B-T052
in	O
each	O
group	B-T078
.	O
It	O
was	O
concluded	O
that	O
there	O
was	O
no significant difference	B-T033
in	O
both	O
groups	B-T078
in	O
the	O
baseline	B-T081
characteristics	B-T080
.	O
The	O
mean duration	B-T079
of	O
dysentery	B-T047
reduced	B-T080
(P	O
<	O
0.05).	O
The	O
mean duration	B-T079
of	O
fever	B-T184
has	O
been	O
significantly	O
reduced	B-T080
in	O
the	O
synbiotic	B-T168
group	B-T078
(1.64	O
±	O
0.87	O
days	B-T079
)	O
in	O
comparison	B-T052
to	O
the	O
placebo	B-T122
group	B-T078
(2.13	O
±	O
0.94	O
days	B-T079
)	O
(P	O
<	O
0.001).	O
Average amount	B-T081
of	O
weight loss	B-T033
was	O
significantly	O
lower	O
in	O
the	O
synbiotic	B-T168
group	B-T078
in	O
comparison	B-T052
to	O
that	O
in	O
the	O
placebo	B-T122
group	B-T078
(129.5	O
±	O
23.388	O
grams	O
and	O
278	O
±	O
28.385	O
grams,	O
resp.;	O
P	O
<	O
0.001).	O
There	O
was	O
no significant difference	B-T033
in	O
the	O
mean duration	B-T079
of	O
hospitalization	B-T058
in	O
both	O
groups	B-T078
(P	O
>	O
0.05).	O
The	O
use	O
of	O
synbiotics	B-T168
as	O
an	O
adjuvant therapy	B-T061
to	O
the	O
standard	B-T080
treatment	B-T061
of	O
dysentery	B-T047
significantly	O
reduces	B-T080
the	O
duration	B-T079
of	O
dysentery	B-T047
,	O
fever	B-T184
,	O
and	O
rate of weight losses	B-T033
.	O
The	O
trial	B-T062
is	O
registered	B-T058
with	O
IRCT201109267647N1.	O

Effect	B-T080
of	O
type 2 diabetes mellitus	B-T047
on	O
the	O
pharmacokinetics	B-T169
and	O
transplacental transfer	B-UnknownType
of	O
nifedipine	B-T109
in	O
hypertensive	B-T047
pregnant women	B-T098
Diabetes mellitus	B-T047
can	O
inhibit	B-T052
cytochrome P450 3A4	B-T116
,	O
an	O
enzyme	B-T116
responsible	O
for	O
the	O
metabolism	B-T044
of	O
nifedipine	B-T109
,	O
used	O
for	O
the	O
treatment	B-T061
of	O
hypertension	B-T047
in	O
pregnant women	B-T098
.	O
We	O
aimed	B-T078
to	O
assess	B-T058
the	O
effect	B-T080
of	O
type 2 diabetes mellitus	B-T047
(	O
T2DM	B-T047
)	O
on	O
the	O
pharmacokinetics	B-T169
,	O
placental transfer	B-UnknownType
and	O
distribution	O
of	O
nifedipine	B-T109
in	O
amniotic fluid	B-T031
in	O
hypertensive	B-T047
pregnant women	B-T098
.	O
The	O
study	B-T062
was	O
conducted	O
in	O
12	O
hypertensive	B-T047
pregnant women	B-T098
[	O
control group	B-T096
(	O
CG	B-T096
)]	O
and	O
10	O
hypertensive	B-T047
pregnant women	B-T098
with	O
T2DM	B-T047
taking	O
slow-release	O
nifedipine	B-T109
(20	O
mg,	O
12/12	O
h).	O
On	O
the	O
34th	O
week	B-T079
of	O
gestation	B-T040
,	O
serial	O
blood samples	B-T031
were	O
collected	O
(0-12	O
h)	O
after	O
administration	B-T061
of	O
the	O
medication	B-T121
.	O
At delivery	B-T079
,	O
samples	B-T031
of	O
maternal	B-T099
and	O
fetal blood	B-T031
and	O
amniotic fluid	B-T031
were	O
collected	O
for	O
determination	B-T059
of	O
nifedipine	B-T109
distribution	O
in	O
these	O
compartments.	O
The	O
median	B-T081
pharmacokinetic	B-T169
parameters	B-T077
of	O
CG	B-T096
were:	O
peak plasma concentration	B-T081
(	O
Cmax	B-T081
)	O
26.41	O
ng	O
ml(-1),	O
time to reach Cmax	B-T081
(	O
tmax	B-T081
)	O
1.79	O
h,	O
area under the plasma concentration	B-T081
vs.	O
time curve	B-T081
from	O
0-12	O
h	O
(	O
AUC	B-T081
0-12)	O
235.99	O
ng.h	O
ml(-1),	O
half-life	B-T079
(t½)	O
4.34	O
h,	O
volume of distribution	B-T081
divided	O
by	O
bioavailability	B-T081
(	O
Vd	B-T081
/	O
F	B-T081
)	O
560.96	O
l,	O
and	O
ClT	B-UnknownType
/	O
F	B-T081
84.77	O
l	O
h(-1).	O
The	O
parameters	B-T077
for	O
T2DM	B-T047
group	B-T098
were:	O
Cmax	B-T081
23.52	O
ng	O
ml(-1),	O
tmax	B-T081
1.48	O
h,	O
AUC	B-T081
0-12	O
202.23	O
ng.h	O
ml(-1),	O
t½	O
5.00	O
h,	O
Vd	B-T081
/	O
F	B-T081
609.40	O
l,	O
and	O
apparent	O
total clearance	B-UnknownType
(	O
ClT	B-UnknownType
/	O
F	B-T081
)	O
98.94	O
l	O
h(-1).	O
The	O
ratios	B-T081
of	O
plasma concentrations	B-T081
of	O
nifedipine	B-T109
in	O
the	O
umbilical vein	B-T018
,	O
intervillous space	B-T030
and	O
amniotic fluid	B-T031
to	O
those	O
in	O
the	O
maternal	B-T099
vein	O
for	O
CG	B-T096
and	O
T2DM	B-T047
were	O
0.53	O
and	O
0.44,	O
0.78	O
and	O
0.87,	O
respectively,	O
with	O
an	O
amniotic fluid	B-T031
/	O
maternal	B-T099
plasma	B-T031
ratio	B-T081
of	O
0.05	O
for	O
both	O
groups	B-T098
.	O
The	O
ratios	B-T081
of	O
plasma concentrations	B-T081
in	O
the	O
umbilical artery	B-T018
to	O
those	O
in	O
the	O
umbilical vein	B-T018
were	O
0.82	O
for	O
CG	B-T096
and	O
0.88	O
for	O
T2DM	B-T047
.	O
There	O
was	O
no	O
influence	B-T077
of	O
T2DM	B-T047
on	O
the	O
pharmacokinetics	B-T169
or	O
placental transfer	B-UnknownType
of	O
nifedipine	B-T109
in	O
hypertensive	B-T047
women	B-T098
with	O
controlled	B-T033
diabetes	B-T047
.	O

Results	B-T169
of	O
an	O
International Postmarketing Surveillance Study	B-T062
of	O
pl-VEGF165	B-T121
Safety	B-T068
and	O
Efficacy	B-T080
in	O
210	O
Patients	B-T101
with	O
Peripheral Arterial Disease	B-T047
The	O
effective	O
treatment	B-T061
of	O
chronic	B-T079
lower limb	B-T023
ischemia	B-T046
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular surgeons	B-T097
.	O
Current	O
pharmacological	B-T169
therapies	B-T061
play	O
an	O
auxiliary	O
role	O
and	O
cannot	O
prevent	O
disease progression	B-T046
,	O
and	O
new	O
treatment methods	B-T061
are	O
needed.	O
pl-VEGF165	B-T121
,	O
a	O
gene therapy	B-T061
drug	B-T121
,	O
was	O
approved	O
in	O
Russia	B-T083
for	O
the	O
treatment	B-T061
of	O
atherosclerotic	B-T169
peripheral arterial disease	B-T047
(	O
PAD	B-T047
)	O
after	O
clinical studies	B-T062
in	O
2011.	O
The	O
study	B-T062
drug	B-T121
is	O
an	O
original	O
gene construction	B-T114
in	O
which	O
pl-VEGF165	B-T121
1.2	O
mg	O
is	O
the	O
active substance	B-T123
.	O
This	O
postmarketing surveillance study	B-T062
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	B-T068
(identification	O
of	O
uncommon	O
side effects	B-T046
)	O
and	O
efficacy	B-T080
of	O
gene therapy	B-T061
in	O
patients	B-T101
in	O
routine	O
clinical practice	B-T057
.	O
In	O
total,	O
210	O
patients	B-T101
with	O
stage II-III	B-T079
chronic	B-T079
limb	B-T023
ischemia	B-T046
(according	O
to	O
the	O
Fontaine classification	B-T170
modified	O
by	O
AV	O
Pokrovsky)	O
in	O
33	O
healthcare facilities	B-T073
in	O
Russia	B-T083
and	O
the	O
Ukraine	B-T083
were	O
enrolled	O
in	O
the	O
study	B-T062
.	O
The	O
control group	B-T096
(n	O
=	O
60)	O
received	O
conservative therapy	B-T061
without	O
prostaglandins	B-T109
and	O
prostacyclins	B-T109
,	O
and	O
the	O
treatment group	B-T098
(n	O
=	O
150)	O
received	O
treatment	B-T061
with	O
pl-VEGF165	B-T121
as	O
two	O
intramuscular injections	B-T169
for	O
a	O
total	O
dose	B-T081
of	O
2.4	O
mg.	O
Pain-free walking distance	B-T033
(	O
PWD	B-T033
)	O
(the	O
primary	O
efficacy	B-T080
criterion	O
for	O
Fontaine	B-T170
stages II-III	B-T079
),	O
blood flow linear velocity	B-T033
(	O
BFLV	B-T033
),	O
and	O
ankle-brachial index	B-T201
(	O
ABI	B-T201
)	O
were	O
monitored	O
for	O
6	O
months	B-T079
.	O
The	O
safety	B-T068
of	O
pl-VEGF165	B-T121
gene transfer	B-T063
in	O
terms	O
of	O
the	O
trial protocol	B-T062
was	O
initially	O
evaluated	O
6	O
months	B-T079
after	O
the	O
start	O
of	O
the	O
study;	O
adverse events	B-T046
(	O
AEs	B-T046
)	O
and	O
serious adverse events	B-T046
(	O
SAEs	B-T046
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	B-T058
and	O
unscheduled	O
requests	O
for	O
medical care	B-T058
.	O
Overall,	O
PWD	B-T033
increased	O
by	O
177%,	O
from	O
100.3	O
±	O
6.9	O
to	O
277.1	O
±	O
16.2	O
m	O
(p	O
=	O
0.0001),	O
in	O
the	O
treatment group	B-T098
,	O
whereas	O
the	O
mean	B-T081
value	O
was	O
unchanged	O
in	O
the	O
control group	B-T096
(p	O
=	O
0.218).	O
Both	O
BFLV	B-T033
and	O
ABI values	B-T201
increased	O
by	O
24%	O
(p	O
=	O
0.0001)	O
in	O
the	O
treatment group	B-T098
but	O
decreased	O
in	O
the	O
control group	B-T096
.	O
The	O
greatest	O
therapeutic effect	B-T201
was	O
observed	O
for	O
stage III	B-T080
disease	B-T047
:	O
PWD	B-T033
increased	O
by	O
683%	O
(p	O
=	O
0.0001).	O
No	B-T033
angiogenic therapy	B-T061
-related	O
AEs	B-T046
or	O
side effects	B-T046
were	O
recorded,	O
and	O
target	O
limb salvage	B-T061
was	O
96	O
and	O
97%	O
in	O
the	O
treatment	B-T098
and	O
control groups	B-T096
,	O
respectively.	O
The	O
results	B-T169
obtained	O
in	O
this	O
study	B-T062
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase IIb	B-T062
/	O
III	B-T062
registration	O
clinical study	B-T062
completed	O
in	O
2011.	O
pl-VEGF165	B-T121
intramuscular	B-T082
gene transfer	B-T063
is	O
an	O
effective	O
treatment	B-T061
for	O
moderate	O
to	O
severe	O
claudication	B-T047
due	O
to	O
chronic	B-T079
lower limb	B-T023
ischemia	B-T046
in	O
routine	O
clinical practice	B-T057
.	O
ClinicalTrials.gov	O
identifier:	O
NCT02369809.	O

Psychological factors	B-T041
associated with	B-T080
NAFLD	B-T047
/	O
NASH	B-T047
:	O
a	O
systematic review	B-T170
Nonalcoholic fatty liver disease	B-T047
(	O
NAFLD	B-T047
)	O
represents	O
one	O
of	O
the	O
most	O
common	O
chronic liver diseases	B-T047
worldwide.	O
So	O
far,	O
the	O
pathogenesis	B-T046
of	O
NAFLD	B-T047
and	O
its	O
more	O
severe	B-T080
variant	O
nonalcoholic steatohepatitis	B-T047
(	O
NASH	B-T047
)	O
is	O
yet	O
unclear,	O
with	O
many	O
mechanisms	B-T169
being	O
proposed	O
as	O
possible	O
causes.	O
This	O
article	O
aims	O
to	O
review	B-T078
the	O
psychological factors	B-T041
associated with	B-T080
NAFLD	B-T047
/	O
NASH	B-T047
.	O
Three	O
main	O
categories	O
of	O
factors	B-T169
have	O
been	O
investigated	B-T169
:	O
emotional	B-T033
,	O
cognitive	B-T169
and	O
behavioral	B-T053
.	O
Five	O
electronic databases	B-T170
were	O
searched,	O
limited	O
to	O
studies	O
published	O
in	O
the	O
English language	B-T171
,	O
during	O
the	O
period	B-T079
2005-2015:	O
PubMed	B-T170
,	O
Thomson ISI - Web of Science	B-T170
,	O
Scopus	B-T170
,	O
ProQuest	B-T170
,	O
and	O
ScienceDirect	B-T170
.	O
Results	O
indicated	O
the	O
most	O
relevant	O
emotional	B-T033
factors	B-T169
to	O
be	O
depression	B-T048
and	O
anxiety	B-T033
.	O
The	O
areas	O
of	O
investigation	B-T169
for	O
cognitive functioning	B-T041
concern	O
those	O
contents	B-T077
and	O
processes	B-T067
related	O
to	O
the	O
ability	O
to	O
initiate	B-T169
and	O
maintain	O
lifestyle changes	B-T054
.	O
The	O
most	O
important	O
behavioral	B-T053
factors	B-T169
identified	O
are	O
physical activity	B-T056
,	O
nutrition	B-T040
/	O
food intake	B-T040
and	O
substance	B-T167
consumption	B-T039
:	O
coffee	B-T168
,	O
alcohol	B-T168
,	O
cigarettes	B-T073
.	O
Some	O
of	O
the	O
factors	B-T169
identified	O
act	O
as	O
protective factors	B-T055
,	O
other	O
as	O
vulnerability factors	B-T033
.	O
NAFLD	B-T047
/	O
NASH	B-T047
may	O
be	O
considered	O
a	O
cognitive-behavioral disease	B-T048
,	O
the	O
most	O
effective	O
management	B-T058
being	O
lifestyle changes	B-T054
,	O
with	O
emphasis	O
on	O
diet	B-T168
and	O
exercise	B-T056
.	O

An	O
approach	O
to	O
functionally	O
relevant	O
clustering	B-T169
of	O
the	O
protein universe	B-T116
:	O
Active site profile-based clustering	B-T169
of	O
protein structures	B-T116
and	O
sequences	B-T087
Protein function	B-T044
identification	O
remains	O
a	O
significant	O
problem.	O
Solving	O
this	O
problem	O
at	O
the	O
molecular functional level	B-T080
would	O
allow	O
mechanistic	O
determinant	O
identification-	O
amino acids	B-T116
that	O
distinguish	O
details	O
between	O
functional families	B-T078
within	O
a	O
superfamily	B-T078
.	O
Active site profiling	B-T062
was	O
developed	O
to	O
identify	O
mechanistic	O
determinants.	O
DASP	B-T170
and	O
DASP2	B-T170
were	O
developed	O
as	O
tools	O
to	O
search	O
sequence databases	B-T170
using	O
active site profiling	B-T062
.	O
Here,	O
TuLIP	B-T170
(	O
Two-Level Iterative clustering Process	B-T170
)	O
is	O
introduced	O
as	O
an	O
iterative,	O
divisive	O
clustering process	B-T169
that	O
utilizes	O
active site profiling	B-T062
to	O
separate	O
structurally	O
characterized	O
superfamily	B-T078
members	O
into	O
functionally	O
relevant	O
clusters	B-T081
.	O
Underlying	O
TuLIP	B-T170
is	O
the	O
observation	O
that	O
functionally relevant families	B-T078
(curated	O
by	O
Structure-Function Linkage Database	B-T170
,	O
SFLD	B-T170
)	O
self-identify	O
in	O
DASP2	B-T170
searches;	O
clusters	B-T081
containing	O
multiple functional families	B-T078
do	O
not.	O
Each	O
TuLIP	B-T170
iteration	O
produces	O
candidate	O
clusters	B-T081
,	O
each	O
evaluated	O
to	O
determine	O
if	O
it	O
self-identifies	O
using	O
DASP2	B-T170
.	O
If	O
so,	O
it	O
is	O
deemed	O
a	O
functionally relevant group	B-T078
.	O
Divisive	O
clustering	B-T169
continues	O
until	O
each	O
structure	O
is	O
either	O
a	O
functionally relevant group	B-T078
member	O
or	O
a	O
singlet.	O
TuLIP	B-T170
is	O
validated	O
on	O
enolase	B-T116
and	O
glutathione transferase	B-T116
structures	B-T116
,	O
superfamilies	B-T078
well-curated	O
by	O
SFLD	B-T170
.	O
Correlation	B-T080
is	O
strong;	O
small	O
numbers	O
of	O
structures	B-T082
prevent	O
statistically significant analysis	B-T062
.	O
TuLIP	B-T170
-identified	O
enolase	B-T116
clusters	B-T081
are	O
used	O
in	O
DASP2 GenBank	B-T170
searches	O
to	O
identify	O
sequences	B-T087
sharing	O
functional	O
site	O
features.	O
Analysis	O
shows	O
a	O
true	O
positive	O
rate	O
of	O
96%,	O
false	O
negative	O
rate	O
of	O
4%,	O
and	O
maximum	O
false	O
positive	O
rate	O
of	O
4%.	O
F-measure	B-T081
and	O
performance analysis	B-T062
on	O
the	O
enolase	B-T116
search	O
results	O
and	O
comparison	O
to	O
GEMMA	B-T170
and	O
SCI-PHY	B-T170
demonstrate	O
that	O
TuLIP	B-T170
avoids	O
the	O
over-division	O
problem	O
of	O
these	O
methods.	O
Mechanistic	O
determinants	O
for	O
enolase families	B-T116
are	O
evaluated	O
and	O
shown	O
to	O
correlate	O
well	O
with	O
literature	B-T170
results.	O

Early	B-T079
high school engagement	B-T065
in	O
students	B-T098
with	O
attention/deficit hyperactivity disorder	B-T048
Students	B-T098
with	O
attention/deficit hyperactivity disorder	B-T048
(	O
ADHD	B-T048
)	O
continue	O
to	O
languish	O
behind	O
their	O
peers	B-T098
with	O
regard	O
to	O
academic achievement	B-T055
and	O
education attainment	B-T033
.	O
School engagement	B-T065
is	O
potentially	O
modifiable,	O
and	O
targeting	O
engagement	B-T065
may	O
be	O
a	O
means	O
to	O
improve	O
education	B-T065
outcomes	B-T169
.	O
To	O
investigate	O
school engagement	B-T065
for	O
students	B-T098
with	O
ADHD	B-T048
during	O
the	O
crucial	O
high school transition	B-T078
period	B-T079
and	O
to	O
identify	O
factors	O
associated	O
with	O
low school engagement	B-T033
.	O
Participants	B-T098
are	O
adolescents	B-T100
(12-15	O
years	B-T079
)	O
in	O
the	O
first	O
and	O
third	O
year	B-T079
of	O
high school	B-T073
with	O
diagnosed	B-T062
ADHD	B-T048
(n	O
=	O
130).	O
Participants	B-T098
were	O
recruited	O
from	O
21	O
paediatric	B-T091
practices	B-T057
.	O
Cross-sectional study	B-T062
assessing	O
school engagement	B-T065
.	O
Data	B-T078
were	O
collected	O
through	O
direct	O
assessment	B-T058
and	O
child	B-T100
,	O
parent	B-T099
,	O
and	O
teacher	B-T097
surveys	B-T170
.	O
School engagement	B-T065
is	O
measured	O
as	O
student attitudes	B-T041
to	O
school	B-T073
(	O
cognitive	B-T041
and	O
emotional	B-T041
)	O
and	O
suspension	B-T033
rates	B-T081
(	O
behavioural	B-T053
).	O
Multivariable regression analyses	B-T170
examined	O
student	B-T098
,	O
family	B-T099
,	O
and	O
school factors	B-UnknownType
affecting	O
engagement	B-T065
.	O
In	O
comparison	O
with	O
state	O
data,	O
students	B-T098
with	O
ADHD	B-T048
in	O
the	O
first	O
year	B-T079
of	O
high school	B-T073
were	O
less	O
motivated	O
(p	O
<	O
.01)	O
and	O
less	O
connected	O
to	O
peers	B-T098
(p	O
<	O
.01).	O
Overall,	O
there	O
was	O
no	O
discordance	O
in	O
third	O
year	B-T079
attitudes	B-T041
.	O
There	O
were	O
high rates of suspension	B-T033
in	O
both	O
years	B-T079
in	O
comparison	O
to	O
state-wide	O
suspensions	B-T033
(21%	O
vs.	O
6%,	O
p	O
<	O
.01).	O
Explanatory	O
factors	O
for	O
poor	O
attitudes	B-T041
include	O
adolescent	B-T100
depression	B-T048
,	O
poor	O
adolescent	B-T100
supervision	B-T061
,	O
and	O
devaluing	B-T041
education	B-T065
.	O
Conduct problems	B-UnknownType
and	O
increased	O
hyperactivity	B-T048
were	O
related	O
to	O
increased likelihood of being suspended	B-T033
,	O
whilst	O
higher	O
cognitive ability	B-T041
,	O
family	B-T099
socio-economic status	B-T080
,	O
and	O
independent	O
schools	B-T073
reduced	O
risk	B-T078
.	O
Potentially	O
modifiable	O
individual	B-T098
and	O
family	B-T099
factors	B-T033
including	O
adolescent	B-T100
depression	B-T048
,	O
behavioural problems	B-T048
,	O
education	B-T065
values	B-T080
,	O
and	O
family	B-T099
supervision	B-T061
could	O
be	O
targeted	O
to	O
better	O
manage	O
the	O
high school transition	B-T078
for	O
students	B-T098
with	O
ADHD	B-T048
.	O

Proliferation	B-T043
-Related	O
Activity	O
in	O
Endothelial Cells	B-T025
Is	O
Enhanced	B-T052
by	O
Micropower	O
Plasma	B-T104
Nonthermal plasma	B-T058
has	O
received	O
a	O
lot	O
of	O
attention	O
as	O
a	O
medical treatment technique	B-UnknownType
in	O
recent	O
years.	O
It	O
can	O
easily	O
create	O
various	O
reactive chemical species	B-T123
(	O
ROS	B-T123
)	O
and	O
is	O
harmless	O
to	O
living body	B-T016
.	O
Although	O
plasma	B-T104
plasma	B-T104
at	O
gas	B-T104
-	O
liquid	B-T167
interface	B-T082
has	O
a	O
potential	O
for	O
a	O
biomedical application	B-T058
,	O
the	O
interactions	O
between	O
the	O
gas	B-T104
-	O
liquid	B-T167
plasma	B-T104
and	O
living cells	B-T025
remain	O
unclear.	O
Here,	O
we	O
show	O
characteristics	O
of	O
a	O
micropower	O
plasma	B-T104
with	O
0.018	O
W	O
of	O
the	O
power	O
input,	O
generated	O
at	O
gas	B-T104
-	O
liquid	B-T167
interface	B-T082
.	O
We	O
also	O
provide	O
the	O
evidence	O
of	O
plasma	B-T104
-induced	O
enhancement	B-T052
in	O
proliferation	B-T043
activity	O
of	O
endothelial cells	B-T025
.	O
The	O
plasma	B-T104
produced	O
H2O2	B-T121
,	O
HNO2	B-T197
,	O
and	O
HNO3	B-T131
in	O
phosphate buffered	B-T121
saline	B-T167
containing	O
Mg(++)	B-T123
and	O
Ca(++)	B-T121
(	O
PBS	B-T121
(+)),	O
and	O
their	O
concentration	B-T081
increased	O
linearly	O
during	O
600-second discharge	B-T079
.	O
The	O
value	O
of	O
pH	B-T081
in	O
PBS	B-T121
(+)	O
against	O
the	O
plasma	B-T104
discharge time	B-T079
was	O
stable	O
at	O
about	O
7.0.	O
Temperature	B-T081
in	O
PBS	B-T121
(+)	O
rose	O
monotonically,	O
and	O
its	O
rise	O
was	O
up	O
to	O
0.8°C	O
at	O
the	O
bottom	O
of	O
a	O
cell-cultured	B-T025
dish	O
by	O
the	O
plasma	B-T104
discharge for 600 s	B-T079
.	O
Short-time	O
treatment	B-T169
treatment	B-T169
of	O
the	O
plasma	B-T104
enhanced	B-T052
proliferation	B-T043
activity	O
of	O
endothelial cells	B-T025
.	O
In	O
contrast,	O
the	O
treatment	B-T169
of	O
H2O2	B-T121
does	O
not	O
enhance	O
the	O
cell proliferation	B-T043
.	O
Thus,	O
the	O
ROS	B-T123
production	O
and	O
the	O
nuclear	O
factor-kappa	O
B	O
(NF-κB)	O
activation	O
due	O
to	O
the	O
plasma	B-T104
treatment	B-T169
might	O
be	O
related	O
to	O
enhancement	B-T052
of	O
the	O
cell proliferation	B-T043
.	O
Our	O
results	O
may	O
potentially	O
provide	O
the	O
basis	O
for	O
developing	O
the	O
biomedical applications	B-T058
using	O
the	O
gas	B-T104
-	O
liquid	B-T167
plasma	B-T104
.	O

pH	B-T081
-Dependent	O
Transmembrane Activity	B-T044
of	O
Peptide	B-T116
-Functionalized	O
Gold Nanostars	B-T121
for	O
Computed Tomography	B-T060
/	O
Photoacoustic Imaging	B-T060
and	O
Photothermal Therapy	B-T061
Progress	B-T169
in	O
multifunctional nanomaterials	B-T073
for	O
tumor therapy	B-T061
mostly	O
depends	O
on	O
the	O
development	B-T169
of	O
tumor	B-T191
-	O
targeting	B-T169
delivery strategies	B-T061
.	O
One	O
approach	B-T169
is	O
to	O
explore	O
a	O
pH	B-T081
-responsive	O
strategy	B-T169
to	O
target	B-T169
the	O
slightly	O
acidic solid tumor microenvironment	B-T070
.	O
A	O
novel	O
class	O
of	O
pH (low) insertion peptides	B-T116
(	O
pHLIPs	B-T116
)	O
with	O
pH	B-T081
-dependent	O
transmembrane activity	B-T044
can	O
fold	B-T082
and	O
rapidly	O
insert	B-T169
into	O
the	O
lipid bilayer	B-T026
of	O
tumor cells	B-T025
triggered	O
by	O
acidity	B-T070
,	O
facilitating	O
the	O
cellular internalization	B-T067
of	O
nanomaterials	B-T073
synchronously	B-T079
.	O
Here,	O
we	O
innovatively	O
decorated	O
gold nanostars	B-T121
(	O
GNSs	B-T121
)	O
with	O
pHLIPs	B-T116
(	O
GNS	B-T121
-	O
pHLIP	B-T116
)	O
to	O
improve	O
their	O
targeting	B-T169
ability	O
and	O
photothermal therapeutic	B-T061
(	O
PTT	B-T061
)	O
efficiency	B-T081
.	O
The	O
obtained	O
GNS	B-T121
-	O
pHLIP	B-T116
exhibited	O
the	O
excellent	O
characteristics	B-T080
of	O
uniform	O
size	B-T082
and	O
good	O
biocompatibility	B-T044
.	O
As	O
compared	O
to	O
GNS	B-T121
-	O
mPEG	B-T109
,	O
the	O
cellular internalization	B-T067
of	O
GNS	B-T121
-	O
pHLIP	B-T116
was	O
1-fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	B-T025
in	O
media	B-T167
at	O
pH	B-T081
6.4	O
than	O
at	O
pH	B-T081
7.4.	O
Moreover,	O
the	O
tumor	B-T191
accumulation	B-T033
of	O
the	O
GNS	B-T121
-	O
pHLIP	B-T116
was	O
3-fold	O
higher	O
than	O
that	O
of	O
GNS	B-T121
-	O
mPEG	B-T109
after	O
intravenous injection	B-T169
into	O
MCF-7	B-T025
breast tumor	B-T191
animal models	B-T050
for	O
24	O
h.	O
Furthermore,	O
GNS	B-T121
-	O
pHLIP	B-T116
exhibited	O
stronger	O
signals	B-T067
than	O
the	O
GNS	B-T121
-	O
mPEG	B-T109
through	O
computed tomography	B-T060
(	O
CT	B-T060
)	O
and	O
photoacoustic (PA) imaging	B-T060
.	O
Simultaneously,	O
the	O
desirable	O
targeting	B-T169
efficiency	B-T081
significantly	O
improved	O
the	O
PTT	B-T061
efficacy	B-T080
to	O
tumors	B-T191
,	O
with	O
low	O
side effects	B-T046
on	O
normal	O
tissues	B-T024
.	O
The	O
results	O
clearly	O
demonstrate	O
that	O
the	O
GNS	B-T121
-	O
pHLIP	B-T116
successfully	O
took	O
advantage	O
of	O
the	O
tumor	B-T191
-	O
targeting	B-T169
ability	O
of	O
pHLIPs	B-T116
and	O
the	O
good	O
characteristics	B-T080
of	O
GNS	B-T121
GNS s	B-T121
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	B-T191
imaging	B-T060
and	O
therapy	B-T061
.	O

Stepwise	O
cyclopropanation	B-T044
on	O
the	O
polycyclopropanated polyketide	B-T109
formation	O
in	O
jawsamycin	B-T109
biosynthesis	B-T169
Jawsamycin	B-T109
is	O
a	O
polyketide	B-T109
-	O
nucleoside	B-T114
hybrid	O
with	O
a	O
unique	O
polycyclopropane	B-T109
moiety	O
on	O
a	O
single	O
polyketide chain	B-T109
.	O
The	O
unexpected	O
isolation	O
of	O
cyclopropane	B-T109
deficient	O
jawsamycin	B-T109
analogs	O
allowed	O
us	O
to	O
propose	O
a	O
stepwise	O
cyclopropanation	B-T044
mechanism	B-T169
for	O
the	O
enzymatic	B-T116
synthesis	B-T169
of	O
this	O
polyketide	B-T109
.	O
The	O
concise	O
timing	O
of	O
the	O
cyclopropanation	B-T044
could	O
be	O
regulated	O
by	O
a	O
delicate	O
balance	O
between	O
reaction rates	B-T079
of	O
the	O
condensation	B-T067
and	O
cyclopropanation reactions	B-T044
.	O

Initial	O
experience	O
with	O
laparoscopic radical antegrade modular pancreatosplenectomy	B-T061
for	O
left-sided pancreatic cancer	B-T191
in	O
a	O
single	O
institution	B-T093
:	O
technical	O
aspects	O
and	O
oncological outcomes	B-T033
Laparoscopic surgery	B-T061
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic cancer	B-T191
due	O
to	O
technical difficulties	B-T067
and	O
concerns	O
about	O
oncological	B-T191
safety	B-T068
.	O
Radical antegrade modular pancreatosplenectomy	B-T061
(	O
RAMPS	B-T061
)	O
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative margin	B-T033
during	O
radical lymph node dissection	B-T061
.	O
We	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	B-T080
as	O
a	O
laparoscopic application	B-T082
due	O
to	O
unique	O
features.	O
Fifteen	O
laparoscopic	B-T060
RAMPS	B-T061
for	O
well-selected	O
patients	B-T101
with	O
left-sided pancreatic cancer	B-T191
were	O
performed	O
from	O
July	O
2011	O
to	O
April	O
2016.	O
Five	O
trocars	B-T074
were	O
usually	O
used,	O
and	O
the	O
operative procedures	B-T061
and	O
range of dissection	B-T061
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
RAMPS	B-T061
described	O
by	O
Strasberg	B-T170
.	O
All	O
medical	O
records	O
and	O
follow-up data	B-T170
were	O
reviewed	O
and	O
analyzed.	O
All	O
patients	B-T101
had	O
pancreatic ductal adenocarcinoma	B-T191
.	O
Mean	O
operative time	B-T079
was	O
219.3	O
±	O
53.8	O
min,	O
and	O
estimated blood loss	B-T033
was	O
250	O
±	O
70	O
ml.	O
The	O
length of postoperative hospital stay	B-T079
was	O
6.1	O
±	O
1.2	O
days,	O
and	O
postoperative	B-T046
morbidities	B-T081
developed	O
in	O
two	O
patients	B-T101
(13.3%)	O
with	O
urinary retention	B-T033
.	O
The	O
median	O
number	O
of	O
retrieved	O
lymph nodes	B-T023
was	O
18.1	O
±	O
6.2	O
and	O
all	O
had	O
negative margins	B-T033
.	O
Median	O
follow-up	B-T058
time	O
was	O
46.0	O
months,	O
and	O
the	O
3-year	O
disease free survival	B-T081
and	O
overall survival rates	B-T081
were	O
56.3%	O
and	O
74.1%,	O
respectively.	O
Our	O
early	O
experience	O
with	O
laparoscopic	B-T060
RAMPS	B-T061
achieved	O
feasible	O
perioperative	B-T079
results	O
accompanied	O
by	O
acceptable	O
survival outcomes	B-T081
.	O
Laparoscopic	B-T060
RAMPS	B-T061
could	O
be	O
a	O
safe	O
and	O
oncologically	B-T191
feasible procedure	B-T080
in	O
well-selected	O
patients	B-T101
with	O
left-sided pancreatic cancer	B-T191
.	O

Individual	B-T098
classification	B-T185
of	O
strong	B-T080
risk	B-T078
attitudes	B-T041
:	O
An	O
application	O
across	O
lottery	B-T081
types	B-T080
and	O
age groups	B-T100
Empirical	B-T080
evaluations	B-T169
of	O
risk	B-T078
attitudes	B-T041
often	O
rely	O
on	O
a	O
weak	B-T080
definition	B-T170
of	O
risk	B-T078
that	O
concerns	O
preferences	O
towards	O
risky	B-T078
and	O
riskless options	B-T169
(e.g.,	O
a	O
lottery	B-T081
vs.	O
a	O
sure	O
outcome	B-T169
).	O
A	O
large	O
body	O
of	O
work	O
has	O
shown	O
that	O
individuals	B-T098
tend	O
to	O
be	O
weak	B-T080
risk	B-T078
averse	O
in	O
choice	B-T052
contexts	B-T078
involving	O
risky	B-T078
and	O
riskless gains	B-T081
but	O
weak	B-T080
risk	B-T078
seeking	O
in	O
contexts	B-T078
involving	O
losses	B-T081
,	O
a	O
phenomenon	B-T067
known	O
as	O
the	O
reflection effect	B-T067
.	O
Recent	O
attempts	O
to	O
evaluate	O
age differences	B-T100
in	O
risk	B-T078
attitudes	B-T041
have	O
relied	O
on	O
this	O
weak	B-T080
definition	B-T170
,	O
testing	O
whether	O
the	O
reflection effect	B-T067
increases	B-T169
or	O
diminishes	B-T081
as	O
we	O
grow	O
older	B-T079
.	O
The	O
present	O
work	O
argues	O
that	O
weak	B-T080
risk	B-T078
attitudes	B-T041
have	O
limited	O
generalizability	B-T080
and	O
proposes	O
the	O
use of	B-T169
a	O
strong	B-T080
strong	B-T080
definition	B-T170
of	O
risk	B-T078
that	O
is	O
concerned	O
with	O
preferences	O
towards	O
options	B-T169
with	O
the	O
same	O
expected	O
value	B-T081
but	O
different	B-T080
degrees	B-T081
of	O
risk	B-T078
(i.e.,	O
outcome	B-T169
variance	B-T080
).	O
A	O
reanalysis	B-T062
of	O
previously-published	O
data	B-T078
and	O
the	O
results	B-T169
from	O
a	O
new	O
study	O
show	O
that	O
only	O
a	O
minority	O
of	O
individuals	B-T098
manifests	B-T169
the	O
reflection effect	B-T067
under	O
a	O
strong	B-T080
definition	B-T170
of	O
risk	B-T078
,	O
and	O
that,	O
when	O
facing	O
certain	O
lottery	B-T081
-	O
pair types	B-T080
,	O
older adults	B-T098
appear	O
to	O
be	O
more	O
risk	B-T078
seeking	O
than	O
younger	B-T079
adults	B-T100
.	O

Treating	B-T169
the	O
binge	B-T048
or	O
the	O
(fat) body	B-T023
?	O
Representations	B-T052
of	O
fatness	B-T033
in	O
a	O
gold standard	B-T080
psychological	B-T169
treatment manual	B-UnknownType
for	O
binge eating disorder	B-T048
This	O
article	O
reports	B-T058
the	O
results	B-T034
of	O
a	O
Foucauldian	B-T016
-informed	O
discourse analysis	B-T062
exploring	O
representations	B-T052
of	O
fatness	B-T033
embedded	O
within	O
an	O
empirically	B-T080
based	O
psychological	B-T169
treatment manual	B-UnknownType
for	O
binge eating disorder	B-T048
,	O
a	O
condition	B-T080
characterized	B-T052
by	O
overvaluation	O
of	O
weight	B-T032
and	O
shape	B-T080
.	O
Analyses	B-T062
indicate	B-T033
that	O
the	O
manual	B-T073
prioritizes	O
weight loss	B-T033
with	O
relatively	B-T080
less	O
emphasis	O
placed	O
on	O
treating	B-T169
the	O
diagnostic	B-T169
symptoms	B-T184
and	O
underlying	O
mechanisms	B-T169
of	O
binge eating disorder	B-T048
.	O
We	O
raise	O
critical concerns	B-T033
about	O
these	O
observations	B-T062
and	O
link	O
our	O
findings	B-T033
to	O
mainstream	O
psychology's	B-T091
adoption	O
of	O
the	O
medical framing	B-T080
of	O
fatness	B-T033
as	O
obesity	B-T047
within	O
the	O
"	O
gold standard	B-T080
"	O
approach	O
to	O
intervention	B-T058
.	O
We	O
recommend	O
that	O
psychology	B-T091
as	O
a	O
discipline	B-T058
abandons	O
the	O
weight loss	B-T033
imperative	O
associated with	B-T080
binge eating disorder	B-T048
and	O
fat bodies	B-T023
.	O
We	O
recommend	O
that	O
practitioners	B-T097
locate	O
the	O
problem	B-T033
of	O
fat shame	B-T041
in	O
society	B-T092
as	O
opposed	O
to	O
the	O
individual	B-T098
person's	O
body	B-T016
and	O
provide	B-T052
individuals	B-T098
with	O
tools	O
to	O
identify	O
and	O
resist	O
fat stigma	B-T033
and	O
oppression	B-T054
,	O
rather	O
than	O
provide	B-T052
them	O
with	O
tools	O
to	O
reshape	O
their	O
bodies	B-T016
.	O

High	O
Diversity	B-T080
of	O
Planctomycetes	B-T007
in	O
Soils	B-T167
of	O
Two	O
Lichen	B-T002
-Dominated	O
Sub-Arctic	B-T083
Ecosystems	B-T070
of	O
Northwestern	B-T082
Siberia	B-T083
A	O
wide	O
variety	O
of	O
terrestrial	B-T082
ecosystems	B-T070
in	O
tundra	B-T083
have	O
a	O
ground	O
vegetation	O
cover	O
composed	O
of	O
reindeer	O
lichens	B-T002
(	O
genera	B-T185
Cladonia	B-T004
and	O
Cetraria	B-T004
).	O
The	O
microbial	B-T001
communities	O
of	O
two	O
lichen	B-T002
-dominated	O
ecosystems	B-T070
typical	O
of	O
the	O
sub-arctic zone	B-T083
of	O
northwestern	B-T082
Siberia	B-T083
,	O
that	O
is	O
a	O
forested	B-T070
tundra	B-T083
soil	B-T167
and	O
a	O
shallow acidic peatland	B-T083
,	O
were	O
examined	O
in	O
our	O
study	B-T062
.	O
As	O
revealed	O
by	O
molecular	O
analyses,	O
soil	B-T167
and	O
peat	B-T167
layers	O
just	O
beneath	O
the	O
lichen	B-T002
cover	O
were	O
abundantly	O
colonized	B-T033
by	O
bacteria	B-T007
from	O
the	O
phylum	B-T185
Planctomycetes	B-T007
.	O
Highest	O
abundance	O
of	O
planctomycetes	B-T007
detected	O
by	O
fluorescence	B-T070
in situ hybridization	B-T063
was	O
in	O
the	O
range	O
2.2-2.7	O
×	O
10(7)	O
cells per gram of wet weight	B-T081
.	O
16S rRNA	B-T114
gene fragments	B-T028
from	O
the	O
Planctomycetes	B-T007
comprised	O
8-13%	O
of	O
total	O
16S rRNA	B-T114
gene	B-T028
reads	O
retrieved	O
using	O
Illumina pair-end sequencing	B-T170
from	O
the	O
soil	B-T167
and	O
peat samples	B-T167
.	O
Lichen	B-T002
-associated	O
assemblages	O
of	O
planctomycetes	B-T007
displayed	O
unexpectedly	O
high	O
diversity	B-T080
,	O
with	O
a	O
total	O
of	O
89,662	O
reads	O
representing	O
1723	O
operational taxonomic units	B-T062
determined	O
at	O
97%	O
sequence identity	B-T081
.	O
The	O
soil	B-T167
of	O
forested	O
tundra	B-T083
was	O
dominated	O
by	O
uncultivated	O
members	O
of	O
the	O
family	B-T077
Planctomycetaceae	B-T007
(53-71%	O
of	O
total	O
Planctomycetes	B-T007
-like	O
reads),	O
while	O
sequences	B-T086
affiliated	O
with	O
the	O
Phycisphaera-related group WD2101	B-T007
(recently	O
assigned	O
to	O
the	O
order	B-T185
Tepidisphaerales	B-T007
)	O
were	O
most	O
abundant	O
in	O
peat	B-T167
(28-51%	O
of	O
total	O
reads).	O
Representatives	O
of	O
the	O
Isosphaera	B-T007
-	O
Singulisphaera group	B-T007
(14-28%	O
of	O
total	O
reads)	O
and	O
the	O
lineages	B-T077
defined	O
by	O
the	O
genera	B-T185
Gemmata	B-T007
(1-4%)	O
and	O
Planctopirus	B-T007
-	O
Rubinisphaera	B-T007
(1-3%)	O
were	O
present	O
in	O
both	O
habitats	B-T082
.	O
Two	O
strains	O
of	O
Singulisphaera-like bacteria	B-T007
were	O
isolated	O
from	O
studied	O
soil	B-T167
and	O
peat samples	B-T167
.	O
These	O
planctomycetes	B-T007
displayed	O
good	O
tolerance	O
of	O
low temperatures	B-T070
(4-15°C)	O
and	O
were	O
capable	O
of	O
growth	B-T040
on	O
a	O
number	O
of	O
polysaccharides	B-T109
,	O
including	O
lichenan	B-T109
,	O
a	O
characteristic	O
component	O
of	O
lichen	B-T002
-derived	O
phytomass	B-T081
.	O

Relationship	B-T080
between	O
polycythemia	B-T047
and	O
in-hospital mortality	B-T080
in	O
chronic obstructive pulmonary disease	B-T047
patients	B-T101
with	O
low-risk	B-T081
pulmonary embolism	B-T047
Pulmonary embolism	B-T047
(	O
PE	B-T047
)	O
is	O
frequent	B-T079
in	O
subjects	B-T098
with	O
chronic obstructive pulmonary disease	B-T047
(	O
COPD	B-T047
)	O
and	O
associated with	B-T080
high	O
mortality	B-T081
.	O
This	O
multi-center retrospective study	B-T062
was	O
performed	O
to	O
investigate	B-T169
if	O
secondary	O
polycythemia	B-T047
is	O
associated with	B-T080
in-hospital mortality	B-T080
in	O
COPD	B-T047
patients	B-T101
with	O
low-risk	B-T081
PE	B-T047
.	O
We	O
identified	O
COPD	B-T047
patients	B-T101
with	O
proven	O
PE	B-T047
between	O
October,	O
2005	O
and	O
October,	O
2015.	O
Patients	B-T101
in	O
risk	O
classes	O
III-V	O
on	O
the	O
basis	O
of	O
the	O
PESI score	B-T033
were	O
excluded.	O
We	O
extracted	O
demographic	B-T090
,	O
clinical	B-T080
and	O
laboratory information	B-UnknownType
at	O
the	O
time of admission	B-T079
from	O
medical records	B-T170
.	O
All	O
subjects	B-T098
were	O
followed	O
until	O
hospital discharge	B-T058
to	O
identify	O
all-cause	O
mortality	B-T081
.	O
We	O
enrolled	O
629	O
consecutive	O
patients	B-T101
with	O
COPD	B-T047
and	O
PE	B-T047
at	O
low risk	B-T081
:	O
132	O
of	O
them	O
(21.0%)	O
with	O
and	O
497	O
(79.0%)	O
without	O
secondary	O
polycythemia	B-T047
.	O
Compared	O
with	O
those	O
without	O
polycythemia	B-T047
,	O
the	O
polycythemia	B-T047
group	O
had	O
significantly lower	B-T081
forced expiratory volume in one second (FEV1) level	B-T060
(0.9±0.3	O
vs.	O
1.4±0.5,	O
P=0.000),	O
lower PaO2	B-T033
and	O
SpO2	B-T042
as	O
well	O
as	O
higher PaCO2	B-T034
(P=0.03,	O
P=0.03	O
and	O
P=0.000,	O
respectively).	O
COPD	B-T047
patients	B-T101
with	O
polycythemia	B-T047
had	O
a	O
higher	B-T080
proportion	B-T081
of	O
arrhythmia	B-T033
in	O
electrocardiogram	B-T033
(	O
ECG	B-T033
)	O
(49.5%	O
vs.	O
35.7%,	O
P=0.02),	O
a	O
longer	O
hospital duration time	B-T081
(15.3±10.1	O
vs.	O
9.7±9.1,	O
P=0.001),	O
a	O
higher	B-T080
mechanical ventilation rate	B-T061
(	O
noninvasive	B-T185
and	O
invasive	B-T080
,	O
51.7%	O
vs.	O
30.3%,	O
P=0.04	O
and	O
31.0%	O
vs.	O
7.9%,	O
P=0.04,	O
respectively),	O
and	O
a	O
higher	B-T080
in-hospital mortality	B-T080
(12.1%	O
vs.	O
6.6%,	O
P=0.04).	O
Multivariate logistic regression analysis	B-UnknownType
revealed	O
that	O
polycythemia	B-T047
was	O
associated with	B-T080
mortality	B-T081
in	O
COPD	B-T047
patients	B-T101
with	O
low-risk	B-T081
PE	B-T047
(adjusted	O
OR	O
1.11;	O
95%	O
CI,	O
1.04-1.66).	O
Polycythemia	B-T047
is	O
an	O
independent	O
risk factor	B-T033
for	O
all-cause	O
in-hospital mortality	B-T080
in	O
COPD	B-T047
patients	B-T101
with	O
PE	B-T047
at	O
low risk	B-T081
.	O

Masitinib	B-T109
for	O
treatment	B-T061
of	O
severely	B-T080
symptomatic	B-T169
indolent systemic mastocytosis	B-T047
:	O
a	O
randomised	B-T062
,	O
placebo-controlled	B-T062
,	O
phase 3 study	B-T062
Indolent systemic mastocytosis	B-T047
,	O
including	O
the	O
subvariant	B-T080
of	O
smouldering systemic mastocytosis	B-T191
,	O
is	O
a	O
lifelong	B-T079
condition	O
associated with	B-T080
reduced quality of life	B-T033
.	O
Masitinib	B-T109
inhibits	B-T052
KIT	B-T116
and	O
LYN kinases	B-T116
that	O
are	O
involved	O
in	O
indolent systemic mastocytosis	B-T047
pathogenesis	B-T046
.	O
We	O
aimed	O
to	O
assess	O
safety	B-T062
and	O
efficacy	B-T062
of	O
masitinib	B-T109
versus	O
placebo	B-T122
in	O
severely symptomatic	B-T033
patients	B-T101
who	O
were	O
unresponsive	B-T169
to	O
optimal	B-T080
symptomatic	B-T169
treatments	B-T061
.	O
In	O
this	O
randomised	B-T062
,	O
double-blind	B-T062
,	O
placebo-controlled	B-T062
,	O
phase 3 study	B-T062
,	O
we	O
enrolled	O
adults	B-T100
(	O
aged	B-T032
18-75	O
years)	O
with	O
indolent	B-T047
or	O
smouldering systemic mastocytosis	B-T191
,	O
according	O
to	O
WHO	B-T093
classification	B-T185
or	O
documented	B-T170
mastocytosis	B-T047
based	O
on	O
histological criteria	B-T201
,	O
at	O
50	O
centres	O
in	O
15	O
countries	B-T083
.	O
We	O
excluded	O
patients	B-T101
with	O
cutaneous	B-T082
or	O
non-severe	O
systemic mastocytosis	B-T047
after	O
a	O
protocol amendment	B-T170
.	O
Patients	B-T101
were	O
centrally	O
randomised	B-T062
(1:1)	O
to	O
receive	O
either	O
oral	B-T169
masitinib	B-T109
(6	O
mg/kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension)	O
or	O
matched	O
placebo	B-T122
with	O
minimisation	O
according	O
to	O
severe symptoms	B-T033
.	O
The	O
primary endpoint	B-T130
was	O
cumulative	O
response	B-T201
(≥75%	O
improvement	B-T077
from	O
baseline	B-T081
within	O
weeks	O
8-24)	O
in	O
at	O
least	O
one	O
severe baseline symptom	B-T033
from	O
the	O
following:	O
pruritus	B-T184
score	B-T081
of	O
9	O
or	O
more,	O
eight	O
or	O
more	O
flushes	O
per	O
week,	O
Hamilton Rating Scale for Depression	B-T170
of	O
19	O
or	O
more,	O
or	O
Fatigue Impact Scale	B-T170
of	O
75	O
or	O
more.	O
We	O
assessed	O
treatment effect	B-T080
using	O
repeated	O
measures	O
methodology	B-T062
for	O
rare diseases	B-T047
via	O
the	O
generalised estimating equation model	B-T170
in	O
a	O
modified	O
intention-to-treat	B-T062
population	B-T098
,	O
including	O
all	O
participants	B-T098
assigned	O
to	O
treatment	B-T061
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment-related cause	B-T033
.	O
We	O
assessed	O
safety	B-T062
in	O
all	O
patients	B-T101
who	O
received	O
at	O
least	O
one	O
dose	B-T081
of	O
study drug	B-T062
.	O
This	O
trial	B-T062
is	O
registered	O
with	O
ClinicalTrials.gov, number NCT00814073	B-T062
.	O
Between	O
Feb	B-T080
19,	O
2009,	O
and	O
July	B-T080
15,	O
2015,	O
135	O
patients	B-T101
were	O
randomly assigned	B-UnknownType
to	O
masitinib	B-T109
(n=71)	O
or	O
placebo	B-T122
(n=64).	O
By	O
24	O
weeks	B-T079
,	O
masitinib	B-T109
was	O
associated with	B-T080
a	O
cumulative	O
response	B-T201
of	O
18·7%	O
in	O
the	O
primary endpoint	B-T130
(122·6	O
responses	B-T201
of	O
656·5	O
possible	O
responses	B-T201
[	O
weighted generalised estimating equation	B-T080
])	O
compared	O
with	O
7·4%	O
for	O
placebo	B-T122
(48·9	O
of	O
656·5;	O
difference	O
11·3%;	O
odds ratio	B-T081
3·6;	O
95%	O
CI	O
1·2-10·8;	O
p=0·0076).	O
Frequent	B-T079
severe adverse events	B-T033
(>4%	O
difference	O
from	O
placebo	B-T122
)	O
were	O
diarrhoea	B-T184
(eight	O
[11%]	O
of	O
70	O
in	O
the	O
masitinib	B-T109
group	B-T078
vs	O
one	O
[2%]	O
of	O
63	O
in	O
the	O
placebo	B-T122
group	B-T078
),	O
rash	O
(four	O
[6%]	O
vs	O
none),	O
and	O
asthenia	B-T184
(four	O
[6%]	O
vs	O
one	O
[2%]).	O
The	O
most	O
frequent	B-T079
serious adverse events	B-T033
were	O
diarrhoea	B-T184
(three	O
patients	B-T101
[4%]	O
vs	O
one	O
[2%])	O
and	O
urticaria	B-T047
(two	O
[3%]	O
vs	O
none),	O
and	O
no	O
life-threatening	B-T033
toxicities	B-T037
occurred.	O
One	O
patient	B-T101
in	O
the	O
placebo	B-T122
group	B-T078
died	B-T033
(	O
unrelated	B-T080
to	O
study treatment	B-T062
).	O
These	O
study findings	B-T033
indicate	O
that	O
masitinib	B-T109
is	O
an	O
effective	B-T080
and	O
well	O
tolerated agent	B-T121
for	O
the	O
treatment	B-T061
of	O
severely symptomatic	B-T033
indolent	B-T047
or	O
smouldering systemic mastocytosis	B-T191
.	O
AB	O
Science	O
(Paris,	O
France).	O

Attributable risk	B-T080
of	O
ambient	B-T080
PM10	B-T167
on	O
daily	O
mortality	B-T081
and	O
years of life lost	B-T081
in	O
Chengdu	B-UnknownType
,	O
China	B-T083
Attributable risk	B-T080
is	O
an	O
important	O
indicator	O
for	O
planning	B-T058
and	O
evaluating public health interventions	B-T058
.	O
However,	O
most	O
current	O
measures	O
of	O
the	O
attributable risk	B-T080
of	O
air pollutants	B-T131
have	O
not	O
considered	O
temporal relationships	B-T079
between	O
exposure	B-T080
and	O
risk	B-T078
.	O
More	O
importantly,	O
limited	O
information	O
is	O
available	O
regarding	O
the	O
attributable risk	B-T080
due	O
to	O
ambient	B-T080
air pollutants	B-T131
in	O
basin regions	B-UnknownType
like	O
the	O
Sichuan Basin	B-UnknownType
,	O
China	B-T083
.	O
To	O
quantify	O
the	O
association	O
between	O
PM10	B-T167
and	O
deaths	B-T033
in	O
the	O
Basin region	B-UnknownType
,	O
we	O
used	O
a	O
measure	O
proposed	O
recently	O
within	O
the	O
framework	O
of	O
the	O
distributed lag non-linear model	B-T081
to	O
estimate	O
the	O
attributable risk	B-T080
in	O
Chengdu	B-UnknownType
,	O
China	B-T083
.	O
Meanwhile,	O
we	O
examined	O
the	O
association	B-T080
between	O
PM10	B-T167
and	O
years of life lost	B-T081
(	O
YLL	B-T081
).	O
Our	O
analysis	B-T062
showed	O
that	O
population-attributable fractions	B-T081
for	O
non-accidental	B-T169
,	O
respiratory	B-T169
,	O
and	O
cardiovascular mortality	B-T081
were	O
0.569%	O
(95%	O
CI:	O
-3.474%,	O
4.374%),	O
0.695%	O
(95%	O
CI:	O
-5.260%,	O
6.457%),	O
and	O
0.631%	O
(95%	O
CI:	O
-6.973%,	O
7.390%),	O
respectively.	O
On	O
average,	O
a	O
1μg/m(3)	O
increase	O
in	O
PM10	B-T167
was	O
associated	O
with	O
cumulative increases	B-T169
of	O
0.26893,	O
0.30437,	O
and	O
0.21924	O
YLL	B-T081
for	O
non-accidental	B-T169
,	O
respiratory	B-T169
,	O
and	O
cardiovascular mortality	B-T081
,	O
respectively,	O
referring	O
to	O
20μg/m(3).	O
In	O
addition,	O
we	O
found	O
an	O
inverse U-shaped pattern	B-T082
for	O
the	O
cumulative risk	B-T078
with	O
350μg/m(3)	O
as	O
the	O
reverse	O
point.	O
With	O
a	O
1μg/m(3)	O
increase	O
in	O
PM10	B-T167
,	O
YLL	B-T081
changed	O
more	O
significantly	O
than	O
mortality	B-T081
.	O
Moreover,	O
PM10	B-T167
demonstrated	O
remarkable	O
effects	B-T080
on	O
YLL	B-T081
among	O
men	B-T098
and	O
the	O
elderly	B-T098
.	O

Far-infrared	B-T070
protects	B-T033
vascular endothelial cells	B-T025
from	O
advanced glycation end products	B-T109
-	O
induced	B-T169
injury	B-T037
via	O
PLZF	B-T116
-mediated	O
autophagy	B-T043
in	O
diabetic mice	B-T015
The	O
accumulation	O
of	O
advanced glycation end products	B-T109
(	O
AGEs	B-T109
)	O
in	O
diabetic	B-T047
patients	B-T101
induces	B-T169
vascular endothelial	B-T024
injury	B-T037
.	O
Promyelocytic leukemia zinc finger protein	B-T116
(	O
PLZF	B-T116
)	O
is	O
a	O
transcription factor	B-T116
that	O
can	O
be	O
activated	B-T039
by	O
low-temperature	B-T070
far-infrared	B-T070
(	O
FIR	B-T070
)	O
irradiation	B-T070
to	O
exert beneficial effects	B-T038
on	O
the	O
vascular endothelium	B-T024
.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
investigated	B-T169
the	O
influence	B-T077
of	O
FIR	B-T070
-	O
induced	B-T169
PLZF	B-T116
activation	B-T039
on	O
AGE	B-T109
-	O
induced	B-T169
endothelial	B-T024
injury	B-T037
both	B-T080
in vitro	B-T062
and	O
in vivo	B-T062
.	O
FIR	B-T070
irradiation	B-T070
inhibited	B-T080
AGE	B-T109
-	O
induced	B-T169
apoptosis	B-T043
in	O
human umbilical vein endothelial cells	B-T025
(	O
HUVECs	B-T025
).	O
PLZF	B-T116
activation	B-T039
increased	B-T081
the	O
expression	B-T045
of	O
phosphatidylinositol-3 kinases	B-T116
(	O
PI3K	B-T116
),	O
which	O
are	O
important	B-T080
kinases	B-T116
in	O
the	O
autophagic	B-T043
signaling pathway	B-T044
.	O
FIR	B-T070
-	O
induced	B-T169
PLZF	B-T116
activation	B-T039
led	O
to	O
autophagy	B-T043
in	O
HUVEC	B-T025
,	O
which	O
was	O
mediated	O
through	B-T169
the	O
upregulation	B-T044
of	O
PI3K	B-T116
.	O
Immunofluorescence	B-T059
staining	B-T059
showed	O
that	O
AGEs	B-T109
were	O
engulfed	O
by	O
HUVECs	B-T025
and	O
localized	B-T082
to	O
lysosomes	B-T026
.	O
FIR	B-T070
-	O
induced	B-T169
autophagy	B-T043
promoted	B-T052
AGEs	B-T109
degradation	B-T169
in	O
HUVECs	B-T025
.	O
In	O
nicotinamide	B-T109
/	O
streptozotocin	B-T109
-	O
induced	B-T169
diabetic mice	B-T015
,	O
FIR	B-T070
therapy	B-T061
reduced	B-T080
serum AGEs	B-T116
and	O
AGEs	B-T109
deposition	B-T169
at	O
the	O
vascular endothelium	B-T024
.	O
FIR	B-T070
therapy	B-T061
also	O
reduced	B-T080
diabetes	B-T047
-	O
induced	B-T169
inflammatory markers	B-T033
in	O
the	O
vascular endothelium	B-T024
and	O
improved	B-T033
vascular endothelial	B-T024
function	B-T042
.	O
These	O
protective effects	B-T039
of	O
FIR	B-T070
therapy	B-T061
were	O
not found	B-T033
in	O
PLZF	B-T116
-	O
knockout mice	B-T015
.	O
Our	O
data	B-T078
suggest	B-T078
that	O
FIR	B-T070
-	O
induced	B-T169
PLZF	B-T116
activation	B-T039
in	O
vascular endothelial cells	B-T025
protects	O
the	O
vascular endothelium	B-T024
in	O
diabetic mice	B-T015
from	O
AGE	B-T109
-	O
induced	B-T169
injury	B-T037
.	O

Ultrasonic computed tomography imaging	B-T060
of	O
iron oxide nanoparticles	B-T130
Iron oxide nanoparticles	B-T130
(	O
IONPs	B-T130
)	O
are	O
becoming	O
increasingly	B-T169
used	O
and	O
intensively investigated	B-T169
in	O
the	O
field	B-T077
of	O
medical imaging	B-T060
.	O
They	O
are	O
currently	B-T079
FDA	B-T093
approved	B-T080
for	O
magnetic resonance imaging	B-T060
(	O
MRI	B-T060
),	O
and	O
it	O
would	O
be	O
highly	B-T080
desirable	O
to	O
visualize	B-T169
them	O
by	O
ultrasound	B-T070
as	O
well.	O
Previous	B-T079
reports	B-T170
using	O
the	O
conventional	B-T080
ultrasound B-scan (pulse-echo) imaging technique	B-T060
have	O
shown	O
very	O
limited	B-T169
detectability	B-T201
of	O
these	O
particles	B-T104
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
is	O
to	O
explore	O
the	O
feasibility	B-T080
of	O
imaging	B-T060
IONPs	B-T130
using	O
the	O
through-transmission ultrasound methodology	B-T078
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic computed tomography	B-T060
(	O
UCT	B-T060
).	O
Commercially	O
available	O
IONPs	B-T130
were	O
acoustically	B-T070
analysed	B-T062
to	O
quantify	B-T081
their	O
effect	B-T080
on	O
the	O
speed	B-T081
of	O
sound	B-T070
(	O
SOS	B-T070
)	O
and	O
acoustic	B-T070
attenuation	B-T052
as	O
a	O
function	B-T169
of	O
concentration	B-T081
.	O
Next,	O
through-transmission projection	B-T060
and	O
UCT imaging	B-T060
were	O
performed	B-T169
on	O
a	O
breast	B-T023
breast mimicking phantom	B-T170
and	O
on	O
an	O
ex vivo	B-T169
ex vivo tissue model	B-T050
,	O
to	O
which	O
IONPs	B-T130
were	O
injected.	O
Finally,	O
an	O
MRI scan	B-T060
was	O
performed	B-T169
to	O
verify	B-T169
that	O
the	O
same	O
particles	B-T104
examined	B-T033
in	O
the	O
ultrasound	B-T070
experiment	B-T062
can	O
be	O
imaged	B-T170
by	O
magnetic resonance	B-T070
,	O
using	O
the	O
same	O
clinically relevant	B-T080
concentrations	B-T081
.	O
The	O
results	B-T033
have	O
shown	O
a	O
consistent	B-T078
concentration	B-T081
dependent	B-T169
speed	B-T081
of	O
sound	B-T070
increase	B-T169
(1.86	O
[Formula:	O
see	O
text]	O
rise	O
per	O
100	O
µg	O
·	O
ml(-1)	O
IONPs	B-T130
).	O
Imaging	B-T060
based	B-T169
on	O
this	O
property	B-T080
has	O
shown	O
a	O
substantial contrast-to-noise ratio	B-T081
improvement	B-T077
(up	O
to	O
5	O
fold,	O
p	O
<	O
0.01).	O
The	O
SOS	B-T070
-related	O
effect	B-T080
generated	O
a	O
well	O
discernible	B-T080
image	B-T170
contrast	B-T080
and	O
allowed	O
the	O
detection	B-T033
of	O
the	O
particles	B-T104
existence	B-T081
and	O
location	B-T082
,	O
in	O
both	B-T080
raster-scan projection	B-T060
and	O
UCT imaging	B-T060
.	O
Conversely,	O
no	O
significant	B-T078
change	B-T169
in	O
the	O
acoustic	B-T070
attenuation coefficient	B-T081
was	O
noted	B-T080
.	O
Based	B-T169
on	O
these	O
findings	B-T033
,	O
it	O
is	O
concluded	B-T078
that	O
IONPs	B-T130
can	O
be	O
used	O
as	O
an	O
effective	B-T080
SOS	B-T070
-	O
based	B-T169
contrast agent	B-T130
,	O
potentially useful	B-T080
for	O
ultrasonic	B-T070
breast	B-T023
imaging	B-T060
.	O
Furthermore,	O
the	O
particle	B-T104
offers	O
the	O
capacity	B-T081
of	O
significantly enhancing	B-T052
diagnosis accuracy	B-T080
using	O
multimodal	B-T060
MRI	B-T060
-	O
ultrasound imaging	B-T060
capabilities	B-T080
.	O

Genetically	B-T169
encoded	B-T052
calcium indicators	B-T130
for	O
studying	O
long-term	B-T079
calcium	B-T121
dynamics	B-T044
during	O
apoptosis	B-T043
Intracellular calcium release	B-T044
is	O
essential	B-T080
for	O
regulating	B-T043
almost	O
all	O
cellular functions	B-T043
.	O
Specific	B-T080
spatio-temporal	B-T062
patterns	B-T082
of	O
cytosolic	B-T026
calcium	B-T121
elevations	B-T080
are	O
critical	B-T080
determinants	B-T169
of	O
cell fate	B-T043
in	O
response	O
to	O
pro-apoptotic	B-T080
cellular	B-T025
stressors	B-T078
.	O
As	O
the	O
apoptotic program	B-T043
can	O
take	O
hours	B-T079
or	O
days	B-T079
,	O
measurement	B-T169
of	O
long-term	B-T079
calcium	B-T121
dynamics	B-T044
are	O
essential	B-T080
for	O
understanding	B-T041
the	O
mechanistic	B-T169
role	B-T077
of	O
calcium	B-T121
in	O
apoptotic cell death	B-T043
.	O
Due	O
to	O
the	O
technical	B-T169
limitations	B-T169
of	O
using	O
calcium	B-T121
-	O
sensitive	B-T169
dyes	B-T130
to	O
measure	B-T081
cytosolic	B-T026
calcium	B-T121
little	O
is	O
known	O
about	O
long-term	B-T079
calcium	B-T121
dynamics	B-T044
in	O
living cells	B-T025
after	O
treatment	B-T061
with	O
apoptosis	B-T043
-	O
inducing	B-T169
drugs	B-T121
.	O
Genetically	B-T169
encoded	B-T052
calcium indicators	B-T130
could	O
potentially	O
overcome	B-T052
some	O
of	O
the	O
limitations	B-T169
of	O
calcium	B-T121
-	O
sensitive	B-T169
dyes	B-T130
.	O
Here,	O
we	O
compared	O
the	O
performance	B-T052
of	O
the	O
genetically	B-T169
encoded	B-T052
calcium	B-T121
indicators	B-T130
GCaMP6s	B-T130
and	O
GCaMP6f	B-T130
with	O
the	O
ratiometric dye	B-T130
Fura-2	B-T109
.	O
GCaMP6s	B-T130
performed	O
as	O
well	O
or	O
better	O
than	O
Fura-2	B-T109
in	O
detecting	O
agonist	B-T121
-	O
induced	B-T169
calcium	B-T121
transients	B-T079
.	O
We	O
then	O
examined	O
the	O
utility	B-T169
of	O
GCaMP6s	B-T130
for	O
continuously	B-T078
measuring	B-T080
apoptotic	B-T080
calcium release	B-T059
over	O
the	O
course	B-T079
of	O
ten	O
hours	B-T079
after	O
treatment	B-T061
with	O
staurosporine	B-T109
.	O
We	O
found	O
that	O
GCaMP6s	B-T130
was	O
suitable	O
for	O
measuring	B-T080
apoptotic	B-T080
calcium release	B-T059
over	O
long	O
time	O
courses	B-T079
and	O
revealed	O
significant	B-T078
heterogeneity	B-T080
in	O
calcium release	B-T059
dynamics	B-T044
in	O
individual	O
cells	B-T025
challenged	O
with	O
staurosporine	B-T109
.	O
Our	O
results	O
suggest	O
GCaMP6s	B-T130
is	O
an	O
excellent	B-T080
indicator	B-T130
for	O
monitoring	B-T058
long-term	B-T079
changes	B-T169
cytosolic	B-T026
calcium	B-T121
during	O
apoptosis	B-T043
.	O

Staphylococcus pseudintermedius	B-T007
Human	B-T016
Infection	B-T046
Cases	B-T169
in	O
Spain	B-T083
:	O
Dog	B-T015
-to-	O
Human	B-T016
Transmission	B-T046
Staphylococcus pseudintermedius	B-T007
is	O
an	O
opportunistic pathogen	B-T001
that	O
has	O
been	O
identified	B-T080
as	O
infectious agent	B-T001
or	O
colonizer	B-T033
mainly	O
in	O
dogs	B-T015
.	O
S. pseudintermedius	B-T007
has	O
been	O
also	O
detected	B-T033
in	O
humans	B-T016
and	O
more	O
specifically	O
in	O
people	B-T098
in	O
contact with	B-T169
dogs	B-T015
.	O
In	O
this	O
study	B-T062
,	O
the	O
possible	B-T033
S. pseudintermedius	B-T007
pet	B-T008
-to-	O
human	B-T016
transmission	B-T046
was	O
analyzed	B-T062
in	O
four	O
clinical	B-T080
human	B-T016
cases	B-T169
.	O
Two	O
patients	B-T101
were	O
dog	B-T015
owners	B-T098
and	O
S. pseudintermedius	B-T007
was	O
also	O
detected	B-T033
as	O
colonizer	B-T033
in	O
these	O
healthy	B-T080
animals	B-T008
.	O
S. pseudintermedius	B-T007
isolates	B-T123
from	O
patients	B-T101
and	O
dogs	B-T015
of	O
the	O
same	O
household	B-T099
showed	O
identical	B-T080
pulsed-field gel electrophoresis	B-T059
patterns	B-T082
,	O
sequence types	B-T033
(	O
STs	B-T033
),	O
and	O
antimicrobial resistance	B-T201
phenotypes and genotypes	B-T032
,	O
and	O
were	O
methicillin susceptible	B-T032
.	O
Resistance	B-T169
to	O
erythromycin	B-T109
,	O
clindamycin	B-T109
,	O
tetracycline	B-T109
,	O
trimetoprim-sulfamethoxazole	B-T121
,	O
and/or	O
ciprofloxacin	B-T109
was	O
identified	B-T080
among	O
S. pseudintermedius	B-T007
strains	B-T001
.	O
The	O
lineages	B-T077
ST241	B-T033
and	O
the	O
new	O
ST521	B-T033
were	O
detected	B-T033
in	O
the	O
strains	B-T001
of	O
the	O
two	O
dog	B-T015
-	O
owner	B-T098
patients	B-T101
,	O
respectively.	O
The	O
strains	B-T001
from	O
the	O
other	B-T080
two	O
patients	B-T101
presented	B-T078
two	O
new	O
STs	B-T033
,	O
ST719	B-T033
and	O
ST720	B-T033
.	O
To	O
our	O
knowledge	B-T170
,	O
this	O
is	O
the	O
first	O
description	B-T170
of	O
human	B-T016
infections	B-T046
caused	O
by	O
S. pseudintermedius	B-T007
in	O
Spain	B-T083
.	O

TANGO	B-T170
-	O
a	O
screening tool	B-T058
to	O
identify	O
comorbidities	B-T078
on	O
the	O
causal pathway	B-T170
of	O
nocturia	B-T047
To	O
develop	O
a	O
robust screening metric	B-T058
for	O
use	O
in	O
identifying	O
non-lower	O
urinary tract	B-T023
comorbidities	B-T078
pertinent	O
to	O
the	O
multidisciplinary assessment	B-T060
of	O
patients	B-T101
with	O
nocturia	B-T047
.	O
Variables	B-T080
having	O
a	O
significant	O
risk	O
association with	B-T080
nocturia	B-T047
of	O
greater	O
than	O
once	O
per	O
night	B-T079
were	O
identified.	O
Discriminating	B-T080
items	O
from	O
validated	O
and	O
reliable	O
tools	B-T058
measuring	O
these	O
comorbidities	B-T078
were	O
identified.	O
A	O
self-completed	O
57-item	O
questionnaire	B-T170
was	O
developed	O
and	O
a	O
medical	B-T169
checklist	B-T170
and	O
pertinent	O
clinical measures	B-T033
added.	O
Pre-determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
Short-Form	B-T170
(	O
SF	B-T170
)	O
screening tool	B-T058
.	O
The	O
tool	B-T058
was	O
administered	O
to	O
252	O
individuals	B-T098
with	O
nocturia	B-T047
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
Sleep	B-T040
,	O
Continence	B-T061
,	O
Falls	B-T033
or	O
Rehabilitation service	B-T058
for	O
routine care	B-T058
.	O
Data collected	B-T033
were	O
subjected	O
to	O
descriptive analysis	B-T170
;	O
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items.	O
Using	O
pre-determined	O
domains,	O
a	O
nocturia	B-T047
screening metric	B-T058
,	O
entitled	O
TANGO	B-T170
,	O
was	O
generated.	O
The	O
acronym	O
TANGO	B-T170
stands	O
for	O
Targeting	B-T169
the	O
individual's Aetiology	B-T169
of	O
Nocturia	B-T047
to	O
Guide	O
Outcomes.	O
The	O
demographic characteristics	B-T102
of	O
the	O
sample	O
are	O
described,	O
along	O
with	O
item	O
endorsement	O
levels.	O
The	O
statistical	B-T062
and	O
structural framework	B-T073
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
TANGO	B-T170
Long-Form	O
to	O
the	O
SF	B-T170
is	O
presented.	O
The	O
resultant	O
TANGO	B-T170
-	O
SF	B-T170
patient	B-T101
-completed	O
nocturia	B-T047
screening tool	B-T058
is	O
reported.	O
A	O
novel	O
all-cause	O
diagnostic	B-T169
metric	O
for	O
identifying	O
co-existing	O
morbidities	B-T081
of	O
clinical relevance	B-T201
to	O
nocturia	B-T047
in	O
patients	B-T101
who	O
present	O
across	O
disciplines	B-T058
and	O
medical specialties	B-T091
has	O
been	O
developed.	O
TANGO	B-T170
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth inequalities	B-T080
associated with	B-T080
a	O
siloed	O
approach	O
to	O
assessment	B-T058
and	O
subsequent	O
care	B-T052
of	O
patients	B-T101
with	O
nocturia	B-T047
.	O

Probabilistic	B-T081
acute	B-T079
risk assessment	B-T058
of	O
cumulative exposure	B-T067
to	O
organophosphorus	B-T109
and	O
carbamate pesticides	B-T109
from	O
dietary vegetables	B-T168
and	O
fruits	B-T168
in	O
Shanghai	B-UnknownType
populations	B-T098
Organophosphorus pesticides	B-T109
(	O
OPs	B-T109
)	O
and	O
carbamate pesticides	B-T109
(	O
CPs	B-T109
)	O
are	O
among	O
the	O
most	O
widely	O
used	O
pesticides	B-T131
in	O
China	B-T083
,	O
playing	O
a	O
major	O
role	O
in	O
protecting	B-T033
agricultural commodities	B-T002
.	O
In	O
this	O
study,	O
we	O
determined	B-T080
the	O
cumulative acute exposure	B-T067
to	O
OPs	B-T109
and	O
CPs	B-T109
of	O
Shanghai	B-UnknownType
residents	B-T098
from	O
vegetables	B-T168
and	O
fruits	B-T168
(	O
VFs	B-T168
).	O
The	O
food consumption	B-T052
data	B-T078
were	O
obtained	B-T169
from	O
the	O
Shanghai Food Consumption Survey	B-T170
(	O
SHFCS	B-T170
)	O
of	O
2012-14	O
including	O
a	O
total	O
of	O
1973	O
participants	B-T098
aged	B-T032
2-90	O
years	B-T079
.	O
The	O
pesticide residue	B-T131
data	B-T078
were	O
obtained	B-T169
from	O
the	O
Shanghai	B-UnknownType
monitoring	B-T058
programme	B-T169
during	O
2008-11	O
with	O
34	O
organophosphates	B-T109
and	O
11	O
carbamates	B-T109
analysed	O
in	O
a	O
total	O
of	O
5335	O
samples	B-T167
of	O
VFs	B-T168
.	O
A	O
probabilistic	B-T081
approach	O
was	O
performed	B-T169
as	O
recommended	B-T078
by	O
the	O
EFSA	B-T170
,	O
using	O
the	O
optimistic model	B-T170
with	O
non-detects	O
set	O
as	O
zero	B-T081
and	O
with	O
processing	B-T057
factors	B-T169
(	O
PFs	B-T169
)	O
being	O
used	O
and	O
the	O
pessimistic model	B-T170
with	O
non-detects	O
replaced by	B-T169
limit of detection	B-T081
(	O
LOD	B-T081
)	O
and	O
without	B-T080
PFs	B-T169
.	O
We	O
used	O
the	O
relative potency factor (RPF) method	B-T170
to	O
normalise	O
the	O
various	O
pesticides	B-T131
to	O
the	O
index compound	B-T103
(	O
IC	B-T103
)	O
of	O
methamidophos	B-T109
and	O
chlorpyrifos	B-T109
separately	B-T080
.	O
Only	O
in	O
the	O
pessimistic model	B-T170
using	O
methamidophos	B-T109
as	O
the	O
IC	B-T103
was	O
there	O
was	O
small	O
risk	B-T078
of	O
exposure	B-T080
exceeding	O
the	O
ARfD	B-T081
(3	O
µg	O
kg(-)(1)	O
bw	O
day	B-T079
(-)(1))	O
in	O
the	O
populations	B-T098
of	O
preschool children	B-T100
(0.029%),	O
school-age children	B-T100
(0.022%)	O
and	O
adults	B-T100
(0.002%).	O
There	O
were	O
no risk	B-T033
of	O
exposure	B-T080
exceeding	O
the	O
ARfD	B-T081
of	O
methamidophos	B-T109
in	O
the	O
optimistic model	B-T170
and	O
of	O
chlorpyrifos	B-T109
(100	O
µg	O
kg(-)(1)	O
bw	O
day	B-T079
(-)(1))	O
in	O
both	O
optimistic	B-T033
and	O
pessimistic models	B-T170
in	O
all	O
three	O
populations	B-T098
.	O
Considering	O
the	O
Chinese habits	B-T033
of	O
overwhelmingly	O
eating	B-T040
processed food	B-T168
(	O
vegetables	B-T168
being	O
cooked	B-T056
,	O
and	O
fruits	B-T168
being	O
washed	B-T078
or	O
peeled	B-T169
),	O
we	O
conclude	O
that	O
little	O
acute	B-T079
risk	B-T078
was	O
found	O
for	O
the	O
exposure to	B-T080
VF	B-T168
-	O
sourced	B-T033
OPs	B-T109
and	O
CPs	B-T109
in	O
Shanghai	B-UnknownType
.	O

MODEM	B-T062
:	O
A	O
comprehensive	B-T080
approach	B-T082
to	O
modelling	B-T062
outcome	B-T080
and	O
costs	B-T081
impacts	B-T080
of	O
interventions	B-T061
for	O
dementia	B-T048
.	O
Protocol	B-T170
paper	B-T073
The	O
MODEM project	B-T062
(A	O
comprehensive	B-T080
approach	B-T082
to	O
MODelling	B-T062
outcome	B-T080
and	O
costs	B-T081
impacts	B-T080
of	O
interventions	B-T061
for	O
DEMentia	B-T048
)	O
explores	O
how	O
changes	B-T169
in	O
arrangements	O
for	O
the	O
future	B-T079
treatment	B-T061
and	O
care	B-T052
of	O
people	B-T098
living	O
with	O
dementia	B-T048
,	O
and	O
support	B-T061
for	O
family	B-T099
and	O
other	O
unpaid	B-T033
carers	B-T097
,	O
could	O
result	B-T169
in	O
better	O
outcomes	B-T080
and	O
more	O
efficient	B-T080
use of	B-T169
resources	B-T078
.	O
MODEM	B-T062
starts	O
with	O
a	O
systematic	B-T169
mapping	B-T052
of	O
the	O
literature	B-T170
on	O
effective	B-T080
and	O
(potentially)	O
cost	B-T081
-	O
effective	B-T080
interventions	B-T061
in	O
dementia	B-T048
care	B-T052
.	O
Those	O
findings	B-T169
,	O
as	O
well	O
as	O
data	B-T078
from	O
a	O
cohort	B-T098
,	O
will	O
then	O
be	O
used	O
to	O
model	B-T170
the	O
quality of life	B-T078
and	O
cost	B-T081
impacts	B-T080
of	O
making	O
these	O
evidence	B-T078
-based	O
interventions	B-T061
more	O
widely	O
available	B-T169
in	O
England	B-T083
over	O
the	O
period	B-T079
from	O
now	O
to	O
2040.	O
Modelling	B-T062
will	O
use	O
a	O
suite	O
of	O
models	B-T170
,	O
combining	B-T080
microsimulation	B-UnknownType
and	O
macrosimulation methods	B-UnknownType
,	O
modelling	B-T062
the	O
costs	B-T081
and	O
outcomes	B-T080
of	O
care	B-T052
,	O
both	O
for	O
an	O
individual	B-T098
over	O
the	O
life-course	B-T079
from	O
the	O
point	O
of	O
dementia diagnosis	B-T048
,	O
and	O
for	O
individuals	B-T098
and	O
England	B-T083
as	O
a	O
whole	B-T081
in	O
a	O
particular	O
year.	O
Project	B-T062
outputs	O
will	O
include	O
an	O
online	B-UnknownType
Dementia Evidence Toolkit	B-T170
,	O
making	O
evidence	B-T078
summaries	B-T170
and	O
a	O
literature	B-T170
database	B-T170
available	B-T169
free	O
to	O
anyone,	O
papers	B-T073
in	O
academic journals	B-T073
and	O
other	O
written	O
outputs,	O
and	O
a	O
MODEM Legacy Model	B-T170
,	O
which	O
will	O
enable	O
local commissioners	B-T097
of	O
services	B-T057
to	O
apply	O
the	O
model	B-T170
to	O
their	O
own	O
populations	B-T098
.	O
Modelling	B-T062
the	O
effects of	B-T080
evidence	B-T078
-based	O
cost	B-T081
-	O
effective	B-T080
interventions	B-T061
and	O
making	O
this	O
information	B-T078
widely	O
available	B-T169
has	O
the	O
potential	B-T080
to	O
improve	B-T033
the	O
health	B-T078
and	O
quality of life	B-T078
both	O
of	O
people	B-T098
with	O
dementia	B-T048
and	O
their	O
carers	B-T097
,	O
while	O
ensuring	O
that	O
resources	B-T078
are	O
used	O
efficiently.	O

Assessment	B-T062
of	O
neuroanatomical	B-T080
and	O
behavioural effects	B-UnknownType
of	O
in ovo	B-T169
methylmercury	B-T109
exposure	B-T080
in	O
zebra finches	B-T012
(	O
Taeniopygia guttata	B-T012
)	O
Methylmercury	B-T109
(	O
MeHg	B-T109
)	O
readily	O
crosses	B-T077
the	O
blood brain barrier	B-T023
and	O
is	O
a	O
known	B-T080
neuro	B-T080
-	O
toxicant	B-T131
.	O
MeHg	B-T109
accumulation	B-T033
in	O
the	O
brain	B-T023
causes	B-T169
histopathological	B-T169
alterations	B-T169
,	O
neurobehavioral	B-T080
changes	B-T169
,	O
and	O
impairments	B-T169
to	O
cognitive	B-T169
motor functions	B-T038
in	O
mammalian	B-T015
models	B-T050
.	O
However,	O
in	O
birds	B-T012
the	O
neurotoxic effects	B-T037
of	O
MeHg	B-T109
on	O
the	O
developing	O
pre	B-T079
-	O
hatching	B-T040
brain	B-T023
and	O
consequent	B-T033
behavioral alterations	B-T055
in	O
adult	B-T100
birds	B-T012
have	O
not	B-T169
received	B-T080
much	O
attention	B-T041
.	O
Moreover,	O
passerine birds	B-T012
are	O
poorly	B-T080
represented	B-T052
in	O
MeHg	B-T109
neurotoxicology	B-T040
studies	B-T062
in	O
comparison	B-T052
to	O
other	O
avian	B-T012
orders	B-T185
.	O
Hence	O
in	O
this	O
study	B-T062
,	O
we	O
used	B-T169
the	O
egg	B-T168
injection method	B-T170
to	O
investigate	B-T169
the	O
long term effects	B-T067
of	O
in ovo	B-T169
MeHg	B-T109
exposure	B-T080
on	O
brain	B-T023
histopathology	B-T169
and	O
courtship behavior	B-T054
in	O
a	O
model	B-T050
songbird	B-T012
species	B-T185
,	O
the	O
zebra finch	B-T012
(	O
Taeniopygia guttata	B-T012
).	O
Egg	B-T168
treatment	B-T169
groups	B-UnknownType
included	B-T169
:	O
a	O
low	B-T080
MeHg	B-T109
dose	B-T081
of	O
0.2μg	O
Hg	B-T131
g(-1)	O
egg	B-T168
,	O
a	O
high	B-T080
MeHg	B-T109
dose	B-T081
of	O
3.2μg	O
Hg	B-T131
g(-1)	O
egg	B-T168
,	O
and	O
a	O
vehicle control	B-T122
(	O
water	B-T121
).	O
No adverse effects	B-T184
of	O
in ovo	B-T169
MeHg	B-T109
treatment	B-T169
were	O
detected	B-T033
on	O
courtship	B-T054
courtship song quality	B-T080
or	O
on	O
mating behavior	B-T040
in	O
experimental	B-T080
males	B-T032
at	O
sexually maturity	B-T033
which	O
would	O
suggest	B-T078
that	O
observable	B-T201
neurobehavioral effects	B-UnknownType
of	O
MeHg	B-T109
exposure	B-T080
may	O
depend	O
on	O
the	O
timing	B-T079
of	O
exposure	B-T080
during	B-T079
offspring	B-T099
development	B-T039
.	O
However,	O
neuroanatomical	B-T080
analysis	B-T062
indicated	B-T033
an	O
increase	B-T169
in	O
telencephalon	B-T023
volume	B-T081
with	O
increased	B-T081
MeHg	B-T109
concentrations	B-T081
which	O
may	O
suggest	B-T078
a	O
prolonged	B-T079
inflammatory response	B-T046
in	O
this	O
region of the brain	B-T029
.	O

Evaluation	B-T058
of	O
the	O
Condom Barriers Scale	B-T170
for	O
Young	B-T100
Black Men Who Have Sex With Men	B-T098
:	O
Reliability and Validity	B-T080
of	O
3	O
Subscales	B-T170
Reliable	B-T080
and	O
valid	B-T080
scale	B-T170
measures	B-T081
of	O
barriers	B-T061
to	O
condom use	B-T055
are	O
not	O
available	O
for	O
young	B-T100
black men who have sex with men	B-T098
(	O
YBMSM	B-T098
).	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
Condom Barriers Scales	B-T170
for	O
application	O
with	O
YBMSM	B-T098
.	O
A	O
clinic-based	B-T080
sample	B-T077
of	O
600	O
YBMSM	B-T098
completed	O
a	O
computer-assisted	B-T059
self-interview	B-T052
.	O
The	O
primary	O
measure	B-T081
was	O
a	O
14-item	O
abbreviated version	B-T170
of	O
the	O
Condom Barriers Scale	B-T170
.	O
Reliability	B-T080
and	O
criterion validity	B-T081
were	O
assessed.	O
All	O
3	O
subscales	B-T170
were	O
reliable	B-T080
:	O
partner	B-T098
-related	O
barriers	B-T061
(	O
Cronbach α	B-T081
=0.73),	O
sensation	B-T042
-related	O
barriers	B-T061
(α=0.70),	O
and	O
motivation	B-T041
-related	O
barriers	B-T061
(α	O
=0.81).	O
A	O
complete absence of barriers	B-T033
was	O
common:	O
47.0%	O
(	O
partner	B-T098
-related),	O
30.7%	O
(	O
sensation	B-T042
-related),	O
and	O
46.5%	O
(	O
motivation	B-T041
-related).	O
Dichotomized	O
subscales	B-T170
were	O
significantly	B-T081
associated with	B-T080
reporting	O
any	O
condomless	B-T033
insertive	B-T054
anal sex	B-T055
(all	O
Ps	B-T081
<	O
0.001)	O
and	O
any	O
condomless	B-T033
receptive	B-T042
anal sex	B-T055
(all	O
Ps	B-T081
<	O
0.001).	O
The	O
subscales	B-T170
were	O
significantly	B-T081
associated with	B-T080
these	O
measures	B-T081
of	O
condomless	B-T033
sex	B-T040
preserved	O
at	O
a	O
continuous	B-T078
level	B-T080
(all	O
Ps	B-T081
<0.001,	O
except	O
for	O
sensation	B-T042
barriers	B-T061
associated with	B-T080
condomless	B-T033
receptive	O
anal sex	B-T055
=	O
0.03).	O
Further,	O
the	O
subscales	B-T170
were	O
significantly	B-T081
associated with	B-T080
reporting	O
any	O
condom use	B-T055
problems	B-T078
(all	O
Ps	B-T081
<0.001)	O
and	O
a	O
measure	B-T081
of	O
condomless	B-T033
oral sex	B-T055
(all	O
Ps	B-T081
<0.001,	O
except	O
for	O
partner	B-T098
-related	O
barriers	B-T061
=0.31).	O
Finally,	O
the	O
sensation	B-T042
-related	O
barriers	B-T061
subscale	B-T170
was	O
significantly	B-T081
associated with	B-T080
testing	O
positive	B-T033
for	O
Chlamydia	B-T007
and/or	O
gonorrhea	B-T047
(P=0.049).	O
The	O
3	O
identified	O
subscales	B-T170
yielded	O
adequate	O
reliability	B-T080
and	O
strong	O
evidence	O
of	O
validity	B-T080
,	O
thereby	O
suggesting	O
the	O
utility	O
of	O
these	O
brief	O
measures	B-T081
for	O
use	O
in	O
observational	B-T062
and	O
experimental research	B-T062
with	O
YBMSM	B-T098
.	O

Variation	B-T070
in	O
the	O
Intensity	B-T080
of	O
Selection	B-T045
on	O
Codon	B-T086
Bias	B-T078
over	O
Time	B-T079
Causes	O
Contrasting Patterns	B-T082
of	O
Base Composition	B-T081
Evolution	B-T045
in	O
Drosophila	B-T204
Four-fold	O
degenerate	B-T169
coding sites	B-T028
form	O
a	O
major	O
component	O
of	O
the	O
genome	B-T028
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	B-T045
and	O
demography	B-T078
,	O
so	O
that	O
understanding	O
their	O
evolution	B-T045
is	O
important.	O
Despite	O
previous	O
efforts,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base composition	B-T081
changes	B-T169
at	O
these	O
sites	B-T028
in	O
Drosophila	B-T204
remain	O
unanswered.	O
To	O
shed	O
further	O
light	O
on	O
this	O
issue	B-T033
,	O
we	O
obtained	O
a	O
new	O
whole-genome polymorphism data set	B-T170
from	O
D. simulans	B-T204
.	O
We	O
analyzed	B-T062
samples	B-T026
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
D. simulans	B-T204
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism data set	B-T170
from	O
an	O
African	O
population	O
of	O
D. melanogaster	B-T204
.	O
By	O
using	O
D. yakuba	B-T204
as	O
an	O
outgroup	B-T098
,	O
we	O
found	O
clear	O
evidence	B-T078
for	O
selection	B-T045
on	O
4-fold	O
sites	B-T028
along	O
both	O
lineages	B-T078
over	O
a	O
substantial period	B-T079
,	O
with	O
the	O
intensity	B-T080
of	O
selection	B-T045
increasing	O
with	O
GC content	B-T081
.	O
Based	O
on	O
an	O
explicit	O
model	B-T075
of	O
base composition	B-T081
evolution	B-T045
,	O
we	O
suggest	O
that	O
the	O
observed	B-T169
AT-	O
biased	B-T078
substitution pattern	B-T082
in	O
both	O
lineages	B-T078
is	O
probably	O
due	O
to	O
an	O
ancestral reduction	B-T080
in	O
selection	B-T045
intensity	B-T080
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	B-T034
of	O
an	O
increase	B-T169
in	O
mutational	B-T045
bias	B-T078
towards	O
AT	O
alone.	O
By	O
using	O
two	O
polymorphism-based methods	B-T060
for	O
estimating	B-T081
selection	B-T045
coefficients	B-T081
over	O
different	O
timescales,	O
we	O
show	O
that	O
the	O
selection	B-T045
intensity	B-T080
on	O
codon	B-T086
usage	O
has	O
been	O
rather	O
stable	B-T080
in	O
D. simulans	B-T204
in	O
the	O
recent	O
past,	O
but	O
the	O
long-term	B-T079
estimates	B-T081
in	O
D. melanogaster	B-T204
are	O
much	O
higher	B-T080
than	O
the	O
short-term	B-T079
ones,	O
indicating	O
a	O
continuing	B-T078
decline	B-T081
in	O
selection	B-T045
intensity	B-T080
,	O
to	O
such	O
an	O
extent	B-T082
that	O
the	O
short-term	B-T079
estimates	B-T081
suggest	O
that	O
selection	B-T045
is	O
only	O
active	B-T169
in	O
the	O
most	O
GC	B-T081
-rich	O
parts	O
of	O
the	O
genome	B-T028
.	O
Finally,	O
we	O
provide	O
evidence	B-T078
for	O
complex	B-T080
evolutionary patterns	B-T082
in	O
the	O
putatively	O
neutral short introns	B-T114
,	O
which	O
cannot	O
be	O
explained	O
by	O
the	O
standard	B-T081
GC	B-T081
-	O
biased	B-T078
gene conversion	B-T045
model	B-T075
.	O
These	O
results	B-T034
reveal	O
a	O
dynamic	B-T169
picture	O
of	O
base composition	B-T081
evolution	B-T045
.	O

A	O
Case	B-T169
of	O
Koch's Spine	B-T047
Treated	B-T169
with	O
Modified	B-T169
Transpedicular Vertebral Curettage	B-T061
and	O
Posterior	B-T082
Fixation	B-T061
:	O
A	O
Novel	O
Technique	B-T169
Tuberculosis	B-T047
(	O
TB	B-T047
)	O
is	O
a	O
chronic	B-T079
granulomatous infection	B-T047
caused	O
by	O
acid-fast mycobacterium tuberculosis bacilli	B-T007
.	O
Spinal involvement	B-T029
occurs	O
in	O
less	O
than	O
one	O
percent	O
of	O
TB	B-T047
.	O
Spinal TB	B-T047
(	O
Pott's disease	B-T047
)	O
accounts	O
for	O
50%	O
of	O
skeletal TB	B-UnknownType
.	O
Though	O
it	O
most	O
commonly	O
affects	O
the	O
thoracolumbar junction	B-T030
,	O
it	O
can	O
occur	O
at	O
any	O
level	B-T080
of	O
the	O
spine	B-T023
.	O
Early	O
diagnosis	B-T033
and	O
treatment	B-T061
is	O
mandatory	O
in	O
order	O
to	O
avoid	O
neurological complications	B-T046
and	O
spinal deformity	B-T190
.	O
We	O
report	B-T170
a	O
case	B-T169
of	O
a	O
young	B-T079
female	B-T032
with	O
tuberculosis	B-T047
of	O
D12-L1	B-T030
who	O
was	O
treated	B-T169
with	O
posterior	B-T082
decompression	B-T061
using	O
a	O
modified	B-T169
transpedicular approach	B-T061
and	O
posterior	B-T082
instrumentation	B-T061
with	O
a	O
successful	O
outcome	B-T169
.	O

A	O
comparison	B-T052
of	O
two	O
comorbidity indices	B-T081
for	O
predicting	B-T078
inpatient	B-T101
rehabilitation	B-T061
outcomes	B-T080
Comorbid conditions	B-T033
are	O
important	O
in	O
health care	B-T058
.	O
The	O
best	O
comorbidity index	B-T081
for	O
predicting	B-T078
the	O
impact	B-T080
of	O
comorbidities	B-T078
on	O
rehabilitation	B-T061
outcomes	B-T080
has	O
not	O
been	O
determined	B-T080
.	O
Compare	B-T052
the	O
associations	B-T080
of	O
comorbidity	B-T078
measured	B-T080
using	O
the	O
Charlson Comorbidity Index	B-T081
(	O
CCI	B-T081
)	O
and	O
the	O
Cumulative Index Rating Scale	B-T081
(	O
CIRS	B-T081
)	O
with	O
key	O
rehabilitation	B-T061
outcomes	B-T080
.	O
Aim	O
was	O
to	O
determine	B-T080
whether	O
either	O
of	O
these	O
comorbidity indices	B-T081
helped	O
explain	O
the	O
variation	B-T080
in	O
key	O
rehabilitation	B-T061
outcomes	B-T080
.	O
Prospective open-cohort study	B-T062
.	O
Inpatient	B-T101
rehabilitation	B-T061
ward	B-T073
,	O
Melbourne	B-T083
,	O
Australia	B-T083
.	O
Adults	B-T100
admitted	B-T058
for	O
inpatient	B-T101
rehabilitation	B-T061
(n=280).	O
The	O
main	O
outcomes	B-T080
were	O
demographic	B-T078
(e.g.	O
age	B-T032
,	O
gender	B-T032
,	O
discharge	B-T058
destination	B-T082
)	O
and	O
clinical	B-T080
outcomes	B-T080
(	O
reason	B-T033
for	O
rehabilitation	B-T061
,	O
length of stay	B-T079
,	O
Functional Independence Measure	B-T170
,	O
CCI	B-T081
and	O
CIRS	B-T081
).	O
A	O
series	O
of	O
regression analyses	B-T170
were	O
performed	B-T169
to	O
determine	B-T080
the	O
influence	B-T077
of	O
comorbidity	B-T078
on	O
three	O
dependent variables	B-T169
:	O
LOS	B-T079
in	O
rehabilitation	B-T061
;	O
2)	O
the	O
change	B-T081
in	O
Functional Independence Measure-motor	B-T170
score	B-T081
between	O
rehabilitation	B-T061
discharge	B-T058
and	O
admission	B-T058
;	O
and	O
3)	O
the	O
discharge	B-T058
destination	B-T082
(	O
home	B-T082
vs	O
other).	O
The	O
mean	B-T081
age	B-T032
was	O
57.7	O
years	B-T079
,	O
there	O
were	O
slightly	O
more	O
females	B-T032
(51%),	O
most	O
(95%)	O
patients	B-T101
previously	B-T079
lived at home	B-T033
with	O
family	B-T099
or	O
other	O
relatives	B-T099
(63%).	O
The	O
most	O
common	O
reason	B-T033
for	O
rehabilitation	B-T061
was	O
orthopaedic	B-T061
or	O
other	O
conditions	B-T080
(52%)	O
and	O
most	O
(80%)	O
people	B-T098
were	O
discharged	B-T058
home	B-T082
.	O
The	O
median	O
LOS	B-T079
was	O
27	O
days	B-T079
.	O
There	O
were	O
100	O
(35.7%)	O
patients	B-T101
who	O
had	O
no	O
comorbidity	B-T078
recorded	B-T170
using	O
the	O
CCI	B-T081
,	O
112	O
(40.0%)	O
and	O
26	O
(9.3%)	O
who	O
three	O
or	O
more.	O
All	O
patients	B-T101
had	O
at	O
least	O
one	O
comorbidity	B-T078
recorded	B-T170
with	O
the	O
CIRS	B-T081
,	O
and	O
264	O
(94.3%)	O
had	O
3	O
or	O
more	O
comorbidities	B-T078
.	O
There	O
was	O
little	O
or	O
no	O
difference	B-T080
between	O
the	O
CCI	B-T081
or	O
CIRS	B-T081
in	O
terms	O
of	O
their	O
ability	B-T032
to	O
explain	O
the	O
variance	B-T080
in	O
LOS	B-T079
(adjusted	O
R2	B-T081
=0.38	O
with	O
and	O
without	O
comorbidities	B-T078
),	O
change	B-T081
in	O
disability	B-T033
during	O
rehabilitation	B-T061
(adjusted	O
R2	B-T081
=0.31	O
-	O
0.33	O
with	O
and	O
without	O
comorbidities	B-T078
)	O
or	O
the	O
discharge	B-T058
destination	B-T082
(AUC=0.72	O
without	O
comorbidities	B-T078
;	O
0.73	O
-	O
0.74	O
with	O
comorbidities	B-T078
)	O
beyond	O
that	O
accounted	O
for	O
by	O
demographic	B-T078
and	O
clinical information	B-T170
.	O
Neither	O
the	O
CIRS	B-T081
nor	O
the	O
CCI	B-T081
in	O
our	O
patient	B-T101
sample	B-T167
provide	B-T052
additional	O
information	B-T078
that	O
explains	O
the	O
impact	B-T080
of	O
comorbidities	B-T078
on	O
key	O
rehabilitation	B-T061
outcomes	B-T080
.	O
Further	O
research	B-T062
is	O
needed	O
to	O
determine	B-T080
the	O
most	O
appropriate	B-T080
measure	B-T081
of	O
comorbidity	B-T078
of	O
relevance	B-T080
to	O
inpatient	B-T101
rehabilitation	B-T061
outcomes	B-T080
.	O

Internet Gaming	B-T056
Disorder	B-T048
Explains	O
Unique Variance	B-T080
in	O
Psychological Distress	B-T048
and	O
Disability	B-T033
After	O
Controlling	O
for	O
Comorbid	B-T033
Depression	B-T048
,	O
OCD	B-T048
,	O
ADHD	B-T048
,	O
and	O
Anxiety	B-T033
This	O
study	B-T062
extends	O
knowledge	B-T170
about	O
the	O
relationship	B-T080
of	O
Internet Gaming Disorder	B-T048
(	O
IGD	B-T048
)	O
to	O
other	O
established	O
mental disorders	B-T048
by	O
exploring	O
comorbidities	B-T078
with	O
anxiety	B-T033
,	O
depression	B-T048
,	O
Attention Deficit Hyperactivity Disorder	B-T048
(	O
ADHD	B-T048
),	O
and	O
obsessive compulsive disorder	B-T048
(	O
OCD	B-T048
),	O
and	O
assessing	B-T058
whether	O
IGD	B-T048
accounts	O
for	O
unique variance	B-T080
in	O
distress	B-T033
and	O
disability	B-T033
.	O
An	O
online survey	B-T170
was	O
completed	O
by	O
a	O
convenience sample	B-T062
that	O
engages	O
in	O
Internet gaming	B-T056
(N	O
=	O
404).	O
Participants	B-T098
meeting criteria	B-T077
for	O
IGD	B-T048
based	O
on	O
the	O
Personal Internet Gaming Disorder Evaluation-9	B-T062
(	O
PIE-9	B-T062
)	O
reported	O
higher comorbidity	B-T078
with	O
depression	B-T048
,	O
OCD	B-T048
,	O
ADHD	B-T048
,	O
and	O
anxiety	B-T033
compared	O
with	O
those	O
who	O
did	O
not	O
meet	O
the	O
IGD	B-T048
criteria	B-T078
.	O
IGD	B-T048
explained	O
a	O
small	O
proportion	B-T081
of	O
unique variance	B-T080
in	O
distress	B-T033
(1%)	O
and	O
disability	B-T033
(3%).	O
IGD	B-T048
accounted	O
for	O
a	O
larger proportion	B-T081
of	O
unique variance	B-T080
in	O
disability	B-T033
than	O
anxiety	B-T033
and	O
ADHD	B-T048
,	O
and	O
a	O
similar	O
proportion	B-T081
to	O
depression	B-T048
.	O
Replications	B-T080
with	O
clinical samples	B-T098
using	O
longitudinal designs	B-T052
and	O
structured diagnostic interviews	B-UnknownType
are	O
required.	O

What	O
Is	O
the	O
Real	B-T080
Impact	B-T080
of	O
Urinary Incontinence	B-T046
on	O
Female Sexual Dysfunction	B-T048
?	O
A	O
Case Control Study	B-T062
Urinary incontinence	B-T046
(	O
UI	B-T046
)	O
has	O
been	O
associated with	B-T080
negative	B-T033
effects	B-T080
on	O
women's	B-T098
sexuality	B-T053
.	O
Women's	B-T098
sexuality	B-T053
and	O
sexual function	B-T040
are	O
a	O
complex	B-T080
issue	B-T033
,	O
and	O
the	O
role	B-T077
of	O
UI	B-T046
is	O
not completely	B-T080
clear.	O
To	O
assess	B-T052
the	O
impact	B-T080
of	O
UI	B-T046
on	O
female sexual function	B-T040
by	O
comparing	B-T052
this	O
population	B-T098
with	O
a	O
control group	B-T096
of	O
continent	B-T080
women	B-T098
.	O
We	O
performed	O
a	O
case-control study	B-T062
from	O
August	O
2012	O
to	O
September	O
2013.	O
We	O
evaluated	B-T058
continent	B-T080
and	O
incontinent	B-T169
women	B-T098
(	O
age	B-T032
range	B-T081
=	O
30-70	O
years)	O
for	O
their	O
sexuality	B-T053
.	O
All	O
patients	B-T101
were	O
evaluated	B-T058
by	O
anamnesis	B-T042
,	O
physical examination	B-T058
,	O
and	O
self-report	B-T062
quality-of-life questionnaires	B-T170
.	O
In	O
addition,	O
incontinent	B-T169
women	B-T098
underwent	O
a	O
1-hour	O
pad test	B-T060
.	O
Patients	B-T101
without	O
sexual activity	B-T053
were	O
evaluated	B-T058
for	O
the	O
role	B-T077
of	O
UI	B-T046
in	O
their	O
sexual abstinence	B-T055
.	O
Sexual abstinence	B-T055
was	O
defined	O
as	O
the	O
absence of sexual activity	B-T033
for	O
more	O
than	O
6	O
months.	O
All	O
sexually active	B-T033
women	B-T098
completed	O
the	O
self-report	B-T062
Sexuality	B-T053
Quotient	B-T081
-	O
Female	B-T032
Version	B-T170
(SQ-F)	O
questionnaire	B-T170
.	O
A	O
total	O
of	O
356	O
women	B-T098
were	O
included	O
in	O
the	O
study	B-T062
(	O
incontinent	B-T169
,	O
n	O
=	O
243;	O
continent	B-T080
,	O
n	O
=	O
113).	O
Sexual abstinence	B-T055
was	O
found	O
in	O
162	O
women	B-T098
(45%).	O
Incontinent	B-T169
women	B-T098
presented	O
a	O
higher prevalence	B-T081
(P	O
<	O
.001)	O
of	O
sexual abstinence	B-T055
than	O
their	O
counterparts	B-T099
(129	O
[53%]	O
and	O
33	O
[29.2%],	O
respectively).	O
Age	B-T032
,	O
marital status	B-T102
,	O
and	O
UI	B-T046
were	O
found	O
to	O
be	O
isolated	B-T169
predictive factors	B-T170
for	O
more	O
sexual abstinence	B-T055
in	O
incontinent	B-T169
women	B-T098
.	O
Sexually active	B-T033
women	B-T098
(	O
incontinent	B-T169
,	O
n	O
=	O
114;	O
continent	B-T080
,	O
n	O
=	O
80)	O
presented	O
similar	O
demographic	B-T090
data	B-T078
.	O
Despite	O
a	O
similar	O
frequency	B-T079
of	O
sexual activity	B-T053
,	O
incontinent	B-T169
women	B-T098
had	O
less	O
sexual desire	B-T048
,	O
foreplay	B-T033
,	O
harmony	B-T054
with	O
a	O
partner	B-T098
,	O
sexual comfort	B-T041
,	O
and	O
sexual satisfaction	B-T041
than	O
their	O
counterparts.	O
Women	B-T098
with	O
greater	B-T081
urinary leakage	B-T033
during	O
the	O
1-hour	O
pad test	B-T060
(	O
weight	B-T081
>	O
11	O
g)	O
had	O
the	O
worst	O
sexual function	B-T040
(SQ-F)	O
score	B-T081
.	O
Women	B-T098
with	O
UI	B-T046
were	O
more	O
likely	O
to	O
be	O
sexual abstinent	B-T055
than	O
continent	B-T080
women	B-T098
.	O
Furthermore,	O
women	B-T098
with	O
UI	B-T046
showed	O
less	O
sexual desire	B-T048
,	O
sexual comfort	B-T041
,	O
and	O
sexual satisfaction	B-T041
than	O
their	O
counterparts	B-T099
despite	O
having	O
a	O
similar	O
frequency	B-T079
of	O
sexual activity	B-T053
.	O

Salvianolic Acids	B-T109
for	O
Injection	B-T122
(	O
SAFI	B-T122
)	O
suppresses	B-T169
inflammatory responses	B-T046
in	O
activated	B-T052
microglia	B-T025
to	O
attenuate	B-T052
brain damage	B-T037
in	O
focal cerebral ischemia	B-T047
Inflammatory reactions	B-T046
induced	O
by	O
microglia	B-T025
in	O
the	O
brain	B-T023
play	O
crucial	O
roles	B-T077
in	O
ischemia	B-T047
/	O
reperfusion (I/R) cerebral injuries	B-T037
.	O
Microglia	B-T025
activation	B-T052
has	O
been	O
shown	O
to	O
be	O
closely	O
related	O
to	O
TLR4	B-T044
/	O
NF-κB signal pathways	B-T045
.	O
Salvianolic acids	B-T109
for	O
injection	B-T122
(	O
SAFI	B-T122
)	O
have	O
been	O
used	O
in	O
clinical practice	B-T057
to	O
treat	B-T169
ischemic stroke	B-T047
with	O
reported	B-T058
neuroprotective effects	B-T169
;	O
however,	O
the	O
underlying	O
mechanisms	B-T169
are	O
still	O
uncertain.	O
First,	O
we	O
studied	B-T062
the	O
effect	B-T080
of	O
SAFI	B-T122
on	O
inflammatory responses	B-T046
in	O
LPS	B-T109
-	O
stimulated	B-T070
BV-2	B-T007
microglia	B-T025
.	O
Then,	O
to	O
discover	B-T052
whether	O
the	O
beneficial	B-T081
in vitro	B-T062
effects	B-T080
of	O
SAFI	B-T122
lead	O
to	O
in vivo	B-T062
therapeutic effect	B-T201
s,	O
an	O
MCAO	B-T020
(	O
Middle cerebral artery occlusion	B-T020
)	O
rat	B-T015
model	B-T050
was	O
further	O
employed	B-T033
to	O
elucidate	O
the	O
probable	O
mechanism	B-T169
of	O
SAFI	B-T122
in	O
treating	B-T169
ischemic stroke	B-T047
.	O
Rats	B-T015
in	O
the	O
SAFI	B-T122
group	B-T078
were	O
given	O
SAFI	B-T122
(23	O
or	O
46mg/kg)	O
before	O
I	B-T047
/	O
R injury	B-T037
.	O
The	O
results	B-T169
showed	O
that	O
SAFI	B-T122
treatment	B-T169
significantly decreased	B-T081
neuroinflammation	B-T046
and	O
the	O
infarction	B-T046
volume	B-T081
compared	O
with	O
the	O
vehicle	B-T122
group	B-T078
.	O
Activation	B-T052
of	O
microglia cells	B-T025
was	O
reduced	B-T080
,	O
and	O
TLR4	B-T044
/	O
NF-κB signals	B-T045
,	O
which	O
were	O
markedly	O
inhibited	B-T080
by	O
SAFI	B-T122
treatment	B-T169
in	O
ischemic	B-T169
hemisphere	B-T023
,	O
were	O
accompanied	O
by	O
reduced	B-T080
expression	B-T045
and	O
release	B-T058
of	O
cytokines	B-T116
IL-1β	B-T116
and	O
IL-6	B-T116
.	O
This	O
study	B-T062
provides	O
evidence	B-T078
that	O
SAFI	B-T122
effectively	B-T080
protects	O
the	O
brain	B-T023
after	O
cerebral ischemia	B-T047
,	O
which	O
may	O
be	O
caused	O
by	O
attenuating	B-T052
inflammation	B-T046
in	O
microglia	B-T025
.	O

Dynamics	B-T070
of	O
bacterial	B-T080
class Bacilli	B-T007
in	O
the	O
deepest valley lake	B-T083
of	O
Kashmir	B-UnknownType
-the	O
Manasbal Lake	B-T083
In	O
recognition	O
of	O
the	O
importance	O
of	O
bacteria	B-T007
as	O
ecological indicators	B-T130
of	O
the	O
aquatic systems	B-T070
a	O
comprehensive and systematic analysis	B-T062
was	O
carried	O
out	O
on	O
Manasbal Lake	B-T083
,	O
the	O
deepest spring fed valley lake	B-T083
of	O
Kashmir	B-UnknownType
.	O
The	O
main	O
objective	O
envisaged	O
was	O
to	O
analyze	B-T062
bacterial community composition	B-T080
(	O
BCC	B-T080
)	O
and	O
for	O
this	O
purpose	O
systematic	B-T081
and	O
regular sampling of waters	B-T057
waters	B-T121
from	O
ten	O
different	O
sampling stations	B-T082
,	O
predetermined	O
in	O
the	O
Lake	B-T083
according	O
to	O
differences	O
in	O
degree of human interference	B-T080
and	O
also	O
as	O
zones	B-T082
of	O
special	O
ecological interests	B-T078
were	O
selected.	O
The	O
isolated	B-T169
species	B-T185
were	O
identified	B-T080
according	O
to	O
Bergey's Manual specification	B-T170
by	O
examining	O
their	O
micro and macro morphological characteristics	B-T080
and	O
biochemical characteristics	B-T080
on	O
different	O
culture media	B-T130
.	O
Further	O
confirmation	B-T033
was	O
done	O
by	O
sequencing	B-T169
the	O
16s rRNA gene	B-T028
by	O
using	O
universal bacterial primers	B-T114
27F	B-T114
and	O
1429R	B-T114
.	O
From	O
all	O
the	O
sampling stations	B-T082
the	O
class Bacilli	B-T007
showed	O
a	O
maximum	B-T081
relative abundance	B-T080
with	O
a	O
contribution	B-T052
of	O
16	O
bacterial species	B-T185
.	O
The	O
whole	O
process	B-T067
resulted	O
in	O
the	O
identification	B-T080
of	O
Bacillus aerius	B-T007
,	O
Bacillus altitudinis	B-T007
,	O
Bacillus anthracis	B-T007
,	O
Bacillus cereus	B-T007
,	O
Bacillus ginsengisoli	B-T007
,	O
Bacillus pumilus	B-T007
,	O
Bacillus safensis	B-T007
,	O
Bacillus stratosphericus	B-T007
,	O
Bacillus subtilis	B-T007
,	O
Bacillus tequilensis	B-T007
,	O
Bacillus thermocopriae	B-T007
,	O
Bacillus thuringiensis	B-T007
,	O
Brevibacillus agri strain	B-T007
,	O
Lysinibacillus boronitolerans	B-T007
,	O
Lysinibacillus pakistanensis	B-T007
and	O
Lysinibacillus sphaericus	B-T007
.	O

A	O
new	O
angle	B-T082
and	O
its	O
relationship	O
with	O
early	O
fixation failure	B-T046
of	O
femoral neck fractures	B-T037
treated	O
with	O
three	O
cannulated compression screws	B-T074
The	O
Pauwels	O
angle	O
has	O
been	O
used	O
widely,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	B-T082
is	O
difficult	O
because	O
of	O
deformity	B-T190
of	O
the	O
affected	B-T169
lower extremity	B-T023
.	O
Therefore	O
we	O
designed	O
a	O
new	O
measurement	B-T169
of	O
the	O
orientation	B-T082
of	O
femoral neck fracture	B-T037
and	O
applied	O
this	O
in	O
a	O
retrospective study	B-T062
to	O
assess:	O
(1)	O
its	O
reproducibility	B-T080
,	O
(2)	O
its	O
advantages	O
compared	O
with	O
the	O
Pauwels	O
angle,	O
(3)	O
its	O
relationship	O
with	O
the	O
short-term prognosis	B-T058
treated	B-T169
with	O
three	O
cannulated compression screws	B-T074
.	O
This	O
new	O
measurement	B-T169
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	B-T061
of	O
femoral neck fractures	B-T037
.	O
Two	O
hundred	O
and	O
twenty-eight	O
patients	B-T101
with	O
femoral neck fractures	B-T037
treated	O
with	O
three	O
cannulated compression screws	B-T074
were	O
retrospectively analyzed	B-T062
.	O
The	O
VN	O
angle,	O
which	O
was	O
the	O
angle	B-T082
between	O
the	O
fracture line	B-T082
and	O
the	O
vertical	B-T082
of	O
the	O
neck axis	B-T082
,	O
and	O
the	O
Pauwels	O
angle	O
were	O
measured	O
respectively.	O
The	O
method	O
of	O
ICC	B-T081
was	O
performed	O
to	O
assess	O
the	O
reproducibility	B-T080
of	O
the	O
two	O
angles	B-T082
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre-operative	B-T079
and	O
post-operative	B-T079
radiographs	B-T060
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	B-T082
.	O
These	O
fractures	B-T037
were	O
divided	O
into	O
four	O
groups	B-T078
according	O
to	O
VN	O
angle	O
(VN<0°	O
(n=92),	O
0°≤VN<10°	O
(n=82),	O
10°≤VN<15°	O
(n=26),	O
VN≥15°	O
(n=28)),	O
and	O
the	O
short-term	O
(within	O
6	O
months	B-T079
)	O
fixation	B-T061
results	O
of	O
radiographs	B-T060
in	O
these	O
fractures	B-T037
were	O
evaluated.	O
The	O
ICC	B-T081
of	O
the	O
VN	O
angle	O
and	O
the	O
Pauwels	O
angle	O
in	O
pre-operative	B-T079
radiographs	B-T060
were	O
0.937	O
(95%	O
confidence interval	B-T081
(	O
CI	B-T081
):	O
0.922-0.950)	O
and	O
0.942	O
respectively	O
(95%	O
CI	B-T081
:	O
0.914-0.970),	O
indicating	O
both	O
angles	B-T082
had	O
a	O
good	O
inter-rater reproducibility	B-T080
.	O
However,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
Pauwels	O
angle	O
in	O
pre-operative	B-T079
and	O
post-operative	B-T079
radiographs	B-T060
(P=0.037),	O
the	O
absolute	O
difference	O
was	O
10.66±6.47	O
(range:	O
1.72-38.48),	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
VN	O
angle	O
(P=0.084)	O
and	O
the	O
absolute	O
difference	O
was	O
2.20±1.63	O
(range:	O
0.05-7.56).	O
The	O
overall	O
fixation failure	B-T046
rate	B-T081
which	O
was	O
defined	O
as	O
screw loosening	B-T046
,	O
varus	O
collapse,	O
obvious	O
fracture displacement	B-T037
or	O
femoral neck	B-T023
shortening	O
was	O
11.84%,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
VN	O
angles	O
were	O
respectively	O
0%,	O
3.24%	O
(95%	O
CI	B-T081
:	O
1.64-4.84),	O
22.69%	O
(95%	O
CI	B-T081
:	O
16.43-28.96),	O
65.45%	O
(95%	O
CI	B-T081
:	O
59.36-71.53).	O
The	O
mean	O
failure rates	B-T081
of	O
fractures	B-T037
according	O
to	O
post-operative	B-T079
Pauwels	O
angle	O
(<30°,	O
30-50°,	O
>50°)	O
were	O
respectively	O
0%,	O
1.46%	O
(95%	O
CI	B-T081
:	O
1.42-1.50)	O
and	O
36.24%	O
(95%	O
CI	B-T081
:	O
34.93-37.54).	O
The	O
VN	O
angle	O
has	O
a	O
good	O
inter-rater reproducibility	B-T080
,	O
a	O
higher	O
reliability	O
than	O
the	O
Pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short-term prognosis	B-T058
of	O
femoral neck fractures	B-T037
treated	O
with	O
cannulated compression screws	B-T074
.	O
Level	O
IV,	O
retrospective	O
diagnostic	O
study.	O

Retirement	B-T033
crisis	B-T033
warnings	B-T080
becoming	O
a	O
reality	B-T078
The	O
figures	B-T081
are	O
startling	B-T033
:	O
the	O
number	O
of	O
NHS	B-T064
staff	B-T097
applying	O
to	O
retire	B-T033
has	O
surged	B-T169
by	O
a	O
quarter	O
since	O
2012.	O
The	O
potential	O
consequences	B-T169
are	O
alarming	B-T080
;	O
a	O
serious	O
shortage	B-T081
of	O
nurses	B-T097
and	O
other	O
healthcare professionals	B-T097
now	O
seems	O
inevitable	B-T080
.	O

The	O
Burden	B-T081
of	O
Mental Disorders	B-T048
in	O
the	O
Eastern Mediterranean Region	B-T083
,	O
1990-2013	O
The	O
Eastern Mediterranean Region	B-T083
(	O
EMR	B-T083
)	O
is	O
witnessing	O
an	O
increase	B-T169
in	O
chronic disorders	B-T047
,	O
including	O
mental illness	B-T048
.	O
With	O
ongoing	O
unrest,	O
this	O
is	O
expected	O
to	O
rise.	O
This	O
is	O
the	O
first	O
study	B-T062
to	O
quantify	O
the	O
burden	B-T081
of	O
mental disorders	B-T048
in	O
the	O
EMR	B-T083
.	O
We	O
used	O
data	B-T078
from	O
the	O
Global Burden of Disease study	B-T170
(	O
GBD	B-T170
)	O
2013.	O
DALYs	B-UnknownType
(	O
disability-adjusted life years	B-UnknownType
)	O
allow	O
assessment	B-T058
of	O
both	O
premature mortality	B-T033
(	O
years of life lost	B-T081
-	O
YLLs	B-T081
)	O
and	O
nonfatal	O
outcomes	O
(	O
years lived with disability	B-T079
-	O
YLDs	B-T079
).	O
DALYs	B-UnknownType
are	O
computed	O
by	O
adding	O
YLLs	B-T081
and	O
YLDs	B-T079
for	O
each	O
age-sex-country	O
group.	O
In	O
2013,	O
mental disorders	B-T048
contributed	O
to	O
5.6%	O
of	O
the	O
total disease burden	B-T081
in	O
the	O
EMR	B-T083
(1894	O
DALYS	B-UnknownType
/100,000	O
population	B-T098
):	O
2519	O
DALYS	B-UnknownType
/100,000	O
(2590/100,000	O
males	B-T032
,	O
2426/100,000	O
females	B-T032
)	O
in	O
high-income	B-T033
high-income countries	B-T083
,	O
1884	O
DALYS	B-UnknownType
/100,000	O
(1618/100,000	O
males	B-T032
,	O
2157/100,000	O
females	B-T032
)	O
in	O
middle-income	B-T080
countries	B-T083
,	O
1607	O
DALYS	B-UnknownType
/100,000	O
(1500/100,000	O
males	B-T032
,	O
1717/100,000	O
females	B-T032
)	O
in	O
low-income	B-T033
countries	B-T083
.	O
Females	B-T032
had	O
a	O
greater	O
proportion	O
of	O
burden	B-T081
due	O
to	O
mental disorders	B-T048
than	O
did	O
males	B-T032
of	O
equivalent	O
ages	B-T032
,	O
except	O
for	O
those	O
under	O
15	O
years of age	B-T079
.	O
The	O
highest	O
proportion	O
of	O
DALYs	B-UnknownType
occurred	O
in	O
the	O
25-49	O
age group	B-T100
,	O
with	O
a	O
peak	O
in	O
the	O
35-39	O
years	O
age group	B-T100
(5344	O
DALYs	B-UnknownType
/100,000).	O
The	O
burden	B-T081
of	O
mental disorders	B-T048
in	O
EMR	B-T083
increased	O
from	O
1726	O
DALYs	B-UnknownType
/100,000	O
in	O
1990	O
to	O
1912	O
DALYs	B-UnknownType
/100,000	O
in	O
2013	O
(10.8%	O
increase).	O
Within	O
the	O
mental disorders group	B-T098
in	O
EMR	B-T083
,	O
depressive disorders	B-T048
accounted	O
for	O
most	O
DALYs	B-UnknownType
,	O
followed	O
by	O
anxiety disorders	B-T048
.	O
Among	O
EMR	B-T083
countries,	O
Palestine	B-UnknownType
had	O
the	O
largest	O
burden of mental disorders	B-T081
mental disorders	B-T048
.	O
Nearly	O
all	O
EMR countries	B-T083
had	O
a	O
higher	O
mental disorder burden	B-T081
compared	O
to	O
the	O
global	O
level.	O
Our	O
findings	O
call	O
for	O
EMR ministries	B-UnknownType
of	O
health	O
to	O
increase	O
provision	B-T033
of	O
mental health services	B-T058
and	O
to	O
address	O
the	O
stigma of mental illness	B-T033
.	O
Moreover,	O
our	O
results	O
showing	O
the	O
accelerating	B-T169
burden of mental health	B-T081
are	O
alarming	O
as	O
the	O
region	O
is	O
seeing	O
an	O
increased	O
level	O
of	O
instability	B-T033
.	O
Indeed,	O
mental health problems	B-T033
,	O
if	O
not	O
properly	O
addressed,	O
will	O
lead	O
to	O
an	O
increased	B-T081
burden of diseases	B-T081
in	O
the	O
region	B-T083
.	O

Like	O
Father	B-T099
,	O
Like	O
Daughter	B-T099
-	O
inherited	B-T169
cutis aplasia	B-T019
occurring	O
in	O
a	O
family	B-T099
with	O
Marfan syndrome	B-T047
:	O
a	O
case report	B-T170
We	O
present	O
the	O
case	B-T169
of	O
a	O
newborn	B-T100
with	O
co-occurrence	B-T079
of	O
Marfan syndrome	B-T047
and	O
aplasia cutis congenita	B-T019
(	O
ACC	B-T019
)	O
and	O
a	O
family history	B-T033
significant	B-T078
for	O
Marfan syndrome	B-T047
and	O
ACC	B-T019
in	O
the	O
father	B-T099
.	O
This	O
case	B-T169
details	B-T080
a	O
previously	O
unreported	O
mutation	B-T045
in	O
Marfan syndrome	B-T047
and	O
describes	O
a	O
novel	O
coinheritance	B-T169
of	O
Marfan syndrome	B-T047
and	O
ACC	B-T019
.	O

Hyperandrogenemia	B-T033
in	O
women	B-T098
with	O
polycystic ovary syndrome	B-T047
:	O
prevalence	B-T081
,	O
characteristics	B-T080
and	O
association with	B-T080
body mass index	B-T201
Hyperandrogenemia	B-T033
is	O
one	O
of	O
the	O
major	O
diagnostic	B-T169
features	O
for	O
the	O
diagnosis	B-T033
of	O
polycystic ovary syndrome	B-T047
(	O
PCOS	B-T047
).	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	B-T081
the	O
prevalence	B-T081
and	O
the	O
characteristics	B-T080
of	O
hyperandrogenemia	B-T033
in	O
women	B-T098
with	O
PCOS	B-T047
and	O
to	O
investigate	B-T169
the	O
association	O
of	O
clinical	B-T080
and	O
biochemical	B-T169
characteristics	B-T080
with	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
according	O
to	O
the	O
presence	B-T033
of	O
hyperandrogenemia	B-T033
.	O
We	O
studied	O
266	O
women	B-T098
diagnosed	B-T033
with	O
PCOS	B-T047
.	O
Hyperandrogenemia	B-T033
was	O
defined	O
by	O
testosterone	B-T109
(	O
T	B-T109
)	O
and/or	O
free testosterone	B-T109
(	O
FT	B-T109
)	O
and/or	O
∆4 androstenedione	B-T109
(	O
Δ4-A	B-T109
)	O
higher	O
than	O
75%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	B-T125
.	O
Patients	B-T101
were	O
stratified	B-T080
in	O
two	O
groups	B-T098
according	O
to	O
a	O
BMI	B-T201
threshold	B-T080
of	O
25	O
kg/m2.	O
Hyperandrogenemia	B-T033
was	O
present	B-T033
in	O
78.2%	O
of	O
the	O
patients	B-T101
.	O
Elevated	B-T080
levels	O
of	O
T	B-T109
were	O
found	O
in	O
58.4%,	O
while	O
elevated	B-T080
levels	O
of	O
FT	B-T109
and	O
Δ4-A	B-T109
were	O
found	O
in	O
42.5%	O
and	O
34.1%	O
of	O
patients	B-T101
.	O
In	O
normal weight	B-T033
women	B-T098
(	O
BMI	B-T201
≤25	O
kg/m2)	O
with	O
hyperandrogenemia	B-T033
lower	O
values	O
of	O
hip circumference	B-T201
and	O
HOMA-IR	B-T059
and	O
increased	B-T081
levels	O
of	O
T	B-T109
,	O
FT	B-T109
,	O
Δ4-A	B-T109
,	O
17-hydroxyprogesterone	B-T109
(	O
17-OHP	B-T109
),	O
dehydroepiandrosterone sulfate	B-T109
(	O
DHEAS	B-T109
),	O
white blood cells	B-T025
(	O
WBC	B-T025
)	O
and	O
neutrophils	B-T025
were	O
observed	O
compared	O
to	O
women	B-T098
without	O
hyperandrogenemia	B-T033
.	O
Also,	O
in	O
overweight	B-T184
women	B-T098
higher	O
levels	O
of	O
T	B-T109
,	O
FT	B-T109
,	O
Δ4-A	B-T109
,	O
17-OHP	B-T109
,	O
DHEAS	B-T109
and	O
cortisol	B-T109
were	O
measured	B-T080
,	O
while	O
lower	O
thyroid-stimulating hormone (TSH) levels	B-T059
were	O
comparable	O
to	O
women	B-T098
without	O
hyperandrogenemia	B-T033
.	O
This	O
study	O
showed	O
high	O
prevalence	B-T081
of	O
hyperandrogenemia	B-T033
in	O
PCOS	B-T047
women	B-T098
.	O
Women	B-T098
with	O
BMI	B-T201
≤25	O
kg/m2	O
have	O
significant	B-T078
differences	O
in	O
androgens	B-T121
,	O
WBC	B-T025
,	O
neutrophils	B-T025
and	O
HOMA-IR	B-T059
and	O
women	B-T098
with	O
BMI	B-T201
≥25	O
kg/m2	O
in	O
androgens	B-T121
,	O
TSH	B-T121
and	O
cortisol	B-T109
according	O
to	O
the	O
presence	B-T033
or	O
not	O
of	O
hyperandrogenemia	B-T033
.	O

A	O
Course	B-T079
-Based	O
Approach	B-T082
to	O
the	O
Doctor	B-T097
of	O
Nursing Practice Project	B-T062
:	O
Supporting	O
Student	B-T098
Growth	O
From	O
Concept	B-T078
to	O
Completion	B-T080
We	O
describe	O
a	O
course	B-T079
-based	O
approach	B-T082
to	O
the	O
doctor	B-T097
of	O
nursing practice project	B-T062
in	O
which	O
students	B-T098
work	B-T057
in	O
groups	B-T078
of	O
8	O
to	O
12	O
with	O
a	O
faculty member	B-T097
to	O
complete	B-T080
individual	O
final	O
projects	B-T077
that	O
require	O
a	O
minimum	B-T080
of	O
360	O
practicum	B-T065
hours	B-T079
in	O
3-	O
semester	B-T079
-long	O
courses	B-T079
.	O
Project teams	B-T096
include	O
agency	B-T092
or	O
community	B-T096
-based	O
mentors	B-T098
.	O
Project findings	B-T033
are	O
disseminated	B-T082
through	O
written	B-T170
and	O
oral reports	B-T170
.	O
This	O
approach	B-T082
preserves	O
faculty	B-T097
resources	B-T169
and	O
provides	O
students	B-T098
with	O
mentoring	B-T065
,	O
opportunities	B-T078
for	O
reflection	B-T054
,	O
and	O
time	B-T079
for	O
project development	B-T169
.	O

Clinical	B-T080
and	O
angiographic	B-T060
correlation	B-T080
of	O
high-sensitivity C-reactive protein	B-T116
with	O
acute ST elevation myocardial infarction	B-T047
Vascular inflammation	B-T047
and	O
associated	O
ongoing	O
inflammatory responses	B-T046
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	B-T046
of	O
acute	B-T079
atherothrombotic	B-T020
events	B-T051
such	O
as	O
acute coronary syndrome	B-T047
(	O
ACS	B-T047
)	O
and	O
myocardial infarction	B-T047
(	O
MI	B-T047
).	O
ST segment elevation myocardial infarction	B-T047
(	O
STEMI	B-T047
)	O
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	B-T080
forms	B-T080
of	O
ACS	B-T047
.	O
Moreover,	O
C-reactive protein	B-T116
(	O
CRP	B-T116
)	O
is	O
an	O
important	O
acute phase prsotein	B-T116
,	O
which	O
may	O
be	O
estimated	O
using	O
high-sensitivity methods	B-T059
(	O
hs-CRP	B-T059
),	O
and	O
its	O
elevated	B-T080
level	B-T034
in	O
body fluids	B-T031
reflects	O
chronic inflammatory	B-T046
status	B-T080
.	O
The	O
circulating	O
hs-CRP	B-T059
level	B-T034
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	B-T046
marker	B-T201
of	O
coronary artery disease	B-T047
(	O
CAD	B-T047
).	O
The	O
present	O
study	B-T062
investigated	B-T169
the	O
correlation	B-T080
of	O
hs-CRP	B-T059
level	B-T034
with	O
clinical	B-T080
and	O
angiographic	B-T060
features	B-T080
of	O
STEMI	B-T047
,	O
various	O
other	O
traditional	O
risk factors	B-T033
,	O
complications	B-T046
of	O
myocardial infarction	B-T047
and	O
angiographically significant	B-T078
CAD	B-T047
.	O
Out	O
of	O
190	O
patients	B-T101
with	O
STEMI	B-T047
that	O
were	O
analyzed	B-T062
,	O
the	O
interval	B-T079
between	O
symptom onset	B-T079
and	O
reperfusion therapy	B-T061
(	O
window period	B-T079
)	O
varied	O
from	O
0.5	O
to	O
24	O
h	B-T079
.	O
The	O
hs-CRP	B-T059
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non-diabetic patients	B-T101
(0.61	O
mg/dl)	O
compared	B-T052
with	O
diabetic	B-T047
patients	B-T101
(0.87	O
mg/dl).	O
Moreover,	O
a	O
significant	O
correlation	B-T080
between	O
hs-CRP	B-T059
and	O
hs-troponin T	B-T059
was	O
also	O
recorded	O
(P<0.001).	O
However,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs-CRP	B-T059
values	B-T080
in	O
patients	B-T101
with	O
or	O
without	O
mortality	B-T081
.	O
It	O
is	O
considered	O
that	O
the	O
present	O
study	B-T062
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	B-T047
in	O
general	O
and	O
may	O
also	O
have	O
clinical applications	B-T058
in	O
the	O
targeting	O
of	O
therapy	B-T061
for	O
this	O
harmful	O
disease	B-T047
.	O

Bioelectrochemical	B-T059
anaerobic	B-T080
sewage treatment	B-T057
technology	B-T090
for	O
Arctic	B-T083
communities	B-T096
This	O
study	B-T062
describes	O
a	O
novel	O
wastewater	B-T083
treatment	B-T169
technology	B-T090
suitable	O
for	O
small	O
remote	B-T082
northern	B-T082
communities	B-T096
.	O
The	O
technology	B-T090
is	O
based	B-T169
on	O
an	O
enhanced	B-T052
biodegradation	B-T070
of	O
organic carbon	B-T104
through	O
a	O
combination	O
of	O
anaerobic	B-T080
methanogenic	B-T194
and	O
microbial	B-T001
electrochemical	B-T059
(	O
bioelectrochemical	B-T059
)	O
degradation processes	B-T169
leading	O
to	O
biomethane	B-T109
production	B-T169
.	O
The	O
microbial	B-T001
electrochemical	B-T059
degradation	B-T169
is	O
achieved	O
in	O
a	O
membraneless flow	B-T033
-through	O
bioanode	B-T073
-	O
biocathode	B-T073
setup	O
operating	B-T169
at	O
an	O
applied	B-T169
voltage	B-T081
below	O
the	O
water	B-T121
electrolysis	B-T061
threshold	B-T080
.	O
Laboratory	B-T073
wastewater	B-T083
treatment	B-T169
tests	B-T170
conducted	O
through	O
a	O
broad range	B-T082
of	O
mesophilic	B-T080
and	O
psychrophilic temperatures	B-T070
(5-23	O
°C)	O
using	O
synthetic	B-T080
wastewater	B-T083
showed	O
a	O
biochemical oxygen demand	B-T059
(	O
BOD5	B-T059
)	O
removal	B-T052
efficiency	B-T081
of	O
90-97%	O
and	O
an	O
effluent	B-T170
BOD5	B-T059
concentration	B-T081
as	O
low	O
as	O
7	O
mg	O
L(-1).	O
An	O
electricity	B-T070
consumption	B-T169
of	O
0.6	O
kWh	O
kg(-1)	O
of	O
chemical oxygen demand	B-T038
(	O
COD	B-T038
)	O
removed	B-T080
was	O
observed	B-T169
.	O
Low	B-T080
energy	B-T081
consumption	B-T169
coupled	O
with	O
enhanced	B-T052
methane	B-T109
production	B-T169
led	O
to	O
a	O
net	O
positive	B-T033
energy	B-T081
balance	B-T169
in	O
the	O
bioelectrochemical	B-T059
treatment	B-T169
system	B-T169
.	O

Impact	B-T080
of	O
femoral artery	B-T023
puncture	B-T058
using	O
digital subtraction angiography	B-T060
and	O
road mapping	B-T052
on	O
vascular	B-T047
and	O
bleeding	B-T046
complications	B-T046
after	O
transfemoral	O
transcatheter aortic valve implantation	B-T061
The	O
use	O
of	O
large	B-T081
-	O
diameter	B-T081
sheaths	O
carries	O
the	O
risk	B-T078
of	O
significant	O
vascular	B-T047
and	O
bleeding	B-T046
complications	B-T046
after	O
transfemoral	O
transcatheter aortic valve implantation	B-T061
(	O
TAVI	B-T061
).	O
In	O
this	O
analysis	B-T062
,	O
we	O
sought	O
to	O
assess	B-T058
the	O
impact	B-T080
of	O
a	O
modified	O
femoral artery	B-T023
puncture	B-T058
technique	B-T169
using	O
digital subtraction angiography	B-T060
(	O
DSA	B-T060
)	O
and	O
road mapping	B-T052
during	O
transfemoral	O
TAVI	B-T061
on	O
periprocedural	B-T046
vascular	B-T023
and	O
bleeding	B-T046
events.	O
This	O
is	O
a	O
retrospective	O
analysis	B-T062
of	O
transfemoral	O
TAVI	B-T061
patients	B-T101
included	O
in	O
a	O
prospective institutional database	B-T170
.	O
The	O
modified	O
femoral artery	B-T023
puncture	B-T058
technique	B-T169
using	O
DSA	B-T060
-derived	O
road mapping	B-T052
guidance	O
was	O
introduced	O
in	O
October	O
2012.	O
Before	O
the	O
introduction	O
of	O
this	O
technique	B-T169
,	O
vascular	B-T023
puncture	B-T058
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-T060
data	B-T078
,	O
the	O
bony	B-T169
iliofemoral	B-T023
landmarks	B-T029
and	O
a	O
radiopaque object	B-T074
.	O
Consecutive	O
patients	B-T101
who	O
underwent	O
TAVI	B-T061
with	O
the	O
road mapping	B-T052
technique	B-T169
(	O
RM group	B-T078
,	O
n=160)	O
were	O
compared	O
with	O
consecutive	O
patients	B-T101
who	O
underwent	O
TAVI	B-T061
without	O
road mapping	B-T052
(	O
control group	B-T096
,	O
n=160)	O
prior	O
to	O
its	O
introduction.	O
A	O
standardised	O
strategy	O
of	O
periprocedural anticoagulation	B-T061
was	O
adopted	O
in	O
both	O
groups	B-T078
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single suture-based closure device	B-T074
.	O
All	O
endpoints	B-T080
were	O
defined	O
according	O
to	O
the	O
VARC-2 criteria	B-T170
for	O
event	O
definition.	O
The	O
mean	O
age	O
in	O
the	O
RM group	B-T078
was	O
80±7.7	O
years	B-T079
compared	O
to	O
81±5.9	O
years	B-T079
in	O
the	O
control group	B-T096
(p=0.19),	O
and	O
females	B-T032
were	O
equally	O
distributed	O
between	O
both	O
groups	B-T078
(63.1%	O
vs.	O
58.1%,	O
p=0.36).	O
The	O
baseline logistic EuroSCORE	B-T170
was	O
20.7±14.4%	O
vs.	O
24.9±15.2%	O
in	O
the	O
RM	B-T078
and	O
control group	B-T096
,	O
respectively	O
(p=0.01).	O
Notably,	O
sheath size	B-T082
was	O
significantly	O
larger	O
in	O
the	O
RM	B-T078
compared	O
to	O
the	O
control group	B-T096
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
Fr	O
sheath	O
(23.8%	O
vs.	O
1.8%,	O
p<0.001,	O
respectively)	O
associated with	B-T080
the	O
more	O
frequent	O
implantation	B-T061
of	O
the	O
29	O
mm	O
Edwards	O
SAPIEN	O
XT	O
valve	O
in	O
the	O
RM group	B-T078
(43.8%	O
vs.	O
7%,	O
respectively,	O
p<0.001).	O
Despite	O
the	O
latter	O
finding,	O
both	O
major	O
vascular complications	B-T047
and	O
major	O
bleeding	B-T046
at	O
30	O
days	B-T079
were	O
significantly	O
lower	B-T080
in	O
the	O
RM group	B-T078
compared	O
to	O
the	O
control group	B-T096
(4.3%	O
vs.	O
11.8%,	O
p=0.01,	O
and	O
14.4%	O
vs.	O
25.6%,	O
p=0.01).	O
An	O
analysis	B-T062
limited	O
to	O
access	O
site-related	O
complications	B-T046
also	O
revealed	O
lower	O
events	O
in	O
the	O
road map group	B-T078
but	O
did	O
not	O
reach	O
statistical significance	B-T081
(8.1%	O
vs.	O
13.8%,	O
p=0.1).	O
Other	O
forms	O
of	O
vascular	B-T047
and	O
bleeding	B-T046
complications	B-T046
as	O
well	O
as	O
all-cause mortality	B-T081
were	O
comparable	O
in	O
both	O
groups	B-T078
.	O
A	O
modified	O
femoral artery	B-T023
puncture	B-T058
technique	B-T169
using	O
DSA	B-T060
and	O
road mapping	B-T052
was	O
associated with	B-T080
a	O
reduction	O
in	O
major	O
vascular	B-T047
and	O
bleeding	B-T046
complications	B-T046
after	O
transfemoral	O
TAVI	B-T061
,	O
and	O
provides	O
a	O
simple	B-T080
and	O
effective	B-T080
strategy	O
for	O
potentially	O
improving	O
patient outcomes	B-T170
.	O

Differential	B-T080
Roles	B-T078
of	O
AXIN1	B-T116
and	O
AXIN2	B-T116
in	O
Tankyrase	B-T116
Inhibitor-Induced	B-T121
Formation	B-T169
of	O
Degradasomes	B-T116
and	O
β-Catenin	B-T116
Degradation	B-T169
Inhibition	B-T039
of	O
the	O
tankyrase enzymes	B-T116
(	O
TNKS1	B-T116
and	O
TNKS2	B-T116
)	O
has	O
recently	O
been	O
shown	O
to	O
induce	O
highly	B-T080
dynamic	B-T169
assemblies	B-T044
of	O
β-catenin	B-T116
destruction complex	B-T104
components	B-T116
known	O
as	O
degradasomes	B-T116
,	O
which	O
promote	B-T052
degradation	B-T169
of	O
β-catenin	B-T116
and	O
reduced	B-T080
Wnt signaling	B-T044
activity	B-T169
in	O
colorectal cancer	B-T191
cells	B-T025
.	O
AXIN1	B-T116
and	O
AXIN2	B-T116
/	O
Conductin	B-T116
,	O
the	O
rate-limiting	B-T169
factors	B-T169
for	O
the	O
stability	B-T080
and	O
function	B-T169
of	O
endogenous	B-T169
destruction complexes	B-T104
,	O
are	O
stabilized	B-T033
upon	O
TNKS	B-T116
inhibition	B-T039
due	O
to	O
abrogated	O
degradation	B-T169
of	O
AXIN	B-T116
by	O
the	O
proteasome	B-T116
.	O
Since	O
the	O
role	B-T078
of	O
AXIN1	B-T116
versus	O
AXIN2	B-T116
as	O
scaffolding proteins	B-T116
in	O
the	O
Wnt signaling pathway	B-T044
still	O
remains	B-T080
incompletely	B-T080
understood	B-T041
,	O
we	O
sought	O
to	O
elucidate	O
their	O
relative	B-T080
contribution	B-T052
in	O
the	O
formation	B-T169
of	O
degradasomes	B-T116
,	O
as	O
these	O
protein	B-T116
assemblies	B-T044
most	O
likely	O
represent	O
the	O
morphological	B-T082
and	O
functional	B-T169
correlates	B-T080
of	O
endogenous	B-T169
β-catenin	B-T116
destruction complexes	B-T104
.	O
In	O
SW480	B-T025
colorectal cancer	B-T191
cells	B-T025
treated	B-T169
with	O
the	O
tankyrase inhibitor	B-T121
(	O
TNKSi	B-T121
)	O
G007-LK	B-T109
we	O
found	B-T033
that	O
AXIN1	B-T116
was	O
not	O
required	O
for	O
degradasome	B-T116
formation	B-T169
.	O
In	O
contrast,	O
the	O
formation	B-T169
of	O
degradasomes	B-T116
as	O
well	O
as	O
their	O
capacity	B-T081
to	O
degrade	B-T169
β-catenin	B-T116
were	O
considerably	B-T078
impaired	B-T169
in	O
G007-LK-treated	B-T109
cells	B-T025
depleted	O
of	O
AXIN2	B-T116
.	O
These	O
findings	B-T033
give	O
novel	B-T080
insights	B-T041
into	O
differential	B-T080
functional roles	B-T077
of	O
AXIN1	B-T116
versus	O
AXIN2	B-T116
in	O
the	O
β-catenin	B-T116
destruction complex	B-T104
.	O

MRI	B-T060
-based	O
prostate cancer	B-T191
detection	B-T033
with	O
high-level representation	B-UnknownType
and	O
hierarchical	B-T169
classification	B-T185
Extracting	O
the	O
high-level feature representation	B-UnknownType
by	O
using	O
deep neural networks	B-T170
for	O
detection	B-T033
of	O
prostate cancer	B-T191
,	O
and	O
then	O
based	O
on	O
high-level feature representation	B-UnknownType
constructing	O
hierarchical	B-T169
classification	B-T185
to	O
refine	O
the	O
detection	B-T033
results	B-T169
.	O
High-level feature representation	B-UnknownType
is	O
first	O
learned	O
by	O
a	O
deep learning network	B-T170
,	O
where	O
multiparametric MR	B-T060
images	B-T170
are	O
used	O
as	O
the	O
input	O
data	B-T078
.	O
Then,	O
based	O
on	O
the	O
learned	O
high-level features	B-T080
,	O
a	O
hierarchical	B-T169
classification	B-T185
method	B-T170
is	O
developed,	O
where	O
multiple random forest classifiers	B-T170
are	O
iteratively constructed	B-T052
to	O
refine	O
the	O
detection	B-T033
results	B-T169
of	O
prostate cancer	B-T191
.	O
The	O
experiments	B-T062
were	O
carried	O
on	O
21	O
real	O
patient	B-T101
subjects,	O
and	O
the	O
proposed	O
method	B-T170
achieves	O
an	O
averaged	O
section-based evaluation	B-T058
(	O
SBE	B-T058
)	O
of	O
89.90%,	O
an	O
averaged	O
sensitivity	B-T169
of	O
91.51%,	O
and	O
an	O
averaged	O
specificity	B-T081
of	O
88.47%.	O
The	O
high-level features	B-T080
learned	O
from	O
our	O
proposed	O
method	B-T170
can	O
achieve	O
better	O
performance	B-T052
than	O
the	O
conventional	B-T081
handcrafted features	B-T080
(e.g.,	O
LBP	B-T080
and	O
Haar-like features	B-T080
)	O
in	O
detecting	B-T033
prostate cancer	B-T191
regions	B-T029
,	O
also	O
the	O
context	B-T078
features	B-T080
obtained	O
from	O
the	O
proposed	O
hierarchical	B-T169
classification	B-T185
approach	O
are	O
effective	B-T080
in	O
refining	O
cancer	B-T191
detection	B-T033
result	B-T169
.	O

Quantitative Susceptibility Mapping	B-T060
using	O
Structural Feature based Collaborative Reconstruction	B-T066
(	O
SFCR	B-T066
)	O
in	O
the	O
Human	B-T016
Brain	B-T023
The	O
reconstruction	B-T066
of	O
MR	B-T070
quantitative susceptibility mapping	B-T060
(	O
QSM	B-T060
)	O
from	O
local phase	B-T079
measurements	B-T169
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization strategies	B-T169
incorporating	O
a	O
priori	B-T079
information	B-T078
extracted	O
from	O
magnitude	B-T081
and	O
phase images	B-T170
have	O
been	O
proposed	B-T080
.	O
However,	O
the	O
anatomy	B-T017
observed	O
in	O
magnitude	B-T081
and	O
phase images	B-T170
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility maps	B-T073
,	O
which	O
could	O
give	O
erroneous	B-T078
estimation	B-T081
in	O
the	O
reconstructed susceptibility map	B-T073
.	O
In	O
this	O
paper,	O
we	O
develop	O
a	O
structural feature based collaborative reconstruction	B-T066
(	O
SFCR	B-T066
)	O
method	O
for	O
QSM	B-T060
including	O
both	O
magnitude	B-T081
and	O
susceptibility	B-T081
based	O
information	B-T078
.	O
The	O
SFCR	B-T066
algorithm	B-T170
is	O
composed	O
of	O
two	O
consecutive steps	B-T077
corresponding	O
to	O
complementary	O
reconstruction models	B-T170
,	O
each	O
with	O
a	O
structural feature	B-T082
based	O
l1	O
norm constraint	B-T169
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm constraint	B-T169
,	O
which	O
allows	O
both	O
the	O
structure	B-T082
edges	O
and	O
tiny	O
features	B-T080
to	O
be	O
recovered,	O
whereas	O
the	O
noise	B-T067
and	O
artifacts	B-T068
could	O
be	O
reduced.	O
In	O
the	O
M-step	B-T077
,	O
the	O
initial	O
susceptibility map	B-T073
is	O
reconstructed	B-T066
by	O
employing	O
a	O
k-space	O
based	O
compressed sensing model	B-T170
incorporating	O
magnitude	B-T081
prior.	O
In	O
the	O
S-step	B-T077
,	O
the	O
susceptibility map	B-T073
is	O
fitted	O
in	O
spatial domain	B-T082
using	O
weighted	O
constraints	B-T169
derived	O
from	O
the	O
initial	O
susceptibility map	B-T073
from	O
the	O
M-step	B-T077
.	O
Simulations	B-T062
and	O
in vivo	B-T082
human	B-T016
experiments	B-T062
at	O
7T	O
MRI	B-T060
show	O
that	O
the	O
SFCR	B-T066
method	O
provides	O
high	O
quality	B-T080
susceptibility maps	B-T073
with	O
improved	O
RMSE	B-T081
and	O
MSSIM	B-T081
.	O
Finally,	O
the	O
susceptibility	B-T081
values	O
of	O
deep	O
gray matter	B-T024
are	O
analyzed	O
in	O
multiple head positions	B-T082
,	O
with	O
the	O
supine position	B-T082
most	O
approximate	O
to	O
the	O
gold	O
standard	O
COSMOS	B-T169
result	B-T169
.	O

High	B-T080
HbA1c	B-T116
at	O
onset	B-T080
cannot	O
be	O
used	O
as	O
a	O
predictor	B-T078
for	O
future	O
metabolic control	B-T044
for	O
the	O
individual	B-T098
child	B-T100
with	O
type 1 diabetes mellitus	B-T047
To	O
study	O
how	O
metabolic control	B-T044
at	O
onset	B-T080
of	O
type 1 diabetes	B-T047
correlates	O
to	O
metabolic control	B-T044
and	O
clinical	B-T080
parameters	B-T033
during	O
childhood	B-T079
until	O
transition	B-T052
from	O
pediatric care	B-T061
to	O
adult	B-T100
diabetes care	B-T061
.	O
Data	B-T078
at	O
onset	B-T080
,	O
three	O
months	B-T079
,	O
one,	O
three,	O
and	O
five	O
years	B-T079
after	O
diagnosis	B-T033
and	O
at	O
transition	B-T052
,	O
on	O
HbA1c	B-T116
and	O
clinical	B-T080
parameters	B-T033
,	O
on	O
8084	O
patients	B-T101
in	O
the	O
Swedish pediatric quality registry, SWEDIABKIDS	B-T170
,	O
were	O
used.	O
Of	O
these	O
patients	B-T101
,	O
26%	O
had	O
been	O
referred	O
to	O
adult	B-T100
diabetes care	B-T061
by	O
2014.	O
Children	B-T100
with	O
HbA1c	B-T116
<	O
72	O
mmol/mol	O
(8.7%)	O
(20%	O
of	O
patients	B-T101
,	O
low	B-T080
group	B-T098
)	O
at	O
diagnosis	B-T033
continued	O
to	O
have	O
good	O
metabolic control	B-T044
during	O
childhood	B-T079
,	O
in	O
contrast	O
to	O
children	B-T100
with	O
HbA1c	B-T116
>	O
114	O
mmol/mol	O
(12.6%)	O
(20%	O
of	O
patients	B-T101
,	O
high	B-T080
group	B-T098
)	O
at	O
diagnosis	B-T033
,	O
who	O
continued	O
to	O
have	O
high	B-T080
HbA1c	B-T116
at	O
follow-up	B-T058
.	O
For	O
the	O
individual	B-T098
,	O
there	O
was	O
no significant	B-T033
correlation	B-T080
between	O
high	B-T080
HbA1c	B-T116
at	O
onset	B-T080
and	O
during	O
follow-up	B-T058
.	O
During	O
follow-up	B-T058
,	O
children	B-T100
in	O
the	O
high	B-T080
group	B-T098
were	O
more	O
often	O
smokers	B-T033
,	O
less	O
physically active	B-T033
,	O
and	O
more	O
often	O
had	O
retinopathy	B-T047
than	O
children	B-T100
in	O
the	O
low	B-T080
group	B-T098
(P	O
<	O
.01,	O
.01,	O
.03	O
respectively).	O
High	B-T080
HbA1c	B-T116
at	O
onset	B-T080
was	O
associated with	B-T080
high	B-T080
HbA1c	B-T116
during	O
follow-up	B-T058
on	O
a	O
group	B-T098
level,	O
but	O
it	O
cannot	O
be	O
used	O
as	O
a	O
predictor	B-T078
of	O
future	O
metabolic control	B-T044
on	O
an	O
individual	B-T098
level.	O
These	O
results	O
emphasize	O
the	O
important	O
work	O
done	O
by	O
the	O
diabetes	B-T047
team	B-T096
in	O
the	O
first	O
years	O
after	O
diagnosis	B-T033
.	O
It	O
is	O
important	O
to	O
continuously	O
set	O
high	B-T080
goals	B-T170
for	O
the	O
achievement	B-T053
of	O
tight	O
metabolic control	B-T044
,	O
in	O
order	O
to	O
decrease	B-T081
the	O
risk	B-T078
of	O
microvascular complications	B-T047
.	O

Photosensitizer	B-T121
Decorated	B-T067
Red Blood Cells	B-T025
as	O
an	O
Ultra-Sensitive Light-Responsive Drug Delivery System	B-T074
Red blood cells	B-T025
(	O
RBCs	B-T025
),	O
the	O
most	O
abundant	B-T080
type	O
of	O
cells	B-T025
in	O
our	O
blood	B-T031
,	O
have	O
shown	O
promises	O
as	O
a	O
natural drug delivery system	B-T070
(	O
DDS	B-T070
)	O
with	O
inherent	O
biocompatibility	B-T044
.	O
Herein,	O
we	O
uncover	O
that	O
a	O
photosensitizer	B-T121
,	O
chlorin e6	B-T109
(	O
Ce6	B-T109
),	O
could	O
be	O
decorated	B-T067
into	O
the	O
membrane	B-T026
of	O
RBCs	B-T025
upon	O
simple	O
mixing	B-T080
,	O
without	O
affecting	O
the	O
membrane	B-T026
integrity	B-T080
and	O
stability	B-T080
in	O
dark.	O
Upon	O
light	B-T070
irradiation	B-T070
with	O
a	O
rather	O
low	O
power	O
density	B-T081
,	O
the	O
generated	B-T052
singlet oxygen	B-T123
by	O
Ce6	B-T109
as	O
the	O
result of photodynamic effect	B-UnknownType
would	O
lead	O
to	O
rather	O
efficient	O
disruption	B-T169
of	O
RBC	B-T025
membrane	B-T026
.	O
With	O
doxorubicin	B-T109
(	O
DOX	B-T109
DOX	B-T109
),	O
a	O
typical	O
chemotherapy	B-T061
drug	B-T121
,	O
as	O
the	O
model	B-T170
,	O
we	O
engineer	O
a	O
unique	O
type	O
of	O
light-responsive RBC-based DDS	B-T074
by	O
decorating	B-T067
Ce6	B-T109
on	O
the	O
cell membrane	B-T026
and	O
loading	O
DOX	B-T109
inside	O
cells	B-T025
.	O
The	O
light	B-T070
triggered	B-T080
cell membrane	B-T026
break	O
down	O
would	O
thus	O
trigger	B-T080
instant	O
release	O
of	O
DOX	B-T109
,	O
enabling	O
light-controlled chemotherapy	B-T061
with	O
great	O
specificity	B-T081
.	O
Beyond	O
that,	O
our	O
RBC	B-T025
system	O
could	O
also	O
be	O
utilized	O
for	O
loading	O
of	O
larger	O
biomolecules	B-T167
such	O
as	O
enzymes	B-T116
,	O
whose	O
release	O
as	O
well	O
as	O
catalytic	B-T070
function	B-T169
is	O
also	O
controlled	O
by	O
light	B-T070
.	O
Our	O
work	B-T057
thus	O
presents	O
a	O
unique	O
type	O
of	O
biocompatible cell-based DDS	B-T074
that	O
can	O
be	O
precisely	O
controlled	O
by	O
mild	O
external	O
stimuli	B-T067
,	O
promising	O
not	O
only	O
for	O
cancer therapy	B-T061
but	O
also	O
for	O
other	O
potential	O
applications	B-T169
in	O
biotechnologies	B-T091
.	O

Validation	B-T062
of	O
the	O
Neogen® Fentanyl	B-T109
ELISA	B-T059
Kit	O
for	O
Blood	B-T031
and	O
Urine	B-T031
The	O
Neogen® Fentanyl	B-T109
ready-to-use	O
enzyme-linked immunosorbent assay	B-T059
kit	O
was	O
validated	O
following	O
the	O
Scientific Working Group	B-T098
for	O
Forensic Toxicology	B-T090
Standard Practices	B-T091
for	O
Method	O
Validation	B-T062
in	O
Forensic Toxicology	B-T090
Laboratory Guidelines.	B-T170
Two	O
decision	O
points,	O
0.5	O
and	O
1	O
ng/mL,	O
were	O
successfully	O
validated	O
for	O
whole blood	B-T031
.	O
For	O
urine	B-T031
,	O
two	O
decision	O
points,	O
1	O
and	O
5	O
ng/mL,	O
were	O
also	O
successfully	O
validated.	O
The	O
validation	B-T062
included	O
the	O
evaluation	B-T058
of	O
sensitivity	B-T081
,	O
precision	B-T080
,	O
specificity	B-T081
,	O
carryover	B-T080
,	O
plate drift	B-T080
,	O
ruggedness/robustness	O
and	O
a	O
case	O
sample	O
evaluation	B-T058
.	O
The	O
empirically	O
determined	O
limit of detection	B-T081
was	O
0.25	O
ng/mL	O
for	O
blood	B-T031
and	O
0.5	O
ng/mL	O
for	O
urine	B-T031
.	O
Precision	B-T080
was	O
determined	O
at	O
five	O
different	O
concentrations	B-T081
ranging	O
from	O
0.25	O
to	O
1.5	O
ng/mL	O
with	O
15	O
replicates	B-T080
at	O
each	O
level	O
for	O
whole blood	B-T031
and	O
demonstrated	O
a	O
<2.4%	O
coefficient of variation	B-T081
(	O
CV	B-T081
).	O
In	O
urine	B-T031
,	O
the	O
CV	B-T081
was	O
<5.6%	O
at	O
six	O
different	O
concentrations	B-T081
from	O
0.5	O
to	O
7.5	O
ng/mL	O
with	O
15	O
replicates	B-T080
at	O
each	O
level.	O
Cross-reactivity	B-T044
was	O
evaluated	B-T058
for	O
norfentanyl	B-T109
,	O
acetyl fentanyl	B-T109
,	O
4-anilino-N-phenethylpiperidine	B-T109
,	O
beta-hydroxythiofentanyl	B-T121
,	O
butyryl fentanyl	B-T121
and	O
furanyl fentanyl	B-T109
.	O

Everolimus	B-T109
for	O
Treatment	B-T061
of	O
Pseudomyogenic Hemangioendothelioma	B-T191
Pseudomyogenic hemangioendothelioma	B-T191
(	O
PMH	B-T191
)	O
is	O
a	O
recently	O
described	O
vascular neoplasm	B-T191
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft tissue	B-T024
of	O
the	O
distal	O
extremities	O
of	O
young adults	B-T100
.	O
Metastatic	B-T169
PMH	B-T191
can	O
be	O
fatal	B-T080
and	O
there	O
are	O
no	O
effective	B-T080
medications	B-T121
.	O
We	O
describe	O
a	O
case	B-T077
of	O
a	O
15-year-old	O
boy	B-T100
with	O
metastatic	B-T169
PMH	B-T191
,	O
who	O
responded to treatment	B-T201
with	O
everolimus	B-T109
,	O
a	O
mammalian target of rapamycin inhibitor	B-T121
.	O
Immunohistochemistry	B-T060
showed	O
that	O
mammalian target of rapamycin	B-T116
was	O
expressed	B-T045
in	O
PMH	B-T191
biopsy specimens	B-T024
,	O
which	O
may	O
explain	O
the	O
reduction	B-T080
in	O
PMH	B-T191
tumor size	B-T082
following	O
treatment	B-T061
.	O

Opposing	O
Roles	B-T080
of	O
Acetylation	B-T044
and	O
Phosphorylation	B-T044
in	O
LIFR	B-T116
-	O
Dependent	B-T169
Self-Renewal	B-T043
Growth	B-T040
Signaling	B-T044
in	O
Mouse Embryonic Stem Cells	B-T025
LIF	B-T116
promotes	O
self-renewal	B-T043
of	O
mouse embryonic stem cells	B-T025
(	O
mESCs	B-T025
),	O
and	O
in	O
its	O
absence	B-T080
,	O
the	O
cells	B-T025
differentiate	B-T169
.	O
LIF	B-T116
binds	O
to	O
the	O
LIF receptor	B-T116
(	O
LIFR	B-T116
)	O
and	O
activates	B-T052
the	O
JAK-STAT3 pathway	B-T044
,	O
but	O
it	O
remains unknown	B-T080
how	O
the	O
receptor complex	B-T026
triggers	B-T080
differentiation	B-T169
or	O
self-renewal	B-T043
.	O
Here,	O
we	O
report	O
that	O
the	O
LIFR	B-T116
cytoplasmic domain	B-T026
contains	O
a	O
self-renewal	B-T043
domain	B-T169
within	O
the	O
juxtamembrane region	B-T026
and	O
a	O
differentiation	B-T169
domain	B-T169
within	O
the	O
C-terminal region	B-T087
.	O
The	O
differentiation	B-T169
domain	B-T169
contains	O
four	O
SPXX repeats	B-T116
that	O
are	O
phosphorylated	B-T044
by	O
MAPK	B-T116
to	O
restrict	B-T169
STAT3 activation	B-T043
;	O
the	O
self-renewal	B-T043
domain	B-T169
is	O
characterized	O
by	O
a	O
3K motif	B-T116
that	O
is	O
acetylated	B-T044
by	O
p300.	O
In	O
mESCs	B-T025
,	O
acetyl-	O
LIFR	B-T116
undergoes	O
homodimerization	B-T044
,	O
leading	O
to	O
STAT3	B-T116
hypo- or hyper-activation	B-T052
depending	B-T169
on	O
the	O
presence	B-T033
or	O
absence	B-T169
of	O
gp130	B-T116
.	O
LIFR	B-T116
-	O
activated	B-T052
STAT3	B-T116
restricts	B-T169
differentiation	B-T169
via	O
cytokine	B-T116
induction	B-T169
.	O
Thus,	O
LIFR	B-T116
acetylation	B-T044
and	O
serine phosphorylation	B-T044
differentially	B-T169
promote	O
stem cell	B-T025
self-renewal	B-T043
and	O
differentiation	B-T169
.	O

Interprofessional	B-T054
primary care	B-T058
team meetings	B-T058
:	O
a	O
qualitative	B-T080
approach	B-T082
comparing	O
observations	B-T062
with	O
personal	B-T032
opinions	B-UnknownType
The	O
number	O
of	O
people	B-T098
with	O
multiple chronic conditions	B-T047
requiring	O
primary care services	B-T058
increases	B-T169
.	O
Professionals	B-T097
from	O
different	O
disciplines	B-T057
collaborate	B-T054
and	O
coordinate	B-T169
care	B-T052
to	O
deal	O
with	O
the	O
complex	O
health care needs	B-T058
.	O
There	O
is	O
lack	B-T080
of	O
information	B-T078
on	O
current	O
practices	O
regarding	O
interprofessional	B-T054
team (IPT) meetings	B-T058
.	O
This	O
study	B-T062
aimed	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
process	O
of	O
interprofessional	B-T054
collaboration	B-T054
in	O
primary care	B-T058
team meetings	B-T058
in	O
the	O
Netherlands	B-T083
by	O
observing	O
the	O
current practice	B-T057
and	O
exploring	O
personal	B-T032
opinions	B-UnknownType
.	O
Qualitative study	B-T062
involving	O
observations	B-T062
of	O
team meeting	B-T058
s	O
and	O
interviews	B-T058
with	O
participants	B-T098
.	O
Eight	O
different	O
IPT meetings	B-T058
(n	O
=	O
8)	O
in	O
different	O
primary care practices	B-T058
were	O
observed	O
by	O
means	O
of	O
video recordings	B-T073
.	O
Experiences	B-T041
were	O
explored	O
by	O
conducting	O
individual	O
semi-structured interviews	B-UnknownType
(n	O
=	O
60)	O
with	O
participants	B-T098
(i.e.	O
health care professionals	B-T097
from	O
different	O
disciplines	B-T057
)	O
of	O
the	O
observed	O
team meetings	B-T058
.	O
The	O
data	B-T078
were	O
analysed	B-T062
by	O
means	O
of	O
content analysis	B-T062
.	O
Most	O
participants	B-T098
expressed	O
favourable	O
opinions	B-UnknownType
about	O
their	O
team meetings	B-T058
.	O
However,	O
observations	B-T062
showed	O
that	O
team meetings	B-T058
were	O
more	O
or	O
less	O
hectic,	O
and	O
lacked	B-T080
a	O
clear	O
structure	O
and	O
team coordinator	B-T097
or	O
leader	B-T097
.	O
There	O
appears	O
to	O
be	O
a	O
discrepancy	B-T033
between	O
findings	B-T033
from	O
observations	B-T062
and	O
interviews	B-T052
.	O
From	O
the	O
interviews	B-T052
,	O
four	O
main	O
themes	O
were	O
extracted:	O
(1)	O
Team structure and composition	B-T098
,	O
(2)	O
Patient-centredness	B-T058
,	O
(3)	O
Interaction	B-T054
and	O
(4)	O
Attitude	B-T041
and	O
motivation	B-T041
.	O
IPT meetings	B-T058
could	O
benefit	O
from	O
improvements	B-T077
in	O
structure,	O
patient-centredness	B-T058
and	O
leadership	B-T054
by	O
the	O
chairpersons	B-T097
.	O
Given	O
the	O
discrepancy	B-T033
between	O
observations	B-T062
and	O
interviews	B-T052
,	O
it	O
would	O
appear	O
useful	O
to	O
improve	B-T077
team members	B-T096
'	O
awareness	B-T041
of	O
aspects	B-T080
that	O
could	O
be	O
improved	B-T077
before	O
training	B-T065
them	O
in	O
dealing	O
with	O
specific	O
challenges	B-T058
.	O

Urachal carcinoma	B-T047
:	O
Report	B-T170
of	O
two	O
cases	B-T077
and	O
review of	B-T169
the	O
literature	B-T170
Urachal carcinoma	B-T047
is	O
a	O
rare	B-T080
tumor	B-T191
that	O
most	O
commonly	O
occurs	O
in	O
ovaries	B-T023
and	O
less often	B-T033
in	O
the	O
adnexal	B-T023
region	B-T029
and	O
urinary system	B-T022
.	O
We	O
herein	O
present	B-T078
two	O
cases	B-T077
of	O
urachal carcinoma	B-T047
:	O
One	O
case	B-T077
was	O
a	O
32-year-old	O
male	B-T098
patient	B-T101
who	O
presented	B-T078
with	O
painless hematuria	B-T184
with	O
blood clots	B-T046
for	O
1	O
month	B-T079
,	O
whereas	O
the	O
other	O
case	B-T077
was	O
a	O
50-year-old	O
woman	B-T098
who	O
presented	B-T078
with	O
gross hematuria	B-T033
with	O
mild	B-T080
dysuria	B-T184
,	O
urgency and frequent urination	B-T047
for	O
1	O
year	B-T079
.	O
Following	O
surgical resection	B-T061
,	O
the	O
two	O
patients	B-T101
were	O
diagnosed	B-T033
with	O
urachal adenocarcinoma	B-T047
(	O
mixed	B-T169
type	B-T080
)	O
and	O
urachal mucinous adenocarcinoma	B-T047
,	O
respectively,	O
based	O
on	O
the	O
histopathological	B-T169
examination	B-T058
.	O
A	O
review of	B-T169
previously	O
published	B-T057
cases	B-T077
and	O
relevant	B-T080
literature	B-T170
is	O
also	O
presented	B-T078
.	O
The	O
aim	B-T078
of	O
the	O
present	B-T033
study	B-T062
was	O
to	O
help	O
understand	B-T041
this	O
disease	B-T191
better	B-T080
,	O
in	O
order	O
to	O
reduce	B-T080
the	O
rate	B-T081
of	O
clinical	B-T080
and	O
pathological	B-T169
misdiagnosis	B-T033
.	O

A	O
Recombinant	B-T063
Human	B-T016
Anti-Platelet scFv Antibody	B-T116
scFv	B-T129
Antibody	O
Produced	O
in	O
Pichia pastoris	B-T004
for	O
Atheroma	B-T046
Targeting	O
Cells	B-T025
of	O
the	O
innate	O
and	O
adaptive	O
immune system	B-T022
are	O
key	O
factors	O
in	O
the	O
progression	B-T046
of	O
atherosclerotic plaque	B-T031
,	O
leading	O
to	O
plaque	B-T033
instability	B-T033
and	O
rupture	B-T037
,	O
potentially	O
resulting	O
in	O
acute	B-T079
atherothrombotic	B-T020
events	O
such	O
as	O
coronary artery disease	B-T047
,	O
cerebrovascular disease	B-T047
and	O
peripheral arterial disease	B-T047
.	O
Here,	O
we	O
describe	O
the	O
cloning	B-T062
,	O
expression	B-T045
,	O
purification	B-T169
,	O
and	O
immunoreactivity	B-T044
assessment	B-T058
of	O
a	O
recombinant	B-T001
single-chain variable fragment	B-T129
(	O
scFv	B-T129
)	O
derived	O
from	O
a	O
human	B-T016
anti-αIIbβ3 antibody	B-T116
(	O
HuAb	B-T116
)	O
selected	O
to	O
target	O
atheromatous	B-T046
lesions	B-T033
for	O
the	O
presence	B-T033
of	O
platelets	B-T025
.	O
Indeed,	O
platelets	B-T025
within	O
atheroma plaques	B-T031
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	B-T046
,	O
in	O
platelet	B-T025
-	O
leucocyte	B-T025
aggregates	B-T080
and	O
in	O
thrombi	B-T046
formation	B-T169
and	O
might	O
thus	O
be	O
considered	O
relevant	B-T080
biomarkers	B-T201
of	O
atherosclerotic	B-T169
progression	B-T046
.	O
The	O
DNA sequence	B-T086
that	O
encodes	B-T052
the	O
anti-αIIbβ3 TEG4 scFv	B-T129
previously	O
obtained	O
from	O
a	O
phage-display selection	B-T063
on	O
activated	B-T052
platelets	B-T025
,	O
was	O
inserted	B-T045
into	O
the	O
eukaryote	B-T204
vector	B-T114
(	O
pPICZαA	B-T114
)	O
in	O
fusion	O
with	O
a	O
tag sequence	B-T086
encoding	B-T052
2	O
cysteines	B-T116
useable	O
for	O
specific	B-T080
probes	O
grafting experiments	B-T059
.	O
The	O
recombinant protein	B-T116
was	O
expressed	B-T045
at	O
high	B-T080
yields	O
in	O
Pichia pastoris	B-T004
(30	O
mg/L	O
culture	B-T130
).	O
The	O
advantage	O
of	O
P. pastoris	B-T004
as	O
an	O
expression	B-T045
system	B-T169
is	O
the	O
production	O
and	O
secretion	B-T038
of	O
recombinant proteins	B-T116
in	O
the	O
supernatant	B-T031
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	B-T129
are	O
produced	O
in	O
the	O
cytoplasm	B-T026
of	O
bacteria	B-T007
(	O
low	B-T080
yield	B-T081
,	O
low	B-T080
solubility	B-T080
and	O
reduced	B-T080
affinity	B-T044
).	O
The	O
improved	B-T033
conditions	O
allowed	O
for	O
the	O
recovery	B-T052
of	O
highly	B-T080
purified	B-T169
and	O
biologically active scFv fragments	B-T123
scFv	B-T129
fragments	O
ready	O
to	O
be	O
grafted	B-T169
in	O
a	O
site	B-T082
-directed	O
way	O
to	O
nanoparticles	B-T073
for	O
the	O
imaging	B-T060
of	O
atherosclerotic plaques	B-T031
involving	O
inflammatory	B-T169
processes	B-T067
and	O
thus	O
at	O
high risk of	B-T033
instability	B-T033
.	O

Identification	B-T080
of	O
MiR-21-5p	B-T114
as	O
a	O
Functional Regulator	B-T028
of	O
Mesothelin	B-T028
Expression	B-T045
Using	O
MicroRNA	B-T114
Capture	O
Affinity	B-T070
Coupled	B-T169
with	O
Next Generation Sequencing	B-T063
MicroRNAs	B-T114
(	O
miRNAs	B-T114
)	O
are	O
small non-coding RNAs	B-T114
that	O
regulate	B-T045
mRNA expression	B-T045
mainly	O
by	O
silencing	B-T045
target	B-T169
transcripts	B-T114
via	O
binding	B-T044
to	O
miRNA recognition elements (MREs)	B-T086
in	O
the	O
3'untranslated region	B-T086
(	O
3'UTR	B-T086
).	O
The	O
identification	B-T080
of	O
bona fide	B-T082
targets	B-T169
is	O
challenging	O
for	O
researchers working	B-T033
on	O
the	O
functional aspect	B-T169
of	O
miRNAs	B-T114
.	O
Recently,	O
we	O
developed	O
a	O
method (miR-CATCH)	B-T169
based	O
on	O
biotinylated	B-T044
DNA	B-T114
antisense oligonucleotides	B-T114
that	O
capture	O
the	O
mRNA	B-T114
of	O
interest	O
and	O
facilitates	O
the	O
characterisation	O
of	O
miRNAs::mRNA interactions	B-T045
in	O
a	O
physiological cellular	B-T043
context.	O
Here,	O
the	O
miR-CATCH technique	B-T169
was	O
applied	O
to	O
the	O
mesothelin (MSLN) gene	B-T028
and	O
coupled	B-T169
with	O
next generation sequencing	B-T063
(	O
NGS	B-T063
),	O
to	O
identify	O
miRNAs	B-T114
that	O
regulate	B-T045
MSLN mRNA	B-T028
and	O
that	O
may	O
be	O
responsible	O
for	O
its	O
increased	O
protein levels	B-T034
found	O
in	O
malignant pleural mesothelioma	B-T191
(	O
MPM	B-T191
).	O
Biotinylated	B-T044
MSLN oligos	B-T028
were	O
employed	O
to	O
isolate	O
miRNA::MSLN mRNA complexes	B-T114
from	O
a	O
normal	O
cell line (Met-5A)	B-T025
which	O
expresses	B-T045
low	O
levels	O
of	O
MSLN	B-T116
.	O
MiRNAs	B-T114
targeting	B-T169
the	O
MSLN mRNA	B-T028
were	O
identified	O
by	O
NGS	B-T063
and	O
miR-21-5p	B-T114
and	O
miR-100-5p	B-T114
were	O
selected	O
for	O
further	O
validation analyses	B-T062
.	O
MiR-21-5p	B-T114
was	O
shown	O
to	O
be	O
able	O
to	O
modulate	B-T082
MSLN	B-T028
expression	B-T045
in	O
miRNA	B-T114
mimic	B-T061
experiments	B-T062
in	O
a	O
panel	O
of	O
malignant	B-T025
and	O
non-malignant	O
cell lines	B-T025
.	O
Further	O
miRNA	B-T114
inhibitor	B-T080
experiments	B-T062
and	O
luciferase	B-T116
assays	B-T059
in	O
Mero-14 cells	B-T025
validated	O
miR-21-5p	B-T114
as	O
a	O
true	O
regulator	B-T028
of	O
MSLN	B-T028
.	O
Moreover,	O
in vitro experiments	B-T062
showed	O
that	O
treatment	B-T061
with	O
miR-21-5p	B-T114
mimic	B-T061
reduced	O
proliferation	B-T169
of	O
MPM	B-T191
cell lines	B-T025
.	O
Altogether,	O
this	O
work	O
shows	O
that	O
the	O
miR-CATCH technique	B-T169
,	O
coupled	B-T169
with	O
NGS	B-T063
and	O
in vitro	B-T080
validation	B-T062
,	O
represents	O
a	O
reliable	O
method	B-T169
to	O
identify	O
native	O
miRNA::mRNA interactions	B-T045
.	O
MiR-21-5p	B-T114
is	O
suggested	O
as	O
novel	O
regulator	B-T028
of	O
MSLN	B-T028
with	O
a	O
possible	O
functional role	B-T169
in	O
cellular growth	B-T043
.	O

Zoonotic	B-T001
and	O
Non-zoonotic	B-T033
Parasites	B-T204
of	O
Wild	B-T170
Rodents	B-T015
in	O
Turkman Sahra, Northeastern Iran	B-T083
This	O
study	B-T062
was	O
conducted	O
to	O
collect informative data	B-T062
on	O
the	O
parasitic infection	B-T047
of	O
wild	B-T170
rodents	B-T015
,	O
emphasizing	O
on	O
finding	B-T033
parasites	B-T204
,	O
which	O
have	O
medical	B-T169
importance	B-T080
to	O
human	B-T016
.	O
During	O
2012-2014,	O
a	O
total number	B-T081
of	O
91	O
wild	B-T170
rodents	B-T015
were	O
captured	B-T169
from	O
rural areas	B-T082
of	O
Turkmen Sahra, Golestan Province	B-T083
,	O
using	O
handmade traps	B-T073
.	O
Animals	B-T008
were	O
anesthetized	B-T033
,	O
surveyed	B-T170
for	O
any	O
ectoparasite	B-T204
and	O
then	O
their	O
carcasses	B-T021
were	O
carefully	O
dissected	B-T169
for	O
examination	B-T033
of	O
endoparsites	B-T204
.	O
Four	O
species	B-T185
of	O
rodents	B-T015
including	B-T169
Mus musculus	B-T015
(52.75%),	O
Rattus norvegicus	B-T015
(38.46%),	O
Rhombomys opimus	B-T015
(4.40%)	O
and	O
Meriones libycus	B-T015
(4.40%)	O
were	O
captured	B-T169
.	O
Parasitic infestation	B-T047
was	O
detected	B-T033
in	O
38.5%	O
of	O
sampled	B-T078
rodents	B-T015
.	O
Parasite infestation	B-T047
rates	B-T081
of	O
sampled	B-T078
rodents	B-T015
was	O
Hymenolepis diminuta	B-T204
=	O
7.7%,	O
Cryptosporidium spp	B-T204
=	O
6.6%,	O
Trichuris spp	B-T204
.=	O
5.5%,	O
Cysticercus fasciolaris	B-T204
=	O
2.20%,	O
Angiostrongylus spp	B-T204
.=	O
2.20%,	O
Capillaria sp	B-T204
.=	O
1.09%,	O
Rhipicephalus spp	B-T204
.	O
=	O
8.70%,	O
Nosopsyllus fasciatus	B-T204
=	O
1.09%,	O
and	O
Laelaps nuttalli	B-T204
=	O
3.29%.	O
Among	O
10	O
genera	B-T185
/	O
species	B-T185
of	O
identified	B-T080
parasites	B-T204
,	O
at	O
least	O
8	O
of	O
them	O
were	O
zoonotic	B-T001
with	O
public health	B-T170
importance	B-T080
.	O
L. nuttalli	B-T204
and	O
N. fasciatus	B-T204
were	O
the	O
only	O
two	O
non-zoonotic	B-T033
detected	B-T033
parasites	B-T204
in	O
this	O
survey	B-T170
.	O
Harboring	B-T169
a	O
wide	B-T082
variety	O
of	O
zoonotic	B-T001
parasites	B-T204
in	O
sampled	B-T078
wild	B-T170
rodents	B-T015
particularly	B-T080
when	O
they	O
live	O
nearby	B-T080
villages	B-T083
,	O
represents	O
a	O
potential	B-T080
risk	B-T078
to	O
native inhabitants	B-T098
.	O
Hence,	O
controlling	B-T169
rodents	B-T015
'	O
population	B-T098
in	O
residential regions	B-T082
and	O
improving	B-T033
awareness	B-T041
of	O
local	B-T082
people	B-T098
about	O
the	O
risk	B-T078
of	O
disease transmission	B-T046
through	O
rodents	B-T015
seems	O
to	O
be	O
entirely	O
necessary	B-T080
.	O

Creative	O
approach	O
for	O
successful	B-T080
aging	B-T040
:	O
A	O
pilot study	B-T062
of	O
an	O
intergenerational	B-T079
health promotion program	B-T058
To	O
develop	O
and	O
evaluate	B-T058
the	O
effectiveness	B-T080
of	O
an	O
intergenerational	B-T079
health promotion program	B-T058
.	O
This	O
was	O
an	O
action	O
research project	B-T062
.	O
A	O
total	B-T080
of	O
34	O
participants	B-T098
attended	O
the	O
12-	O
week	B-T079
program	B-T058
and	O
completed	B-T080
the	O
pre-test and post-test	B-T170
.	O
There	O
were	O
16	O
middle-aged	B-T100
and	O
nine	O
older adults	B-T098
recruited	B-T052
from	O
a	O
district	O
of	O
Taipei	B-T083
,	O
and	O
nine	O
young adults	B-T100
recruited	B-T052
from	O
the	O
principal investigator's	B-T097
university	B-T073
.	O
The	O
"	O
Attitudes toward Aging Scale	B-T170
"	O
and	O
the	O
"	O
Spiritual Health Scale	B-T170
"	O
were	O
two	O
assessment	B-T058
instruments	B-T170
used	O
in	O
the	O
study	B-T062
.	O
The	O
results	B-T033
showed	O
that	O
there	O
were	O
significant	B-T078
improvements	B-T077
in	O
the	O
Attitudes toward Aging Scale	B-T170
for	O
the	O
young adult	B-T100
group	B-T078
(aged	O
18-29	O
years	B-T079
)	O
and	O
in	O
the	O
Spiritual Health Scale	B-T170
for	O
the	O
older adult	B-T098
group	B-T078
(	O
aged	B-T032
65-80	O
years	B-T079
).	O
The	O
evaluation	B-T058
showed	O
that	O
participants	B-T098
were	O
satisfied	B-T041
with	O
the	O
program	B-T058
.	O
The	O
results	B-T033
of	O
the	O
present	O
study	O
provide	O
future	O
directions	O
for	O
successful	B-T080
aging	B-T040
and	O
intergenerational	B-T079
learning	B-T065
.	O
Geriatr	O
Gerontol	O
Int	O
2017;	O
••:	O
••-••.	O

Signs	B-T184
of	O
dysarthria	B-T048
in	O
adults	B-T100
with	O
22q11.2 deletion syndrome	B-T047
The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
investigate	O
how	O
adults	B-T100
with	O
22q11.2 deletion syndrome	B-T047
(	O
22q11DS	B-T047
)	O
performed	O
on	O
dysarthria	B-T048
and	O
intelligibility	B-T041
tests	B-T060
compared	B-T052
with	O
a	O
control group	B-T096
.	O
Ten	O
participants	B-T098
with	O
confirmed	O
22q11.2 deletion	B-T049
,	O
five	O
males	B-T032
and	O
five	O
females	B-T032
with	O
a	O
mean	O
age	B-T032
of	O
31	O
years	B-T079
(range:	O
19-49),	O
were	O
compared	B-T052
with	O
a	O
control group	B-T096
matched	O
for	O
gender	B-T032
and	O
age	B-T032
(five	O
males	B-T032
and	O
five	O
females	B-T032
,	O
mean	O
age	B-T032
:	O
32	O
years	B-T079
,	O
range:	O
19-49).	O
Assessment	B-T052
of	O
non-verbal and verbal tasks	B-T060
reflecting	O
respiration	B-T039
,	O
phonation	B-T042
,	O
oral motor function	B-T042
,	O
velopharyngeal function	B-T059
,	O
articulation	B-T042
,	O
and	O
prosody	B-T033
was	O
performed	O
as	O
well	O
as	O
the	O
Swedish Test of Intelligibility	B-T170
(	O
STI	B-T170
).	O
All	O
assessments	B-T052
were	O
made	O
by	O
two	O
raters;	O
inter-rater	B-T081
and	O
intra-rater reliability	B-T081
was	O
acceptable.	O
The	O
participants	B-T098
with	O
22q11DS	B-T047
had	O
significantly	O
more	O
problems	B-T033
than	O
the	O
control group	B-T096
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
STI	B-T170
.	O
Overall,	O
the	O
severity	O
of	O
their	O
speech deviation	B-T033
was	O
rated	B-T052
as	O
mild	O
to	O
moderate.	O
The	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	B-T040
respiration	B-T039
,	O
phonation	B-T042
,	O
oral motor function	B-T042
,	O
and	O
velopharyngeal function	B-T059
.	O
The	O
results	O
of	O
the	O
present	O
study	B-T062
suggest	O
that	O
a	O
neurological etiology	B-T169
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural etiology	B-T169
explaining	O
the	O
speech difficulties	B-T033
found	O
in	O
22q11DS	B-T047
.	O
Signs	B-T184
of	O
difficulties	O
in	O
both	O
speech motor planning	B-T041
and	O
speech motor programming	B-T041
were	O
found.	O
Further	O
studies	B-T062
are	O
needed	O
to	O
confirm	O
the	O
results	B-T169
,	O
as	O
are	O
studies	B-T062
of	O
the	O
association	O
between	O
structural brain abnormalities	B-T033
and	O
neurological speech symptoms	B-T184
.	O
For	O
clinical purposes	B-T169
,	O
it	O
is	O
important	O
that	O
clinicians	B-T097
have	O
knowledge	O
about	O
the	O
variable	O
speech symptoms	B-T184
that	O
may	O
occur	O
in	O
individuals	B-T098
with	O
22q11DS	B-T047
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	B-T169
of	O
such	O
speech symptoms	B-T184
.	O
©	O
2017	O
Wiley	O
Periodicals,	O
Inc.	O

Sulfur	B-T121
and	O
Zinc	B-T121
Availability	B-T169
from	O
Co-granulated	B-T167
Zn	B-T121
-Enriched	O
Elemental Sulfur	B-T121
Fertilizers	B-T073
Acidification	B-T067
by	O
oxidation	B-T044
of	O
elemental sulfur	B-T121
(	O
ES	B-T121
)	O
can	O
solubilize	O
ZnO	B-T121
,	O
providing	O
slow	B-T080
release	B-T169
of	O
both	O
sulfur	B-T121
(	O
S	B-T121
)	O
and	O
zinc	B-T121
(	O
Zn	B-T121
)	O
in	O
soil.	O
For	O
this	O
study,	O
a	O
new	O
granular	B-T167
fertilizer	B-T073
with	O
ES	B-T121
and	O
ZnO	B-T121
was	O
produced	O
and	O
evaluated	B-T052
.	O
The	O
effect	B-T080
of	O
incorporating	O
microorganisms	B-T001
or	O
a	O
carbon	B-T196
source	B-T033
in	O
the	O
granule	B-T167
was	O
also	O
evaluated	B-T052
.	O
Four	O
granulated	B-T167
ES-Zn fertilizers	B-T167
with	O
and	O
without	B-T080
S-oxidizing microorganisms	B-T001
,	O
a	O
commercial	O
ES	O
pastille,	O
ZnSO4	B-T121
,	O
and	O
ZnO	B-T121
were	O
applied	O
to	O
the	O
center	B-T082
of	O
Petri dishes	B-T074
containing	O
two	O
contrasting	B-T080
pH	B-T081
soils	B-T167
.	O
Soil	B-T167
pH	B-T081
,	O
CaCl2	B-T121
-extractable	O
S	B-T121
and	O
Zn	B-T121
,	O
and	O
remaining	O
ES	B-T121
were	O
evaluated	B-T052
at	O
30	O
and	O
60	O
days	O
in	O
two	O
soil sections	B-T167
(0-5	O
and	O
5-9	O
mm	O
from	O
the	O
fertilizer	B-T073
application site	B-T082
).	O
A	O
visualization test	B-T059
was	O
performed	O
to	O
evaluate	O
Zn	B-T121
diffusion	B-T070
over	O
time.	O
A	O
significant	B-T078
pH decrease	B-T033
was	O
observed	B-T169
in	O
the	O
acidic	B-T103
soil	B-T167
for	O
all	O
ES-Zn fertilizer	B-T167
treatments	B-T169
and	O
in	O
the	O
alkaline	B-T080
soil	B-T167
for	O
the	O
Acidithiobacillus thiooxidans	B-T007
-	O
inoculated treatment	B-T034
only.	O
In	O
agreement	O
with	O
Zn	B-T121
visualization tests	B-T059
,	O
extractable-	O
Zn	B-T121
concentrations	B-T081
were	O
higher	B-T080
from	O
the	O
point	O
of	O
application	O
in	O
the	O
acidic	B-T103
(62.9	O
mg	O
dm(-3))	O
compared	O
to	O
the	O
alkaline	B-T080
soil	B-T167
(5.5	O
mg	O
dm(-3)).	O
Elemental S oxidation	B-T044
was	O
greater	B-T081
in	O
the	O
acidic	B-T103
soil	B-T167
(20.9%)	O
than	O
slightly	O
alkaline	B-T080
soil	B-T167
(12%).	O
The	O
ES-Zn granular fertilizers	B-T167
increased	B-T081
S	B-T121
and	O
Zn	B-T121
concentrations	B-T081
in	O
soil	B-T167
and	O
can	O
provide	O
a	O
strategically	O
slow	B-T080
release	B-T169
of	O
nutrients	B-T168
to	O
the	O
soil	B-T167
.	O

Impact	B-T080
of	O
Blood Transfusions	B-T061
on	O
Survival	B-T052
of	O
Locally	B-T082
Advanced	B-T080
Cervical Cancer	B-T191
Patients	B-T101
Undergoing	O
Neoadjuvant Chemotherapy	B-T061
Plus	O
Radical Surgery	B-T061
Transfusions	B-T061
represent	O
one	O
of	O
the	O
main	O
progresses	B-T169
of	O
modern medicine	B-T079
.	O
However,	O
accumulating	O
evidence	B-T078
supports	O
that	O
transfusions	B-T061
correlate	O
with	O
worse	O
survival	B-T052
outcomes	B-T080
in	O
patients	B-T101
affected	B-T169
by	O
solid cancers	B-T191
.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
aimed	B-T078
to	O
investigate	B-T169
the	O
effects	O
of	O
perioperative	B-T079
blood transfusion	B-T061
in	O
locally	B-T082
advanced	B-T080
cervical cancer	B-T191
.	O
Data	O
of	O
consecutive	O
patients	B-T101
affected	B-T169
by	O
locally	B-T082
advanced	B-T080
cervical cancer	B-T191
scheduled	O
to	O
undergo	O
neoadjuvant chemotherapy	B-T061
plus	O
radical surgery	B-T061
were	O
retrospectively	B-T062
searched	B-T052
to	O
test	B-T169
the	O
impact	B-T080
of	O
perioperative	B-T079
transfusions	B-T061
on	O
survival	B-T052
outcomes	B-T080
.	O
Five-	O
year	B-T079
survival	B-T052
outcomes	B-T080
were	O
evaluated	O
using	O
Kaplan-Meier	B-T062
and	O
Cox models	B-T081
.	O
The	O
study	B-T062
included	O
275	O
patients	B-T101
.	O
Overall,	O
170	O
(62%)	O
patients	B-T101
had	O
blood transfusion	B-T061
.	O
Via	O
univariate analysis	B-T062
,	O
we	O
observed	B-T169
that	O
transfusion	B-T061
correlated	O
with	O
an	O
increased	O
risk	B-T078
of	O
developing	B-T169
recurrence	B-T191
(	O
hazard ratio	B-T081
[	O
HR	B-T081
],	O
2.2;	O
95%	O
confidence interval	B-T081
[	O
CI	B-T081
],	O
1.09-4.40;	O
P	B-T081
=	O
0.02).	O
Other	O
factors	O
associated	O
with	O
5-	O
year	B-T079
disease-free survival	B-T081
were	O
noncomplete	B-T033
clinical response	B-T033
after	O
neoadjuvant chemotherapy	B-T061
(	O
HR	B-T081
,	O
2.99;	O
95%	O
CI	B-T081
,	O
0.92-9.63;	O
P	B-T081
=	O
0.06)	O
and	O
pathological	B-T033
(	O
P	B-T081
=	O
0.03)	O
response	B-T033
at	O
neoadjuvant chemotherapy	B-T061
as	O
well	O
as	O
parametrial	B-T029
(	O
P	B-T081
=	O
0.004),	O
vaginal	B-T023
(	O
P	B-T081
<	O
0.001),	O
and	O
lymph node	B-T023
(	O
P	B-T081
=	O
0.002)	O
involvements.	O
However,	O
via	O
multivariate analysis	B-T081
,	O
only	O
vaginal	B-T023
(	O
HR	B-T081
,	O
3.07;	O
95%	O
CI	B-T081
,	O
1.20-7.85;	O
P	B-T081
=	O
0.01)	O
and	O
lymph node	B-T023
involvements	O
(	O
HR	B-T081
,	O
2.4;	O
95%	O
CI	B-T081
,	O
1.00-6.06;	O
P	B-T081
P	B-T081
=	O
0.05)	O
correlate	O
with	O
worse	O
disease-free survival	B-T081
.	O
No	O
association	O
with	O
worse	O
outcomes	B-T080
was	O
observed	B-T169
for	O
patients	B-T101
undergoing	O
blood transfusion	B-T061
(	O
HR	B-T081
,	O
2.71;	O
95%	O
CI	B-T081
,	O
0.91-8.03;	O
P	B-T081
=	O
0.07).	O
Looking	O
at	O
factors	O
influencing	O
overall survival	B-T081
,	O
we	O
observed	B-T169
that	O
lymph node	B-T023
status	O
(	O
P	B-T081
=	O
0.01)	O
and	O
vaginal	B-T023
involvement	O
(	O
P	B-T081
=	O
0.06)	O
were	O
independently	O
associated	O
with	O
survival	B-T052
.	O
The	O
role	O
of	O
blood transfusions	B-T061
in	O
increasing	O
the	O
risk	B-T078
of	O
developing	B-T169
recurrence	B-T191
in	O
LAAC	B-T191
patients	B-T101
treated	B-T061
by	O
neoadjuvant chemotherapy	B-T061
plus	O
radical surgery	B-T061
remains	O
unclear	B-T033
;	O
further	O
prospective studies	B-T062
are	O
warranted.	O

Tissue	B-T024
reservoirs	O
of	O
antiviral	B-T033
T cell immunity	B-T040
in	O
persistent	O
human	B-T016
CMV infection	B-T047
T cell	B-T025
responses	B-T042
to	O
viruses	B-T005
are	O
initiated	O
and	O
maintained	O
in	O
tissue	B-T024
sites;	O
however,	O
knowledge	O
of	O
human	B-T016
antiviral	B-T033
T cells	B-T025
is	O
largely	O
derived	O
from	O
blood	B-T031
.	O
Cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
persists	O
in	O
most	O
humans	B-T016
,	O
requires	O
T cell immunity	B-T040
to	O
control,	O
yet	O
tissue	B-T024
immune responses	B-T042
remain	O
undefined.	O
Here,	O
we	O
investigated	O
human	B-T016
CMV	B-T005
CMV	B-T005
-specific	O
T cells	B-T025
,	O
virus	B-T005
persistence	B-T081
and	O
CMV	B-T005
-associated	O
T cell	B-T025
homeostasis	B-T038
in	O
blood	B-T031
,	O
lymphoid	B-T024
,	O
mucosa	B-T024
l	O
and	O
secretory tissues	B-T024
of	O
44	O
CMV	B-T005
seropositive	B-T080
and	O
28	O
seronegative	B-T034
donors	B-T098
.	O
CMV	B-T005
-specific	O
T cells	B-T025
were	O
maintained	O
in	O
distinct	O
distribution patterns	B-T082
,	O
highest	O
in	O
blood	B-T031
,	O
bone marrow	B-T024
(	O
BM	B-T024
),	O
or	O
lymph nodes	B-T023
(	O
LN	B-T023
),	O
with	O
the	O
frequency	B-T080
and	O
function	B-T169
in	O
blood	B-T031
distinct	O
from	O
tissues	B-T024
.	O
CMV	B-T005
genomes	B-T028
were	O
detected	B-T033
predominantly	O
in	O
lung	B-T023
and	O
also	O
in	O
spleen	B-T023
,	O
BM	B-T024
,	O
blood	B-T031
and	O
LN	B-T023
.	O
High	O
frequencies	O
of	O
activated	O
CMV	B-T005
-specific	O
T cells	B-T025
were	O
found	O
in	O
blood	B-T031
and	O
BM	B-T024
samples	B-T167
with	O
low	O
virus detection	B-T043
,	O
whereas	O
in	O
lung	B-T023
,	O
CMV	B-T005
-specific	O
T cells	B-T025
were	O
present	O
along	O
with	O
detectable	O
virus	B-T005
.	O
In	O
LNs	B-T023
,	O
CMV	B-T005
-specific	O
T cells	B-T025
exhibited	O
quiescent	O
phenotypes	B-T032
independent	O
of	O
virus	B-T005
.	O
Overall,	O
T cell	B-T025
differentiation	B-T043
was	O
enhanced	B-T052
in	O
sites	O
of	O
viral	B-T169
persistence	B-T081
with	O
age.	O
Together,	O
our	O
results	O
suggest	O
tissue	B-T024
T cell	B-T025
reservoirs	O
for	O
CMV	B-T005
control	B-T058
shaped	O
by	O
both	O
viral	B-T169
and	O
tissue	B-T024
-	O
intrinsic factors	B-T116
,	O
with	O
global	O
effects	O
on	O
homeostasis	B-T038
of	O
tissue	B-T024
T cells	B-T025
over	O
the	O
lifespan	B-T102
.	O

Lipid levels	B-T059
and	O
risk	B-T078
of	O
recurrent venous thrombosis	B-T046
:	O
results	B-T169
from	O
the	O
MEGA follow-up study	B-T062
Essentials	O
The	O
role	O
of	O
lipid levels	B-T059
in	O
the	O
risk	B-T078
of	O
recurrent venous thrombosis	B-T046
is	O
unclear	B-T033
.	O
Lipids	B-T109
were	O
assessed	B-T052
in	O
patients	B-T101
with	O
a	O
first	O
venous thrombosis	B-T046
(n	O
=	O
2106)	O
followed	B-T079
for	O
6.9	O
years	B-T079
.	O
Lipids	B-T109
were	O
not	O
associated with	B-T080
recurrence	B-T067
,	O
overall	O
or	O
in	O
patients	B-T101
with	O
unprovoked	O
first	O
events	B-T051
.	O
Testing lipid levels	B-T059
is	O
not	O
useful	B-T080
to	O
identify	B-T080
patients	B-T101
at	O
an	O
increased	B-T081
risk	B-T078
of	O
recurrence	B-T067
.	O
Background	O
Knowledge	O
of	O
risk factors	B-T033
for	O
recurrent venous thrombosis	B-T046
may	O
guide	O
decisions	O
on	O
duration	B-T079
of	O
anticoagulation	B-T061
.	O
The	O
association	B-T080
between	O
lipid levels	B-T059
and	O
first	O
venous thrombosis	B-T046
has	O
been	O
studied	O
extensively.	O
However,	O
data	B-T078
on	O
the	O
role	O
of	O
lipids	B-T109
in	O
the	O
risk	B-T078
of	O
recurrence	B-T067
are	O
scarce.	O
Objective	O
To	O
assess	B-T052
the	O
association	B-T080
between	O
lipid levels	B-T059
and	O
recurrent venous thrombosis	B-T046
.	O
Patients	B-T101
/Methods	O
Patients	B-T101
with	O
a	O
first	O
venous thrombosis	B-T046
from	O
the	O
MEGA study	B-T062
were	O
included	B-T169
.	O
Follow-up	B-T058
started	B-T080
at	O
the	O
date	B-T079
of	O
end	B-T082
of	O
anticoagulant treatment	B-T061
.	O
Percentile	B-T081
categories	B-T170
of	O
total	B-T109
/	O
low-density lipoprotein	B-T109
/	O
high-density lipoprotein cholesterol	B-T109
,	O
triglycerides	B-T109
and	O
apolipoproteins B	B-T116
and	O
A1	B-T116
were	O
established	B-T080
(<	O
10th,	O
10th-25th,	O
25th-75th	O
[	O
reference	B-T081
],	O
75th-90th,	O
>	O
90th	O
percentile	B-T081
).	O
Lipids	B-T109
were	O
measured	B-T080
at	O
least	O
3	O
months	B-T079
after	O
discontinuing	B-T033
anticoagulation	B-T061
.	O
Results	B-T169
Of	O
2106	O
patients	B-T101
followed	O
for	O
a	O
median	O
of	O
6.9	O
years	B-T079
,	O
326	O
developed	O
recurrence	B-T067
(	O
incidence rate	B-T081
,	O
2.7/100	O
patient	B-T101
-	O
years	B-T079
;	O
95%	O
confidence interval	B-T081
[	O
CI	B-T081
],	O
2.5-3.1).	O
With	O
hazard ratios	B-T081
ranging	B-T081
from	O
0.88	O
(95%	O
CI	B-T081
,	O
0.55-1.42)	O
to	O
1.33	O
(95%	O
CI	B-T081
,	O
0.86-2.04)	O
in	O
the	O
highest	O
percentile	B-T081
category	B-T170
vs.	O
the	O
reference	B-T081
,	O
we	O
found	O
no	O
association	B-T080
across	O
percentile	B-T081
categories	B-T170
between	O
recurrence	B-T067
and	O
lipid levels	B-T059
in	O
age-	B-T032
and	O
sex	B-T032
-adjusted	O
models	B-T075
,	O
nor	O
after	O
further	B-T082
adjustments	B-T169
for	O
body mass index	B-T201
,	O
diabetes	B-T047
,	O
estrogen	B-T109
and	O
statin	B-T109
use	B-T169
,	O
and	O
duration	B-T079
of	O
anticoagulation	B-T061
.	O
Subgroup	B-T185
analyses	B-T062
stratified	B-T080
by	O
unprovoked	O
or	O
provoked	B-T080
first	O
events	B-T051
,	O
location	B-T082
(	O
deep vein thrombosis	B-T047
or	O
pulmonary embolism	B-T047
)	O
and	O
sex	B-T032
also	O
did	O
not	O
reveal	B-T080
an	O
association	B-T080
with	O
any	O
of	O
the	O
lipid levels	B-T059
studied.	O
Conclusions	O
Testing lipid levels	B-T059
did	O
not	O
identify	B-T080
patients	B-T101
at	O
an	O
increased	B-T081
risk	B-T078
of	O
recurrent venous thrombosis	B-T046
in	O
this	O
study	B-T062
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	B-T051
,	O
and	O
these	O
should	O
not	O
influence	B-T077
decisions	O
on	O
duration	B-T079
of	O
anticoagulation	B-T061
.	O

Insecticidal effects	B-T038
of	O
deltamethrin	B-T109
in	O
laboratory	B-T073
and	O
field	B-T077
populations	B-T081
of	O
Culicoides species	B-T204
:	O
how	O
effective	O
are	O
host	B-T001
-	O
contact	B-T067
reduction	B-T080
methods	B-T062
in	O
India	B-T083
?	O
Bluetongue virus	B-T005
(	O
BTV	B-T005
)	O
is	O
transmitted	B-T046
by	O
Culicoides	B-T204
biting midges	B-T204
and	O
causes	O
bluetongue	B-T047
(	O
BT	B-T047
),	O
a	O
clinical disease	B-T047
observed	O
primarily	O
in	O
sheep	B-T015
.	O
BT	B-T047
has	O
a	O
detrimental effect	B-T046
on	O
subsistence	O
farmers	B-T097
in	O
India	B-T083
,	O
where	O
hyperendemic outbreaks	B-T047
impact	O
on	O
smallholdings	O
in	O
the	O
southern states	B-T083
of	O
the	O
country	B-T083
.	O
In	O
this	O
study,	O
we	O
establish	O
a	O
reliable	O
method	B-T062
for	O
testing	O
the	O
toxic effects	B-T037
of	O
deltamethrin	B-T109
on	O
Culicoides	B-T204
and	O
then	O
compare	O
deltamethrin	B-T109
with	O
traditional control methods	B-T062
used	O
by	O
farmers	B-T097
in	O
India	B-T083
.	O
Effects	O
of	O
deltamethrin	B-T109
were	O
initially	O
tested	O
using	O
a	O
colonised strain	B-T080
of	O
Culicoides nubeculosus Meigen	B-T204
and	O
a	O
modified	O
World Health Organisation	B-T093
exposure assay	B-T059
.	O
This	O
method	B-T062
was	O
then	O
applied	O
to	O
field	B-T077
populations	B-T081
of	O
Culicoides spp.	B-T204
in	O
India	B-T083
.	O
The	O
field	B-T077
population	B-T081
of	O
C. oxystoma	B-T204
in	O
India	B-T083
had	O
a	O
greater	O
LC50	O
(0.012	O
±	O
0.009%)	O
for	O
deltamethrin	B-T109
than	O
laboratory-reared	B-T059
C.nubeculosus	B-T204
(0.0013	O
±	O
0.0002%).	O
Exposure	O
of	O
C. nubeculosus	B-T204
to	O
deltamethrin	B-T109
at	O
higher	O
ambient temperatures	B-T070
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality rate	B-T081
at	O
24	O
h	O
post-exposure.	O
Behavioural assays	B-T059
with	O
C. nubeculosus	B-T204
in	O
WHO	B-T093
tubes	B-T077
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	B-T109
.	O
The	O
field	B-T077
experiments	B-T062
in	O
India	B-T083
,	O
however,	O
provided	O
no	O
evidence	O
for	O
repellent	B-T131
or	O
toxic effects	B-T037
of	O
deltamethrin	B-T109
.	O
Traditional methods	B-T062
such	O
as	O
the	O
application	B-T169
of	O
neem oil	B-T109
and	O
burning	B-T067
of	O
neem	B-T002
leaves	B-T002
also	O
provided	O
no	B-T033
protection	B-T033
.	O
Our	O
study	O
demonstrates	O
that	O
field	B-T077
-collected	O
Culicoides	B-T204
in	O
India	B-T083
are	O
less	O
susceptible	O
to	O
deltamethrin	B-T109
exposure	O
than	O
laboratory-bred	B-T059
C. nubeculosus	B-T204
and	O
traditional methods	B-T062
of	O
insect control	B-T068
do	O
not	O
provide	O
protection	B-T033
to	O
sheep	B-T015
.	O
These	O
low	O
levels	O
of	O
susceptibility	B-T038
to	O
deltamethrin	B-T109
have	O
not	O
been	O
recorded	O
before	O
in	O
field	B-T077
populations	B-T081
of	O
Culicoides	B-T204
and	O
suggest	O
resistance	B-T032
to	O
synthetic pyrethrioids	B-T121
.	O
Alternative	O
insect control	B-T068
methods	B-T062
,	O
in	O
addition	O
to	O
vaccination	B-T061
,	O
may	O
be	O
needed	O
to	O
protect	O
Indian	B-T083
livestock	B-T008
from	O
BTV	B-T005
transmission	B-T046
.	O

Correlation	B-T080
of	O
the	O
Lipid	B-T109
Profile	B-T059
,	O
BMI	B-T201
and	O
Bone Mineral Density	B-T201
in	O
Postmenopausal	B-T040
Women	B-T098
To	O
the	O
reduction	B-T080
of	O
bone density	B-T201
and	O
osteoporosis	B-T047
in	O
postmenopausal	B-T040
women	B-T098
contribute	O
elevated	B-T080
lipid	B-T109
parameters	B-T033
and	O
Body Mass Index	B-T201
(	O
BMI	B-T201
).	O
The	O
goal	O
of	O
our	O
study	B-T062
was	O
to	O
determine	O
the	O
correlation	B-T080
between	O
lipid	B-T109
parameters	B-T033
,	O
BMI	B-T201
and	O
osteoporosis	B-T047
in	O
postmenopausal	B-T040
women	B-T098
.	O
The	O
study	B-T062
was	O
carried	O
out	O
by	O
matched	B-T080
type	B-T080
between	O
experimental	B-T080
group	B-T078
and	O
controls	B-T096
.	O
The	O
experimental	B-T080
group	B-T078
consisted	O
of	O
100	O
females	B-T098
at	O
postmenopausal	B-T040
age	B-T032
,	O
in	O
which	O
by	O
the	O
DEXA method	B-T060
was	O
diagnosed	B-T033
osteoporosis	B-T047
at	O
the	O
Department	O
of	O
Endocrinology,	O
Diabetes	O
and	O
Metabolic	O
Diseases,	O
University Medical Center of RS	B-T073
during	O
2015-2016,	O
while	O
the	O
control group	B-T096
consisted	O
of	O
100	O
females	B-T098
in	O
a	O
postmenopausal	B-T040
age	B-T032
but	O
without	O
diagnosed	B-T033
osteoporosis	B-T047
.	O
The	O
groups	B-T078
were	O
matched	B-T080
by	O
age	B-T032
(±	O
2	O
years	B-T079
).	O
To	O
all	O
participants	B-T098
of	O
the	O
study	B-T062
were	O
carried	O
out	O
biochemical analysis of blood	B-T059
,	O
or	O
the	O
analysis	B-T062
of	O
the	O
lipid	B-T109
profile	B-T059
that	O
included	O
total cholesterol	B-T109
,	O
LDL cholesterol	B-T109
,	O
triglycerides	B-T109
(	O
TG	B-T109
)	O
and	O
HDL cholesterol	B-T109
,	O
and	O
was	O
determined	O
the	O
values	B-T080
of	O
BMI	B-T201
and	O
waist circumference	B-T201
(	O
WC	B-T201
).	O
Analysis	B-T062
of	O
the	O
data	B-T078
of	O
our	O
research	B-T062
shows	O
that	O
by	O
the	O
univariate logistic regression	B-T062
the	O
values	B-T080
of	O
lipid	B-T109
parameters	B-T033
total cholesterol	B-T109
(p=0.000),	O
LDL	B-T109
(p=0.005)	O
and	O
TG	B-T109
(p=0.033)	O
were	O
significantly	B-T078
associated with	B-T080
osteoporosis	B-T047
,	O
while	O
in	O
multivariate logistic model	B-T081
only	O
total cholesterol	B-T109
(p=	O
0.018)	O
was	O
found	O
as	O
an	O
independent	B-T078
risk factor	B-T033
for	O
osteoporosis	B-T047
in	O
postmenopausal	B-T040
women	B-T098
.	O
BMI	B-T201
values	B-T080
were	O
not	B-T033
statistically significantly	B-T081
associated with	B-T080
osteoporosis	B-T047
(p=0.727).	O
On	O
the	O
decrease	B-T081
in	O
bone mineral density	B-T201
and	O
osteoporosis	B-T047
in	O
postmenopausal	B-T040
women	B-T098
influence	O
many	O
risk factors	B-T033
whose	O
identification	B-T080
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	B-T080
prevention	B-T080
of	O
this	O
disease	B-T047
in	O
the	O
elderly	B-T098
.	O

Heterotopic ossification	B-T046
after	O
the	O
use	O
of	O
recombinant human bone morphogenetic protein-7	B-T116
To	O
present	O
the	O
incidence	B-T081
of	O
heterotopic ossification	B-T046
after	O
the	O
use	O
of	O
recombinant human bone morphogenetic protein-7	B-T116
(	O
rhBMP-7	B-T116
)	O
for	O
the	O
treatment	B-T061
of	O
nonunions	B-T033
.	O
Bone morphogenetic proteins	B-T116
(	O
BMPs	B-T116
)	O
promote	O
bone formation	B-T042
by	O
auto-induction	B-T044
.	O
Recombinant human BMP-7	B-T116
in	O
combination	O
with	O
bone grafts	B-T122
was	O
used	O
in	O
84	O
patients	B-T101
for	O
the	O
treatment	B-T061
of	O
long bone nonunions	B-T033
.	O
All	O
patients	B-T101
were	O
evaluated	B-T058
radiographicaly	B-T060
for	O
the	O
development	B-T169
of	O
heterotopic ossification	B-T046
during	O
the	O
standard	B-T080
assessment	B-T058
for	O
the	O
nonunion	B-T033
healing	B-T040
.	O
In	O
all	O
patients	B-T101
(80.9%)	O
with	O
radiographic	B-T070
signs	B-T184
of	O
heterotopic ossification	B-T046
,	O
a	O
CT scan	B-T060
was	O
performed.	O
Nonunion	B-T033
site	B-T082
palpation	B-T060
and	O
ROM evaluation	B-T059
of	O
the	O
adjacent	B-T082
joints	B-T030
were	O
also	O
carried	O
out.	O
Factors	B-T169
related	O
to	O
the	O
patient	B-T101
(	O
age	B-T032
,	O
gender	B-T032
),	O
the	O
nonunion	B-T033
(	O
location	B-T082
,	O
size	B-T082
,	O
chronicity	B-T079
,	O
number of previous procedures	B-T169
,	O
infection	B-T046
,	O
surrounding	B-T082
tissues	B-T024
condition	B-T080
)	O
and	O
the	O
surgical procedure	B-T061
(	O
graft	B-T122
and	O
fixation	B-T061
type	B-T080
,	O
amount	B-T081
of	O
rhBMP-7	B-T116
)	O
were	O
correlated	B-T080
with	O
the	O
development	B-T169
of	O
heterotopic ossification	B-T046
and	O
statistical analysis	B-T062
with	O
Pearsons χ (2) test	B-T170
was	O
performed.	O
Eighty	O
point	O
nine	O
percent	O
of	O
the	O
nonunions	B-T033
treated	B-T169
with	O
rhBMP-7	B-T116
,	O
healed	B-T169
with	O
no	O
need	O
for	O
further	O
procedures	B-T169
.	O
Heterotopic bone formation	B-T046
occurred	O
in	O
15	O
of	O
84	O
patients	B-T101
(17.8%)	O
and	O
it	O
was	O
apparent	O
in	O
the	O
routine	O
radiological evaluation	B-T058
of	O
the	O
nonunion	B-T033
site,	O
in	O
a	O
mean time	B-T079
of	O
5.5	O
mo	O
after	O
the	O
rhBMP-7	B-T116
application	B-T169
(range	O
3-12).	O
The	O
heterotopic ossification	B-T046
was	O
located	O
at	O
the	O
femur	B-T023
in	O
8	O
cases	B-T077
,	O
at	O
the	O
tibia	B-T023
in	O
6,	O
and	O
at	O
the	O
humerus	B-T023
in	O
οne	O
patient	B-T101
.	O
In	O
4	O
patients	B-T101
a	O
palpable mass	B-T033
was	O
present	O
and	O
only	O
in	O
one	O
patient	B-T101
,	O
with	O
a	O
para-articular knee nonunion	B-T033
treated	B-T169
with	O
rhBMP-7	B-T116
,	O
the	O
size	B-T082
of	O
heterotopic ossification	B-T046
affected	O
the	O
knee range of motion	B-T033
.	O
All	O
the	O
patients	B-T101
with	O
heterotopic ossification	B-T046
were	O
male	B-T032
.	O
Statistical analysis	B-T062
proved	O
that	O
patient's	B-T101
gender	B-T032
was	O
the	O
only	O
important	O
factor	B-T169
for	O
the	O
development	B-T169
of	O
heterotopic ossification	B-T046
(P	O
=	O
0.007).	O
Heterotopic ossification	B-T046
after	O
the	O
use	O
of	O
rhBMP-7	B-T116
in	O
nonunions	B-T033
was	O
common	O
but	O
it	O
did	O
not	O
compromise	O
the	O
final	O
clinical outcome	B-T169
in	O
most	O
cases	B-T077
,	O
and	O
affected	O
only	O
male	B-T032
patients	B-T101
.	O

Hypocretin/Orexin Peptides	B-T116
Excite	B-T052
Rat	B-T015
Neuroendocrine	B-T022
Dopamine Neurons	B-T025
through	O
Orexin 2 Receptor	B-T116
-Mediated	O
Activation	B-T052
of	O
a	O
Mixed	B-T169
Cation	B-T104
Current	B-T043
Hypocretin/Orexin	B-T116
(	O
H/O	B-T116
)	O
neurons	B-T025
of	O
the	O
lateral hypothalamus	B-T029
are	O
compelling	B-UnknownType
modulator candidates	B-T098
for	O
the	O
chronobiology	B-T091
of	O
neuroendocrine	B-T022
output	B-T077
and,	O
as	O
a	O
consequence	B-T169
,	O
hormone release	B-T125
from	O
the	O
anterior pituitary	B-T023
.	O
Here	O
we	O
investigate	O
the	O
effects	B-T080
of	O
H/O peptides	B-T116
upon	O
tuberoinfundibular dopamine (TIDA) neurons	B-T025
-	O
cells	B-T025
which	O
control	B-T080
,	O
via	O
inhibition	B-T052
,	O
the	O
pituitary	B-T023
secretion of prolactin	B-T043
.	O
In	O
whole cell recordings	B-T062
performed	B-T169
in	O
male	B-T032
rat	B-T015
hypothalamic slices	B-T082
,	O
application	O
of	O
H/O-A	B-T116
,	O
as	O
well	O
as	O
H/O-B	B-T116
,	O
excited	B-T052
oscillating	O
TIDA neurons	B-T025
,	O
inducing	B-T169
a	O
reversible	B-T169
depolarising	B-T046
switch	O
from	O
phasic to tonic discharge	B-T082
.	O
The	O
H/O	B-T116
-	O
induced	B-T169
inward	B-T082
current	B-T043
underpinning	B-T077
this	O
effect	B-T080
was	O
post-synaptic	B-T026
(as	O
it	O
endured	O
in	O
the	O
presence	B-T033
of	O
tetrodotoxin	B-T109
),	O
appeared	B-T080
to	O
be	O
carried	O
by	O
a	O
Na(+)	B-T116
-	O
dependent	B-T080
transient receptor potential-like channel	B-T116
(as	O
it	O
was	O
blocked	B-T169
by	O
2-APB	B-T109
and	O
was	O
diminished	B-T081
by	O
removal	B-T052
of	O
extracellular	B-T026
Na(+)	B-T116
),	O
and	O
was	O
a	O
consequence of	B-T169
OX2R receptor	B-T116
activation	B-T052
(as	O
it	O
was	O
blocked	B-T169
by	O
the	O
OX2R receptor	B-T116
antagonist	B-T120
TCS OX2 29	B-T109
,	O
but	O
not	O
the	O
OX1R receptor	B-T116
antagonist	B-T120
SB 334867	B-T109
).	O
Application	B-T058
of	O
the	O
hormone	B-T125
,	O
melatonin	B-T109
,	O
failed	B-T169
to	O
alter	B-T169
TIDA	B-T025
membrane potential	B-T043
or	O
oscillatory activity	B-T061
.	O
This	O
first	O
description	B-T170
of	O
the	O
electrophysiological effects	B-T060
of	O
H/Os	B-T116
upon	O
the	O
TIDA network	B-T025
identifies	B-T080
cellular mechanisms	B-T044
that	O
may	O
contribute	B-T052
to	O
the	O
circadian rhythmicity	B-T040
of	O
prolactin secretion	B-T043
.	O

Improving	B-T080
exchange	O
with	O
consumers	B-T098
within	O
mental health organizations	B-T093
:	O
Recognizing	O
mental ill health	B-T048
experience	O
as	O
a	O
'sneaky,	O
special	O
degree'	O
Stigmatizing	B-T033
views	O
towards	O
consumers	B-T098
may	O
be	O
held	O
even	O
by	O
those	O
working	B-T057
within	O
mental health organizations	B-T093
.	O
Contemporary	O
mental health policies	B-T170
require	O
organizations	B-T093
to	O
work	B-T057
collaboratively	B-T054
with	O
consumers	B-T098
in	O
producing	B-T169
and	O
delivering	B-T058
services	B-T057
.	O
Using	O
social exchange theory	B-UnknownType
,	O
which	O
emphasises	O
mutual	B-T080
exchange	B-T054
to	O
maximise	B-T081
benefits	B-T081
in	O
partnership	B-T054
,	O
the	O
current	B-T079
study	B-T062
explores	O
the	O
perspectives	B-UnknownType
of	O
those	O
working	B-T057
within	O
organizations	B-T093
that	O
have	O
some	O
level	B-T080
of	O
consumer	B-T098
leadership	B-T054
.	O
Interviews	B-T052
were	O
conducted	O
with	O
14	O
participants	B-T098
from	O
a	O
range	B-T081
of	O
mental health organizations	B-T093
.	O
Data	B-T078
were	O
transcribed,	O
and	O
analyzed	B-T062
using	O
thematic analytic	B-T062
and	O
discursive	B-T033
psychological techniques	B-T060
.	O
Findings	B-T033
suggest	O
stigma	B-T033
is	O
still	O
prevalent	O
even	O
in	O
organizations	B-T093
that	O
have	O
consumers	B-T098
in	O
leadership positions	B-T054
,	O
and	O
consumers	B-T098
are	O
often	O
perceived	B-T041
as	O
less	O
able	O
to	O
work	B-T057
in	O
mental health organizations	B-T093
than	O
non-consumers.	O
Several	O
discourses	B-T054
challenged	O
such	O
a	O
view	O
-	O
showing	O
how	O
consumers	B-T098
bring	O
value	O
to	O
mental health organizations	B-T093
through	O
their	O
expertise	O
in	O
the	O
mental health system	B-T093
,	O
and	O
their	O
ability	B-T032
to	O
provide	O
safety	B-T058
and	O
support	B-T054
to	O
other	O
consumers	B-T098
.	O
Through	O
a	O
social exchange theory	B-UnknownType
lens,	O
the	O
authors	B-T097
call	O
for	O
organizations	B-T093
to	O
challenge	O
stigma	B-T033
and	O
promote	B-T052
the	O
value	O
that	O
consumers	B-T098
can	O
bring	O
to	O
maximize	B-T081
mutual	B-T080
benefits	B-T081
.	O

Does	O
sex	B-T032
really	O
matter?	O
Explaining	O
intraspecies	B-T185
variation	B-T080
in	O
ocean	B-T083
acidification	B-T067
responses	B-T032
Ocean	B-T083
acidification	B-T067
(	O
OA	B-T067
)	O
poses	O
a	O
major threat	B-T078
to	O
marine	O
ecosystems	B-T070
globally	B-T080
,	O
having	O
significant	B-T078
ecological	B-T070
and	O
economic	B-T169
importance	B-T080
.	O
The	O
number	B-T081
and	O
complexity	B-T169
of	O
experiments	B-T062
examining	B-T033
the	O
effects of	B-T080
OA	B-T067
has	O
substantially	B-T078
increased	B-T081
over	O
the	O
past	B-T079
decade	B-T081
,	O
in	O
an	O
attempt	B-T051
to	O
address	B-T078
multi-stressor	B-T078
interactions	B-T169
and	O
long-term	B-T079
responses	B-T032
in	O
an	O
increasing	B-T169
range	B-T081
of	O
aquatic organisms	B-T001
.	O
However,	O
differences	B-T080
in	O
the	O
response	B-T032
of	O
males	B-T032
and	O
females	B-T032
to	O
elevated pCO2	B-T033
have	O
been	O
investigated	B-T169
in	O
fewer	B-T081
than	O
4%	O
of	O
studies	O
to	O
date	B-T079
,	O
often	O
being	O
precluded	O
by	O
the	O
difficulty	B-T080
of	O
determining	O
sex	B-T032
non-destructively	B-T078
,	O
particularly	O
in	O
early life stages	B-T079
.	O
Here	O
we	O
highlight	O
that	O
sex	B-T032
can	O
significantly	B-T078
impact	B-T080
organism	B-T001
responses	B-T032
to	O
OA	B-T067
,	O
differentially	O
affecting	B-T169
physiology	B-T039
,	O
reproduction	B-T040
,	O
biochemistry	B-T169
and	O
ultimately survival	B-T169
.	O
What	O
is	O
more,	O
these	O
impacts	B-T080
do	O
not	O
always	O
conform	O
to	O
ecological theory	B-T078
based	O
on	O
differential	B-T080
resource allocation	B-T081
towards	O
reproduction	B-T040
,	O
which	O
would	O
predict	B-T078
females	B-T032
to	O
be	O
more	O
sensitive	B-T169
to	O
OA	B-T067
owing	O
to	O
the	O
higher	O
production cost	B-T169
of	O
eggs	B-T025
compared	B-T052
with	O
sperm	B-T025
.	O
Therefore,	O
non-	O
sex	B-T032
-	O
specific studies	B-T062
may	O
overlook	O
subtle	O
but	O
ecologically	O
significant	B-T078
differences	B-T080
in	O
the	O
responses	B-T032
of	O
males	B-T032
and	O
females	B-T032
to	O
OA	B-T067
,	O
with	O
consequences	B-T169
for	O
forecasting	B-T079
the	O
fate	O
of	O
natural	B-T169
populations	B-T098
in	O
a	O
near-future	B-T079
ocean	B-T083
.	O

Computational analysis	B-T059
of	O
conserved coil	B-T082
functional residues	B-T077
in	O
the	O
mitochondrial genomic sequences	B-T059
of	O
dermatophytes	B-T004
Dermatophyte	B-T004
is	O
a	O
group	O
of	O
closely	O
related	O
fungi	B-T004
that	O
have	O
the	O
capacity	O
to	O
invade	B-T080
keratinized	B-T169
tissue	B-T024
of	O
humans	B-T016
and	O
other	O
animals	B-T008
.	O
The	O
infection	B-T046
known	O
as	O
dermatophytosis	B-T047
,	O
caused	O
by	O
members	O
of	O
the	O
genera	B-T185
Microsporum	B-T004
,	O
Trichophyton	B-T004
,	O
and	O
Epidermophyton	B-T004
includes	O
infection	B-T046
to	O
the	O
groin	B-T029
(	O
tinea cruris	B-T047
),	O
beard	B-T023
(	O
tinea barbae	B-T047
),	O
scalp	B-T023
(	O
tinea capitis	B-T047
),	O
feet	B-T023
(	O
tinea pedis	B-T047
),	O
glabrous skin	B-T023
(	O
tinea corporis	B-T047
),	O
nail	B-T023
(	O
tinea unguium	B-T047
),	O
and	O
hand	B-T023
(	O
tinea manuum	B-T047
).	O
The	O
identification	O
of	O
evolutionary	B-T045
relationship	B-T080
between	O
these	O
three genera	B-T185
of	O
dermatophyte	B-T004
is	O
epidemiologically important	B-T169
to	O
understand	O
their	O
pathogenicity	B-T032
.	O
Mitochondrial DNA	B-T114
evolves	B-T038
more rapidly	B-T080
than	O
a	O
nuclear DNA	B-T114
due	O
to	O
higher	O
rate of mutation	B-T080
but	O
is	O
very	O
less affected	B-T169
by	O
genetic recombination	B-T045
,	O
making	O
it	O
an	O
important tool	B-T073
for	O
phylogenetic studies	B-T062
.	O
Thus,	O
here	O
we	O
present	O
a	O
novel	O
scheme	O
to	O
identify	O
the	O
conserved coil	B-T082
functional residues	B-T077
of	O
Trichophyton rubrum	B-T004
,	O
Trichophyton mentagrophytes	B-T004
,	O
Epidermophyton floccosum	B-T004
and	O
Microsporum canis	B-T004
.	O
Protein coding sequences	B-T028
of	O
the	O
mitochondrial genome	B-T028
were	O
aligned	O
for	O
their	O
similar sequences	B-T086
and	O
homology modelling	B-T063
was	O
performed	O
for	O
structure	B-T116
and	O
pocket	B-T087
identification	B-T062
.	O
The	O
results	O
obtained	O
from	O
comparative analysis	B-T062
of	O
the	O
protein sequences	B-T087
revealed	O
the	O
presence	O
of	O
functionally	O
active sites	B-T169
in	O
all	O
the	O
species	O
of	O
the	O
genera	B-T185
Trichophyton	B-T004
and	O
Microsporum	B-T004
.	O
However	O
in	O
Epidermophyton floccosum	B-T004
it	O
was	O
observed	O
in	O
three	O
protein sequences	B-T087
of	O
the	O
five	O
studied.	O
The	O
absence	O
of	O
these	O
conserved coil	B-T082
functional residues	B-T077
in	O
E. floccusum	B-T004
may	O
be	O
correlated	O
with	O
lesser infectivity	B-T080
of	O
this	O
organism	B-T001
.	O
The	O
functional residues	B-T077
identified	O
in	O
the	O
present	O
study	O
could	O
be	O
responsible	O
for	O
the	O
disease	B-T047
and	O
thus	O
can	O
act	O
as	O
putative target sites	B-T169
for	O
drug designing	B-T090
.	O

Non-intubated	B-T061
subxiphoid	B-T082
uniportal video-assisted thoracoscopic thymectomy	B-T061
thymectomy	B-T061
using	O
glasses-free	B-T033
3D	B-T082
vision	B-T040
Trans-sternal thymectomy	B-T061
has	O
long	O
been	O
accepted	B-T080
as	O
the	O
standard	B-T080
surgical procedure	B-T061
for	O
thymic masses	B-T023
.	O
Recently	B-T079
,	O
minimally	B-T080
invasive	B-T169
methods	B-T170
,	O
such	O
as	O
video-assisted thoracoscopic surgery	B-T061
(VATS)	B-T061
and,	O
even	O
more	O
recently,	O
non-intubated	B-T061
anesthesia	B-T061
,	O
have	O
emerged	B-T080
.	O
These	O
methods	B-T170
provide	O
advantages	B-T081
including	B-T169
reductions	B-T080
in	O
surgical trauma	B-T033
,	O
postoperative associated pain	B-T184
,	O
and	O
in	O
regards	O
to	O
VATS	B-T061
,	O
provide	O
certain	O
cosmetic	B-T061
benefits	B-T081
.	O
Considering	B-T078
these	O
advantages	B-T081
,	O
we	O
herein	O
present	O
a	O
case	O
of	O
subxiphoid	B-T082
uniportal VATS	B-T061
for	O
thymic mass	B-T024
using	O
a	O
glasses-free	B-T033
3D	B-T082
thoracoscopic	B-T082
display system	B-T170
.	O

Trends	B-T079
in	O
dietary intake	B-T040
among	O
adults	B-T100
with	O
type 2 diabetes	B-T047
:	O
NHANES	B-T062
1988-2012	O
Dietary	B-T168
recommendations	B-T078
for	O
adults	B-T100
with	O
diabetes	B-T047
are	O
to	O
follow	O
a	O
healthy diet	B-T061
in	O
appropriate	O
portion sizes	B-T081
.	O
We	O
determined	O
recent	O
trends	B-T079
in	O
energy	B-T081
and	O
nutrient intakes	B-T081
among	O
a	O
nationally	O
representative	O
sample	O
of	O
US	B-T083
adults	B-T100
with	O
and	O
without	O
type 2 diabetes	B-T047
.	O
Participants	B-T098
were	O
adults	B-T100
aged	B-T032
≥20	O
years	B-T079
from	O
the	O
cross-sectional National Health and Nutrition Examination Surveys	B-T062
,	O
1988-2012	O
(N	O
=	O
49	O
770).	O
Diabetes	B-T047
was	O
determined	O
by	O
self-report	B-T062
of	O
a	O
physician's	B-T097
diagnosis	B-T033
(n	O
=	O
4885).	O
Intake of energy	B-T081
and	O
nutrients	B-T168
were	O
determined	O
from	O
a	O
24-	O
h	B-T079
recall	O
by	O
participants	B-T098
of	O
all	O
food	B-T168
consumed.	O
Linear regression	B-T081
was	O
used	O
to	O
test	B-T169
for	O
trends	B-T079
in	O
mean	O
intake	B-T040
over	O
time	B-T079
for	O
all	O
participants	B-T098
and	O
by	O
demographic characteristics	B-T102
.	O
Among	O
adults	B-T100
with	O
diabetes	B-T047
,	O
overall	O
total	O
energy intake	B-T081
increased	B-T081
between	O
1988-1994	O
and	O
2011-2012	O
(	O
1689 kcal	B-T081
versus	O
1895 kcal	B-T081
;	O
Ptrend	O
<	O
0.001)	O
with	O
evidence	O
of	O
a	O
plateau	B-T081
between	O
2003-2006	O
and	O
2011-2012.	O
In	O
2007-2012,	O
energy intake	B-T081
was	O
greater	O
for	O
younger	B-T100
than	O
older adults	B-T098
,	O
for	O
men	B-T098
than	O
women	B-T098
,	O
and	O
for	O
non-Hispanic whites	B-T098
versus	O
non-Hispanic blacks	B-T098
.	O
There	O
was	O
no	O
change	O
in	O
the	O
percentage	B-T081
of	O
calories	B-T081
from	O
carbohydrate	B-T168
,	O
total fat	B-T109
or	O
protein	B-T168
.	O
Percentage	B-T081
of	O
calories	B-T081
from	O
saturated fat	B-UnknownType
was	O
similar	O
across	O
study	B-T062
periods	B-T079
but	O
remained	O
above	O
recommendations	B-T078
(11.2%	O
in	O
2011-2012).	O
Fibre intake	B-T033
significantly	O
decreased	O
and	O
remained	O
below	O
recommendations	B-T078
(Ptrend	O
=	O
0.002).	O
Sodium	B-T168
,	O
cholesterol	B-T109
and	O
calcium	B-T197
intakes	B-T040
increased	B-T081
.	O
There	O
was	O
no	O
change	O
in	O
energy intake	B-T081
among	O
adults	B-T100
without	O
diabetes	B-T047
and	O
dietary	B-T168
trends	B-T079
were	O
similar	O
to	O
those	O
with	O
diabetes	B-T047
.	O
Future	O
data	B-T078
are	O
needed	O
to	O
confirm	O
a	O
plateau	B-T081
in	O
energy intake	B-T081
among	O
adults	B-T100
with	O
diabetes	B-T047
,	O
although	O
the	O
opportunity	O
exists	O
to	O
increase	B-T169
fibre	B-T168
and	O
reduce	B-T081
saturated fat	B-UnknownType
.	O

Clonal	B-T024
and	O
serotype	B-T170
dynamics	B-T070
of	O
serogroup 6	B-T007
isolates	B-T123
causing	O
invasive pneumococcal disease	B-T047
in	O
Portugal	B-T083
:	O
1999-2012	O
Although	O
serogroup 6	B-T007
was	O
among	O
the	O
first	O
to	O
be	O
recognized	O
among	O
Streptococcus pneumoniae	B-T007
,	O
several	O
new	O
serotypes	B-T170
were	O
identified	B-T080
since	O
the	O
introduction	B-T169
of	O
pneumococcal conjugate vaccines	B-T121
(	O
PCVs	B-T121
).	O
A	O
decrease	B-T081
of	O
the	O
6B-2 variant	B-T080
among	O
invasive pneumococcal disease	B-T047
(	O
IPD	B-T047
),	O
but	O
not	O
6B-1	B-T080
,	O
was	O
noted	O
post	B-T079
conjugate vaccine	B-T121
introduction	B-T169
,	O
underpinned	O
by	O
a	O
decrease	B-T081
of	O
CC273 isolates	B-T123
.	O
Serotype 6C	B-T007
was	O
associated with	B-T080
adult	B-T100
IPD	B-T047
and	O
increased	B-T081
in	O
this	O
age group	B-T100
representing	O
two	O
lineages	B-T078
(	O
CC315	B-T078
and	O
CC395	B-T078
),	O
while	O
the	O
same	O
lineages	B-T078
expressed	B-T045
other	O
serogroup 6	B-T007
serotypes	B-T170
in	O
children	B-T100
.	O
Taken	O
together,	O
these	O
findings	B-T169
suggest	O
a	O
potential	O
cross-protection	B-T044
of	O
PCVs	B-T121
against	O
serotype 6C	B-T007
IPD	B-T047
among	O
vaccinated	B-T033
children	B-T100
but	O
not	O
among	O
adults	B-T100
.	O
Serotype 6A	B-T007
became	O
the	O
most	O
important	O
serogroup 6	B-T007
serotype	B-T170
in	O
children	B-T100
but	O
it	O
decreased	B-T081
in	O
adult	B-T100
IPD	B-T047
.	O
No	O
other	O
serogroup 6	B-T007
serotypes	B-T170
were	O
detected	B-T033
,	O
so	O
available	O
phenotypic	B-T032
or	O
simple	O
genotypic	B-T032
assays	B-T059
remain	O
adequate	B-T080
for	O
distinguishing	O
serotypes	B-T170
within	O
serogroup 6	B-T007
isolates	B-T123
.	O

Minimally invasive	B-T169
percutaneous nephrolithotomy	B-T061
improves	O
stone-free	O
rates	O
for	O
impacted	B-T169
proximal	B-T082
ureteral stones	B-T047
:	O
A	O
systematic review	B-T170
and	O
meta-analysis	B-T062
Urinary stones	B-T047
are	O
common	O
medical	B-T169
disorders	B-T047
and	O
the	O
treatment	B-T169
of	O
impacted proximal ureteral stones	B-T047
proximal	B-T082
ureteral	O
stones	O
(	O
IPUS	B-T047
)	O
is	O
still	O
a	O
challenge	O
for	O
urologists	B-T097
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
compare the efficacy	B-T062
and	O
safety	B-T062
of	O
minimally invasive	B-T169
percutaneous nephrolithotomy	B-T061
(	O
MI	B-T169
-	O
PCNL	B-T061
)	O
and	O
ureteroscopic lithotripsy	B-T061
(	O
URL	B-T061
)	O
in	O
the	O
treatment	B-T169
of	O
IPUS	B-T047
via	O
a	O
meta-analysis	B-T062
.	O
We	O
collected	O
studies	B-T062
using	O
PubMed	B-T170
,	O
Embase	B-T170
,	O
and	O
Cochrane Library	B-T170
from	O
1978 to November 2016	B-T079
and	O
analyzed	B-T062
them	O
using	O
Stata 12.0	B-T170
and	O
RevMan 5.3	B-T170
.	O
Odds ratios	B-T081
(	O
OR	B-T081
s)	O
and	O
standard mean difference	B-T081
(	O
SMD	B-T081
)	O
were	O
calculated	O
for	O
binary	B-T080
and	O
continuous variables	B-T081
respectively,	O
accompanied	O
with	O
95%	O
confidence intervals	B-T081
(	O
CIs	B-T081
).	O
All	O
study	B-T062
procedures	O
followed	O
the	O
PRISMA guidelines	B-T170
.	O
Five	O
prospective studies	B-T062
were	O
included	B-T169
in	O
our	O
meta-analysis	B-T062
,	O
with	O
242	O
MI	B-T169
-	O
PCNL	B-T061
and	O
256	O
URL	B-T061
cases.	O
MI	B-T169
-	O
PCNL	B-T061
was	O
associated with	B-T080
a	O
longer postoperative	B-T079
hospital stay	B-T079
than	O
URL	B-T061
(	O
SMD	B-T081
,	O
3.14;	O
95%	O
CI	B-T081
,	O
1.27	O
to	O
5.55).	O
However,	O
no	O
significant	O
difference	B-T080
was	O
observed	B-T169
in	O
operative time	B-T079
(	O
SMD	B-T081
,	O
-0.38;	O
95%	O
CI	B-T081
,	O
-3.15	O
to	O
2.38).	O
In	O
addition,	O
MI	B-T169
-	O
PCNL	B-T061
had	O
higher	O
initial	O
(	O
OR	B-T081
,	O
11.12;	O
95%	O
CI	B-T081
,	O
5.56	O
to	O
22.24)	O
and	O
overall	O
stone-free	O
rates	O
(	O
OR	B-T081
,	O
8.70;	O
95%	O
CI	B-T081
,	O
3.23	O
to	O
23.45)	O
than	O
URL	B-T061
,	O
along	O
with	O
lower	O
possibilities	O
of	O
surgical conversion	B-T061
(	O
OR	B-T081
,	O
0.11;	O
95%	O
CI	B-T081
,	O
0.03	O
to	O
0.49)	O
and	O
postoperative	B-T079
shock wave lithotripsy	B-T061
(	O
OR	B-T081
,	O
0.06;	O
95%	O
CI	B-T081
,	O
0.02	O
to	O
0.18).	O
Regarding	O
complications	B-T046
,	O
no	O
significant	O
differences	B-T080
were	O
observed	B-T169
between	B-T082
MI	B-T169
-	O
PCNL	B-T061
and	O
URL	B-T061
(	O
OR	B-T081
,	O
1.39;	O
95%	O
CI	B-T081
,	O
0.93	O
to	O
2.10),	O
except	O
for	O
hematuria	B-T047
(	O
OR	B-T081
,	O
4.80;	O
95%	O
CI	B-T081
,	O
1.45	O
to	O
15.94).	O
MI	B-T169
-	O
PCNL	B-T061
is	O
optimal	B-T080
and	O
should	O
be	O
considered	B-T078
as	O
the	O
preferred	B-T078
treatment method	B-T061
for	O
IPUS	B-T047
,	O
as	O
it	O
has	O
better efficacy	B-T080
and	O
a	O
safety	B-T062
profile	O
similar	O
to	O
that	O
of	O
URL	B-T061
.	O
However,	O
further	O
high	O
quality	O
studies	O
with	O
larger	O
sample	O
size	O
are	O
required	B-T169
in	O
future	B-T079
.	O

Predictive Factors	B-T170
for	O
Long-term	B-T079
Outcome	B-T169
of	O
Subthalamic Nucleus	B-T023
Deep Brain Stimulation	B-T061
for	O
Parkinson's Disease	B-T047
Despite	O
the	O
recognition	O
of	O
the	O
usefulness	B-T080
of	O
subthalamic nucleus	B-T023
deep brain stimulation	B-T061
(	O
STN	B-T023
-	O
DBS	B-T061
)	O
for	O
the	O
treatment	B-T169
of	O
Parkinson's disease	B-T047
(	O
PD	B-T047
),	O
preoperative	B-T079
predictive factors	B-T170
for	O
the	O
long-term	B-T079
outcome	B-T169
of	O
STN	B-T023
-	O
DBS	B-T061
are	O
not	B-T169
sufficiently	B-T080
established	B-T080
.	O
We	O
performed	O
this	O
study	B-T062
to	O
determine	O
such	O
predictive factors	B-T170
.	O
The	O
subjects	B-T096
were	O
66	O
patients	B-T101
who	O
were	O
classified	B-T185
into	O
two	B-T081
groups	B-UnknownType
on	O
the	O
basis	B-T169
of	O
their	O
activities of daily living	B-T056
(	O
ADL	B-T056
)	O
evaluated	O
five years	B-T079
after	B-T079
the	O
STN	B-T023
-	O
DBS	B-T061
surgery	B-T061
:	O
33	O
patients	B-T101
were	O
assigned	B-T169
to	O
the	O
independent	B-T169
ADL	B-T056
group	B-UnknownType
(	O
group I	B-UnknownType
)	O
and	O
the	O
remaining	O
33	O
patients	B-T101
to	O
the	O
dependent	B-T169
ADL	B-T056
group	B-UnknownType
(	O
group D	B-UnknownType
).	O
Group I	B-UnknownType
patients	B-T101
showed	O
a	O
Schwab and England (S&E) scale	B-T170
S&E	B-T170
)	O
scale	O
score	B-T081
of	O
more	O
than	O
70	O
during	B-T079
the	O
off-period	B-T079
,	O
indicating	O
that	O
these	O
patients	B-T101
can	O
maintain	O
their	O
independent	B-T169
ADL	B-T056
all the time	B-T079
.	O
Group D	B-UnknownType
patients	B-T101
showed	O
a	O
score	B-T081
of	O
70	O
or	O
lower	B-T080
during	B-T079
the	O
off-period	B-T079
,	O
indicating	O
that	O
these	O
patients	B-T101
cannot	O
maintain	O
their	O
independent	B-T169
ADL	B-T056
for	O
an	O
entire	B-T081
day	B-T079
.	O
We	O
studied	B-T062
the	O
differences	B-T080
in	O
the	O
preoperative state	B-T033
between	O
these	O
two	B-T081
groups	B-UnknownType
.	O
Statistically significant	B-T081
differences	B-T080
were	O
noted	O
in	O
PD	B-T047
onset age	B-T081
,	O
age	B-T032
at	O
surgery	B-T061
,	O
preoperative	B-T079
unified Parkinson's disease rating scale	B-T170
(	O
UPDRS	B-T170
)	O
part I	B-T082
score	B-T081
,	O
part II	B-T082
score	B-T081
,	O
total	B-T080
subscore	B-T081
for	O
axial symptoms	B-T033
in	O
part III	B-T082
,	O
mini-mental state examination (MMSE) score	B-T033
and	O
S&E	B-T170
score	B-T081
.	O
Multiple	O
logistic regression analysis	B-UnknownType
showed	O
that	O
the	O
significant	B-T078
independent	B-T169
variables	B-T080
related	O
to	O
long-term	B-T079
independent	B-T169
ADL	B-T056
were	O
the	O
age	B-T032
at	O
surgery	B-T061
,	O
MMSE score	B-T033
and	O
preoperative	B-T079
S&E scale	B-T170
score	B-T081
during	B-T079
the	O
off-period	B-T079
.	O
The	O
PD	B-T047
onset age	B-T081
,	O
age	B-T032
at	O
surgery	B-T061
,	O
preoperative	B-T079
high	B-T080
-	O
level	B-T080
ADL	B-T056
,	O
cognitive function	B-T041
,	O
and	O
axial symptoms	B-T033
are	O
important	B-T080
predictive factors	B-T170
for	O
the	O
long-term	B-T079
outcome	B-T169
of	O
STN	B-T023
-	O
DBS	B-T061
.	O

Who	O
Persuades	B-T078
Who?	O
An	O
Analysis	B-T062
of	O
Persuasion	B-T078
Choices	B-T055
Related	O
to	O
Antibiotic	B-T195
-	O
Free	B-T080
Food	B-T168
Personal communication	B-T054
,	O
in	O
which	O
one	O
person	B-T098
persuades	B-T078
another	O
to	O
engage	O
in	O
a	O
particular	O
behavior	B-T053
,	O
is	O
one	O
means	O
through	O
which	O
behaviors	B-T053
spread	B-T080
.	O
To	O
better	O
understand	B-T041
how	O
personal communication	B-T054
spreads	B-T080
behavior	B-T053
,	O
we	O
investigated	B-T169
adults'	B-T100
(N	O
=	O
228)	O
likelihood	B-T081
of	O
persuading	B-T078
others	O
in	O
a	O
fictitious	O
social network	B-T098
to	O
buy	B-T052
antibiotic	B-T195
-	O
free	B-T080
food	B-T168
,	O
and	O
who	O
they	O
attempted	B-T051
to	O
persuade	B-T078
,	O
based	O
on	O
behavioral	B-T053
determinants	B-T169
,	O
homophily	B-T080
,	O
and	O
superdiffuser	B-T080
traits	B-T055
.	O
For	O
potential	B-T080
consumers	B-T098
,	O
the	O
findings	B-T033
showed	O
that	O
behavioral	B-T053
determinants	B-T169
,	O
behavioral	B-T053
intentions	B-T041
,	O
and	O
mavenism	B-T080
predicted	B-T078
intentions	B-T041
to	O
persuade	B-T078
others.	O
Homophily	B-T080
,	O
mavenism	B-T080
,	O
and	O
connectivity	B-T169
predicted	B-T078
patterns	B-T082
of	O
interpersonal	B-T054
persuasion	B-T078
.	O
For	O
vegetarians	B-T098
(without	O
homophily	B-T080
in	O
action	B-T052
),	O
behavioral	B-T053
determinants	B-T169
and	O
mavenism	B-T080
predicted	B-T078
persuasion	B-T078
intentions	B-T041
.	O
Persuasiveness	B-T078
was	O
associated with	B-T080
targeting	B-T169
more	O
network	B-T098
members	B-T098
;	O
mavenism	B-T080
was	O
associated with	B-T080
selecting	O
structurally	B-T082
central	B-T082
members	B-T098
.	O

Modeling	B-T062
the	O
flux	B-T070
of	O
metabolites	B-T123
in	O
the	O
juvenile hormone	B-T125
biosynthesis	B-T038
pathway	B-T044
using	O
generalized additive models	B-T075
and	O
ordinary differential equations	B-T170
Juvenile hormone	B-T125
(	O
JH	B-T125
)	O
regulates	O
development	B-T169
and	O
reproductive maturation	B-T040
in	O
insects	B-T204
.	O
The	O
corpora allata	B-T023
(	O
CA	B-T023
)	O
from	O
female	B-T032
adult mosquitoes	B-T204
synthesize	O
fluctuating	B-T079
levels	B-T080
of	O
JH	B-T125
,	O
which	O
have	O
been	O
linked	O
to	O
the	O
ovarian development	B-T042
and	O
are	O
influenced	O
by	O
nutritional	B-T080
signals	B-T043
.	O
The	O
rate	B-T081
of	O
JH	B-T125
biosynthesis	B-T038
is	O
controlled	O
by	O
the	O
rate	B-T081
of	O
flux	B-T070
of	O
isoprenoids	B-T109
in	O
the	O
pathway	B-T044
,	O
which	O
is	O
the	O
outcome	O
of	O
a	O
complex	O
interplay	O
of	O
changes	B-T169
in	O
precursor	B-T167
pools	O
and	O
enzyme	B-T116
levels	B-T080
.	O
A	O
comprehensive	B-T080
study	B-T062
of	O
the	O
changes	B-T169
in	O
enzymatic activities	B-T044
and	O
precursor	B-T167
pool	O
sizes	O
have	O
been	O
previously	O
reported	O
for	O
the	O
mosquito	B-T204
Aedes aegypti	B-T204
JH	B-T125
biosynthesis	B-T038
pathway	B-T044
.	O
In	O
the	O
present	O
studies	B-T062
,	O
we	O
used	O
two	O
different	O
quantitative approaches	B-UnknownType
to	O
describe	O
and	O
predict	O
how	O
changes	B-T169
in	O
the	O
individual	O
metabolic	B-T169
reactions	B-T169
in	O
the	O
pathway	B-T044
affect	O
JH	B-T125
synthesis	B-T038
.	O
First,	O
we	O
constructed	O
generalized additive models	B-T075
(	O
GAMs	B-T075
)	O
that	O
described	O
the	O
association	O
between	O
changes	B-T169
in	O
specific	O
metabolite	B-T123
concentrations	B-T081
with	O
changes	B-T169
in	O
enzymatic activities	B-T044
and	O
substrate	B-T167
concentrations	B-T081
.	O
Changes	B-T169
in	O
substrate	B-T167
concentrations	B-T081
explained	O
50%	O
or	O
more	O
of	O
the	O
model	B-T075
deviances	O
in	O
7	O
of	O
the	O
13	O
metabolic	B-T169
steps	B-T077
analyzed	B-T062
.	O
Addition	O
of	O
information	O
on	O
enzymatic activities	B-T044
almost	O
always	O
improved	O
the	O
fitness	B-T052
of	O
GAMs	B-T075
built	O
solely	O
based	O
on	O
substrate	B-T167
concentrations	B-T081
.	O
GAMs	B-T075
were	O
validated	O
using	O
experimental	B-T080
data	B-T078
that	O
were	O
not	O
included	O
when	O
the	O
model	O
was	O
built.	O
In	O
addition,	O
a	O
system	O
of	O
ordinary differential equations	B-T170
(	O
ODE	B-T170
)	O
was	O
developed	O
to	O
describe	O
the	O
instantaneous	O
changes	B-T169
in	O
metabolites	B-T123
as	O
a	O
function	B-T169
of	O
the	O
levels	B-T080
of	O
enzymatic catalytic activities	B-T044
.	O
The	O
results	B-T169
demonstrated	O
the	O
ability	O
of	O
the	O
models	B-T075
to	O
predict	O
changes	B-T169
in	O
the	O
flux	B-T070
of	O
metabolites	B-T123
in	O
the	O
JH	B-T125
pathway	B-T044
,	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
to	O
design	B-T052
and	O
validate	B-T062
experimental	B-T080
manipulations	B-T169
of	O
JH	B-T125
synthesis	B-T038
.	O

Associations	B-T080
between	O
human breast milk	B-T109
hormones	B-T125
and	O
adipocytokines	B-T116
and	O
infant growth	B-T039
and	O
body composition	B-T032
in	O
the	O
first 6 months of life	B-T033
Much	O
is	O
to	O
be	O
learnt	O
about	O
human breast milk	B-T109
(	O
HBM	B-T109
).	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
HBM	B-T109
by	O
investigating	O
the	O
role	O
of	O
maternal	B-T033
body mass index	B-T201
(	O
BMI	B-T201
),	O
sex	B-T032
and	O
stage of lactation	B-T042
(month	O
1	O
vs.	O
6)	O
on	O
HBM	B-T109
insulin	B-T116
,	O
glucose	B-T109
,	O
leptin	B-T116
,	O
IL-6	B-T116
and	O
TNF-α	B-T116
and	O
their	O
associations	B-T080
with	O
infant	B-T100
body composition	B-T032
.	O
Thirty-seven	O
exclusively	O
breastfeeding infants	B-T033
(n	O
=	O
37;	O
16♀,	O
21♂),	O
and	O
their	O
mothers	B-T033
(19-47	O
kg	O
m(-2))	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	B-T042
.	O
Infants	B-T100
had	O
body composition measured	B-T201
(using	O
dual-energy X-ray absorptiometry	B-T060
)	O
and	O
HBM	B-T109
collected.	O
A	O
significant	O
interaction	B-T169
between	O
maternal	B-T033
BMI	B-T201
and	O
infant sex	B-T032
on	O
insulin levels	B-T059
(p	O
=	O
0.0322)	O
was	O
observed	O
such	O
that	O
insulin was 229% higher	B-T034
in	O
obese	B-T047
mothers	B-T099
nursing	O
female infants	B-T033
than	O
in	O
normal weight	B-T033
mothers	B-T099
nursing	B-T040
nursing	B-T040
female infants	B-T033
and	O
179%	O
higher	O
than	O
obese	B-T047
mothers	B-T099
nursing	O
male infants	B-T033
.	O
For	O
leptin	B-T116
,	O
a	O
significant	O
association	B-T080
with	O
BMI	B-T201
category	O
was	O
observed	O
(p	O
<	O
0.0001)	O
such	O
that	O
overweight	B-T184
and	O
obese	B-T047
mothers	B-T099
had	O
96.5%	O
and	O
315.1%	O
higher leptin levels	B-T033
than	O
normal weight	B-T033
mothers	B-T099
,	O
respectively.	O
Leptin	B-T116
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
(p	O
=	O
0.0004)	O
33.7%	O
decrease	O
from	O
months	O
1	O
to	O
6,	O
controlling	O
for	O
BMI	B-T201
category	O
and	O
sex	B-T032
.	O
A	O
significant	O
inverse	B-T080
relationship	B-T080
between	O
month	O
1	O
leptin	B-T116
levels	B-T080
and	O
infant length	B-T033
(p	O
=	O
0.0257),	O
percent fat	B-T033
(p	O
=	O
0.0223),	O
total fat mass	B-T032
(p	O
=	O
0.0226)	O
and	O
trunk fat mass	B-T032
(p	O
=	O
0.0111)	O
at	O
month	O
6	O
was	O
also	O
found.	O
No	O
associations	B-T080
or	O
interactions	B-T169
were	O
observed	O
for	O
glucose	B-T109
,	O
TNF-α	B-T116
or	O
IL-6	B-T116
.	O
These	O
data	O
demonstrate	O
that	O
maternal	B-T033
BMI	B-T201
,	O
infant	B-T100
sex	B-T032
and	O
stage of lactation	B-T042
affect	O
the	O
compositional	O
make-up	O
of	O
insulin	B-T116
and	O
leptin	B-T116
.	O

Aryl hydrocarbon receptor (AhR) rs2066853	B-T028
gene polymorphism	B-T045
association	O
with	O
infertile	B-T046
oligoasthenoteratozoospermic	B-T047
men	B-T098
and	O
seminal	B-T201
oxidative stress	B-T049
This	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl hydrocarbon receptor (AhR) rs2066853	B-T028
gene polymorphism	B-T045
with	O
infertile	B-T046
oligoasthenoteratozoospermic	B-T047
(	O
OAT	B-T047
)	O
men	B-T098
and	O
seminal	B-T201
oxidative stress	B-T049
(	O
OS	B-T049
).	O
A	O
total	O
of	O
170	O
Egyptian men	B-T098
were	O
allocated	O
according	O
to	O
their	O
semen analysis	B-T059
into	O
fertile	B-T040
normozoospermic controls	B-T033
(n	O
=	O
50)	O
and	O
infertile	B-T046
OAT	B-T047
men	B-T098
(n	O
=	O
120).	O
They	O
were	O
subjected	O
to	O
history taking	B-T058
,	O
clinical examination	B-T201
,	O
semen analysis	B-T059
,	O
estimation	B-T081
of	O
seminal	B-T201
glutathione peroxidase	B-T116
(	O
GPx	B-T116
),	O
and	O
malondialdehyde	B-T109
(	O
MDA	B-T109
).	O
AhR rs2066853	B-T028
gene polymorphism	B-T045
was	O
identified	O
in	O
the	O
blood	B-T031
by	O
PCR	B-T063
-	O
RFLP	B-T049
.	O
Comparing	O
infertile	B-T046
OAT	B-T047
men	B-T098
with	O
fertile	B-T040
controls	B-T096
,	O
AhR rs2066853	B-T028
genotypes	B-T032
showed	O
decreased	B-T081
prevalence	B-T081
for	O
wild	B-T028
homozygous genotype GG	B-T032
(35.8	O
vs	O
56%)	O
and	O
for	O
heterozygous genotype GA	B-T032
(17.5	O
vs	O
30%)	O
and	O
an	O
increased	B-T081
prevalence	B-T081
for	O
homozygous genotype AA	B-T032
(46.7	O
vs	O
14%).	O
Distribution	O
of	O
alleles	B-T028
of	O
AhR rs2066853	B-T028
among	O
OAT	B-T047
men	B-T098
compared	O
with	O
fertile	B-T040
men	B-T098
showed	O
decreased	B-T081
prevalence	B-T081
of	O
G allele	B-T028
(44.6	O
vs	O
71%)	O
and	O
an	O
increased	B-T081
prevalence	B-T081
of	O
A allele	B-T028
(55.4	O
vs	O
29%).	O
Seminal	B-T201
MDA	B-T109
demonstrated	O
significant	O
increase	B-T081
whereas	O
seminal	B-T201
GPx	B-T116
demonstrated	O
significant	O
decrease	B-T081
in	O
cases	O
with	O
AA	B-T032
and	O
GA	B-T032
/	O
AA genotypes	B-T032
compared	O
to	O
cases	O
with	O
GG genotype	B-T032
.	O
It	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
AhR rs2066853	B-T028
genotype	B-T032
polymorphism	B-T045
with	O
decreased	B-T081
sperm	B-T025
parameters	O
as	O
well	O
as	O
increased	B-T081
seminal	B-T201
oxidative stress	B-T049
in	O
infertile	B-T046
OAT	B-T047
men	B-T098
.	O

Associations	B-T080
of	O
gender	B-T032
and	O
a	O
proxy	B-T096
of	O
female	B-T032
menopausal status	B-T201
with	O
histological	B-T169
features	B-T080
of	O
drug-induced liver injury	B-T047
Gender	B-T032
and	O
menopause	B-T039
may	O
contribute	O
to	O
type	B-T080
and	O
severity	B-T080
of	O
drug-induced liver injury	B-T047
(	O
DILI	B-T047
)	O
by	O
influencing	B-T077
host	B-T001
responses	B-T033
to	O
injury	B-T037
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
assess	B-T052
the	O
associations	B-T080
of	O
gender	B-T032
and	O
female	B-T032
age	B-T032
50	O
[a	O
proxy	B-T096
of	O
menopause	B-T039
]	O
with	O
histological	B-T169
features	B-T080
of	O
liver injury	B-T037
in	O
212	O
adults	B-T100
enrolled	O
in	O
the	O
Drug-Induced Liver Injury	B-T047
Network	B-T169
(	O
DILIN	B-T169
)	O
registry	B-T170
.	O
All	O
participants	B-T098
had	O
a	O
causality	B-T169
score	B-T081
of	O
at	O
least	O
'	O
probable	B-T033
',	O
a	O
liver biopsy	B-T060
within	O
30	O
days	O
of	O
DILI	B-T047
onset,	O
and	O
no	O
prior	O
chronic liver disease	B-T047
.	O
Biochemical	B-T169
and	O
histological	B-T169
injury	B-T037
types	B-T080
were	O
classified	O
as	O
hepatocellular	B-T046
or	O
cholestatic/mixed injury	B-T047
.	O
The	O
cohort	B-T098
was	O
divided	B-T169
into	O
three	O
gender	B-T032
/	O
age	B-T032
categories	B-T170
:	O
men	B-T098
(41.0%),	O
women	B-T098
<50	O
years	O
(27.4%)	O
and	O
women	B-T098
≥50	O
years	O
of	O
age	B-T032
(31.6%).	O
Interaction	B-T169
of	O
gender	B-T032
and	O
age	B-T032
category	B-T170
(≥50	O
or	O
not)	O
was	O
assessed	B-T052
.	O
Hepatocellular injury	B-T046
was	O
more	O
prevalent	O
in	O
women	B-T098
<50	O
years	O
vs.	O
others	O
(P=.002).	O
After	O
adjusting	O
for	O
biochemical	B-T169
injury	B-T037
types	B-T080
,	O
black race	B-T098
and	O
possible	B-T033
ageing	B-T040
effects	B-T080
,	O
more	O
severe	B-T080
interface	O
hepatitis	B-T047
was	O
noted	O
in	O
biopsies	B-T060
of	O
women	B-T098
<50	O
years	O
compared	B-T052
to	O
those	O
of	O
men	B-T098
and	O
women	B-T098
≥50	O
years	O
(P=.009	O
and	O
P=.055	O
respectively).	O
Compared	B-T052
to	O
those	O
of	O
men	B-T098
,	O
biopsies	B-T060
of	O
women	B-T098
showed	O
greater	B-T081
plasma cell infiltration	B-T047
,	O
hepatocyte apoptosis	B-T043
,	O
hepatocyte	B-T025
rosettes	B-T033
and	O
lobular	B-T080
disarray	O
but	O
less	O
iron	B-T121
-	O
positive	B-T033
hepatocytes	B-T025
and	O
histological	B-T169
cholestasis	B-T047
(P<.05).	O
These	O
associations	B-T080
persisted	O
after	O
excluding	O
cases	B-T169
of	O
amoxicillin/clavulanic acid	B-T121
,	O
anabolic steroids	B-T109
or	O
nitrofurantoin	B-T109
DILI	B-T047
which	O
showed	O
gender	B-T032
-specific	O
distributions	B-T169
.	O
Gender	B-T032
and	O
a	O
proxy	B-T096
of	O
menopause	B-T039
were	O
associated with	B-T080
various	O
features	B-T080
of	O
inflammation	B-T046
and	O
injury	B-T037
in	O
DILI	B-T047
.	O

A	O
Novel	O
Potent	O
Anticancer Compound	B-T109
Optimized	O
from	O
a	O
Natural	B-T169
Oridonin	B-T109
Scaffold	O
Induces	O
Apoptosis	B-T043
and	O
Cell Cycle Arrest	B-T043
through	O
the	O
Mitochondrial Pathway	B-T045
The	O
cytotoxicity	B-T049
of	O
the	O
natural	B-T169
ent-kaurene diterpenoid	B-T121
,	O
oridonin	B-T109
,	O
has	O
been	O
extensively	O
studied.	O
However,	O
the	O
application	O
of	O
oridonin	B-T109
for	O
cancer therapy	B-T061
was	O
hampered	O
primarily	O
by	O
its	O
moderate potency	B-T038
.	O
In	O
this	O
study,	O
a	O
series	O
of	O
oridonin	B-T109
A-ring modified analogues, and their derivatives	B-T104
bearing	O
various	O
substituents on 14-OH position	B-T104
,	O
were	O
designed,	O
synthesized	B-T052
,	O
and	O
evaluated	B-T058
for	O
anticancer	B-T109
efficacy	B-T080
.	O
Some	O
of	O
the	O
derivatives	B-T104
were	O
significantly	O
more	O
potent	O
than	O
oridonin	B-T109
against	O
both	O
drug	B-T121
-	O
sensitive	B-T169
and	O
drug-resistant	B-T038
cancer cells	B-T025
.	O
The	O
most	O
potent	O
compound, 13p	B-T109
,	O
was	O
200-fold	B-T079
more	O
efficacious	B-T080
than	O
oridonin	B-T109
in	O
MCF-7 cancer cells	B-T025
.	O
Furthermore,	O
13p	B-T109
induced	O
apoptosis	B-T043
and	O
cell cycle arrest	B-T043
at	O
the	O
G2/M phase	B-T043
.	O
A	O
decrease	O
in	O
mitochondrial membrane potential	B-T043
and	O
an	O
increase	O
in	O
Bax/Bcl-2	B-T116
ratio,	O
accompanied	O
by	O
activated caspase-3	B-T116
cleavage	B-T044
,	O
were	O
observed	O
in	O
MCF-7 cells	B-T025
after	O
treatment	B-T061
with	O
13p	B-T109
,	O
suggesting	O
that	O
the	O
mitochondrial pathway	B-T045
was	O
involved	O
in	O
the	O
13p	B-T109
-mediated	O
apoptosis	B-T043
.	O
Moreover,	O
13p	B-T109
significantly	O
inhibited	O
tumor growth	B-T191
in	O
mouse	B-T015
xenograft models	B-T050
and	O
had	O
no observable toxic effect	B-T184
.	O

Stromal alterations	B-T033
in	O
ovarian cancers	B-T191
via	O
wavelength	B-T081
dependent	B-T080
Second Harmonic Generation microscopy	B-T059
and	O
optical scattering	B-T067
Ovarian cancer	B-T191
remains	O
the	O
most	O
deadly	O
gynecological	B-T091
cancer	B-T191
with	O
a	O
poor	O
aggregate	O
survival rate	B-T081
;	O
however,	O
the	O
specific rates	B-T081
are	O
highly	O
dependent	B-T080
on	O
the	O
stage	O
of	O
the	O
disease	B-T047
upon	O
diagnosis	B-T033
.	O
Current	O
screening	B-T058
and	O
imaging tools	B-T074
are	O
insufficient	O
to	O
detect	O
early lesions	B-T033
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	B-T185
of	O
ovarian cancer	B-T191
that	O
may	O
benefit	O
from	O
specific	O
treatments	B-T061
.	O
As	O
an	O
alternative	O
to	O
current	O
screening	B-T058
and	O
imaging tools	B-T074
,	O
we	O
utilized	O
wavelength	B-T081
dependent	B-T080
collagen	B-T116
-specific	O
Second Harmonic Generation (SHG) imaging microscopy	B-T059
and	O
optical scattering measurements	B-T059
to	O
probe	O
the	O
structural	B-T116
differences	B-T080
in	O
the	O
extracellular matrix	B-T024
(	O
ECM	B-T024
)	O
of	O
normal	O
stroma	B-T023
,	O
benign tumors	B-T191
,	O
endometrioid tumors	B-T191
,	O
and	O
low	B-T191
and	O
high-grade serous tumors	B-T191
.	O
The	O
SHG	B-T059
signatures	B-T169
of	O
the	O
emission	O
directionality	O
and	O
conversion	B-T169
efficiency	B-T081
as	O
well	O
as	O
the	O
optical scattering	B-T067
are	O
related	O
to	O
the	O
organization	B-T169
of	O
collagen	B-T116
on	O
the	O
sub-micron	B-T081
size scale	B-T170
and	O
encode	O
structural	B-T116
information	B-T078
.	O
The	O
wavelength	B-T081
dependence	B-T080
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	B-T082
and	O
distribution	B-T169
of	O
collagen fibrils	B-T024
/	O
fibers	B-T024
relative	O
to	O
the	O
interrogating	O
wavelengths	B-T081
.	O
We	O
found	O
a	O
strong	O
wavelength	B-T081
dependence	B-T080
of	O
these	O
metrics	B-T024
that	O
are	O
related	O
to	O
significant	O
structural	B-T116
differences	B-T080
in	O
the	O
collagen	B-T116
organization	B-T169
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	B-T185
of	O
type I and II serous tumors	B-T191
.	O
Moreover,	O
type I endometrioid tumors	B-T191
have	O
strongly	O
differing	O
ECM	B-T024
architecture	O
than	O
the	O
serous malignancies	B-T191
.	O
The	O
SHG	B-T059
metrics	B-T024
and	O
optical scattering measurements	B-T059
were	O
used	O
to	O
form	O
a	O
linear discriminant model	B-T170
to	O
classify	O
the	O
tissues	B-T024
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
(>90%)	O
between	O
high-grade serous tumors	B-T191
from	O
the	O
other	O
tissue types	B-T024
.	O
High-grade serous tumors	B-T191
account	O
for	O
~70%	O
of	O
ovarian cancers	B-T191
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological analysis	B-UnknownType
,	O
understanding	O
the	O
etiology	B-T169
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in vivo	B-T062
screening tool	B-T058
.	O
SHG	B-T059
and	O
optical scattering measurements	B-T059
provide	O
sub-resolution	O
information	B-T078
and	O
when	O
combined	O
provide	O
superior diagnostic power	B-T060
over	O
clinical imaging	B-T060
modalities	B-T169
.	O
Additionally	O
the	O
measurements	B-T169
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	B-T185
of	O
ovarian cancer	B-T191
and	O
may	O
potentially	O
assist	O
in	O
treatment protocols	B-T061
.	O
Understanding	O
the	O
altered	B-T078
collagen	B-T116
assembly	O
can	O
supplement	O
histological analysis	B-UnknownType
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	B-T169
.	O
These	O
methods	O
could	O
become	O
an	O
in vivo	B-T062
screening tool	B-T058
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian malignancies	B-T191
can	O
metastasize	B-T191
while	O
undetectable	O
by	O
current	O
clinical imaging	B-T060
resolution.	O

The	O
Role	O
of	O
Metal-on-Metal Bearings	B-T074
in	O
Total Hip Arthroplasty	B-T061
and	O
Hip Resurfacing	B-T061
:	O
Review Article	B-T170
The	O
current	O
role	O
of	O
metal-on-metal (MoM) bearings	B-T074
in	O
hip arthroplasty	B-T061
remains	O
controversial.	O
The	O
low	O
wear	O
offered	O
by	O
MoM bearings	B-T074
compared	O
to	O
metal-on-polyethylene	B-T074
and	O
the	O
possibility	O
of	O
a	O
lower risk of	B-T081
dislocation	B-T037
with	O
larger head sizes	B-T080
,	O
encouraged	O
a	O
trend	B-T079
towards	O
the	O
re-introduction	B-T061
of	O
the	O
MoM bearing	B-T074
couple.	O
However,	O
recent	O
evidence	B-T078
has	O
shown	O
that	O
not	O
all	O
designs	O
of	O
the	O
MoM bearing	B-T074
have	O
been	O
successful	B-T080
.	O
The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
provide	O
an	O
update	O
on	O
the	O
use	O
of	O
MoM bearings	B-T074
and	O
address	O
the	O
following	O
issues:	O
(1)	O
the	O
reintroduction	B-T061
of	O
metal-on-metal bearings	B-T074
in	O
total hip arthroplasty	B-T061
,	O
(2)	O
the	O
failure	O
of	O
metal-on-metal bearings	B-T074
in	O
stemmed total hip arthroplasty	B-T061
,	O
(3)	O
the	O
role	O
of	O
metal-on-metal hip resurfacing	B-T061
in	O
modern	O
orthopaedics	B-T091
and	O
(4)	O
metal-on-metal hip resurfacing	B-T061
versus	O
total hip arthroplasty	B-T061
.	O
A	O
literature	B-T170
search	O
strategy	B-T041
was	O
conducted	O
using	O
various	O
search	O
terms	O
in	O
MEDLINE	B-T170
and	O
Embase	B-T170
.	O
The	O
highest	O
quality articles	B-T170
that	O
met	O
the	O
inclusion criteria	B-T080
and	O
best	O
answered	O
the	O
topics	O
of	O
focus	O
of	O
this	O
review	B-T170
were	O
selected.	O
Key	O
search	O
terms	O
included	O
'	O
metal-on-metal	B-T074
',	O
'	O
total hip arthroplasty	B-T061
'	O
and	O
'	O
hip resurfacing	B-T061
'.	O
The	O
initial	O
search	O
retrieved	O
1240	O
articles	B-T170
.	O
Twenty-two	O
articles	B-T170
were	O
selected	O
and	O
used	O
in	O
the	O
review	B-T170
.	O
Metal-on-metal hip resurfacing	B-T074
is	O
still	O
a	O
suitable	O
treatment	B-T061
option	O
in	O
specific	B-T080
patient populations	B-T081
with	O
the	O
appropriate	B-T080
implant design	B-T061
and	O
surgical	O
skill,	O
while	O
stemmed	O
metal-on-metal total hip arthroplasty	B-T074
should	O
be	O
avoided	O
in	O
all patient populations	B-T081
.	O
Continued	O
follow-up	B-T058
of	O
patients	B-T101
undergoing	O
metal-on-metal hip resurfacing	B-T061
is	O
critical	B-T080
in	O
order	O
to	O
further	O
understand	O
the	O
long-term	B-T079
outcomes	B-T080
of	O
these	O
patients	B-T101
and	O
why	O
certain	O
complications	B-T046
tend	O
to	O
occur	O
with	O
this	O
procedure.	O

Morphogenetic	B-T040
Alterations	B-T078
of	O
Alternaria alternata	B-T004
Exposed to	B-T080
Dicarboximide Fungicide	B-T131
,	O
Iprodione	B-T109
Fungicide-resistant	B-T169
Alternaria alternata	B-T004
impede	O
the	O
practical	O
control	B-T169
of	O
the	O
Alternaria diseases	B-T047
in	O
crop	B-T002
fields	B-T090
.	O
This	O
study	O
aimed	O
to	O
investigate	B-T169
cytological	B-T169
fungicide	B-T131
resistance	B-T039
mechanisms	B-T169
of	O
A. alternata	B-T004
against	O
dicarboximide fungicide	B-T131
iprodione	B-T109
.	O
A. alternata	B-T004
isolated	B-T169
from	O
cactus	B-T002
brown spot	B-T077
was	O
cultured	B-T059
on	O
potato-dextrose agar	B-T130
(	O
PDA	B-T130
)	O
with	O
or	O
without	B-T080
iprodione	B-T109
,	O
and	O
the	O
fungal cultures	B-T059
with	O
different	B-T080
growth	B-T040
characteristics	B-T080
from	O
no	B-T034
,	O
initial	B-T079
and	O
full	B-T080
growth	B-T040
were	O
observed	B-T169
by	O
light	B-T059
and	O
electron microscopy	B-T059
.	O
Mycelia	B-T004
began	O
to	O
grow	B-T040
from	O
one day after incubation	B-T079
(	O
DAI	B-T079
)	O
and	O
continued	B-T078
to	O
be	O
in	O
full	B-T080
growth	B-T040
(	O
control-growth	B-T040
,	O
Con-G	B-T040
)	O
on	O
PDA	B-T130
without	O
fungicide	B-T131
,	O
while	O
on	O
PDA	B-T130
with	O
iprodione	B-T109
,	O
no fungal growth	B-T034
(	O
iprodione-no growth	B-T034
,	O
Ipr-N	B-T034
)	O
occurred	O
for	O
the	O
first	O
3	O
DAI	B-T079
,	O
but	O
once	O
the	O
initial	B-T079
growth	B-T040
(	O
iprodione-initial growth	B-T040
,	O
Ipr-I	B-T040
)	O
began	O
at	O
4-5	O
DAI	B-T079
,	O
the	O
colonies	B-T025
grew	O
and	O
expanded	B-T082
continuously	B-T078
to	O
be	O
in	O
full	B-T080
growth	B-T040
(	O
iprodione-growth	B-T040
,	O
Ipr-G	B-T040
),	O
suggesting	O
Ipr-I	B-T040
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	B-T040
changes	B-T169
resisting	B-T039
fungicidal	B-T044
toxicity	B-T080
.	O
Con-G	B-T040
formed	O
multicellular conidia	B-T004
with	O
cell walls	B-T026
and	O
septa	B-T026
and	O
intact	B-T080
dense	B-T080
cytoplasm	B-T026
.	O
In	O
Ipr-N	B-T034
,	O
fungal	B-T004
sporulation	B-T043
was	O
inhibited	B-T080
by	O
forming	O
mostly	O
undeveloped	B-T033
unicellular conidia	B-T004
with	O
degraded	B-T033
and	O
necrotic	B-T042
cytoplasm	B-T026
.	O
However,	O
in	O
Ipr-I	B-T040
,	O
conspicuous cellular changes	B-T049
occurred	O
during	O
sporulation	B-T043
by	O
forming	O
multicellular conidia	B-T004
with	O
double layered	B-T033
(	O
thickened	B-T033
)	O
cell walls	B-T026
and	O
accumulation	B-T033
of	O
proliferated	B-T169
lipid bodies	B-T026
in	O
the	O
conidial	B-T004
cytoplasm	B-T026
,	O
which	O
may	O
inhibit	B-T080
the	O
penetration	B-T169
of	O
the	O
fungicide	B-T131
into	O
conidial	B-T004
cells	B-T025
,	O
reducing	O
fungicide	B-T131
-	O
associated	B-T080
toxicity	B-T080
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	B-T081
and	O
nutritional	B-T080
sources	B-T033
,	O
respectively,	O
for	O
the	O
further	O
fungal	B-T004
growth	B-T040
to	O
form	O
mature	B-T079
colonies	B-T025
as	O
in	O
Ipr-G	B-T040
that	O
formed	O
multicellular conidia	B-T004
with	O
cell walls	B-T026
and	O
intact	B-T080
cytoplasm	B-T026
with	O
lipid bodies	B-T026
as	O
in	O
Con-G	B-T040
.	O

Limits	O
of	O
the	O
possible:	O
diagnostic image	B-T078
quality	B-T080
in	O
coronary angiography	B-T060
with	O
third-generation dual-source CT	B-T060
The	O
usage	B-T169
of	O
coronary CT angiography	B-T060
(	O
CTA	B-T060
)	O
is	O
appropriate	O
in	O
patients	B-T101
with	O
acute	B-T184
or	O
chronic chest pain	B-T184
;	O
however	O
the	O
diagnostic accuracy	B-T080
may	O
be	O
challenged	O
with	O
increased	O
Agatston score	B-T081
(	O
AS	B-T081
),	O
increased	O
heart rate	B-T201
,	O
arrhythmia	B-T033
and	O
severe obesity	B-T047
.	O
Thus,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third-generation dual-source CT	B-T060
(	O
DSCT	B-T060
)	O
for	O
CTA	B-T060
in	O
a	O
'real-life'	O
clinical setting	B-T082
.	O
Two	O
hundred	O
and	O
sixty-eight	O
consecutive	O
patients	B-T101
(age:	O
67	O
±	O
10	O
years;	O
BMI	B-T201
:	O
27	O
±	O
5	O
kg/m²;	O
61%	O
male	B-T098
)	O
undergoing	O
clinically	O
indicated	O
CTA	B-T060
with	O
DSCT	B-T060
were	O
included	O
in	O
the	O
retrospective single-center analysis	B-T062
.	O
A	O
contrast-enhanced volume dataset	B-T170
was	O
acquired	O
in	O
sequential	B-T060
(	O
SSM	B-T060
)	O
(n	O
=	O
151)	O
or	O
helical scan mode	B-T060
(	O
HSM	B-T060
)	O
(n	O
=	O
117).	O
Coronary segments	B-T023
were	O
classified	O
in	O
diagnostic	B-T080
or	O
non-diagnostic image quality	B-T080
.	O
A	O
subset	O
underwent	O
invasive angiography	B-T060
to	O
determine	O
the	O
diagnostic accuracy	B-T080
of	O
CTA	B-T060
.	O
SSM	B-T060
(96.8	O
±	O
6%)	O
and	O
HSM	B-T060
(97.5	O
±	O
8%)	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic image	B-T078
quality	B-T080
.	O
However,	O
AS	B-T081
had	O
significant	O
influence	B-T077
on	O
diagnostic image	B-T078
quality	B-T080
exclusively	O
in	O
SSM	B-T060
(B	O
=	O
0.003;	O
p	O
=	O
0.0001),	O
but	O
not	O
in	O
HSM	B-T060
.	O
Diagnostic image	B-T078
quality	B-T080
significantly	O
decreased	O
in	O
SSM	B-T060
in	O
patients	B-T101
with	O
AS	B-T081
≥2,000	O
(p	O
=	O
0.03).	O
SSM	B-T060
(	O
sensitivity	B-T081
:	O
93.9%;	O
specificity	B-T081
:	O
96.7%;	O
PPV	B-T081
:	O
88.6%;	O
NPV	B-T081
:	O
98.3%)	O
and	O
HSM	B-T060
(	O
sensitivity	B-T081
:	O
97.4%;	O
specificity	B-T081
:	O
94.3%;	O
PPV	B-T081
:	O
86.0%;	O
NPV	B-T081
:	O
99.0%)	O
provided	O
comparable	O
diagnostic accuracy	B-T080
(p	O
=	O
n.s.).	O
SSM	B-T060
yielded	O
significantly	O
lower	O
radiation doses	B-T081
as	O
compared	O
to	O
HSM	B-T060
(2.1	O
±	O
2.0	O
vs.	O
5.1	O
±	O
3.3	O
mSv;	O
p	O
=	O
0.0001)	O
in	O
age	B-T098
and	O
BMI	B-T201
-matched	O
cohorts	B-T098
.	O
SSM	B-T060
in	O
third-generation DSCT	B-T060
enables	O
significant	O
dose	B-T081
savings	O
and	O
provides	O
robust	O
diagnostic image	B-T078
quality	B-T080
in	O
patients	B-T101
with	O
AS	B-T081
≤2000	O
independent	O
of	O
heart rate	B-T201
,	O
heart rhythm	B-T042
or	O
obesity	B-T047
.	O

Antagonistic	B-T044
Self-Organizing Patterning	B-T045
Systems	O
Control	B-T169
Maintenance	B-T039
and	O
Regeneration	B-T042
of	O
the	O
Anteroposterior	B-T082
Axis	B-T082
in	O
Planarians	B-T204
Planarian	B-T204
flatworms	B-T204
maintain	B-T039
their	O
body	B-T017
plan	O
in	O
the	O
face	O
of	O
constant	O
internal	O
turnover	O
and	O
can	O
regenerate	B-T169
from	O
arbitrary	B-T080
tissue	B-T024
fragments	B-T031
.	O
Both	O
phenomena	B-T067
require	O
self-maintaining	B-T052
and	O
self-organizing patterning	B-T045
mechanisms	B-T169
,	O
the	O
molecular	B-T080
mechanisms	B-T169
of	O
which	O
remain	O
poorly	O
understood.	O
We	O
show	O
that	O
a	O
morphogenic	B-T044
gradient	B-T081
of	O
canonical Wnt signaling	B-T044
patterns	O
gene expression	B-T045
along	O
the	O
planarian	B-T204
anteroposterior	B-T082
(	O
A/P	B-T082
)	O
axis	B-T082
.	O
Our	O
results	B-T033
demonstrate	O
that	O
gradient	B-T081
formation	B-T169
likely	O
occurs	O
autonomously	B-T169
in	O
the	O
tail	B-T023
and	O
that	O
an	O
autoregulatory	B-T038
module	O
of	O
Wnt	B-T116
-mediated	O
Wnt	B-T028
expression	B-T045
both	O
shapes	O
the	O
gradient	B-T081
at	O
steady state	B-T070
and	O
governs	O
its	O
re-establishment	O
during	O
regeneration	B-T042
.	O
Functional	B-T169
antagonism	B-T044
between	O
the	O
tail	B-T023
Wnt	B-T116
gradient	B-T081
and	O
an	O
unknown	B-T080
head	B-T029
patterning	B-T045
system	O
further	O
determines	O
the	O
spatial	B-T082
proportions	B-T081
of	O
the	O
planarian	B-T204
A/P	B-T082
axis	B-T082
and	O
mediates	O
mutually	B-T080
exclusive	B-T078
molecular fate	B-T044
choices	O
during	B-T079
regeneration	B-T042
.	O
Overall,	O
our	O
results	B-T033
suggest	O
that	O
the	O
planarian	B-T204
A/P	B-T082
axis	B-T082
is	O
patterned	O
by	O
self-organizing patterning	B-T045
systems	O
deployed	B-T052
from	O
either	O
end	O
that	O
are	O
functionally	B-T169
coupled	B-T169
by	O
mutual	B-T080
antagonism	B-T044
.	O

Characterization	B-T052
and	O
Ectopic Expression	B-T045
of	O
CoWRI1	B-T028
,	O
an	O
AP2/EREBP	B-T028
Domain-Containing	O
Transcription Factor	B-T116
from	O
Coconut	B-T002
(	O
Cocos nucifera L	B-T002
.)	O
Endosperm	B-T002
,	O
Changes	O
the	O
Seeds	B-T002
Oil	B-T109
Content	O
in	O
Transgenic	B-T002
Arabidopsis thaliana	B-T002
and	O
Rice	B-T002
(	O
Oryza sativa L	B-T002
.)	O
Coconut	B-T002
(	O
Cocos nucifera L.	B-T002
)	O
is	O
a	O
key	O
tropical	B-T070
crop	B-T002
and	O
a	O
member	O
of	O
the	O
monocotyledonous family	B-T077
Arecaceae	B-T002
(	O
Palmaceae	B-T002
).	O
Few	O
genes	B-T028
and	O
related	O
metabolic processes	B-T040
involved	O
in	O
coconut	B-T002
endosperm	B-T002
development	O
have	O
been	O
investigated	B-T169
.	O
In	O
this	O
study	B-T062
,	O
a	O
new	O
member	O
of	O
the	O
WRI1	B-T028
gene family	B-T028
was	O
isolated	O
from	O
coconut	B-T002
endosperm	B-T002
and	O
was	O
named	O
CoWRI1	B-T028
.	O
Its	O
transcriptional	B-T045
activities	B-T052
and	O
interactions	B-T169
with	O
the	O
acetyl-CoA carboxylase	B-T116
(	O
BCCP2	B-T116
)	O
promoter	B-T114
of	O
CoWRI1	B-T028
were	O
confirmed	O
by	O
the	O
yeast two-hybrid	B-T063
and	O
yeast one-hybrid	B-T063
approaches,	O
respectively.	O
Functional	O
characterization	B-T052
was	O
carried	O
out	O
through	O
seed	B-T002
-specific	O
expression	B-T045
in	O
Arabidopsis	B-T002
and	O
endosperm	B-T002
-specific	O
expression	B-T045
in	O
rice	B-T002
.	O
In	O
transgenic	B-T002
Arabidopsis	B-T002
,	O
high	O
over-expressions	B-T045
of	O
CoWRI1	B-T028
in	O
seven	O
independent	O
T2	B-T002
lines	B-T002
were	O
detected	O
by	O
quantitative real-time PCR	B-T063
.	O
The	O
relative	O
mRNA	B-T114
accumulation	O
of	O
genes	B-T028
encoding	B-T052
enzymes	B-T116
involved	O
in	O
either	O
fatty acid biosynthesis	B-T044
or	O
triacylglycerols	B-T109
assembly	O
(	O
BCCP2	B-T028
,	O
KASI	B-T028
,	O
MAT	B-T028
,	O
ENR	B-T028
,	O
FATA	B-T028
,	O
and	O
GPDH	B-T028
)	O
were	O
also	O
assayed	B-T059
in	O
mature	O
seeds	B-T002
.	O
Furthermore,	O
lipid	B-T109
and	O
fatty acids	B-T109
C16:0	B-T109
and	O
C18:0	B-T109
significantly	O
increased.	O
In	O
two	O
homozygous	B-T032
T2	B-T002
transgenic	B-T002
rice lines	B-T002
(	O
G5	B-T002
and	O
G2	B-T002
),	O
different	O
CoWRI1	B-T028
expression	B-T045
levels	O
were	O
detected,	O
but	O
no	O
CoWRI1	B-T028
transcripts	B-T114
were	O
detected	O
in	O
the	O
wild type	B-T028
.	O
Analyses	B-T062
of	O
the	O
seed	B-T002
oil	B-T109
content,	O
starch	B-T109
content,	O
and	O
total	O
protein	B-T116
content	O
indicated	O
that	O
the	O
two	O
T2	B-T002
transgenic lines	B-T002
showed	O
a	O
significant	O
increase	O
(P	O
<	O
0.05)	O
in	O
seed	B-T002
oil	B-T109
content.	O
The	O
transgenic lines	B-T002
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	B-T109
content,	O
whereas	O
total	O
protein	B-T116
content	O
decreased	O
significantly.	O
Further	O
analysis	B-T062
of	O
the	O
fatty acid	B-T109
composition	O
revealed	O
that	O
palmitic acid	B-T109
(	O
C16:0	B-T109
)	O
and	O
linolenic acid	B-T109
(	O
C18:3	B-T109
)	O
increased	O
significantly	O
in	O
the	O
seeds	B-T002
of	O
the	O
transgenic	B-T002
rice lines	B-T002
,	O
but	O
oleic acid	B-T109
(	O
C18:1	B-T109
)	O
levels	O
significantly	O
declined.	O

Tooth Discoloration	B-T033
Resulting	B-T169
from	O
a	O
Nano	B-T081
Zinc Oxide-Eugenol	B-T122
Sealer	B-T122
A	O
desirable	O
quality	B-T080
of	O
any	O
endodontic sealer	B-T122
is	O
its	O
ability	O
to	O
be	O
tooth color	B-T033
friendly	B-T080
.	O
Therefore	O
the	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
evaluate	O
the	O
tooth discoloration	B-T033
potential	B-T080
of	O
a	O
nano	B-T081
zinc oxide-eugenol	B-T122
(	O
NZOE	B-T122
)	O
sealer	B-T122
.	O
In	O
order	O
to	O
evaluate	O
tooth discoloration	B-T033
,	O
the	O
pulp chamber	B-T030
of	O
60	O
human	B-T016
maxillary central	B-T023
and	O
lateral incisors	B-T023
were	O
filled	B-T052
with	O
one	O
of	O
the	O
sealers	B-T122
,	O
naming	O
AH-26	B-T104
(	O
resin-based sealer	B-T104
),	O
Pulpdent	B-T122
sealer	B-T122
(	O
ZOE	B-T122
-based)	O
and	O
a	O
NZOE	B-T122
experimental	O
sealer	B-T122
.	O
Color	B-T080
measurements	B-T169
was	O
assessed	O
at	O
the	O
baseline	B-T081
(	O
before placement	B-T080
of	O
sealers	B-T122
)	O
(T0),	O
24	O
h	B-T079
(T1)	O
and	O
72	O
h	B-T079
(T2)	O
h	B-T079
,	O
1-	O
week	B-T079
(T3),	O
and	O
1-	O
month	B-T079
(T4)	O
after	O
the	O
placement	O
of	O
sealers	B-T122
using	O
the	O
Easy Shade spectrophotometer	B-T074
.	O
Data	B-T078
were	O
analyzed	B-T062
in	O
SPSS software	B-T073
using	O
one-way ANOVA	B-T081
,	O
and	O
repeated	O
measured	O
ANOVA	B-T081
.	O
No	O
significant	O
differences	O
were	O
observed	B-T169
when	O
the	O
paired comparison test	B-T170
was	O
performed	O
(P>0.05).	O
The	O
tested	O
NZOE	B-T122
sealer	B-T122
had	O
similar	O
tooth discoloration	B-T033
potential	B-T080
in	O
comparison	B-T052
with	O
AH-26	B-T104
and	O
ZOE	B-T122
sealer	B-T122
.	O

On	O
the	O
identity	B-T078
of	O
the	O
Palearctic	B-UnknownType
species	B-T185
of	O
the	O
wolf spider	B-T204
genus	B-T185
<i>	O
Trebacosa	B-T204
</i>(	O
Araneae	B-T204
:	O
Lycosidae	B-T204
)	O
In	O
this	O
paper	B-T170
we	O
propose	O
Trebacosa brunhesi	B-T204
Villepoux,	O
2007	O
as	O
a	O
junior	O
synonym	B-T077
of	O
Trebacosa europaea	B-T204
Szinetár	O
&	O
Kan-csal,	O
2007	O
based	O
on	O
the	O
examination	B-T169
of	O
specimens	B-T167
from	O
all	O
the	O
localities	B-T083
from	O
where	O
those	O
species	B-T185
are	O
known.	O
Illustration	O
of	O
the	O
type	B-T080
species	B-T185
of	O
the	O
genus	B-T185
,	O
Trebacosa marxi	B-T204
(Stone,	O
1890)	O
and	O
specimens	B-T167
from	O
all	O
known	O
localities	B-T083
of	O
T. europaea	B-T204
are	O
given	O
to	O
show	O
both	O
the	O
inter-	B-T080
and	O
the	O
intraspecific differences	B-T080
of	O
the	O
genus	B-T185
.	O
Scanning electron micrographs	B-T059
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	B-T082
of	O
the	O
female's genitalia	B-T023
.	O

A	O
numerical	B-T081
study	B-T062
on	O
the	O
application	O
of	O
the	O
functionally graded materials	B-T073
in	O
the	O
stent	B-T074
design	B-T052
Undesirable	B-T080
deformation	B-T080
of	O
the	O
stent	B-T074
can	O
induce	O
a	O
significant	B-T037
amount	O
of	O
injure	B-T037
not	O
only	O
to	O
the	O
blood vessel	B-T023
but	O
also	O
to	O
the	O
plaque	B-T033
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
reduce/minimize	B-T033
these	O
undesirable	B-T080
deformations	B-T080
by	O
the	O
application	O
of	O
Functionally Graded Materials	B-T073
(	O
FGM	B-T073
).	O
To	O
do	O
this,	O
Finite Element (FE) method	B-T170
was	O
employed	B-T033
to	O
simulate	B-T062
the	O
expansion	B-T169
of	O
a	O
stent	B-T074
and	O
the	O
corresponding	O
displacement	B-T067
of	O
the	O
stenosis	B-T046
plaque	B-T033
.	O
Three	O
hyperelastic	B-T073
plaque	B-T033
types	O
as	O
well	O
as	O
five	O
elastoplastic stents	B-T074
were	O
simulated.	O
Dogboning	B-T169
,	O
foreshortening	B-T033
,	O
maximum	B-T081
stress	B-T033
in	O
the	O
plaque	B-T033
,	O
and	O
the	O
pressure	B-T067
which	O
is	O
needed	O
to	O
fully	O
expand	B-T082
the	O
stent	B-T074
for	O
different	O
stent	B-T074
materials	B-T167
,	O
were	O
acquired.	O
While	O
all	O
FGMs	B-T073
had	O
lower	B-T080
dogboning	B-T169
in	O
comparison	O
to	O
the	O
stents	B-T074
made	O
of	O
the	O
uniform	B-T080
materials	B-T167
,	O
the	O
stent	B-T074
with	O
the	O
lowest	B-T080
heterogeneous index	B-T170
displayed	O
the	O
lowest	B-T080
amount	O
of	O
dogboning	B-T169
.	O
Steel	B-T122
stent	B-T074
showed	O
the	O
lowest	B-T080
foreshortening	B-T033
and	O
fully	O
expansion pressure	B-T081
but	O
the	O
difference	B-T081
was	O
much	O
lower	B-T080
than	O
that	O
the	O
one	O
for	O
dogboning	B-T169
.	O
Therefore,	O
the	O
FGM	B-T073
with	O
the	O
heterogeneous index	B-T170
of	O
0.5	O
is	O
expected	O
to	O
exhibit	O
the	O
most	O
suitable	B-T080
results	B-T169
.	O
In	O
addition,	O
the	O
results	B-T169
revealed	O
that	O
the	O
material	B-T167
parameters	B-T077
has	O
crucial	B-T080
effects	B-T080
on	O
the	O
deformation	B-T080
of	O
the	O
stent	B-T074
and,	O
as	O
a	O
result	B-T169
,	O
as	O
a	O
design	B-T052
point	O
of	O
view	O
the	O
FGM	B-T073
parameters	B-T077
can	O
be	O
tailored	O
to	O
achieve	O
the	O
goal	O
of	O
the	O
biomechanical	B-T081
optimization	B-T052
.	O

Women's	B-T098
perspectives	O
on	O
human papillomavirus	B-T005
self-sampling	B-T060
in	O
the	O
context	O
of	O
the	O
UK	B-T083
cervical	B-T023
screening programme	B-T058
Testing	B-T169
for	O
human papillomavirus	B-T005
(	O
HPV	B-T005
)	O
is	O
being	O
incorporated	O
into	O
the	O
cervical	B-T023
screening programme	B-T058
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
HPV	B-T005
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
HPV	B-T005
self-sampling	B-T060
.	O
In	O
anticipation	O
of	O
this	O
development,	O
we	O
sought	O
to	O
inform	O
future	O
policy	B-T170
and	O
practice	B-T041
by	O
identifying	O
potential	B-T080
barriers	B-T033
to	O
HPV	B-T005
self-sampling	B-T060
.	O
A	O
cross-sectional survey	B-T062
of	O
194	O
women	B-T098
aged	O
20-64	O
years	O
was	O
conducted.	O
Logistic regression analysis	B-UnknownType
was	O
used	O
to	O
identify	O
determinants	B-T169
of	O
self-sampling	B-T060
intentions.	O
A	O
purposive	O
subsample	O
of	O
19	O
women	B-T098
who	O
reported	O
low	O
self-sampling	B-T060
intentions	O
were	O
interviewed.	O
Interviews	B-T052
were	O
framework-analysed.	O
Most	O
survey	B-T170
participants	B-T098
(N=133,	O
69.3%)	O
intended	O
to	O
HPV	B-T005
self-sample.	O
Lower	B-T080
intention	B-T041
was	O
associated with	B-T080
lower	B-T080
self-efficacy	O
(OR=24.96,	O
P≤.001),	O
lower	B-T080
education	B-T065
(OR=6.06,	O
P≤.05)	O
and	O
lower	B-T080
perceived	B-T041
importance	O
of	O
HPV	B-T005
as	O
a	O
cause	O
of	O
cervical cancer	B-T191
(OR=2.33,	O
P≤.05).	O
Interviews	B-T052
revealed	O
personal	B-T032
and	O
system-related	O
barriers	B-T033
.	O
Personal	B-T032
barriers	B-T033
included	O
a	O
lack	O
of	O
knowledge	B-T170
about	O
HPV	B-T005
self-sampling	B-T060
,	O
women's	B-T098
low confidence	B-T033
in	O
their	O
ability	O
to	O
self-sample	O
correctly	O
and	O
low confidence	B-T033
in	O
the	O
subsequent	O
results.	O
System-related	O
factors	O
included	O
a	O
lack of confidence	B-T033
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	B-T023
screening programme	B-T058
,	O
and	O
concerns	O
about	O
sample	B-T167
contamination	B-T078
and	O
identity theft	B-T054
.	O
Insights	O
gained	O
from	O
this	O
research	B-T062
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
HPV	B-T005
self-sampling	B-T060
and	O
to	O
help	O
inform	O
future	O
policy	B-T170
and	O
practice	B-T041
.	O
Personal	B-T032
and	O
system-related barriers	B-T033
including	O
low confidence	B-T033
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	B-T023
screening	B-T058
provision	O
need	O
to	O
be	O
addressed,	O
should	O
HPV	B-T005
self-sampling	B-T060
be	O
incorporated	O
into	O
the	O
cervical	B-T023
screening programme	B-T058
.	O

N-Terminal	B-T087
Hypothesis	B-T078
for	O
Alzheimer's Disease	B-T047
Although	O
the	O
amyloid	B-T116
(	O
abeta peptide	B-T116
,	O
Aβ	B-T116
)	O
hypothesis	B-T078
is	O
25	O
years	B-T079
old,	O
is	O
the	O
dominant	B-T169
model	B-T170
of	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
)	O
pathogenesis	B-T046
,	O
and	O
guides	O
the	O
development	B-T169
of	O
potential	O
treatments	B-T061
,	O
it	O
is	O
still	O
controversial	B-T054
.	O
One	O
possible	O
reason	O
is	O
a	O
lack	B-T080
of	O
a	O
mechanistic path	B-T169
from	O
the	O
cleavage products	B-T167
of	O
the	O
amyloid precursor protein	B-T116
(	O
APP	B-T116
)	O
such	O
as	O
soluble	B-T080
Aβ monomer	B-T116
and	O
soluble	O
molecular	B-T080
fragments	B-T169
to	O
the	O
deleterious effects	B-T080
on	O
synaptic form	B-T042
and	O
function	B-T169
.	O
From	O
a	O
review of	B-T169
the	O
recent	O
literature	B-T170
and	O
our	O
own	O
published work	B-T073
including	O
aggregation kinetics	B-T070
and	O
structural	B-T082
morphology	B-T080
,	O
Aβ	B-T116
clearance	B-T080
,	O
molecular	B-T080
simulations	B-T062
,	O
long-term potentiation	B-T042
measurements	B-T169
with	O
inhibition binding	B-T044
,	O
and	O
the	O
binding	B-T044
of	O
a	O
commercial	O
monoclonal antibody	B-T116
,	O
aducanumab	B-T129
,	O
we	O
hypothesize	B-T078
that	O
the	O
N-terminal domains	B-T087
of	O
neurotoxic	B-T131
Aβ oligomers	B-T116
are	O
implicated	O
in	O
causing	B-T169
the	O
disease	B-T047
.	O

Generation	B-T052
of	O
High-Quality	B-T080
SWATH(®)	B-T170
Acquisition	B-T052
Data	B-T078
for	O
Label-free	B-T033
Quantitative	B-T081
Proteomics Studies	B-T091
Using	O
TripleTOF(®) Mass Spectrometers	B-T074
Data	B-T078
-	O
independent	B-T169
acquisition	B-T052
is	O
a	O
powerful	O
mass spectrometry technique	B-T059
that	O
enables	O
comprehensive	O
MS	B-T059
and	O
MS/MS	B-T063
analysis	B-T062
of	O
all	O
detectable	B-T201
species	B-T071
,	O
providing	O
an	O
information	B-T078
rich	O
data	B-T078
file	O
that	O
can	O
be	O
mined	B-T066
deeply.	O
Here,	O
we	O
describe	O
how	O
to	O
acquire	B-T052
high-quality	B-T080
SWATH(®)	B-T170
Acquisition	B-T052
data	B-T078
to	O
be	O
used	O
for	O
large	B-T081
quantitative	B-T081
proteomic studies	B-T091
.	O
We	O
specifically	O
focus	O
on	O
using	O
variable	B-T080
sized	B-T082
Q1 windows	B-T170
for	O
acquisition	B-T052
of	O
MS/MS	B-T063
data	B-T078
for	O
generating	B-T052
higher	O
specificity	B-T081
quantitative	B-T081
data	B-T078
.	O

A	O
new	O
light	O
on	O
Alkaptonuria	B-T047
:	O
A	O
Fourier-transform infrared microscopy	B-T059
(	O
FTIRM	B-T059
)	O
and	O
low energy X-ray fluorescence microscopy	B-T059
(	O
LEXRF	B-T059
)	O
correlative study	B-T062
on	O
a	O
rare disease	B-T047
Alkaptonuria	B-T047
(	O
AKU	B-T047
)	O
is	O
an	O
ultra-rare disease	B-T047
associated	B-T080
to	O
the	O
lack	B-T080
of	O
an	O
enzyme	B-T116
involved	O
in	O
tyrosine catabolism	B-T044
.	O
This	O
deficiency	B-T169
results	O
in	O
the	O
accumulation	B-T033
of	O
homogentisic acid	B-T109
(	O
HGA	B-T109
)	O
in	O
the	O
form	O
of	O
ochronotic pigment	B-UnknownType
in	O
joint	B-T030
cartilage	B-T024
,	O
leading	O
to	O
a	O
severe	B-T080
arthropathy	B-T047
.	O
Secondary amyloidosis	B-T047
has	O
been	O
also	O
unequivocally	B-T080
assessed	B-T052
as	O
a	O
comorbidity	B-T078
of	O
AKU	B-T047
arthropathy	B-T047
.	O
Composition	O
of	O
ochronotic pigment	B-UnknownType
and	O
how	O
it	O
is	O
structurally	B-T082
related	O
to	O
amyloid	B-T116
is	O
still	O
unknown.	O
We	O
exploited	O
Synchrotron Radiation	B-T067
Infrared	B-T059
and	O
X-Ray Fluorescence microscopies	B-T059
in	O
combination	O
with	O
conventional	O
bio-assays	B-T059
and	O
analytical	B-T062
tools	O
to	O
characterize	O
chemical composition	B-T070
and	O
morphology	B-T080
of	O
AKU	B-T047
cartilage	B-T024
.	O
We	O
evinced	B-T169
that	O
AKU	B-T047
cartilage	B-T024
is	O
characterized	O
by	O
proteoglycans	B-T116
depletion	B-T169
,	O
increased Sodium levels	B-T033
,	O
accumulation	B-T033
of	O
lipids	B-T109
in	O
the	O
peri-lacunar regions	B-T030
and	O
amyloid	B-T116
formation	B-T169
.	O
We	O
also	O
highlighted	O
an	O
increase	B-T169
of	O
aromatic compounds	B-T109
and	O
oxygen-containing species	B-T197
,	O
depletion	B-T169
in	O
overall	O
Magnesium	B-T123
content	B-T081
(although	O
localized	B-T082
in	O
the	O
peri-lacunar region	B-T030
)	O
and	O
the	O
presence	B-T033
of	O
calcium carbonate	B-T121
fragments	O
in	O
proximity	B-T082
of	O
cartilage lacunae	B-T030
.	O
We	O
highlighted	O
common	B-T081
features	O
between	O
AKU	B-T047
and	O
arthropathy	B-T047
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	B-T047
,	O
like	O
presence	B-T033
of	O
amyloids	B-T116
and	O
peculiar	B-T033
calcifications	B-T042
.	O
Our	O
analyses	B-T062
provide	O
a	O
unified	O
picture	O
of	O
AKU	B-T047
cartilage	B-T024
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	B-T047
and	O
opening	O
new	B-T080
perspectives.	O
Ochronotic pigment	B-UnknownType
is	O
a	O
hallmark	O
of	O
AKU	B-T047
and	O
responsible	O
of	O
tissue degeneration	B-T042
.	O
Conventional	O
bio-assays	B-T059
have	O
not	O
yet	O
clarified	O
its	O
composition	B-T070
and	O
its	O
structural	B-T082
relationship	B-T080
with	O
amyloids	B-T116
.	O
The	O
present	B-T079
work	B-T062
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	B-T169
of	O
new	O
analytical	B-T062
approaches	O
with	O
standardized	B-T080
analyses	B-T062
.	O

Unbiased estimates	B-T062
of	O
cerebrospinal fluid	B-T031
β-amyloid 1-42	B-T116
cutoffs	B-T169
in	O
a	O
large	O
memory clinic	B-T073
population	B-T098
We	O
sought	O
to	O
define	O
a	O
cutoff	B-T169
for	O
β-amyloid 1-42	B-T116
in	O
cerebrospinal fluid	B-T031
(	O
CSF	B-T031
),	O
a	O
key	O
marker	B-T201
for	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
),	O
with	O
data-driven	B-T080
Gaussian mixture modeling	B-T081
in	O
a	O
memory clinic	B-T073
population	B-T098
.	O
We	O
performed	O
a	O
combined	O
cross-sectional	B-T062
and	O
prospective cohort study	B-T062
.	O
We	O
selected	O
2462	O
subjects	B-T098
with	O
subjective cognitive decline	B-T046
,	O
mild cognitive impairment	B-T048
,	O
AD	B-T047
-type	O
dementia	B-T048
,	O
and	O
dementia	B-T048
other	O
than	O
AD	B-T047
from	O
the	O
Amsterdam	B-UnknownType
Dementia	B-T048
Cohort	B-T098
.	O
We	O
defined	O
CSF	B-T031
β-amyloid 1-42	B-T116
cutoffs	B-T169
by	O
data-driven	B-T080
Gaussian mixture modeling	B-T081
in	O
the	O
total population	B-T081
and	O
in	O
subgroups	B-T185
based	O
on	O
clinical diagnosis	B-T060
,	O
age	B-T032
,	O
and	O
apolipoprotein E (APOE) genotype	B-T059
.	O
We	O
investigated	B-T169
whether	O
abnormal	B-T033
β-amyloid 1-42	B-T116
as	O
defined	O
by	O
the	O
data-driven	B-T080
cutoff	B-T169
could	O
better	O
predict	B-T078
progression	B-T169
to	O
AD	B-T047
-type	O
dementia	B-T048
than	O
abnormal	B-T033
β-amyloid 1-42	B-T116
defined	O
by	O
a	O
clinical diagnosis	B-T060
-based	O
cutoff	B-T169
using	O
Cox proportional hazards regression	B-T081
.	O
In	O
the	O
total	O
group	B-T078
of	O
patients	B-T101
,	O
we	O
found	O
a	O
cutoff	B-T169
for	O
abnormal	B-T033
CSF	B-T031
β-amyloid 1-42	B-T116
of	O
680	O
pg/ml	O
(95%	O
CI	B-T081
660-705	O
pg/ml).	O
Similar	O
cutoffs	B-T169
were	O
found	O
within	O
diagnostic	B-T033
and	O
APOE genotype	B-T059
subgroups	B-T185
.	O
The	O
cutoff	B-T169
was	O
higher	B-T080
in	O
elderly	B-T098
subjects	B-T098
than	O
in	O
younger	O
subjects	B-T098
.	O
The	O
data-driven	B-T080
cutoff	B-T169
was	O
higher	B-T080
than	O
our	O
clinical diagnosis	B-T060
-based	O
cutoff	B-T169
and	O
had	O
a	O
better	O
predictive	B-T080
accuracy	B-T080
for	O
progression	B-T169
to	O
AD	B-T047
-type	O
dementia	B-T048
in	O
nondemented	O
subjects	B-T098
(	O
HR	B-T081
7.6	O
versus	O
5.2,	O
p	B-T081
<	O
0.01).	O
Mixture modeling	B-T081
is	O
a	O
robust	B-T080
method	B-T170
to	O
determine	O
cutoffs	B-T169
for	O
CSF	B-T031
β-amyloid 1-42	B-T116
.	O
It	O
might	O
better	O
capture	O
biological	B-T080
changes	B-T169
that	O
are	O
related	O
to	O
AD	B-T047
than	O
cutoffs	B-T169
based	O
on	O
clinical diagnosis	B-T060
.	O

Identification	B-T080
of	O
the	O
anti-mycobacterial	B-T121
functional	B-T169
properties	B-T080
of	O
piperidinol derivatives	B-T121
Tuberculosis	B-T047
(	O
TB	B-T047
)	O
remains	O
a	O
major	O
global	B-T080
health	B-T078
threat	B-T078
and	O
is	O
now	O
the	O
leading	O
cause of death	B-T033
from	O
a	O
single	O
infectious agent	B-T001
worldwide	B-T080
.	O
The	O
current	O
TB	B-T047
drug	B-T121
regimen	B-T061
is	O
inadequate	B-T080
,	O
and	O
new	O
anti-tubercular agents	B-T121
are	O
urgently	O
required	O
to	O
be	O
able	O
to	O
successfully	O
combat	O
the	O
increasing	O
prevalence	B-T081
of	O
drug-resistant TB	B-T047
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
a	O
piperidinol compound derivative	B-T121
that	O
is	O
highly	O
active	B-T169
against	O
the	O
Mycobacterium tuberculosis	B-T007
bacillus	B-T007
.	O
The	O
antibacterial	B-T195
properties	B-T080
of	O
the	O
piperidinol compound	B-T121
and	O
its	O
corresponding	O
bis-Mannich base	B-T109
analogue	B-T104
were	O
evaluated	B-T058
against	O
M. smegmatis	B-T007
and	O
Gram-negative organisms	B-T007
.	O
Cytotoxicity	B-T049
studies	B-T062
were	O
undertaken	O
in	O
order	O
to	O
determine	O
the	O
selectivity index	B-T170
for	O
these	O
compounds	B-T121
.	O
Spontaneous	O
resistant	B-T169
mutants	B-T049
of	O
M. smegmatis	B-T007
were	O
generated	O
against	O
the	O
piperidinol	B-T121
and	O
corresponding	O
bis-Mannich base lead derivatives	B-T121
and	O
whole	O
genome sequencing	B-T063
employed	O
to	O
determine	O
the	O
genetic modifications	B-T063
that	O
lead	O
to	O
selection	O
pressure	O
in	O
the	O
presence	O
of	O
these	O
compounds	B-T121
.	O
The	O
piperidinol	B-T121
and	O
the	O
bis-Mannich base analogue	B-T121
were	O
found	O
to	O
be	O
selective	O
for	O
mycobacteria	B-T007
and	O
rapidly	O
kill	O
this	O
organism	B-T001
with	O
a	O
cytotoxicity	B-T049
selectivity index	B-T170
for	O
mycobacteria	B-T007
of	O
>30-fold.	O
Whole	O
genome sequencing	B-T063
of	O
M. smegmatis	B-T007
strains	B-T001
resistant	B-T169
to	O
the	O
lead compounds	B-T121
led	O
to	O
the	O
identification	B-T080
of	O
a	O
number	O
of	O
single nucleotide polymorphisms	B-T086
indicating	O
multiple	O
targets.	O
Our	O
results	B-T033
indicate	O
that	O
the	O
piperidinol moiety	B-T121
represents	O
an	O
attractive	O
compound class	B-T121
in	O
the	O
pursuit	O
of	O
novel	O
anti-tubercular agents	B-T121
.	O

Metatranscriptomics	B-T059
Reveals	O
the	O
Active	O
Bacterial	B-T007
and	O
Eukaryotic Fibrolytic Communities	B-T007
in	O
the	O
Rumen	B-T023
of	O
Dairy Cow	B-T015
Fed	O
a	O
Mixed	B-T169
Diet	B-T168
Ruminants	B-T015
have	O
a	O
unique	O
ability	O
to	O
derive	O
energy	B-T081
from	O
the	O
degradation	B-T169
of	O
plant	B-T002
polysaccharides	B-T109
through	O
the	O
activity	B-T052
of	O
the	O
rumen	B-T023
microbiota	B-T002
.	O
Although	O
this	O
process	B-T067
is	O
well	O
studied	O
in vitro	B-T080
,	O
knowledge	O
gaps	O
remain	O
regarding	O
the	O
relative	O
contribution	O
of	O
the	O
microbiota members	B-T002
and	O
enzymes	B-T116
in vivo	B-T082
.	O
The	O
present	O
study	O
used	O
RNA-sequencing	B-T059
to	O
reveal	O
both	O
the	O
expression	B-T045
of	O
genes	B-T028
encoding	O
carbohydrate-active enzymes	B-T116
(	O
CAZymes	B-T116
)	O
by	O
the	O
rumen	B-T023
microbiota	B-T002
of	O
a	O
lactating dairy cow	B-T015
and	O
the	O
microorganisms	B-T001
forming	O
the	O
fiber	B-T002
-degrading	O
community	B-T096
.	O
Functional analysis	B-T062
identified	O
12,237	O
CAZymes	B-T116
,	O
accounting	O
for	O
1%	O
of	O
the	O
transcripts	B-T114
.	O
The	O
CAZyme	B-T116
profile	O
was	O
dominated	O
by	O
families	O
GH94	B-T116
(	O
cellobiose-phosphorylase	B-T116
),	O
GH13	B-T116
(	O
amylase	B-T116
),	O
GH43	B-T116
and	O
GH10	B-T116
(	O
hemicellulases	B-T116
),	O
GH9	B-T116
and	O
GH48	B-T116
(	O
cellulases	B-T116
),	O
PL11	B-T116
(	O
pectinase	B-T116
)	O
as	O
well	O
as	O
GH2	B-T116
and	O
GH3	B-T116
(	O
oligosaccharidases	B-T116
).	O
Our	O
data	O
support	O
the	O
pivotal	O
role	O
of	O
the	O
most	O
characterized	O
fibrolytic bacteria	B-T007
(	O
Prevotella	B-T007
,	O
Ruminocccus	B-T007
and	O
Fibrobacter	B-T007
),	O
and	O
highlight	O
a	O
substantial,	O
although	O
most	O
probably	O
underestimated,	O
contribution	B-T052
of	O
fungi	B-T004
and	O
ciliate protozoa	B-T204
to	O
polysaccharide	B-T109
degradation	B-T169
.	O
Particularly	O
these	O
results	O
may	O
motivate	O
further	O
exploration	O
of	O
the	O
role	O
and	O
the	O
functions	O
of	O
protozoa	B-T204
in	O
the	O
rumen	B-T023
.	O
Moreover,	O
an	O
important	O
part	O
of	O
the	O
fibrolytic bacterial community	B-T007
remains	O
to	O
be	O
characterized	O
since	O
one	O
third	O
of	O
the	O
CAZyme	B-T116
transcripts	B-T114
originated	O
from	O
distantly	O
related	O
strains	B-T007
.	O
These	O
findings	O
are	O
used	O
to	O
highlight	O
limitations	O
of	O
current	O
metatranscriptomics	B-T059
approaches	O
to	O
understand	O
the	O
functional	O
rumen	B-T023
microbial community	B-T001
and	O
opportunities	O
to	O
circumvent	O
them.	O

Fine Mapping	B-T052
of	O
Carbon Assimilation Rate 8	B-T028
,	O
a	O
Quantitative Trait Locus	B-T028
for	O
Flag Leaf	B-T002
Nitrogen	B-T123
Content	B-T077
,	O
Stomatal	B-T002
Conductance	B-T081
and	O
Photosynthesis	B-T070
in	O
Rice	B-T002
Increasing	B-T169
the	O
rate	B-T081
of	O
leaf photosynthesis	B-T070
is	O
one	O
important	O
approach	O
for	O
increasing	O
grain yield	B-T081
in	O
rice	B-T002
(	O
Oryza sativa	B-T002
).	O
Exploiting	O
the	O
natural	O
variation	B-T080
in	O
CO2 assimilation rate	B-T081
(A)	O
between	O
rice cultivars	B-T002
using	O
quantitative genetics	B-T090
is	O
one	O
promising	O
means	O
to	O
identify	O
genes	B-T028
contributing	O
to	O
higher	O
photosynthesis	B-T070
.	O
In	O
this	O
study,	O
we	O
determined	O
precise	O
location	B-T082
of	O
Carbon Assimilation Rate 8	B-T028
(	O
CAR8	B-T028
)	O
by	O
crossing	B-T045
a	O
high-yielding	O
indica cultivar	B-T002
with	O
a	O
Japanese	B-T083
commercial	B-T170
cultivar	B-T002
.	O
Fine mapping	B-T052
suggested	O
that	O
CAR8	B-T028
encodes	B-T052
a	O
putative Heme Activator Protein 3	B-T116
(	O
OsHAP3	B-T116
)	O
subunit	O
of	O
a	O
CCAAT-box-binding transcription factor	B-T116
called	O
OsHAP3H	B-T028
.	O
Sequencing analysis	B-T063
revealed	O
that	O
the	O
indica	B-T002
allele	B-T028
of	O
CAR8	B-T028
has	O
a	O
1-bp deletion	B-T049
at	O
322	O
bp	B-T044
from	O
the	O
start codon	B-T086
,	O
resulting	O
in	O
a	O
truncated protein	B-T116
of	O
125	O
amino acids	B-T116
.	O
In	O
addition,	O
CAR8	B-T028
is	O
identical	B-T080
to	O
DTH8	B-T028
/	O
Ghd8	B-T028
/	O
LHD1	B-T028
,	O
which	O
was	O
reported	O
to	O
control	O
rice	B-T002
flowering	B-T040
date	B-T079
.	O
The	O
increase	B-T169
of	O
A	B-T081
is	O
largely	O
due	O
to	O
an	O
increase	B-T169
of	O
RuBP regeneration rate	B-T081
via	O
increased	B-T081
leaf	B-T002
nitrogen	B-T123
content	B-T077
,	O
and	O
partially	O
explained	O
by	O
reduced	B-T080
stomatal	B-T002
limitation	B-T169
via	O
increased	B-T081
stomatal	B-T002
conductance	B-T081
relative	O
to	O
A	B-T081
.	O
This	O
allele	B-T028
also	O
increases	O
hydraulic conductivity	B-T080
,	O
which	O
would	O
promote	B-T052
higher	O
stomatal	B-T002
conductance	B-T081
.	O
This	O
indicates	O
that	O
CAR8	B-T028
affects	O
multiple	O
physiological aspects	B-T039
relating	O
to	O
photosynthesis	B-T070
.	O
The	O
detailed	O
analysis	B-T062
of	O
molecular functions	B-T044
of	O
CAR8	B-T028
would	O
help	O
to	O
understand	O
the	O
association	B-T080
between	O
photosynthesis	B-T070
and	O
flowering	B-T040
and	O
demonstrate	O
specific	O
genetic	B-T169
mechanisms	B-T169
that	O
can	O
be	O
exploited	O
to	O
improve	B-T033
photosynthesis	B-T070
in	O
rice	B-T002
and	O
potentially	O
other	O
crops	B-UnknownType
.	O

Allogeneic stem cell transplantation	B-T061
for	O
adult	B-T100
patients	B-T101
with	O
acute lymphoblastic leukemia	B-T191
who	O
had	O
central nervous system involvement	B-T033
:	O
a	O
study	B-T062
from	O
the	O
Adult	B-T100
ALL	B-T191
Working Group	B-T098
of	O
the	O
Japan	B-T083
Society	B-T092
for	O
Hematopoietic Cell Transplantation	B-T061
The	O
prognosis	B-T058
for	O
adult	B-T100
acute lymphoblastic leukemia	B-T191
(	O
ALL	B-T191
)	O
patients	B-T101
with	O
central nervous system (CNS) involvement	B-T033
(	O
CNS+	B-T033
)	O
who	O
received	O
allogeneic hematopoietic stem cell transplantation	B-T061
(	O
allo-SCT	B-T061
)	O
remains	O
unclear.	O
We	O
retrospectively	B-T080
compared	O
the	O
outcomes	B-T080
of	O
allo-SCT	B-T061
for	O
patients	B-T101
with	O
CNS involvement	B-T033
and	O
for	O
patients	B-T101
without	B-T080
CNS involvement	B-T033
(	O
CNS-	B-T033
)	O
using	O
a	O
database	B-T170
in	O
Japan	B-T083
.	O
The	O
eligibility	O
criteria	B-T078
for	O
this	O
study	B-T062
were	O
as	O
follows:	O
diagnosis	B-T062
of	O
ALL	B-T191
,	O
aged	O
more	O
than	O
16	O
years	B-T079
,	O
allo-SCT	B-T061
between	O
2005	O
and	O
2012,	O
and	O
first	B-T081
SCT	B-T061
.	O
Data	B-T078
for	O
2582	O
patients	B-T101
including	O
136	O
CNS+ patients	B-T101
and	O
2446	O
CNS- patients	B-T101
were	O
used	O
for	O
analyses	B-T062
.	O
As	O
compared	O
with	O
CNS- patients	B-T101
,	O
CNS+ patients	B-T101
were	O
younger	B-T079
,	O
had	O
worse	B-T033
disease	B-T047
status	B-T080
at	O
SCT	B-T061
and	O
had	O
poorer	O
performance status	B-T201
(	O
PS	B-T201
)	O
at	O
SCT	B-T061
(P	O
<	O
0.01).	O
Incidence	B-T081
of	O
relapse	B-T067
was	O
higher	O
in	O
CNS+ patients	B-T101
(P	O
=	O
0.02),	O
and	O
incidence	B-T081
of	O
CNS	B-T022
relapse	B-T067
was	O
also	O
higher	O
(P	O
<	O
0.01).	O
The	O
probability	B-T081
of	O
3-	O
year	B-T079
overall survival	B-T081
(	O
OS	B-T081
)	O
was	O
better	O
in	O
CNS- patients	B-T101
(P	O
<	O
0.01)	O
by	O
univariate analysis	B-T062
.	O
However,	O
in	O
patients	B-T101
who	O
received	B-T080
SCT	B-T061
in	O
CR	B-T033
,	O
there	O
was	O
no difference	B-T033
in	O
the	O
probability	B-T081
of	O
OS	B-T081
between	O
CNS+	B-T033
and	O
CNS-	B-T033
patients	B-T101
(P	O
=	O
0.38)	O
and	O
CNS involvement	B-T033
did	O
not	O
have	O
an	O
unfavorable	B-T080
effect	B-T080
on	O
OS	B-T081
by	O
multivariate analysis	B-T081
.	O
CNS+ patients	B-T101
who	O
achieved	O
CR	B-T033
showed	O
OS	B-T081
comparable	O
to	O
that	O
of	O
CNS- patients	B-T101
.	O

Silent strain of caregiving	B-T054
:	O
exploring	O
the	O
best predictors	B-T033
of	O
distress	B-T033
in	O
family carers	B-T099
of	O
geriatric patients	B-T101
The	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best predictors	B-T033
of	O
distress suffered	B-T033
by	O
family carers	B-T099
(	O
FCs	B-T099
)	O
of	O
geriatric patients	B-T101
.	O
A	O
cross-sectional study	B-T062
of	O
100	O
FC	B-T099
-	O
geriatric patient	B-T101
dyads	B-T098
was	O
conducted.	O
The	O
negative impact of care	B-T033
(	O
NIoC	B-T033
)	O
subscale	B-T081
of	O
the	O
COPE index	B-T081
was	O
dichotomized	O
to	O
identify	O
lower stress	B-T033
(score	O
of	O
≤15	O
on	O
the	O
scale)	O
and	O
higher stress	B-T033
(score	O
of	O
≥16	O
on	O
the	O
scale)	O
exerted	O
on	O
FCs	B-T099
by	O
the	O
process of providing care	B-T058
.	O
The	O
set	O
of	O
explanatory	B-T170
variables	B-T033
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	B-T078
and	O
care-related attributes	B-T058
,	O
including	O
patient-related results	B-T033
from	O
comprehensive	O
geriatric assessments	B-T058
and	O
disease	B-T047
profiles	B-T058
.	O
The	O
best	O
combination	O
of	O
explanatory	B-T170
variables	B-T033
that	O
provided	O
the	O
highest predictive powe	B-T080
r	O
for	O
distress	B-T033
among	O
FCs	B-T099
in	O
the	O
multiple logistic regression (LR) model	B-UnknownType
LR	B-UnknownType
)	O
model	O
was	O
determined	O
according	O
to	O
statistical information criteria	B-T081
.	O
The	O
statistical robustness	B-T081
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative power	B-T169
of	O
the	O
model	B-T075
were	O
verified	O
with	O
the	O
cross-validation method	B-T062
.	O
The	O
mean	O
age	B-T032
of	O
FCs	B-T099
was	O
57.2	O
(±10.6)	O
years,	O
whereas	O
that	O
of	O
geriatric patients	B-T101
was	O
81.7	O
(±6.4)	O
years.	O
Despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	B-T170
variables	B-T033
,	O
only	O
five	O
predictors	B-T033
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical model	B-T081
.	O
A	O
higher	O
level	O
of	O
distress	B-T033
was	O
independently	O
predicted	O
by	O
lower self-evaluation of health	B-T058
;	O
worse	O
self-appraisal	B-T041
of	O
coping	B-T055
well	O
as	O
a	O
caregiver	B-T099
;	O
lower	B-T080
sense	O
of	O
general support	B-T058
;	O
more	O
hours	O
of	O
care	B-T052
per	O
week;	O
and	O
the	O
motor retardation	B-T033
of	O
the	O
cared	B-T052
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
Timed Up and Go (TUG) test	B-T060
.	O
Worse	O
performance	O
on	O
the	O
TUG test	B-T060
was	O
only	O
the	O
patient	B-T101
-related	O
predictor	B-T033
of	O
distress	B-T033
among	O
the	O
variables	B-T033
examined	O
as	O
contributors	O
to	O
the	O
higher	O
NIoC	B-T033
.	O
Enhancing	O
the	O
mobility of geriatric patients	B-T061
through	O
suitably	O
tailored	O
kinesitherapeutic methods	B-T061
during	O
their	O
hospital stay	B-T079
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
FCs	B-T099
.	O

Microbiological	B-T170
and	O
Clinical Characteristics	B-T201
of	O
Hypermucoviscous Klebsiella pneumoniae	B-T007
Isolates	B-T123
Associated with	B-T080
Invasive Infections	B-T047
in	O
China	B-T083
A	O
distinctive syndrome	B-T047
caused by	B-T169
hypermucoviscous Klebsiella pneumoniae	B-T007
(	O
HMKP	B-T007
)	O
including	O
pyogenic liver abscess	B-T047
(	O
PLA	B-T047
)	O
is	O
now	O
becoming	O
a	O
globally emerging disease	B-T047
.	O
In	O
the	O
present	O
study	B-T062
,	O
22.8%	O
(84/369)	O
of	O
K. pneumoniae	B-T007
clinical	O
isolates	B-T123
associated with	B-T080
various types	B-T080
of	O
invasive infections	B-T047
were	O
identified	O
as	O
HMKP	B-T007
,	O
with	O
45.2%	O
associated with	B-T080
PLA	B-T047
.	O
Multivariate regression analysis	B-T081
showed	O
that	O
male patients	B-T032
with	O
41-50	O
years	B-T079
,	O
PLA	B-T047
,	O
diabetes mellitus	B-T047
,	O
and	O
hypertension	B-T047
were	O
independent	B-T078
risk factors	B-T033
for	O
HMKP infections	B-T047
.	O
K2	B-T170
(42.9%,	O
36/84)	O
was	O
the	O
most	O
common	O
capsular	B-T082
serotype	B-T170
among	O
HMKP	B-T007
isolates	B-T123
,	O
followed	O
by	O
K1	B-T170
(23.8%,	O
20/84).	O
Seventy-five percentage	B-T081
of	O
K1	B-T170
HMKP	B-T007
isolates	B-T123
were	O
associated with	B-T080
PLA	B-T047
,	O
while	O
K2	B-T170
HMKP	B-T007
isolates	B-T123
accounted	B-T078
for	O
more types	B-T080
of	O
invasive infections	B-T047
.	O
The	O
positive	B-T033
rates	B-T081
of	O
iutA	B-T028
,	O
mrkD	B-T028
,	O
aerobactin	B-T028
,	O
iroN	B-T028
,	O
and	O
rmpA	B-T028
among	O
HMKP	B-T007
isolates	B-T123
were	O
significantly higher	B-T081
than	O
those	O
among	O
non-HMKP	B-T007
isolates	B-T123
(p	O
<	O
0.05).	O
There	O
was	O
a	O
correlation	B-T080
between	O
magA	B-T028
,	O
ybtS	B-T028
,	O
alls	B-T028
,	O
and	O
wcaG	B-T028
and	O
K1	B-T170
isolates	B-T123
.	O
Interestingly,	O
mrkD	B-T028
was	O
exclusively detected	B-T033
among	O
HMKP	B-T007
(32.1%,	O
27/84)	O
and	O
K2	B-T170
isolates	B-T123
(65.9%,	O
27/41).	O
All	O
K1	B-T170
and	O
K2	B-T170
HMKP	B-T007
and	O
non-HMKP	B-T007
isolates	B-T123
were	O
positive	B-T033
for	O
rmpA	B-T028
.	O
Aerobactin	B-T028
was	O
found	B-T033
among	O
95.0	O
and	O
97.5%	O
of	O
K1	B-T170
and	O
K2	B-T170
isolates	B-T123
.	O
ST23	B-T170
was	O
found	B-T033
to	O
be	O
the	O
most prevalent	B-T079
ST	B-T170
among	O
69	O
HMKP	B-T007
isolates	B-T123
with	O
K1	B-T170
,	O
K2	B-T170
,	O
K5	B-T170
,	O
K20	B-T170
,	O
and	O
K57	B-T170
(27.5%,	O
19/69)	O
and	O
was	O
only	O
found	B-T033
among	O
K1	B-T170
isolates	B-T123
.	O
ST65	B-T170
was	O
the	O
second	O
most prevalent	B-T079
ST	B-T170
(26.1%,	O
18/69)	O
and	O
was	O
also	O
only	O
found	B-T033
among	O
K2	B-T170
isolates	B-T123
.	O
ST23-K1	B-T170
HMKP	B-T007
isolates	B-T123
(84.2%,	O
16/19)	O
were	O
associated with	B-T080
PLA	B-T047
,	O
while	O
ST65-K2	B-T170
isolates	B-T123
were	O
correlated	B-T080
with	O
more	O
types of infections	B-T185
relative	O
to	O
ST23-K1	B-T170
isolates	B-T123
.	O
PFGE	B-T059
results	B-T169
showed	O
that	O
the	O
homology	B-T080
of	O
84	O
HMKP	B-T007
isolates	B-T123
was	O
diverse	B-T080
.	O
Only	O
five	B-T081
PFGE	B-T059
clusters	B-T081
with	O
more	O
than	O
75%	O
similarity	B-T080
accounted	B-T078
for	O
more	O
than	O
three	B-T081
isolates	B-T123
.	O
These	O
five	B-T081
PFGE	B-T059
clusters	B-T081
only	O
accounted	B-T078
for	O
35	O
(41.7%,	O
35/84)	O
isolates	B-T123
.	O
In	O
conclusion,	O
our	O
study	B-T062
first	O
found	B-T033
that	O
hypertension	B-T047
and	O
male patients	B-T032
with	O
41-50	O
years	B-T079
old	B-T079
were	O
independent	B-T078
risk factors	B-T033
.	O
The	O
composition	B-T201
of	O
ST types	B-T170
and	O
PFGE	B-T059
clusters	B-T081
among	O
K. pneumoniae	B-T007
K2	B-T170
isolates	B-T123
was	O
more	O
diverse	B-T080
than	O
K1	B-T170
isolates	B-T123
.	O
K1	B-T170
and	O
K2	B-T170
HMKP	B-T007
isolates	B-T123
had	O
respective	O
specific profiles	B-T169
of	O
virulence	B-T038
-	O
associated	B-T078
genes	B-T028
.	O

Haemoglobinopathies	B-T047
and	O
β-Thalassaemia	B-T047
among	O
the	O
Tribals	B-T098
Working	B-T057
in	O
the	O
Tea	B-T168
Gardens	B-T080
of	O
Assam	B-UnknownType
,	O
India	B-T083
Prevalence	B-T081
of	O
haemoglobinopathies	B-T047
and	O
β-thalassaemia	B-T047
are	O
very high	B-T080
in	O
India	B-T083
but	O
information	B-T078
about	O
its	O
status	O
among	O
the	O
tribals	B-T098
working	B-T057
in	O
the	O
tea	B-T168
gardens	B-T080
of	O
Assam	B-UnknownType
is	O
very less	B-T080
.	O
The	O
present	O
study	B-T062
was	O
carried	O
out	O
to	O
determine	O
the	O
prevalence	B-T081
of	O
haemoglobinopathies	B-T047
and	O
β-thalassaemia	B-T047
among	O
the	O
tribals	B-T098
working	B-T057
in	O
the	O
tea	B-T168
gardens	B-T080
of	O
Assam	B-UnknownType
.	O
A	O
total	O
1204	O
samples	O
from	O
the	O
tribals	B-T098
working	B-T057
in	O
tea	B-T168
gardens	B-T080
of	O
Assam	B-UnknownType
were	O
analysed	B-T062
for	O
both	O
Complete Blood Count	B-T059
(	O
CBC	B-T059
)	O
and	O
High Pressure Liquid Chromatography	B-T059
(	O
HPLC	B-T059
)	O
for	O
detection	B-T061
of	O
haemoglobinopathies	B-T047
and	O
β-thalassaemia	B-T047
.	O
This	O
study	B-T062
showed	O
that	O
the	O
prevalence	B-T081
of	O
sickle cell anaemia	B-T047
and	O
β-thalassaemia	B-T047
were	O
very high	B-T080
among	O
this	O
population	B-T098
.	O
Our	O
results	B-T169
indicated	B-T033
a	O
higher	O
prevalence	B-T081
of	O
β-thalassaemia	B-T047
(3.07%)	O
among	O
the	O
Munda ethnic group	B-T098
and	O
higher	O
prevalence	B-T081
of	O
sickle cell anaemia	B-T047
(4.73%)	O
among	O
the	O
Lohar ethnic group	B-T098
.	O
This	O
was	O
the	O
first	O
study	B-T062
to	O
report	O
the	O
presence	B-T033
of	O
HbE	B-T116
among	O
the	O
tribals	B-T098
working	B-T057
in	O
the	O
tea	B-T168
gardens	B-T080
of	O
Assam	B-UnknownType
.	O
Based	O
on	O
the	O
present	O
findings	B-T033
,	O
sickle cell anaemia	B-T047
and	O
β-thalassaemia	B-T047
were	O
major	O
health	B-T078
problem	B-T033
for	O
the	O
tribals	B-T098
working	B-T057
in	O
the	O
tea	B-T168
gardens	B-T080
of	O
Assam	B-UnknownType
.	O
Proper	O
diagnostic facilities	B-T058
for	O
haemoglobinopathy	B-T047
and	O
thalassaemia	B-T047
should	O
be	O
established	B-T080
in	O
these	O
areas	B-T082
,	O
including	O
establishment	O
of	O
haemoglobinopathy	B-T047
and	O
thalassaemia	B-T047
database	B-T170
collection	B-T169
,	O
haematological analysis laboratories	B-T073
,	O
genetic counselling clinics	B-T073
,	O
prenatal diagnosis centres	B-T073
and	O
neonatal screening centres	B-T073
.	O

Long Term	B-T079
Outcome	B-T169
in	O
Patients	B-T101
with	O
Esophageal Stenting	B-T061
for	O
Cancer Esophagus	B-T191
-	O
Our	O
Experience	O
at	O
a	O
Rural Hospital	B-T093
of	O
Punjab	B-UnknownType
,	O
India	B-T083
Cancer of the esophagus	B-T191
is	O
among	O
the	O
leading	O
cause	B-T078
of	O
cancer deaths	B-T081
in	O
Punjab	B-UnknownType
,	O
India	B-T083
.	O
Patients	B-T101
generally	O
present	B-T033
with	O
dysphagia	B-T047
as	O
their	O
first	O
symptom	B-T184
and	O
more	O
often	O
they	O
have	O
advanced disease	B-UnknownType
at	O
the	O
time	B-T079
of	O
presentation	B-T078
to	O
a	O
tertiary care centre	B-T073
.	O
Palliative procedures	B-T061
have	O
important	B-T080
roles	O
in	O
this	O
setting.	O
Stenting	B-T061
is	O
the	O
best	O
option	B-T169
to	O
palliate	B-T080
the	O
symptoms	B-T184
of	O
dysphagia	B-T047
,	O
from	O
which	O
patient	B-T101
is	O
suffering the most	B-T033
.	O
To	O
know	O
the	O
success	B-T080
rate	B-T081
,	O
early	B-T184
and	O
long term	B-T079
complications	B-T046
and	O
mortality	B-T081
in	O
esophageal stenting	B-T061
,	O
when	O
it	O
was	O
done	O
in	O
malignant esophageal stricture	B-T047
patients	B-T101
.	O
One hundred	B-T081
patients	B-T101
,	O
who	O
had	O
undergone	O
esophageal stenting	B-T061
from	O
January	B-T080
2012	O
to	O
January	B-T080
2015,	O
were	O
included	B-T169
in	O
the	O
study	B-T062
.	O
We	O
retrospectively analysed	B-T062
the	O
data	B-T078
for	O
patient	B-T101
characteristics	B-T080
,	O
causes	B-T169
of	O
non-operability	B-T080
,	O
early	B-T184
and	O
long term	B-T079
complications	B-T046
,	O
re-interventions	B-T061
,	O
efficacy	B-T080
and	O
mortality	B-T081
.	O
Out	O
of	O
100	O
patients	B-T101
,	O
indications	B-T078
for	O
stenting	B-T061
were	O
locally	O
advanced disease	B-UnknownType
not	O
amenable	B-T080
to	O
surgery	B-T061
(52%),	O
metastatic disease	B-T191
(35%),	O
CVA	B-T047
(1%),	O
cardiac	B-T033
and	O
respiratory problem	B-T184
(8%),	O
un-willing	O
for	O
surgery	B-T061
in	O
5%	O
of	O
patients	B-T101
.	O
Majority	O
of	O
patients	B-T101
(94%)	O
had	O
squamous cell carcinoma	B-T191
,	O
while	O
only	O
6%	O
had	O
adenocarcinoma	B-T191
.	O
84%	O
of	O
patients	B-T101
presented	B-T078
with	O
dysphagia	B-T047
with	O
or	O
without	O
chest pain	B-T184
and	O
recurrent cough	B-T033
while	O
16%	O
had	O
recurrent vomiting	B-T184
.	O
58%	O
had	O
dysphagia	B-T047
to	O
liquids	B-T167
and	O
solids	B-T167
and	O
17%	O
had	O
complete dysphagia	B-T047
.	O
After	O
stenting	B-T061
93%	O
had	O
significant	B-T078
improvement	B-T077
in	O
dysphagia	B-T047
score	B-T081
from	O
median	O
of	O
3	O
to	O
1.	O
Post procedure	B-T079
stay	B-T079
was	O
3.61±1.0	O
days	B-T079
.	O
One	O
patient	B-T101
had	O
procedure	B-T061
related	O
major	O
complication	B-T046
in	O
the	O
form	O
of	O
post procedural bleed	B-T037
(after	O
16	O
days	B-T079
of	O
stenting	B-T061
)	O
leading	O
to	O
death	B-T033
of	O
that	O
patient	B-T101
.	O
Minor	B-T041
complications	B-T046
were	O
present	B-T033
in	O
52	O
patients	B-T101
treated	B-T169
conservatively	O
not	O
affecting	B-T169
the	O
efficacy	B-T080
of	O
procedure	B-T061
.	O
These	O
include	B-T052
pain	B-T184
after	O
stenting	B-T061
(38%),	O
stent obstruction	B-T046
(23%)	O
and	O
stent migration	B-T046
(6%).	O
All	O
the	O
minor	B-T041
complications	B-T046
were	O
treated	B-T169
conservatively	O
except	B-T169
in	O
six	O
patients	B-T101
in	O
whom	O
re-stenting	B-T061
was	O
done.	O
Esophageal stenting	B-T061
is	O
relatively	O
safe	O
procedure	B-T061
with	O
short	O
stay	B-T079
of	O
the	O
patient	B-T101
in	O
the	O
hospital	B-T073
.	O
Although,	O
it	O
helps	O
in	O
alleviating	O
patients	B-T101
'	O
morbidity	B-T081
very	O
effectively	B-T080
and	O
reliably,	O
there	O
are	O
many	O
technical glitches	B-T067
,	O
which	O
needs	O
to	O
be	O
kept	O
into	O
account	O
and	O
patient	B-T101
should	O
be	O
properly	O
counseled	B-T061
before	O
the	O
procedure	B-T061
to	O
prevent	B-T169
and	O
manage	B-T169
post procedure	B-T079
complications	B-T046
and	O
medico	O
legal	O
aspects.	O

Treatment	B-T169
of	O
Carcinoma In Situ of the Glans Penis	B-T191
With	O
Topical Imiquimod	B-T200
Followed	O
by	O
Carbon Dioxide Laser	B-T074
Excision	B-T061
Different	B-T080
approaches	B-T169
have	O
been	O
described	B-T078
in	O
published	O
studies	O
for	O
carcinoma in situ (CIS) of the glans penis	B-T191
(	O
erythroplasia of Queyrat	B-T191
),	O
including	B-T169
topical chemotherapy	B-T061
or	O
immunotherapy	B-T061
and	O
laser	B-UnknownType
or	O
surgical excision	B-T061
.	O
We	O
evaluated	B-T061
the	O
efficacy	B-T080
of	O
topical imiquimod	B-T200
(	O
IQ	B-T200
)	O
followed	O
by	O
carbon dioxide laser	B-T074
ablation	B-T061
of	O
the	O
lesion	B-T033
.	O
From	O
2010	O
to	O
2015,	O
10	O
patients affected	B-T080
by	O
CIS	B-T191
of	O
the	O
glans	B-T023
were	O
treated	B-T061
by	O
IQ	B-T200
,	O
followed	O
by	O
carbon dioxide laser	B-T074
ablation	B-T061
.	O
For	O
every	O
patient	B-T101
,	O
we	O
performed	B-T169
histologic examination	B-T059
before	B-T079
and	O
after	B-T079
IQ	B-T200
.	O
Local	O
toxicity	B-T037
and	O
adverse effects	B-T046
were	O
recorded.	O
After treatment	B-T079
,	O
histologic examination	B-T059
showed	O
no residual tumor	B-T034
in	O
6	O
patients	B-T101
(	O
complete response	B-T033
[	O
CR	B-T033
]),	O
stable disease	B-T033
in	O
2	O
patients	B-T101
,	O
and	O
progressive disease	B-T047
in	O
2	O
patients	B-T101
.	O
Those	O
with	O
a	O
CR	B-T033
had	O
human papillomavirus	B-T005
-	O
related	B-T080
lesions	B-T033
,	O
and	O
they	O
had	O
no	B-T033
experienced	O
relapses	B-T067
after	B-T079
a	O
mean	O
follow-up	B-T058
of	O
26	O
months	B-T079
.	O
The	O
2	O
patients	B-T101
with	O
progressive disease	B-T047
underwent	O
total	O
penectomy	B-T061
.	O
All	O
patients	B-T101
were	O
alive	B-T033
at	O
the	O
last	O
follow-up examination	B-T033
.	O
All	O
patients	B-T101
experienced	O
a	O
mild	B-T080
local	O
toxicity	B-T037
(	O
burning erythema	B-T184
)	O
but	O
no	B-T033
major	B-T080
adverse effects	B-T046
.	O
Local	O
treatment	B-T169
with	O
IQ	B-T200
for	O
glans	B-T023
CIS	B-T191
is	O
effective	B-T080
mainly	O
for	O
human papillomavirus	B-T005
-	O
related	B-T080
lesions	B-T033
.	O
The	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic examination	B-T059
findings	O
before	B-T079
and	O
after	B-T079
IQ	B-T200
treatment	B-T169
.	O
The	O
small	O
number	O
of	O
patients	B-T101
,	O
owing	O
to	O
the	O
rarity	B-T080
of	O
this	O
disease	B-T047
,	O
was	O
the	O
main	O
limitation	B-T169
of	O
the	O
present	O
study.	O
IQ	B-T200
must	O
be	O
used	O
carefully,	O
and	O
a	O
close	O
follow-up	B-T058
protocol	B-T170
is	O
mandatory	B-T061
because	O
of	O
the	O
lack	B-T080
of	O
long-term	B-T079
efficacy	B-T080
data.	O

Progressive	B-T169
subcortical	B-T029
calcifications	B-T042
secondary	O
to	O
venous hypertension	B-T047
in	O
an	O
intracranial	B-T029
dural arteriovenous fistula	B-T190
Intracranial	B-T029
dural arteriovenous fistulas	B-T190
(	O
dAVF	B-T190
)	O
are	O
acquired lesions	B-T033
,	O
with	O
the	O
most	O
commonly	O
reported	B-T058
findings	B-T033
on	O
CT	B-T060
haemorrhage	B-T046
or	O
focal oedema	B-T046
.	O
We	O
describe	O
a	O
case	O
of	O
progressive	B-T169
subcortical	B-T029
calcification	B-T042
on	O
CT	B-T060
secondary	O
to	O
venous hypertension	B-T047
from	O
a	O
high	O
grade	O
dAVF	B-T190
.	O

Effects	O
of	O
Static Cold Storage	B-T059
and	O
Hypothermic Machine Perfusion	B-T061
on	O
Oxidative Stress Factors	B-T059
,	O
Adhesion Molecules	B-T116
,	O
and	O
Zinc Finger Transcription Factor Proteins	B-T116
Before	O
and	O
After	O
Liver Transplantation	B-T061
BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static cold storage	B-T059
(	O
SCS	B-T059
)	O
and	O
hypothermic machine perfusion	B-T061
(	O
HMP	B-T061
)	O
on	O
the	O
oxidative stress factors	B-T059
(	O
OSF	B-T059
),	O
adhesion molecules	B-T116
(	O
AM	B-T116
),	O
and	O
zinc finger transcription factor	B-T116
(	O
Snail	B-T116
)	O
before	O
and	O
after	O
liver transplantation	B-T061
.	O
MATERIAL	O
AND	O
METHODS	O
Experimental	O
dogs	B-T015
were	O
randomly	O
divided	O
into	O
donor	B-T058
(	O
group	B-T078
A),	O
SCS	B-T059
(	O
group	B-T078
B),	O
and	O
HMP	B-T061
(	O
group	B-T078
C)	O
(n=30)	O
groups	B-T078
.	O
Livers retrieved	B-T061
from	O
group	B-T078
A	O
were	O
transplanted	B-T061
into	O
group	B-T078
B	O
after	O
SCS	B-T059
,	O
and	O
the	O
livers	B-T023
sampled	O
from	O
group	B-T078
B	O
were	O
transplanted	B-T061
into	O
group	B-T078
C	O
after	O
HMP	B-T061
.	O
The	O
dogs	O
in	O
group	B-T078
A	O
were	O
euthanized	B-T058
and	O
discarded,	O
and	O
the	O
livers	B-T023
sampled	O
from	O
group	B-T078
C	O
were	O
used	O
for	O
other	O
experiments.	O
Twenty	O
dogs	B-T015
with	O
successful	O
liver transplants	B-T061
were	O
randomly	O
selected	O
from	O
groups	B-T078
B	O
and	O
C	O
for	O
analysis.	O
RESULTS	O
During	O
the	O
liver	B-T023
sampling process	B-T062
,	O
the	O
levels	O
of	O
OSF	B-T059
,	O
AM	B-T116
,	O
and	O
Snail	O
between	O
the	O
2	O
groups	B-T078
showed	O
no significant differences	B-T033
(P>0.05);	O
before	O
the	O
transplantation	B-T061
,	O
the	O
levels	O
of	O
chemokine CXCL14	B-T116
and	O
Snail	B-T116
between	O
the	O
2	O
groups	B-T078
showed	O
no significant differences	B-T033
(P>0.05),	O
and	O
compared	O
with	O
group	B-T078
B,	O
HIF-1α	O
and	O
P-selectin	B-T116
in	O
group	B-T078
C	O
were	O
lower	O
(P<0.01);	O
60	O
min	O
after	O
the	O
transplantation	B-T061
,	O
HIF-1α	B-T116
,	O
chemokine CXCL14	B-T116
,	O
P-selectin	B-T116
,	O
and	O
Snail	B-T116
in	O
group	B-T078
C	O
were	O
lower	O
than	O
that	O
in	O
group	B-T078
B	O
(P<0.01).	O
CONCLUSIONS	O
HMP	B-T061
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
OSF	B-T059
and	O
inflammatory factors	B-T169
,	O
which	O
is	O
conducive	B-T033
for	O
liver transplantation	B-T061
.	O

Physiology	B-T039
of	O
respiratory disturbances	B-T033
in	O
muscular dystrophies	B-T047
Muscular dystrophy	B-T047
is	O
a	O
group	O
of	O
inherited	O
myopathies	B-T047
characterised	O
by	O
progressive	B-T169
skeletal muscle wasting	B-T046
,	O
including	O
of	O
the	O
respiratory muscles	B-T023
.	O
Respiratory failure	B-T047
,	O
i.e.	O
when	O
the	O
respiratory system	B-T022
fails	B-T169
in	O
its	O
gas exchange functions	B-UnknownType
,	O
is	O
a	O
common	O
feature	B-T080
in	O
muscular dystrophy	B-T047
,	O
being	O
the	O
main	O
cause	O
of	O
death	B-T033
,	O
and	O
it	O
is	O
a	O
consequence of	B-T169
lung	B-T023
failure	B-T047
,	O
pump failure	B-T047
or	O
a	O
combination	O
of	O
the	O
two.	O
The	O
former	O
is	O
due	O
to	O
recurrent	B-T079
aspiration	B-T046
,	O
the	O
latter	O
to	O
progressive	B-T169
weakness of respiratory muscles	B-T033
and	O
an	O
increase	B-T169
in	O
the	O
load	O
against	O
which	O
they	O
must	O
contract	B-UnknownType
.	O
In	O
fact,	O
both	O
the	O
resistive and elastic components	B-T080
of	O
the	O
work	O
of	O
breathing	B-T039
increase	B-T169
due	O
to	O
airway obstruction	B-T047
and	O
chest wall	B-T023
and	O
lung	B-T023
stiffening	B-T184
,	O
respectively.	O
The	O
respiratory disturbances	B-T033
in	O
muscular dystrophy	B-T047
are	O
restrictive pulmonary function	B-T033
,	O
hypoventilation	B-T046
,	O
altered	O
thoracoabdominal	B-T082
pattern,	O
hypercapnia	B-T033
,	O
dyspnoea	B-T184
,	O
impaired regulation of breathing	B-UnknownType
,	O
inefficient cough	B-T033
and	O
sleep disordered breathing	B-T047
.	O
They	O
can	O
be	O
present	O
at	O
different	O
rates	O
according	O
to	O
the	O
type	O
of	O
muscular dystrophy	B-T047
and	O
its	O
progression	B-T046
,	O
leading	O
to	O
different	O
onset	O
of	O
each	O
symptom	B-T184
,	O
prognosis	B-T058
and	O
degree of respiratory involvement	B-T033
.	O
A	O
common	O
feature	B-T080
of	O
muscular dystrophy	B-T047
is	O
respiratory failure	B-T047
,	O
i.e.	O
the	O
inability	O
of	O
the	O
respiratory system	B-T022
to	O
provide	O
proper	O
oxygenation	B-T042
and	O
carbon dioxide elimination	B-T039
.In	O
the	O
lung	B-T023
,	O
respiratory failure	B-T047
is	O
caused	O
by	O
recurrent	B-T079
aspiration	B-T046
,	O
and	O
leads	O
to	O
hypoxaemia	B-T033
and	O
hypercarbia	B-T033
.	O
Ventilatory failure	B-T046
in	O
muscular dystrophy	B-T047
is	O
caused	O
by	O
increased	B-T081
respiratory load	B-T033
and	O
respiratory muscles weakness	B-T033
.	O
Respiratory load	B-T033
increases	B-T169
in	O
muscular dystrophy	B-T047
because	O
scoliosis	B-T190
makes	O
chest wall compliance	B-T034
decrease	B-T081
,	O
atelectasis	B-T046
and	O
fibrosis	B-T046
make	O
lung compliance	B-T042
decrease	B-T081
,	O
and	O
airway obstruction	B-T047
makes	O
airway resistance	B-T042
increase	B-T169
.The	O
consequences of	B-T169
respiratory pump failure	B-T047
are	O
restrictive pulmonary function	B-T033
,	O
hypoventilation	B-T046
,	O
altered	O
thoracoabdominal	B-T082
pattern,	O
hypercapnia	B-T033
,	O
dyspnoea	B-T184
,	O
impaired regulation of breathing	B-UnknownType
,	O
inefficient cough	B-T033
and	O
sleep disordered breathing	B-T047
.	O
To	O
understand	O
the	O
mechanisms	B-T033
leading	O
to	O
respiratory disturbances	B-T033
in	O
patients	B-T101
with	O
muscular dystrophy	B-T047
.To	O
understand	O
the	O
impact	O
of	O
respiratory disturbances	B-T033
in	O
patients	B-T101
with	O
muscular dystrophy	B-T047
.To	O
provide	O
a	O
brief	O
description	B-T170
of	O
the	O
main	O
forms	O
of	O
muscular dystrophy	B-T047
with	O
their	O
respiratory implications	B-T033
.	O

Significance	B-T078
of	O
uterine corpus tumor	B-T191
invasion	B-T033
in	O
early-stage	B-T185
cervical cancer	B-T191
To	O
examine	O
characteristics	B-T080
and	O
survival	B-T052
outcomes	B-T169
of	O
women	B-T098
with	O
surgically-treated	B-T061
cervical cancer	B-T191
exhibiting	O
uterine corpus tumor	B-T191
invasion	B-T033
.	O
We	O
utilized	O
The	O
Surveillance, Epidemiology, and End Results Program	B-T093
to	O
identify	O
cervical cancer	B-T191
patients	B-T101
who	O
underwent	O
hysterectomy	B-T061
between	O
1973	O
and	O
2003.	O
Logistic regression models	B-UnknownType
were	O
used	O
to	O
identify	O
risk factors	B-T033
for	O
uterine corpus tumor	B-T191
invasion	B-T033
on	O
multivariable analysis	B-T081
.	O
Association	B-T080
of	O
uterine corpus tumor	B-T191
invasion	B-T033
and	O
cause-specific survival	B-T081
(	O
CSS	B-T081
)	O
from	O
cervical cancer	B-T191
was	O
examined	O
with	O
Cox proportional hazard regression models	B-T170
on	O
multivariable analysis	B-T081
.	O
We	O
identified	O
837	O
(4.9%)	O
cases	O
of	O
uterine corpus	B-T191
invasion	B-T033
and	O
16,237	O
(95.1%)	O
cases	O
of	O
non-invasion	B-T169
.	O
Median	B-T081
follow-up	B-T058
time	B-T079
was	O
14.0	O
years.	O
There	O
were	O
1642	O
deaths	B-T040
due	O
to	O
cervical cancer	B-T191
.	O
Uterine corpus	B-T191
invasion	B-T033
was	O
independently	B-T078
associated with	B-T080
older age	B-T032
,	O
non-squamous histology	B-T169
,	O
high-grade tumors	B-T191
,	O
large tumor size	B-T082
,	O
and	O
nodal	B-T082
metastasis	B-T191
on	O
multivariable analysis	B-T081
(all,	O
P	O
<	O
0.001).	O
On	O
univariable analysis	B-T062
,	O
uterine corpus tumor	B-T191
invasion	B-T033
was	O
significantly	O
associated with	B-T080
decreased	B-T081
CSS	B-T081
compared	O
to	O
the	O
non-invasion	B-T169
(5-year	O
rates,	O
79.0%	O
versus	O
94.5%,	O
P	O
<	O
0.001).	O
After	O
controlling	B-T067
for	O
other	O
significant	B-T078
prognostic factors	B-T201
,	O
uterine corpus tumor	B-T191
invasion	B-T033
remained	O
an	O
independent	B-T078
prognostic factor	B-T201
for	O
decreased	B-T081
CSS	B-T081
(	O
adjusted-hazard ratio	B-T081
1.45,	O
95%	O
confidence interval	B-T081
1.21-1.74).	O
Among	O
stage T1b	B-T185
cases	O
(n	O
=	O
6730),	O
uterine corpus tumor	B-T191
invasion	B-T033
remained	O
an	O
independent	B-T078
prognostic factor	B-T201
for	O
decreased	B-T081
CSS	B-T081
(	O
adjusted-hazard ratio	B-T081
1.95,	O
95%CI	O
1.47-2.60).	O
Uterine corpus tumor	B-T191
invasion	B-T033
was	O
significantly	O
associated with	B-T080
decreased	B-T081
CSS	B-T081
in	O
stage T1b1	B-T170
disease	B-T191
(74.5%	O
versus	O
90.7%,	O
P	O
<	O
0.001)	O
and	O
in	O
stage T1b2	B-T170
disease	B-T191
(67.0%	O
versus	O
79.5%,	O
P	O
=	O
0.01).	O
Uterine corpus tumor	B-T191
invasion	B-T033
is	O
an	O
independent	B-T078
prognostic factor	B-T201
for	O
decreased	B-T081
survival	B-T052
of	O
women	B-T098
with	O
early-stage	B-T185
cervical cancer	B-T191
.	O

Efficient	O
gene targeting	B-T063
in	O
non-homologous end-joining	B-T169
-deficient	O
Lipomyces starkeyi	B-T004
strains	B-T001
Microbial	B-T001
lipids	B-T109
are	O
sustainable	O
feedstock	O
for	O
the	O
production	B-T057
of	O
oleochemicals	B-T103
and	O
biodiesel	B-T109
.	O
Oleaginous yeasts	B-T004
have	O
recently	O
been	O
proposed	O
as	O
alternative	B-T077
lipid	B-T109
producers	B-T004
to	O
plants	B-T002
and	O
animals	B-T008
to	O
promote	O
sustainability	O
in	O
the	O
chemical	B-T092
and	O
fuel industries	B-T057
.	O
The	O
oleaginous yeast	B-T004
Lipomyces starkeyi	B-T004
has	O
great	O
industrial	O
potential	O
as	O
an	O
excellent	O
lipid	B-T109
producer	B-T004
.	O
However,	O
improvement	O
of	O
its	O
lipid	B-T109
productivity	B-T052
is	O
essential	O
for	O
the	O
cost-effective production	B-T057
of	O
oleochemicals	B-T103
and	O
fuels	B-T073
.	O
Genetic	B-T063
and	O
metabolic engineering	B-T063
of	O
L. starkeyi	B-T004
via	O
gene	O
manipulation	O
techniques	O
may	O
result	O
in	O
improvements	O
in	O
lipid	B-T109
production	B-T057
and	O
our	O
understanding	O
of	O
the	O
mechanisms	B-T169
behind	O
lipid	B-T109
biosynthesis pathways	B-T169
.	O
We	O
previously	O
described	O
an	O
integrative transformation system	B-T169
using	O
a	O
drug	B-T121
-resistant	O
marker	B-T045
for	O
L. starkeyi	B-T004
.	O
However,	O
gene-targeting	B-T063
frequencies	B-T081
were	O
very	O
low	O
because	O
non-homologous recombination	B-T045
is	O
probably	O
predominant	O
in	O
L. starkeyi	B-T004
.	O
Genetic engineering tools	B-T063
for	O
L. starkeyi	B-T004
have	O
not	O
been	O
sufficiently	O
developed.	O
In	O
this	O
study,	O
we	O
describe	O
a	O
new	O
genetic tool	B-T063
and	O
its	O
application	B-T169
in	O
L. starkeyi	B-T004
.	O
To	O
develop	O
a	O
highly	O
efficient	O
gene-targeting system	B-T063
for	O
L. starkeyi	B-T004
,	O
we	O
constructed	O
a	O
series	O
of	O
mutants	B-T028
by	O
disrupting	B-T080
genes	B-T028
for	O
LsKu70p	B-T116
,	O
LsKu80p	B-T116
,	O
and/or	O
LsLig4p	B-T116
,	O
which	O
share	O
homology	B-T080
with	O
other	O
yeasts	B-T004
Ku70p	B-T116
,	O
Ku80p	B-T116
,	O
and	O
Lig4p	B-T116
,	O
respectively,	O
being	O
involved	O
in	O
non-homologous end-joining pathway	B-T169
.	O
Deletion	B-T045
of	O
the	O
LsLIG4 gene	B-T028
dramatically	O
improved	O
the	O
homologous recombination	B-T045
efficiency	B-T081
(80.0%)	O
at	O
the	O
LsURA3	B-T028
locus	B-T082
compared	O
with	O
that	O
in	O
the	O
wild-type	B-T028
strain	B-T001
(1.4%),	O
when	O
2000-bp homologous flanking regions	B-T086
were	O
used.	O
The	O
homologous recombination	B-T045
efficiencies	B-T081
of	O
the	O
double	O
mutant	B-T028
∆l sku70∆lslig4	B-T028
and	O
the	O
triple	O
mutant	B-T028
∆lsku70∆lsku80∆lslig4	B-T028
were	O
also	O
markedly	O
enhanced.	O
Therefore,	O
the	O
L. starkeyi	B-T004
∆lslig4	B-T028
background	O
strains	B-T001
have	O
promise	O
as	O
efficient	O
recipient strains	B-T001
for	O
genetic	B-T063
and	O
metabolic engineering	B-T063
approaches	B-T169
in	O
this	O
yeast	B-T004
.	O

Evaluating	O
clinical	B-T080
,	O
dietary	B-T168
and	O
psychological	B-T169
risk factors	B-T033
for	O
relapse	B-T067
of	O
ulcerative colitis	B-T047
in	O
clinical	B-T080
,	O
endoscopic	B-T082
and	O
histological	B-T169
remission	B-T046
The	O
literature	O
on	O
possible	O
factors	O
that	O
could	O
trigger	O
a	O
relapse	B-T067
in	O
patients	B-T101
with	O
ulcerative colitis	B-T047
(	O
UC	B-T047
)	O
in	O
clinical	B-T080
,	O
endoscopic	B-T082
and	O
histological	B-T169
remission	B-T046
on	O
long	O
term	O
follow up	B-T058
is	O
scarce.	O
To	O
determine	O
the	O
relapse	B-T067
rate	O
in	O
patients	B-T101
with	O
UC	B-T047
in	O
clinical	B-T080
,	O
endoscopic	B-T082
and	O
histological	B-T169
remission	B-T046
and	O
identify	O
factors	O
that	O
may	O
influence	O
the	O
risk	B-T078
of	O
relapse	B-T067
.	O
Patients	B-T101
with	O
UC	B-T047
in	O
clinical	B-T080
,	O
endoscopic	B-T082
and	O
histological	B-T169
remission	B-T046
were	O
enrolled	O
between	O
January-July	O
2010	O
and	O
followed up	B-T058
for	O
1	O
year	B-T079
to	O
determine	O
the	O
effect	O
of	O
clinical	B-T080
,	O
dietary	B-T168
and	O
psychological	B-T169
factors	B-T033
on	O
relapse	B-T067
.	O
Information	O
regarding	O
factors	O
that	O
may	O
affect	O
relapse	B-T067
such	O
as	O
infection	B-T046
,	O
antibiotic	B-T195
or	O
NSAIDs	B-T121
use	O
and	O
any	O
other	O
factor	O
which	O
the	O
patient	B-T101
felt	O
important,	O
and	O
compliance	B-T055
with	O
medications	B-T058
was	O
obtained.	O
97	O
patients	B-T101
(59	O
males	B-T098
,	O
mean	O
age	B-T032
39	O
+	O
11.9	O
years	B-T079
)	O
were	O
followed up	B-T058
for	O
a	O
mean	O
duration	O
of	O
9	O
+	O
2.3	O
months	B-T079
.	O
18(18.6%)	O
relapsed	B-T067
with	O
the	O
median	O
time	O
to	O
relapse	B-T067
being	O
3.5	O
months	B-T079
.	O
On	O
univariate analysis	B-T062
more	O
relapsers	O
had	O
significantly	O
higher	O
NSAIDs	B-T121
use	O
within	O
15	O
days	B-T079
of	O
relapse	B-T067
,	O
respiratory tract infection	B-T047
within	O
4	O
weeks	B-T079
,	O
use	O
of	O
steroids	B-T109
more	O
than	O
once	O
in	O
past,	O
higher	O
consumption	B-T039
of	O
calcium	B-T121
,	O
riboflavin	B-T109
,	O
vitamin A	B-T109
and	O
lower	O
consumption	B-T039
of	O
sugars	B-T109
.	O
On	O
multivariate analysis	B-T081
,	O
NSAIDs	B-T121
use	O
[HR(95%CI):6.41(1.88-21.9)]and	O
intake	B-T169
of	O
Vitamin A	B-T109
[HR(95%CI):1.008(1.000-1.016)]	O
were	O
statistically	O
significant	O
predictors	B-T078
of	O
relapse	B-T067
.	O
With	O
a	O
relapse	B-T067
rate	O
of	O
18.6%	O
over	O
a	O
follow up	B-T058
of	O
9	O
months	B-T079
in	O
patients	B-T101
with	O
UC	B-T047
in	O
clinical	B-T080
,	O
endoscopic	B-T082
and	O
histological	B-T169
remission	B-T046
,	O
independent	O
predictors	B-T078
of	O
relapse	B-T067
were	O
history	O
of	O
NSAIDs	B-T121
use	O
within	O
15	O
days	B-T079
of	O
relapse	B-T067
and	O
higher	O
intake	O
of	O
Vitamin A	B-T109
.	O

High	O
Performance	O
Reduction	B-T070
of	O
H2O2	B-T121
with	O
an	O
Electron Transport	B-T044
Decaheme Cytochrome	B-T116
on	O
a	O
Porous	O
ITO	B-T197
Electrode	B-T073
The	O
decaheme cytochrome MtrC	B-T116
from	O
Shewanella oneidensis MR-1	B-T007
immobilized	B-T116
on	O
an	O
ITO	B-T197
electrode	B-T073
displays	O
unprecedented	O
H2O2	B-T121
reduction	B-T070
activity.	O
Although	O
MtrC	B-T116
showed	O
lower	O
peroxidase activity	B-T044
in	O
solution	O
compared	O
to	O
horseradish peroxidase	B-T116
,	O
the	O
ten	O
heme	B-T109
cofactors	B-T109
enable	O
excellent	O
electronic communication	B-T170
and	O
a	O
superior	O
activity	O
on	O
the	O
electrode	B-T073
surface.	O
A	O
hierarchical	O
ITO	B-T197
electrode	B-T073
enabled	O
optimal	O
immobilization	B-T067
of	O
MtrC	B-T116
and	O
a	O
high	O
current density	B-T081
of	O
1	O
mA	O
cm(-2)	O
at	O
0.4	O
V	O
vs	O
SHE	B-T073
could	O
be	O
obtained	O
at	O
pH	O
6.5	O
(Eonset	O
=	O
0.72	O
V).	O
UV-visible	B-T070
and	O
Resonance Raman spectroelectrochemical studies	B-T059
suggest	O
the	O
formation	O
of	O
a	O
high	O
valent	O
iron-oxo	O
species	O
as	O
the	O
catalytic	B-T070
intermediate.	O
Our	O
findings	O
demonstrate	O
the	O
potential	B-T080
of	O
multiheme cytochromes	B-T116
to	O
catalyze	B-T070
technologically	B-UnknownType
relevant	O
reactions	O
and	O
establish	O
MtrC	B-T116
as	O
a	O
new	O
benchmark	O
in	O
biotechnological	B-T091
H2O2	B-T121
reduction	B-T070
with	O
scope	O
for	O
applications	O
in	O
fuel cells	B-T073
and	O
biosensors	B-T075
.	O

Ophthalmic Manifestations	B-T184
of	O
Facial	B-T029
Dog Bites	B-T037
in	O
Children	B-T100
To	O
characterize	O
ophthalmic manifestations	B-T184
and	O
periocular injuries	B-T037
of	O
pediatric	B-T080
facial	B-T029
dog bites	B-T037
.	O
A	O
retrospective	B-T080
review	B-T170
of	O
all	O
children	B-T100
younger	B-T079
than	O
18	O
years	B-T079
who	O
sought	O
medical	B-T169
attention	B-T041
after	O
a	O
dog bite	B-T037
to	O
the	O
face	B-T029
between	O
January	B-T080
1,	O
2003	O
and	O
May	B-T079
22,	O
2014	O
was	O
performed	B-T169
at	O
a	O
large tertiary	B-T081
pediatric hospital	B-T093
.	O
Data	B-T078
on	O
type	B-T080
and	O
location of injury	B-T033
,	O
surgical intervention	B-T033
,	O
and	O
complications	B-T046
were	O
collected	B-T169
.	O
A	O
total	B-T080
of	O
1,989	O
children	B-T100
aged	B-T032
0.19	O
to	O
17	O
years	B-T079
were	O
identified	B-T080
with	O
dog bite	B-T037
dog bite s	B-T037
.	O
Dog bite	B-T037
Dog bite s	B-T037
to	O
the	O
face	B-T029
occurred	B-T079
in	O
most	B-T081
patients	B-T101
(n	O
=	O
1,	O
414	O
[71%]).	O
Of	O
those	O
children	B-T100
with	O
facial	B-T029
dog bite injuries	B-T037
,	O
230	O
(16%)	O
suffered	B-T048
ophthalmic manifestations	B-T184
.	O
The	O
average	B-T081
age	B-T032
was	O
4.3	O
years	B-T079
.	O
Eyelid injuries	B-T037
occurred	B-T079
in	O
227	O
(99%)	O
of	O
children	B-T100
,	O
47	O
(20%)	O
sustained	B-T169
canalicular system	B-T022
injuries	B-T037
,	O
3	O
(1.3%)	O
suffered	B-T048
corneal abrasions	B-T037
,	O
and	O
2	O
patients	B-T101
sustained	B-T169
facial	B-T029
nerve injury	B-T037
resulting in	B-T169
lagophthalmos	B-T047
.	O
No	O
patients	B-T101
suffered	B-T048
vision loss	B-T033
.	O
Complications	B-T046
occurred	B-T079
in	O
32	O
patients	B-T101
(14%),	O
with	O
the	O
most	B-T081
common	B-T169
being	O
epiphora	B-T204
in	O
9	O
patients	B-T101
(28%),	O
upper eyelid ptosis	B-UnknownType
in	O
8	O
(25%),	O
and	O
prominent	B-T080
scar formation	B-T033
in	O
4	O
patients	B-T101
(13%).	O
Thirteen	O
children	B-T100
(5.7%)	O
needed	B-T080
one	O
or	O
more	O
secondary procedure	B-T061
to	O
correct	B-T080
complications	B-T046
.	O
The	O
authors	B-T097
report	B-T170
the	O
clinical features	B-T080
and	O
management	B-T090
on	O
the	O
largest series	B-T081
of	O
ophthalmic	B-T037
and	O
periocular injuries	B-T037
associated with	B-T080
pediatric	B-T080
facial	B-T029
dog bite	B-T037
dog bite s	B-T037
.	O
These	O
injuries	B-T037
occur	B-T079
in	O
about	O
1	O
in	O
6	O
dog bite	B-T037
dog bite s	B-T037
to	O
the	O
face	B-T029
and	O
primarily	O
involve	O
the	O
ocular adnexa	B-T023
.	O
Despite	O
early	B-T079
and	O
appropriate	B-T080
surgical management	B-T058
,	O
complications	B-T046
and	O
the	O
need	B-T080
for	O
revision surgery	B-T061
are	O
relatively	O
common	B-T169
.	O

Blastocystis subtyping	B-T204
and	O
its	O
association	O
with	O
intestinal parasites	B-T047
in	O
children	B-T100
from	O
different	O
geographical regions of Colombia	B-T083
Blastocystis	B-T204
is	O
a	O
common	O
enteric protist colonizing	B-T033
probably	O
more	O
than	O
1	O
billion	O
people	B-T098
with	O
a	O
large	O
variety	O
of	O
non-human hosts	B-T001
.	O
Remarkable	O
genetic diversity	B-T070
has	O
been	O
observed,	O
leading	O
to	O
the	O
subdivision of the genus	B-T185
into	O
multiple subtypes	B-T185
(	O
ST	B-T185
),	O
some	O
of	O
which	O
are	O
exclusively	O
found	O
in	O
non-human hosts	B-T001
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
distribution	O
of	O
Blastocystis STs	B-T204
/	O
18S alleles	B-T028
in	O
symptomatic	B-T169
(	O
abdominal pain	B-T184
,	O
anal pruritus	B-T184
,	O
diarrhea	B-T184
,	O
headache	B-T184
,	O
nauseas	B-T184
and/or	O
vomit	B-T184
)	O
and	O
asymptomatic	B-T033
children	B-T100
from	O
nine	O
geographical regions of Colombia	B-T083
.	O
A	O
total	O
of	O
2026	O
fecal samples	B-T058
were	O
collected	O
as	O
part	O
of	O
a	O
national survey	B-T062
to	O
estimate	O
the	O
frequency	O
of	O
intestinal parasites	B-T047
in	O
children	B-T100
.	O
A	O
set	O
of	O
256	O
samples	O
that	O
were	O
Blastocystis positive	B-T204
was	O
finally	O
selected.	O
The	O
samples	O
were	O
submitted	O
to	O
DNA extraction	B-T063
,	O
Real Time PCR	B-T063
and	O
sequencing	B-T059
using	O
Blastocystis	B-T047
-specific	O
primers	B-T114
targeting	O
the	O
small subunit	B-T026
rRNA gene	B-T028
for	O
ST identification	B-T059
.	O
DNA	B-T114
of	O
Ascaris lumbricoides	B-T204
(16.4%),	O
Trichuris trichiura	B-T204
(8.2%),	O
hookworms	B-T204
(	O
Necator americanus	B-T204
/	O
Ancylostoma duodenale	B-T204
)	O
(7.3%),	O
Giardia duodenalis	B-T204
(23.1%),	O
Entamoeba complex	B-T204
(82%),	O
Entamoeba coli	B-T204
(55%),	O
Hymenolepis nana	B-T204
(0.8%),	O
Endolimax nana	B-T204
(33.2%)	O
and	O
Neobalantidium coli	B-T204
(2.7%)	O
was	O
detected	O
in	O
the	O
Blastocystis	B-T204
-	O
positive samples	B-T033
.	O
We	O
detected	O
ST1	B-T204
(21.4%),	O
ST2	B-T204
(19.5%),	O
ST3	B-T204
(55.5%),	O
ST4	B-T204
(0.8%),	O
ST6	B-T204
(2%)	O
and	O
ST7	B-T204
(0.8%);	O
alleles	B-T028
1,	O
2,	O
4,	O
81,	O
82	O
and	O
83	O
for	O
ST1	B-T204
;	O
alleles	B-T028
9,	O
11,	O
12,	O
15,	O
67,	O
71	O
and	O
73	O
for	O
ST2	B-T204
;	O
alleles	B-T028
34,	O
36,	O
38,	O
45,	O
49,	O
55,	O
134	O
and	O
128	O
for	O
ST3	B-T204
;	O
allele	B-T028
42	O
for	O
ST4	B-T204
;	O
allele	B-T028
122	O
for	O
ST6	B-T204
,	O
and	O
allele	B-T028
142	O
for	O
ST7	B-T204
.	O
Further	O
studies	O
implementing	O
high-resolution	B-T059
molecular markers	B-T201
are	O
necessary	O
to	O
understand	O
the	O
dynamics	O
of	O
Blastocystis	B-T204
transmission	B-T070
and	O
the	O
role	O
of	O
this	O
Stramenopila	B-T204
in	O
health and disease	B-T070
.	O

Did	O
municipal solid waste	B-T167
landfill	B-T083
have	O
obvious	O
influence	B-T077
on	O
polychlorinated dibenzo-p-dioxins	B-T109
and	O
polychlorinated dibenzofurans	B-T109
(	O
PCDD	B-T109
/	O
Fs	B-T109
)	O
in	O
ambient air	B-T167
:	O
A	O
case study	B-T170
in	O
East China	B-T083
Municipal solid waste	B-T167
(	O
MSW	B-T167
)	O
landfill	B-T083
was	O
a	O
main	O
way	O
to	O
disposal	B-T052
of	O
MSW	B-T167
and	O
almost	O
95%	O
of	O
MSW	B-T167
was	O
disposed	B-T052
by	O
landfills	B-T083
in	O
the	O
world	B-T098
.	O
In	O
order	O
to	O
understand	O
the	O
influence	B-T077
of	O
MSW	B-T167
landfill	B-T083
on	O
polychlorinated dibenzo-p-dioxins	B-T109
and	O
polychlorinated dibenzofurans	B-T109
(	O
PCDD	B-T109
/	O
Fs	B-T109
)	O
in	O
surrounding atmosphere	B-T070
,	O
42	O
ambient air	B-T167
samples	O
were	O
collected	O
and	O
analyzed	B-T062
from	O
surrounding sites	B-T082
,	O
background site	B-T082
,	O
upwind site	B-T082
and	O
downwind site	B-T082
of	O
a	O
MSW	B-T167
landfill	B-T083
in	O
East China	B-T083
.	O
The	O
results	O
of	O
present	O
study	B-T062
were	O
summarized	O
as	O
follows.	O
(1)	O
The	O
total	O
concentrations	B-T081
of	O
PCDD	B-T109
/	O
Fs	B-T109
(∑	O
PCDD	B-T109
/	O
Fs	B-T109
)	O
in	O
ambient air	B-T167
from	O
surrounding sites	B-T082
,	O
background site	B-T082
,	O
upwind site	B-T082
and	O
downwind site	B-T082
were	O
2.215±1.004,	O
2.058±0.458,	O
2.617±1.092	O
and	O
1.822±0.566pgNm(-3),	O
respectively.	O
(2)	O
The	O
toxic equivalent concentrations	B-T081
(	O
TEQ	B-T081
)	O
of	O
PCDD	B-T109
/	O
Fs	B-T109
in	O
ambient air	B-T167
from	O
surrounding sites	B-T082
,	O
background site	B-T082
,	O
upwind site	B-T082
and	O
downwind site	B-T082
were	O
0.103±0.017,	O
0.096±0.015,	O
0.120±0.024	O
and	O
0.108±0.014pg	O
I-TEQNm(-3),	O
respectively.	O
(3)	O
The	O
congener profiles	B-T059
,	O
∑	O
PCDD	B-T109
/	O
Fs	B-T109
and	O
TEQ	B-T081
between	O
background atmosphere	B-T070
and	O
surrounding atmosphere	B-T070
of	O
landfill	B-T083
did	O
not	O
show	O
statistically significant	B-T081
difference.	O
(4)	O
The	O
∑	O
PCDD	B-T109
/	O
Fs	B-T109
and	O
TEQ	B-T081
in	O
ambient air	B-T167
of	O
downwind site	B-T082
were	O
not	O
higher	O
than	O
that	O
of	O
upwind site	B-T082
,	O
suggesting	O
that	O
studied	O
landfill	B-T083
did	O
not	O
have	O
obvious	O
influence	B-T077
on	O
PCDD	B-T109
/	O
Fs	B-T109
in	O
ambient air	B-T167
from	O
downwind site	B-T082
.	O
(5)	O
The	O
95th	O
percentile	B-T081
carcinogenic risk	B-T081
(	O
CR	B-T081
)	O
of	O
PCDD	B-T109
/	O
Fs	B-T109
in	O
ambient air	B-T167
from	O
s	O
urrounding sites	B-T082
,	O
background site	B-T082
,	O
upwind site	B-T082
and	O
downwind site	B-T082
were	O
8.03×10(-9),	O
7.57×10(-9),	O
9.69×10(-9)	O
and	O
8.15×10(-9),	O
respectively,	O
which	O
were	O
much lower than the threshold value	B-T080
of	O
CR	B-T081
(10(-6)),	O
suggesting	O
that	O
studied	O
landfill	B-T083
did	O
not	O
influence	B-T077
the	O
CR	B-T081
of	O
PCDD	B-T109
/	O
Fs	B-T109
in	O
surrounding atmosphere	B-T070
and	O
negligible	O
cancer risk	B-T081
occurred.	O
(6)	O
The	O
non-carcinogenic risk	B-T033
(	O
non-CR	B-T033
)	O
analysis	B-T062
indicated	O
that	O
landfill	B-T083
did	O
not	O
have	O
influence	B-T077
on	O
the	O
non-CR	B-T033
of	O
PCDD	B-T109
/	O
Fs	B-T109
in	O
surrounding atmosphere	B-T070
and	O
no	O
obvious	O
non-carcinogenic effects	B-T080
developed.	O

Methodological considerations	B-T080
for	O
designing	O
a	O
community	B-T096
water fluoridation	B-T069
cessation	B-T052
study	B-T062
High-quality	B-T062
,	O
up-to-date	O
research	B-T062
on	O
community	B-T096
water fluoridation	B-T069
(	O
CWF	B-T069
),	O
and	O
especially	O
on	O
the	O
implications	O
of	O
CWF	B-T069
cessation	B-T052
for	O
dental health	B-T058
,	O
is	O
limited.	O
Although	O
CWF	B-T069
cessation	B-T052
studies	B-T062
have	O
been	O
conducted,	O
they	O
are	O
few	O
in	O
number;	O
one	O
of	O
the	O
major	O
reasons	O
is	O
the	O
methodological complexity	B-T169
of	O
conducting	O
such	O
a	O
study	B-T062
.	O
This	O
article	O
draws	O
on	O
a	O
systematic review	B-T170
of	O
existing	O
cessation	B-T052
studies	B-T062
(n=15)	O
to	O
explore	O
methodological considerations	B-T080
of	O
conducting	O
CWF	B-T069
cessation	B-T052
studies	B-T062
in	O
future	B-T079
.	O
We	O
review	O
nine	O
important	O
methodological aspects	B-T080
(	O
study design	B-T062
,	O
comparison community	B-T096
,	O
target population	B-T098
,	O
time frame	B-T079
,	O
sampling strategy	B-T170
,	O
clinical indicators	B-T169
,	O
assessment criteria	B-T170
,	O
covariates	O
and	O
biomarkers	B-T201
)	O
and	O
provide	O
recommendations	B-T078
for	O
planning	B-T058
future	B-T079
CWF	B-T069
cessation	B-T052
studies	B-T062
that	O
examine	O
effects	O
on	O
dental caries	B-T047
.	O
There	O
is	O
no	O
one	O
ideal	O
study design	B-T062
to	O
answer	O
a	O
research question	B-T078
.	O
However,	O
recommendations	B-T078
proposed	O
regarding	O
methodological aspects	B-T080
to	O
conduct	O
an	O
epidemiological study	B-T062
to	O
observe	O
the	O
effects	O
of	O
CWF	B-T069
cessation	B-T052
on	O
dental caries	B-T047
,	O
coupled	O
with	O
our	O
identification	O
of	O
important	O
methodological	O
gaps,	O
will	O
be	O
useful	O
for	O
researchers	B-T097
who	O
are	O
looking	O
to	O
optimize	B-T052
resources	B-T078
to	O
conduct	O
such	O
a	O
study	B-T062
with	O
standards	O
of	O
rigour.	O

Central Myxoma	B-T191
/	O
Myxofibroma	B-T191
of	O
the	O
Jaws	B-T023
:	O
A	O
Clinico	B-T073
-	O
Epidemiologic	B-T169
Review	B-T170
Myxomas	B-T191
are	O
a	O
group	O
of	O
benign	B-T080
rare tumors	B-T047
of	O
connective-tissue	B-T024
origin	B-T079
that	O
occur	O
in	O
both	O
hard (central)	B-T024
and	O
soft tissues	B-T024
of	O
the	O
body	B-T016
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
is	O
to	O
highlight	O
our	O
experience	O
in	O
the	O
management	O
of	O
central myxoma of the jaw	B-T191
,	O
with	O
emphasis	O
on	O
its	O
clinic	B-T073
-	O
epidemiologic	B-T169
features	O
as	O
seen	O
in	O
our	O
environment	B-T082
.	O
All	O
patients	B-T101
who	O
were	O
managed	O
for	O
central myxoma of the jaw	B-T191
at	O
the	O
Oral and Maxillofacial Surgery department	B-T092
of	O
a	O
regional University Teaching Hospital	B-T073
between	O
September	O
1997	O
and	O
October	O
2015	O
were	O
retrospectively studied	B-T062
.	O
Details	O
sourced	O
included	O
age	B-T032
,	O
sex	B-T032
,	O
site of tumor	B-T082
,	O
duration	B-T079
,	O
signs/symptoms	B-T033
,	O
treatment given	B-T033
,	O
and	O
complications	B-T046
.	O
Data	B-T078
were	O
analyzed	B-T062
using	O
Statistical Package for Social Sciences (SPSS) version 16	B-T073
(	O
SPSS Inc	B-T073
.,	O
Chicago	B-T083
,	O
IL	B-T083
,	O
USA	B-T083
)	O
and	O
Microsoft Excel 2007	B-T073
(	O
Microsoft	B-T073
,	O
Redmond	B-T083
,	O
WA	B-T083
,	O
USA	B-T083
).	O
Results	B-T169
from	O
descriptive statistics	B-T081
were	O
represented	O
in	O
the	O
form	O
of	O
tables	B-T170
and	O
charts	B-T170
,	O
with	O
a	O
test for significance	B-T170
(ρ)	O
using	O
Pearson Chi-square	B-T170
(χ(2))	O
set	O
at	O
0.05.	O
A	O
total	O
of	O
16	O
patients	B-T101
were	O
managed	O
within	O
the	O
period	B-T079
reviewed	B-T080
,	O
consisting	O
of	O
10	O
(62.5%)	O
females	B-T032
and	O
six	O
(37.5%)	O
males	B-T032
,	O
giving	O
a	O
male-to-female ratio	B-UnknownType
of	O
1:1.7.	O
The	O
ages	B-T032
of	O
patients	B-T101
ranged	B-T081
from	O
5	O
to	O
70	O
years	B-T079
,	O
with	O
a	O
mean	O
of	O
27.06±15.45	O
years	B-T079
.	O
The	O
mandible	B-T023
accounted	O
for	O
nine	O
(56.3%)	O
cases	B-T169
and	O
the	O
maxilla	B-T023
for	O
six	O
(37.5%)	O
cases	B-T169
,	O
while	O
a	O
combination	B-T080
of	O
the	O
maxilla	B-T023
and	O
the	O
zygoma	B-T023
were	O
involved	O
in	O
one	O
(6.3%)	O
case	B-T169
.	O
Bucco-lingual	B-T023
or	O
bucco-palatal	B-T023
expansion	B-T082
were	O
the	O
most	O
common	O
presentation	O
(six	O
[46.2%]	O
cases	B-T169
each).	O
Histological	B-T169
assessment	B-T058
of	O
tissue specimens	B-T024
showed	O
that	O
fibromyxoma	B-T191
accounted	B-T078
for	O
seven	O
(43.8%)	O
cases	B-T169
,	O
while	O
the	O
remaining	O
nine	O
(56.3%)	O
cases	B-T169
were	O
diagnosed	B-T033
as	O
myxoma	B-T191
.	O
All	O
patients	B-T101
had	O
jaw resections	B-T061
,	O
and	O
these	O
consisted	O
of	O
mandibulectomies	B-T061
in	O
nine	O
(60.0%)	O
patients	B-T101
and	O
maxillectomies	B-T061
in	O
six	O
(40.0%)	O
patients	B-T101
.	O
The	O
duration of hospital stay	B-T079
ranged	B-T081
from	O
5	O
to	O
29	O
days	B-T079
,	O
with	O
a	O
mean	O
of	O
17.86±7.68	O
days	B-T079
.	O
Complications	B-T046
were	O
noted	O
in	O
three	O
patients	B-T101
,	O
and	O
all	O
were	O
surgical wound infections	B-T046
.	O
Most	O
patients	B-T101
in	O
our	O
environment	B-T082
present	O
late	O
with	O
large tumors	B-T080
and	O
are	O
usually	O
not	O
compliant	O
with	O
follow-up	B-T058
review	B-T078
.	O
Thus,	O
a	O
radical	B-T080
approach	O
is	O
favored	O
in	O
most	O
patients	B-T101
.	O

Pediatric	B-T080
Hypovitaminosis D	B-T047
:	O
Molecular	O
Perspectives	B-T080
and	O
Clinical	B-T201
Implications	B-T078
Vitamin D	B-T109
,	O
a	O
secosteroid	B-T109
,	O
is	O
essential	B-T080
for	O
the	O
development	B-T040
and	O
maintenance	B-T052
of	O
healthy	B-T080
bone	B-T023
in	O
both	O
the	O
adult	B-T100
and	O
pediatric	B-T080
populations	B-T098
.	O
Low level	B-T081
of	O
25-hydroxy vitamin D	B-T121
(	O
25-(OH)-D	B-T121
)	O
is	O
highly	O
prevalent	O
in	O
children	B-T100
worldwide	O
and	O
has	O
been	O
linked	O
to	O
various	O
adverse	B-T046
health outcomes	B-T170
including	O
rickets	B-T047
,	O
osteomalacia	B-T047
,	O
osteomalacic myopathy	B-T047
,	O
sarcopenia	B-T047
,	O
and	O
weakness	B-T184
,	O
growth retardation	B-T046
,	O
hypocalcemia	B-T047
,	O
seizure	B-T184
and	O
tetany	B-T047
,	O
autism	B-T048
,	O
cardiovascular diseases	B-T047
,	O
diabetes mellitus	B-T047
,	O
cancers	B-T191
(	O
prostate	B-T191
,	O
colon	B-T191
,	O
breast	B-T191
),	O
infectious diseases	B-T047
(	O
viral	B-T047
,	O
tuberculosis	B-T047
),	O
and	O
autoimmune diseases,	B-T047
such	O
as	O
multiple sclerosis	B-T047
and	O
Hashimoto's thyroiditis	B-T047
.	O
Risk factors	B-T033
for	O
hypovitaminosis D	B-T047
are	O
people	B-T098
with	O
darker skin pigmentation	B-T042
,	O
use	B-T169
of	O
sunscreen	B-T167
,	O
insufficient	B-T080
ultraviolet B	B-T070
exposure	B-T080
,	O
prematurity	B-T047
,	O
living in northern latitudes	B-T082
,	O
malnutrition	B-T047
,	O
obesity	B-T047
,	O
exclusive breastfeeding	B-T055
,	O
low maternal vitamin D level	B-T033
,	O
certain	O
medications	B-T121
,	O
drinking	B-T040
unfortified cow's milk	B-T168
,	O
liver failure	B-T047
,	O
chronic renal insufficiency	B-T047
,	O
cystic fibrosis	B-T047
,	O
asthma	B-T047
,	O
and	O
sickle cell hemoglobinopathy	B-T047
.	O
This	O
review	B-T170
highlights	O
and	O
summarizes	O
the	O
molecular	O
perspectives	O
of	O
vitamin D deficiency	B-T047
and	O
its	O
potential	O
adverse	B-T046
health outcomes	B-T170
in	O
pediatric	B-T080
age groups	B-T100
.	O
The	O
recommended treatment regimen	B-T033
is	O
beyond	O
the	O
scope	O
of	O
this	O
review	B-T170
.	O

Causes	O
of	O
ecological	B-T082
gradients	B-T081
in	O
leaf	B-T002
margin	B-T082
entirety	B-T081
:	O
Evaluating	B-T170
the	O
roles	B-T077
of	O
biomechanics	B-T091
,	O
hydraulics	B-T090
,	O
vein geometry	B-T090
,	O
and	O
bud	B-T002
packing	B-T052
A	O
recent	B-T079
commentary	B-T170
by	O
Edwards	O
et	O
al.	O
(Am.	O
J.	O
Bot.	O
103:	O
975-978)	O
proposed	B-T080
that	O
constraints	B-T169
imposed	O
by	O
the	O
packing	B-T052
of	O
young	B-T079
leaves	B-T002
in	O
buds	B-T002
could	O
explain	O
the	O
positive	B-T033
association	B-T078
between	O
non-entire	B-T080
leaf	B-T002
margins	B-T082
and	O
latitude	B-T081
but	O
did	O
not	O
thoroughly	O
consider	B-T078
alternative	B-T077
explanations	B-T170
.	O
We	O
review	B-T078
the	O
logic	B-T078
and	O
evidence	B-T078
underlying	O
six	O
major	B-T080
hypotheses	B-T078
for	O
the	O
functional	B-T169
significance	B-T078
of	O
marginal	B-T082
teeth	B-T002
,	O
involving	O
putative	B-T078
effects	B-T080
on	O
(1)	O
leaf	B-T002
cooling	B-T070
,	O
(2)	O
optimal	B-T080
support	O
and	O
supply	O
of	O
the	O
areas	B-T082
served	O
by	O
major	B-T080
veins	B-T023
,	O
(3)	O
enhanced	B-T081
leaf	B-T002
-	O
margin	B-T082
photosynthesis	B-T070
,	O
(4)	O
hydathodal function	B-T043
,	O
(5)	O
defense	B-T077
against	B-T080
herbivores	B-T008
,	O
and	O
(6)	O
bud	B-T002
packing	B-T052
.	O
Theoretical	B-T078
and	O
empirical	B-T080
problems	B-T033
undermine	O
all	O
hypotheses	B-T078
except	B-T169
the	O
support-supply hypothesis	B-T078
,	O
which	O
implies	O
that	O
thinner	B-T080
leaves	B-T002
should	O
have	O
non-entire	B-T080
margins	B-T082
.	O
Phylogenetically	B-T078
structured analyses	B-T062
across	O
angiosperms	B-T002
,	O
the	O
El Yunque	B-UnknownType
flora	B-T033
,	O
and	O
the	O
genus	B-T185
Viburnum	B-T002
all	O
demonstrate	O
that	O
non-entire	B-T080
margins	B-T082
are	O
indeed	B-T080
more	O
common	B-T081
in	O
thinner	B-T080
leaves	B-T002
.	O
Across	O
angiosperms	B-T002
,	O
the	O
association	B-T078
of	O
leaf	B-T002
thickness	B-T080
with	O
non-entire	B-T080
leaf	B-T002
margins	B-T082
is	O
stronger	B-T080
than	O
that	O
of	O
latitude	B-T081
.	O
We	O
outline	B-T170
a	O
synthetic model	B-T170
showing	O
how	O
biomechanics	B-T091
,	O
hydraulics	B-T090
,	O
vein	B-T023
geometry	B-T090
,	O
rates	B-T079
of	O
leaf	B-T002
expansion	B-T043
,	O
and	O
length	O
of	O
development	B-T169
within	O
resting	B-T033
buds	B-T002
,	O
all	O
tied	O
to	O
leaf	B-T002
thickness	B-T080
,	O
drive	B-T033
patterns	B-T082
in	O
the	O
distribution	B-T082
of	O
entire	B-T081
vs.	O
non-entire	B-T080
leaf	B-T002
margins	B-T082
.	O
Our	O
model	B-T170
accounts	O
for	O
dominance	B-T078
of	O
entire	B-T081
margins	B-T082
in	O
the	O
tropics	B-UnknownType
,	O
Mediterranean scrub	B-T083
,	O
and	O
tundra	B-T083
,	O
non-entire	B-T080
margins	B-T082
in	O
cold temperate	B-T070
deciduous forests	B-T070
and	O
tropical	B-UnknownType
vines	B-T002
and	O
early-successional trees	B-T002
,	O
and	O
entire	B-T081
leaf	B-T002
margins	B-T082
in	O
monocots	B-T002
.	O
Spinose-toothed leaves	B-T002
should	O
be	O
favored	O
in	O
short-statured	B-T033
evergreen trees	B-T002
and	O
shrubs	B-T002
,	O
primarily	O
in	O
Mediterranean scrub	B-T083
and	O
related	O
semiarid habitats	B-T082
.	O

Viral Vector	B-T121
Biosafety	B-T170
in	O
Laboratory Animal Research	B-T062
Viral vector	B-T121
research	B-T062
presents	B-T078
unique	B-T080
occupational health	B-T091
and	O
safety	B-T068
challenges	B-T058
to	O
institutions	B-T093
due	O
to	O
the	O
rapid	B-T080
development	B-T169
ofboth	O
in vivo	B-T082
and	O
in vitro	B-T080
gene-editing technologies	B-T063
.	O
Risks	B-T078
to	O
human	B-T016
and	O
animal	B-T008
health	B-T078
make	O
it	O
incumbent	B-T080
on	O
institutions	B-T093
to	O
appropriately	B-T080
evaluate	B-T058
viral vector	B-T121
usage	B-T169
in	O
research	B-T062
on	O
the	O
basis	B-T169
of	O
available	B-T169
information	B-T078
and	O
governmental regulations	B-T064
and	O
guidelines	B-T170
.Here	O
we	O
review	B-T078
the	O
factors	B-T169
related	O
to	O
risk assessment	B-T058
regarding	O
viral vector	B-T121
usage	B-T169
in	O
animals	B-T008
and	O
the	O
relevant	B-T080
regulatory documents	B-T170
associated with	B-T080
this	O
research	B-T062
,	O
and	O
we	O
highlight	O
the	O
most	B-T081
commonly	B-T081
used	O
viral vectors	B-T121
in	O
research	B-T062
today.	O
This	O
review	B-T078
is	O
particularly	B-T080
focused	B-T169
on	O
the	O
background	B-T077
,	O
use	O
in	O
research	B-T062
and	O
associated	B-T080
health	B-T078
and	O
environmental risks	B-T080
related	B-T080
to	O
adenoviral	B-T005
,	O
adeno-associated viral	B-T005
,	O
lentiviral	B-T005
,	O
and	O
herpesviral	B-T005
vectors	B-T121
.	O

Liver Inflammation	B-T047
Relates	O
to	O
Decreased	B-T081
Canalicular	B-T023
Bile Transporter	B-T116
Expression	B-T045
in	O
Pediatric	B-T080
Onset	B-T081
Intestinal Failure	B-T047
Although	O
liver disease	B-T047
is	O
a	O
major	O
complication	B-T046
of	O
parenteral nutrition	B-T061
(	O
PN	B-T061
)	O
for	O
intestinal failure	B-T047
(	O
IF	B-T047
),	O
its	O
pathogenesis	B-T046
remains	O
unclear.	O
We	O
investigated	B-T169
potential	O
molecular	B-T080
mechanisms	B-T169
of	O
liver injury	B-T037
in	O
pediatric	B-T080
onset	B-T081
IF	B-T047
.	O
Liver	B-T023
expression	B-T045
of	O
canalicular	B-T023
phospholipid	B-T109
(	O
ABCB4	B-T116
),	O
bile acid	B-T109
(	O
ABCB11	B-T116
),	O
and	O
sterol	B-T109
(	O
ABCG5/8	B-T116
)	O
transporters	B-T116
,	O
their	O
upstream regulators	B-T116
LXR	B-T116
and	O
FXR	B-T116
as	O
well	O
as	O
pro-inflammatory cytokines	B-T116
interleukin-6	B-T116
(	O
IL6	B-T116
)	O
and	O
tumor necrosis factor	B-T116
(	O
TNF	B-T116
)	O
were	O
investigated	B-T169
among	O
patients	B-T101
with	O
IF	B-T047
[	O
age	B-T032
median	O
3.8	O
(	O
IQR	B-T081
1.2	O
to	O
11)]	O
in	O
relation	O
to	O
biochemical	B-T169
and	O
histologic	B-T169
liver injury	B-T037
,	O
PN	B-T061
,	O
serum	B-T031
plant sterols	B-T109
,	O
fibroblast growth factor 19	B-T116
,	O
and	O
α-tocopherol	B-T109
.	O
Patients	B-T101
receiving	O
PN	B-T061
currently	O
(n	O
=	O
18)	O
showed	O
more	O
advanced	O
liver injury	B-T037
than	O
patients	B-T101
after	O
weaning	B-T033
off	O
PN	B-T061
(n	O
=	O
30).	O
Histologic	B-T169
portal inflammation	B-T033
strongly	O
segregated	O
PN	B-T061
-	O
dependent	B-T169
(44%)	O
from	O
weaned	B-T033
off	O
patients	B-T101
(3%,	O
P	O
=	O
0.001)	O
and	O
coupled	O
with	O
progression	B-T046
of	O
cholestasis	B-T047
and	O
liver fibrosis	B-T047
.	O
Patients	B-T101
with	O
portal inflammation	B-T033
demonstrated	O
markedly	O
induced	O
liver	B-T023
RNA expression	B-T045
of	O
IL6	B-T028
and	O
TNF	B-T028
,	O
repression	B-T045
of	O
FXR	B-T116
and	O
its	O
canalicular	B-T023
bile transporter	B-T116
target	O
gene	B-T028
RNA expression	B-T045
,	O
including	O
ABCB4	B-T028
and	O
ABCB11	B-T028
as	O
well	O
as	O
decreased	B-T081
protein expression	B-T045
of	O
ABCB11	B-T116
and	O
ABCB4	B-T116
.	O
Furthermore,	O
upregulation	B-T044
of	O
LXR	B-T116
and	O
ABCG5/8	B-T028
RNA expression	B-T045
was	O
suppressed	B-T169
in	O
patients	B-T101
with	O
portal inflammation	B-T033
.	O
Current	O
PN	B-T061
,	O
increased	B-T081
serum	B-T031
levels	B-T080
of	O
plant sterols	B-T109
stigmasterol	B-T109
,	O
avenasterol	B-T109
,	O
and	O
sitosterol	B-T109
along	O
with	O
serum	B-T031
citrulline	B-T116
,	O
a	O
marker	B-T201
of	O
enterocyte mass	B-T025
,	O
predicted	O
portal inflammation	B-T033
.	O
In	O
pediatric	B-T080
onset	B-T081
IF	B-T047
,	O
current	O
PN	B-T061
delivery	O
synergistically	O
with	O
intestinal	B-T023
compromise	B-T033
promote	O
liver inflammation	B-T047
,	O
which	O
associates	B-T080
with	O
progression	B-T046
of	O
biochemical	B-T169
and	O
histologic	B-T169
liver injury	B-T037
,	O
while	O
reducing	B-T080
expression	B-T045
of	O
canalicular	B-T023
bile transporters	B-T116
.	O

Impaired mobility	B-T033
,	O
depressed mood	B-T033
,	O
cognitive impairment	B-T048
and	O
polypharmacy	B-T033
are	O
independently	O
associated	O
with	O
disability	B-T033
in	O
older	O
cancer	B-T191
outpatients	B-T101
:	O
The	O
prospective	O
Physical Frailty	B-T033
in	O
Elderly	B-T098
Cancer patients	B-T101
(	O
PF	B-T033
-	O
EC	B-T101
)	O
cohort study	B-T081
To	O
assess	O
the	O
prevalence	O
of	O
disability	B-T033
and	O
the	O
oncologic factors	B-T033
associated	O
with	O
disability	B-T033
in	O
older	O
outpatients	B-T101
with	O
cancer	B-T191
.	O
The	O
Physical Frailty	B-T033
in	O
Elderly	B-T098
Cancer patients	B-T101
(	O
PF	B-T033
-	O
EC	B-T101
)	O
study	O
(	O
France	B-T083
)	O
is	O
a	O
prospective bicentric observational cohort study	B-T062
.	O
Two	O
hundred	O
and	O
ninety	O
outpatients	B-T101
with	O
cancer	B-T191
were	O
included.	O
A	O
cross-sectional analysis	B-T062
of	O
oncologic factors	B-T033
and	O
geriatric	B-T080
variables	B-T080
associated	O
with	O
disability	B-T033
that	O
were	O
collected	O
using	O
a	O
comprehensive	B-T080
geriatric assessment	B-T058
(	O
CGA	B-T058
)	O
was	O
conducted.	O
Disability	B-T033
was	O
defined	O
as	O
impairment	B-T169
in	O
activities of daily living	B-T056
(	O
ADL	B-T056
)	O
and/or	O
instrumental activities of daily living	B-T033
(IADL	B-T033
),	O
simplified	O
to	O
four	O
items.	O
Univariate	B-T062
and	O
multivariate	B-T081
logistic models	B-T081
of	O
disabled patients	B-T101
were	O
performed.	O
The	O
three	O
final	O
multivariate	B-T081
models	B-T081
were	O
compared	O
using	O
the	O
area	O
under	O
the	O
receiver operating characteristic curve	B-T081
(	O
AUC	B-T081
/	O
ROC	B-T081
)	O
of	O
the	O
logistic model	B-T081
.	O
The	O
mean	O
age	O
was	O
80.6years,	O
and	O
51%	O
of	O
the	O
patients	O
were	O
women	B-T098
with	O
various	O
types	O
of	O
cancer	B-T191
.	O
The	O
prevalence	O
of	O
disability	B-T033
was	O
67.6%.	O
No	O
oncologic factors	B-T033
(	O
cancer site	B-T082
,	O
cancer extension	B-T191
)	O
were	O
associated	O
with	O
disability	B-T033
.	O
Impaired mobility	B-T033
,	O
poor functional status	B-T033
,	O
depressive mood	B-T033
,	O
cognitive impairment	B-T048
and	O
polypharmacy	B-T033
were	O
independently	O
associated	O
with	O
disability	B-T033
(P<0.05).	O
The	O
AUC/ROC	O
of	O
the	O
final	O
models	O
was	O
similar.	O
Disability	B-T033
was	O
highly	O
prevalent	O
in	O
older	O
cancer	B-T191
outpatients	B-T101
before	O
cancer treatment	B-T061
but	O
was	O
not	O
associated	O
with	O
oncologic factors	B-T033
.	O
Impaired mobility	B-T033
,	O
depressed mood	B-T033
,	O
cognitive impairment	B-T048
and	O
polypharmacy	B-T033
were	O
the	O
geriatric	O
variables	O
significantly	O
and	O
independently	O
associated	O
with	O
disability	B-T033
.	O
Identifying	O
these	O
factors	O
prior	O
to	O
cancer treatment	B-T061
could	O
enable	O
the	O
implementation	O
of	O
corrective actions	B-T169
to	O
improve	O
patient	B-T101
autonomy	B-T041
before	O
treatment	B-T061
and	O
during	O
follow-up	B-T058
.	O

Synthesis	B-T070
,	O
SAR	B-T080
and	O
molecular docking	B-T063
study	B-T062
of	O
novel	O
non-β-lactam inhibitors	B-T121
of	O
TEM type β-lactamase	B-T116
The	O
novel	O
classes	O
of	O
acylated phenoxyanilide	B-T121
and	O
thiourea compounds	B-T121
were	O
investigated	B-T169
for	O
their	O
ability	O
to	O
inhibit	B-T039
TEM type β-lactamase enzyme	B-T116
.	O
Two	O
compounds 4g	B-T121
and	O
5c	B-T121
reveal	O
the	O
inhibition	B-T039
potency	B-T081
in	O
micromolar	B-T081
range	O
and	O
show	O
their	O
action	B-T052
by	O
non-covalent binding	B-T044
in	O
the	O
vicinity	O
of	O
the	O
TEM-171	B-T116
active site	B-T169
.	O
The	O
structure activity relationship	B-T080
around	O
carbon chain length	B-T081
and	O
different	O
substituents in ortho- and para-positions	B-UnknownType
of	O
acylated phenoxyanilide	B-T121
as	O
well	O
as	O
molecular modelling	B-T062
study	B-T062
has	O
been	O
performed.	O

Metabolic responses	B-T033
of	O
the	O
growing	O
Daphnia similis	B-T204
to	O
chronic	B-T079
AgNPs	B-T073
exposure	O
as	O
revealed	O
by	O
GC-Q-TOF/MS	B-T059
and	O
LC-Q-TOF/MS	B-T059
Silver	B-T196
nanoparticles	B-T073
(	O
AgNPs	B-T073
)	O
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	B-T073
.	O
Their	O
fast-growing	B-T033
utilization	O
has	O
increased	B-T081
the	O
occurrence	O
of	O
AgNPs	B-T073
in	O
the	O
environment	B-T082
,	O
posing	O
potential	O
health and ecological risks	B-T078
.	O
In	O
this	O
study,	O
we	O
conducted	O
chronic toxicity tests	B-T060
and	O
investigated	O
the	O
metabolic	B-T123
changes	B-T169
of	O
the	O
growing	O
Daphna similis	B-T204
with	O
exposure to	B-T080
0,	O
0.02,	O
and	O
1	O
ppb	O
AgNPs	B-T073
,	O
using	O
non-targeted mass spectrometry	B-T059
-based	O
metabolomics	B-T091
.	O
To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	B-T081
metabolite	B-T123
change	B-T169
of	O
a	O
common	O
aquatic organism	B-T001
Daphnia crustacean	B-T204
through	O
its	O
life-cycle	B-T079
.	O
The	O
results	O
show	O
a	O
dynamic kinetic pattern	B-T033
of	O
the	O
growing	O
Daphnia's	B-T204
metabolome	B-T070
underwent	O
a	O
cycle	B-T079
from	O
day	B-T079
0	O
to	O
day	B-T079
21,	O
with	O
the	O
level	B-T080
of	O
metabolites	B-T123
gradually	O
increasing	B-T169
from	O
day	B-T079
0	O
to	O
day	B-T079
13,	O
before	O
falling	O
back	O
to	O
the	O
baseline	B-T081
level	B-T080
of	O
day	B-T079
0	O
on	O
day	B-T079
21.	O
As	O
for	O
the	O
samples	B-T167
exposed to	B-T080
environmental concentrations	B-T081
of	O
AgNPs	B-T073
,	O
although	O
without	O
morphological or structural changes	B-T033
,	O
numerous	O
metabolite	B-T123
changes	B-T169
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	B-T079
,	O
and	O
these	O
changes	B-T169
reached	O
steady state	B-T070
by	O
day	B-T079
13.	O
The	O
significant	O
changes	B-T169
in	O
certain	O
metabolites	B-T123
,	O
such	O
as	O
amino acids	B-T116
(	O
serine	B-T116
,	O
threonine	B-T116
and	O
tyrosine	B-T116
),	O
sugars	B-T109
(	O
d-allose	B-T109
)	O
and	O
fatty acids	B-T109
(	O
arachidonic acid	B-T109
)	O
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	B-T123
in	O
Daphnia	B-T204
respond	O
to	O
chronic	B-T079
AgNPs	B-T073
stress	B-T070
.	O
These	O
findings	B-T169
highlight	O
the	O
capability	B-T080
of	O
metabolomics	B-T091
to	O
discover	O
early	O
metabolic responses	B-T033
to	O
environmental	B-T082
silver	B-T196
nanoparticles	B-T073
.	O

Evaluating	O
the	O
relative effectiveness	B-T081
of	O
high-intensity	B-T185
and	O
low-intensity models	B-T081
of	O
behaviour change	B-T055
communication interventions	B-T061
for	O
abortion	B-T033
care-seeking	B-T055
in	O
Bihar	B-UnknownType
and	O
Jharkhand	B-UnknownType
,	O
India	B-T083
:	O
a	O
cross-sectional study	B-T062
This	O
study	O
aimed	O
to	O
compare	O
the	O
effectiveness	B-T080
of	O
a	O
high-intensity model	B-T185
(	O
HIM	B-T185
)	O
and	O
a	O
low-intensity model	B-T081
(	O
LIM	B-T081
)	O
of	O
behaviour change	B-T055
communication interventions	B-T061
in	O
Bihar	B-UnknownType
and	O
Jharkhand	B-UnknownType
states	O
of	O
India	B-T083
designed	O
to	O
improve	O
women's	B-T098
knowledge	B-T033
and	O
usage	O
of	O
safe abortion	B-T033
services,	O
as	O
well	O
as	O
the	O
dose effect	B-UnknownType
of	O
intervention	B-T061
exposure.	O
We	O
conducted	O
two	O
cross-sectional household surveys	B-T062
among	O
married	B-T033
women	B-T098
aged	B-T032
15-49	O
years	O
in	O
intervention	B-T061
and	O
comparison	O
districts	B-UnknownType
.	O
Difference-in-difference models	B-T081
were	O
used	O
to	O
assess	O
the	O
efficacy	B-T080
of	O
the	O
intervention	B-T061
,	O
adjusting	O
for	O
sociodemographic characteristics	B-T033
.	O
Although	O
both	O
intervention	B-T061
types	O
improved	O
abortion	B-T033
knowledge	B-T170
,	O
the	O
HIM	B-T185
intervention	B-T061
was	O
more	O
effective	O
in	O
improving	O
comprehensive knowledge	B-T170
about	O
abortion	B-T033
.	O
In	O
particular,	O
there	O
were	O
improvements	O
in	O
knowledge	B-T170
on	O
legality of abortion	B-T061
(AOR=2.2;	O
95%	O
CI	O
1.6	O
to	O
2.9)	O
and	O
nearby	O
sources	O
of	O
safe abortion care	B-T058
(AOR=1.7;	O
95%	O
CI	O
1.2	O
to	O
1.3).	O
Higher	O
level	O
of	O
exposure	O
to	O
abortion-related	O
messages	O
was	O
related	O
to	O
more	O
accurate	O
knowledge	B-T170
about	O
abortion	B-T033
within	O
both	O
intervention	B-T061
groups.	O
Evidence	O
was	O
mixed	O
on	O
changes	O
in	O
abortion	B-T033
care-seeking	B-T055
behaviour	B-T053
.	O
More	O
work	O
is	O
needed	O
to	O
ensure	O
that	O
women	B-T098
seek	O
safe abortion	B-T033
services	O
in	O
lieu	O
of	O
informal	O
services	O
that	O
may	O
be	O
more	O
likely	O
to	O
lead	O
to	O
postabortion complications	B-T046
.	O

Tissue	B-T024
MicroRNA	B-T114
profiles	O
as	O
diagnostic	B-T201
and	O
prognostic biomarkers	B-T080
in	O
patients	B-T101
with	O
resectable	B-T061
pancreatic ductal adenocarcinoma	B-T191
and	O
periampullary cancers	B-T191
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
validate	O
previously	O
described	O
diagnostic	B-T169
and	O
prognostic	B-T170
microRNA	B-T114
expression profiles	B-T081
in	O
tissue	B-T024
samples	O
from	O
patients	B-T101
with	O
pancreatic cancer	B-T191
and	O
other	O
periampullary cancers	B-T191
.	O
Expression	B-T045
of	O
46	O
selected	O
microRNAs	B-T114
was	O
studied	O
in	O
formalin	B-T109
-fixed	O
paraffin-embedded tissue	B-T024
from	O
patients	B-T101
with	O
resected	B-T061
pancreatic ductal adenocarcinoma	B-T191
(n	O
=	O
165),	O
ampullary cancer	B-T191
(n=59),	O
duodenal cancer	B-T191
(n	O
=	O
6),	O
distal	B-T082
common bile duct cancer	B-T191
(n	O
=	O
21),	O
and	O
gastric cancer	B-T191
(n	O
=	O
20);	O
chronic pancreatitis	B-T047
(n	O
=	O
39);	O
and	O
normal pancreas	B-T033
(n	O
=	O
35).	O
The	O
microRNAs	B-T114
were	O
analyzed	O
by	O
PCR	B-T063
using	O
the	O
Fluidigm platform	B-T170
.	O
Twenty-two	O
microRNAs	B-T114
were	O
significantly	O
differently	O
expressed	B-T045
in	O
patients	B-T101
with	O
pancreatic cancer	B-T191
when	O
compared	O
to	O
healthy controls	B-T080
and	O
chronic pancreatitis	B-T047
patients	B-T101
;	O
17	O
miRNAs	B-T114
were	O
upregulated	B-T044
(	O
miR-21-5p	B-T028
,	O
-	O
23a-3p	B-T028
,	O
-	O
31-5p	B-T028
,	O
-	O
34c-5p	B-T028
,	O
-	O
93-3p	B-T028
,	O
-	O
135b-3p	B-T028
,	O
-	O
155-5p	B-T028
,	O
-	O
186-5p	B-T028
,	O
-	O
196b-5p,	B-T028
-	O
203	B-T028
,	O
-	O
205-5p	B-T114
,	O
-	O
210	B-T028
,	O
-	O
222-3p	B-T028
,	O
-	O
451	B-T028
,	O
-	O
492	B-T028
,	O
-	O
614	B-T028
,	O
and	O
miR-622	B-T028
)	O
and	O
5	O
were	O
downregulated	B-T044
(	O
miR-122-5p	B-T028
,	O
-	O
130b-3p	B-T028
,	O
-	O
216b	B-T028
,	O
-	O
217	B-T028
,	O
and	O
miR-375	B-T028
).	O
MicroRNAs	B-T114
were	O
grouped	O
into	O
diagnostic	B-T169
indices	O
of	O
varying	O
complexity	B-T080
.	O
Ten	O
microRNAs	B-T114
associated with	B-T080
prognosis	B-T058
were	O
identified	O
(	O
let-7 g	B-T114
,	O
miR-29a-5p	B-T028
,	O
-	O
34a-5p	B-T028
,	O
-	O
125a-3p	B-T028
,	O
-	O
146a-5p	B-T028
,	O
-	O
187	B-T028
,	O
-	O
205-5p	B-T114
,	O
-	O
212-3p	B-T028
,	O
-	O
222-5p	B-T028
,	O
and	O
miR-450b-5p	B-T028
).	O
Prognostic indices	B-T081
based	O
on	O
differences	O
in	O
expression	B-T045
of	O
2	O
different	O
microRNAs	B-T114
were	O
constructed	O
for	O
pancreatic	B-T191
and	O
ampullary cancer	B-T191
combined	O
and	O
separately	O
(30,	O
5,	O
and	O
21	O
indices).	O
The	O
study	B-T062
confirms	O
that	O
pancreatic cancer	B-T191
tissue	B-T024
has	O
a	O
microRNA	B-T114
expression profile	B-T081
that	O
is	O
different	O
from	O
that	O
of	O
other	O
periampullary cancers	B-T191
,	O
chronic pancreatitis	B-T047
,	O
and	O
normal pancreas	B-T033
.	O
We	O
identified	O
prognostic	B-T170
microRNAs	B-T114
and	O
microRNA	B-T114
indices	O
that	O
were	O
associated with	B-T080
shorter	O
overall survival	B-T081
in	O
patients	B-T101
with	O
radically	O
resected	B-T061
pancreatic cancer	B-T191
.	O

Effectiveness	B-T080
of	O
workers	B-T098
'	O
general health examination	B-T060
in	O
Korea	B-T083
by	O
health examination period	B-T058
and	O
compliance	B-T033
:	O
retrospective cohort study	B-T062
using	O
nationwide	O
data	O
Our	O
study	O
evaluated	B-T058
the	O
effectiveness	B-T080
of	O
the	O
Workers	B-T098
'	O
General Health Examination	B-T060
by	O
health examination period	B-T058
and	O
compliance	B-T033
.	O
A	O
retrospective cohort	B-T062
of	O
the	O
health examination	B-T058
participants	B-T098
in	O
2006	O
(baseline	O
year:	O
N�€‰=�€‰6,527,045)	O
was	O
used.	O
We	O
identified	O
newly	O
occurring	O
cardio	B-T047
-	O
cerebrovascular disease	B-T047
over	O
7	O
years	O
(from	O
2007	O
to	O
2013).	O
After	O
stratification	B-T062
by	O
age	B-T032
,	O
sex	B-T032
,	O
and	O
national health insurance type	B-T058
,	O
we	O
identified	O
7	O
years'	O
cumulative	B-T080
incidence	B-T081
of	O
cardio	B-T047
-	O
cerebrovascular disease	B-T047
by	O
health examination	B-T058
compliance	B-T033
and	O
estimated	O
its	O
relative	O
risk	O
by	O
health examination period	B-T058
and	O
compliance	B-T033
.	O
The	O
compliant group	B-T098
presented	O
a	O
lower	O
cumulative	B-T080
incidence	B-T081
of	O
cardio	B-T047
-	O
cerebrovascular disease	B-T047
than	O
the	O
non-compliant group	B-T098
;	O
this	O
result	O
was	O
consistent	O
across	O
sex	B-T032
,	O
working	B-T057
age	B-T032
(40s	O
and	O
50s),	O
and	O
workplace	B-T082
policyholder	B-T078
.	O
Relative	O
risk	O
of	O
cardio	B-T047
-	O
cerebrovascular disease	B-T047
by	O
health examination period	B-T058
(1	O
and	O
2	O
years)	O
showed	O
statistically significant	B-T081
results	O
in	O
ischemic heart disease	B-T047
for	O
male	O
participants	B-T098
.	O
Of	O
men	B-T098
in	O
their	O
40s,	O
office workers	B-T033
(over	O
a	O
2-year	O
period)	O
presented	O
statistically	O
higher relative risk of	B-T033
ischemic heart disease	B-T047
than	O
non-office workers	B-T098
(over	O
a	O
1-year	O
period:	O
1.03;	O
95%	O
confidence interval	B-T081
,	O
1.02-1.03).	O
However,	O
there	O
were	O
no	O
consistent	O
results	O
in	O
ischemic	B-T169
cerebrovascular disease	B-T047
and	O
hemorrhagic	B-T080
cerebrovascular disease	B-T047
for	O
men	B-T098
or	O
cardio	B-T047
-	O
cerebrovascular disease	B-T047
for	O
women	B-T098
.	O
A	O
1-year	O
period	O
of	O
Workers	B-T098
'	O
General Health Examinations	B-T060
in	O
non-office workers	B-T098
had	O
a	O
more	O
significant	O
prevention	B-T061
effect	O
on	O
ischemic heart disease	B-T047
than	O
a	O
2-year	O
period	O
in	O
office workers	B-T033
among	O
working	O
age	B-T032
(40s-50s)	O
men	B-T098
.	O
It	O
is,	O
however,	O
necessary	O
to	O
consider	O
that	O
prevention	B-T061
of	O
cardio	B-T047
-	O
cerebrovascular disease	B-T047
can	O
be	O
partially	O
explained	O
by	O
their	O
occupational characteristics	B-T169
rather	O
than	O
by	O
health examination period	B-T058
.	O

Calibration	B-T081
of	O
Self-Report	B-T062
Measures	B-T081
of	O
Physical Activity	B-T056
and	O
Sedentary Behavior	B-T033
Calibration	B-T081
equations	B-T077
offer	O
potential	B-T080
to	O
improve	B-T080
the	O
accuracy	B-T080
and	O
utility	O
of	O
self-report	B-T062
measures	B-T081
of	O
physical activity	B-T056
(	O
PA	B-T056
)	O
and	O
sedentary behavior	B-T033
(	O
SB	B-T033
)	O
by	O
re-scaling	B-T052
potentially	B-T080
biased	O
estimates	B-T081
.	O
The	O
present	O
study	O
evaluates	O
calibration	B-T081
models	B-T081
designed	O
to	O
estimate	B-T081
PA	B-T056
and	O
SB	B-T033
in	O
a	O
representative	B-T081
sample	O
of	O
adults	B-T100
from	O
the	O
Physical Activity	B-T056
Measurement Survey	B-T062
(	O
PAMS	B-T062
).	O
Participants	B-T098
in	O
the	O
PAMS	B-T062
project	O
completed	O
replicate	O
single	O
day	O
trials	B-T062
that	O
involved	O
wearing	O
a	O
Sensewear armband (SWA)	B-T073
monitor	B-T074
for	O
24 hours	B-T079
followed	O
by	O
a	O
telephone	B-T062
administered	B-T169
24-hour	O
physical activity recall	B-T058
(	O
PAR	B-T058
).	O
Comprehensive	O
statistical model	B-T081
selection	O
and	O
validation	B-T169
procedures	B-T169
were	O
used	O
to	O
develop	O
and	O
test	O
separate	O
calibration	B-T081
models	B-T081
designed	O
to	O
predict	B-UnknownType
objectively	B-T062
-	O
measured	B-T081
SB	B-T033
and	O
moderate to vigorous PA	B-T056
(	O
MVPA	B-T056
from	O
self-reported	B-T062
PAR	B-T058
data.	O
Equivalence	B-UnknownType
testing	O
was	O
used	O
to	O
evaluate	O
the	O
equivalence	B-UnknownType
of	O
the	O
model-	O
predicted	B-UnknownType
values	O
with	O
the	O
objective	B-T062
measures	B-T081
in	O
a	O
separate	O
holdout	O
sample.	O
The	O
final	O
prediction	O
model	O
for	O
both	O
SB	B-T033
and	O
MVPA	B-T056
included	O
reported	O
time	O
spent	O
in	O
SB	B-T033
and	O
MVPA	B-T056
,	O
as	O
well	O
as	O
terms	O
capturing	O
sex	B-T032
,	O
age	B-T033
,	O
education	B-T033
,	O
and	O
BMI	B-T201
.	O
Cross-validation	B-T062
analyses	B-T081
on	O
an	O
independent	O
sample	O
exhibited	O
high	O
correlations	O
with	O
observed	O
SB	B-T033
(r	O
=	O
0.72)	O
and	O
MVPA	B-T056
(r	O
=	O
0.75).	O
Equivalence	B-UnknownType
testing	O
demonstrated	O
that	O
the	O
model-	O
predicted	B-UnknownType
values	O
were	O
statistically	B-T081
equivalent	O
to	O
the	O
corresponding	O
objective	B-T062
values	O
for	O
both	O
SB	B-T033
and	O
MVPA	B-T056
.	O
The	O
results	O
demonstrate	O
that	O
simple	O
regression	B-T170
models	B-T081
can	O
be	O
used	O
to	O
statistically	B-T081
adjust	O
for	O
over	O
or	O
underestimation	O
in	O
self-report	B-T062
measures	B-T081
among	O
different	O
segments	O
of	O
the	O
population	B-T098
.	O
The	O
models	B-T081
produced	O
group	O
estimates	B-T081
from	O
the	O
PAR	B-T058
that	O
were	O
statistically	B-T081
equivalent	O
to	O
the	O
observed	O
time	O
spent	O
in	O
SB	B-T033
and	O
MVPA	B-T056
obtained	O
from	O
the	O
objective	O
SWA	B-T073
monitor	B-T074
;	O
however	O
additional	O
work	O
is	O
needed	O
to	O
correct	O
for	O
estimates	B-T081
of	O
individual behavior	B-T055
.	O

Human	B-T016
amnion	B-T018
epithelial cells	B-T025
rescue	O
cell death	B-T043
via	O
immunomodulation	B-T061
of	O
microglia	B-T025
in	O
a	O
mouse model	B-T050
of	O
perinatal brain injury	B-T037
Human	B-T016
amnion	B-T018
epithelial cells	B-T025
(	O
hAECs	B-T025
)	O
are	O
clonogenic	B-T081
and	O
have	O
been	O
proposed	O
to	O
reduce	B-T081
inflammatory	B-T046
-	O
induced	B-T169
tissue injury	B-T037
.	O
Perturbation	B-T169
of	O
the	O
immune response	B-T042
is	O
implicated	O
in	O
the	O
pathogenesis	B-T046
of	O
perinatal brain injury	B-T037
;	O
modulating	B-T082
this	O
response	B-T042
could	O
thus	O
be	O
a	O
novel	B-T080
therapy	B-T061
for	O
treating	B-T169
or	O
preventing	O
such	O
injury	B-T037
.	O
The	O
immunomodulatory	B-T061
properties	O
of	O
hAECs	B-T025
have	O
been	O
shown	O
in	O
other	O
animal models	B-T008
,	O
but	O
a	O
detailed	O
investigation	B-T058
of	O
the	O
effects	B-T080
on	O
brain	B-T023
immune	B-T169
cells	B-T025
following	O
injury	B-T037
has	O
not	O
been	O
undertaken.	O
Here,	O
we	O
investigate	B-T058
the	O
effects	B-T080
of	O
hAECs	B-T025
on	O
microglia	B-T025
,	O
the	O
first	O
immune responders	B-T042
to	O
injury	B-T037
within	O
the	O
brain	B-T023
.	O
We	O
generated	O
a	O
mouse model	B-T050
combining	O
neonatal	B-T079
inflammation	B-T046
and	O
perinatal	B-T079
hyperoxia	B-T184
,	O
both	O
of	O
which	O
are	O
risk factors	B-T033
associated	O
with	O
perinatal brain injury	B-T037
.	O
On	O
embryonic	B-T042
day	B-T079
16	O
we	O
administered	B-T061
lipopolysaccharide	B-T109
(	O
LPS	B-T109
),	O
or	O
saline	B-T167
(	O
control	B-T167
),	O
intra-amniotically	B-T169
to	O
C57Bl/6 J mouse pups	B-T015
.	O
On	O
postnatal	B-T079
day	B-T079
(P)0,	O
LPS	B-T109
pups	B-T015
were	O
placed	O
in	O
hyperoxia	B-T184
(65%	O
oxygen	B-T121
)	O
and	O
control pups	B-T096
in	O
normoxia	B-T070
for	O
14	O
days	B-T079
.	O
Pups	B-T015
were	O
given	O
either	O
hAECs	B-T025
or	O
saline	B-T167
intravenously	B-T061
on	O
P4.	O
At	O
P14,	O
relative	O
to	O
controls	B-T096
,	O
LPS	B-T109
and	O
hyperoxia	B-T184
pups	B-T015
had	O
reduced	B-T081
body weight	B-T032
,	O
increased	B-T081
density	B-T081
of	O
apoptotic	B-T080
cells	B-T025
(	O
TUNEL	B-T063
)	O
in	O
the	O
cortex	B-T023
,	O
striatum	B-T023
and	O
white matter	B-T024
,	O
astrocytes	B-T025
(	O
GFAP	B-T116
)	O
in	O
the	O
white matter	B-T024
and	O
activated	B-T169
microglia	B-T025
(	O
CD68	B-T116
)	O
in	O
the	O
cortex	B-T023
and	O
striatum	B-T023
,	O
but	O
no	O
change	O
in	O
total	O
microglia	B-T025
density	B-T081
(	O
Iba1	B-T116
).	O
hAEC	B-T025
administration	B-T061
rescued	O
the	O
decreased	B-T081
body weight	B-T032
and	O
reduced	B-T081
apoptosis	B-T043
and	O
astrocyte	B-T025
areal coverage	B-T169
in	O
the	O
white matter	B-T024
,	O
but	O
increased	B-T081
the	O
density	B-T081
of	O
total	O
and	O
activated	B-T169
microglia	B-T025
.	O
We	O
then	O
stimulated	O
primary	B-T080
microglia	B-T025
(	O
CD45	B-T116
(low)	O
CD11b	B-T116
(+))	O
with	O
LPS	B-T109
for	O
24	O
h,	O
followed	O
by	O
co-culture	B-T059
with	O
hAEC	B-T025
conditioned medium	B-T130
for	O
48	O
h.	O
hAEC	B-T025
conditioned medium	B-T130
increased	B-T081
microglial	B-T025
phagocytic activity	B-T043
,	O
decreased	B-T081
microglia	B-T025
apoptosis	B-T043
and	O
decreased	B-T081
M1 activation markers	B-T043
(	O
CD86	B-T116
).	O
Stimulating	O
hAECs	B-T025
for	O
24	O
h	O
with	O
LPS	B-T109
did	O
not	O
alter	O
release	B-T061
of	O
cytokines	B-T116
known	O
to	O
modulate	B-T082
microglia	B-T025
activity	B-T052
.	O
These	O
data	B-T078
demonstrate	O
that	O
hAECs	B-T025
can	O
directly	O
immunomodulate	B-T061
brain	B-T023
microglia	B-T025
,	O
probably	O
via	O
release	B-T061
of	O
trophic factors	B-T116
.	O
This	O
observation	B-T062
offers	O
promise	O
that	O
hAECs	B-T025
may	O
afford	O
therapeutic utility	B-T061
in	O
the	O
management	B-T058
of	O
perinatal brain injury	B-T037
.	O

Identification	B-T080
of	O
Predictive	O
DNA Methylation	B-T044
Biomarkers	B-T123
for	O
Chemotherapy	B-T061
Response	B-T201
in	O
Colorectal Cancer	B-T191
Resistance	B-T038
to	O
5-Fluorouracil	B-T114
(	O
5-FU	B-T114
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	B-T169
of	O
colorectal cancer	B-T191
(	O
CRC	B-T191
)	O
and	O
posed	O
an	O
increased	O
risk of recurrence	B-T081
.	O
DNA methylation	B-T044
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	B-T046
for	O
recurrent disease	B-T047
and	O
its	O
contribution	B-T052
to	O
the	O
development	O
of	O
drug resistance	B-T038
remains	O
to	O
be	O
clarified	B-T052
.	O
This	O
study	B-T062
aimed	O
to	O
determine	O
the	O
methylation	B-T044
phenotype	B-T032
in	O
CRC	B-T191
for	O
identification	B-T080
of	O
predictive	O
markers	B-T123
for	O
chemotherapy	B-T061
response	B-T201
.	O
We	O
performed	O
DNA methylation	B-T044
profiling	B-T169
on	O
43	O
non-recurrent	B-T079
and	O
five	O
recurrent	B-T079
CRC	B-T191
patients	B-T101
using	O
the	O
Illumina Infinium HumanMethylation450 Beadchip assay	B-T063
.	O
In	O
addition,	O
CRC	B-T191
cells	B-T025
with	O
different	O
genetic backgrounds	B-T032
,	O
response	B-T201
to	O
5-FU	B-T114
and	O
global methylation	B-T044
levels	B-T080
(	O
HT29	B-T025
and	O
SW48	B-T025
)	O
were	O
treated	B-T169
with	O
5-FU	B-T114
and	O
DNA methylation	B-T044
inhibitor	B-T080
5-aza-2'-deoxycytidine	B-T114
(	O
5-azadC	B-T114
).	O
The	O
singular	O
and	O
combined	O
effects	B-T080
of	O
these	O
two	O
drug	B-T121
classes	B-T170
on	O
cell viability	B-T043
and	O
global methylation	B-T044
profiles	B-T059
were	O
investigated.	O
Our	O
genome-wide methylation study	B-T063
on	O
the	O
clinical	B-T080
specimens	B-T167
showed	O
that	O
recurrent	B-T079
CRCs	B-T191
exhibited	O
higher	O
methylation	B-T044
levels	B-T080
compared	O
to	O
non-recurrent	B-T079
CRCs	B-T191
.	O
We	O
identified	B-T080
4787	O
significantly	O
differentially	O
methylated genes	B-T028
(P	O
<	O
0.05);	O
3112	O
genes	B-T028
were	O
hyper	B-T033
-	O
while	O
1675	O
genes	B-T028
were	O
hypomethylated	B-T033
in	O
the	O
recurrent	B-T079
group	B-T078
compared	O
to	O
the	O
non-recurrent	B-T079
.	O
Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated and hypomethylated genes	B-T028
have	O
an	O
absolute	O
recurrent	B-T079
/	O
non-recurrent	B-T079
methylation	B-T044
difference	O
of	O
≥20%.	O
Most	O
of	O
the	O
hypermethylated genes	B-T028
were	O
involved	O
in	O
the	O
MAPK signaling pathway	B-T043
which	O
is	O
a	O
key	O
regulator	B-T077
for	O
apoptosis	B-T043
while	O
the	O
hypomethylated genes	B-T028
were	O
involved	O
in	O
the	O
PI3K-AKT signaling pathway	B-T044
and	O
proliferation process	B-T169
.	O
We	O
also	O
demonstrate	O
that	O
5-azadC	B-T114
treatment	B-T169
enhanced	O
response	B-T201
to	O
5-FU	B-T114
which	O
resulted	O
in	O
significant	O
growth inhibition	B-T043
compared	O
to	O
5-FU	B-T114
alone	O
in	O
hypermethylated cell lines SW48	B-T025
.	O
In	O
conclusion,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	B-T028
in	O
recurrent	B-T079
CRCs	B-T191
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	B-T061
targets	B-T169
for	O
patients	B-T101
with	O
chemoresistance	B-T038
.	O
We	O
postulate	O
that	O
aberrant	B-T080
methylation	B-T044
of	O
CCNEI	B-T028
,	O
CCNDBP1	B-T028
,	O
PON3	B-T028
,	O
DDX43	B-T028
,	O
and	O
CHL1	B-T028
in	O
CRC	B-T191
might	O
be	O
associated with	B-T080
the	O
recurrence	B-T067
of	O
CRC	B-T191
and	O
5-azadC	B-T114
-mediated	O
restoration	O
of	O
5-FU	B-T114
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK signaling pathway	B-T043
.	O

Effect	B-T080
of	O
Successive Administration	B-T061
of	O
Vancomycin	B-T116
and	O
Amikacin	B-T109
on	O
Auditory Function	B-T039
of	O
Immature Animals	B-T032
Effect	B-T080
of	O
successive administration	B-T061
vancomycin	B-T116
and	O
amikacin	B-T109
in	O
therapeutic	B-T169
doses	B-T081
on	O
immature	B-T080
auditory organ	B-T022
was	O
compared	B-T052
to	O
single	B-T081
administration	B-T058
of	O
the	O
same	B-T080
drugs	B-T121
in	O
chronic	B-T079
experiments	B-T062
on	O
immature	B-T080
rabbits	B-T015
by	O
recording	B-T080
of	O
short-latency	B-T079
auditory brainstem response	B-T201
(	O
ABR	B-T201
)	O
and	O
distortion product otoacoustic emission	B-T060
(	O
DPOAE	B-T060
).	O
Drug administration	B-T058
always	O
increased	B-T081
significantly	O
the	O
ABR	B-T201
peak	O
I	O
threshold	B-T081
.	O
Ototoxic	B-T037
antibiotics	B-T195
did	O
not	O
change	O
DPOAE	B-T060
,	O
but	O
selectively	O
affected	B-T169
activity	B-T033
of	O
outer hair cells	B-T025
.	O
No	B-T033
enhancement	B-T052
of	O
the	O
ototoxic effects	B-T037
was	O
observed	B-T169
after	O
successive administration	B-T061
of	O
the	O
two	O
antibiotics	B-T195
.	O

Water	B-T121
safety	B-T068
in	O
healthcare facilities	B-T073
.	O
The	O
Vieste Charter	B-T170
The	O
Study Group	B-T097
on	O
Hospital	B-T073
Hygiene	B-T091
of	O
the	O
Italian Society of Hygiene, Preventive Medicine and Public Health	B-T093
(	O
GISIO-SItI	B-T093
)	O
and	O
the	O
Local Health Authority	B-T093
of	O
Foggia	B-T083
,	O
Apulia	B-T083
,	O
Italy	B-T083
,	O
after	O
the	O
National Convention	B-T068
"Safe	O
water	B-T121
in	O
healthcare facilities	B-T073
"	O
held	O
in	O
Vieste-Pugnochiuso	B-T083
on	O
27-28	O
May	O
2016,	O
present	O
the	O
"	O
Vieste Charter	B-T170
",	O
drawn	O
up	O
in	O
collaboration	B-T054
with	O
experts	B-T097
from	O
the	O
National Institute of Health	B-T093
and	O
the Ministry of Health	B-UnknownType
.	O
This	O
paper	O
considers	O
the	O
risk factors	B-T033
that	O
may	O
affect	B-T058
the	O
water	B-T121
safety	B-T068
in	O
healthcare facilities	B-T073
and	O
reports	O
the	O
current	O
regulatory frameworks	B-T170
governing	O
the	O
management of installations	B-T058
and	O
the	O
quality	B-T080
of	O
the	O
water	B-T121
.	O
The	O
Authors	O
promote	O
a	O
careful	O
analysis	O
of	O
the	O
risks	B-T078
that	O
characterize	O
the	O
health facilities	B-T073
,	O
for	O
the	O
control	O
of	O
which	O
specific	O
actions	O
are	O
recommended	O
in	O
various	O
areas,	O
including	O
water safety plans	B-T089
;	O
approval	O
of	O
treatments	B-T169
;	O
healthcare facilities	B-T073
responsibility	B-T055
,	O
installation	O
and	O
maintenance	B-T052
of	O
facilities	B-T073
;	O
multidisciplinary approach	B-T082
;	O
education	B-T065
and	O
research	B-T062
;	O
regional and national coordination	B-T169
;	O
communication	B-T054
.	O

In Vivo	B-T082
Three-Dimensional	B-T082
Patellar	B-T023
Mechanics	B-T070
:	O
Normal	B-T080
Knees	B-T023
Compared	B-T052
with	O
Domed	B-T082
and	O
Anatomic	B-T080
Patellar	B-T023
Components	B-T073
Patellofemoral	B-T030
complications	B-T169
are	O
a	O
major	O
cause	O
of	O
revision surgery	B-T061
following	B-T079
total knee arthroplasty	B-T061
(	O
TKA	B-T061
).	O
High	B-T080
forces	B-T067
occurring	O
at	O
the	O
patellofemoral articulation	B-T030
coupled	B-T169
with	O
a	O
small	B-T081
patellofemoral	B-T030
contact area	B-T082
pose	O
substantial	O
design	B-T052
challenges.	O
In	O
this	O
study	B-T062
,	O
the	O
three-dimensional	B-T082
(	O
3D	B-T082
)	O
in vivo	B-T082
mechanics	B-T070
of	O
domed	B-T082
and	O
anatomically	B-T080
shaped	B-T082
patellar	B-T023
components	B-T073
were	O
compared	B-T052
with	O
those	O
of	O
native	B-T169
patellae	B-T023
.	O
Ten	O
normal	B-T080
knees	B-T023
,	O
10	O
treated with	B-T061
an	O
LCS-PS (low contact stress-posterior stabilized) TKA	B-T061
(	O
anatomically	B-T080
shaped	B-T082
patellar	B-T023
component	B-T073
),	O
and	O
10	O
treated with	B-T061
a	O
PFC Sigma RP-PS (press-fit condylar Sigma rotating platform-posterior stabilized) TKA	B-T061
(	O
domed	B-T082
patellar	B-T023
component	B-T073
)	O
were	O
analyzed	B-T062
under	O
fluoroscopic	B-T060
surveillance	B-T169
while	O
the	O
patient	B-T101
performed	B-T169
a	O
weight-bearing	B-T033
deep	B-T082
knee bend	B-T033
from	O
full	B-T080
knee extension	B-T033
to	O
maximum	B-T081
knee flexion	B-T033
.	O
Relevant	O
bone	O
geometries	O
were	O
segmented	B-T082
out	O
from	O
computed tomography	B-T060
(	O
CT	B-T060
)	O
scans	B-T060
,	O
and	O
computer-assisted-design	B-T066
(	O
CAD	B-T066
)	O
models	B-T170
of	O
the	O
implanted	B-T074
components	B-T073
were	O
obtained	O
from	O
the	O
manufacturer.	O
Three-dimensional	B-T082
patellofemoral	B-T030
kinematics	B-T091
were	O
obtained	O
using	O
a	O
3D	B-T082
-to-	O
2D	B-T082
registration	O
process.	O
Contact mechanics	B-T070
were	O
calculated	B-T052
using	O
a	O
distance map	B-T073
between	O
the	O
articulating patellar	B-T023
and	O
femoral surfaces	B-T029
.	O
Both	O
patellar	B-T023
component	B-T073
designs	O
exhibited	O
good	B-T080
rotational kinematics	B-T091
and	O
tracked	O
well	O
within	O
the	O
femoral trochlea	B-T023
when	O
compared	B-T052
with	O
the	O
normal	B-T080
patella	B-T023
.	O
The	O
contact areas	B-T082
in	O
the	O
TKA	B-T061
groups	B-T078
peaked	O
at	O
60°	O
of	O
knee flexion	B-T033
(	O
mean	B-T081
and	O
standard deviation	B-T081
,	O
201	O
±	O
63.4	O
mm	O
for	O
the	O
LCS-PS group	B-T078
and	O
218	O
±	O
95.4	O
mm	O
for	O
the	O
Sigma RP-PS group	B-T078
),	O
and	O
the	O
areas	B-T082
were	O
substantially	O
smaller	B-T080
than	O
those	O
previously	O
reported	B-T170
for	O
the	O
normal	B-T080
patella	B-T023
.	O
Contact points	B-T082
in	O
the	O
TKA	B-T061
groups	B-T078
stayed	O
close	O
to	O
the	O
center	B-T082
of	O
the	O
patellar	B-T023
components	B-T073
.	O
Both	O
designs	B-T052
performed	B-T169
satisfactorily	B-T080
,	O
although	O
patellofemoral	B-T030
contact areas	B-T082
were	O
reduced	B-T080
in	O
comparison	B-T052
with	O
those	O
in	O
the	O
native	B-T169
patella	B-T023
.	O
Therapeutic	O
Level	O
III.	O
See	O
Instructions	O
for	O
Authors	O
for	O
a	O
complete	O
description	O
of	O
levels	O
of	O
evidence.	O

Assessment	B-T052
of	O
the	O
Extravascular Implantable Defibrillator	B-T074
:	O
Feasibility	B-T080
of	O
Substernal Ventricular Pacing	B-T061
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
assess	B-T052
feasibility	B-T080
of	O
ventricular pacing	B-T061
and	O
thresholds	B-T080
from	O
within	B-T082
the	O
substernal space	B-T029
to	O
examine	O
a	O
new	B-T080
extravascular ICD	B-T074
configuration	B-T082
with	O
pacing	B-T061
capabilities	B-T080
.	O
In	O
patients	B-T101
undergoing	O
midline sternotomy	B-T061
,	O
a	O
duodecapolar diagnostic pacing catheter	B-T074
was	O
positioned	B-T082
in	O
the	O
substernal space	B-T029
anterior	B-T082
to	O
the	O
pericardium	B-T023
,	O
and	O
a	O
cutaneous patch	B-T033
in	O
left lateral position	B-T082
.	O
Different	B-T080
unipolar	B-T082
and	O
bipolar	B-T082
pacing	B-T061
configurations	B-T082
were	O
assessed	B-T052
.	O
Strength-duration curves	B-T059
were	O
performed	B-T169
to	O
identify	O
the	O
optimal	B-T080
output	B-T060
,	O
starting	O
at	O
25	O
mA	B-T081
with	O
a	O
pulse width	B-T081
of	O
10	O
milliseconds	B-T079
.	O
Eight	O
patients	B-T101
with	O
mean	B-T081
age	B-T032
69	O
±	O
9	O
years	B-T079
were	O
included	B-T169
.	O
In	O
5,	O
ventricular	B-T082
capture	O
was	O
achieved	O
in	O
≥1	O
configuration	B-T082
.	O
The	O
mean	B-T081
bipolar	B-T082
pacing	B-T061
thresholds	B-T080
at	O
PW	O
10,	O
5,	O
3,	O
1	O
milliseconds	B-T079
were	O
12.4	O
±	O
3.7	O
mA	B-T081
(5	O
patients	B-T101
),	O
13.3	O
±	O
5.8	O
mA	B-T081
(3	O
patients	B-T101
),	O
18.3	O
±	O
5.7	O
mA	B-T081
(3	O
patients	B-T101
),	O
and	O
25	O
±	O
0	O
mA	B-T081
(2	O
patients	B-T101
),	O
respectively.	O
The	O
60-mm	O
electrode	B-T074
spacing	B-T081
was	O
the	O
most	O
successful	B-T080
bipolar	B-T082
configuration	B-T082
.	O
Unipolar	B-T082
pacing	B-T061
was	O
successful	B-T080
in	O
3	O
out	O
of	O
4	O
patients	B-T101
with	O
mean	B-T081
thresholds	B-T080
of	O
10	O
±	O
0	O
mA	B-T081
at	O
10	O
milliseconds	B-T079
(3	O
patients	B-T101
),	O
15	O
±	O
0	O
mA	B-T081
at	O
5	O
milliseconds	B-T079
(3	O
patients	B-T101
),	O
16.7	O
±	O
2.9	O
mA	B-T081
at	O
3	O
milliseconds	B-T079
(3	O
patients	B-T101
),	O
and	O
20	O
±	O
7.1	O
mA	B-T081
at	O
1	O
milliseconds	B-T079
(2	O
patients	B-T101
).	O
Ventricular pacing	B-T061
pacing	B-T061
from	O
the	O
substernal space	B-T029
in	O
patients	B-T101
with	O
midline sternotomy	B-T061
is	O
feasible	B-T080
.	O
Closed	B-T169
sternum	B-T023
studies	B-T062
are	O
needed	B-T080
to	O
determine	O
pacing	B-T061
thresholds	B-T080
more	O
accurately	B-T080
.	O

Effects	B-T080
of	O
a	O
specific blend	B-T167
of	O
essential oils	B-T109
on	O
apparent	B-T078
nutrient	B-T168
digestion	B-T040
,	O
rumen	B-T023
fermentation	B-T044
and	O
rumen	B-T023
microbial populations	B-T001
in	O
sheep	B-T015
fed	O
a	O
50:50	O
alfalfa hay	B-T002
:	O
concentrate diet	B-T168
An	O
experiment	B-T062
was	O
conducted	O
to	O
investigate	B-T169
the	O
effects	B-T080
of	O
a	O
specific	O
mixture	B-T167
of	O
essential oils	B-T109
(	O
MEO	B-T109
),	O
containing	O
thyme	B-T109
,	O
clove	B-T109
and	O
cinnamon EO	B-T109
,	O
on	O
rumen	B-T023
microbial fermentation	B-T044
,	O
nutrient	B-T168
apparent	B-T078
digestibility	B-T033
and	O
blood	B-T031
metabolites	B-T123
in	O
fistulated sheep	B-T015
.	O
Six	O
sheep	B-T015
fitted	O
with	O
ruminal fistulas	B-T190
were	O
used	O
in	O
a	O
repeated measurement design	B-T170
with	O
two	O
24-d	O
periods	B-T079
to	O
investigate	O
the	O
effect	B-T080
of	O
adding	O
MEO	B-T109
at	O
0	O
(control),	O
0.8,	O
and	O
1.6	O
mL/d	O
on	O
apparent	B-T078
nutrient	B-T168
digestibility	B-T033
,	O
rumen	B-T023
fermentation	B-T044
characteristics	B-T080
,	O
rumen	B-T023
microbial population	B-T001
and	O
blood	B-T031
chemical metabolites	B-T123
.	O
Animals	B-T008
were	O
fed	O
with	O
a	O
50:50	O
alfalfa hay	B-T002
:	O
concentrate diet	B-T168
.	O
Ruminal pH	B-T081
,	O
total	O
volatile fatty acids	B-T109
(	O
VFA	B-T109
)	O
concentration	B-T081
,	O
molar proportion of individual	B-T081
VFA	B-T109
,	O
acetate: propionate ratio	B-T081
and	O
methane production	B-T040
were	O
not	O
affected	O
with	O
MEO	B-T109
.	O
Relative	O
to	O
the	O
control	B-T096
,	O
Small peptides	B-T116
Small peptides plus amino acid nitrogen	B-T081
and	O
large peptides	B-T116
large peptides nitrogen concentration	B-T081
in	O
rumen fluid	B-T031
were	O
not	O
affected	O
with	O
MEO	B-T109
supplementation	B-T061
;	O
while,	O
rumen fluid	B-T031
ammonia	B-T121
nitrogen	O
concentration	B-T081
at	O
0	O
and	O
6	O
h	O
after	O
morning feeding	B-T052
in	O
sheep	B-T015
fed	O
with	O
1.6	O
mL/d	O
of	O
MEO	B-T109
was	O
lower	O
(p<0.05)	O
compared	O
to	O
the	O
control	B-T096
and	O
0.8	O
mL/d	O
of	O
MEO	B-T109
.	O
At	O
0	O
h	O
after	O
morning feeding	B-T052
,	O
ammonia	B-T121
nitrogen concentration	B-T081
was	O
higher	O
(p<0.05)	O
in	O
sheep	B-T015
fed	O
0.8	O
mL/d	O
of	O
MEO	B-T109
relative	O
to	O
1.6	O
mL/d	O
and	O
control	B-T096
diet	B-T168
.	O
Ruminal protozoa	B-T204
and	O
hyper ammonia producing (HAP) bacteria	B-T007
counts	B-T059
were	O
not	O
affected	O
by	O
addition	O
of	O
MEO	B-T109
in	O
the	O
diet	B-T168
.	O
Relative	O
to	O
the	O
control	B-T096
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
red	B-T059
and	O
white blood cells	B-T034
,	O
hemoglobin	B-T059
,	O
hematocrit	B-T033
,	O
glucose	B-T059
,	O
beta-hydroxybutyric acid	B-T109
,	O
cholesterol	B-T059
,	O
total protein	B-T059
,	O
albumin	B-T059
,	O
blood urea nitrogen	B-T059
and	O
aspartate aminotransferase	B-T059
and	O
alanine aminotransferase	B-T059
concentration	B-T081
.	O
Apparent	B-T078
total tract digestibility	B-T033
of	O
dry matter	B-T167
,	O
crude proten	B-T116
,	O
organic matter	B-T167
,	O
and	O
neutral detergent fiber	B-T167
were	O
not	O
influenced	O
by	O
MEO	B-T109
supplementation	B-T061
.	O
The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
supplementation	B-T061
of	O
MEO	B-T109
may	O
have	O
limited effects	B-T080
on	O
apparent	B-T078
nutrient	B-T168
digestibility	B-T033
,	O
ruminal fermentation	B-T044
and	O
protozoa	B-T204
and	O
HAP bacteria	B-T007
count	B-T059
,	O
blood cells	B-T025
and	O
metabolites	B-T123
.	O

High throughput	B-T060
selection	B-T052
of	O
antibiotic-resistant	B-T032
transgenic	B-T002
Arabidopsis plants	B-T002
Kanamycin	B-T109
resistance	B-T032
is	O
the	O
most	B-T081
frequently	B-T079
used	O
antibiotic-resistance	B-T032
marker	B-T201
for	O
Arabidopsis	B-T002
transformations	B-T039
,	O
however,	O
this	O
method	B-T170
frequently	B-T079
causes	O
escape	B-T055
of	O
untransformed plants	B-T002
,	O
particularly	O
at	O
the	O
high	B-T080
seedling	B-T002
density	B-T081
during	O
the	O
selection	B-T052
.	O
Here	O
we	O
developed	B-T169
a	O
robust	B-T080
high	B-T080
-	O
density	B-T081
selection	B-T052
method	B-T170
using	O
top	B-T082
agar	B-T109
for	O
Arabidopsis thaliana	B-T002
.	O
Top	B-T082
agar	B-T109
effectively	B-T080
suppressed	B-T080
growth	B-T039
of	O
untransformed wild-type plants	B-T002
on	O
selection	B-T052
media	B-T130
at	O
high	B-T080
density	B-T081
.	O
Survival	B-T052
of	O
the	O
transformed	B-T039
plants	B-T002
during	O
the	O
selection	B-T052
were	O
confirmed	B-T033
by	O
production	O
of	O
green	B-T080
true	B-T080
leaves	B-T002
and	O
expression	B-T045
of	O
a	O
firefly luciferase	B-T116
reporter gene	B-T028
.	O
Top	B-T082
agar	B-T109
method	B-T170
allowed	O
selection	B-T052
using	O
a	O
large	B-T081
amount	B-T081
of	O
seeds	B-T002
in	O
Arabidopsis	B-T002
transformation	B-T039
.	O

Limb	B-T023
remote ischaemic postconditioning	B-T061
-	O
induced	B-T169
elevation	B-T081
of	O
fibulin-5	B-T116
confers	O
neuroprotection	B-T043
to	O
rats	B-T015
with	O
cerebral ischaemia	B-T047
/	O
reperfusion injury	B-T037
:	O
Activation	B-T052
of	O
the	O
AKT pathway	B-T044
Limb	B-T023
remote ischaemic postconditioning	B-T061
(	O
RIPostC	B-T061
)	O
is	O
an	O
effective	O
and	O
well-acknowledged	O
treatment	B-T061
for	O
brain ischaemia injury	B-T037
.	O
The	O
present	O
study	B-T062
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
fibulin-5	B-T116
in	O
the	O
neuroprotection	B-T043
of	O
RIPostC	B-T061
against	O
cerebral ischaemia	B-T047
/	O
reperfusion (I/R) injury	B-T037
in	O
rats	B-T015
.	O
The	O
middle cerebral artery occlusion	B-T020
(	O
MCAO	B-T020
)	O
model	B-T075
was	O
established	O
in	O
rats	B-T015
and	O
then	O
RIPostC	B-T061
was	O
carried	O
out	O
by	O
three	O
cycles	O
of	O
10	O
minutes	B-T079
occlusion	B-T020
/10	O
minutes	B-T079
release	O
of	O
the	O
bilateral	B-T082
femoral artery	B-T023
at	O
the	O
beginning	O
of	O
the	O
reperfusion	B-T061
.	O
To	O
downregulate	B-T044
the	O
fibulin-5	B-T116
level	B-T080
,	O
fibulin-5 siRNA	B-T114
was	O
injected	B-T061
into	O
the	O
lateral ventricle	B-T030
24	O
hours	B-T079
before	O
MCAO	B-T020
.	O
According	O
to	O
our	O
present	O
study	B-T062
,	O
RIPostC	B-T061
attenuated	B-T052
cerebral I	B-T047
/	O
R injury	B-T037
by	O
decreasing	B-T033
infarct	B-T046
volume	B-T081
,	O
improving	O
neurobehavioral score	B-T081
and	O
suppressing	B-T169
blood brain barrier	B-T023
(	O
BBB	B-T023
)	O
leakage	B-T046
.	O
Moreover,	O
the	O
mRNA	B-T114
and	O
protein levels	B-T034
of	O
fibulin-5	B-T116
were	O
upregulated	B-T044
by	O
RIPostC	B-T061
at	O
24	O
hours	B-T079
and	O
72	O
hours	B-T079
after	O
reperfusion	B-T061
.	O
Downregulation	B-T044
of	O
fibulin-5	B-T116
attenuated	B-T052
the	O
neuroprotection	B-T043
of	O
RIPostC	B-T061
.	O
Finally,	O
the	O
result	O
showed	O
that	O
fibulin-5	B-T116
was	O
upregulated	B-T044
by	O
RIPostC	B-T061
via	O
activation	B-T052
of	O
the	O
PI3K/AKT pathway	B-T044
.	O
Taken	O
together,	O
these	O
results	B-T169
provide	O
evidence	B-T078
that	O
upregulation	B-T044
of	O
fibulin-5	B-T116
is	O
involved	O
in	O
the	O
beneficial	O
effect	O
of	O
RIPostC	B-T061
against	O
cerebral I	B-T047
/	O
R injury	B-T037
.	O

Optomechanical Control	B-T169
of	O
Quantum Yield	B-T081
in	O
Trans-Cis Ultrafast Photoisomerization	B-T044
of	O
a	O
Retinal	B-T109
Chromophore	B-T120
Model	B-T075
The	O
quantum yield	B-T081
of	O
a	O
photochemical reaction	B-T070
is	O
one	O
of	O
the	O
most	O
fundamental quantities	B-T081
in	O
photochemistry	B-T090
,	O
as	O
it	O
measures	O
the	O
efficiency	O
of	O
the	O
transduction of light energy into chemical energy	B-T043
.	O
Nature	B-T078
has	O
evolved	O
photoreceptors	B-T025
in	O
which	O
the	O
reactivity	B-UnknownType
of	O
a	O
chromophore	B-T120
is	O
enhanced	O
by	O
its	O
molecular environment	B-T082
to	O
achieve	O
high	O
quantum yields	B-T081
.	O
The	O
retinal	B-T109
chromophore	B-T120
sterically	O
constrained	O
inside	O
rhodopsin proteins	B-T116
represents	O
an	O
outstanding	O
example	O
of	O
such	O
a	O
control.	O
In	O
a	O
more	O
general	O
framework,	O
mechanical forces	B-T067
acting	O
on	O
a	O
molecular system	B-T080
can	O
strongly	O
modify	O
its	O
reactivity	B-UnknownType
.	O
Herein,	O
we	O
show	O
that	O
the	O
exertion	O
of	O
tensile forces	B-T081
on	O
a	O
simplified	O
retinal	B-T109
chromophore	B-T120
model	B-T075
provokes	O
a	O
substantial and regular increase	B-T080
in	O
the	O
trans-to-cis photoisomerization	B-T044
quantum yield	B-T081
in	O
a	O
counterintuitive	O
way,	O
as	O
these	O
extension	O
forces	O
facilitate	O
the	O
formation	O
of	O
the	O
more	O
compressed	O
cis photoisomer	B-T104
.	O
A	O
rationale	B-T078
for	O
the	O
mechanochemical effect	B-T070
on	O
this	O
photoisomerization mechanism	B-T070
is	O
also	O
proposed.	O

Quality	B-T080
of	O
nursing intensity data	B-T073
:	O
inter-rater reliability	B-T081
of	O
the	O
patient	B-T101
classification	B-T185
after	O
two decades	B-T081
in	O
clinical	B-T080
use	B-T169
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
measure	B-T081
the	O
inter-rater reliability	B-T081
of	O
the	O
Oulu Patient Classification	B-T185
and	O
to	O
discuss	O
existing	O
methods	B-T169
of	O
reliability testing	B-T081
.	O
The	O
Oulu Patient Classification	B-T185
,	O
part	O
of	O
the	O
RAFAELA(®) System	B-T170
,	O
has	O
been	O
developed	O
to	O
assist	B-T080
nursing managers	B-T097
with	O
the	O
proper	O
allocation	B-T052
of	O
nursing	B-T058
resources	B-T078
.	O
Due	O
to	O
the	O
increased	B-T081
intensity	B-T080
of	O
inpatient care	B-T058
during	O
recent	O
years	B-T079
,	O
there	O
is	O
a	O
need	O
for	O
the	O
reliability testing	B-T081
of	O
the	O
classification	B-T185
,	O
which	O
has	O
been	O
in	O
clinical	B-T080
use	B-T169
for	O
20	O
years	B-T079
.	O
Retrospective	B-T080
statistical study	B-T170
.	O
To	O
test	B-T081
inter-rater reliability	B-T081
,	O
a	O
pair	O
of	O
nurses	B-T097
classified	B-T185
the	O
same	O
patients	B-T101
,	O
without	O
knowledge	O
of	O
each	O
other's	O
ratings	B-T052
,	O
as	O
a	O
part	O
of	O
annually	B-T079
conducted	O
standardization	B-T062
.	O
Data	B-T078
on	O
the	O
parallel classifications	B-T185
(n	O
=	O
19,997)	O
was	O
obtained	B-T169
from	O
inpatient	B-T101
units	O
(n	O
=	O
32)	O
with	O
different	B-T080
specialties	B-T091
at	O
a	O
university hospital	B-T073
in	O
Finland	B-T083
during	O
2010-2015.	O
Parallel classification	B-T185
practices	B-T091
were	O
also	O
analysed.	O
The	O
reliability	B-T081
of	O
the	O
overall	O
classification	B-T185
and	O
its	O
subareas	O
were	O
calculated	B-T052
using	O
suitable	O
statistical coefficients	B-T081
.	O
Inter-rater reliability	B-T081
coefficients	B-T081
were	O
a	O
reliable	O
or	O
almost	O
perfect	O
means	O
of	O
considering	O
the	O
nursing	B-T058
intensity	B-T080
category	B-T170
and	O
various	O
practices	B-T091
,	O
but	O
there	O
were	O
detectable	B-T033
differences	B-T080
between	O
subareas.	O
The	O
lowest	O
agreement	B-T080
levels	B-T080
occurred	B-T052
in	O
the	O
subareas	O
'	O
Planning and Coordination of Nursing Care	B-T058
'	O
and	O
'	O
Guiding of Care	B-T058
/	O
Continued Care	B-T058
and	O
Emotional Support	B-T058
'.	O
There	O
is	O
a	O
need	O
to	O
develop	O
the	O
descriptions	B-T170
of	O
subareas	O
and	O
to	O
clarify	B-T052
the	O
related	O
concepts	B-T078
.	O
Precise	O
nursing documentation	B-T058
can	O
promote	B-T052
a	O
high	O
level	B-T080
of	O
agreement	B-T080
and	O
reliable	O
results	B-T169
.	O
The	O
traditional	O
overall	O
proportion	O
of	O
agreement	B-T080
does	O
not	O
provide	O
an	O
adequate	O
picture	O
of	O
reliability	O
-	O
weighted	O
kappa coefficients	B-T081
should	O
be	O
used	O
instead.	O

Water pipe	B-T073
(Shisha,	O
Hookah,	O
Arghile)	O
Smoking	B-T055
and	O
Secondhand Tobacco Smoke	B-T037
Effects	B-T080
on	O
CYP1A2	B-T116
and	O
CYP2A6	B-T116
Phenotypes	B-T032
as	O
Measured	O
by	O
Caffeine Urine Test	B-T059
Public policies	B-T097
to	O
stop	O
or	O
reduce	O
cigarette smoking	B-T055
and	O
exposure	B-T080
to	O
secondhand smoke	B-T037
and	O
associated diseases	B-T046
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade.	O
Yet,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco consumption	B-T055
,	O
water pipe	B-T073
smoking	B-T055
,	O
has	O
received	O
relatively	O
less	O
attention.	O
To	O
the	O
best	O
of	O
our	O
knowledge,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water pipe	B-T073
smoking	B-T055
on	O
cytochrome P450 (CYP450) activities	B-T044
and	O
drug interaction	B-T044
potential	B-T080
in	O
humans	B-T016
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand smoke	B-T037
on	O
drug metabolism	B-T044
.	O
In	O
a	O
sample	O
of	O
99	O
healthy volunteers	B-T098
(28	O
water pipe smokers	B-T055
,	O
30	O
secondhand tobacco smoke	B-T037
exposed	O
persons	B-T098
,	O
and	O
41	O
controls	B-T096
),	O
we	O
systematically compared	B-T052
CYP1A2	B-T116
and	O
CYP2A6	B-T116
enzyme activities	B-T044
in vivo	B-T082
using	O
caffeine urine test	B-T059
.	O
The	O
median	O
self-reported	B-T062
duration	B-T079
of	O
water pipe	B-T073
smoking	B-T055
was	O
7.5	O
h	B-T079
/	O
week	B-T079
and	O
3	O
years	B-T079
of	O
exposure	B-T080
in	O
total.	O
The	O
secondhand smoke	B-T037
group	B-T098
had	O
a	O
median	O
of	O
14	O
h	B-T079
of	O
self-reported	B-T062
weekly	B-T079
exposure	B-T080
to	O
tobacco smoke	B-T131
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	B-T073
were	O
smoked	B-T131
/	O
hour	B-T079
for	O
a	O
total	O
of	O
3.5	O
years	B-T079
(median).	O
Analysis	B-T062
of	O
variance	B-T080
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
CYP1A2	B-T116
and	O
CYP2A6	B-T116
activities	B-T044
among	O
the	O
three	O
study	B-T062
groups	B-T098
(p	O
>	O
0.05).	O
Nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water pipe	B-T073
or	O
secondhand smoke	B-T037
exposure	B-T080
and	O
the	O
CYP1A2	B-T116
and	O
CYP2A6	B-T116
activities	B-T044
(p	O
>	O
0.05).	O
Further	O
analysis	B-T062
in	O
a	O
subsample	O
with	O
smoke	O
exposure	B-T080
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	B-T096
.	O
Although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water pipe	B-T073
smoke	O
and	O
secondhand smoke	B-T037
on	O
in vivo	B-T082
activities	B-T044
of	O
these	O
two	O
drug metabolism	B-T044
pathways	B-T044
,	O
variability	O
in	O
smoke	O
constituents	B-T167
from	O
different	O
tobacco consumption	B-T055
methods	O
(e.g.,	O
water pipe	B-T073
)	O
might	O
affect	O
drug metabolism	B-T044
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette smoke	B-T131
.	O
Further	O
studies	B-T062
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water pipe	B-T073
and	O
secondhand tobacco smoke	B-T037
effects	O
on	O
CYP450	B-T116
function,	O
particularly	O
at	O
higher	O
smoke	B-T131
exposure	B-T080
conditions.	O

How	O
do	O
wettability	B-T080
,	O
zeta potential	B-T067
and	O
hydroxylation	B-T070
hydroxylation degree	B-T033
affect	O
the	O
biological response	B-T033
of	O
biomaterials	B-T122
?	O
It	O
is	O
well	O
known	O
that	O
composition	B-T080
,	O
electric charge	B-T070
,	O
wettability	B-T080
and	O
roughness	B-T080
of	O
implant	B-T074
surfaces	B-T082
have	O
great	O
influence	B-T077
on	O
their	O
interaction	B-T169
with	O
the	O
biological fluids	B-T031
and	O
tissues	B-T024
,	O
but	O
systematic studies	B-T062
of	O
different	O
materials	B-T167
in	O
the	O
same	O
experimental conditions	B-T080
are	O
still	O
lacking	B-T080
in	O
the	O
scientific literature	B-T170
.	O
The	O
aim	O
of	O
this	O
research	B-T062
is	O
to	O
investigate	B-T169
the	O
correlations	B-T080
between	O
some	O
surface characteristics	B-T080
(	O
wettability	B-T080
,	O
zeta potential	B-T067
and	O
hydroxylation	B-T070
hydroxylation degree	B-T033
)	O
and	O
the	O
biological response	B-T033
(	O
protein	B-T116
protein adsorption	B-T033
,	O
blood	B-T031
wettability	B-T080
,	O
cell	B-T043
and	O
bacterial adhesion	B-T040
)	O
to	O
some	O
model	O
biomaterials	B-T122
.	O
The	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	B-T082
for	O
implantable biomaterials	B-T122
.	O
Roughness	B-T080
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature:	O
smooth surfaces	B-T082
prepared	O
by	O
a	O
controlled protocol	B-T170
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness effects	B-T080
.	O
Three	O
oxides	B-T197
(	O
ZrO2	B-T197
,	O
Al2O3	B-T122
,	O
SiO2	B-T122
),	O
three	O
metals	B-T197
(	O
316LSS steel	B-T122
,	O
Ti	B-T196
,	O
Nb	B-T196
)	O
and	O
two	O
polymers	B-T104
(	O
corona treated polystyrene	B-T109
for	O
cell culture	B-T059
and	O
untreated polystyrene	B-T109
for	O
bacteria culture	B-T059
),	O
widely	O
used	O
for	O
biomedical applications	B-T073
,	O
were	O
considered.	O
The	O
surfaces	B-T082
were	O
characterized	B-T052
by	O
contact profilometry	B-T062
,	O
SEM	B-T059
-	O
EDS	B-T059
,	O
XPS	B-T059
,	O
FTIR	B-T062
,	O
zeta potential	B-T067
and	O
wettability	B-T080
with	O
different	O
fluids	B-T167
.	O
Protein	B-T116
Protein adsorption	B-T033
,	O
blood	B-T031
wettability	B-T080
,	O
bacterial	B-T040
and	O
cell adhesion	B-T043
were	O
evaluated	O
in	O
order	O
to	O
investigate	B-T169
the	O
correlations	B-T080
between	O
the	O
surface physiochemical properties	B-T070
and	O
biological responses	B-T033
.	O
From	O
a	O
methodological	O
standpoint,	O
XPS	B-T059
and	O
electrokinetic measurements	B-T081
emerged	O
as	O
the	O
more	O
suitable	O
techniques	B-T169
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	B-T070
hydroxylation degree	B-T033
and	O
surface charge	B-T081
/	O
isoelectric point	B-T081
.	O
Moreover,	O
determination	O
of	O
wettability	B-T080
by	O
blood	B-T031
appeared	O
a	O
specific	O
and	O
crucial	O
test	B-T170
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	B-T170
.	O
Hydroxylation	B-T070
Hydroxylation degree	B-T033
resulted	O
correlated	O
to	O
the	O
wettability	B-T080
by	O
water	B-T121
,	O
but	O
not	O
directly	O
to	O
surface charge	B-T081
.	O
Wetting tests	B-T062
with	O
different	O
media	B-T167
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look-alike	O
materials	B-T167
.	O
A	O
dependence	O
of	O
protein	B-T116
protein absorption	B-T033
on	O
hydroxylation	B-T070
hydroxylation degree	B-T033
,	O
charge	B-T081
and	O
wettability	B-T080
was	O
evidenced	O
and	O
its	O
maximum	B-T081
was	O
registered	O
for	O
surfaces	B-T082
with	O
low	O
wettability	B-T080
in	O
both	O
water	B-T121
based	O
and	O
protein	B-T116
containing	O
media	B-T167
and	O
a	O
moderate	O
surface charge	B-T081
.	O
As	O
far	O
as	O
bacterial adhesion	B-T040
is	O
concerned,	O
no effect	B-T080
of	O
surface charge	B-T081
or	O
protein	B-T116
protein adsorption	B-T033
was	O
evidenced,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid component	B-T080
of	O
the	O
surface energy	B-T081
appeared	O
significant.	O
Finally,	O
the	O
combination	O
of	O
hydroxylation	B-T070
hydroxylation degree	B-T033
,	O
wettability	B-T080
,	O
surface charge	B-T081
and	O
energy	B-T081
(	O
polar component	B-T080
)	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell adhesion	B-T043
and	O
viability	B-T043
.	O

Persistent	B-T079
effects	B-T080
of	O
pre-Columbian	B-T081
plant	B-T002
domestication	B-T078
on	O
Amazonian forest	B-T070
composition	B-T201
The	O
extent	O
to	O
which	O
pre-Columbian	B-T081
societies	B-T092
altered	O
Amazonian	B-T070
landscapes	B-T082
is	O
hotly	O
debated.	O
We	O
performed	O
a	O
basin-wide analysis	B-T062
of	O
pre-Columbian	B-T081
impacts	B-T080
on	O
Amazonian forests	B-T070
by	O
overlaying	O
known	O
archaeological sites	B-T082
in	O
Amazonia	B-UnknownType
with	O
the	O
distributions	O
and	O
abundances	B-T080
of	O
85	O
woody	B-T002
species	B-T185
domesticated	B-T078
by	O
pre-Columbian	B-T081
peoples	B-T098
.	O
Domesticated	B-T078
species	B-T185
are	O
five	O
times	O
more	O
likely	O
than	O
nondomesticated species	B-T185
to	O
be	O
hyperdominant	B-T169
.	O
Across	O
the	O
basin,	O
the	O
relative	O
abundance	B-T080
and	O
richness	B-T080
of	O
domesticated	B-T078
species	B-T185
increase	O
in	O
forests	B-T070
on	O
and	O
around	O
archaeological sites	B-T082
.	O
In	O
southwestern and eastern Amazonia	B-UnknownType
,	O
distance	O
to	O
archaeological sites	B-T082
strongly	O
influences	O
the	O
relative	O
abundance	B-T080
and	O
richness	O
of	O
domesticated	B-T078
species	B-T185
.	O
Our	O
analyses	B-T062
indicate	O
that	O
modern	O
tree	B-T002
communities	B-T096
in	O
Amazonia	B-UnknownType
are	O
structured	O
to	O
an	O
important	O
extent	O
by	O
a	O
long	O
history	B-T169
of	O
plant	B-T002
domestication	B-T078
by	O
Amazonian	B-T070
peoples	B-T098
.	O

Halogenated phenolic compounds	B-T109
in	O
wild fish	B-T013
from	O
Canadian Areas	B-T083
of	O
Concern	B-T078
Concentrations	O
of	O
halogenated phenolic compounds	B-T109
were	O
measured	O
in	O
the	O
plasma	B-T031
of	O
brown bullhead	B-T013
(	O
Ameiurus nebulosus	B-T013
)	O
from	O
4	O
Canadian Areas	B-T083
of	O
Concern	B-T078
(	O
AOCs	B-T083
),	O
to	O
assess	O
exposure	O
to	O
suspected	O
thyroid	B-T023
-	O
disrupting chemicals	B-T131
.	O
Hydroxylated polychlorinated biphenyls	B-T109
(	O
OH-PCBs	B-T109
)	O
were	O
detected	O
in	O
every	O
sample	O
collected	O
in	O
3	O
of	O
the	O
AOCs	B-T083
;	O
the	O
detection	B-T061
frequency	B-T079
was	O
lower	O
in	O
samples	O
from	O
the	O
Detroit River	B-T070
AOC	B-T083
.	O
The	O
OH-PCBs	B-T109
most	O
frequently	O
detected	O
were	O
pentachloro, hexachloro, and heptachloro congeners	B-T104
,	O
which	O
are	O
structurally	O
similar	O
to	O
thyroid hormones	B-T116
.	O
Pentachlorophenol	B-T109
(	O
PCP	B-T109
)	O
was	O
detected	O
at	O
highest	O
concentrations	O
(1.8	O
ng/g)	O
in	O
fish	B-T013
from	O
Prince Edward Bay	B-T083
,	O
the	O
Bay of Quinte Lake reference site	B-T083
,	O
and	O
Hillman Marsh	B-T073
(	O
the Wheatley Harbour reference site	B-T073
),	O
suggesting	O
local	O
sources of contamination	B-T057
.	O
Elevated PCP concentrations	B-T059
were	O
also	O
detected	O
in	O
the	O
plasma	B-T031
of	O
brown bullhead	B-T013
from	O
exposed	O
sites	O
in	O
the	O
Toronto and Region AOC	B-T083
(0.4-0.6	O
ng/g).	O
Triclosan	B-T109
was	O
consistently	O
detected	O
in	O
the	O
Toronto and Region AOC	B-T083
(0.05-0.9	O
ng/g),	O
consistent	O
with	O
wastewater	B-T083
emission.	O
Greater	O
concentrations	O
were	O
occasionally	O
detected	O
in	O
the	O
plasma	B-T031
of	O
brown bullhead	B-T013
from	O
the	O
Bay of Quinte	B-T083
AOC	B-T083
.	O
Concentrations	O
of	O
polybrominated diphenyl ethers	B-T109
were	O
highest	O
in	O
the	O
Toronto and Region AOC	B-T083
,	O
and	O
at	O
2	O
of	O
the	O
Bay of Quinte	B-T083
AOC	B-T083
exposed	O
sites	O
near	O
Trenton and Belleville	B-T083
.	O
Distribution patterns	B-T082
reflected	O
the	O
properties	B-T070
and	O
usage	B-T169
of	O
the	O
compounds	O
under	O
investigation	B-T062
and	O
the	O
characteristics	B-T080
of	O
each	O
AOC	B-T083
.	O
Environ	O
Toxicol	O
Chem	O
2017;9999:1-8.	O
©	O
2017	O
SETAC.	O

The	O
genetic	B-T169
basis	O
for	O
variation	B-T070
in	O
resistance	B-T039
to	O
infection	B-T046
in	O
the	O
Drosophila melanogaster genetic reference panel	B-T204
Individuals	B-T098
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	B-T047
but	O
the	O
genetic	B-T169
basis	O
of	O
this	O
variation	B-T070
is	O
not	O
fully	O
understood.	O
We	O
found	O
substantial	O
individual	B-T098
variation	B-T070
in	O
resistance	B-T039
and	O
tolerance	B-T080
to	O
the	O
fungal pathogen Metarhizium anisopliae Ma549	B-T004
using	O
the	O
Drosophila melanogaster Genetic Reference Panel	B-T204
(	O
DGRP	B-T204
).	O
In	O
addition,	O
we	O
found	O
that	O
host defense	B-T042
to	O
Ma549	B-T004
was	O
correlated	O
with	O
defense	B-T077
to	O
the	O
bacterium	B-T007
Pseudomonas aeruginosa Pa14	B-T007
,	O
and	O
several	O
previously	O
published	O
DGRP	B-T204
phenotypes	B-T032
including	O
oxidative stress	B-T049
sensitivity	B-T169
,	O
starvation	B-T033
stress resistance	B-UnknownType
,	O
hemolymph	B-T031
glucose levels	B-T059
,	O
and	O
sleep	B-T040
indices	B-T170
.	O
We	O
identified	O
polymorphisms	B-T045
associated with	B-T080
differences	B-T080
between	O
lines	O
in	O
both	O
their	O
mean survival times	B-T081
and	O
microenvironmental	B-T082
plasticity	B-T070
,	O
suggesting	O
that	O
lines	O
differ	B-T080
in	O
their	O
ability	B-T032
to	O
adapt	B-T038
to	O
variable	B-T080
pathogen	B-T001
exposures	B-T080
.	O
The	O
majority	O
of	O
polymorphisms	B-T045
increasing	B-T169
resistance	B-T039
to	O
Ma549	B-T004
were	O
sex biased	B-T078
,	O
located	O
in	O
non-coding regions	B-T114
,	O
had	O
moderately	O
large	O
effect	B-T080
and	O
were	O
rare,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	B-T077
.	O
Nevertheless,	O
host defense	B-T042
was	O
not	O
negatively	O
correlated	B-T080
with	O
overall	O
longevity	B-T079
and	O
fecundity	B-T040
.	O
In	O
contrast	O
to	O
Ma549	B-T004
,	O
minor alleles	B-T028
were	O
concentrated	O
in	O
the	O
most	O
Pa14	B-T007
-	O
susceptible	B-T169
as	O
well	O
as	O
the	O
most	O
Pa14	B-T007
-	O
resistant	B-T039
lines.	O
A	O
pathway	B-T077
based	O
analysis	B-T062
revealed	O
a	O
network	O
of	O
Pa14	B-T007
and	O
Ma549	B-T004
-	O
resistance	B-T039
genes	B-T028
that	O
are	O
functionally	B-T169
connected	O
through	O
processes	B-T067
that	O
encompass	O
phagocytosis	B-T043
and	O
engulfment	B-T043
,	O
cell mobility	B-T043
,	O
intermediary metabolism	B-T040
,	O
protein phosphorylation	B-T044
,	O
axon guidance	B-T043
,	O
response to DNA damage	B-T043
,	O
and	O
drug metabolism	B-T044
.	O
Functional	B-T169
testing	B-T169
with	O
insertional mutagenesis	B-T045
lines	O
indicates	O
that	O
12/13	O
candidate genes	B-T028
tested	B-T169
influence	B-T077
susceptibility	B-T169
to	O
Ma549	B-T004
.	O
Many	O
candidate genes	B-T028
have	O
homologs	B-T085
identified	O
in	O
studies	B-T062
of	O
human	B-T016
disease	B-T047
,	O
suggesting	O
that	O
genes	B-T028
affecting	O
variation	B-T070
in	O
susceptibility	B-T169
are	O
conserved	O
across	O
species	B-T185
.	O

Surrogate	B-T099
inaccuracy	B-T080
in	O
predicting	O
older adults'	B-T098
desire	B-T041
for	O
life-sustaining interventions	B-T061
in	O
the	O
event	O
of	O
decisional	B-T041
incapacity	B-T201
:	O
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	B-T078
quality-of-life assessments	B-T060
?	O
Family members	B-T099
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	B-T041
for	O
an	O
incapacitated	O
relative	B-T099
.	O
Yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one's	O
desire	B-T041
to	O
receive	O
treatments	B-T061
in	O
hypothetical	O
situations.	O
We	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality-of-life assessments	B-T060
.	O
The	O
data	B-T078
come	O
from	O
235	O
community-dwelling	B-T056
adults	B-T100
aged	O
70	O
years	B-T079
and	O
over	O
who	O
rated	O
their	O
quality of life	B-T078
and	O
desire	B-T041
for	O
specified	O
interventions	B-T061
in	O
four	O
health states	B-T033
(	O
current state	B-T033
,	O
mild	B-T080
to	O
moderate	B-T080
stroke	B-T047
,	O
incurable	O
brain cancer	B-T191
,	O
and	O
severe	B-T080
dementia	B-T048
).	O
All	O
ratings	B-T052
were	O
made	O
on	O
Likert-type scales	B-T170
.	O
Using	O
identical	O
rating scales	B-T081
,	O
a	O
surrogate	B-T099
chosen	O
by	O
the	O
older adult	B-T098
was	O
asked	O
to	O
predict	O
the	O
latter's	O
responses.	O
Linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality-of-life	B-T078
ratings	B-T052
between	O
the	O
older adult	B-T098
and	O
surrogate	B-T099
were	O
associated	O
with	O
surrogates'	B-T099
inaccuracy	B-T080
in	O
predicting	O
desire	B-T041
for	O
treatment	B-T061
.	O
The	O
difference	O
in	O
quality-of-life	B-T078
ratings	B-T052
was	O
a	O
significant	O
predictor	B-T078
of	O
prediction	O
inaccuracy	B-T080
for	O
the	O
three	O
hypothetical	O
health states	B-T033
(p	O
<	O
0.01)	O
and	O
nearly	O
significant	O
for	O
the	O
current health state	B-T033
(p	O
=	O
0.077).	O
All	O
regression coefficients	B-T081
were	O
negative	B-T033
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	B-T099
overestimated	O
quality of life	B-T078
compared	O
to	O
the	O
older adult	B-T098
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older adult	B-T098
's	O
desire	B-T041
to	O
be	O
treated.	O
Discrepant	O
quality-of-life	B-T078
ratings	B-T052
are	O
associated	O
with	O
surrogates'	B-T099
difficulty	O
in	O
predicting	O
desire	B-T041
for	O
life-sustaining interventions	B-T061
in	O
hypothetical	O
situations.	O
This	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality of life	B-T078
in	O
states	O
of	O
cognitive decline	B-T046
,	O
to	O
better	O
prepare	O
family members	B-T099
for	O
making	O
difficult	O
decisions	B-T041
for	O
their	O
loved	O
ones.	O
ISRCTN89993391.	O

Gain-of-function mutation	B-T045
in	O
SCN5A	B-T028
causes	O
ventricular arrhythmias	B-T047
and	O
early onset	B-T033
atrial fibrillation	B-T047
Mutations	B-T045
in	O
SCN5A	B-T028
,	O
the	O
gene	B-T028
encoding	B-T052
the	O
α-subunit	O
of	O
the	O
cardiac	B-T023
sodium channel (NaV1.5)	B-T116
,	O
are	O
associated	O
with	O
a	O
broad	O
spectrum	B-T077
of	O
inherited	B-T169
cardiac arrhythmia disorders	B-T033
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
identify	O
the	O
genetic	B-T169
and	O
functional determinants	B-T169
underlying	O
a	O
Dutch	B-T098
family	B-T099
that	O
presented	O
with	O
a	O
combined	O
phenotype	B-T032
of	O
ventricular arrhythmias	B-T047
with	O
a	O
likely	O
adrenergic	B-T169
component	B-T077
,	O
either	O
in	O
isolation	B-T169
or	O
in	O
combination	B-T080
with	O
a	O
mildly	O
decreased	O
heart function	B-T042
and	O
early onset	B-T033
(<55	O
years	B-T079
)	O
atrial fibrillation	B-T047
.	O
We	O
performed	O
next	O
generation	B-T079
sequencing	B-T086
in	O
the	O
proband	B-T099
of	O
a	O
two-	O
generation	B-T079
Dutch	B-T098
family	B-T099
and	O
demonstrated	O
a	O
novel	O
missense mutation	B-T045
in	O
SCN5A-(p.M1851V)	B-T028
which	O
co-segregated	O
with	O
the	O
clinical	B-T080
phenotype	B-T032
in	O
the	O
family	B-T099
.	O
We	O
functionally	B-T169
evaluated	O
the	O
putative	O
genetic	B-T169
defect	B-T169
by	O
patch clamp	B-T062
electrophysiological studies	B-T060
in	O
human embryonic	B-T018
kidney cells	B-T025
transfected	B-T063
with	O
mutant	B-T049
or	O
wild-type Nav1.5	B-T028
.	O
The	O
current	B-T070
inactivation	B-T169
was	O
slower	O
and	O
recovery	O
from	O
inactivation	B-T169
was	O
faster	O
in	O
SCN5A-M1851V channels	B-T116
.	O
The	O
voltage	B-T081
dependence	B-T169
of	O
inactivation	B-T169
was	O
shifted	O
towards	O
more	O
positive	B-T033
potentials	B-T080
and	O
consequently,	O
a	O
larger	O
TTX	B-T109
-	O
sensitive	B-T169
window current	B-T070
was	O
observed	O
in	O
SCN5A-M1851V channels	B-T116
.	O
Furthermore,	O
a	O
higher	O
upstroke velocity	B-T081
was	O
observed	O
for	O
the	O
SCN5A-M1851V channels	B-T116
,	O
while	O
the	O
depolarization voltage	B-T081
was	O
more	O
negative	B-T033
,	O
both	O
indicating	O
increased	O
excitability.	O
This	O
mutation	B-T045
leads	O
to	O
a	O
gain-of-function mechanism	B-T169
based	O
on	O
increased	O
channel	B-T116
availability	O
and	O
increased	O
window current	B-T070
,	O
fitting	O
the	O
observed	O
clinical	B-T080
phenotype	B-T032
of	O
(likely	O
adrenergic-induced)	O
ventricular arrhythmias	B-T047
and	O
atrial fibrillation	B-T047
.	O
These	O
findings	B-T033
further	O
expand	O
the	O
range	O
of	O
cardiac arrhythmias	B-T033
associated	O
with	O
mutations	B-T045
in	O
SCN5A	B-T028
.	O

The	O
cancer	B-T191
Warburg effect	B-T049
may	O
be	O
a	O
testable	B-T169
example	B-T077
of	O
the	O
minimum	B-T080
entropy	B-T067
production rate	B-T081
principle	B-T078
Cancer cells	B-T025
consume	B-T169
more	O
glucose	B-T109
by	O
glycolytic fermentation	B-T044
to	O
lactate	B-T109
than	O
by	O
respiration	B-T039
,	O
a	O
characteristic	B-T080
known	O
as	O
the	O
Warburg effect	B-T049
.	O
In	O
contrast	O
with	O
the	O
34	O
moles	B-T081
of	O
ATP	B-T114
produced	O
by	O
respiration	B-T039
,	O
fermentation	B-T044
produces	O
two	O
moles	B-T081
of	O
ATP	B-T114
per	O
mole	B-T081
of	O
glucose	B-T109
consumed	B-T169
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	B-T169
of	O
the	O
Warburg effect	B-T049
.	O
Productions	B-T169
of	O
free energy	B-T070
(	O
ΔG	B-T070
),	O
enthalpy	B-T081
(	O
ΔH	B-T081
)	O
and	O
entropy	B-T067
(	O
ΔS	B-T080
)	O
per	O
mole	B-T081
linearly	B-T082
vary	O
with	O
the	O
fraction (x) of	B-T081
glucose	B-T109
consumed	B-T169
by	O
fermentation	B-T044
that	O
is	O
frequently	B-T079
estimated	B-T081
around	O
0.9.	O
Hence,	O
calculation	B-T052
shows	O
that,	O
in	O
respect	O
to	O
pure	B-T080
respiration	B-T039
,	O
the	O
predominant	O
fermentative	B-T044
metabolism	B-T040
decreases	B-T081
around	O
10%	O
the	O
production	B-T169
of	O
entropy	B-T067
per	O
mole	B-T081
of	O
glucose	B-T109
consumed	B-T169
in	O
cancer cells	B-T025
.	O
We	O
hypothesize	B-T078
that	O
increased	B-T081
fermentation	B-T044
could	O
allow	O
cancer cells	B-T025
to	O
accomplish	B-T080
the	O
Prigogine theorem	B-T170
of	O
the	O
trend	B-T079
to	O
minimize	B-T081
the	O
rate	B-T081
of	O
production	B-T169
of	O
entropy	B-T067
.	O
According	O
the	O
theorem	B-T170
,	O
open cellular systems	B-T025
near	O
the	O
steady state	B-T070
could	O
evolve	B-T169
to	O
minimize	B-T081
the	O
rates	B-T081
of	O
entropy	B-T067
production	B-T169
that	O
may	O
be	O
reached	O
by	O
modified	B-T033
replicating	B-T080
cells	B-T025
producing	O
entropy	B-T067
at	O
low	O
rate	B-T081
.	O
Remarkably,	O
at	O
CO2	B-T123
concentrations	B-T081
above	O
930	O
ppm	B-T081
,	O
glucose	B-T109
respiration	B-T039
produces	O
less	O
entropy	B-T067
than	O
fermentation	B-T044
,	O
which	O
suggests	O
experimental	B-T080
tests	B-T059
to	O
validate	B-T080
the	O
hypothesis	B-T078
of	O
minimization	B-T081
of	O
the	O
rate	B-T081
of	O
entropy	B-T067
production	B-T169
through	O
the	O
Warburg effect	B-T049
.	O

Potential	B-T080
drug-drug interactions	B-T044
among	O
prescriptions	B-T058
for	O
elderly	B-T098
patients	B-T101
in	O
primary health care	B-T058
Elderly	B-T098
patients	B-T101
are	O
at	O
high risk	B-T033
from	O
drug-drug interactions	B-T044
(	O
DDIs	B-T044
).	O
This	O
study	B-T062
evaluates	B-T058
the	O
potential	B-T080
DDIs	B-T044
in	O
Turkish	O
elderly	B-T098
patients	B-T101
at	O
a	O
primary health care	B-T058
outpatient clinic	B-T073
.	O
Online database systems	B-T170
were	O
used	O
to	O
examine	O
DDIs	B-T044
on	O
the	O
prescriptions	B-T058
of	O
patients	B-T101
(n	O
=	O
1206).	O
The	O
clinical severity	B-T033
of	O
DDIs	B-T044
was	O
classified	O
by	O
the	O
Lexi-Interact Online database	B-T170
.	O
Of	O
the	O
5059	O
prescriptions	B-T058
,	O
33%	O
were	O
found	O
to	O
have	O
DDIs	B-T044
.	O
We	O
detected	B-T033
29	O
(0.9%)	O
A,	O
380	O
(11.8%)	O
B,	O
2494	O
(77.7%)	O
C,	O
289	O
(9%)	O
D,	O
and	O
18	O
(0.6%)	O
X	O
risk	O
rating	O
category	O
DDIs	B-T044
among	O
the	O
prescriptions	B-T058
.	O
Prescriptions	B-T058
of	O
female	O
patients	B-T101
and	O
patients	B-T101
aged	O
between	O
65	O
and	O
72	O
years	O
showed	O
significantly higher	B-T081
number	O
of	O
DDIs	B-T044
.	O
The	O
frequency	B-T079
of	O
DDIs	B-T044
increased	B-T081
both	O
with	O
the	O
number	O
of	O
drugs	B-T121
and	O
combined	O
preparations	O
per	O
prescription	B-T058
.	O
Acetylsalicylic acid	B-T109
and	O
salbutamol	B-T109
were	O
the	O
most	O
frequently	B-T079
prescribed	B-T058
drugs	B-T121
contributing	O
to	O
clinically important	B-T033
DDIs	B-T044
.	O
Additionally,	O
acetylsalicylic acid	B-T109
and	O
escitalopram	B-T109
,	O
which	O
interact	B-T169
with	O
each	O
other,	O
were	O
found	O
on	O
the	O
list	O
of	O
Beers criteria	B-T080
.	O
The	O
most	O
predicted clinical outcomes	B-T033
of	O
DDIs	B-T044
were	O
increase	O
in	O
therapeutic efficacy	B-T080
and	O
adverse	B-T046
/	O
toxic reactions	B-T033
.	O
Conclusions:	O
Prediction	B-T078
of	O
DDIs	B-T044
in	O
elderly	B-T098
patients	B-T101
will	O
provide	O
better	O
prescribing	B-T058
and	O
drug safety	B-T080
.	O
Use	O
of	O
nonsteroidal anti-inflammatory agents	B-T121
,	O
selective serotonin reuptake inhibitors	B-T121
,	O
and	O
beta-2 adrenergic receptor agonists	B-T121
should	O
be	O
closely	O
monitored.	O

Discontinued	B-T033
Splenogonadal Fusion	B-T019
and	O
Bilateral Empty Scrotum	B-T019
in	O
an	O
18-	O
Month	B-T032
-Old	O
Boy	B-T100
Splenogonadal fusion	B-T019
is	O
a	O
rare	B-T080
benign	O
congenital anomaly	B-T019
defined	O
as	O
the	O
presence	O
of	O
splenic tissue	B-T024
adherent	B-T169
to	O
gonads	B-T023
.	O
It	O
was	O
first	O
described	O
in	O
1883	O
by	O
Bostroem	B-T016
,	O
a	O
German	B-T098
pathologist	B-T097
.	O
We	O
present	O
a	O
case	B-T077
of	O
an	O
18-	O
month	B-T032
-old	O
boy	B-T100
who	O
was	O
referred	O
as	O
a	O
case	B-T077
of	O
bilateral empty scrotum	B-T019
since	O
birth.	O
During	O
routine	B-T080
laparoscopic	B-T060
exploration	B-T061
,	O
right vas deferens	B-T023
and	O
testicular vessels	B-T023
were	O
entering	O
the	O
right internal inguinal ring	B-T023
so	O
right inguinal	B-T029
exploration	B-T061
was	O
done,	O
which	O
revealed	O
blind ending	B-T033
vas deferens	B-T023
and	O
testicular vessels	B-T023
and	O
the	O
left testis	B-T023
was	O
found	O
intra-abdominally	B-T082
near	O
the	O
left	O
internal ring	B-T030
with	O
a	O
mass	B-T184
on	O
its	O
upper pole	B-T023
.	O
Wedge biopsy	B-T060
was	O
taken	O
from	O
the	O
upper pole of the testicle	B-T023
(	O
site	B-T029
of	O
the	O
mass	B-T184
)	O
for	O
tissue diagnosis	B-T185
followed	O
by	O
orchidopexy	B-T061
.	O
Histology	B-T059
showed	O
splenic tissue	B-T024
.	O
Although	O
splenogonadal fusion	B-T019
is	O
a	O
rare	B-T080
condition	B-T047
,	O
surgeons	B-T097
should	O
be	O
aware	O
of	O
this	O
rare disease	B-T047
entity	O
to	O
avoid	O
unnecessary	B-T058
aggressive	O
interventions	B-T061
such	O
as	O
orchiectomy	B-T061
.	O

Real-world impact	B-T080
of	O
non-breast cancer-specific death	B-T033
on	O
overall survival	B-T081
in	O
resectable	B-T080
breast cancer	B-T191
The	O
real-world	O
occurrence rate	B-T081
of	O
non-breast cancer-specific death	B-T033
(	O
non-BCSD	B-T033
)	O
and	O
its	O
impact	B-T080
on	O
patients	B-T101
with	O
breast cancer	B-T191
are	O
poorly	O
recognized.	O
Women	B-T098
with	O
resectable	B-T080
breast cancer	B-T191
from	O
1990	O
to	O
2007	O
in	O
the	O
Surveillance, Epidemiology, and End Results database	B-T093
(n	O
=	O
199,963)	O
were	O
analyzed	B-T062
.	O
The	O
outcome	B-T169
events	B-T051
of	O
breast cancer	B-T191
were	O
classified	O
as	O
breast cancer-specific death	B-T081
(	O
BCSD	B-T081
),	O
non-BCSD	B-T033
,	O
or	O
survival	B-T052
.	O
Binary logistics	B-T062
was	O
used	O
to	O
estimate	B-T081
the	O
occurrence rates	B-T081
of	O
non-BCSD	B-T033
and	O
BCSD	B-T081
with	O
different	O
clinicopathological factors	B-T169
.	O
The	O
Gray method	B-T170
was	O
used	O
to	O
measure	B-T081
the	O
cumulative incidence	B-T081
of	O
non-BCSD	B-T033
and	O
BCSD	B-T081
.	O
The	O
ratio	B-T081
of	O
non-BCSDs	B-T033
to	O
all	O
causes of death	B-T033
and	O
stacked	B-T082
cumulative incidence	B-T081
function plots	B-T170
were	O
used	O
to	O
present	O
the	O
impact	B-T080
of	O
non-BCSD	B-T033
on	O
overall survival	B-T081
(	O
OS	B-T081
).	O
Models of Cox proportional hazards regression	B-T081
and	O
competing risk regression	B-T170
were	O
compared	O
to	O
highlight	O
the	O
suitable model	B-T170
.	O
There	O
were	O
12,879	O
non-BCSDs	B-T033
(6.44%)	O
and	O
28,784	O
BCSDs	B-T081
(14.39%).	O
The	O
oldest age group	B-T100
(>62	O
years),	O
black race	B-T098
,	O
and	O
a	O
single or divorced marital status	B-T033
were	O
associated with	B-T080
more	O
non-BCSDs	B-T033
.	O
With	O
adjustments	O
for	O
age	B-T032
,	O
a	O
hormone receptor-positive (HoR+) status	B-T191
was	O
no	O
longer	O
related	O
to	O
increased	B-T081
non-BCSD	B-T033
s.	O
In	O
patients	B-T101
with	O
grade 1, stage I disease	B-T047
and	O
an	O
HoR+ status	B-T191
as	O
well	O
as	O
the	O
oldest	O
subgroup,	O
a	O
great	O
dilution	O
of	O
non-BCSD	B-T033
on	O
all	O
causes of death	B-T033
could	O
be	O
observed,	O
and	O
this	O
led	O
to	O
incorrect interpretations	B-T033
.	O
The	O
inaccuracy	B-T080
,	O
caused	O
by	O
the	O
commonly	O
used	O
Cox proportional hazards model	B-T081
,	O
could	O
be	O
corrected	O
by	O
a	O
competing risk model	B-T170
.	O
OS	B-T081
was	O
largely	O
impaired	B-T169
by	O
non-BCSD	B-T033
during	O
early	O
breast cancer	B-T191
.	O
For	O
some	O
future	O
clinical trial	B-T062
planning	B-T058
,	O
especially	O
for	O
the	O
oldest	B-T100
patients	B-T101
and	O
those	O
with	O
HoR+	B-T191
breast cancer	B-T191
,	O
non-BCSD	B-T033
should	O
be	O
considered	O
a	O
competing risk event	B-UnknownType
.	O
Cancer	O
2017.	O
©	O
2017	O
American Cancer Society	B-T094
.	O

Hip	B-T023
segmentation	B-T066
from	O
MRI	B-T060
volumes	O
in	O
infants	B-T100
for	O
DDH	B-T019
diagnosis	B-T033
and	O
treatment planning	B-T170
Diagnosis	B-T033
and	O
surgical management	B-T058
of	O
Developmental Dysplasia of the Hip	B-T019
(	O
DDH	B-T019
)	O
relies	O
on	O
physical examination	B-T058
and	O
2D	O
ultrasound scanning	B-T060
.	O
Magnetic Resonance Imaging	B-T060
(	O
MRI	B-T060
)	O
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	B-T169
and	O
could	O
be	O
advantageous	O
in	O
treatment planning	B-T170
due	O
to	O
its	O
larger	O
field	O
of	O
view.	O
In	O
this	O
paper	O
we	O
propose	O
a	O
semi-automatic	B-T169
method	B-T170
to	O
segment surface models	B-T170
of	O
the	O
acetabulum	B-T023
from	O
MRI	B-T060
images	B-T078
.	O
The	O
method	B-T170
incorporates	O
clinical	B-T080
knowledge	B-T170
in	O
the	O
form	O
of	O
intensity priors	B-T170
which	O
are	O
integrated	O
into	O
a	O
Random Walker (RW) formulation	B-T170
.	O
We	O
use	O
a	O
modified	B-T169
RW	B-T170
framework	O
which	O
compensates	B-T080
for	O
incomplete	B-T080
or	O
blurred	B-T080
boundaries	B-T185
in	O
the	O
image	B-T078
by	O
using	O
information	B-T078
from	O
neighboring slices	B-T082
in	O
the	O
sequence	B-T169
incorporated	O
as	O
node weights	B-T081
.	O
We	O
conducted	O
a	O
pilot study	B-T062
to	O
evaluate	B-T058
the	O
segmentation	B-T066
on	O
a	O
set	O
of	O
10	O
infant	B-T100
hip	B-T023
MRI	B-T060
sequences	B-T169
using	O
a	O
1.5	O
Tesla	O
MR scanner	B-T074
.	O
Contours	B-T082
obtained	O
from	O
the	O
semi-automated	B-T169
segmentation	B-T066
were	O
compared	B-T052
against	O
manually	B-T033
segmented	B-T066
hip	B-T023
contours	B-T082
using	O
Dice Ratio	B-T081
(	O
DR	B-T081
),	O
Hausdorff Distance	B-T081
(	O
HD	B-T081
)	O
and	O
Root Mean Square	B-T081
(	O
RMS	B-T081
)	O
distance.	O
The	O
proposed	O
method	B-T170
gave	O
values	O
of	O
(	O
DR	B-T081
=	O
0.84	O
±	O
0.5,	O
HD	B-T081
=3.0	O
±	O
0.7,	O
RMS	B-T081
=1.9	O
±	O
0.3)	O
and	O
(	O
DR	B-T081
=0.86	O
±	O
0.2,	O
HD	B-T081
=3.0	O
±	O
0.1,	O
RMS	B-T081
=	O
2.0	O
±	O
0.6)	O
for	O
right	B-T029
and	O
left acetabular contours	B-T029
respectively	O
which	O
was	O
higher	B-T080
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	B-T080
RW	B-T170
segmentation	B-T066
.	O
The	O
execution	B-T052
time	B-T079
of	O
the	O
segmentation	B-T066
algorithm	B-T170
was	O
less	O
than	O
~4	O
seconds	B-T079
on	O
a	O
3.5	O
GHz	O
CPU	B-T073
.	O

Automated	O
basal cell carcinoma	B-T191
detection	O
in	O
high-definition optical coherence tomography	B-T060
Basal cell carcinoma	B-T191
(	O
BCC	B-T191
)	O
is	O
the	O
most	O
common	O
non-melanoma skin cancer	B-T191
.	O
Conventional	O
diagnosis	O
of	O
BCC	B-T191
requires	O
invasive	B-T080
biopsies	B-T060
.	O
Recently,	O
a	O
high-definition optical coherence tomography	B-T060
(	O
HD-OCT	B-T060
)	O
technique	O
has	O
been	O
developed,	O
which	O
provides	O
a	O
non-invasive	B-T169
in vivo imaging method	B-T059
of	O
skin	B-T022
.	O
Good	O
agreements	O
of	O
BCC	B-T191
features	O
between	O
HD-OCT	B-T060
images	B-T078
and	O
histopathological architecture	B-T169
have	O
been	O
found.	O
Therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
BCC	B-T191
using	O
HD-OCT	B-T060
.	O
This	O
paper	O
presents	O
a	O
novel	O
BCC	B-T191
detection method	B-T060
that	O
consists	O
of	O
four	O
steps:	O
graph	O
based	O
skin surface	B-T029
segmentation	B-T058
,	O
surface flattening	B-T169
,	O
deep	O
feature	O
extraction	O
and	O
the	O
BCC	B-T191
classification.	O
The	O
effectiveness	B-T080
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5,040	O
images.	O
It	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
BCC	B-T191
.	O

Fall	B-T033
risk factors	B-T033
analysis	B-T062
based	O
on	O
sample entropy	B-T067
of	O
plantar	B-T029
kinematic	B-T070
signal	B-T067
during	O
stance phase	B-T033
Falls	B-T033
are	O
a	O
multi-causal phenomenon	B-T067
with	O
a	O
complex	B-T080
interaction	B-T169
.	O
The	O
aim	O
of	O
our	O
research	B-T062
is	O
to	O
study	B-T062
the	O
effect	B-T080
of	O
multiple	B-T081
variables	B-T080
for	O
potential	B-T080
risk of falls	B-T033
and	O
construct	B-T185
an	O
elderly fall risk assessment model	B-T170
based	O
on	O
demographics	B-T090
data	B-T078
and	O
gait characteristics	B-T033
.	O
A	O
total	O
of	O
101	O
subjects	B-T098
,	O
whom	O
belong	O
to	O
Malianwa Street	B-T073
,	O
aged	B-T032
above	O
50	O
years old	B-T079
and	O
participated	B-T169
in	O
questionnaire	B-T170
survey	B-T170
.	O
Participants	B-T098
were	O
classified	O
into	O
three	O
groups	B-T078
(	O
high	B-T098
,	O
medium	B-T098
and	O
low risk	B-T081
group	B-T078
)	O
according	O
to	O
the	O
score	B-T081
of	O
elderly fall risk assessment scale	B-T170
.	O
In	O
addition,	O
the	O
data	B-T078
of	O
ground reaction force	B-T070
(	O
GRF	B-T070
)	O
and	O
ground reaction moment	B-T070
(	O
GRM	B-T070
)	O
was	O
record	B-T080
when	O
they	O
performed	B-T169
walking	B-T056
at	O
comfortable state	B-T033
.	O
The	O
demographic	B-T102
variables	B-T080
,	O
sample entropy	B-T067
of	O
GRF	B-T070
and	O
GRM	B-T070
,	O
and	O
impulse difference	B-T081
of	O
bilateral foot	B-T023
were	O
considered	O
as	O
potential	B-T080
explanatory	B-T170
variables	B-T080
of	O
risk assessment	B-T058
model	B-T170
.	O
Firstly,	O
we	O
investigated	B-T169
whether	O
different	O
groups	B-T078
could	O
present	O
difference	B-T081
in	O
every	O
variable	B-T080
.	O
Statistical differences	B-T081
were	O
found	B-T033
for	O
the	O
following	O
variables	B-T080
:	O
age	B-T032
(p=2.28e-05);	O
impulse difference	B-T081
(p=0.02036);	O
sample entropy	B-T067
of	O
GRF	B-T070
in	O
vertical	B-T082
direction	B-T082
(p=0.0144);	O
sample entropy	B-T067
of	O
GRM	B-T070
in	O
anterior-posterior	B-T082
direction	B-T082
(p=0.0387).	O
Finally,	O
the	O
multiple	B-T081
regression analysis	B-T170
results	B-T169
indicated	B-T033
that	O
age	B-T032
,	O
impulse difference	B-T081
and	O
sample entropy	B-T067
of	O
resultant	O
GRM	B-T070
could	O
identify	O
individuals	B-T098
who	O
had	O
different	O
levels of fall risk	B-T058
.	O
Therefore,	O
those	O
results	B-T169
could	O
potentially	B-T080
be	O
useful	B-T080
in	O
the	O
fall risk assessment	B-T058
and	O
monitor	B-T058
the	O
state	B-T169
of	O
physical function	B-T033
in	O
elderly population	B-T098
.	O

Endurance	B-T033
based	O
personalized fitness planner	B-T170
Endurance	B-T033
is	O
an	O
important	B-T080
factor	B-T169
of	O
cardiovascular fitness	B-T040
indicating	O
the	O
capacity	B-T081
of	O
an	O
individual	B-T098
to	O
perform	B-T169
exercise	B-T056
for	O
a	O
longer duration	B-T079
with	O
increased	B-T081
intensity	B-T080
.	O
Various	O
subject specific	B-T080
and	O
exercise	B-T056
related	O
parameters	B-T077
affect	O
endurance	B-T033
of	O
an	O
individual	B-T098
.	O
In	O
this	O
work,	O
we	O
propose	O
a	O
statistical technique	B-T062
to	O
model	B-T170
endurance	B-T033
as	O
a	O
function	O
of	O
these	O
factors	B-T169
incorporating	O
the	O
serial	O
dependence	O
of	O
observations	B-T062
generated	O
by	O
individuals	B-T098
over time	B-T079
.	O
The	O
proposed	B-T080
model	B-T170
provides	O
a	O
device	B-T074
to	O
predict	O
future	O
endurance	B-T033
of	O
a	O
test	O
subject	B-T096
following	O
particular	O
exercise regime	B-T061
.	O
This	O
facilitates	O
a	O
test user	B-T078
with	O
a	O
fitness planner	B-T170
with	O
the	O
provision	O
to	O
fix	O
exercise regimes	B-T061
to	O
reach	O
a	O
set	O
fitness	B-T056
goal	B-T170
.	O

Heart rate	B-T201
variability	B-T077
as	O
a	O
biomarker	B-T201
for	O
sedation depth	B-T033
estimation	B-T081
in	O
ICU	B-T073
patients	B-T101
An	O
automated patient-specific system	B-T170
to	O
classify	O
the	O
level of sedation	B-T033
in	O
ICU	B-T073
patients	B-T101
using	O
heart rate	B-T201
variability	B-T077
signal	B-T067
is	O
presented	B-T078
in	O
this	O
paper	B-T170
.	O
ECG	B-T033
from	O
70	O
mechanically ventilated	B-T061
adult	B-T100
patients	B-T101
with	O
administered	B-T169
sedatives	B-T121
in	O
an	O
ICU setting	B-T073
were	O
used	O
to	O
develop	O
a	O
support vector machine	B-T081
based	O
system	O
for	O
sedation depth	B-T033
monitoring	B-T058
using	O
several	O
heart rate	B-T201
variability	B-T077
measures	B-T081
.	O
A	O
leave-one-subject-out cross validation	B-T062
was	O
used	O
for	O
classifier	B-T169
training	B-T065
and	O
performance	B-T052
evaluations	B-T058
.	O
The	O
proposed	O
patient-specific system	B-T170
provided	B-T052
a	O
sensitivity	B-T081
,	O
specificity	B-T081
and	O
an	O
AUC	B-T081
of	O
64%,	O
84.8%	O
and	O
0.72,	O
respectively.	O
It	O
is	O
hoped	O
that	O
with	O
the	O
help	O
of	O
additional	O
physiological	B-T169
signals	B-T067
the	O
proposed	O
patient	B-T101
-	O
specific	B-T080
sedation level	B-T033
prediction	B-T078
system	B-T169
could	O
lead	O
to	O
a	O
fully	O
automated multimodal system	B-T170
to	O
assist	O
clinical	B-T080
staff	B-T097
in	O
ICUs	B-T073
to	O
interpret	B-T169
the	O
sedation level	B-T033
of	O
the	O
patient	B-T101
.	O

RELIABILITY AND VALIDITY	B-T080
OF	O
THE	O
DIABETES EATING PROBLEM SURVEY-REVISED	B-T058
ON	O
TURKISH	B-T098
CHILDREN	B-T100
AND	O
ADOLESCENTS	B-T100
WITH	O
TYPE 1 DIABETES MELLITUS	B-T047
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
examine	B-T169
the	O
reliability and validity	B-T080
of	O
Turkish	B-T098
version	B-T170
of	O
Diabetes Eating Problem Survey-Revised	B-T058
(	O
DEPS-R	B-T058
)	O
for	O
children	B-T100
and	O
adolescent	B-T100
with	O
Type 1 Diabetes Mellitus	B-T047
.	O
A	O
total	O
of	O
200	O
children	B-T100
and	O
adolescents	B-T100
with	O
type 1 diabetes	B-T047
,	O
ages	B-T032
9-18	O
years	B-T079
,	O
completed	O
the	O
DEPS-R	B-T058
Turkish	B-T098
version	B-T170
.	O
In	O
addition	O
to	O
tests	B-T169
of	O
validity	B-T081
,	O
confirmatory factor analysis	B-T080
was	O
conducted	O
to	O
investigate	B-T169
the	O
factor structure	B-T081
of	O
the	O
16-item	O
Turkish	B-T098
version	B-T170
of	O
DEPS-R	B-T058
.	O
The	O
Turkish	B-T098
version	B-T170
of	O
DEPS-R	B-T058
demonstrated	O
satisfactory	B-T080
Cronbach's	B-T081
∝	O
(0.847)	O
and	O
was	O
significantly	O
correlated	B-T080
with	O
ag	B-T032
e	O
(r=0.194;	O
p<0.01),	O
hemoglobin A1c levels	B-T034
(r=0.303;	O
p<0.01)	O
and	O
BMI	B-T201
-	O
SDS	B-T081
(r=0.412;	O
p<0.01)	O
indicating	O
criterion validity	B-T081
.	O
Median	O
DEPS-R	B-T058
scores	B-T081
of	O
Turkish	B-T098
version	B-T170
for	O
the	O
total	O
samples	B-T098
,	O
females	B-T032
and	O
males	B-T032
were	O
as	O
follows:	O
11.0,	O
11.5	O
and	O
10.5	O
respectively.	O
Disturbed eating behaviors	B-T048
and	O
insulin	B-T116
restriction	B-T169
were	O
associated	O
with	O
poor	O
metabolic control	B-T044
.	O
A	O
short,	O
self-administered	B-T169
diabetes	B-T047
specific	O
screening	B-T058
tool	O
for	O
disordered eating behavior	B-T048
can	O
be	O
used	O
routinely	O
in	O
the	O
clinical	B-T080
care	B-T058
of	O
adolescents	B-T100
with	O
type 1 diabetes	B-T047
.	O
The	O
Turkish	B-T098
version	B-T170
of	O
DEPS-R	B-T058
is	O
a	O
valid	O
screening	B-T058
tool	O
for	O
disordered eating behaviors	B-T048
in	O
type 1 diabetes	B-T047
and	O
it	O
is	O
potentially	O
important	O
to	O
early	O
detect	O
disordered eating behaviors	B-T048
.	O

A	O
comparison	B-T052
of	O
the	O
localization	B-T169
of	O
rectal carcinomas	B-T191
according	O
to	O
the	O
general	B-T082
rules	B-T170
of	O
the	O
Japanese classification of colorectal carcinoma	B-T185
(	O
JCCRC	B-T185
)	O
and	O
Western	B-T082
guidelines	B-T170
The	O
aim	B-T078
of	O
this	O
study	O
was	O
to	O
compare	B-T052
the	O
localization	B-T169
of	O
rectal cancers	B-T191
as	O
classified	B-T185
according	O
to	O
the	O
general	B-T082
rules	B-T170
of	O
the	O
Japanese classification of colorectal carcinoma	B-T185
(	O
JCCRC	B-T185
)	O
and	O
also	O
according	O
to	O
the	O
European Society for Medical Oncology	B-T093
(	O
ESMO	B-T093
)	O
and	O
the	O
National Comprehensive Cancer Network	B-T093
(	O
NCCN	B-T093
)	O
guidelines	B-T170
,	O
which	O
are	O
based	O
on	O
rigid endoscopic	B-T060
measurements	B-T169
.	O
The	O
medical records	B-T170
of	O
patients	B-T101
scheduled	B-T080
to	O
receive	B-T080
curative surgery	B-T061
for	O
histologically	B-T169
proven	O
rectal adenocarcinoma	B-T191
during	B-T079
2009-2015	O
were	O
investigated	B-T169
(n	O
=	O
230).	O
Rigid proctoscopy	B-T060
was	O
performed	B-T169
in	O
patients	B-T101
with	O
rectal cancer	B-T191
located in	B-T082
the	O
upper	B-T082
(	O
Ra	B-T082
)	O
or	O
lower	B-T082
(	O
Rb	B-T082
)	O
division	B-T061
using	O
double-contrast barium enema	B-T060
.	O
The	O
median	B-T081
values	O
of	O
height	B-T032
from	O
the	O
anal verge	B-T023
were	O
7.5	O
cm	O
(	O
range	B-T081
2-12)	O
and	O
3	O
cm	O
(0-9.5)	O
on	O
rigid proctoscopy	B-T060
for	O
cancers	B-T191
assigned	B-T169
as	O
Ra	B-T082
and	O
Rb	B-T082
,	O
respectively.	O
All	O
159	O
cancers	B-T191
at	O
Ra	B-T082
or	O
Rb	B-T082
were	O
located	B-T082
within	B-T082
12	O
cm	O
from	O
the	O
anal verge	B-T023
by	O
rigid proctoscopy	B-T060
,	O
while	O
only	O
79.7%	O
of	O
Ra	B-T082
or	O
82.1%	O
of	O
Rb	B-T082
cancers	B-T191
were	O
located in	B-T082
the	O
mid	B-T082
(5.1-10	O
cm)	O
or	O
low	B-T080
(≤5	O
cm)	O
rectum	B-T023
,	O
respectively.	O
Ra	B-T082
and	O
Rb	B-T082
cancers	B-T191
are	O
deemed	O
to	O
be	O
rectal cancers	B-T191
according	O
to	O
NCCN	B-T093
guidelines	B-T170
,	O
but	O
these	O
classifications	B-T185
are	O
not	O
interchangeable	O
with	O
mid-	B-T082
and	O
low	B-T080
-	O
rectal cancers	B-T191
,	O
respectively,	O
according	O
to	O
the	O
ESMO	B-T093
guidelines	B-T170
.	O

Natural orifice transluminal endoscopic surgery	B-T061
with	O
a	O
snake-mechanism	B-T169
using	O
a	O
movable pulley	B-T074
Natural orifice transluminal endoscopic surgery	B-T061
is	O
an	O
emerging	O
technique	B-T169
.	O
We	O
aimed	O
to	O
develop	B-T169
an	O
advanced	B-T080
surgical robot	B-T074
mechanism	B-T169
for	O
natural orifice surgery	B-T061
.	O
We	O
propose	O
the	O
active-controlled overtube-type platform	B-T075
with	O
multiple	O
channels	B-T082
for	O
an	O
endoscopic camera	B-T074
and	O
surgical	B-T061
tools	B-T073
.	O
To	O
make	O
such	O
a	O
platform	B-T075
,	O
we	O
suggest	B-T078
an	O
advanced	B-T080
snake mechanism	B-T169
comprising	O
movable pulleys	B-T074
to	O
make	O
a	O
snake mechanism	B-T169
with	O
multiple	O
degrees of freedom	B-T169
and	O
high	O
operating	O
force.	O
The	O
stiffness	B-T080
and	O
maneuverability	B-T080
of	O
the	O
active-controlled platform	B-T075
appeared	O
satisfactory	B-T080
.	O
Using	O
prototypes	B-T170
and	O
ex vivo	B-T169
experiments	B-T062
,	O
we	O
confirmed	O
that	O
the	O
mechanism	B-T169
was	O
suitable	O
for	O
a	O
snake-like robotic	B-T073
platform	B-T075
for	O
natural orifice surgery	B-T061
.	O
The	O
suggested	B-T078
snake mechanism	B-T169
using	O
movable pulleys	B-T074
has	O
the	O
advantages	O
of	O
stiffness	B-T080
and	O
maneuverability	B-T080
.	O
This	O
new	O
mechanism	B-T169
can	O
be	O
an	O
alternative	B-T077
platform	B-T075
for	O
natural orifice surgery	B-T061
.	O

Real	O
role	O
of	O
β-blockers	B-T121
in	O
regression	B-T046
of	O
left ventricular mass	B-T033
in	O
hypertension	B-T047
patients	B-T101
:	O
Bayesian network	B-T081
meta-analysis	B-T062
Left ventricular hypertrophy	B-T047
(	O
LVH	B-T047
)	O
is	O
commonly	O
present	O
in	O
patients	B-T101
with	O
hypertension	B-T047
(	O
HT	B-T047
).	O
According	O
to	O
the	O
expert consensus document	B-T170
from	O
American	B-T098
,	O
angiotensin-converting enzyme inhibitor	B-T121
(	O
ACEI	B-T121
)	O
and	O
angiotensin receptor blockers	B-T121
(	O
ARBs	B-T121
)	O
were	O
recommended	O
as	O
1st-line	O
therapeutic drugs	B-T121
.	O
However,	O
none	O
noticed	O
the	O
different	O
efficacy	B-T080
between	O
fat-soluble and selective β1-receptor blockers	B-T121
(	O
FS-β-B	B-T121
)	O
and	O
other	O
β-blockers	B-T121
on	O
regression	B-T046
of	O
LVH	B-T047
before.	O
The	O
aim	O
of	O
this	O
analysis	B-T062
was	O
to	O
compare	B-T052
the	O
efficacy	B-T080
of	O
FS-β-B	B-T121
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive drugs	B-T121
(	O
ACEI	B-T121
,	O
ARBs	B-T121
,	O
calcium channel blockers	B-T121
[	O
CCBs	B-T121
],	O
and	O
diuretics	B-T121
)	O
on	O
regression	B-T046
of	O
LVH	B-T047
.	O
Relative	B-T080
trials	B-T062
were	O
identified	O
in	O
the	O
PubMed	B-T170
,	O
Web of Science	B-T170
,	O
OVID EBM Reviews	B-T170
and	O
Cochrane databases	B-T170
,	O
and	O
the	O
relevant	O
papers	B-T170
were	O
examined	B-T169
.	O
We	O
performed	O
both	O
traditional	O
and	O
Bayesian	B-T081
meta-analysis	B-T062
of	O
randomized controlled trials	B-T062
(	O
RCTs	B-T062
)	O
about	O
the	O
regression	B-T046
of	O
LVH	B-T047
.	O
Sensitivity analysis	B-T062
and	O
regression analysis	B-T170
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	B-T080
.	O
Inconsistency analysis	B-T062
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	B-T062
of	O
the	O
trials	B-T062
in	O
the	O
network	B-T081
was	O
indeed	O
consistent	B-T078
.	O
A	O
total	O
of	O
41	O
RCTs	B-T062
involving	O
2566	O
patients	B-T101
with	O
HT	B-T047
and	O
LVH	B-T047
were	O
included	O
in	O
this	O
analysis	B-T062
.	O
Bayesian network	B-T081
meta-analysis	B-T062
indicated	O
no	O
statistically significant	B-T081
differences	O
between	O
these	O
groups	B-T078
:	O
FS-β-B	B-T121
and	O
ACEI	B-T121
(MD,	O
-7.09;	O
95%	O
CI	B-T081
,	O
-14.99,	O
1.27);	O
FS-β-B	B-T121
and	O
ARB	B-T121
(MD,	O
-2.66;	O
95%	O
Cl	B-T081
,	O
-12.02,	O
6.31).	O
Although	O
FS-β-B	B-T121
showed	O
greater	O
efficacy	B-T080
when	O
compared	B-T052
with	O
diuretic	B-T121
(MD,	O
13.04;	O
95%	O
CI	B-T081
,	O
3.38,	O
22.59)	O
or	O
CCB	B-T121
(MD,	O
10.90;	O
95%	O
CI	B-T081
,	O
1.98,	O
19.49).	O
The	O
probabilities	B-T081
of	O
being	O
among	O
the	O
most	O
efficacious	B-T080
treatments	B-T061
were:	O
FS-β-B	B-T121
(72%),	O
ARB	B-T121
(27%),	O
ACEI	B-T121
(0.01%),	O
CCB	B-T121
(0.00%),	O
and	O
diuretic	B-T121
(0.00%).	O
Evidence	O
from	O
our	O
analysis	B-T062
reveals	O
that	O
FS-β-B	B-T121
have	O
potential	O
to	O
become	O
1st-line	O
therapeutic drugs	B-T121
in	O
HT	B-T047
and	O
LVH	B-T047
patients	B-T101
.	O
However,	O
the	O
real	O
efficacy	B-T080
of	O
FS-β-B	B-T121
on	O
regression	B-T046
of	O
LVH	B-T047
should	O
be	O
confirmed	O
by	O
further	O
large,	O
high	O
quality	B-T080
trials	B-T062
considering	O
the	O
limitation	O
of	O
the	O
study	O
number.	O

Improved	B-T033
risk	B-T078
stratification	B-T062
for	O
patients	B-T101
with	O
high-grade	O
urothelial carcinoma	B-T191
following	O
application	O
of	O
the	O
Paris	B-T083
System	B-T169
for	O
Reporting	B-T058
Urinary Cytology	B-T059
The	O
Paris	B-T083
System	B-T169
for	O
Reporting	B-T058
Urinary Cytology	B-T059
(	O
TPS	B-T059
)	O
requires	O
4	O
cytomorphologic	B-T026
criteria	B-T078
for	O
a	O
definitive	O
diagnosis	B-T033
of	O
high-grade urothelial carcinoma	B-T191
(	O
HGUC	B-T191
)	O
in	O
urinary tract cytology	B-T059
(	O
UTC	B-T059
)	O
specimens	B-T167
:	O
an	O
elevated	B-T080
nuclear-to-cytoplasmic (N/C) ratio	B-T049
(at	O
or	O
above	O
0.7),	O
markedly	O
atypical	B-T080
nuclear	B-T026
borders	B-T082
,	O
moderate	B-T080
to	O
severe	B-T080
hyperchromasia	B-T033
,	O
and	O
coarse chromatin	B-T033
.	O
However,	O
malignant	B-T080
UTC	B-T059
specimens	B-T167
often	O
contain	O
degenerative	B-T169
changes	B-T169
,	O
and	O
this	O
limits	O
the	O
number	O
of	O
malignant cells	B-T025
meeting	O
all	O
4	O
TPS	B-T059
cytomorphologic	B-T026
criteria	B-T078
.	O
One	O
hundred	O
twelve	O
UTC	B-T059
specimens	B-T167
from	O
patients	B-T101
with	O
a	O
subsequent	O
diagnosis	B-T033
of	O
HGUC	B-T191
were	O
reviewed	B-T080
and	O
reclassified	B-T080
according	O
to	O
TPS	B-T059
criteria	B-T078
.	O
The	O
presence	B-T033
of	O
TPS	B-T059
cytomorphologic	B-T026
criteria	B-T078
for	O
HGUC	B-T191
in	O
each	O
specimen	B-T167
was	O
recorded,	O
as	O
was	O
the	O
proportion	O
of	O
atypical	B-T080
cells	B-T025
meeting	O
all	O
4	O
criteria	B-T078
.	O
The	O
number	O
of	O
specimens	B-T167
definitively	O
diagnosed	B-T033
as	O
HGUC	B-T191
did	O
not	O
significantly	B-T078
change	B-T169
upon	O
reclassification	B-T185
.	O
However,	O
approximately	B-T080
40%	O
of	O
indeterminate	B-T078
specimens	B-T167
(21	O
of	O
51)	O
were	O
reclassified	B-T080
into	O
a	O
higher	O
risk	B-T078
category	B-T170
.	O
The	O
most	O
restrictive	O
cytomorphologic	B-T026
criterion	O
was	O
an	O
N/C ratio	B-T049
of	O
0.7	O
or	O
higher	O
(seen	O
in	O
78%	O
of	O
specimens	B-T167
),	O
and	O
approximately	B-T080
half	O
of	O
specimens	B-T167
specimens	B-T167
containing	O
all	O
4	O
cytomorphologic	B-T026
criteria	B-T078
did	O
not	O
meet	O
TPS	B-T059
's	O
numerical	O
criterion	O
for	O
HGUC	B-T191
(at	O
least	O
5	O
malignant cells	B-T025
).	O
In	O
the	O
majority	O
of	O
specimens	B-T167
qualifying	O
for	O
HGUC	B-T191
by	O
TPS	B-T059
standards,	O
only	O
a	O
small	O
fraction of	B-T081
atypical	B-T080
cells	B-T025
(10%-20%)	O
met	O
all	O
the	O
criteria	B-T078
.	O
When	O
applied	O
to	O
malignant	B-T080
UTC	B-T059
specimens	B-T167
,	O
TPS	B-T059
criteria	B-T078
improved	B-T033
specimen	B-T167
risk	B-T078
stratification	B-T062
by	O
upgrading	O
approximately	B-T080
40%	O
of	O
indeterminate	B-T078
specimens	B-T167
into	O
higher	O
risk	B-T078
categories	B-T170
while	O
not	O
significantly	B-T078
changing	B-T169
the	O
frequency	B-T079
of	O
HGUC	B-T191
diagnoses	B-T033
.	O
Cancer	B-T191
Cytopathol	O
2017.	O
©	O
2017	O
American Cancer Society	B-T094
.	O

Questionable	O
diagnostic	B-T169
benefit	B-T081
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee venom	B-T116
components	B-T077
For	O
many	O
years	B-T079
,	O
only	O
the	O
major	O
allergen	B-T129
rApi m 1	B-T129
has	O
been	O
available	O
on	O
the	O
ImmunoCAP system	B-T170
for	O
routine	O
diagnosis	B-T033
of	O
bee venom (BV) allergy	B-T046
.	O
Now,	O
there	O
are	O
five	O
components	B-T077
available,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	B-T081
and	O
specificity	B-T081
of	O
rApi m 1	B-T129
,	O
2	B-T129
,	O
3	B-T129
,	O
5	B-T129
,	O
and	O
10	B-T129
in	O
BV-allergic	B-T046
patients	B-T101
.	O
We	O
further	O
evaluated	O
the	O
sensitivity	B-T081
of	O
rApi m 1	B-T129
and	O
2	B-T129
of	O
an	O
alternative	O
platform	O
and	O
investigated	B-T169
possible	O
differences	O
in	O
the	O
sensitization	B-T040
profile	O
between	O
monosensitization	B-T040
and	O
clinically	O
relevant	O
double sensitization	B-T040
.	O
Analysis	B-T062
of	O
the	O
whole	O
panel	O
of	O
BV	B-T116
allergens	B-T129
of	O
the	O
CAP system	B-T170
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	B-T081
than	O
analysis	B-T062
of	O
the	O
combination	O
of	O
rApi m 1	B-T129
and	O
2	B-T129
of	O
the	O
Immulite	B-T073
(71.6%	O
vs	O
85.8%).	O
Sensitization	B-T040
rate	B-T081
of	O
rApi m 5	B-T129
was	O
more	O
than	O
doubled	O
in	O
double-sensitized	B-T040
patients	B-T101
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi m 2	B-T129
.	O
The	O
benefit	B-T081
of	O
the	O
commercially	O
available	O
panel	O
of	O
BV	B-T116
components	B-T077
is	O
questionable,	O
due	O
to	O
the	O
insufficient	B-T080
sensitivity	B-T081
and	O
still	O
unavailable	O
important	O
cross-reacting	B-T044
allergens	B-T129
.	O

Orai1	B-T116
-Mediated	O
Antimicrobial	B-T121
Secretion	B-T031
from	O
Pancreatic Acini	B-T023
Shapes	O
the	O
Gut Microbiome	B-T001
and	O
Regulates	B-T040
Gut	B-T023
Innate Immunity	B-T032
The	O
gut microbiome	B-T001
participates	O
in	O
numerous	O
physiologic functions	B-T039
and	O
communicates	B-T033
intimately	O
with	O
the	O
host	B-T001
immune system	B-T022
.	O
Antimicrobial peptides	B-T116
are	O
critica	B-T080
l	O
components	B-T116
of	O
intestinal	B-T023
innate immunity	B-T032
.	O
We	O
report	O
a	O
prominent	B-T080
role	O
for	O
antimicrobials secreted	B-T043
by	O
pancreatic acini	B-T023
in	O
shaping	O
the	O
gut microbiome	B-T001
that	O
is	O
essential	O
for	O
intestinal	B-T023
innate immunity	B-T032
,	O
barrier function	B-T042
,	O
and	O
survival	B-T169
.	O
Deletion	B-T052
of	O
the	O
Ca(2+) channel Orai1	B-T028
in	O
pancreatic acini	B-T023
of	O
adult	O
mice	B-T015
resulted	O
in	O
60%-70%	O
mortality	B-T081
within	O
3	O
weeks.	O
Despite	O
robust	O
activation of the intestinal innate immune response	B-T040
,	O
mice	B-T015
lacking	O
acinar	B-T082
Orai1	B-T028
exhibited	O
intestinal	B-T023
bacterial	B-T080
outgrowth	B-T043
and	O
dysbiosis	B-T184
,	O
ultimately	O
causing	O
systemic	B-T169
translocation	B-T043
,	O
inflammation	B-T046
,	O
and	O
death	B-T040
.	O
While	O
digestive enzyme	B-T116
supplementation	B-T061
was	O
ineffective	B-T078
,	O
treatments	B-T061
constraining	O
bacterial	B-T080
outgrowth	B-T043
(	O
purified	B-T169
liquid diet	B-T061
,	O
broad-spectrum antibiotics	B-T195
)	O
rescued	O
survival	B-T169
,	O
feeding	B-T052
,	O
and	O
weight gain	B-T033
.	O
Pancreatic levels	B-T034
of	O
cathelicidin	B-T116
-related	O
antimicrobial peptide	B-T116
(	O
CRAMP	B-T116
)	O
were	O
reduced	B-T080
,	O
and	O
supplement	B-T169
of	O
synthetic	O
CRAMP	B-T116
prevented	O
intestinal disease	B-T047
.	O
These	O
findings	B-T033
reveal	O
a	O
critical	B-T080
role	O
for	O
antimicrobial	B-T121
pancreatic secretion	B-T042
in	O
gut	B-T023
innate immunity	B-T032
.	O

Palliative Care	B-T091
with	O
Attachment	B-T052
Hybrid Removable Prosthesis	B-T061
Abutment	B-T023
injury	B-T037
,	O
unsatisfactory	B-T080
aesthetics	B-T090
and	O
lesser	O
retention	B-T061
exist	O
with	O
the	O
cast partial denture	B-UnknownType
.	O
Though	O
these	O
constraints	O
exist	O
in	O
the	O
Removable Partial Denture	B-T074
(	O
RPD	B-T074
)	O
it	O
is	O
still	O
widely	O
used	O
because	O
of	O
the	O
simplicity	O
in	O
design	B-T058
,	O
fabrication	B-T067
,	O
economics	B-T169
and	O
patient comfort	B-T058
.	O
This	O
clinical report	B-T170
describes	O
a	O
hybrid	O
RPD	B-T074
technique	B-T169
which	O
uses	O
extra	O
coronal	B-T082
attachment	B-T052
that	O
reduces	B-T080
the	O
limitations	O
and	O
provides	O
better	O
comfort	B-T041
for	O
the	O
patient	B-T101
.	O

CXCL5	B-T116
Plays	O
a	O
Promoting	O
Role	O
in	O
Osteosarcoma	B-T191
Cell Migration and Invasion	B-T191
in	O
Autocrine	B-T042
-	O
and	O
Paracrine	B-T039
-Dependent	O
Manners	O
CXCL5	B-T116
,	O
a	O
CXC-type chemokine	B-T116
,	O
is	O
an	O
important	O
attractant	O
for	O
granulocytic immune cells	B-T025
by	O
binding to its receptor CXCR2	B-T044
.	O
Recently,	O
CXCL5	B-T116
/	O
CXCR2	B-T116
has	O
been	O
found	O
to	O
play	O
an	O
oncogenic	B-T116
role	O
in	O
many	O
human	B-T016
cancers	B-T191
.	O
However,	O
the	O
exact	O
role	O
of	O
CXCL5	B-T116
in	O
osteosarcoma	B-T191
cell migration and invasion	B-T191
has	O
not	O
been	O
revealed.	O
Here	O
we	O
found	O
that	O
the	O
protein expression	B-T045
of	O
CXCL5	B-T116
was	O
significantly	O
increased	B-T081
in	O
osteosarcoma	B-T191
tissues	B-T024
compared	O
with	O
that	O
in	O
matched adjacent nontumor tissues	B-T024
.	O
Moreover,	O
the	O
expression	B-T045
of	O
CXCL5	B-T116
was	O
significantly	O
associated	O
with	O
advanced clinical stage	B-T079
and	O
metastasis	B-T046
.	O
Further	O
investigation	O
showed	O
that	O
the	O
CXCL5	B-T116
expression levels	B-T081
were	O
also	O
significantly	O
increased	B-T081
in	O
osteosarcoma	B-T191
cell lines	B-T025
,	O
including	O
Saos-2	B-T025
,	O
MG63	B-T025
,	O
U2OS	B-T025
,	O
and	O
SW1353	B-T025
,	O
when	O
compared	O
with	O
those	O
in	O
normal osteoblast	B-T025
hFoB1.19 cells	B-T025
.	O
U2OS cells	B-T025
were	O
further	O
transfected	B-T045
with	O
CXCL5	B-T028
-	O
specific siRNA	B-T114
or	O
overexpression	B-T045
plasmid	B-T114
.	O
Knockdown	B-T063
of	O
CXCL5	B-T028
significantly	O
suppressed	B-T169
U2OS	B-T025
cell migration and invasion	B-T191
.	O
On	O
the	O
contrary,	O
overexpression	B-T045
of	O
CXLC5	B-T116
remarkably	O
promoted	O
the	O
migration and invasion	B-T191
of	O
U2OS cells	B-T025
.	O
Interestingly,	O
both	O
exogenous	B-T169
CXCL5	B-T116
treatment	B-T169
and	O
the	O
conditioned	O
medium	O
of	O
CXCL5	B-T116
-	O
overexpressing	B-T045
hFoB1.19 cells	B-T025
could	O
also	O
enhance	O
the	O
migration and invasion	B-T191
of	O
U2OS cells	B-T025
,	O
suggesting	O
that	O
the	O
promoting	O
role	O
of	O
CXCL5	B-T116
in	O
U2OS	B-T025
cell migration and invasion	B-T191
is	O
also	O
in	O
a	O
paracrine	B-T039
-dependent	O
manner.	O
According	O
to	O
these	O
data,	O
our	O
study	O
demonstrates	O
that	O
CXCL5	B-T116
is	O
upregulated	O
in	O
osteosarcoma	B-T191
and	O
may	O
play	O
an	O
oncogenic	B-T116
role	O
in	O
osteosarcoma	B-T191
metastasis	B-T046
.	O
Therefore,	O
CXCL5	B-T116
may	O
become	O
a	O
potential	B-T080
therapeutic target	B-T169
for	O
osteosarcoma	B-T191
treatment	B-T169
.	O

Integrating	B-T052
molecular	B-T080
QTL	B-T028
data	B-T078
into	O
genome-wide genetic association analysis	B-T063
:	O
Probabilistic	B-T081
assessment	B-T169
of	O
enrichment	B-T077
and	O
colocalization	B-T169
We	O
propose	O
a	O
novel	O
statistical framework	B-T081
for	O
integrating	B-T052
the	O
result	B-T169
from	O
molecular	B-T080
quantitative trait loci	B-T028
(	O
QTL	B-T028
)	O
mapping	B-T052
into	O
genome-wide genetic association analysis	B-T063
of	O
complex	B-T080
traits	B-T032
,	O
with	O
the	O
primary	O
objectives	O
of	O
quantitatively	B-T081
assessing	B-T169
the	O
enrichment	B-T077
of	O
the	O
molecular	B-T080
QTLs	B-T028
in	O
complex	B-T080
trait	B-T032
-	O
associated	B-T080
genetic variants	B-T028
and	O
the	O
colocalizations	B-T169
of	O
the	O
two	O
types	B-T080
of	O
association	B-T080
signals	B-T067
.	O
We	O
introduce	O
a	O
natural Bayesian hierarchical model	B-T081
that	O
treats	O
the	O
latent	O
association	B-T080
status	O
of	O
molecular	B-T080
QTLs	B-T028
as	O
SNP	B-T086
-	O
level	B-T080
annotations	O
for	O
candidate	O
SNPs	B-T086
of	O
complex	B-T080
traits	B-T032
.	O
We	O
detail	O
a	O
computational	B-T052
procedure	B-T169
to	O
seamlessly	O
perform	O
enrichment	B-T077
,	O
fine-mapping	B-T052
and	O
colocalization	B-T169
analyses	B-T062
,	O
which	O
is	O
a	O
distinct feature	B-T080
compared	B-T052
to	O
the	O
existing	O
colocalization	B-T169
analysis	B-T062
procedures	B-T169
in	O
the	O
literature	B-T170
.	O
The	O
proposed	O
approach	B-T082
is	O
computationally	B-T052
efficient	B-T080
and	O
requires	O
only	O
summary	B-T170
-	O
level	B-T080
statistics	B-T081
.	O
We	O
evaluate	B-T169
and	O
demonstrate	O
the	O
proposed	O
computational	B-T052
approach	B-T082
through	O
extensive	B-T080
simulation	B-T066
studies	B-T062
and	O
analyses	B-T062
of	O
blood lipid	B-T109
data	B-T078
and	O
the	O
whole blood	B-T031
eQTL	B-T028
data	B-T078
from	O
the	O
GTEx project	B-T062
.	O
In	O
addition,	O
a	O
useful	O
utility	B-T170
from	O
our	O
proposed	O
method	B-T170
enables	O
the	O
computation	B-T052
of	O
expected	O
colocalization	B-T169
signals	B-T067
using	O
simple	O
characteristics	B-T080
of	O
the	O
association	B-T080
data	B-T078
.	O
Using	O
this	O
utility	B-T170
,	O
we	O
further	O
illustrate	O
the	O
importance	O
of	O
enrichment	B-T077
analysis	B-T062
on	O
the	O
ability	O
to	O
discover	O
colocalized	B-T169
signals	B-T067
and	O
the	O
potential	B-T080
limitations	B-T169
of	O
currently	O
available	O
molecular	B-T080
QTL	B-T028
data	B-T078
.	O
The	O
software	B-T073
pipeline	O
that	O
implements	O
the	O
proposed	O
computation	B-T052
procedures	B-T169
,	O
enloc	B-T170
,	O
is	O
freely	O
available	O
at	O
https://github.com/xqwen/integrative	B-T170
.	O

Engineering	B-T063
the	O
ribosomal DNA	B-T114
in	O
a	O
megabase synthetic chromosome	B-T075
We	O
designed	O
and	O
synthesized	O
a	O
976,067-base pair linear chromosome	B-T075
,	O
synXII	B-T075
,	O
based	O
on	O
native	O
chromosome XII	B-T026
in	O
Saccharomyces cerevisiae	B-T004
SynXII	B-T075
was	O
assembled	O
using	O
a	O
two-step method	B-T169
,	O
specified	O
by	O
successive	O
megachunk integration	B-T063
and	O
meiotic recombination-mediated assembly	B-T063
,	O
producing	O
a	O
functional	B-T169
chromosome	B-T026
in	O
S. cerevisiae	B-T004
.	O
Minor growth defect	B-T169
"	O
bugs	B-T169
"	O
detected	B-T033
in	O
synXII	B-T075
,	O
caused	O
by	O
deletion	B-T045
of	O
tRNA	B-T114
genes	B-T028
,	O
were	O
rescued	O
by	O
introducing	O
an	O
ectopic copy	B-T028
of	O
a	O
single tRNA	B-T114
gene	B-T028
.	O
The	O
ribosomal gene cluster	B-T028
(	O
rDNA	B-T028
)	O
on	O
synXII	B-T075
was	O
left	O
intact	O
during	O
the	O
assembly process	B-T063
and	O
subsequently	O
replaced	O
by	O
a	O
modified	B-T169
rDNA	B-T028
unit	O
used	O
to	O
regenerate	B-T169
rDNA	B-T028
at	O
three	O
distinct	O
chromosomal locations	B-T026
.	O
The	O
signature	O
sequences	B-T086
within	O
rDNA	B-T028
,	O
which	O
can	O
be	O
used	O
to	O
determine	O
species	B-T185
identity	B-T033
,	O
were	O
swapped	O
to	O
generate	O
a	O
Saccharomyces	B-T004
synXII	B-T075
strain	B-T001
that	O
would	O
be	O
identified	B-T080
as	O
Saccharomyces bayanus	B-T004
by	O
standard	B-T080
DNA	O
barcoding	O
procedures.	O

Reversible	O
Humidity	B-T070
Sensitive	B-T169
Clothing	B-T073
for	O
Personal Thermoregulation	B-T061
Two	O
kinds	O
of	O
humidity	B-T070
-	O
induced	B-T169
,	O
bendable	O
smart clothing	B-T073
have	O
been	O
designed to reversibly adapt	B-T062
their	O
thermal insulation functionality	B-T073
.	O
The	O
first	O
design	O
mimics	O
the	O
pores	B-T023
in	O
human skin	B-T022
,	O
in	O
which	O
pre-cut	O
flaps	O
open	O
to	O
produce	O
pores	B-T023
in	O
Nafion	B-T109
sheets	B-T073
when	O
humidity	B-T070
increases,	O
as	O
might	O
occur	O
during	O
human sweating	B-T033
thus	O
permitting	O
air flow	B-T067
and	O
reducing	O
both	O
the	O
humidity	B-T070
level	O
and	O
the	O
apparent temperature	B-T081
.	O
Like	O
the	O
smart	O
human sweating pores	B-T023
,	O
the	O
flaps	O
can	O
close	O
automatically	O
after	O
the	O
perspiration	B-T033
to	O
keep	O
the	O
wearer warm	B-T073
.	O
The	O
second	O
design	O
involves	O
thickness	B-T080
adjustable clothes	B-T073
by	O
inserting	O
the	O
bent polymer sheets	B-T073
between	O
two	O
fabrics	B-T073
.	O
As	O
the	O
humidity	B-T070
increases,	O
the	O
sheets	B-T073
become	O
thinner,	O
thus	O
reducing	O
the	O
gap	O
between	O
the	O
two	O
fabrics	B-T073
to	O
reduce	O
the	O
thermal insulation	B-T169
.	O
The	O
insulation layer	B-T073
can	O
recover	O
its	O
original	O
thickness	B-T080
upon	O
humidity	B-T070
reduction	O
to	O
restore	O
its	O
warmth-preservation	B-T039
function.	O
Such	O
humidity	B-T070
sensitive	B-T169
smart	O
polymer materials	B-T073
can	O
be	O
utilized	O
to	O
adjust	O
personal comfort	B-T041
,	O
and	O
be	O
effective	O
in	O
reducing energy consumption	B-T033
for	O
building	O
heating or cooling	B-T169
with	O
numerous	O
smart design	B-T052
.	O

Development	B-T039
of	O
an	O
automaton model	B-T075
of	O
rotational activity	B-T052
driving	O
atrial fibrillation	B-T047
Atrial fibrillation	B-T047
(	O
AF	B-T047
)	O
is	O
difficult	O
to	O
treat	B-T061
effectively	B-T080
,	O
owing	O
to	O
uncertainty	B-T033
in	O
where	O
to	O
best	O
ablate	B-T061
to	O
eliminate	B-T052
arrhythmogenic	B-T046
substrate	B-T167
.	O
A	O
model	B-T075
providing	O
insight	O
into	O
the	O
electrical	B-T169
activation	B-T052
events	B-T051
would	O
be	O
useful	O
to	O
guide	O
catheter ablation strategy	B-T061
.	O
Method	O
A	O
two-dimensional	B-T082
,	O
576×576 node automaton	B-T073
was	O
developed	O
to	O
simulate	B-T052
atrial	B-T023
atrial electrical activity	B-T042
.	O
The	O
substrate	B-T167
field	O
was	O
altered	O
by	O
the	O
presence	O
of	O
differing	B-T080
refractory period	B-T043
at	O
varying	O
locations	B-T082
.	O
Fibrosis	B-T046
was	O
added	O
in	O
the	O
form	O
of	O
short,	O
randomly	O
positioned	O
lines	O
of	O
conduction	B-T042
block	B-T047
.	O
Larger	B-T081
areas	B-T082
of	O
block	B-T046
were	O
used	O
to	O
simulate	B-T052
ablation lesions	B-T033
.	O
Anisotropy	B-T070
was	O
imposed	O
in	O
a	O
2:1	O
ratio	B-T081
.	O
A	O
premature	B-T079
electrical impulse	B-T043
from	O
one	O
of	O
four	O
grid	O
corners	O
was	O
utilized	O
to	O
initiate	B-T078
activation	B-T052
.	O
Rotational activity	B-T052
was	O
uninducible	O
when	O
refractory patch dimensions	B-T081
were	O
less	O
than	O
20×20mm.	O
For	O
larger	B-T081
refractory regions	B-T082
,	O
a	O
single	O
premature	B-T079
stimulus	B-T067
was	O
capable	O
of	O
inducing	B-T169
an	O
average	B-T081
of	O
1.19±1.10	O
rotors	B-T074
,	O
which	O
often	O
formed	O
near	O
the	O
patch edges	B-T082
.	O
A	O
maximum	B-T081
of	O
5	O
rotors	B-T074
formed	O
when	O
refractory patch dimensions	B-T081
approached	O
the	O
size	B-T082
of	O
the	O
entire	O
left atrial	B-T023
virtual field	B-T082
.	O
Rotors	B-T074
formed	O
along	O
a	O
refractory patch edge	B-T082
,	O
after	O
wavefront arrival was delayed	B-T033
at	O
turning	O
points	O
or	O
due	O
to	O
the	O
presence	O
of	O
a	O
fiber	B-T024
cluster	B-T081
of	O
sufficient	O
size	B-T082
.	O
However,	O
rotational activity	B-T052
could	O
also	O
occur	O
around	O
a	O
large	B-T081
fiber	B-T024
cluster	B-T081
without	O
the	O
need	O
of	O
spatially variable refractoriness	B-T080
.	O
When	O
obstacles	B-T080
to	O
conduction	B-T042
were	O
lacking	B-T080
in	O
size	B-T082
,	O
nascent rotors	B-T074
drifted	O
and	O
either	O
extinguished,	O
or	O
stabilized	B-T033
upon	O
anchoring	B-T044
at	O
a	O
sufficiently	O
large	B-T081
fiber	B-T024
cluster	B-T081
elsewhere	O
in	O
the	O
field.	O
Transient	B-T079
rotors	B-T074
terminated	O
when	O
traversing	B-T052
a	O
region	B-T082
with	O
differing	O
refractory periods	B-T043
,	O
if	O
no	O
obstacle	B-T080
to	O
conduction	B-T042
was	O
present	O
to	O
sufficiently	O
delay wavefront arrival	B-T033
beyond	O
the	O
longest	B-T080
refractory period	B-T043
.	O
Other	O
rotors	B-T074
were	O
annihilated	O
when	O
a	O
nearby	O
rotor	B-T074
with	O
faster	O
spin rate	B-T081
gradually	O
interrupted	O
the	O
activation pathway	B-T044
.	O
Elimination	B-T052
of	O
anchors	B-T061
by	O
removal	B-T061
,	O
or	O
by	O
simulated	O
ablation	B-T061
over	O
a	O
sufficient	O
region	B-T082
,	O
prevented	O
rotor	B-T074
onset	B-T080
at	O
a	O
particular	O
location	B-T029
where	O
it	O
would	O
otherwise	O
form.	O
The	O
presence	O
of	O
obstacles	B-T080
to	O
conduction	B-T042
and	O
spatial differences	B-T033
in	O
refractory period	B-T043
are	O
important	O
parameters	B-T078
for	O
initiating	O
and	O
maintaining	B-T169
rotational activity	B-T052
in	O
this	O
simulation	B-T062
of	O
an	O
atrial	B-T023
substrate	B-T167
.	O

Multimodal brain imaging	B-T060
with	O
magnetoencephalography	B-T060
:	O
A	O
method	B-T060
for	O
measuring	B-T169
blood pressure	B-T040
and	O
cardiorespiratory oscillations	B-T040
Studies	B-T062
with	O
magnetoencephalography	B-T060
(	O
MEG	B-T060
)	O
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-T060
that	O
can	O
provide	O
a	O
metabolic dimension	B-T169
to	O
MEG	B-T060
investigation	B-T058
s.	O
In	O
addition,	O
continuous	O
blood pressure measurements	B-T058
which	O
comply	O
with	O
MEG	B-T060
compatibility	O
requirements	O
are	O
lacking.	O
For	O
instance,	O
by	O
combining	O
methods	B-T060
reflecting	O
neurovascular status	B-T058
one	O
could	O
obtain	O
more	O
information	O
on	O
low frequency	B-T079
fluctuations	B-T184
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional connectivity	B-T169
within	O
brain networks	B-T023
.	O
This	O
paper	O
presents	O
a	O
multimodal brain imaging	B-T060
setup,	O
capable	O
to	O
non-invasively	B-T169
and	O
continuously	O
measure	O
cerebral	B-T023
hemodynamic	B-T042
,	O
cardiorespiratory	B-T060
and	O
blood pressure	B-T040
oscillations	B-T040
simultaneously	O
with	O
MEG	B-T060
.	O
In	O
the	O
setup,	O
all	O
methods	B-T060
apart	O
from	O
MEG	B-T060
rely	O
on	O
the	O
use	O
of	O
fibre optics	B-T090
.	O
In	O
particular,	O
we	O
present	O
a	O
method	B-T060
for	O
measuring	B-T169
of	O
blood pressure	B-T040
and	O
cardiorespiratory oscillations	B-T040
continuously	O
with	O
MEG	B-T060
.	O
The	O
potential	B-T080
of	O
this	O
type	O
of	O
multimodal	B-T060
setup	O
for	O
brain research	B-T062
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	B-T016
,	O
showing	O
effects of	B-T080
mild hypercapnia	B-T033
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
modalities	B-T169
.	O

Effect of	B-T080
peritoneal lavage	B-T058
solution	B-T167
temperature	B-T081
on	O
body temperature	B-T032
in	O
anaesthetised	B-T033
cats	B-T015
and	O
small	O
dogs	B-T015
A	O
prospective	B-T062
,	O
randomised	B-T062
,	O
non-blinded	B-T062
,	O
clinical study	B-T062
to	O
assess	O
the	O
effect of	B-T080
peritoneal lavage	B-T058
using	O
warmed	B-T070
fluid	B-T167
on	O
body temperature	B-T032
in	O
anesthetised	B-T033
cats	B-T015
and	O
dogs	B-T015
of	O
less	O
than	O
10	O
kg	O
body mass	B-T033
undergoing	O
coeliotomy	B-T061
.	O
A	O
standardised anaesthetic protocol	B-T170
was	O
used.	O
Oesophageal	B-T058
and	O
rectal temperatures	B-T033
were	O
measured	B-T080
at	O
various time points	B-T079
.	O
At	O
the	O
end	O
of	O
surgery	B-T061
,	O
group 1 patients	B-T101
(n=10)	O
were	O
lavaged	B-T061
with	O
200	O
ml/kg	O
sterile	B-T080
isotonic saline	B-T121
at	O
34±1°C	O
and	O
group	B-T096
2	O
(n=10)	O
at	O
40±1°C.	O
Groups	B-T096
were	O
similar	O
with	O
respect	O
to	O
age	B-T100
,	O
mass	B-T081
,	O
body condition	B-T033
and	O
surgical incision	B-T061
length.	O
Duration	B-T079
of	O
anaesthesia	B-T061
,	O
surgical procedures	B-T061
and	O
peritoneal lavage	B-T058
was	O
similar	O
between	O
groups	B-T096
.	O
Linear regression	B-T081
showed	O
no significant change	B-T033
in	O
oesophageal temperature	B-T058
during	O
the	O
lavage	B-T061
period	B-T079
for	O
group	B-T096
1	O
(P=0.64),	O
but	O
a	O
significant	O
increase	O
for	O
group 2 patients	B-T101
(P<0.0001),	O
with	O
mean	B-T081
temperature changes	B-T080
of	O
-0.5°C	O
(from	O
(36.3°C	O
to	O
35.9°C)	O
and	O
+0.9°C	O
(from	O
35.4°C	O
to	O
36.3°C),	O
respectively.	O
Similar	O
results	B-T033
were	O
found	O
for	O
rectal temperature	B-T033
,	O
with	O
mean	B-T081
changes	O
of	O
-0.5°C	O
and	O
+0.8°C	O
(P=0.922	O
and	O
0.045),	O
respectively.	O
The	O
use	O
of	O
isotonic	B-T121
crystalloid solution	B-T121
for	O
peritoneal lavage	B-T058
at	O
a	O
temperature	B-T081
of	O
40±1°C	O
significantly	O
warms	B-T070
small animal patients	B-T101
,	O
when	O
applied	O
in	O
a	O
clinical setting	B-T082
,	O
compared	O
with	O
lavage	B-T061
solution	O
at	O
34±1°C.	O

Bioengineered	B-T090
3D	B-T082
Models	B-T075
for	O
Studying	B-T062
Human	B-T016
Cell	B-T025
-	O
Tuberculosis	B-T007
Interactions	B-T169
In vivo	B-T082
animal models	B-T008
have	O
intrinsic	O
limitations	O
for	O
studying	B-T062
relationships	B-T080
between	O
tuberculosis	B-T007
and	O
its	O
host	B-T001
and	O
there	O
is	O
a	O
need	O
for	O
alternative,	O
in vitro	B-T080
cellular models	B-T075
.	O
A	O
microsphere	B-T074
-based	O
3D	B-T082
in vitro	B-T080
culture system	B-T063
of	O
Mycobacterium tuberculosis	B-T007
-infected	O
human	B-T016
blood	B-T031
mononuclear cells	B-T025
was	O
reported	O
to	O
address	O
specific	O
aspects	O
of	O
host	B-T001
-	O
pathogen	B-T001
interactions	B-T169
.	O

Perspectives	B-T078
on	O
cardiovascular	B-T022
effects of	B-T080
incretin	B-T116
-based	O
drugs	B-T121
:	O
From	O
bedside	O
to	O
bench,	O
return	O
trip	O
Recently,	O
cardiovascular	B-T022
outcome	B-T169
trials	B-T062
with	O
glucose	B-T109
-lowering	O
drugs	B-T121
used	O
in	O
type 2 diabetes mellitus	B-T047
,	O
namely	O
glucagon-like peptide-1 receptor	B-T192
agonists	B-T121
(	O
GLP-1RA	B-T121
),	O
liraglutide	B-T116
and	O
semaglutide	B-T116
,	O
showed	O
a	O
reduction	B-T081
in	O
cardiovascular events	B-T033
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	B-T062
with	O
other	O
incretin	B-T116
-based	O
drugs	B-T121
,	O
such	O
as	O
lixisenatide	B-T116
or	O
with	O
dipeptidyl peptidase-4 inhibitors	B-T121
(	O
DPP4i	B-T121
).	O
Mechanisms	B-T169
underlying	O
the	O
observed	O
cardiovascular	B-T022
differences	B-T080
between	O
DPP4i	B-T121
and	O
GLP1-RA	B-T121
,	O
and	O
across	O
individual	O
GLP1-RA	B-T121
are	O
poorly	O
understood.	O
This	O
review	B-T170
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	B-T078
from	O
experimental	B-T062
and	O
mechanistic studies	B-T062
on	O
the	O
action	B-T052
of	O
GLP1-RA	B-T121
and	O
DPP4i	B-T121
on	O
the	O
cardiovascular system	B-T022
,	O
both	O
deriving	O
from	O
clinical	B-T081
and	O
pre-clinical sources	B-T081
.	O
The	O
results	B-T169
of	O
cardiovascular	B-T022
outcome	B-T169
trials	B-T062
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	B-T062
preclinical data	B-T170
available,	O
paying	O
particular	O
attention	O
to	O
the	O
heart failure	B-T047
results	B-T169
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	B-T078
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	B-T169
of	O
cardioprotection	B-T169
of	O
incretin	B-T116
-based	O
drugs	B-T121
.	O
In	O
particular,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	B-T116
cardiovascular	B-T022
effects of	B-T080
a	O
direct	O
cardiac	B-T023
action	B-T052
of	O
GLP-1	B-T116
metabolites	B-T123
through	O
GLP-1 receptor	B-T192
-independent	O
pathways	B-T044
,	O
and	O
of	O
DPP4	B-T116
substrates	B-T167
other	O
than	O
GLP-1	B-T116
.	O

Role	O
of	O
breast magnetic resonance imaging	B-T060
in	O
predicting	B-T078
residual	B-T080
lobular carcinoma in situ	B-T191
after	O
initial	B-T079
excision	B-T061
Breast magnetic resonance (MR) imaging	B-T060
is	O
a	O
useful	O
screening	B-T060
modality	B-T078
in	O
detecting	B-T061
suspicious	B-T033
lesions	B-T033
in	O
patients	B-T101
with	O
a	O
history	B-T033
of	O
lobular carcinoma in situ	B-T191
(	O
LCIS	B-T191
).	O
This	O
study	B-T062
aimed	B-T078
to	O
evaluate	B-T058
the	O
effectiveness	B-T080
of	O
breast MR imaging	B-T060
in	O
detecting	B-T061
remnant	B-T018
LCIS	B-T191
lesions	B-T033
after	B-T079
initial	B-T079
excision	B-T061
.	O
Between	O
2011	O
and	O
2015,	O
29	O
patients	B-T101
with	O
LCIS	B-T191
who	O
underwent	B-T033
initial	B-T079
excision	B-T061
were	O
enrolled.	O
Breast ultrasonography	B-T060
and	O
breast MR imaging	B-T060
was	O
conducted	O
after	B-T079
initial	B-T079
excision	B-T061
.	O
Imaging findings	B-T034
were	O
compared	B-T052
with	O
pathologic	B-T046
results	B-T169
.	O
There	O
were	O
nine	O
(31.0%)	O
cases	B-T077
with	O
positive margins	B-T033
after	B-T079
initial	B-T079
excision	B-T061
;	O
they	O
were	O
LCIS	B-T191
(n=8)	O
and	O
atypical lobular hyperplasia	B-T046
(n=1).	O
Residual	B-T080
lesions	B-T033
were	O
identified	B-T080
in	O
12	O
cases	B-T077
;	O
they	O
were	O
invasive lobular carcinoma	B-T191
(n=1;	O
3.4%),	O
LCIS	B-T191
(n=9;	O
31.0%),	O
atypical lobular hyperplasia	B-T046
(n=1;	O
3.4%),	O
and	O
papillary carcinoma in situ	B-T191
(n=1;	O
3.4%).	O
Prior	B-T079
to	O
the	O
second	B-T081
operation	B-T061
,	O
these	O
lesions	B-T033
could	O
be	O
detected	O
in	O
seven	O
cases	B-T077
using	O
ultrasonography	B-T060
(	O
sensitivity	B-T081
,	O
53.3%;	O
specificity	B-T081
,	O
100%)	O
and	O
in	O
10	O
cases	B-T077
using	O
breast MR imaging	B-T060
(	O
sensitivity	B-T081
,	O
83.3%;	O
specificity	B-T081
,	O
100%).	O
Breast MR imaging	B-T060
showed	O
higher	B-T080
sensitivity	B-T081
than	O
breast ultrasonography	B-T060
in	O
detecting	B-T061
remnant	B-T018
LCIS	B-T191
lesions	B-T033
.	O
If	O
a	O
suspicious	B-T033
lesion	B-T033
was	O
found	O
using	O
breast MR imaging	B-T060
,	O
a	O
second	B-T081
operation	B-T061
should	O
be	O
considered	B-T078
because	O
of	O
the	O
possibility	B-T033
of	O
multifocality	B-T033
,	O
even	O
if	O
LCIS	B-T191
was	O
confirmed	B-T033
at	O
the	O
initial	B-T079
operation	B-T061
.	O

Construction	B-T070
of	O
Fused Polyheterocycles	B-T104
through	O
Sequential	B-T080
[4 + 2] and [3 + 2] Cycloadditions	B-T067
A	O
method	O
for	O
Pd	B-T196
-	O
catalyzed	B-T070
aerobic	B-T080
oxidative reaction	B-T044
of	O
quinazolinones	B-T109
and	O
alkynes	B-T109
has	O
been	O
developed	O
for	O
sequential	B-T080
[4 + 2] and [3 + 2] cycloadditions	B-T067
to	O
assemble	B-T052
a	O
novel	B-T080
fused-polycyclic system	B-T104
containing	O
tetrahydropyridine	B-T109
and	O
dihydrofuran rings	B-T109
.	O
The	O
reaction process	B-T067
involves	O
C-H and N-H bond	B-T044
functionalization	O
for	O
the	O
formation	B-T169
of	O
tetrahydropyridine	B-T109
and	O
an	O
oxygen radical	B-T121
cyclization	B-T070
for	O
the	O
dihydrofuran ring	B-T109
.	O
This	O
atom	B-T196
-	O
and	O
step-	O
economical synthesis	B-T090
is	O
highly	O
efficient	O
and	O
has	O
good	O
substrate	B-T167
tolerance	B-T080
,	O
which	O
provides	O
a	O
new	O
approach	O
for	O
the	O
construction	B-T070
of	O
polycyclic molecules	B-T104
with	O
potential	O
pharmaceutical interest.	B-T091

Biological	B-T080
basis	B-T121
of	O
radiation protection	B-T061
needs	O
rejuvenation	B-T061
Human beings	B-T016
encounter	O
radiation	B-T070
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	B-T082
to	O
radioactive waste	B-T069
sites	B-T082
to	O
participation	B-T169
in	O
medical procedures	B-T058
using	O
X-rays	B-T070
etc.	O
Limits	O
for	O
radiation exposures	B-T037
are	O
legally regulated	B-T064
;	O
however,	O
current	O
radiation protection	B-T061
policy	B-T170
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	B-T080
,	O
cellular	B-T059
and	O
molecular	B-T080
effects of	B-T080
low doses	B-T081
and	O
low	O
dose rates	B-T081
of	O
radiation	B-T070
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high dose	B-T081
radiation exposures	B-T037
.	O
Recent	O
technical developments	B-T169
in	O
biology	B-T091
and	O
medicine	B-T091
,	O
from	O
single cell techniques	B-T059
to	O
big data computational research	B-T059
,	O
have	O
enabled	O
new	O
approaches	B-T169
for	O
study	B-T062
of	O
biology	B-T091
of	O
low doses	B-T081
of	O
radiation	B-T070
.	O
Results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	B-T077
the	O
idea	B-T078
that	O
low doses	B-T081
of	O
radiation	B-T070
have	O
effects	O
that	O
differ	O
from	O
those	O
associated with	B-T080
high dose	B-T081
exposures	B-T037
;	O
this	O
work,	O
however,	O
is	O
far	O
from	O
sufficient	B-T080
for	O
the	O
development	B-T169
of	O
a	O
new	O
theoretical framework	B-T170
needed	O
for	O
the	O
understanding	O
of	O
low dose	B-T081
radiation exposures	B-T037
.	O
Mechanistic	O
understanding	O
of	O
radiation effects	B-T067
at	O
low doses	B-T081
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation protection	B-T061
policy	B-T170
.	O

Gleason grade grouping	B-T185
of	O
prostate cancer	B-T191
is	O
of	O
prognostic value	B-T201
in	O
Asian	B-T098
men	B-T098
The	O
International Society of Urological Pathology	B-T093
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade Groups	B-T185
(	O
GG	B-T185
)	O
originally	O
described	O
by	O
Epstein	B-T170
and	O
colleagues	B-T098
over	O
Gleason score	B-T033
(	O
GS	B-T033
)	O
alone	O
in	O
2014,	O
which	O
was	O
subsequently	O
adopted	B-T033
by	O
the	O
WHO classification	B-T185
in	O
2016.	O
The	O
majority	O
of	O
studies	B-T062
validating	O
this	O
revision	B-T079
have	O
been	O
in	O
Caucasian populations	B-T098
.	O
We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG system	B-T185
was	O
retrospectively	O
associated	O
with	O
biochemical disease-free survival	B-T081
in	O
a	O
mixed-ethnicity	B-T098
cohort	B-T098
of	O
Asian	B-T098
men	B-T098
.	O
A	O
total	O
of	O
680	O
radical prostatectomies	B-T061
(	O
RPs	B-T061
)	O
from	O
2005	O
to	O
2014	O
were	O
included.	O
GS	B-T033
from	O
initial	O
biopsy	B-T060
and	O
RP	B-T061
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	B-T169
to	O
GG	B-T185
,	O
defined	O
as:	O
1	O
(	O
GS	B-T033
≤6);	O
2	O
(	O
GS	B-T033
3+4=7);	O
3	O
(	O
GS	B-T033
4+3=7);	O
4	O
(	O
GS	B-T033
4+4=8/5+3=8/3+5=8)	O
and	O
5	O
(	O
GS	B-T033
9-10).	O
Biochemical recurrence	B-T033
was	O
defined	O
as	O
two	O
consecutive	O
post-	O
RP	B-T061
prostate-specific antigen	B-T116
(	O
PSA	B-T116
)	O
levels	O
of	O
>0.2	O
ng/mL	O
after	O
post-	O
RP	B-T061
PSA	B-T116
reaching	O
the	O
nadir	B-T080
of	O
<0.1	O
ng/mL.	O
Our	O
data	B-T078
showed	O
that	O
Kaplan-Meier analysis	B-T081
revealed	O
significant	O
differences	O
in	O
biochemical recurrence	B-T033
within	O
Gleason GG	B-T185
based	O
on	O
either	O
biopsy	B-T060
or	O
prostatectomy	B-T061
scoring	B-T081
.	O
Multivariate analysis	B-T081
further	O
confirmed	O
that	O
a	O
higher	O
GG	B-T185
was	O
significantly	O
associated	O
with	O
risk	B-T078
of	O
biochemical recurrence	B-T033
.	O
This	O
GG system	B-T185
had	O
a	O
higher	O
prognostic	B-T081
discrimination	B-T169
for	O
both	O
initial	O
biopsy	B-T060
and	O
RP	B-T061
than	O
GS	B-T033
.	O
Our	O
study	B-T062
validates	B-T062
the	O
use	O
of	O
the	O
revised	B-T079
and	O
updated	B-T079
GG system	B-T185
in	O
a	O
mixed-ethnicity population	B-T098
of	O
Asian	B-T098
men	B-T098
.	O
Higher	O
GG	B-T185
was	O
significantly	O
associated	O
with	O
increased	O
risk	B-T078
of	O
biochemical recurrence	B-T033
.	O
We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical management	B-T058
for	O
patients	B-T101
with	O
prostate cancer	B-T191
.	O

Membrane	B-T026
nanoclusters	B-T081
of	O
FcγRI	B-T116
segregate	O
from	O
inhibitory	B-T052
SIRPα	B-T116
upon	O
activation of human macrophages	B-T043
Signal integration	B-T043
between	O
activating	B-T052
Fc receptors	B-T116
and	O
inhibitory	B-T052
signal regulatory protein α	B-T116
(	O
SIRPα	B-T116
)	O
controls	O
macrophage	B-T025
phagocytosis	B-T043
.	O
Here,	O
using	O
dual-color direct stochastic optical reconstruction microscopy	B-T059
,	O
we	O
report	O
that	O
Fcγ receptor I	B-T116
(	O
FcγRI	B-T116
),	O
FcγRII	B-T116
,	O
and	O
SIRPα	B-T116
are	O
not	O
homogeneously	B-T080
distributed	O
at	O
macrophage	B-T025
surfaces	B-T026
but	O
are	O
organized	O
in	O
discrete	B-T080
nanoclusters	B-T081
,	O
with	O
a	O
mean	O
radius	O
of	O
71	O
±	O
11	O
nm,	O
60	O
±	O
6	O
nm,	O
and	O
48	O
±	O
3	O
nm,	O
respectively.	O
Nanoclusters	B-T081
of	O
FcγRI	B-T116
,	O
but	O
not	O
FcγRII	B-T116
,	O
are	O
constitutively	O
associated with	B-T080
nanoclusters	B-T081
of	O
SIRPα	B-T116
,	O
within	O
62	O
±	O
5	O
nm,	O
mediated	O
by	O
the	O
actin cytoskeleton	B-T026
.	O
Upon	O
Fc receptor	B-T116
activation	B-T043
,	O
Src-family kinase	B-T116
signaling	B-T043
leads	O
to	O
segregation	O
of	O
FcγRI	B-T116
and	O
SIRPα	B-T116
nanoclusters	B-T081
to	O
be	O
197	O
±	O
3	O
nm	O
apart.	O
Co-ligation	B-T044
of	O
SIRPα	B-T116
with	O
CD47	B-T116
abrogates	O
nanocluster	B-T081
segregation.	O
If	O
the	O
balance	O
of	O
signals	B-T043
favors	O
activation	B-T052
,	O
FcγRI	B-T116
nanoclusters	B-T081
reorganize	B-T078
into	O
periodically	B-T079
spaced	O
concentric rings	B-T082
.	O
Thus,	O
a	O
nanometer	B-T081
-	O
and	O
micron-scale	B-T081
reorganization	B-T078
of	O
activating	B-T052
and	O
inhibitory	B-T052
receptors	B-T116
occurs	O
at	O
the	O
surface	O
of	O
human macrophages	B-T025
concurrent	B-T079
with	O
signal integration	B-T043
.	O

Firecracker	B-T073
eye exposure	B-T033
:	O
experimental study	B-T062
and	O
simulation	B-T062
Understanding	O
the	O
mechanisms	B-T169
of	O
traumatic	B-T169
ocular injury	B-T037
is	O
helpful	O
to	O
make	O
accurate	B-T080
diagnoses	B-T033
before	O
the	O
symptoms	B-T184
emerge	O
and	O
to	O
develop	O
specific	O
eye protection	B-T073
.	O
The	O
comprehension	B-T041
of	O
the	O
dynamics	B-T070
of	O
primary	B-T080
blast injury	B-T037
mechanisms	B-T169
is	O
a	O
challenging	O
issue	B-T033
.	O
The	O
question	O
is	O
whether	O
the	O
pressure	B-T067
wave	B-T070
propagation	B-T067
and	O
reflection	B-T081
alone	O
could	O
cause	B-T078
ocular damage	B-T033
.	O
To	O
date,	O
there	O
are	O
dissenting	B-T054
opinions	B-T041
and	O
no	O
conclusive	B-T080
evidence	B-T078
thereupon.	O
A	O
previous	O
numerical investigation	B-T058
of	O
blast	B-T070
trauma	B-T037
highlighted	O
the	O
dynamic	B-T169
effect	B-T080
of	O
pressure	B-T067
propagation	B-T067
and	O
its	O
amplification	B-T067
by	O
the	O
geometry	B-T090
of	O
the	O
bony orbit	B-T023
,	O
inducing	B-T169
a	O
resonance	B-T070
cavity	B-T030
effect	B-T080
and	O
a	O
standing wave	B-T070
hazardous	B-T080
for	O
eye	B-T023
tissues	B-T024
.	O
The	O
objective	O
of	O
the	O
current	O
work	O
is	O
to	O
find	O
experimental	B-T080
evidence	B-T078
of	O
the	O
numerically	B-T081
identified	B-T080
phenomenon	B-T067
.	O
Therefore,	O
tests	B-T170
aimed	O
at	O
evaluating	B-T058
the	O
response	B-T032
of	O
porcine	B-T015
eyes	B-T023
to	O
blast	B-T070
overpressure	B-T067
generated	O
by	O
firecrackers	B-T073
explosion	B-T067
were	O
performed	B-T169
.	O
The	O
orbital cavity	B-T030
effect	B-T080
was	O
considered	O
mounting	O
the	O
enucleated eyes	B-T037
inside	O
a	O
dummy	O
orbit	B-T030
.	O
The	O
experimental	B-T080
measurements	B-T169
obtained	B-T169
during	O
the	O
explosion	B-T067
tests	B-T170
presented	O
in	O
this	O
paper	B-T170
corroborate	B-T080
the	O
numerical evidence	B-T078
of	O
a	O
high-frequency	B-T079
pressure	B-T067
amplification	B-T067
,	O
enhancing	B-T052
the	O
loading	O
on	O
the	O
ocular	B-T023
tissues	B-T024
,	O
attributable	B-T041
to	O
the	O
orbital bony walls	B-T029
surrounding	O
the	O
eye	B-T023
.	O

The	O
platelet-activating receptor	B-T116
C-type lectin receptor-2	B-T116
plays	O
an	O
essential	O
role	B-T077
in	O
liver regeneration	B-T042
after	O
partial hepatectomy	B-T061
in	O
mice	B-T015
Essentials	O
Regeneration	B-T042
role	B-T077
of	O
C-type lectin receptor-2	B-T116
(	O
CLEC-2	B-T116
)	O
after	O
70% hepatectomy	B-T061
(	O
HPx	B-T061
)	O
was	O
investigated.	O
Wild-type	B-T028
or	O
CLEC-2	B-T028
deleted	B-T045
from	O
platelets	B-T025
of	O
chimeric mice	B-T015
(	O
flKO	B-T015
)	O
underwent	O
HPx	B-T061
.	O
The	O
liver/body weight ratio	B-T081
was	O
significantly	O
lower	O
in	O
the	O
flKO	B-T015
than	O
in	O
the	O
wild-type	B-T015
.	O
CLEC-2	B-T116
plays	O
an	O
essential	O
role	B-T077
in	O
liver regeneration	B-T042
after	O
HPx	B-T061
.	O
Background	O
and	O
aim	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	B-T077
of	O
C-type lectin receptor (CLEC)-2	B-T116
in	O
liver regeneration	B-T042
following	O
partial liver resection	B-T061
in	O
mice	B-T015
.	O
Materials	O
and	O
methods	O
Irradiated	O
chimeric mice	B-T015
transplanted	B-T169
with	O
fetal	B-T169
liver cells	B-T025
from	O
wild-type (WT) mice	B-T015
,	O
CLEC-2	B-T028
-	O
deleted	B-T045
(KO)	O
mice	B-T015
or	O
mice	B-T015
with	O
CLEC-2	B-T028
deleted	B-T045
specifically	O
from	O
platelets	B-T025
(flKO)	O
were	O
generated	B-T052
.	O
Mice	B-T015
underwent	O
70% partial hepatectomy	B-T061
(	O
PH	B-T061
).	O
Immunohistochemical staining	B-T059
was	O
performed	O
to	O
investigate	O
the	O
expression	B-T045
of	O
the	O
endogenous	B-T169
ligand	B-T103
for	O
CLEC-2	B-T116
,	O
podoplanin	B-T116
.	O
The	O
accumulation	B-T043
of	O
platelets	B-T025
in	O
the	O
liver	B-T023
was	O
also	O
quantified	B-T081
.	O
The	O
hepatic	B-T029
expression	B-T045
of	O
the	O
IL-6	B-T116
/	O
gp130	B-T116
and	O
STAT3	B-T116
,	O
Akt	B-T116
and	O
ERK1/2	B-T116
was	O
also	O
examined.	O
Results	O
The	O
liver/body weight ratio	B-T081
and	O
expression	B-T045
of	O
all	O
cell proliferation	B-T043
markers	B-T059
were	O
significantly	O
lower	O
in	O
the	O
flKO group	B-T015
than	O
in	O
the	O
WT group	B-T015
.	O
The	O
expression	B-T045
of	O
phosphorylated (p) Akt	B-T116
and	O
pERK1	B-T116
/2	O
was	O
similar	O
in	O
the	O
WT	B-T015
and	O
flKO groups	B-T015
.	O
On	O
the	O
other	O
hand,	O
the	O
expression	B-T045
of	O
pSTAT3	B-T116
and	O
IL-6	B-T116
was	O
significantly	O
stronger	O
in	O
the	O
WT group	B-T015
than	O
in	O
the	O
flKO group	B-T015
.	O
The	O
expression	B-T045
of	O
podoplanin	B-T116
was	O
detected	O
in	O
the	O
hepatic sinusoids	B-T023
of	O
both	O
groups	B-T078
.	O
However,	O
the	O
extent	O
to	O
which	O
platelets	B-T025
accumulated	O
in	O
hepatic sinusoids	B-T023
was	O
significantly	O
less	O
in	O
the	O
flKO group	B-T015
than	O
in	O
the	O
WT group	B-T015
.	O
Conclusion	O
CLEC-2	B-T116
was	O
involved	O
in	O
hepatic regeneration	B-T042
after	O
liver resection	B-T061
and	O
CLEC-2	B-T116
-related	O
liver regeneration	B-T042
was	O
attributed	O
to	O
the	O
interaction	O
between	O
platelets	B-T025
and	O
sinusoidal	B-T030
endothelial cells	B-T025
.	O

Temporal	B-T079
Stability	B-T080
of	O
Heavy Drinking	B-T033
Days	O
and	O
Drinking	B-T055
Reductions	B-T061
Among	O
Heavy Drinkers	B-T055
in	O
the	O
COMBINE Study	B-T062
Recently,	O
the	O
Food and Drug Administration	B-T093
(	O
FDA	B-T093
)	O
proposed	O
to	O
expand	B-T082
the	O
options	O
for	O
primary	B-T080
end points	B-T080
in	O
the	O
development	B-T169
of	O
medications	B-T058
for	O
alcohol use disorder	B-T048
to	O
include	O
either	O
abstinence	B-T061
from	O
alcohol	B-T168
or	O
a	O
nonabstinent	B-T033
outcome	B-T169
:	O
no	O
heavy drinking	B-T033
days	O
(with	O
a	O
heavy drinking	B-T033
day	O
defined	B-T170
as	O
more	O
than	O
3	O
drinks	B-T168
per	O
day	O
for	O
women	B-T098
and	O
more	O
than	O
4	O
drinks	B-T168
per	O
day	O
for	O
men	B-T098
[>3/>4	O
cutoff	B-T169
]).	O
The	O
FDA	B-T093
also	O
suggested	B-T078
that	O
6	O
months	B-T079
would	O
be	O
the	O
most	O
appropriate	B-T080
length for a clinical trial	B-T062
to	O
demonstrate	O
the	O
stability	B-T080
of	O
this	O
nonabstinent	B-T033
drinking	B-T055
outcome	B-T169
.	O
However,	O
few	O
alcohol	O
clinical trials	B-T062
have	O
examined	B-T033
the	O
stability	B-T080
of	O
nonheavy drinking	B-T033
during	B-T079
and	O
after treatment	B-T058
.	O
In	O
a	O
secondary analysis	B-UnknownType
of	O
the	O
COMBINE study	B-T062
data	B-T078
(n	O
=	O
1,383),	O
we	O
examined	B-T033
transitions	B-T052
in	O
heavy drinking	B-T033
days	O
during the course of treatment	B-T079
(	O
months	B-T079
1	O
through	O
4),	O
during	B-T079
the	O
transition	B-T052
out	O
of	O
treatment	B-T061
(	O
months	B-T079
4	O
through	O
7),	O
and	O
up	O
to	O
12	O
months	B-T079
afterward	O
(	O
months	B-T079
13	O
through	O
16)	O
using	O
latent variable mixture models	B-UnknownType
.	O
Heavy drinking	B-T033
and	O
nonheavy drinking	B-T033
were	O
relatively	O
stable	B-T080
in	O
consecutive	B-T080
months	B-T079
(	O
minimum	B-T080
agreement	O
[kappa]	O
=	O
0.64	O
for	O
months	B-T079
1	O
to	O
2).	O
Most	O
individuals	B-T098
were	O
stable	B-T080
low-risk	B-T081
drinkers	B-T033
/	O
abstainers	B-UnknownType
or	O
heavy drinkers	B-T055
by	O
the	O
end	O
of	O
treatment	B-T061
,	O
as	O
characterized	B-T052
by	O
a	O
10%	O
probability	B-T081
(or	O
less)	O
of	O
transitioning	B-T052
out	O
of	O
either	O
a	O
no	O
heavy drinking	B-T033
state	B-T169
or	O
a	O
heavy drinking	B-T033
state	B-T169
.	O
More	O
than	O
two-thirds	O
of	O
the	O
heavy drinkers	B-T055
who	O
exceeded	O
the	O
heavy drinking	B-T033
threshold	B-T080
during treatment	B-T079
reported	B-T058
,	O
on	O
average	B-T081
,	O
a	O
64%	O
reduction	B-T061
in	O
drinking frequency	B-T033
and	O
a	O
38%	O
reduction	B-T061
in	O
drinking	B-T055
intensity	O
from	O
pretreatment	B-T052
drinking	B-T055
levels	B-T080
.	O
The	O
results	B-T034
show	O
stability	B-T080
of	O
no	O
heavy drinking	B-T033
as	O
an	O
outcome	B-T169
within	O
the	O
first	O
4	O
months	B-T079
of	O
treatment	B-T061
and	O
that	O
the	O
>3/>4	O
drink	B-T168
cutoff	B-T169
may	O
mask	O
substantial	O
reductions	B-T061
in	O
alcohol consumption	B-T055
among	O
some	O
patients	B-T101
.	O
Future	O
studies	B-T062
should	O
explore	O
the	O
clinical	B-T080
utility	O
of	O
reduction	B-T061
end points	B-T080
.	O

Oral health	B-T058
in	O
transition	B-T052
:	O
The	O
Hadza foragers	B-T098
of	O
Tanzania	B-T083
Conventional	B-T080
wisdom	O
holds	O
that	O
a	O
decline	B-T081
in	O
oral health	B-T058
accompanies	O
the	O
transition	B-T052
from	O
hunting	B-T056
and	O
gathering	B-T056
to	O
agriculture	B-T090
,	O
given	O
increased	B-T081
consumption	B-T039
of	O
carbohydrates	B-T109
.	O
This	O
widely	O
touted	O
example	B-T077
of	O
the	O
mismatch	B-T080
between	O
our	O
biology	B-T091
and	O
modern lifestyle	B-T054
has	O
been	O
intuited	O
largely	O
from	O
the	O
bioarchaeological record	B-T170
of	O
the	O
Neolithic Revolution	B-T109
in	O
the	O
New World	B-T098
.	O
Recent	O
studies	B-T062
of	O
other	O
populations	B-T081
have,	O
however,	O
challenged	O
the	O
universality	O
of	O
this	O
assertion	B-T080
.	O
Here,	O
we	O
present	O
the	O
first	O
comprehensive	B-T080
study	B-T062
of	O
oral health	B-T058
among	O
a	O
living population	B-T098
in	O
transition	B-T052
from	O
the	O
bush	B-T002
to	O
village life	B-T054
,	O
the	O
Hadza	B-T098
hunter	B-T097
-	O
gatherers	B-T098
of	O
Tanzania	B-T083
,	O
to	O
test	O
the	O
hypothesis	B-T078
that	O
the	O
shift	B-T052
from	O
foraging	B-T055
to	O
farming	B-T090
,	O
or	O
agricultural intensification	B-T090
,	O
inevitably	O
leads	O
to	O
increased	B-T081
periodontal disease	B-T047
,	O
caries	B-T047
,	O
and	O
orthodontic	B-T169
disorders	B-T047
.	O
Our	O
results	B-T169
showed	O
that	O
women	B-T098
living	B-T080
in	O
villages	B-T083
consuming	B-T039
a	O
mostly	O
agricultural	B-T002
diet	B-T168
exhibited	O
more	O
caries	B-T047
and	O
periodontal disease	B-T047
than	O
those	O
living	B-T080
in	O
the	O
bush	B-T002
consuming	B-T039
a	O
mostly	O
wild-food diet	B-T168
.	O
Furthermore,	O
men	B-T098
living	B-T080
in	O
the	O
bush	B-T002
consuming	B-T039
mostly	O
a	O
wild-food diet	B-T168
had	O
more	O
than	O
those	O
living	B-T080
in	O
the	O
village	B-T083
consuming	B-T039
a	O
mostly	O
agricultural	B-T002
diet	B-T168
.	O
These	O
findings	B-T033
are	O
explained	O
by	O
the	O
high	B-T080
incidence	B-T081
of	O
maize	B-T168
consumption	B-T039
in	O
village	B-T083
settings,	O
along	O
with	O
previously	O
recognized	O
variation	B-T080
in	O
rate	B-T081
of	O
caries	B-T047
between	O
men	B-T098
and	O
women	B-T098
.	O
The	O
unexpected	O
discovery	O
of	O
high	B-T080
caries	B-T047
incidences	B-T081
for	O
men	B-T098
in	O
the	O
bush	B-T002
is	O
likely	O
explained	O
by	O
heavy	O
reliance	O
on	O
honey	B-T168
,	O
and	O
perhaps	O
differential	O
access	O
to	O
tobacco	B-T167
and	O
marijuana.	B-T109
These	O
data	B-T078
support	O
the	O
notions	O
that	O
mechanisms	B-T169
of	O
cariogenesis	B-T047
are	O
multifactorial	B-T033
and	O
that	O
the	O
relationships	B-T080
between	O
oral health	B-T058
and	O
the	O
shift	B-T052
from	O
a	O
predominantly	O
wild-food diet	B-T168
to	O
one	O
dominated	O
by	O
cultigens	B-T002
are	O
nuanced.	O

The	O
R2R3MYB	B-T116
VvMYBPA1	B-T116
from	O
grape	B-T002
reprograms	O
the	O
phenylpropanoid pathway	B-T044
in	O
tobacco	B-T002
flowers	B-T002
This	O
work	O
shows	O
that,	O
in	O
tobacco	B-T002
,	O
the	O
ectopic expression	B-T045
of	O
VvMYBPA1	B-T116
,	O
a	O
grape	B-T002
regulator	B-T077
of	O
proanthocyanidin	B-T109
biosynthesis,	O
up- or down-regulates	B-T043
different	O
branches	O
of	O
the	O
phenylproanoid pathway	B-T044
,	O
in	O
a	O
structure-specific	O
fashion.	O
Proanthocyanidins	B-T109
are	O
flavonoids	B-T109
of	O
paramount	O
importance	O
for	O
animal	B-T168
and	O
human diet	B-T168
.	O
Research	B-T062
interest	O
increasingly	O
tilts	O
towards	O
generating	O
crops	B-T002
enriched	O
with	O
these	O
health	B-T078
-promoting	O
compounds	B-T080
.	O
Flavonoids	B-T109
synthesis	B-T052
is	O
regulated	O
by	O
the	O
MBW	B-T026
transcriptional complex	B-T026
,	O
made	O
of	O
R2R3MYB	B-T116
,	O
bHLH	B-T116
and	O
WD40 proteins	B-T116
,	O
with	O
the	O
MYB	B-T116
components	O
liable	O
for	O
channeling	B-T082
the	O
complex	B-T104
towards	O
specific	O
branches	O
of	O
the	O
pathway	B-T044
.	O
Hence,	O
using	O
tobacco	B-T002
as	O
a	O
model	B-T075
,	O
here,	O
we	O
tested	B-T169
if	O
the	O
ectopic expression	B-T045
of	O
the	O
proanthocyanidin	B-T109
regulator	B-T077
VvMYBPA1	B-T116
from	O
grape	B-T002
induces	B-T169
the	O
biosynthesis	B-T169
of	O
these	O
compounds	B-T080
in	O
not-naturally	O
committed cells	B-T025
.	O
Here,	O
we	O
show,	O
via	O
targeted	O
transcriptomic	B-T045
and	O
metabolic	B-T169
analyses	B-T062
of	O
primary	O
transgenic lines	B-T002
and	O
their	O
progeny	B-T099
,	O
that	O
VvMYBPA1	B-T116
alters	O
the	O
phenylpropanoid pathway	B-T044
in	O
tobacco	B-T002
floral organs	B-T002
,	O
in	O
a	O
structure-specific	O
fashion.	O
We	O
also	O
report	O
that	O
a	O
modest	O
VvMYBPA1	B-T116
expression	B-T045
is	O
sufficient	O
to	O
induce	O
the	O
expression	B-T045
of	O
both	O
proanthocyanidin	B-T109
-specific	O
and	O
early genes	B-T028
of	O
the	O
phenylpropanoid pathway	B-T044
.	O
Consequently,	O
proanthocyanidins	B-T109
and	O
chlorogenic acids	B-T109
are	O
induced	O
or	O
de novo	B-T078
synthetised	O
in	O
floral limbs, tubes	B-T002
and	O
stamens	B-T002
.	O
Other	O
phenylpropanoid branches	B-T044
are	O
conversely	O
induced	O
or	O
depleted	B-T169
according	O
to	O
the	O
floral structure	B-T002
.	O
Our	O
study	O
documents	O
a	O
novel	B-T080
and	O
distinct	O
function	O
of	O
VvMYBPA1	B-T116
with	O
respect	O
to	O
other	O
MYBs	B-T116
regulating	O
proanthocyanidins	B-T109
.	O
Present	O
findings	B-T169
may	O
have	O
major	O
implications	O
in	O
designing strategies	B-T041
for	O
enriching	O
crops	B-T002
with	O
health	B-T078
-promoting	O
compounds	B-T080
.	O

Genome-wide association mapping	B-T063
in	O
winter barley	B-T002
for	O
grain	B-T002
yield	B-T081
and	O
culm	B-T002
cell wall	B-T026
polymer	B-UnknownType
content	B-T081
using	O
the	O
high-throughput	O
CoMPP technique	B-T059
A	O
collection	B-T169
of	O
112	O
winter barley varieties	B-T002
(	O
Hordeum vulgare L.	B-T002
)	O
was	O
grown	B-T040
in	O
the	O
field	B-T082
for	O
two	O
years	B-T079
(2008/09	O
and	O
2009/10)	O
in	O
northern	B-T082
Italy	B-T083
and	O
grain	B-T002
and	O
straw	B-T109
yields	B-T081
recorded.	O
In	O
the	O
first	O
year	B-T079
of	O
the	O
trial,	O
a	O
severe	O
attack	O
of	O
barley yellow mosaic virus	B-T005
(	O
BaYMV	B-T005
)	O
strongly	O
influenced	B-T077
final	O
performances	B-T052
with	O
an	O
average	B-T081
reduction	B-T080
of	O
~	O
50%	O
for	O
grain	B-T002
and	O
straw	B-T109
harvested	B-T169
in	O
comparison	B-T052
to	O
the	O
second	B-T081
year	B-T079
.	O
The	O
genetic determination	B-T059
(	O
GD	B-T059
)	O
for	O
grain	B-T002
yield	B-T081
was	O
0.49	O
and	O
0.70,	O
for	O
the	O
two	O
years	B-T079
respectively,	O
and	O
for	O
straw	B-T109
yield	B-T081
GD	B-T059
was	O
low	O
in	O
2009	O
(0.09)	O
and	O
higher	O
in	O
2010	O
(0.29).	O
Cell wall	B-T026
polymers	B-UnknownType
in	O
culms	B-T002
culms	B-T002
were	O
quantified	B-T081
by	O
means	O
of	O
the	O
monoclonal antibodies	B-T116
LM6	B-T129
,	O
LM11	B-T129
,	O
JIM13	B-T129
and	O
BS-400-3	B-T129
and	O
the	O
carbohydrate-binding module CBM3a	B-T129
using	O
the	O
high-throughput	O
CoMPP technique	B-T059
.	O
Of	O
these,	O
LM6	B-T129
,	O
which	O
detects	B-T033
arabinan	B-T109
components	B-T077
,	O
showed	O
a	O
relatively	O
high	O
GD	B-T059
in	O
both	O
years	B-T079
and	O
a	O
significantly	B-T078
negative	B-T033
correlation	B-T080
with	O
grain	B-T002
yield	B-T081
(	O
GYLD	B-T081
).	O
Overall,	O
heritability	B-T081
(	O
H2	B-T081
)	O
was	O
calculated	B-T052
for	O
GYLD	B-T081
,	O
LM6	B-T129
and	O
JIM	B-T129
and	O
resulted	O
to	O
be	O
0.42,	O
0.32	O
and	O
0.20,	O
respectively.	O
A	O
total	B-T080
of	O
4,976	O
SNPs	B-T086
from	O
the	O
9K	O
iSelect	O
array	O
were	O
used	O
in	O
the	O
study	B-T062
for	O
the	O
analysis	O
of	O
population structure	B-T090
,	O
linkage disequilibrium	B-T081
(	O
LD	B-T081
)	O
and	O
genome-wide association study	B-T063
(	O
GWAS	B-T063
).	O
Marker-trait associations	B-T090
(	O
MTA	B-T090
)	O
were	O
analyzed	O
for	O
grain	B-T002
yield	B-T081
and	O
cell wall	B-T026
determination	O
by	O
LM6	B-T129
and	O
JIM13	B-T129
as	O
these	O
were	O
the	O
traits	O
showing	O
significant	B-T078
correlations	B-T080
between	O
the	O
years	B-T079
.	O
A	O
single QTL	B-T028
for	O
GYLD	B-T081
containing	O
three	O
MTAs	B-T090
was	O
found	O
on	O
chromosome 3H	B-T026
located	O
close	O
to	O
the	O
Hv-eIF4E gene	B-T028
,	O
which	O
is	O
known	O
to	O
regulate	O
resistance	B-T169
to	O
BaYMV	B-T005
.	O
Subsequently	O
the	O
QTL	B-T028
was	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
rym4	B-T028
,	O
a	O
locus	B-T082
for	O
resistance	B-T169
to	O
the	O
virus	B-T005
.	O
GWAs	B-T063
on	O
arabinans	B-T109
quantified	B-T081
by	O
LM6	B-T129
resulted	O
in	O
the	O
identification	B-T080
of	O
major	B-T080
QTLs	B-T028
closely	O
located	O
on	O
3H	B-T026
and	O
hypotheses	O
regarding	O
putative candidate genes	B-T028
were	O
formulated	O
through	O
the	O
study	B-T062
of	O
gene expression	B-T045
levels	B-T081
based	O
on	O
bioinformatics	B-T091
tools.	O

The	O
Prevalence	B-T081
and	O
Clinical	B-T080
Relevance	B-T080
of	O
ASA	B-T109
Nonresponse	B-T033
After	O
Cardiac Surgery	B-T061
We	O
aimed	O
to	O
identify	O
the	O
prevalence	B-T081
of	O
acetylsalicylic acid	B-T109
(	O
ASA	B-T109
)	O
nonresponse	B-T033
in	O
patients	B-T101
after	O
coronary artery bypass graft (CABG) surgery	B-T061
and	O
the	O
possible	O
consequences	B-T169
for	O
the	O
rate	O
of	O
major	O
cardiovascular events	B-T033
.	O
This	O
prospective	B-T062
,	O
observational	B-T062
,	O
bicentric cohort study	B-T081
was	O
conducted	O
in	O
two	O
German University hospitals	B-T073
.	O
A	O
total	O
of	O
400	O
patients	B-T101
(200	O
in	O
each	O
study	O
center)	O
undergoing	O
elective	B-T061
CABG surgery	B-T061
were	O
enrolled	O
after	O
written	O
informed	O
consent.	O
Platelet function	B-T043
was	O
analyzed	O
on	O
day	O
3	O
(d3)	O
and	O
day	O
5	O
(d5)	O
postoperatively	B-T079
following	O
stimulation	O
with	O
arachidonic acid	B-T109
(	O
ASPItest	B-T059
)	O
and	O
with	O
thrombin receptor-activating peptide 6	B-T116
(	O
TRAPtest	B-T059
)	O
using	O
multiple electrode aggregometry	B-T059
(	O
Multiplate	B-T059
).	O
Individuals	O
with	O
an	O
ASPItest	B-T059
≥40	O
AU·min	O
were	O
categorized	O
as	O
ASA	B-T109
nonresponders	B-T033
.	O
A	O
1-year	O
follow-up	B-T058
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular events	B-T033
,	O
hospital admissions	B-T058
,	O
or	O
deaths	B-T033
related	O
to	O
cardiovascular disease	B-T047
.	O
The	O
prevalence	B-T081
of	O
ASA	B-T109
nonresponse	B-T033
was	O
51.5%	O
on	O
d3,	O
and	O
it	O
significantly	B-T078
increased	B-T081
to	O
71.3%	O
on	O
d5	O
(P	O
=	O
.0049).	O
The	O
area	O
under	O
the	O
aggregation curve	B-T059
in	O
the	O
TRAPtest	B-T059
(P	O
<	O
.0001),	O
the	O
platelet count	B-T059
on	O
d5	O
(P	O
=	O
.009),	O
and	O
the	O
cardiopulmonary bypass time	B-T033
(P	O
=	O
.01)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
ASA	B-T109
nonresponse	B-T033
.	O
A	O
1-year	O
follow-up	B-T058
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end point	B-T080
with	O
no	O
difference	O
between	O
ASA	B-T109
responders	B-T033
and	O
nonresponders	B-T033
.	O
This	O
study	B-T062
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	B-T079
ASA	B-T109
nonresponse	B-T033
in	O
patients	B-T101
following	O
CABG	B-T061
.	O
No	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular events	B-T033
was	O
recorded	O
in	O
the	O
1-year	O
follow-up	B-T058
.	O
Therefore,	O
a	O
randomized dosage adjustment trial	B-T062
should	O
elucidate	O
whether	O
a	O
tailored	O
ASA	B-T109
treatment	B-T061
after	O
CABG surgery	B-T061
represents	O
a	O
useful	O
concept.	O

Genome Sequences	B-T085
of	O
Mycobacteriophages Jane and Sneeze	B-T005
,	O
New	O
Members	O
of	O
Cluster	O
G	O
Jane	O
and	O
Sneeze	O
are	O
newly	O
isolated	B-T169
phages	B-T005
of	O
Mycobacterium smegmatis mc(2)155	B-T007
from	O
Hillsborough	B-T083
,	O
NJ	B-T083
,	O
and	O
Palo Verde	B-T083
,	O
Costa Rica	B-T083
,	O
respectively.	O
Both	O
are	O
cluster	O
G,	O
subcluster	O
G1	O
mycobacteriophages	B-T005
.	O
Notable	O
nucleotide	B-T114
differences	B-T080
exist	O
between	O
genomes	B-T028
in	O
the	O
right	O
half,	O
including	O
the	O
presence	O
of	O
mycobacteriophage	B-T005
mobile element 1	B-T114
(MPME1)	O
in	O
Jane.	O

Effect	B-T080
of	O
Punica granatum	B-T002
fruit peel	B-T168
on	O
glucose-6-phosphate dehydrogenase	B-T116
and	O
malate dehydrogenase	B-T116
in	O
amphistome	B-T204
Gastrothylax indicus	B-T204
Increasing	B-T169
anthelmintic	B-T121
resistance	B-T038
and	O
the	O
impact	B-T080
of	O
conventional	O
anthelmintics	B-T121
on	O
the	O
environment	B-T082
,	O
it	O
is	O
important	O
to	O
look	O
for	O
alternative	O
strategies	O
against	O
helminth parasite	B-T204
in	O
sheep	B-T015
.	O
Important	O
lipogenic enzymes	B-T116
like	O
glucose-6-phosphate dehydrogenase	B-T116
(	O
G-6-PDH	B-T116
)	O
and	O
malate dehydrogenase	B-T116
(	O
MDH	B-T116
)	O
show	O
subcellular	B-T026
distribution pattern	B-T082
.	O
Activity	B-T044
of	O
G-6-PDH	B-T116
was	O
largely	O
restricted	O
to	O
cytosolic fraction	B-T026
while	O
MDH	B-T116
was	O
found	O
in	O
both	O
cytosolic	B-T026
and	O
mitochondrial fraction	B-T026
in	O
Gastrothylax indicus	B-T204
.	O
Following	O
in vitro	B-T080
treatment	B-T169
with	O
ethanolic	B-T109
and	O
aqueous extracts	B-T167
of	O
Punica granatum	B-T002
fruit peel	B-T168
and	O
commercial	O
anthelmintic	B-T121
,	O
albendazole	B-T109
G-6-PDH	B-T116
activity	B-T044
was	O
decreased	B-T080
by	O
19-32	O
%,	O
whereas	O
MDH	B-T116
was	O
suppressed	B-T169
by	O
24-41	O
%,	O
compared	O
to	O
the	O
respective	O
control	B-T167
.	O
Albendazole	B-T109
was	O
quite	O
effective	B-T080
when	O
compared	O
with	O
negative control	B-T077
and	O
both	O
the	O
extracts	B-T167
.	O
The	O
results	B-T169
indicate	O
that	O
phytochemicals	B-T109
of	O
plant	B-T002
may	O
act	O
as	O
potential	B-T080
vermifuge	B-T121
or	O
vermicide	B-T131
.	O

Remitting Seronegative Symmetrical Synovitis With Pitting Edema	B-T047
:	O
Appearance	O
on	O
FDG PET/CT	B-T060
Remitting seronegative symmetrical synovitis with pitting edema	B-T047
(	O
RS3PE	B-T047
)	O
is	O
a	O
rare condition	B-T047
in	O
the	O
elderly	B-T098
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	B-T080
of	O
rheumatic	B-T047
and	O
malignant diseases	B-T047
.	O
We	O
presented	O
a	O
62-	O
year	B-T079
-old	O
man	B-T098
with	O
the	O
diagnosis	B-T033
of	O
RS3PE	B-T047
based	O
on	O
the	O
clinical sign	B-T184
and	O
laboratory data	B-T078
.	O
Because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	B-T191
in	O
RS3PE	B-T047
,	O
FDG PET/CT	B-T060
was	O
performed	O
to	O
exclude	O
occult tumors	B-T191
.	O
The	O
images	B-T170
showed	O
multiple	B-T081
,	O
symmetrically	B-T033
,	O
diffusely	B-T082
increased	B-T081
F-FDG	B-T109
uptake	B-T039
in	O
the	O
soft tissue	B-T024
around	O
joints	B-T030
and	O
bones	B-T023
in	O
the	O
shoulders	B-T029
,	O
hips	B-T023
,	O
knees	B-T023
,	O
and	O
ankles	B-T029
.	O

Parks	B-T073
as	O
Social	B-T169
and	O
Cultural	B-T169
Spaces	B-T082
Among	O
U.S	B-T083
.-	O
and	O
Foreign	B-T080
-	O
Born	B-T040
Latinas	B-T098
Parks	B-T073
provide	O
opportunities	B-UnknownType
for	O
people	B-T098
to	O
engage	O
in	O
activities	B-T052
that	O
can	O
promote	B-T052
physical	B-T169
and	O
emotional	B-T033
well-being	B-T078
.	O
Using	O
focus groups	B-T096
and	O
personal	B-T032
interviews	B-T052
conducted	O
in	O
selected	O
neighborhoods	O
of	O
a	O
Northeastern	B-T082
city	B-T083
with	O
a	O
high	B-T080
rate	B-T081
of	O
obesity	B-T047
,	O
we	O
examined	B-T033
perceptions	B-T041
of	O
barriers	B-T078
and	O
facilitators	B-T080
regarding	O
the	O
use of	B-T169
parks	B-T073
and	O
park	B-T073
features	B-T080
that	O
would	O
promote	B-T052
physical activity	B-T056
among	O
Latina	B-T098
women	B-T098
(N	O
=	O
39).	O
Foreign	B-T080
-	O
born	B-T040
Latinas	B-T098
emphasized	O
the	O
environmental	B-T082
characteristics	B-T080
of	O
parks	B-T073
and	O
the	O
types	B-T080
of	O
amenities	B-T073
that	O
can	O
support	O
preferred	O
cultural	B-T052
and	O
social activities	B-T054
,	O
while	O
U.S.	B-T083
-	O
born	B-T040
Latinas	B-T098
emphasized	O
the	O
use	O
of	O
parks	B-T073
for	O
physical activity	B-T056
and	O
weight	B-T032
management	B-T052
.	O
Most	O
striking	O
were	O
the	O
different	O
ways	O
in	O
which	O
foreign	B-T080
-	O
born	B-T040
participants	B-T098
conceptualized	B-T041
parks	B-T073
as	O
sociocultural family centers	B-T082
,	O
extending	O
more	O
common	B-T081
conceptualizations	B-T041
centered	O
on	O
exercise	B-T056
or	O
individual	B-T098
health	B-T078
gain	B-T081
.	O
These	O
findings	B-T169
suggest	O
the	O
need	O
for	O
new	B-T080
policies	B-T170
that	O
incorporate	O
culturally	B-T169
specific	B-T080
park	B-T073
programming	B-T077
to	O
promote	B-T052
national	O
goals	B-T170
of	O
increasing	B-T169
levels	B-T080
of	O
physical activity	B-T056
for	O
health	B-T078
.	O

The	O
impact	B-T080
of	O
childhood maltreatment	B-T048
on	O
the	O
differential	B-T080
efficacy	B-T080
of	O
CBASP	B-T061
versus	O
escitalopram	B-T109
in	O
patients	B-T101
with	O
chronic depression	B-T048
:	O
A	O
secondary analysis	B-UnknownType
Childhood maltreatment	B-T048
(	O
CM	B-T048
)	O
has	O
been	O
indicated	B-T033
as	O
a	O
predictor	B-T078
of	O
a	O
differential	B-T080
response	B-T032
to	O
antidepressant treatment	B-T061
with	O
psychotherapy	B-T061
compared	B-T052
to	O
medication	B-T121
.	O
In	O
this	O
secondary analysis	B-UnknownType
,	O
we	O
investigated	B-T169
whether	O
the	O
presence	B-T080
of	O
CM	B-T048
results	B-T169
in	O
a	O
differential	B-T080
indication	B-T078
for	O
the	O
Cognitive Behavioral Analysis System of Psychotherapy	B-T061
(	O
CBASP	B-T061
)	O
or	O
escitalopram	B-T109
plus	O
clinical management	B-T058
(	O
ESC	B-T109
).	O
Sixty	O
patients	B-T101
with	O
chronic depression	B-T048
were	O
randomized	B-T062
to	O
either	O
22	O
sessions	B-T077
of	O
CBASP	B-T061
or	O
ESC	B-T109
over	O
the	O
course	B-T079
of	O
8 weeks	B-T079
of	O
acute	B-T079
and	O
20 weeks	B-T079
of	O
extended	B-T169
treatment	B-T061
at	O
2	O
German	B-T083
treatment sites	B-T082
.	O
CM	B-T048
was	O
assessed	B-T052
using	O
the	O
Childhood	B-T079
Trauma	B-T080
Questionnaire	B-T170
and	O
the	O
clinician	B-T097
rated	B-T052
Early Trauma Inventory	B-T170
.	O
Intention-to-treat analyses	B-T062
were	O
used	O
to	O
examine	O
the	O
impact	B-T080
of	O
CM	B-T048
on	O
depression	B-T048
,	O
global functioning	B-T060
,	O
and	O
quality of life	B-T078
.	O
The	O
presence	B-T080
of	O
CM	B-T048
did	O
not	O
result	B-T169
in	O
significant	B-T078
differences	B-T080
in	O
treatment response	B-T201
to	O
CBASP	B-T061
or	O
ESC	B-T109
on	O
any	O
outcome measure	B-T081
after	O
28 weeks	B-T079
of	O
treatment	B-T061
independent of	B-T169
the	O
type	O
of	O
CM	B-T048
assessment	B-T058
.	O
After	O
8 weeks	B-T079
,	O
a	O
significant	B-T078
CM	B-T048
×	O
treatment	B-T061
interaction	B-T169
was	O
found	B-T033
for	O
scores	B-T081
on	O
the	O
Montgomery-Asberg Depression Rating Scale	B-T170
.	O
Patients	B-T101
with	O
a	O
history	B-T033
of	O
CM	B-T048
receiving	B-T080
CBASP	B-T061
had	O
a	O
significantly lower	B-T081
response rate	B-T079
compared	B-T052
to	O
patients	B-T101
without	O
CM	B-T048
and	O
to	O
those	O
receiving	B-T080
ESC	B-T109
after	O
8 weeks	B-T079
.	O
Conclusively	B-T080
,	O
CBASP	B-T061
and	O
ESC	B-T109
are	O
equally	O
effective	B-T080
treatment	B-T061
options	O
for	O
the	O
difficult	B-T080
to	O
treat	B-T169
subgroup	B-T185
of	O
patients	B-T101
with	O
chronic depression	B-T048
and	O
a	O
history	B-T033
of	O
CM	B-T048
.	O
CM	B-T048
may	O
be	O
a	O
predictor	B-T078
of	O
a	O
longer	B-T080
latency	B-T079
of	O
treatment response	B-T201
in	O
the	O
case	B-T169
of	O
psychotherapy	B-T061
.	O
CBASP	B-T061
and	O
escitalopram	B-T109
are	O
equally	O
effective	B-T080
treatment	B-T061
options	O
for	O
chronic depression	B-T048
.	O
Both	O
treatments	B-T061
are	O
also	O
equally	O
effective	B-T080
for	O
the	O
difficult	B-T080
to	O
treat	B-T169
subgroup	B-T185
of	O
patients	B-T101
with	O
chronic depression	B-T048
and	O
a	O
history	B-T033
of	O
childhood maltreatment	B-T048
.	O
Childhood maltreatment	B-T048
may	O
result	B-T169
in	O
a	O
longer	B-T080
latency	B-T079
of	O
treatment response	B-T201
in	O
the	O
case	B-T169
of	O
psychotherapy	B-T061
.	O

A	O
role	O
for	O
the	O
locus coeruleus	B-T023
in	O
the	O
analgesic efficacy	B-T033
of	O
N-acetylaspartylglutamate peptidase	B-T116
(	O
GCPII	B-T116
)	O
inhibitors	B-T121
ZJ43	B-T109
and	O
2-PMPA	B-T109
N-acetylaspartylglutamate	B-T116
(	O
NAAG	B-T116
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	B-T123
in	O
the	O
mammalian	B-T015
nervous system	B-T022
.	O
NAAG	B-T116
activates	B-T052
a	O
group II metabotropic glutamate receptor	B-T116
(	O
mGluR3	B-T116
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular enzyme, glutamate carboxypeptidase II	B-T116
(	O
GCPII	B-T116
)	O
in vivo	B-T082
.	O
Inhibitors of this enzyme	B-T121
are	O
analgesic	B-T109
in	O
animal models	B-T008
of	O
inflammatory	B-T184
,	O
neuropathic	B-T033
and	O
bone cancer	B-T191
pain	B-T184
.	O
NAAG	B-T116
and	O
GCPII	B-T116
are	O
present	O
in	O
the	O
locus coeruleus	B-T023
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	B-T044
inhibitory	B-T052
pain	O
system.	O
In	O
the	O
formalin	B-T109
footpad	B-T023
model	B-T050
,	O
systemic	B-T169
treatment	B-T169
with	O
GCPII inhibitors	B-T121
reduces	O
both	O
phases	O
of	O
the	O
inflammatory pain	B-T184
response	B-T032
and	O
increases	O
release	O
of	O
spinal	B-T082
noradrenaline	B-T109
.	O
This	O
analgesic efficacy	B-T033
is	O
blocked	B-T169
by	O
systemic	B-T169
injection	B-T061
of	O
a	O
group II mGluR	B-T116
antagonist	B-T121
,	O
by	O
intrathecal (spinal) injection	B-T061
of	O
an	O
alpha 2 adrenergic receptor antagonist	B-T121
and	O
by	O
microinjection	B-T061
of	O
an	O
α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist	B-T121
directly	O
into	O
the	O
contralateral	B-T082
locus coeruleus	B-T023
.	O
Footpad	B-T023
inflammation	B-T046
increases	O
release	O
of	O
glutamate	B-T116
in	O
the	O
contralateral	B-T082
locus coeruleu	B-T023
s	O
and	O
systemic	B-T169
treatment	B-T169
with	O
a	O
GCPII inhibitor	B-T121
blocks	B-T169
this	O
increase.	O
Direct	B-T080
injection	B-T061
of	O
GCPII inhibitors	B-T121
into	O
the	O
contralateral	B-T082
or	O
ipsilatera	B-T082
l	O
locus coeruleus	B-T023
reduces	O
both	O
phases	O
of	O
the	O
inflammatory pain	B-T184
response	B-T032
in	O
a	O
dose-dependent	B-T081
manner	O
and	O
the	O
contralateral	B-T082
effect	B-T080
also	O
is	O
blocked	B-T169
by	O
intrathecal injection	B-T061
of	O
an	O
alpha 2 adrenergic receptor antagonist	B-T121
.	O
These	O
data	O
support	O
the	O
hypothesis	B-T078
that	O
the	O
analgesic efficacy	B-T033
of	O
systemically	O
administered	O
GCPII inhibitors	B-T121
is	O
mediated,	O
at	O
least	O
in	O
part,	O
by	O
the	O
contralatera	B-T082
l	O
locus coeruleus	B-T023
via	O
group II mGluR	B-T116
,	O
AMPA	B-T116
and	O
alpha 2 adrenergic receptors	B-T116
.	O

Association	B-T080
of	O
physical activity	B-T056
on	O
body composition	B-T032
,	O
cardiometabolic risk factors	B-T033
,	O
and	O
prevalence	B-T081
of	O
cardiovascular disease	B-T047
in	O
the	O
Korean population	B-T098
(from	O
the	O
fifth	O
Korea	B-T083
national health and nutrition examination survey	B-T062
,	O
2008-2011)	O
Data	B-T078
regarding	O
associations	B-T080
among	O
physical activity	B-T056
(	O
PA	B-T056
)	O
level	B-T080
,	O
body composition	B-T032
,	O
and	O
prevalence	B-T081
of	O
cardiovascular diseases	B-T047
in	O
Asian populations	B-T081
are	O
rare	B-T080
.	O
The	O
International Physical Activity Questionnaire	B-T170
(	O
IPAQ	B-T170
)	O
was	O
utilized	O
to	O
estimate	B-T081
PA	B-T056
levels	B-T080
and	O
analyze	B-T062
the	O
association	B-T080
of	O
PA	B-T056
level	B-T080
with	O
various	O
body composition	B-T032
parameters	B-T077
and	O
the	O
prevalence	B-T081
of	O
cardiovascular diseases	B-T047
by	O
using	O
data	B-T078
from	O
the	O
Korean	B-T083
National Health and Nutrition Examination Survey	B-T062
from	O
2008	O
to	O
2011.	O
Moderate	B-T080
and	O
high	B-T080
PA	B-T056
levels	B-T080
were	O
associated	B-T080
with	O
lower prevalence	B-T081
of	O
hypertension	B-T047
and	O
diabetes mellitus	B-T047
,	O
and	O
lower	B-T080
concentrations	B-T081
of	O
serum ferritin	B-T033
,	O
parathyroid hormone	B-T033
,	O
and	O
alkaline phosphatase	B-T033
.	O
Sarcopenia	B-T047
(	O
low	B-T080
vs.	O
moderate	B-T080
vs.	O
high	B-T080
PA	B-T056
group	B-T078
:	O
14.3%	O
vs.	O
10.5%	O
vs.	O
7.3%,	O
p	B-T081
=	O
0.001),	O
underweight	B-T033
(5.7%	O
vs.	O
4.9%	O
vs.	O
3.5%,	O
p	O
=	O
0.001),	O
and	O
central obesity	B-T033
(7.8%	O
vs.	O
6.9%	O
vs.	O
6.3%,	O
p	O
=	O
0.002)	O
were	O
more	O
often	O
observed	B-T169
in	O
the	O
low	B-T080
PA	B-T056
group	B-T078
.	O
The	O
prevalence	B-T081
rates	B-T081
of	O
cardiovascular diseases	B-T047
were	O
lower	B-T080
in	O
the	O
moderate	B-T080
(	O
odds ratio	B-T081
[	O
OR	B-T081
],	O
0.822;	O
95%	O
confidence interval	B-T081
[	O
CI	B-T081
],	O
0.737-0.916;	O
p	B-T081
=	O
0.001)	O
and	O
high	B-T080
activity	B-T056
groups	B-T078
(	O
OR	B-T081
,	O
0.663;	O
95%	O
CI	B-T081
,	O
0.589-0.748;	O
p	B-T081
=	O
0.001)	O
than	O
in	O
the	O
low	B-T080
activity	B-T056
group	B-T078
,	O
even	O
after	O
adjusting	O
for	O
age	B-T032
,	O
sex	B-T032
,	O
smoking	B-T055
,	O
underlying disease	B-T047
,	O
and	O
general	B-T047
or	O
abdominal obesity	B-T033
and	O
muscle mass	B-T033
.	O
Regular physical activity	B-UnknownType
was	O
associated	B-T080
with	O
a	O
low prevalence	B-T081
of	O
cardiovascular diseases	B-T047
(	O
stroke	B-T037
,	O
myocardial infarction	B-T047
,	O
stable angina	B-T047
,	O
and	O
chronic renal disease	B-T047
),	O
which	O
was	O
independent of	B-T169
body composition	B-T032
and	O
conventional	O
risk factors	B-T033
in	O
the	O
Korean population	B-T098
,	O
with	O
a	O
positive	B-T033
dose-response relationship	B-T038
.	O

Treated	B-T061
Prevalence	B-T081
of	O
Attention-Deficit/Hyperactivity Disorder	B-T048
Increased	B-T081
from	O
2009	O
to	O
2015	O
Among	O
School-Aged Children	B-T100
and	O
Adolescents	B-T100
in	O
the	O
United States	B-T083
The	O
purpose	B-T169
of	O
this	O
brief	O
is	O
to	O
describe	B-T078
changes	B-T169
in	O
the	O
treated	B-T061
prevalence	B-T081
of	O
medically	B-T169
managed	B-T058
attention-deficit/hyperactivity disorder	B-T048
(	O
ADHD	B-T048
)	O
among	O
insured	B-T170
school-aged children	B-T100
and	O
adolescents	B-T100
in	O
the	O
United States	B-T083
from	O
2009	O
to	O
2015.	O
We	O
examine	B-T033
the	O
differences	B-T081
between	O
those	O
with	O
employer-sponsored insurance	B-T081
(	O
ESI	B-T081
)	O
and	O
with	O
Medicaid insurance	B-T058
.	O
We	O
utilized	O
two	O
large	O
longitudinal	B-T082
administrative datasets	B-T170
containing	O
medical	B-T169
and	O
drug	B-T121
claims	B-T058
data	B-T078
on	O
individuals	B-T098
with	O
ESI	B-T081
and	O
Medicaid insurance	B-T058
from	O
Truven Health MarketScan(®) Administrative Claims Databases	B-T170
.	O
Treated	B-T061
prevalence	B-T081
was	O
measured	B-T080
as	O
the	O
percentage	B-T081
of	O
school-aged children	B-T100
and	O
adolescents	B-T100
enrolled	O
in	O
a	O
calendar year	B-T079
who	O
met	O
the	O
criteria	B-T078
for	O
medically	B-T169
managed	B-T058
ADHD	B-T048
in	O
the	O
same	O
calendar year	B-T079
.	O
Subjects	B-T098
were	O
eligible	B-T080
for	O
inclusion	B-T080
if	O
they	O
were	O
aged	B-T032
6-17	O
years	B-T079
and	O
were	O
continuously	B-T078
enrolled	O
during	O
a	O
calendar year	B-T079
.	O
The	O
annual	B-T079
prevalence	B-T081
of	O
treated	B-T061
ADHD	B-T048
among	O
school-aged children	B-T100
and	O
adolescents	B-T100
with	O
ESI	B-T081
increased	B-T081
from	O
4.5%	O
in	O
2009	O
to	O
6.7%	O
in	O
2015.	O
Among	O
those	O
with	O
Medicaid	B-T058
it	O
increased	B-T081
from	O
11.3%	O
in	O
2009	O
to	O
13.3%	O
in	O
2012,	O
and	O
fell	O
after	O
2012,	O
remaining	O
steady	B-T080
from	O
2013	O
through	O
2015.	O
Treated	B-T061
prevalence	B-T081
of	O
ADHD	B-T048
increased	B-T081
continuously	B-T078
over	O
time	B-T079
among	O
school-aged children	B-T100
and	O
adolescents	B-T100
with	O
ESI	B-T081
,	O
but	O
declined	B-T081
slightly	O
after	O
2012	O
among	O
those	O
in	O
the	O
Medicaid sample	B-T058
.	O

Acute	B-T079
macular edema	B-T047
and	O
peripapillary	B-T082
soft	B-T080
exudate	B-T031
after	O
pancreas transplantation	B-T061
with	O
accelerated	B-T169
progression	B-T046
of	O
diabetic retinopathy	B-T047
The	O
effect	O
of	O
pancreas transplantation	B-T061
on	O
diabetic retinopathy	B-T047
remains	O
inconclusive	B-T080
.	O
Herein,	O
we	O
report	O
six	O
patients	B-T101
with	O
type 1 diabetes mellitus	B-T047
(	O
DM	B-T047
)	O
who	O
underwent	O
pancreas transplantation	B-T061
and	O
developed	O
acute	B-T079
macular edema	B-T047
and	O
peripapillary	B-T082
soft	B-T080
exudate	B-T031
with	O
rapid	B-T080
progression	B-T046
to	O
proliferative diabetic retinopathy	B-T047
.	O
In	O
this	O
retrospective observational study	B-T062
,	O
diabetic	B-T047
patients	B-T101
who	O
underwent	O
pancreas transplantation	B-T061
in	O
a	O
single	B-T081
medical center	B-T073
and	O
developed	O
symptomatic	B-T169
acute	B-T079
macular edema	B-T047
and	O
peripapillary	B-T082
soft	B-T080
exudate	B-T031
within	B-T082
3 months	B-T079
after	B-T079
the	O
operation	B-T061
were	O
enrolled.	O
The	O
complete	B-T080
ophthalmic course	B-T079
and	O
medical records	B-T170
of	O
the	O
patients	B-T101
were	O
retrospectively	B-T080
reviewed	B-T080
.	O
Diabetic retinopathy	B-T047
and	O
progression	B-T046
following	B-T079
treatment	B-T061
after	O
pancreas transplantation	B-T061
were	O
measured	B-T080
.	O
Six	O
Chinese	B-T098
women	B-T098
with	O
type 1 DM	B-T047
were	O
enrolled	O
in	O
this	O
study	B-T062
.	O
Mean	O
hemoglobin (Hb) A1c	B-T116
was	O
13.4%	O
prior	O
to	O
transplantation	B-T061
and	O
decreased	B-T081
rapidly	B-T080
to	O
6.5%	O
within	B-T082
2 months	B-T079
postsurgery	B-T079
.	O
The	O
patients	B-T101
had	O
no	B-T169
or	O
mild	B-T080
pretransplant	B-T169
diabetic retinopathy	B-T047
and	O
developed	O
acute	B-T079
symptomatic	B-T169
macular edema	B-T047
and	O
peripapillary	B-T082
soft	B-T080
exudate	B-T031
in	O
both eyes	B-T023
after	O
pancreas transplantation	B-T061
.	O
All	O
macular edema	B-T047
resolved	B-T033
either	O
with	O
or	O
without	B-T080
treatment	B-T061
.	O
Five	O
cases	B-T169
progressed	B-T046
to	O
proliferative diabetic retinopathy	B-T047
and	O
received	B-T080
panretinal photocoagulation	B-T061
.	O
Diabetic retinopathy	B-T047
remained	O
stable	B-T080
in	O
all	B-T081
eyes	B-T023
after	B-T079
treatment	B-T061
,	O
and	O
the	O
visual	B-T169
prognosis was good	B-T033
,	O
except	B-T169
in	O
one	B-T081
eye	B-T023
that	O
had	O
macular	B-T082
branch retinal artery occlusion	B-T047
with	O
foveal	B-T023
involvement	B-T169
.	O
Acute	B-T079
macular edema	B-T047
after	O
pancreas transplantation	B-T061
has	O
a	O
favorable	B-T080
treatment outcome	B-T080
despite	O
rapid	O
progression	B-T046
to	O
proliferative diabetic retinopathy	B-T047
.	O
High	B-T080
pretransplant	B-T169
HbA1c	B-T116
and	O
abrupt	B-T080
blood sugar	B-T109
normalization	B-T169
may	O
be	O
related	O
to	O
the	O
disease course	B-T046
.	O

Anger	B-T041
and	O
aggression	B-T055
in	O
borderline personality disorder	B-T048
and	O
attention deficit hyperactivity disorder	B-T048
-	O
does	O
stress	B-T033
matter?	O
The	O
impact	B-T080
of	O
stress	B-T033
on	O
anger	B-T041
and	O
aggression	B-T055
in	O
Borderline Personality Disorder	B-T048
(	O
BPD	B-T048
)	O
and	O
Attention Deficit Hyperactivity Disorder	B-T048
(	O
ADHD	B-T048
)	O
has	O
not	O
been	O
thoroughly	O
investigated	B-T169
.	O
The	O
goal	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
different	O
aspects	O
of	O
anger	B-T041
and	O
aggression	B-T055
in	O
patients	B-T101
with	O
these	O
disorders	B-T047
.	O
Twenty-nine	O
unmedicated	B-T033
female	B-T032
BPD	B-T048
patients	B-T101
,	O
28	O
ADHD	B-T048
patients	B-T101
and	O
30	O
healthy controls	B-T080
(	O
HC	B-T080
)	O
completed	O
self-reports	B-T062
measuring	B-T080
trait	B-T032
anger	B-T041
,	O
aggression	B-T055
and	O
emotion regulation	B-T041
capacities.	O
A	O
modified	O
version	O
of	O
the	O
Point Subtraction Aggression Paradigm	B-T062
and	O
a	O
state anger measurement	B-T062
were	O
applied	O
under	O
resting	B-T080
and	O
stress conditions	B-T080
.	O
Stress	B-T033
was	O
induced	B-T169
by	O
the	O
Mannheim Multicomponent Stress Test	B-T060
(	O
MMST	B-T060
).	O
Both	O
patient	B-T101
groups	O
scored	B-T081
significantly	O
higher	O
on	O
all	O
self-report	B-T062
measures	B-T080
compared	B-T052
to	O
HCs	B-T080
.	O
Compared	B-T052
to	O
ADHD	B-T048
patients	B-T101
,	O
BPD	B-T048
patients	B-T101
reported	O
higher	O
trait	B-T032
aggression	B-T055
and	O
hostility	B-T041
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	B-T041
when	O
provoked	O
and	O
to	O
direct	O
anger	B-T041
inwardly.	O
Furthermore,	O
BPD	B-T048
patients	B-T101
exhibited	O
higher	O
state	O
anger	B-T041
than	O
HCs	B-T080
and	O
ADHD	B-T048
patients	B-T101
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress-dependent	B-T169
anger	B-T041
increase.	O
At	O
the	O
behavioral level	B-T053
,	O
no	O
significant	O
effects	O
were	O
found.	O
In	O
BPD	B-T048
patients	B-T101
,	O
aggression	B-T055
and	O
anger	B-T041
were	O
positively	O
correlated	O
with	O
emotion regulation	B-T041
deficits	B-T080
.	O
Our	O
findings	B-T033
suggest	O
a	O
significant	O
impact	B-T080
of	O
stress	B-T033
on	O
self-perceived	O
state	O
anger	B-T041
in	O
BPD	B-T048
patients	B-T101
but	O
not	O
on	O
aggressive behavior	B-T055
towards	O
others	O
in	O
females	B-T032
with	O
BPD	B-T048
or	O
ADHD	B-T048
.	O
However,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	B-T041
which	O
is	O
of	O
clinical	B-T080
importance	B-T080
in	O
BPD	B-T048
patients	B-T101
.	O

Interferon gamma	B-T028
and	O
interleukin 10	B-T028
polymorphisms	B-T045
in	O
Chinese	B-T098
children	B-T100
with	O
hemophagocytic lymphohistiocytosis	B-T047
The	O
aim	O
of	O
the	O
study	B-T062
is	O
to	O
investigate	B-T169
the	O
association	O
of	O
interferon gamma	B-T028
(	O
IFN-γ	B-T028
)	O
and	O
interleukin-10	B-T028
(	O
IL-10	B-T028
)	O
gene	B-T028
single nucleotide polymorphisms	B-T086
with	O
the	O
susceptibility	B-T201
of	O
hemophagocytic lymphohistiocytosis	B-T047
(	O
HLH	B-T047
)	O
in	O
Chinese	B-T098
children	B-T100
without known family history of	B-T033
HLH	B-T047
.	O
Forty	O
children	B-T100
with	O
HLH	B-T047
and	O
160	O
age	B-T032
-	O
and	O
gender	B-T032
-matched	O
healthy controls	B-T080
from	O
Xuzhou Children's Hospital	B-T073
were	O
enrolled	O
in	O
the	O
study	B-T062
.	O
Serum	B-T031
IFN-γ	B-T116
and	O
IL-10	B-T116
levels	O
were	O
measured	B-T080
by	O
enzyme linked-immunosorbent assay	B-T059
.	O
Polymorphisms	B-T045
of	O
the	O
IFN-γ gene	B-T028
at	O
position	O
+874	O
and	O
+2109,	O
and	O
IL-10	B-T028
at	O
position	O
-1082	O
were	O
analyzed	B-T033
by	O
allele	B-T028
-	O
specific	B-T080
PCR	B-T063
.	O
Median serum	B-T031
concentrations	B-T081
of	O
IFN -γ	B-T116
and	O
IL-10	B-T116
were	O
significantly higher	B-T081
in	O
children	B-T100
with	O
HLH	B-T047
compared	B-T052
to	O
healthy controls	B-T080
.	O
The	O
frequencies	B-T079
of	O
IFN-γ	B-T028
+874	O
T/A and T/T genotypes	B-T032
,	O
as	O
well	O
as	O
T allele	B-T028
,	O
were	O
significantly higher	B-T081
in	O
the	O
HLH	B-T047
group	O
compared	B-T052
with	O
those	O
in	O
the	O
control group	B-T096
.	O
The	O
frequencies	B-T079
of	O
IL-10	B-T028
-1082	O
G/A genotype	B-T032
and	O
G allele	B-T028
were	O
significantly increased	B-T081
in	O
HLH	B-T047
patients	B-T101
compared	B-T052
with	O
healthy controls	B-T080
.	O
No significant	B-T033
difference	B-T033
was	O
found	O
in	O
the	O
distribution	B-T169
of	O
IFN-γ	B-T028
+2109	O
G/A genotypes	B-T032
between	O
children	B-T100
with	O
HLH	B-T047
and	O
controls	B-T080
.	O
This	O
study	B-T062
presents	B-T033
preliminary	B-T079
evidence	B-T078
for	O
the	O
association	O
between	O
IFN	B-T028
+874	O
T/A, T/T	B-T032
,	O
IL-10	B-T028
-1082	O
A/G genotypes	B-T032
,	O
and	O
HLH	B-T047
susceptibility	B-T201
in	O
Chinese	B-T098
children	B-T100
with	O
HLH	B-T047
.	O

Data	B-T078
-Driven	O
Implementation	B-T052
of	O
Alarm	B-T074
Reduction	B-T080
Interventions	B-T061
in	O
a	O
Cardiovascular Surgical ICU	B-T073
Alarm fatigue	B-T033
in	O
the	O
ICU	B-T073
setting	B-T082
has	O
been	O
well	O
documented	B-T058
in	O
the	O
literature	B-T170
.	O
The	O
ICU's	B-T073
high-intensity	B-T185
environment	B-T082
requires	O
staff's	B-T097
vigilant	B-T041
attention	B-T041
,	O
and	O
distraction	B-T053
from	O
false	B-T080
and	O
non-actionable	O
alarms	B-T074
pulls	O
staff	B-T097
away	O
from	O
important	O
tasks	B-T057
,	O
creates	O
dissatisfaction	B-T041
,	O
and	O
is	O
a	O
potential	O
patient safety	B-T058
risk	B-T078
if	O
alarms	B-T074
are	O
missed	B-T080
or	O
ignored	B-T078
.	O
This	O
project	O
was	O
intended	O
to	O
improve	O
patient safety	B-T058
by	O
optimizing	O
alarm	B-T074
systems	B-T169
in	O
a	O
cardiovascular surgical intensive care unit	B-T073
(	O
CVSICU	B-T073
).	O
Specific	O
aims	O
were	O
to	O
examine	B-T033
nurses	B-T097
'	O
attitudes	B-T041
toward	O
clinical	B-T080
alarm	B-T074
signals	B-T067
,	O
assess	O
nurses	B-T097
'	O
ability	O
to	O
discriminate	O
audible alarm	B-T073
signals	B-T067
,	O
and	O
implement	B-T052
a	O
bundled	O
set	O
of	O
best practices	B-T078
for	O
monitor alarm	B-T033
reduction	B-T080
without	O
undermining	O
patient safety	B-T058
.	O
CVSICU	B-T073
nurses	B-T097
completed	O
an	O
alarm	B-T074
perception survey	B-T170
and	O
participated	O
in	O
alarm	B-T074
discriminability testing	B-T169
.	O
Nurse survey data	B-T170
and	O
baseline	B-T081
monitor	O
alarm	B-T074
data	B-T078
were	O
used	O
to	O
select	O
targeted	B-T169
alarm	B-T074
reduction	B-T080
interventions	B-T061
,	O
which	O
were	O
progressively	O
phased	O
in.	O
Monitor	O
alarm	B-T074
data	B-T078
and	O
cardiorespiratory event	B-T033
data	B-T078
were	O
trended	O
over	O
one	O
year	B-T079
.	O
Five	O
of	O
the	O
most	O
frequent	O
CVSICU	B-T073
monitor alarm	B-T033
types-	O
pulse oximetry	B-T060
,	O
heart rate	B-T201
,	O
systolic	B-T033
and	O
diastolic blood pressure	B-T047
,	O
pulse oximetry	B-T060
sensor	B-T073
,	O
and	O
ventricular tachycardia	B-T047
>	O
2-were	O
targeted	B-T169
.	O
After	O
implementation	B-T052
,	O
there	O
was	O
a	O
61%	O
reduction	B-T080
in	O
average	O
alarms	B-T074
per	O
monitored	O
bed	B-T073
and	O
a	O
downward	O
trend	O
in	O
cardiorespiratory events	B-T033
.	O
To	O
reduce	B-T080
alarm fatigue	B-T033
it	O
is	O
important	O
to	O
decrease	B-T081
alarm	B-T074
burden	B-T078
through	O
targeted	B-T169
interventions	B-T061
.	O
Methods	O
to	O
reduce	O
non-actionable	O
alarms	B-T074
include	O
adding	O
short	O
delays	B-T079
to	O
allow	O
alarm	B-T074
self-correction	B-T169
,	O
adjusting	O
default	O
alarm	B-T074
threshold	B-T080
limits	B-T169
,	O
providing	O
alarm	B-T074
notification	B-T058
through	O
a	O
secondary device	B-T074
,	O
and	O
teaching	B-T065
staff	B-T097
to	O
optimize	O
alarm	B-T074
settings	O
for	O
individual	B-T098
patients	B-T101
.	O

The	O
NCAM1 gene set	B-T028
is	O
linked	O
to	O
depressive symptoms	B-T184
and	O
their	O
brain structural	B-T023
correlates	B-T039
in	O
healthy individuals	B-T098
Depressive symptoms	B-T184
exist	O
on	O
a	O
continuum,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive disorders	B-T048
.	O
Utilizing	O
the	O
continuous spectrum	B-T059
of	O
depressive symptoms	B-T184
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological underpinnings	B-T033
of	O
depression	B-T048
.	O
Gene set enrichment analysis	B-T059
(	O
GSEA	B-T059
)	O
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene groups	B-T028
linked	O
to	O
complex traits	B-T032
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome-wide association study	B-T063
(	O
GWAS	B-T063
)	O
data of depression scores	B-T033
and	O
their	O
brain-level structural	B-T023
correlates	B-T039
in	O
healthy young individuals	B-T098
.	O
On	O
symptom level	B-T033
(i.e.	O
depression scores	B-T033
),	O
robust	B-T080
enrichment	O
was	O
identified	O
for	O
two	O
gene sets	B-T028
:	O
NCAM1	B-T028
Interactions	B-T045
and	O
Collagen Formation	B-T044
.	O
Depression scores	B-T033
were	O
also	O
associated with	B-T080
decreased	B-T081
fractional anisotropy	B-T070
(	O
FA	B-T070
)	O
-	O
a	O
brain white matter property	B-T023
-	O
within the forceps minor	B-T023
and	O
the	O
left superior temporal longitudinal fasciculus	B-T023
.	O
Within	O
each	O
of	O
these	O
tracts,	O
mean FA	B-T070
value	O
of	O
depression score	B-T033
-	O
associated voxels	B-T077
was	O
used	O
as	O
a	O
phenotype	B-T032
in	O
a	O
subsequent	O
GSEA	B-T059
.	O
The	O
NCAM1	B-T028
Interactions	B-T045
gene set	B-T028
was	O
significantly	O
enriched	O
in	O
these	O
tracts.	O
By	O
linking	O
the	O
NCAM1	B-T028
Interactions	B-T045
gene set	B-T028
to	O
depression scores	B-T033
and	O
their	O
structural brain	B-T023
correlates	B-T039
in	O
healthy participants	B-T098
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular underpinnings	B-T033
of	O
depressive symptomatology	B-T184
.	O

The	O
burden	O
of	O
HPV	B-T005
-related	O
diseases	B-T047
in	O
Italy	B-T083
,	O
2001-12	O
Human papillomavirus (HPV) infection	B-T047
is	O
the	O
main	O
cause	O
of	O
cervical cancer	B-T191
and	O
plays	O
a	O
relevant	O
role	O
in	O
the	O
development	B-T169
of	O
genital warts	B-T047
and	O
of	O
the	O
cancer	B-T191
of	O
penis	B-T023
and	O
anus	B-T023
,	O
head	B-T029
/	O
neck	B-T029
,	O
oropharynx	B-T029
and	O
genitourinary system	B-T022
.	O
The	O
aim	O
of	O
this	O
study	B-T062
is	O
the	O
evaluation	B-T169
of	O
hospitalizations	B-T058
due	O
to	O
HPV-related pathologies	B-T047
in	O
2001-12	O
in	O
Italy	B-T083
.	O
The	O
national hospital discharge	B-T058
forms	B-T073
were	O
provided	O
by	O
the	O
Ministry of Health	B-T093
.	O
The	O
HPV	B-T005
-related	O
hospitalizations	B-T058
were	O
identified	O
using	O
specific	O
diagnostic	B-T169
codes	B-T170
,	O
accordingly	O
to	O
the	O
ICD-9-CM	B-T170
coding system	B-T185
.	O
The	O
proportion	O
of	O
hospitalizations	B-T058
of	O
potentially	O
HPV-related pathologies	B-T047
,	O
obtained	O
from	O
the	O
literature	B-T170
,	O
was	O
evaluated	B-T169
as	O
well	O
as	O
the	O
hospitalization rates	B-T081
(	O
hr	B-T081
)	O
and	O
their	O
trend	B-T079
over	O
time	B-T079
.	O
Uterine cervical cancer	B-T191
and	O
CIN III	B-T191
accounted	O
for	O
40%	O
of	O
hospitalizations	B-T058
(	O
hr	B-T081
:	O
15.6/100	O
000	O
and	O
17.6/100	O
000,	O
respectively).	O
Head	B-T029
/	O
neck	B-T029
and	O
oropharynx	B-T029
pathologies	B-T169
accounted	O
for	O
24.5%	O
of	O
cases	B-T169
(	O
hr	B-T081
:	O
16/100	O
000	O
and	O
3.9/100	O
000,	O
in	O
males	B-T032
and	O
females	B-T032
,	O
respectively),	O
followed	O
by	O
genital warts	B-T047
(17.3%	O
of	O
hospitalizations	B-T058
;	O
hr	B-T081
:	O
7.5/100	O
000	O
in	O
males	B-T032
and	O
8.52/100	O
000	O
in	O
females	B-T032
),	O
anal	B-T191
(8.1%	O
of	O
hospitalizations	B-T058
),	O
genitourinary	B-T191
(7.7%)	O
and	O
penis cancers	B-T191
(2.2%).	O
The	O
study	B-T062
,	O
even	O
if	O
limited	O
to	O
the	O
evaluation	B-T169
of	O
hospitalizations	B-T058
,	O
points	O
out	O
how	O
HPV-related pathologies	B-T047
continue	O
to	O
be	O
a	O
relevant	O
public health	B-T078
issue	B-T033
in	O
Italy	B-T083
with	O
a	O
high	O
impact	B-T080
on	O
population	B-T098
.	O

The	O
discovery	B-T052
of	O
potent	B-T080
and	O
selective	B-T080
kynurenine 3-monooxygenase	B-T116
inhibitors	B-T121
for	O
the	O
treatment	B-T061
of	O
acute pancreatitis	B-T047
A	O
series	B-T081
of	O
potent	B-T080
,	O
competitive	B-T080
and	O
highly	B-T080
selective	B-T080
kynurenine monooxygenase	B-T116
inhibitors	B-T121
have	O
been	O
discovered	B-T052
via	O
a	O
substrate	B-T167
-based	O
approach	B-T082
for	O
the	O
treatment	B-T061
of	O
acute pancreatitis	B-T047
.	O
The	O
lead	B-T169
compound	B-T103
demonstrated	O
good	B-T080
cellular	B-T025
potency	B-T080
and	O
clear	O
pharmacodynamic	B-T038
activity	B-T052
in vivo	B-T082
.	O

Draft Genome	B-T028
Sequence	B-T086
of	O
Providencia stuartii PS71	B-T007
,	O
a	O
Multidrug-Resistant	B-T032
Strain	B-T001
Associated with	B-T080
Nosocomial Infections	B-T047
in	O
Greece	B-T083
Providencia stuartii	B-T007
is	O
frequently	B-T079
associated with	B-T080
nosocomial outbreaks	B-T047
and	O
displays	O
intrinsic	B-T082
resistance	B-T169
to	O
many	O
commonly	B-T081
used	O
antimicrobials	B-T121
.	O
We	O
report	O
here	O
the	O
draft genome	B-T028
sequence	B-T086
of	O
a	O
P. stuartii strain	B-T007
carrying	O
acquired	B-T080
resistance genes	B-T028
conferring	O
panresistance	B-T169
to	O
cephalosporins	B-T109
(	O
blaSHV-5	B-T028
and	O
blaVEB-1	B-T028
),	O
carbapenems	B-T109
(	O
blaVIM-1	B-T028
),	O
and	O
aminoglycosides	B-T109
(	O
rmtB	B-T028
)	O
involved	O
in	O
an	O
outbreak	B-T067
in	O
Greek	B-T083
hospitals	B-T073
.	O

Impact	B-T080
of	O
diabetic ketoacidosis	B-T047
management	B-T058
in	O
the	O
medical intensive care unit	B-T073
after	O
order set	B-T170
implementation	B-T052
To	O
determine	O
the	O
rate	B-T081
of	O
compliance	B-T058
to	O
the	O
2006	O
and	O
2009	O
ADA DKA guidelines	B-T170
in	O
the	O
medical intensive care unit	B-T073
(	O
MICU	B-T073
)	O
at	O
a	O
large	O
academic medical centre	B-T073
after	O
the	O
implementation	B-T052
of	O
a	O
computerised DKA order set	B-T170
and	O
protocol	B-T061
.	O
Retrospective	B-T080
chart review	B-T170
of	O
adult patients	B-T101
with	O
DKA	B-T047
admitted	B-T058
to	O
the	O
MICU	B-T073
.	O
Results	O
of	O
pre-order set	B-T170
(	O
PRE	B-T170
)	O
were	O
compared	O
to	O
those	O
of	O
data	O
post-order set	B-T170
(	O
POST	B-T170
).	O
The	O
primary outcome	B-T169
was	O
a	O
composite	O
administration	B-T061
of	O
intravenous fluid resuscitation	B-T061
in	O
the	O
first	O
24	O
h,	O
insulin	B-T116
bolus	B-T061
and	O
initial	B-T079
insulin	B-T116
infusion rate	B-T079
.	O
Twelve	O
of	O
60	O
patients	B-T101
(20%)	O
in	O
the	O
PRE group	B-UnknownType
received	O
treatment	B-T061
compliant	B-T080
with	O
the	O
2006	O
guidelines	B-T170
versus	O
14	O
of	O
55	O
patients	B-T101
(25.5%)	O
in	O
the	O
POST group	B-UnknownType
(	O
OR	B-T081
1.22	O
95%	O
CI	B-T081
0.44	O
to	O
3.4,	O
P	O
=	O
0.51).	O
Compliance	B-T058
to	O
the	O
2009	O
guidelines	B-T170
was	O
significantly higher	B-T081
in	O
the	O
POST group	B-UnknownType
(31.7%	O
versus	O
65.5%,	O
OR	B-T081
4.44	O
95%	O
CI	B-T081
1.8	O
to	O
10.92,	O
P	O
=	O
0.0004).	O
Compliance	B-T058
for	O
individual	O
components	O
was	O
26.7%	O
versus	O
70.9%	O
for	O
fluid resuscitation	B-T061
(P	O
=	O
0.0001),	O
55%	O
versus	O
49.1%	O
for	O
insulin	B-T116
bolus	B-T061
(P	O
=	O
0.58)	O
and	O
60%	O
versus	O
81.3%	O
for	O
initial	B-T079
insulin	B-T116
infusion rate	B-T079
(P	O
=	O
0.014),	O
respectively.	O
Time	B-T079
to	O
DKA	B-T047
resolution	B-T077
was	O
decreased	B-T081
(P	O
=	O
0.04),	O
and	O
hypoglycaemia	B-T047
was	O
increased	B-T081
(P	O
=	O
0.0022).	O
Implementation	B-T052
of	O
a	O
computerised DKA order set	B-T170
and	O
protocol	B-T061
was	O
associated with	B-T080
improved	B-T033
compliance	B-T058
to	O
the	O
2009	O
ADA DKA guidelines	B-T170
,	O
24-h	O
fluid resuscitation	B-T061
,	O
initial	B-T079
insulin	B-T116
infusion rate	B-T079
,	O
time	B-T079
to	O
DKA	B-T047
resolution	B-T077
and	O
appropriate	O
transition	B-T052
to	O
subcutaneous	B-T082
insulin	B-T116
.	O
However,	O
patients	B-T101
in	O
the	O
POST implementation group	B-UnknownType
were	O
more	O
likely	O
to	O
exhibit	O
hypoglycaemia	B-T047
.	O
Future	O
assessment	O
is	O
warranted.	O

Construction	O
of	O
an	O
Acetylcholinesterase	B-T116
Sensor	B-T075
Based	O
on	O
Synthesized Paramagnetic Nanoparticles	B-T130
,	O
a	O
Simple	O
Tool	O
for	O
Neurotoxic Compounds	B-T131
Assay	B-T059
Magnetic particles	B-T130
(	O
MPs	B-T130
)	O
have	O
been	O
widely	O
used	O
in	O
biological applications	B-T169
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	B-T167
.	O
Their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	B-T067
molecules	B-T167
including	O
enzymes	B-T116
.	O
Acetylcholinesterase	B-T116
(	O
AChE	B-T116
)	O
is	O
an	O
enzyme	B-T116
playing	O
crucial	O
role	O
in	O
neurotransmission	B-T043
and	O
the	O
enzyme	B-T116
is	O
targeted	B-T169
by	O
various	O
molecules	B-T167
like	O
Alzheimer's	B-T047
drugs	B-T121
,	O
pesticides	B-T131
and	O
warfare agents	B-T109
.	O
In	O
this	O
work,	O
an	O
electrochemical biosensor	B-T075
having	O
AChE	B-T116
immobilized	B-T116
onto	O
MPs	B-T130
and	O
stabilized	B-T033
through	O
glutaraldehyde (GA) molecule	B-T109
was	O
proposed	O
for	O
assay	B-T059
of	O
the	O
neurotoxic compounds	B-T131
.	O
The	O
prepared nanoparticles	B-T073
were	O
modified by	B-T080
pure AChE	B-T116
and	O
they	O
were	O
used	O
for	O
the	O
measurement	B-T169
anti-Alzheimer's	B-T033
drug	B-T121
galantamine	B-T109
and	O
carbamate pesticide	B-T109
carbofuran	B-T109
with	O
limit	B-T078
of	O
detection	B-T033
1.5	O
µM	O
and	O
20	O
nM,	O
respectively.	O
All	O
measurements	B-T169
were	O
carried	O
out	O
using	O
screen-printed sensor	B-T075
with	O
carbon	B-T196
working	B-T074
,	O
silver	B-T196
reference	B-T074
,	O
and	O
carbon	B-T196
auxiliary electrode	B-T074
.	O
Standard Ellman's assay	B-T059
was	O
used	O
for	O
validation	B-T062
measurement	B-T169
of	O
both	O
inhibitors	B-T120
.	O
Part	O
of	O
this	O
work	O
was	O
the	O
elimination	B-T052
of	O
reversible	B-T169
inhibitors	B-T120
represented	O
by	O
galantamine	B-T109
from	O
the	O
active site	B-T169
of	O
AChE	B-T116
.	O
For	O
this	O
purpose,	O
we	O
used	O
a	O
lower	B-T052
pH	B-T081
to	O
get	O
the	O
original	B-T078
activity	B-T052
of	O
AChE	B-T116
after	O
inhibition	B-T052
by	O
galantamine	B-T109
.	O
We	O
also	O
observed	B-T169
decarbamylation	B-T067
of	O
the	O
AChE	B-T116
-	O
carbofuran	B-T109
adduct	B-T104
.	O
Influence	O
of	O
organic solvents	B-T109
to	O
AChE	B-T116
as	O
well	O
as	O
repeatability	O
of	O
measurement	B-T169
with	O
MPs	B-T130
with	O
AChE	B-T116
was	O
also	O
established.	O

Alanine Aminotransferase	B-T116
Is	O
a	O
Marker	B-T201
of	O
Lipotoxicity	B-T047
Consequences	B-T169
and	O
Hyperandrogenemia	B-T033
in	O
Women	B-T098
with	O
Polycystic Ovary Syndrome	B-T047
Several	O
studies	B-T062
have	O
reported	O
higher	O
levels	O
of	O
Alanine aminotransferase	B-T116
(	O
ALT	B-T116
)	O
in	O
women	B-T098
with	O
polycystic ovary syndrome	B-T047
(	O
PCOS	B-T047
)	O
compared	O
with	O
control subjects	B-T096
.	O
Plasma ALT levels	B-T059
are	O
considered	O
a	O
marker	B-T201
of	O
hepatic	B-T029
lipotoxicity	B-T047
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	B-T029
metabolic	O
dysfunctions,	O
such	O
as	O
hepatic steatosis	B-T047
and	O
hepatic	B-T029
insulin resistance	B-T046
.	O
Retrospective chart	B-T170
review	O
aiming	O
to	O
assess,	O
in	O
PCOS	B-T047
women	B-T098
,	O
the	O
relationship	O
between	O
ALT levels	B-T059
and	O
measures	O
of	O
lipotoxicity	B-T047
consequences	B-T169
that	O
are	O
available	O
clinically,	O
both	O
during	O
fasting	B-T059
and	O
using	O
the	O
oral glucose tolerance test	B-T060
.	O
Women	B-T098
(n	O
=	O
132)	O
with	O
PCOS	B-T047
,	O
were	O
in	O
average	O
27.9	O
years	B-T079
of	O
age	B-T032
,	O
with	O
a	O
mean	O
body mass index	B-T201
of	O
34.1	O
kg/m(2)	O
and	O
49%	O
had	O
a	O
metabolic syndrome	B-T047
(	O
MetS	B-T047
).	O
ALT levels	B-T059
were	O
significantly	O
correlated	O
with	O
homeostatic model assessment for insulin resistance	B-T059
(r	O
=	O
0.42,	O
P	O
<	O
0.001),	O
HDL-C	B-T109
(r	O
=	O
-0.31,	O
P	O
<	O
0.001),	O
Matsuda index	B-T170
(-0.45,	O
P	O
<	O
0.001),	O
insulin secretion-sensitivity index-2	B-T060
(-0.26,	O
P	O
=	O
0.043),	O
and	O
free testosterone	B-T109
(0.38,	O
P	O
<	O
0.001),	O
but	O
not	O
with	O
fasting glucose	B-T034
and	O
triglyceride levels	B-T034
.	O
ALT	B-T116
cutoff	O
≥24	O
IU/L	O
was	O
associated	O
with	O
all	O
these	O
parameters,	O
including	O
fasting glucose	B-T034
(P	O
=	O
0.021)	O
and	O
triglyceride levels	B-T034
(P	O
=	O
0.041),	O
and	O
detected	O
more	O
women	B-T098
with	O
the	O
MetS	B-T047
(59.2%	O
vs.	O
36.1%,	O
P	O
=	O
0.008)	O
and	O
whole-body insulin resistance	B-T046
(	O
Matsuda index	B-T170
<12.3	O
L(2)·10/mmol(2),	O
85.3%	O
vs.	O
51.9%,	O
P	O
=	O
0.004).	O
Plasma ALT levels	B-T059
seem	O
to	O
be	O
a	O
strong	O
predictor	B-T078
not	O
only	O
of	O
liver	B-T023
lipotoxicity	B-T047
but	O
also	O
of	O
systemic lipotoxic	B-T047
consequences	B-T169
and	O
hyperandrogenemia	B-T033
in	O
women	B-T098
with	O
PCOS	B-T047
.	O
Although	O
it	O
requires	O
validation	B-T062
in	O
another	O
study	B-T062
,	O
an	O
ALT	B-T116
cutoff	O
of	O
≥24	O
IU/L	O
may	O
help	O
clinicians	B-T097
identify	O
women	B-T098
with	O
increased	O
metabolic risks	B-T201
.	O

Opioid	B-T109
Use	O
in	O
Chronic Pain	B-T184
Patients	B-T101
with	O
Chronic Kidney Disease	B-T047
:	O
A	O
Systematic Review	B-T170
To	O
investigate	O
the	O
prevalence	B-T081
of	O
chronic pain	B-T184
and	O
opioid	B-T109
management	B-T058
among	O
patients	B-T101
with	O
chronic kidney disease	B-T047
(	O
CKD	B-T047
).	O
Systematic review	B-T170
.	O
A	O
systematic	O
search	O
was	O
performed,	O
including	O
citations	O
from	O
1960	O
to	O
May	O
2015.	O
The	O
review	O
highlights	O
methodological quality assessment	B-UnknownType
of	O
the	O
selected	O
studies	B-T170
;	O
prevalence	B-T081
of	O
pain	B-T184
;	O
type	B-T080
,	O
dose	B-T081
,	O
and	O
reason	O
for	O
opioid	B-T109
use;	O
effectiveness	B-T080
of	O
pain control	B-T061
and	O
associated	O
adverse effects	B-T046
of	O
opioids	B-T109
in	O
CKD	B-T047
patients	B-T101
.	O
Twelve	O
of	O
131	O
articles	O
met	O
inclusion criteria	B-T080
.	O
There	O
were	O
no	O
randomized controlled trials	B-T062
(	O
RCT	B-T062
)	O
evaluable,	O
and	O
12	O
were	O
observational studies	B-T170
.	O
Out	O
of	O
12	O
studies	B-T170
,	O
four	O
were	O
of	O
high	B-T080
quality	B-T080
,	O
six	O
were	O
of	O
moderate	B-T081
quality	B-T080
,	O
and	O
the	O
remaining	O
two	O
were	O
low	B-T080
-	O
quality	B-T080
studies	B-T170
.	O
The	O
studies	B-T170
were	O
from	O
different	O
countries	B-T083
with	O
sample size	B-T081
ranging	O
from	O
10	O
to	O
12,782.	O
Several	O
studies	B-T170
showed	O
a	O
high	O
prevalence	B-T081
of	O
chronic	B-T079
uncontrolled pain	B-T184
.	O
The	O
effectiveness	O
of	O
different	O
categories	O
of	O
opioids	B-T109
,	O
dose	B-T081
,	O
duration	B-T081
,	O
and	O
commonly	O
prescribed	B-T058
opioids	B-T109
varied	O
across	O
studies	B-T170
.	O
Based	O
on	O
a	O
systematic review	B-T170
of	O
the	O
current	O
literature,	O
there	O
is	O
fair	O
evidence	O
for	O
the	O
high	O
prevalence	B-T081
of	O
chronic pain	B-T184
among	O
patients	B-T101
with	O
CKD	B-T047
,	O
which	O
is	O
not	O
being	O
effectively	O
managed,	O
probably	O
due	O
to	O
underprescription	B-UnknownType
of	O
analgesics	B-T109
or	O
opioids	B-T109
in	O
the	O
CKD	B-T047
population	B-T081
.	O
Clinicians	B-T097
are	O
in	O
need	O
of	O
additional	O
and	O
well-designed	O
randomized control trials	B-T062
that	O
focus	O
on	O
the	O
indications	O
for	O
opioid	B-T109
therapy	B-T061
,	O
appropriate	O
opioid	B-T109
doses	B-T081
and	O
dosing	B-T081
intervals	B-T079
,	O
outcomes	O
with	O
adequacy	B-T080
of	O
symptom control	B-T061
,	O
and	O
reporting	O
on	O
the	O
incidence	O
of	O
adverse side effects	B-T046
.	O

Cognitive impairment	B-T048
in	O
first-episode	B-T079
drug-naïve patients	B-T101
with	O
schizophrenia	B-T048
:	O
Relationships	B-T080
with	O
serum concentrations	B-T081
of	O
brain-derived neurotrophic factor	B-T116
and	O
glial cell line-derived neurotrophic factor	B-T116
Evidence	O
suggests	O
that	O
brain-derived neurotrophic factor	B-T116
(	O
BDNF	B-T116
)	O
and	O
glial cell line -derived neurotrophic factor	B-T116
(	O
GDNF	B-T116
)	O
are	O
important	O
in	O
the	O
regulation of synaptic plasticity	B-T042
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive processes	B-T041
in	O
psychiatric disorders	B-T048
.	O
Our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	B-T080
between	O
serum	B-T031
BDNF	B-T116
and	O
GDNF	B-T116
levels	O
and	O
cognitive functions	B-T041
in	O
first-episode drug-naïve (FEDN) patients	B-T101
with	O
schizophrenia	B-T048
.	O
The	O
BDNF	B-T116
and	O
GDNF	B-T116
levels	O
of	O
58	O
FEDN patients	B-T101
and	O
55	O
age	B-T032
-	O
and	O
sex	B-T032
-matched	O
healthy controls	B-T080
were	O
measured	O
and	O
test subjects	B-T096
were	O
examined	O
using	O
several	O
neurocognitive tests	B-T060
including	O
the	O
verbal fluency test	B-T060
(	O
VFT	B-T060
),	O
the	O
trail making test	B-T170
(	O
TMT	B-T170
),	O
the	O
digit span test	B-T170
(	O
DST	B-T170
),	O
and	O
the	O
Stroop test	B-T060
.	O
Patients	B-T101
performed	O
significantly	O
worse	O
than	O
controls	B-T096
in	O
nearly	O
all	O
neurocognitive performances	B-T060
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
DST	B-T170
.	O
BDNF	B-T116
levels	B-T080
were	O
inversely	O
correlated	O
to	O
TMT-part B scores	B-T080
and	O
positively	O
correlated	O
to	O
VFT-action	B-T060
in	O
the	O
FEDN	O
group.	O
GDNF	B-T116
levels	B-T080
showed	O
a	O
positive	O
correlation	O
with	O
VFT-action scores	B-T080
and	O
a	O
negative	O
correlation	O
with	O
TMT-part B scores	B-T080
of	O
these	O
patients	B-T101
.	O
Current	O
data	O
suggests	O
that	O
cognitive dysfunction	B-T048
widely	O
exists	O
in	O
the	O
early stages	B-T079
of	O
schizophrenia	B-T048
.	O
BDNF	B-T116
and	O
GDNF	B-T116
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	B-T169
mechanisms	B-T169
involved	O
in	O
cognitive impairment	B-T048
in	O
FEDN patients	B-T101
with	O
schizophrenia	B-T048
.	O

Comprehensive	B-T080
functional analysis	B-T062
of	O
large	O
lists	O
of	O
genes	B-T028
and	O
proteins	B-T116
The	O
interpretation	B-T170
of	O
high dimensional datasets	B-T170
resulting	O
from	O
genomic	B-T062
and	O
proteomic experiments	B-T062
in	O
a	O
timely	O
and	O
efficient	O
manner	O
is	O
challenging.	O
ClueGO software	B-T073
is	O
a	O
Cytoscape App	B-T170
that	O
extracts	O
representative	O
functional	O
biological	B-T080
information	B-T078
for	O
large	O
lists	O
of	O
genes	B-T028
or	O
proteins	B-T116
.	O
The	O
functional enrichment analysis	B-T062
is	O
based	O
on	O
the	O
latest	O
publicly	O
available	O
data	B-T078
from	O
multiple	O
annotation	B-T170
and	O
ontology	B-T090
resources	B-T078
that	O
can	O
be	O
automatically	B-T169
accessed	B-T082
through	O
ClueGO	B-T073
.	O
Predefined settings	B-T170
for	O
the	O
selection	B-T052
of	O
the	O
terms	B-T078
are	O
provided	O
to	O
facilitate	O
the	O
analysis	B-T062
.	O
Results	B-T169
are	O
visualized	O
as	O
networks	B-T169
in	O
which	O
Gene Ontology	B-T170
(	O
GO	B-T170
)	O
terms	O
and	O
pathways	B-T077
are	O
grouped	O
based	O
on	O
their	O
biological	O
role.	O
Many	O
species	B-T185
are	O
now	O
supported	O
by	O
ClueGO	B-T073
and	O
additional	O
organisms	B-T001
are	O
added	O
on	O
demand.	O
ClueGO	B-T073
can	O
be	O
used	O
together	O
with	O
the	O
CluePedia App	B-T170
to	O
enable	O
the	O
visualization	O
of	O
protein-protein interactions	B-T044
within	O
or	O
between	O
pathways	B-T077
.	O

Management	B-T061
of	O
precipitated opiate withdrawal syndrome	B-T048
induced	B-T169
by	O
nalmefene	B-T109
mistakenly	O
prescribed	B-T058
in	O
opiate	B-T121
-	O
dependent patients	B-T169
:	O
a	O
review	B-T170
for	O
clinicians	B-T097
Nalmefene	B-T109
,	O
a	O
long-acting µ-opioid antagonist	B-T121
approved	B-T080
to	O
treat	B-T169
alcohol use disorder	B-T048
,	O
is	O
occasionally	B-T079
mistakenly	O
prescribed	B-T058
to	O
opiate	B-T121
-	O
dependent	B-T169
or	O
opioid	B-T109
-	O
treated	B-T169
patients	B-T101
.	O
We	O
review	B-T078
recent	O
literature	B-T170
on	O
drug-drug interactions	B-T044
between	O
nalmefene	B-T109
and	O
opioids	B-T109
that	O
lead	O
to	O
precipitated opioid withdrawal	B-T048
,	O
and	O
focus	O
on	O
its	O
management	B-T061
and	O
planning	B-T169
for	O
care	B-T058
at	O
discharge	B-T058
.	O
Areas	O
covered:	O
This	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive review	B-T058
of	O
management	O
of	O
precipitated opioid withdrawal syndrome	B-T048
when	O
nalmefene	B-T109
is	O
associated with	B-T080
an	O
opioid	B-T109
,	O
whether	O
misused	B-T033
or	O
legally	B-T169
prescribed	B-T058
.	O
Expert opinion	B-T077
:	O
When	O
treating	B-T169
an	O
opiate	B-T121
-	O
dependent patient	B-T169
with	O
co-occurring	O
alcohol use disorder	B-T048
,	O
both	O
conditions	B-T080
need	O
to	O
be	O
a	O
focus	O
of	O
clinical attention	B-T080
.	O
New	B-T080
drugs	B-T121
for	O
alcohol use disorder	B-T048
have	O
been	O
approved	B-T080
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	B-T080
drug-drug interactions	B-T044
with	O
opioid	B-T109
medications	B-T170
.	O
Opiate	B-T121
-	O
dependent patients	B-T169
should	O
be	O
intensively	O
monitored	O
for	O
risk factors	B-T033
of	O
alcohol use disorder	B-T048
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment maintenance	B-T061
.	O
When	O
nalmefene	B-T109
is	O
administered	B-T058
to	O
opiate	B-T121
-	O
dependent patients	B-T169
,	O
acute	B-T079
opioid withdrawal syndrome	B-T048
may	O
occur	B-T052
.	O
Management	B-T061
of	O
precipitated	O
acute	B-T079
opioid withdrawal	B-T048
may	O
include	B-T052
short	O
or	O
long-acting µ-opioid agonists	B-T044
during	O
hospitalization	B-T058
,	O
in	O
addition	O
to	O
supportive treatment	B-T061
.	O
The	O
best	O
management	B-T058
of	O
polydrug abusers	B-T033
is	O
based	O
on	O
a	O
multidisciplinary approach	B-T060
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	B-T033
through	B-T169
continuing medical education	B-T078
.	O

Discovering	O
key	O
residues	B-T077
of	O
dengue virus	B-T005
NS2b-NS3-protease	B-T116
:	O
New	O
binding sites	B-T192
for	O
antiviral inhibitors	B-UnknownType
design	O
The	O
NS2B-NS3 protease	B-T116
is	O
essential	O
for	O
the	O
Dengue Virus	B-T005
(	O
DENV	B-T005
)	O
replication process	B-T045
.	O
This	O
complex	B-T026
constitutes	O
a	O
target	B-T169
for	O
efficient	O
antiviral	B-T121
discovery	B-T052
because	O
a	O
drug	B-T121
could	O
inhibit	O
the	O
viral polyprotein processing	B-T043
.	O
Furthermore,	O
since	O
the	O
protease	B-T116
is	O
highly	O
conserved	B-T086
between	O
the	O
four	O
Dengue virus	B-T005
serotypes	B-T170
,	O
it	O
is	O
probable	O
that	O
a	O
drug	B-T121
would	O
be	O
equally	O
effective	O
against	O
all	O
of	O
them.	O
In	O
this	O
article,	O
a	O
strategy	O
is	O
reported	O
that	O
allowed	O
us	O
to	O
identify	O
influential	B-T078
residues	B-T077
on	O
the	O
function	O
of	O
the	O
Dengue	B-T005
NS2b-NS3 Protease	B-T116
.	O
Moreover,	O
this	O
is	O
a	O
strategy	O
that	O
could	O
be	O
applied	O
to	O
virtually	O
any	O
protein	B-T116
for	O
the	O
search	O
of	O
alternative	O
influential	B-T078
residues	B-T077
,	O
and	O
for	O
non-competitive inhibitor	B-UnknownType
development	B-T169
.	O
First,	O
we	O
incorporated	O
several	O
features	O
derived	O
from	O
computational	B-T091
alanine	B-T116
scanning mutagenesis	B-T063
,	O
sequence	B-T086
,	O
structure conservation	B-T086
,	O
and	O
other	O
structure	B-T082
-based	O
characteristics	B-T080
.	O
Second,	O
these	O
features	O
were	O
used	O
as	O
variables	O
to	O
obtain	O
a	O
multilayer perceptron model	B-T170
to	O
identify	O
defined	O
groups	B-T078
(clusters)	O
of	O
key	O
residues	B-T077
as	O
possible	O
candidate	O
pockets	O
for	O
binding sites	B-T192
of	O
new	O
leads	O
on	O
the	O
DENV	B-T005
protease	B-T116
.	O
The	O
identified	O
residues	B-T077
included:	O
i)	O
amino acids	B-T116
close	O
to	O
the	O
beta sheet	B-T082
-loop-	O
beta sheet	B-T082
known	O
to	O
be	O
important	O
in	O
its	O
closed conformation	B-T082
for	O
NS2b	B-T116
ii)	O
residues	B-T077
close	O
to	O
the	O
active site	B-T169
,	O
iii)	O
several	O
residues	B-T077
evenly	O
spread	O
on	O
the	O
NS2b-NS3	B-T116
contact	O
surface,	O
and	O
iv)	O
some	O
inner	O
residues	B-T077
most	O
likely	O
related	O
to	O
the	O
overall	O
stability	B-T080
of	O
the	O
protease	B-T116
.	O
In	O
addition,	O
we	O
found	O
concordance	O
on	O
our	O
list	O
of	O
residues	B-T077
with	O
previously	O
identified	O
amino acids	B-T116
part	O
of	O
a	O
highly	O
conserved	O
peptide	B-T116
studied	O
for	O
vaccine development	B-T062
.	O

Association	B-T080
of	O
Toll-Like Receptor 4	B-T116
on	O
Human	B-T016
Monocyte	B-T025
Subsets	B-T185
and	O
Vulnerability	B-T033
Characteristics	B-T080
of	O
Coronary	B-T023
Plaque	B-T033
as	O
Assessed	B-T052
by	O
64-Slice Multidetector Computed Tomography	B-T060
Although	O
Toll-like receptor 4	B-T116
(	O
TLR-4	B-T116
)	O
is	O
involved	O
in	O
monocyte activation	B-T043
in	O
patients	B-T101
with	O
accelerated	B-T169
forms	O
of	O
atherosclerosis	B-T047
,	O
the	O
relationship	B-T080
between	O
the	O
expression	B-T045
of	O
TLR-4	B-T116
on	O
circulating	B-T169
monocyte	B-T025
s	O
and	O
coronary	B-T023
plaque	B-T033
vulnerability	B-T033
has	O
not	O
previously	O
been	O
evaluated	B-T058
.	O
We	O
investigated	O
this	O
relationship	B-T080
using	O
64-slice multidetector computed tomography	B-T060
(	O
MDCT	B-T060
)	O
in	O
patients	B-T101
with	O
stable angina pectoris	B-T047
(	O
SAP	B-T047
).Methods	O
and	O
Results:We	O
enrolled	O
65	O
patients	B-T101
with	O
SAP	B-T047
who	O
underwent	O
MDCT	B-T060
.	O
Three	O
monocyte	B-T025
subsets	B-T185
(	O
CD14(++)CD16(-)	B-T025
,	O
CD14(++)CD16(+)	B-T025
,	O
and	O
CD14(+)CD16(+)	B-T025
)	O
and	O
expression	B-T045
of	O
TLR-4	B-T116
were	O
measured	O
by	O
flow cytometry	B-T059
.	O
Intracoronary	B-T023
plaques	B-T033
were	O
assessed	B-T052
by	O
64-slice MDCT	B-T060
.	O
We	O
defined	O
vulnerability	B-T033
of	O
intracoronary	B-T023
plaques	B-T033
according	O
to	O
the	O
presence	O
of	O
positive remodeling	B-T046
(	O
remodeling index	B-T033
>1.05)	O
and/or	O
low	O
CT	B-T060
attenuation	B-T081
(<35	O
HU).	O
The	O
circulating	B-T169
CD14(++)CD16(+)monocytes	B-T025
more	O
frequently	O
expressed	B-T045
TLR-4	B-T116
than	O
CD14(++)CD16(-)	B-T025
and	O
CD14(+)CD16(+)monocytes	B-T025
(P<0.001).	O
The	O
relative	O
proportion	O
of	O
the	O
expression	B-T045
of	O
TLR-4	B-T116
on	O
CD14(++)CD16(+)monocytes	B-T025
was	O
significantly	O
greater	O
in	O
patients	B-T101
with	O
vulnerable plaque	B-T033
compared	O
with	O
those	O
without	O
(10.4	O
[4.1-14.5]	O
%	O
vs.	O
4.5	O
[2.8-7.8]	O
%,	O
P=0.012).	O
In	O
addition,	O
the	O
relative	O
proportion	O
of	O
TLR-4	B-T116
expression	B-T045
on	O
CD14(++)CD16(+)monocytes	B-T025
positively	O
correlated	B-T080
with	O
the	O
remodeling index	B-T033
(r=0.28,	O
P=0.025)	O
and	O
negatively	O
correlated	B-T080
with	O
CT	B-T060
attenuation value	B-T081
(r=-0.31,	O
P=0.013).	O
Upregulation	B-T044
of	O
TLR-4	B-T116
on	O
CD14(++)CD16(+)monocytes	B-T025
might	O
be	O
associated with	B-T080
coronary	B-T023
plaque	B-T033
vulnerability	B-T033
in	O
patients	B-T101
with	O
SAP	B-T047
.	O

Delta-frequency	B-T033
stimulation	B-T070
of	O
cerebellar	B-T023
projections	B-T082
can	O
compensate	B-T080
for	O
schizophrenia	B-T048
-related	O
medial frontal dysfunction	B-T048
Schizophrenia	B-T048
involves	O
abnormalities	B-T033
in	O
the	O
medial frontal cortex	B-T023
that	O
lead	O
to	O
cognitive deficits	B-T048
.	O
Here	O
we	O
investigate	B-T169
a	O
novel	B-T080
strategy	B-T041
to	O
normalize	B-T062
medial frontal brain	B-T024
activity	B-T039
by	O
stimulating	B-T070
cerebellar	B-T023
projections	B-T082
.	O
We	O
used	O
an	O
interval timing	B-T079
task	O
to	O
study	B-T062
elementary	O
cognitive processing	B-T041
that	O
requires	O
both	O
frontal	B-T023
and	O
cerebellar networks	B-T023
that	O
are	O
disrupted	B-T080
in	O
patients	B-T101
with	O
schizophrenia	B-T048
.	O
We	O
report	O
three	O
novel	B-T080
findings	B-T033
.	O
First,	O
patients	B-T101
with	O
schizophrenia	B-T048
had	O
dysfunctional	O
delta rhythms	B-T042
between	O
1-4	O
Hz	O
in	O
the	O
medial frontal cortex	B-T023
.	O
We	O
explored	O
cerebellar	B-T023
-	O
frontal	B-T023
interactions	B-T169
in	O
animal models	B-T008
and	O
found	O
that	O
both	O
frontal	B-T023
and	O
cerebellar neurons	B-T025
were	O
modulated	B-T082
during	O
interval timing	B-T079
and	O
had	O
delta-frequency	B-T033
interactions	B-T169
.	O
Finally,	O
delta-frequency	B-T033
optogenetic	B-T063
stimulation	B-T070
of	O
thalamic	B-T023
synaptic terminals	B-T026
of	O
lateral	B-T082
cerebellar	B-T023
projection	B-T082
neurons	B-T025
rescued	O
timing	O
performance	O
as	O
well	O
as	O
medial frontal	B-T024
activity	B-T039
in	O
a	O
rodent model	B-T050
of	O
schizophrenia-related	B-T048
frontal dysfunction	B-T048
.	O
These	O
data	B-T078
provide	O
insight	O
into	O
how	O
the	O
cerebellum	B-T023
influences	B-T077
medial frontal networks	B-T029
and	O
the	O
role	O
of	O
the	O
cerebellum	B-T023
in	O
cognitive processing	B-T041
.	O

Variables	B-T080
associated with	B-T080
unplanned	B-T080
general adult	B-T100
ICU admission	B-T058
in	O
hospitalised patients	B-T101
:	O
protocol	B-T170
for	O
a	O
systematic	B-T169
review	B-T078
Failure	B-T169
to	O
promptly	O
identify	B-T080
deterioration	B-T067
in	O
hospitalised patients	B-T101
is	O
associated with	B-T080
delayed	B-T079
admission to intensive care units	B-T058
(	O
ICUs	B-T073
)	O
and	O
poor	B-T080
outcomes	B-T080
.	O
Existing	B-T077
vital sign	B-T201
-based	O
Early Warning Score	B-T081
(EWS)	B-T081
algorithms	B-T170
do	O
not	O
have	O
a	O
sufficiently	B-T080
high	B-T080
positive	B-T077
predictive value	B-T080
to	O
be	O
used	O
for	O
automated	B-T169
activation	B-T052
of	O
an	O
ICU	B-T073
outreach team	B-T097
.	O
Incorporating	B-T169
additional	O
patient data	B-T170
might	O
improve	B-T033
the	O
predictive	B-T080
power	B-T081
of	O
EWS	B-T081
algorithms	B-T170
;	O
however,	O
it	O
is	O
currently	B-T079
not	O
known	O
which	O
patient data	B-T170
(or	O
variables	B-T080
)	O
are	O
most	O
predictive	B-T080
of	O
ICU admission	B-T058
.	O
We	O
describe	O
the	O
protocol	B-T170
for	O
a	O
systematic	B-T169
review	B-T078
of	O
variables	B-T080
associated with	B-T080
ICU admission	B-T058
.	O
MEDLINE	B-T170
,	O
EMBASE	B-T170
,	O
CINAHL	B-T170
and	O
the	O
Cochrane Library	B-T170
,	O
including	B-T169
Cochrane Database of Systematic Reviews	B-T170
and	O
the	O
Cochrane Central Register of Controlled Trials	B-T170
(CENTRAL)	B-T170
will	O
be	O
searched	B-T052
for	O
studies	B-T062
that	O
assess	B-T058
the	O
association	B-T080
of	O
routinely	B-T080
recorded	B-T170
variables	B-T080
associated with	B-T080
subsequent	B-T079
unplanned	B-T080
ICU admission	B-T058
.	O
Only	O
studies	B-T062
involving	B-T169
adult	B-T100
patients	B-T101
admitted to	B-T058
general	B-T082
ICUs	B-T073
will	O
be	O
included	B-T169
.	O
We	O
will	O
extract	B-T080
data	B-T078
relating to	B-T080
the	O
statistical association	B-T062
between	O
ICU admission	B-T058
and	O
predictor	B-T078
variables	B-T080
,	O
the	O
quality	B-T080
of	O
the	O
studies	B-T062
and	O
the	O
generalisability	B-T082
of	O
the	O
findings	B-T033
.	O
The	O
results	B-T169
of	O
this	O
review	B-T078
will	O
aid	B-T080
the	O
development	B-T169
of	O
future	O
models	B-T170
which	O
predict	B-T078
the	O
risk	B-T078
of	O
unplanned	B-T080
ICU admission	B-T058
.	O
PROSPERO:	O
CRD42015029617.	O

Diagnosis	B-T033
of	O
retinal	B-T023
health	B-T078
in	O
digital fundus images	B-T060
using	O
continuous wavelet transform	B-T062
(	O
CWT	B-T062
)	O
and	O
entropies	B-T067
Vision	B-T040
is	O
paramount	O
to	O
humans	B-T016
to	O
lead	O
an	O
active	O
personal	B-T032
and	O
professional life	B-T090
.	O
The	O
prevalence	B-T081
of	O
ocular diseases	B-T047
is	O
rising,	O
and	O
diseases	B-T047
such	O
as	O
glaucoma	B-T047
,	O
Diabetic Retinopathy	B-T047
(	O
DR	B-T047
)	O
and	O
Age-related Macular Degeneration	B-T047
(	O
AMD	B-T047
)	O
are	O
the	O
leading	B-T169
causes	B-T169
of	O
blindness	B-T033
in	O
developed countries	B-T080
.	O
Identifying	O
these	O
diseases	B-T047
in	O
mass screening programmes	B-T058
is	O
time-consuming	B-T080
,	O
labor	B-T057
-intensive	O
and	O
the	O
diagnosis	B-T033
can	O
be	O
subjective	B-T080
.	O
The	O
use	O
of	O
an	O
automated computer aided diagnosis system	B-T060
will	O
reduce	O
the	O
time	O
taken	O
for	O
analysis	B-T062
and	O
will	O
also	O
reduce	O
the	O
inter-observer subjective variabilities	B-T081
in	O
image interpretation	B-T060
.	O
In	O
this	O
work,	O
we	O
propose	O
one	O
such	O
system	O
for	O
the	O
automatic	B-T169
classification	B-T185
of	O
normal	B-T080
from	O
abnormal	B-T033
(	O
DR	B-T047
,	O
AMD	B-T047
,	O
glaucoma	B-T047
)	O
images	B-T070
.	O
We	O
had	O
a	O
total	O
of	O
404	O
normal	B-T080
and	O
1082	O
abnormal	B-T033
fundus images	B-T060
in	O
our	O
database	B-T170
.	O
As	O
the	O
first	O
step,	O
2D-Continuous Wavelet Transform	B-T062
(	O
CWT	B-T062
)	O
decomposition	O
on	O
the	O
fundus images	B-T060
of	O
two	O
classes	O
was	O
performed.	O
Subsequently,	O
energy	B-T081
features	O
and	O
various	O
entropies	B-T067
namely	O
Yager,	O
Renyi,	O
Kapoor,	O
Shannon,	O
and	O
Fuzzy	O
were	O
extracted	O
from	O
the	O
decomposed	O
images	B-T070
.	O
Then,	O
adaptive	O
synthetic	O
sampling approach	B-T170
was	O
applied	O
to	O
balance	O
the	O
normal	B-T080
and	O
abnormal	B-T033
datasets	B-T170
.	O
Next,	O
the	O
extracted	O
features	O
were	O
ranked	O
according	O
to	O
the	O
significances	O
using	O
Particle Swarm Optimization	B-T170
(	O
PSO	B-T170
).	O
Thereupon,	O
the	O
ranked	O
and	O
selected	O
features	O
were	O
used	O
to	O
train	O
the	O
random	O
forest	O
classifier	O
using	O
stratified	B-T080
10-fold	O
cross validation	B-T062
.	O
Overall,	O
the	O
proposed	O
system	O
presented	O
a	O
performance rate	B-T081
of	O
92.48%,	O
and	O
a	O
sensitivity	B-T081
and	O
specificity	B-T081
of	O
89.37%	O
and	O
95.58%	O
respectively	O
using	O
15	O
features.	O
This	O
novel	O
system	O
shows	O
promise	O
in	O
detecting	O
abnormal	B-T033
fundus images	B-T060
,	O
and	O
hence,	O
could	O
be	O
a	O
valuable	O
adjunct	O
eye	B-T023
health	B-T078
screening tool	B-T058
that	O
could	O
be	O
employed	O
in	O
polyclinics	B-T073
,	O
and	O
thereby	O
reduce	O
the	O
workload	B-T081
of	O
specialists	B-T097
at	O
hospitals	B-T073
.	O

The	O
epigenetic landscape	B-T045
of	O
age	B-T032
-	O
related	B-T169
diseases	B-T047
:	O
the	O
geroscience	B-T090
perspective	B-T078
In	O
this	O
review	B-T170
,	O
we	O
summarize	O
current	O
knowledge	O
regarding	O
the	O
epigenetics	B-T045
of	O
age	B-T032
-	O
related	B-T169
diseases	B-T047
,	O
focusing	O
on	O
those	O
studies	B-T062
that	O
have	O
described	O
DNA methylation landscape	B-T044
in	O
cardio-vascular diseases	B-T047
,	O
musculoskeletal function	B-T042
and	O
frailty	B-T033
.	O
We	O
stress	O
the	O
importance	O
of	O
adopting	O
the	O
conceptual framework	B-T077
of	O
"	O
geroscience	B-T090
",	O
which	O
starts	O
from	O
the	O
observation	O
that	O
advanced	B-T098
age	B-T032
is	O
the	O
major	O
risk factor	B-T033
for	O
several	O
of	O
these	O
pathologies	B-T169
and	O
aims	B-T078
at	O
identifying	O
the	O
mechanistic links	B-T080
between	O
aging	B-T040
and	O
age	B-T032
-	O
related	B-T169
diseases	B-T047
.	O
DNA methylation	B-T044
undergoes	O
a	O
profound	O
remodeling	B-UnknownType
during	O
aging	B-T040
,	O
which	O
includes	O
global hypomethylation	B-T045
of	O
the	O
genome	B-T028
,	O
hypermethylation	B-T045
at	O
specific	B-T080
loci	B-T028
and	O
an	O
increase	B-T169
in	O
inter-individual variation	B-T070
and	O
in	O
stochastic	B-T081
changes	B-T169
of	O
DNA methylation	B-T044
values	B-T080
.	O
These	O
epigenetic	B-T045
modifications	B-T033
can	O
be	O
an	O
important	O
contributor	O
to	O
the	O
development	B-T169
of	O
age	B-T032
-	O
related	B-T169
diseases	B-T047
,	O
but	O
our	O
understanding	O
on	O
the	O
complex	B-T080
relationship	B-T080
between	O
the	O
epigenetic signatures	B-T045
of	O
aging	B-T040
and	O
age	B-T032
-	O
related	B-T169
disease	B-T047
is	O
still	O
poor.	O
The	O
most	O
relevant	B-T080
results	B-T033
in	O
this	O
field	O
come	O
from	O
the	O
use	O
of	O
the	O
so	O
called	O
"	O
epigenetics clocks	B-T045
"	O
in	O
cohorts	B-T098
of	O
subjects	B-T098
affected	B-T169
by	O
age	B-T032
-	O
related	B-T169
diseases	B-T047
.	O
We	O
report	O
these	O
studies	B-T062
in	O
final	O
section	O
of	O
this	O
review	B-T170
.	O

Beneficial Effects	B-T080
of	O
Phyllanthus amarus	B-T002
Against	O
High Fructose Diet	B-T168
Induced	O
Insulin Resistance	B-T046
and	O
Hepatic Oxidative Stress	B-T049
in	O
Male	B-T032
Wistar Rats	B-T015
Insulin resistance	B-T046
(	O
IR	B-T046
)	O
is	O
a	O
characteristic	O
feature	O
of	O
obesity	B-T047
,	O
type 2 diabetes mellitus	B-T047
,	O
and	O
cardiovascular diseases	B-T047
.	O
Emerging	O
evidence	O
suggests	O
that	O
the	O
high-fructose	B-T109
consumption	B-T039
is	O
a	O
potential	B-T080
and	O
important	O
factor	B-T169
responsible	O
for	O
the	O
rising incidence	B-T169
of	O
IR	B-T046
.	O
The	O
present	O
study	B-T062
investigates	B-T169
the	O
beneficial effects	B-T080
of	O
aqueous extract	B-T167
of	O
Phyllanthus amaru	B-T002
s	O
(	O
PAAE	B-T167
)	O
on	O
IR	B-T046
and	O
oxidative stress	B-T049
in	O
high-fructose	B-T109
(	O
HF	B-T109
)	O
fed	O
male	B-T032
Wistar rats	B-T015
.	O
HF diet	B-T168
(66%	O
of	O
fructose)	O
and	O
PAAE	B-T167
(200	O
mg/kg	O
body	O
weight/day)	O
were	O
given	O
concurrently	B-T079
to	O
the	O
rats	B-T015
for	O
a	O
period	O
of	O
60	O
days.	O
Fructose-fed	B-T080
rats	B-T015
showed	O
weight gain	B-T033
,	O
hyperglycemia	B-T047
,	O
hyperinsulinemia	B-T047
,	O
impaired glucose tolerance	B-T047
,	O
impaired insulin sensitivity	B-T046
,	O
dyslipidemia	B-T047
,	O
hyperleptinemia	B-T047
,	O
and	O
hypoadiponectinemia	B-T047
(P	O
<	O
0.05)	O
after	O
60	O
days.	O
Co-administration	B-T061
of	O
PAAE	B-T167
along	O
with	O
HF diet	B-T168
significantly	O
ameliorated	O
all	O
these	O
alterations	B-T078
.	O
Regarding	O
hepatic	B-T029
antioxidant status	B-T044
,	O
higher	O
lipid peroxidation	B-T044
and	O
protein oxidation	B-T044
,	O
lower	O
reduced glutathione	B-T034
levels	O
and	O
lower activities	B-T038
of	O
enzymatic antioxidants	B-T121
,	O
and	O
the	O
histopathological changes	B-T169
like	O
mild	O
to	O
severe	O
distortion	B-T080
of	O
the	O
normal	O
architecture	O
as	O
well	O
as	O
the	O
prominence	O
and	O
widening	O
of	O
the	O
liver sinusoids	B-T023
observed	O
in	O
the	O
HF diet	B-T168
-fed	O
rats	B-T015
were	O
significantly	O
prevented	O
by	O
PAAE	B-T167
treatment	B-T061
.	O
These	O
findings	O
indicate	O
that	O
PAAE	B-T167
is	O
beneficial	O
in	O
improving	O
insulin sensitivity	B-T046
and	O
attenuating	O
metabolic syndrome	B-T047
and	O
hepatic oxidative stress	B-T049
in	O
fructose-fed	B-T080
rats	B-T015
.	O

Environmental factors	B-T169
and	O
hypertension	B-T047
Environmental factors	B-T169
are	O
a	O
major	O
cause	O
of	O
poor health	B-T033
worldwide	B-T098
.	O
The	O
most	O
solid	O
evidence	B-T078
is	O
for	O
air pollution	B-T069
,	O
leading	O
to	O
increased	O
disability-adjusted life years	B-UnknownType
.	O
Outdoor	B-UnknownType
temperature	B-T081
and	O
other	O
seasonal	B-T079
climate changes	B-T070
may	O
also	O
influence	O
cardiovascular	B-T029
health	B-T078
,	O
according	O
to	O
their	O
direct	O
modulation	O
of	O
air pollution	B-T069
.	O
Moreover,	O
an	O
increasing	O
body	O
of	O
evidence	B-T078
associates	O
environmental exposure	B-T037
to	O
noise	B-T067
with	O
poor cardiovascular outcome	B-T033
,	O
and	O
in	O
particular	O
with	O
hypertension	B-T047
.	O
This	O
review	O
is	O
aimed	O
at	O
reviewing	O
current	O
evidence	B-T078
about	O
the	O
role	O
of	O
these	O
environmental factors	B-T169
in	O
cardiovascular disease	B-T047
and	O
specifically	O
hypertension	B-T047
.	O
In	O
particular,	O
the	O
impact	B-T080
of	O
air pollution	B-T069
,	O
with	O
its	O
short-term	B-T079
and	O
long-term effects	B-T067
,	O
the	O
outdoor	B-UnknownType
temperature	B-T081
and	O
noise pollution	B-T069
will	O
be	O
investigated.	O
People	B-T098
belonging	O
to	O
low	B-T080
social classes	B-T080
,	O
as	O
well	O
as	O
children	B-T100
,	O
women	B-T098
,	O
older people	B-T098
and	O
those	O
with	O
established	O
cardiovascular diseases	B-T047
,	O
seem	O
to	O
have	O
a	O
greater	O
susceptibility	B-T169
to	O
the	O
effects	B-T080
of	O
environmental stressors	B-T033
,	O
recalling	O
the	O
concept	B-T078
of	O
"	O
environmental justice	B-T078
".	O
The	O
accumulating	O
strong	O
scientific	O
evidence	B-T078
may	O
thus	O
support	O
public health policies	B-T064
aimed	O
at	O
reducing	O
social inequalities	B-T080
in	O
cardiovascular	B-T029
health	B-T078
.	O

The	O
effects of	B-T080
probiotic	B-T007
and	O
synbiotic	B-T168
supplementation	B-T061
on	O
metabolic syndrome	B-T047
indices	B-T078
in	O
adults	B-T100
at	O
risk	B-T078
of	O
type 2 diabetes	B-T047
:	O
study protocol	B-T170
for	O
a	O
randomized controlled trial	B-T062
The	O
incidence	B-T081
of	O
type 2 diabetes	B-T047
,	O
cardiovascular diseases	B-T047
,	O
and	O
obesity	B-T047
has	O
been	O
rising	B-T169
dramatically;	O
however,	O
their	O
pathogenesis	B-T046
is	O
particularly	O
intriguing	B-T041
.	O
Recently,	O
dysbiosis	B-T046
of	O
the	O
intestinal microbiota	B-T001
has	O
emerged	O
as	O
a	O
new	B-T080
candidate	B-T078
that	O
may	O
be	O
linked	O
to	O
metabolic diseases	B-T047
.	O
We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal microbiota	B-T001
by	O
probiotic	B-T007
or	O
synbiotic	B-T168
supplementation	B-T061
may improve	B-T080
metabolic dysfunction	B-T047
and	O
prevent	B-T080
diabetes	B-T047
in	O
prediabetics	B-T047
.	O
In	O
this	O
study	B-T062
,	O
a	O
synthesis	B-T052
and	O
study	B-T062
of	O
synbiotics	B-T168
will	O
be	O
carried	B-T052
out	O
for	O
the	O
first	O
time	O
in	O
Iran	B-T083
.	O
In	O
a	O
randomized triple-blind controlled clinical trial	B-T062
,	O
120	O
adults	B-T100
with	O
impaired glucose tolerance	B-T047
based	O
on	O
the	O
inclusion criteria	B-T080
will	O
be	O
selected	B-T052
by	O
a	O
simple	O
random	B-T080
sampling method	B-T170
and	O
will	O
be	O
randomly	B-T080
allocated	B-T052
to	O
6	O
months	B-T079
of	O
6	O
g/d	O
probiotic	B-T007
,	O
synbiotic	B-T168
or	O
placebo	B-T122
.	O
The	O
fecal	B-T031
abundance	B-T080
of	O
bacteria	B-T007
,	O
blood pressure	B-T040
,	O
height	B-T032
,	O
weight	B-T032
,	O
and	O
waist	B-T201
and	O
hip circumferences	B-T201
will	O
be	O
measured	B-T080
at	O
baseline	B-T081
and	O
following	B-T079
treatment	B-T061
.	O
Also,	O
plasma lipid profiles	B-T059
,	O
HbA1C	B-T116
,	O
fasting plasma glucose	B-T059
,	O
and	O
insulin	B-T116
levels	B-T080
,	O
will	O
be	O
measured	B-T080
and	O
insulin resistance	B-T059
(	O
HOMA-IR	B-T059
)	O
and	O
beta-cell function	B-T059
(	O
HOMA-B	B-T059
)	O
will	O
be	O
calculated	B-T052
at	O
baseline	B-T081
and	O
will	O
be	O
repeated	B-T169
at	O
months	B-T079
3,	O
6,	O
12,	O
and	O
18.	O
The	O
data	B-T078
will	O
be	O
compared	B-T052
within	O
and	O
between	O
groups	B-UnknownType
using	B-T169
statistical methods	B-T062
.	O
The	O
results	B-T169
of	O
this	O
trial	B-T062
could	O
contribute	B-T052
to	O
the	O
evidence-based clinical guidelines	B-T170
that	O
address	O
gut microbiota	B-T001
manipulation	B-T061
to	O
maximize	B-T169
health benefits	B-T081
in	O
prevention	B-T061
and	O
management	B-T058
of	O
metabolic syndrome	B-T047
in	O
prediabetes	B-T047
.	O
Iranian Registry	B-T170
of	O
Clinical Trials	B-T062
:	O
IRCT201511032321N2	B-T170
.	O
Registered	O
on	O
27	O
February	O
2016.	O

Evaluation	B-T052
of	O
the	O
relationship	B-T080
between	O
the	O
static	B-T080
measurement	B-T169
of	O
transverse arch	B-T029
flexibility	B-T080
of	O
the	O
forefoot	B-T023
and	O
gait	B-T033
parameters	B-T077
in	O
healthy subjects	B-T098
[	O
Purpose	B-UnknownType
]	O
To	O
investigate	B-T169
the	O
relationship	B-T080
between	O
the	O
static	B-T080
measurement	B-T169
of	O
the	O
transverse arch	B-T029
of	O
the	O
forefoot	B-T023
,	O
using	O
a	O
3-dimensional	B-T082
(	O
3D	B-T082
)	O
foot scanner	B-T074
,	O
and	O
kinetics	B-T070
and	O
kinematics	B-T091
of	O
gait	B-T033
parameters	B-T077
in	O
the	O
sagittal plane	B-T029
.	O
[	O
Subjects	B-T098
and	O
Methods	B-T170
]	O
Twenty	O
healthy subjects	B-T098
participated	O
in	O
this	O
study	B-T062
.	O
The	O
transverse arch	B-T029
of	O
the	O
forefoot	B-T023
was	O
measured	B-T080
under	O
three	O
conditions	B-T080
as	O
follows:	O
condition	B-T080
1,	O
sitting	B-T033
;	O
condition	B-T080
2,	O
standing	B-T082
;	O
and	O
condition	B-T080
3,	O
foot	B-T023
forward	B-T082
and	O
lower leg	B-T023
tilting	B-T080
anteriorly	B-T082
to	O
the	O
maximum	B-T081
position	B-T082
with	O
heel	B-T029
contact	B-T169
.	O
Gait	B-T033
parameters	B-T077
were	O
recorded	B-T081
using	O
a	O
3D motion analysis system	B-T073
and	O
force plate	B-T074
.	O
Correlation	B-T080
coefficients	B-T081
between	O
TAF	B-T080
for	O
each	O
comparison	B-T052
of	O
conditions	B-T080
and	O
gait	B-T033
parameters	B-T077
were	O
calculated	B-T052
using	O
the	O
Spearman correlation analysis	B-T062
.	O
[	O
Results	B-T169
]	O
Rates	B-T081
of	O
the	O
transverse arch	B-T029
of	O
the	O
forefoot	B-T023
width	B-T081
and	O
height	B-T032
between	O
condition	B-T080
2	O
and	O
condition	B-T080
3	O
were	O
significantly correlated	B-T080
with	O
the	O
anterior	B-T082
and	O
posterior	B-T082
component	B-T077
of	O
ground reaction forces	B-T067
,	O
the	O
hip joint	B-T030
extension	B-T169
angle	B-T082
,	O
and	O
the	O
ankle	B-T029
plantar flexion moment	B-T042
.	O
[	O
Conclusion	B-T078
]	O
Our	O
study's	B-T062
findings	B-T033
indicated	B-T033
that	O
increased	B-T081
stiffness	B-T184
of	O
the	O
transverse arch	B-T029
of	O
the	O
forefoot	B-T023
was	O
related	B-T080
to	O
the	O
increase	B-T169
in	O
ankle	B-T029
plantar moment	B-T042
,	O
and	O
decreased	B-T081
stiffness	B-T184
of	O
the	O
transverse arch	B-T029
of	O
the	O
forefoot	B-T023
was	O
related	B-T080
to	O
the	O
increase	B-T169
in	O
hip joint	B-T030
extension	B-T169
angle	B-T082
during	O
gait	B-T033
.	O

Management	B-T058
and	O
Case Outcome	B-T062
of	O
Gastric Impaction	B-T020
in	O
Four	O
Raptors	B-T012
:	O
A	O
Case Series	B-T062
Four	O
captive	O
raptors	B-T012
,	O
an	O
American kestrel	B-T012
(	O
Falco sparverius	B-T012
),	O
peregrine falcon	B-T012
(	O
Falco peregrinus	B-T012
),	O
golden eagle	B-T012
(	O
Aquila chrysaetos	B-T012
),	O
and	O
barn owl	B-T012
(	O
Tyto alba	B-T012
),	O
were	O
diagnosed	B-T033
with	O
ventricular	B-T023
and/or	O
proventricular	B-T023
foreign material	B-T037
impactions	B-T046
consisting	O
of	O
artificial turf substrate	B-T167
,	O
paper	B-T073
and	O
plastic substrate	B-T073
,	O
grass	B-T002
,	O
and	O
newspaper	B-T073
.	O
Partial or total anorexia	B-T047
was	O
reported	O
in	O
all	O
birds	B-T012
and	O
decreased	B-T081
casting	B-T061
in	O
2	O
birds	B-T012
.	O
Survey	B-T170
radiographs	B-T060
confirmed	O
presence	O
of	O
gastric	B-T023
enlargement	B-T061
in	O
all	O
4	O
birds	B-T012
.	O
The	O
kestrel	B-T012
and	O
eagle	B-T012
were	O
treated	B-T169
unsuccessfully	O
with	O
gastroscopy	B-T060
and	O
gastric lavage	B-T061
,	O
respectively,	O
followed	O
by	O
surgical intervention	B-T033
to	O
remove	O
the	O
ventricular	B-T023
impactions	B-T046
.	O
Both	O
birds	B-T012
died of undetermined causes	B-T033
after surgery	B-T079
.	O
The	O
peregrine falcon	B-T012
died	B-T033
before medical	B-T061
or	O
surgical intervention	B-T033
was	O
started,	O
and	O
the	O
owl	B-T012
was	O
managed	O
successfully	O
with	O
oral mineral oil	B-T200
and	O
liquid diet	B-T061
to	O
facilitate egestion of the foreign material	B-T037
as	O
a	O
pellet	B-T081
.	O
Lead poisoning	B-T037
was	O
suspected	O
as	O
the	O
predisposing cause	B-T079
for	O
foreign body ingestion	B-T037
in	O
the	O
eagle	B-T012
,	O
but	O
underlying causes	B-T169
for	O
pica	B-T048
in	O
the	O
other	O
birds	B-T012
were	O
not determined	B-T080
.	O
Radiographs	B-T060
can	O
provide	O
useful	O
diagnostic information	B-T058
in	O
sick	B-T184
raptors	B-T012
that	O
exhibit vomiting	B-T184
or	O
changes in appetite	B-T033
or	O
casting frequency	B-T061
,	O
and	O
may	O
help	O
guide	O
treatment decisions	B-T061
of	O
impacted	B-T169
birds	B-T012
.	O
Careful	O
consideration	B-T033
of	O
substrate	B-T167
,	O
enrichment items	B-T073
,	O
and	O
access	O
to	O
potential	B-T080
foreign material that could be ingested	B-T037
may	O
be	O
the	O
best	O
pre-emptive	O
management strategy	B-T058
in	O
captive	O
raptors	B-T012
.	O

Anti-inflammatory	B-T033
activity	B-T052
of	O
Elaeagnus angustifolia	B-T002
fruit extract	B-T109
on	O
rat	B-T015
paw	B-T023
edema	B-T184
The	O
Elaeagnus angustifolia	B-T002
fruit	B-T168
has	O
been	O
traditionally	O
used	O
in	O
Iranian	B-T083
herbal medicine	B-T121
to	O
treat	B-T169
diarrhea	B-T184
and	O
rheumatoid arthritis	B-T047
.	O
In	O
the	O
present	O
study,	O
the	O
effects	B-T080
of	O
E. angustifolia	B-T002
fruit extract	B-T109
on	O
the	O
acute	B-T079
and	O
chronic phases	B-T079
of	O
formalin	B-T109
-	O
induced	B-T169
rat	B-T015
paw	B-T023
edema	B-T184
were	O
examined	B-T033
.	O
The	O
acute	B-T079
and	O
chronic	B-T079
anti-inflammatory effects	B-T033
of	O
E. angustifolia	B-T002
fruit extract	B-T109
were	O
investigated	B-T169
through	O
the	O
subcutaneous injection	B-T169
of	O
100	O
μL	O
of	O
formalin	B-T109
(2.5%)	O
into	O
a	O
rat's	B-T015
hind	O
paw	B-T023
.	O
Thirty minutes	B-T079
before	O
the	O
procedure	B-T169
,	O
the	O
experimental	B-T080
groups	B-T078
were	O
treated	B-T169
intraperitoneally	B-T082
with	O
hydroalcoholic fruit extracts	B-T109
of	O
E. angustifolia	B-T002
(	O
concentrations	B-T081
of	O
100,	O
300,	O
700,	O
and	O
1000	O
mg/kg);	O
sodium salicylate	B-T109
(	O
SS	B-T109
,	O
400	O
mg/kg)	O
and	O
distilled water	B-T121
were	O
used	O
as	O
positive	B-T033
and	O
negative	B-T033
control groups	B-T096
,	O
respectively.	O
Treatment	B-T169
with	O
SS	B-T109
and	O
the	O
fruit extracts	B-T109
were	O
performed	B-T169
daily	B-T079
for	O
8	O
days	B-T079
,	O
and	O
the	O
degree	B-T081
of	O
edema	B-T184
was	O
measured	B-T080
by	O
using	O
mercury plethysmometer	B-T074
and	O
digital caliper	B-T074
.	O
In	O
the	O
acute	B-T079
anti-inflammatory	B-T033
study	B-T062
,	O
the	O
extract	B-T167
showed	O
a	O
significant	O
anti-inflammatory effect	B-T080
in	O
a	O
dose-dependent	B-T081
manner.	O
The	O
results	B-T169
of	O
1000	O
mg/kg	O
of	O
the	O
extract	B-T167
was	O
significantly	O
different	B-T080
compared with	B-T052
the	O
negative	B-T033
control group	B-T096
(p<0.05)	O
and	O
was	O
comparable	O
to	O
sodium salicylate	B-T109
(p<0.05).	O
Results	B-T169
from	O
the	O
chronic	B-T079
study	B-T062
suggested	B-T078
that	O
E. angustifolia	B-T002
extract	B-T167
significantly	O
reduced	B-T080
paw	B-T023
edema	B-T184
and	O
inflammation	B-T046
in	O
a	O
dose-dependent	B-T081
manner.	O
The	O
results	B-T169
also	O
showed	O
that	O
the	O
measurement	B-T169
by	O
digital caliper	B-T074
and	O
mercury plethysmometer	B-T074
were	O
both	O
reliable	O
and	O
might	O
be	O
applied	O
interchangeably	O
(p<0.01).	O
Phytochemical tests	B-T059
indicated	O
that	O
the	O
hydroalcoholic fruit extract	B-T109
of	O
E. angustifolia	B-T002
was	O
positive	B-T033
for	O
cardiac glycosides	B-T109
,	O
flavonoids	B-T109
,	O
terpenoids	B-T109
,	O
and	O
saponins	B-T109
.	O
Based	O
on	O
our	O
findings	B-T033
,	O
the	O
E. angustifolia	B-T002
fruit extract	B-T109
probably	O
has	O
acute	B-T079
and	O
chronic	B-T079
anti-inflammatory	B-T033
activities	B-T052
to	O
support	O
its	O
applications	O
in	O
folk medicine	B-T061
.	O

Increased	B-T081
cerebral blood volume	B-T032
pulsatility	B-T080
during	O
head-down tilt	B-T082
with	O
elevated carbon dioxide	B-T033
elevated carbon dioxide	B-T033
:	O
The	O
SPACECOT Study	B-T062
Astronauts	B-T097
aboard	O
the	O
International	O
Space	O
Station	O
(ISS)	O
have	O
exhibited	O
hyperopic shifts	B-T047
,	O
posterior	B-T082
eye globe	B-T023
flattening	B-T169
,	O
dilated	B-T033
optic nerve sheaths	B-T023
,	O
and	O
even	O
optic disc swelling	B-T047
from	O
spaceflight	B-T057
.	O
Elevated intracranial pressure	B-T047
(	O
ICP	B-T047
)	O
consequent	O
to	O
cephalad	B-T082
fluid shifts	B-T039
is	O
commonly	O
hypothesized	B-T078
as	O
contributing	O
to	O
these	O
ocular changes	B-T033
.	O
Head-down tilt	B-T082
(	O
HDT	B-T082
)	O
is	O
frequently	O
utilized	O
as	O
an	O
Earth	B-T083
-based	O
analog	O
to	O
study	O
similar	B-T080
fluid shifts	B-T039
.	O
Sealed environments	B-T082
like	O
the	O
ISS	O
also	O
exhibit	O
elevated	B-T080
carbon dioxide	B-T123
(	O
CO2	B-T123
),	O
a	O
potent	B-T080
arteriolar vasodilator	B-T121
that	O
could	O
further	O
affect	O
cerebral blood volume	B-T032
and	O
flow	B-T033
,	O
intracranial	B-T029
compliance	B-T033
,	O
and	O
ICP	B-T047
.	O
A	O
collaborative pilot study	B-T062
between	O
the	O
National Space Biomedical Research Institute	B-T093
and	O
the	O
German Aerospace Center	B-T092
tested	O
the	O
hypotheses	B-T078
that:	O
(1)	O
HDT	B-T082
and	O
elevated	B-T080
CO2	B-T123
physiologically	B-T169
interact	B-T169
,	O
and	O
(2)	O
cerebrovascular	B-T080
pulsatility	B-T080
is	O
related	O
to	O
HDT	B-T082
and/or	O
elevated	B-T080
CO2	B-T123
In	O
a	O
double-blind	B-T062
crossover study	B-T062
(n=6),	O
we	O
measured	O
cerebral blood volume	B-T032
(	O
CBV	B-T032
)	O
pulsatility	B-T080
via	O
near-infrared spectroscopy	B-T059
,	O
alongside	O
non-invasive	B-T169
ICP	B-T047
and	O
intraocular pressure	B-T042
(	O
IOP	B-T042
)	O
during	O
28-hr	O
-12°	O
HDT	B-T082
at	O
both	O
nominal	B-T081
(0.04%)	O
and	O
elevated	B-T080
(0.5%)	O
ambient	B-T080
CO2	B-T123
In	O
our	O
cohort	B-T098
,	O
CBV	B-T032
pulsatility	B-T080
increased significantly	B-T081
over	O
time	O
at	O
cardiac	B-T082
frequencies	B-T079
(0.031±0.009	O
μM/hr	O
increase	B-T169
in	O
[HbT]	O
pulsatility	B-T080
amplitude	B-T082
)	O
and	O
Mayer wave frequencies	B-T079
(0.019±0.005	O
μM/hr	O
increase	B-T169
).	O
The	O
HDT	B-T082
-	O
CO2	B-T123
interaction	B-T169
on	O
pulsatility	B-T080
was	O
not	O
robust,	O
but	O
rather	O
driven	O
by	O
an	O
individual	B-T098
.	O
Significant	O
differences	B-T080
between	O
atmospheres	B-T070
were	O
not detected	B-T033
in	O
ICP	B-T047
or	O
IOP	B-T042
.	O
Further	O
work	O
is	O
needed	O
to	O
reproduce	O
these	O
findings	O
in	O
a	O
larger	O
cohort	B-T098
,	O
to	O
determine	O
whether	O
a	O
"water hammer" effect	B-T033
in	O
cerebral	B-T023
pulsatility	B-T080
is	O
also	O
present	O
during	O
spaceflight	B-T057
,	O
and	O
whether	O
it	O
is	O
associated with	B-T080
ocular changes	B-T033
in	O
astronauts	B-T097
.	O

Shift Work	B-T090
Is	O
Associated with	B-T080
Metabolic Syndrome	B-T047
in	O
Young	B-T079
Female	B-T032
Korean	B-T098
Workers	B-T090
Shift work	B-T090
is	O
associated with	B-T080
health problems	B-T078
,	O
including	O
metabolic syndrome	B-T047
.	O
This	O
study	B-T062
investigated	O
the	O
association	B-T080
between	O
shift work	B-T090
and	O
metabolic syndrome	B-T047
in	O
young	B-T079
workers	B-T090
.	O
A	O
total	O
of	O
3,317	O
subjects	B-T098
aged	O
20-40	O
years	O
enrolled	O
in	O
the	O
2011-2012	O
Korean	B-T098
National Health and Nutrition Examination Survey	B-T062
were	O
divided	O
into	O
shift	B-T033
and	O
day workers	B-T033
.	O
We	O
conducted	O
a	O
cross-sectional study	B-T062
and	O
calculated	B-T169
odds ratios	B-T081
using	O
multivariate	B-T081
logistic regression analysis	B-UnknownType
in	O
order	O
to	O
examine	B-T033
the	O
association	B-T080
between	O
shift work	B-T090
and	O
metabolic syndrome	B-T047
.	O
The	O
prevalence	B-T081
of	O
metabolic syndrome	B-T047
was	O
14.3%	O
and	O
7.1%	O
among	O
male	B-T032
and	O
female	B-T032
shift workers	B-T033
,	O
respectively.	O
After	O
adjusting	O
for	O
confounding factors	B-T169
,	O
shift work	B-T090
was	O
associated with	B-T080
metabolic syndrome	B-T047
in	O
female	B-T032
workers	B-T090
(	O
odds ratio	B-T081
,	O
2.53;	O
95%	O
confidence interval	B-T081
,	O
1.12	O
to	O
5.70).	O
Shift work	B-T090
was	O
associated with	B-T080
metabolic syndrome	B-T047
in	O
young	B-T079
women	B-T098
.	O
Timely	O
efforts	O
are	O
necessary	O
to	O
manage	B-T058
metabolic syndrome	B-T047
in	O
the	O
workplace	B-T082
.	O

In Vitro	B-T080
Differentiation	B-T043
of	O
Human	B-T016
Pluripotent Stem Cells	B-T025
into	O
Trophoblastic Cells	B-T025
The	O
placenta	B-T018
is	O
the	O
first	O
organ	B-T023
to	O
develop	O
during	O
embryogenesis	B-T042
and	O
is	O
required	O
for	O
the	O
survival	B-T052
of	O
the	O
developing	O
embryo	B-T018
.	O
The	O
placenta	B-T018
is	O
comprised	O
of	O
various	O
trophoblastic cells	B-T025
that	O
differentiate	B-T043
from	O
the	O
extra-embryonic trophectoderm cells	B-T043
of	O
the	O
preimplantation	B-T039
blastocyst	B-T018
.	O
As	O
such,	O
our	O
understanding	O
of	O
the	O
early	O
differentiation events	B-T043
of	O
the	O
human	B-T016
placenta	B-T018
is	O
limited	O
because	O
of	O
ethical	O
and	O
legal	O
restrictions	O
on	O
the	O
isolation	B-T061
and	O
manipulation	B-T061
of	O
human	B-T016
embryogenesis	B-T042
.	O
Human pluripotent stem cells	B-T025
(	O
hPSCs	B-T025
)	O
are	O
a	O
robust	O
model system	B-T170
for	O
investigating	O
human development	B-T039
and	O
can	O
also	O
be	O
differentiated	B-T043
in vitro	B-T080
into	O
trophoblastic cells	B-T025
that	O
express	O
markers	O
of	O
the	O
various	O
trophoblast	B-T025
cell types	B-T025
.	O
Here,	O
we	O
present	O
a	O
detailed	O
protocol	O
for	O
differentiating	B-T043
hPSCs	B-T025
into	O
trophoblastic cells	B-T025
using	O
bone morphogenic protein 4	B-T116
and	O
inhibitors	B-T080
of	O
the	O
Activin	B-T116
/	O
Nodal signaling pathways	B-T044
.	O
This	O
protocol	O
generates	O
various	O
trophoblast	B-T025
cell types	B-T025
that	O
can	O
be	O
transfected	B-T063
with	O
siRNAs	B-T114
for	O
investigating	O
loss-of-function	O
phenotypes	B-T032
or	O
can	O
be	O
infected	B-T033
with	O
pathogens	B-T001
.	O
Additionally,	O
hPSCs	B-T025
can	O
be	O
genetically	O
modified	O
and	O
then	O
differentiated	B-T043
into	O
trophoblast	B-T018
progenitors	B-T025
for	O
gain-of-function	O
analyses.	O
This	O
in vitro	B-T080
differentiation method	B-T043
for	O
generating	O
human	B-T016
trophoblasts	B-T018
starting	O
from	O
hPSCs	B-T025
overcomes	O
the	O
ethical	O
and	O
legal	O
restrictions	B-T169
of	O
working	O
with	O
early	O
human	B-T016
embryos	B-T018
,	O
and	O
this	O
system	O
can	O
be	O
used	O
for	O
a	O
variety	O
of	O
applications,	O
including	O
drug discovery	B-T062
and	O
stem cell research	B-T062
.	O

Metabolomics	B-T123
analysis	B-T062
of	O
anaphylactoid reaction	B-T046
reveals	B-T080
its	O
mechanism	B-T169
in	O
a	O
rat	B-T015
model	B-T008
Anaphylactoid reactions	B-T046
,	O
accounting	O
for	O
more	O
than	O
77%	O
of	O
all	O
immune-mediated immediate hypersensitivity reactions	B-T047
,	O
have	O
become	O
a	O
serious	B-T080
threat	B-T078
to	O
public health	B-T058
,	O
but	O
their	O
effect	B-T080
mechanism	B-T169
is	O
not clear	B-T033
and	O
diagnostic tests	B-T060
are	O
limited	B-T169
.	O
Comprehensive	B-T080
metabolite	B-T123
analysis	B-T062
may	O
reveal	B-T080
the	O
anaphylactoid	B-T080
effect	B-T080
mechanism	B-T169
systematically	B-T169
and	O
provide	B-T052
reference	B-T081
for	O
future	B-T079
diagnostic	B-T169
purposes	B-T169
.	O
Plasma	B-T031
from	O
Brown Norway rats	B-T015
given	O
intravenous injection	B-T169
of	O
saline	B-T167
,	O
compound 48/80	B-T109
(2.5	O
mL/kg)	O
or	O
ovalbumin	B-T116
(20	O
mL/kg)	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	B-T169
to	O
study	B-T062
the	O
effect	B-T080
mechanism	B-T169
of	O
anaphylactoid reactions	B-T046
through	O
metabolomics	B-T123
(	O
UPLC-qTOF-MS/MS	B-T063
).	O
Metabolomics	B-T123
integrated	O
with	O
proteomics data	B-T170
were	O
used	B-T169
to	O
analyze	B-T062
the	O
anaphylactoid	B-T080
pathways	B-T044
by	O
MetaboAnalyst	B-T170
followed by	B-T079
integrated	O
pathway analysis	B-T170
.	O
Thirty	O
metabolites	B-T123
were	O
identified	B-T080
through	O
the	O
METLIN database	B-T170
by	O
MS/MS	B-T063
and	O
18	O
of	O
them	O
were	O
confirmed by	B-T080
authentic standards	B-T081
.	O
The	O
results	B-T169
showed	O
that	O
adenosine	B-T114
,	O
histamine	B-T109
,	O
N-acetylhistamine	B-T109
,	O
N(α)-γ-glutamylhistamine	B-T109
,	O
malate	B-T109
and	O
xanthine	B-T114
are	O
important	B-T080
indices	O
for	O
anaphylactoid reactions	B-T046
.	O
It	O
could	O
be	O
concluded	O
that	O
the	O
effect	B-T080
mechanism	B-T169
is	O
mainly	O
composed	O
of	O
histidine metabolism	B-T044
,	O
arachidonic acid metabolism	B-T044
,	O
energy metabolism	B-T039
,	O
purine metabolism	B-T169
and	O
other	B-T080
small	B-T081
molecules	B-T167
through	B-T169
30	O
metabolites	B-T123
.	O
Multiple linear regression analysis	B-UnknownType
indicated	B-T033
that	O
not	B-T169
only	B-T081
histamine	B-T109
but	O
also	O
N(α)-γ-glutamylhistamine	B-T109
and	O
arachidonic acid	B-T109
could	O
be	O
used	B-T169
to	O
evaluate	O
anaphylactoid	B-T080
symptoms	B-T184
of	O
animals	B-T008
.	O
Furthermore,	O
the	O
citrate cycle	B-T044
,	O
histidine metabolism	B-T044
and	O
arachidonic acid metabolism	B-T044
could	O
be	O
the	O
main	B-T080
pathways	B-T044
of	O
anaphylactoid reactions	B-T046
as	O
determined by	B-T080
MetaboAnalyst	B-T170
.	O
The	O
results	B-T169
may	O
provide	B-T052
a	O
reference	B-T170
to	O
improve	B-T033
diagnostic accuracy	B-T080
and	O
predict	B-T078
and	O
monitor	O
treatment efficacy	B-T080
in	O
anaphylactoid reactions	B-T046
in	O
the	O
clinical setting	B-T082
.	O

The	O
Prevalence	B-T081
of	O
Sleep Apnea	B-T047
in	O
Type B Aortic Dissection	B-T190
:	O
Implications	O
for	O
False	B-T080
Lumen	B-T030
Thrombosis	B-T046
Obstructive sleep apnea	B-T047
(	O
OSA	B-T047
)	O
has	O
been	O
implicated	O
in	O
aortic dissection	B-T047
.	O
Thrombosis	B-T046
of	O
the	O
false	B-T080
lumen	B-T030
is	O
associated with	B-T080
a	O
prognosis	B-T058
of	O
type B aortic dissection	B-T190
(	O
AoD	B-T190
),	O
and	O
partial thrombosis	B-T020
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	B-T170
of	O
mortality	B-T081
.	O
This	O
study	B-T062
sought	O
to	O
explore	O
whether	O
the	O
severity	B-T080
of	O
OSA	B-T047
is	O
associated with	B-T080
false	B-T080
lumen	B-T030
thrombosis	B-T046
.	O
In	O
this	O
observational study	B-T062
,	O
151	O
type B AoD	B-T190
patients	B-T101
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015.	O
The	O
status	O
of	O
the	O
false	B-T080
lumen	B-T030
was	O
classified	O
as	O
patent,	O
partially	B-T081
thrombosed	B-T046
,	O
or	O
completely	O
thrombosed	B-T046
based	O
on	O
a	O
computer tomography angiography	B-T060
image	B-T078
.	O
Patients	B-T101
were	O
divided	O
into	O
non-OSA group	B-UnknownType
(	O
apnea-hypopnea index	B-T170
[	O
AHI	B-T170
]	O
<	O
5),	O
and	O
mild	B-UnknownType
(5	O
≤	O
AHI	B-T170
≤	O
15),	O
moderate	B-UnknownType
(15	O
<	O
AHI	B-T170
≤	O
30),	O
and	O
severe OSA groups	B-UnknownType
(	O
AHI	B-T170
>	O
30)	O
using	O
the	O
AHI	B-T170
.	O
The	O
prevalence	B-T081
of	O
OSA	B-T047
in	O
type B dissection	B-T190
was	O
66.2%.	O
Among	O
151	O
cases	B-T077
,	O
51	O
patients	B-T101
(33.8%)	O
were	O
in	O
the	O
non-OSA group	B-UnknownType
,	O
56	O
(37.1%)	O
were	O
in	O
the	O
mild group	B-UnknownType
,	O
21	O
(13.9%)	O
were	O
in	O
the	O
moderate group	B-UnknownType
,	O
and	O
23	O
(15.2%)	O
were	O
in	O
the	O
severe group	B-UnknownType
.	O
Additionally,	O
a	O
partially	B-T081
thrombosed	B-T046
false	B-T080
lumen	B-T030
was	O
observed	O
in	O
88	O
patients	B-T101
(58.3%).	O
Multivariable analysis	B-T081
revealed	O
that	O
OSA	B-T047
severity	B-T080
was	O
positively	B-T033
associated with	B-T080
partial	B-T081
thrombosis	B-T046
(	O
odds ratio	B-T081
,	O
1.784,	O
95%	O
confidence interval	B-T081
:	O
1.182-2.691,	O
P	O
=	O
.006)	O
after	O
adjusting	O
for	O
other	O
confounding factors	B-T169
.	O
OSA	B-T047
was	O
present	O
in	O
two-thirds	O
of	O
patients	B-T101
with	O
type B AoD	B-T190
.	O
The	O
severity	B-T080
of	O
OSA	B-T047
was	O
significantly	O
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
of	O
partial	B-T081
false	B-T080
lumen	B-T030
thrombosis	B-T046
.	O
OSA	B-T047
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	B-T169
and	O
prognosis	B-T058
of	O
AoD	B-T190
.	O

Contextual Factors	B-T041
for	O
Stunting	B-T046
Among	O
Children	B-T100
of	O
Age	B-T032
6	O
to	O
24	O
Months	B-T079
in	O
an	O
Under-Privileged Community	B-T096
of	O
Dhaka	B-T083
,	O
Bangladesh	B-T083
To	O
determine	O
factors	B-T169
associated with	B-T080
stunting	B-T046
among	O
children	B-T100
aged	B-T032
6	O
to	O
24	O
months	B-T079
in	O
a	O
slum	B-T080
of	O
Dhaka	B-T083
,	O
Bangladesh	B-T083
.	O
We	O
conducted	O
this	O
case control study	B-T062
during	O
November	O
2009	O
to	O
December	O
2012.	O
Children	B-T100
were	O
classified	O
as	O
case	O
if	O
length-for-age Z-score	B-T081
(	O
LAZ	B-T081
)	O
was	O
<-2	O
and	O
as	O
control	B-T096
if	O
LAZ	B-T081
was	O
>-1	O
SD.	O
The	O
logistic regression model	B-UnknownType
was	O
used	O
to	O
find	O
the	O
factors	B-T169
associated with	B-T080
stunting	B-T046
.	O
The	O
significant	O
risk factors	B-T033
for	O
stunting	B-T046
were:	O
child's	B-T100
age	B-T032
>12	O
months	B-T079
,	O
maternal	B-T099
undernutrition	B-T047
,	O
mother's education	B-T033
<5	O
years	B-T079
,	O
consumption	B-T040
of	O
untreated drinking water	B-T167
and	O
monthly	B-T079
family	B-T099
income	B-T081
<100	O
USD	B-T081
.	O
The	O
findings	B-T033
of	O
this	O
study	B-T062
reiterated	O
the	O
role	O
of	O
maternal	B-T099
undernutrition	B-T047
and	O
less education	B-T033
,	O
consumption	B-T040
of	O
untreated drinking water	B-T167
and	O
poor	O
family	B-T099
income	B-T081
as	O
important	O
associated	B-T080
factors	B-T169
of	O
childhood	B-T079
stunting	B-T046
in	O
resource-poor	O
setting.	O

Most	O
Americans	B-T098
Have	O
Good Health	B-T080
,	O
Little	O
Unmet Need	B-T033
,	O
And	O
Few	O
Health Care Expenses	B-T081
The	O
distribution	O
of	O
health care expenditures	B-T081
remains	O
highly	O
concentrated	B-T081
,	O
but	O
most	O
Americans	B-T098
use	O
few	O
health care resources	B-T078
and	O
have	O
low	O
out-of-pocket spending	B-T054
.	O
More	O
than	O
93	O
percent	O
of	O
"	O
low spenders	B-T098
"	O
(those	O
in	O
the	O
bottom	O
half	O
of	O
the	O
population	B-T098
)	O
believe	O
they	O
have	O
received	B-T080
all	O
needed	O
care	B-T058
in	O
a	O
timely	B-T080
manner.	O
The	O
low	O
spending	B-T054
by	O
the	O
majority	O
of	O
the	O
population	B-T098
has	O
remained	O
almost	O
unchanged	O
during	O
the	O
thirty-seven-	O
year	B-T079
period	B-T079
examined	B-T033
.	O

Penile Erosion	B-T020
in	O
a	O
Paraplegic	B-T047
Man	B-T098
With	O
Indwelling Urinary Catheter	B-T074
and	O
Scrotal Edema	B-T033
The	O
chronic	B-T079
use of	B-T169
urinary indwelling catheters	B-T074
is	O
a	O
common	O
practice	O
in	O
the	O
setting	O
of	O
long-term	B-T079
patient care	B-T058
and	O
is	O
associated	O
with	O
numerous	O
complications	B-T046
.	O
More	O
awareness	B-T041
about	O
urogenital	B-T022
trauma	B-T037
from	O
urinary catheterization	B-T061
is	O
needed,	O
as	O
it	O
is	O
as	O
common	O
as	O
symptomatic	B-T169
urinary tract infections	B-T047
.	O
There	O
are	O
a	O
number	O
of	O
preventable measures	B-T080
that	O
can	O
be	O
taken	O
to	O
decrease	B-T081
the	O
risk	B-T078
of	O
mechanical trauma	B-T037
to	O
the	O
urethra	B-T023
and	O
glans penis	B-T023
caused	O
by	O
chronic	B-T079
catheterization	B-T061
.	O
We	O
present	O
a	O
case	O
of	O
a	O
27-	O
year	B-T079
old	B-T079
paraplegic	B-T047
male	B-T032
needing	O
a	O
chronic	B-T079
indwelling catheter	B-T074
that	O
acquired	B-T080
ventral	B-T082
penile erosion	B-T020
while	O
being	O
cared	B-T052
for	O
in	O
the	O
ICU setting	B-T073
.	O

Modified	B-T169
anastomotic technique	B-T061
for	O
thoracolaparoscopic Ivor-Lewis esophagectomy	B-T061
:	O
early	B-T079
outcomes	B-T080
and	O
technical details	B-T080
Thoracoscopic intrathoracic esophagogastrostomy	B-T061
is	O
a	O
technically	O
demanding	O
operation;	O
these	O
technical requirements	B-UnknownType
restrict	O
the	O
extensive	O
application of	B-T169
minimally	B-T080
invasive	B-T080
Ivor-Lewis esophagectomy	B-T061
.	O
In	O
an	O
attempt	O
to	O
reduce	B-T081
the	O
difficulty	O
of	O
this	O
surgical procedure	B-T061
,	O
this	O
study	O
developed	O
a	O
modified	B-T169
anastomotic technique	B-T061
for	O
thoracolaparoscopic Ivor-Lewis esophagectomy	B-T061
.	O
During	O
the	O
entirety	O
of	O
this	O
modified	B-T169
approach	B-T169
,	O
neither	O
technically	O
challenging	O
operations	B-T061
such	O
as	O
intrathoracic suturing	B-T061
or	O
knotting	B-T061
,	O
nor	O
special	O
instruments	B-T074
such	O
as	O
an	O
OrVil system	B-T074
or	O
a	O
reverse-puncture head	B-T074
are	O
required.	O
Between	O
October	O
2015	O
and	O
January	O
2016,	O
15	O
consecutive	B-T080
patients	B-T101
with	O
cancer	B-T191
in	O
the	O
distal third of the esophagus	B-T029
or	O
the	O
gastric cardia	B-T029
underwent	O
this	O
modified	B-T169
surgical procedure	B-T061
.	O
The	O
good	O
short-term	B-T079
outcomes	B-T080
that	O
were	O
achieved	O
suggest	O
that	O
the	O
modified	B-T169
anastomotic technique	B-T061
is	O
safe	O
and	O
feasible	O
for	O
thoracolaparoscopic Ivor-Lewis esophagectomy	B-T061
.	O

Quantitative analysis	B-UnknownType
of	O
cell proliferation	B-T043
by	O
a	O
dye dilution assay	B-T060
:	O
Application	B-T169
to	O
cell lines	B-T025
and	O
cocultures	B-T059
Cell proliferation	B-T043
represents	O
one	O
of	O
the	O
most	O
fundamental	O
processes in biological systems	B-T038
,	O
thus	O
the	O
quantitative analysis	B-UnknownType
of	O
cell proliferation	B-T043
is	O
important	O
in	O
many	O
biological	B-T091
applications	B-T169
such	O
as	O
drug screening	B-T059
,	O
production	O
of	O
biologics	B-T121
,	O
and	O
assessment	B-T058
of	O
cytotoxicity	B-T049
.	O
Conventional	B-T080
proliferation assays	B-T062
mainly	O
quantify	O
cell number	B-T059
based	O
on	O
a	O
calibration curve	B-T081
of	O
a	O
homogeneous	B-T080
cell population	B-T025
,	O
and	O
therefore	O
are	O
not	O
applicable	O
for	O
the	O
analysis	B-T062
of	O
cocultured cells	B-T025
.	O
Moreover,	O
these	O
assays	B-T059
measure	B-T169
cell proliferation	B-T043
indirectly,	O
based	O
on	O
cellular metabolic activity	B-T043
or	O
DNA content	B-T081
.	O
To	O
overcome	B-T052
these	O
shortcomings,	O
a	O
dye dilution assay	B-T060
employing	O
fluorescent cell tracking dyes	B-T130
that	O
are	O
retained	B-T169
within	O
cells	B-T025
was	O
applied	O
and	O
was	O
diluted	B-T169
proportionally	B-T080
by	O
subsequent	O
cell divisions	B-T043
.	O
Here,	O
it	O
was	O
demonstrated	O
that	O
this	O
assay	B-T059
could	O
be	O
implemented	O
to	O
quantitatively analyze	B-UnknownType
the	O
cell proliferation	B-T043
of	O
different	O
types	O
of	O
cell lines	B-T025
,	O
and	O
to	O
concurrently	B-T079
analyze	B-T062
the	O
proliferation	B-T169
of	O
two	O
types	O
of	O
cell lines	B-T025
in	O
coculture	B-T059
by	O
utilizing	O
cell tracking	B-T062
dyes	B-T130
with	O
different	O
spectral	B-T081
characteristics	B-T080
.	O
The	O
mean division time	B-T081
estimated	B-T081
by	O
the	O
dye dilution assay	B-T060
is	O
compared	O
with	O
the	O
population doubling time	B-T079
obtained	O
from	O
conventional	B-T080
methods	B-T170
and	O
values	B-UnknownType
from	O
literature	B-T170
.	O
Additionally,	O
dye	B-T130
transfer	O
between	O
cocultured cells	B-T025
was	O
investigated	B-T169
and	O
it	O
was	O
found	O
that	O
it	O
is	O
a	O
characteristic	B-T080
of	O
the	O
cells	B-T025
rather	O
than	O
a	O
characteristic	B-T080
of	O
the	O
dye	B-T130
.	O
It	O
was	O
suggested	O
that	O
this	O
method	O
can	O
be	O
easily	O
combined	O
with	O
other	O
flow cytometric analyses	B-T059
of	O
cellular	B-T025
properties	B-T080
,	O
providing	O
valuable	B-T080
information	B-T078
on	O
cell status	B-T080
under	O
diverse	B-T080
conditions	B-T080
.	O
©	O
2017	O
International	O
Society	O
for	O
Advancement	O
of	O
Cytometry.	O

Engineering	B-T063
and	O
In Vivo	B-T082
Applications	B-T169
of	O
Riboswitches	B-T114
Riboswitches	B-T114
are	O
common	B-T081
gene regulatory units	B-T028
mostly	O
found	O
in	O
bacteria	B-T007
that	O
are	O
capable	B-T080
of	O
altering	B-T078
gene expression	B-T045
in	O
response	B-T032
to	O
a	O
small molecule	B-T109
.	O
These	O
structured RNA elements	B-T114
consist	O
of	O
two	O
modular	B-T077
subunits	B-T081
:	O
an	O
aptamer domain	B-T114
that	O
binds	B-T044
with	O
high	B-T080
specificity	B-T081
and	O
affinity	B-T070
to	O
a	O
target	B-T169
ligand	B-T103
and	O
an	O
expression	B-T045
platform	O
that	O
transduces	B-T043
ligand binding	B-T044
to	O
a	O
gene expression	B-T045
output.	O
Significant	B-T078
progress	B-T169
has	O
been	O
made	O
in	O
engineering	B-T063
novel	B-T080
aptamer domains	B-T114
for	O
new	B-T080
small molecule	B-T109
inducers	B-T167
of	O
gene expression	B-T045
.	O
Modified	B-T169
expression	B-T045
platforms	O
have	O
also	O
been	O
optimized	B-T052
to	O
function	B-T169
when	O
fused	B-T169
with	O
both	O
natural	B-T169
and	O
synthetic	B-T080
aptamer domains	B-T114
.	O
As	O
this	O
field	B-T077
expands,	O
the	O
use	O
of	O
these	O
privileged	B-T078
scaffolds	B-T073
has	O
permitted	O
the	O
development	B-T169
of	O
tools	B-T073
such	O
as	O
RNA	B-T114
-based	O
fluorescent	B-T070
biosensors	B-T075
.	O
In	O
this	O
review	B-T170
,	O
we	O
summarize	B-T170
the	O
methods	B-T170
that	O
have	O
been	O
developed	O
to	O
engineer	B-T057
new	O
riboswitches	B-T114
and	O
highlight	O
applications	B-T169
of	O
natural	B-T169
and	O
synthetic	B-T080
riboswitches	B-T114
in	O
enzyme	B-T059
and	O
strain engineering	B-T091
,	O
in	O
controlling	O
gene expression	B-T045
and	O
cellular physiology	B-T043
,	O
and	O
in	O
real-time imaging	B-T060
of	O
cellular metabolites	B-T123
and	O
signals	B-T044
.	O
Expected	O
final	O
online	O
publication	O
date	O
for	O
the	O
Annual	O
Review	O
of	O
Biochemistry	O
Volume	O
86	O
is	O
June	O
20,	O
2017.	O
Please	O
see	O
http://www.annualreviews.org/page/journal/pubdates	O
for	O
revised	O
estimates.	O

A	O
novel	B-T080
assay	B-T059
to	O
measure	B-T081
tertiary	B-T197
and	O
quaternary amines	B-T109
in	O
wastewater	B-T069
:	O
An	O
indicator	B-T169
for	O
NDMA	B-T109
wastewater	B-T069
precursors	B-T078
This	O
study	B-T059
examined	B-T033
the	O
potential	B-T080
of	O
using	O
a	O
novel	B-T080
bulk amine assay	B-T059
as	O
an	O
approximation	B-T080
for	O
the	O
tertiary	B-T197
and	O
quaternary amine	B-T109
load	O
in	O
wastewaters	B-T069
and	O
surface	B-T082
water samples	B-T197
,	O
and	O
this	O
approximation	B-T080
was	O
compared	B-T052
to	O
N-nitrosodimethylamine	B-T109
(	O
NDMA	B-T109
)	O
formation	B-T169
potential	B-T080
using	O
chloramines	B-T109
.	O
An	O
existing	O
colorimetric method	B-T059
was	O
examined	B-T033
and	O
optimized	O
for	O
the	O
detection	B-T033
of	O
amines	B-T109
in	O
environmental	B-T082
water samples	B-T197
.	O
The	O
method	B-T059
consists	O
of	O
liquid-liquid extraction	B-T059
followed	O
by	O
a	O
catalyzed	B-T169
reaction	B-T067
to	O
form	O
a	O
yet-	O
undefined	B-T078
product	B-T071
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	B-T080
chromophore	B-T120
and	O
fluorophore	B-T121
.	O
Previous	O
work	O
verified	O
that	O
this	O
reaction	B-T067
was	O
effectively	O
catalyzed	B-T169
by	O
a	O
number	B-T081
of	O
compounds	B-T080
containing	O
tertiary	B-T197
and	O
quaternary amine	B-T109
moieties	B-T077
.	O
Many	O
tertiary	B-T197
and	O
quaternary compounds	B-T109
are	O
also	O
efficient	B-T080
producers	B-T169
of	O
NDMA	B-T109
under	O
chloramination	B-T070
conditions	B-T080
,	O
and	O
a	O
linear correlation	B-T080
was	O
consequently	B-T033
derived	O
from	O
the	O
bulk amine signals	B-T067
vs.	O
NDMA	B-T109
formation	B-T169
potential	B-T080
in	O
various	O
wastewater	B-T069
samples	B-T167
(R(2)	O
=	O
0.74;	O
n	O
=	O
24;	O
p-value	O
<	O
0.05).	O
The	O
results	O
provide	O
evidence	B-T078
that	O
approximately	B-T080
2%	O
of	O
the	O
tertiary	B-T197
and	O
quaternary	O
amines	O
measured	B-T080
can	O
form	O
NDMA	B-T109
and	O
an	O
estimated	B-T081
0.01-1.3%	O
of	O
nitrogen	B-T123
in	O
dissolved organic nitrogen originates	B-T109
from	O
these	O
bulk amines	B-T109
.	O
The	O
normalization	B-T062
of	O
NDMA	B-T109
concentration	B-T081
by	O
the	O
amine	B-T109
measurement	B-T169
revealed	O
that	O
ozone	B-T103
effectively	B-T080
destroyed	B-T052
those	O
tertiary	B-T197
and	O
quaternary amine	B-T109
structures	B-T082
more	O
likely	O
to	O
form	O
NDMA	B-T109
in	O
treated	B-T169
wastewater	B-T069
samples	B-T167
.	O
This	O
bulk amine assay	B-T059
illustrates	O
that	O
proxy	O
measurements	B-T169
of	O
tertiary	B-T197
and	O
quaternary amines	B-T109
can	O
be	O
linked	O
to	O
the	O
NDMA	B-T109
formation	B-T169
potential	B-T080
of	O
a	O
given	O
sample	B-T167
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	B-T080
as	O
a	O
characterizing	B-T052
tool	B-T169
for	O
NDMA	B-T109
precursors	B-T078
in	O
wastewater	B-T069
.	O

Chlamydia pneumoniae	B-T007
infection	B-T046
promotes	B-T052
vascular endothelial cell	B-T025
angiogenesis	B-T042
through	O
an	O
IQGAP1	B-T116
-related	O
signaling pathway	B-T044
Chlamydia pneumoniae	B-T007
(	O
C. pneumoniae	B-T007
)	O
infection	B-T046
plays	O
a	O
potential role	B-T077
in	O
angiogenesis	B-T042
.	O
However,	O
it	O
is	O
still	O
an	O
enigma	O
how	O
C. pneumoniae	B-T007
is	O
involved	B-T169
in	O
this	O
process	B-T067
.	O
Therefore,	O
we	O
investigated	B-T169
the	O
effect	B-T080
of	O
C. pneumoniae	B-T007
infection	B-T046
on	O
angiogenesis	B-T042
,	O
and	O
then	O
explored	O
the	O
roles	B-T077
of	O
IQGAP1	B-T116
-related	O
signaling	B-T044
in	O
C. pneumoniae	B-T007
infection	B-T046
-	O
induced	B-T169
angiogenesis	B-T042
.	O
C. pneumoniae	B-T007
infection	B-T046
significantly enhanced	B-T052
angiogenesis	B-T042
as	O
assessed	B-T052
by	O
the	O
tube formation assay	B-T059
possibly	B-T033
by	O
inducing	B-T169
vascular endothelial cell	B-T025
(	O
VEC	B-T025
)	O
migration	B-T052
in	O
the	O
wound healing	B-T040
and	O
Transwell migration assays	B-T059
.	O
Subsequently	B-T079
,	O
immunoprecipitation	B-T059
,	O
Western blot	B-T059
and	O
tube formation assay	B-T059
results	B-T034
showed	O
that	O
the	O
phosphorylation	B-T044
of	O
both	O
IQGAP1	B-T116
and	O
N-WASP	B-T116
was	O
required	B-T169
for	O
the	O
angiogenesis	B-T042
induced	B-T169
by	O
C. pneumoniae	B-T007
infection	B-T046
.	O
Our	O
co-immunoprecipitation	B-T059
study	B-T059
revealed	B-T080
that	O
IQGAP1	B-T116
physically	O
associated with	B-T080
N-WASP	B-T116
after	O
C. pneumoniae	B-T007
infection	B-T046
of	O
VECs	B-T025
.	O
Actin polymerization	B-T043
assay	B-T059
further	O
showed	O
that	O
in	O
C. pneumoniae	B-T007
-	O
infected	B-T033
VECs	B-T025
,	O
both	O
IQGAP1	B-T116
and	O
N-WASP	B-T116
were	O
recruited	O
to	O
filamentous actin	B-T116
,	O
and	O
shared	O
some	O
common	B-T081
compartments	O
localized	B-T082
at	O
the	O
leading edge	B-T026
of	O
lamellipodia	B-T026
,	O
which	O
was	O
impaired	B-T169
after	O
the	O
depletion	B-T169
of	O
IQGAP1	B-T116
by	O
using	O
the	O
small interference RNA	B-T114
.	O
Moreover,	O
the	O
knockdown	B-T063
of	O
IQGAP1	B-T028
also	O
significantly decreased	B-T081
N-WASP	B-T116
phosphorylation	B-T044
at	O
Tyr256	B-T116
induced	B-T169
by	O
C. pneumoniae	B-T007
infection	B-T046
.	O
We	O
conclude	B-T078
that	O
C. pneumoniae	B-T007
infection	B-T046
promotes	B-T052
VEC	B-T025
migration	B-T052
and	O
angiogenesis	B-T042
presumably	O
through	O
the	O
IQGAP1	B-T116
-related	O
signaling pathway	B-T044
.	O

Four-Dimensional	B-T082
Graded	B-T185
Consciousness	B-T041
Both	O
the	O
multidimensional	B-T082
phenomenon	B-T067
and	O
the	O
polysemous notion	B-T080
of	O
consciousness	B-T041
continue	O
to	O
prove	O
resistant	B-T169
to	O
consistent	B-T078
measurement	B-T169
and	O
unambiguous definition	B-T170
.	O
This	O
is	O
hardly	O
surprising,	O
given	O
that	O
there	O
is	O
no agreement	B-T033
even	O
as	O
regards	O
the	O
most	O
fundamental	O
issues	B-T033
they	O
involve.	O
One	O
of	O
the	O
basic	O
disagreements	B-T054
present	O
in	O
the	O
continuing	O
debate	B-T052
about	O
consciousness	B-T041
pertains	O
to	O
its	O
gradational	B-T185
nature	B-T078
.	O
The	O
general	O
aim	O
of	O
this	O
article	B-T170
is	O
to	O
show	O
how	O
consciousness	B-T041
might	O
be	O
graded	B-T185
and	O
multidimensional	B-T082
at	O
the	O
same	O
time	B-T079
.	O
We	O
therefore	O
focus	O
on	O
the	O
question	B-T170
of	O
what	O
it	O
is,	O
exactly,	O
that	O
is	O
or	O
could	O
be	O
graded	B-T185
in	O
cases	B-T169
of	O
consciousness	B-T041
,	O
and	O
how	O
we	O
can	O
measure	B-T081
it.	O
Ultimately,	O
four	O
different	O
gradable	B-T185
aspects	B-T080
of	O
consciousness	B-T041
will	O
be	O
described:	O
quality	B-T080
,	O
abstractness	B-T170
,	O
complexity	B-T041
and	O
usefulness	B-T080
,	O
which	O
belong	O
to	O
four	O
different	O
dimensions	B-T081
,	O
these	O
being	O
understood,	O
respectively,	O
as	O
phenomenal	B-T080
,	O
semantic	B-T078
,	O
physiological	B-T169
,	O
and	O
functional	B-T169
.	O
Consequently,	O
consciousness	B-T041
may	O
be	O
said	O
to	O
vary	O
with	O
respect	O
to	O
phenomenal	B-T080
quality	B-T080
,	O
semantic	B-T078
abstraction	B-T170
,	O
physiological	B-T169
complexity	B-T041
,	O
and	O
functional	B-T169
usefulness	B-T080
.	O
It	O
is	O
hoped	O
that	O
such	O
a	O
four-dimensional	B-T082
approach	O
will	O
help	O
to	O
clarify	O
and	O
justify	O
claims	O
about	O
the	O
hierarchical nature	B-T078
of	O
consciousness	B-T041
.	O
The	O
approach	B-T082
also	O
proves	O
explanatorily	O
advantageous	B-T080
,	O
as	O
it	O
enables	O
us	O
not	O
only	O
to	O
draw	O
attention	B-T041
to	O
certain	O
new	O
and	O
important	B-T080
differences	B-T080
in	O
respect	O
of	O
subjective	B-T080
measures	B-T081
of	O
awareness	B-T041
and	O
to	O
justify	O
how	O
a	O
given	O
creature	B-T008
may	O
be	O
ranked	B-T170
higher	B-T080
in	O
one	O
dimension	O
of	O
consciousness	B-T041
and	O
lower	O
in	O
terms	O
of	O
another,	O
but	O
also	O
allows	O
for	O
innovative explanations	B-T170
of	O
a	O
variety	O
of	O
well-known	O
phenomena	B-T067
(amongst	O
these,	O
the	O
interpretations	B-T170
of	O
blindsight	B-T080
and	O
locked-in syndrome	B-T047
will	O
be	O
briefly	O
outlined	O
here).	O
Moreover,	O
a	O
4D	B-T082
framework	O
makes	O
possible	O
many	O
predictions	B-T078
and	O
hypotheses	B-T078
that	O
may	O
be	O
experimentally	B-T062
tested	B-T169
(We	O
point	O
out	O
a	O
few	O
such	O
possibilities	O
pertaining	O
to	O
interdimensional dependencies	B-T169
).	O

Synthesis	B-T052
of	O
Some	O
Unique	O
Carbamate	B-T109
Derivatives	B-T104
bearing	O
2-Furoyl-1-piperazine	B-T123
as	O
a	O
Valuable	O
Therapeutic Agents	B-T121
The	O
aim	B-T078
of	O
the	O
research work	B-T062
was	O
to	O
synthesize	O
different	O
biologically active	B-T123
carbamate	B-T109
derivatives	B-T104
bearing	O
2-furoyl-1-piperazine	B-T123
and	O
having	O
modest	O
toxicity	B-T037
.	O
The	O
synthesis	B-T052
was	O
completed	O
as	O
a	O
multiple sequence	B-T169
.	O
The	O
structural	B-T082
confirmation	B-T033
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
EI-MS	B-T059
,	O
IR	B-T059
and	O
1H-NMR	B-T060
spectral	O
data.	O
The	O
enzyme inhibition	B-T039
and	O
antibacterial potential	B-T033
of	O
the	O
synthesized compounds	B-T123
was	O
evaluated	B-T058
.	O
To	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	B-T123
as	O
possible	O
therapeutic agents	B-T121
their	O
cytotoxicity	B-T049
was	O
also	O
checked.	O
All	O
the	O
compounds	B-T123
were	O
active	B-T169
against	O
acetylcholinesterase enzyme	B-T116
,	O
especially	O
12	B-T123
and	O
14	B-T123
showed	O
very	O
good	B-T080
inhibitory potential	B-T042
relative	O
to	O
Eserine	B-T109
,	O
a	O
reference standard	B-T081
.	O
Almost	O
all	O
the	O
compounds	B-T123
showed	O
good	O
activities	O
against	O
both	O
Gram-positive	B-T007
and	O
Gram-negative bacterial strains	B-T007
.	O

Epidemiology	B-T091
and	O
outcomes	B-T057
of	O
injuries	B-T037
in	O
Kenya	B-T083
:	O
A	O
multisite surveillance study	B-T057
Injury	B-T037
is	O
a	O
leading	O
cause	O
of	O
disability	B-T033
and	O
death	B-T033
worldwide,	O
accounting	O
for	O
over	O
5	O
million	O
deaths	B-T033
each	O
year	B-T079
.	O
The	O
injury	B-T037
burden	B-T078
is	O
higher	O
in	O
low- and middle-income countries	B-T083
where	O
more	O
than	O
90%	O
of	O
injury	B-T037
injury -related deaths	B-T033
occur.	O
Despite	O
this	O
burden	B-T078
,	O
the	O
use	O
of	O
prospective	O
trauma	B-T037
registries	B-T170
to	O
describe	O
injury	B-T037
epidemiology	B-T091
and	O
outcomes	B-T057
is	O
limited	O
in	O
low- and middle-income countries	B-T083
.	O
Kenya	B-T083
lacks	O
robust	O
data	B-T078
to	O
describe	O
injury	B-T037
epidemiology	B-T091
and	O
care	B-T052
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
epidemiology	B-T091
and	O
outcomes	B-T057
of	O
injuries	B-T037
at	O
4	O
referral hospitals	B-T073
in	O
Kenya	B-T083
using	O
hospital	B-T073
-based	O
trauma	B-T037
registries	B-T170
.	O
From	O
January	B-T080
2014	O
to	O
May	B-T079
2015,	O
all	O
injured patients	B-T101
presenting	O
to	O
the	O
casualty departments	B-T073
of	O
Kenyatta National	B-T073
,	O
Thika Level 5	B-T073
,	O
Machakos Level 5	B-T073
,	O
and	O
Meru Level 5 Hospitals	B-T073
were	O
enrolled	O
prospectively.	O
Data collected	B-T062
included	O
demographic characteristics	B-T102
,	O
type	B-T080
of	O
prehospital care	B-T058
received	B-T080
,	O
prehospital time	B-T079
,	O
injury pattern	B-T037
,	O
and	O
outcomes	B-T057
.	O
A	O
total	O
of	O
14,237	O
patients	B-T101
were	O
enrolled	O
in	O
our	O
study.	O
Patients	B-T101
were	O
predominantly	O
male	B-T032
(76.1%)	O
and	O
young	B-T079
(	O
mean age	B-T032
28	O
years	B-T079
).	O
The	O
most	O
common	O
mechanisms of injury	B-T169
were	O
road	B-T073
traffic injuries	B-T037
(36.8%),	O
falls	B-T037
(26.4%),	O
and	O
being	O
struck/hit by	B-T169
a	O
person	B-T098
or	O
object	B-T072
(20.1%).	O
Burn	B-T037
was	O
the	O
most	O
common	O
mechanism of injury	B-T169
in	O
the	O
age	B-T032
category	B-T170
under	O
5	O
years	B-T079
.	O
Body regions	B-T029
commonly	O
injured	B-T169
were	O
lower extremity	B-T023
(35.1%),	O
upper extremity	B-T023
(33.4%),	O
and	O
head	B-T029
(26.0%).	O
The	O
overall	O
mortality rate	B-T081
was	O
2.4%.	O
Significant predictors	B-T078
of	O
mortality	B-T081
from	O
multivariate analysis	B-T081
were	O
Glasgow Coma Scale ≤12	B-T033
,	O
estimated	O
injury severity score	B-T170
≥9,	O
burns	B-T037
,	O
and	O
gunshot injuries	B-T037
.	O
Hospital	B-T073
-based	O
trauma	B-T037
registries	B-T170
can	O
be	O
important	O
sources of data	B-T081
to	O
study the epidemiology	B-T062
of	O
injuries	B-T037
in	O
low- and middle-income countries	B-T083
.	O
Data	B-T078
from	O
such	O
trauma	B-T037
registries	B-T170
can	O
highlight	O
key	O
needs	O
and	O
be	O
used	O
to	O
design	O
public	B-T092
health	B-T078
interventions	B-T061
and	O
quality-of-care improvement programs	B-T058
.	O

A	O
child	B-T100
with	O
phenylketonuria	B-T047
and	O
focal segmental glomerulosclerosis	B-T047
,	O
the	O
bright	O
side	O
of	O
proteinuria	B-T033
Phenylketonuria	B-T047
(	O
PKU	B-T047
)	O
is	O
the	O
most	O
common	B-T081
inborn error of amino acid metabolism	B-T047
.	O
Phenylalanine hydroxylase	B-T116
is	O
the	O
underlying	O
deficient	B-T169
enzyme	B-T116
.	O
If	O
left	O
untreated	B-T033
,	O
growth failure	B-T047
,	O
microcephaly	B-T019
,	O
global developmental delay	B-T048
,	O
seizures	B-T184
and	O
severe intellectual impairment	B-T048
would	O
characterize	B-T052
the	O
clinical picture	B-T201
of	O
PKU	B-T047
.	O
On	O
the	O
other	O
side	O
of	O
protein	B-T116
homeostasis	B-T038
lies	O
nephrotic syndrome	B-T047
.	O
It	O
is	O
a	O
well-known	O
quantitative	B-T081
defect	B-T169
due	O
to	O
significant	B-T078
proteinuria	B-T033
.	O
Focal segmental glomerulosclerosis	B-T047
(	O
FSGS	B-T047
)	O
is	O
a	O
special	B-T080
congenital	B-T080
variant	B-T080
affecting	B-T169
children	B-T100
and	O
adults	B-T100
.	O
Hereby,	O
we	O
describe	O
a	O
three-	O
year	O
old	O
male	B-T032
child	B-T100
who	O
presented	B-T033
with	O
generalized edema	B-T033
and	O
global developmental delay	B-T048
.	O
Investigations	B-T058
revealed	B-T080
PKU	B-T047
along	O
with	O
FSGS	B-T047
.	O
We	O
assume	O
that	O
congenital nephrosis	B-T047
ameliorated	B-T033
the	O
picture	O
of	O
PKU	B-T047
,	O
and	O
had	O
a	O
salutary effect	B-T080
on	O
the	O
growth and development	B-T040
.	O
Such	O
coexistence	O
between	O
PKU	B-T047
and	O
FSGS	B-T047
hasn't	O
been	O
described	O
before.	O

Gastrointestinal disorders	B-T047
in	O
Curry-Jones syndrome	B-T047
:	O
Clinical	B-T080
and	O
molecular	B-T080
insights	B-T041
from	O
an	O
affected	B-T169
newborn	B-T100
Curry-Jones syndrome	B-T047
(	O
CJS	B-T047
)	O
is	O
a	O
pattern	B-T082
of	O
malformation	B-T190
that	O
includes	O
craniosynostosis	B-T047
,	O
pre-axial polysyndactyly	B-T033
,	O
agenesis of the corpus callosum	B-T019
,	O
cutaneous	B-T033
and	O
gastrointestinal	B-T082
gastrointestinal abnormalities	B-T019
.	O
A	O
recurrent	B-T079
,	O
mosaic mutation	B-T045
of	O
SMO (c.1234 C>T; p.Leu412Phe)	B-T049
causes	B-T169
CJS	B-T047
.	O
This	O
report	B-T170
describes	O
the	O
gastrointestinal	B-T082
and	O
surgical findings	B-T033
in	O
a	O
baby	B-T100
with	O
CJS	B-T047
who	O
presented	O
with	O
abdominal obstruction	B-T047
and	O
reviews	B-T169
the	O
spectrum of gastrointestinal malformations	B-T033
gastrointestinal	B-T082
malformations	O
in	O
this	O
rare disorder	B-T047
.	O
A	O
41-	O
week	B-T079
,	O
4,165	O
g,	O
female	B-T032
presented	O
with	O
craniosynostosis	B-T047
,	O
pre-axial polysyndactyly	B-T033
,	O
and	O
cutaneous findings	B-T033
consistent	O
with	O
a	O
clinical diagnosis	B-T060
of	O
CJS	B-T047
.	O
The	O
infant	B-T100
developed	O
abdominal distension	B-T033
beginning	B-T079
on	O
the	O
second	B-T081
day	B-T079
of	O
life	B-T078
.	O
Surgical exploration	B-T060
revealed	B-T080
an	O
intestinal malrotation	B-T019
for	O
which	O
she	O
underwent	O
a	O
Ladd procedure	B-T061
.	O
Multiple small nodules	B-T033
were	O
found	B-T033
on	O
the	O
surface of the small and large bowel	B-T029
in addition to	B-T169
an	O
apparent	B-T078
intestinal duplication	B-T019
that	O
seemed	O
to	O
originate	O
posterior	B-T082
to	O
the	O
pancreas	B-T023
.	O
Histopathology	B-T169
of	O
serosal	B-T029
nodules	B-T020
revealed	B-T080
bundles of smooth muscle	B-T024
with associated	B-T080
ganglion cells	B-T025
.	O
Molecular analysis	B-T063
demonstrated	O
the	O
SMO c.1234 C>T mutation	B-T049
in	O
varying	O
amounts	O
in	O
affected	B-T169
skin	B-T022
(up	O
to	O
35%)	O
and	O
intestinal hamartoma	B-T191
(26%).	O
Gastrointestinal	B-T082
features	B-T033
including	O
structural malformations	B-T033
malformations	B-T190
,	O
motility disorders	B-T046
,	O
and	O
upper GI bleeding	B-T046
are	O
major	O
causes	B-T169
of	O
morbidity	B-T081
in	O
CJS	B-T047
.	O
Smooth muscle	B-T024
Smooth muscle hamartomas	B-T191
are	O
a	O
recognized feature	B-T033
of	O
children	B-T100
with	O
CJS	B-T047
typically	O
presenting	O
with	O
abdominal obstruction	B-T047
requiring surgical intervention	B-T033
.	O
A	O
somatic mutation	B-T049
in	O
SMO	B-T028
likely	O
accounts	O
for	O
the	O
structural malformations	B-T033
malformations	B-T190
and	O
predisposition	B-T032
to	O
form	O
bowel hamartomas	B-T191
and	O
myofibromas	B-T191
.	O
The	O
mutation	B-T045
burden	B-T078
in	O
the	O
involved	B-T169
tissues	B-T024
likely	O
accounts	O
for	O
the	O
variable manifestations	B-T033
.	O

Sella turcica bridging	B-T190
and	O
dental anomalies	B-T033
:	O
is	O
there	O
an	O
association	B-T080
?	O
Sella turcica bridging	B-T190
(	O
STB	B-T190
),	O
or	O
calcification	B-T042
of	O
the	O
interclinoid ligament	B-T024
of	O
sella turcica	B-T023
,	O
has	O
been	O
reported	O
to	O
be	O
associated with	B-T080
some	O
dental anomalies	B-T033
(	O
palatal canine	B-T033
impaction	B-T190
and	O
transposition	B-T190
).	O
The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
find	O
any	O
association	B-T080
between	O
canine	B-T033
impaction	B-T190
,	O
hyperdontia	B-T033
or	O
hypodontia	B-T019
and	O
sellar	B-T023
dimensions	B-T081
or	O
bridging	B-T190
.	O
Lateral	B-T082
cephalometric	B-T060
radiographs	B-T060
from	O
78	O
patients	B-T101
with	O
impacted	B-T190
canines	B-T033
,	O
68	O
with	O
dental agenesis	B-T019
and	O
17	O
with	O
hyperdontia	B-T033
were	O
collected.	O
Linear	B-T082
dimensions	B-T081
of	O
sella turcica	B-T023
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control group	B-T096
(47	O
individuals	B-T098
).	O
A	O
standardize scoring scale	B-T170
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
STB	B-T190
from	O
each	O
radiographs	B-T060
.	O
The	O
frequency	B-T079
of	O
partial	B-T081
and	O
complete	B-T080
calcifications	B-T042
of	O
sella	B-T023
in	O
patients	B-T101
with	O
dental anomalies	B-T033
is	O
increased	B-T081
when	O
compared	O
to	O
controls	B-T096
.	O
STB	B-T190
can	O
influence	O
the	O
interclinoid distance	B-T081
but	O
does	O
not	O
affect	O
other	O
linear	B-T082
dimensions	B-T081
of	O
sella	B-T023
.	O
No	O
statistically significant	B-T081
difference	O
has	O
been	O
found	O
in	O
sellar	B-T023
dimensions	B-T081
and	O
STB	B-T190
expression	O
when	O
evaluating	O
radiographs	B-T060
at	O
different	O
ages	B-T032
.	O
STB	B-T190
is	O
frequently	O
found	O
in	O
patients	B-T101
with	O
dental abnormalities	B-T033
.	O

Coxiella burnetii	B-T007
isolates	B-T123
originating	O
from	O
infected cattle	B-T015
induce	B-T169
a	O
more	O
pronounced	O
proinflammatory cytokine response	B-T043
compared	O
to	O
isolates	B-T123
from	O
infected goats	B-T015
and	O
sheep	B-T015
Coxiella burnetii	B-T007
is	O
the	O
causative agent	B-T033
of	O
Q fever	B-T047
.	O
Although	O
the	O
prevalence	B-T081
of	O
C. burnetii	B-T007
in	O
cattle	B-T015
is	O
much	O
higher	O
than	O
in	O
goats	B-T015
and	O
sheep	B-T015
,	O
infected cattle	B-T015
are	O
rarely	O
associated with	B-T080
human	B-T016
outbreaks	B-T067
.	O
We	O
investigated	B-T169
whether	O
the	O
immune response	B-T042
of	O
humans	B-T016
differs	O
after	O
contact	O
with	O
C. burnetii	B-T007
isolates	B-T123
from	O
different	O
host origins	B-T001
or	O
with	O
different	O
multilocus variable number of tandem repeat analysis	B-T059
(	O
MLVA	B-T059
)	O
genotypes	B-T032
.	O
Cytokine responses	B-T043
were	O
measured	O
in	O
human	B-T016
peripheral blood mononuclear cells	B-T025
(	O
PBMCs	B-T025
)	O
stimulated	B-T070
with	O
16	O
C. burnetii	B-T007
isolates	B-T123
with	O
known	O
MLVA	B-T059
genotype	B-T032
from	O
goats	B-T015
,	O
sheep	B-T015
,	O
cattle	B-T015
,	O
acute	B-T047
and	O
chronic Q fever	B-T047
patients	B-T101
.	O
Coxiella burnetii	B-T007
isolates	B-T123
originating	O
from	O
cattle	B-T015
induce	B-T169
significantly	O
more	O
IL-1β	B-T116
,	O
TNF-α	B-T116
and	O
IL-22	B-T116
than	O
the	O
isolates	B-T123
from	O
goats	B-T015
,	O
sheep	B-T015
or	O
chronic Q fever	B-T047
patients	B-T101
.	O
Comparing	O
the	O
cytokine	B-T116
induction	B-T169
of	O
the	O
isolates	B-T123
based	O
on	O
their	O
MVLA	B-T059
genotype	B-T032
did	O
not	O
reveal	O
differences	O
in	O
response	B-T043
between	O
the	O
MLVA	B-T059
genotypes	B-T032
.	O
The	O
proinflammatory cytokine response	B-T043
induced	B-T169
in	O
human	B-T016
PBMCs	B-T025
by	O
C. burnetii	B-T007
isolates	B-T123
from	O
cattle	B-T015
may	O
explain	O
the	O
low	O
incidence	B-T081
of	O
human	B-T016
Q fever	B-T047
outbreaks	B-T067
caused	O
by	O
cattle	B-T015
.	O
The	O
cytokine	B-T116
cytokine profile	B-T081
of	O
PBMCs	B-T025
stimulated	B-T070
with	O
C. burnetii	B-T007
isolates	B-T123
from	O
chronic Q fever	B-T047
patients	B-T101
resembles	O
isolates	B-T123
from	O
goats	B-T015
.	O
Furthermore,	O
cytokine responses	B-T043
seem	O
to	O
be	O
depending	O
on	O
host origin	B-T001
than	O
on	O
MLVA	B-T059
genotype	B-T032
.	O

A	O
Novel	O
BRCA1-Associated Protein-1	B-T116
Isoform	B-T116
Affects	B-T077
Response	B-T032
of	O
Mesothelioma Cells	B-T191
to	O
Drugs	B-T121
Impairing	B-T169
BRCA1	B-T116
-Mediated	O
DNA Repair	B-T045
BRCA1 associated protein1	B-T116
(	O
BAP1	B-T116
)	O
is	O
a	O
tumor suppressor	B-T116
involved	O
in	O
multiple	B-T081
cellular processes	B-T043
such	O
as	O
transcriptional regulation	B-T045
,	O
chromatin modification	B-T045
by	O
deubiquitinating	B-T044
histone 2A	B-T116
,	O
and	O
DNA repair	B-T045
.	O
BAP1	B-T116
mutations	B-T045
are	O
frequent	B-T079
in	O
malignant pleural mesothelioma	B-T191
(	O
MPM	B-T191
).	O
Our	O
aim	B-T078
was	O
to	O
functionally	B-T169
characterize	B-T080
a	O
newly	O
identified	B-T080
isoform	B-T116
of BAP1	B-T116
and	O
investigate	B-T169
the	O
effects	B-T080
of	O
its	O
expression	B-T045
on	O
drug sensitivity	B-T032
in	O
MPM	B-T191
.	O
Expression	B-T045
of	O
BAP1	B-T116
isoforms	O
was	O
detected	B-T033
by	O
quantitative polymerase chain reaction	B-T059
in	O
MPM	B-T191
and	O
normal	B-T080
mesothelium	B-T024
cell lines	B-T025
and	O
tumor	B-T024
and	O
nontumor samples	B-T024
.	O
Histone H2A	B-T116
ubiquitination	B-T044
levels	B-T080
were	O
analyzed	B-T062
by	O
Western blot	B-T059
after	O
acidic extraction	B-T059
of	O
core histones	B-T116
.	O
Subcellular	B-T026
localization	B-T169
of	O
BAP1	B-T116
isoforms	B-T116
was	O
examined	B-T033
by	O
immunofluorescence	B-T059
.	O
MPM	B-T191
cell survival	B-T043
in	O
response	B-T032
to	O
poly(adenosine diphosphate-ribose) polymerase	B-T116
(	O
PARP	B-T116
)	O
and	O
dual	O
phosphoinositide 3-kinase	B-T116
(	O
PI3K	B-T116
)-	O
mammalian target of rapamycin	B-T116
(	O
mTOR	B-T116
)	O
inhibitors	B-T121
was	O
analyzed	B-T062
by	O
in vitro assays	B-T062
.	O
We	O
have	O
identified	B-T080
a	O
novel	O
alternative splice isoform	B-T116
of	O
BAP1	B-T116
(	O
BAP1Δ	B-T028
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic domain	B-T087
.	O
Cells	B-T025
transfected	B-T063
with	O
BAP1Δ	B-T028
showed	O
reduced	B-T080
deubiquitinating activity	B-T044
compared	B-T052
with	O
full-length	O
BAP1	B-T116
.	O
The	O
expression	B-T045
of	O
BAP1Δ	B-T028
transcript	B-T114
is	O
more	O
abundant	B-T080
in	O
nontumor	B-T024
than	O
in	O
tumor	O
samples.	O
MPM	B-T191
cell lines	B-T025
expressing	B-T045
more	O
than	O
20%	O
of	O
BAP1Δ	B-T028
are	O
more	O
sensitive	B-T169
to	O
olaparib	B-T109
(a	O
PARP1	B-T116
inhibitor	B-T121
)	O
cytotoxicity	B-T049
,	O
and	O
this	O
sensitivity	B-T169
is	O
enhanced	B-T052
when	O
olaparib	B-T109
treatment	B-T058
is	O
combined	B-T080
with	O
GDC0980	B-T121
(a	O
dual	O
PI3K	B-T116
-	O
mTOR	B-T116
inhibitor	B-T121
),	O
which	O
induces	B-T169
downregulation	B-T044
of	O
BRCA1	B-T116
.	O
These	O
observations	B-T062
suggest	O
that	O
BAP1Δ	B-T028
does	O
regulate DNA damage response	B-T043
and	O
influences	B-T077
drug sensitivity	B-T032
.	O
It	O
might	O
therefore	O
be	O
relevant	B-T080
to	O
investigate	B-T169
whether	O
patients	B-T101
with	O
high	B-T080
expression	B-T045
of	O
BAP1Δ	B-T028
may	O
be	O
responsive	B-T201
to	O
PARP	B-T116
/	O
PI3K	B-T116
-	O
mTOR	B-T116
inhibitors	B-T121
.	O

Cucurbitacin B	B-T109
Protects	O
Against	O
Pressure	B-T184
Overload	B-UnknownType
Induced	O
Cardiac Hypertrophy	B-T046
Lack	O
of	O
effective	O
anti-cardiac hypertrophy drugs	B-T121
creates	O
a	O
major	O
cause	B-T169
for	O
the	O
increasing	O
prevalence	B-T081
of	O
heart failure	B-T047
.	O
In	O
the	O
present	O
study,	O
we	O
determined	O
the	O
anti-hypertrophy	B-T033
and	O
anti-fibrosis	B-T033
potential	B-T080
of	O
a	O
natural plant	B-T002
triterpenoid	B-T109
,	O
Cucurbitacin B	B-T109
both	O
in vitro	B-T062
and	O
in vivo	B-T062
.	O
Aortic banding	B-T061
(	O
AB	B-T061
)	O
was	O
performed	O
to	O
induce	O
cardiac hypertrophy	B-T046
.	O
After	O
1	O
week	O
of	O
surgery	B-T061
,	O
mice	B-T015
were	O
receive	O
cucurbitacin B	B-T109
treatment	B-T061
(	O
Gavage	B-T169
,	O
0.2	O
mg/kg	O
body weight	B-T032
/2	O
day).	O
After	O
4	O
weeks	O
of	O
AB	B-T061
,	O
cucurbitacin B	B-T109
demonstrated	O
a	O
strong	O
anti-hypertrophy	B-T033
and	O
-fibrosis	B-T033
ability	O
as	O
evidenced	O
by	O
decreased	O
of	O
heart	B-T023
weight	B-T081
,	O
myocardial cell	B-T025
cross-sectional area	B-T201
and	O
interstitial fibrosis	B-T046
,	O
ameliorated	O
of	O
systolic	B-T079
and	O
diastolic	B-T201
abnormalities	B-T033
,	O
normalized	O
in	O
gene expression	B-T045
of	O
hypertrophic	B-T046
and	O
fibrotic	B-T169
markers	B-T201
,	O
reserved	O
microvascular density	B-T080
in	O
pressure	B-T184
overload	B-UnknownType
induced	O
hypertrophic	B-T046
mice	B-T015
.	O
Cucurbitacin B	B-T109
also	O
showed	O
significant	O
hypertrophy	B-T046
inhibitory effect	B-T033
in	O
phenylephrine	B-T109
stimulated	B-T070
cardiomyocytes	B-T025
.	O
The	O
Cucurbitacin B	B-T109
-mediated	O
mitigated	B-T067
cardiac hypertrophy	B-T046
was	O
attributable	O
to	O
the	O
increasing	O
level	O
of	O
autophagy	B-T043
,	O
which	O
was	O
associated with	B-T080
the	O
blockade	B-T169
of	O
Akt	B-T116
/	O
mTOR	B-T116
/	O
FoxO3a	B-T116
signal pathway	B-T044
,	O
validated	O
by	O
SC79	B-T109
,	O
MK2206	B-T109
,	O
and	O
3-MA	B-T114
,	O
the	O
Akt	B-T116
agonist	B-T121
,	O
inhibitor	B-T120
and	O
autophagy	B-T043
inhibitor	B-T120
in vitro	B-T062
.	O
The	O
overexpression	B-T045
of	O
constitutively	O
active	O
Akt	B-T116
completely	O
abolished	O
the	O
Cucurbitacin B	B-T109
-mediated	O
protection	O
of	O
cardiac hypertrophy	B-T046
in	O
human	B-T016
cardiomyocytes AC16	B-T025
.	O
Collectively,	O
our	O
findings	O
suggest	O
that	O
cucurbitacin B	B-T109
protects	O
against	O
cardiac hypertrophy	B-T046
through	O
increasing	O
the	O
autophagy	B-T043
level	O
in	O
cardiomyocytes	B-T025
,	O
which	O
is	O
associated with	B-T080
the	O
inhibition	B-T043
of	O
Akt	B-T116
/	O
mTOR	B-T116
/	O
FoxO3a	B-T116
signal axis	B-T044
.	O
J.	O
Cell.	O
Biochem.	O
9999:	O
1-12,	O
2017.	O
©	O
2017	O
Wiley	O
Periodicals,	O
Inc.	O

Inflammatory	B-T169
and	O
Oxidative Stress	B-T049
Markers	B-T201
in	O
Experimental	B-T080
Allergic Asthma	B-T047
Ovalbumin	B-T116
-	O
induced	B-T169
allergic lung inflammation	B-T047
(	O
ALI	B-T047
)	O
is	O
a	O
condition	B-T080
believed	O
to	O
be	O
mediated	O
by	O
cytokines	B-T116
,	O
extracellular matrix	B-T024
remodeling	B-T038
,	O
and	O
redox	B-T044
imbalance	B-T184
.	O
In	O
this	O
study	B-T062
,	O
we	O
evaluated	B-T058
pulmonary function	B-T042
together	O
with	O
inflammatory	B-T169
markers	B-T201
as	O
interleukin-4	B-T116
(	O
IL-4	B-T116
),	O
myeloperoxidase	B-T116
(	O
MPO	B-T116
),	O
eosinophil cells	B-T025
,	O
and	O
redox	B-T044
markers	B-T201
in	O
the	O
lungs	B-T023
of	O
BALB/c mice	B-T015
after	O
ovalbumin	B-T116
(	O
OVA	B-T116
)	O
sensitization	B-T040
and	O
challenge	B-T059
.	O
Our	O
results	B-T169
showed	O
an	O
increase	B-T169
in	O
bronchial hyperresponsiveness	B-T047
stimulated	B-T070
by	O
methacholine	B-T109
(	O
Mch	B-T109
),	O
inflammatory	B-T169
cell influx	B-T043
,	O
especially	O
eosinophils	B-T025
together	O
with	O
an	O
increase	B-T169
of	O
high mobility group box 1	B-T116
(	O
HMGB1	B-T116
)	O
and	O
altered	O
lipid peroxidation	B-T044
(	O
LP	B-T044
)	O
and	O
antioxidant	B-T121
defenses	B-T077
in	O
the	O
OVA	B-T116
group	B-UnknownType
compared	O
to	O
the	O
control group	B-T096
(p	O
≤	O
0.5).	O
Thus,	O
we	O
demonstrated	O
that	O
OVA	B-T116
-	O
induced	B-T169
ALI	B-T047
altered	O
redox	B-T044
status	O
concomitantly	B-T079
with	O
impaired	B-T169
lung function	B-T039
,	O
which	O
was	O
associated with	B-T080
HMGB1	B-T116
expression	B-T045
and	O
proteolytic	B-T044
remodeling	B-T038
.	O
Taken	O
together	O
all	O
results	B-T169
found	O
here,	O
we	O
may	O
suggest	O
HMGB1	B-T116
is	O
an	O
important	B-T080
therapeutic	B-T169
target	B-T169
for	O
asthma	B-T047
,	O
once	O
orchestrates	B-T080
the	O
redox	B-T044
signaling	B-T038
,	O
inflammation	B-T046
,	O
and	O
remodeling	B-T038
that	O
contribute	O
to	O
the	O
disease	B-T047
development	B-T169
.	O

Association	B-T080
among	O
prematurity	B-T047
(	O
<30 weeks' gestational age	B-T032
),	O
blood pressure	B-T040
,	O
urinary	B-T080
albumin	B-T116
,	O
calcium	B-T121
,	O
and	O
phosphate	B-T121
in	O
early childhood	B-T079
There	O
is	O
a	O
paucity	O
of	O
data	B-T078
on	O
blood pressures	B-T040
(	O
BP	B-T040
),	O
urinary	B-T080
albumin	B-T116
,	O
and	O
mineral	B-T197
excretion	B-T039
in	O
early childhood	B-T079
in	O
contemporary	B-T079
cohorts	B-T098
of	O
extremely	B-T080
low	B-T080
gestational age	B-T032
(	O
GA	B-T032
)	O
neonates	B-T100
.	O
Our	O
aim	O
was	O
to	O
compare	B-T052
BPs	B-T040
and	O
the	O
urinary	B-T080
excretion	B-T039
of	O
albumin	B-T116
,	O
calcium	B-T121
,	O
and	O
phosphate	B-T121
in	O
preterm	B-T079
and	O
term-born	B-T040
cohorts	B-T098
in	O
early childhood	B-T079
.	O
This	O
was	O
a	O
prospective observational study	B-T062
conducted	O
at	O
a	O
single	B-T081
center	B-T073
,	O
involving	B-T169
children	B-T100
<5 years age	B-T032
,	O
born preterm	B-T033
(	O
GA <30 weeks	B-T033
)	O
or	O
at term	B-T040
(	O
≥37 weeks' GA	B-T033
).	O
Urinary albumin	B-T034
(mg/L),	O
calcium	B-T034
and	O
phosphate levels	B-T034
indexed	B-T170
to	O
creatinine	B-T109
(mg/dL),	O
and	O
BP	B-T040
were	O
measured	B-T080
.	O
The	O
median	B-T082
(	O
IQR	B-T081
)	O
follow-up	B-T058
age	B-T032
of	O
our	O
cohort	B-T098
(n	O
=	O
106)	O
was	O
30	O
(16-48)	O
months	B-T079
.	O
Preterm-born children	B-T100
(n	O
=	O
55)	O
had	O
a	O
significantly lower	B-T081
mean	B-T081
GA	B-T032
and	O
birth weight	B-T032
and	O
higher	B-T080
mean	B-T081
systolic	B-T201
,	O
diastolic	B-T201
,	O
and	O
mean BPs	B-T033
,	O
compared	B-T052
with	O
term	B-T040
(n	O
=	O
51)	O
controls	B-T096
.	O
A	O
significantly higher	B-T081
proportion	B-T081
of	O
preterm-born children	B-T100
weighed	B-T032
<10th centile	B-T033
and	O
had	O
systolic BP	B-T201
>95th centile	B-T033
at	O
follow-up	B-T058
.	O
Albumin	B-T116
and	O
calcium	B-T121
excretion	B-T039
did	O
not differ	B-T033
between	O
the	O
groups	B-UnknownType
;	O
median	B-T081
urine-phosphate creatinine ratios	B-T201
were	O
higher	B-T080
in	O
the	O
preterm group	B-T100
.	O
On	O
logistic regression	B-T062
,	O
lower	B-T080
GA	B-T032
and	O
younger	B-T079
age	B-T032
at	O
follow-up	B-T058
were	O
significantly	B-T078
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
of	O
systolic	B-T201
and	O
diastolic BP	B-T201
above	O
the	O
95th centile	B-T033
;	O
male gender	B-T032
was	O
associated with	B-T080
decreased	B-T081
risk	B-T078
of	O
diastolic hypertension	B-T047
.	O
Even	O
in	O
early childhood	B-T079
,	O
children born preterm	B-T100
had	O
significantly	B-T078
elevated	B-T080
BP	B-T040
,	O
compared	B-T052
with	O
their	O
term-born	B-T040
counterparts	B-T096
.	O
Closer	O
monitoring	B-T058
of	O
BPs	B-T040
in	O
this	O
population	B-T098
may	O
be	O
warranted.	O

Recombinant	B-T116
protein transduction domain	B-T087
-	O
Cu/Zn superoxide dismutase	B-T116
alleviates	B-T080
bone cancer	B-T191
pain	B-T184
via	O
peroxiredoxin 4	B-T116
modulation	B-T044
and	O
antioxidation	B-T044
Bone cancer	B-T191
pain	B-T184
(	O
BCP	B-T184
)	O
is	O
a	O
serious	B-T080
chronic	B-T079
clinical condition	B-T080
and	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
)	O
were	O
considered	B-T078
to	O
be	O
involved	B-T169
in	O
its	O
development	B-T169
and	O
persistency	B-T079
.	O
Normally	B-T080
,	O
superoxide dismutase	B-T116
(	O
SOD	B-T116
)	O
converts	O
superoxide anions	B-T196
to	O
hydrogen peroxide	B-T121
(	O
H2O2	B-T121
)	O
and	O
H2O2	B-T121
is	O
then	O
naturalized	O
to	O
be	O
water	B-T121
by	O
peroxiredoxin 4	B-T116
.	O
We	O
reported	B-T170
previously	O
that	O
recombinant	B-T116
protein transduction domain	B-T087
(	O
PTD	B-T087
)-	O
Cu/Zn SOD	B-T116
effectively	B-T080
scavenged	B-T044
excessive	B-T080
ROS	B-T123
and	O
prevented	B-T169
cardiomyocytes	B-T025
from	O
hypoxia-reoxygenation	B-T169
damage	B-T169
.	O
However,	O
whether	O
PTD	B-T087
-	O
Cu/Zn SOD	B-T116
would	O
prevent	B-T169
BCP	B-T184
development	B-T169
is	O
unknown	B-T080
.	O
In	O
the	O
current	B-T079
study	B-T062
,	O
we	O
found	B-T033
that	O
an	O
implanted	B-T074
carcinoma	B-T191
in	O
the	O
rat	B-T015
tibia	B-T023
induced	B-T169
remarkable	O
hyperalgesia	B-T184
,	O
increased	B-T081
H2O2	B-T121
levels	B-T080
and	O
decreased	B-T081
SOD	B-T116
and	O
peroxiredoxin 4	B-T116
levels	B-T080
.	O
After	O
administration	B-T169
of	O
recombinant	B-T116
PTD	B-T087
-	O
Cu/Zn SOD	B-T116
to	O
these	O
tumor-burden	B-T081
rats	B-T015
,	O
their	O
hyperalgesia	B-T184
was	O
significantly	B-T078
attenuated	B-T052
and	O
peroxiredoxin 4	B-T116
expression	B-T045
was	O
significantly increased	B-T081
.	O
In addition	B-T169
,	O
an	O
increased	B-T081
expression	B-T045
of	O
N-methyl-d-aspartic acid (NMDA) receptors	B-T116
and	O
a	O
decreased	B-T081
expression	B-T045
of	O
γ-aminobutyric acid (GABA) receptors	B-T116
in	O
this	O
cancer pain	B-T184
were	O
prevented	B-T169
by	O
PTD	B-T087
-	O
Cu/Zn SOD	B-T116
administration	B-T169
or	O
peroxiredoxin 4	B-T116
overexpression	B-T045
.	O
Our	O
data	B-T078
suggested	B-T078
that	O
reactive oxygen species	B-T123
,	O
at	O
least	O
in	O
part,	O
play	O
a	O
role	B-T077
in	O
cancer metastatic	B-T191
pain	B-T184
development	B-T169
and	O
persistency	B-T079
which	O
can	O
be	O
attenuated by	B-T080
the	O
adminstration	B-T169
of	O
recombinant PTD	B-T116
-	O
Cu/Zn SOD	B-T116
via	O
the	O
peroxiredoxin 4	B-T116
modulation	B-T044
from	O
oxidative stress	B-T049
.	O

Immune dysregulation	B-T033
in	O
offspring	B-T099
of	O
a	O
bipolar	B-T048
parent	B-T099
.	O
Altered	O
serum	B-T031
levels	B-T080
of	O
immune	B-T169
growth factors	B-T116
at	O
adolescent age	B-T100
Immune dysregulation	B-T033
plays	O
a	O
role	O
in	O
the	O
vulnerability	B-T033
for	O
mood disorders	B-T048
.	O
Immune	B-T169
growth factors	B-T116
,	O
such	O
as	O
Stem Cell Factor	B-T116
(	O
SCF	B-T116
),	O
Insulin-like Growth Factor-Binding Protein-2	B-T116
(	O
IGF-BP2	B-T116
),	O
Epidermal Growth Factor	B-T116
(	O
EGF	B-T116
),	O
IL-7	B-T116
and	O
sCD25	B-T116
have	O
repeatedly	O
been	O
reported	O
altered	B-T169
in	O
patients	B-T101
with	O
mood disorders	B-T048
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
levels	B-T080
of	O
these	O
factors	B-T116
in	O
serum	B-T031
of	O
adolescent	B-T100
bipolar	B-T048
offspring	B-T099
,	O
who	O
have	O
a	O
heightened	B-T080
risk	B-T078
for	O
mood disorder	B-T048
development	B-T169
and	O
to	O
also	O
analyze	B-T062
the	O
data	B-T078
combined	O
with	O
previously	O
published data	B-T170
.	O
Growth factors	B-T116
were	O
assessed	B-T052
by	O
CBA	B-T059
/	O
ELISA	B-T059
in	O
adolescent	B-T100
bipolar	B-T048
offspring	B-T099
(n=96,	O
mean	B-T081
age	B-T032
=16	O
years	B-T079
)	O
and	O
in	O
age	B-T032
-	O
and	O
gender	B-T032
-	O
matched	B-T080
healthy	B-T080
controls	B-T096
(n=50).	O
EGF	B-T116
belonged	O
to	O
a	O
mutually	O
correlating	B-T080
cluster	B-T081
of	O
mainly	O
neurotrophic compounds	B-T116
including	O
S100B	B-T116
and	O
BDNF	B-T116
,	O
which	O
were	O
in	O
general	O
decreased	B-T081
in	O
serum	B-T031
.	O
IL-7	B-T116
,	O
SCF	B-T116
,	O
IGF-BP2	B-T116
and	O
sCD25	B-T116
,	O
belonged	O
to	O
a	O
different	O
mutually	O
correlating	B-T080
cluster	B-T081
of	O
immune	B-T169
growth factors	B-T116
,	O
which	O
were	O
in	O
general	O
increased	B-T081
:	O
IGF-BP2	B-T116
significantly	B-T078
in	O
serum	B-T031
of	O
offspring	B-T099
without	O
a	O
mood disorder	B-T048
,	O
IL-7	B-T116
and	O
SCF	B-T116
in	O
serum	B-T031
of	O
offspring	B-T099
who	O
had	O
expirienced	B-T041
a	O
mood episode	B-T048
.	O
This	O
pattern	B-T082
of	O
de	B-T081
-	O
and	O
increases	B-T169
was	O
not	O
different	O
between	O
bipolar	B-T048
offspring	B-T099
that	O
developed	O
or	O
did	O
not	O
develop	O
a	O
mood disorder	B-T048
over	O
time	B-T079
,	O
apart	O
from	O
the	O
IGF-BP2	B-T116
level	B-T080
,	O
which	O
was	O
near	O
significantly	B-T078
higher	O
in	O
offspring	B-T099
later	O
developing	O
a	O
mood disorder	B-T048
.	O
Correlations	B-T080
with	O
the	O
previously	O
published	B-T170
immune-cellular abnormalities	B-T190
were	O
not	O
found.	O
In	O
conclusion	B-T078
non-affected	O
adolescents	B-T100
at	O
familial	B-T169
mood disorder	B-T048
development	B-T169
risk	B-T078
were	O
characterized	B-T052
by	O
a	O
distinct	O
pattern	B-T082
of	O
a	O
series	O
of	O
compounds	B-T116
operating	O
in	O
a	O
network	B-T169
of	O
hematopoiesis	B-T042
,	O
neurogenesis	B-T040
and	O
inflammation	B-T046
.	O

eNOS	B-T116
S-nitrosylates	B-T044
β-actin	B-T116
on	O
Cys374	B-T116
and	O
regulates	B-T044
PKC-θ	B-T116
at	O
the	O
immune synapse	B-T026
by	O
impairing	B-T169
actin binding	B-T044
to	O
profilin-1	B-T116
The	O
actin cytoskeleton coordinates the organization	B-T043
of	O
signaling microclusters	B-T129
at	O
the	O
immune synapse	B-T026
(	O
IS	B-T026
);	O
however,	O
the	O
mechanisms	B-T044
involved	O
remain	O
poorly	O
understood.	O
We	O
show	O
here	O
that	O
nitric oxide	B-T121
(	O
NO	B-T121
)	O
generated	O
by	O
endothelial nitric oxide synthase	B-T116
(	O
eNOS	B-T116
)	O
controls	O
the	O
coalescence	O
of	O
protein kinase C-θ	B-T116
(	O
PKC-θ	B-T116
)	O
at	O
the	O
central supramolecular activation cluster	B-T026
(	O
c-SMAC	B-T026
)	O
of	O
the	O
IS	B-T026
.	O
eNOS	B-T116
translocated	B-T043
with	O
the	O
Golgi	B-T026
to	O
the	O
IS	B-T026
and	O
partially	O
colocalized	B-T082
with	O
F-actin	B-T116
around	O
the	O
c-SMAC	B-T026
.	O
This	O
resulted	O
in	O
reduced	O
actin polymerization	B-T043
and	O
centripetal	O
retrograde flow	B-T067
of	O
β-actin	B-T116
and	O
PKC-θ	B-T116
from	O
the	O
lamellipodium-like	B-T026
distal	B-T082
(d)-SMAC	B-T026
,	O
promoting	B-T052
PKC-θ	B-T116
activation	B-T044
.	O
Furthermore,	O
eNOS	B-T116
-derived	O
NO	B-T121
S-nitrosylated	B-T044
β-actin	B-T116
on	O
Cys374	B-T116
and	O
impaired	B-T169
actin binding	B-T044
to	O
profilin-1	B-T116
(	O
PFN1	B-T116
),	O
as	O
confirmed	O
with	O
the	O
transnitrosylating	B-T044
agent	O
S-nitroso-L-cysteine	B-T109
(	O
Cys-NO	B-T109
).	O
The	O
importance	O
of	O
NO	B-T121
and	O
the	O
formation	O
of	O
PFN1-actin complexes	B-T116
on	O
the	O
regulation	B-T044
of	O
PKC-θ	B-T116
was	O
corroborated	O
by	O
overexpression	B-T045
of	O
PFN1	B-T028
-	O
and	O
actin-binding	B-T044
defective	O
mutants	B-T049
of	O
β-actin (C374S)	B-T028
and	O
PFN1 (H119E)	B-T028
,	O
respectively,	O
which	O
reduced	O
the	O
coalescence	O
of	O
PKC-θ	B-T116
at	O
the	O
c-SMAC	B-T026
.	O
These	O
findings	O
unveil	O
a	O
novel	O
NO	B-T121
-dependent	O
mechanism	B-T044
by	O
which	O
the	O
actin cytoskeleton controls the organization	B-T043
and	O
activation	B-T052
of	O
signaling microclusters	B-T129
at	O
the	O
IS	B-T026
.	O

Dobutamine Stress Echocardiography	B-T060
:	O
Impact	B-T080
of	O
Abnormal	B-T033
Blood Potassium Levels	B-T034
on	O
Cardiac Arrhythmias	B-T033
Guidelines	B-T170
suggest	O
that	O
an	O
abnormal	B-T033
blood potassium level	B-T034
is	O
a	O
relative	O
contraindication	B-T080
to	O
performing	B-T169
dobutamine stress echocardiography	B-T060
(	O
DSE	B-T060
).	O
However,	O
this	O
has	O
not	O
been	O
previously	O
studied.	O
We	O
reviewed	B-T080
a	O
consecutive series of patients	B-T062
who	O
had	O
potassium	B-T123
testing	B-T169
within	O
48	O
hours	B-T079
of	O
undergoing	O
DSE	B-T060
for	O
the	O
evaluation	B-T058
of	O
myocardial ischemia	B-T047
over	O
a	O
10-	O
year	B-T079
period	B-T079
(N	O
=	O
13,198).	O
Normal	O
potassium	B-T123
range	B-T081
in	O
our	O
laboratory	B-T073
is	O
3.6-5.2	O
mmol/L.	O
Hemolyzed samples	B-T033
were	O
not	O
included.	O
The	O
association	B-T080
of	O
potassium levels	B-T033
with	O
the	O
development	B-T169
of	O
supraventricular	B-T046
and	O
ventricular arrhythmias	B-T047
was	O
assessed	B-T052
.	O
The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	B-T033
was	O
very	O
low	B-T080
(	O
supraventricular tachycardia	B-T047
/	O
atrial fibrillation	B-T047
,	O
4.9%;	O
nonsustained ventricular tachycardia	B-T046
,	O
2.9%;	O
sustained ventricular tachycardia	B-T047
or	O
ventricular fibrillation	B-T047
,	O
0.1%),	O
confirming	O
the	O
overall safety	B-T068
of	O
DSE	B-T060
.	O
Most	O
arrhythmias	B-T033
(88%)	O
occurred	O
in	O
patients	B-T101
with	O
normal	O
potassium levels	B-T033
,	O
and	O
arrhythmia	B-T033
rates	B-T081
remained	O
low	B-T080
in	O
patients	B-T101
with	O
potassium	B-T123
abnormalities	B-T033
.	O
Patients	B-T101
with	O
hyperkalemia	B-T033
had	O
a	O
lower	O
risk	B-T078
of	O
developing	O
mild	B-T080
(	O
odds ratio	B-T081
[	O
OR	B-T081
],	O
0.39;	O
95%	O
CI	B-T081
,	O
0.22-0.71)	O
and	O
severe	B-T080
(	O
OR	B-T081
,	O
0.13;	O
95%	O
CI	B-T081
,	O
0.01-0.68)	O
supraventricular arrhythmias	B-T046
as	O
well	O
as	O
mild	B-T080
ventricular arrhythmias	B-T047
(	O
OR	B-T081
,	O
0.58;	O
95%	O
CI	B-T081
,	O
0.40-0.83).	O
Even	O
though	O
events	O
were	O
rare	B-T080
,	O
patients	B-T101
with	O
severe	B-T080
hypokalemia	B-T033
(	O
potassium levels	B-T033
≤	O
3.1	O
mmol/L)	O
had	O
an	O
increased	B-T081
risk	B-T078
of	O
supraventricular arrhythmia	B-T046
and	O
ventricular ectopy	B-T047
.	O
DSE	B-T060
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	B-T033
in	O
blood potassium concentrations	B-T034
,	O
and	O
hence	O
cancellation	O
of	O
DSE	B-T060
in	O
patients	B-T101
with	O
potassium	B-T123
abnormalities	B-T033
does	O
not	O
appear	O
warranted.	O
Elevated	B-T080
potassium levels	B-T033
are	O
associated with	B-T080
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	B-T046
and	O
ventricular arrhythmias	B-T047
.	O
While	O
remaining	O
at	O
relatively	O
low	B-T080
risk	B-T078
,	O
patients	B-T101
with	O
very	O
low	B-T080
potassium levels	B-T033
(≤3.1	O
mmol/L)	O
at	O
the	O
time	O
of	O
DSE	B-T060
have	O
a	O
modestly	O
increased	B-T081
risk	B-T078
of	O
arrhythmia	B-T033
.	O
Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	B-T080
hypokalemia	B-T033
prior	B-T079
to	O
DSE	B-T060
.	O

Anatomical	B-T080
subgroup	B-T185
analysis	B-T062
of	O
the	O
MERIDIAN	B-UnknownType
cohort	B-T098
:	O
Posterior fossa abnormalities	B-T033
To	O
assess	B-T058
the	O
diagnostic	B-T169
and	O
clinical	B-T080
contribution	B-T052
of	O
in utero magnetic resonance (iuMR) imaging	B-T060
in	O
fetuses	B-T018
diagnosed	B-T033
with	O
abnormalities of the posterior fossa	B-T033
as	O
the	O
only	O
intracranial abnormality	B-T033
recognised	O
on	O
antenatal ultrasonography	B-T060
(	O
USS	B-T060
).	O
We	O
report	B-T170
a	O
sub-group	B-T185
analysis	B-T062
of	O
fetuses	B-T018
with	O
abnormalities of the posterior fossa	B-T033
diagnosed	B-T033
on	O
antenatal USS	B-T060
(with	O
or	O
without	O
ventriculomegaly	B-UnknownType
)	O
from	O
the	O
MERIDIAN	B-UnknownType
cohort	B-T098
who	O
had	O
iuMR imaging	B-T060
within	O
2	O
weeks	O
of	O
USS	B-T060
and	O
outcome	B-T080
reference data	B-T078
were	O
available	B-T169
.	O
The	O
diagnostic accuracy	B-T080
of	O
USS	B-T060
and	O
iuMR	B-T060
are	O
reported	B-T170
as	O
well	O
as	O
indicators	B-T130
of	O
diagnostic confidence	B-T080
and	O
effects	B-T080
on	O
prognosis	B-T058
and	O
clinical management	B-T058
.	O
Abnormalities confined to the posterior fossa	B-T033
according	O
to	O
USS	B-T060
were	O
found	O
in	O
81	O
fetuses	B-T018
(67	O
with	O
parenchymal	B-T025
and	O
14	O
with	O
CSF	B-T031
-containing	O
lesions	B-T033
).	O
The	O
overall	O
diagnostic accuracy	B-T080
for	O
detecting	B-T033
an	O
isolated	B-T169
posterior fossa abnormality	B-T033
was	O
65%	O
for	O
USS	B-T060
and	O
88%	O
for	O
iuMR	B-T060
(	O
difference	B-T081
=	O
22%,	O
95%	O
CI:	O
14.0	O
to	O
30.5%,	O
p	O
<	O
0.0001).	O
There	O
was	O
an	O
improvement	B-T077
in	O
'	O
appropriate	B-T080
'	O
diagnostic confidence	B-T080
as	O
assessed	B-T058
by	O
a	O
score	B-T081
-	O
based	B-T169
weighted	B-T081
average	B-T081
'	O
method	B-T170
(p	O
<	O
0.0001)	O
and	O
a	O
three-fold	O
reduction	B-T061
in	O
'high	B-T080
confidence	O
but	O
incorrect	B-T080
diagnoses	B-T033
'	O
was	O
achieved	O
by	O
using	O
iuMR imaging	B-T060
.	O
The	O
prognostic information	B-T058
given	O
to	O
the	O
women	B-T098
after	O
iuMR imaging	B-T060
changed	O
in	O
44%	O
of	O
cases	B-T077
and	O
the	O
overall	B-T080
effect	B-T080
of	O
iuMR	B-T060
on	O
clinical management	B-T058
was	O
considered	O
to	O
be	O
'	O
significant	B-T078
',	O
'	O
major	B-T080
'	O
or	O
'	O
decisive	B-T033
'	O
in	O
35%	O
of	O
cases	B-T077
.	O
Our	O
data	B-T078
suggests	O
that	O
any	O
woman	B-T098
whose	O
fetus	B-T018
has	O
a	O
posterior fossa abnormality	B-T033
as	O
the	O
only	O
intracranial finding	B-T033
on	O
USS	B-T060
should	O
have	O
iuMR imaging	B-T060
for	O
further	O
evaluation	B-T058
.	O
This	O
is	O
on	O
the	O
basis	B-T169
of	O
improved	B-T033
diagnostic accuracy	B-T080
and	O
confidence	B-T080
which	O
has	O
substantial	B-T080
effects	B-T080
on	O
the	O
prognostic information	B-T058
given	O
to	O
women	B-T098
and	O
changes	O
in	O
clinical management	B-T058
.	O

Design	B-T052
,	O
synthesis	B-T052
,	O
and	O
evaluation	B-T058
of	O
curcumin	B-T109
derivatives	B-T104
as	O
Nrf2	B-T116
activators	B-T045
and	O
cytoprotectors	B-T039
against	O
oxidative death	B-T043
Activation	B-T045
of	O
nuclear factor erythroid-2-related factor 2	B-T116
(	O
Nrf2	B-T116
)	O
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
means	O
to	O
prevent	O
the	O
development	O
of	O
cancer	B-T191
,	O
and	O
natural	O
curcumin	B-T109
stands	O
out	O
as	O
a	O
potent	O
Nrf2	B-T116
activator	B-T045
and	O
cancer	B-T191
chemopreventive agent	B-T121
.	O
In	O
this	O
study	B-T062
,	O
we	O
synthesized	O
a	O
series	O
of	O
curcumin	B-T109
analogs	B-T104
by	O
introducing	O
the	O
geminal dimethyl substituents on the active methylene group	B-T104
to	O
find	O
more	O
potent	O
Nrf2	B-T116
activators	B-T045
and	O
cytoprotectors	B-T039
against	O
oxidative death	B-T043
.	O
The	O
geminally dimethylated	B-T104
and	O
catechol	B-T109
-type	O
curcumin	B-T109
analog	B-T104
(	O
compound 3	B-T121
)	O
was	O
identified	O
as	O
a	O
promising	O
lead molecule	B-T121
in	O
terms	O
of	O
its	O
increased	O
stability	B-T044
and	O
cytoprotective	B-T039
activity	B-T052
against	O
the	O
tert-butyl hydroperoxide	B-T109
(	O
t-BHP	B-T109
)-induced	O
death	B-T043
of	O
HepG2 cells	B-T025
.	O
Mechanism	B-T169
studies	B-T062
indicate	O
that	O
its	O
cytoprotective	B-T039
effects	B-T080
are	O
mediated	O
by	O
activating	B-T052
the	O
Nrf2	B-T116
signaling pathway	B-T044
in	O
the	O
Michael acceptor	B-T121
-	O
and	O
catechol	B-T109
-dependent	O
manners.	O
Additionally,	O
we	O
verified	O
by	O
using	O
copper	B-T121
and	O
iron	B-T121
ion	B-T196
chelators	B-T121
that	O
the	O
two	O
metal	B-T197
ion	B-T196
-mediated	O
oxidations	B-T044
of	O
compound 3	B-T121
to	O
its	O
corresponding	O
electrophilic	O
o-quinone	B-T109
,	O
contribute	O
significantly	O
to	O
its	O
Nrf2	B-T116
-dependent	O
cytoprotection	B-T039
.	O
This	O
work	O
provides	O
an	O
example	O
of	O
successfully	O
designing	B-T052
natural	B-T169
curcumin	B-T109
-directed	O
Nrf2	B-T116
activators	B-T045
by	O
a	O
stability	B-T044
-increasing	O
and	O
proelectrophilic	B-T070
strategy.	O

Safe	B-T068
with	O
Self-Injury	B-T037
:	O
A	O
Practical Guide	B-T170
to	O
Understanding	B-T041
,	O
Responding	B-T053
and	O
Harm-reduction	B-T061
Inckle Kay	B-T170
Safe	B-T068
with	O
Self-Injury	B-T037
:	O
A	O
Practical Guide	B-T170
to	O
Understanding	B-T041
,	O
Responding	B-T053
and	O
Harm-reduction	B-T061
274pp	O
£23.99	O
PCCS	O
Books	O
9781910919163	O
1910919160	O
[Formula:	O
see	O
text	O
The	O
author	B-T097
begins	O
her	O
book	B-T170
with	O
a	O
concise	B-T081
exploration	B-T169
of	O
the	O
stereotypes	B-T041
and	O
truths	B-T080
of	O
self-harm	B-T037
.	O
In	O
the	O
following	O
seven	O
chapters	B-T170
,	O
she	O
sets	O
out	O
a	O
grounded	B-T170
and	O
often	O
challenging view	B-T082
of	O
how	O
self-harm	B-T037
is	O
understood	B-T041
from	O
differing	O
perspectives	B-T041
.	O

Pre-hospital	B-T079
policies	B-T170
for	O
the	O
care of patients	B-T058
with	O
acute coronary syndromes	B-T047
in	O
India	B-T083
:	O
A	O
policy	B-T170
document	B-T170
analysis	B-T062
Ischemic heart disease	B-T184
is	O
the	O
leading	B-T169
cause of death	B-T033
in	O
India	B-T083
.	O
In	O
high-income	B-T033
countries	B-T083
,	O
pre-hospital systems of care	B-T058
have	O
been	O
developed	O
to	O
manage	B-T058
acute	B-T079
manifestations of	B-T080
ischemic heart disease	B-T184
,	O
such	O
as	O
acute coronary syndrome	B-T047
(	O
ACS	B-T047
).	O
However,	O
it	O
is	O
unknown	B-T080
whether	O
guidelines	B-T170
,	O
policies	B-T170
,	O
regulations	B-T064
,	O
or	O
laws	B-T089
exist	B-T077
to	O
guide	O
pre-hospital	B-T079
ACS	B-T047
care	B-T058
in	O
India	B-T083
.	O
We	O
undertook	O
a	O
nation-wide	B-T082
document	B-T170
analysis	B-T062
to	O
address	O
this	O
gap	O
in	O
knowledge	B-T170
.	O
From	O
November	B-T079
2014	O
to	O
May	B-T079
2016,	O
we	O
searched	B-T052
for	O
publicly	B-T080
available	B-T169
emergency care	B-T061
guidelines	B-T170
and	O
legislation	B-T170
addressing	O
pre-hospital	B-T079
ACS	B-T047
care	B-T058
in	O
all	O
29	O
Indian	B-T083
states	B-T083
and	O
7	O
Union Territories	B-T083
via	O
Internet	B-T073
search	B-T052
and	O
direct	B-T080
correspondence	B-T170
.	O
We	O
found	B-T033
two	O
documents	B-T170
addressing	O
pre-hospital	B-T079
ACS	B-T047
care	B-T058
.	O
Though	O
India	B-T083
has	O
legislation mandating	B-UnknownType
acute care	B-T058
for	O
emergencies	B-T067
such	O
as	O
trauma	B-T037
,	O
regulations	B-T064
or	O
laws	B-T089
to	O
guide	O
pre-hospital	B-T079
ACS	B-T047
care	B-T058
are	O
largely	O
absent	B-T169
.	O
Policy makers	B-T097
urgently	B-T079
need	B-T080
to	O
develop	O
comprehensive	B-T080
,	O
multi-stakeholder	B-T080
policies	B-T170
for	O
pre-hospital	B-T079
emergency	B-T067
cardiovascular care	B-T058
in	O
India	B-T083
.	O

Lack	B-T080
of	O
antimicrobial	B-T034
efficacy	B-T080
of	O
mecetronium etilsulfate	B-T109
in	O
propanol	B-T109
-based	O
hand rubs	B-T121
for	O
surgical	B-T061
hand disinfection	B-T058
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
determine	O
if	O
mecetronium etilsulfate	B-T109
(	O
MES	B-T109
)	O
contributes	O
to	O
overall	O
efficacy	B-T080
in	O
surgical	B-T061
hand disinfection	B-T058
.	O
Three	O
blinded	O
hand rubs	B-T121
(45%	O
iso-propanol	B-T109
,	O
30%	O
n-propanol	B-T109
)	O
were	O
applied	B-T169
for	O
1.5	O
min	O
and	O
compared	B-T052
with	O
the	O
EN 12791	B-T121
reference	O
procedure	B-T169
(	O
crossover design	B-T062
).	O
One	O
commercial	B-T170
hand rub	B-T121
contained	O
0.2%	O
MES	B-T109
,	O
and	O
the	O
two	O
other	O
hand rubs	B-T121
were	O
identical	B-T080
apart	O
from	O
0.2%	O
MES	B-T109
.	O
None	O
of	O
the	O
formulations	B-T077
had	O
a	O
log10	B-T081
reduction	B-T080
after	O
3	O
h	O
that	O
was	O
significantly	O
better	B-T080
compared	B-T052
with	O
the	O
reference	O
procedure	B-T169
[	O
mean	B-T081
1.72	O
(	O
standard deviation	B-T081
1.15)].	O
The	O
antimicrobial	B-T034
contribution	B-T052
of	O
MES	B-T109
in	O
hand rubs	B-T121
is	O
questionable.	O

Skin Conductance	B-T042
Responses	B-T032
and	O
Neural	B-T169
Activations	B-T052
During	O
Fear	B-T041
Conditioning	B-T041
and	O
Extinction	B-T041
Recall	B-T041
Across	O
Anxiety Disorders	B-T048
The	O
fear	B-T041
conditioning	B-T041
and	O
extinction	B-T041
neurocircuitry	B-T062
has	O
been	O
extensively	B-T080
studied	B-T062
in	O
healthy	B-T080
and	O
clinical	B-T080
populations	B-T098
,	O
with	O
a	O
particular focus	B-T082
on	O
posttraumatic stress disorder	B-T048
.	O
Despite	O
significant	B-T078
overlap	B-T079
of	O
symptoms	B-T184
between	O
posttraumatic stress disorder	B-T048
and	O
anxiety disorders	B-T048
,	O
the	O
latter	O
has	O
received	B-T080
less	B-T081
attention	B-T041
.	O
Given	O
that	O
dysregulated	O
fear	B-T041
levels	B-T080
characterize	B-T052
anxiety disorders	B-T048
,	O
examining	B-T058
the	O
neural	B-T169
correlates	B-T080
of	O
fear	B-T041
and	O
extinction	B-T041
learning	B-T041
may	O
shed	O
light	O
on	O
the	O
pathogenesis	B-T046
of	O
underlying	O
anxiety disorders	B-T048
.	O
To	O
investigate	B-T169
the	O
psychophysiological	B-T041
and	O
neural	B-T169
correlates	B-T080
of	O
fear	B-T041
conditioning	B-T041
and	O
extinction	B-T041
recall	B-T041
in	O
anxiety disorders	B-T048
and	O
to	O
document	B-T170
how	O
these	O
features	B-T080
differ	O
as	O
a	O
function	B-T169
of	O
multiple	B-T081
diagnoses	B-T033
or	O
anxiety	B-T033
severity	B-T080
.	O
This	O
investigation	B-T058
was	O
a	O
cross-sectional	B-T062
,	O
case-control	B-T058
,	O
functional magnetic resonance imaging	B-T060
study	B-T062
at	O
an	O
academic medical center	B-T073
.	O
Participants	B-T098
were	O
healthy	B-T080
controls	B-T096
and	O
individuals	B-T098
with	O
at	O
least	O
1	O
of	O
the	O
following	B-T079
anxiety disorders	B-T048
:	O
generalized anxiety disorder	B-T048
,	O
social anxiety disorder	B-T048
,	O
specific phobia	B-T048
,	O
and	O
panic disorder	B-T048
.	O
The	O
study	B-T062
dates	B-T079
were	O
between	O
March	O
2013	O
and	O
May	O
2015.	O
Two-day	O
fear	B-T041
conditioning	B-T041
and	O
extinction	B-T041
paradigm	B-T062
.	O
Skin conductance	B-T042
responses	B-T032
,	O
blood oxygenation level-dependent	B-T042
responses	B-T032
,	O
trait	B-T032
anxiety scores	B-T033
from	O
the	O
State Trait Anxiety Inventory	B-T060
-	O
Trait	B-T032
Form	B-T080
,	O
and	O
functiona	B-T169
l	O
connectivity	B-T169
.	O
This	O
study	B-T062
included	B-T052
21	O
healthy	B-T080
controls	B-T096
(10	O
women	B-T098
)	O
and	O
61	O
individuals	B-T098
with	O
anxiety disorders	B-T048
(36	O
women	B-T098
).	O
P values	B-T081
reported	B-T058
for	O
the	O
neuroimaging	B-T060
results	B-T034
are	O
all	O
familywise	B-T099
error	B-T080
corrected	B-T080
.	O
Skin conductance	B-T042
responses	B-T032
during	O
extinction	B-T041
recall	B-T041
did	O
not	O
differ	O
between	O
individuals	B-T098
with	O
anxiety disorders	B-T048
and	O
healthy	B-T080
controls	B-T096
(	O
ηp2	B-T081
=	O
0.001,	O
P	O
=	O
.79),	O
where	O
ηp2	B-T081
is	O
partial eta squared	B-T081
.	O
The	O
anxiety	B-T033
group	B-T098
had	O
lower	B-T080
activation	B-T052
of	O
the	O
ventromedial prefrontal cortex	B-T023
(	O
vmPFC	B-T023
)	O
during	O
extinction	B-T041
recall	B-T041
(	O
ηp2	B-T081
=	O
0.178,	O
P	O
=	O
.02).	O
A	O
similar	O
hypoactive	B-T033
pattern	B-T082
was	O
found	O
during	O
early	B-T079
conditioning	B-T041
(	O
ηp2	B-T081
=	O
0.106,	O
P	O
=	O
.009).	O
The	O
vmPFC	B-T023
hypoactivation	B-T052
was	O
associated with	B-T080
anxiety symptom	B-T033
severity	B-T080
(r	O
=	O
-0.420,	O
P	O
=	O
.01	O
for	O
conditioning	B-T041
and	O
r	O
=	O
-0.464,	O
P	O
=	O
.004	O
for	O
extinction	B-T041
recall	B-T041
)	O
and	O
the	O
number	B-T081
of	O
co-occuring	B-T052
anxiety disorders	B-T048
diagnosed	B-T033
(	O
ηp2	B-T081
=	O
0.137,	O
P	O
=	O
.009	O
for	O
conditioning	B-T041
and	O
ηp2	B-T081
=	O
0.227,	O
P	O
=	O
.004	O
for	O
extinction	B-T041
recall	B-T041
).	O
Psychophysiological	B-T041
interaction analyses	B-T081
revealed	B-T080
that	O
the	O
fear	B-T041
network connectivity	B-T040
differed	O
between	O
healthy	B-T080
controls	B-T096
and	O
the	O
anxiety	B-T033
group	B-T098
during	O
fear	B-T041
learning	B-T041
(	O
ηp2	B-T081
range	B-T081
between	O
0.088	O
and	O
0.176	O
and	O
P	B-T081
range	B-T081
between	O
0.02	O
and	O
0.003)	O
and	O
extinction	B-T041
recall	B-T041
(	O
ηp2	B-T081
range	B-T081
between	O
0.111	O
and	O
0.235	O
and	O
P	B-T081
range	B-T081
between	O
0.02	O
and	O
0.002).	O
Despite	O
no	O
skin conductance	B-T042
response	B-T032
group	B-T098
differences	B-T081
during	O
extinction	B-T041
recall	B-T041
,	O
brain	B-T023
activation	B-T052
patterns	B-T082
between	O
anxious	B-T048
and	O
healthy	B-T080
individuals	B-T098
differed.	O
These	O
findings	B-T033
encourage	O
future	B-T079
studies	B-T062
to	O
examine	B-T058
the	O
conditions	B-T080
longitudinally	B-T062
and	O
in	O
the	O
context	B-T078
of	O
treatment trials	B-T062
to	O
improve	B-T033
and	O
guide therapeutics	B-T061
via	O
advanced	B-T080
neurobiological	B-T091
understanding	B-T041
of	O
each	O
disorder	B-T047
.	O

Extracellular vesicles	B-T026
from	O
bone marrow	B-T024
derived	O
mesenchymal stem cells	B-T025
protect	B-T033
against	O
murine	B-T015
hepatic ischemia	B-T046
hepatic ischemia - reperfusion injury	B-T037
reperfusion injury	B-T037
Hepatic ischemia-reperfusion injury	B-T037
(	O
IRI	B-T037
)	O
and	O
associated inflammation	B-T046
contributes	O
to	O
liver dysfunction	B-T046
and	O
complications	B-T046
after	O
liver surgery	B-T061
and	O
transplantation	B-T061
.	O
Mesenchymal stem cells	B-T025
(	O
MSC	B-T025
)	O
have	O
been	O
reported	O
to	O
reduce	B-T080
hepatic IRI	B-T037
because	O
of	O
their	O
reparative	B-T058
immunomodulatory	B-T121
immunomodulatory effects	B-T080
in	O
injured	B-T169
tissues	B-T024
.	O
Recent	O
studies	O
have	O
highlighted	O
beneficial effects	B-T080
of	O
extracellular vesicles	B-T026
from	O
MSCs	B-T025
(	O
MSC	B-T025
-	O
EV	B-T026
)	O
on	O
tissue injury	B-T033
.	O
The	O
effects	O
of	O
systemically administered	B-UnknownType
mouse bone marrow	B-T024
derived	O
MSC	B-T025
-	O
EV	B-T026
were	O
evaluated	B-T062
in	O
an	O
experimental murine model	B-T008
of	O
hepatic IRI	B-T037
induced	B-T169
by	O
cross clamping	B-T169
the	O
hepatic artery	B-T023
and	O
portal vein	B-T023
for	O
90	O
minutes	B-T079
followed	O
by	O
reperfusion	B-T061
for	O
periods	B-T079
of	O
upto	O
6	O
hours	B-T079
.	O
Compared	O
with	O
controls, intravenous administration	B-T082
of	O
MSC	B-T025
-	O
EV	B-T026
30	O
minutes	B-T079
prior	O
to	O
IRI	B-T037
dramatically reduced	B-T080
the	O
extent	O
of	O
tissue necrosis	B-T042
,	O
decreased	B-T081
caspase-3 positive	B-T116
and	O
apoptotic cells	B-T026
,	O
and	O
reduced	B-T080
serum	O
aminotransferase	B-T116
levels.	O
MSC	B-T025
-	O
EV	B-T026
increased	B-T081
hepatic	B-T029
mRNA expression	B-T045
of	O
NACHT, LRR and PYD domains-containing protein 12	B-T028
(	O
Nlrp12	B-T028
),	O
and	O
the	O
chemokine (C-X-C motif) ligand 1	B-T028
(	O
CXCL1	B-T028
),	O
and	O
reduced	B-T080
mRNA expression	B-T045
of	O
several	O
inflammatory	B-T169
cytokines	B-T116
such	O
as	O
IL-6	B-T116
during	O
IRI	B-T037
.	O
MSC	B-T025
-	O
EV	B-T026
increased	B-T081
cell viability	B-T043
and	O
suppressed	B-T169
both	O
oxidative	B-T169
injury	B-T080
and	O
NF-κB	B-T116
activity	B-T052
in	O
AML12 murine hepatocytes	B-T025
in vitro	B-T080
.	O
In	O
conclusion,	O
the	O
administration	B-T061
of	O
EV	B-T026
derived	O
from	O
bone marrow	B-T024
derived	O
MSCs	B-T025
may	O
ameliorate	B-T033
hepatic IRI	B-T037
by	O
reducing	B-T080
hepatic injury	B-T037
through	O
modulation	B-T082
of	O
the	O
inflammatory response	B-T046
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Nucleic acid detection	B-T059
with	O
CRISPR	B-T114
-	O
Cas13a	B-T116
/	O
C2c2	B-T116
Rapid	B-T080
,	O
inexpensive,	O
and	O
sensitive	B-T169
nucleic acid detection	B-T059
may	O
aid	B-T080
point-of-care	B-T078
pathogen	B-T001
detection	B-T061
,	O
genotyping	B-T059
,	O
and	O
disease	B-T047
monitoring	B-T058
.	O
The	O
RNA	B-T114
-guided,	O
RNA	B-T114
-	O
targeting	B-T169
clustered regularly interspaced short palindromic repeats	B-T114
(	O
CRISPR	B-T114
)	O
effector	B-T116
Cas13a	B-T116
(previously	O
known	O
as	O
C2c2	B-T116
)	O
exhibits	O
a	O
"	O
collateral	B-T082
effect	B-T080
"	O
of	O
promiscuous	O
ribonuclease activity	B-T045
upon	O
target	B-T169
recognition	B-T044
.	O
We	O
combine	B-T080
the	O
collateral	B-T082
effect	B-T080
of	O
Cas13a	B-T116
with	O
isothermal amplification	B-T059
to	O
establish	B-T080
a	O
CRISPR	B-T114
-based	O
diagnostic	B-T169
(	O
CRISPR	B-T114
-	O
Dx	B-T169
),	O
providing	O
rapid	B-T080
DNA	B-T114
or	O
RNA	B-T114
detection	B-T061
with	O
attomolar sensitivity	B-T081
and	O
single-base	B-T114
mismatch	B-T080
specificity	B-T081
.	O
We	O
use	O
this	O
Cas13a	B-T116
-based	O
molecular	B-T080
detection	B-T061
platform	B-T075
,	O
termed	O
Specific High-Sensitivity Enzymatic Reporter UnLOCKing	B-T075
(	O
SHERLOCK	B-T075
),	O
to	O
detect	B-T033
specific	B-T080
strains	B-T001
of	O
Zika	B-T005
and	O
Dengue virus	B-T005
,	O
distinguish	O
pathogenic	B-T001
bacteria	B-T007
,	O
genotype	B-T032
human	B-T016
DNA	B-T114
,	O
and	O
identify	B-T080
mutations	B-T045
in	O
cell-free	B-T026
tumor DNA	B-T114
.	O
Furthermore,	O
SHERLOCK	B-T075
reaction	B-T169
reagents	B-T130
can	O
be	O
lyophilized	B-T059
for	O
cold-chain	B-T066
independence	O
and	O
long-term	B-T079
storage	B-T169
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field applications	B-UnknownType
.	O

A	O
plea	O
for	O
thoracoscopic	B-T058
resection	B-T061
of	O
solitary pulmonary nodule	B-T191
in	O
cancer	B-T191
patients	B-T101
Solitary pulmonary nodules	B-T191
(	O
SPN	B-T191
)	O
are	O
frequently	O
detected	B-T033
in	O
cancer	B-T191
patients	B-T101
.	O
These	O
lesions	B-T033
are	O
often	O
considered	O
as	O
pulmonary metastases	B-T191
and	O
increasingly	B-T169
treated	B-T169
by	O
non-surgical techniques	B-T061
without	O
histological	B-T169
confirmation	B-T033
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
histological	B-T169
nature	B-T169
of	O
SPN	B-T191
resected	B-T080
by	O
thoracoscopy	B-T058
and	O
to	O
identify	O
risk factors	B-T033
of	O
malignancy	B-T191
.	O
Single-institution retrospective analysis	B-T062
of	O
all	O
consecutive	B-T080
patients	B-T101
with	O
previously	O
known	O
malignancies	B-T191
who	O
underwent	O
thoracoscopic	B-T058
resection	B-T061
of	O
SPN	B-T191
with	O
unknown	B-T080
diagnosis	B-T033
between	O
2001	O
and	O
2014.	O
One	O
hundred	O
and	O
forty	O
cancer	B-T191
patients	B-T101
underwent	O
thoracoscopic	B-T058
resection	B-T061
of	O
a	O
SPN	B-T191
.	O
The	O
resected	B-T080
SPN	B-T191
was	O
benign	B-T080
in	O
34	O
patients	B-T101
(24.3%)	O
and	O
malignant	B-T080
in	O
106	O
patients	B-T101
.	O
The	O
latter	O
were	O
metastasis	B-T191
in	O
70	O
patients	B-T101
(50%)	O
and	O
a	O
primary	B-T080
lung cancer	B-T191
in	O
36	O
patients	B-T101
(25.7%).	O
Upon	O
univariate analysis	B-T062
,	O
malignancy	B-T191
was	O
significantly	O
associated with	B-T080
age	B-T032
>60	O
years	B-T079
,	O
disease	B-T047
-free	O
interval	B-T079
≥24	O
months	B-T079
,	O
SPN	B-T191
size	B-T082
>8	O
mm,	O
upper lobe	B-T023
localization	B-T169
and	O
SUVmax	B-T081
>	O
2.5	O
on	O
PET-CT	B-T060
.	O
Upon	O
multivariate analysis	B-T081
,	O
upper lobe	B-T023
localization	B-T169
and	O
SUVmax	B-T081
>	O
2.5	O
were	O
associated with	B-T080
malignancy	B-T191
.	O
Smoking	B-T055
was	O
significantly	O
associated with	B-T080
SPN	B-T191
containing	O
primary	B-T080
lung cancer	B-T191
.	O
In	O
this	O
series	B-T081
,	O
only	O
50%	O
of	O
SPN	B-T191
in	O
patients	B-T101
with	O
known	O
malignant disease	B-T047
were	O
pulmonary metastases	B-T191
and	O
25%	O
had	O
a	O
newly diagnosed	B-T080
NSCLC	B-T191
.	O
Smoking	B-T055
was	O
associated with	B-T080
primary	B-T080
lung cancer	B-T191
but	O
no	B-T033
other	O
predictor	B-T078
was	O
found	O
to	O
allow	O
the	O
distinction	O
between	O
pulmonary metastasis	B-T191
and	O
lung cancer	B-T191
.	O
These	O
results	O
endorse	O
the	O
need	O
of	O
histological	B-T169
confirmation	B-T033
of	O
SPN	B-T191
in	O
patients	B-T101
with	O
previous	B-T079
malignancies	B-T191
to	O
avoid	O
diagnostic	B-T169
uncertainty	B-T033
and	O
suboptimal	B-T080
treatments	B-T061
.	O

Reliability	B-T080
of	O
Fear Assessment	B-T058
in	O
Growing	B-T033
Pigs	B-T015
Exposed to	B-T080
a	O
Novel	B-T080
Object	B-T072
Test	B-T169
in	O
Commercial	B-T170
Conditions	B-T080
The	O
objective	B-T170
of	O
this	O
study	O
was	O
to	O
assess	B-T052
the	O
reliability	B-T080
and	O
feasibility	B-T062
of	O
a	O
novel	B-T080
object	B-T072
test	B-T169
assessing fear	B-T058
in	O
pigs	B-T015
in	O
commercial	B-T170
conditions	B-T080
.	O
A	O
total	O
of	O
18	O
commercial	B-T170
farms	B-T082
were	O
visited,	O
and	O
321	O
pens housing	B-T073
4,220	O
growing	B-T033
pigs	B-T015
were	O
assessed	B-T052
.	O
Three	O
balloons	B-T073
were	O
used	O
as	O
a	O
novel	B-T015
stimulus	B-T067
.	O
Measures	B-T081
were	O
(a)	O
the	O
time	B-T079
it	O
took	O
for	O
the	O
first	O
pig	B-T015
to	O
contact	B-T067
1	O
of	O
the	O
balloons	B-T073
,	O
(b)	O
percentage	O
of	O
nonhuman	B-T015
animals	B-T008
watching	B-T041
the	O
balloons	B-T073
each	O
for	O
10	O
s,	O
and	O
(c)	O
percentage	O
of	O
animals	B-T008
touching	B-T169
the	O
balloons	B-T073
during	O
periods	B-T079
of	O
5	O
s.	O
The	O
time	B-T079
of	O
the	O
first	O
pig	B-T015
to	O
contact	B-T067
1	O
of	O
the	O
balloons	B-T073
ranged	B-T081
from	O
0	O
s	O
to	O
362	O
s.	O
An	O
effect	B-T080
of	O
the	O
farm	B-T082
was	O
found	O
(p	O
<	O
.0001)	O
for	O
contact	B-T067
latency	B-T079
,	O
ranging	B-T081
from	O
6.8	O
s	O
to	O
73.3	O
s,	O
but	O
little	O
difference	B-T080
was	O
found	O
in	O
terms	O
of	O
intrafarm	B-T082
variability	B-T077
.	O
Interobserver repeatability	B-T170
was	O
also	O
high	B-T080
in	O
this	O
measure	B-T081
,	O
ranging	B-T081
from	O
r	O
=	O
.74	O
to	O
r	O
=	O
.96.	O
As	O
a	O
result,	O
it	O
is	O
concluded	O
that	O
contact	B-T067
latency	B-T079
could	O
be	O
a	O
good	O
measure	B-T081
to	O
assess	B-T052
fear	B-T041
of	O
a	O
novel	O
stimulus	B-T067
in	O
commercial	B-T170
farms	B-T082
.	O

Precise	O
prediction	B-T078
of	O
activators	B-T121
for	O
the	O
human	B-T016
constitutive androstane receptor	B-T116
using	O
structure	B-T085
-based	O
three-dimensional quantitative structure-activity relationship	B-T081
methods	B-T170
The	O
constitutive androstane receptor	B-T116
(	O
CAR	B-T116
,	O
NR1I3)	B-T116
regulates the expression	B-T045
of	O
numerous	B-T081
drug-metabolizing	B-T044
enzymes	B-T116
and	O
transporters	B-T116
.	O
The	O
upregulation	B-T044
of	O
various	O
enzymes	B-T116
,	O
including	O
CYP2B6	B-T116
,	O
by	O
CAR	B-T116
activators	B-T121
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	B-T080
drug-drug interactions	B-T044
(	O
DDIs	B-T044
).	O
To	O
date,	O
however,	O
few	O
effective	B-T080
computational approaches	B-T062
for	O
identifying	O
CAR	B-T116
activators	O
exist.	O
In	O
this	O
study,	O
we	O
aimed	O
to	O
develop	O
three-dimensional quantitative structure-activity relationship	B-T081
(	O
3D-QSAR	B-T081
)	O
models	B-T170
to	O
predict	O
the	O
CAR	B-T116
activating	B-T043
potency	B-T080
of	O
compounds	B-T121
emerging	O
in	O
the	O
drug-discovery	B-T062
process	B-T067
.	O
Models	B-T170
were	O
constructed	O
using	O
comparative molecular field analysis	B-T063
(	O
CoMFA	B-T063
)	O
based	O
on	O
the	O
molecular	B-T167
alignments	B-T081
of	O
ligands binding	B-T044
to	O
CAR	B-T116
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand-docking	B-T044
using	O
28 compounds	B-T121
as	O
a	O
training	O
set.	O
The	O
CoMFA	B-T063
model	B-T170
,	O
modified by	B-T080
adding	O
a	O
lipophilic	B-T081
parameter	B-T081
with	O
calculated	O
logD7.4	O
(S+logD7.4),	O
demonstrated	O
statistically	O
good	O
predictive ability	B-T080
(r(2)	O
=	O
0.99,	O
q(2)	O
=	O
0.74).	O
We	O
also	O
confirmed	O
the	O
excellent	O
predictability	B-T081
of	O
the	O
3D-QSAR	B-T081
model	B-T170
for	O
CAR	B-T116
activation	B-T043
(r(2)pred	O
=	O
0.71)	O
using	O
seven	O
compounds	B-T121
as	O
a	O
test	O
set	O
for	O
external validation	B-T062
.	O
Collectively,	O
our	O
results	B-T169
indicate	O
that	O
the	O
3D-QSAR	B-T081
model	B-T170
developed	O
in	O
this	O
study	O
provides	O
precise	B-T080
prediction	B-T078
of	O
CAR	B-T116
activating	B-T043
potency	B-T080
and,	O
thus,	O
should	O
be	O
useful	O
for	O
selecting	O
drug candidates	B-T121
with	O
minimized	B-T080
DDI	B-T044
risk	B-T078
related	O
to	O
enzyme-induction	B-T045
in	O
the	O
early	B-T079
drug-discovery	B-T062
stage	B-T079
.	O

Effects of	B-T080
siRNA	B-T114
-mediated	O
suppression	B-T045
of	O
HPV-11 L1	B-T028
expression	B-T045
on	O
the	O
proliferation	B-T043
and	O
apoptosis	B-T043
of	O
vaginal epithelial cells	B-T025
The	O
aim	B-T078
of	O
the	O
present	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
effects of	B-T080
human papillomavirus (HPV) infection	B-T047
on	O
the	O
gynecological disease	B-T047
of	O
vaginitis	B-T047
and	O
to	O
demonstrate	O
how	O
the	O
small interfering RNA	B-T114
(	O
siRNA	B-T114
)	O
method	O
may	O
be	O
used	O
for	O
HPV	B-T005
prevention	B-T061
in	O
the	O
clinic	B-T073
.	O
Human	B-T016
vaginal epithelial cells	B-T025
were	O
transfected	B-T063
with	O
HPV-11 L1	B-T028
expression vector	B-T114
and	O
siRNA	B-T114
-	O
HPV-11 L1	B-T028
vectors	B-T114
and	O
a	O
control group	B-T096
was	O
transfected	B-T063
with	O
scrambled	O
siRNA	B-T114
.	O
Cell proliferation	B-T043
in	O
each	O
group	O
was	O
analyzed	O
using	O
the	O
MTT assay	B-T059
and	O
the	O
expression	B-T045
of	O
apoptosis	B-T043
-associated	O
proteins	B-T116
was	O
measured	B-T080
by	O
western blot analysis	B-T059
.	O
Compared	B-T052
with	O
the	O
control group	B-T096
,	O
HPV-11 L1	B-T028
mRNA	B-T114
and	O
protein levels	B-T034
were	O
significantly	O
increased	B-T081
following	O
transfection	B-T063
with	O
the	O
HPV-11 L1	B-T028
expression vector	B-T114
in	O
cells	B-T025
(P<0.05),	O
but	O
this	O
result	O
was	O
significantly	O
reversed	O
by	O
silencing	B-T045
of	O
HPV-11 L1	B-T028
(P<0.05).	O
In	O
addition,	O
cell proliferation	B-T043
in	O
the	O
HPV-11 group	B-T078
was	O
lower	B-T080
than	O
that	O
in	O
the	O
control group	B-T096
;	O
however,	O
cell proliferation	B-T043
was	O
significantly	O
increased	B-T081
in	O
cells	B-T025
transfected	B-T063
with	O
silenced	B-T045
L1	B-T028
compared	O
with	O
that	O
in	O
the	O
control group	B-T096
(P<0.05).	O
Furthermore,	O
silencing	B-T045
of	O
HPV-11 L1	B-T028
significantly	O
decreased	B-T081
caspase-3	B-T028
and	O
caspase-9	B-T028
expressions	B-T045
in	O
cells	B-T025
,	O
whereas	O
the	O
expression	B-T045
was	O
increased	B-T081
in	O
the	O
HPV-11 L1	B-T028
group	O
(P<0.05).	O
The	O
present	O
study	B-T062
suggested	O
that	O
siRNA	B-T114
-mediated	O
silencing	B-T045
of	O
HPV-11 L1	B-T028
may	O
have	O
potential	O
therapeutic applications	B-T061
for	O
treating	O
gynecological diseases	B-T047
associated with	B-T080
HPV-11	B-T005
infection	B-T046
.	O

An	O
evaluation	B-T058
of	O
neuroendocrine	B-T022
dysfunction	B-T077
following	O
acute	B-T079
aneurysmal subarachnoid hemorrhage	B-T046
:	O
A	O
prospective study	B-T062
The	O
aim	B-T078
was	O
to	O
investigate	B-T169
the	O
incidence	O
and	O
pattern	B-T082
of	O
neuroendocrine	B-T022
changes	O
in	O
cases	B-T101
of	O
acute	B-T079
aneurysmal subarachnoid hemorrhage	B-T046
(	O
SAH	B-T046
).	O
Endocrine	B-T022
assessment	B-T058
was	O
performed	O
in	O
100	O
consecutive	O
cases	B-T101
of	O
acute	B-T079
aneurysmal SAH	B-T046
presenting	O
within	O
7	O
days	B-T079
of	O
ictus	B-T047
.	O
The	O
gonadotropic	B-T116
,	O
somatotrophic	B-T116
,	O
thyrotropic	B-T116
,	O
and	O
corticotrophic	B-T116
axes	O
were	O
evaluated	B-T058
for	O
their	O
possible	O
dysfunction	B-T077
.	O
A	O
total	O
of	O
100	O
cases	B-T101
(38	O
males	B-T032
,	O
62	O
females	B-T032
;	O
age	B-T032
range	B-T081
-	O
17-76	O
years	B-T079
;	O
mean	B-T081
age	B-T032
-	O
43.6	O
years	B-T079
)	O
of	O
acute	B-T079
SAH	B-T046
were	O
studied	B-T062
.	O
The	O
aneurysms	B-T047
were	O
located	O
in	O
the	O
anterior circulation	B-T042
(n	O
=	O
95)	O
and	O
posterior circulation	B-T042
(n	O
=	O
5).	O
The	O
most	O
common	O
hormone deficiency	B-T047
was	O
of	O
growth hormone	B-T116
(n	O
=	O
67),	O
followed	O
by	O
gonadotrophin	B-T116
(n	O
=	O
50),	O
corticotrophin	B-T116
(n	O
=	O
49)	O
and	O
thyrotrophin	B-T116
(n	O
=	O
35).	O
Hyperprolactinemia	B-T047
was	O
noted	O
in	O
10	O
cases	B-T101
.	O
One-pituitary hormone axis deficiency	B-T033
was	O
noted	O
in	O
26	O
cases	B-T101
while	O
67	O
cases	B-T101
had	O
two	O
or	O
more	O
pituitary hormone	B-T116
axes	O
dysfunction	B-T077
.	O
A	O
total	O
of	O
93	O
cases	B-T101
had	O
hormonal	B-T125
dysfunction	B-T077
in	O
one	O
or	O
more	O
pituitary hormone axes	B-T116
,	O
and	O
seven	O
cases	B-T101
had	O
no	O
hormonal	B-T125
dysfunction	B-T077
.	O
Endocrine dysfunction	B-T047
occurs	O
in	O
93%	O
cases	B-T101
of	O
acute	B-T079
SAH	B-T046
and	O
multiple	O
pituitary hormone axes	B-T116
dysfunction	B-T077
occurs	O
in	O
67%	O
cases	B-T101
.	O
It	O
is	O
suggested	O
that	O
hormonal	B-T125
evaluation	B-T058
should	O
be	O
considered	O
as	O
part	O
of	O
management	O
of	O
acute	B-T079
SAH	B-T046
.	O

Validity	B-T081
and	O
reliability	B-T081
of	O
fluoroscopy	B-T060
for	O
digital radiography	B-T060
:	O
a	O
new	O
way	O
to	O
evaluate	B-T058
diaphragmatic	B-T023
mobility	B-T070
Fluoroscopy	B-T060
is	O
considered	O
the	O
most	O
accurate	O
method	B-T062
to	O
evaluate	B-T058
the	O
diaphragm	B-T023
,	O
yet	O
most	O
existing	O
methods	B-T062
for	O
measuring	O
diaphragmatic	B-T023
mobility	B-T070
using	O
fluoroscopy	B-T060
are	O
complex.	O
To	O
assess	O
the	O
validity	B-T081
and	O
reliability	B-T081
of	O
a	O
new	O
evaluation method	B-T062
of	O
diaphragmatic	B-T023
motion	B-T070
using	O
fluoroscopy	B-T060
by	O
digital radiography	B-T060
of	O
healthy	B-T080
adults	B-T100
.	O
Twenty-six	O
adults	B-T100
were	O
evaluated	B-T058
,	O
according	O
to	O
the	O
parameters:	O
anthropometry	B-T062
and	O
pulmonary function test	B-T060
.	O
The	O
evaluation	B-T058
of	O
diaphragm	B-T023
mobility	B-T070
by	O
means	O
of	O
fluoroscopy	B-T060
by	O
digital radiography	B-T060
method	B-T062
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
(A	O
and	O
B).	O
The	O
Pearson correlation coefficient	B-T081
and	O
the	O
intraclass correlation coefficient	B-T081
(	O
ICC	B-T081
)	O
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	B-T081
.	O
The	O
inter-rater	O
and	O
intra-rater	O
reliability	B-T081
of	O
the	O
measurement	B-T169
of	O
diaphragmatic	B-T023
motion	B-T070
was	O
determined	O
using	O
ICC	B-T081
and	O
a	O
confidence	O
interval	O
of	O
95%.	O
There	O
was	O
a	O
relationship	B-T080
in	O
the	O
assessment	B-T058
of	O
the	O
concurrent	O
validity	B-T081
.	O
There	O
was	O
good	O
inter-rater	O
reliability	B-T081
for	O
right	O
hemidiaphragm	B-T023
mobility	B-T070
and	O
moderate	O
reliability	B-T081
for	O
left hemidiaphragm	B-T023
in	O
the	O
first	O
assessment	B-T058
.	O
In	O
the	O
second	O
assessment	B-T058
,	O
there	O
was	O
good	O
reliability	B-T081
for	O
the	O
mobility	B-T070
of	O
both	O
hemidiaphragms	B-T023
.	O
There	O
was	O
good	O
intra-rater	O
reliability	B-T081
in	O
the	O
mobility	B-T070
of	O
both	O
hemidiaphragms	B-T023
for	O
raters	O
A	O
and	O
B.	O
The	O
evaluation	B-T058
of	O
diaphragmatic	B-T023
motion	B-T070
using	O
fluoroscopy	B-T060
by	O
digital radiography	B-T060
proved	O
to	O
be	O
a	O
valid	B-T080
and	O
reliable	B-T080
method	B-T062
of	O
healthy	B-T080
adults	B-T100
.	O

Loss of control	B-T080
over	O
alcohol seeking	B-UnknownType
in	O
rats	B-T015
depends	O
on	O
individual	B-T098
vulnerability	B-T033
and	O
duration	O
of	O
alcohol consumption	B-T055
experience	O
Alcohol use disorder	B-T048
(	O
AUD	B-T048
)	O
is	O
characterized	O
by	O
excessive alcohol use	B-T033
and	O
persistent	B-T079
alcohol seeking	B-UnknownType
despite	O
knowledge	O
of	O
its	O
negative	O
consequences.	O
Importantly,	O
AUD	B-T048
typically	O
develops	O
after	O
chronic	B-T079
excessive alcohol use	B-T033
in	O
a	O
subgroup	B-T185
of	O
individuals	B-T098
who	O
drink alcohol	B-T033
,	O
suggesting	O
that	O
AUD	B-T048
results	O
from	O
an	O
interaction	B-T169
between	O
individual	B-T098
vulnerability	B-T033
and	O
prolonged alcohol exposure	B-T051
.	O
The	O
present	O
study	B-T062
assessed	B-T052
the	O
contribution	O
of	O
prolonged exposure to alcohol	B-T051
and	O
individual levels of alcohol intake	B-T055
to	O
the	O
development	B-T169
of	O
loss of control	B-T080
over	O
alcohol seeking	B-UnknownType
in	O
a	O
conditioned suppression model	B-T170
.	O
To	O
investigate	B-T169
the	O
impact	O
of	O
prolonged alcohol exposure	B-T051
,	O
conditioned suppression	B-T169
of	O
alcohol seeking	B-UnknownType
was	O
assessed	B-T052
after	O
2	O
and	O
4	O
months	O
of	O
intermittent alcohol access	B-T079
(	O
IAA	B-T079
)	O
in	O
a	O
subgroup	B-T185
of	O
rats	B-T015
drinking	O
moderate	O
amounts	O
of	O
alcohol.	O
We	O
observed	O
that	O
suppression	B-T169
of	O
alcohol seeking	B-UnknownType
was	O
reduced	O
after	O
4	O
months	O
compared	O
with	O
2	O
months	O
of	O
IAA	B-T079
.	O
The	O
influence	B-T077
of	O
individual	O
levels	O
of	O
alcohol intake	B-T055
on	O
loss of control	B-T080
over	O
alcohol seeking	B-UnknownType
was	O
subsequently	O
determined by	B-T080
assessing	B-T052
conditioned suppression	B-T169
in	O
subgroups	B-T185
of	O
low and high alcohol drinking	B-T080
rats	B-T015
.	O
Unlike	O
the	O
low alcohol drinking	B-T080
rats	B-T015
,	O
the	O
high alcohol drinking	B-T080
rats	B-T015
showed	O
aversion-resistant	B-T169
alcohol seeking	B-UnknownType
after	O
2	O
months	O
of	O
IAA	B-T079
,	O
although	O
both	O
groups	B-T078
showed	O
comparable	O
levels	O
of	O
conditioned	O
freezing.	O
These	O
findings	O
show	O
that	O
the	O
development	O
of	O
loss of control	B-T080
over	O
alcohol seeking	B-UnknownType
,	O
a	O
key	O
characteristic	O
of	O
AUD	B-T048
in	O
humans	B-T016
,	O
is	O
dependent	O
on	O
both	O
the	O
extent	O
of	O
alcohol exposure	B-T051
and	O
the	O
individual's	B-T098
propensity	O
to	O
consume	O
alcohol.	O

Neural	B-T169
correlates	B-T041
of	O
experimental	B-T080
trauma	B-T037
memory retrieval	B-T041
Traumatic	B-T169
memories	B-T041
such	O
as	O
intrusions	B-T185
and	O
flashbacks	B-T033
play	O
a	O
major	O
role	O
in	O
the	O
development	B-T169
and	O
maintenance	B-T052
of	O
post-traumatic stress disorder	B-T048
(	O
PTSD	B-T048
).	O
A	O
thorough	O
understanding	O
of	O
the	O
neural	B-T169
mechanisms	B-T169
underlying	O
traumatic	B-T169
memories	B-T041
is	O
indispensable	O
for	O
precise	O
diagnosis	B-T033
,	O
for	O
personalized	B-T080
treatment	B-T061
and	O
prevention	B-T061
.	O
In	O
particular,	O
the	O
identification	B-T080
of	O
early	O
neural	B-T169
predictor variables	B-T170
for	O
intrusion	B-T185
development	B-T169
shortly	O
after	O
trauma	B-T037
exposure	B-T080
requires	O
detailed	O
investigation	B-T058
.	O
Here,	O
we	O
examined	B-T033
the	O
neural correlates	B-T041
of	O
early	O
experimental	B-T080
trauma	B-T037
memory retrieval	B-T041
in	O
a	O
traumatic film paradigm	B-T062
in	O
42	O
young	O
healthy	B-T080
females	B-T032
,	O
using	O
both	O
implicit	B-T033
and	O
explicit	B-T041
retrieval tasks	B-T041
.	O
We	O
show	O
that	O
implicit	B-T033
experimental	B-T080
trauma	B-T037
retrieval	B-T041
specifically	O
involved	O
the	O
retrosplenial cortex	B-T023
and	O
the	O
anterior cingulate cortex	B-T023
(	O
ACC	B-T023
),	O
while	O
both	O
retrieval tasks	B-T041
resulted	O
in	O
trauma-related	B-T033
activity	B-T052
in	O
the	O
posterior cingulate cortex	B-T023
(	O
PCC	B-T023
)	O
and	O
the	O
precuneus	B-T023
.	O
Importantly,	O
neural	B-T169
activity	B-T052
early	O
after	O
experimental	B-T080
trauma	B-T037
exposure	B-T080
predicted	B-T078
later	O
intrusion	B-T185
development	B-T169
,	O
with	O
independent	B-T078
contributions	B-T052
from	O
activity	B-T052
in	O
the	O
retrosplenial cortex	B-T023
(	O
implicit	B-T033
retrieval	B-T041
)	O
and	O
the	O
PCC	B-T023
(	O
explicit	B-T041
retrieval	B-T041
).	O
Additional	B-T169
analyses	B-T062
revealed	B-T080
a	O
stronger	O
connectivity	B-T169
between	O
the	O
bilateral amygdala	B-T023
and	O
the	O
supplementary motor area	B-T029
,	O
precentral	B-T023
and	O
paracentral lobule	B-T023
for	O
the	O
control group	B-T096
compared	O
to	O
the	O
experimental	B-T080
trauma	B-T037
group	B-T078
.	O
Our	O
study	B-T062
gives	O
new	O
insights	O
in	O
the	O
neural	B-T169
correlates	B-T041
of	O
experimental	B-T080
trauma	B-T037
memory retrieval	B-T041
and	O
their	O
predictive value	B-T080
for	O
subsequent	B-T079
symptom	B-T184
development	B-T169
.	O
Our	O
results	B-T169
could	O
provide	O
the	O
basis	O
for	O
personalized	B-T080
early treatment	B-UnknownType
and	O
prevention	B-T080
of	O
PTSD	B-T048
.	O
Hum	O
Brain	O
Mapp,	O
2017.	O
©	O
2017	O
Wiley	O
Periodicals,	O
Inc.	O

Targeting	B-T044
the	O
Nrf2	B-T116
/	O
Amyloid-Beta Liaison	B-T044
in	O
Alzheimer's Disease	B-T047
:	O
A	O
Rational Approach	B-T081
Amyloid	B-T116
is	O
a	O
prominent	B-T080
feature	B-T080
of	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
).	O
Yet,	O
a	O
linear	B-T082
linkage	B-T080
between	O
amyloid-β peptide	B-T116
(	O
Aβ	B-T116
)	O
and	O
the	O
disease onset	B-T079
and	O
progression	B-T046
has	O
recently	O
been	O
questioned.	O
In	O
this	O
context	B-T078
,	O
the	O
crucial	O
partnership	B-T080
between	O
Aβ	B-T044
and	O
Nrf2 pathways	B-T044
is	O
acquiring	B-T080
paramount	B-T080
importance	B-T080
,	O
offering	O
prospects	O
for	O
deciphering	B-T169
the	O
Aβ	B-T116
-centered	O
disease	B-T047
network	B-T169
.	O
Here,	O
we	O
report	O
on	O
a	O
new	B-T080
class	O
of	O
antiaggregating agents	B-T121
rationally	O
designed	O
to	O
simultaneously	B-T079
activate transcription	B-T045
-based	O
antioxidant	B-T121
responses	B-T040
,	O
whose	O
lead 1	B-T121
showed	O
interesting	O
properties	B-T080
in	O
a	O
preliminary	B-T079
investigation.	O
Relying	O
on	O
the	O
requirements	B-T033
of	O
Aβ	B-T116
recognition	B-T044
,	O
we	O
identified	B-T080
the	O
catechol derivative 12	B-T121
.	O
In	O
SH-SY5Y neuroblastoma cells	B-UnknownType
,	O
12	B-T121
combined	B-T080
remarkable	O
free radical scavenger	B-T120
properties	B-T080
to	O
the	O
ability	O
to	O
trigger	B-T080
the	O
Nrf2 pathway	B-T044
and	O
induce	B-T045
the	O
Nrf2	B-T116
-	O
dependent	B-T169
defensive	B-T033
gene NQO1	B-T028
by	O
means	O
of	O
electrophilic activation	B-T070
of	O
the	O
transcriptional response	B-T045
.	O
Moreover,	O
12	O
prevented	O
the	O
formation	B-T169
of	O
cytotoxic	B-T169
stable	B-T080
oligomeric intermediates	B-T121
,	O
being	O
significantly	B-T078
more	B-T081
effective	B-T080
,	O
and	O
per	O
se	O
less toxic	B-T037
,	O
than	O
prototype 1	B-T121
.	O
More	O
importantly,	O
as	O
different	B-T080
chemical features	B-T070
were	O
exploited	O
to	O
regulate Nrf2	B-T045
and	O
Aβ	B-T116
activities	B-T044
,	O
the	O
two	O
pathways	B-T044
could	O
be	O
tuned	O
independently.	O
These	O
findings	O
point	O
to	O
compound 12	B-T121
and	O
its	O
derivatives	B-T121
as	O
promising	O
tools	O
for	O
investigating	O
the	O
therapeutic	B-T169
potential	B-T080
of	O
the	O
Nrf2	B-T116
/	O
Aβ	B-T116
cellular	B-T025
network	B-T169
,	O
laying	O
foundation	O
for	O
generating	B-T052
new	O
drug leads	B-T121
to	O
confront	O
AD	B-T047
.	O

Young	B-T079
people	B-T098
,	O
mental health	B-T041
practitioners	B-T097
and	O
researchers	B-T097
co-produce	O
a	O
Transition Preparation Programme	B-T170
to	O
improve	O
outcomes	B-T169
and	O
experience	B-T041
for	O
young	B-T079
people	B-T098
leaving	O
Child and Adolescent Mental Health Services	B-T058
(	O
CAMHS	B-T058
)	O
In	O
the	O
UK	B-T083
young	B-T079
people	B-T098
attending	O
child and adolescent mental health services	B-T058
(	O
CAMHS	B-T058
)	O
are	O
required	O
to	O
move	O
on,	O
either	O
through	O
discharge	B-T079
or	O
referral to	B-T058
an	O
adult service	B-T058
,	O
at	O
age	B-T032
17/18,	O
a	O
period	B-T079
of	O
increased	B-T081
risk	B-T078
for	O
onset of	B-T080
mental health problems	B-T033
and	O
other	O
complex	B-T080
psychosocial	B-T169
and	O
physical	B-T169
changes	B-T169
.	O
CAMHS	B-T058
transitions	B-T052
are	O
often	O
poorly	O
managed	O
with	O
negative	B-T033
outcomes	B-T169
for	O
young	B-T079
people	B-T098
.	O
Better	O
preparation	B-T052
may	O
improve	O
outcomes	B-T169
and	O
experience	B-T041
.	O
This	O
study	B-T062
aimed	O
to	O
co-produce,	O
with	O
young	B-T079
people	B-T098
who	O
had	O
transitioned	B-T052
or	O
were	O
facing	O
transition	B-T052
from	O
CAMHS	B-T058
,	O
a	O
CAMHS	B-T058
Transition Preparation Programme	B-T170
(	O
TPP	B-T170
),	O
deliverable	O
in	O
routine	B-T080
NHS	B-T058
settings.	O
Eighteen	O
young	B-T079
people	B-T098
,	O
aged	O
17-22,	O
from	O
three	O
UK	B-T083
National Health Service	B-T058
(	O
NHS	B-T058
)	O
mental	O
health	O
foundation	O
trusts	O
participated	O
in	O
creative,	O
participatory research workshops	B-T065
.	O
Seven	O
parents	B-T099
completed	O
short	O
questionnaires	B-T170
.	O
Thirty	O
clinical staff	B-T097
from	O
two	O
trusts	O
took	O
part	O
in	O
workshops	B-T065
to	O
ensure	O
deliverability	O
of	O
young	B-T079
people's	B-T098
ideas	B-T078
.	O
Young	B-T079
people	B-T098
were	O
offered	O
co-research opportunities	B-T062
.	O
Most	O
young	B-T079
people	B-T098
felt	O
anxious	B-T033
,	O
fearful	B-T041
and	O
uncertain	O
on	O
leaving	O
CAMHS	B-T058
and	O
perceived	B-T041
mental health services	B-T058
as	O
uncaring.	O
Participants	B-T098
outlined	O
transition	B-T052
procedures	B-T169
and	O
drafted	O
a	O
range	O
of	O
preparation activities	B-T052
,	O
centred	O
around	O
dedicated	O
Transition	B-T052
Peer Support	B-T061
and	O
a	O
transition	B-T052
booklet	B-T073
,	O
which	O
should	O
be	O
offered	O
to	O
all	O
CAMHS	B-T058
leavers	B-T098
,	O
irrespective	O
of	O
discharge	B-T079
or	O
transfer	B-T078
to	O
an	O
adult service	B-T058
.	O
Preparation	B-T052
should	O
aim	O
to	O
build	O
confidence	B-T041
to	O
help	O
young	B-T079
people	B-T098
take	O
responsibility	B-T055
for	O
themselves	O
and	O
flourish	O
in	O
the	O
adult	B-T100
world	B-T098
:	O
coping	O
or	O
getting	O
through	O
it	O
was	O
not	O
enough.	O
Some	O
clinicians	B-T097
also	O
felt	O
anxious	B-T033
at	O
transition	B-T052
and	O
recognised	O
the	O
potential	O
impact	B-T080
on	O
young	B-T079
people	B-T098
of	O
poor	O
communication	B-T054
and	O
lack	B-T080
of	O
understanding	O
between	O
services	B-T058
.	O
Parents	B-T099
would	O
appreciate	O
help	O
to	O
support	B-T054
their	O
offspring	B-T099
during	O
the	O
transition	B-T052
period	B-T079
.	O
Clinicians	B-T097
cited	O
lack	B-T080
of	O
funding	O
and	O
inflexible	O
NHS	B-T058
procedures	B-T169
and	O
policies	B-T170
as	O
potential	O
barriers	B-T080
to	O
the	O
implementation	B-T052
of	O
young	B-T079
people's	B-T098
ideas	B-T078
.	O
Nine	O
young	B-T079
people	B-T098
took	O
up	O
co-research opportunities	B-T062
.	O
Mental health services	B-T058
underestimate	O
the	O
anxiety	B-T033
of	O
CAMHS	B-T058
leavers	B-T098
.	O
Young	B-T079
people	B-T098
have	O
clear	O
ideas	B-T078
about	O
the	O
preparation	B-T052
they	O
require	O
to	O
leave	O
CAMHS	B-T058
with	O
the	O
confidence	B-T041
to	O
take	O
responsibility	B-T055
for	O
their	O
own	O
health care	B-T058
.	O
Close	O
collaboration	B-T054
of	O
NHS	B-T058
staff	B-T097
and	O
researchers	B-T097
facilitates	O
the	O
implementation	B-T052
of	O
research	B-T062
findings	B-T169
.	O

The	O
Histone Acetyltransferase Gcn5	B-T116
Positively Regulates T Cell Activation	B-T043
Histone acetyltransferases	B-T116
(	O
HATs	B-T116
)	O
regulate inducible transcription	B-T045
in	O
multiple	B-T081
cellular processes	B-T043
and	O
during	O
inflammatory	B-T046
and	O
immune response	B-T042
.	O
However,	O
the	O
functions	B-T044
of	O
general control nonrepressed-protein 5	B-T116
(	O
Gcn5	B-T116
),	O
an	O
evolutionarily	O
conserved	O
HAT	B-T116
from	O
yeast	B-T004
to	O
human	B-T016
,	O
in	O
immune regulation	B-T040
remain	O
unappreciated.	O
In	O
this	O
study	B-T062
,	O
we	O
conditionally	O
deleted	B-T045
Gcn5	B-T116
(	O
encoded	B-T052
by	O
the	O
Kat2a gene	B-T028
)	O
specifically	O
in	O
T lymphocytes	B-T025
by	O
crossing	B-T045
floxed Gcn5	B-T028
and	O
Lck-Cre	B-T028
mice	B-T015
,	O
and	O
demonstrated	O
that	O
Gcn5	B-T116
plays	O
important roles	B-T077
in	O
multiple	O
stages	B-T079
of	O
T cell functions	B-T043
including	O
development	B-T043
,	O
clonal expansion	B-T046
,	O
and	O
differentiation	B-T043
.	O
Loss of	B-T033
Gcn5	B-T116
functions	O
impaired T cell proliferation	B-T049
,	O
IL-2 production	B-T040
,	O
and	O
Th1	B-T025
/	O
Th17	B-T025
,	O
but	O
not	O
Th2	B-T025
and	O
regulatory T cell differentiation	B-T043
.	O
Gcn5	B-T116
is	O
recruited	O
onto	O
the	O
il-2	B-T028
promoter	B-T114
by	O
interacting	B-T169
with	O
the	O
NFAT	B-T116
in	O
T cells	B-T025
upon	O
TCR	B-T116
TCR stimulation	B-T044
.	O
Interestingly,	O
instead	O
of	O
directly	O
acetylating	B-T044
NFAT	B-T116
,	O
Gcn5	B-T116
catalyzes	B-T070
histone H3 lysine H9 acetylation	B-T044
to	O
promote	B-T052
IL-2 production	B-T040
.	O
T cell	B-T025
-specific	O
suppression	B-T169
of	O
Gcn5	B-T116
partially	O
protected	O
mice	B-T015
from	O
myelin oligodendrocyte glycoprotein	B-T116
-	O
induced	B-T169
experimental autoimmune encephalomyelitis	B-T050
,	O
an	O
experimental model	B-T170
for	O
human	B-T016
multiple sclerosis	B-T047
.	O
Our	O
study	O
reveals	B-T080
previously	O
unknown	O
physiological functions	B-T039
for	O
Gcn5	B-T116
and	O
a	O
molecular mechanism	B-T044
underlying	O
these	O
functions	B-T044
in	O
regulating T cell immunity	B-T038
.	O
Hence	O
Gcn5	B-T116
may	O
be	O
an	O
important	O
new	O
target	O
for	O
autoimmune disease	B-T047
therapy	B-T061
.	O

Minor physical anomalies	B-T019
and	O
dermatoglyphic	B-T029
signs	O
in	O
affective disorders	B-T048
:	O
A	O
systematic review	B-T170
The	O
increased	B-T081
prevalence	B-T081
of	O
minor physical anomalies	B-T019
(	O
MPAs	B-T019
)	O
and	O
the	O
abnormalities of dermatoglyphic patterns	B-T019
may	O
be	O
physical	B-T169
manifestations	B-T169
of	O
neurodevelopmental disruption	B-UnknownType
in	O
affective disorders	B-T048
.	O
This	O
paper	O
aims	O
to	O
review	B-T170
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	B-T079
of	O
MPAs	B-T019
and	O
dermatoglyphic abnormalities	B-T019
in	O
mood disorders	B-T048
.	O
A	O
MEDLINE	B-T170
,	O
PsychInfo	B-T170
and	O
Web of Science search	B-T170
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	B-T073
on	O
the	O
frequency	B-T079
of	O
MPAs	B-T019
and	O
on	O
dermatoglyphic traits	B-T190
in	O
bipolar disorder	B-T048
and	O
unipolar depression	B-T048
.	O
24	O
studies	B-T062
on	O
MPAs	B-T019
,	O
19	O
on	O
dermatoglyphics	B-T059
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	B-T033
findings	B-T169
.	O
The	O
relative	B-T080
contribution	B-T052
of	O
neurodevelopmental retardation	B-UnknownType
to	O
the	O
aetiology	B-T169
of	O
affective disorders	B-T048
remains	O
undetermined,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	B-T062
.	O
Increased	B-T169
recognition	B-T041
of	O
neurodevelopmental	B-T042
processes	B-T067
in	O
the	O
origin	B-T079
of	O
affective disorders	B-T048
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	B-T080
intervention	B-T061
and	O
prevention	B-T061
.	O

Novel Strategy	B-T062
to	O
Expand	O
Super-Charged NK Cells	B-T025
with	O
Significant Potential	B-T080
to	O
Lyse	B-T046
and	O
Differentiate	B-T080
Cancer Stem Cells	B-T025
:	O
Differences	B-T081
in	O
NK Expansion	B-T043
and	O
Function	B-T169
between	O
Healthy	B-T098
and	O
Cancer Patients	B-T101
Natural killer (NK) cells	B-T025
are	O
known	O
to	O
target	O
cancer stem cells	B-T025
and	O
undifferentiated tumors	B-T191
.	O
In	O
this	O
paper,	O
we	O
provide	O
a	O
novel strategy	B-T062
for	O
expanding	O
large	O
numbers	O
of	O
super-charged NK cells	B-T025
with	O
significant potential	B-T080
to	O
lyse	B-T046
and	O
differentiate	B-T080
cancer stem cells	B-T025
and	O
demonstrate	O
the	O
differences	B-T081
in	O
the	O
dynamics	B-T070
of	O
NK cell	B-T025
expansion	B-T043
between	O
healthy donors	B-T098
and	O
cancer patients	B-T101
.	O
Decline in cytotoxicity	B-T033
and	O
lower	B-T082
interferon (IFN)-γ secretion	B-T043
by	O
osteoclast	B-T025
(	O
OC	B-T025
)-expanded	O
NK cells	B-T025
from	O
cancer patients	B-T101
correlates	O
with	O
faster	B-T080
expansion	B-T043
of	O
residual	O
contaminating	B-T169
T cells	B-T025
within	O
purified	B-T169
NK cells	B-T025
,	O
whereas	O
healthy donors	B-T098
'	O
OCs	B-T025
continue	O
expanding	O
super-charged NK cells	B-T025
while	O
limiting	O
T cell	B-T025
expansion	B-T043
for	O
up	O
to	O
60	O
days	B-T079
.	O
Similar	O
to	O
patient	B-T101
NK cells	B-T025
,	O
NK cells	B-T025
from	O
tumor	B-T191
-bearing	O
BLT-humanized mice	B-T050
promote	O
faster	B-T080
expansion	B-T043
of	O
residual	O
T cells resulting in decreased numbers	B-T033
and	O
function	B-T169
of	O
NK cells	B-T025
,	O
whereas	O
NK cells	B-T025
from	O
mice	B-T015
with	O
no	B-T033
tumor	B-T191
continue	O
expanding	B-T043
NK cells	B-T025
and	O
retain	O
their	O
cytotoxicity	B-T049
.	O
In	O
addition,	O
dendritic cells	B-T025
(	O
DCs	B-T025
)	O
in	O
contrast	O
to	O
OCs	B-T025
are	O
found	O
to	O
promote	O
faster	B-T080
expansion	B-T043
of	O
residual	O
T cells	B-T025
within	O
purified	B-T169
NK cells	B-T025
resulting	O
in	O
the	O
decline in NK cell numbers	B-T033
from	O
healthy individuals	B-T098
.	O
Addition	O
of	O
anti-CD3 mAb	B-T116
inhibits	O
T cell proliferation	B-T043
while	O
enhancing	B-T052
NK cell	B-T025
expansion	B-T043
;	O
however,	O
expanding	B-T043
NK cells	B-T025
have	O
lower	B-T082
cytotoxicity	B-T049
but	O
higher	B-T080
secretion of IFN-γ	B-T043
.	O
Expansion	B-T043
and	O
functional	B-T169
activation	B-T052
of	O
super-charged NK cells	B-T025
by	O
OCs	B-T025
is	O
dependent	B-T080
on	O
interleukin (IL)-12	B-T116
and	O
IL-15	B-T116
.	O
Thus,	O
in	O
this	O
report,	O
we	O
not	O
only	O
provide	O
a	O
novel strategy	B-T062
to	O
expand	B-T043
super-charged NK cells	B-T025
,	O
but	O
also	O
demonstrate	O
that	O
rapid and sustained expansion	B-T043
of	O
residual	O
T cells	B-T025
within	O
the	O
purified	B-T169
NK cells	B-T025
during	O
expansion	B-T043
with	O
DCs	B-T025
or	O
OCs	B-T025
could	O
be	O
a	O
potential	B-T080
mechanism	B-T169
by	O
which	O
the	O
numbers	B-T081
and	O
function	B-T169
of	O
NK cells decline	B-T033
in	O
cancer patients	B-T101
and	O
in	O
BLT-humanized mice	B-T050
.	O

Extremely	B-T080
Giant Liver Hemangioma	B-T191
(50	O
cm)	O
with	O
Kasabach-Merritt Syndrome	B-T047
A	O
33-	O
year	B-T079
-	O
old	B-T079
male	B-T032
has	O
been	O
found	B-T033
with	O
a	O
giant liver hemangioma	B-T191
of	O
initial	B-T079
size	B-T082
29	O
cm	O
for	O
5	O
years	B-T079
.	O
He	O
received	B-T080
arterial embolization	B-T061
twice	B-T081
in	O
order	O
to	O
shrink	B-T082
the	O
tumor	B-T191
;	O
however,	O
no effect	B-T080
was	O
obtained	B-T169
.	O
The	O
tumor	B-T191
had	O
rapidly	B-T080
grown	B-T067
to	O
50	O
cm	O
and	O
caused	O
abnormalities	B-T033
in	O
the	O
hematological	B-T022
and	O
coagulative	B-T042
systems	B-T169
.	O
Preoperative	B-T079
computed tomography	B-T060
revealed	B-T080
that	O
the	O
right	B-T082
hepatic vein	B-T023
,	O
right	B-T082
hepatic artery	B-T023
,	O
and	O
right	B-T082
portal vein	B-T023
were	O
not involved	B-T033
by	O
the	O
hemangioma	B-T191
.	O
Resection	B-T061
of	O
the	O
giant liver hemangioma	B-T191
was	O
successfully	B-T080
performed	B-T169
after	O
intraoperative	B-T079
intentional	B-T080
bloodletting	B-T061
with	O
concurrent	B-T079
blood salvage	B-T061
.	O
All	O
hematological	B-T022
and	O
coagulative	B-T042
abnormalities	B-T033
had	O
returned	B-T080
to	O
normal	B-T080
after	O
the	O
procedure	B-T061
.	O

Role	B-T077
of	O
cysteine	B-T116
residues	B-T077
in	O
regulation	B-T169
of	O
peptidyl-prolyl cis-trans isomerase activity	B-T044
of	O
wheat	B-T168
cyclophilin	B-T116
TaCYPA-1	B-T028
Oxidative	B-T169
conditions	B-T080
result	O
in	O
inhibition	B-T052
of	O
peptidyl-prolyl cis-trans isomerase (PPIase) activity	B-T044
of	O
several	O
cyclophilins	B-T116
.	O
Thiol	B-T109
groups	O
have	O
been	O
implicated	O
in	O
redox	B-T044
regulation	B-T169
of	O
these	O
proteins	B-T116
.	O
In	O
our	O
previous	O
study,	O
we	O
proposed	O
that	O
activity	B-T044
of	O
wheat	B-T168
cyclophilin	B-T116
,	O
TaCYPA-1	B-T028
,	O
may	O
be	O
modulated	B-T082
through	O
a	O
novel	O
dual	O
mechanism	B-T169
of	O
redox	B-T044
regulation	B-T169
.	O
To	O
further	O
understand	O
the	O
regulation	B-T169
of	O
PPIase activity	B-T044
of	O
TaCYPA-1	B-T028
,	O
we	O
generated	O
mutants	B-T049
of	O
TaCYPA-1	B-T028
by	O
substituting	B-T052
cysteine	B-T116
residues	B-T077
at	O
positions	B-T082
-40	O
and	O
-122	O
with	O
serine	B-T116
,	O
and	O
at	O
-126	O
with	O
proline	B-T116
.	O
Comparative analysis	B-T062
of	O
their	O
PPIase activity	B-T044
revealed	O
that	O
catalytic	B-T070
efficiencies	B-T081
(Kcat/Km)	O
of	O
TaCYPA-1C40S	B-T116
(0.37	O
X	O
106	O
M-1	O
s-1)	O
and	O
TaCYPA-1C122S	B-T116
(0.31	O
X	O
106	O
M-1	O
s-1)	O
were	O
significantly lower	B-T081
as	O
compared	O
to	O
the	O
native	O
TaCYPA-1	B-T116
(1.33	O
X	O
106	O
M-1	O
s-1),	O
whereas	O
Kcat/Km	O
of	O
the	O
double	O
mutant	B-T049
TaCYPA-1C40S/C122S	B-T116
was	O
significantly higher	B-T081
(2.36	O
X	O
106	O
M-1	O
s-1).	O
Compared	O
to	O
wild-type	B-T028
TaCYPA-1	B-T028
,	O
the	O
different	O
mutants	B-T049
also	O
showed	O
differential	B-T080
sensitivity	B-T169
to	O
Cu2+	B-T121
.	O
Furthermore,	O
the	O
results	B-T169
of	O
this	O
study	B-T062
also	O
revealed	B-T080
that	O
despite	O
lacking	B-T080
PPIase activity	B-T044
,	O
the	O
mutant	B-T049
TaCYPA-1C126P	B-T028
was	O
able	O
to	O
confer	O
partial	B-T081
protection	B-T033
against	O
heat stress	B-T039
.	O
These	O
observations	B-T062
suggest	O
that	O
the	O
mechanism	B-T169
of	O
TaCYPA-1	B-T028
-induced	O
thermotolerance	B-T039
may	O
also	O
involve	O
other	O
activities	B-T052
besides	O
cis to trans isomerisation	B-T044
,	O
which	O
needs	O
to	O
be	O
identified	B-T080
further.	O

Association	B-T080
of	O
Exclusive Breastfeeding	B-T055
Duration	B-T079
With	O
Systemic Inflammation	B-T047
Markers	B-T201
in	O
Adolescents	B-T100
:	O
A	O
Cross-Sectional Study	B-T062
Breastfeeding duration	B-T033
has	O
been	O
associated with	B-T080
less	B-T081
low-grade	B-T080
inflammation	B-T046
in	O
healthy	B-T080
adolescents	B-T100
,	O
but	O
there	O
is	O
scarce	B-T080
information	B-T078
regarding	O
obese	B-T047
subjects.	O
This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
exclusive breastfeeding	B-T055
is	O
related	O
to	O
serum concentrations	B-T081
of	O
inflammatory	B-T169
markers	B-T201
in	O
a	O
population	B-T098
of	O
Spanish	B-T098
adolescents	B-T100
.	O
A	O
cross-sectional study	B-T062
was	O
performed	B-T169
on	O
1,001	O
adolescents	B-T100
(13.2	O
±	O
1.2	O
years)	O
randomly	O
recruited	O
from	O
schools	B-T073
in	O
southeast	B-T082
Spain	B-T083
.	O
Data	B-T078
on	O
breastfeeding duration	B-T033
were	O
collected	B-T169
via	O
a	O
parental questionnaire	B-T170
.	O
Interleukin-6	B-T116
(	O
IL-6	B-T116
)	O
and	O
tumor necrosis factor-alpha	B-T116
(	O
TNF-α	B-T116
)	O
were	O
determined by	B-T080
enzyme-linked immunosorbent assay	B-T059
.	O
C-reactive protein	B-T116
(	O
CRP	B-T116
)	O
was	O
determined by	B-T080
solid-phase chemiluminescent immunometric assay	B-T059
.	O
Nonadjusted	O
and	O
adjusted	O
multivariate	B-T081
correlation analyses	B-T062
confirmed	B-T080
a	O
strong	B-T080
association	B-T080
(p	O
<	O
.001,	O
95%	O
confidence interval	B-T081
)	O
between	O
the	O
three	O
markers	B-T201
of	O
inflammation	B-T046
and	O
exclusive breastfeeding	B-T055
duration	B-T079
.	O
No significant	B-T033
differences	B-T080
were	O
observed	B-T169
for	O
IL-6	B-T116
,	O
TNF-α	B-T116
,	O
and	O
CRP	B-T116
serum concentrations	B-T081
among	O
normal weight	B-T201
,	O
overweight	B-T184
,	O
and	O
obese	B-T047
adolescents	B-T100
,	O
except for	B-T169
IL-6	B-T116
between	O
normal weight	B-T201
and	O
obese	B-T047
subjects	B-T100
.	O
Likewise,	O
no significant	B-T033
association	B-T080
was	O
found	B-T033
between	O
these	O
markers	B-T201
of	O
inflammation	B-T046
and	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
z-score	B-T081
.	O
We	O
found	B-T033
a	O
possible	B-T033
association	B-T080
between	O
inflammatory	B-T169
markers	B-T201
and	O
exclusive breastfeeding	B-T055
duration	B-T079
in	O
adolescents	B-T100
,	O
regardless	B-T080
of	O
their	O
BMI	B-T201
.	O
This	O
finding	B-T033
suggests	B-T078
that	O
increased	B-T081
body weight	B-T032
or	O
obesity	B-T047
might	O
not	O
mediate	O
the	O
association	B-T080
between	O
breastfeeding	B-T040
and	O
inflammation	B-T046
.	O
These	O
results	B-T169
contribute	O
to	O
the	O
understanding	B-T041
of	O
the	O
relationship	B-T080
between	O
breastfeeding	B-T040
and	O
inflammatory	B-T169
markers	B-T201
in	O
adolescents	B-T100
.	O

Effect	B-T080
of	O
ultrasound	B-T070
and	O
enzymatic	B-T116
pre-treatment	B-T052
on	O
yield	B-T081
and	O
properties	B-T080
of	O
banana	B-T168
juice	B-T168
Effect	B-T080
of	O
ultrasound	B-T070
and	O
enzymatic	B-T116
pre-treatments	B-T052
with	O
cellulase	B-T116
and	O
pectinase	B-T116
on	O
yield	B-T081
and	O
properties	B-T080
of	O
banana	B-T168
juice	B-T168
were	O
investigated	B-T169
.	O
A	O
two-level full factorial design	B-UnknownType
was	O
employed.	O
The	O
factors	O
selected	O
were	O
ultrasonication time	B-T079
(0	O
and	O
30	O
min	B-T079
),	O
cellulase	B-T116
concentration	B-T081
(0	O
and	O
0.2%)	O
and	O
pectinase	B-T116
concentration	B-T081
(0	O
and	O
0.2%).	O
The	O
responses	O
studied	O
were	O
yield	B-T081
,	O
viscosity	B-T070
,	O
clarity	B-T059
,	O
total soluble solids	B-T081
(	O
TSS	B-T081
)	O
and	O
pH	B-T081
.	O
It	O
was	O
observed	O
that	O
pectinase	B-T116
was	O
more	O
effective	B-T080
in	O
increasing	B-T169
the	O
yield	B-T081
of	O
juice	B-T168
compared	O
to	O
cellulase	B-T116
.	O
Ultrasonic pre-treatment	B-T052
alone	O
did	O
not	B-T033
significantly increase	B-T169
the	O
yield	B-T081
of	O
juice	B-T168
.	O
When	O
ultrasound	B-T070
was	O
combined	O
with	O
pre-treatment	B-T052
with	O
both	O
the	O
enzymes	B-T116
maximum yield	B-T081
of	O
89.40%	O
was	O
obtained	O
compared	O
to	O
47.30%	O
in	O
the	O
control	B-T096
.	O
The	O
viscosity	B-T070
of	O
the	O
juice	B-T168
decreased	B-T081
with	O
addition	O
of	O
enzymes	B-T116
and	O
with	O
application	O
of	O
ultrasound	B-T070
.	O
The	O
clarity	B-T080
of	O
the	O
juice	B-T168
was	O
not	O
affected	O
by	O
cellulase	B-T116
treatment	B-T169
,	O
but	O
improved	B-T033
with	O
pectinase	B-T116
treatment	B-T169
.	O
Ultrasonication	B-T070
alone	O
was	O
found	O
to	O
be	O
more	O
effective	B-T080
than	O
pectinase	B-T116
or	O
cellulase	B-T116
treatment	B-T169
in	O
improving	B-T080
the	O
clarity	B-T201
of	O
the	O
juice	B-T168
.	O
The	O
TSS	B-T081
increased	B-T081
with	O
enzymatic	B-T116
treatment	B-T169
,	O
ultrasonication	B-T070
and	O
their	O
combination.	O
pH	B-T081
was	O
not	O
affected	O
by	O
treatment	B-T169
type,	O
but	O
was	O
found	O
to	O
be	O
lower	O
for	O
the	O
treated	B-T169
juices	B-T168
.	O
Significant correlations	B-T080
were	O
observed	O
between	O
the	O
various	O
responses.	O

Electrocardiographic appearance	B-T034
of	O
aortic stenosis	B-T047
before	O
and	O
after	O
aortic valve replacement	B-T061
So	O
far,	O
the	O
specific	O
appearance	O
of	O
QRS complex	B-T033
,	O
ST-segment	B-T033
,	O
and	O
T wave	B-T033
was	O
observed	B-T169
in	O
aortic stenosis	B-T047
(	O
AS	B-T047
).	O
S-wave	B-T033
dynamic	B-T169
change	B-T169
in	O
leads V1	B-T029
-	O
V3	B-T029
was	O
not	O
reported	O
in	O
AS	B-T047
.	O
In	O
a	O
single-center,	O
prospective study	B-T062
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1.175	O
patients	B-T101
who	O
underwent	O
surgical	B-T061
aortic valve replacement	B-T061
(	O
AVR	B-T061
).	O
We	O
conducted	O
3-year	O
gathering	O
of	O
patients	B-T101
with	O
symptomatic	B-T169
and	O
asymptomatic	B-T033
severe	O
AS	B-T047
,	O
and	O
separated	O
them	O
by	O
hemodynamic stability	B-T039
into	O
groups	O
A	O
and	O
B,	O
through	O
EFLV	B-T201
(of	O
more	O
or	O
less	O
than	O
50%),	O
AVA	B-T032
(of	O
more	O
or	O
less	O
than	O
0.9	O
cm(2)),	O
PG	B-T201
(between	O
55	O
and	O
75	O
mm Hg	B-T081
or	O
over	O
75	O
mm Hg	B-T081
),	O
and	O
end-diastolic LV dimension	B-T033
(of	O
more	O
or	O
less	O
than	O
56	O
mm).	O
We	O
evaluated	B-T058
the	O
impact	B-T080
of	O
S-wave	B-T033
magnitude	B-T081
in	O
right precordial	B-T184
leads	O
before	O
and	O
after	O
AVR	B-T061
in	O
all	O
patients	B-T101
.	O
We	O
followed	O
S-wave	B-T033
changes	B-T169
in	O
electrocardiogram	B-T033
altogether	O
with	O
hemodynamic measurements	B-T061
derived	O
from	O
echocardiography	B-T060
.	O
Analysis	B-T062
of	O
echocardiographic	B-T060
parameters	B-T033
,	O
measured	B-T080
in	O
patients	B-T101
before	O
surgery	B-T061
,	O
did	O
not	O
show	O
statistical significance	B-T081
between	O
asymptomatic	B-T033
and	O
symptomatic	B-T169
group.	O
The	O
statistical significance	B-T081
was	O
observed	B-T169
in	O
the	O
change	B-T169
in	O
S-wave	B-T033
magnitude	B-T081
in	O
the	O
right precordial	B-T184
leads	O
in	O
both	O
subsets	O
of	O
patients	B-T101
before	O
AVR	B-T061
.	O
We	O
found	O
statistically significant	B-T081
predictive value	B-T080
of	O
S-wave	B-T033
magnitude	B-T081
in	O
leads V2	B-T029
-	O
V3	B-T029
for	O
dependent variables	B-T169
PG	B-T201
and	O
end-diastolic LV dimension	B-T033
.	O
S-wave	B-T033
changes	O
in	O
right precordial	B-T184
leads	O
can	O
predict	O
increase	B-T169
in	O
PG	B-T201
and	O
critical	O
narrowing	O
of	O
AVA	B-T032
,	O
suggestive of	B-T169
timely	O
referral for	B-T058
AVR	B-T061
.	O

Anemia	B-T047
complicating	B-T169
type 2 diabetes	B-T047
:	O
Prevalence	B-T081
,	O
risk factors	B-T033
and	O
prognosis	B-T058
To	O
determine	O
the	O
prevalence	B-T081
,	O
risk factors	B-T033
and	O
prognosis	B-T058
of	O
anemia	B-T047
in	O
representative	B-T097
community-based	O
patients	B-T101
with	O
type 2 diabetes	B-T047
.	O
Data	O
from	O
the	O
Fremantle Diabetes Study Phase II	B-T062
(	O
FDS2	B-T062
;	O
n=1551,	O
mean	O
age	O
65.7years,	O
51.9%	O
males	B-T032
)	O
and	O
Busselton Diabetes Study	B-T062
(	O
BDS	B-T062
;	O
n=186,	O
mean	O
age	O
70.2years,	O
50.0%	O
males	B-T032
)	O
cohorts	B-T098
,	O
and	O
from	O
186	O
matched	O
BDS	B-T062
participants	B-T098
without	O
diabetes	B-T047
,	O
were	O
analyzed	B-T062
.	O
The	O
prevalence	B-T081
of	O
anemia	B-T047
(	O
hemoglobin	B-T116
≤130g/L	O
males	B-T032
,	O
≤120g/L	O
females	B-T032
)	O
was	O
determined	B-T080
in	O
each	O
sample	B-T031
.	O
In	O
FDS2	B-T062
,	O
associates	O
of	O
anemia	B-T047
were	O
assessed	B-T052
using	O
multiple	O
logistic regression	B-T062
and	O
Cox proportional hazards modeling	B-T081
identified	O
predictors	B-T033
of	O
death	B-T040
during	O
4.3±1.2years	O
post-recruitment.	O
The	O
prevalence	B-T081
of	O
anemia	B-T047
at	O
baseline	O
was	O
11.5%	O
in	O
FDS2	B-T062
participants	B-T098
,	O
17.8%	O
in	O
BDS	B-T062
type	O
2	O
patients	B-T101
and	O
5.4%	O
in	O
BDS	B-T062
participants	B-T098
without	O
diabetes	B-T047
.	O
In	O
FDS2	B-T062
,	O
163	O
of	O
178	O
patients	B-T101
with	O
anemia	B-T047
(91.6%)	O
had	O
at	O
least	O
one	O
other	O
risk factor	B-T033
(	O
serum vitamin B12	B-T059
<140pmol/L,	O
serum ferritin	B-T033
<30μg/L	O
and/or	O
transferrin saturation	B-T059
<20%,	O
serum testosterone	B-T059
<10nmol/L	O
(	O
males	B-T032
),	O
glitazone	B-T109
therapy	B-T061
,	O
estimated glomerular filtration rate	B-T059
(	O
eGFR	B-T059
)	O
<60mL/min	O
1.73m(2),	O
malignancy	B-T191
,	O
hemoglobinopathy	B-T047
).	O
More	O
anemic	B-T033
than	O
non-anemic	B-T033
FDS2	B-T062
patients	B-T101
died	O
(28.7%	O
versus	O
8.0%;	O
P<0.001).	O
After	O
adjustment	O
for	O
other	O
independent	O
predictors	B-T033
(age	O
as	O
time-scale,	O
male	O
sex,	O
Aboriginality	B-T033
,	O
marital status	B-T102
,	O
smoking	B-T055
,	O
eGFR	B-T059
),	O
anemia	B-T047
was	O
associated with	B-T080
a	O
57%	O
increase	B-T169
in	O
mortality	O
(P=0.015).	O
Type 2 diabetes	B-T047
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	B-T047
but	O
other	O
mostly	O
modifiable	O
risk factors	B-T033
are	O
usually	O
present	B-T033
.	O
Anemia	B-T047
is	O
associated with	B-T080
an	O
increased risk of death	B-T033
after	O
adjustment	O
for	O
other	O
predictors	B-T033
.	O

Succinic acid	B-T109
production	B-T052
by	O
immobilized	B-T025
cultures	B-T059
using	O
spent sulphite liquor	B-T167
as	O
fermentation	B-T044
medium	B-T167
Spent sulphite liquor	B-T130
(	O
SSL	B-T130
)	O
was	O
used	O
as	O
carbon	B-T196
source	B-T033
for	O
the	O
production	B-T052
of	O
succinic acid	B-T109
using	O
immobilized	B-T025
cultures	B-T059
of	O
Actinobacillus succinogenes	B-T007
and	O
Basfia succiniciproducens	B-T007
on	O
two	O
different	O
supports	B-T167
,	O
delignified cellulosic material	B-T121
(	O
DCM	B-T121
)	O
and	O
alginate	B-T109
beads	B-T167
.	O
Fed-batch immobilized cultures	B-T059
with	O
A. succinogenes	B-T007
in	O
alginates	B-T109
resulted	O
in	O
higher	B-T080
sugar	B-T109
to	O
succinic acid	B-T109
conversion yield	B-T081
(0.81g/g)	O
than	O
the	O
respective	O
yield	B-T081
achieved	O
(0.65g/g)	O
when	O
DCM	B-T121
immobilized	B-T025
cultures	B-T059
were	O
used.	O
The	O
final	O
succinic acid	B-T109
concentration	B-T081
and	O
yield	B-T081
achieved	O
in	O
fed-batch	B-T059
with	O
immobilized	B-T025
cultures	B-T059
of	O
B. succiniciproducens	B-T007
in	O
alginates	B-T109
(45g/L	O
and	O
0.66g/g)	O
were	O
higher	B-T080
than	O
A. succinogenes	B-T007
immobilized	B-T025
cultures	B-T059
(35.4g/L	O
and	O
0.61g/g)	O
using	O
nano	B-T081
-	O
filtrated SSL	B-T167
as	O
fermentation	B-T044
medium	B-T167
.	O
Immobilized	B-T025
cultures	B-T059
of	O
B. succiniciproducens	B-T007
in	O
alginate	B-T109
beads	B-T167
were	O
reused	O
in	O
four	O
sequential fed-batch	B-T059
fermentations	B-T044
of	O
nano	B-T081
-	O
filtrated SSL	B-T130
leading	O
to	O
the	O
production	B-T052
of	O
64.7g	O
of	O
succinic acid	B-T109
with	O
a	O
yield	B-T081
range	O
of	O
0.42-0.67g/g	O
and	O
productivity	B-T081
range	O
of	O
0.29-0.65g/L/h.	O
The	O
immobilized	B-T025
cultures	B-T059
improved	O
the	O
efficiency	B-T081
of	O
succinic acid	B-T109
production	B-T052
as	O
compared	B-T052
to	O
free cell cultures	B-T059
.	O

Interventions	B-T058
to	O
Improve	B-T033
Grandparent	B-T099
Caregivers'	B-T099
Mental	B-T041
and	O
Physical Health	B-T033
:	O
An	O
Integrative Review	B-T170
The	O
aim	B-T078
of	O
this	O
integrative review	B-T170
is	O
to	O
appraise	O
grandparent	B-T099
caregiver	B-T099
interventions	B-T058
that	O
are	O
designed	O
to	O
improve	B-T033
their	O
physical	B-T033
and	O
mental health	B-T041
.	O
A	O
database	B-T170
search	B-T052
was	O
performed	O
to	O
identify	O
relevant	B-T080
studies	B-T062
published	B-T057
between	O
January	O
1,	O
1980,	O
and	O
December	O
31,	O
2014.	O
Thirteen	O
publications	B-T073
,	O
including	O
11	O
studies	B-T062
,	O
met	O
all	O
inclusion	B-T080
and	O
exclusion criteria	B-T169
.	O
All	O
studies	B-T062
included	O
grandparent	B-T099
mental health	B-T041
outcomes	B-T169
with	O
fewer	O
focusing	O
on	O
physical health	B-T033
and	O
social relations	B-T098
.	O
Improvements	B-T077
were	O
found	O
in	O
all	O
three	O
areas	B-T082
with	O
fewer	O
improvements	B-T077
seen	O
in	O
physical health	B-T033
.	O
However,	O
small effect sizes	B-T081
were	O
seen	O
with	O
most	O
measures	B-T169
of	O
these	O
outcomes	B-T169
.	O
Although	O
the	O
interventions	B-T058
led	O
to	O
positive	O
grandparent	B-T099
caregiver	B-T099
outcomes,	O
the	O
studies	B-T062
were	O
limited	B-T169
by	O
their	O
design	B-T052
,	O
only	O
one	O
of	O
which	O
was	O
a	O
randomized controlled trial	B-T062
.	O
Also,	O
interventions	B-T058
did	O
not	O
consider	O
variations	B-T080
in	O
the	O
grandchild's	B-T099
or	O
parent's	B-T099
ages	B-T032
or	O
if	O
the	O
grandparent	B-T099
provided	O
primary	B-T080
or	O
shared	B-T054
care	B-T052
.	O
These	O
gaps	O
should	O
be	O
addressed	O
in	O
future	B-T079
research	B-T062
.	O

An	O
attenuated	B-T052
Mycobacterium tuberculosis	B-T007
clinical	B-T080
strain	B-T001
with	O
a	O
defect	B-T169
in	O
ESX-1	B-T116
secretion	B-T038
induces	O
minimal	B-T080
host	B-T001
immune responses	B-T042
and	O
pathology	B-T091
Although	O
Mycobacterium tuberculosis (M.tb) DK9897	B-T007
is	O
an	O
attenuated	B-T052
strain	B-T001
,	O
it	O
was	O
isolated	B-T169
from	O
a	O
patient	B-T101
with	O
extrapulmonary tuberculosis	B-T047
and	O
vaccination	B-T061
with	O
a	O
subunit vaccine	B-T121
(	O
H56	B-T121
)	O
induced	B-T169
poor	B-T080
protection	B-T033
against	O
it.	O
Both	O
attenuation	B-T052
and	O
lack	B-T080
of	O
protection	B-T033
are	O
because	O
M.tb DK9897	B-T007
cannot	O
secrete	B-T038
the	O
EsxA	B-T116
virulence factor	B-T109
nor	O
induce	O
a	O
host response	B-T042
against	O
it.	O
Genome sequencing	B-T063
identified	O
a	O
frameshift mutation	B-T049
in	O
the	O
eccCa1 gene	B-T028
.	O
Since	O
the	O
encoded	B-T052
EccCa1 protein	B-T116
provides	O
energy	B-T081
for	O
ESX-1	B-T116
secretion	B-T038
,	O
it	O
suggested	O
a	O
defect	B-T169
in	O
the	O
ESX-1	B-T116
type VII secretion system	B-T043
.	O
Genetic complementation	B-T045
with	O
a	O
plasmid	B-T114
carrying	O
the	O
M.tb H37Rv	B-T007
sequence	O
of	O
eccCa1-eccCb1-pe35	B-T114
re-established	O
EsxA	B-T116
secretion	B-T038
,	O
host	B-T001
specific	O
EsxA	B-T116
T-cell	B-T025
responses	B-T042
,	O
and	O
increased	B-T081
strain	B-T001
virulence	B-T038
.	O
The	O
ESX-1	B-T116
secretion	B-T038
defect	B-T169
prevents	B-T169
several	O
virulence factors	B-T109
from	O
being	O
functional	O
during	O
infection	B-T046
and	O
therefore	O
attenuates	B-T052
M.tb	B-T007
.	O
It	O
precludes	O
specific	O
T-cell	B-T025
responses	B-T042
against	O
strong	O
antigens	B-T129
and	O
we	O
found	O
very	O
little	O
in vivo	B-T082
cytokine production	B-T040
,	O
gross pathology	B-T034
or	O
granuloma formation	B-T038
in	O
lungs	B-T023
from	O
M.tb DK9897	B-T007
infected animals	B-T033
.	O
This	O
coincides	O
with	O
M.tb DK9897	B-T007
being	O
unable	O
to	O
disrupt	O
the	O
phagosome membrane	B-T026
and	O
make	O
contact	O
to	O
the	O
cytosol	B-T026
.	O

Results	B-T033
for	O
patients	B-T101
with	O
sarcoma	B-T191
not otherwise specified	B-T080
and	O
other	O
diagnoses	B-T033
than	O
Ewing sarcoma	B-T191
treated	B-T033
according	O
to	O
the	O
Euro-EWING 99 trial	B-T062
Euro-EWING 99 trial	B-T062
of	O
the	O
European	B-T098
Ewing tumor	B-T191
Working	B-T057
Initiative	B-T033
of	O
National	B-T092
Groups	B-T078
(	O
EE99	B-T170
)	O
was	O
an	O
international	B-T078
phase III study	B-T062
in	O
patients	B-T101
with	O
Ewing sarcoma	B-T191
.	O
The	O
German Society of Pediatric Oncology and Hematology (GPOH) data center	B-T093
registered	B-T058
and	O
followed	O
patients	B-T101
with	O
other	O
diagnoses	B-T033
than	O
Ewing sarcoma	B-T191
who	O
were	O
treated	B-T033
according	O
to	O
the	O
EE99 protocol	B-T170
in	O
an	O
additional	O
non-Ewing database	B-T170
.	O
Data	B-T078
of	O
27	O
patients	B-T101
with	O
other	O
diagnoses	B-T033
than	O
Ewing sarcoma	B-T191
treated	B-T033
according	O
to	O
the	O
EE99 protocol	B-T170
were	O
analyzed	B-T062
.	O
Patients	B-T101
had	O
miscellaneous	B-T080
histologic	B-T169
diagnoses	B-T033
,	O
the	O
majority	B-T081
were	O
diagnosed	B-T033
with	O
sarcoma	B-T191
not otherwise specified	B-T080
(	O
NOS	B-T080
)	O
arising	O
in	O
bone	B-T024
and	O
soft tissue	B-T024
(63%).	O
The	O
median	B-T081
age	B-T032
at	O
diagnosis	B-T033
was	O
16.9	O
years	O
(range	O
4.5-41.4).	O
Localized disease	B-T047
was	O
diagnosed	B-T033
in	O
61.5%	O
of	O
the	O
patients	B-T101
and	O
38.5%	O
had	O
distant metastases	B-T191
at	O
time	O
of	O
primary	B-T080
diagnosis	B-T033
.	O
The	O
median	B-T081
follow-up	B-T058
time	B-T079
was	O
3.7	O
years	O
(range	O
0.5-9.5).	O
Patients	B-T101
with	O
localized disease	B-T047
showed	O
a	O
3-year	O
event-free survival	B-T081
(	O
EFS	B-T081
)	O
of	O
68%,	O
compared	O
to	O
3-year	O
EFS	B-T081
of	O
20%	O
in	O
patients	B-T101
with	O
metastases	B-T191
(P	O
=	O
0.042).	O
Three-year	O
EFS	B-T081
for	O
patients	B-T101
with	O
sarcoma	B-T191
NOS	B-T080
was	O
52%,	O
patients	B-T101
with	O
localized	B-T047
and	O
metastatic disease	B-T191
showed	O
3-year	O
EFS	B-T081
of	O
66	O
and	O
20%,	O
respectively.	O
EFS	B-T081
in	O
patients	B-T101
with	O
other	O
diagnoses	B-T033
than	O
Ewing sarcoma	B-T191
treated	B-T033
according	O
to	O
EE99	B-T170
was	O
significantly	B-T078
higher	O
in	O
patients	B-T101
with	O
localized	B-T047
than	O
metastatic disease	B-T191
.	O
Sarcomas	B-T191
of	O
soft tissue	B-T024
and	O
bone	B-T024
that	O
cannot	O
be	O
classified	B-T185
to	O
current	B-T079
diagnostic categories	B-T185
constitute	O
a	O
therapeutic	B-T169
challenge	B-T058
.	O

Capsular Polysaccharide	B-T109
Types	B-T080
and	O
Virulence-Related	B-T038
Traits	B-T032
of	O
Epidemic	B-T067
KPC	B-T047
-	O
Producing	B-T169
Klebsiella pneumoniae	B-T007
Isolates	B-T123
in	O
a	O
Chinese	B-T083
University Hospital	B-T073
Klebsiella pneumoniae	B-T007
is	O
an	O
important	B-T080
human	B-T016
pathogen	B-T001
associated with	B-T080
a	O
variety	B-T077
of	O
diseases	B-T047
and	O
the	O
prevalence	B-T081
of	O
blaKPC	B-T028
carrying	O
K. pneumoniae	B-T007
(	O
KPC-Kp	B-T007
)	O
is	O
rapidly increasing	B-T169
.	O
Capsule	B-T116
is	O
an	O
important	B-T080
virulence factor	B-T109
in	O
K. pneumoniae	B-T007
.	O
In	O
this	O
study	B-T062
,	O
we	O
determined	O
to	O
first	O
systematically	B-T169
characterize	B-T052
capsular polysaccharide	B-T109
(	O
CPS	B-T109
)	O
and	O
virulence	B-T038
traits	B-T032
in	O
KPC-Kp	B-T007
strains	B-T001
.	O
A	O
total	O
of	O
56	O
KPC-Kp	B-T007
isolates	B-T123
were	O
recovered	B-T080
from	O
clinical samples	B-T167
in	O
a	O
Chinese hospital	B-T073
,	O
which	O
were	O
assigned	B-T169
to	O
clonal lineages	B-T078
by	O
multilocus sequence typing	B-T062
(	O
MLST	B-T062
).	O
Capsule	B-T116
typing	B-T058
(	O
wzi sequencing	B-T059
and	O
wzc polymerase chain reaction	B-T063
[	O
PCR	B-T063
])	O
and	O
virulence	B-T038
genes	B-T028
were	O
characterized	B-T052
by	O
molecular approaches	B-T059
.	O
The	O
virulence	B-T038
of	O
these	O
strains	B-T001
was	O
determined	O
by	O
biofilm formation	B-T043
,	O
serum	B-T031
killing	B-T043
resistance	B-T169
,	O
phagocytosis	B-T043
,	O
and	O
infection	B-T046
models	B-T170
.	O
Six	O
different	O
STs	B-T033
were	O
found	B-T033
among	O
56	O
KPC-Kp	B-T007
isolates	B-T123
:	O
76.8%	O
(43	O
of	O
56	O
isolates	B-T123
)	O
belonged	O
to	O
ST11	B-T033
,	O
6	B-T033
isolates	B-T123
belonged	O
to	O
ST147	B-T033
,	O
4	O
isolates	B-T123
belonged	O
to	O
ST15	B-T033
,	O
1	O
isolate	O
belonged	O
to	O
ST1456	B-T033
,	O
1	O
isolate	O
belonged	O
to	O
ST65	B-T033
,	O
and	O
1	O
isolate	O
was	O
ST23	B-T033
.	O
Based	O
on	O
the	O
wzi gene DNA sequences	B-T059
and	O
wzc PCR	B-T063
,	O
these	O
56	O
strains	B-T001
were	O
classified	O
as	O
capsular	B-T116
type	B-T080
wzi47-K47	B-T116
(n	O
=	O
37),	O
wzi64-K64	B-T116
(n	O
=	O
8),	O
wzi8-K8	B-T116
(n	O
=	O
4),	O
wzi37-K37	B-T116
(n	O
=	O
4),	O
wzi53-K53	B-T116
(n	O
=	O
1),	O
wzi125-K2	B-T116
(n	O
=	O
1),	O
and	O
wzi1-K1	B-T116
(n	O
=	O
1).	O
Heterogeneity	B-T032
was	O
detected	B-T033
in	O
biofilm formation	B-T043
and	O
phagocytosis	B-T043
among	O
different	O
CPS	B-T109
types	B-T080
.	O
ST11	B-T033
strains	B-T001
were	O
less	O
virulent	B-T080
than	O
other	O
ST	B-T033
strains	B-T001
.	O
KPC-Kp	B-T007
strains	B-T001
exhibit	O
variability	B-T077
of	O
virulence-associated	B-T038
traits	B-T032
.	O
Differences	O
were	O
associated	O
with	O
the	O
ST	B-T033
types	B-T080
and	O
CPS	B-T109
.	O

Interaction-driven	B-T169
distinctive	O
electronic states	B-T082
of	O
artificial atoms	B-T196
at	O
the	O
ZnO	B-T121
interface	B-T080
We	O
have	O
investigated	B-T169
the	O
electronic states	B-T082
of	O
planar quantum dots	B-T073
at	O
the	O
ZnO	B-T121
interface	B-T080
containing	O
a	O
few	O
interacting	B-T169
electrons	B-T196
in	O
an	O
externally applied	B-T169
magnetic field	B-T070
.	O
The	O
electron-electron	B-T196
interaction	B-T169
effects	B-T080
are	O
expected	O
to	O
be	O
much stronger	B-T080
in	O
this	O
case	B-T169
than	O
in	O
traditional semiconductor quantum systems	B-T169
,	O
such	O
as	O
in	O
GaAs	B-T197
or	O
InAs	B-T197
quantum dots	B-T073
.	O
In	O
order	O
to	O
highlight	O
that	O
stronger	B-T080
Coulomb effects	B-T080
in	O
the	O
ZnO	B-T121
quantum dots	B-T073
,	O
we	O
have	O
compared	B-T052
the	O
energy spectra	B-T067
and	O
the	O
magnetization	B-T070
in	O
this	O
system	B-T169
to	O
those	O
of	O
the	O
InAs	B-T197
quantum dots	B-T073
.	O
We	O
have	O
found	O
that	O
in	O
the	O
ZnO	B-T121
quantum dots	B-T073
the	O
signatures	O
of	O
stronger	B-T080
Coulomb interaction	B-T169
manifests	B-T169
in	O
an	O
unique	B-T080
ground state	B-T082
that	O
has	O
very	O
different	B-T080
properties	B-T077
than	O
the	O
corresponding	O
ones	O
in	O
the	O
InAs	B-T197
dot	B-T073
.	O
Our	O
results	B-T169
for	O
the	O
magnetization	B-T070
also	O
exhibits behaviors	B-T080
never	B-T079
before	B-T079
observed	B-T169
in	O
a	O
quantum dot	B-T073
for	O
a	O
realistic set of parameters	B-T081
.	O
We	O
have	O
found	O
a	O
stronger	B-T080
temperature	B-T081
dependence	B-T080
and	O
other	O
unexpected features	B-T080
,	O
such	O
as	O
paramagnetic-like behavior	B-T070
at	O
high temperatures	B-T081
for	O
a	O
quantum-dot	B-T073
helium	B-T121
.	O

Evaluation	B-T058
of	O
Tobacco Control Policies	B-T064
in	O
San Francisco	B-T083
Homeless	B-T098
Housing Programs	B-UnknownType
The	O
2014	O
Surgeon General's Report	B-T170
noted	B-T080
that	O
high	B-T080
smoking rates	B-T033
in	O
vulnerable populations	B-T098
such	O
as	O
the	O
homeless	B-T098
have	O
been	O
a	O
persistent	B-T079
public	B-T092
health problem	B-T033
;	O
smoking	B-T055
prevalence	B-T081
among	O
individuals	B-T098
experiencing	B-T055
homelessness	B-T033
exceeds	O
70%.	O
Historically,	O
service providers	B-T058
for	O
the	O
homeless	B-T098
have	O
not	O
enacted	O
comprehensive	B-T080
tobacco control policies	B-T064
.	O
We	O
conducted	B-T169
a	O
qualitative study	B-T062
of	O
homeless	B-T098
housing programs	B-UnknownType
in	O
San Francisco	B-T083
.	O
Administrators	B-T097
representing	B-T052
9	O
of	O
the	O
city's	O
11	O
homeless service agencies	B-T092
were	O
interviewed	B-T052
to	O
assess	B-T058
institutional	B-T078
smoking	B-T055
-related	O
policies	B-T170
and	O
cessation	B-T055
programs	B-T169
and	O
perceived	B-T041
barriers	B-T080
and	O
receptivity	B-T169
to	O
instituting	B-T078
tobacco	B-T109
control	B-T169
interventions	B-T061
.	O
Respondents	B-T098
indicated	B-T033
that	O
although	O
most	O
programs	B-T169
had	O
adopted	B-T080
smoke	B-T131
-	O
free	B-T169
grounds	B-T082
and	O
some	O
had	O
eliminated	B-T080
evidence	B-T078
of	O
staff	B-T097
smoking	B-T055
,	O
the	O
smoking	B-T055
status	B-T080
of	O
clients	B-T096
was	O
assessed	B-T052
only	O
when	O
required	B-T169
by	O
funders.	O
None	O
of	O
the	O
programs	B-T169
offered	B-T033
smoking cessation	B-T055
interventions	B-T061
.	O
Most	O
administrators	B-T097
were	O
receptive	B-T169
to	O
adopting	B-T080
policies	B-T170
that	O
would	O
promote	B-T052
a	O
tobacco	B-T109
-	O
free	B-T169
culture	B-T092
;	O
however,	O
they	O
noted	B-T080
that	O
their	O
clients	B-T096
had	O
unique	B-T080
challenges	B-T058
that	O
made	O
traditional	B-T169
smoking cessation	B-T055
programs	B-T169
unfeasible.	O
Homeless	B-T098
housing programs	B-UnknownType
in	O
San Francisco	B-T083
have	O
not	O
yet	O
adopted	B-T080
a	O
tobacco	B-T109
-	O
free	B-T169
culture	B-T092
.	O
Existing	B-T077
policies	B-T170
were	O
created	B-T052
in	O
response	B-T032
to	O
external	B-T082
mandates	B-T170
,	O
and	O
smoking cessation	B-T055
programs	B-T169
may	O
need	O
to	O
be	O
modified	B-T169
in	O
order	O
to	O
effectively	B-T080
reach	O
clients	B-T096
.	O

Identification	O
of	O
low	O
micromolar	B-T081
dual	O
inhibitors	B-T121
for	O
aldose reductase	B-T116
(	O
ALR2	B-T116
)	O
and	O
poly (ADP-ribose) polymerase	B-T116
(	O
PARP-1	B-T116
)	O
using	O
structure	B-T082
based	O
design	B-T052
approach	O
Clinical studies	B-T062
have	O
revealed	O
that	O
diabetic retinopathy	B-T047
is	O
a	O
multifactorial	O
disorder	B-T047
.	O
Moreover,	O
studies	O
also	O
suggest	O
that	O
ALR2	B-T116
and	O
PARP-1	B-T116
co-occur	O
in	O
retinal	B-T023
cells	B-T025
,	O
making	O
them	O
appropriate	O
targets	B-T169
for	O
the	O
treatment	B-T061
of	O
diabetic retinopathy	B-T047
.	O
To	O
find	O
the	O
dual	O
inhibitors	B-T121
of	O
ALR2	B-T116
and	O
PARP-1	B-T116
,	O
the	O
structure	B-T082
based	O
design	B-T052
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	B-T169
proteins	B-T116
.	O
A	O
series	O
of	O
novel	O
thiazolidine-2,4-dione	B-T109
(	O
TZD	B-T109
)	O
derivatives	B-T169
were	O
therefore	O
rationally	O
designed	B-T052
,	O
synthesized	B-T052
and	O
their	O
in vitro	B-T080
inhibitory activities	B-T044
against	O
ALR2	B-T116
and	O
PARP-1	B-T116
were	O
evaluated.	O
The	O
experimental results	B-T033
showed	O
that	O
compounds 5b	B-T121
and	O
5f	B-T121
,	O
with	O
2-chloro	O
and	O
4-fluoro	O
substitutions,	O
showed	O
biochemical	B-T169
activities	B-T052
in	O
micromolar	B-T081
and	O
submicromolar	B-T081
range	B-T081
(	O
IC50	B-T081
1.34-5.03μM)	O
against	O
both	O
the	O
targeted	B-T169
enzymes	B-T116
.	O
The	O
structure-activity relationship	B-T080
elucidated	O
for	O
these	O
novel	O
inhibitors	B-T121
against	O
both	O
the	O
enzymes	B-T116
provide	O
new	O
insight	O
into	O
the	O
binding	B-T044
mode	B-T169
of	O
the	O
inhibitors	B-T121
to	O
the	O
active sites	B-T169
of	O
enzymes	B-T116
.	O
The	O
positive	B-T033
results	B-T033
of	O
the	O
biochemical	B-T169
assay	B-T059
suggest	O
that	O
these	O
compounds	B-T121
may	O
be	O
further	O
optimized	B-T052
and	O
utilized	B-T169
for	O
the	O
treatment	B-T061
of	O
diabetic retinopathy	B-T047
.	O

Microbiology	B-T059
of	O
the	O
Upper	B-T030
and	O
Lower Airways	B-T039
in	O
Pediatric	B-T080
Cystic Fibrosis	B-T047
Patients	B-T101
Objective	O
To	O
evaluate	O
the	O
microbiology	O
of	O
the	O
upper	O
and	O
lower	O
airways	O
in	O
pediatric	B-T080
cystic fibrosis	B-T047
(	O
CF	B-T047
)	O
patients	B-T101
who	O
underwent	O
sinus surgery	B-T061
.	O
Study	O
Design	O
Retrospective	B-T062
case	O
series	O
with	O
chart	O
review.	O
Setting	O
Tertiary care	B-T073
children's hospital	B-T093
.	O
Subjects	O
and	O
Methods	O
A	O
total	O
of	O
201	O
paired	O
sinus	B-T059
and	O
pulmonary cultures	B-T059
from	O
105	O
CF	B-T047
patients	B-T101
were	O
identified	O
between	O
1996	O
and	O
2014.	O
Demographics	B-T062
and	O
culture	B-T059
results	B-T169
were	O
analyzed	B-UnknownType
.	O
Results	B-T169
The	O
mean	O
age	O
of	O
patients	B-T101
was	O
11.2	O
±	O
5.4	O
years	O
(range,	O
1-27	O
years),	O
and	O
approximately	O
one-half	O
were	O
female	B-T098
.	O
Methicillin	B-T109
-	O
sensitive	B-T169
Staphylococcus aureus	B-T007
was	O
the	O
most	O
common	O
pathogen	B-T001
overall.	O
A	O
significantly	O
higher	O
prevalence	B-T081
of	O
Pseudomonas aeruginosa	B-T007
(32%	O
for	O
pulmonary	B-T059
and	O
37%	O
for	O
sinus cultures	B-T059
)	O
was	O
observed	O
in	O
older	B-T098
patients	B-T101
versus	O
younger	B-T100
patients	B-T101
(	O
P	B-T081
<	O
.001).	O
There	O
was	O
low	O
to	O
moderate	B-T080
agreement	B-T080
between	O
sinus	B-T059
and	O
pulmonary cultures	B-T059
(	O
Kappa	B-T170
statistic range	B-T081
,	O
0.03-0.56).	O
The	O
prevalence	B-T081
of	O
methicillin-resistant S aureus	B-T007
(	O
MRSA	B-T007
)	O
increased	O
significantly	B-T081
for	O
lower respiratory tract culture	B-T059
(from	O
5%	O
to	O
16%)	O
and	O
sinus culture	B-T059
(from	O
5%	O
to	O
27%)	O
between	O
1996-2004	O
and	O
2010-2014	O
(	O
P	B-T081
=	O
.016	O
and	O
P	B-T081
<	O
.001,	O
respectively).	O
The	O
prevalence	B-T081
of	O
positive	B-T033
sinus cultures	B-T059
increased	O
from	O
40%	O
to	O
85%	O
between	O
1996-2004	O
and	O
2010-2014	O
(	O
P	B-T081
=	O
.018).	O
Patients	B-T101
with	O
pulmonary	B-T080
MRSA	B-T007
were	O
more	O
likely	O
to	O
be	O
coinfected	B-T047
with	O
pulmonary	B-T080
P aeruginosa	B-T007
(	O
risk ratio	B-T081
,	O
2.4;	O
95%	O
CI	B-T081
,	O
1.2-4.8;	O
P	O
=	O
.015)	O
or	O
Aspergillus fumigatus	B-T004
(	O
risk ratio	B-T081
,	O
2.2;	O
95%	O
CI	B-T081
,	O
1.2-4.8;	O
P	O
=	O
.035).	O
Conclusions	O
There	O
is	O
low	O
to	O
moderate	B-T080
correlation	B-T080
between	O
pulmonary	B-T080
and	O
sinus	B-T030
pathogens	B-T001
in	O
CF	B-T047
patients	B-T101
.	O
This	O
is	O
important	O
to	O
consider	O
when	O
treating	B-T061
infections	B-T046
.	O
The	O
prevalence	B-T081
of	O
MRSA	B-T007
in	O
sinus cultures	B-T059
has	O
increased	O
over	O
time	O
and	O
warrants	O
further	O
investigation	B-T058
.	O

The	O
role	O
of	O
miR-451	B-T114
in	O
the	O
switching	O
between	O
proliferation	B-T169
and	O
migration	B-T039
in	O
malignant glioma	B-T191
cells	B-T025
:	O
AMPK	B-T116
signaling	B-T038
,	O
mTOR	B-T116
modulation	B-T082
and	O
Rac1	B-T116
activation	B-T045
required	O
Glioblastoma multiforme	B-T191
(	O
GBM	B-T191
),	O
WHO grade IV astrocytoma	B-T191
,	O
is	O
the	O
most	O
common	O
primary neoplasm	B-T191
of	O
the	O
central nervous system	B-T022
(	O
CNS	B-T022
)	O
and	O
has	O
the	O
highest	O
malignancy	B-T191
and	O
mortality rates	B-T081
.	O
The	O
invasive nature	B-T080
of	O
GBM	B-T191
complicates	O
surgical resection	B-T061
and	O
restricts	O
chemotherapeutic access	B-T061
,	O
contributing	O
to	O
poor	O
patient	B-T101
prognosis	B-T058
.	O
The	O
migration	B-T039
of	O
tumor cells	B-T025
is	O
closely	O
related	O
to	O
the	O
tumor cell	B-T025
proliferation	B-T169
.	O
The	O
acquisition	B-T052
of	O
migratory	B-T169
capability	B-T080
,	O
in	O
addition	O
to	O
intracellular	B-T082
factors	B-T169
,	O
is	O
proposed	O
to	O
be	O
a	O
crucial mechanism	B-T169
during	O
the	O
progression	B-T169
of	O
invasion	B-T033
.	O
Using	O
qRT-PCR	B-T063
analysis	B-T062
,	O
we	O
determined	O
that	O
the	O
expression	B-T045
of	O
miR-451	B-T028
in	O
glioma	B-T191
tissue	B-T024
was	O
lower	O
than	O
in	O
control brain tissue	B-T023
,	O
especially	O
in	O
the	O
central	B-T082
portions	B-T082
of	O
the	O
tumor	B-T191
.	O
In	O
glioma	B-T191
cell lines	B-T025
,	O
we	O
found	O
that	O
decreased	B-T081
miR-451	B-T028
expression	B-T045
suppressed	B-T169
tumor cell	B-T025
proliferation	B-T169
but	O
enhanced	O
migration	B-T039
with	O
a	O
concomitant	B-T079
low	O
level	O
of	O
CAB39	B-T116
/	O
AMPK	B-T116
/	O
mTOR	B-T116
pathway activation	B-T169
and	O
high	O
level	O
of	O
Rac1	B-T116
/	O
cofilin	B-T116
pathway activation	B-T169
,	O
respectively.	O
Notably,	O
the	O
effect	O
of	O
miR-451	B-T114
on	O
cytological behavior	B-T169
and	O
on	O
the	O
activation	B-T045
of	O
mTOR	B-T116
and	O
Rac1	B-T116
was	O
limited	O
when	O
AMPKα1	B-T116
expression	B-T045
was	O
knocked-down	O
with	O
a	O
synthetic	B-T052
shRNA	B-T114
.	O
We	O
suggest	O
that	O
the	O
glioma	B-T191
microenvironment	B-T070
results	O
in	O
heterogeneity	B-T080
of	O
miR-451	B-T028
expression	B-T045
.	O
Our	O
data	O
indicated	O
that	O
miR-451	B-T114
relays	O
environmental	O
signals	O
by	O
upregulating	B-T044
the	O
activity	O
of	O
AMPK	B-T116
signaling	B-T038
,	O
thereby	O
modulating	B-T082
the	O
activation	B-T045
of	O
mTOR	B-T116
and	O
Rac1	B-T116
/	O
cofilin	B-T116
which,	O
in	O
turn,	O
play	O
key	O
roles	O
in	O
glioma	B-T191
cell	O
proliferation	B-T169
and	O
migration	B-T039
,	O
respectively.	O
Our	O
results	O
highlight	O
the	O
need	O
to	O
consider	O
opposing	O
roles	O
of	O
a	O
therapeutic	B-T169
target	O
which,	O
while	O
suppressing	B-T169
tumor cell	B-T025
proliferation	B-T169
,	O
could	O
also	O
promote	O
cell	B-T025
infiltration	B-T046
.	O

Comparison	B-T052
of	O
Gasoline Direct-Injection	B-T073
(	O
GDI	B-T073
)	O
and	O
Port Fuel Injection	B-T073
(	O
PFI	B-T073
)	O
Vehicle Emissions	B-T131
:	O
Emission	B-T131
Certification	B-T064
Standards	B-T170
,	O
Cold-Start	B-T033
,	O
Secondary	O
Organic	B-T080
Aerosol	B-T073
Formation	B-T169
Potential	B-T080
,	O
and	O
Potential	B-T080
Climate	B-T070
Impacts	B-T080
Recent	O
increases	B-T081
in	O
the	O
Corporate	B-T080
Average Fuel Economy	B-T081
standards	B-T170
have	O
led	O
to	O
widespread	B-T082
adoption	O
of	O
vehicles	B-T073
equipped	O
with	O
gasoline direct-injection	B-T073
(	O
GDI	B-T073
)	O
engines	B-T073
.	O
Changes	O
in	O
engine	B-T073
technologies	B-T090
can	O
alter	O
emissions	B-T131
.	O
To	O
quantify	B-T081
these	O
effects	B-T080
,	O
we	O
measured	B-T080
gas-	B-T104
and	O
particle-phase	B-T104
emissions	B-T131
from	O
82	O
light-duty	B-T080
gasoline	B-T073
vehicles	B-T073
recruited	O
from	O
the	O
California	B-T083
in-use	O
fleet	O
tested	B-T170
on	O
a	O
chassis	B-T073
dynamometer	B-T073
using	O
the	O
cold-start	B-T033
unified	O
cycle.	O
The	O
fleet	O
included	O
15	O
GDI	B-T073
vehicles	B-T073
,	O
including	O
8	O
GDIs	B-T073
certified	B-T064
to	O
the	O
most-stringent	O
emissions	B-T131
standard	B-T170
,	O
superultra-low-emission vehicles	B-T185
(	O
SULEV	B-T185
).	O
We	O
quantified	B-T081
the	O
effects of	B-T080
engine	B-T073
technology	B-T090
,	O
emission	B-T131
certification	B-T064
standards	B-T170
,	O
and	O
cold-start	B-T033
on	O
emissions	B-T131
.	O
For	O
vehicles	B-T073
certified	B-T064
to	O
the	O
same	O
emissions	B-T131
standard	B-T170
,	O
there	O
is	O
no	O
statistical	B-T090
difference	B-T081
of	O
regulated	O
gas-phase	B-T104
pollutant	B-T131
emissions	B-T131
between	O
PFIs	B-T073
and	O
GDIs	B-T073
.	O
However,	O
GDIs	B-T073
had,	O
on	O
average	B-T081
,	O
a	O
factor	B-T169
of	O
2	O
higher	O
particulate matter	B-T167
(	O
PM	B-T167
)	O
mass	O
emissions	B-T131
than	O
PFIs	B-T073
due	O
to	O
higher	O
elemental carbon	B-T196
(	O
EC	B-T196
)	O
emissions	B-T131
.	O
SULEV	B-T185
certified	B-T064
GDIs	B-T073
have	O
a	O
factor	B-T169
of	O
2	O
lower	O
PM	B-T167
mass	O
emissions	B-T131
than	O
GDIs	B-T073
certified	B-T064
as	O
ultralow-emission vehicles	B-T185
(3.0	O
±	O
1.1	O
versus	O
6.3	O
±	O
1.1	O
mg/mi),	O
suggesting	O
improvements	B-T077
in	O
engine	B-T073
design	B-T052
and	O
calibration	B-T081
.	O
Comprehensive	B-T080
organic	B-T080
speciation	O
revealed	B-T080
no	O
statistically significant	B-T081
differences	B-T081
in	O
the	O
composition	B-T070
of	O
the	O
volatile	B-T080
organic compounds	B-T109
emissions	B-T131
between	O
PFI	B-T073
and	O
GDIs	B-T073
,	O
including	O
benzene	B-T109
,	O
toluene	B-T109
,	O
ethylbenzene	B-T109
,	O
and	O
xylenes	B-T109
(	O
BTEX	B-T109
).	O
Therefore,	O
the	O
secondary	O
organic	B-T080
aerosol	B-T073
and	O
ozone	B-T103
formation	B-T169
potential	B-T080
of	O
the	O
exhaust	B-T131
does	O
not	O
depend	O
on	O
engine	B-T073
technology	B-T090
.	O
Cold-start	B-T033
contributes	B-T052
a	O
larger	B-T081
fraction of	B-T081
the	O
total	O
unified	O
cycle	O
emissions	B-T131
for	O
vehicles	B-T073
meeting	O
more-stringent	O
emission	B-T131
standards	B-T170
.	O
Organic	B-T080
gas	B-T104
emissions	B-T131
were	O
the	O
most	O
sensitive	B-T169
to	O
cold-start	B-T033
compared	B-T052
to	O
the	O
other	O
pollutants	B-T131
tested	B-T170
here.	O
There	O
were	O
no	O
statistically significant	B-T081
differences	B-T081
in	O
the	O
effects of	B-T080
cold-start	B-T033
on	O
GDIs	B-T073
and	O
PFIs	B-T073
.	O
For	O
our	O
test	O
fleet,	O
the	O
measured	B-T080
14.5%	O
decrease	B-T081
in	O
CO2	B-T123
emissions	B-T131
from	O
GDIs	B-T073
was	O
much	O
greater	B-T081
than	O
the	O
potential	B-T080
climate	B-T070
forcing	O
associated with	B-T080
higher	O
black carbon	B-T121
emissions	B-T131
.	O
Thus,	O
switching	O
from	O
PFI	B-T073
to	O
GDI	B-T073
vehicles	B-T073
will	O
likely	O
lead	O
to	O
a	O
reduction	B-T080
in	O
net	O
global warming	B-T069
.	O

TRIB3	B-T116
downregulation	B-T044
enhances	B-T052
doxorubicin	B-T109
-	O
induced	B-T169
cytotoxicity	B-T049
in	O
gastric cancer	B-T191
cells	B-T025
TRIB3	B-T116
,	O
which	O
is	O
a	O
pseudokinase	B-T116
known	O
to	O
regulate multiple pro-survival pathways	B-T038
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	B-T061
target	B-T169
for	O
the	O
treatment	B-T061
of	O
human	B-T016
tumors	B-T191
.	O
However,	O
its	O
precise	O
role	O
in	O
cancer	B-T191
is	O
controversial,	O
as	O
TRIB3	B-T116
protein levels	B-T034
have	O
been	O
associated	O
with	O
both	O
good	B-T033
and	O
poor prognosis	B-T033
in	O
cancer patients	B-T101
.	O
Here,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	B-T116
expression	B-T045
in	O
the	O
survival	B-T043
of	O
gastric cancer	B-T191
cells	B-T025
exposed	O
to	O
anticancer drugs	B-T109
.	O
We	O
found	O
that	O
the	O
tested	B-T169
anticancer drug	B-T109
,	O
doxorubicin	B-T109
,	O
induced	B-T169
cytotoxicity	B-T049
by	O
decreasing	O
TRIB3	B-T028
transcription	B-T045
,	O
which	O
was	O
followed	O
by	O
apoptotic cell death	B-T043
.	O
Moreover,	O
TRIB3 siRNA	B-T114
knockdown	B-T063
appeared	O
to	O
enhance	B-T052
doxorubicin	B-T109
-	O
induced	B-T169
apoptosis	B-T043
in	O
gastric cancer	B-T191
cells	B-T025
,	O
concurrently	O
with	O
altering	O
the	O
expression	B-T045
of	O
downstream	B-T082
apoptotic factors	B-T116
.	O
Conversely,	O
overexpression	B-T045
of	O
TRIB3	B-T116
significantly	O
protected cells	B-T025
against	O
doxorubicin	B-T109
-	O
induced	B-T169
apoptosis	B-T043
.	O
Our	O
results	O
indicate	O
that	O
downregulation	B-T044
of	O
TRIB3	B-T116
appears	O
to	O
promote	B-T052
cell death	B-T043
and	O
enhance	B-T052
doxorubicin	B-T109
-	O
induced	B-T169
apoptosis	B-T043
,	O
supporting	O
the	O
anti-apoptotic	B-T120
role	O
of	O
TRIB3	B-T116
.	O
The	O
inductions	B-T045
of	O
three	O
classes	O
of	O
MAPKs	B-T116
failed	O
to	O
affect	O
doxorubicin	B-T109
-mediated	O
TRIB3	B-T116
downregulation	B-T044
,	O
while	O
TRIB3	B-T116
overexpression	B-T045
did	O
not	O
affect	O
doxorubicin	B-T109
-	O
induced	B-T169
MAPK activation	B-T044
.	O
In	O
sum,	O
our	O
findings	B-T033
indicate	O
that	O
TRIB3	B-T116
plays	O
an	O
anti-apoptotic	B-T120
role	O
in	O
doxorubicin	B-T109
-treated	O
gastric cancer	B-T191
cell lines	B-T025
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	B-T116
expression	B-T045
in	O
response	O
to	O
anticancer drugs	B-T109
,	O
such	O
as	O
doxorubicin	B-T109
,	O
irinotecan	B-T109
or	O
oxaliplatin	B-T109
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer therapy	B-T061
.	O

Digital	B-T023
Myopericytoma	B-T191
:	O
A	O
Case Report	B-T170
and	O
Systematic Literature Review	B-T170
A	O
myopericytoma	B-T191
(	O
MP	B-T191
)	O
is	O
an	O
exceedingly	O
rare	O
perivascular tumor	B-T191
of	O
unknown etiology	B-T033
.	O
Given	O
their	O
potential	B-T080
for	O
mimicry	B-T044
and	O
malignancy	B-T191
,	O
MP tumors	B-T191
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	B-T097
and	O
may	O
be	O
overlooked	O
on	O
differential diagnosis	B-T060
.	O
We	O
present	O
a	O
case report	B-T170
of	O
an	O
otherwise	O
healthy	B-T080
33-year-old	O
right-hand dominant	B-T032
male	B-T098
who	O
presented	O
to	O
our	O
outpatient clinic	B-T073
with	O
a	O
2-month	O
history	O
of	O
painless	B-T169
swelling	B-T033
and	O
erythema of the pulp of his left index finger	B-T033
.	O
Subsequent	O
plain film X-ray	B-T060
showed	O
near-complete	B-T080
bony destruction	B-T033
of	O
his	O
distal phalanx	B-T023
.	O
Pathological	B-T046
evaluation	B-T058
of	O
an	O
incisional biopsy	B-T060
showed	O
a	O
benign variant	B-T191
of	O
MP	B-T191
.	O
The	O
lesion	B-T033
was	O
treated	O
by	O
excision	B-T061
with	O
tumor	B-T191
shelling	B-T061
,	O
and	O
there	O
was	O
no evidence of	B-T080
recurrence	B-T067
81	O
days	O
postoperatively	B-T079
.	O
A	O
systematic	O
literature	O
review	O
of	O
the	O
management	B-T058
and	O
outcome	B-T080
of	O
all	O
known	O
cases	B-T170
of	O
hand and wrist	B-T029
MP	B-T191
is	O
presented.	O

Gene expression	B-T045
reveals	O
evidence	B-T078
for	O
EGFR	B-T116
-dependent	O
proximal-distal limb	B-T023
patterning	B-T045
in	O
a	O
myriapod	B-T204
Evolution	B-T045
of	O
segmented limbs	B-T023
is	O
one	O
of	O
the	O
key	O
innovations	O
of	O
Arthropoda	B-T204
,	O
allowing	O
development	O
of	O
functionally	O
specific	O
specialized	O
head	B-T029
and	O
trunk	B-T029
appendages	B-T023
,	O
a	O
major	O
factor	O
behind	O
their	O
unmatched	O
evolutionary	O
success.	O
Proximodistal limb	B-T023
patterning	B-T045
is	O
controlled	O
by	O
two	O
regulatory networks	B-T044
in	O
the	O
vinegar fly	B-T204
Drosophila melanogaster	B-T204
,	O
and	O
other	O
insects	B-T204
.	O
The	O
first	O
is	O
represented	O
by	O
the	O
function	O
of	O
the	O
morphogens	B-T123
Wingless	B-T116
(	O
Wg	B-T116
)	O
and	O
Decapentaplegic	B-T116
(	O
Dpp	B-T116
);	O
the	O
second	O
by	O
the	O
EGFR-signaling cascade	B-T044
.	O
While	O
the	O
role	O
of	O
Wg	B-T116
and	O
Dpp	B-T116
has	O
been	O
studied	B-T062
in	O
a	O
wide	O
range	O
of	O
arthropods	B-T204
representing	O
all	O
main	O
branches,	O
that	O
is,	O
Pancrustacea	B-T204
(=	O
Hexapoda	B-T204
+	O
Crustacea	B-T204
),	O
Myriapoda	B-T204
and	O
Chelicerata	B-T204
,	O
investigation	B-T169
of	O
the	O
potential	O
role	O
of	O
EGFR-signaling	B-T044
is	O
restricted	O
to	O
insects	B-T204
(	O
Hexapoda	B-T204
).	O
Gene expression analysis	B-T063
of	O
Egfr	B-T116
,	O
its	O
potential	B-T080
ligands	B-T103
,	O
and	O
putative downstream factors	B-T116
in	O
the	O
pill millipede	B-T204
Glomeris marginata	B-T204
(	O
Myriapoda	B-T204
:	O
Diplopoda	B-T204
),	O
reveals	O
that-in	O
at	O
least	O
mandibulate	B-T204
arthropods	B-T204
-	O
EGFR-signaling	B-T044
is	O
likely	O
a	O
conserved	O
regulatory mechanism	B-T033
in	O
proximodistal limb	B-T023
patterning	B-T045
.	O

Pirfenidone	B-T109
normalizes	B-T169
the	O
tumor microenvironment	B-T070
to	O
improve	O
chemotherapy	B-T061
Normalization	B-T061
of	O
the	O
tumor microenvironment	B-T070
by	O
selectively	O
targeting	B-T169
components	B-T026
of	O
the	O
tumor	B-T191
extracellular matrix	B-T024
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	B-T080
to	O
decompress	B-T169
tumor	B-T191
blood vessels	B-T023
,	O
increase	B-T169
vessel	B-T023
perfusion	B-T042
and	O
thus,	O
improve	O
drug delivery	B-T061
and	O
the	O
efficacy	B-T080
of	O
cancer therapy	B-T061
.	O
Therefore,	O
we	O
now	O
need	O
to	O
identify	B-T080
safe	O
and	O
well	O
tolerated	B-T033
pharmaceutical agents	B-T121
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	B-T070
of	O
solid tumors	B-T191
and	O
enhance	B-T052
chemotherapy	B-T061
.	O
In	O
this	O
study	B-T062
,	O
we	O
repurposed	O
Pirfenidone	B-T109
,	O
a	O
clinically	B-T080
approved	B-T080
anti-fibrotic drug	B-T121
for	O
the	O
treatment	B-T061
of	O
idiopathic pulmonary fibrosis	B-T047
,	O
to	O
investigate	B-T169
its	O
possible	O
role	O
on	O
tumor microenvironment	B-T070
normalization	B-T061
.	O
Using	O
two	O
orthotopic	B-T082
mammary	B-T023
tumor models	B-T170
we	O
demonstrate	O
that	O
Pirfenidone	B-T109
reduces	B-T081
collagen	B-T116
and	O
hyaluronan	B-T109
levels	B-T080
and,	O
as	O
a	O
result	B-T169
,	O
significantly	B-T078
increases	B-T169
blood vessel	B-T023
functionality	B-T169
and	O
perfusion	B-T042
and	O
improves	O
the	O
anti-tumor efficacy	B-T080
of	O
doxorubicin	B-T109
.	O
Reduction	B-T080
of	O
extracellular matrix components	B-T026
were	O
mediated	O
via	O
TGFβ signaling pathway	B-T169
inhibition	B-T052
due	O
to	O
downregulation	B-T044
of	O
TGFβ1	B-T028
,	O
COL1A1	B-T028
,	O
COL3A1	B-T028
,	O
HAS2	B-T028
,	O
HAS3	B-T028
expression	B-T045
levels	B-T080
.	O
Our	O
findings	B-T033
provide	O
evidence	B-T078
that	O
repurposing	O
Pirfenidone	B-T109
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	B-T062
to	O
enhance	B-T052
drug delivery	B-T061
to	O
solid tumors	B-T191
by	O
normalizing	B-T061
the	O
tumor microenvironment	B-T070
.	O

Serum	B-T031
vascular endothelial growth factor receptor-3	B-T116
levels	B-T081
in	O
patients	B-T101
with	O
esophageal squamous cell cancer	B-T191
Esophageal cancer	B-T191
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors of the gastrointestinal tract	B-T191
.	O
In	O
this	O
study,	O
we	O
quantified	O
the	O
serum	B-T031
vascular endothelial growth factor-3	B-T116
(	O
VEGFR-3	B-T116
)	O
expression	B-T045
in	O
patients	B-T101
with	O
esophageal squamous cell carcinoma	B-T191
(	O
ESCC	B-T191
)	O
to	O
evaluate	O
the	O
role	O
of	O
VEGFR-3	B-T116
in	O
ESCC	B-T191
.	O
Ninety	O
five	O
patients	B-T101
with	O
ESCC	B-T191
were	O
studied.	O
Pre-therapy	B-T079
and	O
preoperative	B-T079
samples	B-T031
were	O
stored	O
and	O
ELISA	B-T059
was	O
used	O
to	O
designate	O
the	O
concentrations	O
of	O
VEGFR-3	B-T116
.	O
The	O
serum values	B-T081
of	O
VEGFR-3	B-T116
were	O
significantly	O
higher	O
in	O
patients	B-T101
with	O
ESCC	B-T191
than	O
in	O
healthy	B-T080
donors	B-T098
(p<0.0001).	O
The	O
results	O
imply	O
a	O
very	O
good	O
sensitivity	B-T081
of	O
VEGFR-3	B-T116
in	O
ESCC	B-T191
.	O
VEGFR-3	B-T116
may	O
be	O
a	O
good	O
diagnostic	B-T169
biomarker	B-T201
for	O
ESCC	B-T191
.	O
Biomarker	B-T201
,	O
ESCC	B-T191
,	O
VEGFR-3	B-T116
.	O

Zinc	B-T121
and	O
Wound Healing	B-T040
:	O
A	O
Review of	B-T169
Zinc	B-T121
Physiology	B-T039
and	O
Clinical Applications	B-T169
Our	O
understanding	B-T041
of	O
the	O
role	O
of	O
zinc	B-T121
in	O
normal	O
human	B-T016
physiology	B-T039
is	O
constantly	B-T080
expanding,	O
yet	O
there	O
are	O
major	O
gaps	B-T082
in	O
our	O
knowledge	O
with	O
regard	O
to	O
the	O
function	B-T169
of	O
zinc	B-T121
in	O
wound healing	B-T040
.	O
This	O
review	B-T170
aims	B-T078
to	O
provide	O
the	O
clinician	B-T097
with	O
sufficient	B-T080
understanding	O
of	O
zinc	B-T121
biology	B-T091
and	O
an	O
up-to-date	O
perspective	O
on	O
the	O
role	O
of	O
zinc	B-T121
in	O
wound healing	B-T040
.	O
Zinc	B-T121
is	O
an	O
essential	O
ion	B-T196
that	O
is	O
crucial	O
for	O
maintenance	O
of	O
normal	O
physiology	B-T039
,	O
and	O
zinc deficiency	B-T047
has	O
many	O
manifestations	B-T169
ranging	O
from	O
delayed	B-T079
wound healing	B-T040
to	O
immune dysfunction	B-T047
and	O
impairment	B-T169
of	O
multiple	B-T081
sensory systems	B-T022
.	O
While	O
consensus	B-T054
has	O
been	O
reached	O
regarding	O
the	O
detrimental effects	B-T080
of	O
zinc deficiency	B-T047
on	O
wound healing	B-T040
,	O
there	O
is	O
considerable	O
discord	B-T054
in	O
the	O
literature	B-T170
on	O
the	O
optimal methods	B-T170
and	O
true benefits	B-T081
of	O
zinc	B-T121
supplementation.	O

Receipt	O
of	O
thyroid hormone deficiency	B-T047
treatment	B-T061
and	O
risk	B-T078
of	O
herpes zoster	B-T047
Thyroid hormone	B-T116
(	O
TH	B-T116
)	O
has	O
been	O
suggested	O
to	O
control	O
herpes virus	B-T005
gene expression	B-T045
and	O
replication	B-T045
in	O
neurons	B-T025
via	O
epigenetics	B-T045
through	O
its	O
nuclear receptors	B-T116
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
patients	B-T101
with	O
hypothyroidism	B-T047
are	O
predisposed	O
to	O
herpes zoster	B-T047
(	O
HZ	B-T047
),	O
suggesting	O
that	O
the	O
TH deficiency	B-T047
may	O
be	O
a	O
risk factor	B-T033
for	O
varicella zoster virus	B-T005
(	O
VZV	B-T005
)	O
reactivation	B-T052
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
test	O
the	O
hypothesis	B-T078
that	O
TH treatment	B-T061
will	O
ameliorate	O
the	O
complication	B-T046
of	O
HZ	B-T047
.	O
This	O
study	B-T062
investigated	B-T169
the	O
hypothesis	B-T078
by	O
enquiring	O
into	O
a	O
comprehensive medical database	B-T170
at	O
Kaiser Permanente Southern California	B-T093
(	O
KPSC	B-T093
)	O
to	O
verify	O
whether	O
patients	B-T101
taking	O
TH	B-T116
medication	B-T058
experience	O
a	O
reduction	O
in	O
HZ	B-T047
occurrence.	O
It	O
was	O
shown	O
by	O
Kaplan-Meier analysis	B-T081
that	O
hypothyroidism	B-T047
patients	B-T101
taking	O
TH	B-T116
medicines	B-T121
had	O
a	O
lower	O
risk	B-T078
of	O
HZ	B-T047
.	O
The	O
fully	O
adjusted	O
analysis	B-T062
indicated	O
that	O
patients	B-T101
receiving	O
medication	B-T058
for	O
the	O
treatment	B-T061
of	O
TH deficiency	B-T047
exhibited	O
a	O
reduced	O
risk	B-T078
of	O
HZ	B-T047
(	O
hazard ratio	B-T081
0.60,	O
95%	O
confidence interval	B-T081
0.51-0.71).	O
This	O
lower	O
risk	B-T078
of	O
HZ	B-T047
was	O
significant	O
in	O
all	O
age groups	B-T100
except	O
the	O
18-39	O
years	B-T079
cohort	B-T098
.	O
In	O
addition,	O
female	B-T032
patients	B-T101
taking	O
TH treatment	B-T061
exhibited	O
a	O
lower	O
risk	B-T078
than	O
their	O
male	B-T032
counterparts.	O
Together	O
these	O
findings	B-T033
support	O
the	O
hypothesis	B-T078
that	O
a	O
constant	O
level	O
of	O
TH	B-T116
will	O
provide	O
a	O
degree	O
of	O
protection	O
from	O
contracting	O
HZ	B-T047
.	O
More	O
studies	B-T062
are	O
underway	O
to	O
evaluate the laboratory data	B-T058
for	O
an	O
analysis	B-T062
of	O
hormonal	B-T080
effects	B-T080
on	O
individuals	B-T098
.	O

Peer	B-T098
Exclusion	B-T052
During	O
the	O
Pubertal	B-T033
Transition	B-T052
:	O
The	O
Role	O
of	O
Social Competence	B-T054
For	O
some	O
youth	B-T100
,	O
early puberty	B-T047
is	O
accompanied	O
by	O
peer	B-T098
exclusion	B-T052
.	O
Yet	O
early	B-T079
developers	B-T098
may	O
experience	B-T041
less	O
peer	B-T098
exclusion	B-T052
if	O
they	O
have	O
social competence	B-T054
,	O
which	O
would	O
bolster	B-T169
their	O
ability	O
to	O
develop	B-T169
and	O
maintain	B-T052
positive	B-T033
relationships	B-T080
with	O
their	O
peers	B-T098
.	O
Accordingly,	O
the	O
present	B-T033
study	B-T062
tests	O
whether	O
pubertal	B-T033
timing	B-T079
and	O
tempo	B-T079
predicts	B-T078
decrements	B-T080
in	O
children's	B-T100
social competence	B-T054
and	O
whether	O
decrements	B-T080
in	O
social competence	B-T054
account	O
for	O
associations	B-T080
between	O
puberty	B-T039
(	O
timing	B-T079
and	O
tempo	B-T079
)	O
and	O
peer	B-T098
exclusion	B-T052
over	O
time	B-T079
.	O
Longitudinal	B-T062
data	B-T078
were	O
drawn	O
from	O
1364	O
families	B-T099
(48%	O
female	B-T098
;	O
76%	O
White	B-T098
;	O
M	O
=	O
9.32	O
years	B-T079
,	O
SD	O
=	O
.48,	O
at	O
Wave	O
3)	O
who	O
participated	B-T169
in	O
Waves	O
3-5	O
(i.e.,	O
grades	O
4-6)	O
of	O
Phase III	B-T062
of	O
the	O
NICHD	B-T093
-	O
SECCYD	B-T062
.	O
The	O
results	B-T169
from	O
latent growth curve models	B-UnknownType
indicated	O
that	O
earlier	B-T079
pubertal	B-T033
timing	B-T079
and	O
more	O
rapid	B-T080
pubertal	B-T033
tempo	B-T079
among	O
girls	B-T100
were	O
associated with	B-T080
high	B-T080
initial	B-T079
levels	B-T080
of	O
peer	B-T098
exclusion	B-T052
.	O
Moreover,	O
mediation analyses	B-UnknownType
revealed	O
that	O
early	B-T079
developers'	B-T098
susceptibility	B-T169
to	O
peer	B-T098
exclusion	B-T052
was	O
associated with	B-T080
their	O
initial	B-T079
level	B-T080
of	O
social competence	B-T054
.	O
In	O
boys	B-T100
,	O
pubertal	B-T033
timing	B-T079
and	O
tempo	B-T079
were	O
not	O
directly	O
associated with	B-T080
peer	B-T098
exclusion	B-T052
;	O
instead,	O
indirect	O
effects of	B-T080
pubertal	B-T033
timing	B-T079
on	O
peer	B-T098
exclusion	B-T052
(	O
intercept	B-T081
,	O
slope	B-T081
)	O
occurred	O
through	O
initial	B-T079
levels	B-T080
of	O
social competence	B-T054
.	O
On	O
average	B-T081
,	O
early	B-T079
developers'	B-T098
who	O
had	O
low	B-T080
levels	B-T080
of	O
social competence	B-T054
also	O
had	O
high	B-T080
initial	B-T079
levels	B-T080
of	O
peer	B-T098
exclusion	B-T052
but	O
experienced	B-T041
decrements	B-T080
in	O
peer	B-T098
exclusion	B-T052
over	O
time.	O
The	O
association	B-T080
between	O
the	O
intercepts	B-T081
for	O
puberty	B-T039
and	O
peer	B-T098
exclusion	B-T052
and	O
the	O
slopes	B-T081
for	O
social competence	B-T054
and	O
peer	B-T098
exclusion	B-T052
were	O
stronger	B-T080
for	O
boys	B-T100
than	O
girls	B-T100
.	O
Overall,	O
our	O
findings	B-T033
suggest	O
that	O
early	B-T079
developers'	B-T098
susceptibility	B-T169
to	O
and	O
experiences	B-T041
of	O
peer	B-T098
exclusion	B-T052
are	O
associated with	B-T080
their	O
development	B-T169
of	O
social competence	B-T054
.	O

Air pollution	B-T069
characteristics	B-T080
and	O
health risks	B-T061
in	O
Henan Province	B-T083
,	O
China	B-T083
Events	O
of	O
severe	B-T080
air pollution	B-T069
occurred	O
frequently	O
in	O
China	B-T083
recently,	O
thus	O
understanding	O
of	O
the	O
air pollution	B-T069
characteristics	B-T080
and	O
its	O
health	B-T078
risks	B-T078
is	O
very	O
important.	O
In	O
this	O
work,	O
we	O
analyzed	O
a	O
two-year	O
dataset	B-T170
(March	O
2014	O
-	O
February	O
2016)	O
including	O
daily	B-T079
concentrations	B-T081
of	O
six	O
criteria	O
pollutants	B-T131
(	O
PM2.5	B-T167
,	O
PM10	B-T167
,	O
CO	B-T131
,	O
SO2	B-T131
,	O
NO2	B-T131
,	O
and	O
O3	B-T103
)	O
from	O
18	O
cities	O
in	O
Henan province	B-T083
.	O
Results	O
reveal	O
the	O
serious	O
air pollution	B-T069
status	B-T080
in	O
Henan province	B-T083
,	O
especially	O
the	O
northern part	B-T082
,	O
and	O
Zhengzhou	B-T083
is	O
the	O
city	B-T083
with	O
the	O
worst	B-T080
air quality	B-T080
.	O
Annual	O
average	O
PM2.5	B-T167
concentrations	B-T081
exceed	O
the	O
second	O
grade	O
of	O
Chinese Ambient Air Quality Standard	B-T081
(75μg/m(3))	O
at	O
both	O
2014	O
and	O
2015.	O
PM2.5	B-T167
is	O
typically	O
the	O
major	O
pollutant	B-T131
,	O
but	O
ozone	B-T103
pollution	B-T069
can	O
be	O
significant	O
during	O
summer	B-T079
.	O
Furthermore,	O
as	O
the	O
commonly	O
used	O
air quality index	B-T170
(	O
AQI	B-T170
)	O
neglects	O
the	O
mutual	O
health	B-T078
effects	O
from	O
multiple	O
pollutants	B-T131
,	O
we	O
introduced	O
the	O
aggregate air quality index	B-T170
(	O
AAQI	B-T170
)	O
and	O
health-risk based air quality index	B-T170
(	O
HAQI	B-T170
)	O
to	O
evaluate the health risks	B-T061
.	O
Results	O
show	O
that	O
based	O
on	O
HAQI	B-T170
,	O
the	O
current	O
AQI	B-T170
system	O
likely	O
significantly	O
underestimate	O
the	O
health	B-T078
risks	B-T078
of	O
air pollution	B-T069
,	O
highlighting	O
that	O
the	O
general public	B-T098
may	O
need	O
stricter	O
health protection measures	B-T058
.	O
The	O
population	B-T081
-weighted	O
two-year	O
average	O
HAQI	B-T170
data	O
further	O
demonstrates	O
that	O
all	O
population	B-T081
in	O
the	O
studied	O
cities	B-T083
in	O
Henan province	B-T083
live	O
with	O
polluted air	B-T069
-	O
72%	O
of	O
the	O
population	B-T081
is	O
exposed to	B-T080
air	B-T167
that	O
is	O
unhealthy	B-T033
for	O
sensitive	B-T169
people	B-T098
,	O
while	O
28%	O
of	O
people	B-T098
is	O
exposed to	B-T080
air	B-T167
that	O
can	O
be	O
harmful	O
to	O
healthy	B-T080
people	B-T098
;	O
and	O
the	O
health	B-T078
risks	B-T078
are	O
much	O
greater	O
during	O
winter	B-T079
than	O
during	O
other	O
seasons	B-T079
.	O
Future	O
works	O
should	O
further	O
improve	O
the	O
HAQI	B-T170
algorithm	B-T170
,	O
and	O
validate	O
the	O
links	O
between	O
the	O
clinical	B-T170
/	O
epidemiologic	B-T169
data	B-T170
and	O
the	O
HAQI	B-T170
values.	O

Increased	B-T081
risk	B-T078
of	O
PTLD	B-T191
in	O
lung transplant recipients	B-T033
with	O
cystic fibrosis	B-T047
Post-transplant lymphoproliferative disease	B-T191
(	O
PTLD	B-T191
)	O
is	O
an	O
important	O
cause	O
of	O
morbidity	B-T081
and	O
mortality	B-T081
following	O
lung transplantation	B-T061
.	O
Recipients	B-T101
with	O
cystic fibrosis	B-T047
(	O
CF	B-T047
)	O
may	O
have	O
an	O
increased	B-T081
risk	B-T078
of	O
PTLD	B-T191
although	O
the	O
literature	B-T170
is	O
limited	O
to	O
single center cohorts	B-T098
.	O
Our	O
primary	O
aim	O
is	O
to	O
examine	O
PTLD	B-T191
in	O
an	O
adult	B-T100
lung transplant	B-T061
population	B-T098
by	O
utilizing	O
the	O
International Society for Heart and Lung Transplantation Registry	B-T170
.	O
We	O
studied	B-T062
30,598	O
adult	B-T100
recipients	B-T098
of	O
lung transplants	B-T061
performed	O
between	O
1999	O
and	O
2011.	O
The	O
primary	O
outcome	B-T169
was	O
development	B-T169
of	O
and	O
time	B-T079
to	O
PTLD	B-T191
.	O
In	O
addition	O
to	O
indication	O
for	O
transplant	B-T061
,	O
other	O
predictors	B-T078
examined	O
included	O
Epstein-Barr virus	B-T005
(	O
EBV	B-T005
)	O
and	O
cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
serostatus	B-T201
,	O
gender	B-T032
,	O
and	O
age	B-T032
.	O
Outcomes	B-T169
were	O
assessed	B-T052
with	O
univariable	B-T062
and	O
multivariable Cox proportional hazard models	B-T081
to	O
obtain	O
hazard ratios	B-T081
(	O
HR	B-T081
).	O
17%	O
of	O
the	O
cohort	B-T098
had	O
a	O
diagnosis	B-T033
of	O
CF	B-T047
.	O
PTLD	B-T191
developed	O
in	O
2%	O
of	O
CF	B-T047
recipients	B-T101
compared	O
to	O
1%	O
for	O
non-CF recipients	B-T033
(p<0.001).	O
Compared	O
to	O
non-CF recipients	B-T033
,	O
CF	B-T047
recipients	B-T101
had	O
higher prevalence	B-T081
of	O
EBV	B-T005
and	O
CMV seronegativity	B-T034
and	O
higher prevalences	B-T081
of	O
high risk	B-T078
EBV	B-T005
and	O
CMV	B-T005
mismatch	O
(D+/R-).	O
There	O
is	O
a	O
significant	O
association	O
between	O
CF	B-T047
and	O
the	O
development	B-T169
of	O
PTLD	B-T191
[	O
HR	B-T081
1.66	O
(95%	O
CI	O
1.30-2.12)].	O
Stratified multivariable analysis	B-T081
controlling	O
for	O
age	B-T032
revealed	O
EBV	B-T005
negative	B-T033
non-CF recipients	B-T033
have	O
an	O
almost	O
2	O
fold	O
increased	B-T081
risk	B-T078
of	O
developing	O
PTLD	B-T191
,	O
whereas	O
EBV	B-T005
negative	O
CF	B-T047
recipients	B-T101
had	O
an	O
almost	O
6.5	O
fold	O
increased	B-T081
risk	B-T078
.	O
CF	B-T047
recipients	B-T101
have	O
a	O
higher	O
risk	B-T078
for	O
PTLD	B-T191
compared	O
to	O
non-CF recipients	B-T033
.	O
Further	O
studies	B-T062
are	O
needed	O
to	O
account	O
for	O
additional	O
risk factors	B-T033
and	O
management	B-T058
in	O
this	O
population post-transplant	B-T033
.	O

Methods	B-T170
,	O
tools	B-UnknownType
and	O
current	B-T079
perspectives	B-T078
in	O
proteogenomics	B-T091
With	O
combined	O
technological advancements	B-UnknownType
in	O
high-throughput next-generation sequencing	B-T063
and	O
deep mass spectrometry	B-T059
-based	O
proteomics	B-T091
,	O
proteogenomics	B-T091
,	O
i.e.,	O
the	O
integrative analysis	B-T062
of	O
proteomic and genomic data	B-T078
,	O
has	O
emerged	O
as	O
a	O
new	O
research field	B-UnknownType
.	O
Early	O
efforts	O
in	O
the	O
field	B-UnknownType
were	O
focused	O
on	O
improving	O
protein	B-T116
identification	B-T080
using	O
sample-specific genomic	B-T170
and	O
transcriptomic sequencing data	B-T170
.	O
More	O
recently,	O
integrative analysis	B-T062
of	O
quantitative	B-T081
measurements	B-T169
from	O
genomic and proteomic studies	B-T062
have	O
identified	B-T080
novel	O
insights	O
into	O
gene expression regulation	B-T045
,	O
cell signaling	B-T043
,	O
and	O
disease	B-T047
.	O
Many	O
methods	B-T170
and	O
tools	B-UnknownType
have	O
been	O
developed	O
or	O
adapted	O
to	O
enable	O
an	O
array	B-T082
of	O
integrative proteogenomic approaches	B-T169
and	O
in	O
this	O
article	B-T170
,	O
we	O
systematically	B-T169
classify	B-T185
published	B-T057
methods	B-T170
and	O
tools	B-UnknownType
into	O
four	O
major categories	B-T185
,	O
(1)	O
Sequence	B-T086
Sequence -centric proteogenomics	B-T091
;	O
(2)	O
Analysis	B-T062
of	O
proteogenomic relationships	B-T080
;	O
(3)	O
Integrative modeling	B-T062
of	O
proteogenomic data	B-T078
;	O
and	O
(4)	O
Data sharing	B-T054
and	O
visualization	B-T041
.	O
We	O
provide	O
a	O
comprehensive	B-T080
review of	B-T169
methods	B-T170
and	O
available	B-T169
tools	B-UnknownType
in	O
each	O
category	B-T170
and	O
highlight	O
their	O
typical	B-T080
applications	B-T169
.	O

Plasma	B-T031
DNA	B-T114
and	O
RNA	B-T114
differentially	B-T080
impact	B-T080
coagulation	B-T042
during	O
abdominal sepsis	B-T047
-an	O
explorative study	B-T062
Cell-free DNA	B-T114
(	O
cfDNA	B-T114
)	O
and	O
extracellular	B-T026
RNA	B-T114
(	O
exRNA	B-T114
)	O
are	O
both	O
suspected	B-T078
to	O
activate	B-T169
coagulation cascades	B-T047
in	O
sepsis	B-T047
.	O
Therefore,	O
our	O
study	B-T062
investigated	B-T169
the	O
influence	B-T077
of	O
plasmatic	B-T031
nucleic acids	B-T114
on	O
coagulation	B-T042
in	O
septic	B-T169
patients	B-T101
in	O
comparison	B-T052
to	O
patients	B-T101
after	O
major	O
abdominal surgery	B-T061
.	O
A	O
total	O
of	O
15	O
patients	B-T101
with	O
sepsis	B-T047
,	O
10	O
postoperative	B-T079
patients	B-T101
,	O
and	O
10	O
healthy volunteers	B-T098
were	O
included	B-T169
in	O
this	O
longitudinal study	B-T062
.	O
Blood	B-T031
was	O
collected	B-T078
at	O
sepsis	B-T047
onset	B-T079
and	O
after	O
surgery	B-T061
respectively,	O
as	O
well	O
as	O
after	O
24,	O
72	O
and	O
168	O
h.	O
Levels	B-T080
of	O
cfDNA	B-T114
and	O
exRNA	B-T114
were	O
measured	B-T080
by	O
quantitative	B-T081
probe-based	B-T074
polymerase chain reaction	B-T063
.	O
In	O
addition,	O
thromboelastography	B-T059
for	O
coagulation	B-T042
as	O
well	O
as	O
thromboaggregometry	B-T059
for	O
platelet function	B-T043
was	O
conducted.	O
Both	O
cfDNA	B-T114
and	O
exRNA	B-T114
were	O
elevated	B-T080
in	O
patients	B-T101
with	O
sepsis	B-T047
compared	B-T052
with	O
postoperative	B-T079
patients	B-T101
and	O
healthy volunteers	B-T098
.	O
While	O
higher	B-T080
exRNA	B-T114
levels	B-T080
correlated	B-T080
with	O
a	O
faster clotting time	B-T034
and	O
more	O
stable clots	B-T046
,	O
cfDNA	B-T114
correlated	B-T080
with	O
a	O
shorter clotting time	B-T034
but	O
also	O
less	O
fibrinolysis	B-T039
.	O
In	O
addition,	O
higher	B-T080
cfDNA	B-T114
seems	O
to	O
be	O
associated with	B-T080
kidney dysfunction	B-T046
as	O
well	O
as	O
with	O
general	O
markers	B-T201
of	O
cell damage	B-T049
(	O
lactate dehydrogenase	B-T116
and	O
lactate	B-T109
).	O
Both	O
nucleic acid	B-T114
species	O
might	O
be	O
associated with	B-T080
different	B-T080
effects	B-T080
on	O
coagulation	B-T042
during	O
sepsis	B-T047
,	O
with	O
an	O
overall	B-T080
procoagulatory	B-T042
influence	B-T077
.	O
For	O
this	O
reason,	O
individualized	B-T080
therapeutic approaches	B-T061
in	O
patients	B-T101
suffering	B-T184
from	O
coagulation	B-T042
-	O
associated	B-T033
organ dysfunction	B-T047
might	O
be	O
feasible.	O

Association	B-T080
of	O
Fat Mass	B-T032
and	O
Obesity	B-T047
-	O
associated	B-T080
Gene Variant	B-T028
with	O
Lifestyle	B-T054
Factors	B-T169
and	O
Body Fat	B-T201
in	O
Indian	B-T098
Children	B-T100
Common	O
intronic variants	B-T028
of	O
the	O
fat mass	B-T032
and	O
obesity	B-T047
-	O
associated	B-T080
(FTO) gene	B-T028
have	O
been	O
associated with	B-T080
obesity	B-T047
-related	O
traits	B-T032
in	O
humans	B-T016
.	O
(1)	O
The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
study	B-T062
the	O
distribution	O
of	O
FTO gene	B-T028
variants	B-T028
across	O
different	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
categories	O
and	O
(2)	O
to	O
explore	O
the	O
association	B-T080
between	O
FTO gene	B-T028
variants	B-T028
and	O
lifestyle	B-T054
factors	B-T169
in	O
obese	B-T047
and	O
normal weight	B-T033
Indian	B-T098
children	B-T100
.	O
Fifty-six	O
children	B-T100
(26	O
boys	B-T100
,	O
mean	O
age	B-T032
10.3	O
±	O
2.2	O
years	B-T079
)	O
were	O
studied	B-T062
.	O
Height	B-T032
,	O
weight	B-T032
,	O
and	O
waist	B-T201
and	O
hip circumference	B-T201
were	O
measured	B-T080
.	O
Physical activity	B-T056
(	O
questionnaire	B-T170
)	O
and	O
food	B-T168
intake	B-T169
(	O
food frequency questionnaire	B-T170
)	O
were	O
assessed	B-T052
.	O
Body fat percentage	B-T201
(	O
%BF	B-T201
)	O
was	O
measured	O
by	O
dual-energy X-ray absorptiometry	B-T060
.	O
FTO allelic variants	B-T028
at	O
rs9939609 site	B-T082
were	O
detected	O
by	O
SYBR Green Amplification Refractory Mutation System real-time polymerase chain reaction	B-T063
using	O
allele	B-T028
-	O
specific	B-T080
primers	B-T114
.	O
Generalized linear model	B-T081
was	O
used	O
to	O
investigate	B-T169
the	O
simultaneous	B-T079
influence	B-T077
of	O
genetic	B-T169
and	O
lifestyle	B-T054
factors	B-T169
on	O
%BF	B-T201
.	O
Mean	O
height	B-T032
,	O
weight	B-T032
,	O
and	O
BMI	B-T201
of	O
normal	B-T080
and	O
obese	B-T047
children	B-T100
were	O
130.6	O
±	O
7.1	O
versus	O
143.2	O
±	O
15.6,	O
24.0	O
±	O
5.2	O
versus	O
53.1	O
±	O
15.8,	O
and	O
13.9	O
±	O
2.1	O
versus	O
25.3	O
±	O
3.2,	O
respectively.	O
The	O
frequency	O
of	O
AA allele	B-T028
was	O
57%	O
among	O
obese	B-T047
children	B-T100
and	O
35%	O
in	O
normal weight	B-T033
children	B-T100
.	O
Children	B-T100
with	O
the	O
AA allele	B-T028
who	O
were	O
obese	B-T047
had	O
least	O
physical activity	B-T056
,	O
whereas	O
children	B-T100
with	O
AT allele	B-T028
and	O
obesity	B-T047
had	O
the	O
highest	B-T080
intake of calories	B-T081
when	O
compared	B-T052
to	O
children	B-T100
who	O
had	O
AT allele	B-T028
and	O
were	O
normal	B-T080
.	O
%BF	B-T201
was	O
positively	O
associated with	B-T080
AA alleles	B-T028
and	O
junk food	B-T168
intake	B-T169
and	O
negatively	O
with	O
healthy	B-T080
food	B-T168
intake	B-T169
and	O
moderate	O
physical activity	B-T056
.	O
Healthy lifestyle	B-T055
with	O
high	O
physical activity	B-T056
and	O
diet	B-T168
low	B-T080
in	O
calories	B-T081
and	O
fat	B-T109
may	O
help	O
in	O
modifying	B-T169
the	O
risk	B-T078
imposed	O
by	O
FTO variants	B-T028
in	O
children	B-T100
.	O

Museum	B-T073
specimen	B-T167
data	B-T078
reveal	O
emergence	O
of	O
a	O
plant disease	B-T047
may	O
be	O
linked	O
to	O
increases	B-T169
in	O
the	O
insect vector	B-T204
insect vector population	B-T098
The	O
emergence rate	B-T081
of	O
new	O
plant diseases	B-T047
is	O
increasing	B-T169
due	O
to	O
novel	O
introductions,	O
climate change	B-T070
,	O
and	O
changes	B-T169
in	O
vector populations	B-T098
,	O
posing	O
risks	B-T078
to	O
agricultural	B-T090
agricultural sustainability	B-T169
.	O
Assessing and managing	B-T052
future	O
disease	B-T047
risks	B-T078
depends	O
on	O
understanding	O
the	O
causes	O
of	O
contemporary and historical emergence events	B-T051
.	O
Since	O
the	O
mid-1990s,	O
potato growers	B-T097
in	O
the	O
western United States	B-T083
,	O
Mexico	B-T083
,	O
and	O
Central America	B-T083
have	O
experienced	O
severe	O
yield loss	B-T081
from	O
Zebra Chip disease	B-T047
and	O
have	O
responded	O
by	O
increasing	O
insecticide	B-T131
use	O
to	O
suppress	O
populations	B-T098
of	O
the	O
insect vector	B-T204
,	O
the	O
potato psyllid	B-T204
,	O
Bactericera cockerelli	B-T204
(	O
Hemiptera	B-T204
:	O
Triozidae	B-T204
).	O
Despite	O
the	O
severe	O
nature	O
of	O
Zebra Chip	B-T047
outbreaks	B-T067
,	O
the	O
causes	O
of	O
emergence	O
remain	O
unknown.	O
We	O
tested	O
the	O
hypotheses	B-T078
that	O
1)	O
B. cockerelli	B-T204
occupancy	B-T080
has	O
increased	B-T081
over	O
the	O
last	O
century	B-T121
in	O
California	B-T083
and	O
2)	O
such	O
increases	O
are	O
related	O
to	O
climate change	B-T070
,	O
specifically	O
warmer winters	B-T079
.	O
We	O
compiled	O
a	O
dataset	B-T170
of	O
87,000	O
museum	B-T073
specimen	B-T167
occurrence	O
records	B-T170
across	O
the	O
order	O
Hemiptera	B-T204
collected	O
between	O
1900	O
and	O
2014.	O
We	O
then	O
analyzed	B-T062
changes	O
in	O
B. cockerelli	B-T204
distribution	O
using	O
a	O
hierarchical occupancy model	B-T170
using	O
changes	O
in	O
background	O
species	B-T185
species lists	B-T170
to	O
correct	O
for	O
collecting	O
effort.	O
We	O
found	O
evidence	B-T078
that	O
B. cockerelli	B-T204
occupancy	B-T080
has	O
increased	B-T081
over	O
the	O
last	O
century	B-T121
.	O
However,	O
these	O
changes	O
appear	O
to	O
be	O
unrelated	O
to	O
climate changes	B-T070
,	O
at	O
least	O
at	O
the	O
scale	O
of	O
our	O
analysis	B-T062
.	O
To	O
the	O
extent	O
that	O
species	B-T185
occupancy	B-T080
is	O
related	O
to	O
abundance,	O
our	O
analysis	B-T062
provides	O
the	O
first	O
quantitative	O
support	O
for	O
the	O
hypothesis	B-T078
that	O
B. cockerelli	B-T204
population	B-T098
abundance	O
has	O
increased	B-T081
,	O
but	O
further	O
work	O
is	O
needed	O
to	O
link	O
B. cockerelli	B-T204
population	B-T098
dynamics	B-T070
to	O
Zebra Chip	B-T047
Zebra Chip epidemics	B-T047
.	O
Finally,	O
we	O
demonstrate	O
how	O
this	O
historical macro-ecological approach	B-T082
provides	O
a	O
general	O
framework	O
for	O
comparative risk assessment	B-T058
of	O
future	O
pest	B-T204
and	O
insect vector	B-T204
outbreaks	B-T067
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Effect	B-T080
of	O
halotolerant rhizobacteria	B-T007
isolated	B-T169
from	O
halophytes	B-T002
on	O
the	O
growth	B-T040
of	O
sugar beet	B-T002
(	O
Beta vulgaris L	B-T002
.)	O
under	O
salt stress	B-T043
Utilization	B-T169
of	O
rhizobacteria	B-T007
that	O
have	O
associated with	B-T080
plant roots	B-T002
in	O
harsh	B-T033
environments	B-T082
could	O
be	O
a	O
feasible strategy	B-T062
to	O
deal	O
with	O
limits	O
to	O
agricultural production	B-T090
caused	O
by	O
soil	B-T167
salinity	B-T034
.	O
Halophytes	B-T002
occur	O
naturally	O
in	O
high	B-T080
-	O
salt environments	B-T082
,	O
and	O
their	O
roots	B-T002
may	O
be	O
associated with	B-T080
promising	O
microbial candidates	B-T001
for	O
promoting	B-T052
growth	B-T040
and	O
salt tolerance	B-T043
in	O
crops	B-T002
.	O
This	O
study	B-T062
aimed	O
to	O
isolate	B-T169
efficient	O
halotolerant plant	B-T002
-	O
growth	B-T040
-	O
promoting	B-T052
rhizobacterial	B-T080
strains	B-T001
from	O
halophytes	B-T002
and	O
evaluate	B-T052
their	O
activity	B-T052
and	O
effects	B-T080
on	O
sugar beet	B-T002
(	O
Beta vulgaris L	B-T002
.)	O
growth	B-T040
under	O
salinity stress	B-T043
.	O
A	O
total	O
of	O
23	O
isolates	B-T123
were	O
initially	O
screened	O
for	O
their	O
ability	B-T032
to	O
secrete	O
1-aminocyclopropane-1-carboxylate deaminase	B-T116
(	O
ACD	B-T116
)	O
as	O
well	O
as	O
other	O
plant-growth	B-T040
-	O
promoting	B-T052
characteristics	B-T080
and	O
subsequently	O
identified	B-T080
by	O
sequencing	B-T169
the	O
16S rRNA	B-T114
gene	B-T028
.	O
Three	O
isolates	B-T123
,	O
identified	O
as	O
Micrococcus yunnanensis	B-T007
,	O
Planococcus rifietoensis	B-T007
and	O
Variovorax paradoxus	B-T007
,	O
enhanced	B-T052
salt stress	B-T043
tolerance	B-T080
remarkably	O
in	O
sugar beet	B-T002
,	O
resulting in	B-T169
greater	B-T081
seed germination	B-T040
and	O
plant	B-T002
biomass	B-T081
,	O
higher	B-T080
photosynthetic	B-T070
capacity	B-T081
and	O
lower	B-T080
stress	B-T033
-	O
induced	B-T169
ethylene	B-T109
production	B-T169
at	O
different	B-T080
NaCl	B-T121
concentrations	B-T081
(50-125	O
mM).	O
These	O
results	B-T169
demonstrate	O
that	O
salinity	B-T034
-	O
adapted	B-T038
,	O
ACD	B-T116
-producing	O
bacteria	B-T007
isolated	B-T169
from	O
halophytes	B-T002
could	O
promote	B-T052
sugar beet	B-T002
growth	B-T040
under	O
saline stress conditions	B-T043
.	O

Potential	B-T080
Sunitinib	B-T109
-	O
Induced	B-T169
Coronary Artery	B-T023
and	O
Aortic Dissections	B-T047
Small-molecule multitargeted tyrosine kinase inhibitor (TKI) therapy	B-T061
is	O
used	O
in	O
different	O
types	O
of	O
cancer	B-T191
.	O
These	O
drugs	B-T121
have	O
been	O
associated with	B-T080
cardiovascular toxicity	B-T037
,	O
including	O
aortic dissection	B-T047
.	O
To	O
our	O
knowledge	B-T170
,	O
this	O
is	O
the	O
first time	B-T079
that	O
a	O
coronary dissection	B-T047
potentially	B-T080
associated with	B-T080
a	O
TKI treatment	B-T061
has	O
been	O
described.	O

Recovery of	B-T052
orthographic	B-T090
processing	B-T041
after	O
stroke	B-T047
:	O
A	O
longitudinal	B-T062
fMRI	B-T060
study	O
An	O
intact	O
orthographic	B-T090
processing	B-T041
system	O
is	O
critical	O
for	O
normal reading and spelling	B-T048
.	O
Here	O
we	O
investigate	O
the	O
neural changes	B-T169
associated	O
with	O
impairment	B-T169
and	O
subsequent	O
recovery	B-T052
of	O
the	O
orthographic	B-T090
lexical processing	B-T041
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	B-T046
left posterior cerebral artery (PCA) stroke	B-T047
.	O
This	O
work	O
describes	O
a	O
longitudinal case study	B-T062
of	O
a	O
patient,	O
whose	O
initials	O
are	O
MMY	B-T016
,	O
with	O
impairments	B-T169
in	O
orthographic	B-T090
lexical processing	B-T041
for	O
reading and spelling	B-T048
at	O
stroke	B-T047
onset	B-T079
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	B-T047
.	O
We	O
tested	O
the	O
hypothesis	B-T078
that	O
this	O
acute	B-T079
impairment	B-T169
to	O
reading and spelling	B-T048
would	O
be	O
associated	O
with	O
a	O
selective	O
loss of	B-T081
neural activation	B-T169
in	O
the	O
left fusiform gyrus	B-T023
(	O
FG	B-T023
),	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain of	B-T081
neural activation	B-T169
in	O
this	O
region.	O
MMY's	B-T016
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural changes	B-T169
because	O
she	O
demonstrated	O
a	O
behavioral	B-T053
recovery of naming as well	B-T040
;	O
i.e.,	O
if	O
there	O
is	O
neural recovery	B-T169
for	O
reading and spelling	B-T048
,	O
but	O
not	O
naming,	O
then	O
these	O
neural changes	B-T169
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	B-T090
processing	B-T041
.	O
To	O
test	O
our	O
hypothesis,	O
we	O
examined	O
longitudinal behavioral	B-T062
and	O
functional magnetic resonance imaging	B-T060
(	O
fMRI	B-T060
)	O
data	O
of	O
reading	B-T041
,	O
spelling	B-UnknownType
,	O
and	O
visual object naming	B-T170
acquired	O
acutely,	O
3	O
weeks,	O
5	O
months,	O
and	O
one	O
year	O
post	O
stroke	B-T047
.	O
In	O
confirmation	O
of	O
our	O
hypothesis	B-T078
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	B-T090
lexical processing	B-T041
was	O
associated	O
with	O
up-regulation	B-T044
of	O
neural activation	B-T169
in	O
areas	O
previously	O
associated	O
with	O
orthographic	B-T090
lexical processing	B-T041
:	O
i.e.,	O
the	O
left mid-FG	B-T029
and	O
inferior frontal junction	B-T023
(	O
IFJ	B-T023
).	O
Furthermore,	O
these	O
neural changes	B-T169
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	B-T090
processing	B-T041
,	O
as	O
they	O
were	O
observed	O
for	O
reading	B-T041
and	O
spelling	B-UnknownType
,	O
but	O
not	O
for	O
visual object naming	B-T170
within	O
the	O
left mid-FG	B-T029
.	O
This	O
work	O
shows	O
that	O
left PCA stroke	B-T047
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	B-T090
lexical processing	B-T041
system,	O
not	O
only	O
in	O
the	O
posterior region	B-T082
adjacent	B-T082
to	O
the	O
stroke	B-T047
,	O
but	O
also	O
in	O
relatively	O
distant frontal	B-T082
orthographic	B-T090
processing	B-T041
regions.	O

Nodal	B-T082
skip	B-T033
metastasis	B-T191
in	O
thoracic esophageal squamous cell carcinoma	B-T191
:	O
a	O
cohort study	B-T081
Nodal	B-T082
skip	B-T033
metastasis	B-T191
is	O
a	O
prognostic factor	B-T201
in	O
some	O
sites	O
of	O
malignancies	B-T191
,	O
but	O
its	O
role	O
in	O
esophageal cancer	B-T191
is	O
still	O
unclear	B-T033
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	B-T169
occurrence	O
and	O
effect	B-T080
of	O
nodal	B-T082
skip	B-T033
metastases	O
in	O
thoracic esophageal squamous cell carcinoma	B-T191
.	O
All	O
578	O
patients	B-T101
undergoing	O
esophagectomy	B-T061
for	O
thoracic esophageal squamous cell carcinoma	B-T191
at	O
the	O
Center for Esophageal Diseases	B-T093
located	O
in	O
Padova	B-UnknownType
between	O
January	B-T080
1992	O
and	O
December	B-T080
2010	O
were	O
retrospectively evaluated	B-T062
.	O
Selection criteria	B-T080
were	O
R0 resection	B-T033
,	O
pathological	B-T169
M0 stage	B-T033
and	O
pathological	B-T169
lymph node involvement	B-T033
.	O
Patients	B-T101
receiving	O
neoadjuvant therapy	B-T061
were	O
excluded.	O
The	O
selection	O
identified	O
88	O
patients	B-T101
with	O
lymph node involvement	B-T033
confirmed	O
by	O
pathological	B-T169
evaluation	B-T058
.	O
Sixteen	O
patients	B-T101
(18.2%)	O
had	O
nodal	B-T082
skip	B-T033
metastasis	B-T191
.	O
Adjusting	O
for	O
the	O
number	O
of	O
lymph node metastases	B-T191
,	O
patient	B-T101
with	O
nodal	B-T082
skip	B-T033
metastasis	B-T191
had	O
similar	O
5-year	O
overall survival	B-T081
(14%	O
vs.	O
13%,	O
p	O
=	O
0.93)	O
and	O
5-year	O
disease free survival	B-T081
(14%	O
vs.	O
9%,	O
p	O
=	O
0.48)	O
compared	O
to	O
patients	B-T101
with	O
both	O
peritumoral	B-T082
and	O
distant	B-T082
lymph node metastases	B-T191
.	O
The	O
risk	O
difference	O
of	O
nodal	B-T082
skip	B-T033
metastasis	B-T191
was:	O
-24.1%	O
(95%	O
C.I	B-T081
.	O
-43.1%	O
to	O
-5.2%)	O
in	O
patients	B-T101
with	O
more	O
than	O
one	O
lymph node metastasis	B-T191
compared	O
to	O
those	O
with	O
one	O
lymph node metastasis	B-T191
;	O
-2.3%	O
(95%	O
C.I	B-T081
.	O
-29.8%	O
to	O
25.2%)	O
in	O
middle	B-T082
thoracic esophagus	B-T023
and	O
-23.0%	O
(95%	O
C.I	B-T081
.	O
-47.8%	O
to	O
1.8%)	O
in	O
lower	B-T082
thoracic esophagus	B-T023
compared	O
to	O
upper	B-T082
thoracic esophagus	B-T023
;	O
18.1%	O
(95%	O
C.I.	B-T081
3.2%	O
to	O
33.0%)	O
in	O
clinical	B-T080
N0 stage	B-T033
vs.	O
clinical	B-T080
N+ stage	B-T033
.	O
Nodal	B-T082
skip	B-T033
metastasis	B-T191
is	O
a	O
common	O
pattern	O
of	O
metastatic lymph involvement	B-T033
in	O
thoracic esophageal squamous cell carcinoma	B-T191
.	O
However,	O
neither	B-T080
overall survival	B-T081
nor	O
disease free survival	B-T081
are	O
associated with	B-T080
nodal	B-T082
skip	B-T033
metastasis	B-T191
occurrence.	O

Association	B-T080
of	O
leukemia inhibitory factor gene	B-T028
polymorphism	B-T045
and	O
in vitro	B-T080
fertilization	B-T040
outcome	B-T169
in	O
a	O
population	B-T098
in	O
northern Iran	B-T083
Several	O
studies	B-T062
have	O
been	O
demonstrated	O
that	O
endometrial	B-T082
leukemia inhibitory factor	B-T116
(	O
LIF	B-T116
)	O
is	O
important	O
in	O
embryo implantation	B-T040
.	O
LIF	B-T116
is	O
a	O
secreted	O
glycoprotein	B-T116
with	O
a	O
variety	O
of	O
biological functions	B-T038
including	O
stimulation	B-T070
of	O
cell proliferation	B-T043
,	O
differentiation	B-T043
and	O
survival	B-T043
that	O
are	O
all	O
essential	B-T080
for	O
blastocyete	B-T018
development	B-T169
and	O
implantation	B-T040
.	O
The	O
LIF receptor	B-T116
activates	B-T052
several	O
signaling pathways	B-T044
in	O
diverse cell types	B-T170
,	O
including	O
Jak/STAT	B-T169
,	O
MAPK	B-T116
and	O
PI3-kinase	B-T116
pathways	B-T044
in	O
the	O
endometrium	B-T023
of	O
fertile	B-T040
woman	B-T098
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	B-T045
of	O
LIF	B-T116
in	O
proliferative	B-T046
phase	B-T079
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	B-T169
of	O
implantation	B-T061
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
association	B-T080
between	O
maternal	B-T033
genotype	B-T032
of	O
SNP 3951C/T	B-T086
LIF	B-T116
and	O
in vitro fertilization	B-T061
and	O
embryo transfer	B-T061
(	O
IVF	B-T061
-	O
ET	B-T061
)	O
outcome	B-T080
in	O
infertile	B-T046
women	B-T098
.	O
This	O
case-control study	B-T062
was	O
comprised	O
of	O
infertile	B-T046
patients	B-T101
(n=70)	O
and	O
women	B-T098
having	O
one	O
healthy child	B-T033
as	O
controls	B-T096
(n=73).	O
Genotyping	B-T059
for	O
SNP-3951C/T	B-T086
was	O
performed	O
by	O
PCR/RFLP	B-T059
.	O
Allele	B-T028
and	O
genotype	B-T032
distribution	B-T169
did	O
not	O
differ	O
significantly	O
between	O
patients	B-T101
and	O
controls	B-T096
(P>0.05).	O
The	O
LIF	B-T116
genotype	B-T032
frequencies	B-T081
amongst	O
the	O
70	O
cases	B-T169
were	O
C/C	B-T086
=40%,	O
C/T	B-T086
=52.8%	O
and	O
T/T	B-T086
=7.2%;	O
the	O
C	O
and	O
T	O
allele	B-T028
frequencies	B-T081
were	O
66%	O
and	O
34%,	O
respectively.	O
The	O
LIF	B-T116
genotype	B-T032
frequencies	B-T081
amongst	O
the	O
73	O
controls	B-T096
were	O
C/C	B-T086
=45.20%,	O
C/T	B-T086
=50.70%	O
and	O
T/T	B-T086
=4.1%;	O
the	O
C	O
and	O
T	O
allele	B-T028
frequencies	B-T081
were	O
70%	O
and	O
30%,	O
respectively.	O
In	O
conclusion,	O
the	O
results	B-T169
of	O
this	O
study	O
indicate	O
that	O
SNP 3951C/T	B-T086
of	O
LIF	B-T116
may	O
not	O
be	O
associated with	B-T080
IVF	B-T061
-	O
ET	B-T061
outcome	B-T080
in	O
this	O
population	B-T098
.	O
Although	O
more	O
studies	B-T062
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	B-T101
and	O
control subjects	B-T096
to	O
confirm	B-T080
our	O
results	B-T169
.	O

ANTI ANGIOGENIC EFFECT	B-T033
OF	O
CHEBULAGIC ACID	B-T109
INVOLVES	O
INHIBITION	B-T052
OF	O
VEGFR2	B-T044
AND	O
GSK3β DEPENDENT SIGNALING PATHWAYS	B-T044
Inhibition	B-T052
of	O
angiogenesis	B-T042
is	O
a	O
useful	O
strategy	B-T170
to	O
prevent	B-T080
cancer growth	B-T191
,	O
which	O
targets	B-T169
new	O
vessels	B-T023
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	B-T169
tumor cells	B-T025
.	O
Endothelial cells	B-T025
can	O
use	O
a	O
number	O
of	O
different	O
pathways	B-T044
to	O
cause	O
angiogenesis	B-T042
and	O
each	O
step	O
in	O
these	O
pathways	B-T044
can	O
be	O
targeted	B-T169
.	O
The	O
use	O
of	O
multi targeted drugs	B-T121
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario.	O
Our	O
previous	O
results	O
have	O
shown	O
the	O
anti angiogenic effect	B-T033
of	O
Chebulagic acid	B-T109
-	O
a	O
benzopyran	B-T109
tannin	B-T109
present	O
in	O
the	O
fruits	B-T168
of	O
Terminalia chebula	B-T002
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular mechanism	B-T044
of	O
the	O
anti angiogenic effect	B-T033
of	O
chebulagic acid	B-T109
.	O
Results	O
of	O
our	O
investigations	O
using	O
molecular docking studies	B-T170
and	O
HUVECs	B-T025
in	O
culture	B-T059
suggested	O
that	O
Chebulagic acid	B-T109
inhibited	B-T052
GSK-3β	B-T116
dependent	B-T169
β-catenin	B-T116
phosphorylation	B-T044
,	O
an	O
important	O
mediator	O
of	O
VE-cadherin	B-T116
/	O
β-catenin	B-T116
signaling	B-T044
and	O
VEGFR2	B-T116
phosphorylation	B-T044
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
VEGF signaling	B-T044
.	O
Chebulagic acid	B-T109
inhibits	B-T052
angiogenesis	B-T042
by	O
blocking	B-T169
both	O
VEGF	B-T116
/	O
VEGFR2	B-T116
and	O
cell-cell contact dependent downstream signaling pathway	B-T044
.	O

Identification	O
of	O
protective	O
B-cell epitopes	B-T129
within	O
the	O
novel	O
malaria vaccine	B-T121
candidate	O
P. falciparum Schizont Egress Antigen-1	B-T116
Naturally	B-T169
-acquired	O
antibodies	B-T116
to	O
PfSEA-1A	B-T116
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	B-T047
in	O
children	B-T100
.	O
Vaccination	B-T061
of	O
mice	B-T015
with	O
PbSEA-1A	B-T129
decreases	O
parasitemia	B-T047
and	O
prolongs	O
survival	O
following	O
Plasmodium berghei ANKA	B-T204
challenge.	O
To	O
enhance	O
the	O
immunogenicity	B-T038
of	O
PfSEA-1A	B-T116
,	O
we	O
identified	O
five	O
linear,	O
B-cell epitopes	B-T129
using	O
peptide	B-T116
microarrays	B-T075
probed	O
with	O
anti-sera	B-T116
from	O
rPfSEA-1A	B-T116
-	O
vaccinated	B-T033
non-human	O
primates	B-T015
.	O
We	O
evaluated	B-T058
the	O
relationship	O
between	O
epitope	B-T129
-specific	O
antibody	B-T116
levels	O
and	O
protection	O
from	O
parasitemia	B-T047
in	O
a	O
longitudinal	O
treatment	B-T061
-	O
reinfection	B-T169
cohort	B-T098
in	O
Western Kenya	B-T083
.	O
Antibodies	B-T116
to	O
three	O
epitopes	B-T129
were	O
associated	O
with	O
16-17%	O
decreased	O
parasitemia	B-T047
over	O
an	O
18-	O
week	B-T079
high	O
transmission	B-T070
season.	O
We	O
are	O
currently	O
designing	O
immunogens	B-T116
to	O
enhance	O
antibody responses	B-T038
to	O
these	O
three	O
epitopes	B-T129
.	O

Estrogen	B-T109
deficiency	B-T169
accelerates	B-T169
lumbar facet joints	B-T030
arthritis	B-T047
Dramatic	O
increase	B-T169
in	O
the	O
prevalence	B-T081
of	O
lumbar facet joint	B-T030
(	O
LFJ	B-T030
)	O
arthritis	B-T047
in	O
women	B-T098
around	O
the	O
age	B-T032
of	O
menopause	B-T039
indicates	O
a	O
protective role	B-T078
for	O
estrogen	B-T109
in	O
LFJ	B-T030
arthritis	B-T047
.	O
To	O
date,	O
there	O
is	O
no evidence	B-T080
for	O
this	O
indication	B-T078
and	O
the	O
mechanism	B-T169
of	O
such	O
an	O
effect	B-T080
remains	O
poorly	O
understood.	O
In	O
this	O
study	B-T062
,	O
ovariectomized (OVX) mice	B-T015
were	O
used	O
to	O
mimic	O
the	O
estrogen	B-T109
-	O
deficient	B-T169
status	B-T080
of	O
post-menopausal	B-T040
women	B-T098
.	O
Micro-CT	B-T060
and	O
immunohistochemistry	B-T060
was	O
employed	O
to	O
assess	B-T058
the	O
morphological	B-T082
and	O
molecular	B-T080
changes	B-T169
in	O
ovariectomy	B-T061
-	O
induced	B-T169
LFJ	B-T030
arthritis	B-T047
.	O
The	O
results	B-T169
show	O
that	O
the	O
LFJ	B-T030
subchondral bone mass	B-T201
was	O
significantly	O
decreased	B-T081
in	O
OVX mice	B-T015
,	O
with	O
increased	B-T081
cavities	B-T030
on	O
the	O
interface	B-T082
of	O
the	O
subchondral bone	B-T023
.	O
Severe	B-T080
cartilage	B-T024
degradation	B-T169
was	O
observed	O
in	O
ovariectomy	B-T061
-	O
induced	B-T169
LFJ	B-T030
arthritis	B-T047
.	O
Increased	B-T081
blood vessels	B-T023
and	O
innervations	B-T080
were	O
also	O
found	O
in	O
degenerated	B-T046
LFJ	B-T030
,	O
particularly	O
in	O
the	O
subchondral bone	B-T023
area	B-T029
.	O
17β-Estradiol	B-T109
treatment	B-T061
efficiently	O
suppressed	B-T169
LFJ	B-T030
subchondral bone turnover	B-T033
,	O
markedly	O
inhibited	B-T080
cartilage	B-T024
degradation	B-T169
,	O
and	O
increased	B-T081
blood vessel	B-T023
and	O
nerve ending	B-T026
growth	B-T040
in	O
degenerated	B-T046
LFJ	B-T030
in	O
OVX mice	B-T015
.	O
Our	O
study	B-T062
reveals	O
that	O
estrogen	B-T109
is	O
a	O
key	O
factor	B-T169
in	O
regulating LFJ metabolism	B-T169
.	O
Severe	B-T080
LFJ	B-T030
degeneration	B-T046
occurs	O
when	O
estrogen	B-T109
is	O
absent	B-T169
in vivo	B-T082
.	O
Collapsed	B-T169
subchondral bone	B-T023
may	O
be	O
the	O
initiation	B-T169
of	O
this	O
process	B-T067
,	O
and	O
estrogen replacement therapy	B-T061
can	O
effectively	O
prevent	O
degeneration	B-T046
of	O
LFJ	B-T030
under	O
estrogen	B-T109
-	O
deficient	B-T169
conditions	B-T080
.	O

Dexmedetomidine	B-T109
Effect	B-T080
on	O
Emergence Agitation	B-T048
and	O
Delirium	B-T048
in	O
Children	B-T100
Undergoing	O
Laparoscopic Hernia Repair	B-T061
:	O
a	O
Preliminary	B-T079
Study	B-T062
Objective	O
To	O
evaluate	O
the	O
safety	B-T080
and	O
efficacy	B-T080
of	O
dexmedetomidine	B-T109
(	O
Dex	B-T109
)	O
to	O
prevent	O
emergence agitation	B-T048
(	O
EA	B-T048
)	O
and	O
delirium	B-T048
(	O
ED	B-T048
)	O
in	O
children	B-T100
undergoing	O
laparoscopic hernia repair	B-T061
under	O
general anesthesia	B-T061
.	O
Methods	O
100	O
children	B-T100
(1-5	O
years	B-T079
,	O
10-25	O
kg)	O
were	O
randomized	B-T062
into	O
four	O
groups	B-T078
:	O
controls	B-T096
(	O
saline	B-T167
)	O
and	O
intravenous	B-T082
Dex	B-T109
at	O
0.25,	O
0.5,	O
and	O
1.0	O
µg/kg	O
(	O
D1	B-T081
,	O
D2	B-T081
,	O
D3	B-T081
,	O
respectively).	O
Dex	B-T109
/	O
saline	B-T167
infusion	B-T061
was	O
started	O
following	O
anesthesia	B-T121
.	O
EA	B-T048
and	O
ED	B-T048
were	O
evaluated	O
on	O
a	O
5-point scale	B-T170
.	O
Results	O
For	O
the	O
C	B-T096
,	O
D1	B-T081
,	O
D2	B-T081
,	O
and	O
D3	B-T081
groups	B-T078
,	O
respectively,	O
EA	B-T048
frequencies	B-T079
were	O
45.8%,	O
30.4%,	O
12%,	O
4%;	O
ED	B-T048
frequencies	B-T079
29.1%,	O
13%,	O
4%,	O
4%;	O
CHIPPS	B-T170
scores	B-T081
8,	O
6,	O
3,	O
3;	O
sevoflurane	B-T109
doses	B-T081
from	O
13.2	O
±	O
3.4	O
(	O
controls	B-T096
)	O
to	O
9.4	O
±	O
3.5	O
ml	O
(	O
D3	B-T081
).	O
Intervals	B-T079
until	O
mask	B-T074
removal	B-T052
/	O
spontaneous eye opening	B-T082
were	O
significantly	O
longer	B-T080
for	O
D2	B-T081
and	O
D3	B-T081
than	O
controls	B-T096
.	O
PACU	B-T073
stay	B-T079
was	O
longer	B-T080
for	O
D3	B-T081
.	O
Conclusions	O
There	O
was	O
significantly	O
less	O
postoperative	B-T079
EA	B-T048
and	O
pain	B-T184
,	O
with	O
less	O
sevoflurane	B-T109
required,	O
using	O
Dex	B-T109
.	O

Farnesylthiosalicylic acid	B-T109
-loaded	O
lipid-polyethylene glycol-polymer hybrid nanoparticles	B-T121
for	O
treatment	B-T061
of	O
glioblastoma	B-T191
We	O
aimed	O
to	O
develop	O
lipid-polyethylene glycol (PEG)-polymer hybrid nanoparticles	B-T121
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour tissue	B-T024
with	O
active ingredient	B-T120
,	O
a	O
new	O
generation	B-T079
antineoplastic drug	B-T109
,	O
farnesylthiosalicylic acid	B-T109
(	O
FTA	B-T109
)	O
for	O
treatment	B-T061
of	O
glioblastoma	B-T191
.	O
Farnesylthiosalicylic acid	B-T109
-loaded	O
poly(lactic-co-glycolic acid)-1,2 distearoyl-glycerol-3-phospho-ethanolamine-N [methoxy (PEG)-2000] ammonium salt	B-T121
(	O
PLGA-DSPE-PEG	B-T121
)	O
with	O
or	O
without	O
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) hybrid nanoparticles	B-T121
has	O
been	O
prepared	B-T033
and	O
evaluated	B-T058
for	O
in-vitro characterization	B-T062
.	O
Cytotoxicity	B-T049
of	O
FTA-loaded nanoparticles	B-T109
along	O
with	O
its	O
efficacy	B-T081
on	O
rat glioma-2 (RG2) cells	B-T025
was	O
also	O
evaluated	B-T058
both	O
in vitro	B-T062
(in	O
comparison	O
with	O
non-malignant cell line, L929	B-T025
)	O
and	O
in vivo	B-T062
.	O
Scanning electron microscopy studies	B-T059
showed	O
that	O
all	O
formulations prepared	B-T077
had	O
smooth surface	B-T201
and	O
spherical in shape	B-T082
.	O
FTA	B-T109
and	O
FTA-loaded nanoparticles	B-T109
have	O
cytotoxic activity	B-T049
against	O
RG2 glioma cell lines	B-T025
in	O
cell culture studies	B-UnknownType
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
DOTAP	B-T121
.	O
Magnetic resonance imaging	B-T060
and	O
histopathologic	B-T091
evaluation	B-T058
on	O
RG2 tumour cells	B-T025
in	O
rat glioma model	B-T050
(49	O
female	O
Wistar rats	B-T015
,	O
250-300	O
g)	O
comparing	O
intravenous	B-T169
and	O
intratumoral injections	B-T169
of	O
the	O
drug	B-T121
have	O
been	O
performed	O
and	O
FTA-loaded nanoparticles	B-T109
reduced	O
tumour size	B-T082
significantly	O
in	O
in-vivo studies	B-T062
,	O
with	O
higher	O
efficiency	B-T081
of	O
intratumoral administration	B-T169
than	O
intravenous route	B-T169
.	O
Farnesylthiosalicylic acid	B-T109
-loaded	O
PLGA-DSPE-PEG-DOTAP hybrid nanoparticles	B-T121
are	O
proven	O
to	O
be	O
effective	B-T080
against	O
glioblastoma	B-T191
in	O
both	O
in-vitro	B-T062
and	O
in-vivo experiments	B-T062
.	O

Map learning	B-T041
and	O
working memory	B-T041
:	O
Multimodal	O
learning strategies	B-T065
The	O
current	O
research	B-T062
investigated	O
whether	O
learning spatial	B-T041
information	B-T078
from	O
a	O
map	B-T073
involves	O
different modalities	B-T169
,	O
which	O
are	O
managed	O
by	O
discrete	O
components	O
in	O
working memory	B-T041
.	O
In	O
four	O
experiments,	O
participants	B-T098
studied	O
a	O
map	O
either	O
while	O
performing	O
a	O
simultaneous	B-T079
interference task	B-T041
(high	O
cognitive load	B-T081
)	O
or	O
without interference	B-T041
(low	O
cognitive load	B-T081
).	O
The	O
modality	B-T078
of	O
interference	B-T041
varied	O
between	O
experiments.	O
Experiment	O
1	O
used	O
a	O
tapping task	B-T041
(	O
visuospatial	B-T041
),	O
Experiment	O
2	O
a	O
backwards counting task	B-T041
(	O
verbal	B-T080
),	O
Experiment	O
3	O
an	O
articulatory	B-T048
suppression task	B-T059
(	O
verbal	B-T080
)	O
and	O
Experiment	O
4	O
an	O
n-back task	B-T041
(	O
central executive	B-T041
).	O
Spatial recall	B-T033
was	O
assessed	B-T052
in	O
two	O
tests,	O
directional judgements	B-T041
and	O
map drawing	B-UnknownType
.	O
Cognitive load	B-T081
was	O
found	O
to	O
affect	O
spatial recall	B-T033
detrimentally	O
regardless	B-T080
of	O
interference	B-T041
modality	B-T078
.	O
The	O
findings	O
suggest	O
that	O
when	O
learning maps	B-T041
people	O
use	O
a	O
multimodal	O
learning strategy	B-T065
,	O
utilising	O
resources	B-T078
from	O
all	O
components	O
of	O
working memory	B-T041
.	O

4-Anilino-2-pyridylquinazolines	B-T109
and	O
-	O
pyrimidines	B-T114
as	O
Highly	O
Potent	B-T080
and	O
Nontoxic	B-T080
Inhibitors	B-T120
of	O
Breast Cancer Resistance Protein	B-T116
(	O
ABCG2	B-T116
)	O
Multidrug resistance	B-T032
(	O
MDR	B-T032
)	O
mediated	O
by	O
ATP-binding cassette (ABC) transport proteins	B-T116
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic treatment	B-T061
of	O
cancer	B-T191
and	O
might	O
be	O
overcome	B-T052
by	O
inhibition	B-T052
of	O
the	O
transporter	B-T116
.	O
Because	O
of	O
the	O
lack	O
of	O
understanding,	O
the	O
complex	O
mechanisms	B-T169
involved	O
in	O
the	O
transport process	B-T044
,	O
in	O
particular	O
for	O
breast cancer resistance protein	B-T116
(	O
BCRP	B-T116
/	O
ABCG2	B-T116
),	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	B-T120
of	O
ABCG2	B-T116
.	O
In	O
this	O
study,	O
we	O
investigated	B-T169
a	O
systematic	O
series	O
of	O
4-substituted-2-pyridylquinazolines	B-T109
in	O
terms	O
of	O
their	O
inhibitory	B-T052
potency	B-T080
as	O
well	O
as	O
selectivity	B-T081
toward	O
ABCG2	B-T116
.	O
For	O
comparison,	O
the	O
quinazoline scaffold	B-T109
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4-methylpyrimidine	B-T114
basic	O
structure.	O
Furthermore,	O
the	O
cytotoxicity	B-T049
and	O
the	O
ability	O
to	O
reverse	B-T169
MDR	B-T032
was	O
tested	O
with	O
the	O
chemotherapeutic agents	B-T121
SN-38	B-T109
and	O
mitoxantrone	B-T109
(	O
MX	B-T109
).	O
Interaction	B-T169
of	O
the	O
compounds	B-T103
with	O
ABCG2	B-T116
was	O
investigated	B-T169
by	O
a	O
colorimetric	B-T059
ATPase	B-T116
assay	B-T059
.	O
Enzyme kinetic studies	B-T090
were	O
carried	O
out	O
with	O
Hoechst 33342	B-T121
as	O
fluorescent dye	B-T130
and	O
substrate	B-T167
of	O
ABCG2	B-T116
to	O
elucidate	O
the	O
compounds	B-T103
binding modes	B-T052
.	O

The	O
Value	O
of	O
Biosamples	B-T077
in	O
Smoking Cessation	B-T055
Trials	B-T062
:	O
A	O
Review	O
of	O
Genetic	B-T034
,	O
Metabolomic	B-T091
,	O
and	O
Epigenetic	B-T045
Findings	B-T033
Evidence	O
is	O
emerging	O
that	O
certain	O
genotypes	B-T032
and	O
biomarkers	B-T201
are	O
associated	O
with	O
smoking cessation	B-T055
success	O
and	O
efficacy	O
of	O
smoking cessation treatments	B-T061
.	O
We	O
review	O
key	O
findings	O
that	O
open	O
potential	O
avenues	O
for	O
personalizing	O
smoking cessation treatment	B-T061
according	O
to	O
an	O
individual's	B-T098
genetic	B-T059
or	O
metabolic profile	B-T039
.	O
These	O
results	O
provide	O
important	O
incentive	B-T080
for	O
smoking cessation	B-T055
researchers	B-T097
to	O
collect	O
biosamples	B-T077
and	O
perform	O
genotyping	B-T059
in	O
research studies	B-T062
and	O
clinical trials	B-T062
.	O

ACR	B-T094
Appropriateness Criteria	B-T078
(®)	O
Radiologic	B-T169
Management	B-T058
of	O
Mesenteric Ischemia	B-T047
Mesenteric vascular insufficiency	B-T047
is	O
a	O
serious	O
medical condition	B-T033
that	O
may	O
lead	O
to	O
bowel infarction	B-T047
,	O
morbidity	B-T081
,	O
and	O
mortality	B-T081
that	O
may	O
approach	B-T082
50%.	O
Recommended	O
therapy	B-T061
for	O
acute mesenteric ischemia	B-T047
includes	O
aspiration	B-T061
embolectomy	B-T061
,	O
transcatheter	B-T061
thrombolysis	B-T061
,	O
and	O
angioplasty	B-T061
with	O
or	O
without	O
stenting	B-T061
for	O
the	O
treatment	B-T061
of	O
underlying	O
arterial stenosis	B-T190
.	O
Nonocclusive mesenteric ischemia	B-T047
may	O
respond	O
to	O
transarterial infusion	B-T061
of	O
vasodilators	B-T121
such	O
as	O
nitroglycerin	B-T109
,	O
papaverine	B-T109
,	O
glucagon	B-T116
,	O
and	O
prostaglandin E1	B-T109
.	O
Recommended	O
therapy	B-T061
for	O
chronic mesenteric ischemia	B-T047
includes	O
angioplasty	B-T061
with	O
or	O
without	O
stent placement	B-T061
and,	O
if	O
an	O
endovascular approach	B-T061
is	O
not	O
possible,	O
surgical bypass	B-T061
or	O
endarterectomy	B-T061
.	O
The	O
diagnosis	B-T033
of	O
median arcuate ligament syndrome	B-T047
is	O
controversial,	O
but	O
surgical	B-T061
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical situation	B-T080
.	O
Venous	B-T082
mesenteric ischemia	B-T047
may	O
respond	O
to	O
systemic	B-T169
anticoagulation	B-T061
alone.	O
Transhepatic	B-T082
or	O
transjugular	B-T082
superior mesenteric vein	B-T023
catheterization and thrombolytic infusion	B-T060
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	B-T184
,	O
condition of the patient	B-T033
,	O
and	O
response	B-T032
to	O
systemic	B-T169
anticoagulation	B-T061
.	O
Adjunct	B-T169
transjugular intrahepatic portosystemic shunt creation	B-T061
can	O
be	O
considered	O
for	O
outflow	O
improvement	B-T077
.	O
The	O
American College of Radiology	B-T094
Appropriateness Criteria	B-T078
are	O
evidence-based	B-T169
guidelines	B-T170
for	O
specific	O
clinical conditions	B-T033
that	O
are	O
reviewed	B-T080
annually	B-T079
by	O
a	O
multidisciplinary expert panel	B-T097
.	O
The	O
guideline	B-T170
development	B-T169
and	O
revision	B-T079
include	O
an	O
extensive analysis	B-T062
of	O
current	O
medical literature	B-T078
from	O
peer-reviewed journals	B-T170
and	O
the	O
application	O
of	O
well-established	O
methodologies	B-T062
(	O
RAND	B-T170
/	O
UCLA	B-T170
Appropriateness	B-T080
Method	O
and	O
Grading of Recommendations Assessment, Development, and Evaluation	B-T170
or	O
GRADE	B-T170
)	O
to	O
rate	O
the	O
appropriateness	B-T080
of	O
imaging	B-T060
and	O
treatment procedures	B-T061
for	O
specific	O
clinical	B-T080
scenarios	B-T169
.	O
In	O
those	O
instances	B-T078
where	O
evidence	B-T078
is	O
lacking	B-T080
or	O
equivocal	B-T080
,	O
expert opinion	B-T077
may	O
supplement	B-T169
the	O
available	O
evidence	B-T078
to	O
recommend	O
imaging	B-T060
or	O
treatment	B-T061
.	O

Blur	B-T080
perception	B-T041
throughout	O
the	O
visual field	B-T082
in	O
myopia	B-T047
and	O
emmetropia	B-T033
We	O
evaluated	B-T058
the	O
ability	B-T032
of	O
emmetropic	B-T033
and	O
myopic	B-T047
observers	B-T096
to	O
detect	B-T033
and	O
discriminate	B-T080
blur	B-T080
across	O
the	O
retina	B-T023
under	O
monocular	B-T042
or	O
binocular viewing	B-T041
conditions	B-T080
.	O
We	O
recruited	B-T052
39	O
young	B-T079
(23-30	O
years)	O
healthy adults	B-T033
(n	O
=	O
19	O
myopes	B-T047
)	O
with	O
best-corrected	B-T080
visual acuity	B-T201
0.0	O
LogMAR (20/20)	B-T074
or	O
better	B-T080
in	O
each	O
eye	B-T023
and	O
no binocular	B-T033
or	O
accommodative dysfunction	B-T033
.	O
Monocular	B-T042
and	O
binocular	B-T041
blur	B-T080
discrimination	B-T080
thresholds	B-T080
were	O
measured	B-T080
as	O
a	O
function	B-T170
of	O
pedestal blur	B-T080
using	O
naturalistic	B-T169
stimuli	B-T067
with	O
an	O
adaptive 4AFC procedure	B-T060
.	O
Stimuli	B-T067
were	O
presented	B-T078
in	O
a	O
46°	O
diameter	B-T081
window	O
at	O
40	O
cm.	O
Gaussian blur pedestals	B-T080
were	O
confined	B-T169
to	O
an	O
annulus	B-T073
at	O
either	O
0°,	O
4°,	O
8°,	O
or	O
12°	O
eccentricity	B-T042
,	O
with	O
a	O
blur	B-T080
increment	B-T081
applied	B-T169
to	O
only	O
one quadrant	B-T082
of	O
the	O
image	B-T170
.	O
The	O
adaptive procedure	B-T060
efficiently	B-T080
estimated	B-T081
a	O
dipper shaped	B-T033
blur	B-T080
discrimination	B-T080
threshold	B-T080
function	B-T170
with	O
two	B-T081
parameters	B-T077
:	O
intrinsic	B-T082
blur	B-T080
and	O
blur	B-T080
sensitivity	B-T169
.	O
The	O
amount	B-T081
of	O
intrinsic	B-T082
blur	B-T080
increased	B-T081
for	O
retinal eccentricities	B-T042
beyond	O
4°	O
(p	O
<	O
0.001)	O
and	O
was	O
lower	B-T052
in	O
binocular	B-T041
than	O
monocular	B-T042
conditions	B-T080
(p	O
<	O
0.001),	O
but	O
was	O
similar	B-T080
across	O
refractive	B-T042
groups	B-T078
(p	O
=	O
0.47).	O
Blur	B-T080
sensitivity	B-T169
decreased	B-T081
with	O
retinal eccentricity	B-T042
(p	O
<	O
0.001)	O
and	O
was	O
highest	B-T080
for	O
binocular	B-T041
viewing,	O
but	O
only	O
for	O
central vision	B-T042
(p	O
<	O
0.05).	O
Myopes	B-T047
showed	O
worse	B-T033
blur	B-T080
sensitivity	B-T169
than	O
emmetropes	B-T033
monocularly	B-T042
(p	O
<	O
0.05)	O
but	O
not	O
binocularly	B-T041
(p	O
=	O
0.66).	O
As	O
expected,	O
blur	B-T080
perception	B-T041
worsens	B-T033
in	O
the	O
visual periphery	B-T041
and	O
binocular	B-T041
summation	B-T042
is	O
most	O
evident	B-T078
in	O
central vision	B-T042
.	O
Furthermore,	O
myopes	B-T047
exhibit	O
a	O
monocular	B-T042
impairment	B-T169
in	O
blur	B-T080
sensitivity	B-T169
that	O
improves	B-T033
under	O
binocular	B-T041
conditions	B-T080
.	O
Implications	B-T041
for	O
the	O
development	B-T169
of	O
myopia	B-T047
are	O
discussed.	O

Risk Factors	B-T033
of	O
Neurological Deterioration	B-T184
in	O
Patients	B-T101
with	O
Cerebral Infarction	B-T047
due	O
to	O
Large-Artery Atherosclerosis	B-T047
In	O
some	O
patients	B-T101
with	O
acute	B-T079
ischemic stroke	B-T047
,	O
neurological deterioration	B-T184
(	O
ND	B-T184
)	O
is	O
observed	B-T169
,	O
and	O
it	O
is	O
difficult	B-T080
to	O
predict	B-T078
at	O
the	O
time of admission	B-T079
.	O
Especially	O
in	O
some	O
patients	B-T101
with	O
large-artery atherosclerosis	B-T047
(	O
LAA	B-T047
),	O
aggressive	B-T079
medical treatments	B-T058
and	O
surgical interventions	B-T058
might	O
be	O
helpful	B-T080
to	O
prevent	O
ND	B-T184
.	O
Therefore,	O
we	O
investigated	B-T169
factors	B-T169
associated with	B-T080
ND	B-T184
in	O
patients	B-T101
with	O
LAA	B-T047
.	O
We	O
studied	B-T062
patients	B-T101
with	O
LAA	B-T047
who	O
were	O
admitted to our hospital	B-T058
.	O
We	O
divided	B-T169
them	O
into	O
2	O
groups	B-T078
with	O
(	O
group	B-T078
1)	O
and	O
without	O
deterioration	B-T046
(	O
group	B-T078
2),	O
and	O
evaluated	B-T058
their	O
medical records	B-T170
,	O
risk factors	B-T033
,	O
and	O
radiological	B-T077
findings	B-T033
,	O
such	O
as	O
number	O
of	O
diffusion	B-T070
-	O
positive	B-T033
lesion	B-T033
and	O
degree of stenosis	B-T201
.	O
Our	O
study population	B-T098
consisted	O
of	O
171	O
patients	B-T101
;	O
71	O
(41.5%)	O
did	O
and	O
100	O
(58.5%)	O
did	O
not	O
suffer	B-T048
deterioration	B-T046
.	O
By	O
univariate analysis	B-T062
,	O
blood pressure	B-T040
(	O
BP	B-T040
),	O
heart rate	B-T201
,	O
National Institutes of Health Stroke Scale (NIHSS) score	B-T033
,	O
number	O
of	O
diffusion	B-T070
-	O
positive	B-T033
lesion	B-T033
,	O
count of red blood cell	B-T059
,	O
high-density lipoprotein	B-T116
,	O
and	O
degree of stenosis	B-T201
differed	O
significantly	B-T078
between	O
the	O
2	O
groups	B-T078
.	O
By	O
multivariate analysis	B-T081
,	O
systolic BP	B-T201
(≥170	O
mm	O
Hg,	O
odds ratio	B-T081
:	O
7.20,	O
P	O
<.001)	O
was	O
associated with	B-T080
ND	B-T184
.	O
Furthermore,	O
number	O
of	O
diffusion-weighted image	B-T060
(	O
DWI	B-T060
)-	O
positive	B-T033
lesion	B-T033
(≥8),	O
degree of stenosis	B-T201
(>80.0%),	O
and	O
NIHSS score	B-T033
(≥4)	O
were	O
also	O
independent	B-T078
factors	B-T169
associated with	B-T080
ND	B-T184
.	O
High BP	B-T047
,	O
severity	B-T080
of	O
neurological deficit	B-T033
at	O
the	O
time of admission	B-T079
,	O
and	O
radiological	B-T077
findings	B-T033
,	O
such	O
as	O
degree of stenosis	B-T201
and	O
number	O
of	O
DWI	B-T060
-	O
positive	B-T033
lesion	B-T033
,	O
are	O
independently	B-T033
associated with	B-T080
ND	B-T184
in	O
patients	B-T101
with	O
LAA	B-T047
.	O

Development	B-T169
and	O
validation	B-T062
of	O
an	O
easy-to-use	O
risk assessment tool	B-T058
for	O
cumulative	O
low back	B-T023
loading	B-T032
:	O
The	O
Lifting Fatigue Failure Tool	B-T122
(	O
LiFFT	B-T122
)	O
Recent	O
evidence	O
suggests	O
that	O
musculoskeletal disorders	B-T047
(	O
MSDs	B-T047
)	O
may	O
be	O
the	O
result	O
of	O
a	O
fatigue	B-T184
failure process	B-T169
in	O
affected	B-T169
tissues	B-T024
.	O
This	O
paper	O
describes	O
a	O
new	O
low back exposure	B-T032
assessment tool	B-T122
(the	O
Lifting Fatigue Failure Tool	B-T122
[	O
LiFFT	B-T122
]),	O
which	O
estimates	O
a	O
"	O
daily dose	B-T081
"	O
of	O
cumulative	B-T080
loading	B-T032
on	O
the	O
low back	B-T023
using	O
fatigue	B-T184
failure	B-T169
principles	B-T078
.	O
Only	O
three	O
variables	B-T080
are	O
necessary	O
to	O
derive	O
the	O
cumulative	B-T080
load	B-T032
associated with	B-T080
a	O
lifting	B-T052
task	B-T057
:	O
the	O
weight of the load	B-T081
,	O
the	O
maximum	O
horizontal distance	B-T081
from	O
the	O
spine	B-T023
to the load	B-T032
,	O
and	O
the	O
number	O
of	O
repetitions	B-T169
for	O
tasks performed	B-T061
during	O
the	O
workday	B-T079
.	O
The	O
new tool	B-T122
was	O
validated	B-T062
using	O
two	O
existing	O
epidemiological	B-T169
databases	B-T170
:	O
the	O
Lumbar Motion	B-T033
Lumbar Motion Monitor	B-T033
(	O
LMM	B-T033
)	O
database	B-T170
,	O
and	O
a	O
database	B-T170
from	O
a	O
U.S	B-T083
.	O
automotive manufacturer	B-T090
.	O
The	O
LiFFT	B-T122
cumulative damage metric	B-T058
explained	O
92%	O
of	O
the	O
deviance	O
in	O
low back disorders	B-T184
(	O
LBDs	B-T184
)	O
in	O
the	O
LMM database	B-UnknownType
and	O
72-95%	O
of	O
the	O
deviance	O
in	O
low back outcomes	B-T080
in	O
the	O
automotive database	B-T073
(depending	O
on	O
the	O
outcome measure	B-T081
).	O
Thus,	O
LiFFT	B-T122
is	O
practitioner friendly	B-T080
and	O
its	O
cumulative	B-T080
damage metric	B-T058
highly	O
related	O
to	O
low back outcomes	B-T080
.	O

Genetic Diversity	B-T070
in	O
Various	O
Accessions	B-T170
of	O
Pineapple	B-T002
[	O
Ananas comosus (L.) Merr.	B-T002
]	O
Using	O
ISSR	B-T114
and	O
SSR	B-T114
Markers	B-T086
Inter simple sequence repeat	B-T114
(	O
ISSR	B-T114
)	O
and	O
simple sequence repeat	B-T114
(	O
SSR	B-T114
)	O
markers	B-T086
were	O
used	O
to	O
assess	O
the	O
genetic diversity	B-T070
of	O
36	O
pineapple	B-T002
accessions	B-T170
that	O
were	O
introduced	O
from	O
10	O
countries	B-T083
/	O
regions	B-T083
.	O
Thirteen	O
ISSR	B-T114
primers	B-T114
amplified	B-T059
96	O
bands,	O
of	O
which	O
91	O
(93.65%)	O
were	O
polymorphic	B-T080
,	O
whereas	O
20	O
SSR	B-T114
primers	B-T114
amplified	B-T059
73	O
bands,	O
of	O
which	O
70	O
(96.50%)	O
were	O
polymorphic	B-T080
.	O
Nei's gene diversity	B-T170
(	O
h	B-T170
=	O
0.28),	O
Shannon's information index	B-T170
(	O
I	B-T170
=	O
0.43),	O
and	O
polymorphism information content	B-T170
(	O
PIC	B-T170
=	O
0.29)	O
generated	O
using	O
the	O
SSR	B-T114
primers	B-T114
were	O
higher	O
than	O
that	O
with	O
ISSR	B-T114
primers	B-T114
(	O
h	B-T170
=	O
0.23,	O
I	B-T170
=	O
0.37,	O
PIC	B-T170
=	O
0.24),	O
thereby	O
suggesting	O
that	O
the	O
SSR system	B-T114
is	O
more	O
efficient	O
than	O
the	O
ISSR system	B-T114
in	O
assessing	O
genetic diversity	B-T070
in	O
various	O
pineapple	B-T002
accessions	B-T170
.	O
Mean	O
genetic	B-T169
similarities	B-T080
were	O
0.74,	O
0.61,	O
and	O
0.69,	O
as	O
determined	O
using	O
ISSR	B-T114
,	O
SSR	B-T114
,	O
and	O
combined	O
ISSR	B-T114
/	O
SSR	B-T114
,	O
respectively.	O
These	O
results	O
suggest	O
that	O
the	O
genetic diversity	B-T070
among	O
pineapple	B-T002
accessions	B-T170
is	O
very	O
high.	O
We	O
clustered	B-T062
the	O
36	O
pineapple	B-T002
accessions	B-T170
into	O
three	O
or	O
five	O
groups	O
on	O
the	O
basis	O
of	O
the	O
phylogenetic trees	B-T080
constructed	O
based	O
on	O
the	O
results	O
of	O
ISSR	B-T114
,	O
SSR	B-T114
,	O
and	O
combined	O
ISSR	B-T114
/	O
SSR	B-T114
analyses	B-T062
using	O
the	O
unweighted pair-group with arithmetic averaging (UPGMA) method	B-T170
.	O
The	O
results	O
of	O
principal components analysis	B-T081
(	O
PCA	B-T081
)	O
also	O
supported	O
the	O
UPGMA	B-T170
clustering	B-T062
.	O
These	O
results	O
will	O
be	O
useful	O
not	O
only	O
for	O
the	O
scientific	O
conservation	O
and	O
management	O
of	O
pineapple	B-T002
germplasm	B-T002
but	O
also	O
for	O
the	O
improvement	O
of	O
the	O
current	O
pineapple	B-T002
breeding strategies	B-T040
.	O

Advanced age	B-T098
is	O
not	O
a	O
barrier	B-T169
to	O
creating	O
a	O
functional	B-T169
arteriovenous fistula	B-T020
:	O
a	O
retrospective study	B-T062
Arteriovenous fistulas	B-T020
(	O
AVFs	B-T020
)	O
are	O
the	O
recommended	O
form	O
of	O
vascular access	B-T074
for	O
hemodialysis	B-T061
.	O
However,	O
controversy	B-T054
exists	O
regarding	O
whether	O
AVFs	B-T020
are	O
suitable	O
for	O
elderly	B-T098
patients	B-T101
.	O
Single-center retrospective review	B-T062
to	O
investigate	B-T169
the	O
impact	B-T080
of	O
age	B-T032
on	O
AVF	B-T020
outcomes	B-T169
.	O
Five	O
hundred	O
and	O
twenty-five	O
patients	B-T101
with	O
AVF	B-T020
creation	B-T052
were	O
stratified	B-T080
based	O
on	O
age	B-T032
<65	B-T100
,	O
65-75	B-T100
,	O
and	O
>75	B-T100
years	B-T079
.	O
AVF	B-T020
outcomes	B-T169
including	O
primary	B-T080
failure	B-T169
,	O
AVF	B-T020
patency	B-T042
(	O
primary	B-T080
,	O
secondary	B-T080
,	O
and	O
functional	B-T169
),	O
and	O
AVF	B-T020
complications	B-T046
were	O
studied	O
for	O
3	O
years	B-T079
following	O
AVF	B-T020
creation	B-T052
.	O
The	O
cohort	B-T098
was	O
63%	O
male	B-T098
,	O
44%	O
Caucasian	B-T098
,	O
and	O
55%	O
had	O
diabetes	B-T047
or	O
cardiovascular disease	B-T047
.	O
39%	O
were	O
aged	B-T032
<65	B-T100
years	B-T079
,	O
33%	O
65-75	B-T100
years	B-T079
,	O
and	O
28%	O
were	O
aged	B-T032
>75	B-T100
years	B-T079
.	O
No	O
differences	O
in	O
rates	O
of	O
primary	B-T080
failure	B-T169
,	O
loss	O
of	O
primary	B-T080
patency	B-T042
,	O
complications	B-T046
,	O
or	O
need	O
for	O
intervention	B-T061
were	O
observed	O
between	O
age groups	B-T100
.	O
There	O
was	O
a	O
significant	O
association	B-T080
of	O
age	B-T032
with	O
secondary	B-T080
patency	B-T042
and	O
functional	B-T169
patency	B-T042
,	O
with	O
age	B-T032
>75	B-T100
being	O
an	O
independent	O
risk factor	B-T033
for	O
shortened	B-T080
lifespan	B-T079
of	O
the	O
fistula.	O
For	O
patients	B-T101
aged	B-T032
>75	B-T100
years	B-T079
,	O
secondary	B-T080
patency	B-T042
at	O
3	O
years	B-T079
was	O
64%	O
compared	O
to	O
75%-78%	O
for	O
younger	B-T079
patients	B-T101
.	O
Functional	B-T169
patency	B-T042
at	O
2	O
years	B-T079
was	O
69%	O
for	O
those	O
aged	B-T032
>75	B-T100
years	B-T079
compared	O
to	O
78%-81%	O
for	O
younger	B-T079
patients	B-T101
.	O
We	O
found	O
no	O
difference	O
in	O
AVF	B-T020
maturation	B-T039
,	O
primary	B-T080
patency	B-T042
,	O
complications	B-T046
,	O
or	O
interventions	B-T061
in	O
those	O
over	O
the	O
age	B-T032
of	O
75	B-T100
compared	O
to	O
younger	B-T079
counterparts.	O
While	O
secondary	B-T080
and	O
functional	B-T169
patency	B-T042
rates	B-T081
were	O
significantly	O
lower	O
in	O
those	O
aged	B-T032
>75	B-T100
years	B-T079
,	O
the	O
magnitude	O
of	O
difference	O
is	O
likely	O
not	O
clinically	O
relevant.	O
Therefore,	O
we	O
recommend	O
that	O
advanced age	B-T098
alone	O
should	O
not	O
preclude	O
patients	B-T101
from	O
AVF	B-T020
creation	B-T052
.	O

A	O
modified	B-T169
ESBL	B-T116
ESBL Nordmann/Dortet/Poirel-based protocol	B-T059
to	O
optimize	B-T052
early	B-T079
sepsis	B-T047
management	B-T058
We	O
evaluated	B-T169
a	O
modification	B-T169
of	O
a	O
colorimetric test	B-T059
recently	O
described	O
by	O
Dortet	O
et	O
al.	O
(2015)	O
for	O
the	O
rapid	O
detection	B-T061
of	O
ESBL	B-T116
-producing	O
Enterobacteriaceae	B-T007
directly	O
from	O
positive	B-T033
blood cultures	B-T059
that	O
requires	O
less	O
manipulation	B-T059
,	O
materials	B-T167
and	O
hands-on	O
time	B-T079
.	O
The	O
simplified	O
protocol	B-T059
showed	O
a	O
sensitivity	B-T169
and	O
specificity	B-T081
of	O
100%	O
and	O
95.7%	O
respectively.	O

The	O
use	O
of	O
informativity	O
in	O
the	O
development	B-T169
of	O
robust viromics	B-T028
-based	O
examinations	B-T062
Metagenomics	B-T090
-based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial communities	B-T001
responsible	O
for	O
maintaining life on this planet	B-T058
.	O
Sequencing	B-T063
efforts	O
often	O
uncover	O
novel	O
genetic content	B-T028
;	O
this	O
is	O
most	O
evident	O
for	O
phage communities	B-T005
,	O
in	O
which	O
upwards	O
of	O
90%	O
of	O
all	O
sequences	B-T059
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	B-T059
in	O
current	O
data repositories	B-T073
.	O
For	O
the	O
small fraction	B-T081
that	O
can	O
be	O
identified,	O
the	O
top	O
BLAST	B-T170
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	B-T052
of	O
a	O
viral taxon	B-T170
present	O
in	O
the	O
sample	O
of	O
origin.	O
Homology	B-T080
-based	O
classification	B-T185
,	O
however,	O
can	O
be	O
misleading	O
as	O
sequence repositories	B-T170
capture	O
but	O
a	O
small fraction	B-T081
of	O
phage diversity	B-T005
.	O
Furthermore,	O
lateral	B-T082
gene transfer	B-T063
is	O
pervasive	B-T082
within	O
phage communities	B-T005
.	O
As	O
such,	O
the	O
presence	O
of	O
a	O
particular gene	B-T028
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular viral species	B-T005
.	O
Rather,	O
it	O
is	O
just	O
that:	O
an	O
indication	B-T078
of	O
the	O
presence	O
of	O
a	O
specific gene	B-T028
.	O
To	O
circumvent	O
this	O
limitation	B-T169
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis of viral metagenomic datasets	B-T059
.	O
BLAST	B-T170
hits	O
are	O
weighted,	O
integrating the sequence identity	B-T170
and	O
length of alignments	B-T063
as	O
well	O
as	O
a	O
taxonomic signal	B-T169
,	O
such	O
that	O
each gene	B-T028
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information content	B-T078
.	O
Through	O
this	O
quantifiable metric	B-T081
,	O
predictions	B-T078
of	O
viral community	B-T001
structure	O
can	O
be	O
made	O
with	O
confidence.	O
As	O
a	O
proof-of-concept	B-T078
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	B-T052
and	O
applied	O
to	O
seven	O
freshwater viral metagenomes	B-T028
.	O
While	O
providing	O
a	O
robust method	B-T080
for	O
evaluating	O
viral metagenomic data	B-T090
,	O
the	O
tool	B-T170
is	O
versatile	B-T080
and	O
can	O
easily	O
be	O
customized	B-T052
to	O
investigations	B-T058
of	O
any	O
environment	B-T082
or	O
biome	B-T001
.	O

PRESENCE OF	B-T033
CITRININ	B-T109
IN	O
GRAINS	B-T168
AND	O
ITS	O
POSSIBLE	B-T033
HEALTH	B-T078
EFFECTS	B-T080
Citrinin	B-T109
is	O
a	O
mycotoxin	B-T109
produced	B-T169
by	O
several	O
species	B-T185
of	O
the	O
genera Aspergillus	B-T004
,	O
Penicillium	B-T004
and	O
Monascus	B-T004
and	O
it	O
occurs	B-T052
mainly	O
in	O
stored grain	B-T168
.	O
Citrinin	B-T109
is	O
generally	O
formed	B-T169
after	O
harvest	B-T169
and	O
occurs	B-T052
mainly	O
in	O
stored grains	B-T168
,	O
it	O
also	O
occurs	B-T052
in	O
other plant products	B-UnknownType
.	O
Often,	O
the	O
co-occurrence	B-T079
with	O
other	O
mycotoxins	B-T109
is	O
observed	B-T169
,	O
especially	O
ochratoxin A	B-T109
,	O
which	O
is	O
usually	O
associated with	B-T080
endemic nephropathy	B-T047
.	O
At	O
the	O
European Union	B-T092
level	B-T080
,	O
systematic	B-T169
monitoring	B-T058
of	O
Citrinin	B-T109
in	O
grains	B-T168
began	O
with	O
the	O
aim	B-T078
of	O
determining	B-T080
its	O
highest	O
permissible amount	B-T081
in	O
food	B-T168
.	O
Thus,	O
far	O
the	O
systematic	B-T169
monitoring	B-T058
of	O
the	O
above mentioned mycotoxin	B-T109
in	O
Croatia	B-T083
is	O
yet	O
to	O
begin	B-T079
.	O
The	O
main goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	B-T080
the	O
presence of	B-T033
Citrinin	B-T109
in	O
grains	B-T168
sampled	B-T078
in	O
the	O
area	B-T082
of	O
Međimurje	B-T083
,	O
Osijek-Baranja	B-T083
,	O
Vukovar-Srijem	B-T083
and	O
Brod-Posavina County	B-T083
.	O
For	O
the	O
purpose	B-T169
of	O
identification	B-T080
and	O
quantification	B-T081
of	O
citrinin	B-T109
,	O
high performance liquid chromatograph (HPLC) with fluorescence	B-T059
was	O
used	B-T033
(	O
Calibration curve	B-T081
k	O
>	O
0.999;	O
Intra assay CV	B-T170
=	O
2.1%;	O
Inter assay CV	B-T170
=	O
4.3%;	O
LOQ	B-T081
<	O
1	O
μg/kg).	O
From	O
the	O
area	B-T082
of	O
Međimurje County	B-T083
,	O
10	O
samples	B-T167
of	O
corn	B-T168
and	O
10	O
samples	B-T167
of	O
wheat	B-T168
were	O
analyzed	B-T062
.	O
None	O
of	O
the	O
samples	B-T167
contained	B-T052
Citrinin	B-T109
(<1	O
μg/kg).	O
From	O
the	O
area	B-T082
of	O
Osijek-Baranja	B-T083
and	O
Vukovar-Srijem County	B-T083
,	O
15	O
samples	B-T167
from	O
each	O
County	B-T083
were	O
analyzed	B-T062
.	O
The	O
mean value	B-T081
for	O
the	O
samples	B-T167
of	O
Osijek-Baranja County	B-T083
was	O
19.63	O
μg/kg	O
(	O
median	B-T081
=15.8	O
μg/kg),	O
while	O
for	O
Vukovar-Srijem County	B-T083
the	O
mean value	B-T081
of	O
citrinin	B-T109
was	O
14,6	O
μg/kg	O
(	O
median	B-T081
=1.23	O
μg/kg).	O
From	O
5	O
analyzed	B-T062
samples	B-T167
from	O
Brod-Posavina County	B-T083
,	O
one	O
of	O
the	O
samples	B-T167
contained	B-T052
citrinin	B-T109
in	O
the	O
amount	B-T081
of	O
23.8	O
μg/kg,	O
while	O
the	O
registered	B-T058
amount	B-T081
s	O
in	O
the	O
other	O
samples	B-T167
were	O
<1	O
μg/kg.	O
The	O
results	B-T169
show	O
that	O
grains	B-T168
from	O
several	B-T081
Counties	B-T083
contain	B-T052
certain	O
amounts	B-T081
of	O
Citrinin	B-T109
possibly	O
indicating	B-T033
a	O
significant	B-T078
intake	B-T169
of	O
citrinin	B-T109
in	O
humans	B-T016
.	O
It	O
must	O
be	O
stated	O
that	O
grains	B-T168
and	O
grain-based products	B-T168
are	O
the	O
basis	O
of	O
everyday	B-T079
diet	B-T168
of	O
all	O
age groups	B-T100
,	O
especially	O
small children	B-T100
,	O
where	O
higher	B-T080
intake	B-T169
of	O
citrinin	B-T109
can	O
occur	B-T052
.	O
Consequently,	O
we	O
emphasize	B-T080
the	O
need	O
for	O
systematic	B-T169
analysis	B-T062
of	O
larger amount	B-T081
of	O
samples	B-T167
,	O
from	O
both	O
large grains	B-T168
and	O
small grains	B-T168
,	O
especially	O
in	O
the	O
area	B-T082
of	O
Brod-Posavina County	B-T083
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	B-T109
contamination	B-T078
of	O
grains	B-T168
and	O
to	O
asses	B-T052
the	O
health	B-T078
risk	B-T078
in	O
humans	B-T016
.	O

Recurrent noncoding regulatory mutations	B-T045
in	O
pancreatic ductal adenocarcinoma	B-T191
The	O
contributions	B-T052
of	O
coding mutations	B-T045
to	O
tumorigenesis	B-T191
are	O
relatively	O
well	O
known;	O
however,	O
little	O
is	O
known	O
about	O
somatic alterations	B-T049
in	O
noncoding DNA	B-T114
.	O
Here	O
we	O
describe	O
GECCO	O
(Genomic	O
Enrichment	O
Computational	O
Clustering	O
Operation)	O
to	O
analyze	O
somatic noncoding alterations	B-T049
in	O
308	O
pancreatic ductal adenocarcinomas	B-T191
(	O
PDAs	B-T191
)	O
and	O
identify	O
commonly	O
mutated regulatory regions	B-T086
.	O
We	O
find	O
recurrent noncoding mutations	B-T045
to	O
be	O
enriched	O
in	O
PDA	B-T191
pathways	B-T044
,	O
including	O
axon guidance	B-T043
and	O
cell adhesion	B-T043
,	O
and	O
newly	O
identified	B-T080
processes	B-T067
,	O
including	O
transcription	B-T045
and	O
homeobox genes	B-T028
.	O
We	O
identified	B-T080
mutations	B-T045
in	O
protein binding sites	B-T087
correlating	O
with	O
differential	B-T080
expression	B-T045
of	O
proximal	B-T082
genes	B-T028
and	O
experimentally	O
validated	O
effects of	B-T080
mutations	B-T045
on	O
expression	B-T045
.	O
We	O
developed	O
an	O
expression modulation score	B-T081
that	O
quantifies	B-T081
the	O
strength	B-T078
of	O
gene regulation	B-T045
imposed	O
by	O
each	O
class	O
of	O
regulatory elements	B-T028
,	O
and	O
found	O
the	O
strongest	O
elements	B-T028
were	O
most	O
frequently	O
mutated,	O
suggesting	O
a	O
selective	O
advantage.	O
Our	O
detailed	O
single-cancer analysis	B-T059
of	O
noncoding alterations	B-T045
identifies	O
regulatory mutations	B-T045
as	O
candidates	B-T080
for	O
diagnostic	B-T201
and	O
prognostic markers	B-T080
,	O
and	O
suggests	O
new	O
mechanisms	B-T169
for	O
tumor evolution	B-T191
.	O

Distal	B-T082
posterior cerebral artery	B-T023
revascularization	B-T061
for	O
a	O
fusiform	B-T077
PCA	B-T023
aneurysm	B-T047
:	O
A	O
lesson	O
learned	O
The	O
need	O
for	O
revascularization	B-T061
with	O
proximal	B-T082
posterior cerebral artery	B-T023
occlusion	B-T020
in	O
the	O
treatment	B-T169
of	O
giant	B-T047
and	O
fusiform aneurysms	B-T190
is	O
unclear.	O
While	O
early	O
series	O
demonstrated	O
only	O
about	O
a	O
10%	O
chance	O
of	O
infarction	B-T046
following	O
posterior cerebral artery	B-T023
occlusion	B-T020
,	O
recently	O
several	O
authors	B-T097
have	O
advocated	O
a	O
bypass	B-T061
prior	O
to	O
parent	O
vessel	B-T023
sacrifice	O
in	O
all	O
cases.	O
We	O
present	O
the	O
case	O
of	O
an	O
adult	O
man	O
with	O
a	O
fusiform aneurysm	B-T190
of	O
the	O
right	O
posterior cerebral artery	B-T023
at	O
the	O
P2-P3 junction	B-UnknownType
.	O
He	O
clinically failed	B-T033
a	O
balloon test occlusion	B-T058
preoperatively	B-T079
and	O
therefore	O
underwent	O
an	O
occipital artery	B-T023
to	O
distal	B-T082
posterior cerebral artery	B-T023
bypass	B-T061
with	O
subsequent	O
endovascular occlusion of the parent vessel	B-T061
and	O
aneurysm	B-T047
.	O
Despite	O
the	O
fact	O
that	O
the	O
immediate	O
and	O
6	O
month	O
follow up	B-T058
cerebral angiography	B-T060
confirmed	O
a	O
patent	O
bypass	B-T061
,	O
the	O
patient	B-T101
still	O
developed	O
a	O
posterior cerebral artery	B-T023
territory stroke	B-T047
.	O
We	O
believe	O
this	O
case	O
demonstrates	O
that	O
successful	O
distal	B-T082
revascularization	B-T061
in	O
the	O
setting	O
of	O
proximal	B-T082
posterior cerebral artery	B-T023
occlusion	B-T020
does	O
not	O
guarantee	O
against	O
cerebral ischemia	B-T047
and	O
infarction	B-T046
even	O
in	O
those	O
patients	B-T101
that	O
fail	O
a	O
test occlusion	B-T058
.	O

When	O
Is	O
a	O
Test Score	B-T080
Fair	B-T080
for	O
the	O
Individual	B-T098
Who	O
Is	O
Being	O
Tested	B-T170
?	O
Effects of	B-T080
Different	O
Scoring Procedures	B-T062
across	O
Multiple	B-T081
Attempts	B-T051
When	O
Testing	B-T169
a	O
Motor Skill	B-T040
Task	B-T057
Tests	B-T170
or	O
test batteries	B-T170
used	O
for	O
assessing	B-T052
motor skills	B-T040
,	O
either	O
in	O
research studies	B-T062
or	O
in	O
clinical settings	B-T062
,	O
apply	O
a	O
variety	O
of	O
procedures	B-T169
for	O
scoring	B-T062
performances	B-T055
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	B-T051
,	O
of	O
which	O
the	O
best	O
is	O
scored	B-T081
or	O
an	O
average	B-T081
is	O
computed	B-T059
.	O
The	O
rationale	O
behind	O
scoring	B-T062
procedures	B-T169
is	O
rarely	O
stated,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	B-T051
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	B-T062
.	O
It	O
is	O
uncertain	O
whether	O
procedures	B-T169
fairly	O
capture	O
an	O
individual's	B-T098
skill	B-T040
level	B-T080
.	O
Thus,	O
the	O
validity	O
of	O
the	O
tests	B-T170
may	O
be	O
compromised.	O
The	O
present	O
study	B-T062
tested	B-T170
24	O
young	O
female	B-T098
soccer	B-T056
players	B-T097
on	O
the	O
juggling	B-T056
of	O
a	O
soccer ball	B-T073
.	O
They	O
were	O
given	O
10	O
attempts	B-T051
,	O
and	O
trials	B-T062
were	O
scored	B-T081
according	O
to	O
nine	O
different	O
procedures	B-T169
including	O
the	O
'	O
best of	B-T080
'	O
or	O
'	O
mean of	B-T081
'	O
either	O
one,	O
two,	O
three,	O
five,	O
or	O
ten	O
attempts	B-T051
.	O
Individual	B-T098
raw scores	B-T081
differed	O
widely	O
across	O
trials	B-T062
,	O
but	O
no general effect	B-T080
of	O
trials	B-T062
was	O
found.	O
The	O
mean (SD) percentage difference	B-T081
between	O
the	O
lowest	B-T080
and	O
highest	B-T080
scores	B-T081
was	O
27.7(9.9)%,	O
with	O
17	O
players	B-T097
(71%)	O
demonstrating	O
a	O
significant	B-T078
change	O
from	O
lowest	B-T080
to	O
highest	B-T080
score	B-T081
.	O
Correlations	B-T080
between	O
raw scores	B-T081
were	O
low	B-T080
across	O
trials	B-T062
,	O
while	O
they	O
were	O
generally	O
higher	B-T080
across	O
scoring	B-T062
procedures	B-T169
.	O
The	O
first	O
trial	B-T062
was	O
significantly	B-T078
different	B-T080
from	O
the	O
remaining	O
both	O
as	O
a	O
raw score	B-T081
and	O
as	O
scoring	B-T062
procedure	B-T169
.	O
The	O
mean percentage difference	B-T081
between	O
best-of-two	B-T081
and	O
best-of-ten scores	B-T081
was	O
95%,	O
with	O
50	O
%	O
of	O
the	O
players	B-T097
demonstrating	O
a	O
significant	B-T078
difference	B-T080
between	O
the	O
two	O
scoring	B-T062
procedures	B-T169
.	O
No significant differences	B-T033
were	O
found	O
across	O
mean-of-rule scorings	B-T081
.	O
Best-of-rule	B-T081
and	O
mean-of-rule scorings	B-T081
were	O
significantly	B-T078
different	B-T080
except	O
for	O
the	O
best-of-two	B-T081
vs.	O
mean-of-two	B-T081
.	O
The	O
mean difference	B-T081
between	O
highest	B-T080
and	O
lowest	B-T080
rank	B-T170
across	O
players	B-T097
was	O
6.7	O
(3.6),	O
with	O
individual	B-T098
rankings	B-T170
within	O
the	O
group	B-T098
varying	O
33%	O
on	O
average	O
across	O
procedures	B-T169
.	O
One	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	B-T169
differences	B-T080
.	O
Therefore,	O
it	O
is	O
concluded	O
that	O
scoring	B-T062
procedures	B-T169
affect	O
results	B-T034
and	O
may	O
have	O
an	O
impact	O
on	O
test outcomes	B-T034
.	O
This	O
may	O
present	O
consequences	O
for	O
decision-making	O
from	O
test results	B-T034
,	O
such	O
as	O
diagnosing	B-T033
and	O
selection	O
of	O
intervention	B-T061
groups	B-T078
.	O
We	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	B-T062
into	O
the	O
scoring	B-T062
procedures	B-T169
of	O
the	O
vast	O
amount	O
of	O
tests	B-T170
and	O
tasks	O
in	O
common	O
use.	O

A	O
Fast Peak-Searching Algorithm	B-T170
for	O
Ultrasonic Elastography	B-T060
Tissue axial strain estimation with ultrasound elastography	B-T060
has	O
become	O
a	O
hot	O
field	O
in	O
recent	O
years.	O
However,	O
for	O
keypoints	O
tracking-based elastography algorithms	B-T170
,	O
locating	B-T033
extrema	B-T080
in	O
multimodal	O
ultrasonic	B-T169
radiofrequency	B-T070
signals	B-T067
is	O
still	O
a	O
challenging	O
problem	B-T033
.	O
In	O
this	O
paper,	O
a	O
new	O
method	O
is	O
proposed	B-T080
to	O
locate	B-T033
the	O
local	O
maxima	B-T081
and	O
minima	B-T080
of	O
the	O
RF	B-T070
signals	B-T067
directly	O
without	O
derivation	B-T080
operation	B-T052
.	O
This	O
algorithm	B-T170
can	O
accurately	O
locate	B-T033
extrema	B-T080
even	O
if	O
disturbed	O
peaks	B-T080
resulting	O
from	O
different	O
noise	B-T067
exist.	O
Furthermore,	O
the	O
new	O
algorithm	B-T170
can	O
speed	O
up	O
approximately	O
79%	O
of	O
the	O
implementation	B-T052
process	O
as	O
compared	B-T052
with	O
the	O
standard cross-correlation method	B-T062
on	O
the	O
same	O
computing	B-T052
platform.	O
In	O
addition,	O
the	O
elastographic	O
signal-to-noise ratio	B-T081
and	O
the	O
contrast-to-noise ratio	B-T081
are	O
also	O
significantly	O
improved	O
with	O
this	O
new	O
method.	O

Audiovisual	B-T039
integration	B-T040
supports	O
face	B-T029
-	O
name	B-T170
associative	B-T041
memory formation	B-T041
Prior	O
multisensory	B-T080
experience	B-T041
influences	O
how	O
we	O
perceive	O
our	O
environment	B-T082
,	O
and	O
hence	O
how	O
memories	B-T041
are	O
encoded	O
for	O
subsequent	O
retrieval	B-T041
.	O
This	O
study	B-T062
investigated	O
if	O
audiovisual	B-T039
(	O
AV	B-T039
)	O
integration	B-T040
and	O
associative	B-T041
memory formation	B-T041
rely	O
on	O
overlapping	O
or	O
distinct	O
processes.	O
Our	O
functional	O
magnetic resonance imaging	B-T060
results	O
demonstrate	O
that	O
the	O
neural	B-T025
mechanisms	B-T169
underlying	O
AV	B-T039
integration	B-T040
and	O
associative	B-T041
memory	B-T041
overlap	B-T079
substantially.	O
In	O
particular,	O
activity	B-T052
in	O
anterior superior temporal sulcus	B-T030
(	O
STS	B-T030
)	O
is	O
increased	O
during	O
AV	B-T039
integration	B-T040
and	O
also	O
determines	O
the	O
success	O
of	O
novel	O
AV	B-T039
face	B-T029
-	O
name	B-T170
association	O
formation.	O
Dynamic causal modeling	B-UnknownType
results	O
further	O
demonstrate	O
how	O
the	O
anterior STS	B-T030
interacts	O
with	O
the	O
associative	B-T041
memory system	B-T041
to	O
facilitate	O
successful	O
memory formation	B-T041
for	O
AV	B-T039
face	B-T029
-	O
name	B-T170
associations	B-T041
.	O
Specifically,	O
the	O
connection	O
of	O
fusiform gyrus	B-T023
to	O
anterior STS	B-T030
is	O
enhanced	O
while	O
the	O
reverse	O
connection	O
is	O
reduced	O
when	O
participants	B-T098
subsequently	O
remembered	B-T041
both	O
face	B-T029
and	O
name	B-T170
.	O
Collectively,	O
our	O
results	O
demonstrate	O
how	O
multisensory	B-T080
associative	B-T041
memories	B-T041
can	O
be	O
formed	O
for	O
subsequent	O
retrieval	B-T041
.	O

Liquid chromatography-tandem mass spectrometry	B-T059
quantification	B-T081
of	O
acetamiprid	B-T109
and	O
thiacloprid	B-T109
residues	B-T131
in	O
butterbur	B-T002
grown	O
under	O
regulated conditions	B-T082
An	O
analytical method	B-T170
was	O
developed	O
to	O
quantify	B-T081
the	O
residual	B-T131
levels	B-T080
of	O
the	O
neonicotinoid insecticides	B-T131
,	O
acetamiprid	B-T109
and	O
thiacloprid	B-T109
,	O
in	O
field-incurred	B-T169
butterbur	B-T002
samples	B-T167
using	O
liquid chromatography-tandem mass spectrometry	B-T059
(	O
LC-MS/MS	B-T059
).	O
Samples	B-T167
were	O
extracted	B-T059
with	O
acetonitrile	B-T109
and	O
partitioned	O
with	O
dichloromethane	B-T109
.	O
After	O
partitioning,	O
purification	B-T169
was	O
conducted	O
using	O
a	O
Florisil(®) cartridge	B-T074
.	O
Linearity	B-T082
of	O
a	O
matrix-matched calibration curve	B-T081
of	O
the	O
two	O
compounds	B-T131
over	O
a	O
concentration	B-T081
range	B-T081
of	O
0.004-0.4μg/g	O
was	O
excellent,	O
with	O
determination coefficients	B-T081
(	O
R(2)	B-T081
)≥0.9998.	O
The	O
limits of detection	B-T081
(	O
LOD	B-T081
)	O
and	O
quantitation	B-T081
(	O
LOQ	B-T081
)	O
for	O
both	O
acetamiprid	B-T109
and	O
thiacloprid	B-T109
were	O
0.0006	O
and	O
0.002mg/kg,	O
respectively.	O
The	O
average	O
recoveries	O
for	O
acetamiprid	B-T109
and	O
thiacloprid	B-T109
at	O
two	O
spiking levels	B-T080
(0.02	O
and	O
0.1mg/kg,	O
i.e.,	O
10×	O
LOQ	B-T081
and	O
50×	O
LOQ	B-T081
)	O
were	O
between	O
78.23	O
to	O
82.17%,	O
with	O
relative standard deviations	B-T081
(	O
RSDs	B-T081
)≤7.22%.	O
The	O
method	B-T170
was	O
successfully	O
applied	O
to	O
field-incurred	B-T169
samples	B-T167
treated	B-T169
with	O
a	O
commercial	B-T170
pesticide product	B-T131
,	O
either	O
once	O
(zero	O
or	O
7	O
days	B-T079
before	O
harvest	B-T169
)	O
or	O
twice	O
(0	O
and	O
7,	O
7	O
and	O
14,	O
or	O
14	O
and	O
21	O
days	B-T079
before	O
harvest	B-T169
).	O
The	O
highest	O
and	O
lowest	O
residues	B-T131
were	O
obtained	O
for	O
the	O
7	O
and	O
0	O
days	B-T079
'	O
treatment	B-T169
and	O
the	O
21	O
and	O
14	O
days	B-T079
'	O
treatment	B-T169
,	O
respectively.	O
The	O
developed	O
method	B-T170
is	O
simple	O
and	O
accurate	B-T080
and	O
can	O
be	O
extrapolated	O
to	O
other	O
leafy vegetables	B-T168
.	O

Percentile	B-T081
categorization	B-T185
of	O
QT interval	B-T033
as	O
an	O
approach	B-T082
for	O
identifying	B-T058
adult	B-T100
patients	B-T101
at	O
risk	B-T078
for	O
cardiovascular death	B-T201
The	O
results	O
from	O
studies	O
of	O
the	O
association	O
of	O
QT prolongation	B-T033
with	O
cardiovascular death	B-T201
(	O
CVD	B-T201
)	O
have	O
been	O
inconsistent	B-T080
.	O
The	O
purpose of this study	B-UnknownType
was	O
to	O
compare	B-T052
the	O
major	O
correction formulas	B-T081
to	O
percentile values	B-T081
of	O
QT	B-T081
for	O
heart rate	B-T201
ranges	B-T081
as	O
to	O
their	O
ability	B-T032
to	O
remove	B-T052
the	O
relationship	B-T080
of	O
QT	B-T081
to	O
heart rate	B-T201
and	O
to	O
predict	O
CVD	B-T201
.	O
Participants	B-T098
were	O
16,531	O
veterans	B-T098
who	O
had	O
an	O
initial	O
ECG	B-T033
at	O
the	O
Veterans Affairs Medical Center	B-T170
,	O
Palo Alto	B-T083
,	O
between	O
March	B-T079
31,	O
1987,	O
and	O
December	B-T080
20,	O
1999,	O
and	O
were	O
followed	O
for	O
CVD	B-T201
.	O
The	O
4	O
major	O
correction formulas	B-T081
(	O
Bazett	B-T081
,	O
Fridericia	B-T081
,	O
Framingham	B-T081
,	O
and	O
Hodges	B-T081
)	O
were	O
used	O
to	O
correct	O
QT interval	B-T033
.	O
In	O
addition,	O
the	O
percentiles	B-T081
for	O
heart rate	B-T201
ranges	B-T081
as	O
proposed	O
by	O
Schwartz	B-T016
were	O
calculated.	O
During	O
median	B-T082
follow-up	O
of	O
17.8	O
years	B-T079
,	O
455	O
CVD	B-T201
events	O
occurred.	O
When	O
compared	O
to	O
the	O
other	O
equations	B-T077
,	O
QTc	O
Bazett	O
had	O
the	O
greatest	O
dependence	O
on	O
heart rate	B-T201
(R(2)	O
=	O
0.18).	O
The	O
hazard ratio	B-T081
(95%	O
confidence interval	B-T081
)	O
for	O
CVD	B-T201
was	O
2.08	O
(1.28-3.9)	O
for	O
the	O
98th	O
percentile	B-T081
of	O
QT interval	B-T033
by	O
heart rate	B-T201
ranges	B-T081
,	O
2.05	O
(1.27-3.33)	O
for	O
QTc Bazett	B-T081
,	O
1.39	O
(0.44-4.34)	O
for	O
QTc	O
Fridericia,	O
1.05	O
(0.26-4.24)	O
for	O
QTc Hodges	B-T081
,	O
and	O
1.12	O
(0.28-4.52)	O
for	O
QTc Framingham	B-T081
.	O
The	O
hazard	O
ratio	O
of	O
QTc Bazett	B-T081
was	O
significantly higher	B-T081
than	O
the	O
other	O
formulas	B-T170
except	O
for	O
the	O
98th	O
percentile	B-T081
method.	O
The	O
Framingham	B-T081
,	O
Hodges	B-T081
,	O
and	O
Fridericia equations	B-T081
remove	B-T052
the	O
effect	B-T080
of	O
heart rate	B-T201
on	O
QT interval	B-T033
significantly	O
better	O
than	O
the	O
Bazett equation	B-T081
.	O
Using	O
QT-interval	B-T033
percentiles	B-T081
based	O
on	O
heart rate	B-T201
provides	O
a	O
consistent	O
approach	B-T082
both	O
for	O
identifying	O
those	O
whose	O
QT intervals	B-T033
prolong	O
due	O
to	O
drugs	B-T061
or	O
other	O
stressors	B-T078
and	O
for	O
assessing	O
CVD	B-T201
risk	B-T078
.	O

How	O
Should	O
I	O
Study	O
for	O
the	O
Exam	B-UnknownType
?	O
Self-Regulated Learning	B-T041
Strategies	B-T065
and	O
Achievement	B-T065
in	O
Introductory Biology	B-T091
In	O
college	B-T073
introductory science	B-T090
courses	B-T065
,	O
students	B-T098
are	O
challenged	O
with	O
mastering	O
large	O
amounts	O
of	O
disciplinary content	B-T080
while	O
developing	O
as	O
autonomous	B-UnknownType
and	O
effective	B-T080
learners	B-T098
.	O
Self-regulated learning	B-T041
(	O
SRL	B-T041
)	O
is	O
the	O
process	O
of	O
setting	O
learning goals	B-T078
,	O
monitoring	O
progress	B-T169
toward	O
them,	O
and	O
applying	O
appropriate	O
study strategies	B-T065
.	O
SRL	B-T041
characterizes	O
successful,	O
"expert"	O
learners	B-T098
,	O
and	O
develops	O
with	O
time	O
and	O
practice.	O
In	O
a	O
large,	O
undergraduate	B-T170
introductory biology	B-T091
course	B-T065
,	O
we	O
investigated:	O
1)	O
what	O
SRL	B-T041
strategies	B-T065
students	B-T098
reported	O
using	O
the	O
most	O
when	O
studying	O
for	O
exams	B-UnknownType
,	O
2)	O
which	O
strategies	B-T065
were	O
associated	O
with	O
higher	O
achievement	B-T053
and	O
with	O
grade	B-T185
improvement	B-T033
on	O
exams	B-UnknownType
,	O
and	O
3)	O
what	O
study	O
approaches	O
students	B-T098
proposed	O
to	O
use	O
for	O
future	O
exams	B-UnknownType
.	O
Higher	B-T080
-	O
achieving	B-T053
students	B-T098
,	O
and	O
students	B-T098
whose	O
exam	B-UnknownType
grades	B-T185
improved	B-T033
in	O
the	O
first half	B-T033
of	O
the	O
semester	B-T079
,	O
reported	O
using	O
specific	O
cognitive	B-T041
and	O
metacognitive strategies	B-T041
significantly	O
more	O
frequently	B-T079
than	O
their	O
lower	B-T052
-	O
achieving	B-T053
peers	B-T098
.	O
Lower	B-T052
-	O
achieving	B-T053
students	B-T098
more	O
frequently	B-T079
reported	O
that	O
they	O
did	O
not	O
implement	O
their	O
planned	O
strategies	B-T065
or,	O
if	O
they	O
did,	O
still	O
did	O
not	O
improve	O
their	O
outcomes	B-T169
.	O
These	O
results	O
suggest	O
that	O
many	O
students	B-T098
entering	O
introductory biology	B-T091
have	O
limited	B-T169
knowledge	B-T065
of	O
SRL	B-T041
strategies	B-T065
and/or	O
limited	B-T169
ability	O
to	O
implement	O
them,	O
which	O
can	O
impact	B-T080
their	O
achievement	B-T065
.	O
Course	B-T065
-specific	O
interventions	B-T058
that	O
promote	O
SRL	B-T041
development	O
should	O
be	O
considered	O
as	O
integral	O
pedagogical tools	B-T090
,	O
aimed	O
at	O
fostering	B-T056
development	O
of	O
students	B-T098
'	O
lifelong	B-T079
learning skills	B-T041
.	O

Characterising	B-T052
bias	B-T078
in	O
regulatory risk	B-T078
and	O
decision analysis	B-T090
:	O
An	O
analysis	B-T062
of	O
heuristics	B-T170
applied	O
in	O
health technology	B-T058
appraisal	B-T058
,	O
chemicals	B-T103
regulation	B-T064
,	O
and	O
climate change	B-T070
governance	B-T052
In	O
many	O
environmental	B-T185
and	O
public health domains	B-T170
,	O
heuristic methods	B-T170
of	O
risk	B-T078
and	O
decision analysis	B-T090
must	O
be	O
relied	O
upon,	O
either	O
because	O
problem structures	B-T033
are	O
ambiguous,	O
reliable	O
data	B-T078
is	O
lacking	B-T080
,	O
or	O
decisions	B-T041
are	O
urgent.	O
This	O
introduces	O
an	O
additional	O
source	B-T033
of	O
uncertainty	B-T033
beyond	O
model	B-T170
and	O
measurement error	B-T081
-	O
uncertainty	B-T033
stemming	O
from	O
relying	O
on	O
inexact	O
inference rules	B-T170
.	O
Here	O
we	O
identify	B-T169
and	O
analyse	B-T169
heuristics	B-T170
used	O
to	O
prioritise	O
risk	B-T078
objects	B-T077
,	O
to	O
discriminate	B-T080
between	O
signal	B-T067
and	O
noise	B-T067
,	O
to	O
weight	B-T081
evidence	B-T078
,	O
to	O
construct	O
models	B-T170
,	O
to	O
extrapolate	O
beyond	O
datasets	B-T170
,	O
and	O
to	O
make	O
policy	B-T170
.	O
Some	O
of	O
these	O
heuristics	B-T170
are	O
based	O
on	O
causal	O
generalisations	B-T080
,	O
yet	O
can	O
misfire	O
when	O
these	O
relationships	B-T080
are	O
presumed	O
rather	O
than	O
tested	O
(e.g.	O
surrogates	B-T099
in	O
clinical trials	B-T062
).	O
Others	O
are	O
conventions	B-T080
designed	O
to	O
confer	O
stability	B-T080
to	O
decision analysis	B-T090
,	O
yet	O
which	O
may	O
introduce	O
serious	O
error	B-T080
when	O
applied	O
ritualistically	O
(e.g.	O
significance testing	B-T169
).	O
Some	O
heuristics	B-T170
can	O
be	O
traced	O
back	O
to	O
formal	O
justifications	B-T078
,	O
but	O
only	O
subject	O
to	O
strong	O
assumptions	B-T078
that	O
are	O
often	O
violated	O
in	O
practical applications	B-T169
.	O
Heuristic	B-T170
decision rules	B-T170
(e.g.	O
feasibility rules	B-T170
)	O
in	O
principle	O
act	O
as	O
surrogates	B-T099
for	O
utility maximisation	B-T080
or	O
distributional	B-T169
concerns	B-T078
,	O
yet	O
in	O
practice	B-T077
may	O
neglect	O
costs and benefits	B-T081
,	O
be	O
based	O
on	O
arbitrary	B-T080
thresholds	B-T080
,	O
and	O
be	O
prone	O
to	O
gaming.	O
We	O
highlight	O
the	O
problem	B-T033
of	O
rule-entrenchment	B-T067
,	O
where	O
analytical choices	B-T052
that	O
are	O
in	O
principle	O
contestable	O
are	O
arbitrarily	O
fixed	O
in	O
practice	B-T077
,	O
masking	O
uncertainty	B-T033
and	O
potentially	O
introducing	O
bias	B-T078
.	O
Strategies	B-T041
for	O
making	O
risk	B-T078
and	O
decision analysis	B-T090
more	O
rigorous	O
include:	O
formalising	O
the	O
assumptions	B-T078
and	O
scope	B-T077
conditions	B-T078
under	O
which	O
heuristics	B-T170
should	O
be	O
applied;	O
testing	B-T169
rather	O
than	O
presuming	O
their	O
underlying	O
empirical	B-T078
or	O
theoretical justifications	B-T078
;	O
using	O
sensitivity	B-T081
analysis	B-T062
,	O
simulations	B-T062
,	O
multiple bias analysis	B-T062
,	O
and	O
deductive systems of inference	B-T170
(e.g.	O
directed acyclic graphs	B-T170
)	O
to	O
characterise	O
rule	B-T170
uncertainty	B-T033
and	O
refine	O
heuristics	B-T170
;	O
adopting	O
"	O
recovery schemes	B-T170
"	O
to	O
correct	O
for	O
known	O
biases;	B-T078
and	O
basing	O
decision rules	B-T170
on	O
clearly	O
articulated	O
values	B-T080
and	O
evidence	B-T078
,	O
rather	O
than	O
convention	B-T080
.	O

Multicentric Castleman disease	B-T191
of	O
hyaline	B-T031
vascular	B-T023
variant	B-T080
presenting	O
with	O
unusual	B-T080
systemic	B-T169
manifestations	B-T080
:	O
a	O
case report	B-T170
Castleman disease	B-T191
is	O
a	O
rare	B-T080
lymphoproliferative disorder	B-T191
presenting	O
with	O
localized	B-T082
or	O
disseminated	B-T082
lymphadenopathy	B-T047
and	O
systemic	B-T169
manifestations	B-T080
.	O
It	O
can	O
be	O
categorized	B-T185
in	O
numerous	B-T081
ways,	O
such	O
as	O
unicentric	B-T047
versus	O
multicentric	B-T191
,	O
histopathological	B-T169
variants	B-T080
(	O
hyaline	B-T031
-	O
vascular	B-T023
,	O
plasma cell	B-T025
,	O
and	O
mixed	B-T080
),	O
or	O
subtypes	B-T185
based	O
on	O
causative	B-T033
viral infections	B-T047
(	O
human immunodeficiency virus	B-T005
,	O
human herpesvirus-8	B-T005
,	O
or	O
Kaposi sarcoma herpesvirus	B-T005
).	O
Presentation	O
ranges	O
from	O
asymptomatic	B-T033
to	O
symptoms	B-T184
involving	O
multiple	B-T081
organs	B-T023
.	O
Even	O
though	O
the	O
exact	O
mechanism	B-T169
of	O
pathogenesis	B-T046
is	O
unknown,	O
treatment	B-T169
is	O
directed	B-T080
toward	O
possible	O
etiologies	B-T169
such	O
as	O
interleukin-6	B-T116
,	O
cluster of differentiation 20	B-T116
,	O
and	O
viral agents	B-T169
.	O
A	O
36-	O
year	B-T079
-old	O
Sri Lankan	B-T098
woman	B-T098
presented	O
with	O
generalized	O
body swelling	B-T184
and	O
foamy urine	B-T184
of	O
2	O
weeks	B-T079
'	O
duration	B-T079
.	O
Examination	B-T058
revealed	O
pallor	B-T033
;	O
generalized edema	B-T033
;	O
axillary	B-T029
,	O
cervical	B-T082
,	O
and	O
inguinal lymphadenopathy	B-T047
;	O
hypertension	B-T047
;	O
and	O
hepatomegaly	B-T033
.	O
Investigations	B-T058
showed	O
bicytopenia	B-T034
,	O
nephrotic range proteinuria	B-T033
with	O
hypoalbuminemia	B-T047
,	O
hypogammaglobulinemia	B-T047
,	O
and	O
features	B-T080
of	O
hyaline	B-T031
-	O
vascular	B-T023
type	B-T080
Castleman disease	B-T191
in	O
a	O
lymph node biopsy	B-T060
.	O
She	O
was	O
managed	B-T058
with	O
rituximab	B-T116
and	O
had	O
good	O
clinical	B-T080
improvement	B-T077
.	O
Castleman disease	B-T191
has	O
a	O
broad	B-T082
spectrum	B-T077
of	O
clinical	B-T080
manifestations	B-T080
,	O
disease	B-T047
pathogeneses	B-T046
,	O
and	O
associations	B-T080
and/or	O
complications	B-T046
.	O
Medical	B-T169
professionals	B-T097
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	B-T077
because	O
timely	O
diagnosis	B-T033
and	O
aggressive targeted therapy	B-T061
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
patients	B-T101
.	O

The	O
AGES-Reykjavik study atlases	B-T073
:	O
Non-linear	B-T077
multi-spectral template	B-T078
and	O
atlases	B-T073
for	O
studies	B-T062
of	O
the	O
ageing	B-T040
brain	B-T023
Quantitative analyses	B-T081
of	O
brain	B-T023
structures	B-T082
from	O
Magnetic Resonance	B-T060
(	O
MR	B-T060
)	O
image	B-T060
data	B-T078
are	O
often	O
performed	O
using	O
automatic	B-T169
segmentation	B-T066
algorithms	B-T170
.	O
Many	O
of	O
these	O
algorithms	B-T170
rely	O
on	O
templates	B-T078
and	O
atlases	B-T073
in	O
a	O
common	O
coordinate space	B-T170
.	O
Most	O
freely	B-T080
available	B-T169
brain	B-T023
atlases	B-T073
are	O
generated	O
from	O
relatively	O
young	B-T079
individuals	B-T098
and	O
not	O
always	O
derived	O
from	O
well-defined	O
cohort studies	B-T081
.	O
In	O
this	O
paper,	O
we	O
introduce	O
a	O
publicly	B-T092
available	B-T169
multi-spectral template	B-T078
with	O
corresponding	O
tissue	B-T024
probability	B-T081
atlases	B-T073
and	O
regional	B-T082
atlases	B-T073
,	O
optimised	B-T052
to	O
use	O
in	O
studies	B-T062
of	O
ageing	B-T040
cohorts	B-T098
(mean	O
age	O
75	O
±	O
5	O
years).	O
Furthermore,	O
we	O
provide	O
validation	B-T062
data	B-T078
from	O
a	O
regional	B-T082
segmentation	B-T066
pipeline	O
to	O
assure	O
the	O
integrity	B-T080
of	O
the	O
dataset	B-T170
.	O

Comparative	B-T062
and	O
evolutionary analysis	B-T062
of	O
an	O
adapter molecule MyD88	B-T028
in	O
invertebrate	B-T204
metazoans	B-T204
The	O
myeloid differentiation factor 88	B-T028
(	O
MyD88	B-T028
)	O
is	O
an	O
essential	O
adapter	O
in	O
Toll-like receptor	B-T116
(	O
TLR	B-T116
)	O
signalling pathways	B-T043
,	O
with	O
TLR	B-T116
the	O
first	O
pattern-recognition receptor	B-T116
(	O
PRR	B-T116
)	O
that	O
was	O
discovered	O
in	O
Drosophila	B-T204
.	O
In	O
the	O
present	O
study	B-T062
,	O
a	O
MyD88 gene	B-T028
was	O
identified	B-T080
and	O
characterized	B-T052
from	O
a	O
commercially	O
important	O
shellfish	B-T204
,	O
Scapharca subcrenata	B-T204
,	O
including	O
a	O
DEATH domain	B-T087
and	O
TIR domain	B-T082
conserved	O
within	O
other	O
molluscs	B-T204
.	O
Furthermore,	O
comparative genomic evidence	B-T063
revealed	O
that	O
MyD88	B-T028
was	O
of	O
different	B-T080
lengths	B-T081
and	O
contained	O
quantitative	B-T081
exon	B-T114
and	O
intron regions	B-T114
,	O
which	O
might	O
be	O
involved	O
in	O
specific mechanisms	B-T169
.	O
To	O
further	O
explore	O
the	O
phylogenetic relationships	B-T062
of	O
invertebrate	B-T204
metazoan	B-T204
MyD88	B-T028
,	O
we	O
applied	O
MrBayes and PhyML software	B-T170
to	O
construct	B-T185
phylogenetic trees	B-T080
using	O
Bayesian	B-T081
and	O
maximum likelihood approaches	B-T081
,	O
respectively,	O
which	O
suggested	O
that	O
the	O
MyD88	B-T028
of	O
Arthropoda	B-T204
was	O
closely	O
related	O
to	O
lower	B-T080
invertebrates	B-T204
,	O
in	O
contrast	B-T080
to	O
morphological	B-T082
taxonomy	B-T090
.	O
Finally,	O
we	O
investigated	B-T169
the	O
evolutionary patterns	B-T045
and	O
location	O
of	O
positive selection sites	B-T028
(	O
PSSs	B-T028
)	O
in	O
the	O
MyD88 gene	B-T028
from	O
Arthropoda	B-T204
,	O
Mollusca	B-T204
and	O
Insecta	B-T204
using	O
PAML software	B-T170
with	O
the	O
maximum likelihood method	B-T170
.	O
The	O
data	B-T078
showed	O
that	O
positive selection sites	B-T028
were	O
detected	B-T033
in	O
these	O
groups	B-T098
,	O
and	O
partial sites	B-T087
were	O
located	O
in	O
the	O
TIR domain	B-T082
but	O
were	O
not found	B-T033
in	O
the	O
DEATH domain	B-T087
.	O
To	O
summarize,	O
in	O
this	O
study	B-T062
,	O
we	O
report	O
on	O
the	O
diversification	B-T057
of	O
MyD88	B-T028
in	O
invertebrate	B-T204
metazoans	B-T204
,	O
the	O
specific	B-T080
evolutionary position	B-T045
of	O
Arthropoda	B-T204
MyD88	B-T028
,	O
and	O
the	O
positive	B-T033
selection pressures	B-T045
on	O
MyD88	B-T028
of	O
Arthropoda	B-T204
,	O
Mollusca	B-T204
and	O
Insecta	B-T204
.	O
These	O
results	B-T169
are	O
a	O
valuable contribution	B-T052
to	O
understand	O
and	O
clarify	B-T052
the	O
evolutionary pattern	B-T045
of	O
TLR	B-T116
/	O
MyD88	B-T028
signalling pathways	B-T043
in	O
invertebrate	B-T204
and	O
vertebrate taxa	B-T010
.	O

Rubinstein-Taybi Syndrome	B-T047
Associated with	B-T080
Pituitary Macroadenoma	B-T191
:	O
A	O
Case Report	B-T170
Rubinstein-Taybi Syndrome	B-T047
(	O
RSTS	B-T047
)	O
is	O
an	O
autosomal dominant disorder	B-T047
that	O
is	O
classically	O
characterized	B-T052
by	O
prenatal	B-T079
and	O
postnatal	B-T079
growth restriction	B-T046
,	O
microcephaly	B-T019
,	O
dysmorphic craniofacial features	B-T019
,	O
broad thumbs	B-T033
and	O
toes	B-T033
,	O
and	O
intellectual disability	B-T048
.	O
We	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary macroadenoma	B-T191
associated with	B-T080
RSTS	B-T047
.	O
A	O
39-year-old	O
Caucasian	B-T098
female	B-T098
with	O
a	O
past medical history	B-T033
of	O
RSTS	B-T047
diagnosed	B-T033
at	O
age	B-T032
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	B-T130
-enhancing	O
pituitary mass	B-T190
on	O
magnetic resonance imaging	B-T060
(	O
MRI	B-T060
)	O
of	O
the	O
brain	B-T023
three	O
years	B-T079
ago	O
during	O
workup	O
for	O
migraine-like headaches	B-T184
.	O
Subsequent	O
serial	O
imaging	B-T060
showed	O
radiographic evidence	B-T078
of	O
growth	B-T040
up	O
to	O
11.5	O
x	O
14.0	O
x	O
10.0	O
mm	O
in	O
size	B-T082
.	O
The	O
pituitary	B-T023
sellar lesion	B-T033
was	O
resected	B-T061
through	O
an	O
endoscopic	B-T082
transnasal	B-T082
transsphenoidal approach	B-T082
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph adenoma	B-T191
.	O
RSTS	B-T047
is	O
a	O
rare	B-T080
,	O
neurodevelopmental	B-T048
genetic disease	B-T047
where	O
most	O
patients with disabilities	B-T101
survive	B-T052
into	O
adulthood	B-T079
.	O
The	O
disorder	B-T047
is	O
associated with	B-T080
an	O
increased	B-T081
predisposition	B-T032
for	O
development	B-T169
of	O
nervous system tumors	B-T191
,	O
including	O
pituitary adenomas	B-T191
.	O

The	O
clinico-	O
radiological	B-T091
paradox	B-T033
of	O
cognitive function	B-T041
and	O
MRI	B-T060
burden	B-T078
of	O
white matter	B-T024
lesions	B-T033
in	O
people	B-T098
with	O
multiple sclerosis	B-T047
:	O
A	O
systematic review	B-T170
and	O
meta-analysis	B-T170
Moderate	B-T080
correlation	B-T080
exists	O
between	O
the	O
imaging quantification	B-T052
of	O
brain	B-T023
white matter	B-T024
lesions	B-T033
and	O
cognitive	B-T169
performance	B-T055
in	O
people	B-T098
with	O
multiple sclerosis	B-T047
(	O
MS	B-T047
).	O
This	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	B-T080
,	O
including	O
subvisible	O
pathology	B-T091
,	O
or	O
methodological	B-T078
limitations	B-T169
of	O
the	O
primary	B-T080
literature	B-T170
.	O
To	O
summarise	O
the	O
cognitive	B-T169
clinico-	O
radiological	B-T091
paradox	B-T033
and	O
explore	O
the	O
potential	B-T080
methodological	B-T078
factors	B-T169
that	O
could	O
influence	O
the	O
assessment	B-T052
of	O
this	O
relationship	B-T080
.	O
Systematic review	B-T170
and	O
meta-analysis	B-T170
of	O
primary	B-T080
research	B-T062
relating	O
cognitive function	B-T041
to	O
white matter	B-T024
lesion	B-T033
burden	B-T078
.	O
Fifty	O
papers	B-T073
met	O
eligibility criteria	B-T080
for	O
review	B-T170
,	O
and	O
meta-analysis	B-T170
of	O
overall	O
results	B-T169
was	O
possible	O
in	O
thirty-two	O
(2050	O
participants	B-T098
).	O
Aggregate	B-T080
correlation	B-T080
between	O
cognition	B-T041
and	O
T2	B-T033
lesion	B-T033
burden	B-T078
was	O
r	O
=	O
-0.30	O
(95%	O
confidence interval	B-T081
:	O
-0.34,	O
-0.26).	O
Wide	O
methodological	B-T078
variability	B-T077
was	O
seen,	O
particularly	O
related	O
to	O
key	O
factors	B-T169
in	O
the	O
cognitive	B-T169
data	B-T078
capture	O
and	O
image analysis techniques	B-T059
.	O
Resolving	O
the	O
persistent	O
clinico-	O
radiological	B-T091
paradox	B-T033
will	O
likely	O
require	O
simultaneous	O
evaluation	B-T058
of	O
multiple	B-T081
components	B-T077
of	O
the	O
complex	B-T080
pathology	B-T091
using	O
optimum	B-T080
measurement	B-T169
techniques	B-T169
for	O
both	O
cognitive	B-T169
and	O
MRI	B-T060
feature	B-T080
quantification	B-T081
.	O
We	O
recommend	O
a	O
consensus	B-T054
initiative	O
to	O
support	O
common	O
standards	B-T080
for	O
image analysis	B-T059
in	O
MS	B-T047
,	O
enabling	O
benchmarking	B-T081
while	O
also	O
supporting	O
ongoing	O
innovation	B-T170
.	O

Long Non-Coding RNA	B-T114
SNHG6	B-T028
as	O
a	O
Potential	O
Biomarker	B-T123
for	O
Hepatocellular Carcinoma	B-T191
Long Non-coding RNAs	B-T114
(	O
lncRNAs	B-T114
)	O
refer	O
to	O
all	O
non-protein coding	B-T114
transcripts	B-T114
longer	O
than	O
200	O
nucleotides	B-T114
.	O
Their	O
critical	O
roles	O
in	O
different	O
biological	B-T080
pathways	B-T077
have	O
been	O
already	O
well	O
established.	O
Altered	O
expression	B-T045
of	O
lncRNAs	B-T114
can	O
be	O
involved	O
in	O
the	O
cancer initiation	B-T191
and/or	O
progression	B-T191
.	O
Since	O
patients	B-T101
with	O
hepatocellular carcinoma	B-T191
(	O
HCC	B-T191
)	O
are	O
usually	O
diagnosed	B-T033
in	O
late stages	B-T079
,	O
developing	O
diagnostic methods	B-T060
seems	O
to	O
be	O
essential.	O
In	O
this	O
study	B-T062
,	O
the	O
expression	B-T045
levels	O
of	O
different	O
lncRNAs	B-T114
were	O
systematically	O
analysed	B-T062
in	O
different	O
genomic	B-T170
and	O
transcriptome datasets	B-T170
.	O
The	O
analyses	B-T062
showed	O
that	O
SNHG6	B-T028
is	O
among	O
the	O
lncRNAs	B-T114
with	O
distinctive	O
dysregulation	B-T045
of	O
expression	B-T045
and	O
copy	O
number	O
variation	O
in	O
HCC tumors	B-T191
compared	O
with	O
normal tissues	B-T024
.	O
The	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	B-T045
of	O
SNHG6	B-T028
is	O
highly	O
cancer	B-T191
type	O
specific.	O
Through	O
co-occurrence	O
analyses	B-T062
,	O
we	O
found	O
that	O
SNHG6	B-T028
and	O
its	O
related	O
co-expressed	B-T045
genes	B-T028
on	O
8q	B-T086
are	O
involved	O
in	O
the	O
structural	B-T082
integrity	B-T080
of	O
ribosome	B-T026
and	O
translation	B-T045
.	O
This	O
comprehensive	B-T080
in silico	B-T066
analysis	B-T062
,	O
provides	O
a	O
resource	O
for	O
investigating	B-T169
SNHG6	B-T028
in	O
hepatocellular carcinoma	B-T191
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
researches	B-T062
.	O

Expressional	B-T045
divergence	B-T082
of	O
insect	B-T204
GOX genes	B-T028
:	O
From	O
specialist	O
to	O
generalist	O
glucose oxidase	B-T116
Insect herbivores	B-T204
often	O
secrete	B-T043
glucose oxidase	B-T116
(	O
GOX	B-T116
)	O
onto	O
plants	B-T002
to	O
counteract	B-T053
plant	B-T002
defenses	B-T077
and	O
potential	B-T080
pathogens	B-T001
.	O
Whether	O
generalist	O
herbivores	B-T204
always	O
have	O
significantly higher	B-T081
GOX	B-T116
activities	B-T052
than	O
their	O
specialist	O
counterparts	B-T053
at	O
any	O
comparable	O
stage	O
or	O
conditions	O
and	O
how	O
this	O
is	O
realized	O
remain	O
unknown.	O
To	O
address	O
these	O
two	O
general	O
questions,	O
we	O
subjected	O
larvae	B-T204
of	O
a	O
pair	O
of	O
sister	O
species	B-T185
differed	O
mainly	O
in	O
host	O
range,	O
the	O
generalist	O
Helicoverpa armigera	B-T204
and	O
its	O
specialist	O
counterpart	B-T053
Helicoverpa assulta	B-T204
,	O
to	O
the	O
same	O
sets	O
of	O
stage,	O
protein	B-T116
to	O
digestible	B-T040
carbohydrate	B-T168
(P:C)	O
ratio,	O
allelochemical	B-T123
or	O
host plant	B-UnknownType
treatments	B-T169
for	O
simultaneous	O
analyses	O
of	O
GOX	B-T028
transcripts	B-T114
and	O
activities	B-T052
in	O
their	O
labial glands	B-T023
.	O
GOX	B-T028
activity	B-T052
and	O
transcripts	B-T114
are	O
upregulated	B-T044
concurrently	O
with	O
food	B-T168
ingestion	B-T038
and	O
body growth	B-T040
,	O
downregulated	B-T044
with	O
stopping	O
ingestion	B-T038
and	O
wandering	B-T053
for	O
pupation	B-T040
in	O
both	O
species	B-T185
.	O
The	O
three	O
tested	O
host plants	B-UnknownType
upregulated	B-T044
GOX	B-T028
transcripts	B-T114
,	O
and	O
to	O
a	O
lesser	O
extent,	O
GOX	B-T028
activity	B-T052
in	O
both	O
species	B-T185
.	O
There	O
were	O
significant	O
differences	O
in	O
both	O
GOX	B-T028
transcripts	B-T114
and	O
activity	B-T052
elicited	O
by	O
allelochemicals	B-T123
,	O
but	O
only	O
in	O
GOX	B-T028
transcripts	B-T114
by	O
P:C	O
ratios	O
in	O
both	O
species	B-T185
.	O
GOX	B-T116
activities	B-T052
were	O
higher	O
in	O
H. armigera	B-T204
than	O
H. assulta	B-T204
in	O
all	O
the	O
comparable	O
treatments,	O
but	O
GOX	B-T028
transcripts	B-T114
were	O
significantly higher	B-T081
either	O
in	O
generalists	O
or	O
in	O
specialists,	O
depending	O
on	O
the	O
developmental stages	B-T079
,	O
host plants	B-UnknownType
,	O
P:C	O
ratio	O
and	O
allelochemicals	B-T123
they	O
encounter	B-T053
.	O
These	O
data	B-T078
indicate	O
that	O
the	O
greater	B-T081
GOX	B-T116
activity	B-T052
in	O
generalist	O
herbivores	B-T204
is	O
not	O
achieved	O
by	O
greater	B-T081
transcription	B-T045
rate,	O
but	O
by	O
greater	O
transcript	B-T114
stability,	O
greater	O
translation	B-T045
rate,	O
better enzyme stability	B-T044
and/or	O
their	O
combination.	O

Propranolol	B-T109
Effects	O
on	O
Decompression Sickness	B-T047
in	O
a	O
Simulated	O
DISSUB	B-T073
Rescue	B-T057
in	O
Swine	B-T015
Disabled submarine	B-T073
(	O
DISSUB	B-T073
)	O
survivors	B-T096
may	O
face	O
elevated CO2 levels	B-T033
and	O
inert gas saturation	B-UnknownType
,	O
putting	O
them	O
at	O
risk	O
for	O
CO2	B-T123
toxicity	B-T080
and	O
decompression sickness	B-T047
(	O
DCS	B-T047
).	O
Propranolol	B-T109
was	O
shown	O
to	O
reduce CO2 production	B-T059
in	O
an	O
experimental	O
DISSUB	B-T073
model	B-T075
in	O
humans	B-T016
but	O
its	O
effects	O
on	O
DCS	B-T047
in	O
a	O
DISSUB	B-T073
rescue scenario	B-T057
are	O
unknown.	O
A	O
100%	O
oxygen prebreathe	B-T039
(	O
OPB	B-T039
)	O
reduces	O
DCS	B-T047
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
DISSUB	B-T073
rescue protocols	B-T057
.	O
We	O
used	O
a	O
swine model	B-T015
of	O
DISSUB	B-T073
rescue	B-T057
to	O
study	O
the	O
effect	O
of	O
propranolol	B-T109
on	O
DCS	B-T047
incidence	O
and	O
mortality	B-T081
with	O
and	O
without	O
an	O
OPB	B-T039
.	O
In	O
Experiment	O
1,	O
male	B-T032
Yorkshire Swine	B-T015
(70	O
kg)	O
were	O
pressurized	B-T067
to	O
2.8	O
ATA	O
for	O
22	O
h.	O
Propranolol	B-T109
1.0	O
mg	O
·	O
kg-1	O
(IV)	O
was	O
administered at	B-T169
21.25	O
h.	O
At	O
22	O
h,	O
the	O
animal	B-T008
was	O
rapidly decompressed	B-T169
and	O
observed	O
for	O
DCS	B-T047
type,	O
onset time	B-T079
,	O
and	O
mortality	B-T081
.	O
Experimental	O
animals	B-T008
(N	O
=	O
21;	O
69	O
±	O
4.1	O
kg),	O
PROP1.0	B-T109
,	O
were	O
compared	O
to	O
PROP1.0	B-T109
-	O
OPB45	B-T039
(N	O
=	O
8;	O
69	O
±	O
2.8	O
kg)	O
with	O
the	O
same	O
dive	B-T032
profile,	O
except	O
for	O
a	O
45	O
min	O
OPB	B-T039
prior	O
to	O
decompression	B-T169
.	O
In	O
Experiment	O
2,	O
the	O
same	O
methodology	B-T078
was	O
used	O
with	O
the	O
following	O
changes:	O
swine	B-T015
pressurized	B-T067
to	O
2.8	O
ATA	O
for	O
28	O
h;	O
experimental	O
group	O
(N	O
=	O
25;	O
67	O
±	O
3.3	O
kg),	O
PROP0.5	B-T109
bis,	O
propranolol	B-T109
0.5	O
mg	O
·	O
kg-1	O
bis	O
(twice)	O
(IV)	O
was	O
administered at	B-T169
22	O
h	O
and	O
26	O
h.	O
Control animals	B-T008
(N	O
=	O
25;	O
67	O
±	O
3.9	O
kg)	O
received	O
normal saline	B-T121
.	O
OPB	B-T039
reduced mortality	B-T081
in	O
PROP1.0	B-T109
-	O
OBP45	B-T039
compared	O
to	O
PROP1.0	B-T109
(0%	O
vs.	O
71%).	O
PROP0.5	B-T109
bis	O
had	O
increased mortality	B-T081
compared	O
to	O
CONTROL	O
(60-%	O
vs.	O
4%).	O
Administration	O
of	O
beta blockers	B-T121
prior	O
to	O
saturation decompression	B-T169
appears	O
to	O
increase	O
DCS	B-T047
and	O
worsen mortality	B-T081
in	O
a	O
swine	B-T015
model	B-T075
;	O
however,	O
their	O
effects	O
in	O
bounce diving	B-T032
remain	O
unknown.Forbes	O
AS,	O
Regis	O
DP,	O
HallAA,	O
Mahon	O
RT,	O
Cronin	O
WA.	O
Propranolol	O
effects	O
on	O
decompression	O
sickness	O
in	O
a	O
simulated	O
DISSUB	O
rescue	O
in	O
swine.	O
Aerosp	O
Med	O
Hum	O
Perform.	O
2017;	O
88(4):385-391.	O

Gut microbiota	B-T001
-mediated	O
protection	B-T033
against	O
diarrheal	B-T184
infections	B-T046
The	O
mammalian	B-T015
gut microbiota	B-T001
is	O
a	O
highly	O
abundant	O
and	O
diverse	O
microbial	B-T001
community	B-T096
that	O
resides	B-T052
in	O
the	O
gastrointestinal tract	B-T022
.	O
One	O
major	O
benefit	O
that	O
the	O
gut microbiota	B-T001
provides	O
to	O
its	O
host	B-T001
is	O
colonization	B-T033
resistance	B-T169
-the	O
ability	O
to	O
prevent	B-T169
colonization	B-T033
by	O
foreign microbes	B-T001
,	O
including	O
diarrheal	B-T184
pathogens	B-T001
such	O
as	O
Clostridium difficile	B-T007
,	O
Salmonella enterica serovar Typhimurium	B-T007
and	O
diarrheagenic Escherichia coli	B-T007
.	O
We	O
conducted	O
a	O
literature review	B-T170
of	O
the	O
effects of	B-T080
the	O
gut microbiota	B-T001
on	O
infection	B-T046
by	O
diarrheal	B-T184
pathogens	B-T001
.	O
We	O
used	O
PubMed	B-T170
to	O
search	O
for	O
relevant	O
articles	B-T170
published	O
before	O
July	O
2016,	O
as	O
well	O
as	O
incorporated	O
data	B-T078
from	O
our	O
laboratory	B-T073
.	O
The	O
gut microbiota	B-T001
provides	O
protection	B-T033
from	O
diarrheal	B-T184
infections	B-T046
both	O
by	O
direct	B-T080
inhibition	B-T052
of	O
pathogens	B-T001
and	O
by	O
indirect	B-T080
effects	B-T080
on	O
host	B-T001
functions	B-T169
.	O
Direct	B-T080
effects of	B-T080
the	O
microbiota	B-T001
on	O
diarrheal	B-T184
pathogens	B-T001
include	O
competing	O
for	O
nutrients	B-T168
and	O
producing	O
metabolites	B-T123
that	O
inhibit	B-T169
pathogen	B-T001
growth	B-T040
or	O
virulence	B-T038
.	O
Indirect	B-T080
effects of	B-T080
the	O
gut microbiota	B-T001
include	O
promoting	O
maintenance	B-T052
of	O
the	O
gut mucosal barrier	B-T042
and	O
stimulating	O
innate	B-T032
and	O
adaptive immunity	B-T039
.	O
Human	B-T016
epidemiological studies	B-T062
and	O
experimental	B-T080
infections	B-T046
of	O
laboratory animals	B-T008
both	O
demonstrate	O
that	O
antibiotic treatment	B-T061
can	O
alter	O
the	O
gut microbial	B-T001
community	B-T096
and	O
thereby	O
reduce	O
colonization	B-T033
resistance	B-T169
against	O
diarrheal	B-T184
pathogens	B-T001
.	O
Further	O
research	B-T062
might	O
lead	O
to	O
the	O
development	B-T169
of	O
next-generation probiotics	B-T007
that	O
could	O
be	O
used	O
to	O
bolster	O
colonization	B-T033
resistance	B-T169
and	O
thus	O
prevent	B-T169
travellers' diarrheal	B-T047
.	O

Ecotoxicity	B-T037
testing	B-T169
and	O
environmental risk assessment	B-T058
of	O
iron	B-T121
nanomaterials	B-T073
for	O
sub-surface	O
remediation	B-T069
-	O
Recommendations	B-T078
from	O
the	O
FP7 project NanoRem	B-T062
Nanoremediation	B-T069
with	O
iron	B-T121
(	O
Fe	B-T121
)	O
nanomaterials	B-T073
opens	O
new	O
doors	O
for	O
treating	B-T169
contaminated	B-T169
soil	B-T167
and	O
groundwater	B-T121
,	O
but	O
is	O
also	O
accompanied	O
by	O
new	O
potential risks	B-T078
as	O
large	O
quantities	O
of	O
engineered nanomaterials	B-T073
are	O
introduced	O
into	O
the	O
environment	B-T082
.	O
In	O
this	O
study	B-T062
,	O
we	O
have	O
assessed	B-T052
the	O
ecotoxicity	B-T037
of	O
four	O
engineered	O
Fe	B-T121
nanomaterials	B-T073
,	O
specifically,	O
Nano-Goethite	B-T197
,	O
Trap-Ox Fe-zeolites	B-T121
,	O
Carbo-Iron	B-T121
(®)	O
and	O
FerMEG12	B-T121
,	O
developed	O
within	O
the	O
European FP7 project NanoRem	B-T062
for	O
sub-surface	O
remediation	B-T069
towards	O
a	O
test battery	B-T059
consisting	O
of	O
eight	O
ecotoxicity	B-T037
tests	B-T059
on	O
bacteria	B-T007
(	O
V. fisheri	B-T007
,	O
E. coli	B-T007
),	O
algae	B-T204
(	O
P. subcapitata	B-T002
,	O
Chlamydomonas sp.	B-T002
),	O
crustaceans	B-T204
(	O
D. magna	B-T204
),	O
worms	B-T204
(	O
E. fetida	B-T204
,	O
L. variegatus	B-T204
)	O
and	O
plants	B-T002
(	O
R. sativus	B-T002
,	O
L. multiflorum	B-T002
).	O
The	O
tested	O
materials	O
are	O
commercially	O
available	O
and	O
include	O
Fe oxide	B-T121
and	O
nanoscale zero valent iron	B-T121
(	O
nZVI	B-T121
),	O
but	O
also	O
hybrid	O
products	O
with	O
Fe	B-T121
loaded	O
into	O
a	O
matrix	B-T082
.	O
All	O
but	O
one	O
material	B-T167
,	O
a	O
ball milled nZVI	B-T121
(	O
FerMEG12	B-T121
),	O
showed	O
no toxicity	B-T033
in	O
the	O
test battery	B-T059
when	O
tested	O
in	O
concentrations	B-T081
up	O
to	O
100	O
mg/L,	O
which	O
is	O
the	O
cutoff	B-T169
for	O
hazard	B-T080
labeling	B-T064
in	O
chemicals regulation	B-T064
in	O
Europe	B-T083
.	O
However	O
it	O
should	O
be	O
noted	O
that	O
Fe	B-T121
nanomaterials	B-T073
proved	O
challenging	O
to	O
test	O
adequately	O
due	O
to	O
their	O
turbidity	B-T080
,	O
aggregation	B-T169
and	O
sedimentation behavior	B-T070
in	O
aqueous	B-T080
media	B-T167
.	O
This	O
paper	O
provides	O
a	O
number	O
of	O
recommendations	B-T078
concerning	O
future testing	B-T169
of	O
Fe	B-T121
nanomaterials	B-T073
and	O
discusses	O
environmental risk assessment	B-T058
considerations	O
related	O
to	O
these.	O

Grade Group	B-T185
Underestimation	B-T033
in	O
Prostate Biopsy	B-T060
:	O
Predictive Factors	B-T170
and	O
Outcomes	B-T033
in	O
Candidates	B-T098
for	O
Active Surveillance	B-T058
We	O
intended	O
to	O
analyze	O
the	O
outcomes	B-T033
and	O
predictive factors	B-T170
for	O
underestimating	O
the	O
prostate cancer	B-T191
(	O
PCa	B-T191
)	O
grade group	B-T185
(	O
GG	B-T185
)	O
from	O
prostate biopsies	B-T060
in	O
a	O
large	O
monocentric cohort	B-T098
of	O
patients	B-T101
treated	B-T169
by	O
minimally invasive radical prostatectomy	B-T061
(	O
RP	B-T061
).	O
Using	O
a	O
monocentric prospectively maintained database	B-T170
,	O
we	O
included	O
3062	O
patients	B-T101
who	O
underwent	O
minimally invasive RP	B-T061
between	O
2006	O
and	O
2013.	O
We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	B-T033
associated with	B-T080
a	O
GG	B-T185
upgrade	O
from	O
biopsy	B-T060
to	O
RP	B-T061
.	O
Multivariate logistic regression	B-T062
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	B-T170
to	O
predict	O
upgrading	O
for	O
GG1	B-T185
.	O
Biopsy	B-T060
GG	B-T185
was	O
upgraded	O
after	O
RP	B-T061
in	O
51.5%	O
of	O
cases.	O
Patients	B-T101
upgraded	O
from	O
GG1	B-T185
to	O
GG2	B-T185
or	O
GG3	B-T185
after	O
RP	B-T061
had	O
a	O
longer time	B-T079
to	O
biochemical recurrence	B-T033
than	O
those	O
with	O
GG2	B-T185
or	O
GG3	B-T185
respectively,	O
on	O
both	O
biopsy	B-T060
and	O
RP	B-T061
,	O
but	O
a	O
shorter time	B-T079
to	O
biochemical recurrence	B-T033
than	O
those	O
who	O
remained	O
GG1	B-T185
after	O
RP	O
(P	O
<	O
.0001).	O
In	O
multivariate analyses	B-T081
,	O
variables	B-T081
predicting	O
upgrading	O
for	O
GG1	B-T185
PCa	B-T191
were	O
age	B-T032
(P	O
=	O
.0014),	O
abnormal digital rectal examination	B-T060
(P	O
<	O
.0001),	O
prostate	B-T023
prostate -specific antigen density	B-T033
(P	O
<	O
.0001),	O
percentage of positive cores	B-T033
(P	O
<	O
.0001),	O
and	O
body mass index	B-T170
(P	O
=	O
.037).	O
A	O
nomogram	B-T170
was	O
generated	O
and	O
validated	O
internally.	O
Biopsy	B-T060
grading system	B-T058
is	O
misleading	O
in	O
approximately	O
50%	O
of	O
cases.	O
Upgrading	O
GG	B-T185
from	O
biopsy	B-T060
to	O
RP	B-T061
may	O
have	O
consequences	O
on	O
clinical outcomes	B-T033
.	O
A	O
nomogram	B-T170
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	B-T081
of	O
needing	O
to	O
upgrade	O
GG1	B-T185
patients	B-T101
at	O
their	O
initial	O
evaluation	B-T058
.	O

Characterization	B-T052
of	O
electrocorticogram	B-T060
high	B-T080
-	O
gamma	B-T070
signal	B-T067
in	O
response	B-T032
to	O
varying	B-T080
upper extremity	B-T023
movement	B-T040
velocity	B-T081
The	O
mechanism	B-T169
by	O
which	O
the	O
human	B-T016
primary motor cortex	B-T029
(	O
M1	B-T029
)	O
encodes	B-T052
upper extremity	B-T023
movement	B-T040
kinematics	B-T091
is	O
not	O
fully	O
understood.	O
For	O
example,	O
human	B-T016
electrocorticogram	B-T060
(	O
ECoG	B-T060
)	O
signals	B-T067
have	O
been	O
shown	O
to	O
modulate	B-T082
with	O
upper extremity	B-T023
movement	B-T040
s;	O
however,	O
this	O
relationship	B-T080
has	O
not	O
been	O
explicitly	B-T080
characterized	B-T052
.	O
To	O
address	O
this	O
issue	B-T033
,	O
we	O
recorded	B-T081
high	B-T080
-	O
density	B-T081
ECoG	B-T060
signals	B-T067
from	O
patients	B-T101
undergoing	O
epilepsy	B-T047
surgery	B-T061
evaluation	B-T058
as	O
they	O
performed	B-T169
elementary	B-T167
upper extremity	B-T023
movements	B-T040
while	O
systematically	B-T169
varying	B-T080
movement	B-T040
speed	B-T081
and	O
duration	B-T079
.	O
Specifically	B-T080
,	O
subjects	B-T096
performed	B-T169
intermittent	B-T079
pincer grasp	B-T033
/	O
release	B-T169
,	O
elbow flexion	B-T033
/	O
extension	B-T169
,	O
and	O
shoulder flexion	B-T033
/	O
extension	B-T169
at	O
slow	B-T080
,	O
moderate	B-T080
,	O
and	O
fast	B-T080
speeds	B-T081
.	O
In	O
all	O
movements	B-T040
,	O
bursts	B-T081
of	O
power	B-T081
in	O
the	O
high	B-T080
-[Formula:	O
see	O
text]	O
band	O
(80-160	O
Hz)	O
were	O
observed	B-T169
in	O
M1	B-T029
.	O
In	O
addition	B-T169
,	O
the	O
amplitude	B-T082
of	O
these	O
power	B-T081
bursts	B-T081
and	O
the	O
area	B-T082
of	O
M1	B-T029
with	O
elevated	B-T080
high	B-T080
-[Formula:	O
see	O
text]	O
activity	B-T052
were	O
directly	B-T080
proportional	B-T080
to	O
the	O
movement	B-T040
speed	B-T081
.	O
Likewise,	O
the	O
duration	B-T079
of	O
elevated	B-T080
high	B-T080
-[Formula:	O
see	O
text]	O
activity	B-T052
increased	B-T081
with	O
movement	B-T040
duration	B-T079
.	O
Based	B-T169
on	O
linear regression	B-T081
,	O
M1	B-T029
high	B-T080
-[Formula:	O
see	O
text]	O
power	B-T081
amplitude	B-T082
and	O
duration	B-T079
covaried	B-T080
with	O
movement	B-T040
speed	B-T081
and	O
duration	B-T079
,	O
respectively,	O
with	O
an	O
average	B-T081
[Formula:	O
see	O
text]	O
of	O
[Formula:	O
see	O
text]	O
and	O
[Formula:	O
see	O
text].	O
These	O
findings	B-T033
indicate	B-T078
that	O
the	O
encoding	B-T052
of	O
upper extremity	B-T023
movement	B-T040
speed	B-T081
by	O
M1	B-T029
high	B-T080
-[Formula:	O
see	O
text]	O
activity	B-T052
is	O
primarily	B-T080
linear	B-T082
.	O
Also,	O
the	O
fact	O
that	O
this	O
activity	B-T052
remained	O
elevated	B-T080
throughout	O
a	O
movement	B-T040
suggests	O
that	O
M1	B-T029
does	O
not	O
merely	O
generate	O
transient	B-T079
instructions	B-T170
for	O
a	O
specific	B-T080
movement	B-T040
duration	B-T079
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	B-T081
of	O
the	O
movement	B-T040
.	O
Finally,	O
the	O
spatial distribution	B-T082
of	O
high	B-T080
-[Formula:	O
see	O
text]	O
activity	B-T052
suggests	O
the	O
presence	B-T033
of	O
a	O
recruitment	B-T052
phenomenon	B-T067
in	O
which	O
higher	B-T080
speeds	B-T081
or	O
increased	B-T081
muscle	B-T024
activity	B-T052
involve	O
activation	B-T052
of	O
larger	O
M1	B-T029
area	B-T082
s.	O

Fatty Acids	B-T109
Have	O
Different	B-T080
Adipogenic Differentiation	B-T044
Potentials	B-T080
in	O
Stromal Vascular Cells	B-T025
Isolated	B-T169
from	O
Abdominal Fat	B-T024
in	O
Laying	B-T040
Hens	B-T012
This	O
study	B-T062
was	O
conducted	O
to	O
examine	O
the	O
effects of	B-T080
fatty acids	B-T109
(	O
FA	B-T109
)	O
with/without	O
chicken serum	B-T129
(	O
CS	B-T129
)	O
on	O
the	O
expression	B-T045
of	O
adipogenic	B-T044
transcripts	B-T114
and	O
adipogenesis	B-T044
in	O
chicken	B-T012
stromal vascular cells	B-T025
(	O
SVC	B-T025
).	O
In	O
experiment	O
1,	O
SVC	B-T025
were	O
grown	O
in	O
DMEM	B-T121
containing	O
10%	O
FBS	B-T130
(	O
Control	B-T096
)	O
and	O
treated	B-T169
with	O
300	O
µM	O
oleic acid	B-T109
(	O
OLA	B-T109
)	O
+	O
FBS	B-T130
,	O
linoleic acid	B-T109
(	O
LNA	B-T109
)	O
+	O
FBS	B-T130
,	O
palmitic acid	B-T109
(	O
PAM	B-T109
)	O
+	O
FBS	B-T130
,	O
or	O
stearic acid	B-T109
(	O
STA	B-T109
)	O
+	O
FBS	B-T130
for	O
48	O
h.	O
In	O
experiment	O
2,	O
cells	B-T025
were	O
grown	O
in	O
DMEM	B-T121
containing	O
5%	O
CS	B-T129
and	O
treated	B-T169
with	O
300	O
µM	O
OLA	B-T109
(	O
CS	B-T129
+	O
OLA	B-T109
),	O
PAM	B-T109
(	O
CS	B-T129
+	O
PAM	B-T109
),	O
STA	B-T109
(	O
CS	B-T129
+	O
STA	B-T109
)	O
or	O
200	O
µM	O
LNA	B-T109
(	O
CS	B-T129
+	O
LNA	B-T109
)	O
for	O
48	O
h.	O
Adipogenesis	B-T044
was	O
determined	O
using	O
Oil Red O staining	B-T059
and	O
glycerol-3-phosphate dehydrogenase (GPDH) activity	B-T044
.	O
The	O
proportion	O
of	O
OLA	B-T109
,	O
PAM	B-T109
,	O
or	O
STA	B-T109
was	O
increased	B-T081
(P	O
<	O
0.05)	O
in	O
SVC	B-T025
grown	O
in	O
either	O
FBS	B-T130
or	O
CS	B-T129
with	O
OLA	B-T109
,	O
PAM	B-T109
or	O
STA	B-T109
.	O
Adipogenesis	B-T044
was	O
induced	B-T169
in	O
FBS	B-T130
+	O
OLA	B-T109
,	O
FBS	B-T130
+	O
LNA	B-T109
,	O
FBS	B-T130
+	O
PAM	B-T109
,	O
FBS	B-T130
+	O
STA	B-T109
,	O
CS	B-T129
+	O
OLA	B-T109
,	O
CS	B-T129
+	O
LNA	B-T109
,	O
CS	B-T129
+	O
PAM	B-T109
,	O
or	O
CS	B-T129
+	O
STA	B-T109
compared	O
to	O
FBS	B-T130
.	O
GPDH activity	B-T044
was	O
significantly higher	B-T081
in	O
FBS	B-T130
+	O
OLA	B-T109
and	O
FBS	B-T130
+	O
LNA	B-T109
than	O
one	O
in	O
FBS	B-T130
.	O
Compared	O
to	O
FBS	B-T130
,	O
the	O
expression	B-T045
of	O
FABP4	B-T028
mRNA	B-T114
increased	B-T081
(P	O
<	O
0.05)	O
in	O
FBS	B-T130
+	O
OLA	B-T109
,	O
FBS	B-T130
+	O
LNA	B-T109
,	O
or	O
FBS	B-T130
+	O
PAM	B-T109
,	O
whereas	O
that	O
of	O
C/EBPα	B-T028
,	O
C/EBPβ	B-T028
,	O
and	O
ATGL	B-T028
increased	B-T081
(P	O
<	O
0.05)	O
in	O
FBS	B-T130
+	O
OLA	B-T109
or	O
FBS	B-T130
+	O
LNA	B-T109
cells	B-T025
.	O
Expression	B-T045
of	O
FABP4	B-T028
and	O
C/EBPβ	B-T028
mRNA	B-T114
was	O
higher	B-T080
in	O
CS	B-T129
,	O
CS	B-T129
+	O
OLA	B-T109
,	O
CS	B-T129
+	O
LNA	B-T109
,	O
CS	B-T129
+	O
PAM	B-T109
,	O
or	O
CS	B-T129
+	O
STA	B-T109
compared	B-T052
with	O
(	O
FBS	B-T130
,	O
whereas	O
the	O
expression	B-T045
of	O
ATGL	B-T028
and	O
C/EBPα	B-T028
was	O
higher	B-T080
in	O
CS	B-T129
,	O
CS	B-T129
+	O
OLA	B-T109
,	O
or	O
CS	B-T129
+	O
LNA	B-T109
than	O
FBS	B-T130
cells	B-T025
.	O
In	O
conclusion,	O
these	O
results	B-T033
showed	O
that	O
FA	B-T109
have	O
different	B-T080
potentials	B-T080
to	O
induce	B-T169
adipogenesis	B-T044
,	O
LNA	B-T109
is	O
the	O
most	O
potent	B-T080
among	O
the	O
tested	O
FA	B-T109
,	O
and	O
these	O
potentials	B-T080
can	O
be	O
improved	O
in	O
the	O
presence	B-T033
of	O
CS	B-T129
.	O

A	O
novel	B-T080
rapid	B-T080
analysis	B-T062
using	O
mass spectrometry	B-T059
to	O
evaluate	O
downstream	B-T082
refolding	B-T044
of	O
recombinant human insulin-like growth factor-1	B-T116
(	O
mecasermin	B-T116
)	O
Mecasermin	B-T116
is	O
used	O
to	O
treat	O
elevated blood sugar	B-T047
as	O
well	O
as	O
growth hormone	B-T116
-	O
resistant	B-T169
Laron-type dwarfism	B-T047
.	O
Mecasermin	B-T116
isolated	O
from	O
inclusion bodies	B-T026
in	O
extracts	O
of	O
E.coli	B-T007
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity.	O
However,	O
there	O
is	O
no	O
rapid	B-T080
analytical method	B-T170
for	O
monitoring	O
refolding	B-T044
during	O
the	O
purification	B-T059
process.	O
We	O
prepared	O
mecasermin	B-T116
drug product	B-T121
,	O
in-process	O
samples	B-T167
during	O
the	O
oxidation	B-T044
of	O
mecasermin	B-T116
,	O
forced-reduced	O
mecasermin	B-T116
,	O
and	O
aerially	O
oxidized	O
mecasermin	B-T116
after	O
forced	O
reduction	B-T070
.	O
Desalted	O
mecasermin	B-T116
samples	B-T167
were	O
analyzed	O
using	O
MALDI-ISD	B-T059
.	O
The	O
peak intensity ratio	B-T081
of	O
product	O
to	O
precursor	O
ion	O
was	O
determined.	O
The	O
charge state distribution	B-T080
(	O
CSD	B-T080
)	O
of	O
mecasermin	B-T116
ions	O
was	O
evaluated	O
using	O
ESI-MS	B-T059
coupled	O
with	O
SEC-mode	O
HPLC	B-T059
.	O
The	O
drift time	B-T081
and	O
collision cross-sectional areas	B-T081
(	O
CCS	B-T081
)	O
of	O
mecasermin	B-T116
ions	O
were	O
evaluated	O
using	O
ESI-IMS-MS	B-T059
coupled	B-T169
with	O
SEC-mode	O
HPLC	B-T059
.	O
MALDI-ISD	B-T059
data,	O
CSD values	B-T081
determined	O
using	O
ESI-MS	B-T059
,	O
and	O
the	O
CCS	B-T081
acquired	O
using	O
ESI-IMS-MS	B-T059
revealed	O
the	O
relationship	B-T080
between	O
the	O
folded	B-T082
and	O
unfolded	B-T082
proteoforms	B-T116
of	O
forced-reduced	O
mecasermin	B-T116
and	O
aerially	O
oxidized	O
mecasermin	B-T116
with	O
the	O
free-SH: protein ratio	B-T081
of	O
mecasermin	B-T116
drug product	B-T121
.	O
The	O
collision cross-sectional area	B-T081
,	O
which	O
is	O
determined	O
using	O
ESI-IMS-MS	B-T059
,	O
provided	O
proteoform	B-T116
information	O
through	O
rapid	B-T080
monitoring	O
(<2	O
min)	O
of	O
in-process	O
samples	B-T167
during	O
the	O
manufacture	O
of	O
mecasermin	B-T116
.	O
ESI-IMS-MS	B-T059
coupled	O
with	O
SEC-mode	O
HPLC	B-T059
is	O
a	O
rapid	B-T080
and	O
robust	B-T080
method	O
for	O
analyzing	O
the	O
free-SH: protein ratio	B-T081
of	O
mecasermin	B-T116
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	B-T116
changes	O
during	O
the	O
oxidation	B-T044
of	O
mecasermin	B-T116
.	O
ESI-IMS-MS	B-T059
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
"	O
critical	B-T080
quality	B-T080
attributes	B-T080
"	O
and	O
implementing	O
"	O
quality	B-T080
by	O
design	B-T052
"	O
for	O
manufacturing	O
mecasermin	B-T116
.	O

Regulated	B-T045
Intron	B-T114
Removal	B-T052
Integrates	O
Motivational State	B-T041
and	O
Experience	B-T041
Myriad	O
experiences	B-T041
produce	O
transient memory	B-T041
,	O
yet,	O
contingent	O
on	O
the	O
internal state	B-T041
of	O
the	O
organism	B-T001
and	O
the	O
saliency	O
of	O
the	O
experience	B-T041
,	O
only	O
some	O
memories	B-T041
persist	O
over	O
time	B-T079
.	O
How	O
experience	B-T041
and	O
internal state	B-T041
influence	B-T077
the	O
duration	B-T079
of	O
memory	B-T041
at	O
the	O
molecular	O
level	O
remains	O
unknown.	O
A	O
self-assembled aggregated	B-T080
state	O
of	O
Drosophila Orb2A protein	B-T116
is	O
required	O
specifically	O
for	O
long-lasting memory	B-T041
.	O
We	O
report	O
that	O
in	O
the	O
adult fly	B-T204
brain	B-T023
the	O
mRNA	B-T114
encoding	B-T052
Orb2A protein	B-T116
exists	O
in	O
an	O
unspliced non-protein-coding form	B-T114
.	O
The	O
convergence	B-T052
of	O
experience	B-T041
and	O
internal drive	B-T041
transiently	O
increases	B-T169
the	O
spliced protein-coding Orb2A mRNA	B-T114
.	O
A	O
screen	O
identified	O
pasilla	B-T116
,	O
the	O
fly	B-T204
ortholog	O
of	O
mammalian	B-T015
Nova-1	B-T116
/	O
2	B-T116
,	O
as	O
a	O
mediator	B-T116
of	O
Orb2A mRNA	B-T114
processing	B-T045
.	O
A	O
single-nucleotide	B-T114
substitution	B-T044
in	O
the	O
intronic	B-T114
region	O
that	O
reduces	B-T080
Pasilla	B-T116
binding	B-T044
and	O
intron	B-T114
removal	B-T052
selectively	O
impairs	B-T169
long-term memory	B-T041
.	O
We	O
posit	O
that	O
pasilla	B-T116
-mediated	O
processing	B-T045
of	O
unspliced Orb2A mRNA	B-T114
integrates	O
experience	B-T041
and	O
internal state	B-T041
to	O
control	O
Orb2A protein	B-T116
abundance	B-T080
and	O
long-term memory	B-T041
formation	B-T169
.	O

The	O
FLASHE Study	B-T170
:	O
Survey	B-T170
Development	B-T169
,	O
Dyadic	B-T098
Perspectives,	O
and	O
Participant	B-T098
Characteristics	B-T080
The	O
National Cancer Institute	B-T093
developed	O
the	O
Family Life	B-T054
,	O
Activity	B-T052
,	O
Sun	B-T070
,	O
Health	B-T078
,	O
and	O
Eating	B-T040
(	O
FLASHE	B-T170
)	O
Study	B-T170
to	O
examine	O
multiple	O
cancer preventive	B-T061
behaviors	B-T055
within	O
parent	B-T099
-	O
adolescent	B-T100
dyads	B-T098
.	O
The	O
purpose	O
of	O
creating	O
FLASHE	B-T170
was	O
to	O
enable	O
the	O
examination	O
of	O
physical activity	B-T056
,	O
diet	B-T168
,	O
and	O
other	O
cancer preventive behaviors	B-T061
and	O
potential	O
correlates	O
among	O
parent	B-T099
-	O
adolescent	B-T100
dyads	B-T098
.	O
FLASHE surveys	B-T170
were	O
developed	O
from	O
a	O
process	O
involving	O
literature reviews	B-T170
,	O
scientific	B-T090
input	B-T077
from	O
experts	B-T097
in	O
the	O
field,	O
cognitive testing	B-T060
,	O
and	O
usability	O
testing.	O
This	O
cross-sectional	B-T062
,	O
web-based study	B-T062
of	O
parents	B-T099
and	O
their	O
adolescent	B-T100
children	B-T099
(aged	O
12-17	O
years)	O
was	O
administered	B-T169
between	O
April	B-T079
and	O
October	B-T079
2014.	O
The	O
nationwide	O
sample	O
consisted	O
of	O
1,573	O
parent	B-T099
-	O
adolescent	B-T100
dyads	B-T098
(1,699	O
parents	B-T099
and	O
1,581	O
adolescents	B-T100
)	O
who	O
returned	O
all	O
FLASHE surveys	B-T170
.	O
FLASHE	B-T170
assessed	O
parent	B-T099
and	O
adolescent	B-T100
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	B-T080
domains	O
(including	O
psychosocial variables	B-T080
,	O
parenting	B-T054
,	O
and	O
the	O
community	B-T080
and	O
home environments	B-T082
).	O
On	O
a	O
subset	O
of	O
example	O
FLASHE	B-T170
items	O
across	O
these	O
domains,	O
responses	B-T078
of	O
parents	B-T099
and	O
adolescents	B-T100
within	O
the	O
same	O
dyads	B-T098
were	O
positively	O
and	O
significantly	O
correlated	B-T081
(r	O
=0.32-0.63).	O
Analyses	O
were	O
run	O
in	O
2015-2016.	O
FLASHE	B-T170
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research questions	B-T078
among	O
individuals	B-T098
or	O
dyads	B-T098
,	O
including	O
the	O
ability	B-T032
to	O
examine	O
similarity	B-T080
between	O
parents	B-T099
and	O
adolescents	B-T100
on	O
many	O
constructs	O
relevant	O
to	O
cancer preventive behaviors	B-T061
.	O
FLASHE	B-T170
data	O
are	O
publicly	O
available	O
for	O
researchers	B-T097
and	O
practitioners	B-T097
to	O
help	O
advance	O
research	B-T062
on	O
cancer preventive	B-T061
health behaviors	B-T055
.	O

Sex differences	B-T032
in	O
the	O
effect of	B-T080
chronic mild stress	B-UnknownType
on	O
mouse	B-T015
prefrontal cortical	B-T023
BDNF	B-T116
levels:	O
A	O
role	O
of	O
major	O
ovarian hormones	B-T109
Depression	B-T048
induced	B-T169
by	O
stress	B-T033
is	O
affected	O
by	O
sex	B-T032
,	O
age	B-T032
and	O
hormonal	B-T080
status	O
of	O
the	O
animal	B-T008
and	O
also	O
by	O
duration	B-T079
and	O
type	O
of	O
the	O
stressors	B-T078
.	O
Moreover,	O
higher	O
prevalence	O
of	O
depression	B-T048
and	O
comorbidities	B-T078
in	O
women	B-T098
than	O
men	B-T098
implies	O
the	O
need	O
to	O
include	O
the	O
sex	B-T032
variable	O
in	O
studies	O
on	O
animal models	B-T008
of	O
depression	B-T048
.	O
The	O
present	O
study	O
was	O
therefore	O
initiated	O
to	O
evaluate	O
the	O
effect of	B-T080
sex	B-T032
and	O
ovarian hormones	B-T109
on	O
depression	B-T048
-like	O
phenotypes	B-T032
in	O
mice	B-T015
exposed	O
to	O
a	O
21-day	O
Chronic Variable Mild Stress	B-UnknownType
(	O
CVMS	B-UnknownType
)	O
paradigm	B-T062
.	O
Adult	B-T100
male	B-T032
,	O
intact female	B-T033
and,	O
ovariectomized (OVX) female	B-T033
mice	B-T015
exposed	O
to	O
CVMS	B-UnknownType
displayed	O
despair	O
behavior	B-T053
,	O
a	O
depression	B-T048
-like	O
phenotype	B-T032
,	O
in	O
all	O
the	O
groups.	O
However,	O
intact females	B-T033
alone,	O
but	O
not	O
males	B-T032
and	O
OVX females	B-T033
,	O
showed	O
anhedonia	B-T048
,	O
another	O
depression	B-T048
-like	O
phenotype	B-T032
.	O
At	O
the	O
molecular level	B-T081
,	O
the	O
expression	B-T045
of	O
Brain-Derived Neurotrophic Factor	B-T116
(	O
BDNF	B-T116
),	O
a	O
neuropeptide	B-T116
associated with	B-T080
depression	B-T048
,	O
and	O
few	O
other	O
stress	B-T033
-specific	O
genes	B-T028
CRH	B-T028
,	O
NR3C1	B-T028
,	O
CART	B-T028
,	O
and	O
NPY	B-T028
were	O
measured	O
in	O
the	O
Prefrontal Cortex	B-T023
(	O
PFC	B-T023
)	O
region	O
of	O
the	O
reward	O
circuitry.	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
BDNF	B-T116
protein expression	B-T045
along	O
with	O
an	O
increase	O
in	O
the	O
mRNA expression	B-T045
of	O
CRH	B-T028
,	O
NR3C1	B-T028
,	O
CART	B-T028
,	O
and	O
NPY	B-T028
in	O
intact females	B-T033
,	O
but	O
not	O
in	O
the	O
other	O
two	O
groups	O
of	O
mice	B-T015
.	O
OVX females	B-T033
resembled	O
males	B-T032
in	O
behavioral	B-T033
and	O
molecular responses	B-T033
to	O
CVMS	B-UnknownType
.	O
17β-Estradiol	B-T109
(	O
E2	B-T109
)	O
administration	B-T061
,	O
not	O
Progesterone	B-T109
(	O
P4	B-T109
),	O
to	O
OVX female	B-T033
stress	B-T033
mice	B-T015
,	O
mitigated	O
despair	O
and	O
enhanced	O
hedonic	O
capacity	O
with	O
an	O
increased	O
expression	B-T045
of	O
BDNF	B-T116
in	O
PFC	B-T023
.	O
This	O
study	O
strengthens	O
the	O
evidence	O
for	O
the	O
beneficial	O
effects of	B-T080
E2	B-T109
administration	B-T061
in	O
stress	B-T033
condition.	O

Development	B-T169
and	O
Evaluation	B-T062
of	O
the	O
ADHD	B-T048
ADHD Cognitions Scale	B-T170
for	O
Adults	B-T100
The	O
clinical literature	B-T170
on	O
ADHD	B-T048
in	O
adults	B-T100
suggests	O
that	O
"	O
overly positive	B-T041
"	O
or	O
optimistic cognitions	B-T041
may	O
contribute	O
to	O
impairment	B-T169
and	O
failure	B-T055
to	O
use	O
self-regulation skills	B-T055
in	O
this	O
population	B-T098
,	O
yet	O
the	O
research	B-T062
literature	B-T170
on	O
this	O
topic	O
is	O
limited.	O
We	O
developed	O
the	O
ADHD	B-T048
ADHD Cognitions Scale	B-T170
(	O
ACS	B-T170
),	O
a	O
brief	O
self-report	B-T062
measure	B-T081
of	O
ADHD	B-T048
-related	O
thoughts	B-T041
,	O
and	O
evaluated	O
its	O
psychometric properties	B-T080
.	O
We	O
collected	O
self-report	B-T062
measures	B-T081
,	O
inculding	O
the	O
ACS	B-T170
,	O
from	O
two	O
large	O
community samples	B-T096
(Ns	O
=	O
262,	O
304).	O
The	O
measure	O
demonstrated	O
a	O
one-factor solution	B-T081
that	O
replicated	B-T169
in	O
the	O
second	O
sample	B-T096
.	O
Evidence	O
of	O
good	O
internal consistency	B-T081
and	O
also	O
convergent	B-T080
and	O
divergent validity	B-T080
was	O
obtained	O
for	O
both	O
samples	B-T096
.	O
Scores	B-T081
on	O
the	O
ACS	B-T170
correlated	O
with	O
functional impairment	B-T033
,	O
time management problems	B-T033
,	O
and	O
avoidant coping	B-T033
strategies	B-T041
.	O
With	O
additional	O
study	B-T062
,	O
the	O
ACS	B-T170
may	O
be	O
useful	O
to	O
identify	O
and	O
track	O
maladaptive	B-T033
ADHD	B-T048
-related	O
cognitions	B-T041
during	O
cognitive-behavioral treatment	B-T061
,	O
and	O
to	O
further	O
study	B-T062
the	O
role	O
of	O
these	O
thoughts	B-T041
in	O
ADHD	B-T048
ADHD -related impairment	B-T033
.	O

Visual	B-T169
Confidence	B-T041
Visual	B-T169
confidence	B-T041
refers	O
to	O
an	O
observer's	B-T096
ability	B-T032
to	O
judge	B-T041
the	O
accuracy	B-T080
of	O
her	O
perceptual decisions	B-T041
.	O
Even	O
though	O
confidence	B-T041
judgments	B-T041
have	O
been	O
recorded	O
since	O
the	O
early	O
days	O
of	O
psychophysics	B-T091
,	O
only	O
recently	O
have	O
they	O
been	O
recognized	O
as	O
essential	O
for	O
a	O
deeper	O
understanding	O
of	O
visual perception	B-T041
.	O
The	O
reluctance	O
to	O
study	O
visual	B-T169
confidence	B-T041
may	O
have	O
come	O
in	O
part	O
from	O
obtaining	O
convincing	O
experimental evidence	B-T078
in	O
favor	O
of	O
metacognitive abilities	B-T041
rather	O
than	O
just	O
perceptual sensitivity	B-T041
.	O
Some	O
effort	O
has	O
thus	O
been	O
dedicated	O
to	O
offer	O
different	O
experimental paradigms	B-T062
to	O
study	B-T062
visual	B-T169
confidence	B-T041
in	O
humans	B-T016
and	O
nonhuman animals	B-T008
.	O
To	O
understand	O
the	O
origins	B-T079
of	O
confidence	B-T041
judgments	B-T041
,	O
investigators	B-T097
have	O
developed	O
two	O
competing	O
frameworks.	O
The	O
approach	O
based	O
on	O
signal decision theory	B-T170
is	O
popular	O
but	O
fails	B-T169
to	O
account	O
for	O
response times	B-T079
.	O
In	O
contrast,	O
the	O
approach	O
based	O
on	O
accumulation	O
of	O
evidence	B-T078
models	B-T170
naturally	O
includes	O
the	O
dynamics	B-T070
of	O
perceptual decisions	B-T041
.	O
These	O
models	B-T170
can	O
explain	O
a	O
range	O
of	O
results	B-T169
,	O
including	O
the	O
apparently	O
paradoxical	B-T080
dissociation	B-T048
between	O
performance	B-T055
and	O
confidence	B-T041
that	O
is	O
sometimes	O
observed.	O

Grapevine	B-T002
Subtilase Family	B-T116
:	O
Update	O
on	O
New	O
Sequences	B-T086
and	O
Nomenclature Proposal	B-T170
In	O
grapevine	B-T002
,	O
serine peptidases	B-T116
from	O
the	O
subtilase family	B-T116
were	O
recently	O
associated	O
to	O
Plasmopara viticola	B-T002
resistance	B-T169
.	O
This	O
family	O
in	O
grapevine	B-T002
,	O
first	O
characterized	O
in	O
2014,	O
was	O
re-analyzed	B-T062
last	O
year	O
and	O
82	O
subtilase	B-T116
genes	B-T028
were	O
identified.	O
However,	O
in	O
November	O
of	O
2016,	O
the	O
National Center for Biotechnology Information	B-T092
database	B-T170
(	O
NCBI	B-T092
)	O
made	O
a	O
new	O
public	O
release	O
of	O
the	O
grapevine	B-T002
genome annotation	B-T063
based	O
on	O
new	O
sequencing data	B-T170
and	O
better	O
prediction	B-T078
algorithms	B-T170
.	O
As	O
a	O
consequence	B-T169
,	O
some	O
gene annotations	B-T063
and	O
lengths	O
changed.	O
Here	O
we	O
present	O
an	O
update	O
to	O
the	O
grapevine	B-T002
subtilase	B-T116
gene family	B-T028
sequences	B-T086
(	O
SBT	B-T116
),	O
namely	O
sequence identifiers	B-T170
,	O
bioinformatic	B-T091
predictions	B-T078
and	O
recommend	O
a	O
nomenclature	B-T170
for	O
the	O
grapevine	B-T002
SBT	B-T116
genes	B-T028
.	O
Our	O
results	B-T034
show	O
that	O
grapevine	B-T002
subtilase	B-T116
gene family	B-T028
is	O
now	O
constituted	O
by	O
87	O
subtilase	B-T116
genes	B-T028
encoding	B-T052
for	O
109	O
subtilase proteins	B-T116
and,	O
despite	O
the	O
reported	O
alterations	B-T045
,	O
expression	B-T045
data	B-T078
on	O
subtilases	B-T116
associated	O
to	O
grapevine	B-T002
resistance	B-T169
to	O
P. viticola	B-T002
pathosystem	B-T001
did	O
not	O
suffer	O
any	O
alteration	B-T045
.	O

Shared Decision Making	B-T041
and	O
the	O
promise	B-T078
of	O
a	O
respectful	O
and	O
equitable	O
healthcare system	B-T093
in	O
Peru	B-T083
Peru	B-T083
has	O
achieved	O
sustained development	B-T070
in	O
the	O
last	O
two	O
decades	B-T081
.	O
However,	O
despite	O
this	O
achievement,	O
it	O
has	O
not	O
been	O
matched	O
with	O
improvements	B-T057
in	O
the	O
quality of education	B-T080
and	O
health	B-T058
;	O
investment	O
in	O
both	O
sectors	B-T078
is	O
among	O
the	O
lowest	O
in	O
the	O
region	B-T083
.	O
This	O
situation	O
perpetuates	O
huge	O
gaps	B-T033
in	O
infrastructure	B-T058
and	O
also	O
conditions	O
a	O
poor literacy level	B-T033
of	O
the	O
population	B-T098
specifically	O
in	O
health	B-T078
.	O
Currently,	O
there	O
is	O
a	O
fragmented	O
model	B-T170
of	O
patient care	B-T058
,	O
in	O
which	O
the	O
systems	B-T093
are	O
exclusive	O
of	O
each	O
other.	O
They	O
do	O
not	O
cooperate	B-T054
or	O
communicate	B-T054
with	O
each	O
other;	O
and	O
if	O
there	O
is	O
no	O
vertical	O
communication	B-T054
within	O
the	O
system	B-T093
,	O
preventing	O
referral of patients	B-T058
directly	O
from	O
the	O
basic level	B-T033
to	O
the	O
complex level	B-T033
of	O
care	B-T058
when	O
needed.	O
In	O
addition,	O
there	O
has	O
been	O
no	O
progress	O
in	O
the	O
development	B-T169
of	O
an	O
empathetic,	O
respectful	O
or	O
person-centered clinical practice	B-T058
;	O
instead,	O
economic	B-T169
,	O
social	B-T169
and	O
educational	B-T065
differences	O
perpetuate	O
a	O
paternalistic	O
clinical practice	B-T058
.	O
The	O
task	O
of	O
orienting	O
medical training	B-T065
towards	O
the	O
development	B-T169
of	O
humanism	B-T078
is	O
pending.	O
The	O
patient	B-T101
is	O
the	O
center	O
of	O
the	O
medical act	B-T062
and	O
the	O
main	O
objective	O
of	O
doctors'	B-T097
actions.	O
A	O
humanistic care approach	B-T052
will	O
not	O
only	O
empower	O
the	O
person	B-T098
in	O
the	O
clinical	O
encounter	O
-	O
to	O
participate	O
and	O
make	O
decisions	O
related	O
to	O
his/her	O
health care	B-T058
-	O
but	O
it	O
will	O
allow	O
us	O
to	O
move	O
towards	O
an	O
empathetic,	O
caring	B-T055
,	O
respectful	B-T054
and	O
kind	O
model	B-T170
of	O
clinical practice	B-T058
.	O

Identification	O
of	O
markers	B-T201
for	O
quiescent	B-T080
pancreatic stellate cells	B-T025
in	O
the	O
normal	B-T080
human	B-T016
pancreas	B-T023
Pancreatic stellate cells	B-T025
(	O
PSCs	B-T025
)	O
play	O
a	O
central	O
role	O
as	O
source	O
of	O
fibrogenic cells	B-T025
in	O
pancreatic cancer	B-T191
and	O
chronic pancreatitis	B-T047
.	O
In	O
contrast	O
to	O
quiescent	B-T080
hepatic stellate cells	B-T025
(	O
qHSCs	B-T025
),	O
a	O
specific	O
marker	B-T201
for	O
quiescent	B-T080
PSCs	B-T025
(	O
qPSCs	B-T025
)	O
that	O
can	O
be	O
used	O
in	O
formalin-fixed and paraffin embedded (FFPE) normal human pancreatic tissue	B-T024
has	O
not	O
been	O
identified.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
a	O
marker	O
enabling	O
the	O
identification	O
of	O
qPSCs	B-T025
in	O
normal	B-T080
human	B-T016
FFPE pancreatic tissue	B-T024
.	O
Immunohistochemical	B-T059
(	O
IHC	B-T059
),	O
double-IHC	B-T059
,	O
immunofluorescence	B-T059
(	O
IF	B-T059
)	O
and	O
double-IF analyses	B-T059
were	O
carried	O
out	O
using	O
a	O
tissue microarray	B-T075
consisting	O
of	O
cores	O
with	O
normal	B-T080
human	B-T016
pancreatic tissue	B-T024
.	O
Cores	O
with	O
normal	B-T080
human	B-T016
liver	B-T023
served	O
as	O
control	B-T096
.	O
Antibodies	B-T116
directed	O
against	O
adipophilin	B-T116
,	O
α-SMA	B-T116
,	O
CD146	B-T116
,	O
CRBP-1	B-T116
,	O
cytoglobin	B-T116
,	O
desmin	B-T116
,	O
GFAP	B-T116
,	O
nestin	B-T116
,	O
S100A4	B-T116
and	O
vinculin	B-T116
were	O
examined,	O
with	O
special	O
emphasis	O
on	O
their	O
expression	O
in	O
periacinar	B-T082
cells	B-T025
in	O
the	O
normal	B-T080
human	B-T016
pancreas	B-T023
and	O
perisinusoidal cells	B-T025
in	O
the	O
normal	B-T080
human	B-T016
liver	B-T023
.	O
The	O
immunolabelling	B-T059
capacity	B-T081
was	O
evaluated	O
according	O
to	O
a	O
semiquantitative scoring system	B-T057
.	O
Double-IF	B-T059
of	O
the	O
markers	B-T201
of	O
interest	O
together	O
with	O
markers	B-T201
for	O
other	O
periacinar	B-T082
cells	B-T025
was	O
performed.	O
Moreover,	O
the	O
utility	O
of	O
histochemical stains	B-T059
for	O
the	O
identification	O
of	O
human	B-T016
qPSCs	B-T025
was	O
examined,	O
and	O
their	O
ultrastructure	B-T078
was	O
revisited	O
by	O
electron microscopy	B-T059
.	O
Adipophilin	B-T116
,	O
CRBP-1	B-T116
,	O
cytoglobin	B-T116
and	O
vinculin	B-T116
were	O
expressed	O
in	O
qHSCs	B-T025
in	O
the	O
liver	B-T023
,	O
whereas	O
cytoglobin	B-T116
and	O
adipophilin	B-T116
were	O
expressed	O
in	O
qPSCs	B-T025
in	O
the	O
pancreas	B-T023
.	O
Adipophilin	B-T116
immunohistochemistry	B-T060
was	O
highly	O
dependent	O
on	O
the	O
preanalytical time interval	B-T079
(	O
PATI	B-T079
)	O
from	O
removal	O
of	O
the	O
tissue	B-T024
to	O
formalin fixation	B-T059
.	O
Cytoglobin	B-T116
,	O
S100A4	B-T116
and	O
vinculin	B-T116
were	O
expressed	O
in	O
periacinar	B-T082
fibroblasts	B-T025
(	O
FBs	B-T025
).	O
The	O
other	O
examined	O
markers	B-T201
were	O
negative	O
in	O
human	B-T016
qPSCs	B-T025
.	O
Our	O
data	O
indicate	O
that	O
cytoglobin	B-T116
and	O
adipophilin	B-T116
are	O
markers	B-T201
of	O
qPSCs	B-T025
in	O
the	O
normal	B-T080
human	B-T016
pancreas	B-T023
.	O
However,	O
the	O
use	O
of	O
adipophilin	B-T116
as	O
a	O
qPSC	B-T025
marker	O
may	O
be	O
limited	O
due	O
to	O
its	O
high	O
dependence	O
on	O
optimal	O
PATI	B-T079
.	O
Cytoglobin	B-T116
,	O
on	O
the	O
other	O
hand,	O
is	O
a	O
sensitive	O
marker	B-T201
for	O
qPSCs	B-T025
but	O
is	O
expressed	O
in	O
FBs	B-T025
as	O
well.	O

Biomagnetic monitoring	B-T059
of	O
atmospheric pollution	B-UnknownType
:	O
a	O
review of	B-T169
magnetic	B-T070
signatures	O
from	O
biological sensors	B-T075
Biomagnetic monitoring	B-T059
of	O
atmospheric pollution	B-UnknownType
is	O
a	O
growing	O
application	O
in	O
the	O
field	O
of	O
environmental	B-T082
magnetism	B-T070
.	O
Particulate matter	B-T167
(	O
PM	B-T167
)	O
in	O
atmospheric pollution	B-UnknownType
contains	O
readily-	O
measurable	B-T169
concentrations	O
of	O
magnetic minerals	B-T197
.	O
Biological	B-T080
surfaces	B-T082
,	O
exposed	O
to	O
atmospheric pollution	B-UnknownType
,	O
accumulate	O
magnetic	B-T070
particles	B-T104
over	O
time,	O
providing	O
a	O
record	O
of	O
location	B-T082
-	O
specific	B-T080
,	O
time-integrated	B-T033
air quality	B-T080
information	B-T078
.	O
This	O
review	B-T170
summarizes	O
current	O
knowledge	O
of	O
biological material	B-T075
('	O
sensors	B-T075
')	O
used	O
for	O
biomagnetic monitoring	B-T059
purposes.	O
Our	O
work	O
addresses:	O
the	O
range	O
of	O
magnetic properties	B-T070
reported	O
for	O
lichens	B-T002
,	O
mosses	B-T002
,	O
leaves	B-T002
,	O
bark	B-T002
,	O
trunk wood	B-T002
,	O
insects	B-T204
,	O
crustaceans	B-T204
,	O
mammal	B-T015
and	O
human tissues	B-T024
;	O
their	O
associations	O
with	O
atmospheric pollutant species	B-T131
(	O
PM	B-T167
,	O
NOx	B-T197
,	O
trace elements	B-T123
,	O
PAHs	B-T109
);	O
the	O
pros and cons	B-T033
of	O
biomagnetic monitoring	B-T059
of	O
atmospheric pollution	B-UnknownType
;	O
current	O
challenges	O
for	O
large-scale implementation	B-UnknownType
of	O
biomagnetic monitoring	B-T059
;	O
and	O
future	B-T079
perspectives.	O
A	O
summary	O
table	O
is	O
presented,	O
with	O
the	O
aim	O
of	O
aiding	O
researchers	B-T097
and	O
policy makers	B-T097
in	O
selecting	O
the	O
most	O
suitable	O
biological sensor	B-T075
for	O
their	O
intended	O
biomagnetic monitoring	B-T059
purpose.	O

Role	O
of	O
infrared spectroscopy	B-T059
and	O
imaging	B-T060
in	O
cancer	B-T191
diagnosis	B-T033
FTIR	B-T062
imaging	B-T060
has	O
been	O
used	O
to	O
diagnose	B-T033
and	O
differentiate	B-T080
the	O
molecular	B-T080
differences	B-T080
between	O
normal	B-T024
and	O
diseased	B-T047
tissues	B-T024
.	O
The	O
differences	B-T080
correspond	O
to	O
the	O
distribution	B-T169
and	O
structure	B-T082
of	O
lipids	B-T109
,	O
proteins	B-T116
,	O
nucleic acids	B-T114
as	O
well	O
as	O
other	O
metabolites	B-T123
.	O
These	O
differences	B-T080
depended	O
on	O
the	O
type	B-T033
and	O
the	O
grade	O
of	O
cancer	B-T191
.	O
The	O
sensitivity	B-T169
of	O
chemotherapy	B-T061
drugs	B-T121
on	O
individual	B-T098
specific	O
was	O
also	O
discussed.	O
Here,	O
we	O
emphasize	O
that	O
FTIR spectroscopy	B-T062
and	O
imaging	B-T060
can	O
be	O
considered	O
as	O
a	O
promising	O
technique	B-T169
and	O
will	O
find	O
its	O
place	O
on	O
the	O
detection	B-T061
of	O
this	O
dreadful disease	B-T047
because	O
of	O
high sensitivity	B-T059
,	O
accuracy	B-T080
and	O
inexpensive	O
technique	B-T169
.	O
Now	O
the	O
medical community	B-T073
started	O
using	O
and	O
accepting	O
this	O
technique	B-T169
for	O
early stage	B-T079
cancer	B-T191
detection	B-T061
.	O
But,	O
this	O
technique	B-T169
endures	O
several	O
challenges	B-T058
on	O
its	O
application	O
into	O
the	O
diagnosis	B-T033
of	O
cancer	B-T191
in	O
regards	O
of	O
sample preparations	B-T059
,	O
data interpretation	B-T058
,	O
and	O
data analysis	B-T057
.	O
In	O
general,	O
more	O
research	B-T062
is	O
needed	O
in	O
this	O
field	O
and	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
morphology	B-T080
and	O
biology	B-T091
of	O
the	O
sample	O
before	O
using	O
the	O
spectroscopy	B-T062
and	O
imaging	B-T060
because	O
invaluable	B-T080
information	B-T078
to	O
be	O
figured	O
out.	O

The	O
CLASP2	B-T116
Protein Interaction Network	B-T169
in	O
Adipocytes	B-T025
Links	O
CLIP2	B-T116
to	O
AGAP3	B-T116
,	O
CLASP2	B-T116
to	O
G2L1	B-T116
,	O
MARK2	B-T116
,	O
and	O
SOGA1	B-T116
,	O
and	O
Identifies	O
SOGA1	B-T116
as	O
a	O
Microtubule-Associated Protein	B-T116
CLASP2	B-T116
is	O
a	O
microtubule-associated protein	B-T116
that	O
undergoes	O
insulin	B-T116
-	O
stimulated	B-T045
phosphorylation	B-T044
and	O
co-localization	B-T169
with	O
reorganized	B-T078
actin	B-T116
and	O
GLUT4	B-T116
at	O
the	O
plasma membrane	B-T026
.	O
To	O
gain	B-T081
insight	B-T041
to	O
the	O
role	B-T077
of	O
CLASP2	B-T116
in	O
this	O
system	B-T043
,	O
we	O
developed	B-T169
and	O
successfully	B-T080
executed	B-T052
a	O
streamlined	B-T080
interactome	B-T044
approach	B-T082
and	O
built	O
a	O
CLASP2	B-T116
protein network	B-T169
in	O
3T3-L1 adipocytes	B-T025
.	O
Using	O
two	O
different	B-T080
commercially	B-T170
available	B-T169
antibodies	B-T116
for	O
CLASP2	B-T116
and	O
an	O
antibody	B-T116
for	O
epitope	B-T129
-tagged,	O
overexpressed	B-T045
CLASP2	B-T116
,	O
we	O
performed	B-T169
multiple	B-T081
affinity purification	B-T059
coupled	B-T169
with	O
mass spectrometry	B-T059
(	O
AP	B-T059
-	O
MS	B-T059
)	O
experiments	B-T062
in	O
combination	B-T080
with	O
label-free	B-T033
quantitative	B-T081
proteomics	B-T091
and	O
analyzed	B-T062
the	O
data	B-T078
with	O
the	O
bioinformatics	B-T091
tool	B-T170
Significance Analysis of Interactome	B-T170
(	O
SAINT	B-T170
).	O
We	O
discovered	B-T052
that	O
CLASP2	B-T116
co-immunoprecipitates	B-T129
(	O
co-IPs	B-T129
)	O
the	O
novel	O
protein	B-T116
SOGA1	B-T116
,	O
the	O
microtubule-associated protein kinase	B-T116
MARK2	B-T116
,	O
and	O
the	O
microtubule	B-T026
/	O
actin	B-T116
-	O
regulating	B-T038
protein	B-T116
G2L1	B-T116
.	O
The	O
GTPase-activating proteins	B-T116
AGAP1	B-T116
and	O
AGAP3	B-T116
were	O
also	O
enriched	O
in	O
the	O
CLASP2	B-T116
interactome	B-T044
,	O
although	O
subsequent	B-T079
AGAP3	B-T116
and	O
CLIP2	B-T116
interactome	B-T044
analysis	B-T062
suggests	O
a	O
preference	B-T078
of	O
AGAP3	B-T116
for	O
CLIP2	B-T116
.	O
Follow-up	O
MARK2	B-T116
interactome	B-T044
analysis	B-T062
confirmed	B-T033
reciprocal	B-T080
co-IP	B-T129
of	O
CLASP2	B-T116
and	O
also	O
revealed	O
MARK2	B-T116
can	O
co-IP	B-T129
SOGA1	B-T116
,	O
glycogen synthase	B-T116
,	O
and	O
glycogenin	B-T116
.	O
Investigating	B-T169
the	O
SOGA1	B-T116
interactome	B-T044
confirmed	B-T033
SOGA1	B-T116
can	O
reciprocal	B-T080
co-IP	B-T129
both	O
CLASP2	B-T116
and	O
MARK2	B-T116
as	O
well	O
as	O
glycogen synthase	B-T116
and	O
glycogenin	B-T116
.	O
SOGA1	B-T116
was	O
confirmed	B-T033
to	O
colocalize	B-T082
with	O
CLASP2	B-T116
and	O
also	O
with	O
tubulin	B-T116
,	O
which	O
identifies	O
SOGA1	B-T116
as	O
a	O
new	O
microtubule-associated protein	B-T116
.	O
These	O
results	B-T033
introduce	O
the	O
metabolic function	B-T044
of	O
these	O
proposed	B-T080
novel	O
protein networks	B-T169
and	O
their	O
relationship	B-T080
with	O
microtubules	B-T026
as	O
new	O
fields	O
of	O
cytoskeleton	B-T026
-	O
associated	B-T080
protein biology	B-T091
.	O

